<SEC-DOCUMENT>0001127537-22-000037.txt : 20220808
<SEC-HEADER>0001127537-22-000037.hdr.sgml : 20220808
<ACCEPTANCE-DATETIME>20220808162830
ACCESSION NUMBER: 0001127537-22-000037
CONFORMED SUBMISSION TYPE: 10-Q
PUBLIC DOCUMENT COUNT: 80
CONFORMED PERIOD OF REPORT: 20220630
FILED AS OF DATE: 20220808
DATE AS OF CHANGE: 20220808
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pulmonx Corp
CENTRAL INDEX KEY: 0001127537
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 10-Q
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39562
FILM NUMBER: 221144800
BUSINESS ADDRESS:
STREET 1: 700 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 650-364-0400
MAIL ADDRESS:
STREET 1: 700 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
FORMER COMPANY:
FORMER CONFORMED NAME: PULMONX
DATE OF NAME CHANGE: 20001031
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>lung-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:e27afbe0-c876-445c-ac79-0e3a22d99ad7,g:11f7fccd-ac30-49f3-b9c8-08334e4a7c01,d:784ba2f3210d43dcbb23721a3c553397--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:lung="http://www.pulmonx.com/20220630" xmlns:srt="http://fasb.org/srt/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>
<title>lung-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180L2ZyYWc6ODBmNzhmZDMyYmJjNGJmMTg0ZDIzNGExOTFkZmMwMzgvdGFibGU6MmRkMGQ4OGUzMzUyNGUwYTg4ZWQ2ZWIxZTFlMWQ3NWYvdGFibGVyYW5nZToyZGQwZDg4ZTMzNTI0ZTBhODhlZDZlYjFlMWUxZDc1Zl8xLTEtMS0xLTM5Mzgz_c8afca6e-62ed-435a-91b6-0d7d8613d2ff">0001127537</ix:nonNumeric><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180L2ZyYWc6ODBmNzhmZDMyYmJjNGJmMTg0ZDIzNGExOTFkZmMwMzgvdGFibGU6MmRkMGQ4OGUzMzUyNGUwYTg4ZWQ2ZWIxZTFlMWQ3NWYvdGFibGVyYW5nZToyZGQwZDg4ZTMzNTI0ZTBhODhlZDZlYjFlMWUxZDc1Zl8yLTEtMS0xLTM5Mzgz_de70f126-4b6d-4455-a1cf-2c57d251ad12">12/31</ix:nonNumeric><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180L2ZyYWc6ODBmNzhmZDMyYmJjNGJmMTg0ZDIzNGExOTFkZmMwMzgvdGFibGU6MmRkMGQ4OGUzMzUyNGUwYTg4ZWQ2ZWIxZTFlMWQ3NWYvdGFibGVyYW5nZToyZGQwZDg4ZTMzNTI0ZTBhODhlZDZlYjFlMWUxZDc1Zl8zLTEtMS0xLTM5Mzgz_1d53f4d9-949e-4e61-b02c-94f8bbe93931">2022</ix:nonNumeric><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180L2ZyYWc6ODBmNzhmZDMyYmJjNGJmMTg0ZDIzNGExOTFkZmMwMzgvdGFibGU6MmRkMGQ4OGUzMzUyNGUwYTg4ZWQ2ZWIxZTFlMWQ3NWYvdGFibGVyYW5nZToyZGQwZDg4ZTMzNTI0ZTBhODhlZDZlYjFlMWUxZDc1Zl80LTEtMS0xLTM5Mzgz_1ba74fdc-1a0e-49b5-a057-e711a752851c">Q2</ix:nonNumeric><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180L2ZyYWc6ODBmNzhmZDMyYmJjNGJmMTg0ZDIzNGExOTFkZmMwMzgvdGFibGU6MmRkMGQ4OGUzMzUyNGUwYTg4ZWQ2ZWIxZTFlMWQ3NWYvdGFibGVyYW5nZToyZGQwZDg4ZTMzNTI0ZTBhODhlZDZlYjFlMWUxZDc1Zl81LTEtMS0xLTM5Mzgz_969c9ce8-1e85-406f-8597-2a13caf97e6f">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lung-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13c4ccdef36a4923ac2f86f39c238d7f_I20220729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i23debaac8bf94b7195e8771f793b80bb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c4697ae1aaa496dbaaf2d4679704499_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia24f369469a741168a30ae622482853d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10ab7cd963514359bca3cc91d92e2ecc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id78b13f427954c0c9d0eaf7f535da90f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19fb5ca4a6fb4af091d289bfc12b61a0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i725a772a7daa4c27b7de453c618f8b63_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i652d00700fc04edeacaed27e5bb45f8e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie32244cce0bb4ac7b0db5c54bbe3378f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f6b9352f27c4329bd7774ca5b92761f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i194ccf658b8d40dcad4baa33b8140830_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90fc2f64290846f9bd78af8a90169410_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e2da5d082cb42229835e719c252d985_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdb2a33757594e479f11368bdb9206b3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib259775b9b9c44278d3b14fa3bc4487c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec7ebe8c89a545d9a436b69816b227eb_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9eb715cb0da94d3da06eec36cb1cb264_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72eebbb0bfb6442c835ff9de3799eae7_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6858cf3ac89b40e1aa7df89ed53b2a24_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91bd715107e14e01ba109bc345441fd3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99751b578e1948aab49db6044f4428c2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64d27f95511a463b9e9c935f31dfb113_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i259f3776dc6e4cc2a3830d0cb8f9c7c9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i937e6c62ae494af082d55df28a206b08_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4bd41d858f34c15860558f9397212b7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65dfe455b40043c5879a699696671342_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55ca82439e3f4c70b50cc76b61427123_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if30e4595cd6d463086f867a5956e9dc6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8540e99599c44addac72e276711f6cec_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia82be87509cd48adba02800ee6d7620c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d577c6b24e74d95b9308b0abbea21c0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6381f3fa151c4fa79031cfd4c59f3dd1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8cfddbc76454c0a86d25df73ca052b8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i386654d89dcd4305bc2796578a912387_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9301a7535db44e52b62db20ea7d35b36_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26b8aa74725440cfacefcfa508e23b8f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if58fbcaf779342d48308a3b41be27d24_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9dc423e8a1c41408784d828d38bb8af_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c2c4ec32c314b51a25e847eceb0629a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71e36e6ab000490aa878482c47257f1f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i313147cc93cf4996b2b891fed6afd2c8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87c0f954d15f47f997c03b4bbe0a518c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93f25af4132544699f7cc1911016ca93_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ab786f6b9094a30a403c16621efc3b8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0536fa32537e48f3b61cc43f596ef9ef_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf8348b6ab644a16943adf5d6b3b01d1_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10d78353ceec4f248af8e917fdcbaa2c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ae7a2862d6f4d7a954dd9a21f9f83d8_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f765278d59148a1ab87392a73044ec0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bcdc8fb272d48f49898d46b5eed3af6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia14d74e4d29945248008eebccb61e736_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43daee278edf4dd48795e6f8a76b68e6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a1831dadd354b61891c517232e12cb6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92dd2cd839a240b486dff359bb786a00_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a66461de3154691bdf882e2e5dcd6c5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e4dba1228e34cd98a8abd85532d7cb9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac94117f850b41d5b799ede5098093da_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a3f4a74924a4f12a1736df2d0a45713_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee1e914ebc684f0b943cae94c69a0f1a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c2edf2f82884f7b832d7b6ce96cef26_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id934753eb5f84d74951453f74f1c8782_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i513514d73a6d48d88da16ce034ab1bb4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33985b0fd2d14a9dbba59257abcfcfbb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d7ee987153a4b9e864751c124470915_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93d1d7e68d6546828a3bdc6fdcf003c5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48eb072a814e40a1b0c537a5e8d1ed0b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i675913f6b3cc4a0d80c3aedb6ff16277_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1db3a72d8ab94a5290123d21241fdea7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbcdc9fe2df04354bea1a37f7049921b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38d15624d6984f4c8c651151aab177be_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cff6d84193e4dc3b07c75074e60392b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i327e3148cf134e40be0e4c43a80759bb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c4a433674ca4a14a572851571072b9b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa4a290d955f4814b581d6476ee9dc7d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfc26381124441d290073fcf4b193645_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib192c97ab709429e8d8bace98b7c84f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i042fafa9d9b249748a84902a33a8986a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e96426a76854bbeaa9ad9992e1a9dc0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a0edcb9b6dd478a89e87ca1f2ce26eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85fa5ce9fad74f399f8c8d25570c9689_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45edc210ab0745a5aa6286bb72d334b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb589de7e36549c6a8aab0ff0cad6898_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e16bb634cd6409fb8caa8fde1661af6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if24e988586d6451fab56769a5c714496_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55d83c7769d745868fef46644ba31985_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cd5fa1e86444765a02ded926ba518e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1438553a44e74136882a9e6307daa44c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b3656c560c64ebe973f848fc48ad5ad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id36ebdf32a5a4301a2002cf016417bf4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2007efd115d4f399413c5ee0cf7dbee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id29e377b291b419eba3b2d065798ef5c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id75b22a41add4eceb26a8efffed5d602_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife09428d3f97465496a4b2c6bd0ba97f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibeec9606af284a379aa614910d3a61ab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a302b35b1a8429293ae6b864424ecc3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50bcd4c228d24da381ad2f53d3c36667_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i838adf7de26c4611806f98bea73a4138_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec39bddb1fc94428b8d0d9084e2aba6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if09b01b3b49e4c1cb9a520fc3d129aa1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e482a0f02a04e4e9a095186ae75202f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8327b71a4e547faac046ef1de96ead9_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec403174da4d4b6f9ff96570a7e5a8f5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b44ef956ce14264a4103fec3f984838_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf3e46dc35da4ebb90badd8b66929912_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1840bfb02e1b469bbd139ead973986ca_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i809590d3637c40e798f0aed4272f42ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i339317d369b543779f5eb59e6be6a75b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i178bc0d657d34b21aa1fd8fd4e374909_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc8aa7e2c53d4718b1022132994a93ab_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40fb5bdc0f7e47eba46c35d13149ff1a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63e0fd137e3246b38ec39ff427bd5719_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0aa7a0e30fc4971a837f40cff89c0d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia81181d7be0d45bcb4069dea54e60219_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb23404694384f0c8275849d24245f2e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad04ff000fc942258f4e9cf9f39d4fb5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95b7e760966d41e297348550b546a87e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3cb7048a6fa4bb2bc49e5f307bee1ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c65329af5944c1e8409cad224f99d17_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69fa9455e50e46f4af26f9c44e3cb740_I20200220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i662aa5e4c8f94ee688483281db66fe8e_D20200220-20200220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementTrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-20</xbrli:startDate><xbrli:endDate>2020-02-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i517ce1c551384aa19ddce0f3e57a8444_I20200220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementTrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i365110653de64470b9da2fd7e9534eff_I20200220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementTrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i543c3e76e6bb46e1b76eef8fae5afbeb_D20200220-20200220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-20</xbrli:startDate><xbrli:endDate>2020-02-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i125e5025f90d4542857c5e912e248efa_D20200220-20200220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-20</xbrli:startDate><xbrli:endDate>2020-02-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i31de136071f4464fa0afd580b08736c2_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f999a2b8cd8404da746d5c0e0b4fa69_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementTrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="payment"><xbrli:measure>lung:payment</xbrli:measure></xbrli:unit><xbrli:context id="i6f1e6dd7364444de8ff46bdf5cd1eb03_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i484ba17f04d144eb9aee8b4620710100_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementTrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77dd9039bef24911aa020653e86f93f4_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77c3dfcc442f4078a50db735a19d5748_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if05f081a56284af8acd87cd18fcceda5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a6b51ede0b348778de030ce71e1beb5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7679901e2d74b97a73e37442ab74242_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8396a841b0dd4c458e576ad2b5d930b5_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35a8e4b3abcb47d78dd4215a8467d650_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i397678ceafef497b86b6e43ad8ea3a3b_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lung:PulmonxInternationalSarlMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:COVID19CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="chf"><xbrli:measure>iso4217:CHF</xbrli:measure></xbrli:unit><xbrli:context id="ic26de67cef4149c0ad6d575b9330bbf0_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lung:PulmonxInternationalSarlMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:COVID19CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>lung:installment</xbrli:measure></xbrli:unit><xbrli:context id="i70d3599672cd4f2badc8f100594638fe_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lung:PulmonxInternationalSarlMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa8e0cdfe47448be927a5cd420c16bf9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i366bdd6cbcb6417f82564f08de535cb9_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a0e06bbd8104d1395b00aeca775a8d3_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i857cff753eff4ea1888bf30b01ede179_I20131231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd03a7896aaf49d6b9c4280b7685c129_D20130101-20131231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2013-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd1f11aa0462419c94ba74321f470d3a_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc991623af8d40e28c3edf61bacb8247_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0aef2c60dfff4d2db3ecc2c60e4ab869_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lease"><xbrli:measure>lung:lease</xbrli:measure></xbrli:unit><xbrli:context id="ied7db64668494d679f77a1d8d708db3b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc840713d1034829bc01ad7b74a40d23_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">lung:ServiceAgreementPurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25ca1d294bfa44ee92ff709c2ea930e0_D20220501-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">lung:ServiceAgreementPurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>lung:vote</xbrli:measure></xbrli:unit><xbrli:context id="i784f45acac5747a384b861bd3aabc902_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lung:ShareBasedCompensationEmployeeStockOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide3a7a3105f148a0abc9848ed7ec1d00_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lung:ShareBasedCompensationEmployeeStockOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22f7f50179034850b9053aba0a68231a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lung:CommonStockRestrictedStockUnitsIssuedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaba5025a1e5243a2b17b2e5661ec7f35_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lung:CommonStockRestrictedStockUnitsIssuedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i714b2da3efed4e42a97fe4d4b6b47a99_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lung:ShareBasedCompensationEmployeeStockAvailableForGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e39fbc0a48a47e2a202f2c8f30f4b79_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lung:ShareBasedCompensationEmployeeStockAvailableForGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1275d322af1b4c98ba3c7706239395c7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaa47ca5f34841d0a65dd43f53a08359_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieaf5f38983f147c5b391b683b2a5d265_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7b4e5d4bcbd4d4186b94f94cf2b2e0d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id02f38cc7de8443687c4dbf744ee7d4a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib214e6ee760c4adcbb895883d757b122_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91b890405bde48749a209fc48ed3fd13_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i883a9ab8eaca4207ba3cadcb80ef8eda_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b981dc82dd04a02bb8a9147b2a333de_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i114ea887bbd14b4a95901ff225d7572e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51ff2e29588048e09a217bf20a23f15e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i405811c8a7064e599bb9622e46610a53_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58118a88d93b4eb694a8bc9332e744f5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9b029b9144a4e10b3a37d170bf1098c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ed501dd475d4cf48aa805abbe19f088_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08e66e05527d4ffd827c77748a29ae59_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dfbc2d6814744a0ad594767a7b3921c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia73aa5beaf714619a089f8546ba50e49_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id37e4fe079bc43a8b78bc7d2ed7d7f5a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27f5ea6853044003b5d3fe259686cfed_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lung:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4b62e5c7e4d41e599a13d60481720d5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lung:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6ad1ceb870840e0aff0a566353c7eca_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lung:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1fb7c022d3f4c5a8ce371332cda0d8e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lung:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34dd8820c0384b9f99643fd8282fcfed_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18e4908c4d83487a804ab3bb691cfdfd_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5532b33c0264e07931c620be5ee4fdb_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i913beb06228a48059034fdbd19194be1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie13307b791954390abb618142b11755f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">lung:InventoryNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac319f186e3c4549bf1291d73e9ef0c2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">lung:InventoryNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50d7120120ae48429357a6f238139dcd_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">lung:InventoryNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53b7b623056a4e2eb2ea7a0f65fc71e9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">lung:InventoryNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee27527c02e7424fb0b8f40670bc3dae_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">lung:CostOfGoodsAndServicesSoldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa0cb1b19d894f169cd980e74653f9fb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">lung:CostOfGoodsAndServicesSoldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77bf9d3e0a0b48409b6cb9f129526c9c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">lung:CostOfGoodsAndServicesSoldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife4a8ff7e8fb4ffe9f2b64e74d5e97cf_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">lung:CostOfGoodsAndServicesSoldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00e81a622be642048db364ba63b6897c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lung:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b60336143e4446eab2f9aef31e69da0_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8534ceb95304df4a061131854586927_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i493a546e223e4e349b281de37224fec9_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88dc40bd83d7401a9672d7d2df0cbd44_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaa76627fc8f47fca67ba3fd4f6b2423_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lung:ShareBasedCompensationUnvestedEarlyExercisedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c2550a59e904c9fa8983370b3a88d6d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lung:ShareBasedCompensationUnvestedEarlyExercisedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04828ea9cac9458c9dc603bf1c75ae3e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd4dd78630cd4ade8407c6236aa12b7d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>lung:segment</xbrli:measure></xbrli:unit><xbrli:context id="ie1359c30612540db9f7d34a1c01b3ad0_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76aa19c427d84d68b1168f403a4d9cf0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i289c4b693d0f4b78a133aca081e4ec62_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dbda9b7680c4fbbb2d796862b9cc528_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60c47462ac8c42278751a5e88cebb16c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9f15921237f4455b73e6cc819e646c3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80d96e293cf64c4a8bc6f7a1a5311f2e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic858ed7791a6420b80be0581b72d5fe2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95b08bdad4d14d5ebf4d2815ee5d2afa_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6331c9bd120d452f9dbc7f5077c0b308_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58327cae2f9545909843bc0298fc7738_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide14511124ea4c19b7d0d17cf44f7565_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf783eb979ba4c2990809ef7ba464ec1_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lung:OtherInternationalGeographicalAreasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88d9fce60fb74d2b9219ae5f5695bac4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lung:OtherInternationalGeographicalAreasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2da15985d8f46c7813cfdff913a5506_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lung:OtherInternationalGeographicalAreasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b0e39f7311c4c8dafe667c0cc5deee3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lung:OtherInternationalGeographicalAreasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92b67fa545b64980b9a2e36077a0e919_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39dcbe49829e478bae65bf4ad7ebe73b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie37b898ed5f549b6a2584d0735ebc6a8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff16a3996ed74e9185638c285d8180e7_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id116f3f4ef654103a4a17291f98e96cd_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14ce772deb444cdc87b44503d5d9c1d5_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia90e44e3c9a34436a33d109bdf77b945_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i800d29a3bc944cd193e54a8b9a0f6afb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fe4d5c850434aa89e016828fdf266ed_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5796864d445f4298b6b97e81ee3b2e14_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5926e07811564c14a1a7947cce7b6f48_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d545a4cc5594760b939659357af4982_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2011b63fd9c4fd7bbc64ec2a1f0ca7a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74632ce2458d45f882a429075d1c2a21_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001127537</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i784ba2f3210d43dcbb23721a3c553397_1"></div><div style="min-height:27pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:0.25pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8yMDU4_cd540b55-ea98-49ba-a963-8e6928e95cb2">10-Q</ix:nonNumeric></span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:6.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.987%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGFibGU6OGJlNTFmNDU0NmFkNDQwZDhkYzg2MjI3NGRhODcxYmUvdGFibGVyYW5nZTo4YmU1MWY0NTQ2YWQ0NDBkOGRjODYyMjc0ZGE4NzFiZV8wLTAtMS0xLTM5Mzgz_ab325400-f284-4882-8fc6-92badd248afc">☒</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8xMjY_a17a1b9a-9772-4cb6-bd31-3d45d286186b">June 30, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:6.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.987%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGFibGU6NTBiOGZkNTUxNTIyNDE1MWFjMmZlMDRmZGJkNTQyNDAvdGFibGVyYW5nZTo1MGI4ZmQ1NTE1MjI0MTUxYWMyZmUwNGZkYmQ1NDI0MF8wLTAtMS0xLTM5Mzgz_327f98fc-67c7-4d02-8075-096b91c84255">☐</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from        to</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8yMDQ2_ddc36137-1fe2-4991-b4cd-d939bb72d929">001-39562</ix:nonNumeric></span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8yMDU5_124d5aab-0752-4d4b-b446-14062f0f586b">PULMONX CORPORATION</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGFibGU6YzEwYTBmYWI4YmE1NDZjNzhhNzgxNjhkMzg4Y2U1YjQvdGFibGVyYW5nZTpjMTBhMGZhYjhiYTU0NmM3OGE3ODE2OGQzODhjZTViNF8xLTAtMS0xLTM5Mzgz_2c2929d0-5214-4bd8-82fd-d2f1c3e2ce1a">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGFibGU6YzEwYTBmYWI4YmE1NDZjNzhhNzgxNjhkMzg4Y2U1YjQvdGFibGVyYW5nZTpjMTBhMGZhYjhiYTU0NmM3OGE3ODE2OGQzODhjZTViNF8xLTItMS0xLTM5Mzgz_54a97625-fc32-4bd5-8d5e-7e84026be970">77-0424412</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification Number)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8yMDUz_f44001a5-55bb-48aa-a0d6-149196e7d1e3">700 Chesapeake Drive</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8yMDQ4_b743fb74-99dd-412d-aa6b-04dfb2ae7457">Redwood City</ix:nonNumeric>, <ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8yMDYw_b38c17c3-476f-438f-bc5d-22a481e3b228">California</ix:nonNumeric> <ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8yMDYx_8aa4b98a-c7b5-4000-899d-49e2d71720c1">94063</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:CountryRegion" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8yMDUy_cbc7a1f8-c4c6-46e8-9515-f4a696337a0d">1</ix:nonNumeric>-<ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8yMDUw_3a41243c-0f9c-4ce7-aec2-5ac8bf5b464c">650</ix:nonNumeric>-<ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8yMDYy_23b54d73-9bc3-4ee4-bc18-345e5997be42">364-0400</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:37.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.735%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGFibGU6Y2Q4ZWU2YTZkYjA0NDNmOWE3Y2I1ZmQ3MmM3MzI2OWQvdGFibGVyYW5nZTpjZDhlZTZhNmRiMDQ0M2Y5YTdjYjVmZDcyYzczMjY5ZF8xLTAtMS0xLTM5Mzgz_930c8953-b762-425a-8d4f-0cb30b612e54">Common Stock, $0.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGFibGU6Y2Q4ZWU2YTZkYjA0NDNmOWE3Y2I1ZmQ3MmM3MzI2OWQvdGFibGVyYW5nZTpjZDhlZTZhNmRiMDQ0M2Y5YTdjYjVmZDcyYzczMjY5ZF8xLTEtMS0xLTM5Mzgz_258e0458-e795-4648-afd0-3719584a230e">LUNG</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGFibGU6Y2Q4ZWU2YTZkYjA0NDNmOWE3Y2I1ZmQ3MmM3MzI2OWQvdGFibGVyYW5nZTpjZDhlZTZhNmRiMDQ0M2Y5YTdjYjVmZDcyYzczMjY5ZF8xLTItMS0xLTM5Mzgz_49552f6b-6092-4918-86ec-fda7afe353f2">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ <ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8yMDYz_3dd0b64d-cc1d-460a-b3a1-91d54c4d181f">Yes</ix:nonNumeric> ☐ No</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ <ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8yMDU2_d7f3b9ac-56e4-443a-9f3f-6d15714f2d65">Yes</ix:nonNumeric> ☐ No</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.545%"><tr><td style="width:1.0%"></td><td style="width:19.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGFibGU6YTYzZTRhMmU3YmNiNGNiNWIwYWU2ZmM2ZjlkNTdmYWQvdGFibGVyYW5nZTphNjNlNGEyZTdiY2I0Y2I1YjBhZTZmYzZmOWQ1N2ZhZF8wLTAtMS0xLTQxNTgx_296daf4e-3bcb-4d91-aeb1-210cc44d202f">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">☒</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">☐</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">☐</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGFibGU6YTYzZTRhMmU3YmNiNGNiNWIwYWU2ZmM2ZjlkNTdmYWQvdGFibGVyYW5nZTphNjNlNGEyZTdiY2I0Y2I1YjBhZTZmYzZmOWQ1N2ZhZF8xLTQtMS0xLTM5Mzgz_4375e7af-c015-432e-bcb7-96ad523152d9">☒</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGFibGU6YTYzZTRhMmU3YmNiNGNiNWIwYWU2ZmM2ZjlkNTdmYWQvdGFibGVyYW5nZTphNjNlNGEyZTdiY2I0Y2I1YjBhZTZmYzZmOWQ1N2ZhZF8yLTQtMS0xLTM5Mzgz_8276e383-f787-4fda-b2e8-00e534c94594">☐</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes <ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8xMjA5NDYyNzkwNzY1MQ_2094f1bc-5ac3-4033-a237-46a58c52a0e7">☒</ix:nonNumeric> No</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of July 29, 2022 there were <ix:nonFraction unitRef="shares" contextRef="i13c4ccdef36a4923ac2f86f39c238d7f_I20220729" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8xOTYy_fb332fad-fbff-4815-b406-43c0542797a2">37,268,450</ix:nonFraction> shares of the Registrant’s Common Stock, par value $0.001 per share, outstanding.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div></div><div id="i784ba2f3210d43dcbb23721a3c553397_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_13">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_16">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_19">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_19">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_22">Condensed Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_22">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_25">Condensed Consolidated Statements of Stockholders’ Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_25">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_28">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_28">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_31">Notes to Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_31">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_82">Management’s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_82">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_115">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_115">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_118">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_118">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_121">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_121">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_124">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_124">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_127">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_127">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_130">Unregistered Sales of Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_130">101</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_133">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_133">101</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_136">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_136">101</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_139">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_139">101</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_142">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_142">101</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_145">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_145">103</a></span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i784ba2f3210d43dcbb23721a3c553397_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial condition, business strategy, plans, and objectives of management for future operations and statements that are necessarily dependent upon future events are forward-looking statements. In some cases, you can identify forward-looking statements by words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “target,” “should,” “will,” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of known and unknown risks, uncertainties, and assumptions, including risks described in the section entitled “Risk Factors.” These risks are not exhaustive. Other sections of this Quarterly Report on Form 10-Q include additional factors that could harm our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in, or implied by, any forward-looking statements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely on these forward-looking statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Quarterly Report on Form 10-Q or to conform these statements to actual results or to changes in our expectations, whether as a result of any new information, future events, changed circumstances or otherwise. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to design, develop, manufacture and market innovative products to treat patients with challenging medical conditions, particularly those with severe chronic obstructive pulmonary disease (“COPD”) and emphysema;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the impact of the COVID-19 pandemic on our business; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expected future growth, including growth in international sales;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expected future growth of our sales and marketing organization;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and growth potential of the markets for our products, and our ability to serve those markets;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance of our products;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">coverage and reimbursement for procedures performed using our products;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the performance of third parties in connection with the development of our products, including third-party suppliers;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the United States and foreign countries;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to research, develop and commercialize our products and any other approved or cleared product;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to retain and hire our senior management and other highly qualified personnel;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the development, regulatory approval, efficacy and commercialization of competing products and technologies in our industry;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop and maintain our corporate infrastructure, including an effective system of internal controls and the remediation of any material weaknesses thereunder;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance and capital requirements; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding our ability to obtain and maintain intellectual property protection for our products, as well as our ability to operate our business without infringing the intellectual property rights of others.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed as exhibits to this report with the understanding that our actual future results, levels of activity, performance and achievements may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">All brand names or trademarks appearing in this Quarterly Report on Form 10-Q are the property of their respective holders. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to “Pulmonx” the “Company,” “we,” “us,” and “our” refer to Pulmonx Corporation.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><div id="i784ba2f3210d43dcbb23721a3c553397_13"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part I. Financial Information</span></div><div id="i784ba2f3210d43dcbb23721a3c553397_16"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements</span></div><div id="i784ba2f3210d43dcbb23721a3c553397_19"></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pulmonx Corporation</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"><tr><td style="width:1.0%"></td><td style="width:72.114%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.049%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfNC0xLTEtMS0zOTM4Mw_ca655d49-0329-4b4b-9392-b85559887da6">121,947</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfNC0zLTEtMS0zOTM4Mw_e38b1063-be23-4300-a1ed-7f0a8efc75d2">148,480</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfNS0xLTEtMS0zOTM4Mw_4ec3f7a6-0097-456c-a700-7770e2ef0e27">231</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfNS0zLTEtMS0zOTM4Mw_32ba07f5-603d-44fd-be23-97e3a139534d">231</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfNi0xLTEtMS0zOTM4Mw_340a4776-b78c-4b08-83b5-b75ede7deaaa">40,139</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfNi0zLTEtMS0zOTM4Mw_ff888272-5b83-472b-8790-e8f620744de7">31,561</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfNy0xLTEtMS0zOTM4Mw_526eaa12-8710-4d81-8216-470c6f1c8e04">7,521</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfNy0zLTEtMS0zOTM4Mw_bdcf657a-35cd-4db3-b7c1-427e7b447c3a">6,562</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfOC0xLTEtMS0zOTM4Mw_5229570f-38fb-48ed-bd7d-d54a8158cf5b">19,212</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfOC0zLTEtMS0zOTM4Mw_9575d66a-64be-4f1b-bda2-e8e7e33bf441">16,285</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfOS0xLTEtMS0zOTM4Mw_ffb500ab-2ac5-4a67-aaa9-eca5b5d940d6">3,731</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfOS0zLTEtMS0zOTM4Mw_9b4f7a33-9c50-448f-8125-7a79a72a2204">4,883</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTAtMS0xLTEtMzkzODM_5e9d7606-dc22-4eba-adbc-b2b8feeed902">192,781</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTAtMy0xLTEtMzkzODM_45fddbd4-34ce-46cc-89a4-e615235b090d">208,002</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTEtMS0xLTEtMzkzODM_208cab8d-2a8a-42c1-be00-28c566117e0f">4,684</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTEtMy0xLTEtMzkzODM_dcb69c1c-da47-4b3d-886b-9be137cc6ddb">10,941</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTItMS0xLTEtMzkzODM_c5d606b6-2842-4973-acdd-53c079813c5b">4,932</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTItMy0xLTEtMzkzODM_b17b376e-0387-4cb0-9ecf-1f39fdd727d6">4,814</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTMtMS0xLTEtMzkzODM_26bfdd6e-69e3-41aa-912a-c2e6a6654dd0">2,333</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTMtMy0xLTEtMzkzODM_180f65ca-d586-46fc-a8e0-3337920e52e9">2,333</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTQtMS0xLTEtMzkzODM_11e71908-b5d3-4fb5-8757-9f770a72d1ee">216</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTQtMy0xLTEtMzkzODM_6cebf19c-a6df-4320-8283-b1f869b01045">277</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTUtMS0xLTEtMzkzODM_8f133f09-1b09-4896-ba95-9aab599d8093">6,987</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTUtMy0xLTEtMzkzODM_8e662c2c-6e49-407d-bc7f-a6161f109be4">8,075</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTYtMS0xLTEtMzkzODM_f47c0472-fbd5-4b31-a4a0-5d4f69b380cc">796</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTYtMy0xLTEtMzkzODM_8bec0d26-e7df-4b14-a3b5-1d7ddd8085f2">731</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTctMS0xLTEtMzkzODM_204e7168-e56b-489e-b809-bceea10bd672">212,729</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTctMy0xLTEtMzkzODM_3afe376d-d455-42e5-b621-1068f474e947">235,173</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders’ Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjEtMS0xLTEtMzkzODM_d3bd33dc-c8dc-46ce-a36e-a01024dd2d86">2,599</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjEtMy0xLTEtMzkzODM_620bf6ff-039c-4483-9c4e-fc5babf53d5f">1,582</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjItMS0xLTEtMzkzODM_2ea98760-6ab5-4658-a8b6-8f570bc3eebd">11,734</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjItMy0xLTEtMzkzODM_47b03635-efdc-4156-a47a-cc87cdde73e5">13,366</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjMtMS0xLTEtMzkzODM_099caeb6-6577-4c63-ab6d-524b8337a1dd">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjMtMy0xLTEtMzkzODM_007f1614-2ce5-4222-8d2b-00caa0599d82">147</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjQtMS0xLTEtMzkzODM_bdd725c6-79b4-4e28-8446-ed06ed28470b">131</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjQtMy0xLTEtMzkzODM_478f705e-d97c-4f67-bd70-ce72d5ccdf88">163</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjUtMS0xLTEtMzkzODM_9d4ca4f5-1457-479b-8466-da1882c7e176">2,921</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:ShortTermBorrowings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjUtMy0xLTEtMzkzODM_baad15dd-cecf-4d15-a614-717df19fcb47">91</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjYtMS0xLTEtMzkzODM_01982077-c42f-46c7-87f4-c07fc23b42fe">3,061</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjYtMy0xLTEtMzkzODM_a6164455-2903-482d-90ff-13bc3686cea3">2,201</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjctMS0xLTEtMzkzODM_3f5818d5-a3f1-438b-93db-1167cf3753f9">20,446</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjctMy0xLTEtMzkzODM_7b7b959d-4d4e-4ed5-a1c9-be8543b680c2">17,550</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjgtMS0xLTEtMzkzODM_36d6e0ca-0c61-4ad0-81a7-eacc7ed6c002">47</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjgtMy0xLTEtMzkzODM_0457a91d-d4a2-46cc-b747-24ba9adbb935">37</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjktMS0xLTEtMzkzODM_87076136-2155-4983-b203-dd650d9f8af4">5,415</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjktMy0xLTEtMzkzODM_defbd06c-8dab-4e7d-86a4-353bc87e7815">6,844</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzAtMS0xLTEtMzkzODM_5842a6a4-01cb-40d3-bf80-bee3dcbea69b">14,460</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzAtMy0xLTEtMzkzODM_dcd0c6f7-dca3-4daf-8a13-79dc1f1a2074">17,324</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzEtMS0xLTEtMzkzODM_e60b1ee3-d68a-4b06-974b-066408827a1d">179</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzEtMy0xLTEtMzkzODM_50512954-ab15-43f5-a6d9-8318794461b2">179</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzItMS0xLTEtMzkzODM_a25062bb-cd37-4a3d-aafd-c9af5fd239aa">40,547</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzItMy0xLTEtMzkzODM_e875eac6-0cc6-4f97-b163-c9e5ae63277c">41,934</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 8)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzMtMS0xLTEtMzkzODM_1fcab47d-e44e-4b08-a2db-05883c108ca1"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzMtMy0xLTEtMzkzODM_60658fb0-1124-4879-8c63-f8152f4ae17f"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders’ equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"><tr><td style="width:1.0%"></td><td style="width:72.114%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.049%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzUtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjMzNiYjEwNjE1YmQ0NGZhOTg1YmYwZGRkZDUzNTg1NF8yMQ_66436922-1a1a-4f2c-b762-1bbe2055fce1"><ix:nonFraction unitRef="usdPerShare" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzUtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjMzNiYjEwNjE1YmQ0NGZhOTg1YmYwZGRkZDUzNTg1NF8yMQ_cd99bbdd-ee1c-42a4-a9eb-c7888a29d8d1">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzUtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjMzNiYjEwNjE1YmQ0NGZhOTg1YmYwZGRkZDUzNTg1NF8zNQ_2ddf76dc-d865-474a-a235-6dcd7843d28f"><ix:nonFraction unitRef="shares" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzUtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjMzNiYjEwNjE1YmQ0NGZhOTg1YmYwZGRkZDUzNTg1NF8zNQ_baf6bc24-de69-4420-b3e8-41e82adb653a">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzUtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjMzNiYjEwNjE1YmQ0NGZhOTg1YmYwZGRkZDUzNTg1NF81Nw_04433138-9565-446e-aedd-b04e4aa832c0"><ix:nonFraction unitRef="shares" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzUtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjMzNiYjEwNjE1YmQ0NGZhOTg1YmYwZGRkZDUzNTg1NF81Nw_3395dfd0-07da-44b5-b1ba-c109629c97a1"><ix:nonFraction unitRef="shares" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzUtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjMzNiYjEwNjE1YmQ0NGZhOTg1YmYwZGRkZDUzNTg1NF81Nw_8a0f62c2-3d6f-42ce-b2e5-07e70787fb17"><ix:nonFraction unitRef="shares" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzUtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjMzNiYjEwNjE1YmQ0NGZhOTg1YmYwZGRkZDUzNTg1NF81Nw_cc2c6b07-bb0a-48db-8bfa-d1b02bbe7e05">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June 30, 2022 and December 31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzUtMS0xLTEtMzkzODM_9f71c4f0-b15b-4f78-8321-46f5a08e404a">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzUtMy0xLTEtMzkzODM_8872d57e-c68c-4b12-8958-b656aad883f9">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzYtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjYjQ0OTE0ZmZkMDA0Y2Y2YmNjMzM5Y2E0MGFkYjkyMF8xNjQ5MjY3NDQxOTA4_67ce159b-ddfe-40e3-b96b-9922ec3958db"><ix:nonFraction unitRef="usdPerShare" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzYtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjYjQ0OTE0ZmZkMDA0Y2Y2YmNjMzM5Y2E0MGFkYjkyMF8xNjQ5MjY3NDQxOTA4_6b42299c-6210-4be0-a70d-b9d68c32c501">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzYtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjYjQ0OTE0ZmZkMDA0Y2Y2YmNjMzM5Y2E0MGFkYjkyMF8xNjQ5MjY3NDQxOTIy_12cde9a3-a5bb-4deb-b3a4-fcb4927bd624"><ix:nonFraction unitRef="shares" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzYtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjYjQ0OTE0ZmZkMDA0Y2Y2YmNjMzM5Y2E0MGFkYjkyMF8xNjQ5MjY3NDQxOTIy_9a5d2434-1c2a-4b80-892f-bfb84af74bfd">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of June 30, 2022 and December 31, 2021; <ix:nonFraction unitRef="shares" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzYtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjYjQ0OTE0ZmZkMDA0Y2Y2YmNjMzM5Y2E0MGFkYjkyMF8xNjQ5MjY3NDQxOTM1_5e9a73a3-2524-49dc-ac0f-c52bd3fe0383"><ix:nonFraction unitRef="shares" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzYtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjYjQ0OTE0ZmZkMDA0Y2Y2YmNjMzM5Y2E0MGFkYjkyMF8xNjQ5MjY3NDQxOTM1_bf029d27-77e1-4ee2-9b49-4c9995767ea1">37,266,030</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June 30, 2022 and <ix:nonFraction unitRef="shares" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzYtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjYjQ0OTE0ZmZkMDA0Y2Y2YmNjMzM5Y2E0MGFkYjkyMF8xNjQ5MjY3NDQxOTQ4_4d952d45-c0ca-49ec-95cc-c592328c6d5e"><ix:nonFraction unitRef="shares" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzYtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjYjQ0OTE0ZmZkMDA0Y2Y2YmNjMzM5Y2E0MGFkYjkyMF8xNjQ5MjY3NDQxOTQ4_b6b738bf-31ee-4749-92da-db07e24babd5">36,931,762</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzYtMS0xLTEtMzkzODM_1dd709e2-6b46-49e5-8744-0ba7d526e822">37</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzYtMy0xLTEtMzkzODM_52b16cc3-77e2-45f1-92fe-c02d66687718">37</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzctMS0xLTEtMzkzODM_8f8a8e9a-d843-49de-9a1f-9e452c2e83e7">492,651</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzctMy0xLTEtMzkzODM_b749ff6e-8015-486e-bf32-c17c73916669">482,885</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzgtMS0xLTEtMzkzODM_8ff78d4c-520b-4726-94ec-75821a911cac">1,357</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzgtMy0xLTEtMzkzODM_ffa6c870-7b42-48ed-8ba2-e1fcfa749952">1,712</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzktMS0xLTEtMzkzODM_be74fe0e-61b1-492a-bad0-8d71b9401333">321,863</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzktMy0xLTEtMzkzODM_df173d92-5bc7-4044-9bd4-54e8db366b28">291,395</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders’ equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfNDAtMS0xLTEtMzkzODM_cebb5806-d465-4e38-9ae7-6b5ee13c9107">172,182</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfNDAtMy0xLTEtMzkzODM_4bf38458-3c0a-4405-9b76-e383fb9209a4">193,239</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders’ equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfNDEtMS0xLTEtMzkzODM_60de5e64-63c9-4d9c-b797-907a89083397">212,729</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfNDEtMy0xLTEtMzkzODM_c212e30f-b07a-419c-b5b6-08bae3b82ab7">235,173</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i784ba2f3210d43dcbb23721a3c553397_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pulmonx Corporation</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMi0xLTEtMS0zOTM4Mw_fd43648a-d568-4a76-9921-137fa36dfecc">13,950</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMi0zLTEtMS0zOTM4Mw_893e56c2-b513-4549-9fe1-44c08028ac65">12,203</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMi01LTEtMS0zOTM4Mw_b5dcab7c-e859-4a7b-b143-54b8c8baf401">24,735</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMi03LTEtMS0zOTM4Mw_6683842a-57c9-4e54-81a1-726e8c9ce5c3">21,447</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMy0xLTEtMS0zOTM4Mw_82f02f00-eb4b-40b2-8151-cee30a125d2a">3,532</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMy0zLTEtMS0zOTM4Mw_78d18683-1b61-4e9a-a693-52de7e57f6fc">3,174</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMy01LTEtMS0zOTM4Mw_28c3a010-04cf-4ccc-932c-215b688b9c90">6,206</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMy03LTEtMS0zOTM4Mw_33b4bdd3-f593-479b-9f39-b725e3d09234">5,807</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfNC0xLTEtMS0zOTM4Mw_0a543788-637b-4e58-b109-5e64eff7b860">10,418</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfNC0zLTEtMS0zOTM4Mw_f8d1cfca-3bb9-40b8-acfe-d64002ce69b3">9,029</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfNC01LTEtMS0zOTM4Mw_dbe20fc9-cbf2-4541-951c-37ac066a2dfd">18,529</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfNC03LTEtMS0zOTM4Mw_929e37f1-6cab-4e6a-b92a-7f1510533e0c">15,640</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfNi0xLTEtMS0zOTM4Mw_ba22bead-4c73-4a46-99eb-6bfef410fdf3">3,594</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfNi0zLTEtMS0zOTM4Mw_2f8a178f-7b90-421e-af89-bc2a2f4d9987">3,506</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfNi01LTEtMS0zOTM4Mw_759bfd0d-ad1f-4902-8535-fc057873c73c">7,128</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfNi03LTEtMS0zOTM4Mw_fa3653d3-ae2d-4d1f-8fa1-fddad18ec8b2">6,540</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfNy0xLTEtMS0zOTM4Mw_d8192ce8-694b-4932-857f-39a043dce2d0">21,235</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfNy0zLTEtMS0zOTM4Mw_bae72cf3-11bb-4b4d-b3be-b0426b34e0c8">18,205</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfNy01LTEtMS0zOTM4Mw_2971851b-6c3e-44eb-9615-7fe0eb7d9a89">41,480</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfNy03LTEtMS0zOTM4Mw_3dec3c36-b7e7-4e49-9e49-4af5eca7cd17">34,276</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfOC0xLTEtMS0zOTM4Mw_9bff6479-72fa-4fd5-b3ca-9bbcd2491f78">24,829</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfOC0zLTEtMS0zOTM4Mw_5b0a503b-4756-41d0-ab64-addf35bd1e62">21,711</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfOC01LTEtMS0zOTM4Mw_8631fd85-1bc5-4f5a-8374-042f8b152c56">48,608</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfOC03LTEtMS0zOTM4Mw_b2a7fb38-d459-4de5-a4aa-7ff592a06d6d">40,816</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfOS0xLTEtMS0zOTM4Mw_d2b2c109-cdd6-4216-9ff3-289e07d387c4">14,411</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfOS0zLTEtMS0zOTM4Mw_006b2c63-13a2-4e5a-b37a-6b4674a3ea78">12,682</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfOS01LTEtMS0zOTM4Mw_d29616e1-1b59-4802-9812-57036d706180">30,079</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfOS03LTEtMS0zOTM4Mw_e91c796e-a8da-4f6c-a43e-732901a4e3c6">25,176</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTAtMS0xLTEtMzkzODM_94dca236-4e4b-47be-8743-6764203843b2">199</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTAtMy0xLTEtMzkzODM_3040c917-537b-46af-ab26-f5a79395fe0d">102</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTAtNS0xLTEtMzkzODM_dfaca4d9-ddc5-46c6-85f0-39756bc571cd">304</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTAtNy0xLTEtMzkzODM_dbf0b965-c7b5-4416-abfb-ce0cb79f70d5">207</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTEtMS0xLTEtMzkzODM_3cb2c77b-1755-4539-97a0-ee8728dcc0fa">223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTEtMy0xLTEtMzkzODM_31545c95-1927-40b3-b2cf-014c5f6d5339">206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTEtNS0xLTEtMzkzODM_048b9000-2ca0-4e51-81bf-5c863bef43a4">421</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTEtNy0xLTEtMzkzODM_336f7538-5b66-470e-b143-ec607e18215f">423</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTItMS0xLTEtMzkzODM_f9c2f791-240d-4f39-a9eb-7fc0fab1f78b">165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTItMy0xLTEtMzkzODM_4392614e-f900-4103-8688-689813147459">96</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTItNS0xLTEtMzkzODM_47686a91-511f-415f-aba4-a36443fa43d7">165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTItNy0xLTEtMzkzODM_3c1b80c4-9d37-42ff-804b-4ade4dabd9e6">65</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTMtMS0xLTEtMzkzODM_80374340-027b-42ff-a89c-9171fd0e083c">14,600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTMtMy0xLTEtMzkzODM_fc9751e5-e236-4e53-b858-2292bfa16513">12,882</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTMtNS0xLTEtMzkzODM_acc67732-4bd4-4dfa-8699-1372ed5b7cf3">30,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTMtNy0xLTEtMzkzODM_2d9b6d25-aabd-4c3e-b2ea-cb53c9222e94">25,327</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTQtMS0xLTEtMzkzODM_08a781d9-a851-4704-9db5-d04418868277">40</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTQtMy0xLTEtMzkzODM_e982e621-4f0d-41a4-b7e3-0c1e0d23887d">80</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTQtNS0xLTEtMzkzODM_a7556ed4-736a-4067-819c-d05205022653">107</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTQtNy0xLTEtMzkzODM_fd396c75-789d-4361-ac0d-dabe967c9e8a">147</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTUtMS0xLTEtMzkzODM_5bbad26d-609d-45a8-84f2-5e43cef0565d">14,640</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTUtMy0xLTEtMzkzODM_5c696de7-bdd7-46a0-851b-9978d3594579">12,962</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTUtNS0xLTEtMzkzODM_3fcb00ad-bc1a-4266-a822-dcc54769d901">30,468</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTUtNy0xLTEtMzkzODM_48db93d0-d1a5-4c08-90df-d4bfc483cf6a">25,474</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTctMS0xLTEtMzkzODM_95622538-7a7b-4612-af0a-459b9bc25aa1">6</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTctMy0xLTEtMzkzODM_73346061-46fb-4fe9-a464-bb759b3ebbeb">66</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTctNS0xLTEtMzkzODM_238e090a-ede1-4bc8-b9c1-07eb305714ed">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTctNy0xLTEtMzkzODM_866ae9c2-2c55-404a-9e32-cf47d3bf5601">206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unrealized gain (loss) on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTgtMS0xLTEtMzkzODM_14a03607-8189-414e-a465-00bf59ef3aad">92</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTgtMy0xLTEtMzkzODM_f2e56044-48b6-4d01-bdc1-0ebbec09ec79">3</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTgtNS0xLTEtMzkzODM_aba9ecb8-e6ab-4bd5-8c44-89a602121886">337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTgtNy0xLTEtMzkzODM_58338394-3887-48e8-baec-7ff2fff193ab">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTktMS0xLTEtMzkzODM_c8a5f587-09b9-41e3-8673-9164ba6ecc70">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTktMy0xLTEtMzkzODM_f7838a30-1886-40d6-9fb4-b06a1b4c72c2">69</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTktNS0xLTEtMzkzODM_61ddd2fa-5a0d-4bc9-aa13-7be5e3048880">355</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTktNy0xLTEtMzkzODM_49c238cf-0c5e-49dc-893b-16919fe6ba60">206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjAtMS0xLTEtMzkzODM_0c8666d2-2583-445d-9923-06d856a06f81">14,726</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjAtMy0xLTEtMzkzODM_54bacd86-d6d5-45ee-88bc-489cd5bb0c98">12,893</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjAtNS0xLTEtMzkzODM_e01754f6-baaa-4c58-a423-640a4754ea2c">30,823</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjAtNy0xLTEtMzkzODM_a8ac0f73-319f-4920-bec8-71d4cb9d7ac1">25,680</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders, basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjEtMS0xLTEtMzkzODM_8ea0300b-f355-45d3-b9ea-b0078e465415"><ix:nonFraction unitRef="usdPerShare" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjEtMS0xLTEtMzkzODM_bc08b91b-e263-48b0-8876-8b658f0ad83a">0.40</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjEtMy0xLTEtMzkzODM_94c2871d-e2ef-4e3f-8281-468e68668650"><ix:nonFraction unitRef="usdPerShare" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjEtMy0xLTEtMzkzODM_e07f1e5f-2021-4cd5-b3a1-16cceb9b08ba">0.36</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjEtNS0xLTEtMzkzODM_5da0a3e7-88b5-4d19-9080-5bd711e520fb"><ix:nonFraction unitRef="usdPerShare" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjEtNS0xLTEtMzkzODM_97ffffdb-a71d-4137-90d7-b0db784f2bfa">0.83</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjEtNy0xLTEtMzkzODM_42cc7c7a-f7d2-4a40-82d4-5da510704000"><ix:nonFraction unitRef="usdPerShare" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjEtNy0xLTEtMzkzODM_6f308815-15ae-4258-913a-7a1cfd5edfbe">0.71</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjItMS0xLTEtMzkzODM_133e299e-0de6-4c04-bf59-e426bdc6e465"><ix:nonFraction unitRef="shares" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjItMS0xLTEtMzkzODM_84653b4f-29b0-403b-a3f3-cafe38accf2c">37,003,443</ix:nonFraction></ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjItMy0xLTEtMzkzODM_26ba52f7-fd5e-4e71-9dd3-1152a9e89adc"><ix:nonFraction unitRef="shares" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjItMy0xLTEtMzkzODM_33655c27-7e76-4dc4-b8f9-5e5da3b98f64">36,042,614</ix:nonFraction></ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjItNS0xLTEtMzkzODM_74d11cca-c0b4-45d0-a53e-edc6492b05c3"><ix:nonFraction unitRef="shares" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjItNS0xLTEtMzkzODM_a9702e8b-1cf6-43a0-abe0-935737d9fc93">36,904,952</ix:nonFraction></ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjItNy0xLTEtMzkzODM_481eb5e1-23fb-479a-87c3-df33268108b3"><ix:nonFraction unitRef="shares" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjItNy0xLTEtMzkzODM_b7339be8-211c-4657-af2f-2f21a017f74c">35,708,548</ix:nonFraction></ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i784ba2f3210d43dcbb23721a3c553397_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pulmonx Corporation</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders’ Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.703%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional <br/>Paid-In <br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br/>Other <br/>Comprehensive <br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total <br/>Stockholders’ <br/>Equity</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balances at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7c4697ae1aaa496dbaaf2d4679704499_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMi0yLTEtMS0zOTM4Mw_530e1eeb-5257-4315-ac23-a5d4a563a57a">36,931,762</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c4697ae1aaa496dbaaf2d4679704499_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMi00LTEtMS0zOTM4Mw_0bf886cb-560d-40fc-b21f-ad31d8b37aab">37</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia24f369469a741168a30ae622482853d_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMi02LTEtMS0zOTM4Mw_9607faf4-26a4-4917-a8ed-d3e09c22abce">482,885</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10ab7cd963514359bca3cc91d92e2ecc_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMi04LTEtMS0zOTM4Mw_c7d204c3-0fbe-4979-a3a0-1155268449ff">1,712</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id78b13f427954c0c9d0eaf7f535da90f_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMi0xMC0xLTEtMzkzODM_8c0193af-af7d-4105-9d2d-6a995bf1d494">291,395</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMi0xMi0xLTEtMzkzODM_316778cd-e96b-4a14-bfe7-a240421d2676">193,239</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i19fb5ca4a6fb4af091d289bfc12b61a0_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMy0yLTEtMS0zOTM4Mw_3405b843-c2cd-4c96-8ab8-ae0352de9e6e">21,392</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i19fb5ca4a6fb4af091d289bfc12b61a0_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfNC0yLTEtMS00MzYxMg_3041d336-e40e-4d09-abd2-e77eed6123f6">99,265</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i725a772a7daa4c27b7de453c618f8b63_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfNC02LTEtMS00MzYxMg_836997e3-c6a7-4ca5-9068-78c131107612">221</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i652d00700fc04edeacaed27e5bb45f8e_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfNC0xMi0xLTEtNDQ5NTE_ed4e2d96-9d78-449d-95f4-fb7e84a86176">221</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of shares pursuant to Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i19fb5ca4a6fb4af091d289bfc12b61a0_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfNC0yLTEtMS0zOTM4Mw_4a671d8c-0cfb-4b0d-8d61-52bc1bbdfceb">46,002</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i725a772a7daa4c27b7de453c618f8b63_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfNC02LTEtMS0zOTM4Mw_43ce8daa-2063-4dfd-ad3c-0e75791a5212">1,108</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i652d00700fc04edeacaed27e5bb45f8e_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfNC0xMi0xLTEtNDE2MDM_40867b61-3944-4c7a-9e12-84f9a7460020">1,108</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in shares subject to repurchase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i725a772a7daa4c27b7de453c618f8b63_D20220101-20220331" decimals="-3" name="lung:AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfNS02LTEtMS0zOTM4Mw_6da8c6e1-9c51-4b20-8dd8-4994ad66828e">59</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i652d00700fc04edeacaed27e5bb45f8e_D20220101-20220331" decimals="-3" name="lung:AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfNS0xMi0xLTEtMzkzODM_9a00de90-c07f-4fec-8df2-a6814a86e240">59</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i725a772a7daa4c27b7de453c618f8b63_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfNi02LTEtMS0zOTM4Mw_84b17089-15a9-4d87-b4e3-0fd53af8900b">3,615</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i652d00700fc04edeacaed27e5bb45f8e_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfNi0xMi0xLTEtMzkzODM_0c35041c-17b9-49d4-8710-52ab12001c08">3,615</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie32244cce0bb4ac7b0db5c54bbe3378f_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfNy04LTEtMS0zOTM4Mw_4fb3f5ed-75cc-4b95-ab01-9bfa5adc6e12">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i652d00700fc04edeacaed27e5bb45f8e_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfNy0xMi0xLTEtMzkzODM_0481db54-0cba-4a0b-8d5d-7a9c684ed517">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized losses on marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie32244cce0bb4ac7b0db5c54bbe3378f_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfOC04LTEtMS0zOTM4Mw_81bc8451-203d-4fcd-a567-3be690100692">245</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i652d00700fc04edeacaed27e5bb45f8e_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfOC0xMi0xLTEtMzkzODM_f71fb51d-38d0-49df-a8b8-1d91297e152e">245</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f6b9352f27c4329bd7774ca5b92761f_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfOS0xMC0xLTEtMzkzODM_5c933424-bd5e-48f3-a4c2-629c7edfbe61">15,828</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i652d00700fc04edeacaed27e5bb45f8e_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfOS0xMi0xLTEtMzkzODM_9de9ed71-3abc-45a7-899c-cbbc107d4fda">15,828</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balances at March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i194ccf658b8d40dcad4baa33b8140830_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTAtMi0xLTEtMzkzODM_26900f13-b0ba-450d-b870-a44c15801fa7">37,098,421</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i194ccf658b8d40dcad4baa33b8140830_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTAtNC0xLTEtMzkzODM_9ae01611-36c9-4b7b-a10d-61d058a645d6">37</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90fc2f64290846f9bd78af8a90169410_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTAtNi0xLTEtMzkzODM_479762fe-f714-4df9-a358-732d9557acdb">487,888</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2da5d082cb42229835e719c252d985_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTAtOC0xLTEtMzkzODM_0aa20e67-21a9-401d-b9e4-d06863abd0d0">1,443</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifdb2a33757594e479f11368bdb9206b3_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTAtMTAtMS0xLTM5Mzgz_f1b1bc2a-cf8d-4a85-aafe-4880cd5364c3">307,223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib259775b9b9c44278d3b14fa3bc4487c_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTAtMTItMS0xLTM5Mzgz_d7d79545-925f-4928-87ef-99ee54933c36">182,145</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iec7ebe8c89a545d9a436b69816b227eb_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTEtMi0xLTEtMzkzODM_0e153202-dde8-483c-9f8f-8c7b3939b36b">93,988</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iec7ebe8c89a545d9a436b69816b227eb_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTItMi0xLTEtNDAwODc_cfbc14d0-365f-4b19-8a6b-6736fb0983da">73,621</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eb715cb0da94d3da06eec36cb1cb264_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTItNi0xLTEtNDAwODc_2cb7fef2-4e39-4747-b855-bb36d2d26706">151</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTItMTItMS0xLTQxNTkz_e98ce3bd-ef5a-4dcf-850a-56ead05fd843">151</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in shares subject to repurchase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eb715cb0da94d3da06eec36cb1cb264_D20220401-20220630" decimals="-3" name="lung:AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTItNi0xLTEtMzkzODM_44af6c18-76c7-43ed-b398-590820afef01">58</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-3" name="lung:AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTItMTItMS0xLTM5Mzgz_e96b231d-7be9-4e70-a90c-75394325f924">58</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eb715cb0da94d3da06eec36cb1cb264_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTQtNi0xLTEtMzkzODM_39482dfe-dcca-4b3a-a1e8-698b1c349970">4,554</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTQtMTItMS0xLTM5Mzgz_21377b3b-ce9f-4720-b5b9-7368cd0bf5d7">4,554</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72eebbb0bfb6442c835ff9de3799eae7_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTUtOC0xLTEtMzkzODM_d764b8e5-ab08-477b-a26f-643b0a656301">6</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTUtMTItMS0xLTM5Mzgz_70101f8f-2ab6-4b8c-bea5-de70d973729e">6</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized losses on marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72eebbb0bfb6442c835ff9de3799eae7_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTYtOC0xLTEtMzkzODM_691627ee-6208-4b62-abcb-aed359ef25ed">92</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTYtMTItMS0xLTM5Mzgz_d8ef50de-edf8-4746-a15a-619c325f691d">92</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6858cf3ac89b40e1aa7df89ed53b2a24_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTctMTAtMS0xLTM5Mzgz_c7c6221c-11d3-4441-9a4c-40e0b0564f90">14,640</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTctMTItMS0xLTM5Mzgz_dd46e8fe-a782-445e-87fa-2c77e4854178">14,640</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balances at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91bd715107e14e01ba109bc345441fd3_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTgtMi0xLTEtMzkzODM_bdbf3ca2-cde4-4355-8d73-39646c743a68">37,266,030</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91bd715107e14e01ba109bc345441fd3_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTgtNC0xLTEtMzkzODM_de069342-4382-4f23-a9de-d4f544e6ee4e">37</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99751b578e1948aab49db6044f4428c2_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTgtNi0xLTEtMzkzODM_509bbde3-fdc1-4665-a0d8-83fccc1c5cee">492,651</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64d27f95511a463b9e9c935f31dfb113_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTgtOC0xLTEtMzkzODM_252ee733-48f3-417d-be37-c305697774e7">1,357</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i259f3776dc6e4cc2a3830d0cb8f9c7c9_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTgtMTAtMS0xLTM5Mzgz_d2b81dc4-172c-4bab-8274-4395cc56f334">321,863</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTgtMTItMS0xLTM5Mzgz_d8f9b001-49b4-4024-bdf8-12669d4ea90a">172,182</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.703%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional <br/>Paid-In <br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br/>Other <br/>Comprehensive <br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total <br/>Stockholders’ <br/>Deficit</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balances at January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i937e6c62ae494af082d55df28a206b08_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMi01LTEtMS0zOTM4Mw_9f4c4ec4-d9e9-4579-9631-6a33812f13cd">35,693,753</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i937e6c62ae494af082d55df28a206b08_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMi03LTEtMS0zOTM4Mw_0f7a9b36-cee6-4529-b95a-dc4a663022bd">36</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4bd41d858f34c15860558f9397212b7_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMi05LTEtMS0zOTM4Mw_4e029c16-b94c-4c22-afe6-3d0dbd107f29">467,147</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65dfe455b40043c5879a699696671342_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMi0xMS0xLTEtMzkzODM_abb3bf9e-1a4f-4ceb-9763-f7ba3836d5e1">1,685</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55ca82439e3f4c70b50cc76b61427123_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMi0xMy0xLTEtMzkzODM_09f7a880-c41e-45b7-9bc5-41af563a028b">242,734</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if30e4595cd6d463086f867a5956e9dc6_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMi0xNS0xLTEtMzkzODM_f3baec5b-e633-495d-bb7c-c4ecc9f95414">226,134</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8540e99599c44addac72e276711f6cec_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMy01LTEtMS0zOTM4Mw_80c2e111-d06a-4c32-9ec2-ed950ca33e39">122,856</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia82be87509cd48adba02800ee6d7620c_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMy05LTEtMS0zOTM4Mw_c76362a8-8124-4470-87c0-8c3e224fc888">273</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d577c6b24e74d95b9308b0abbea21c0_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMy0xMi0xLTEtNDE2MDc_aeceebb0-bc60-45cd-904f-72175b070d0c">273</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of early exercised common stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8540e99599c44addac72e276711f6cec_D20210101-20210331" decimals="INF" name="lung:StockRepurchasedDuringPeriodExerciseOfEarlyStockOptionsShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfNC01LTEtMS0zOTM4Mw_d93a28e1-f0ac-493b-bb33-d4782e7752a3">12,945</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in shares subject to repurchase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia82be87509cd48adba02800ee6d7620c_D20210101-20210331" decimals="-3" name="lung:AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfNS05LTEtMS0zOTM4Mw_e336e459-a967-4341-93a3-7002c2a03955">66</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d577c6b24e74d95b9308b0abbea21c0_D20210101-20210331" decimals="-3" name="lung:AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfNS0xNS0xLTEtMzkzODM_772a7b42-a91c-4306-94da-d49379e75ab6">66</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia82be87509cd48adba02800ee6d7620c_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfNi05LTEtMS0zOTM4Mw_7f7047ec-db30-4197-854f-e7448063f9f0">2,462</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d577c6b24e74d95b9308b0abbea21c0_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfNi0xNS0xLTEtMzkzODM_cc5e0d05-8886-4a09-b5df-300dd250e065">2,462</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6381f3fa151c4fa79031cfd4c59f3dd1_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfNy0xMS0xLTEtMzkzODM_c1678a03-d8ed-4723-8a00-2800242bae81">272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d577c6b24e74d95b9308b0abbea21c0_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfNy0xNS0xLTEtMzkzODM_77947bfb-b4c1-4c9b-b3ae-2484ec337d6f">272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized losses on marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6381f3fa151c4fa79031cfd4c59f3dd1_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfOC0xMS0xLTEtMzkzODM_7576da49-788c-4414-9c03-1e0df6fe54dd">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d577c6b24e74d95b9308b0abbea21c0_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfOC0xNS0xLTEtMzkzODM_110e3286-3442-4aa0-ad17-3246a165970e">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8cfddbc76454c0a86d25df73ca052b8_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfOS0xMy0xLTEtMzkzODM_d0ee8a3d-2c82-4134-a85a-74aca11b5e42">12,512</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d577c6b24e74d95b9308b0abbea21c0_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfOS0xNS0xLTEtMzkzODM_573a8590-c90f-42d8-b659-3677881ee4bf">12,512</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balances at March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i386654d89dcd4305bc2796578a912387_I20210331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTAtNS0xLTEtMzkzODM_d2e5593c-d677-4fe0-92e8-39a1cbac8f41">35,803,664</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i386654d89dcd4305bc2796578a912387_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTAtNy0xLTEtMzkzODM_eb3c5489-fc55-48bb-bb6e-2e514e6f3e70">36</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9301a7535db44e52b62db20ea7d35b36_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTAtOS0xLTEtMzkzODM_c557b550-3d97-4d88-a173-74b8b1d7d821">469,948</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b8aa74725440cfacefcfa508e23b8f_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTAtMTEtMS0xLTM5Mzgz_785d1361-bf3d-4b11-8ef7-41ee47e142bb">1,410</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if58fbcaf779342d48308a3b41be27d24_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTAtMTMtMS0xLTM5Mzgz_47770663-d0b8-4c06-9925-d17a1c714a2c">255,246</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9dc423e8a1c41408784d828d38bb8af_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTAtMTUtMS0xLTM5Mzgz_36ceb990-5e0d-4ea4-a4db-5866ea664692">216,148</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c2c4ec32c314b51a25e847eceb0629a_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTEtNS0xLTEtMzkzODM_ae75b7af-b1f5-43b1-97a1-f3cc2f765a84">653,609</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e36e6ab000490aa878482c47257f1f_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTEtOS0xLTEtMzkzODM_65579f58-6a43-4918-ba41-ac0ab9cb951d">1,133</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTEtMTUtMS0xLTM5Mzgz_27c2e8dc-ef6c-46a4-9d9a-53f800ace7e8">1,133</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of shares pursuant to Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c2c4ec32c314b51a25e847eceb0629a_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTItMi0xLTEtNDAwNTQ_d0ae7783-1fb7-4dc0-a8fb-d52852dcf05b">123,344</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e36e6ab000490aa878482c47257f1f_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTItNi0xLTEtNDAwNTQ_c9f1601b-6c1a-4307-a22f-73c9169ba141">1,992</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTItMTItMS0xLTQwMDU0_1a41554b-20b5-4a72-83a0-f39525791a28">1,992</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in shares subject to repurchase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e36e6ab000490aa878482c47257f1f_D20210401-20210630" decimals="-3" name="lung:AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTItOS0xLTEtMzkzODM_b0e23493-d8a1-40f7-a5ea-a16aa4b1a451">12</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" name="lung:AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTItMTUtMS0xLTM5Mzgz_31be5e6f-ff47-479d-801e-f41ebb90e7fb">12</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71e36e6ab000490aa878482c47257f1f_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTMtOS0xLTEtMzkzODM_2748e451-e23b-446a-9798-cdbfd209f32b">2,476</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTMtMTUtMS0xLTM5Mzgz_c691c594-b56b-4a9a-a2ff-2cb9833e2643">2,476</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313147cc93cf4996b2b891fed6afd2c8_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTQtMTEtMS0xLTM5Mzgz_d3e71106-1a22-439f-b2fd-ad5dd70112dd">66</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTQtMTUtMS0xLTM5Mzgz_96f450f1-62e9-42b8-bb70-6a458b04948a">66</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized (losses) gains on marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313147cc93cf4996b2b891fed6afd2c8_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTUtMTEtMS0xLTM5Mzgz_f5165a85-abeb-4eb3-bbfd-648b8c3ac8d1">3</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTUtMTUtMS0xLTM5Mzgz_5f600e4f-c38b-4499-a221-fecdc6596b20">3</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87c0f954d15f47f997c03b4bbe0a518c_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTYtMTMtMS0xLTM5Mzgz_2396c03a-f64d-4881-8836-76a2ab7799b4">12,962</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTYtMTUtMS0xLTM5Mzgz_ffe86ae9-23a0-4653-9521-3ec78b39a23b">12,962</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balances at June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93f25af4132544699f7cc1911016ca93_I20210630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTctNS0xLTEtMzkzODM_dffbd63c-a544-4819-988b-7c931714bc1d">36,580,617</ix:nonFraction> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f25af4132544699f7cc1911016ca93_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTctNy0xLTEtMzkzODM_5ba5ea67-bba0-44c4-a78e-3a8ab5469cfd">36</ix:nonFraction> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ab786f6b9094a30a403c16621efc3b8_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTctOS0xLTEtMzkzODM_c05cdaa5-1648-4dd1-8ab8-a9995cb9a396">475,561</ix:nonFraction> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0536fa32537e48f3b61cc43f596ef9ef_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTctMTEtMS0xLTM5Mzgz_e3a93963-f948-43c8-9e6f-5ccdcd724bad">1,479</ix:nonFraction> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf8348b6ab644a16943adf5d6b3b01d1_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTctMTMtMS0xLTM5Mzgz_753b23cf-87cc-4676-91fb-a6fb1cfca58c">268,208</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10d78353ceec4f248af8e917fdcbaa2c_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTctMTUtMS0xLTM5Mzgz_b0ef5aa9-167f-4929-9aca-12b02bda06be">208,868</ix:nonFraction> </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i784ba2f3210d43dcbb23721a3c553397_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pulmonx Corporation</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMy0xLTEtMS0zOTM4Mw_a27f2394-8797-4f72-990e-7e87b2399c21">30,468</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMy0zLTEtMS0zOTM4Mw_4a8de7bc-ec11-4046-85ce-25598a4033fd">25,474</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNS0xLTEtMS0zOTM4Mw_f43fcb3b-f682-4ffa-b754-9f52a75238b4">7,896</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNS0zLTEtMS0zOTM4Mw_261a7e93-4544-4d1f-9397-b1f2db93e08e">4,580</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on disposal of fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNi0xLTEtMS0zOTM4Mw_37a97c0f-a87a-4793-a10b-193ff9b6d05d">1</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNi0zLTEtMS0zOTM4Mw_a49e390c-a1d8-4e71-927d-bbec35547231">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNy0xLTEtMS0zOTM4Mw_18fdd592-d5af-4cfe-b415-accc62034e1a">1</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNy0zLTEtMS0zOTM4Mw_576c63d7-1032-4064-aaf4-fd33dbf7d288">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory write-downs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:InventoryWriteDown" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfOC0xLTEtMS0zOTM4Mw_856e5e03-8dc9-448f-af48-c44f439c69d2">111</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:InventoryWriteDown" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfOC0zLTEtMS0zOTM4Mw_89f9ad62-a484-4427-b560-84d9e2e3a657">665</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:OtherDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfOS0xLTEtMS0zOTM4Mw_f8459d60-95af-425d-b4e9-2697549248a1">744</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:OtherDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfOS0zLTEtMS0zOTM4Mw_26ae12dd-f649-43c9-9aea-69e42e79dd86">287</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTAtMS0xLTEtMzkzODM_3ecc346e-74d3-40b1-bd92-b32c7c79ada5">32</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTAtMy0xLTEtMzkzODM_73611f06-b703-469d-a1f1-a635d28bb0a0">64</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of premiums and discounts on short-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTItMS0xLTEtMzkzODM_73fb6fb3-b3ab-4b8b-89e4-aa3dfdfeee1c">19</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTItMy0xLTEtMzkzODM_c687780f-9ef3-4744-9142-04378d4b513f">16</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTMtMS0xLTEtMzkzODM_e959804b-a463-4cbc-ae82-65485d93fbeb">1,226</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTMtMy0xLTEtMzkzODM_9290a18d-2ea8-462a-aed4-4907e093685f">1,149</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTUtMS0xLTEtMzkzODM_aa516bfa-c471-48ac-874b-6ef0f346a618">1,073</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTUtMy0xLTEtMzkzODM_f32dde1c-e764-46d1-b6e5-4d69a67adad0">2,732</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTYtMS0xLTEtMzkzODM_1c0fbda1-9245-4f03-9606-7bcd8ba567ed">3,030</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTYtMy0xLTEtMzkzODM_67c69833-1a8b-4b55-bca3-380347372250">3,125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTctMS0xLTEtMzkzODM_8ff00384-577b-46da-9e4b-ec67e3fe8d3a">1,065</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTctMy0xLTEtMzkzODM_1c7b4b6e-43fc-428d-9730-165297075409">216</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTgtMS0xLTEtMzkzODM_dec49826-9855-4fab-94fa-0608965eeae5">6</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTgtMy0xLTEtMzkzODM_258038e5-eddc-40b0-b9b0-4b8ce8713aa7">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTktMS0xLTEtMzkzODM_c076fd79-0e2b-4d5a-be52-89816383027d">1,062</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTktMy0xLTEtMzkzODM_dcfbedcd-0e6f-4706-9b80-f867e1857a37">293</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjAtMS0xLTEtMzkzODM_98b9a4e2-d79d-417f-b658-c8d1362949b8">1,296</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjAtMy0xLTEtMzkzODM_fad36c37-0d36-43f1-a848-6c1f1b00e450">2,926</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjEtMS0xLTEtMzkzODM_c0f31fe8-f2d1-4bc0-a35c-e8d35ba9cd9a">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjEtMy0xLTEtMzkzODM_41ee32d8-a74a-4d16-a315-67ed2c7c4f0e">87</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjItMS0xLTEtMzkzODM_7f609752-1cc3-4be9-9abc-79bc3b7e26b9">707</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjItMy0xLTEtMzkzODM_82db8984-f765-426f-b257-56382bad8132">1,137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjMtMS0xLTEtMzkzODM_71742d92-8d90-40e3-b781-43827c1ee1cb">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjMtMy0xLTEtMzkzODM_f88a1073-1849-4779-9d07-9c6425453328">11</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjQtMS0xLTEtMzkzODM_a5b8bb77-b6ab-4fe5-90cd-0905b4487b2c">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjQtMy0xLTEtMzkzODM_767cb779-7f94-415b-afc6-da6467fb653f">16</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjUtMS0xLTEtMzkzODM_0ba0b923-257c-4b39-8135-f3fe15c71b4c">24,590</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjUtMy0xLTEtMzkzODM_d19ea31f-3311-44ff-a6d9-2122be1a6cef">22,362</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjctMS0xLTEtMzkzODM_770ca16e-96f4-4efd-8a5f-392149c7b8b1">21,959</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjctMy0xLTEtMzkzODM_da541463-cf2e-4f22-9aca-d8775946b815">15,314</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Maturities of short-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjgtMS0xLTEtMzkzODM_18929e73-42f4-4f90-b9c7-4bbd796a392f">19,280</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjgtMy0xLTEtMzkzODM_c301a711-b959-4a50-acb6-0716c210901c">2,500</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjktMS0xLTEtMzkzODM_546670a1-0833-4ce0-ae86-495b8d51130d">863</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjktMy0xLTEtMzkzODM_45b1ca2e-b388-4924-961e-a5e48a8f1af1">903</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMzAtMS0xLTEtMzkzODM_f2a1cfd4-3e98-4690-a8fa-dfde1403ec6e">3,542</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMzAtMy0xLTEtMzkzODM_320ca49a-f994-446c-b8fe-9da9e0cf8358">13,717</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of Credit Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMzMtMS0xLTEtMzkzODM_7e448ca0-940a-4b3d-912a-96b8b447e439">44</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMzMtMy0xLTEtMzkzODM_6e1b8888-7fdb-4e02-a16a-3886c5b123bd">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMzgtMS0xLTEtMzkzODM_f7a0c97d-8630-41d3-9e49-db7de8f5e7d0">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMzgtMy0xLTEtMzkzODM_bfcac854-d65a-4072-a2fa-42f00ffdaf88">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercise of common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDEtMS0xLTEtMzkzODM_6c3c3d5c-9afe-45e1-9130-d8d3d796f298">382</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDEtMy0xLTEtMzkzODM_fa72c4e0-1fe1-499f-a577-bab233664920">1,381</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under the employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromRepaymentOfLoansToPurchaseCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDItMS0xLTEtMzkzODM_55d44172-aaf3-4932-9a7a-c080c7d83a97">1,108</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromRepaymentOfLoansToPurchaseCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDItMy0xLTEtMzkzODM_6aafd813-9a60-4917-8cb8-54e30fddc0f4">1,992</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for repurchase of early exercised common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDMtMS0xLTEtMzkzODM_161899f5-eb9e-4add-b64e-619ebb65fb7a">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDMtMy0xLTEtMzkzODM_a567fe28-f56c-4d9d-b33e-62c36be0e193">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDQtMS0xLTEtMzkzODM_b0fd9fe9-4ea4-4e6d-8fee-7854e0bc637e">1,446</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDQtMy0xLTEtMzkzODM_6cf87b7c-9390-4cca-9103-84e8b1b350f6">3,306</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDUtMS0xLTEtMzkzODM_4847d25b-4bfe-446d-a10e-aab0f7799056">153</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDUtMy0xLTEtMzkzODM_ba69924f-0b14-43ad-a627-566ee94891ab">85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDYtMS0xLTEtMzkzODM_3c3ac9d7-3cd4-44f6-bd4d-08be193964c1">26,533</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDYtMy0xLTEtMzkzODM_cbb21c4a-9970-4e4d-80f3-cb550ee3ba1d">32,858</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, at beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDctMS0xLTEtMzkzODM_2c272739-9031-4af0-8bde-08b61d54cba4">148,711</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if30e4595cd6d463086f867a5956e9dc6_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDctMy0xLTEtMzkzODM_e0ffa24d-4ca0-49f4-871d-f1acd20f7989">231,792</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, at end of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDgtMS0xLTEtMzkzODM_14f7c450-b046-4e27-ace4-3314947bea64">122,178</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10d78353ceec4f248af8e917fdcbaa2c_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDgtMy0xLTEtMzkzODM_68085a3e-4c5f-4216-87cc-613ae20e61b3">198,934</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reconciliation of cash, cash equivalents and restricted cash to consolidated balance sheets:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNTAtMS0xLTEtMzkzODM_ca655d49-0329-4b4b-9392-b85559887da6">121,947</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10d78353ceec4f248af8e917fdcbaa2c_I20210630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNTAtMy0xLTEtMzkzODM_390e41dd-9e3e-4818-bae3-3d5bf2a4d40d">198,703</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNTEtMS0xLTEtMzkzODM_4ec3f7a6-0097-456c-a700-7770e2ef0e27">231</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10d78353ceec4f248af8e917fdcbaa2c_I20210630" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNTEtMy0xLTEtMzkzODM_7e38f443-7596-46c6-bc3d-ffe28b9d711c">231</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash in consolidated balance sheets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNTItMS0xLTEtMzkzODM_2e1753a0-12d4-48e9-9c22-2f2ff4970685">122,178</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10d78353ceec4f248af8e917fdcbaa2c_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNTItMy0xLTEtMzkzODM_4b3462cf-8c9c-41e4-bc52-1367fb404a1a">198,934</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental non-cash items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lapse in repurchase rights of common stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="lung:IncreaseLapseInRepurchaseOfCommonStockRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNTUtMS0xLTEtMzkzODM_dd4db4c4-3092-45de-9cf1-dc025c696486">117</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="lung:IncreaseLapseInRepurchaseOfCommonStockRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNTUtMy0xLTEtMzkzODM_d3b724a3-2b85-47cf-8166-f6a12c4c27d6">78</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment in accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNTYtMS0xLTEtMzkzODM_f62b672b-1a08-4d58-9d63-fe02790371b2">486</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNTYtMy0xLTEtMzkzODM_c9ad85f5-75f2-4258-bdb6-f13e2bc11b73">608</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount receivable from exercise of common stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="lung:ReceivableFromExerciseOfCommonStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNTktMS0xLTEtMzkzODM_171081cb-a56a-4bb0-ade5-b8d63e590d5a">1</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="lung:ReceivableFromExerciseOfCommonStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNTktMy0xLTEtMzkzODM_89d9d673-a72a-4666-9c09-d3766d81d3e2">25</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right of use assets obtained in exchange for new lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNjAtMS0xLTEtMzkzODM_43091dec-ef36-4123-a327-41881adb43df">138</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNjAtMy0xLTEtMzkzODM_14033202-8546-4e76-b817-edadce525b81">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNjItMS0xLTEtMzkzODM_0e8807d7-fd7e-4af9-9f92-c9dc337b4310">228</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNjItMy0xLTEtMzkzODM_3827d520-5d64-449b-84ad-f7138dcc6016">226</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNjMtMS0xLTEtMzkzODM_4de1820f-60d1-4416-8423-7230ff031554">375</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNjMtMy0xLTEtMzkzODM_bf713b88-532d-4a78-8938-d0bfa0ccaab3">360</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i784ba2f3210d43dcbb23721a3c553397_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pulmonx Corporation</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Interim Condensed Consolidated Financial Statements (Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="i784ba2f3210d43dcbb23721a3c553397_34"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.    <ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNC9mcmFnOmQ5MjE1NjdmMjViOTQzZmFhMWQyOWQ1NGUzNzVlMDFlL3RleHRyZWdpb246ZDkyMTU2N2YyNWI5NDNmYWExZDI5ZDU0ZTM3NWUwMWVfNTIyNw_cb9105bd-1eda-46c9-8621-c0ac16bebb58" continuedAt="i47f4cd80342f4cc39ebbf56c4ddd346f" escape="true">Formation and Business of the Company</ix:nonNumeric></span></div><ix:continuation id="i47f4cd80342f4cc39ebbf56c4ddd346f"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pulmonx Corporation (the “Company”) was incorporated in the state of California in December 1995 as Pulmonx and reincorporated in the state of Delaware in December 2013. The Company is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (“COPD”). The Company’s solution, which is comprised of the Zephyr Endobronchial Valve (“Zephyr Valve”), the Chartis Pulmonary Assessment System (“Chartis System”) and the StratX Lung Analysis Platform (“StratX Platform”), is designed to treat a broad pool of patients for whom medical management has reached its limits and either do not want or are ineligible for surgical approaches. The Company has subsidiaries in Germany, Switzerland, Australia, the United Kingdom, Italy, France, Hong Kong, and Japan.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Going Concern</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred operating losses and negative cash flows from operations to date and has an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNC9mcmFnOmQ5MjE1NjdmMjViOTQzZmFhMWQyOWQ1NGUzNzVlMDFlL3RleHRyZWdpb246ZDkyMTU2N2YyNWI5NDNmYWExZDI5ZDU0ZTM3NWUwMWVfMjQzNA_b153b4ba-94ec-412c-b43e-4002b229b854">321.9</ix:nonFraction> million as of June 30, 2022. During the six months ended June 30, 2022 and June 30, 2021, the Company used $<ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNC9mcmFnOmQ5MjE1NjdmMjViOTQzZmFhMWQyOWQ1NGUzNzVlMDFlL3RleHRyZWdpb246ZDkyMTU2N2YyNWI5NDNmYWExZDI5ZDU0ZTM3NWUwMWVfMjUwMg_decd3397-de82-4ba9-a760-f086910ab971">24.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNC9mcmFnOmQ5MjE1NjdmMjViOTQzZmFhMWQyOWQ1NGUzNzVlMDFlL3RleHRyZWdpb246ZDkyMTU2N2YyNWI5NDNmYWExZDI5ZDU0ZTM3NWUwMWVfMjUwOQ_fc1d4ad6-f340-4f51-961f-0273b523a148">22.4</ix:nonFraction> million of cash in its operating activities, respectively. As of June 30, 2022, the Company had cash, cash equivalents and marketable securities of $<ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-5" name="lung:CashAndCashEquivalentsAndMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNC9mcmFnOmQ5MjE1NjdmMjViOTQzZmFhMWQyOWQ1NGUzNzVlMDFlL3RleHRyZWdpb246ZDkyMTU2N2YyNWI5NDNmYWExZDI5ZDU0ZTM3NWUwMWVfMjY0MQ_85107599-56ee-4d5d-8f61-555a4b90635e">166.8</ix:nonFraction> million. Historically, the Company’s activities have been financed through the sale of equity securities, debt financing arrangements and sales of our products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s condensed consolidated financial statements have been prepared on the basis of the Company continuing as a going concern for the next 12 months. Management believes that the Company’s existing cash, cash equivalents and marketable securities will allow the Company to continue its planned operations for at least the next 12 months from the date of the issuance of these unaudited interim condensed consolidated financial statements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of the COVID-19 Pandemic</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There continues to be widespread significant impact from the COVID-19 pandemic, which has delayed clinical trials and FDA operations and adversely impacted the number of procedures performed using our products. In the markets in which we operate, elective, specialty and other procedures and appointments have been, and continue to be, suspended or canceled to avoid non-essential patient exposure to medical environments and potential infection with COVID-19 and to focus limited resources and personnel capacity toward the treatment of COVID-19 patients. As a result, the COVID-19 pandemic and the measures taken by many countries in response have materially adversely affected, and could in the future materially adversely affect, our business, financial condition and results of operations, as well as the price of our common stock, from a decrease and delay of procedures involving our products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company saw some level of recovery in procedure volumes in our U.S. and larger international markets in the second quarter of 2022, the smaller international markets were hampered by a slower recovery, including continued lockdowns in China. The Company may continue to see regional variations in procedure volumes in the U.S. and international markets from the COVID-19 pandemic and its variants.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s unaudited interim condensed consolidated financial statements reflect judgments and estimates that could change in the future as a result of the COVID-19 pandemic. The COVID-19 pandemic has adversely impacted the Company’s business, financial condition and results of operations by decreasing and delaying procedures performed using its products. While many regions begin to stabilize with improvements in procedure volumes, there continues to be variability and uncertainty as variants of the virus emerge. The Company can make no assurance regarding any future level of demand for the Company’s products, and COVID-19 may adversely impact the results of operations and financial condition.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i784ba2f3210d43dcbb23721a3c553397_37"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pulmonx Corporation</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Interim Condensed Consolidated Financial Statements (Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.    <ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfMTA3MjI_859cc17b-1de6-4bcb-a772-1c3a234227be" continuedAt="ie80508c8c920459cac6e1ddd44cb390b" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ie80508c8c920459cac6e1ddd44cb390b" continuedAt="ic74da819aa084fcb85f76632c707b677"><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfMTA3MjM_497c89e6-1168-43d7-8ccd-4e65757212a9" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfMTA3MTg_39a53d20-6732-4125-abc5-d271fed2f979" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span></div></ix:nonNumeric><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of December 31, 2021 was derived from the Company’s audited financial statements, but does not include all disclosures required by GAAP. The accompanying unaudited condensed consolidated financial statements as of June 30, 2022 and for the three and six months ended June 30, 2022 and 2021, have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. Accordingly, these financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2021 and notes thereto, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the SEC on March 1, 2022. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company’s condensed consolidated financial position as of June 30, 2022 and condensed consolidated results of operations for the three and six months ended June 30, 2022 and 2021 and condensed consolidated cash flows for the six months ended June 30, 2022 and 2021 have been made. The results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2022.</span></div><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfMTA3MTk_36bbe82a-f563-476a-af8a-eadcc1f8071b" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions include reserves and write-downs related to inventories, the recoverability of long term assets, valuation of common stock, stock-based compensation, intangible assets, goodwill, debt and related features, deferred tax assets and related valuation allowances and impact of contingencies.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfMTA3MjQ_dd52a59d-773a-4bc9-9190-e4fbaf6dfada" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the Company’s financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the term loan approximates their fair value. The fair value of marketable debt securities is estimated using Level 2 inputs based on their quoted market values (Note 4).</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pulmonx Corporation</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Interim Condensed Consolidated Financial Statements (Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="ic74da819aa084fcb85f76632c707b677" continuedAt="i2f358ed4dc1c4d6a9b195e2b37ba4325"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfMTA3MjA_ed534a31-b21a-4cca-9d1a-431720118e39" continuedAt="ia0837236e475414a8e9bd5749b065538" escape="true">Concentration of Credit Risk </ix:nonNumeric></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia0837236e475414a8e9bd5749b065538">Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash, cash equivalents and accounts receivable. The Company maintains its cash and cash equivalents balances with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance Corporation (“FDIC”) insured limits.</ix:continuation> As of June 30, 2022 and December 31, 2021, the Company also had cash on deposit with foreign banks of approximately $<ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-5" name="us-gaap:CashUninsuredAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfNTI4Ng_249b2db6-5175-4e4b-9dd5-95d2424998b9">3.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-5" name="us-gaap:CashUninsuredAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfNTI5Mw_cddaa5ba-9d62-4250-82eb-f526b2bea5d9">4.6</ix:nonFraction> million, respectively, that was not federally insured.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company earns revenue from the sale of its products to distributors and other customers such as hospitals. Sales of Zephyr Valves and delivery catheters accounted for most of the Company’s revenue for the six months ended June 30, 2022 and 2021. The Company’s accounts receivable are derived from revenue earned from customers and distributors. The Company performs ongoing credit evaluations of its customers’ and distributors’ financial condition and generally requires no collateral from its customers and distributors. At June 30, 2022 and December 31, 2021, no customer or distributor accounted for more than 10% of accounts receivable. During the three and six months ended June 30, 2022 and June 30, 2021, no customer or distributor accounted for more than 10% of revenue.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on single source suppliers for the components, sub-assemblies and materials for its products. These components, sub-assemblies and materials are critical and there are no or relatively few alternative sources of supply. The Company’s suppliers have generally met the Company’s demand for their products and services on a timely basis in the past.</span></div><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfMTA3MjY_89a70483-33c3-45f6-a05d-b9ddde5b4436" continuedAt="i23add86cd99a4cda82627e06d55e1c2a" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Transaction Gains and Losses</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currencies of the Company’s wholly owned subsidiaries in Switzerland, Germany, Australia, the United Kingdom, France and Hong Kong are the Swiss franc. The functional currency of the Company’s subsidiary in Italy is the Euro. Accordingly, asset and liability accounts of Switzerland, Germany, Australia, the United Kingdom, Italy and Hong Kong operations are translated into U.S. dollars using the current exchange rate in effect at the balance sheet date and equity accounts are translated into U.S. dollars using historical rates. The revenues and expenses are translated using the average exchange rates in effect during the period, and gains and losses from foreign currency translation adjustments are included as a component of accumulated other comprehensive income in the condensed consolidated balance sheet. Foreign currency translation adjustments are recorded in other comprehensive income (loss) in the condensed consolidated statements of operations and comprehensive loss and was less than $<ix:nonFraction unitRef="usd" contextRef="i2ae7a2862d6f4d7a954dd9a21f9f83d8_D20220401-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfMTA5OTUxMTY0MTE1MQ_e4621f1f-fb23-4cab-ad28-26adf6b16362">0.1</ix:nonFraction> million and less than $<ix:nonFraction unitRef="usd" contextRef="i1f765278d59148a1ab87392a73044ec0_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfMTA5OTUxMTY0MTIzOA_764f7855-a34e-4b00-ba98-cd1490321358">0.1</ix:nonFraction> million during the three months ended June 30, 2022 and 2021, respectively, and less than $(<ix:nonFraction unitRef="usd" contextRef="i1bcdc8fb272d48f49898d46b5eed3af6_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfMTA5OTUxMTY0MTE3MA_ba552559-d07e-4ebb-a2f5-c365cadc48ef">0.1</ix:nonFraction>) million and $(<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfODU1NA_33fb6b75-6ee7-40cb-9204-f82a17861fb3">0.2</ix:nonFraction>) million during the six months ended June 30, 2022 and 2021, respectively.</span></div></ix:nonNumeric><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i23add86cd99a4cda82627e06d55e1c2a">Foreign currency transaction gains and losses are included in other income (expense), net in the condensed consolidated statements of operations and comprehensive loss</ix:continuation> and was $(<ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfODc4Ng_0cd60af5-b16c-4ebd-9d4f-3a005b195a4b">0.2</ix:nonFraction>) million and $(<ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfODc5Mw_b173257b-79ed-4f64-b0ca-9eb3ab3bc781">0.1</ix:nonFraction>) million during the three months ended June 30, 2022 and 2021, respectively, and $(<ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfODg1NQ_89c33a1e-5ce8-479f-88eb-7e07140915cd">0.2</ix:nonFraction>) million and $<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-5" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfODg2Mg_ba6c76de-633d-46f4-bd44-8fd1c4706d34">0.1</ix:nonFraction> million during the six months ended June 30, 2022 and 2021, respectively.</span></div><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfMTA3MjE_6cbc46f0-e7d6-4d43-8b14-733815f4335a" continuedAt="i79b873b6d2d64755aa342a9865ea95fb" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share Attributable to Common Stockholders</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, stock options, and common stock subject to repurchase related to early exercise of stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities. The Company considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities, because holders of such shares have non-forfeitable </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pulmonx Corporation</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Interim Condensed Consolidated Financial Statements (Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2f358ed4dc1c4d6a9b195e2b37ba4325"><ix:continuation id="i79b873b6d2d64755aa342a9865ea95fb">dividend rights in the event a dividend is paid on common stock. The holders of the shares issued upon early exercise of stock options subject to repurchase do not have a contractual obligation to share in the Company’s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</ix:continuation></ix:continuation></span></div><div id="i784ba2f3210d43dcbb23721a3c553397_43"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.    <ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180My9mcmFnOmIzMTc5ODM3NDAzNjQ1ZjViMjdmOGU5Njk4YTU0YTFlL3RleHRyZWdpb246YjMxNzk4Mzc0MDM2NDVmNWIyN2Y4ZTk2OThhNTRhMWVfNDQyNQ_09d1ef12-ede4-4b9f-84a5-70b525040bce" continuedAt="i42c0ac94b769447794c61ea62a97a5f5" escape="true">Recent Accounting Pronouncements</ix:nonNumeric></span></div><ix:continuation id="i42c0ac94b769447794c61ea62a97a5f5"><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180My9mcmFnOmIzMTc5ODM3NDAzNjQ1ZjViMjdmOGU5Njk4YTU0YTFlL3RleHRyZWdpb246YjMxNzk4Mzc0MDM2NDVmNWIyN2Y4ZTk2OThhNTRhMWVfNDQyNg_4fad172d-3d19-4072-ba07-80509bb96905" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848) (“ASU 2020-04”). The amendments in ASU 2020-04 provide optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in ASU 2020-04 are effective for all entities as of March 12, 2020 through December 31, 2022. An entity may elect to apply the amendments for contract modifications by Topic or Industry Subtopic as of any date from the beginning an interim period that includes or is subsequent to March 12, 2020, or prospectively from the date that the financial statements are available to be issued. Once elected for a Topic or an Industry Subtopic, the amendments must be applied prospectively for all eligible contract modifications for that Topic or Industry Subtopic. The Company may elect to apply ASU 2020-04 as its contracts referenced in London Interbank Offered Rate (“LIBOR”) are impacted by reference rate reform. The Company is currently evaluating the impact of the adoption of this ASU on the Company’s consolidated financial statements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments – Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new guidance will require financial instruments to be measured at amortized cost, and trade accounts receivable to be presented at the net amount expected to be collected. The new model requires an entity to estimate credit losses based on historical information, current information and reasonable and supportable forecasts, including estimates of prepayments. In November 2019, the FASB issued ASU 2019-10, according to which, the new standard is effective for public business entities that meet the definition of an SEC filer, excluding entities eligible to be smaller reporting companies (“SRC”) as defined by the SEC, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. For all other entities, including the Company, the new standard is effective for fiscal years beginning after December 15, 2022, and interim periods within that fiscal year. Early adoption is permitted. The Company is currently evaluating the impact of the new standard on the Company’s consolidated financial statements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other newly issued accounting pronouncements not yet effective have been deemed either immaterial or not applicable.</span></div></ix:nonNumeric></ix:continuation><div id="i784ba2f3210d43dcbb23721a3c553397_46"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.    <ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RleHRyZWdpb246YWU0YjcxMGRlYjJhNDU2Y2JlYTNhNjIxZTM5Mjc1YTZfNTA3Mg_8344fa73-9ba2-4adb-8b24-81b201e92e7b" continuedAt="ic2d90544f2d44eb890d865f54b19316e" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="ic2d90544f2d44eb890d865f54b19316e" continuedAt="i9880bf051b4f4eec84daca638b478a0b"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities are as follows:</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1—Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2—Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities;</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pulmonx Corporation</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Interim Condensed Consolidated Financial Statements (Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i9880bf051b4f4eec84daca638b478a0b" continuedAt="i80097dded63145fd94bd191017129773"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3—Unobservable inputs for the asset or liability only used when there is little, if any, market activity for the asset or liability at the measurement date. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Financial assets and liabilities held by the Company measured at fair value on a recurring basis include money market funds and marketable securities.</span></div><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RleHRyZWdpb246YWU0YjcxMGRlYjJhNDU2Y2JlYTNhNjIxZTM5Mjc1YTZfNTA3Mw_6d0224ee-433c-4fd3-b661-c8a5477f7463" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Measured and Recorded at Fair Value on a Nonrecurring Basis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company determines the fair value of long-lived assets held and used, such as intangible assets, by reference to independent appraisals, quoted market prices (e.g. an offer to purchase) and other factors. An impairment charge is recorded when the carrying value of the asset exceeds its fair value. As noted above, there have been no impairment charges recorded to date. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the term loan approximates the fair value and is classified as a Level 2 liability. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RleHRyZWdpb246YWU0YjcxMGRlYjJhNDU2Y2JlYTNhNjIxZTM5Mjc1YTZfNTA3NA_83218604-f8ca-4155-bd53-7c09ab39e138" continuedAt="if636d233967a477684914acdd9d31d85" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:45.127%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.744%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia14d74e4d29945248008eebccb61e736_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfMy0xLTEtMS0zOTM4Mw_9a8bc5dc-a631-47d5-af81-70e4622275d1">2,192</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43daee278edf4dd48795e6f8a76b68e6_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfMy0zLTEtMS0zOTM4Mw_fd430442-a2d7-4f6a-ad82-16ddb940111a">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1831dadd354b61891c517232e12cb6_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfMy01LTEtMS0zOTM4Mw_b4cd75b0-2ba2-4a1a-ba14-f8c9a598ba75">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92dd2cd839a240b486dff359bb786a00_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfMy03LTEtMS0zOTM4Mw_b0b75572-3cca-4639-9670-cbc00b00c804">2,192</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a66461de3154691bdf882e2e5dcd6c5_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfNC0xLTEtMS0zOTM4Mw_63509cfa-7242-48da-8623-20a56b078a8b">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e4dba1228e34cd98a8abd85532d7cb9_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfNC0zLTEtMS0zOTM4Mw_1808b27f-07dc-4e70-85ac-6a2914477ab4">2,497</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac94117f850b41d5b799ede5098093da_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfNC01LTEtMS0zOTM4Mw_ffc21905-84b4-4458-984e-d212696efb62">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a3f4a74924a4f12a1736df2d0a45713_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfNC03LTEtMS0zOTM4Mw_4d29bde0-8f78-4615-a703-d2a5cd9d64c6">2,497</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1e914ebc684f0b943cae94c69a0f1a_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfNS0xLTEtMS0zOTM4Mw_72901445-c582-42c5-8b38-e31f29065da9">2,192</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c2edf2f82884f7b832d7b6ce96cef26_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfNS0zLTEtMS0zOTM4Mw_0a587708-bc97-4a15-9d18-07c9ab0820fb">2,497</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id934753eb5f84d74951453f74f1c8782_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfNS01LTEtMS0zOTM4Mw_9fd2347c-cbb7-45ea-a83a-2e8241a88f81">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i513514d73a6d48d88da16ce034ab1bb4_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfNS03LTEtMS0zOTM4Mw_b02d8af2-12d4-4356-964c-16af04f0c8ae">4,689</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33985b0fd2d14a9dbba59257abcfcfbb_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfNy0xLTEtMS0zOTM4Mw_383eb077-1dee-4af2-9085-5f0290bcb1dc">25,171</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d7ee987153a4b9e864751c124470915_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfNy0zLTEtMS0zOTM4Mw_590ee445-2f7e-4f37-b0a8-98a7e7cd7090">8,971</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93d1d7e68d6546828a3bdc6fdcf003c5_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfNy01LTEtMS0zOTM4Mw_59529b00-b871-41a1-b432-b59facf26877">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48eb072a814e40a1b0c537a5e8d1ed0b_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfNy03LTEtMS0zOTM4Mw_73a0f442-2f22-4d8a-806c-298d4e90a7a7">34,142</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i675913f6b3cc4a0d80c3aedb6ff16277_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfOS0xLTEtMS0zOTM4Mw_6842e40a-8bdb-41cb-a18d-46f9fe627e5d">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1db3a72d8ab94a5290123d21241fdea7_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfOS0zLTEtMS0zOTM4Mw_785a4dac-d04d-4345-bbb0-99270b0f72de">10,681</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbcdc9fe2df04354bea1a37f7049921b_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfOS01LTEtMS0zOTM4Mw_d8988366-31b0-449c-bdca-bb7f6819de4f">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d15624d6984f4c8c651151aab177be_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfOS03LTEtMS0zOTM4Mw_3197d5b5-b178-472a-8da3-09f34dede8ad">10,681</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1e914ebc684f0b943cae94c69a0f1a_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfMTAtMS0xLTEtMzkzODM_ae2a47cf-7fb9-4b78-bc9f-99f90a86f773">25,171</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c2edf2f82884f7b832d7b6ce96cef26_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfMTAtMy0xLTEtMzkzODM_9cd970a3-3ae0-448a-bfc4-c453cfd8bf0f">19,652</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id934753eb5f84d74951453f74f1c8782_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfMTAtNS0xLTEtMzkzODM_beac7994-2149-45e7-abb3-27a824c397ec">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i513514d73a6d48d88da16ce034ab1bb4_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfMTAtNy0xLTEtMzkzODM_aca4f79f-0fae-44eb-abc1-51736e5ed53f">44,823</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1e914ebc684f0b943cae94c69a0f1a_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfMTEtMS0xLTEtMzkzODM_e9ceea79-1add-4e4e-8608-714d3aa51540">27,363</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c2edf2f82884f7b832d7b6ce96cef26_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfMTEtMy0xLTEtMzkzODM_077caca6-a898-4ff1-882f-4c2d3e5db741">22,149</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id934753eb5f84d74951453f74f1c8782_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfMTEtNS0xLTEtMzkzODM_7de9e71d-2981-4ae0-9946-389821495516">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i513514d73a6d48d88da16ce034ab1bb4_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfMTEtNy0xLTEtMzkzODM_f6bc6f44-0321-4c1c-a849-e6e5b5bc5c74">49,512</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="i513514d73a6d48d88da16ce034ab1bb4_I20220630" decimals="INF" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RleHRyZWdpb246YWU0YjcxMGRlYjJhNDU2Y2JlYTNhNjIxZTM5Mjc1YTZfMzI5ODUzNDg5MDY4Ng_ff951349-028a-4b88-8d3d-8b1c79260938">no</ix:nonFraction> liabilities measured at fair value on a recurring and non-recurring basis as of June 30, 2022.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pulmonx Corporation</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Interim Condensed Consolidated Financial Statements (Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i80097dded63145fd94bd191017129773"><ix:continuation id="if636d233967a477684914acdd9d31d85"><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:45.127%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.744%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cff6d84193e4dc3b07c75074e60392b_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMy0xLTEtMS0zOTM4Mw_7ace098c-d19c-4b9b-913e-9d92da41d129">831</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i327e3148cf134e40be0e4c43a80759bb_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMy0zLTEtMS0zOTM4Mw_d1c1193c-0b6d-4c6a-b3f2-d1fc85e8478a">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c4a433674ca4a14a572851571072b9b_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMy01LTEtMS0zOTM4Mw_fea34d76-73d7-4dfe-bcb5-9ae447387fd5">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa4a290d955f4814b581d6476ee9dc7d_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMy03LTEtMS0zOTM4Mw_c8e09e73-4ed5-4f7a-920e-7d922bf9e370">831</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc26381124441d290073fcf4b193645_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfNC0xLTEtMS0zOTM4Mw_97fe4c38-0fdb-4c17-8989-f54e43f3f893">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib192c97ab709429e8d8bace98b7c84f5_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfNC0zLTEtMS0zOTM4Mw_b318580e-4ad3-48df-a657-3f1e04dd2a54">2,000</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i042fafa9d9b249748a84902a33a8986a_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfNC01LTEtMS0zOTM4Mw_86ff5cb7-5087-4ce3-876b-7c6fb0298e81">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e96426a76854bbeaa9ad9992e1a9dc0_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfNC03LTEtMS0zOTM4Mw_adffef9b-df2b-41a7-9dc5-0c674200398e">2,000</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a0edcb9b6dd478a89e87ca1f2ce26eb_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfNS0xLTEtMS0zOTM4Mw_e977b7f6-6592-414c-b37f-72db769d4dfb">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85fa5ce9fad74f399f8c8d25570c9689_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfNS0zLTEtMS0zOTM4Mw_be0afb3a-2bad-4b63-a77f-5469672428e4">4,410</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45edc210ab0745a5aa6286bb72d334b4_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfNS01LTEtMS0zOTM4Mw_16cdc3a3-af9c-4973-b252-8c9f79c8958d">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb589de7e36549c6a8aab0ff0cad6898_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfNS03LTEtMS0zOTM4Mw_ca7794bb-aff7-40a3-a5bb-f040a0bbfddc">4,410</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e16bb634cd6409fb8caa8fde1661af6_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfNi0xLTEtMS00MDIxNQ_34d466e9-42e6-482d-b59a-09d1780552d3">831</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if24e988586d6451fab56769a5c714496_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfNi0zLTEtMS00MDIxNQ_5ba2eebc-6131-4352-b1ff-54ef9d0fab8b">6,410</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55d83c7769d745868fef46644ba31985_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfNi01LTEtMS00MDIxNQ_06c39159-f464-499b-9116-a8792faee288">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cd5fa1e86444765a02ded926ba518e5_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfNi03LTEtMS00MDIxNQ_e858ef82-927a-4cbc-8578-1957c516dfaf">7,241</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1438553a44e74136882a9e6307daa44c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfOC0xLTEtMS00MDIxNQ_b44e1910-e8d5-452c-a381-cdbcf5a43edb">14,977</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b3656c560c64ebe973f848fc48ad5ad_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfOC0zLTEtMS00MDIxNQ_15d54d42-ee3b-4a44-9e1f-494fc7eeb802">5,504</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id36ebdf32a5a4301a2002cf016417bf4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfOC01LTEtMS00MDIxNQ_ea58cd79-cd2b-4bbd-9d8b-76fd099604d2">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2007efd115d4f399413c5ee0cf7dbee_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfOC03LTEtMS00MDIxNQ_d9d58f14-f716-4be8-a1e6-27730682b3ec">20,481</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id29e377b291b419eba3b2d065798ef5c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfOS0xLTEtMS00MDIxNQ_cb079bf9-0413-4607-bdfd-52c757317021">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id75b22a41add4eceb26a8efffed5d602_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfOS0zLTEtMS00MDIxNQ_bb88d59c-44c4-44a2-8ac9-e691aecca1bd">19,107</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife09428d3f97465496a4b2c6bd0ba97f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfOS01LTEtMS00MDIxNQ_79a5ff2e-2e2f-4f63-900f-0d1c9b001c1d">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeec9606af284a379aa614910d3a61ab_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfOS03LTEtMS00MDIxNQ_f4b9d50c-622a-44c0-952c-8dc445c50a5f">19,107</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a0edcb9b6dd478a89e87ca1f2ce26eb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMTAtMS0xLTEtNDAyMTU_90159a06-3dab-43d8-92a2-aa8a468e4395">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85fa5ce9fad74f399f8c8d25570c9689_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMTAtMy0xLTEtNDAyMTU_67f83dfb-6294-4e95-9cde-60c1de6775ff">2,914</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45edc210ab0745a5aa6286bb72d334b4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMTAtNS0xLTEtNDAyMTU_6ed23069-c7a4-400a-8a60-5911b93af7c1">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb589de7e36549c6a8aab0ff0cad6898_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMTAtNy0xLTEtNDAyMTU_d1274910-b2cc-4c50-9b8d-ffc8da4e0311">2,914</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e16bb634cd6409fb8caa8fde1661af6_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMTEtMS0xLTEtNDAyMTU_96937b30-1f70-4359-9b58-193c7ff4da40">14,977</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if24e988586d6451fab56769a5c714496_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMTEtMy0xLTEtNDAyMTU_ea4094bc-700c-43d7-8420-22adc56ef152">27,525</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55d83c7769d745868fef46644ba31985_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMTEtNS0xLTEtNDAyMTU_18e4f507-b02b-4b40-bcb5-9b485d652323">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cd5fa1e86444765a02ded926ba518e5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMTEtNy0xLTEtNDAyMTU_009e2d02-803d-4664-97ed-46bb76373be6">42,502</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e16bb634cd6409fb8caa8fde1661af6_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMTItMS0xLTEtNDAyMTU_8afc240e-256f-4f8f-a5c9-e58cd17f28ce">15,808</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if24e988586d6451fab56769a5c714496_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMTItMy0xLTEtNDAyMTU_74fa063b-874c-490a-99ca-91703d3d66ab">33,935</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55d83c7769d745868fef46644ba31985_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMTItNS0xLTEtNDAyMTU_e849189b-ac92-4ff4-ba27-c0aaad91e814">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cd5fa1e86444765a02ded926ba518e5_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMTItNy0xLTEtNDAyMTU_3316011a-4cd2-4b48-8bfa-aca2ceab48e4">49,743</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="i4cd5fa1e86444765a02ded926ba518e5_I20211231" decimals="INF" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RleHRyZWdpb246YWU0YjcxMGRlYjJhNDU2Y2JlYTNhNjIxZTM5Mjc1YTZfMzI5ODUzNDg5MDY5NA_ccdbed28-94a6-4d51-9435-3e58eaa9d92c">no</ix:nonFraction> liabilities measured at fair value on a recurring and non-recurring basis as of December 31, 2021.</span></div></ix:continuation><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RleHRyZWdpb246YWU0YjcxMGRlYjJhNDU2Y2JlYTNhNjIxZTM5Mjc1YTZfNTA3NQ_252e416a-70db-416d-953d-99111bc83a88" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the cost, unrealized gains and losses and fair value of marketable securities (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:45.127%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.744%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a302b35b1a8429293ae6b864424ecc3_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfMy0xLTEtMS0zOTM4Mw_99c0cc45-0e52-4b7a-a1f1-57e66eec4a34">34,462</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a302b35b1a8429293ae6b864424ecc3_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfMy0zLTEtMS0zOTM4Mw_705607d8-0edb-43c5-86ee-be82990d78b4">320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a302b35b1a8429293ae6b864424ecc3_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfMy01LTEtMS0zOTM4Mw_96ed11ff-8248-4fd3-b9d4-98755d431bc1">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a302b35b1a8429293ae6b864424ecc3_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfMy03LTEtMS0zOTM4Mw_8e0f7259-74e5-4927-b254-c7de1830e4bf">34,142</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50bcd4c228d24da381ad2f53d3c36667_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfNS0xLTEtMS0zOTM4Mw_0482761c-308c-4c4e-baf2-b07de93dd790">10,721</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50bcd4c228d24da381ad2f53d3c36667_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfNS0zLTEtMS0zOTM4Mw_836a7ca4-1a15-44c5-8204-29eb317c24c8">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50bcd4c228d24da381ad2f53d3c36667_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfNS01LTEtMS0zOTM4Mw_e1fe3007-6cd8-4c25-8d59-7bbc1ef72945">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50bcd4c228d24da381ad2f53d3c36667_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfNS03LTEtMS0zOTM4Mw_4413f436-b15c-43e4-b529-ed9063965cac">10,681</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfNi0xLTEtMS0zOTM4Mw_71e39e8d-8e40-475a-85c9-204063215541">45,183</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfNi0zLTEtMS0zOTM4Mw_de119801-65a8-4af3-a1d8-6c3829989baf">360</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfNi01LTEtMS0zOTM4Mw_1767a5d7-c7d3-4a5b-9db9-f1a76d3ca5d8">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfNi03LTEtMS0zOTM4Mw_d36e30c4-456f-4410-a315-d6c49676207d">44,823</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized on the consolidated balance sheet</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfOS03LTEtMS0zOTM4Mw_f618a57a-5a64-4745-a725-7bf5da5b0601">40,139</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Long-term marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfMTAtNy0xLTEtMzkzODM_ef5cc73d-c3e9-4674-a9a5-de5f14bfbebb">4,684</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="lung:CashCashEquivalentsAndAvailableForSaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfMTEtNy0xLTEtMzkzODM_3ea7f001-e13e-4076-b8a2-61c92007d638">44,823</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:45.127%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.744%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i838adf7de26c4611806f98bea73a4138_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfMi0xLTEtMS00MDMxMQ_7c35b8bf-920a-4866-8871-63ee3cb1523c">20,509</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i838adf7de26c4611806f98bea73a4138_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfMi0zLTEtMS00MDMxMQ_f392ac1e-aab2-4389-ad35-dda96de4c0ac">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i838adf7de26c4611806f98bea73a4138_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfMi01LTEtMS00MDMxMQ_1dec1304-8be3-4a32-850a-40bd6afa673c">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i838adf7de26c4611806f98bea73a4138_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfMi03LTEtMS00MDMxMQ_9919dd43-fbeb-4745-a869-3188d60814da">20,481</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec39bddb1fc94428b8d0d9084e2aba6b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfMy0xLTEtMS00MDMxMQ_1ca7bce7-f2a5-4381-850f-b8ca7ee4897f">2,915</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec39bddb1fc94428b8d0d9084e2aba6b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfMy0zLTEtMS00MDMxMQ_2e8bb929-bc0d-4b40-9209-d3e0302b3d9f">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec39bddb1fc94428b8d0d9084e2aba6b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfMy01LTEtMS00MDMxMQ_fa0b2cd0-c2c4-4fc4-81c2-5c2f0c7a5128">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec39bddb1fc94428b8d0d9084e2aba6b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfMy03LTEtMS00MDMxMQ_525d4e20-b2d5-475e-a2eb-d2bcc8e57bed">2,914</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if09b01b3b49e4c1cb9a520fc3d129aa1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfNC0xLTEtMS00MDMxMQ_391a4e72-4764-4b24-8d83-a7dff7d13867">19,102</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if09b01b3b49e4c1cb9a520fc3d129aa1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfNC0zLTEtMS00MDMxMQ_1bb86935-b8f9-46cd-98e6-47c5d2fc92dd">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if09b01b3b49e4c1cb9a520fc3d129aa1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfNC01LTEtMS00MDMxMQ_e4c3475d-c8a3-45cf-aeb4-4cadba2f6f07">5</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if09b01b3b49e4c1cb9a520fc3d129aa1_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfNC03LTEtMS00MDMxMQ_5c0f7675-f77b-42f2-8515-8e5fecffcf48">19,107</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfNS0xLTEtMS00MDMxMQ_92f3cdbd-2562-4a8a-84ac-c1f10a9a704b">42,526</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfNS0zLTEtMS00MDMxMQ_725039ba-1064-4cb6-8cd3-ac1c1e83e179">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfNS01LTEtMS00MDMxMQ_e0907f6b-f31e-4bb4-9710-83d5b126a14e">5</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfNS03LTEtMS00MDMxMQ_49e04848-562f-454d-8fa4-421366760bf4">42,502</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized on the consolidated balance sheet</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfNy03LTEtMS00MDMxMQ_af036517-d609-4156-8937-35f8e88bdfb5">31,561</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Long-term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfOC03LTEtMS00MDMxMQ_9c0c7dbd-3a06-4d24-8fdb-ff8d9f3cdf23">10,941</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="lung:CashCashEquivalentsAndAvailableForSaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfOS03LTEtMS00MDMxMQ_630848b3-e180-4cc5-8399-1fb16a02eb05">42,502</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivable on marketable securities of less than $<ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RleHRyZWdpb246YWU0YjcxMGRlYjJhNDU2Y2JlYTNhNjIxZTM5Mjc1YTZfMzI2Ng_ab5cfaa6-fe31-4517-8223-f8da410dc222">0.1</ix:nonFraction> million and less than $<ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RleHRyZWdpb246YWU0YjcxMGRlYjJhNDU2Y2JlYTNhNjIxZTM5Mjc1YTZfMTA5OTUxMTYzNTIzMw_445e65aa-0782-4e0d-aeb6-8e3619ad176e">0.1</ix:nonFraction> million as of June 30, 2022 and December 31, 2021, respectively, is included in prepaid expenses and other current assets on the condensed consolidated balance sheet.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i784ba2f3210d43dcbb23721a3c553397_49"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pulmonx Corporation</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Interim Condensed Consolidated Financial Statements (Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.    <ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTczMw_fb19bd5d-41b2-447b-bd0b-4218709948fc" continuedAt="ic537480260c648ac85b42c18dea1a016" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="ic537480260c648ac85b42c18dea1a016" continuedAt="i77fe72e1f7bc46b8ade7ff9bb6739459"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTczNA_5c067f3f-13b7-49a6-a40f-6a314ece0960" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s cash and cash equivalents consist of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjEzMmY1M2NmZDVkNDQ1ODE5MDBiOGM3MmJmMjRjOTc2L3RhYmxlcmFuZ2U6MTMyZjUzY2ZkNWQ0NDU4MTkwMGI4YzcyYmYyNGM5NzZfMi0xLTEtMS0zOTM4Mw_37ddb384-8a2a-428a-9f16-317099387546">117,258</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjEzMmY1M2NmZDVkNDQ1ODE5MDBiOGM3MmJmMjRjOTc2L3RhYmxlcmFuZ2U6MTMyZjUzY2ZkNWQ0NDU4MTkwMGI4YzcyYmYyNGM5NzZfMi0zLTEtMS0zOTM4Mw_1b3b96de-eb53-493a-a46e-a2c57d6ae6dc">141,239</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:MoneyMarketFundsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjEzMmY1M2NmZDVkNDQ1ODE5MDBiOGM3MmJmMjRjOTc2L3RhYmxlcmFuZ2U6MTMyZjUzY2ZkNWQ0NDU4MTkwMGI4YzcyYmYyNGM5NzZfNC0xLTEtMS0zOTM4Mw_5116d8ff-09dd-4bc0-9653-c347b1c94790">2,192</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjEzMmY1M2NmZDVkNDQ1ODE5MDBiOGM3MmJmMjRjOTc2L3RhYmxlcmFuZ2U6MTMyZjUzY2ZkNWQ0NDU4MTkwMGI4YzcyYmYyNGM5NzZfNC0zLTEtMS0zOTM4Mw_cd8adb9e-3d62-4a55-893e-43b6aba5baf1">831</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:CommercialPaperAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjEzMmY1M2NmZDVkNDQ1ODE5MDBiOGM3MmJmMjRjOTc2L3RhYmxlcmFuZ2U6MTMyZjUzY2ZkNWQ0NDU4MTkwMGI4YzcyYmYyNGM5NzZfNS0xLTEtMS0zOTM4Mw_0d085edc-76b1-4a1c-a387-4acaa62440ed">2,497</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:CommercialPaperAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjEzMmY1M2NmZDVkNDQ1ODE5MDBiOGM3MmJmMjRjOTc2L3RhYmxlcmFuZ2U6MTMyZjUzY2ZkNWQ0NDU4MTkwMGI4YzcyYmYyNGM5NzZfNS0zLTEtMS0zOTM4Mw_736c90a6-3848-41c1-b00f-2fa1ece08c7c">2,000</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="lung:CorporateBondsDebtSecuritiesAtCarryingValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjEzMmY1M2NmZDVkNDQ1ODE5MDBiOGM3MmJmMjRjOTc2L3RhYmxlcmFuZ2U6MTMyZjUzY2ZkNWQ0NDU4MTkwMGI4YzcyYmYyNGM5NzZfNi0xLTEtMS00MDM0Mg_0d792856-935d-4cf4-9e7f-7cadf7bdcc15">—</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="lung:CorporateBondsDebtSecuritiesAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjEzMmY1M2NmZDVkNDQ1ODE5MDBiOGM3MmJmMjRjOTc2L3RhYmxlcmFuZ2U6MTMyZjUzY2ZkNWQ0NDU4MTkwMGI4YzcyYmYyNGM5NzZfNi0zLTEtMS00MDM0Mg_e6062e07-8807-4446-affd-375bcd114b78">4,410</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjEzMmY1M2NmZDVkNDQ1ODE5MDBiOGM3MmJmMjRjOTc2L3RhYmxlcmFuZ2U6MTMyZjUzY2ZkNWQ0NDU4MTkwMGI4YzcyYmYyNGM5NzZfNi0xLTEtMS0zOTM4Mw_16fe8f72-30e1-479b-9b4d-59805a9beb41">121,947</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjEzMmY1M2NmZDVkNDQ1ODE5MDBiOGM3MmJmMjRjOTc2L3RhYmxlcmFuZ2U6MTMyZjUzY2ZkNWQ0NDU4MTkwMGI4YzcyYmYyNGM5NzZfNi0zLTEtMS0zOTM4Mw_59981612-77a2-4924-9418-bc5f30033b91">148,480</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTczNQ_96fd4eae-8bb4-4f8c-9232-6a05d263bfd1" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjc1MDFhOGEwNDNmYTRjNzVhMjJjZDMzYTQ4NjA3NjBkL3RhYmxlcmFuZ2U6NzUwMWE4YTA0M2ZhNGM3NWEyMmNkMzNhNDg2MDc2MGRfMi0xLTEtMS0zOTM4Mw_1d6bdefd-194a-4a76-ab08-cc7557c29ffc">3,776</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjc1MDFhOGEwNDNmYTRjNzVhMjJjZDMzYTQ4NjA3NjBkL3RhYmxlcmFuZ2U6NzUwMWE4YTA0M2ZhNGM3NWEyMmNkMzNhNDg2MDc2MGRfMi0zLTEtMS0zOTM4Mw_02f3cc44-3196-47ec-9c33-d6fb8c0dd5dc">3,738</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjc1MDFhOGEwNDNmYTRjNzVhMjJjZDMzYTQ4NjA3NjBkL3RhYmxlcmFuZ2U6NzUwMWE4YTA0M2ZhNGM3NWEyMmNkMzNhNDg2MDc2MGRfMy0xLTEtMS0zOTM4Mw_9b101eac-f15c-4a6e-9b97-57d2b8acc21b">784</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjc1MDFhOGEwNDNmYTRjNzVhMjJjZDMzYTQ4NjA3NjBkL3RhYmxlcmFuZ2U6NzUwMWE4YTA0M2ZhNGM3NWEyMmNkMzNhNDg2MDc2MGRfMy0zLTEtMS0zOTM4Mw_bb0f3b28-a1ca-42c4-aba3-6a61cd65d376">518</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjc1MDFhOGEwNDNmYTRjNzVhMjJjZDMzYTQ4NjA3NjBkL3RhYmxlcmFuZ2U6NzUwMWE4YTA0M2ZhNGM3NWEyMmNkMzNhNDg2MDc2MGRfNC0xLTEtMS0zOTM4Mw_08f5e7a4-a164-44c2-bc54-7abc8806ea29">14,652</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjc1MDFhOGEwNDNmYTRjNzVhMjJjZDMzYTQ4NjA3NjBkL3RhYmxlcmFuZ2U6NzUwMWE4YTA0M2ZhNGM3NWEyMmNkMzNhNDg2MDc2MGRfNC0zLTEtMS0zOTM4Mw_3936d3ca-c7c0-4e37-b692-91e7ce541a67">12,029</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjc1MDFhOGEwNDNmYTRjNzVhMjJjZDMzYTQ4NjA3NjBkL3RhYmxlcmFuZ2U6NzUwMWE4YTA0M2ZhNGM3NWEyMmNkMzNhNDg2MDc2MGRfNS0xLTEtMS0zOTM4Mw_668ab112-2063-4c15-ab64-855cbbf7975c">19,212</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjc1MDFhOGEwNDNmYTRjNzVhMjJjZDMzYTQ4NjA3NjBkL3RhYmxlcmFuZ2U6NzUwMWE4YTA0M2ZhNGM3NWEyMmNkMzNhNDg2MDc2MGRfNS0zLTEtMS0zOTM4Mw_a8449b7d-764c-4dbb-a9f6-833fb658d83c">16,285</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTczNg_bccd94ab-7194-4520-8211-11b8f3e24bfa" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands): </span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmRjMmY0MTU3Y2Y5NTQyNjI4NjM2NzMzMjk5ODE5ZDc5L3RhYmxlcmFuZ2U6ZGMyZjQxNTdjZjk1NDI2Mjg2MzY3MzMyOTk4MTlkNzlfMi0xLTEtMS0zOTM4Mw_7c83402b-56bf-4e70-98e3-2666b4a50b88">2,886</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmRjMmY0MTU3Y2Y5NTQyNjI4NjM2NzMzMjk5ODE5ZDc5L3RhYmxlcmFuZ2U6ZGMyZjQxNTdjZjk1NDI2Mjg2MzY3MzMyOTk4MTlkNzlfMi0zLTEtMS0zOTM4Mw_2140779d-890f-400f-a2c6-c38e619de975">1,869</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmRjMmY0MTU3Y2Y5NTQyNjI4NjM2NzMzMjk5ODE5ZDc5L3RhYmxlcmFuZ2U6ZGMyZjQxNTdjZjk1NDI2Mjg2MzY3MzMyOTk4MTlkNzlfMy0xLTEtMS0zOTM4Mw_d5a953bf-8ca0-477c-bda5-a55387eb9834">820</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmRjMmY0MTU3Y2Y5NTQyNjI4NjM2NzMzMjk5ODE5ZDc5L3RhYmxlcmFuZ2U6ZGMyZjQxNTdjZjk1NDI2Mjg2MzY3MzMyOTk4MTlkNzlfMy0zLTEtMS0zOTM4Mw_f5b551e0-e85f-4879-8c0d-45f0d12db641">2,305</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT and other receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmRjMmY0MTU3Y2Y5NTQyNjI4NjM2NzMzMjk5ODE5ZDc5L3RhYmxlcmFuZ2U6ZGMyZjQxNTdjZjk1NDI2Mjg2MzY3MzMyOTk4MTlkNzlfNC0xLTEtMS0zOTM4Mw_62b87909-f9d6-4f0f-8ae0-c9b673f28a9f">25</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmRjMmY0MTU3Y2Y5NTQyNjI4NjM2NzMzMjk5ODE5ZDc5L3RhYmxlcmFuZ2U6ZGMyZjQxNTdjZjk1NDI2Mjg2MzY3MzMyOTk4MTlkNzlfNC0zLTEtMS0zOTM4Mw_bd50b920-d73f-40e0-967e-f628fb004d3e">362</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmRjMmY0MTU3Y2Y5NTQyNjI4NjM2NzMzMjk5ODE5ZDc5L3RhYmxlcmFuZ2U6ZGMyZjQxNTdjZjk1NDI2Mjg2MzY3MzMyOTk4MTlkNzlfNS0xLTEtMS0zOTM4Mw_c275e643-a58a-49e8-83a0-d63b64b6c774">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmRjMmY0MTU3Y2Y5NTQyNjI4NjM2NzMzMjk5ODE5ZDc5L3RhYmxlcmFuZ2U6ZGMyZjQxNTdjZjk1NDI2Mjg2MzY3MzMyOTk4MTlkNzlfNS0zLTEtMS0zOTM4Mw_ac826a64-9e91-4744-af2d-3e1e5bf8209f">347</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmRjMmY0MTU3Y2Y5NTQyNjI4NjM2NzMzMjk5ODE5ZDc5L3RhYmxlcmFuZ2U6ZGMyZjQxNTdjZjk1NDI2Mjg2MzY3MzMyOTk4MTlkNzlfNi0xLTEtMS0zOTM4Mw_211f304d-8bdc-4c24-8ed3-72f02022133e">3,731</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmRjMmY0MTU3Y2Y5NTQyNjI4NjM2NzMzMjk5ODE5ZDc5L3RhYmxlcmFuZ2U6ZGMyZjQxNTdjZjk1NDI2Mjg2MzY3MzMyOTk4MTlkNzlfNi0zLTEtMS0zOTM4Mw_193fb91d-f464-438f-ac1e-c49609a132d0">4,883</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capitalized Implementation Costs of a Hosting Arrangement</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has several software systems that are cloud-based hosting arrangements with service contracts. The Company accounts for costs incurred in connection with the implementation of these various software systems under ASU 2018-15, Intangibles—Goodwill and Other—Internal Use Software (Subtopic 350–40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract. The Company expenses all costs (internal and external) that are incurred in the planning and post-implementation operation stages. As of June 30, 2022, the Company has capitalized approximately $<ix:nonFraction unitRef="usd" contextRef="i5e482a0f02a04e4e9a095186ae75202f_I20220630" decimals="-5" name="us-gaap:HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTY0OTI2NzQ0NDY2NQ_89d72d4c-275f-4d22-8419-1c48251928fc">0.6</ix:nonFraction> million in implementation costs related to the application development stage. The capitalized costs are amortized on a straight-line basis over the non-cancelable contract terms, which are generally <ix:nonNumeric contextRef="ia8327b71a4e547faac046ef1de96ead9_D20220401-20220630" name="lung:HostingArrangementServiceContractImplementationCostCapitalizedAmortizationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTY0OTI2NzQ0NDY3OA_1f97ca34-df99-451b-98a8-eacce0965a03">three years</ix:nonNumeric>. As of June 30, 2022, approximately $<ix:nonFraction unitRef="usd" contextRef="iec403174da4d4b6f9ff96570a7e5a8f5_I20220630" decimals="-5" name="us-gaap:HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTY0OTI2NzQ0NDY5Nw_5222215e-673a-435e-a47c-c8316101b48c">0.2</ix:nonFraction> million </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pulmonx Corporation</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Interim Condensed Consolidated Financial Statements (Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i77fe72e1f7bc46b8ade7ff9bb6739459" continuedAt="ie7dca8b02f5043a39a884357fb351de1"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="i5b44ef956ce14264a4103fec3f984838_I20220630" decimals="-5" name="us-gaap:HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTY0OTI2NzQ0NDcxMQ_dbd4ec40-6497-46d2-9502-ba0433f0cd35">0.4</ix:nonFraction> million capitalized costs were included in prepaid expenses and other current assets, and other long-term assets, respectively. Amortization expense, which was included in SG&A expenses, was less than $<ix:nonFraction unitRef="usd" contextRef="ia8327b71a4e547faac046ef1de96ead9_D20220401-20220630" decimals="-5" name="us-gaap:HostingArrangementServiceContractImplementationCostExpenseAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTY0OTI2NzQ0NDcyNQ_f161c36a-25be-4f51-8cb6-abe8c16a8143">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idf3e46dc35da4ebb90badd8b66929912_D20220101-20220630" decimals="-5" name="us-gaap:HostingArrangementServiceContractImplementationCostExpenseAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTY0OTI2NzQ0NDgwOQ_c23b14f9-4f7b-4d21-98c5-c863d8a0e682">0.1</ix:nonFraction> million for the three and six months ended June 30, 2022.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTczNw_23c236ee-951b-4fcb-9139-f56793e3e908" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1840bfb02e1b469bbd139ead973986ca_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfMi0xLTEtMS0zOTM4Mw_c1353280-d1e6-41b4-bba3-a7d111a94f5b">1,956</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i809590d3637c40e798f0aed4272f42ca_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfMi0zLTEtMS0zOTM4Mw_d891d619-7f3a-4258-9d57-85f2fee9d221">1,635</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i339317d369b543779f5eb59e6be6a75b_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfMy0xLTEtMS0zOTM4Mw_d644d584-2538-4a2b-93e0-866cad32e158">1,623</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i178bc0d657d34b21aa1fd8fd4e374909_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfMy0zLTEtMS0zOTM4Mw_c538ee06-37f2-4a48-8560-0463f4affbc0">1,561</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc8aa7e2c53d4718b1022132994a93ab_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfNC0xLTEtMS0zOTM4Mw_56cc3b72-18b6-4ad8-a0a9-1c10abeb8844">262</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40fb5bdc0f7e47eba46c35d13149ff1a_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfNC0zLTEtMS0zOTM4Mw_f19c8d0a-611d-4043-bed6-f44420f3b261">252</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e0fd137e3246b38ec39ff427bd5719_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfNS0xLTEtMS0zOTM4Mw_9d00e41c-5618-4955-936a-ff2e9de480b6">2,277</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0aa7a0e30fc4971a837f40cff89c0d8_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfNS0zLTEtMS0zOTM4Mw_5f758dbb-5ba2-4ab3-9eac-f7f878200bf0">2,277</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia81181d7be0d45bcb4069dea54e60219_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfNi0xLTEtMS0zOTM4Mw_e5167e7f-e22d-4b3b-92cf-7fb483b78f43">1,677</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb23404694384f0c8275849d24245f2e_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfNi0zLTEtMS0zOTM4Mw_57070b65-0d71-4d16-915c-cf02dd230c6c">1,332</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfNy0xLTEtMS0zOTM4Mw_f9f7c4e1-db07-4a13-bc98-d1ccc6936187">7,795</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfNy0zLTEtMS0zOTM4Mw_0cf3bbfe-b6b2-431f-98f3-1fe3a646d1d2">7,057</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfOC0xLTEtMS0zOTM4Mw_22b878d9-bf42-49fa-af8c-e25e1dbf7c7d">2,863</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfOC0zLTEtMS0zOTM4Mw_e5b40d84-275d-407b-86d8-add48cf50ed8">2,243</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfOS0xLTEtMS0zOTM4Mw_ed970c1b-9a53-405a-bbf0-61123f19d008">4,932</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfOS0zLTEtMS0zOTM4Mw_4ac34ff9-e4bc-4820-98b1-86ac452af8e2">4,814</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three months ended June 30, 2022 and June 30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfNDk1_31ba6960-436f-41f3-91c9-bc195f733dda">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfNTAy_4dd4ab64-c276-49df-a263-0e23842b36cd">0.1</ix:nonFraction> million, respectively. Depreciation expense for the six months ended June 30, 2022 and June 30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfNTgw_8e7fabf6-b817-4be2-ae33-ba692bcb2156">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfNTg3_d1e421c7-a92f-4149-bcb7-3d9be123d325">0.2</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill was $<ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfNjI3_832a6d58-4f7a-42ef-9a0c-7c57ed17020a"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfNjI3_e466f5a0-1536-441c-bb47-b12e38e3240d">2.3</ix:nonFraction></ix:nonFraction> million as of June 30, 2022 and December 31, 2021 arising from the Company’s acquisition of Emphasys Medical, Inc, in March 2009. <ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="INF" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfNzI2_4e9378a7-cd62-4d88-b6e4-16c733a5568d">No</ix:nonFraction> goodwill impairment losses have been recognized since the acquisition. There were <ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="INF" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfODEx_49d6fd56-3ccb-4932-a0c5-34f48bc1c15d"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="INF" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfODEx_8d52c6a5-bc79-41be-9845-427ff30881e7"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="INF" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfODEx_e448ad3d-6420-4baf-9231-4cac175f75a6"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="INF" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfODEx_ee6fc928-b6e2-423b-825c-d4d71dd7951b">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> acquisitions or dispositions of goodwill in six months ended June 30, 2022 and 2021. The Company assesses goodwill for impairment annually, or more frequently, when events or changes in circumstances indicate there may be impairment. Through June 30, 2022, there have been no events or changes in circumstances that indicated that the carrying value of goodwill may not be recoverable. As a result, <ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTE4OA_8bfcada9-10f7-407d-a4af-c7b1441ac3b0">no</ix:nonFraction> impairment charge was recorded during the six months ended June 30, 2022.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pulmonx Corporation</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Interim Condensed Consolidated Financial Statements (Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="ie7dca8b02f5043a39a884357fb351de1"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTczOA_a0ff3a1d-f7d5-42d2-a3e1-32dd8b7cd66d" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad04ff000fc942258f4e9cf9f39d4fb5_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjg4ZWViYjVmNjZjNTQxMzBhNDY0YTk5YmEzYTliOTRkL3RhYmxlcmFuZ2U6ODhlZWJiNWY2NmM1NDEzMGE0NjRhOTliYTNhOWI5NGRfMi0xLTEtMS0zOTM4Mw_f0370542-a3af-4c39-bac0-8bdcff6e2745">1,658</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad04ff000fc942258f4e9cf9f39d4fb5_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjg4ZWViYjVmNjZjNTQxMzBhNDY0YTk5YmEzYTliOTRkL3RhYmxlcmFuZ2U6ODhlZWJiNWY2NmM1NDEzMGE0NjRhOTliYTNhOWI5NGRfMi0zLTEtMS0zOTM4Mw_cc8f2949-66bc-4dd0-913f-fe0222f2706a">1,464</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad04ff000fc942258f4e9cf9f39d4fb5_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjg4ZWViYjVmNjZjNTQxMzBhNDY0YTk5YmEzYTliOTRkL3RhYmxlcmFuZ2U6ODhlZWJiNWY2NmM1NDEzMGE0NjRhOTliYTNhOWI5NGRfMi01LTEtMS0zOTM4Mw_710d7eae-fa14-4184-b66f-3409c7add2f8">194</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95b7e760966d41e297348550b546a87e_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjg4ZWViYjVmNjZjNTQxMzBhNDY0YTk5YmEzYTliOTRkL3RhYmxlcmFuZ2U6ODhlZWJiNWY2NmM1NDEzMGE0NjRhOTliYTNhOWI5NGRfMy0xLTEtMS0zOTM4Mw_5b45dc8a-25fd-4c3d-81fc-97343e66ffd9">191</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95b7e760966d41e297348550b546a87e_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjg4ZWViYjVmNjZjNTQxMzBhNDY0YTk5YmEzYTliOTRkL3RhYmxlcmFuZ2U6ODhlZWJiNWY2NmM1NDEzMGE0NjRhOTliYTNhOWI5NGRfMy0zLTEtMS0zOTM4Mw_026a471a-2424-499c-ab5f-3287861c55bf">169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95b7e760966d41e297348550b546a87e_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjg4ZWViYjVmNjZjNTQxMzBhNDY0YTk5YmEzYTliOTRkL3RhYmxlcmFuZ2U6ODhlZWJiNWY2NmM1NDEzMGE0NjRhOTliYTNhOWI5NGRfMy01LTEtMS0zOTM4Mw_defaace5-45d6-4b0d-b1f5-da93789844f0">22</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjg4ZWViYjVmNjZjNTQxMzBhNDY0YTk5YmEzYTliOTRkL3RhYmxlcmFuZ2U6ODhlZWJiNWY2NmM1NDEzMGE0NjRhOTliYTNhOWI5NGRfNC0xLTEtMS0zOTM4Mw_cdb3a6c9-ab78-4fe6-a52a-b4207e0ed835">1,849</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjg4ZWViYjVmNjZjNTQxMzBhNDY0YTk5YmEzYTliOTRkL3RhYmxlcmFuZ2U6ODhlZWJiNWY2NmM1NDEzMGE0NjRhOTliYTNhOWI5NGRfNC0zLTEtMS0zOTM4Mw_ff07d1cf-6fec-4164-b950-434136569f15">1,633</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjg4ZWViYjVmNjZjNTQxMzBhNDY0YTk5YmEzYTliOTRkL3RhYmxlcmFuZ2U6ODhlZWJiNWY2NmM1NDEzMGE0NjRhOTliYTNhOWI5NGRfNC01LTEtMS0zOTM4Mw_26cd660f-d0bf-4dd5-8d8f-bcb2b2847bd8">216</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3cb7048a6fa4bb2bc49e5f307bee1ae_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmY1ODU1YmNiNjRmMjQ3M2RiN2YzNGRmNmZkNzJhOGI5L3RhYmxlcmFuZ2U6ZjU4NTViY2I2NGYyNDczZGI3ZjM0ZGY2ZmQ3MmE4YjlfMi0xLTEtMS0zOTM4Mw_9243e469-b279-489e-9ad2-2bb8e21af867">1,658</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3cb7048a6fa4bb2bc49e5f307bee1ae_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmY1ODU1YmNiNjRmMjQ3M2RiN2YzNGRmNmZkNzJhOGI5L3RhYmxlcmFuZ2U6ZjU4NTViY2I2NGYyNDczZGI3ZjM0ZGY2ZmQ3MmE4YjlfMi0zLTEtMS0zOTM4Mw_6472a21d-bf68-4ad9-8738-8b6b1b63a8d1">1,410</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3cb7048a6fa4bb2bc49e5f307bee1ae_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmY1ODU1YmNiNjRmMjQ3M2RiN2YzNGRmNmZkNzJhOGI5L3RhYmxlcmFuZ2U6ZjU4NTViY2I2NGYyNDczZGI3ZjM0ZGY2ZmQ3MmE4YjlfMi01LTEtMS0zOTM4Mw_4a205029-6cd0-4428-ab0c-ac2299f0e984">248</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c65329af5944c1e8409cad224f99d17_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmY1ODU1YmNiNjRmMjQ3M2RiN2YzNGRmNmZkNzJhOGI5L3RhYmxlcmFuZ2U6ZjU4NTViY2I2NGYyNDczZGI3ZjM0ZGY2ZmQ3MmE4YjlfMy0xLTEtMS0zOTM4Mw_5554ccda-b78d-48f4-a45e-b6e59b8256cd">191</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c65329af5944c1e8409cad224f99d17_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmY1ODU1YmNiNjRmMjQ3M2RiN2YzNGRmNmZkNzJhOGI5L3RhYmxlcmFuZ2U6ZjU4NTViY2I2NGYyNDczZGI3ZjM0ZGY2ZmQ3MmE4YjlfMy0zLTEtMS0zOTM4Mw_c7633750-812b-4e8f-bf6d-2a717076cefb">162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c65329af5944c1e8409cad224f99d17_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmY1ODU1YmNiNjRmMjQ3M2RiN2YzNGRmNmZkNzJhOGI5L3RhYmxlcmFuZ2U6ZjU4NTViY2I2NGYyNDczZGI3ZjM0ZGY2ZmQ3MmE4YjlfMy01LTEtMS0zOTM4Mw_ce3239f7-b7b6-4221-aa4f-521397272165">29</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmY1ODU1YmNiNjRmMjQ3M2RiN2YzNGRmNmZkNzJhOGI5L3RhYmxlcmFuZ2U6ZjU4NTViY2I2NGYyNDczZGI3ZjM0ZGY2ZmQ3MmE4YjlfNC0xLTEtMS0zOTM4Mw_af8c88a9-90f6-420e-8a25-2ad58f6b0d4a">1,849</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmY1ODU1YmNiNjRmMjQ3M2RiN2YzNGRmNmZkNzJhOGI5L3RhYmxlcmFuZ2U6ZjU4NTViY2I2NGYyNDczZGI3ZjM0ZGY2ZmQ3MmE4YjlfNC0zLTEtMS0zOTM4Mw_d242c4bb-9490-414e-9877-37497896d488">1,572</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmY1ODU1YmNiNjRmMjQ3M2RiN2YzNGRmNmZkNzJhOGI5L3RhYmxlcmFuZ2U6ZjU4NTViY2I2NGYyNDczZGI3ZjM0ZGY2ZmQ3MmE4YjlfNC01LTEtMS0zOTM4Mw_7d2574d2-502c-44d0-8cb8-479e3cc9920c">277</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense relating to the intangibles totaled less than $<ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTQwMg_577ce3d7-d867-48c0-8f01-a0a3f15d4db9"><ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTQwMg_fe87b0ef-7cd1-43d0-bbda-ddfdd71c807d">0.1</ix:nonFraction></ix:nonFraction> million during each of the three months ended June 30, 2022 and June 30, 2021, respectively. Amortization expense relating to the intangibles totaled $<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTUyNQ_a09a661a-f233-43d5-bceb-ec33210a5003"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTUyNQ_f844cfcb-5818-4886-9ecc-12a17f8bc2b8">0.1</ix:nonFraction></ix:nonFraction> million during each six months ended June 30, 2022 and June 30, 2021, respectively.</span></div><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTczOQ_b9cf0929-0409-42f9-837d-4d1ff6ab702f" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense is as follows as of June 30, 2022 (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining six months)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmU4NDJkYTkzYmYzZjQ3OTc5NDNhMGYzYmM2NDllZDFiL3RhYmxlcmFuZ2U6ZTg0MmRhOTNiZjNmNDc5Nzk0M2EwZjNiYzY0OWVkMWJfMi0xLTEtMS0zOTM4Mw_b5b08737-7c8f-4b5e-9e2d-c95d6e27cd27">62</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmU4NDJkYTkzYmYzZjQ3OTc5NDNhMGYzYmM2NDllZDFiL3RhYmxlcmFuZ2U6ZTg0MmRhOTNiZjNmNDc5Nzk0M2EwZjNiYzY0OWVkMWJfMy0xLTEtMS0zOTM4Mw_61a84535-6acd-4562-a7a2-79851fd60d0d">123</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmU4NDJkYTkzYmYzZjQ3OTc5NDNhMGYzYmM2NDllZDFiL3RhYmxlcmFuZ2U6ZTg0MmRhOTNiZjNmNDc5Nzk0M2EwZjNiYzY0OWVkMWJfNC0xLTEtMS0zOTM4Mw_b922bd6f-1d48-4d67-ac5f-fef330a0be8e">31</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization expense</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmU4NDJkYTkzYmYzZjQ3OTc5NDNhMGYzYmM2NDllZDFiL3RhYmxlcmFuZ2U6ZTg0MmRhOTNiZjNmNDc5Nzk0M2EwZjNiYzY0OWVkMWJfNS0xLTEtMS0zOTM4Mw_33dccf3f-d44a-4465-84c9-ed0424817cb1">216</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities</span></div><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTczMg_4f6fb075-a567-4c55-82c0-9621f1a41755" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee bonuses and commissions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:AccruedBonusesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfMi0xLTEtMS0zOTM4Mw_53d01b9f-d114-4f24-9ace-4bc8377cffc9">3,179</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:AccruedBonusesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfMi0zLTEtMS0zOTM4Mw_99016fd1-bb26-4bec-a35c-eaf1e8688a71">4,741</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued vacation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:AccruedVacationCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfMy0xLTEtMS0zOTM4Mw_05d9e310-7749-4a58-98b7-30d5dcc0e778">2,134</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:AccruedVacationCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfMy0zLTEtMS0zOTM4Mw_7e3c28c4-60ce-4a5f-9c3d-cd1fb928e08e">1,850</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued personnel related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:OtherEmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfNC0xLTEtMS0zOTM4Mw_60576fef-0238-40de-9518-766bfed5a657">2,308</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:OtherEmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfNC0zLTEtMS0zOTM4Mw_8f69108e-3c97-4b85-88dd-74331f8e9836">2,145</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfNS0xLTEtMS0zOTM4Mw_3c1f05ef-e0f5-42e2-83f7-96aca8ebe707">2,233</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfNS0zLTEtMS0zOTM4Mw_815ac690-0ed6-4851-9139-a0763afe8ee8">2,420</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales taxes, franchise tax and VAT</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:TaxesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfNi0xLTEtMS0zOTM4Mw_94d0f6ca-a53e-4aea-b27e-ce3306560752">602</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:TaxesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfNi0zLTEtMS0zOTM4Mw_76c77bfd-2f03-415f-b884-d67a81b7dee3">730</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for early exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfNy0xLTEtMS0zOTM4Mw_00fc5d71-7d28-44dc-977f-045daef356e1">282</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfNy0zLTEtMS0zOTM4Mw_ae42984c-67dd-434f-9522-46a24d6dc203">399</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued inventory purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="lung:AccruedInventoryPurchasesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfOC0xLTEtMS0zOTM4Mw_bbdaa6cc-6e00-4a7b-86e2-0a3711dc819c">128</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="lung:AccruedInventoryPurchasesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfOC0zLTEtMS0zOTM4Mw_f5d3b9fe-5cd5-43c2-a69d-d2913b63fed4">258</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfOS0xLTEtMS0zOTM4Mw_01dbf71f-1cd3-4aef-9718-bf473a0d99cc">868</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfOS0zLTEtMS0zOTM4Mw_5a1a6399-4244-4a7a-99a0-01301034c882">823</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfMTAtMS0xLTEtMzkzODM_b4490161-907c-4cc6-9a5b-57019cd7427d">11,734</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfMTAtMy0xLTEtMzkzODM_7a0c1819-30f5-4928-a5dc-2fbfc3257a9b">13,366</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i784ba2f3210d43dcbb23721a3c553397_52"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pulmonx Corporation</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Interim Condensed Consolidated Financial Statements (Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.    <ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMTIxOTI_9c921bfb-6aed-488e-a7e4-272ac1d00b11" continuedAt="i8ef27d9bfa85432ba4670933a93717b1" escape="true">Long Term Debt and Convertible Notes</ix:nonNumeric></span></div><ix:continuation id="i8ef27d9bfa85432ba4670933a93717b1" continuedAt="i937269569ef34ca9a85c8d91915c166e"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Term Loan</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CIBC Loan</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2020, the Company executed a Loan and Security Agreement (the “CIBC Agreement”) with Canadian Imperial Bank of Commerce (“CIBC”) to raise up to $<ix:nonFraction unitRef="usd" contextRef="i69fa9455e50e46f4af26f9c44e3cb740_I20200220" decimals="INF" name="lung:DebtInstrumentFaceAmountIncludingAccordionFeature" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMzAzMw_e662d16c-9048-408a-a6ae-92dd9a45d656">32.0</ix:nonFraction> million in debt financing (“CIBC Loan”) consisting of $<ix:nonFraction unitRef="usd" contextRef="i662aa5e4c8f94ee688483281db66fe8e_D20200220-20200220" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMzA4Mg_696efd8f-5376-4094-9e62-d159d413b6af">17.0</ix:nonFraction> million advanced at the closing of the agreement (“Tranche A”), with the option to draw up to an additional $<ix:nonFraction unitRef="usd" contextRef="i517ce1c551384aa19ddce0f3e57a8444_I20200220" decimals="INF" name="lung:DebtInstrumentAccordionFeatureIncreaseFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMzE4OA_374710c8-6507-48fa-8993-327e99efd759">8.0</ix:nonFraction> million (“Tranche B”) and an additional financing tranche (“Tranche C”) of up to $<ix:nonFraction unitRef="usd" contextRef="i365110653de64470b9da2fd7e9534eff_I20200220" decimals="INF" name="lung:DebtInstrumentAccordionFeatureIncreaseFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMzMyNA_f46e3a1b-1354-4859-9787-b508cdd8f360">7.0</ix:nonFraction> million on or prior to February 20, 2022. Neither Tranche B nor Tranche C was drawn before the expiration date. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CIBC Loan originally had a <ix:nonNumeric contextRef="i543c3e76e6bb46e1b76eef8fae5afbeb_D20200220-20200220" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMTIxOTM_152c4018-abe3-43a2-9476-3ae3ee8b45fd">five-year</ix:nonNumeric> term maturing on February 20, 2025, which included <ix:nonNumeric contextRef="i543c3e76e6bb46e1b76eef8fae5afbeb_D20200220-20200220" name="lung:DebtInstrumentPeriodicPaymentInterestOnlyTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMzgxMw_58cd35da-5938-49e3-9ebb-7dd9bbdd72a6">24</ix:nonNumeric> months of interest only payments followed by <ix:nonNumeric contextRef="i543c3e76e6bb46e1b76eef8fae5afbeb_D20200220-20200220" name="lung:DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMzg2MQ_c634a1b6-e202-4759-8a29-cf9d77c44c07">36</ix:nonNumeric> months of equal payments of principal and interest. The CIBC Loan bears interest at a floating rate equal to <ix:nonFraction unitRef="number" contextRef="i125e5025f90d4542857c5e912e248efa_D20200220-20200220" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfNDExNw_cd8f0a0c-12d9-4501-9fb1-9c88c428d870">1.0</ix:nonFraction>% above the Wall Street Journal Prime Rate at any time. The CIBC Loan is collateralized by substantially all of the Company’s assets, including cash and cash equivalents, accounts receivable, intellectual property and equipment. The Company may prepay the loan, subject to certain requirements. The CIBC Agreement includes customary restrictive covenants, financial covenants, events of default and other customary terms and conditions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company entered into a First Amendment to CIBC Agreement that changed the maturity date to March 15, 2022, which would be automatically extended to February 20, 2025 if the maturity of all outstanding convertible notes was extended to a date no earlier than May 21, 2025 or all convertible notes converted into convertible preferred stock of the Company. An amendment fee of $<ix:nonFraction unitRef="usd" contextRef="i31de136071f4464fa0afd580b08736c2_I20200430" decimals="-5" name="us-gaap:DebtInstrumentFeeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfNTA4NA_56113432-4638-4167-b4c4-dc0a138154f9">0.2</ix:nonFraction> million was paid. The amendment was accounted for as a debt modification and <ix:nonFraction unitRef="usd" contextRef="i0f999a2b8cd8404da746d5c0e0b4fa69_D20200401-20200430" decimals="INF" name="lung:GainLossOnAmendmentOfDebtInstrument" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfNTQ2NA_36d79038-61d1-40b2-981f-58f9a25a4e0d">no</ix:nonFraction> gain or loss was recognized. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, to address certain post-close covenants for which the Company was not in compliance, the Company entered into a Second Amendment to the CIBC Agreement that extended the compliance of such covenants to June 30, 2021. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company entered into an Amended and Restated CIBC Agreement which extended the maturity date from March 15, 2022 to February 20, 2025, and modified certain financial covenants. Per the amended terms, <ix:nonFraction unitRef="payment" contextRef="i69fa9455e50e46f4af26f9c44e3cb740_I20200220" decimals="INF" name="lung:DebtInstrumentNumberOfPeriodicPayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfNTk0OA_35f2bea7-1294-47bf-9b5f-bae4e9e44615">36</ix:nonFraction> equal payments of principal plus accrued interest would be due beginning March 31, 2022. In connection with the Amended and Restated agreement, the Company paid fees to CIBC of less than $<ix:nonFraction unitRef="usd" contextRef="i6f1e6dd7364444de8ff46bdf5cd1eb03_D20210301-20210331" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfNjI4Mg_878868de-8106-4cc1-90d1-c4ff28e38e5c">0.1</ix:nonFraction> million which were recorded as a discount on the CIBC Loan and are being accreted over the life of the term loan using the effective interest method. The amendment was accounted for as a debt modification and <ix:nonFraction unitRef="usd" contextRef="i484ba17f04d144eb9aee8b4620710100_D20210301-20210331" decimals="INF" name="lung:GainLossOnAmendmentOfDebtInstrument" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfNjQ4Ng_92b7ae8c-50da-4ee4-a68e-fe0527b5b9d8">no</ix:nonFraction> gain or loss was recognized.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company entered into a First Amendment to the Amended and Restated Loan and Security agreement with CIBC that extended the compliance of certain post-close covenants to March 31, 2022. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into a Second Amendment to the Amended and Restated Loan and Security Agreement with CIBC, which extended the interest only period of the loan from <ix:nonNumeric contextRef="i77dd9039bef24911aa020653e86f93f4_D20211001-20211031" name="lung:DebtInstrumentPeriodicPaymentInterestOnlyTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMzI5ODUzNDkwNDAzOQ_f8aee47c-6d95-4164-8a7a-47ebeffe6919">24</ix:nonNumeric> months to <ix:nonNumeric contextRef="i77dd9039bef24911aa020653e86f93f4_D20211001-20211031" name="lung:DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMzI5ODUzNDkwNDA1Mg_c529ff6f-149a-44d7-97ed-5439343ddddf">36</ix:nonNumeric> months. Under the amended terms, principal repayment will begin in February 2023. There was <ix:nonFraction unitRef="number" contextRef="i77dd9039bef24911aa020653e86f93f4_D20211001-20211031" decimals="INF" name="lung:IncreaseInLoanInterestRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMzI5ODUzNDkwNDA2NQ_bf5a353f-c052-4bde-9dd9-b78a12ef649d">no</ix:nonFraction> change to the loan interest rate or maturity date.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the CIBC Loan had an annual effective interest rate of <ix:nonFraction unitRef="number" contextRef="i77c3dfcc442f4078a50db735a19d5748_I20220630" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfNjc2NQ_88d84ed0-9fce-4262-ae81-cb889837caf9">4.71</ix:nonFraction>% per year.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial covenants in the CIBC Agreement require that, when the cash and cash equivalents of the Company is less than $<ix:nonFraction unitRef="usd" contextRef="i69fa9455e50e46f4af26f9c44e3cb740_I20200220" decimals="-5" name="lung:DebtInstrumentCovenantCashAndCashEquivalentsMinimumThresholdTriggerForRevenueRequirement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfNjkwMQ_ac7ecb79-873b-42a5-a2b7-1e90d15c96f2">100.0</ix:nonFraction> million, the Company have revenue for the trailing <ix:nonNumeric contextRef="i543c3e76e6bb46e1b76eef8fae5afbeb_D20200220-20200220" name="lung:DebtInstrumentCovenantMinimumRevenueRequirementPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMTIxODg_015ea02c-7733-42fc-89ac-a7dd1e6a9a1b">three-month</ix:nonNumeric> period ending on the last day of each fiscal quarter of not less than <ix:nonFraction unitRef="number" contextRef="i69fa9455e50e46f4af26f9c44e3cb740_I20200220" decimals="INF" name="lung:DebtInstrumentCovenantMinimumRevenueRequirementsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfNzAyNg_0eb009bb-6d18-42bd-a541-abb21661388a">80.0</ix:nonFraction>% of the revenue for the trailing <ix:nonNumeric contextRef="i543c3e76e6bb46e1b76eef8fae5afbeb_D20200220-20200220" name="lung:DebtInstrumentCovenantMinimumRevenueRequirementPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMTIxODQ_030e7f19-c0af-4797-9afe-4d5e2b818278">three-month</ix:nonNumeric> period, as set forth in the annual projections delivered to the CIBC. Further, the Company is required to maintain unrestricted cash in an aggregate amount equal to or greater than the Adjusted EBITDA loss as defined in the CIBC Agreement for the <ix:nonNumeric contextRef="i543c3e76e6bb46e1b76eef8fae5afbeb_D20200220-20200220" name="lung:DebtInstrumentCovenantUnrestrictedCashRequirementPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMTIxODk_9a693f10-c958-4212-a153-bf0cdbc52af5">four-month</ix:nonNumeric> period ending on any date of determination. As of June 30, 2022, the Company was in compliance with all covenants contained in CIBC Agreement.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pulmonx Corporation</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Interim Condensed Consolidated Financial Statements (Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i937269569ef34ca9a85c8d91915c166e"><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMTIxOTA_e7787031-7962-4b40-b300-ccfbd7fc087c" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CIBC Loan consists of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.573%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;padding-right:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c3dfcc442f4078a50db735a19d5748_I20220630" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmJjZmQ0NWZhNTBlZTRlOTdiZmMzZDg4NWFiYWZmMzAzL3RhYmxlcmFuZ2U6YmNmZDQ1ZmE1MGVlNGU5N2JmYzNkODg1YWJhZmYzMDNfMi0yLTEtMS0zOTM4Mw_2f00dca1-0d47-4f20-8f19-8913bf2403bd">17,000</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if05f081a56284af8acd87cd18fcceda5_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmJjZmQ0NWZhNTBlZTRlOTdiZmMzZDg4NWFiYWZmMzAzL3RhYmxlcmFuZ2U6YmNmZDQ1ZmE1MGVlNGU5N2JmYzNkODg1YWJhZmYzMDNfMi00LTEtMS0zOTM4Mw_3076fd9e-e2f6-48fe-8646-7678066139c9">17,000</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;padding-right:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt issuance costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77c3dfcc442f4078a50db735a19d5748_I20220630" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmJjZmQ0NWZhNTBlZTRlOTdiZmMzZDg4NWFiYWZmMzAzL3RhYmxlcmFuZ2U6YmNmZDQ1ZmE1MGVlNGU5N2JmYzNkODg1YWJhZmYzMDNfMy0yLTEtMS0zOTM4Mw_83f4215f-0968-45ab-a3e3-c2a3330c4f2d">99</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if05f081a56284af8acd87cd18fcceda5_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmJjZmQ0NWZhNTBlZTRlOTdiZmMzZDg4NWFiYWZmMzAzL3RhYmxlcmFuZ2U6YmNmZDQ1ZmE1MGVlNGU5N2JmYzNkODg1YWJhZmYzMDNfMy00LTEtMS0zOTM4Mw_a58cb214-00e8-454f-b460-78bb66c5cab4">131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;padding-right:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77c3dfcc442f4078a50db735a19d5748_I20220630" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmJjZmQ0NWZhNTBlZTRlOTdiZmMzZDg4NWFiYWZmMzAzL3RhYmxlcmFuZ2U6YmNmZDQ1ZmE1MGVlNGU5N2JmYzNkODg1YWJhZmYzMDNfNC0yLTEtMS0zOTM4Mw_0f7a1eea-8ced-46a1-b44a-f27a3a19e4ff">16,901</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if05f081a56284af8acd87cd18fcceda5_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmJjZmQ0NWZhNTBlZTRlOTdiZmMzZDg4NWFiYWZmMzAzL3RhYmxlcmFuZ2U6YmNmZDQ1ZmE1MGVlNGU5N2JmYzNkODg1YWJhZmYzMDNfNC00LTEtMS0zOTM4Mw_d72b46fe-b8bb-4e4a-9c42-76b665cf7635">16,869</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid $<ix:nonFraction unitRef="usd" contextRef="i543c3e76e6bb46e1b76eef8fae5afbeb_D20200220-20200220" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfNzUzMw_47cf2a50-8358-40f3-aa83-4f7a3c52e867">0.4</ix:nonFraction> million fees to the lender and third parties which is reflected as a discount on the CIBC Loan and is being accreted over the life of the term loan using the effective interest method. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022 and 2021, the Company recorded interest expense related to debt discount and debt issuance costs of CIBC Loan of less than $<ix:nonFraction unitRef="usd" contextRef="i2a6b51ede0b348778de030ce71e1beb5_D20220401-20220630" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMTA5OTUxMTY0ODY5OA_54f9d73e-afac-4701-83c0-9e685dae7637">0.1</ix:nonFraction> million and less than $<ix:nonFraction unitRef="usd" contextRef="ib7679901e2d74b97a73e37442ab74242_D20210401-20210630" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfNzg2OQ_3203efdb-f960-4a16-a417-3b62f11fa01b">0.1</ix:nonFraction> million, respectively. During the six months ended June 30, 2022 and 2021, the Company recorded interest expense related to debt discount and debt issuance costs of CIBC Loan of less than $<ix:nonFraction unitRef="usd" contextRef="i8396a841b0dd4c458e576ad2b5d930b5_D20220101-20220630" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMTA5OTUxMTY0ODk0OQ_5237b537-8a95-455b-a2f0-60f71d6908a7">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i35a8e4b3abcb47d78dd4215a8467d650_D20210101-20210630" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMTA5OTUxMTY0ODk1Nw_22fd1ed9-76e0-4bd9-ab0c-d97f67a13815">0.1</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense on the CIBC Loan amounted $<ix:nonFraction unitRef="usd" contextRef="i2a6b51ede0b348778de030ce71e1beb5_D20220401-20220630" decimals="-5" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfODEwNw_669e2451-3cb2-4328-9975-14c4119756a5">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib7679901e2d74b97a73e37442ab74242_D20210401-20210630" decimals="-5" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfODExNA_cdcb4031-34cb-46ef-b20b-3d497b28a035">0.2</ix:nonFraction> million during the three months ended June 30, 2022 and 2021, respectively. Interest expense on the CIBC Loan amounted $<ix:nonFraction unitRef="usd" contextRef="i8396a841b0dd4c458e576ad2b5d930b5_D20220101-20220630" decimals="-5" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfODIxNQ_90261c67-c2a0-4170-a131-8cdb9d612d48">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i35a8e4b3abcb47d78dd4215a8467d650_D20210101-20210630" decimals="-5" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfODIyMg_d4e80c7c-4c7d-458e-8412-77d961f1677b">0.4</ix:nonFraction> million during the six months ended June 30, 2022 and 2021, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, Pulmonx International Sàrl, a wholly-owned subsidiary of the Company, entered into a COVID-19 Credit Agreement with UBS Switzerland AG to receive up to <ix:nonFraction unitRef="chf" contextRef="i397678ceafef497b86b6e43ad8ea3a3b_I20200430" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfODQ2Mg_96390558-61f6-40b0-a773-6c503862d216">0.5</ix:nonFraction> million Swiss Francs ($<ix:nonFraction unitRef="usd" contextRef="i397678ceafef497b86b6e43ad8ea3a3b_I20200430" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfODQ3OQ_1adc85cb-7b72-45a7-8d80-cbe5763e790f">0.5</ix:nonFraction> million U.S. dollar equivalent) under Swiss Federal Government program to mitigate the economic impact of the spread of the coronavirus. In May 2020, Pulmonx International Sàrl received $<ix:nonFraction unitRef="chf" contextRef="ic26de67cef4149c0ad6d575b9330bbf0_D20200501-20200531" decimals="-5" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfODY2MA_1c4e50fe-635a-44ce-9319-a0ba2e4125b1">0.5</ix:nonFraction> million Swiss Francs ($<ix:nonFraction unitRef="usd" contextRef="ic26de67cef4149c0ad6d575b9330bbf0_D20200501-20200531" decimals="-5" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfODY3Nw_9ad471d7-5bdb-4663-b10b-3d1e719eba77">0.5</ix:nonFraction> million U.S. dollar equivalent) under the COVID-19 Credit Agreement. The COVID-19 Credit Agreement bears no interest and is being repaid in <ix:nonFraction unitRef="installment" contextRef="i397678ceafef497b86b6e43ad8ea3a3b_I20200430" decimals="INF" name="lung:NumberOfInstallmentsForRepayment" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMzI5ODUzNDkwNDA3NA_9e619da1-52eb-4522-b611-c833decf8ead">twelve</ix:nonFraction> equal installments, paid semi-annually, beginning in March of 2022. As of June 30, 2022, Pulmonx International Sàrl paid less than $<ix:nonFraction unitRef="usd" contextRef="i70d3599672cd4f2badc8f100594638fe_D20220101-20220630" decimals="-5" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMTA5OTUxMTY0NTQzMA_d3a7083f-8fb9-4fa0-a0d8-f04408717e93">0.1</ix:nonFraction> million to the lender.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Maturities of Financing Obligations</span></div><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMTIxOTE_2ec8bfcc-7fdc-4bd4-93f4-00c6fbda7b22" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the aggregate future payments under the CIBC Loan and Credit Agreement (including interest payments) are as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining six months)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmVlZDM1ZWU2MjVjMzRlMjg5OWViZTJmNzdkMjhmM2QwL3RhYmxlcmFuZ2U6ZWVkMzVlZTYyNWMzNGUyODk5ZWJlMmY3N2QyOGYzZDBfMC0xLTEtMS0zOTM4Mw_b3da4ce5-fcb5-404c-8fb2-8d8caf01e2e8">410</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmVlZDM1ZWU2MjVjMzRlMjg5OWViZTJmNzdkMjhmM2QwL3RhYmxlcmFuZ2U6ZWVkMzVlZTYyNWMzNGUyODk5ZWJlMmY3N2QyOGYzZDBfMS0xLTEtMS0zOTM4Mw_0ea676d5-bf52-4e37-81e4-0e64d975c318">7,779</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmVlZDM1ZWU2MjVjMzRlMjg5OWViZTJmNzdkMjhmM2QwL3RhYmxlcmFuZ2U6ZWVkMzVlZTYyNWMzNGUyODk5ZWJlMmY3N2QyOGYzZDBfMi0xLTEtMS0zOTM4Mw_747d295f-a2ed-400d-934b-593453b6b26e">8,843</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmVlZDM1ZWU2MjVjMzRlMjg5OWViZTJmNzdkMjhmM2QwL3RhYmxlcmFuZ2U6ZWVkMzVlZTYyNWMzNGUyODk5ZWJlMmY3N2QyOGYzZDBfMy0xLTEtMS0zOTM4Mw_aabb5437-c30e-4b1e-9caf-684ce7c4bc70">1,510</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmVlZDM1ZWU2MjVjMzRlMjg5OWViZTJmNzdkMjhmM2QwL3RhYmxlcmFuZ2U6ZWVkMzVlZTYyNWMzNGUyODk5ZWJlMmY3N2QyOGYzZDBfNC0xLTEtMS0zOTM4Mw_f8a4339a-fae7-4741-8cca-147c0fa062b9">87</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmVlZDM1ZWU2MjVjMzRlMjg5OWViZTJmNzdkMjhmM2QwL3RhYmxlcmFuZ2U6ZWVkMzVlZTYyNWMzNGUyODk5ZWJlMmY3N2QyOGYzZDBfNS0xLTEtMS00MDYxMw_aed36d98-4659-460c-8684-964b55c625c1">87</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmVlZDM1ZWU2MjVjMzRlMjg5OWViZTJmNzdkMjhmM2QwL3RhYmxlcmFuZ2U6ZWVkMzVlZTYyNWMzNGUyODk5ZWJlMmY3N2QyOGYzZDBfNS0xLTEtMS0zOTM4Mw_97e998d7-d11c-4614-b0f0-0516b7b3b352">18,716</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmVlZDM1ZWU2MjVjMzRlMjg5OWViZTJmNzdkMjhmM2QwL3RhYmxlcmFuZ2U6ZWVkMzVlZTYyNWMzNGUyODk5ZWJlMmY3N2QyOGYzZDBfNi0xLTEtMS0zOTM4Mw_bed1adfa-e909-42bc-bcc9-933f5762f532">99</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmVlZDM1ZWU2MjVjMzRlMjg5OWViZTJmNzdkMjhmM2QwL3RhYmxlcmFuZ2U6ZWVkMzVlZTYyNWMzNGUyODk5ZWJlMmY3N2QyOGYzZDBfNy0xLTEtMS0zOTM4Mw_6980e638-f050-41ce-bbbc-acfc6a84524a">1,236</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Term loan and credit agreement</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmVlZDM1ZWU2MjVjMzRlMjg5OWViZTJmNzdkMjhmM2QwL3RhYmxlcmFuZ2U6ZWVkMzVlZTYyNWMzNGUyODk5ZWJlMmY3N2QyOGYzZDBfOC0xLTEtMS0zOTM4Mw_764625c4-df38-445d-8825-eb37ac3a536f">17,381</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i784ba2f3210d43dcbb23721a3c553397_55"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.    <ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181NS9mcmFnOmE1OWM0YmRiMmU3MDQ4YjE5Zjk4NDA3MjExNjZhYmZkL3RleHRyZWdpb246YTU5YzRiZGIyZTcwNDhiMTlmOTg0MDcyMTE2NmFiZmRfNTc4_e50111ac-b037-451a-920d-2ca74af08e52" continuedAt="i911f799f066a4f71a3bbd91f31faa820" escape="true">Revenue Recognition</ix:nonNumeric></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i911f799f066a4f71a3bbd91f31faa820" continuedAt="i5b06e13143e64490a5033c3c01401e6d">The Company’s contract liabilities consist of deferred revenue for remaining performance obligations by the Company to the customer after delivery, which was $<ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181NS9mcmFnOmE1OWM0YmRiMmU3MDQ4YjE5Zjk4NDA3MjExNjZhYmZkL3RleHRyZWdpb246YTU5YzRiZGIyZTcwNDhiMTlmOTg0MDcyMTE2NmFiZmRfMTA5OTUxMTYyODM1Nw_e3d76ded-419c-44eb-b077-d0fa4adaa5a0">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181NS9mcmFnOmE1OWM0YmRiMmU3MDQ4YjE5Zjk4NDA3MjExNjZhYmZkL3RleHRyZWdpb246YTU5YzRiZGIyZTcwNDhiMTlmOTg0MDcyMTE2NmFiZmRfMTA5OTUxMTYyODM2Nw_5deb6401-8641-44aa-843f-2559ea79a659">0.2</ix:nonFraction> million as of June 30, 2022 and </ix:continuation></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pulmonx Corporation</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Interim Condensed Consolidated Financial Statements (Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i5b06e13143e64490a5033c3c01401e6d"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021, respectively. The deferred revenue as of December 31, 2020 was $<ix:nonFraction unitRef="usd" contextRef="iaa8e0cdfe47448be927a5cd420c16bf9_D20200101-20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181NS9mcmFnOmE1OWM0YmRiMmU3MDQ4YjE5Zjk4NDA3MjExNjZhYmZkL3RleHRyZWdpb246YTU5YzRiZGIyZTcwNDhiMTlmOTg0MDcyMTE2NmFiZmRfMTA5OTUxMTYyODQyNw_4554c0b5-ae1b-4a56-9702-9022f08b94fa">0.1</ix:nonFraction> million, which was recognized as revenue during the year ended December 31, 2021. The deferred revenue as of December 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181NS9mcmFnOmE1OWM0YmRiMmU3MDQ4YjE5Zjk4NDA3MjExNjZhYmZkL3RleHRyZWdpb246YTU5YzRiZGIyZTcwNDhiMTlmOTg0MDcyMTE2NmFiZmRfNjU5NzA2OTc2NzM0NQ_f2f1eda6-3195-4729-8ee3-eee55a622db4">0.2</ix:nonFraction> million, which was recognized as revenue during the six months ended June 30, 2022.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates its revenue by major geographic region, which has been disclosed in Note 12, “Segment Information”.</span></div></ix:continuation><div id="i784ba2f3210d43dcbb23721a3c553397_58"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.    <ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfNDQxOQ_4a65bd1d-f0c2-4c89-a45e-c94e1470d3bd" continuedAt="if6447b20fcba46c5b53bd6cebc341cc4" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="if6447b20fcba46c5b53bd6cebc341cc4" continuedAt="if2ef2fa98e9c41b0acc412e0edcab3dd"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a lease for its headquarters location in Redwood City, California. In October 2019, the Company renewed its lease for the headquarters location in Redwood City, California for an additional <ix:nonNumeric contextRef="i366bdd6cbcb6417f82564f08de535cb9_I20200831" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMjU4_96c08da0-c102-4e24-9b73-716e2c780a26">five years</ix:nonNumeric> commencing in August 2020 and expiring in July 2025. The monthly base rent during the renewed term is $<ix:nonFraction unitRef="usd" contextRef="i3a0e06bbd8104d1395b00aeca775a8d3_D20200801-20200831" decimals="-5" name="lung:OperatingLeaseMonthlyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMzYz_9e0a7418-18f4-460b-b0fe-0c97246cc89a">0.1</ix:nonFraction> million and is subject to an annual increase of <ix:nonFraction unitRef="number" contextRef="i3a0e06bbd8104d1395b00aeca775a8d3_D20200801-20200831" decimals="INF" name="lung:OperatingLeaseExpenseAnnualIncreaseRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfNDA2_95451cfe-a212-4608-ba30-768b19b0b5e8">3.5</ix:nonFraction>%. The Company is responsible for its share of real estate taxes, common area maintenance and management fees. The Company is eligible to receive a tenant improvement allowance of $<ix:nonFraction unitRef="usd" contextRef="i366bdd6cbcb6417f82564f08de535cb9_I20200831" decimals="-5" name="lung:TenantImprovementAllowanceReceivableUponLeaseRenewal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfNTg3_48937c0c-6a2c-4ac6-839d-b96015d1d85f">0.2</ix:nonFraction> million on commencement of the renewal term in August 2020.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2013, the Company entered into a <ix:nonNumeric contextRef="i857cff753eff4ea1888bf30b01ede179_I20131231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfNDQyMA_42ee71fd-7762-4d00-8837-34f67a3cef37">five-year</ix:nonNumeric> lease for office facilities in Switzerland. The Company had an option to extend the lease through January 2022, which was not exercised by the Company. Per the lease terms, in the event the option to extend is not exercised, the lease remains in force and can be terminated with <ix:nonNumeric contextRef="ifd03a7896aaf49d6b9c4280b7685c129_D20130101-20131231" name="lung:LesseeOperatingLeaseOptionToTerminateNoticePeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfOTY5_b977858e-fc6b-4dee-8fd0-abb83377a79c">12</ix:nonNumeric>-months’ notice.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company executed a sublease for another office facility in Redwood City, California for a <ix:nonNumeric contextRef="icd1f11aa0462419c94ba74321f470d3a_D20200401-20200430" name="lung:LesseeOperatingSubleaseTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfNDQyMQ_72819b9f-7b5e-4f61-96f0-231552c592e6">three-year</ix:nonNumeric> term commencing on June 1, 2020. The lease agreement provides for early termination if the Company or Sublandlord elects to terminate the lease by providing the other party at least <ix:nonNumeric contextRef="icd1f11aa0462419c94ba74321f470d3a_D20200401-20200430" name="lung:LesseeOperatingSubleaseOptionToTerminateNoticePeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMTI4Nw_bdd2b4dd-2e29-47fc-85e2-e5994ce48645">180</ix:nonNumeric> days prior written notice. The early termination may only occur on or after the expiration of the <ix:nonNumeric contextRef="icd1f11aa0462419c94ba74321f470d3a_D20200401-20200430" name="lung:LesseeOperatingSubleaseOptionToTerminateTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMTM4OA_2d805eb6-72b3-4b19-8072-af1c4114b709">18</ix:nonNumeric>th full calendar month of the sublease term. The monthly base rent during the term is less than $<ix:nonFraction unitRef="usd" contextRef="icd1f11aa0462419c94ba74321f470d3a_D20200401-20200430" decimals="-5" name="lung:LesseeOperatingSubleaseMonthlyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMTY0Mg_8621964c-34c1-4129-b744-684f44857488">0.1</ix:nonFraction> million and is subject to an annual increase of <ix:nonFraction unitRef="number" contextRef="icd1f11aa0462419c94ba74321f470d3a_D20200401-20200430" decimals="3" name="lung:LesseeOperatingSubleaseExpenseAnnualIncreaseRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMTY4NQ_53a9d758-741b-4455-96eb-37a8e853e1fe">3.5</ix:nonFraction>%. The Company is responsible for its share of real estate taxes, common area maintenance and management fees.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company amended a sublease agreement entered into in April 2020, to include additional facility space in Redwood City, California for a <ix:nonNumeric contextRef="idc991623af8d40e28c3edf61bacb8247_D20200901-20200930" name="lung:LesseeOperatingSubleaseTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfNDQyMg_4c361851-7123-4d62-bc5d-2d33a1e02c42">four-year</ix:nonNumeric> term. The amendment was accounted as a separate sublease agreement. The sublease agreement contained a rent-free period through February 14, 2021, after which rent is approximately $<ix:nonFraction unitRef="usd" contextRef="idc991623af8d40e28c3edf61bacb8247_D20200901-20200930" decimals="-5" name="lung:LesseeOperatingSubleaseMonthlyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMjE0MA_6800015b-12d8-4611-ace0-ba3e87b973bd">0.1</ix:nonFraction> million per month and is subject to an annual increase of <ix:nonFraction unitRef="number" contextRef="idc991623af8d40e28c3edf61bacb8247_D20200901-20200930" decimals="3" name="lung:LesseeOperatingSubleaseExpenseAnnualIncreaseRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMjE5Mw_d0e3d2bc-1bd1-4c14-8b22-d79a7275bfef">3.5</ix:nonFraction>%. The Company is responsible for its share of real estate taxes, common area maintenance and management fees. The Company is eligible to receive a tenant improvement allowance of $<ix:nonFraction unitRef="usd" contextRef="i0aef2c60dfff4d2db3ecc2c60e4ab869_I20200930" decimals="-5" name="lung:LesseeOperatingSubleaseTenantImprovementAllowanceReceivableUponLeaseRenewal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMjM3NA_20888a38-1ca9-4220-8364-ced02fa1de09">0.7</ix:nonFraction> million to fund facility enhancements. The sublease agreement can be extended for an additional <ix:nonNumeric contextRef="idc991623af8d40e28c3edf61bacb8247_D20200901-20200930" name="lung:LesseeOperatingSubleaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMTY0OTI2NzQ0NzI0NA_a187da34-c5cb-478d-991c-e2e260566230">twelve-month</ix:nonNumeric> period, at the Company’s option. For accounting purposes, the lease term is <ix:nonNumeric contextRef="idc991623af8d40e28c3edf61bacb8247_D20200901-20200930" name="lung:LesseeOperatingSubleaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMjU1MA_215582e2-1200-4968-8976-71b8e55a198a">4</ix:nonNumeric> years as it is not reasonably certain that the Company will exercise the renewal option. The amendment also changed the lease term entered into in April 2020, which was extended until May 31, 2024, but left the early termination clause unchanged. In September 2021, the Company became reasonably certain that the early termination clause would not be exercised as capital expenditures on the facility build-out created sufficient disincentive to terminate the lease early. The lease term was reevaluated and extended from November 30, 2021 to May 31, 2024.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has leases on <ix:nonFraction unitRef="lease" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="INF" name="lung:NumberOfVehicleLeases" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMjg0Mw_4b846a5a-88fd-4cc5-b17c-6297e4c1bf68">eight</ix:nonFraction> vehicles with an average term of <ix:nonNumeric contextRef="ied7db64668494d679f77a1d8d708db3b_I20220630" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMTA5OTUxMTYzMzMzMA_6c2f0bd9-a06a-45e4-9bf4-2de591501513">2.9</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pulmonx Corporation</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Interim Condensed Consolidated Financial Statements (Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="if2ef2fa98e9c41b0acc412e0edcab3dd" continuedAt="i0828aeb3b47a4ffeb107c9e4eb9887db"><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfNDQyMw_f8e526d0-9abd-496d-a3de-05bbc7102b99" continuedAt="i68593df9edf84dc49307f95b391a2a70" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost consists of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:67.118%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.471%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjNkNTZhOTlkZjllNzQ0ZGQ5Mzk0NDNhMmIwMWVlMWI5L3RhYmxlcmFuZ2U6M2Q1NmE5OWRmOWU3NDRkZDkzOTQ0M2EyYjAxZWUxYjlfMi0xLTEtMS0zOTM4Mw_771d12e8-cfa1-4c35-8908-8bd475abfc15">1,446</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjNkNTZhOTlkZjllNzQ0ZGQ5Mzk0NDNhMmIwMWVlMWI5L3RhYmxlcmFuZ2U6M2Q1NmE5OWRmOWU3NDRkZDkzOTQ0M2EyYjAxZWUxYjlfMi0zLTEtMS0zOTM4Mw_c65924ab-8637-4f49-8bcd-13832c4b47e8">1,452</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjNkNTZhOTlkZjllNzQ0ZGQ5Mzk0NDNhMmIwMWVlMWI5L3RhYmxlcmFuZ2U6M2Q1NmE5OWRmOWU3NDRkZDkzOTQ0M2EyYjAxZWUxYjlfMy0xLTEtMS0zOTM4Mw_7f27a344-cf42-49ed-a268-94691d8a8de3">16</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjNkNTZhOTlkZjllNzQ0ZGQ5Mzk0NDNhMmIwMWVlMWI5L3RhYmxlcmFuZ2U6M2Q1NmE5OWRmOWU3NDRkZDkzOTQ0M2EyYjAxZWUxYjlfMy0zLTEtMS0zOTM4Mw_b4f239de-d107-446e-97de-96224c359ce8">6</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjNkNTZhOTlkZjllNzQ0ZGQ5Mzk0NDNhMmIwMWVlMWI5L3RhYmxlcmFuZ2U6M2Q1NmE5OWRmOWU3NDRkZDkzOTQ0M2EyYjAxZWUxYjlfNC0xLTEtMS0zOTM4Mw_905ab33d-9e15-4f40-aa8d-300df80ed42f">290</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjNkNTZhOTlkZjllNzQ0ZGQ5Mzk0NDNhMmIwMWVlMWI5L3RhYmxlcmFuZ2U6M2Q1NmE5OWRmOWU3NDRkZDkzOTQ0M2EyYjAxZWUxYjlfNC0zLTEtMS0zOTM4Mw_3caef42f-468b-4a2d-85c0-acee5c172ad2">293</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjNkNTZhOTlkZjllNzQ0ZGQ5Mzk0NDNhMmIwMWVlMWI5L3RhYmxlcmFuZ2U6M2Q1NmE5OWRmOWU3NDRkZDkzOTQ0M2EyYjAxZWUxYjlfNS0xLTEtMS0zOTM4Mw_ce8997f6-c896-4861-8c18-3d67318e9aa8">1,752</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjNkNTZhOTlkZjllNzQ0ZGQ5Mzk0NDNhMmIwMWVlMWI5L3RhYmxlcmFuZ2U6M2Q1NmE5OWRmOWU3NDRkZDkzOTQ0M2EyYjAxZWUxYjlfNS0zLTEtMS0zOTM4Mw_a84b07f5-31d9-475b-8ff5-c29e335faa78">1,751</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfNDQyNA_9cd27035-ef3a-47a2-9793-ae517b63ac5f" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes a maturity analysis of the Company’s lease liabilities showing the aggregate lease payments as of June 30, 2022 (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining six months)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjgzMmFlYzFhMTRlNTRhYThiYjkwYjZiNTZjZDYwYzYyL3RhYmxlcmFuZ2U6ODMyYWVjMWExNGU1NGFhOGJiOTBiNmI1NmNkNjBjNjJfMS0xLTEtMS0zOTM4Mw_12d87d5c-4f72-4c6a-aa1c-3854a90ac6bc">1,721</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjgzMmFlYzFhMTRlNTRhYThiYjkwYjZiNTZjZDYwYzYyL3RhYmxlcmFuZ2U6ODMyYWVjMWExNGU1NGFhOGJiOTBiNmI1NmNkNjBjNjJfMi0xLTEtMS0zOTM4Mw_2fcc7c11-b19f-494e-afbc-23f38a961982">3,452</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjgzMmFlYzFhMTRlNTRhYThiYjkwYjZiNTZjZDYwYzYyL3RhYmxlcmFuZ2U6ODMyYWVjMWExNGU1NGFhOGJiOTBiNmI1NmNkNjBjNjJfMy0xLTEtMS0zOTM4Mw_19848c59-1c53-48e1-9463-7312df05a26b">2,919</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjgzMmFlYzFhMTRlNTRhYThiYjkwYjZiNTZjZDYwYzYyL3RhYmxlcmFuZ2U6ODMyYWVjMWExNGU1NGFhOGJiOTBiNmI1NmNkNjBjNjJfNC0xLTEtMS0zOTM4Mw_ff172713-22ff-4fc0-af71-e5de87ca1407">1,020</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjgzMmFlYzFhMTRlNTRhYThiYjkwYjZiNTZjZDYwYzYyL3RhYmxlcmFuZ2U6ODMyYWVjMWExNGU1NGFhOGJiOTBiNmI1NmNkNjBjNjJfNS0xLTEtMS0zOTM4Mw_9f21d26b-8131-46f2-bec9-d3aa309892fe">9,112</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjgzMmFlYzFhMTRlNTRhYThiYjkwYjZiNTZjZDYwYzYyL3RhYmxlcmFuZ2U6ODMyYWVjMWExNGU1NGFhOGJiOTBiNmI1NmNkNjBjNjJfNi0xLTEtMS0zOTM4Mw_6e7673ce-ecf1-4b70-858e-34ccc3a17cf5">636</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjgzMmFlYzFhMTRlNTRhYThiYjkwYjZiNTZjZDYwYzYyL3RhYmxlcmFuZ2U6ODMyYWVjMWExNGU1NGFhOGJiOTBiNmI1NmNkNjBjNjJfNy0xLTEtMS0zOTM4Mw_320a8152-bf92-4334-beb7-e71d10eeceeb">8,476</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjgzMmFlYzFhMTRlNTRhYThiYjkwYjZiNTZjZDYwYzYyL3RhYmxlcmFuZ2U6ODMyYWVjMWExNGU1NGFhOGJiOTBiNmI1NmNkNjBjNjJfOC0xLTEtMS0zOTM4Mw_01982077-c42f-46c7-87f4-c07fc23b42fe">3,061</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjgzMmFlYzFhMTRlNTRhYThiYjkwYjZiNTZjZDYwYzYyL3RhYmxlcmFuZ2U6ODMyYWVjMWExNGU1NGFhOGJiOTBiNmI1NmNkNjBjNjJfOS0xLTEtMS0zOTM4Mw_3f4b6409-5c94-4436-aa8b-288cd50d7353">5,415</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:continuation id="i68593df9edf84dc49307f95b391a2a70"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes additional information related to the Company’s operating leases (in thousands, except weighted average data):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjc3MmQ3ZTAwYjJiZDRhYWFhOThiMjEzMWI1YWU2ZWMyL3RhYmxlcmFuZ2U6NzcyZDdlMDBiMmJkNGFhYWE5OGIyMTMxYjVhZTZlYzJfMS0xLTEtMS0zOTM4Mw_f43a5da1-3922-4a03-8e6d-6fa9b1feb99d">6,987</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjc3MmQ3ZTAwYjJiZDRhYWFhOThiMjEzMWI1YWU2ZWMyL3RhYmxlcmFuZ2U6NzcyZDdlMDBiMmJkNGFhYWE5OGIyMTMxYjVhZTZlYzJfMS0zLTEtMS0zOTM4Mw_030e0b13-4b34-4a7a-b16b-2e786ecdb739">8,075</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjc3MmQ3ZTAwYjJiZDRhYWFhOThiMjEzMWI1YWU2ZWMyL3RhYmxlcmFuZ2U6NzcyZDdlMDBiMmJkNGFhYWE5OGIyMTMxYjVhZTZlYzJfMi0xLTEtMS0zOTM4Mw_ccc091d4-f40d-4281-ae9b-48815ff2ce1b">2.43</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjc3MmQ3ZTAwYjJiZDRhYWFhOThiMjEzMWI1YWU2ZWMyL3RhYmxlcmFuZ2U6NzcyZDdlMDBiMmJkNGFhYWE5OGIyMTMxYjVhZTZlYzJfMi0zLTEtMS0zOTM4Mw_4bf3a545-5162-48f6-8e57-e43a72b6bad7">3.17</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate (percent)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjc3MmQ3ZTAwYjJiZDRhYWFhOThiMjEzMWI1YWU2ZWMyL3RhYmxlcmFuZ2U6NzcyZDdlMDBiMmJkNGFhYWE5OGIyMTMxYjVhZTZlYzJfMy0xLTEtMS0zOTM4Mw_2f58988a-4549-4703-a082-d522668d1d00">5.9</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjc3MmQ3ZTAwYjJiZDRhYWFhOThiMjEzMWI1YWU2ZWMyL3RhYmxlcmFuZ2U6NzcyZDdlMDBiMmJkNGFhYWE5OGIyMTMxYjVhZTZlYzJfMy0zLTEtMS0zOTM4Mw_5ff70610-0c91-4796-9804-ed2ea6e47b2b">6.0</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes other supplemental information related to the Company’s operating leases (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:4.5pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities included in cash flows used in operating activities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjBjNWZkZGE4ZjgzYzQ3NzA5NmNiMTE0NGVjY2FiNzBlL3RhYmxlcmFuZ2U6MGM1ZmRkYThmODNjNDc3MDk2Y2IxMTQ0ZWNjYWI3MGVfMi0xLTEtMS0zOTM4Mw_e7d87371-07fb-4486-9b95-77f81aae1829">966</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjBjNWZkZGE4ZjgzYzQ3NzA5NmNiMTE0NGVjY2FiNzBlL3RhYmxlcmFuZ2U6MGM1ZmRkYThmODNjNDc3MDk2Y2IxMTQ0ZWNjYWI3MGVfMi0zLTEtMS0zOTM4Mw_8bdbee30-f448-4679-9369-2d3e55613c4b">1,330</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjBjNWZkZGE4ZjgzYzQ3NzA5NmNiMTE0NGVjY2FiNzBlL3RhYmxlcmFuZ2U6MGM1ZmRkYThmODNjNDc3MDk2Y2IxMTQ0ZWNjYWI3MGVfMy0xLTEtMS0zOTM4Mw_2aa5ee39-0daa-4e49-8758-b9fdeb41b7e2">138</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjBjNWZkZGE4ZjgzYzQ3NzA5NmNiMTE0NGVjY2FiNzBlL3RhYmxlcmFuZ2U6MGM1ZmRkYThmODNjNDc3MDk2Y2IxMTQ0ZWNjYWI3MGVfMy0zLTEtMS0zOTM4Mw_23d60f14-562a-4370-9276-801ef8e2890f">—</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Agreement</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the Company entered into an agreement with a service provider which requires total minimum purchases of $<ix:nonFraction unitRef="usd" contextRef="ibc840713d1034829bc01ad7b74a40d23_I20220430" decimals="-5" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMTY0OTI2NzQ0ODYwMA_c599d25c-e118-4ec6-8df5-f9eb07859df3">0.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ibc840713d1034829bc01ad7b74a40d23_I20220430" decimals="-5" name="us-gaap:PurchaseObligationDueInSecondYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMTY0OTI2NzQ0ODYxNA_020dff5a-a191-4c67-aed0-e7021ac91569">0.4</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="ibc840713d1034829bc01ad7b74a40d23_I20220430" decimals="-5" name="us-gaap:PurchaseObligationDueInThirdYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMTY0OTI2NzQ0ODYyOA_b21bc3a9-3e22-43aa-b2bd-be36cacca32d">0.4</ix:nonFraction> million over the next three years. Since the inception of the </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pulmonx Corporation</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Interim Condensed Consolidated Financial Statements (Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i0828aeb3b47a4ffeb107c9e4eb9887db" continuedAt="ic5aa7ff494a94ecabe3dd3e754c78d08"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreement, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i25ca1d294bfa44ee92ff709c2ea930e0_D20220501-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMTY0OTI2NzQ0ODY0Mg_1c3eb175-0bc0-4576-826f-69444e874205">0.2</ix:nonFraction> million of expense for services related to this agreement in cost of goods sold during the three months ended June 30, 2022.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div></ix:continuation><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic5aa7ff494a94ecabe3dd3e754c78d08">From time to time, the Company may be a party to various litigation claims in the normal course of business. Legal fees and other costs associated with such actions are expensed as incurred. The Company assesses, in conjunction with legal counsel, the need to record a liability for litigation and contingencies. Accrual estimates are recorded when and if it is determinable that such a liability for litigation and contingencies are both probable and reasonably estimable.</ix:continuation> </span></div><div id="i784ba2f3210d43dcbb23721a3c553397_61"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.    <ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N182MS9mcmFnOmQwMWY1ZGM3YmU4MjQ4NTM4ZjYzODU5ZGQ4YjAyN2Q2L3RleHRyZWdpb246ZDAxZjVkYzdiZTgyNDg1MzhmNjM4NTlkZDhiMDI3ZDZfMTAyMA_5babaeff-2f4d-4f18-b941-6553733ee43e" continuedAt="icb82030c50fc4a54b0fc79ed0336ad49" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icb82030c50fc4a54b0fc79ed0336ad49" continuedAt="i49678a0d7cdf43cd8b8e30aff9492061">The income tax expense for the three months ended June 30, 2022 and 2021 was less than $<ix:nonFraction unitRef="usd" contextRef="i2ae7a2862d6f4d7a954dd9a21f9f83d8_D20220401-20220630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N182MS9mcmFnOmQwMWY1ZGM3YmU4MjQ4NTM4ZjYzODU5ZGQ4YjAyN2Q2L3RleHRyZWdpb246ZDAxZjVkYzdiZTgyNDg1MzhmNjM4NTlkZDhiMDI3ZDZfMTA5OTUxMTYzMDI2Mg_4d91c627-f570-4399-a3e7-112cc1e7e585">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N182MS9mcmFnOmQwMWY1ZGM3YmU4MjQ4NTM4ZjYzODU5ZGQ4YjAyN2Q2L3RleHRyZWdpb246ZDAxZjVkYzdiZTgyNDg1MzhmNjM4NTlkZDhiMDI3ZDZfMTA5OTUxMTYzMDQ3Nw_4b89a76c-28d8-4483-afed-f737a5a6538f">0.1</ix:nonFraction> million, respectively. The income tax expense for the six months ended June 30, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N182MS9mcmFnOmQwMWY1ZGM3YmU4MjQ4NTM4ZjYzODU5ZGQ4YjAyN2Q2L3RleHRyZWdpb246ZDAxZjVkYzdiZTgyNDg1MzhmNjM4NTlkZDhiMDI3ZDZfMTA5OTUxMTYzMDYxMg_4622579d-1a84-4748-9883-050e4147094e">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N182MS9mcmFnOmQwMWY1ZGM3YmU4MjQ4NTM4ZjYzODU5ZGQ4YjAyN2Q2L3RleHRyZWdpb246ZDAxZjVkYzdiZTgyNDg1MzhmNjM4NTlkZDhiMDI3ZDZfMTA5OTUxMTYzMDYyMA_b8219d44-1414-4292-a220-e09cc77dd78e">0.1</ix:nonFraction> million, respectively. The income tax expense was determined based upon estimates of the Company’s effective income tax rates in various jurisdictions. The difference between the Company’s effective income tax rate and the U.S. federal statutory rate is primarily attributable to state income taxes, foreign income taxes, and a full valuation allowance against net deferred tax assets. </ix:continuation></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i49678a0d7cdf43cd8b8e30aff9492061">The income tax expense for the six months ended June 30, 2022 and 2021 relates primarily to state minimum income tax and income tax on the Company’s earnings in foreign jurisdictions.</ix:continuation> </span></div><div id="i784ba2f3210d43dcbb23721a3c553397_70"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.    <ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMzE5Nw_55637243-d81d-40c5-b25b-1297063f724b" continuedAt="id7752aad8295462887c2b3a3fd499361" escape="true">Stockholders’ Equity</ix:nonNumeric></span></div><ix:continuation id="id7752aad8295462887c2b3a3fd499361" continuedAt="ib7b838a087324192a9e1b562b0cd6249"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, the Company’s certificate of incorporation authorized the Company to issue up to <ix:nonFraction unitRef="shares" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTQx_48fae339-24f4-4ba1-b3bf-06a8905bbca2"><ix:nonFraction unitRef="shares" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTQx_88b658c2-b0be-4f45-a307-4a07dfeab8c8">200,000,000</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTA5OTUxMTYzMDk4NA_48fae339-24f4-4ba1-b3bf-06a8905bbca2"><ix:nonFraction unitRef="shares" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTA5OTUxMTYzMDk4NA_88b658c2-b0be-4f45-a307-4a07dfeab8c8">200,000,000</ix:nonFraction></ix:nonFraction> shares of common stock, respectively. Common stockholders are entitled to dividends as and when declared by the Board of Directors, subject to the rights of holders of all classes of stock outstanding having priority rights as to dividends. There have been <ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="INF" name="us-gaap:DividendsCommonStock" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMzg3_d960956e-bfe1-4847-be20-bcc879564eff">no</ix:nonFraction> dividends declared to date. The holder of each share of common stock is entitled to <ix:nonFraction unitRef="vote" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="INF" name="lung:NumberOfVotesForEachShareOfCommonStockHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfNDc0_5925ebe1-da13-452f-94ff-85b45ee6d4dc">one</ix:nonFraction> vote.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shares Reserved for Future Issuance </span></div><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMzE5Mw_0d6a8fbe-0900-4d00-b228-fd73a54c60a6" escape="true"><div style="margin-bottom:12pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reserved shares of common stock for future issuances as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options issued and outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i784f45acac5747a384b861bd3aabc902_I20220630" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjA3MmQzM2ZlMjMwYTRjZjg4NTczM2NmOGU0NDJkOWFmL3RhYmxlcmFuZ2U6MDcyZDMzZmUyMzBhNGNmODg1NzMzY2Y4ZTQ0MmQ5YWZfMi0xLTEtMS0zOTM4Mw_e3a80942-a4ff-42a6-8b49-4a85ad8caad6">2,600,237</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide3a7a3105f148a0abc9848ed7ec1d00_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjA3MmQzM2ZlMjMwYTRjZjg4NTczM2NmOGU0NDJkOWFmL3RhYmxlcmFuZ2U6MDcyZDMzZmUyMzBhNGNmODg1NzMzY2Y4ZTQ0MmQ5YWZfMi0zLTEtMS0zOTM4Mw_b16358eb-8043-437a-9173-17e7faf7a8bb">2,145,131</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock restricted stock units issued and outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22f7f50179034850b9053aba0a68231a_I20220630" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjA3MmQzM2ZlMjMwYTRjZjg4NTczM2NmOGU0NDJkOWFmL3RhYmxlcmFuZ2U6MDcyZDMzZmUyMzBhNGNmODg1NzMzY2Y4ZTQ0MmQ5YWZfMy0xLTEtMS00MDkzOQ_5e1c82ff-fff9-4580-9301-b5b96e1bf096">1,091,957</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaba5025a1e5243a2b17b2e5661ec7f35_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjA3MmQzM2ZlMjMwYTRjZjg4NTczM2NmOGU0NDJkOWFmL3RhYmxlcmFuZ2U6MDcyZDMzZmUyMzBhNGNmODg1NzMzY2Y4ZTQ0MmQ5YWZfMy0zLTEtMS00MDkzOQ_33009022-0cbd-4f53-870a-f15c94b8cf54">442,428</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock available for future grants</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i714b2da3efed4e42a97fe4d4b6b47a99_I20220630" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjA3MmQzM2ZlMjMwYTRjZjg4NTczM2NmOGU0NDJkOWFmL3RhYmxlcmFuZ2U6MDcyZDMzZmUyMzBhNGNmODg1NzMzY2Y4ZTQ0MmQ5YWZfMy0xLTEtMS0zOTM4Mw_48ad0d0d-3d94-4a25-b424-c07db1c8d4f0">3,838,605</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e39fbc0a48a47e2a202f2c8f30f4b79_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjA3MmQzM2ZlMjMwYTRjZjg4NTczM2NmOGU0NDJkOWFmL3RhYmxlcmFuZ2U6MDcyZDMzZmUyMzBhNGNmODg1NzMzY2Y4ZTQ0MmQ5YWZfMy0zLTEtMS0zOTM4Mw_9557189e-06cf-4318-8d4d-61fa92d940d9">3,751,115</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock available for ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1275d322af1b4c98ba3c7706239395c7_I20220630" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjA3MmQzM2ZlMjMwYTRjZjg4NTczM2NmOGU0NDJkOWFmL3RhYmxlcmFuZ2U6MDcyZDMzZmUyMzBhNGNmODg1NzMzY2Y4ZTQ0MmQ5YWZfNC0xLTEtMS0zOTM4Mw_979f2c10-c86d-4f8a-8c74-ee6cefd24615">1,255,773</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifaa47ca5f34841d0a65dd43f53a08359_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjA3MmQzM2ZlMjMwYTRjZjg4NTczM2NmOGU0NDJkOWFmL3RhYmxlcmFuZ2U6MDcyZDMzZmUyMzBhNGNmODg1NzMzY2Y4ZTQ0MmQ5YWZfNC0zLTEtMS0zOTM4Mw_51f4d8f2-328c-4b40-a3df-9aceab6149b7">932,458</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjA3MmQzM2ZlMjMwYTRjZjg4NTczM2NmOGU0NDJkOWFmL3RhYmxlcmFuZ2U6MDcyZDMzZmUyMzBhNGNmODg1NzMzY2Y4ZTQ0MmQ5YWZfNS0xLTEtMS0zOTM4Mw_279051bf-1e72-47a9-8e84-af7d95c6912e">8,786,572</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjA3MmQzM2ZlMjMwYTRjZjg4NTczM2NmOGU0NDJkOWFmL3RhYmxlcmFuZ2U6MDcyZDMzZmUyMzBhNGNmODg1NzMzY2Y4ZTQ0MmQ5YWZfNS0zLTEtMS0zOTM4Mw_74c8c908-a04c-463c-a566-b2c15ba20ac8">7,271,132</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pulmonx Corporation</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Interim Condensed Consolidated Financial Statements (Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="ib7b838a087324192a9e1b562b0cd6249" continuedAt="i6aed83ab1116459f867e322a2985b9c8"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Plan</span></div><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMzE5OA_64c2f4f6-d90c-4f1a-99af-5561cfd1a62e" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the six months ended June 30, 2022 is set forth below:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding Options</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjUxNTJjMWQyZjIwMjRhNGViMGE3OWU5ZWEzNzc2MDUwL3RhYmxlcmFuZ2U6NTE1MmMxZDJmMjAyNGE0ZWIwYTc5ZTllYTM3NzYwNTBfMi0xLTEtMS0zOTM4Mw_fdb0b08e-eb0f-4930-8d78-ba25dbf1a875">2,145,131</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjUxNTJjMWQyZjIwMjRhNGViMGE3OWU5ZWEzNzc2MDUwL3RhYmxlcmFuZ2U6NTE1MmMxZDJmMjAyNGE0ZWIwYTc5ZTllYTM3NzYwNTBfMi0zLTEtMS0zOTM4Mw_d6c8a3c9-12bc-4803-9203-39bccd589209">13.44</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjUxNTJjMWQyZjIwMjRhNGViMGE3OWU5ZWEzNzc2MDUwL3RhYmxlcmFuZ2U6NTE1MmMxZDJmMjAyNGE0ZWIwYTc5ZTllYTM3NzYwNTBfMy0xLTEtMS0zOTM4Mw_73cb5fff-8854-4e51-9bed-141080ea8edd">655,200</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjUxNTJjMWQyZjIwMjRhNGViMGE3OWU5ZWEzNzc2MDUwL3RhYmxlcmFuZ2U6NTE1MmMxZDJmMjAyNGE0ZWIwYTc5ZTllYTM3NzYwNTBfMy0zLTEtMS0zOTM4Mw_1316485c-e2aa-4af5-9ca5-0b87b12cd482">26.56</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjUxNTJjMWQyZjIwMjRhNGViMGE3OWU5ZWEzNzc2MDUwL3RhYmxlcmFuZ2U6NTE1MmMxZDJmMjAyNGE0ZWIwYTc5ZTllYTM3NzYwNTBfNC0xLTEtMS0zOTM4Mw_e11a0ff0-1819-40df-9358-e729729cb479">172,886</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjUxNTJjMWQyZjIwMjRhNGViMGE3OWU5ZWEzNzc2MDUwL3RhYmxlcmFuZ2U6NTE1MmMxZDJmMjAyNGE0ZWIwYTc5ZTllYTM3NzYwNTBfNC0zLTEtMS0zOTM4Mw_802e35cd-8e5b-4385-9d6c-496d6995fd47">2.15</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjUxNTJjMWQyZjIwMjRhNGViMGE3OWU5ZWEzNzc2MDUwL3RhYmxlcmFuZ2U6NTE1MmMxZDJmMjAyNGE0ZWIwYTc5ZTllYTM3NzYwNTBfNS0xLTEtMS0zOTM4Mw_dd437897-b5ce-4f1d-94d0-21e673014dfc">27,208</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjUxNTJjMWQyZjIwMjRhNGViMGE3OWU5ZWEzNzc2MDUwL3RhYmxlcmFuZ2U6NTE1MmMxZDJmMjAyNGE0ZWIwYTc5ZTllYTM3NzYwNTBfNS0zLTEtMS0zOTM4Mw_2a5800c3-74ef-4462-9d89-268a1ae34782">19.96</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjUxNTJjMWQyZjIwMjRhNGViMGE3OWU5ZWEzNzc2MDUwL3RhYmxlcmFuZ2U6NTE1MmMxZDJmMjAyNGE0ZWIwYTc5ZTllYTM3NzYwNTBfNi0xLTEtMS0zOTM4Mw_ec8a3642-4c67-4aec-8892-707335f68cdc">2,600,237</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjUxNTJjMWQyZjIwMjRhNGViMGE3OWU5ZWEzNzc2MDUwL3RhYmxlcmFuZ2U6NTE1MmMxZDJmMjAyNGE0ZWIwYTc5ZTllYTM3NzYwNTBfNi0zLTEtMS0zOTM4Mw_632ca1c1-4731-4066-ad77-dbe34531c729">17.43</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding as of June 30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfODIz_319355d8-866f-4b75-bdfe-8d258587a63b">15.0</ix:nonFraction> million.</span></div><div style="margin-bottom:12pt"><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMzE5OQ_2e445103-093b-4a78-9cd9-261d9a84a0d6" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:56.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.565%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.565%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Contractual Life (in Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjQ5YjQ1ODBmYWEzMjQ5MjhhZDc5YTdmM2IyNDJjNDRlL3RhYmxlcmFuZ2U6NDliNDU4MGZhYTMyNDkyOGFkNzlhN2YzYjI0MmM0NGVfMi0xLTEtMS0zOTM4Mw_7c494cb9-6dfa-4a0b-85e8-a38957e739ed">904,464</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="2" name="lung:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjQ5YjQ1ODBmYWEzMjQ5MjhhZDc5YTdmM2IyNDJjNDRlL3RhYmxlcmFuZ2U6NDliNDU4MGZhYTMyNDkyOGFkNzlhN2YzYjI0MmM0NGVfMi0zLTEtMS0zOTM4Mw_31a43d14-7249-45b0-acc5-9a03c49566e2">11.56</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="lung:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjQ5YjQ1ODBmYWEzMjQ5MjhhZDc5YTdmM2IyNDJjNDRlL3RhYmxlcmFuZ2U6NDliNDU4MGZhYTMyNDkyOGFkNzlhN2YzYjI0MmM0NGVfMi01LTEtMS0zOTM4Mw_98a87011-ad70-4536-833f-a9dc860c249f">7.30</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjQ5YjQ1ODBmYWEzMjQ5MjhhZDc5YTdmM2IyNDJjNDRlL3RhYmxlcmFuZ2U6NDliNDU4MGZhYTMyNDkyOGFkNzlhN2YzYjI0MmM0NGVfMy0xLTEtMS0zOTM4Mw_011aee97-7aee-4856-8652-0f2cfc538e00">2,600,237</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjQ5YjQ1ODBmYWEzMjQ5MjhhZDc5YTdmM2IyNDJjNDRlL3RhYmxlcmFuZ2U6NDliNDU4MGZhYTMyNDkyOGFkNzlhN2YzYjI0MmM0NGVfMy0zLTEtMS0zOTM4Mw_47e35f64-e794-4101-90e5-91a4384bc03b">17.43</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjQ5YjQ1ODBmYWEzMjQ5MjhhZDc5YTdmM2IyNDJjNDRlL3RhYmxlcmFuZ2U6NDliNDU4MGZhYTMyNDkyOGFkNzlhN2YzYjI0MmM0NGVfMy01LTEtMS0zOTM4Mw_3439c797-fd56-4e5b-bda1-e2d444e4b243">8.26</ix:nonNumeric></span></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intrinsic value of options vested as of June 30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfODk2_47c029bd-7be0-4c57-9841-8bfc8a42fa54">7.5</ix:nonFraction> million.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Early Exercise of Stock Options</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the individual option grants, options are fully exercisable on the grant date, subject to the Company’s repurchase right at the original exercise price. Accordingly, options may be exercised prior to vesting. The shares are subject to the Company’s lapsing repurchase right upon termination of employment or over the options’ vesting period of generally <ix:nonNumeric contextRef="ieaf5f38983f147c5b391b683b2a5d265_D20220101-20220630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTMwOQ_7ff5e6dd-1440-401b-b337-df092192105e">four years</ix:nonNumeric> at the original purchase price. The proceeds initially are recorded in other liabilities from the early exercise of stock options and are reclassified to additional paid-in capital as the Company’s repurchase right lapses. During the six months ended June 30, 2022, the Company did <ix:nonFraction unitRef="shares" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTA5OTUxMTYzMTIwNw_d976e6dd-7133-4117-98dd-0ddb556ed185">no</ix:nonFraction>t repurchase shares of common stock. During the six months ended June 30, 2021, the Company repurchased <ix:nonFraction unitRef="shares" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTU5MA_562d5b9e-78aa-47e0-b04d-fcbbd7ace56a">12,945</ix:nonFraction> shares of common stock for less than $<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTYzMA_5717351d-cd28-43b1-b2dd-bcaedafe8140">0.1</ix:nonFraction> million. As of June 30, 2022 and December 31, 2021, <ix:nonFraction unitRef="shares" contextRef="ieaf5f38983f147c5b391b683b2a5d265_D20220101-20220630" decimals="INF" name="lung:ShareBasedPaymentArrangementSharesSubjectToRepurchase" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTczNw_866e5d19-ac31-4281-ad32-e1eac8733070">155,969</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic7b4e5d4bcbd4d4186b94f94cf2b2e0d_D20210101-20211231" decimals="INF" name="lung:ShareBasedPaymentArrangementSharesSubjectToRepurchase" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTc0NA_b3a83805-5054-4f33-b944-a2f2604e9bb1">223,195</ix:nonFraction> shares, respectively, were subject to repurchase, with an aggregate exercise price of $<ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-5" name="lung:ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTgzMw_a7b05711-028c-4aac-a737-1b4f8bd3e9a8">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-5" name="lung:ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTg0MA_b8a95538-01cc-4f76-b408-73971093918d">0.4</ix:nonFraction> million, respectively, and were recorded in other current liabilities.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pulmonx Corporation</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Interim Condensed Consolidated Financial Statements (Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i6aed83ab1116459f867e322a2985b9c8"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMzE5NA_34233d3e-49f6-4e6e-a983-6bc568465565" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity with respect to restricted stock units was as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares Underlying Outstanding Restricted Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id02f38cc7de8443687c4dbf744ee7d4a_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOmUzMzdiNWU2ZmY5MTQzNGQ5NTExM2JiMjUyOWFhZjFmL3RhYmxlcmFuZ2U6ZTMzN2I1ZTZmZjkxNDM0ZDk1MTEzYmIyNTI5YWFmMWZfMS0xLTEtMS0zOTM4Mw_7e6597e8-edde-4a63-8af1-a739aba143a1">442,428</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="id02f38cc7de8443687c4dbf744ee7d4a_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOmUzMzdiNWU2ZmY5MTQzNGQ5NTExM2JiMjUyOWFhZjFmL3RhYmxlcmFuZ2U6ZTMzN2I1ZTZmZjkxNDM0ZDk1MTEzYmIyNTI5YWFmMWZfMS0zLTEtMS0zOTM4Mw_d45a64f3-85b5-4b75-b1d5-6d78adbeecb2">42.36</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib214e6ee760c4adcbb895883d757b122_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOmUzMzdiNWU2ZmY5MTQzNGQ5NTExM2JiMjUyOWFhZjFmL3RhYmxlcmFuZ2U6ZTMzN2I1ZTZmZjkxNDM0ZDk1MTEzYmIyNTI5YWFmMWZfMi0xLTEtMS0zOTM4Mw_850e5ee3-551d-44ef-98d9-3c91337ed969">799,320</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib214e6ee760c4adcbb895883d757b122_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOmUzMzdiNWU2ZmY5MTQzNGQ5NTExM2JiMjUyOWFhZjFmL3RhYmxlcmFuZ2U6ZTMzN2I1ZTZmZjkxNDM0ZDk1MTEzYmIyNTI5YWFmMWZfMi0zLTEtMS0zOTM4Mw_b0f0a741-6e27-43e9-b4cc-d8b70e704b2b">25.47</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib214e6ee760c4adcbb895883d757b122_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOmUzMzdiNWU2ZmY5MTQzNGQ5NTExM2JiMjUyOWFhZjFmL3RhYmxlcmFuZ2U6ZTMzN2I1ZTZmZjkxNDM0ZDk1MTEzYmIyNTI5YWFmMWZfMy0xLTEtMS00MTAxMA_9c2770a5-6093-445e-a52f-8d650ff59974">115,380</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib214e6ee760c4adcbb895883d757b122_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOmUzMzdiNWU2ZmY5MTQzNGQ5NTExM2JiMjUyOWFhZjFmL3RhYmxlcmFuZ2U6ZTMzN2I1ZTZmZjkxNDM0ZDk1MTEzYmIyNTI5YWFmMWZfMy0zLTEtMS00MTAxMA_bd5ceb3c-b537-4115-81ed-cb1d2a013811">37.64</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib214e6ee760c4adcbb895883d757b122_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOmUzMzdiNWU2ZmY5MTQzNGQ5NTExM2JiMjUyOWFhZjFmL3RhYmxlcmFuZ2U6ZTMzN2I1ZTZmZjkxNDM0ZDk1MTEzYmIyNTI5YWFmMWZfNC0xLTEtMS00MTAxMA_f61ba8f9-7c48-4f81-a447-c5002413c6c8">34,411</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib214e6ee760c4adcbb895883d757b122_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOmUzMzdiNWU2ZmY5MTQzNGQ5NTExM2JiMjUyOWFhZjFmL3RhYmxlcmFuZ2U6ZTMzN2I1ZTZmZjkxNDM0ZDk1MTEzYmIyNTI5YWFmMWZfNC0zLTEtMS00MTAxMA_94aaebdc-c0b1-4152-a125-16631b0b0b86">33.22</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91b890405bde48749a209fc48ed3fd13_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOmUzMzdiNWU2ZmY5MTQzNGQ5NTExM2JiMjUyOWFhZjFmL3RhYmxlcmFuZ2U6ZTMzN2I1ZTZmZjkxNDM0ZDk1MTEzYmIyNTI5YWFmMWZfMy0xLTEtMS0zOTM4Mw_37645a6d-2252-47ab-8ce4-241aac6b84cc">1,091,957</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i91b890405bde48749a209fc48ed3fd13_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOmUzMzdiNWU2ZmY5MTQzNGQ5NTExM2JiMjUyOWFhZjFmL3RhYmxlcmFuZ2U6ZTMzN2I1ZTZmZjkxNDM0ZDk1MTEzYmIyNTI5YWFmMWZfMy0zLTEtMS0zOTM4Mw_af052ae8-9869-4a2f-bcbe-3fab08c93216">30.78</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of restricted stock units outstanding as of June 30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i91b890405bde48749a209fc48ed3fd13_I20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTA5OTUxMTYzMTM3NQ_07606402-df5a-4321-a4f2-e69260822a50">16.1</ix:nonFraction> million.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Stock-Based Compensation</span></div><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMzIwMQ_acdea86d-5f71-4962-8c0f-08137a9089ce" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is reflected in the statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i883a9ab8eaca4207ba3cadcb80ef8eda_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfMi0xLTEtMS0zOTM4Mw_5b91c544-5d1a-4073-a899-5ad71eb1bae6">189</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0b981dc82dd04a02bb8a9147b2a333de_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfMi0zLTEtMS0zOTM4Mw_62cb1d4c-c639-4f51-83dd-2c5fe898fda4">120</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i114ea887bbd14b4a95901ff225d7572e_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfMi01LTEtMS0zOTM4Mw_14fc5a69-613c-4ba5-a787-ddeb4e5d0694">336</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i51ff2e29588048e09a217bf20a23f15e_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfMi03LTEtMS0zOTM4Mw_14067072-7a37-4721-9839-22cde34142d7">210</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i405811c8a7064e599bb9622e46610a53_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfMy0xLTEtMS0zOTM4Mw_32628216-0b01-40e5-ab5f-8f7cc421e794">556</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i58118a88d93b4eb694a8bc9332e744f5_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfMy0zLTEtMS0zOTM4Mw_b2eb8270-81e2-4849-b6c4-46eb9ca60668">288</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if9b029b9144a4e10b3a37d170bf1098c_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfMy01LTEtMS0zOTM4Mw_c73b646c-fd2b-4768-aee3-4d6abdb75854">977</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0ed501dd475d4cf48aa805abbe19f088_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfMy03LTEtMS0zOTM4Mw_c9ad433d-0af3-41b7-b61a-c7bf6e3ffda8">606</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e66e05527d4ffd827c77748a29ae59_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfNC0xLTEtMS0zOTM4Mw_f6ebb384-3b96-4aa9-ad3b-aca160ba5205">3,638</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dfbc2d6814744a0ad594767a7b3921c_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfNC0zLTEtMS0zOTM4Mw_fe8d2fd2-9daf-4dec-a220-40a257ba1ba7">1,904</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73aa5beaf714619a089f8546ba50e49_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfNC01LTEtMS0zOTM4Mw_89a4627d-0147-4fc8-8328-ad5a55b0e5a7">6,583</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id37e4fe079bc43a8b78bc7d2ed7d7f5a_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfNC03LTEtMS0zOTM4Mw_e4efe167-3005-45ef-a393-5071ecac6069">3,764</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfNS0xLTEtMS0zOTM4Mw_00d69dc0-f601-46bc-9eae-004fc78013a5">4,383</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfNS0zLTEtMS0zOTM4Mw_2a27c9eb-d9aa-4553-b37a-514c0348f092">2,312</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfNS01LTEtMS0zOTM4Mw_95387d77-c59a-473b-889b-f345ea17ad05">7,896</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfNS03LTEtMS0zOTM4Mw_023992aa-537f-492c-a77a-7c46becec460">4,580</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above stock-based compensation expense related to the following equity-based awards (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and restricted stock units</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i27f5ea6853044003b5d3fe259686cfed_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjhhZDQxNmNlMzlhZTQyYTY5YmE4ZWM0NDZhMzYzMDE4L3RhYmxlcmFuZ2U6OGFkNDE2Y2UzOWFlNDJhNjliYThlYzQ0NmEzNjMwMThfMi0xLTEtMS0zOTM4Mw_71f9bcb5-c4ad-4e05-bc3d-566b7096f200">4,209</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia4b62e5c7e4d41e599a13d60481720d5_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjhhZDQxNmNlMzlhZTQyYTY5YmE4ZWM0NDZhMzYzMDE4L3RhYmxlcmFuZ2U6OGFkNDE2Y2UzOWFlNDJhNjliYThlYzQ0NmEzNjMwMThfMi0zLTEtMS0zOTM4Mw_01e559d0-8a0b-4044-ac80-b38b56a781ee">1,520</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id6ad1ceb870840e0aff0a566353c7eca_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjhhZDQxNmNlMzlhZTQyYTY5YmE4ZWM0NDZhMzYzMDE4L3RhYmxlcmFuZ2U6OGFkNDE2Y2UzOWFlNDJhNjliYThlYzQ0NmEzNjMwMThfMi01LTEtMS0zOTM4Mw_bfaf224d-cc18-4ff2-809e-c17b3eaeaf60">7,521</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if1fb7c022d3f4c5a8ce371332cda0d8e_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjhhZDQxNmNlMzlhZTQyYTY5YmE4ZWM0NDZhMzYzMDE4L3RhYmxlcmFuZ2U6OGFkNDE2Y2UzOWFlNDJhNjliYThlYzQ0NmEzNjMwMThfMi03LTEtMS0zOTM4Mw_65526315-4fce-42c2-8061-317da4d04ded">2,559</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34dd8820c0384b9f99643fd8282fcfed_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjhhZDQxNmNlMzlhZTQyYTY5YmE4ZWM0NDZhMzYzMDE4L3RhYmxlcmFuZ2U6OGFkNDE2Y2UzOWFlNDJhNjliYThlYzQ0NmEzNjMwMThfMy0xLTEtMS0zOTM4Mw_252a9f88-27cf-4bbd-9145-87ea6c88134d">174</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18e4908c4d83487a804ab3bb691cfdfd_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjhhZDQxNmNlMzlhZTQyYTY5YmE4ZWM0NDZhMzYzMDE4L3RhYmxlcmFuZ2U6OGFkNDE2Y2UzOWFlNDJhNjliYThlYzQ0NmEzNjMwMThfMy0zLTEtMS0zOTM4Mw_f0f2113a-2e55-4cd3-8607-abf8ff84d090">792</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5532b33c0264e07931c620be5ee4fdb_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjhhZDQxNmNlMzlhZTQyYTY5YmE4ZWM0NDZhMzYzMDE4L3RhYmxlcmFuZ2U6OGFkNDE2Y2UzOWFlNDJhNjliYThlYzQ0NmEzNjMwMThfMy01LTEtMS0zOTM4Mw_0047812c-2454-48c4-991b-3b9bee9b60a6">375</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i913beb06228a48059034fdbd19194be1_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjhhZDQxNmNlMzlhZTQyYTY5YmE4ZWM0NDZhMzYzMDE4L3RhYmxlcmFuZ2U6OGFkNDE2Y2UzOWFlNDJhNjliYThlYzQ0NmEzNjMwMThfMy03LTEtMS0zOTM4Mw_7c44fee1-dd83-4fe3-ad6c-99cbac5192a9">2,021</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjhhZDQxNmNlMzlhZTQyYTY5YmE4ZWM0NDZhMzYzMDE4L3RhYmxlcmFuZ2U6OGFkNDE2Y2UzOWFlNDJhNjliYThlYzQ0NmEzNjMwMThfNC0xLTEtMS0zOTM4Mw_b270ab7c-3a7d-4296-8ca3-b7cf6d26597c">4,383</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjhhZDQxNmNlMzlhZTQyYTY5YmE4ZWM0NDZhMzYzMDE4L3RhYmxlcmFuZ2U6OGFkNDE2Y2UzOWFlNDJhNjliYThlYzQ0NmEzNjMwMThfNC0zLTEtMS0zOTM4Mw_4c19f92a-fe70-49b6-87c6-bfdb92930939">2,312</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjhhZDQxNmNlMzlhZTQyYTY5YmE4ZWM0NDZhMzYzMDE4L3RhYmxlcmFuZ2U6OGFkNDE2Y2UzOWFlNDJhNjliYThlYzQ0NmEzNjMwMThfNC01LTEtMS0zOTM4Mw_7e17517e-087c-477b-bd85-722e9558863e">7,896</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjhhZDQxNmNlMzlhZTQyYTY5YmE4ZWM0NDZhMzYzMDE4L3RhYmxlcmFuZ2U6OGFkNDE2Y2UzOWFlNDJhNjliYThlYzQ0NmEzNjMwMThfNC03LTEtMS0zOTM4Mw_28c6d2dc-b38e-42d5-8198-61fb6d1eda63">4,580</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation of $<ix:nonFraction unitRef="usd" contextRef="ie13307b791954390abb618142b11755f_D20220401-20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMjI5MA_5f9b17c9-9c91-4143-9c40-27796e1f7bac">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iac319f186e3c4549bf1291d73e9ef0c2_D20210401-20210630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTA5OTUxMTYzMTM5Nw_b34d0326-db9d-488a-bbc3-f585a0afa5a5">0.3</ix:nonFraction> million was capitalized into inventory for the three months ended June 30, 2022 and 2021, respectively. Stock-based compensation of $<ix:nonFraction unitRef="usd" contextRef="i50d7120120ae48429357a6f238139dcd_D20220101-20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMjQxMQ_a1634e7a-6fa8-4587-bf90-a31f40bcecb0">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i53b7b623056a4e2eb2ea7a0f65fc71e9_D20210101-20210630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTA5OTUxMTYzMTQwMw_1ed93d45-8040-49c1-9dc9-8b73d4e06ff7">0.5</ix:nonFraction> million was capitalized into inventory for the six months ended June 30, 2022 and 2021, respectively. Stock-based compensation capitalized in prior periods of $<ix:nonFraction unitRef="usd" contextRef="iee27527c02e7424fb0b8f40670bc3dae_D20220401-20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMjU1OQ_67030b9b-35d7-44b0-a4b1-219ea4b04807">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifa0cb1b19d894f169cd980e74653f9fb_D20210401-20210630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTA5OTUxMTYzMTQxMA_072495ce-9b23-4e6c-8449-44c5e12d2ee5">0.1</ix:nonFraction> million was recognized as cost of sales in the three months ended June 30, 2022 and 2021, respectively. Stock-based compensation capitalized in prior periods of $<ix:nonFraction unitRef="usd" contextRef="i77bf9d3e0a0b48409b6cb9f129526c9c_D20220101-20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMjcwOQ_8dd82025-0fc1-489e-a609-dd7a7c1094a8">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ife4a8ff7e8fb4ffe9f2b64e74d5e97cf_D20210101-20210630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTA5OTUxMTYzMTQxNg_a946a2e0-6920-414d-ba39-4b26a57aa860">0.2</ix:nonFraction> million was recognized as cost of sales in the six months ended June 30, 2022 and 2021, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i00e81a622be642048db364ba63b6897c_I20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMjgxOQ_da44a799-5d99-4200-bb28-f61f25befccf">52.6</ix:nonFraction> million of unrecognized compensation costs related to non-vested common stock options and restricted stock units, expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="id6ad1ceb870840e0aff0a566353c7eca_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMjk4OA_d90bcca5-b1f4-44ea-a506-bf6ffbc10ff3">3.14</ix:nonNumeric> years. The total grant date fair value of shares vested during the three and six months ended June 30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i27f5ea6853044003b5d3fe259686cfed_D20220401-20220630" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTA5OTUxMTYzMTUxMg_4ff7904b-9203-4566-9bc6-ecae7c652855">4.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id6ad1ceb870840e0aff0a566353c7eca_D20220101-20220630" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTA5OTUxMTYzMTkwOA_9b8792bf-802a-4906-9208-6d14b6b78313">7.4</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the Company had unrecognized employee stock-based compensation relating to ESPP awards of approximately $<ix:nonFraction unitRef="usd" contextRef="i1275d322af1b4c98ba3c7706239395c7_I20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMzExMg_972a8a45-6489-43cc-8fc4-365fcc8f9592">0.1</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="ia5532b33c0264e07931c620be5ee4fdb_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMzE5Ng_d36ebdbe-4d79-4cc6-8988-884047a48bf4">0.1</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i784ba2f3210d43dcbb23721a3c553397_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pulmonx Corporation</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Interim Condensed Consolidated Financial Statements (Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.    <ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RleHRyZWdpb246NTkyZTlmMzQzYTZhNDY4ZmIwYWJiYTM3NmUwMWYzYWZfOTUx_41e92070-9b81-44ab-b50c-15d6d649b97b" continuedAt="i25d0e4703a5a4f04b3da2f275a518ea5" escape="true">Net Loss per Share Attributable to Common Stockholders</ix:nonNumeric></span></div><ix:continuation id="i25d0e4703a5a4f04b3da2f275a518ea5"><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RleHRyZWdpb246NTkyZTlmMzQzYTZhNDY4ZmIwYWJiYTM3NmUwMWYzYWZfOTUy_35dcb62f-4d54-455e-acde-167093c56d18" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders which excludes shares which are legally outstanding, but subject to repurchase by the Company (in thousands, except share and per share amounts):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfMy0yLTEtMS0zOTM4Mw_1300edc3-037d-4864-a6e5-988a038b4269"><ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfMy0yLTEtMS0zOTM4Mw_735b1399-fd87-4d36-94ba-0faed66ab21b">14,640</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfMy00LTEtMS0zOTM4Mw_27304d71-abd5-47aa-a46e-14a0f574c33c"><ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfMy00LTEtMS0zOTM4Mw_85391273-3c97-412c-b697-706b5f8676df">12,962</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfMy02LTEtMS0zOTM4Mw_ba04d341-a5b6-4598-a4e0-ba026132c96f"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfMy02LTEtMS0zOTM4Mw_f6f50916-fc5a-4879-895b-a6bcc04bb3ae">30,468</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfMy04LTEtMS0zOTM4Mw_66b31552-11be-4ca4-9104-f299201ea615"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfMy04LTEtMS0zOTM4Mw_a05f6493-c1f4-4581-bc87-3a3e9082d514">25,474</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common stock outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNS0yLTEtMS0zOTM4Mw_390923d9-07a6-4cd5-a6f8-b57dbeacbb0c">37,171,893</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNS00LTEtMS0zOTM4Mw_9e941d00-48d2-4d10-abf8-f52d4dd78f0f">36,324,022</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNS02LTEtMS0zOTM4Mw_424c2e9b-a66f-480f-99ea-e34bbe6c4839">37,090,164</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNS04LTEtMS0zOTM4Mw_afe12c90-7bd9-4d8d-8b5a-e6cca06ad4ac">36,021,469</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: weighted-average common shares subject to repurchase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNi0yLTEtMS0zOTM4Mw_af26a41e-7c7a-4c2e-b84a-dd918e72d128">168,450</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNi00LTEtMS0zOTM4Mw_ea791c2b-05c6-4fdc-8bce-01cbb533aad7">281,408</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNi02LTEtMS0zOTM4Mw_93ff9803-545b-4ee6-b3b1-654cc37a1670">185,212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNi04LTEtMS0zOTM4Mw_32176c72-063e-44a0-8099-cfa7e257af7d">312,921</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares used to compute basic and diluted net loss per share</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNy0yLTEtMS0zOTM4Mw_084a4c83-30d7-4f40-9f30-64d24ea2a7e2"><ix:nonFraction unitRef="shares" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNy0yLTEtMS0zOTM4Mw_1539839a-d97b-4bb3-b225-9abeb9815d96">37,003,443</ix:nonFraction></ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNy00LTEtMS0zOTM4Mw_aab4bb85-53d1-41ae-bdb5-ab97ea5c3e3d"><ix:nonFraction unitRef="shares" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNy00LTEtMS0zOTM4Mw_e55808de-aa77-45da-b4fb-176aae32a9b0">36,042,614</ix:nonFraction></ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNy02LTEtMS0zOTM4Mw_970c1f52-8586-4b2c-b50b-6da9feccc708"><ix:nonFraction unitRef="shares" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNy02LTEtMS0zOTM4Mw_da351c5d-31ac-410e-b68d-904aa0875882">36,904,952</ix:nonFraction></ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNy04LTEtMS0zOTM4Mw_87c81359-050c-48c6-9ab1-cc3255051708"><ix:nonFraction unitRef="shares" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNy04LTEtMS0zOTM4Mw_e61c1187-918d-434b-8f21-8f05c8d88359">35,708,548</ix:nonFraction></ix:nonFraction> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfOC0yLTEtMS0zOTM4Mw_1ae17aa8-9a40-461b-96ab-1be3a44b7774"><ix:nonFraction unitRef="usdPerShare" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfOC0yLTEtMS0zOTM4Mw_c6fd9aa2-d6e9-407a-9aff-43f36157347f">0.40</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfOC00LTEtMS0zOTM4Mw_509b8717-9bca-4efe-884c-7af185b03a5b"><ix:nonFraction unitRef="usdPerShare" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfOC00LTEtMS0zOTM4Mw_ccf2418a-fe13-476f-b552-ce5a377383a3">0.36</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfOC02LTEtMS0zOTM4Mw_6b232008-ea15-4bf7-9e53-33bf6a25f62a"><ix:nonFraction unitRef="usdPerShare" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfOC02LTEtMS0zOTM4Mw_70f7ef33-13cc-47c0-b2d1-5085c6cbbefd">0.83</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfOC04LTEtMS0zOTM4Mw_f2bb9f78-0f04-477e-aa57-48bddf1f3647"><ix:nonFraction unitRef="usdPerShare" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfOC04LTEtMS0zOTM4Mw_f6ca3583-896c-4e87-b7c5-c2dfca4dbf2f">0.71</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RleHRyZWdpb246NTkyZTlmMzQzYTZhNDY4ZmIwYWJiYTM3NmUwMWYzYWZfOTUw_31e64118-4b72-475a-be5a-9113e44320c9" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company’s net loss, in common stock equivalent shares:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b60336143e4446eab2f9aef31e69da0_D20220101-20220630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOmQxNDEzYzViNzZhMjRjMWE5Y2VmZTY4MzZiMWFjYjdhL3RhYmxlcmFuZ2U6ZDE0MTNjNWI3NmEyNGMxYTljZWZlNjgzNmIxYWNiN2FfMy0xLTEtMS0zOTM4Mw_1df612d9-8914-413e-9137-d4e43de9a84c">2,600,244</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if8534ceb95304df4a061131854586927_D20210101-20210630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOmQxNDEzYzViNzZhMjRjMWE5Y2VmZTY4MzZiMWFjYjdhL3RhYmxlcmFuZ2U6ZDE0MTNjNWI3NmEyNGMxYTljZWZlNjgzNmIxYWNiN2FfMy0zLTEtMS0zOTM4Mw_b29819ed-e485-405c-8110-9c8afdc68840">2,483,364</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i493a546e223e4e349b281de37224fec9_D20220101-20220630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOmQxNDEzYzViNzZhMjRjMWE5Y2VmZTY4MzZiMWFjYjdhL3RhYmxlcmFuZ2U6ZDE0MTNjNWI3NmEyNGMxYTljZWZlNjgzNmIxYWNiN2FfMy0xLTEtMS00MTE3NQ_96d20056-6f69-4ea1-85bf-446680b1b87c">1,091,957</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88dc40bd83d7401a9672d7d2df0cbd44_D20210101-20210630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOmQxNDEzYzViNzZhMjRjMWE5Y2VmZTY4MzZiMWFjYjdhL3RhYmxlcmFuZ2U6ZDE0MTNjNWI3NmEyNGMxYTljZWZlNjgzNmIxYWNiN2FfMy0zLTEtMS00MTE3NQ_d50fb62e-b57d-4482-87ca-ea695050078c">438,550</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested early exercised common stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icaa76627fc8f47fca67ba3fd4f6b2423_D20220101-20220630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOmQxNDEzYzViNzZhMjRjMWE5Y2VmZTY4MzZiMWFjYjdhL3RhYmxlcmFuZ2U6ZDE0MTNjNWI3NmEyNGMxYTljZWZlNjgzNmIxYWNiN2FfNC0xLTEtMS0zOTM4Mw_58a17c5a-884f-44c6-8a8c-49a5b4d454cd">155,969</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3c2550a59e904c9fa8983370b3a88d6d_D20210101-20210630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOmQxNDEzYzViNzZhMjRjMWE5Y2VmZTY4MzZiMWFjYjdhL3RhYmxlcmFuZ2U6ZDE0MTNjNWI3NmEyNGMxYTljZWZlNjgzNmIxYWNiN2FfNC0zLTEtMS0zOTM4Mw_464dc07a-4942-4f17-8f67-3899d683fbef">294,577</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares committed under ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i04828ea9cac9458c9dc603bf1c75ae3e_D20220101-20220630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOmQxNDEzYzViNzZhMjRjMWE5Y2VmZTY4MzZiMWFjYjdhL3RhYmxlcmFuZ2U6ZDE0MTNjNWI3NmEyNGMxYTljZWZlNjgzNmIxYWNiN2FfNi0xLTEtMS0zOTM4Mw_b9375b22-24b1-4a8f-b35d-9a992e5cdf15">33,035</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd4dd78630cd4ade8407c6236aa12b7d_D20210101-20210630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOmQxNDEzYzViNzZhMjRjMWE5Y2VmZTY4MzZiMWFjYjdhL3RhYmxlcmFuZ2U6ZDE0MTNjNWI3NmEyNGMxYTljZWZlNjgzNmIxYWNiN2FfNi0zLTEtMS0zOTM4Mw_0c14313c-f197-45f2-868e-ad467c41dd69">6,865</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOmQxNDEzYzViNzZhMjRjMWE5Y2VmZTY4MzZiMWFjYjdhL3RhYmxlcmFuZ2U6ZDE0MTNjNWI3NmEyNGMxYTljZWZlNjgzNmIxYWNiN2FfNy0xLTEtMS0zOTM4Mw_11559874-f808-4178-ad6b-65db76143031">3,881,205</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOmQxNDEzYzViNzZhMjRjMWE5Y2VmZTY4MzZiMWFjYjdhL3RhYmxlcmFuZ2U6ZDE0MTNjNWI3NmEyNGMxYTljZWZlNjgzNmIxYWNiN2FfNy0zLTEtMS0zOTM4Mw_32d14486-e48a-4ffe-a035-6c9d0f4cbb51">3,223,356</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i784ba2f3210d43dcbb23721a3c553397_76"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.    <ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RleHRyZWdpb246YTk4NTUyMzk2MDNmNDBiYTk5NGM2N2VkNTZjMGExZjdfMTY1Nw_5199bc16-fb62-4795-9f3d-cc12000986fb" continuedAt="i4ed80a736ab448b8a896603d9fdec76f" escape="true">Segment Information</ix:nonNumeric></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4ed80a736ab448b8a896603d9fdec76f" continuedAt="ie61f6dc6ad504034a6a93432fff631cb">The chief operating decision maker for the Company is the Chief Executive Officer. The Company’s Chief Executive Officer reviews financial information presented on a consolidated basis, accompanied by information about revenue by geographic region, for purposes of allocating resources and evaluating financial performance. The Company has <ix:nonFraction unitRef="segment" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RleHRyZWdpb246YTk4NTUyMzk2MDNmNDBiYTk5NGM2N2VkNTZjMGExZjdfMzY5_169ec9c3-07ee-4bac-8f51-b0d2866e10b3"><ix:nonFraction unitRef="segment" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RleHRyZWdpb246YTk4NTUyMzk2MDNmNDBiYTk5NGM2N2VkNTZjMGExZjdfMzY5_d9f5c99e-403f-4ea5-9d4b-9d43c4bb357c">one</ix:nonFraction></ix:nonFraction> business activity and there are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated unit level. Accordingly, the Company has determined that it has a single reportable and operating segment structure. The Company’s Chief Executive Officer evaluates performance based primarily on revenue in the geographic locations in which the Company operates.</ix:continuation></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i784ba2f3210d43dcbb23721a3c553397_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pulmonx Corporation</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Interim Condensed Consolidated Financial Statements (Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="ie61f6dc6ad504034a6a93432fff631cb"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by geographic area is based on the billing address of the customer. <ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RleHRyZWdpb246YTk4NTUyMzk2MDNmNDBiYTk5NGM2N2VkNTZjMGExZjdfMTY1OA_67c596a0-fe7f-41cf-a1d2-86aadc166f58" continuedAt="i7da72b80f843480585ee416363e9562f" escape="true">The following table sets forth the Company’s revenue by geographic area (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:12pt"><ix:continuation id="i7da72b80f843480585ee416363e9562f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1359c30612540db9f7d34a1c01b3ad0_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfMi0xLTEtMS0zOTM4Mw_4290c043-6d56-430f-bcf2-ff2f36cee421">8,616</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76aa19c427d84d68b1168f403a4d9cf0_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfMi0zLTEtMS0zOTM4Mw_7721f2da-5c73-4e5e-88b4-cdba29d12d7f">6,567</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i289c4b693d0f4b78a133aca081e4ec62_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfMi01LTEtMS0zOTM4Mw_75b565a1-e287-4ca7-92b2-a92773d693a7">14,629</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dbda9b7680c4fbbb2d796862b9cc528_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfMi03LTEtMS0zOTM4Mw_6c0c88a5-98ea-4af1-ad9a-697fc3e47c76">10,856</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle-East and Africa (“EMEA”)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60c47462ac8c42278751a5e88cebb16c_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfMy0xLTEtMS0zOTM4Mw_6c2e7ca9-eef6-437f-aab6-a4d9999d3215">4,570</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9f15921237f4455b73e6cc819e646c3_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfMy0zLTEtMS0zOTM4Mw_a09cfb68-9dac-4588-bf76-397e0dd6572b">4,749</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80d96e293cf64c4a8bc6f7a1a5311f2e_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfMy01LTEtMS0zOTM4Mw_170e059f-6638-4194-ae92-4bec212194c0">8,623</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic858ed7791a6420b80be0581b72d5fe2_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfMy03LTEtMS0zOTM4Mw_94a9ad32-d29d-4d36-bf23-b6cdc2b82299">8,793</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95b08bdad4d14d5ebf4d2815ee5d2afa_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfNC0xLTEtMS0zOTM4Mw_5df11b1f-1830-499c-b0c6-6a630105ad62">724</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6331c9bd120d452f9dbc7f5077c0b308_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfNC0zLTEtMS0zOTM4Mw_a5f0414b-e268-4c17-84e0-a18ce3a212b0">875</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58327cae2f9545909843bc0298fc7738_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfNC01LTEtMS0zOTM4Mw_1ee2f727-69f6-4d02-87c9-616a8486d84e">1,443</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide14511124ea4c19b7d0d17cf44f7565_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfNC03LTEtMS0zOTM4Mw_c792cb48-585b-4c62-abea-70091e63ee03">1,786</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf783eb979ba4c2990809ef7ba464ec1_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfNS0xLTEtMS0zOTM4Mw_d92f7da9-aca5-4caa-83f4-66bd73f02dd0">40</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88d9fce60fb74d2b9219ae5f5695bac4_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfNS0zLTEtMS0zOTM4Mw_64ea0241-5cd5-4f44-b60c-27b3dabbda74">12</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2da15985d8f46c7813cfdff913a5506_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfNS01LTEtMS0zOTM4Mw_195f2fae-52d2-45f0-a560-093aa35b84af">40</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b0e39f7311c4c8dafe667c0cc5deee3_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfNS03LTEtMS0zOTM4Mw_c95e3e22-b0cd-49fc-9a31-081c0d673423">12</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfNi0xLTEtMS0zOTM4Mw_9f46a855-c004-4a49-a1c2-0c2bd950bdda">13,950</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfNi0zLTEtMS0zOTM4Mw_fc55f348-dce5-46c9-b923-b740bf20c28e">12,203</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfNi01LTEtMS0zOTM4Mw_fba71138-4cfe-4f6a-b391-c059515b460b">24,735</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfNi03LTEtMS0zOTM4Mw_8778202d-fec5-4438-bd75-c4dfb1b1cfab">21,447</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from Germany and France represented <ix:nonFraction unitRef="number" contextRef="i92b67fa545b64980b9a2e36077a0e919_D20220401-20220630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RleHRyZWdpb246YTk4NTUyMzk2MDNmNDBiYTk5NGM2N2VkNTZjMGExZjdfMTAxMw_8c40d8a0-400e-4e5f-8a53-c7d22428d760">10</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i39dcbe49829e478bae65bf4ad7ebe73b_D20220401-20220630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RleHRyZWdpb246YTk4NTUyMzk2MDNmNDBiYTk5NGM2N2VkNTZjMGExZjdfMTAyMA_9cc876b5-c04f-4389-a8f5-c415a1f2f8c1">9</ix:nonFraction>%, respectively, of total revenue for the three months ended June 30, 2022. Revenue from Germany and France represented <ix:nonFraction unitRef="number" contextRef="ie37b898ed5f549b6a2584d0735ebc6a8_D20210401-20210630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RleHRyZWdpb246YTk4NTUyMzk2MDNmNDBiYTk5NGM2N2VkNTZjMGExZjdfMTE0MA_8aff97b7-6375-4283-a177-c415c1badda5">11</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="iff16a3996ed74e9185638c285d8180e7_D20210401-20210630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RleHRyZWdpb246YTk4NTUyMzk2MDNmNDBiYTk5NGM2N2VkNTZjMGExZjdfMTE0Nw_7a1e595c-9ca3-4a5e-a1df-a5fc5995791f">9</ix:nonFraction>%, respectively, of total revenue for the three months ended June 30, 2021. Revenue from Germany and France represented <ix:nonFraction unitRef="number" contextRef="id116f3f4ef654103a4a17291f98e96cd_D20220101-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RleHRyZWdpb246YTk4NTUyMzk2MDNmNDBiYTk5NGM2N2VkNTZjMGExZjdfMTI2Nw_f1fc0ab7-cc67-4640-83b2-e6247ae5fdce">12</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i14ce772deb444cdc87b44503d5d9c1d5_D20220101-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RleHRyZWdpb246YTk4NTUyMzk2MDNmNDBiYTk5NGM2N2VkNTZjMGExZjdfMTI3NA_2a3ea56d-e16f-4222-9cb1-1682a3b555eb">8</ix:nonFraction>%, respectively, of total revenue for the six months ended June 30, 2022. Revenue from Germany and France represented <ix:nonFraction unitRef="number" contextRef="ia90e44e3c9a34436a33d109bdf77b945_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RleHRyZWdpb246YTk4NTUyMzk2MDNmNDBiYTk5NGM2N2VkNTZjMGExZjdfMTM5Mg_dc04ee38-a8f9-40fb-8ba8-c5dda5e02fdc">12</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i800d29a3bc944cd193e54a8b9a0f6afb_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RleHRyZWdpb246YTk4NTUyMzk2MDNmNDBiYTk5NGM2N2VkNTZjMGExZjdfMTM5OQ_a8f6bc13-4cf0-42d6-b66d-958aafcf22dc">10</ix:nonFraction>%, respectively, of total revenue for the six months ended June 30, 2021. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets by geographic area are based on physical location of those assets. <ix:nonNumeric contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RleHRyZWdpb246YTk4NTUyMzk2MDNmNDBiYTk5NGM2N2VkNTZjMGExZjdfMTY1OQ_40ae2448-11e6-4551-a562-5aa88a0d201c" continuedAt="i2e480ce752e64538af0b1b0c52e40e8e" escape="true">The following table sets forth the Company’s long-lived assets by geographic area (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:12pt"><ix:continuation id="i2e480ce752e64538af0b1b0c52e40e8e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fe4d5c850434aa89e016828fdf266ed_I20220630" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjBlYzQyM2RmNjE0NDQ5YThiYWJjNTMzZGQ0ZjAyMzNmL3RhYmxlcmFuZ2U6MGVjNDIzZGY2MTQ0NDlhOGJhYmM1MzNkZDRmMDIzM2ZfMi0xLTEtMS0zOTM4Mw_f64a22d1-3411-46d7-8a96-d94d5b3820f5">4,871</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5796864d445f4298b6b97e81ee3b2e14_I20211231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjBlYzQyM2RmNjE0NDQ5YThiYWJjNTMzZGQ0ZjAyMzNmL3RhYmxlcmFuZ2U6MGVjNDIzZGY2MTQ0NDlhOGJhYmM1MzNkZDRmMDIzM2ZfMi0zLTEtMS0zOTM4Mw_ef336995-c147-467f-9379-35f76a8f1c43">4,767</ix:nonFraction> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EMEA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5926e07811564c14a1a7947cce7b6f48_I20220630" decimals="-3" name="us-gaap:NoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjBlYzQyM2RmNjE0NDQ5YThiYWJjNTMzZGQ0ZjAyMzNmL3RhYmxlcmFuZ2U6MGVjNDIzZGY2MTQ0NDlhOGJhYmM1MzNkZDRmMDIzM2ZfMy0xLTEtMS0zOTM4Mw_8faf6c9a-fb6c-4d90-b8d2-26f0cbe31c26">58</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d545a4cc5594760b939659357af4982_I20211231" decimals="-3" name="us-gaap:NoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjBlYzQyM2RmNjE0NDQ5YThiYWJjNTMzZGQ0ZjAyMzNmL3RhYmxlcmFuZ2U6MGVjNDIzZGY2MTQ0NDlhOGJhYmM1MzNkZDRmMDIzM2ZfMy0zLTEtMS0zOTM4Mw_f80d9b22-e73f-41dc-9fdb-8d2cc76fff55">42</ix:nonFraction> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2011b63fd9c4fd7bbc64ec2a1f0ca7a_I20220630" decimals="-3" name="us-gaap:NoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjBlYzQyM2RmNjE0NDQ5YThiYWJjNTMzZGQ0ZjAyMzNmL3RhYmxlcmFuZ2U6MGVjNDIzZGY2MTQ0NDlhOGJhYmM1MzNkZDRmMDIzM2ZfNC0xLTEtMS0zOTM4Mw_8e7debdf-6c6d-4bf6-b94c-fbff0da32ce1">3</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74632ce2458d45f882a429075d1c2a21_I20211231" decimals="-3" name="us-gaap:NoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjBlYzQyM2RmNjE0NDQ5YThiYWJjNTMzZGQ0ZjAyMzNmL3RhYmxlcmFuZ2U6MGVjNDIzZGY2MTQ0NDlhOGJhYmM1MzNkZDRmMDIzM2ZfNC0zLTEtMS0zOTM4Mw_37fd4f0b-be42-4237-96f5-4ba76c175be4">5</ix:nonFraction> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjBlYzQyM2RmNjE0NDQ5YThiYWJjNTMzZGQ0ZjAyMzNmL3RhYmxlcmFuZ2U6MGVjNDIzZGY2MTQ0NDlhOGJhYmM1MzNkZDRmMDIzM2ZfNS0xLTEtMS0zOTM4Mw_cc40c7b1-a960-408c-98c0-beb034e0ab8c">4,932</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjBlYzQyM2RmNjE0NDQ5YThiYWJjNTMzZGQ0ZjAyMzNmL3RhYmxlcmFuZ2U6MGVjNDIzZGY2MTQ0NDlhOGJhYmM1MzNkZDRmMDIzM2ZfNS0zLTEtMS0zOTM4Mw_6c71a908-e9c4-4761-ba97-6906f6a817c1">4,814</ix:nonFraction> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i784ba2f3210d43dcbb23721a3c553397_79"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i784ba2f3210d43dcbb23721a3c553397_82"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q. This discussion and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions, that are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the sections of this Quarterly Report entitled “Forward-Looking Statements” and “Risk Factors,” under Part II, Item 1A and those discussed in our Annual Report on Form 10-K for the year ending December 31, 2021 filed with the Securities and Exchange Commission (“SEC”) on March 1, 2022.</span></div><div id="i784ba2f3210d43dcbb23721a3c553397_85"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (“COPD”). Our solution, which is comprised of the Zephyr Endobronchial Valve (“Zephyr Valve”), the Chartis Pulmonary Assessment System (“Chartis System”) and the StratX Lung Analysis Platform (“StratX Platform”), is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. We estimate our solution currently addresses approximately 500,000 patients in the United States and 700,000 patients in select international markets, which represents a global market opportunity of approximately $12 billion.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a compelling body of clinical evidence with over 100 scientific articles published regarding the clinical benefits of Zephyr Valves, including in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The New England Journal of Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Lancet </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> American Journal of Respiratory and Critical Care Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Multiple randomized controlled clinical trials have demonstrated that patients selected with the Chartis System and successfully treated with Zephyr Valves have shown statistically and clinically significant improvements in lung function, exercise capacity and quality of life compared to medical management alone.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, we received pre-market approval (“PMA”) by the U.S. Food and Drug Administration (“FDA”) as a result of our breakthrough technology designation. The Zephyr Valve is now commercially available in more than 25 countries, with over 100,000 valves used to treat more than 25,000 patients. We have established reimbursement in major markets in North America, Europe and Asia Pacific and the Zephyr Valve has been included in treatment guidelines for COPD worldwide.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market and sell our products in the United States through a direct sales organization. Our sales territory managers are focused on promoting awareness and increasing adoption of our solution primarily among the pulmonologists performing interventional pulmonary procedures across approximately 500 high volume hospitals in the United States. We are expanding our commercial operations in the United States while continuing to foster our international growth. We employ both direct and distributor-based sales models, with over 90% of our revenue generated in markets where we sell directly.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, our solution is reimbursed based on established Category I Current Procedural Terminology (“CPT”) and ICD-10 Procedure Coding System (“PCS”) codes and associated APC and MS-DRG payment groupings. Current reimbursement in the United States is believed to cover the hospital costs of the procedure and related inpatient care. Commercial payors such as Aetna, Humana, and many of the largest Blue Cross Blue Shield plans including Anthem, Health Care Service Corporation, and BCBS Michigan have issued positive coverage policies for the Zephyr Valve, and United Healthcare no longer considers the procedure unproven or experimental. Medicare covers our solution for patients when medically necessary, and other commercial insurers are approving pre-authorization requests on a case-by-case basis. Outside the United States, our solution is covered by major health systems across much of Europe, Australia and South Korea. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture all our products at our headquarters located in Redwood City, California. This facility supports production and distribution operations, including manufacturing, quality control, raw material and finished goods storage. We have manufactured all our products at this facility for over ten years. We also store finished goods at secondary facilities. We seek to maintain higher levels of inventory to protect ourselves from supply interruptions and have an established distribution system for both U.S. and international customers.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have financed our operations primarily through the sale of equity securities, debt financing arrangements and sales of our products. We have devoted substantially all of our resources to research and development activities related to our solution, including clinical and regulatory initiatives to obtain marketing approval, sales and marketing activities, and investing in general and administrative infrastructure. We generated revenue of $14.0 million, with a gross margin of 74.7% and a net loss of $14.6 million, for the three months ended June 30, 2022 compared to revenue of $12.2 million, with a gross margin of 74.0% and a net loss of $13.0 million, for the three months ended June 30, 2021. For the six months ended June 30, 2022, we generated revenue of $24.7 million, with a gross margin of 74.9% and a net loss of $30.5 million, compared to revenue of $21.4 million, with a gross margin of 72.9% and a net loss of $25.5 million, for the six months ended June 30, 2021. As of June 30, 2022, we had an accumulated deficit of $321.9 million, cash, cash equivalents and marketable securities of $166.8 million, and $17.4 million of outstanding term loans and credit agreements, net of debt discount and debt issuance costs. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested heavily in product development. Our research and development activities have been centered on driving continuous improvements to our solution. We have also made significant investments in clinical studies to demonstrate the safety and efficacy of the Zephyr Valve and to support regulatory submissions. We intend to make significant investments building our sales and marketing organization by increasing the number of sales territory managers and continuing our marketing efforts in existing and new markets throughout the United States, Europe and Asia Pacific. We also intend to continue to make investments in research and development efforts to develop our next generation products and support our future regulatory submissions to increase our addressable market and to expand indications and new markets. Because of these and other factors, we expect to continue to incur net losses for the next several years and we expect to require substantial additional funding, which may include future equity and debt financings.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the Company’s existing cash, cash equivalents and marketable securities will allow the Company to continue its operations for at least the next 12 months from the date of the issuance of our condensed consolidated financial statements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of the COVID-19 Pandemic</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There continues to be widespread significant impact from the COVID-19 pandemic, which has delayed clinical trials and FDA operations and adversely impacted the number of procedures performed using our products. In the markets in which we operate, elective, specialty and other procedures and appointments have been, and continue to be, suspended or canceled to avoid non-essential patient exposure to medical environments and potential infection with COVID-19 and to focus limited resources and personnel capacity toward the treatment of COVID-19 patients. As a result, the COVID-19 pandemic and the measures taken by many countries in response have materially adversely affected, and could in the future materially adversely affect, our business, financial condition and results of operations, as well as the price of our common stock, from a decrease and delay of procedures involving our products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we saw some level of recovery in procedure volumes in our U.S. and larger international markets in the second quarter of 2022, our smaller international markets were hampered by a slower recovery, including continued lockdowns in China. We are encouraged for the longer term, and we believe the following key indicators are contributing to the stabilization of our business:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued opening of new accounts;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strong physician participation in trainings;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a strong patient pipeline evidenced by StratX report activity, patient calls into hospitals inquiring about our procedure, and patient calls to our reimbursement support service; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a resumption of elective procedures at hospitals and centers. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the COVID-19 pandemic, we implemented a variety of measures intended to help us manage the impact of the pandemic and position us to resume operations quickly and efficiently as restrictions, recommendations, and best practices evolve. These measures have included, and continue to include:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing safety protocols, facility enhancements, and work-from-home strategies to protect our employees;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ensuring that our manufacturing and supply chain operations remain intact and operational, and building up our inventory;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">keeping our workforce intact and continuing to build our team;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continuing to focus on new account openings and resuming physician training programs;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">accelerating our physician education programs and direct-to-patient marketing efforts through social media or other virtual forums; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continuing to invest in research and development activities in order to advance our AeriSeal clinical programs.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite signs of recovery of our business, we cannot be certain that any recovery will be sustained, or that a further resurgence of COVID-19 or variants of the virus will not occur. The measures adopted in response to, and challenges resulting from, the COVID-19 pandemic may continue to adversely affect our employees, including our sales force, hospitals, physicians, patients, communities and business operations, and may continue to contribute to significant volatility and negative pressure on the U.S. and world economy and financial markets. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we cannot assure you that our recent volume of Zephyr Valves sold are indicative of future results. The number of Zephyr Valves sold in the future may decrease due to a resurgence of the COVID-19 pandemic. In addition, there may be limited provider capacity due to labor shortages, or for other reasons, which could limit the ability of patients to receive treatment with Zephyr Valves. Limited provider and hospital capacity has had a material adverse effect on our business, financial condition and results of operations and may continue to materially adversely affect us even as the pandemic subsides. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent of the impact of COVID-19, including the macroeconomic conditions, on our future operational and financial performance will depend on certain developments, which are highly uncertain and cannot be predicted, including impact on employees, clinical trials and procedure volumes, new information which may emerge concerning the severity and spread of COVID-19 and variant strains, governmental and societal response to contain and treat COVID-19 and variant strains, and the availability and distribution of vaccines and public acceptance of vaccines, among others.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information about risks, uncertainties and potential impacts related to the COVID-19 pandemic that may impact our business, financial condition and results of operations, please refer to Part II, Item 1A, “Risk Factors” of this Quarterly Report on Form 10-Q.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i784ba2f3210d43dcbb23721a3c553397_88"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Factors Affecting our Business and Results of Operations</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe there are several important factors that have impacted and that we expect will continue to impact our business and results of operations. These factors include:</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Ability to Recruit, Train and Retain Our Sales Force and its Productivity</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made, and intend to continue to make, significant investments in recruiting, training and retaining our direct sales force. This process requires significant education and training for our sales personnel to achieve the level of technical competency with our products that is expected by physicians and to gain experience building demand for our products. Upon completion of the training, our sales personnel typically require time in the field to grow their network of accounts and increase their productivity to the levels we expect. Successfully recruiting, training and retaining additional sales personnel will be required to achieve growth. In addition, inability to attract qualified sales personnel or the loss of any productive sales personnel would have a negative impact on our ability to grow our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in the past and expect in the future to enter into different compensation arrangements with our sales professionals, which include minimum guaranteed commissions. This has impacted our compensation expenses in the past and we expect it will do so in the future.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Physician, Patient and Hospital Awareness and Acceptance of Our Solution</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to establish our solution as a standard of care for severe emphysema. We intend to continue to promote awareness of our solution through training and educating physicians, pulmonary rehabilitation centers, key opinion leaders and various medical societies on the proven clinical benefits of Zephyr Valves. In addition, we intend to continue to publish additional clinical data in various industry and scientific journals and online and to present at various industry conferences. We plan to continue building patient awareness through our direct-to-patient marketing initiatives, which include advertising, social media and online education. We also intend to continue helping physicians in their outreach to patients and other healthcare providers. These efforts require significant investment by our marketing and sales organization, and vary depending upon the physician’s practice specialization, and personal preferences and geographic location of physicians, pulmonary rehabilitation centers and patients. In order to grow our business, we will need to continue to make significant investments in training and educating hospitals, physicians and patients on the advantages of our solution for the treatment of severe emphysema.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-Party Reimbursement</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since achieving regulatory approval in the United States in June 2018, we have launched the Zephyr Valve treatment and have made progress securing third-party payor reimbursement. The majority of our patients are Medicare beneficiaries. We estimate that roughly 75% of the potential Zephyr Valve patient population are Medicare/Medicaid beneficiaries, of which approximately 30% have managed Medicare/Medicaid and the remaining 45% have traditional Medicare/Medicaid. Approximately 25% of the potential Zephyr Valve patient population is under third-party commercial payor policies. A key element of our strategy remains to broaden our coverage by private third-party payor policies. Commercial payors such as Aetna, Humana, and many of the largest Blue Cross Blue Shield plans including Anthem, Health Care Service Corporation, and BCBS Michigan have issued positive coverage policies for the Zephyr Valve, and United Healthcare no longer considers the procedure unproven or experimental. Some commercial payors do not yet consider our solution medically necessary, but these same plans are approving pre-authorization requests on a case-by-case basis. Medicare, currently without a public coverage policy, covers our solution for patients when medically necessary on a case-by-case basis and other commercial insurers not described above are approving pre-authorization requests on a case-by-case basis. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a dedicated patient reimbursement support team in the United States that works collaboratively with patients and providers to help secure the appropriate prior authorization approvals in advance of treatment. We continue to educate private insurers in the United States on our clinical data and patient selection tools in an effort to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">continue to expand the number of positive coverage policies, in order to increase our revenue. Outside the United States, our solution is covered by major health systems across much of Europe, Australia and South Korea. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our industry is highly competitive and subject to rapid change from the introduction of new products and technologies and other activities of industry participants. Our goal is to establish our solution as a standard of care for severe emphysema. Existing treatments include medical management, lung volume reduction surgery (“LVRS”), lung transplantation as well as other minimally invasive treatments. Some of our competitors have several competitive advantages, including established relationships with pulmonologists who commonly treat patients with emphysema, significantly greater name recognition and significantly greater sales and marketing resources. In addition to competing for market share, we also compete against these companies for personnel, including qualified sales and other personnel that are necessary to grow our business. Certain of our competitors may challenge our intellectual property, may develop additional competing or superior technologies and processes and compete more aggressively and sustain that competition over a longer period of time than we could. In addition to existing competitors, other companies may acquire or in-license competitive products and could directly compete with us. We must continue to successfully compete in light of our competitors’ existing and future products and related pricing and their resources to successfully market to the physicians who use our products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leveraging Our Manufacturing Capacity is Critical to Improving Our Gross Margin</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With our current operating model and infrastructure, we have the capacity to significantly increase our manufacturing production. If we grow our revenue and sell more units, our fixed manufacturing costs will be spread over more units, which we believe will reduce our manufacturing costs on a per-unit basis and in turn improve our gross margin. In addition, we intend to continue investing in manufacturing efficiencies in order to reduce our overall manufacturing costs. However, other factors will continue to impact our gross margins such as geographic mix, pricing and customer discounts, incentives, support services and potential seasonality.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing in Research and Development to Foster Innovation to Expand Our Addressable Market</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue investing in existing and next generation technologies to further improve our products and clinical outcomes, enhance patient selection and broaden the patient population that can be treated with our products. In addition, we are continuing to invest in the accuracy and features of our patient assessment tools. Moreover, we are conducting clinical research of AeriSeal, a potential product in development for the treatment of severe emphysema patients who are not qualified for Zephyr Valve treatment due to excessive collateral ventilation. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While research and development and clinical testing are time consuming and costly, we believe that a pipeline of new products and product enhancements that improve efficacy, safety and cost effectiveness is critical to increasing the adoption of our solution. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Seasonality</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, we have experienced seasonality outside of the United States, primarily in the first and third quarters and anticipate this trend to continue. In addition, as our sales grow in the United States, we may experience seasonality based on holidays, vacations and other factors because this is an elective procedure.</span></div><div id="i784ba2f3210d43dcbb23721a3c553397_91"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Our Results of Operations</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently derive substantially all our revenue from the sale of our products to hospitals and distributors. We market and sell our products through a direct sales organization in the United States and through direct sales and several third-party distributors in select markets outside the United States. We currently generate most of our revenue from the sales of Zephyr Valves and delivery catheters. We also generate a smaller amount of our revenue </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from our Chartis System, which is comprised of sales of the balloon catheters, usage fees and sales of the Chartis console. The StratX Platform, while used to identify patients eligible for treatment with Zephyr Valves, does not independently generate any revenue for us. No single customer accounted for more than 10% of our revenue during the three and six months ended June 30, 2022 and June 30, 2021.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales of our products fluctuates based on volume of cases (procedures performed), the average number of Zephyr Valves used for a patient, pricing, discounts, incentives and mix of U.S. and international sales. Our revenue also fluctuates and in the future will continue to fluctuate from quarter-to-quarter due to a variety of factors, including the availability of reimbursement, the size and success of our sales force, the number of hospitals and physicians who are aware of and perform the procedures using our solution and seasonality. Our revenue from international sales may also be impacted by fluctuations in foreign currency exchange rates between the U.S. dollar (our reporting currency) and the local currency. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold and Gross Margin</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold consists primarily of payroll and personnel-related expenses for our manufacturing and quality assurance employees, costs related to materials, components and subassemblies, third-party costs, manufacturing overhead, equipment depreciation, charges for excess, obsolete and non-sellable inventories. Overhead costs include the cost of quality assurance, testing, material procurement, inventory control, operations supervision and management and an allocation facilities overhead cost, including rent and utilities. Cost of goods sold also includes certain direct costs such as those incurred for shipping our products and costs related to providing analysis services for patient scans. We record adjustments to our inventory valuation for estimated excess, obsolete and non-sellable inventories based on assumptions about future demand, past usage, changes to manufacturing processes and overall market conditions. We expect cost of goods sold to increase in absolute dollars to the extent more of our products are sold.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate gross margin as gross profit divided by revenue. Our gross margin has been and will continue to be affected by a variety of factors, primarily by our manufacturing costs, pricing pressures and, to a lesser extent, the percentage of products we sell in the United States versus internationally and the percentage of products we sell to distributors versus directly to hospitals. Our gross margin is typically higher on products we sell directly to hospitals as compared to products we sell through distributors.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gross margin may increase over the long term to the extent our production volume increases as our fixed manufacturing costs would be spread over a larger number of units, thereby reducing our per-unit manufacturing costs. We expect our gross margin to fluctuate from period to period, however, based upon the factors described above and seasonality.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating expenses have consisted solely of research and development costs and selling, general and administrative costs.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities primarily consist of engineering and research programs associated with our products under development and improvements to our existing products. Research and development expenses include payroll and personnel-related costs for our research and development employees, including expenses related to stock-based compensation, for employees engaged in research and development, consulting services, clinical trial expenses, regulatory expenses, prototyping, testing, laboratory supplies, and an allocation of facility overhead costs. Our clinical trial expenses include costs associated with clinical trial design, clinical trial site development and study costs, data management costs, related travel expenses, the cost of products used for clinical activities, and internal and external costs associated with our regulatory compliance. We expense research and development costs as they are incurred. We expect our research and development expenses, including related stock-based compensation </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense, to increase in absolute dollars as we hire additional personnel to develop new product offerings and product enhancements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our selling, general and administrative expenses consist of payroll and personnel-related costs for our sales and marketing personnel, including variable sales compensation, travel expenses, consulting, public relations costs, direct marketing, customer training, trade show and promotional expenses, stock-based compensation and allocated facility overhead costs, and for administrative personnel that support our general operations such as information technology, executive management, financial accounting, customer services and human resources personnel. We expense sales variable compensation at the time of the sale. Selling, general and administrative expenses also include costs attributable to professional fees for legal and accounting services, insurance, consulting fees, recruiting fees, travel expense, bad debt expense and depreciation.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue to increase our sales and marketing spending to generate sales opportunities. We expect expenses to increase in absolute dollars as we increase our sales support infrastructure and add additional marketing programs in order to more fully penetrate the global opportunity. We also expect our administrative expenses, including stock-based compensation expense, to increase as we increase our headcount and expand our facilities and information technology to support our operations as a public company. Additionally, we anticipate increased expenses related to audit, legal, regulatory and tax-related services associated with being a public company, compliance with exchange listing and SEC requirements, director and officer insurance premiums and investor relations costs. We also saw an increase in our stock-based compensation expense with the establishment of our 2020 Equity Incentive Plan and related grants either in the form of restricted stock units or options. Our selling, general and administrative expenses may fluctuate from period to period due to the seasonality of our business and as we continue to add direct sales territory managers in new territories.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense and Income</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists primarily of interest expense related to our term loan facilities, including amortization of debt discount and issuance costs. Interest income is predominantly derived from investing surplus cash in money market funds and marketable securities.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net primarily consists of foreign currency exchange gains and losses.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i784ba2f3210d43dcbb23721a3c553397_94"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations:</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Three Months Ended June 30, 2022 and 2021</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the period indicated:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,950 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs of goods sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,418 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,029 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,389 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,594 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,506 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,829 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,711 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,118 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,411)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,682)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,729)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,600)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,882)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,718)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,640)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,962)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,678)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue increased by $1.7 million, or 14.3%, to $14.0 million during the three months ended June 30, 2022, compared to $12.2 million during the three months ended June 30, 2021. The sale of products in the United States increased by $2.0 million to $8.6 million during the three months ended June 30, 2022, compared to $6.6 million for the three months ended June 30, 2021. The sale of products in international markets decreased by $0.3 million to $5.3 million during the three months ended June 30, 2022, compared to $5.6 million for the three months ended June 30, 2021. The increase in U.S. revenue reflects continued growth of Zephyr Valve procedure volumes, while the decrease in international revenue reflects the impact of foreign currency exchange rates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold and Gross Margin </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold increased by $0.4 million, or 11.3%, to $3.5 million during the three months ended June 30, 2022, compared to $3.2 million during the three months ended June 30, 2021. Gross margin was 74.7% during the six months ended June 30, 2022 and 74.0% during the six months ended June 30, 2021. The increase was primarily due to improved production efficiencies.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $0.1 million, or 2.5%, to $3.6 million during the three months ended June 30, 2022, compared to $3.5 million during the three months ended June 30, 2021. The increase in research and development expense was primarily due to increases of $0.4 million in personnel related expenses including stock-based compensation as we invested in research and development activities, $0.1 million in testing expenses, and $0.1 million in facilities and other expenses, offset by decreases of $0.5 million in costs associated with our clinical trials, including fees paid to contract research organizations (“CROs”).</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased by $3.0 million, or 16.6%, to $21.2 million during the three months ended June 30, 2022, compared to $18.2 million during the three months ended June 30, 2021. The increase in selling, general and administrative expenses was primarily due to $2.0 million of payroll and personnel-related expenses including stock-based compensation for our sales, marketing and administrative personnel, an increase of $0.7 million in advertising expenses, $0.2 million in software implementation related expenses, an increase of $0.3 million in global travel and conference related expenses, and an increase of $0.1 million in facility related expenses. These increases were offset by a decrease of $0.3 million in consulting and other expenses.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense and Income</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense of $0.2 million was flat during the three months ended June 30, 2022 compared to the three months ended June 30, 2021 due to constant outstanding debt principal. Interest income increased by $0.1 million for the three months ended June 30, 2022 compared to the three months ended June 30, 2021, primarily due to an increase in interest income as a result of higher returns on cash, cash equivalents and marketable securities balances.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), decreased by $0.1 million to ($0.2) million during the three months ended June 30, 2022, compared to $(0.1) million during the three months ended June 30, 2021, primarily due to foreign currency exchange losses.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Six Months Ended June 30, 2022 and 2021</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the period indicated:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,447 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs of goods sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,206 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,807 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,529 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,640 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,889 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,128 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,204 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,608 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,816 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,792 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,079)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,176)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,903)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(421)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(423)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(353.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,361)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,327)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,034)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,468)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,474)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,994)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue increased by $3.3 million, or 15.3%, to $24.7 million during the six months ended June 30, 2022, compared to $21.4 million during the six months ended June 30, 2021. The sale of products in the United States increased by $3.8 million to $14.6 million during the six months ended June 30, 2022, compared to $10.8 million for </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the six months ended June 30, 2021. The sale of products in international markets decreased by $0.5 million to $10.1 million during the six months ended June 30, 2022, compared to $10.6 million for the six months ended June 30, 2021. The increase in U.S. revenue reflects continued growth of Zephyr Valve procedure volumes, while the decrease in international revenue reflects the impact of foreign currency exchange rates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold and Gross Margin </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold increased by $0.4 million, or 6.9%, to $6.2 million during the six months ended June 30, 2022, compared to $5.8 million during the six months ended June 30, 2021. Gross margin was 74.9% during the six months ended June 30, 2022 and 72.9% during the six months ended June 30, 2021. The increase was primarily due to improved production efficiencies.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $0.6 million, or 9.0%, to $7.1 million during the six months ended June 30, 2022, compared to $6.5 million during the six months ended June 30, 2021. The increase in research and development expense was primarily due to increases of $0.7 million in personnel related expenses including stock-based compensation as we invested in research and development activities and $0.4 million in testing and facilities related expenses, offset by decreases of $0.5 million in costs associated with our clinical trials, including fees paid to CROs.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased by $7.2 million, or 21.0%, to $41.5 million during the six months ended June 30, 2022, compared to $34.3 million during the six months ended June 30, 2021. The increase in selling, general and administrative expenses was primarily due to $4.9 million of payroll and personnel-related expenses including stock-based compensation for our sales, marketing and administrative personnel, an increase of $1.4 million in advertising expenses, $0.4 million in software implementation related expenses, an increase of $0.7 million in global travel and conference related expenses, and an increase of $0.3 million in facility related expenses. These increases were offset by a decrease of $0.5 million in consulting and other expenses.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense and Income</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense of $0.4 million was flat during the six months ended June 30, 2022 compared to the six months ended June 30, 2021 due to constant outstanding debt principal. Interest income increased by $0.1 million for the six months ended June 30, 2022 compared to the six months ended June 30, 2021, primarily due to an increase in interest income as a result of higher returns on cash, cash equivalents and marketable securities balances.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net decreased by $0.2 million to ($0.2) million during the six months ended June 30, 2022, compared to less than $0.1 million during the six months ended June 30, 2021, primarily due to foreign currency exchange losses.</span></div><div id="i784ba2f3210d43dcbb23721a3c553397_97"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources; Plan of Operation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have financed operations primarily through the sale of equity securities, debt financing arrangements and sales of our products. As of June 30, 2022, we had cash, cash equivalents and marketable securities of $166.8 million, an accumulated deficit of $321.9 million, and $17.4 million outstanding under the CIBC Loan and Credit Agreement, net of debt discount and debt issuance costs.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CIBC Loan</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2020, we executed a Loan and Security Agreement with Canadian Imperial Bank of Commerce (“CIBC”), which we subsequently amended on April 17, 2020, December 28, 2020, March 29, 2021, and October 21, 2021 (as amended, the “CIBC Agreement”). The CIBC Agreement provided us with the ability to borrow up to $32.0 million in debt financing consisting of $17.0 million advanced at the closing of the agreement (“Tranche A”), with the option to draw up to an additional $8.0 million (“Tranche B”) on or before February 20, 2022 and an additional $7.0 million (“Tranche C”) on or before February 20, 2022. Neither Tranche B nor Tranche C was drawn before the expiration date. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loan bears interest at a floating rate equal to 1.0% above the Wall Street Journal Prime Rate at any time. The Tranche C loan will bear interest at a floating rate equal to 1.5% above the Wall Street Journal Prime Rate at any time. The loan is collateralized by substantially all of our assets, including cash and cash equivalents, accounts receivable, intellectual property and equipment. We may prepay the loan, subject to certain requirements. The CIBC Agreement includes customary restrictive covenants, financial covenants, events of default and other customary terms and conditions. In December 2020, to address certain post-close covenants for which we were not in compliance, we entered into a Second Amendment to the CIBC Agreement that extended the compliance date for certain post-close covenants to June 30, 2021. In March 2021, we entered into a Third Amendment to the CIBC Agreement which extended the loan maturity date from March 15, 2022 to February 20, 2025, and modified certain financial covenants. Under the amended terms, principal repayment will begin in February 2023. There was no change to the loan interest rate or maturity date.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We paid $0.4 million fees to the lender and third parties which is reflected as a discount on the CIBC Loan and is being accreted over the life of the term loan using the effective interest method. During the three months ended June 30, 2022 and 2021, the Company recorded interest expense related to debt discount and debt issuance costs of CIBC Loan of less than $0.1 million and less than $0.1 million, respectively. During the six months ended June 30, 2022 and 2021, the Company recorded interest expense related to debt discount and debt issuance costs of CIBC Loan of less than $0.1 million and $0.1 million, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense on the CIBC Loan amounted $0.2 million and $0.2 million during the three months ended June 30, 2022 and 2021, respectively. Interest expense on the CIBC Loan amounted $0.4 million and $0.4 million during the six months ended June 30, 2022 and 2021, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, Pulmonx International Sàrl, our wholly-owned subsidiary, entered into a COVID-19 Credit Agreement with UBS Switzerland AG to receive up to 0.5 million Swiss Francs ($0.5 million U.S. dollar equivalent) under Swiss Federal Government program to mitigate the economic impact of the spread of the coronavirus. In May 2020, Pulmonx International Sàrl received 0.5 million Swiss Francs ($0.5 million U.S. dollar equivalent) under the COVID-19 Credit Agreement. The COVID-19 Credit Agreement bears no interest and will be repaid within 60 months after receipt of funds, in twelve equal installments, paid semi-annually, beginning in March of 2022. As of June 30, 2022, Pulmonx International Sàrl paid less than $0.1 million to the lender.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary Statement of Cash Flows</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the primary sources and uses of cash and cash equivalents for the period presented below: </span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,590)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,362)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,542)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,717)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,446 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) increase in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,533)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,858)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $24.6 million for the six months ended June 30, 2022. Cash used in operating activities was primarily a result of the net loss of $30.5 million, an increase in inventory of $3.0 million due to continued production to build inventory to meet projected increase in sales, an increase in accounts receivable of $1.1 million, a decrease in accrued liabilities of $1.3 million, a decrease in lease liabilities of $0.7 million due to lease payments, and a decrease in income taxes payable of $0.1 million, partially offset by an increase in accounts payable of $1.1 million due to timing of payments to our vendors, and a decrease in prepaid expenses and other current assets of $1.1 million, stock-based compensation expense of $7.9 million, non-cash lease expense of $1.2 million, write-down of inventory of $0.1 million and depreciation and amortization expense of $0.7 million.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $22.4 million for the six months ended June 30, 2021. Cash used in operating activities was primarily a result of the net loss of $25.5 million, an increase in inventory of $3.1 million due to continued production to build inventory to meet projected increase in sales, an increase in accounts receivable of $2.7 million, a decrease in income taxes payable of $0.1 million, and a decrease in lease liabilities of $1.1 million due to lease payments partially offset by an increase in accrued liabilities of $2.9 million and an increase in accounts payable of $0.3 million due to timing of payments to our vendors, and a decrease in prepaid expenses and other current assets of $0.2 million, stock-based compensation expense of $4.6 million, non-cash lease expense of $1.1 million, write-down of inventory of $0.7 million and depreciation and amortization expense of $0.3 million.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities in the six months ended June 30, 2022 was $3.5 million consisting of purchases of marketable securities of $21.9 million and purchases of property and equipment of $0.9 million partially offset by proceeds from maturities of marketable securities of $19.3 million.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities in the six months ended June 30, 2021 was $13.7 million consisting of purchases of marketable securities of $15.3 million and purchases of property and equipment of $0.9 million partially offset by proceeds from maturities of marketable securities of $2.5 million.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities in the six months ended June 30, 2022 of $1.4 million primarily relates to proceeds from the exercise of stock options of $0.4 million and proceeds from issuance of common stock under the employee stock purchase plan of $1.1 million, offset by repayment of Credit Agreement of less than $0.1 million.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities in the six months ended June 30, 2021 of $3.3 million primarily relates to proceeds from the exercise of stock options of $1.4 million and proceeds from issuance of common stock under the employee stock purchase plan of $2.0 million.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Material Cash Requirements</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net cash operating expenditures were $24.6 million in the six months ended June 30, 2022 and $22.4 million in the six months ended June 30, 2021, and we intend to continue to make investments in the development of our products, including ongoing research and development programs. Our cash outflows for capital expenditures were $0.9 million in the six months ended June 30, 2022 and $0.9 million in the six months ended June 30, 2021, respectively, and we expect to maintain the level of expenditures in the future in support of our commercial infrastructure, sales force and other commercialization efforts. Recent and expected working and other capital requirements include amounts related to future lease payments for operating lease obligations, which totaled $9.1 million as of June 30, 2022, with $3.4 million expected to be paid within the next 12 months, and amounts related to future long-term debt which total $18.7 million, with $3.6 million expected to be paid within the next 12 months. Lastly, we may undertake additional expenses to further expand our commercial organization and efforts, enhance our research and development efforts and pursue product expansion opportunities.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, we had cash, cash equivalents and marketable securities of $166.8 million. Based on our current planned operations, we expect that our cash and cash equivalents will enable us to fund our operating expenses for at least 12 months from the issuance of our condensed consolidated financial statements as of and for the six months ended June 30, 2022. We believe we will meet longer-term expected future cash requirements and obligations through a combination of available cash, cash equivalents and marketable securities, debt financings, and access to other public or private equity offerings. We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with research, development and commercialization of medical devices, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on many factors, including:</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs of commercialization activities related to commercializing our products in the United States and elsewhere, including expanding territories, increasing sales and marketing personnel, actual and anticipated product sales, marketing programs, manufacturing and distribution costs; </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of the COVID-19 pandemic on our business;</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the research and development activities we intend to undertake, product enhancements that we intend to pursue;</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">whether or not we pursue acquisitions or investments in businesses, products or technologies that are complementary to our current business; </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the degree and rate of market acceptance of our products in the United States and elsewhere; </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes or fluctuations in our inventory supply needs and forecasts of our supply needs; </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our need to implement additional infrastructure and internal systems; </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to hire additional personnel to support our operations as a public company; and </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the emergence of competing technologies or other adverse market developments.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings and collaborations or licensing arrangements. There can be no assurance that our efforts to procure additional financing will be successful or that, if they are successful, the terms and conditions of such financing will be favorable to us or our stockholders. If we do raise additional capital through public or private equity or convertible debt offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional capital through collaborations agreements, licensing arrangements or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses that may not be favorable to us. If we are unable to raise capital when needed, we will need to delay, limit, reduce or terminate planned commercialization or product development activities, or grant rights to develop and commercialize products or product candidates that we would otherwise prefer to develop and market ourselves in order to reduce costs.</span></div><div id="i784ba2f3210d43dcbb23721a3c553397_106"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses incurred during the reporting periods. Our estimates are based on our knowledge of current events and actions we may undertake in the future and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may materially differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management’s judgments and estimates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting policies are described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Estimates” in our Annual Report on Form 10-K filed with the SEC on March 15, 2021, and the notes to the unaudited condensed consolidated financial statements included in “Part I, Item 1 — Financial Statements” of this Quarterly Report on Form 10-Q. During the six months ended June 30, 2022, except as described in Note 2 to the unaudited interim condensed financial statements appearing elsewhere in this Quarterly Report on Form 10-Q, there were no material changes to our critical accounting policies from those discussed in our Annual Report on Form 10-K filed with the SEC on March 15, 2021.</span></div><div id="i784ba2f3210d43dcbb23721a3c553397_112"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See “Recent Accounting Pronouncements” in Note 3 to our consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for additional information.</span></div><div id="i784ba2f3210d43dcbb23721a3c553397_115"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to certain market risks in the ordinary course of our business. These risks primarily include interest rate and currency exchange risks as follows:</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to interest rate risks related to our cash, cash equivalents and borrowings. We had cash, cash equivalents and marketable securities of $166.8 million as of June 30, 2022, which consist of cash, money market funds, U.S. government agency bonds, corporate bonds and commercial paper. We held cash in foreign banks of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately $3.5 million at June 30, 2022 that was not federally insured. Interest-earning money market funds carry a degree of interest rate risk; however, historical fluctuations in interest income have not been significant.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had outstanding debt of $16.9 million under the CIBC Agreement with an interest rate of 4.71% as of June 30, 2022. In the ordinary course of business, we may enter into contractual arrangements to reduce our exposure to interest rate risks. We believe that a 10% change in interest rates would not have a significant impact on our consolidated financial statements. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in countries other than the United States and are exposed to foreign currency risks. Revenue from sales outside of the United States represented 40.9% and 49.4% of our total revenue for the six months ended June 30, 2022 and 2021, respectively. We bill most direct sales outside of the United States in local currencies, which are mostly comprised of the Swiss franc, the Euro, the British pound, and the Australian dollar. Operating expenses related to these sales are largely denominated in the same respective currency, thereby limiting our transaction risk exposure. We therefore believe that the risk of a significant impact on our operating income from foreign currency fluctuations is not significant. The risk of a significant impact on our operating income from foreign currency fluctuations will further diminish as revenue from sales to customers in the United States increases and represents a greater proportion of total revenues. A 10% change in weighted average foreign currency exchange rates would have changed our revenues and operating expenses for the six months ended June 30, 2022 by approximately $1.0 million and $0.8 million, respectively, with a net impact of $0.2 million on our net income. A 10% change in weighted average foreign currency exchange rates would have changed our revenues and operating expenses for the six months ended June 30, 2021 by approximately $1.1 million and $0.7 million, respectively, with a net impact of $0.4 million on our net income. We do not currently hedge our exposure to foreign currency exchange rate fluctuations; however, we may choose to hedge our exposure in the future. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflation Risk</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent months, inflation has continued to increase significantly in the U.S. and overseas resulting in rising transportation, wages, and other costs. Inflation may generally affect us by increasing our cost of labor, commercial support, manufacturing and clinical trial expenditures. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, if our costs become subject to significant inflationary pressures, we may not be able to fully offset such higher costs with increased revenues. Our inability or failure to do so could harm our business, financial condition, and results of operations.</span></div><div id="i784ba2f3210d43dcbb23721a3c553397_118"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosure controls and procedures, as defined in Rule 13a-15(e) under the Exchange Act, are controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, our management, including our Chief Executive Officer and Chief Financial Officer, has concluded that, due to the material weakness described below, our disclosure controls and procedures were not effective as of June 30, 2022.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Material Weakness</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified a material weakness in our internal control over financial reporting for the year ended December 31, 2021 which remains unremediated as of June 30, 2022. We determined a material weakness existed relating to ineffective information technology general controls in the areas of user access and segregation of duties related to certain information technology systems that support our financial reporting process specifically related to expenditures. Although these control weaknesses did not result in any material misstatement of our consolidated financial statements for the periods presented, they could lead to a material misstatement of account balances or disclosures. Accordingly, our management has concluded that these control weaknesses constitute a material weakness.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Plan for Remediation of Material Weakness</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, under the oversight of our Audit Committee of our Board of Directors and in consultation with outside advisors, continue to evaluate and implement measures designed to ensure that control deficiencies contributing to the material weakness are remediated, such that these controls are designed, implemented, and operating effectively. These remediation actions are ongoing and include, but are not limited to: (i) evaluating and implementing enhanced process controls around user access management; and (ii) expanding the management and governance over user access and system controls. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the above actions will be effective in remediating the material weakness and we will continue to devote time and attention to these remedial efforts. However, as we continue to evaluate and take actions to improve our internal control over financial reporting, we may take additional actions to address control deficiencies or modify certain of the remediation measures described above. Our remediation efforts will not be considered complete until the applicable controls operate for a sufficient period of time and our management has concluded, through testing, that these controls are operating effectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the material weakness described above, our management has concluded that the consolidated financial statements included in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form 10-Q present fairly, in all material respects, our financial position, results of operations and cash flows in conformity with GAAP.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Controls</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the identification of the material weakness and remediations activities described above, there were no changes in our internal control over financial reporting that occurred during the three months ended June 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of any system of internal control over financial reporting, including ours, is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely. Accordingly, in designing and evaluating the disclosure controls and procedures, management recognizes that any system of internal control over financial reporting, including ours, no matter how well designed and operated, can only provide reasonable, not absolute assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. Moreover, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. We intend to continue to monitor and upgrade our internal controls as necessary or appropriate for our business, but cannot assure you that such improvements will be sufficient to provide us with effective internal control over financial reporting.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="i784ba2f3210d43dcbb23721a3c553397_121"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II. Other Information</span></div><div style="margin-bottom:12pt"><span><br/></span></div><div id="i784ba2f3210d43dcbb23721a3c553397_124"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be subject to legal proceedings and claims arising in the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows.</span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="i784ba2f3210d43dcbb23721a3c553397_127"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business involves significant risks, some of which are described below. You should carefully consider these risks, as well as the other information in this Quarterly Report on Form 10-Q, including the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the financial statements and the related notes. The occurrence of any of the events or developments described below could have a material adverse effect on our business, results of operations, financial condition, prospects and stock price. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. This Quarterly Report on Form 10-Q also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this Quarterly Report on Form 10-Q. We have marked with an asterisk (*) those risks described below that reflect substantive changes from, or additions to, the risks described in our Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Risk Factor</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves significant risks, some of which are described below. The principal factors and uncertainties that make investing in our common stock risky include, among others:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a history of significant net losses, which we expect to continue, and we may not be able to achieve or sustain profitability in the future;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have limited experience marketing and selling our solution;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently rely on a single product, the Zephyr Valve, which can only be marketed for limited indications, and if we are not successful in commercializing the Zephyr Valve, our business, financial condition and results of operations will be negatively affected;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business is dependent on hospital, physician and patient adoption of our solution as a treatment for severe emphysema. If hospitals, physicians or patients are unwilling to change current practices to adopt our solution, it will negatively affect our business, financial condition and results of operations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to receive access to hospital facilities our sales may decrease;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The COVID-19 pandemic has had a material adverse impact on our business, financial condition and results of operations, and may continue to impact us in the future;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Use of the Zephyr Valve involves risks and may result in complications, including pneumothorax or death, and is contraindicated in certain patients, which may limit adoption and negatively affect our business, financial condition and results of operations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to achieve and maintain adequate levels of coverage or reimbursement for our solution, or any future products we may seek to commercialize, or if patients are left with significant out-of-pocket costs, our commercial success may be severely hindered;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to retain marketing and sales personnel and, as we grow, fail to increase our marketing and sales capabilities or develop broad awareness of our solution in a cost-effective manner, we may not be able to generate revenue growth;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have limited long-term data regarding the safety and effectiveness of our solution, including the Zephyr Valve. The only safety and effectiveness data of our solution, including the Zephyr Valve, is limited to one year following placement and we are required to conduct extension studies to follow up on safety and effectiveness out to five years;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have limited experience manufacturing our products in significant commercial quantities and we face manufacturing risks that may adversely affect our ability to manufacture our products, reduce our gross margins and negatively affect our business, financial condition and results of operations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The sizes of the markets for our current and future products have not been established with precision and may be smaller than we estimate and may decline. Certain patients may not have regions of the lung with little to no collateral ventilation, making them poor candidates for the Zephyr Valve. In addition, if the overall rate of smokers continues to decline, this may eventually decrease the number of patients suffering from COPD and emphysema and, accordingly, who would benefit from our solution;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We expect to continue to incur net losses for the next several years and we expect to require substantial additional capital to finance our planned operations, which may include future equity and debt financings. This additional capital may not be available to us on acceptable terms or at all. Our failure to obtain additional financing when needed on acceptable terms, or at all, could force us to delay, limit, reduce or eliminate our commercialization, sales and marketing efforts, product development programs or other operations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our products and operations are subject to extensive government regulation and oversight both in the United States and abroad. If we fail to obtain and maintain necessary regulatory approvals for the Zephyr Valve and related products, or if approvals for future products and indications are delayed or not issued, it will negatively affect our business, financial condition and results of operations; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may become a party to intellectual property litigation or administrative proceedings that could be costly and could interfere with our ability to sell and market our products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Strategy</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a history of significant net losses, which we expect to continue, and we may not be able to achieve or sustain profitability in the future. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since our inception. For the six months ended June 30, 2022 and June 30, 2021, we had net losses of $30.5 million and $25.5 million, respectively, and we expect to continue to incur additional losses. As of June 30, 2022, we had an accumulated deficit of $321.9 million. We expect to continue to incur significant sales and marketing, research and development, regulatory and other expenses as we grow our sales force and expand our marketing efforts to increase adoption of our products, expand existing relationships with our customers, obtain regulatory clearances or approvals for our planned or future products, conduct clinical trials on our existing and planned or future products and develop new products or add new features to our existing products. The net losses that we incur may fluctuate significantly from period to period. We will need to generate significant additional revenue in order to achieve and sustain profitability. Even if we achieve profitability, we cannot be sure that we will remain profitable for any substantial period of time.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited experience marketing and selling our solution.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began commercializing our solution and the Zephyr Valve in the United States in 2018 and, through our predecessors, in Europe in 2003. Our limited commercialization experience and limited number of approved or cleared products make it difficult to evaluate our current business and predict our future prospects. These factors also make it difficult for us to forecast our future financial performance and growth, and such forecasts are subject to a number of uncertainties, including our ability to successfully complete clinical trials and obtain pre-market approval or 510(k) clearance by the FDA for future planned products in the United States or in key international markets. Our commercialization efforts will depend on the efforts of our management and sales team, our third-party suppliers, physicians and hospitals, and general economic conditions, among other factors, including the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our marketing and sales efforts in the United States and internationally;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our success in educating physicians and patients about the benefits, administration and use of the Zephyr Valves;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the acceptance by physicians, patients and payors of the safety and effectiveness of the Zephyr Valves, including the long-term data;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third-party suppliers’ ability to supply the components of the Zephyr Valves in a timely manner, in accordance with our specifications and in compliance with applicable regulatory requirements, and to remain in good standing with regulatory agencies;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic on our business, financial condition and results of operations;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing therapies;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, maintain and enforce our intellectual property rights in and to the Zephyr Valves;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the emergence of competing technologies and other adverse market developments, and our need to enhance the Zephyr Valves or develop new products to maintain market share in response to such competing technologies or market developments;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise additional capital on acceptable terms, or at all, if needed to support the commercialization of the Zephyr Valves; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to achieve and maintain compliance with all regulatory requirements applicable to the Zephyr Valves.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our assumptions regarding the risks and uncertainties we face, which we use to plan our business, are incorrect or change due to circumstances in our business or our markets, or if we do not address these risks successfully, it will negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently rely on a single product, the Zephyr Valve, which can only be marketed for limited indications, and if we are not successful in commercializing the Zephyr Valve, our business, financial condition and results of operations will be negatively affected.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business currently depends entirely on our ability to successfully commercialize the Zephyr Valve, as well as our overall solution, in a timely manner. We have no other therapeutic products currently approved for sale in the United States and we may never be able to develop additional marketable products or enhancements to the Zephyr Valve solution. Currently, our solution is only available to treat patients with severe emphysema in the United States and additional limited indications internationally where we have obtained the necessary regulatory approvals or clearances. Therefore, we are dependent on widespread market adoption of our solution for this limited use-case and we will continue to be dependent on this use-case for the foreseeable future. There can be no assurance that our solution will gain a substantial degree of market acceptance among specialty physicians, patients or healthcare providers. Our failure to successfully increase sales of our solution or develop solutions that address forms of COPD beyond severe emphysema and obtain any necessary regulatory approvals or clearances in connection therewith could negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends in large part on the success of the Zephyr Valve. If we are unable to successfully market and sell the Zephyr Valves, as well as our overall solution, to patients with severe emphysema, it will negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend on our ability to bring awareness to our solution, and the Zephyr Valve in particular, and educate hospitals and physicians regarding the benefits of our solution over existing products and services and to encourage those parties to recommend our solution to their patients. Sales of Zephyr Valves and delivery catheters accounted for most of our revenue for the six months ended June 30, 2022 and 2021 and we expect that sales of Zephyr Valves and delivery catheters will continue to account for most of our revenue going forward. We do not know if our solution will be successful over the long term. Moreover, market acceptance may be hindered if physicians are not presented with compelling data demonstrating the efficacy of our solution compared to alternative procedures and technologies. Any studies we, or third parties which we sponsor, may conduct comparing our solution with alternative treatments for severe emphysema will be expensive, time consuming and may not yield positive results. Additionally, adoption will be directly influenced by a number of financial factors, including the ability of providers to obtain sufficient reimbursement from payors for deploying our solution. The safety, efficacy, performance and cost-effectiveness of our solution, on a stand-alone basis and relative to competing treatments and services, will determine the willingness of payors to cover the procedure. While we have established positive coverage policies with major national private payors, such as Aetna, Anthem Blue Cross Blue Shield, Blue Cross Blue Shield of Michigan, Humana, Health Care Service Corporation, and Highmark, other commercial payors, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including other plans in the Blue Cross Blue Shield family of plans, do not currently consider our solution medically necessary. No matter the level of coverage by the commercial payor, each patient is generally considered on a case-by-case basis. In addition, Medicare, currently without a public coverage policy, covers our solution for patients when medically necessary on a case-by-case basis. Physicians may be reluctant to recommend our solution to patients covered by such plans with no specific policies because of the uncertainty surrounding reimbursement, rates and the administrative burden of interfacing with patients to answer their questions and support their efforts to obtain adequate reimbursement for our solution. If physicians do not adopt and recommend our solution, it will negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is dependent on hospital, physician and patient adoption of our solution as a treatment for severe emphysema. If hospitals, physicians or patients are unwilling to change current practices to adopt our solution, it will negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary strategy to grow our revenue is to take a stepwise approach to market development across key stakeholders in severe emphysema treatment, such as hospitals, physicians and patients. To succeed, our sales force must build deep relationships with pulmonary physicians to encourage them and their hospitals to develop emphysema centers of excellence, where physicians are instructed in the workup of advanced COPD and performance of bronchoscopic lung volume reduction using our solution, that offer our solution as a treatment for severe emphysema. In addition, we utilize direct-to-patient marketing initiatives to increase demand through patient empowerment. While the number of hospitals incorporating our solution has increased in recent years, there is a significant group of hospitals and physicians who have not yet adopted our solution, and additional hospitals and physicians may choose not to adopt our solution for a number of reasons, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inadequate recruiting or training of talented sales force in existing and new markets to facilitate outreach and further adoption and awareness of Zephyr Valve;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of experience with our solution and the Zephyr Valve as a treatment alternative; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure of key opinion leaders to continue to provide recommendations regarding the Zephyr Valve, or to assure physicians, patients and healthcare payors of the benefits of the Zephyr Valve as an attractive alternative to other treatment options; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceived inadequacy of evidence supporting clinical benefits or cost-effectiveness of our solution over existing alternatives; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a perception among some physicians of patients’ inability to tolerate the procedure required to implant our solution; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">liability risks generally associated with the use of new products and procedures; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the training required to use new products;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of availability of adequate third-party payor coverage or reimbursement;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">access to hospital bidding processes;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease or delay in the number of procedures performed using our solution as a result of the COVID-19 pandemic;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing products and alternatives; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introduction of other novel alternative therapies to treat severe emphysema.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We focus our sales, marketing and training efforts primarily on pulmonologists. However, physicians from other disciplines, including primary care physicians, as well as other medical professionals, such as nurse practitioners, respiratory technicians, radiologists and community physicians, are often the initial point of contact for patients with severe emphysema.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These physicians and other medical professionals commonly screen and treat patients with severe emphysema, and are likely to recommend medical management, inhaled medications, pulmonary rehabilitation and supplemental oxygen, or more invasive LVRS or lung transplantations. We believe that educating physicians in these disciplines and other medical professionals about the clinical merits and patient benefits of our solution as a minimally invasive treatment for severe emphysema is a key element of increasing the adoption of our solution. If additional physicians or other medical professionals do not adopt, or existing physician customers cease referring patients to, our solution for any reason, including those listed above, our ability to execute our growth strategy will be impaired, and it will negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patients will not qualify for our solution if, among other potential reasons, their lung anatomy has collateral ventilation that does not allow for effective treatment with the Zephyr Valve. Patients may not adopt our solution if they are reluctant to undergo a minimally invasive procedure, if they are worried about potential adverse effects of our solution, such as infection, discomfort or weakness, or if they are unable to obtain adequate third-party coverage or reimbursement.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to receive access to hospital facilities, our sales may decrease.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, in order for physicians to use the Zephyr Valve, we expect that the hospital facilities where these physicians treat patients will typically require us to enter into purchasing contracts setting forth the terms and conditions under which the hospital facilities will purchase Zephyr Valves. This process can be lengthy and time-consuming and require extensive negotiations and management time, and potentially result in delays and increases to the sales cycle before we can sell the Zephyr Valve to these hospitals. In the European Union, certain institutions may require us to engage in a contract bidding process in the event that such institutions are considering making purchase commitments that exceed specified cost thresholds, which vary by jurisdiction. These processes are only open at certain periods of time, and we may not be successful in the bidding process. If we do not receive access to hospital facilities via these contracting processes or otherwise, or if we are unable to secure contracts or tender successful bids, our sales may decrease, and our operating results may be harmed. Furthermore, we may expend significant effort in these time-consuming processes and still may not obtain a purchase contract from such hospitals.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The COVID-19 pandemic has had a material adverse impact on our business, financial condition and results of operations, and may continue to impact us in the future.*</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has had a material adverse impact on our business, financial condition and results of operations by decreasing and delaying procedures performed using our products, and the pandemic may continue to adversely impact our business, financial condition and results of operations in the future. Similar to the general trend in elective and other surgical procedures, the number of procedures performed using our products have been substantially impacted as healthcare organizations across the globe have prioritized the treatment of patients with COVID-19 or have altered their operations to respond to the pandemic. For example, in the U.S., governmental authorities recommended, and, in certain cases, required, that elective, specialty and other procedures and appointments be suspended or canceled to avoid non-essential patient exposure to medical environments and potential infection with COVID-19 and to focus limited resources and personnel capacity toward the treatment of COVID-19 patients. As a result, the COVID-19 pandemic has adversely impacted the number of procedures using the Zephyr Valve as hospitals have had to focus on COVID-19 and as patients generally sought to postpone healthcare visits and treatments. The COVID-19 pandemic and related governmental and societal responses to mitigate its impact have caused, and may in the future cause, decreased demand for procedures using our products, a global slowdown of economic activity, volatility and disruption of financial markets, supply chain disruptions, and changes in behavior of healthcare organizations. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2022, procedure volumes in our U.S. and larger international markets benefited from a recovery in procedure volumes following the winter COVID-19 surge. Procedure volumes in our smaller international markets were hampered by a slower recovery, including continued lockdowns in China. We may continue to see regional variations in procedure volumes in our U.S. and international markets from the COVID-19 pandemic and its variants.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the measures adopted in response to, and challenges resulting from, COVID-19 may continue for the duration of the pandemic, which is uncertain, and could significantly reduce our revenue and adversely impact our business, financial condition and results of operations for the duration of the pandemic. As a result, we cannot assure you that our recent volume of Zephyr Valves sold are indicative of future results or that we will not experience additional adverse or materially adverse impacts associated with the COVID-19 pandemic. Further, there may be limited provider capacity due to labor shortages, or for other reasons, which could limit the ability of patients to receive treatment with Zephyr Valves. This limited provider and hospital capacity could have a material adverse effect on our business, financial condition and results of operations as the pandemic subsides and following the end of the pandemic.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The severity, magnitude and duration of the COVID-19 pandemic, the public health responses and its economic consequences, as well as the efficacy, availability and distribution of vaccines, remain uncertain, rapidly changing and difficult to predict. The pandemic’s impact on our financial condition and results of operations performance, as well as its impact on our ability to successfully execute our business strategies and initiatives, also remains uncertain and difficult to predict. To the extent the pandemic continues to disrupt economic activity globally, it could adversely affect our ability to access capital, which could in the future negatively affect our liquidity. In addition, depressed economic activity resulting from the COVID-19 pandemic has had, and could in the future have, a material adverse effect on our long-term business as hospitals curtail and reduce capital and overall spending. For example, economic market disruptions have resulted, and may in the future result, in significant job losses and reductions in disposable income. If patients are unable to obtain or maintain health insurance policies, it may significantly impact their ability to pay for the procedures utilizing our products, further negatively impacting our business, financial condition and results of operations. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor the rapidly evolving situation and guidance from domestic and international authorities, including federal, state and local public health authorities, and there may be developments outside our control requiring us to adjust our business strategies and operating plan. To the extent the COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this “Risk Factors” section.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of our solution requires appropriate physician training, and inadequate training may lead to negative patient outcomes and negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful implantation of the Zephyr Valve depends in part on the training and skill of the physician performing the procedure and on adherence to appropriate patient selection and proper techniques provided in training sessions conducted by our training faculty. For example, we train physicians to ensure correct patient selection and treatment planning using the StratX Platform and Chartis System, and proper placement of the Zephyr Valve. Physicians could experience difficulty with the technique necessary to successfully implant the valve and may not achieve the technical competency necessary to complete the training program, or they could fail to properly learn how to interpret our StratX Platform or Chartis System. Moreover, physicians rely on their previous medical training and experience when using our solution, and we cannot guarantee that all such physicians will have the necessary skills to properly identify ideal candidates and to perform the procedure. We do not control which physicians use our solution or how much training they receive, and physicians who have not completed our training sessions may nonetheless attempt to use our solution. If physicians implant the Zephyr Valve incorrectly, or do so in a manner that is inconsistent with its labeled indications, with components that are not our products, in patients who are not good candidates, or without adhering to or completing our training sessions, their patient outcomes may not be consistent with the outcomes achieved in our clinical trials. This result may negatively impact the perception of patient benefit and safety, and limit adoption of our solution as a treatment for severe emphysema and our products that facilitate the procedure, which will negatively affect our business, financial condition and results of operations.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may experience difficulty growing the number of physicians who complete our training program if patient demand is low, if the length of time necessary to train each physician is longer than expected, if the capacity of our commercial organization to train physicians is less than expected or if we are unable to sufficiently grow our sales force. All these events would lead to fewer trained physicians qualified to implant the Zephyr Valve, which could negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of the Zephyr Valve involves risks and may result in complications, including pneumothorax or death, and is contraindicated in certain patients, which may limit adoption and negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most common serious complications relating to the use of the Zephyr Valve include pneumothoraces, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea, respiratory failure and, in rare cases, death. Pneumothoraces occur when a lung collapses due to an air leak inside the lung and may result from rapid shifts in air volume in the chest as the target lobe deflates and the neighboring lobe expands following the Zephyr Valve treatment. A pneumothorax typically requires placement of a chest tube to manage the air leak. While most pneumothoraces can be readily managed with standard medical care, in rare cases they can be life-threatening, particularly if left untreated. In the event the pneumothorax does not resolve with standard management, one or more valves can be removed to re-inflate the lung; these are typically replaced later when the pneumothorax has resolved. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our clinical trials, pneumothoraces occurred in 18-34% of patients treated with the Zephyr Valve, and in the LIBERATE study, 17% of the pneumothorax events required no intervention and resolved on their own. Patients who have had their pneumothoraces successfully treated had comparable outcomes to those who did not experience a pneumothorax, other than that their hospital stays were extended by approximately a week compared to the three nights for patients without pneumothoraces. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the LIBERATE study, the majority of pneumothoraces (76%) occurred within three days following a bronchoscopy procedure. During the Treatment Period (day of procedure to 45 days), there were a total of four deaths (3.1%) in the Zephyr Valve Group (which received Zephyr Valves plus medical management) and none in the Control Group (which received medical management alone). Three of the four deaths were deemed by the investigators to be definitely related to treatment with Zephyr Valves and the remaining one was deemed by the investigators to be probably related to treatment with Zephyr Valves. Each patient that died experienced pneumothorax, with three deaths directly attributed to the pneumothorax and the fourth death the result of respiratory failure, after the pneumothorax had resolved. Two of the pneumothorax-related deaths occurred early in the study when patients were being kept in the hospital for one night after the procedure. In order to more closely monitor patients, the study protocol was subsequently amended to keep patients in the hospital for five nights. Based on the full study data, current practice is to keep patients in the hospital for a minimum of three nights post-treatment. Post-hoc analysis has helped to identify risk factors for the group of patients at a higher risk of having a complex pneumothorax event (complex pneumothorax defined as requiring removal of all valves or resulting in death) should one occur. Such high-risk patients include those who are not treated in the most diseased lobe and have greater than 60% destruction of the untreated lung. All four patients who experienced a pneumothorax and died were within this high-risk group. This learning is incorporated in our physician training program for physicians to identify such high-risk patients and to consider alternative targets or other risk mitigation strategies. During the Longer-Term Period (46 days after procedure to 12 months), there was one death (0.8%) in the Zephyr Valve Group from a COPD exacerbation, deemed by the investigators not to be related to treatment with Zephyr Valves, and one cardiac arrhythmia related death in the Control Group (1.6%).</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of clinical trials, patients treated with the Zephyr Valve have also experienced serious complications, including pneumothoraces and death related to the Zephyr Valve.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Serious complications as a result of treatment with Zephyr Valves, and any increase in the rate of complications in or outside of clinical trials, could cause doctors, hospitals and patients to limit adoption of our solution and subject us to costly litigation, require us to pay substantial amounts of money to patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts, which may negatively impact adoption as well as our business, financial </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condition and results of operations. Even in a circumstance in which we do not believe that a complication is related to the Zephyr Valve or treatment with the Zephyr Valve, the investigation into the circumstance may be time-consuming or inconclusive and may interrupt our sales efforts or impact and limit the type of regulatory approvals the Zephyr Valve receives or maintains and any related claims may negatively impact adoption as well as our business, financial condition and results of operations. Moreover, perceptions regarding the safety of the Zephyr Valve could be affected even if such complications are unrelated to the Zephyr Valve or treatment with the Zephyr Valve.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, our current products are contraindicated, and therefore should not be used, in certain patients, including those for whom bronchoscopic procedures are contraindicated, with evidence of active pulmonary infection, with known allergies to Nitinol (nickel-titanium) or its constituent metals (nickel or titanium) or silicone, who have not quit smoking, or with large bullae encompassing greater than 30% of either lung, and such contraindication may limit adoption and, as a result, negatively impact our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to achieve and maintain adequate levels of coverage or reimbursement for our solution, or any future products we may seek to commercialize, or if patients are left with significant out-of-pocket costs, our commercial success may be severely hindered.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently derive substantially all of our revenue from the sale of our products to hospitals and distributors and expect this to continue for the foreseeable future. We primarily sell Zephyr Valves through a direct sales force that primarily engages with pulmonologists in the United States, Europe and Asia Pacific. Hospitals typically bill various third-party payors to cover all or a portion of the costs and fees associated with the procedures in which our solution is used and bill patients for any deductibles or co-payments. As of June 30, 2022, commercial payors such as Aetna, Humana, and many of the largest Blue Cross Blue Shield plans including Anthem, Health Care Service Corporation, and BCBS Michigan have issued positive coverage policies for endobronchial valve procedures. United Healthcare removed the endobronchial valve codes from their non-covered list, and as such no longer considers the procedure unproven or experimental. Other commercial payors, including other plans in the Blue Cross Blue Shield family of plans, do not yet consider our solution medically necessary. Medicare, currently without a public coverage policy, covers our solution for patients when medically necessary on a case-by-case basis, and other commercial insurers not described above are approving pre-authorization requests on a case-by-case basis. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Centers for Medicare & Medicaid Services (“CMS”) have established guidelines for the coverage and reimbursement of certain products and procedures by Medicare. In general, in order to be reimbursed by Medicare, a healthcare procedure furnished to a Medicare beneficiary must be reasonable and necessary for the diagnosis or treatment of an illness or injury, or to improve the functioning of a malformed body part. The methodology for determining coverage status and the amount of Medicare reimbursement varies based upon, among other factors, the setting in which a Medicare beneficiary received healthcare products and services. Any changes in federal legislation, regulations and policy affecting CMS coverage and reimbursement relative to the procedure using our products could have a material effect on our performance. While no national coverage determination (“NCD”) or local coverage determination (“LCD”) exists for endobronchial valves currently, CMS could develop an NCD, or one or more Medicare contractors could develop an LCD that either restricts coverage or restricts the patient population deemed appropriate for the treatment. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physicians that insert the Zephyr Valve, or the hospitals for which they work, may be subject to reimbursement claim denials upon submission of the claim. Physicians or hospitals may also be subject to recovery of overpayments if a payor makes payment for the claim and subsequently determines that the payor’s coding, billing or coverage policies were not followed. Whenever possible, pre-authorization for coverage for the procedure is recommended before the procedure is performed. When pre-authorization is not obtained or not allowed, and the procedure is performed and not covered by third-party payors, physicians or hospitals typically directly bill patients enrolled with these third-party payors for the costs and fees associated with the procedures in which our products are used. Moreover, because there is often no separate reimbursement for supplies used in surgical procedures, the additional cost associated with the use of our solution can affect the profit margin of the hospital or surgery center where the procedure is performed. Some of our target physicians and hospitals may be unwilling to adopt our products in light of the additional associated cost. Further, any decline in the amount payors are willing to reimburse physicians and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hospitals could make it difficult for existing physicians and hospitals to continue using or to adopt our solution and could create additional pricing pressure for us. If we are forced to lower the price we charge for our solution, our gross margins will decrease, which will negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the United States, reimbursement levels vary significantly by country and by patient. Reimbursement is obtained from a variety of sources, including government sponsors, hospital budgets, or private health insurance plans, or combinations thereof. We have established reimbursement access in countries across Europe and Asia Pacific, including Australia, Austria, Belgium, France, Germany, the Netherlands, United Kingdom (the “UK”), Scotland, Switzerland and South Korea, and other countries. Even if we succeed in bringing our products to market in additional foreign countries, uncertainties regarding future healthcare policy, legislation and regulation, as well as private market practices, could affect our ability to sell our products in commercially acceptable quantities at acceptable prices.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In addition, no uniform policy of coverage and reimbursement for procedures using our solution exists among third-party payors. Therefore, coverage and reimbursement for procedures using our products can differ significantly from payor to payor. Payors continually review new and existing technologies for possible coverage and can, without notice, deny or reverse coverage for new or existing products and procedures. There can be no assurance that third-party payor policies will provide coverage for procedures in which our products are used. If we are not successful in reversing existing non-coverage policies, if third-party payors that currently cover or reimburse our products and related procedures reverse or limit their coverage in the future or if other third-party payors issue similar policies, this will negatively affect our business, financial condition and results of operations. Further, coverage policies and third-party payor reimbursement rates may change at any time. Therefore, even if favorable coverage is established on one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we believe that future coverage and reimbursement may be subject to increased restrictions, such as additional prior authorization requirements, both in the United States and in international markets. Third-party coverage and reimbursement for procedures using our solution or any of our products in development for which we may receive regulatory approval may not be available or adequate in either the United States or international markets, which will negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party payors and physicians who do not cover or use the Zephyr Valve may require additional clinical data prior to maintaining coverage of or adopting the Zephyr Valve.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends on physician and third-party payor acceptance of our solution as an effective treatment option for patients with severe emphysema. If physicians or payors do not find our body of published clinical evidence and data compelling or wish to wait for additional studies, they may choose not to use or provide coverage and reimbursement for our solution.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the long-term effects of use of the Zephyr Valve to treat severe emphysema are not yet known. Certain physicians, hospitals and payors may prefer to see longer-term safety and efficacy data published than we have produced. Further, we cannot provide assurance that any data that we or others may generate in the future will be consistent with that observed in our existing clinical studies.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to retain marketing and sales personnel and, as we grow, fail to increase our marketing and sales capabilities or develop broad awareness of our solution in a cost-effective manner, we may not be able to generate revenue growth.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited experience marketing and selling our solution. We currently rely on our direct sales force to sell our solution in targeted geographic regions and distributors in certain regions outside the United States, and any failure to maintain and grow our direct sales force will negatively affect our business, financial condition and results of operations. The members of our direct sales force are highly trained and possess substantial technical expertise, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which we believe is critical in increasing adoption of our solution. The members of our U.S. sales force are at-will employees. The loss of these personnel to competitors, or otherwise, will negatively affect our business, financial condition and results of operations. If we are unable to retain our direct sales force personnel or replace them with individuals of equivalent technical expertise and qualifications, or if we are unable to successfully instill such technical expertise in replacement personnel, it may negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to generate future growth, we plan to continue to expand and leverage our sales and marketing infrastructure to increase the number of customers and emphysema centers of excellence. Identifying and recruiting qualified sales and marketing personnel and training them on our solution, on applicable federal and state laws and regulations and on our internal policies and procedures requires significant time, expense and attention. It often takes several months or more before a sales representative is fully trained and productive. Our sales force may subject us to higher fixed costs than those of companies with competing techniques or products that utilize independent third parties, which could place us at a competitive disadvantage. It will negatively affect our business, financial condition and results of operations if our efforts to expand and train our sales force do not generate a corresponding increase in revenue, and our higher fixed costs may slow our ability to reduce costs in the face of a sudden decline in demand for our solution. Any failure to hire, develop and retain talented sales personnel, to achieve desired productivity levels in a reasonable period of time or timely reduce fixed costs, could negatively affect our business, financial condition and results of operations. Our ability to increase our customer base and achieve broader market acceptance of our solution will depend to a significant extent on our ability to expand our marketing efforts. We plan to dedicate significant resources to our marketing programs. It will negatively affect our business, financial condition and results of operations if our marketing efforts and expenditures do not generate a corresponding increase in revenue. In addition, we believe that developing and maintaining broad awareness of our solution in a cost-effective manner is critical to achieving broad acceptance of our solution and expanding domestically and internationally. Promotion activities may not generate patient or physician awareness or increase revenue, and even if they do, any increase in revenue may not offset the costs and expenses we incur in building our brand. If we fail to successfully promote, maintain and protect our brand, we may fail to attract or retain the physician acceptance necessary to realize a sufficient return on our brand building efforts, or to achieve the level of brand awareness that is critical for broad adoption of our solution.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited long-term data regarding the safety and effectiveness of our solution, including the Zephyr Valve.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The only safety and effectiveness data of our solution, including the Zephyr Valve, is limited to one year following placement and we are required to conduct extension studies to follow up on safety and effectiveness out to five years.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have demonstrated the safety, effectiveness and clinical advantages of our solution in multiple clinical trials in approximately 450 patients selected using the Chartis System, the Zephyr Valve is still a relatively new treatment for severe emphysema. The long-term effects of using our solution in a large number of patients have not been studied and the results of short-term clinical use of such products do not necessarily predict long-term clinical benefits or reveal long-term adverse effects. We are required to conduct the LIBERATE extension study to follow up on safety and effectiveness out to five years. After the completion of the one-year follow up, 115 Zephyr Valve patients and 47 crossover patients (162 total patients) entered the LIBERATE extension study. The results of this extension study will not be available until February 2023. Our ability to interpret the data from this long-term follow-up of patients with this progressive disease may be limited by the fact that the matched control group exited the study after one year. The results of clinical trials of our solution conducted to date and ongoing or future studies and trials of our current, planned or future products may not be predictive of the results of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Our interpretation of data and results from our clinical trials do not ensure that we will achieve similar results in future clinical trials in other patient populations. In addition, pre-clinical and clinical data are often susceptible to various interpretations and analyses, and many companies that have believed their products performed satisfactorily in pre-clinical studies and earlier clinical trials have nonetheless failed to replicate results in later clinical trials and subsequently failed to obtain marketing approval. Products in later stages of clinical trials may fail to show the desired safety and efficacy despite having progressed through nonclinical studies and earlier clinical trials.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The continuing development of our products depends upon our maintaining strong working relationships with physicians.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research, development, marketing and sale of our current products and potential new and improved products or future product indications for which we receive regulatory clearance or approval depend upon our maintaining working relationships with physicians. We rely on these professionals to provide us with considerable knowledge and experience regarding the development, marketing and sale of our products. Physicians assist us in clinical trials and in marketing, and as researchers, product consultants and public speakers. If we cannot maintain our strong working relationships with these professionals and continue to receive their advice and input, the development and marketing of our products could suffer, which could negatively affect our business, financial condition and results of operations. At the same time, the medical device industry’s relationship with physicians is under increasing scrutiny by the U.S. Department of Health and Human Services Office of Inspector General (“OIG”), the U.S. Department of Justice (“DOJ”), the state attorneys general and other foreign and domestic government agencies. Our failure to comply with requirements governing the industry’s relationships with physicians or an investigation into our compliance by the OIG, the DOJ, state attorneys general and other government agencies, could negatively affect our business, financial condition and results of operations. Additional information regarding the laws impacting our relationships with physicians and other healthcare professionals can be found below under “Risks Related to Government Regulation and Our Industry.”</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to perform certain aspects of the CT scan analysis within the StratX Platform. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party service providers to upload and analyze CT scan data on the StratX Platform. In order to make the StratX Platform available to physicians, we contract with a third-party cloud service. This third-party cloud service enables physicians to upload CT scan data while removing protected health information (PHI) of patients from that data, in case the physicians have, inadvertently, not removed the PHI themselves. We also contract with additional third-party service providers to analyze the CT scan data using their proprietary software, and provide quantitative results via an easy-to-read report that we designed for our solution (“StratX Lung Report”). The StratX Lung Report is then made available to physicians in the third-party cloud service.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This service is critical and there are relatively few alternatives. These third-party service providers may be unwilling or unable to provide the necessary services reliably and at the levels we anticipate or that are required by the market. While these third-party service providers have generally met our demand for their services on a timely basis in the past, we cannot guarantee that they will in the future be able to meet our demand for their services, either because of acts of nature, the nature of our agreements or potential disputes with those service providers or our relative importance to them as a customer, and our service providers may decide in the future to discontinue or reduce the level of business they conduct with us. If we are required to change service providers for any reason, including due to any change in or termination of our relationships with these third parties, we may lose sales, experience delays, incur increased costs or otherwise experience impairment to our customer relationships. We cannot guarantee that we will be able to establish alternative relationships on similar terms, without delay or at all.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on a limited number of single-source suppliers to manufacture our products, which makes us vulnerable to supply shortages and price fluctuations that could negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on single-source suppliers for the components, sub-assemblies and materials for our products. These components, sub-assemblies and materials are critical and there are no or relatively few alternative sources of supply. These single-source suppliers may be unwilling or unable to supply the necessary materials and components or manufacture and assemble our products reliably and at the levels we anticipate or that are required by the market. While our suppliers have generally met our demand for their products and services on a timely basis in the past, we cannot guarantee that they will in the future be able to meet our demand for their products, either because of acts of nature, the nature of our agreements with those manufacturers or our relative importance to them as a customer, and our suppliers may decide in the future to discontinue or reduce the level of business they conduct with us. If we are required to change suppliers due to any change in or termination of our relationships with these third parties, or if our suppliers are unable to obtain the materials they need to produce our products at consistent prices or at all, we </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may lose sales, experience manufacturing or other delays, incur increased costs or otherwise experience impairment to our customer relationships. We cannot guarantee that we will be able to establish alternative relationships on similar terms, without delay or at all.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not qualified or obtained necessary regulatory approvals for additional suppliers for most of these components, sub-assemblies and materials, and we do not carry a significant inventory of these items. While we believe that alternative sources of supply may be available, we cannot be certain whether they will be available if and when we need them, or that any alternative suppliers would be able to provide the quantity and quality of components and materials that we would need to manufacture our products if our existing suppliers were unable to satisfy our supply requirements. To utilize other supply sources, we would need to identify and qualify new suppliers to our quality standards and obtain any additional regulatory approvals required to change suppliers, which could result in manufacturing delays and increase our expenses.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we require our third-party suppliers to supply us with components that meet our specifications and comply with applicable provisions of the FDA’s Quality System Regulation (“QSR”) and other applicable legal and regulatory requirements in our agreements and contracts, and we perform incoming inspection, testing or other acceptance activities to ensure the components meet our requirements, there is a risk that our suppliers will not always act consistent with our best interests, and may not always supply components that meet our requirements or supply components in a timely manner.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited experience manufacturing our products in significant commercial quantities and we face manufacturing risks that may adversely affect our ability to manufacture our products, reduce our gross margins and negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy depends on our ability to manufacture our current and future products in sufficient quantities and on a timely basis to meet customer demand, while adhering to product quality standards, complying with regulatory quality system requirements and managing manufacturing costs. We have a facility located in Redwood City, California, where we assemble, inspect, package, release and ship our products. We currently produce the Zephyr Valve and Chartis System at this facility, and we do not have redundant facilities. We also store finished goods at secondary facilities in Redwood City, California, Memphis, Tennessee and the Netherlands. If these facilities suffer damage, or a force majeure event, this could materially impact our ability to operate.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to numerous other risks relating to our manufacturing capabilities, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">quality and reliability of components, sub-assemblies and materials that we source from third-party suppliers, that are required to meet our quality specifications, many of whom are our single source suppliers for the products they supply;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to secure components, sub-assemblies and materials in a timely manner, in sufficient quantities or on commercially reasonable terms;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to maintain compliance with quality system requirements or pass regulatory quality inspections;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions in our production schedule and ability to manufacture and assemble products due to the COVID-19 pandemic;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to increase production capacity or volumes to meet demand;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to design or modify production processes to enable us to produce future products efficiently or implement changes in current products in response to design or regulatory requirements; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty identifying and qualifying, and obtaining new regulatory approvals, for alternative suppliers for components in a timely manner.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These risks are likely to be exacerbated by our limited experience with our current products and manufacturing processes. As demand for our solution increases, we will have to invest additional resources to purchase components, sub-assemblies and materials, hire and train employees and enhance our manufacturing processes. If we fail to increase our production capacity efficiently, we may not be able to fill customer orders on a timely basis, our sales may not increase in line with our expectations and our operating margins could fluctuate or decline. In addition, even if future products in development share product features, components, sub-assemblies and materials with our existing products, the manufacture of these products may require modification of our current production processes or unique production processes, the hiring of specialized employees, the identification of new suppliers for specific components, sub-assemblies and materials or the development of new manufacturing technologies. It may not be possible for us to manufacture these products at a cost or in quantities sufficient to make these products commercially viable or to maintain current operating margins, all of which will negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations will be materially harmed if we are unable to accurately forecast customer demand for our solution and manage our inventory.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To ensure adequate inventory supply, we must forecast inventory needs and manufacture the Zephyr Valve and Chartis System based on our estimates of future demand for our solution. Our ability to accurately forecast demand for our solution could be negatively affected by many factors, including our failure to accurately manage our expansion strategy, product introductions by competitors, an increase or decrease in customer demand for our solution or for products of our competitors, our failure to accurately forecast customer acceptance of new products, unanticipated changes in general market conditions or regulatory matters and weakening of economic conditions or consumer confidence in future economic conditions. Inventory levels in excess of customer demand may result in inventory write-downs or write-offs, which would cause our gross margin to be adversely affected and could impair the strength of our brand. Conversely, if we underestimate customer demand for our solution, our internal manufacturing team may not be able to deliver products to meet our requirements, and this could result in damage to our reputation and customer relationships. In addition, if we experience a significant increase in demand, additional supplies of raw materials or additional manufacturing capacity may not be available when required on terms that are acceptable to us, or at all, or suppliers or may not be able to allocate sufficient capacity in order to meet our increased requirements, which will negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to maintain sufficient levels of inventory in order to protect ourselves from supply interruptions. As a result, we are subject to the risk that a portion of our inventory will become obsolete or expire, which could have a material adverse effect on our earnings and cash flows due to the resulting costs associated with the inventory impairment charges and costs required to replace such inventory.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. Accordingly, the results of any one quarter or period should not be relied upon as an indication of future performance. Our quarterly and annual operating results may fluctuate as a result of a variety of factors, many of which are outside our control and, as a result, may not fully reflect the underlying performance of our business. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of demand for our products and any future products, which may vary significantly;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenditures that we may incur to acquire, develop or commercialize additional products and technologies;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and cost of obtaining regulatory approvals or clearances for planned or future products or indications;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated pricing pressures; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate at which we grow our sales force and the speed at which newly hired salespeople become effective, and the cost and level of investment therein;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to expand the geographic reach of our sales force;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the degree of competition in our industry and any change in the competitive landscape of our industry, including consolidation among our competitors or future partners;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">coverage and reimbursement policies with respect to our products, and potential future products that compete with our products;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and success or failure of pre-clinical studies or clinical trials for our products or any future products we develop or competing products;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">positive or negative coverage in the media or clinical publications of our products or products of our competitors or our industry;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of customer orders or medical procedures using our products and the number of available selling days in any quarterly period, which can be impacted by holidays, the mix of products sold and the geographic mix of where products are sold, including any related foreign currency impact;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seasonality, including possible seasonal slowing of demand for our products in the beginning and end of the year and summer months based on the elective nature of procedures performed using our products, and which may become more pronounced in the future as our business grows;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ongoing and global impact that the COVID-19 pandemic had and may continue to have on our business and the number of patients treated with Zephyr Valves, or any other pandemic, epidemic or outbreak of an infectious disease;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and cost of, and level of investment in, research, development, licenses, regulatory approval, commercialization activities, acquisitions and other strategic transactions, or other significant events relating to our products, which may change from time to time;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing our products, which may vary depending on the quantity of production and the terms of our agreements with third-party suppliers and manufacturers; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the average number of Zephyr Valves used for a patient, pricing, discounts and incentives; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future accounting pronouncements or changes in our accounting policies.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Further, our historical results are not necessarily indicative of results expected for any future period, and quarterly results are not necessarily indicative of the results to be expected for the full year or any other period, and accordingly should not be relied upon as indicative of future performance.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, it will negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The sizes of the markets for our current and future products have not been established with precision and may be smaller than we estimate and may decline. Certain patients may not have regions of the lung with little to no collateral ventilation, making them poor candidates for the Zephyr Valve. In addition, if the overall rate of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">smokers continues to decline, this may eventually decrease the number of patients suffering from COPD and emphysema and, accordingly, who would benefit from our solution.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of the annual total addressable markets for our current solution and products under development are based on a number of internal and third-party estimates, including, without limitation, the number of patients with severe emphysema treatable by our solution and the assumed prices at which we can sell our solution in markets that have not yet been established. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, certain of these patients may not have regions of the lung with little to no collateral ventilation, making them poor candidates for the Zephyr Valve. As a result, our estimates of the annual total addressable market for our current or future products may prove to be incorrect.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, cigarette smoking is one of the leading causes of COPD and emphysema. It is estimated that smoking accounts for as many as 80% of COPD-related deaths and 38% of the nearly 16 million adults in the United States diagnosed with COPD report being current smokers. The overall rate of smoking among the U.S. adult population has been steadily declining from 42.4% in 1965 to a record low of 13.7% in 2018 and there are increased efforts to decrease the rate of smoking globally. If the overall rate of smokers continues to decline, this may eventually decrease the number of patients suffering from COPD and emphysema and, accordingly, who would benefit from our solution.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the actual number of patients who would benefit from our solution, the price at which we can sell future products, or the annual total addressable market for our solution is smaller than we have estimated, it may impair our sales growth and negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure of a key information technology system, process, or site could negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on our information technology systems for the efficient functioning of our business, including the manufacture, distribution and maintenance of our products, as well as for accounting, data storage, compliance, purchasing and inventory management. We also depend on the information technology systems of third parties for the analysis, data storage and communication associated with the StratX Platform. We currently do not have redundant information technology systems. Our information technology systems, and those of third parties, may be subject to computer viruses, ransomware or other malware, attacks by computer hackers, failures during the process of upgrading or replacing software, databases or components thereof, power outages, damage or interruption from fires or other natural disasters, hardware failures, telecommunication failures and user errors, among other malfunctions. We, or the third parties we rely upon, could be subject to an unintentional event that involves a third party gaining unauthorized access to our or its systems, which could disrupt our operations, corrupt our data or result in release of our confidential information. Technological interruptions would disrupt our operations, including our ability to timely ship and track product orders, project inventory requirements, manage our supply chain and otherwise adequately service our customers or disrupt our customers’ ability use our products for treatments. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, a disruption in access to the system that controls the StratX Platform would prevent physicians using our solution from receiving the StratX Lung Report indicating whether their patients are good candidates for the Zephyr Valve. In the event we experience significant disruptions, we may be unable to repair our systems in an efficient and timely manner. Accordingly, such events may disrupt or reduce the efficiency of our entire operation and negatively affect our business, financial condition and results of operations. Currently, we carry business interruption coverage to mitigate certain potential losses but this insurance is limited in amount, and we cannot be certain that such potential losses will not exceed our policy limits. Further, we do not carry any cyber insurance, which may expose us to certain potential losses for damages or result in penalization with fines in an amount exceeding our resources. We are increasingly dependent on complex information technology to manage our infrastructure. Our information systems require an ongoing commitment of significant resources to maintain, protect and enhance our existing </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">systems. Failure to maintain or protect our information systems and data integrity effectively could negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation against us could be costly and time-consuming to defend and could result in additional liabilities.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may from time to time be subject to legal proceedings and claims that arise in the ordinary course of business or otherwise, such as claims brought by our customers in connection with commercial disputes and employment claims made by our current or former employees. Claims may also be asserted by or on behalf of a variety of other parties, including government agencies, patients or vendors of our customers, or stockholders. For example, our Swiss subsidiary is currently party to a lawsuit with a former distributor outside the United States alleging that our Swiss subsidiary conducted unfair competitive practices and violated the exclusive distribution rights as a result of its termination of its distribution agreement. Our Swiss subsidiary is also currently party to a lawsuit with a former distributor outside the United States alleging that our Swiss subsidiary terminated the agreement without proper compensation. While we believe these claims are meritless and, if successful, we do not believe the impact of such claims will be material to the Company’s results of operations or financial position, an unfavorable outcome in this litigation could harm our business. Further, in the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities, and this risk is especially relevant to industries that experience significant stock price volatility. Any litigation involving us may result in substantial costs, operationally restrict our business, and may divert management’s attention and resources, which may negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face the risk of product liability claims that would be expensive, divert management’s attention and harm our reputation and business. We may not be able to maintain adequate product liability insurance.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business exposes us to the risk of product liability claims that are inherent in the testing, manufacturing and marketing of medical devices. This risk exists even if a device is cleared or approved for commercial sale by the FDA and manufactured in facilities licensed and regulated by the FDA or an applicable foreign regulatory authority. The Zephyr Valve is designed to affect, and any future products will be designed to affect, important bodily functions and processes. Any side effects, manufacturing defects, misuse or abuse associated with the Zephyr Valve could result in patient injury or death. The medical device industry has historically been subject to extensive litigation over product liability claims, and we cannot offer any assurance that we will not face product liability suits. There were procedure-related deaths in our LIBERATE Study and we may be subject to product liability claims if the Zephyr Valve causes, or merely appears to have caused, patient injury or death. In addition, an injury that is caused by the activities of our suppliers, such as those who provide us with components and raw materials, may be the basis for a claim against us. Product liability claims may be brought against us by patients, physicians, or others selling or otherwise coming into contact with the Zephyr Valve, among others. If we cannot successfully defend ourselves against product liability claims, we will incur substantial liabilities and reputational harm. In addition, regardless of merit or eventual outcome, product liability claims may result in:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of litigation; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distraction of management’s attention from our primary business; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize our solution or new products; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our products; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">damage to our business reputation; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls or withdrawals from the market; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to patients or other claimants; or </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of sales.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we may attempt to manage our product liability exposure by proactively recalling or withdrawing from the market any defective products, any recall or market withdrawal of our products may delay the supply of those products to our customers and may impact our reputation. We can provide no assurance that we will be successful in initiating appropriate market recall or market withdrawal efforts that may be required in the future or that these efforts will have the intended effect of preventing product malfunctions and the accompanying product liability that may result. Such recalls and withdrawals may also be used by our competitors to harm our reputation for safety or be perceived by patients as a safety risk when considering the use of our solution, either of which could negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not carry insurance for all categories of risk that our business may encounter. Although we have product liability and clinical study liability insurance that we believe is appropriate, this insurance is subject to deductibles and coverage limitations. Our current product liability insurance may not continue to be available to us on acceptable terms, if at all, and, if available, coverage may not be adequate to protect us against any future product liability claims. If we are unable to obtain insurance at an acceptable cost or on acceptable terms or otherwise protect against potential product liability claims, we could be exposed to significant liabilities. A product liability claim, recall or other claim with respect to uninsured liabilities or for amounts in excess of insured liabilities could negatively affect our business, financial condition and results of operations. We do not carry specific hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended. Additionally, we do not carry cyber insurance, which may expose us to certain potential losses for damages or result in penalization with fines in an amount exceeding our resources.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also expect that operating as a public company will make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our board of directors, on our board committees or as executive officers. We do not know, however, if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our indebtedness may limit our flexibility in operating our business and negatively affect our business, financial condition, results of operations and competitive position.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we executed a Loan and Security Agreement (the “CIBC Agreement”) with Canadian Imperial Bank of Commerce (“CIBC”), which provided us with the ability to borrow up to $32.0 million in debt financing. As of June 30, 2022, we have borrowed $17.0 million under the CIBC Agreement. See the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations⸺Liquidity and Capital Resources; Plan of Operation⸺CIBC Loan” and the notes to our consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to service this indebtedness and any additional indebtedness we may incur in the future, we need to generate cash from our operating activities. Our ability to generate cash is subject, in part, to our ability to successfully execute our business strategy, as well as general economic, financial, competitive, regulatory and other factors beyond our control. We cannot assure you that our business will be able to generate sufficient cash flow from operations or that future borrowings or other financings will be available to us in an amount sufficient to enable us to service our indebtedness and fund our other liquidity needs. To the extent we are required to use cash from operations or the proceeds of any future financing to service our indebtedness instead of funding working capital, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capital expenditures or other general corporate purposes, we will be less able to plan for, or react to, changes in our business, industry and in the economy generally. This will place us at a competitive disadvantage compared to our competitors that have less indebtedness.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the CIBC Agreement contains, and any agreements evidencing or governing other future indebtedness may contain, certain covenants that limit our ability to engage in certain transactions that may be in our long-term best interests. Subject to certain limited exceptions, these covenants limit our ability to, among other things:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">convey, sell, lease, transfer, assign, dispose of or otherwise make cash payments consisting of all or any part of our business or property; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effect certain changes in our business, management, ownership or business locations; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">merge or consolidate with, or acquire all or substantially all of the capital stock or assets of, any other company; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">create, incur, assume or be liable for any additional indebtedness, or create, incur, allow or permit to exist any additional liens; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pay cash dividends on, make any other distributions in respect of, or redeem, retire or repurchase, any shares of our capital stock; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make certain investments; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into transactions with our affiliates; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">under certain circumstances, settle pending or threatened litigation for greater amounts than are disclosed to CIBC in writing from time to time.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no guarantee that we will not breach these covenants. Our ability to comply with these covenants may be affected by events and factors beyond our control. In the event that we breach one or more covenants, our lender may choose to declare an event of default and require that we immediately repay all amounts outstanding, terminate any commitment to extend further credit and foreclose on the collateral granted to it to collateralize such indebtedness. The occurrence of any of these events could negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our industry is highly competitive, and we may not be able to compete successfully with larger companies, companies with longer operating histories or more established products, or companies with greater resources.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our industry is subject to rapid change from the introduction of new products and technologies and other activities of industry participants. Our goal is to establish our solution as a standard of care for severe emphysema. Existing treatments include medical management, LVRS, lung transplantation as well as other minimally invasive treatments. The major competitive products include the Spiration Valve System (Olympus Corporation) and the InterVapor System (Broncus Medical, Inc.; not approved for use in the United States). The Spiration Valve System is an endobronchial technology designed to offer patients with severe emphysema a minimally invasive treatment option for lung volume reduction by redirecting air away from diseased areas of the lung to healthier tissue so that patients may breathe easier. Like Zephyr Valves, the Spiration Valve System is indicated to treat patients with heterogeneous emphysema; however, the Spiration Valve System is contraindicated for patients with homogeneous emphysema. The InterVapor System offers a non-surgical and non-implant therapy developed for lung disease including emphysema and lung cancer where vapor ablation is simply the application of heated pure water to tissue. These technologies, other products that are in current clinical trials, new drugs or additional indications for existing drugs could demonstrate better safety, effectiveness, clinical results, lower costs or greater physician and patient acceptance.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete, or may compete in the future, against other companies which have longer operating histories, more established products and greater resources, which may prevent us from achieving significant market penetration or improved operating results. These companies enjoy several competitive advantages, including established relationships with pulmonologists who commonly treat patients with emphysema, significantly greater name recognition and significantly greater sales and marketing resources.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to existing competitors, other larger and more established companies may acquire or in-license competitive products and could directly compete with us. These competitors may also try to compete with us on price both directly, through rebates and promotional programs to high volume physicians and coupons to patients, and indirectly, through attractive product bundling with complementary products that offer convenience and an effectively lower price compared to the total price of purchasing each product separately. Larger competitors may also be able to offer greater customer loyalty benefits to encourage repeat use of their products and finance a sustained global advertising campaign to compete with commercialization efforts of our products. Our competitors may seek to discredit our products by challenging our short operating history or relatively limited number of scientific studies and publications. Smaller companies could also launch new or enhanced products and services that we do not offer and that could gain market acceptance quickly. Additionally, certain of our competitors may challenge our intellectual property, may develop additional competing or superior technologies and processes and compete more aggressively and sustain that competition over a longer period of time than we could. Our technologies and products may be rendered obsolete or uneconomical by technological advances or entirely different approaches developed by one or more of our competitors. As more companies develop new intellectual property in our market, there is the possibility of a competitor acquiring patents or other rights that may limit our ability to update our technologies and products which may impact demand for our products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have increased the size of our organization and expect to further increase it in the future. If we are unable to manage the anticipated growth, our business, financial condition and results of operations will be negatively affected. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any growth that we experience in the future will require us to expand our sales personnel and manufacturing operations and general and administrative infrastructure. As a public company, we will need to support managerial, operational, financial and other resources. In addition to the need to scale our organization, future growth will impose significant added responsibilities on management, including the need to identify, recruit, train and integrate additional employees. Rapid expansion in personnel could mean that less experienced people manufacture, market and sell our solution, which could result in inefficiencies and unanticipated costs, reduced quality and disruptions to our operations. In addition, rapid and significant growth may strain our administrative and operational infrastructure. Our ability to manage our business and growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. If we are unable to manage our growth effectively, it may be difficult for us to execute our business strategy and negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As demand for our solution or any of our future products increases, we will need to continue to scale our capacity, expand customer service, billing and systems processes and enhance our internal quality assurance program. We cannot assure you that any increases in scale, related improvements and quality assurance will be successfully implemented or that appropriate personnel will be available to facilitate the growth of our business. Failure to implement necessary procedures, transition to new processes or hire the necessary personnel could result in higher costs of processing data or inability to meet increased demand. If we encounter difficulty meeting market demand, quality standards or physician expectations, our reputation will be harmed and negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to continue to incur net losses for the next several years and we expect to require substantial additional capital to finance our planned operations, which may include future equity and debt financings. This additional capital may not be available to us on acceptable terms or at all. Our failure to obtain additional financing when </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">needed on acceptable terms, or at all, could force us to delay, limit, reduce or eliminate our commercialization, sales and marketing efforts, product development programs or other operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant net losses and expect to continue to incur net losses for the foreseeable future. Since our inception, our operations have been financed primarily through the sale of equity securities, debt financing arrangements and sales of our products. As of June 30, 2022, we had $166.8 million in cash, cash equivalents and short-term marketable securities, and an accumulated deficit of $321.9 million. Based on our current planned operations, we expect our cash, cash equivalents and short-term marketable securities, together with available borrowings under the CIBC Agreement, will enable us to fund our operating expenses for at least the next twelve months. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to make substantial investments in clinical trials that are designed to provide clinical evidence of the safety and efficacy of our solution. We intend to continue to make significant investments in our sales and marketing organization by increasing the number of U.S. sales territory managers and expanding our international sales and marketing programs to help promote awareness and increase adoption of our solution primarily among the pulmonologists performing interventional pulmonary procedures across approximately 500 high volume hospitals. In order to continue to grow our business, we will need to hire additional sales personnel to efficiently serve the market. We also expect to continue to make investments in research and development, regulatory affairs and clinical studies to develop future generations of our solution, broaden the addressable market and expand indications, support regulatory submissions and demonstrate the clinical efficacy of our solution. Moreover, we expect to incur additional expenses associated with operating as a public company, including legal, accounting, insurance, exchange listing and Securities and Exchange Commission (“SEC”) compliance, investor relations and other expenses. Because of these and other factors, we expect to continue to incur substantial net losses and negative cash flows from operations for the foreseeable future. Our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost, timing and results of our clinical trials and regulatory reviews;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of establishing sales, marketing and distribution capabilities;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic on our business;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and timing of any other collaborative, licensing and other arrangements that we may establish;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and amount of sales from our current solution and potential future products;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the degree of success we experience in continuing to commercialize our solution;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the emergence of competing or complementary technologies;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of preparing, filing, prosecuting, maintaining, defending and enforcing any patent claims and other intellectual property rights; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or invest in businesses, products or technologies, although we currently have no commitments or agreements relating to any of these types of transactions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will require additional financing to fund working capital and pay our obligations. We may seek to raise any necessary additional capital through a combination of public or private equity offerings or debt financings. There can be no assurance that we will be successful in acquiring additional funding at levels sufficient to fund our operations or on terms favorable to us. If adequate funds are not available on acceptable terms when needed, we may be required to significantly reduce operating expenses, which may negatively affect our business, financial condition and results of operations. If we do raise additional capital through public or private equity or convertible debt offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Additional capital may not be available on reasonable terms, or at all.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the quality of our solution does not meet the expectations of physicians or patients, then our business and reputation may be harmed.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the course of conducting our business, we must adequately address quality issues that may arise with our solution, including defects in third-party components included in our solution. Although we have established internal procedures designed to minimize risks that may arise from quality issues, there can be no assurance that we will be able to eliminate or mitigate occurrences of these issues and associated liabilities. In addition, even in the absence of quality issues, we may be subject to claims and liability if the performance of the Zephyr Valves does not live up to the expectations of physicians or patients as a result of the physician’s implantation of the valve. For example, a physician may improperly implant the Zephyr Valve. If the quality of our solution does not meet the expectations of physicians or patients, then our business and reputation with those physicians or patients may negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our facilities become damaged or inoperable, we will be unable to continue to research, develop and supply our solution which could negatively affect our business, financial condition and results of operations until we are able to secure a new facility and rebuild our inventory.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have redundant facilities. We perform substantially all of our manufacturing, research and development and back office activity in a single location at our headquarters in Redwood City, California. We store our finished goods inventory at our headquarters and secondary facilities in Redwood City, California, Memphis, Tennessee, and the Netherlands. Our facilities, equipment and inventory would be costly to replace and could require substantial lead time to repair or replace. The facilities will be harmed or rendered inoperable by natural or man-made disasters, including, but not limited to, earthquakes, flooding, fire and power outages, which may render it difficult or impossible for us to perform our research, development and commercialization activities for some period of time. The inability to perform those activities, combined with the time it may take to rebuild our manufacturing capabilities, inventory of finished product, may result in the loss of customers or harm to our reputation. Although we possess insurance for damage to our property and the disruption of our business, this insurance may not be sufficient to cover all of our potential losses and this insurance may not continue to be available to us on acceptable terms, or at all.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance issues, service interruptions or price increases by our shipping carriers could negatively affect our business, financial condition and results of operations and harm our reputation and the relationship between us and the hospitals with which we work.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expedited, reliable shipping is essential to our operations. We rely heavily on providers of transport services for reliable and secure point-to-point transport of the Zephyr Valve and Chartis System to our customers and for tracking of these shipments. Should a carrier encounter delivery performance issues such as loss, damage or destruction of any systems, it would be costly to replace such systems in a timely manner and such occurrences may damage our reputation and lead to decreased demand for our solution and increased cost and expense to our business. In addition, any significant increase in shipping rates could adversely affect our operating margins and results of operations. Similarly, strikes, severe weather, natural disasters or other service interruptions affecting delivery services we use would adversely affect our ability to process orders for the Zephyr Valve on a timely basis.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on our senior management team and the loss of one or more key employees or an inability to attract and retain highly skilled employees will negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and other personnel. We are highly dependent upon our management team, particularly our Chief Executive Officer, and the rest of our senior management, and other key personnel. Although we have entered into </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">employment letter agreements with all of our executive officers, each of them may terminate their employment with us at any time. The replacement of any of our key personnel likely would involve significant time and costs and may significantly delay or prevent the achievement of our business objectives and could therefore negatively affect our business, financial condition and results of operations. In addition, we do not carry any key person insurance policies that could offset potential loss of service under applicable circumstances.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our research and development programs and clinical operations depend on our ability to attract and retain highly skilled engineers and medical researchers. We may not be able to attract or retain qualified engineers and medical researchers in the future due to the competition for qualified personnel. We have from time to time experienced, and we expect to continue to experience, difficulty in hiring and retaining employees with appropriate qualifications. Many of the companies with which we compete for experienced personnel have greater resources than us. If we hire employees from competitors or other companies, their former employers may attempt to assert that these employees or we have breached legal obligations, resulting in a diversion of our time and resources and, potentially, damages. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, job candidates and existing employees, particularly in the San Francisco Bay Area, often consider the value of the stock awards they receive in connection with their employment. If the perceived value of our stock awards declines, it may harm our ability to recruit and retain highly skilled employees. Many of our employees have become or will soon become vested in a substantial amount of our common stock or a number of common stock options. Our employees may be more likely to leave us if the shares they own have significantly appreciated in value relative to the original purchase prices of the shares, or if the exercise prices of the options that they hold are significantly below the market price of our common stock, particularly after the expiration of the lock-up agreements described herein. Our future success also depends on our ability to continue to attract and retain additional executive officers and other key employees. If we fail to attract new personnel or fail to retain and motivate our current personnel, it will negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have significant international operations, and to successfully market and sell our products in such international markets we must address international business risks with which we have limited experience.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales in markets outside of the United States accounted for approximately 40.9% and 49.4% of our revenue for the six months ended June 30, 2022 and June 30, 2021, respectively. We currently focus our international sales and marketing efforts in Australia, Austria, Belgium, China, Denmark, France, Germany, Ireland, Italy, the Netherlands, South Korea, Spain, Switzerland and the United Kingdom. International sales are subject to a number of risks, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in staffing and managing our international operations; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased competition as a result of more products and procedures receiving regulatory approval or otherwise free to market in international markets; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">longer accounts receivable payment cycles and difficulties in collecting accounts receivable; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced or varied protection for intellectual property rights in some countries; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">export restrictions, trade regulations and foreign tax laws; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in currency exchange rates; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign certification and regulatory clearance or approval requirements; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in developing effective marketing campaigns in unfamiliar foreign countries; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">customs clearance and shipping delays; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">political, social, and economic instability abroad, including as a result of armed conflict, war or the threat of war, terrorist activity and other security concerns in general;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">global health epidemics or other contagious diseases, including the impact of the COVID-19 pandemic;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preference for locally produced products; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potentially adverse tax consequences, including the complexities of foreign value-added tax systems, tax inefficiencies related to our corporate structure, and restrictions on the repatriation of earnings; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing payment and reimbursement regimes;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the burdens of complying with a wide variety of foreign laws and different legal standards; and </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased financial accounting and reporting burdens and complexities.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the COVID-19 pandemic significantly decreased and may continue to have an adverse impact on the sale of our products and the number of patients treated with our solution. The outbreak has also resulted in disruptions or restrictions on physicians, hospitals and other healthcare providers from treating patients that are eligible for our products due to the uncertain health effects of the coronavirus on the respiratory system and resources that are diverted to prioritize treatment and containment of the coronavirus outbreak. In addition, the COVID-19 pandemic has also resulted in business closures and disruptions that may continue to affect various suppliers of ancillary products used in the delivery of our product (e.g. gowns, face masks or gloves), including disruptions and restrictions on transportation of our products and could result in significant delays. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a significant outbreak of another contagious diseases could result in a widespread health crisis that could adversely affect the economies and financial markets worldwide, resulting in an economic downturn that could affect demand for our products and impact our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If one or more of these risks are realized, it will negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our information technology systems or data is or were compromised, we could experience adverse impacts resulting from such compromise, including, but not limited to, interruptions to our operations such as our clinical trials, claims that we breached our data protection obligations, harm to our reputation, and a loss of customers or sales.*</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we or the third parties upon whom we rely, may collect, store, transmit or otherwise process proprietary, confidential, and sensitive data (including but not limited to intellectual property, proprietary business information and personal data). For example, we may fail to remove all PHI from CT scan data on the StratX Platform. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely extensively on information technology (“IT”) systems, networks and services, including internet sites, data hosting and processing facilities and tools, physical security systems and other hardware, software and technical applications and platforms, some of which are managed, hosted, provided or used by third-parties or their vendors, to assist in conducting our business. Our ability to monitor these third parties’ information security practices is limited, and these third parties may not have adequate information security measures in place. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are in the process of implementing policies and procedures designed to ensure compliance with applicable data privacy and information security laws and regulations and we take measures to protect sensitive information from unauthorized access or disclosure, our IT and infrastructure, and other third parties, including technology partners and providers, may be vulnerable to a variety of evolving threats, including but not limited to social engineering attacks (including through phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks (such as credential </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stuffing), ransomware attacks, software bugs, server malfunction, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, earthquakes, fire, flood, and other similar threats. In addition to traditional computer “hackers,” threat actors, “hacktivists,” organized criminal threat actors, personnel misconduct or error (such as theft or misuse), sophisticated nation-state and nation-state supported actors now engage and are expected to continue to engage in cyberattacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties upon whom we rely may be vulnerable to a heightened risk of these attacks, including retaliatory cyberattacks that could materially disrupt our systems, operations and supply chain.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ransomware attacks, including those perpetrated by organized criminal threat actors, nation-states, and nation-state supported actors, are becoming increasingly prevalent and severe and can lead to significant interruptions in our operations, loss of data and income, reputational harm, and diversion of funds. To alleviate the financial, operational and reputational impact of a ransomware attack, it may be preferable to make extortion payments, but we may be unwilling or unable to do so (including, for example, if applicable laws or regulations prohibit such payments). Similarly, supply chain attacks have increased in frequency and severity, and we cannot guarantee that third parties and infrastructure in our supply chain have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach of or disruption to our platform, systems and networks or the systems and networks of third parties that support us and our services. Additionally, the COVID-19 pandemic and our remote workforce poses increased risks to our information technology systems and data, as more of our employees work from home, utilizing network connections outside our premises.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the aggregate impact of security incidents on our operations and financial condition has not been material to date, we have occasionally been the target of events of this nature and expect them to continue as security threats have been rapidly evolving in sophistication and becoming more prevalent in the industry. Advances in computer capabilities, new technological discoveries or other developments may result in cyberattacks becoming more sophisticated and more difficult to detect. We and our third-party service providers may not have the resources or technical sophistication to anticipate or prevent all such cyberattacks. Moreover, techniques used to obtain unauthorized access to systems or other information technology infrastructure change frequently and may not be detected until after an incident has occurred. We are investing in protections and monitoring practices of our data and IT to reduce these risks and continue to monitor our systems on an ongoing basis for any current or potential threats. We cannot assure you, however, that our efforts will prevent breakdowns or breaches to our or our third-party providers’ databases or systems, and such breakdowns and breaches could negatively affect our business, financial condition and results of operations and our reputation.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our third-party service providers experience, or are perceived to have experienced, material security incidents, it may result in: government enforcement actions that could include investigations, fines, penalties, audits and inspections; additional reporting requirements and/or oversight; temporary or permanent bans on all or some processing of personal data; or orders to destroy or not use personal data. Applicable data privacy and information security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosures or the failure to comply with such requirements, could lead to adverse impacts. Further, individuals or other relevant stakeholders could sue us for our actual or perceived failure to comply with our security obligations, including, without limitation, in class action litigation. Security incidents could also result in indemnity obligations, negative publicity and financial loss. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Security incidents and vulnerabilities may cause some of our customers and users to stop using our services and our failure, or perceived failure, to meet expectations with regard to the security, integrity, availability and confidentiality of our systems and sensitive data could damage our reputation and affect our ability to retain customers, attract new customers and grow our business. Any of these results could harm our growth prospects, our business and our reputation. Moreover, security incidents can result in the diversion of funds, and interruptions, delays, or outages in our operations and services, including due to ransomware attacks. Failures or significant downtime of our information technology or telecommunication systems or those used by our third-party service providers could cause significant interruptions to our operations and adversely impact the confidentiality, integrity and availability of sensitive, proprietary or confidential information, and prevent us from administering our business. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that limitations of liability in our contracts are sufficient to protect us from claims related to our security obligations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may enter into collaborations, in-licensing arrangements, joint ventures, strategic alliances or partnerships with third parties that may not result in the development of commercially viable products, product improvements or the generation of significant future revenues.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we may enter into collaborations, in-licensing arrangements, joint ventures, strategic alliances, partnerships or other arrangements to develop new products or product improvements and to pursue new markets. Proposing, negotiating and implementing collaborations, in-licensing arrangements, joint ventures, strategic alliances or partnerships may be a lengthy and complex process. Other companies, including those with substantially greater financial, marketing, sales, technology or other business resources, may compete with us for these opportunities or arrangements. We may not identify, secure, or complete any such transactions or arrangements in a timely manner, on a cost-effective basis, on acceptable terms or at all. We have limited institutional knowledge and experience with respect to these business development activities, and we may also not realize the anticipated benefits of any such transaction or arrangement. In particular, these collaborations may not result in the development of products that achieve commercial success or viable product improvements or result in significant revenues and could be terminated prior to developing any products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we may not be in a position to exercise sole decision making authority regarding the transaction or arrangement, which could create the potential risk of creating impasses on decisions, and our future collaborators may have economic or business interests or goals that are, or that may become, inconsistent with our business interests or goals. It is possible that conflicts may arise with our collaborators, such as conflicts concerning the achievement of performance milestones, or the interpretation of significant terms under any agreement, such as those related to financial obligations or the ownership or control of intellectual property developed during the collaboration. If any conflicts arise with any future collaborators, they may act in their self-interest, which may be adverse to our best interest, and they may breach their obligations to us. In addition, we may have limited control over the amount and timing of resources that any future collaborators devote to our or their future products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes between us and our collaborators may result in litigation or arbitration which would increase our expenses and divert the attention of our management. Further, these transactions and arrangements will be contractual in nature and will generally be terminable under the terms of the applicable agreements and, in such event, we may not continue to have rights to the products relating to such transaction or arrangement or may need to purchase such rights at a premium. If we enter into in-bound intellectual property license agreements, we may not be able to fully protect the licensed intellectual property rights or maintain those licenses. Future licensors could retain the right to prosecute and defend the intellectual property rights licensed to us, in which case we would depend on the ability of our licensors to obtain, maintain and enforce intellectual property protection for the licensed intellectual property. These licensors may determine not to pursue litigation against other companies or may pursue such litigation less aggressively than we would. Further, entering into such license agreements could impose various diligence, commercialization, royalty or other obligations on us. Future licensors may allege that we have breached our license agreement with them, and accordingly seek to terminate our license, which could adversely affect our competitive business position and harm our business prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Unfavorable global economic conditions, including as a result of the conflict in Ukraine, could negatively affect our business, financial condition or results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn, such as the global financial crisis of 2008, could result in a variety of risks to our business, including weakened demand for our solution, and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy, including due to the impact of the COVID-19 pandemic or inflationary pressures, could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. Any of the foregoing will negatively affect our business, financial condition and results of operations and we cannot anticipate all of the ways in which </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the economic climate and financial market conditions could negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, in late February 2022, Russia initiated significant military action against Ukraine. In response, the United States, the European Union, the United Kingdom and certain other countries imposed significant sanctions and trade actions against Russia, and could impose further sanctions, trade restrictions and other retaliatory actions should the conflict continue or worsen. It is not possible to predict the broader consequences of the conflict, including related geopolitical tensions, and the measures and retaliatory actions taken by the United States and other countries in respect thereof, as well as any counter measures or retaliatory actions by Russia in response, which is likely to cause regional instability, geopolitical shifts and could materially adversely affect global trade, currency exchange rates, regional economies and the global economy. In particular, while it is difficult to anticipate the impact of any of the foregoing on the Company, the conflict and actions taken in response to the conflict could increase our costs, disrupt our supply chain, reduce our sales and earnings, impair our ability to raise additional capital when needed on acceptable terms, if at all, or otherwise adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may acquire other companies or technologies, which could divert our management’s attention, result in additional dilution to our stockholders and otherwise negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future seek to acquire or invest in businesses, applications or technologies that we believe could complement or expand our current business, enhance our technical capabilities or otherwise offer growth opportunities. Accordingly, although we have no current commitments with respect to any acquisition or investment, we may in the future pursue the acquisition of, or joint ventures relating to, complementary businesses, applications or technologies instead of developing them ourselves. The pursuit of potential acquisitions may divert the attention of management and cause us to incur various costs and expenses in identifying, investigating and pursuing suitable acquisitions, whether or not they are consummated. We may not be able to identify desirable acquisition targets or be successful in entering into an agreement with any particular target or obtain the expected benefits of any acquisition or investment.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to successfully integrate acquired personnel, operations and technologies, or effectively manage the combined business following an acquisition. Acquisitions could also result in dilutive issuances of equity securities, the use of our available cash, or the incurrence of debt, which will harm our operating results. In addition, if an acquired business fails to meet our expectations, it will negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation in the healthcare industry or group purchasing organizations could lead to demands for price concessions, which may affect our ability to sell our products at prices necessary to support our current business strategies.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial payor industry is undergoing significant consolidation. When payors combine their operations, the combined company may elect to reimburse our products at the lowest rate paid by any of the participants in the consolidation or use its increased size to negotiate reduced rates. If one of the payors participating in the consolidation does not reimburse for the Zephyr Valve and our solution at all, the combined company may elect not to reimburse for the same, which would adversely impact our operating results.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our long-term growth depends on our ability to enhance our solution, expand our indications and develop and commercialize additional products. If we fail to identify, acquire and develop other products, we may be unable to grow our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is important to our business that we continue to enhance the Zephyr Valve, Chartis System and StratX Platform and develop and introduce new products. Developing products is expensive and time-consuming and could divert </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management’s attention away from our core business. The success of any new product offering or product enhancements to our solution will depend on several factors, including our ability to:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">assemble sufficient resources to acquire or discover additional products;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">properly identify and anticipate physician and patient needs; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop and introduce new products and product enhancements in a timely manner; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">avoid infringing upon the intellectual property rights of third parties; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">demonstrate, if required, the safety and efficacy of new products with data from pre-clinical studies and clinical trials; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain the necessary regulatory clearances or approvals for expanded indications, new products or product modifications; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be fully FDA-compliant with marketing of new devices or modified products; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">produce new products in commercial quantities at an acceptable cost;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide adequate training to potential users of our products; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receive adequate coverage and reimbursement for procedures performed with our products; and </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop an effective and dedicated sales and marketing team.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not successful in expanding our indications and developing and commercializing new products and product enhancements, our ability to increase our revenue may be impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may choose to focus our efforts and resources on a potential products or indication that ultimately prove to be unsuccessful, or to license or purchase a marketed product that does not meet our financial expectations. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other potential products or other diseases that may later prove to have greater commercial potential, or relinquish valuable rights to such potential products through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to retain sole development and commercialization rights, which could adversely impact our business, financial condition and results of operations. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus on research programs and products and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other products or product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to timely capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and products and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product or product candidate, we may relinquish valuable rights to that product or product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to anti-bribery, anti-corruption, and anti-money laundering laws, including the U.S. Foreign Corrupt Practices Act, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, which could negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we grow our international presence and global operations, we will be increasingly exposed to trade and economic sanctions and other restrictions imposed by the United States, the European Union and other governments and organizations. The U.S. Departments of Justice, Commerce, State and Treasury and other federal agencies and authorities have a broad range of civil and criminal penalties they may seek to impose against corporations and individuals for violations of economic sanctions laws, export control laws, the U.S. Foreign Corrupt Practices Act (“FCPA”), and other federal statutes and regulations, including those established by the Office of Foreign Assets Control (“OFAC”). In addition, the U.K. Bribery Act of 2010 (“Bribery Act”) prohibits both domestic and international bribery, as well as bribery across both private and public sectors. An organization that fails to prevent bribery by anyone associated with the organization can be charged under the Bribery Act unless the organization can establish the defense of having implemented adequate procedures to prevent bribery. Under these laws and regulations, as well as other anti-corruption laws, anti-money laundering laws, export control laws, customs laws, sanctions laws and other laws governing our operations, various government agencies may require export licenses, may seek to impose modifications to business practices, including cessation of business activities in sanctioned countries or with sanctioned persons or entities and modifications to compliance programs, which may increase compliance costs, and may subject us to fines, penalties and other sanctions. A violation of these laws or regulations would negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in the process of enhancing policies and procedures designed to ensure compliance by us and our directors, officers, employees, representatives, consultants and agents with the FCPA, OFAC restrictions, the Bribery Act and other export control, anti-corruption, anti-money-laundering and anti-terrorism laws and regulations. We cannot assure you, however, that our policies and procedures are or will be sufficient or that directors, officers, employees, representatives, consultants and agents have not engaged and will not engage in conduct for which we may be held responsible, nor can we assure you that our business partners have not engaged and will not engage in conduct that could materially affect their ability to perform their contractual obligations to us or even result in our being held liable for such conduct. Violations of the FCPA, OFAC restrictions, the Bribery Act or other export control, anti-corruption, anti-money laundering and anti-terrorism laws or regulations may result in severe criminal or civil sanctions, and we may be subject to other liabilities, which could negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results may be impacted by changes in foreign currency exchange rates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant proportion of our sales are outside of the United States, and a majority of those are denominated in foreign currencies, which exposes us to foreign currency risks, including changes in currency exchange rates. We do not currently engage in any hedging transactions. If we are unable to address these risks and challenges effectively, our international operations may not be successful, and our business could be harmed.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and research and development credit may be limited.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (“Code”) a corporation that undergoes an ownership change, generally defined as a greater than 50% change by value in its equity ownership over a three-year period, is subject to limitations on its ability to utilize its pre-change net operating losses (“NOLs”) and its research and development credit carryforwards to offset future taxable income. Our existing NOLs and research and development credit carryforwards may be subject to limitations arising from previous ownership changes, and if we undergo an ownership change, our ability to utilize NOLs and research and development credit carryforwards could be further limited by Sections 382 and 383 of the Code. In addition, our ability to deduct net interest expense may be limited if we have insufficient taxable income for the year during which the interest is incurred, and any carryovers of such disallowed interest would be subject to the limitation rules similar to those applicable to NOLs and other attributes. Future changes in our stock ownership, some of which </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">might be beyond our control, could result in an ownership change under Section 382 of the Code. For these reasons, in the event we experience a change of control, we may not be able to utilize a material portion of the NOLs, research and development credit carryforwards or disallowed interest expense carryovers, even if we attain profitability.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to achieve or maintain satisfactory pricing and margins for our products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers of medical devices have a history of price competition, and we can give no assurance that we will be able to achieve satisfactory prices for our solution or maintain prices at the levels we have historically achieved. Any decline in the amount that payors reimburse our customers for the Zephyr Valve and related products could make it difficult for customers to continue using, or to adopt, our solution and could create additional pricing pressure for us. If we are forced to lower the price we charge for our solution, our gross margins will decrease, which will adversely affect our ability to invest in and grow our business. If we are unable to maintain our prices, or if our costs increase and we are unable to offset such increase with an increase in our prices, our margins could erode. We will continue to be subject to significant pricing pressure, which will negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governmental export or import controls could limit our ability to compete in foreign markets and subject us to liability if we violate them.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products may be subject to U.S. export controls. Governmental regulation of the import or export of our products, or our failure to obtain any required import or export authorization for our products, when applicable, will harm our international sales and adversely affect our revenue. Compliance with applicable regulatory requirements regarding the export of our products may create delays in the introduction of our products in international markets or, in some cases, prevent the export of our products to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments and persons targeted by U.S. sanctions. If we fail to comply with export and import regulations and such economic sanctions, we may be fined or other penalties could be imposed, including a denial of certain export privileges. Moreover, any new export or import restrictions, new legislation or shifting approaches in the enforcement or scope of existing regulations, or in the countries, persons or technologies targeted by such regulations, could result in decreased use of our products by, or in our decreased ability to export our products to existing or potential customers with international operations. Any decreased use of our products or limitation on our ability to export or sell access to our products would likely negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation and Our Industry</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products and operations are subject to extensive government regulation and oversight both in the United States and abroad. If we fail to obtain and maintain necessary regulatory approvals for the Zephyr Valve and related products, or if approvals for future products and indications are delayed or not issued, it will negatively affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Zephyr Valve is subject to extensive regulation by the FDA in the United States and by our Notified Body in the European Union. Government regulations specific to medical devices are wide ranging and govern, among other things:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product design, development, manufacture, and release;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laboratory, pre-clinical and clinical testing, labeling, packaging, storage and distribution;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product safety and efficacy;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">premarketing clearance or approval;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">service operations;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">record keeping;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product marketing, promotion and advertising, sales and distribution; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">post-marketing surveillance, including reporting of deaths or serious injuries and recalls and correction and removals; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">post-market approval studies; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product import and export.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Either the 510(k) or PMA process can be expensive, lengthy and unpredictable. We may not be able to obtain any necessary clearances or approval or may be unduly delayed in doing so, which will negatively affect our business, financial condition and results of operations. Furthermore, even if we are granted regulatory clearances or approvals, they may include significant limitations on the indicated uses for the product, which may limit the market for the product. Although we have obtained PMA approval to market the Zephyr Valve, our approval can be revoked if safety or efficacy problems develop.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA can delay, limit or deny clearance or approval of a device for many reasons, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to demonstrate to the satisfaction of the FDA or the applicable regulatory entity or notified body that our products are safe or effective for their intended uses; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the disagreement of the FDA or the applicable foreign regulatory body with the design or implementation of our clinical trials or the interpretation of data from pre-clinical studies or clinical trials;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">serious and unexpected adverse device effects experienced by participants in our clinical trials; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data from our pre-clinical studies and clinical trials may be insufficient to support clearance or approval, where required; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to demonstrate that the clinical and other benefits of the device outweigh the risks; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the manufacturing process or facilities we use may not meet applicable requirements; and </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential for approval policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly in a manner rendering our clinical data or regulatory filings insufficient for clearance or approval.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to remain in compliance with applicable European laws and directives, we would be unable to continue to affix the CE mark to our products, which would prevent us from selling them within the European Economic Area (“EEA”).</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and state and international authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements could result in enforcement action by any such agency, which may include any of the following sanctions:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse publicity, warning letters, fines, injunctions, consent decrees and civil penalties;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">repair, replacement, refunds, recall or seizure of our products;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating restrictions, partial suspension or total shutdown of production;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">denial of our requests for regulatory clearance or premarket approval of new products or services, new intended uses or modifications to existing products or services;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of regulatory clearance or premarket approvals that have already been granted; or</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">criminal prosecution.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events were to occur, it will negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in the regulatory environment may constrain or require us to restructure our operations, which may harm our revenue and operating results. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare laws and regulations change frequently and may change significantly in the future. We may not be able to adapt our operations to address every new regulation, and new regulations may negatively affect our business, financial condition and results of operations. We cannot assure you that a review of our business by courts or regulatory authorities would not result in a determination that adversely affects our revenue and operating results, or that the healthcare regulatory environment will not change in a way that restricts our operations. In addition, there is risk that the U.S. Congress may implement changes in laws and regulations governing healthcare service providers, including measures to control costs, or reductions in reimbursement levels, which may negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal government is considering ways to change, and has changed, the manner in which healthcare services are paid for in the United States. CMS establishes Medicare payment levels for hospitals and physicians on an annual basis, which can increase or decrease payment to such entities. CMS, as well as insurers, have increased their efforts to control the cost, utilization and delivery of healthcare services. From time to time, the U.S. Congress has considered and implemented changes in the CMS fee schedules in conjunction with budgetary legislation. Further reductions of reimbursement by CMS for services or changes in policy regarding coverage of tests or other services provided or other requirements for payment, such as prior authorization or a physician’s or qualified practitioner’s signature on test/service requisitions, may be implemented from time to time. Individual states may also enact legislation that impacts Medicaid payments to hospitals and physicians. Reductions in the reimbursement rates and changes in payment policies of other third-party payors may occur as well. Similar changes in the past have resulted in reduced payments as well as added costs and have added more complex regulatory and administrative requirements. Further changes in federal, state, local and third-party payor regulations or policies may negatively affect our business, financial condition and results of operations. Actions by agencies regulating insurance or changes in other laws, regulations, or policies may also negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to changes to the regulatory environment in the United States, there have been changes to the regulatory environment in certain foreign jurisdiction in which we operate. For example, the Medical Devices Regulation became applicable in 2021. These modifications may have an effect on the way we conduct our business in the EEA. Additional regulatory changes may negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in funding for, or disruptions caused by global health concerns impacting, the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed, cleared or approved or commercialized in a timely manner, which could negatively impact our business. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, statutory, regulatory, and policy changes and other events that may otherwise affect the FDA’s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new devices to be reviewed and/or approved or cleared by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. Separately, in response to the COVID-19 pandemic, the FDA has had to postpone inspections of certain foreign and domestic manufacturing facilities and products, and is conducting inspections on a risk-based basis. Other regulatory authorities have adopted similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting business as usual or conducting inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A recall of our products, either voluntarily or at the direction of the FDA or another governmental authority, or the discovery of serious safety issues with our products that leads to corrective actions, could have a significant adverse impact on us.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and similar foreign governmental authorities have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture of a product or in the event that a product poses an unacceptable risk to health. The FDA’s authority to require a recall must be based on an FDA finding that there is reasonable probability that the device would cause serious injury or death. Manufacturers may also, under their own initiative, recall a product if any material deficiency in a device is found or withdraw a product to improve device performance or for other reasons. The FDA requires that certain classifications of recalls be reported to the FDA within ten working days after the recall is initiated. A government-mandated or voluntary recall by us could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing errors, design or labeling defects or other deficiencies and issues. Similar regulatory agencies in other countries have similar authority to recall devices because of material deficiencies or defects in design or manufacture that could endanger health. Any recall would divert management attention and financial resources and could cause the price of our stock to decline, expose us to product liability or other claims and harm our reputation with customers. A future recall announcement will harm our reputation with customers and negatively affect our sales. In addition, the FDA or a foreign governmental authority could take enforcement action for failing to report the recalls when they were conducted.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the FDA’s medical device reporting regulations (“MDRs”), we are required to report to the FDA any incident in which our product may have caused or contributed to a death or serious injury or in which our product malfunctioned and, if the malfunction were to recur, would likely cause or contribute to death or serious injury. Repeated product malfunctions may result in a voluntary or involuntary product recall. We are also required to follow detailed recordkeeping requirements for all firm-initiated medical device corrections and removals, and to report such corrective and removal actions to FDA if they are carried out in response to a risk to health and have not otherwise been reported under the MDRs. Depending on the corrective action we take to redress a product’s deficiencies or defects, the FDA may require, or we may decide, that we will need to obtain new approvals or clearances for the device before we may market or distribute the corrected device. Seeking such approvals or clearances may delay our ability to replace the recalled devices in a timely manner. Moreover, if we do not adequately address problems associated with our devices, we may face additional regulatory enforcement action, including FDA warning letters, product seizure, injunctions, administrative penalties, or civil or criminal fines. We may also be required to bear other costs or take other actions that may have a negative impact on our sales as well as face significant adverse publicity or regulatory consequences, which will negatively affect our business, financial condition and results of operations, including our ability to market our products in the future.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse event involving our products, whether in the United States or abroad, could result in future voluntary corrective actions, such as recalls or customer notifications, or agency action, such as inspection, mandatory recall or other enforcement action. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a lawsuit, will require the dedication of our time and capital, distract management from operating our business and may harm our reputation and financial results.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to certain federal, state and foreign fraud and abuse laws, health information privacy and security laws and transparency laws, which, if violated, could subject us to substantial penalties and negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The products and services we offer are highly regulated, and there can be no assurance that the regulatory environment in which we operate will not change significantly and adversely in the future. Our arrangements with physicians, hospitals and clinics may expose us to broadly applicable fraud and abuse and other laws and regulations that may restrict the financial arrangements and relationships through which we market, sell and distribute our products and services. Federal and state healthcare laws and regulations that may affect our ability to conduct business, include, without limitation:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal and state laws and regulations regarding billing and claims payment applicable to our solution and regulatory agencies enforcing those laws and regulations;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, any person or entity from knowingly and willfully offering, soliciting, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs, such as Medicare and Medicaid;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal false claims laws, including the False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, false claims, or knowingly using false statements, to obtain payment from the federal government;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payments Sunshine Act, created under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the “Affordable Care Act”) and its implementing regulations, which requires certain manufacturers of drugs, medical devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid, or the Children’s Health Insurance Program to report annually to CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other health care professionals (such as physician assistants and nurse practitioners) and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), as amended by the Health Information Technology for Economic and Clinical Health Act (“HITECH”), and its implementing regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information on covered entities, including certain healthcare providers, health plans and healthcare clearinghouses, and their respective business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity as well as their covered subcontractors; HIPAA also created criminal liability for, among other things, knowingly and willfully falsifying or concealing a material fact or making a materially false statement in connection with the delivery of or payment for healthcare benefits, items or services;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Federal Drug & Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal physician self-referral prohibition, commonly known as the Stark Law , which prohibits, among other things, physicians who have a financial relationship, including an investment, ownership or compensation relationship with an entity, from referring Medicare and Medicaid patients to that entity for designated health services, which include clinical laboratory services, unless an exception applies. Similarly, entities may not bill Medicare, Medicaid or any other party for services furnished pursuant to a prohibited referral;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">similar healthcare laws and regulations in the European Union and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers and laws governing the privacy and security of certain protected information, such as the General Data Protection Regulation (“GDPR”), which imposes obligations and restrictions on the collection and use of personal data relating to individuals located in the European Union (including health data).</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Affordable Care Act was enacted in 2010. The Affordable Care Act, among other things, amended the intent requirement of the federal Anti-Kickback Statute and criminal healthcare fraud statutes, including those created under HIPAA. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. In addition, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To enforce compliance with the healthcare regulatory laws, certain enforcement bodies have continued their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Responding to investigations can be time and resource-consuming and can divert management’s attention from the business. Additionally, as a result of these investigations, healthcare providers and entities may have to agree to additional compliance and reporting requirements as part of a consent decree or corporate integrity agreement. Any such investigation or settlement could increase our costs or otherwise negatively affect our business, financial condition and results of operations. Even an unsuccessful challenge or investigation into our practices could cause adverse publicity and be costly to respond to. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have adopted policies and procedures designed to comply with these laws and regulations and conduct internal reviews of our compliance with these laws, our activities, including those relating to the reporting of discount and rebate information and other information affecting federal, state and third-party reimbursement of our products (such as our patient reimbursement support program) and the sale and marketing of our products, may be subject to scrutiny by under these laws. Because of the breadth of these laws and the narrowness of available statutory exceptions and regulatory safe harbors, it is possible that some of our activities could be subject to challenge under one or more such laws. The growth of our business and sales organization and our expansion outside of the United States may increase the potential of violating these laws or our internal policies and procedures. Any action brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. If our operations are found to be in violation of any of the federal, state and foreign laws described above or any other current or future fraud and abuse or other healthcare laws and regulations that apply to us, we may be subject to significant penalties, including significant criminal, civil, and administrative penalties, damages, fines, imprisonment for individuals, additional oversight and reporting obligations, exclusion from participation in government programs, such as Medicare and Medicaid, imprisonment, contractual damages, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reputation harm and disgorgement and we could be required to curtail or cease our operations. Any of the foregoing consequences will negatively affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we modify the Zephyr Valve, we may need to seek additional clearances or approvals, which, if not granted, would prevent us from selling our modified products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the Zephyr Valve is marketed pursuant to a PMA order issued by the FDA. Any modifications to a PMA-approved device that could significantly affect its safety or effectiveness, including significant design and manufacturing changes, or that would constitute a major change in its intended use, manufacture, design, components, or technology requires approval of a new PMA application or PMA supplement. However, certain changes to a PMA-approved device do not require submission and approval of a new PMA or PMA supplement and may only require notice to FDA in a PMA 30-Day Notice, Special PMA Supplement—Changes Being Effected or PMA Annual Report. The FDA requires every manufacturer to make this determination in the first instance, but the FDA may review any manufacturer’s decision. The FDA may not agree with our decisions regarding whether new approvals are necessary. If the FDA disagrees with our determination and requires us to seek new PMA approvals for modifications to our previously approved products for which we have concluded that new approvals are unnecessary, we may be required to cease marketing or to recall the modified product until we obtain clearance or approval, and we may be subject to significant regulatory fines or penalties. Furthermore, our products could be subject to recall if the FDA determines, for any reason, that our products are not safe or effective or that appropriate regulatory submissions were not made. Delays in receipt or failure to receive approvals, the loss of previously received approvals, or the failure to comply with any other existing or future regulatory requirements, could reduce our sales, profitability and future growth prospects.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to comply with post-marketing regulatory requirements could subject us to enforcement actions, including substantial penalties, and might require us to recall or withdraw a product from the market. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even though we have obtained approval for the Zephyr Valve, we are subject to ongoing and pervasive regulatory requirements governing, among other things, the manufacture, marketing, advertising, medical device reporting, sale, promotion, registration, and listing of devices. For example, we must submit periodic reports to the FDA as a condition of PMA approval. These reports include safety and effectiveness information about the device after its approval. Failure to submit such reports, or failure to submit the reports in a timely manner, could result in enforcement action by the FDA. Following its review of the periodic reports, the FDA might ask for additional information or initiate further investigation. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the PMA approval for the Zephyr Valve was subject to several conditions of approval, including extended follow-up of the pre-market study cohort and post market study. Though we believe we have complied with these conditions to date, any failure to comply with the conditions of approval could result in the withdrawal of PMA approval and the inability to continue to market the device. Failure to conduct the required studies in accordance with Institutional Review Board (“IRB”) and informed consent requirements, or adverse findings in these studies, could also be grounds for withdrawal of approval of the PMA. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations to which we are subject are complex and have become more stringent over time. Regulatory changes could result in restrictions on our ability to continue or expand our operations, higher than anticipated costs, or lower than anticipated sales. Even after we have obtained the proper regulatory approval to market a device, we have ongoing responsibilities under FDA regulations and applicable foreign laws and regulations. Our failure to comply with applicable regulatory requirements could result in enforcement action by the FDA, state or foreign regulatory authorities, which will negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If treatment guidelines for severe emphysema or the standard of care evolves, we may need to redesign and seek new marketing authorization from the FDA for one or more of our products. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If treatment guidelines for severe emphysema changes or the standard of care for this condition evolves, we may need to redesign the applicable product and seek new approvals from the FDA. Our PMA approvals from the FDA are based on current treatment guidelines. If treatment guidelines change so that different treatments become </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">desirable, the clinical utility of one or more of our products could be diminished and will negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our suppliers fail to comply with the FDA’s QSR or the European Union Medical Devices Regulation, our manufacturing or distribution operations could be delayed or shut down and our revenue could suffer.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing and design processes and those of our third-party suppliers are required to comply with the FDA’s QSR and the European Union MDR, both of which cover procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of Zephyr Valves. We are also subject to similar state requirements and licenses, and to ongoing International Organization for Standardization (“ISO”) compliance in all operations, including design, manufacturing, and service, to maintain our CE Mark. In addition, we must engage in extensive recordkeeping and reporting and must make available our facilities and records for periodic unannounced inspections by governmental agencies, including the FDA, state authorities, European Union Notified Bodies and comparable agencies in other countries. If we fail a regulatory inspection, our operations could be disrupted and our manufacturing interrupted. Failure to take adequate corrective action in response to an adverse regulatory inspection could result in, among other things, a shutdown of our manufacturing or product distribution operations, significant fines, suspension of marketing clearances and approvals, seizures or recalls of our device, operating restrictions and criminal prosecutions, any of which would negatively affect our business, financial condition and results of operations. Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with applicable regulatory requirements, which may result in manufacturing delays for our product and cause our revenue to decline.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are registered with the FDA as a manufacturer. The FDA has broad post-market and regulatory enforcement powers. We are subject to unannounced inspections by the FDA and the Food and Drug Branch of the CDPH to determine our compliance with the QSR and other regulations at our manufacturing facility, and these inspections may include the manufacturing facilities of our suppliers. Our design facilities in Redwood City, California were most recently audited by the FDA in November 2016 and no observations resulting in a warning letter were identified. We believe that we are in compliance, in all material respects, with the QSR.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also maintain a certificate of registration for the design, manufacture, service, and distribution of our product from the BSI in the Netherlands, our European Notified Body. Most recently, BSI completed an ISO 13485 surveillance audit of our design, manufacturing and service operations in April 2020 and we believe that we are in compliance, in all material respects, with the MDR.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We can provide no assurance that we will continue to remain in compliance with the QSR or MDR. If the FDA, CDPH or BSI inspect any of our facilities and discover compliance problems, we may have to cease manufacturing and product distribution until we can take the appropriate remedial steps to correct the audit findings. Taking corrective action may be expensive, time consuming and a distraction for management and if we experience a delay at our manufacturing facility, we may be unable to produce our solutions, which will negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The misuse or off-label use of our solution will harm our image in the marketplace, result in injuries that lead to product liability suits or result in costly investigations and sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which will negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our solution has been approved by the FDA for specific indications. We train our marketing and direct sales force to not promote our products for uses outside of the FDA-approved indications for use, known as “off-label” uses. We cannot, however, prevent a physician from using our products off-label, when in the physician’s independent professional medical judgment, he or she deems it appropriate. There may be increased risk of injury to patients if physicians attempt to use our products off-label. Furthermore, the use of our products for indications other than those approved by the FDA or any foreign regulatory body may not effectively treat such conditions, which will harm our reputation in the marketplace among physicians and patients.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physicians may also misuse our products or use improper techniques if they are not adequately trained, potentially leading to injury and an increased risk of product liability. If our products are misused or used with improper technique, we may become subject to costly litigation by our customers or their patients. Product liability claims could divert management’s attention from our core business, be expensive to defend, and result in sizable damage awards against us that may not be covered by insurance. In addition, if the FDA or any foreign regulatory body determines that our promotional materials or training constitute promotion of an off-label use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, injunction, seizure, civil fine or criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our business activities to constitute promotion of an off-label use, which could result in significant penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs, and the curtailment of our operations. Any of these events will negatively affect our business, financial condition and results of operations and cause our stock price to decline.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to regulatory or enforcement actions if we engage in improper marketing or promotion of our products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our educational and promotional activities and training methods must comply with FDA and other applicable laws, including the prohibition of the promotion of a medical device for a use that has not been cleared or approved by the FDA. Use of a device outside of its cleared or approved indications is known as “off-label” use. Physicians may use our products off-label in their professional medical judgment, as the FDA does not restrict or regulate a physician’s choice of treatment within the practice of medicine. However, if the FDA determines that our educational and promotional activities or training constitutes promotion of an off-label use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance of warning letters, untitled letters, fines, penalties, injunctions, or seizures, which could have an adverse impact on our reputation and financial results. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our educational and promotional activities or training methods to constitute promotion of an off-label use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. In that event, our reputation could be damaged, and adoption of the products could be impaired. Although our policy is to refrain from statements that could be considered off-label promotion of our products, the FDA or another regulatory agency could disagree and conclude that we have engaged in off-label promotion. It is also possible that other federal, state or foreign enforcement authorities might take action, such as federal prosecution under the federal civil False Claims Act, if they consider our business activities constitute promotion of an off-label use, which could result in significant penalties, including, but not limited to, criminal, civil or administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations. In addition, the off-label use of our products may increase the risk of product liability claims. Product liability claims are expensive to defend and could divert our management’s attention, result in substantial damage awards against us, and harm our reputation.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The clinical trial process required to obtain regulatory approvals is lengthy and expensive with uncertain outcomes. If clinical studies of our future products do not produce results necessary to support regulatory clearance or approval in the United States or, with respect to our current or future products, elsewhere, we will be unable to expand the indications for or commercialize these products and may incur additional costs or experience delays in completing, or ultimately be unable to complete, the commercialization of those products. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained PMA approval for the Zephyr Valve. In order to obtain PMA approval for a device, the sponsor must conduct well-controlled clinical trials designed to assess the safety and efficacy of the product candidate. Conducting clinical trials is a complex and expensive process, can take many years, and outcomes are inherently uncertain. We incur substantial expense for, and devote significant time to, clinical trials but cannot be certain that the trials will ever result in commercial revenue. We may experience significant setbacks in clinical trials, even after earlier clinical trials showed promising results, and failure can occur at any time during the clinical trial process. Any of our products may malfunction or may produce undesirable adverse effects that could cause us or regulatory </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">authorities to interrupt, delay or halt clinical trials. We, the FDA, or another regulatory authority may suspend or terminate clinical trials at any time to avoid exposing trial participants to unacceptable health risks. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful results of pre-clinical studies are not necessarily indicative of future clinical trial results, and predecessor clinical trial results may not be replicated in subsequent clinical trials. Additionally, the FDA may disagree with our interpretation of the data from our pre-clinical studies and clinical trials, or may find the clinical trial design, conduct or results inadequate to prove safety or efficacy, and may require us to pursue additional pre-clinical studies or clinical trials, which could further delay the clearance or approval of our products. The data we collect from our pre-clinical studies and clinical trials may not be sufficient to support FDA clearance or approval, and if we are unable to demonstrate the safety and efficacy of our future products in our clinical trials, we will be unable to obtain regulatory clearance or approval to market our products. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may estimate and publicly announce the anticipated timing of the accomplishment of various clinical, regulatory and other product development goals, which are often referred to as milestones. These milestones could include the obtainment of the right to affix the CE mark in the European Union; the submission to the FDA of an Investigational Device Exemption (“IDE”) application to commence a pivotal clinical trial for a new product candidate; the enrollment of patients in clinical trials; the release of data from clinical trials; and other clinical and regulatory events. The actual timing of these milestones could vary dramatically compared to our estimates, in some cases for reasons beyond our control. We cannot assure you that we will meet our projected milestones and if we do not meet these milestones as publicly announced, the commercialization of our products may be delayed and, as a result, our stock price may decline. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are necessary to support PMA applications and may be necessary to support PMA supplements for modified versions of our marketed device products. This would require the enrollment of large numbers of suitable subjects, which may be difficult to identify, recruit and maintain as participants in the clinical trial. Adverse outcomes in the post-approval studies could also result in restrictions or withdrawal of approval of the PMA. We will likely need to conduct additional clinical studies in the future to support new indications for our products or for approvals or clearances of new product lines, or for the approval of the use of our products in some foreign countries. Clinical testing is difficult to design and implement, can take many years, can be expensive and carries uncertain outcomes. The initiation and completion of any of these studies may be prevented, delayed, or halted for numerous reasons. We may experience a number of events that could adversely affect the costs, timing or successful completion of our clinical trials, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to submit an IDE application to the FDA, which must become effective prior to commencing human clinical trials, and the FDA may reject our IDE application and notify us that we may not begin investigational trials; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators and other comparable foreign regulatory authorities may disagree as to the design or implementation of our clinical trials; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators, IRBs or other reviewing bodies may not authorize us or our investigators to commence a clinical trial, or to conduct or continue a clinical trial at a prospective or specific trial site; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not reach agreement on acceptable terms with prospective contract research organizations (“CROs”) and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of subjects or patients required for clinical trials may be larger than we anticipate, enrollment in these clinical trials may be insufficient or slower than we anticipate, and the number of clinical trials being conducted at any given time may be high and result in fewer available patients for any given clinical trial, or patients may drop out of these clinical trials at a higher rate than we anticipate; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third-party contractors, including those manufacturing products or conducting clinical trials on our behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we might have to suspend or terminate clinical trials for various reasons, including a finding that the subjects are being exposed to unacceptable health risks; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have to amend clinical trial protocols or conduct additional studies to reflect changes in regulatory requirements or guidance, which we may be required to submit to an IRB or regulatory authority for re-examination; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators, IRBs, or other parties may require or recommend that we or our investigators suspend or terminate clinical research for various reasons, including safety signals or noncompliance with regulatory requirements; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of clinical trials may be greater than we anticipate; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical sites may not adhere to the clinical protocol or may drop out of a clinical trial; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to recruit a sufficient number of clinical trial sites; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators, IRBs, or other reviewing bodies may fail to approve or subsequently find fault with our manufacturing processes or facilities of third-party supplier with which we enter into agreement for clinical and commercial supplies, the supply of devices or other materials necessary to conduct clinical trials may be insufficient, inadequate or not available at an acceptable cost, or we may experience interruptions in supply; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval policies or regulations of the FDA or applicable foreign regulatory agencies may change in a manner rendering our clinical data insufficient for approval; and </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our current or future products may have undesirable side effects or other unexpected characteristics. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment in clinical trials and completion of patient follow-up depend on many factors, including the size of the patient population, the nature of the trial protocol, the proximity of patients to clinical sites, the eligibility criteria for the clinical trial, patient compliance, competing clinical trials and clinicians’ and patients’ perceptions as to the potential advantages of the product being studied in relation to other available therapies, including any new treatments that may be approved for the indications we are investigating. For example, patients may be discouraged from enrolling in our clinical trials if the trial protocol requires them to undergo extensive post-treatment procedures or follow-up to assess the safety and efficacy of a product candidate, or they may be persuaded to participate in contemporaneous clinical trials of a competitor’s product candidate or provider’s competing clinical trial. In addition, patients participating in our clinical trials may drop out before completion of the trial or experience adverse medical events unrelated to our products. Delays in patient enrollment or failure of patients to continue to participate in a clinical trial may delay commencement or completion of the clinical trial, cause an increase in the costs of the clinical trial and delays, or result in the failure of the clinical trial. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials must be conducted in accordance with the laws and regulations of the FDA and other applicable regulatory authorities’ legal requirements, regulations or guidelines, and are subject to oversight by these governmental agencies and IRBs at the medical institutions where the clinical trials are conducted. In addition, clinical trials must be conducted with supplies of our devices produced under current good manufacturing practice, requirements and other regulations. Furthermore, we may rely on CROs, and clinical trial sites to ensure the proper and timely conduct of our clinical trials and we may have limited influence over their actual performance. We depend on our collaborators and on medical institutions and CROs to conduct our clinical trials in compliance with good clinical practice (“GCP”) requirements. To the extent our collaborators or the CROs fail to enroll participants for our clinical trials, fail to conduct the study to GCP standards or are delayed for a significant time in the execution </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of trials, including achieving full enrollment, we may be affected by increased costs, program delays or both. In addition, clinical trials that are conducted in countries outside the United States may subject us to further delays and expenses as a result of increased shipment costs, additional regulatory requirements and the engagement of non-U.S. CROs, as well as expose us to risks associated with clinical investigators who are unknown to the FDA, and different standards of diagnosis, screening and medical care.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our future products are cleared or approved in the United States, commercialization of our products in foreign countries would require clearance or approval by regulatory authorities in those countries. Clearance or approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials. Any of these occurrences could have an adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products may cause or contribute to adverse medical events or be subject to failures or malfunctions that we are required to report to the FDA, and if we fail to do so, we would be subject to sanctions that could negatively affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to file various reports with the FDA and European regulators, including reports required by the MDRs that require that we report to the regulatory authorities if our solutions may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur and we have filed such reports in the past. The timing of our obligation to report is triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events of which we become aware within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of the product. If these reports are not filed in a timely manner, regulators may impose sanctions and we may be subject to product liability or regulatory enforcement actions, all of which will negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we initiate a correction or removal for the Zephyr Valve to reduce a risk to health posed by it, we would be required to submit a publicly available correction and removal report to the FDA and, in many cases, similar reports to other regulatory agencies. This report could be classified by the FDA as a device recall which could lead to increased scrutiny by the FDA, other international regulatory agencies and our customers regarding the quality and safety of our solutions. Furthermore, the submission of these reports could be used by competitors against us and cause physicians to delay or cancel prescriptions, which will harm our reputation.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we assess a potential quality issue or complaint as not requiring either field action or notification, respectively, regulators may review documentation of that decision during a subsequent audit. If regulators disagree with our decision, or take issue with either our investigation process or the resulting documentation, regulatory agencies may impose sanctions and we may be subject to regulatory enforcement actions, including warning letters, all of which will negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain and maintain international regulatory registrations or approvals for our products, we will be unable to market and sell our products outside of the United States. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products outside of the United States are subject to foreign regulatory requirements that vary widely from country to country. In addition, the FDA regulates exports of medical devices from the United States. While the regulations of some countries may not impose barriers to marketing and selling our products or only require notification, others require that we obtain the approval of a specified regulatory body. Complying with foreign regulatory requirements, including obtaining registrations or approvals, can be expensive and time-consuming, and we may not receive regulatory approvals in each country in which we plan to market our products, or we may be unable to do so on a timely basis. The time required to obtain registrations or approvals, if required by other countries, may be longer than that required for FDA approval, and requirements for such registrations, clearances or approvals may significantly differ from FDA requirements. If we modify our products, we may need to apply for additional regulatory approvals before we are permitted to sell the modified product. In addition, we may not continue to meet the quality and safety standards required to maintain the authorizations that we have received. If we </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are unable to maintain our authorizations in a particular country, we will no longer be able to sell the applicable product in that country. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory approval by the FDA does not ensure registration, clearance or approval by regulatory authorities in other countries, and registration, clearance or approval by one or more foreign regulatory authorities does not ensure registration, clearance or approval by regulatory authorities in other foreign countries or by the FDA. However, a failure or delay in obtaining registration or regulatory clearance or approval in one country may have a negative effect on the regulatory process in others. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare reform measures could hinder or prevent the commercial success of our solutions.*</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system in ways that will harm our future revenues and profitability and the demand for our solutions. Federal and state lawmakers regularly propose and, at times, enact legislation that would result in significant changes to the healthcare system, some of which are intended to contain or reduce the costs of medical products and services. Current and future legislative proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for the procedures associated with the use of our products. The cost containment measures that payors and providers are instituting and the effect of any healthcare reform initiative implemented in the future could impact our revenue from the sale of our products. For example, the Affordable Care Act contains a number of provisions that continue to impact the healthcare industry.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been executive, judicial and congressional challenges to certain aspects of the Affordable Care Act. For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the “individual mandate” was repealed by Congress. Thus, the Affordable Care Act will remain in effect in its current form. In addition, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. It is possible that the Affordable Care Act will be subject to judicial or congressional challenges in the future, including congressional legislation to modify or replace the Affordable Care Act or elements of the Affordable Care Act. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the Affordable Care Act and our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, the Budget Control Act of 2011, among other things, included reductions to CMS payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, including the Infrastructure Investment and Jobs Act, will remain in effect until 2031 unless additional congressional action is taken. However, COVID-19 relief legislation suspended the 2% Medicare sequester from May 1, 2020 through March 31, 2022. Under current legislation the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester. Additionally, the American Taxpayer Relief Act of 2012, among other things, reduced CMS payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biden administration and Congress may pursue significant changes to the current healthcare laws. The impact of those changes on us and potential effect on the medical device industry as a whole is currently unknown. Any changes to the Affordable Care Act are likely to have an impact on our results of operations, and may negatively affect our business, financial condition and results of operations. We cannot predict what other healthcare programs and regulations will ultimately be implemented at the federal or state level or the effect of any future legislation or regulation in the United States may negatively affect our business, financial condition and results of operations.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare will harm:</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to set a price that we believe is fair for the Zephyr Valve;</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to generate revenue and achieve or maintain profitability; and</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the availability of capital.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in healthcare policy could increase our costs and subject us to additional regulatory requirements that may interrupt commercialization of our current and future solutions. In addition, changes in healthcare policy could increase our costs, decrease our revenue and impact sales of and reimbursement for our current and future products. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent and changing obligations related to data privacy and information security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; a disruption of our business operations; reputational harm; and other adverse business impacts.*</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we or the third parties upon whom we rely, may collect, store, transmit or otherwise process proprietary, confidential, and sensitive data (including but not limited to intellectual property, proprietary business information and personal data). </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to diverse laws and regulations relating to data privacy and information security. Our data processing activities may also subject us to numerous other data privacy and information security obligations, such as external and internal privacy and security policies, contracts, and other obligations that govern the processing of personal data by us and on our behalf. In addition, privacy advocates and industry groups have proposed, and may propose in the future, standards by which we are legally or contractually bound to comply. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New privacy rules are being enacted in the United States and globally, and existing ones are being updated and strengthened. For example, in June 2018, the State of California enacted the CCPA, which went into effect on January 1, 2020 and requires companies that process personal data on California residents to make new disclosures to consumers about their data collection, use and sharing practices, and allow consumers to opt out of certain data sharing with third parties. The CCPA also provides for civil penalties for violations (up to $7,500 per violation), as well as a private right of action for certain data breaches that is expected to increase data breach litigation. Moreover, although the CCPA includes limited exceptions from its prescriptions, including exceptions for personal health information collected by covered entities or business associates subject to HIPAA, among others, the CCPA may regulate or impact our processing of personal data depending on the context. In addition, it is anticipated that the CPRA, effective January 1, 2023, will expand the CCPA. For example, the CPRA establishes a new California Privacy Protection Agency to implement and enforce the CCPA (as amended), which could increase the risk of an enforcement action. The CPRA may require additional compliance investment and potential business process changes in the meantime. Other states, such as Virginia, Colorado, Utah and Connecticut, have also passed comprehensive privacy laws, and similar laws are being considered in several other states. Complying with these numerous, complex and often changing regulations is expensive and difficult, and failure to comply with any data privacy and information security laws or any security incident or breach involving the misappropriation, loss or other unauthorized use or disclosure of sensitive data, such as personal data, confidential patient or consumer information, whether by us, one of our business associates or another third-party, could negatively affect our business, financial condition and results of operations, including but not limited to: investigation costs, material fines and penalties; compensatory, special, punitive and statutory damages; litigation; consent orders regarding our privacy and security practices; requirements that we provide notices, credit monitoring services or credit restoration services or other relevant services to impacted individuals; adverse actions against our licenses to do business; and injunctive relief. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The privacy laws in Europe have also been significantly reformed. In May 2018, the GDPR took effect in the EEA. The GDPR governs the collection, use, disclosure, transfer or other processing of personal data of European persons, replacing data protection laws issued by each European Union member state based on the Directive 95/46/EC (“Directive”). Unlike the Directive, which needed to be transposed at a national level, the GDPR text is directly applicable in each European Union member state, resulting in a more uniform application of data privacy laws across the EU. Among other things, the GDPR sets out extensive compliance requirements, including providing detailed disclosures about how personal data is collected and processed, demonstrating that an appropriate legal basis is in place or otherwise exists to justify data processing activities; granting new rights for data subjects in regard to their personal data, as well as enhancing pre-existing rights (e.g., data subject access requests); introducing the obligation to notify data protection regulators or supervisory authorities (and in certain cases, affected individuals) of significant data breaches; imposing limitations on retention of personal data; maintaining a record of data processing; complying with the principle of accountability and the obligation to demonstrate compliance through policies, procedures, training and audit; and expanding the definition of personal data to include coded data and requiring changes to informed consent practices, as well as more detailed notices for clinical trial subjects and investigators. The GDPR imposes substantial fines for breaches and violations (up to the greater of €20 million or 4% of our global turnover). The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain jurisdictions have enacted data localization laws and cross-border personal data transfers laws. For example, the GDPR increases the scrutiny of transfers of personal data from the EEA to the United States and other jurisdictions that the European Commission does not recognize as having “adequate” data protection laws. Notably, these requirements will regulate the transfer of personal data from our clinical trial sites located in the EEA to jurisdictions outside of the EEA. The European Commission released a set of “Standard Contractual Clauses” (“SCCs”) that are designed to be a valid mechanism by which entities can transfer personal data out of the EEA to jurisdictions that the European Commission has not found to provide an adequate level of protection. Currently, the SCCs are a valid mechanism to transfer personal data outside of the EEA. The SCCs, however, require parties that rely upon that legal mechanism to comply with additional obligations such as conducting transfer impact assessments to determine whether additional security measures are necessary to protect the at-issue personal data. If we are unable to implement a valid compliance mechanism for cross-border personal data transfers, we may face increased exposure to regulatory actions, substantial fines and injunctions against processing or transferring personal data from Europe, which could limit our ability to conduct clinical trial activities in Europe. In addition, laws in Switzerland similarly restrict personal data transfers outside of those jurisdictions to countries such as the United States that do not provide an adequate level of personal data protection. Other jurisdictions have enacted or are considering similar cross-border personal data transfer laws and local personal data residency laws, any of which could increase the cost and complexity of doing business. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the withdrawal of the United Kingdom from the European Union on January 31, 2020, and the expiration of the transition period, from January 1, 2021, companies have had to comply with both the GDPR and the UK GDPR, which, together with the amended United Kingdom Data Protection Act 2018 (“UK GDPR”), largely retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of €20 million (£17.5 million) or 4% of global turnover. Laws in the United Kingdom restrict personal data transfers outside of those jurisdictions to countries that do not provide an adequate level of personal data protection. The United Kingdom has adopted the international data transfer agreement (“IDTA”), the international data transfer addendum to the European Commission’s SCCs (“Addendum”) and a document setting out transitional provisions, which came into force on March 21, 2022. The IDTA and Addendum replaced the SCCs as a transfer tool to comply with Article 46 of the UK GDPR when making restricted transfers from the United Kingdom. In June 2021, the European Commission adopted an adequacy decision in favor of the United Kingdom, enabling data transfers from EEA member states to the United Kingdom without additional safeguards. In the event of a violation of the GDPR and UK GDPR affecting data subjects in both the United Kingdom and the EEA, we could be investigated by the ICO in the United Kingdom and supervisory authorities in the EEA. Compliance with the GDPR and UK GDPR is a rigorous and time-intensive process that may increase our cost of doing business in Europe or require us to put in place additional mechanisms to ensure compliance with such protection rules and will increase our responsibility and potential liability in relation to personal data that we process.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that our third-party service providers with access to our or our customers’, suppliers’, trial patients’ and employees’ personally identifiable and other sensitive or confidential information in relation to which we are responsible will not breach contractual obligations imposed by us, or that they will not experience data security breaches or attempts thereof, which could have a corresponding effect on our business, including putting us in breach of our obligations under privacy laws and regulations, which could in turn adversely affect our business, results of operations and financial condition. We cannot assure you that our contractual measures and our own privacy and security-related safeguards will protect us from the risks associated with the third-party processing, storage and transmission of such information. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, complying with the various data privacy and information security laws that are applicable to us could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Any failure (or perceived failure) to comply could result in government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business. Claims that we have violated individuals’ privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend, could result in adverse publicity and could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential liability related to the privacy of health information we obtain.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most healthcare providers, including hospitals from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA, as amended by the HITECH. We are not currently classified as a covered entity or business associate under HIPAA and thus are not subject to its requirements or penalties. However, any person may be prosecuted under HIPAA’s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA’s requirements for disclosure of individually identifiable health information. In addition, we may maintain sensitive personally identifiable information, including health information, that we receive throughout the clinical trial process, in the course of our research collaborations, and directly from individuals (or their healthcare providers) who enroll in our patient reimbursement support programs. As such, we may be subject to state laws requiring notification of affected individuals and state regulators in the event of a breach of personal data, which is a broader class of information than the health information protected by HIPAA. Our clinical trial programs outside the United States may implicate international data protection laws, including the European Union Data Protection Directive and legislation of the European Union member states implementing it.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities outside the United States impose additional compliance requirements and generate additional risks of enforcement for noncompliance. Failure by third-party contractors to comply with the strict rules on the transfer of personal data outside of the European Union into the United States may result in the imposition of criminal and administrative sanctions on such collaborators, which could adversely affect our business. Furthermore, certain health privacy laws, data breach notification laws, consumer protection laws and genetic testing laws may apply directly to our operations or those of our collaborators and may impose restrictions on our collection, use and dissemination of individuals’ health information.</span></div><div style="margin-bottom:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, patients about whom we or our collaborators obtain health information, as well as the providers who share this information with us, may have statutory or contractual rights that limit our ability to use and disclose the information. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws. Claims that we have violated individuals’ privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could negatively affect our business, financial condition and results of operations. If we or third-party contractors or consultants fail to comply with applicable federal, state or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our or our contractors’ ability to develop and commercialize our product candidates and could harm or prevent sales of any affected products that we are able to commercialize, or could substantially increase the costs and expenses of developing, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercializing and marketing our products. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, consultants, and other commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, consultants, and other commercial partners and business associates may engage in fraudulent or illegal activity. Misconduct by these parties could include intentional, reckless or negligent conduct or other unauthorized activities that violate the regulations of the FDA and non-U.S. regulators, including those laws requiring the reporting of true, complete and accurate information to such regulators, manufacturing standards, healthcare fraud and abuse laws and regulations in the United States and internationally or laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and business arrangements in the healthcare industry, including the sale of medical devices, are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. It is not always possible to identify and deter misconduct by our employees, consultants and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of significant fines or other sanctions, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of operations, any of which could adversely affect our ability to operate our business and our results of operations. Whether or not we are successful in defending against such actions or investigations, we could incur substantial costs, including legal fees and reputational harm, and divert the attention of management in defending ourselves against any of these claims or investigations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with environmental laws and regulations could be expensive, and the failure to comply with these laws and regulations could subject us to significant liability.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research, development and manufacturing operations involve the use of hazardous substances, and we are subject to a variety of federal, state, local and foreign environmental laws and regulations relating to the storage, use, handling, generation, manufacture, treatment, discharge and disposal of hazardous substances. Our products may also contain hazardous substances, and they are subject laws and regulations relating to labeling requirements and to their sale, collection, recycling, treatment, storage and disposal. Compliance with these laws and regulations may be expensive and noncompliance could result in substantial fines and penalties. Environmental laws and regulations also impose liability for the remediation of releases of hazardous substances into the environment and for personal injuries resulting from exposure to hazardous substances, and they can give rise to substantial remediation costs and to third-party claims, including for property damage and personal injury. Liability under environmental laws and regulations can be joint and several and without regard to fault or negligence, and they tend to become more stringent over time, imposing greater compliance costs and increased risks and penalties associated with violations. We cannot assure you that violations of these laws and regulations, or releases of or exposure to hazardous substances, will not occur in the future or have not occurred in the past, including as a result of human error, accidents, equipment failure or other causes. The costs of complying with environmental laws and regulations, and liabilities that may be imposed for violating them, or for remediation obligations or responding to third-party claims, could negatively affect our business, financial condition and results of operations.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become a party to intellectual property litigation or administrative proceedings that could be costly and could interfere with our ability to sell and market our products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry has been characterized by extensive litigation regarding patents, trademarks, trade secrets, and other intellectual property rights, and companies in the industry have used intellectual property litigation to gain a competitive advantage. It is possible that U.S. and foreign patents and pending patent applications or trademarks controlled by third parties may be alleged to cover our products, or that we may be accused of misappropriating third parties’ trade secrets. Additionally, our products include components that we purchase from vendors, and may include design components that are outside of our direct control. Our competitors, many of which have substantially greater resources and have made substantial investments in patent portfolios, trade secrets, trademarks, and competing technologies, may have applied for or obtained, or may in the future apply for or obtain, patents or trademarks that will prevent, limit or otherwise interfere with our ability to make, use, sell or export our products or to use our technologies or product names. Moreover, in recent years, individuals and groups that are non-practicing entities, commonly referred to as patent trolls, have purchased patents and other intellectual property assets for the purpose of making claims of infringement in order to extract settlements. From time to time, we may receive threatening letters, notices or invitations to license, or may be the subject of claims that our products and business operations infringe or violate the intellectual property rights of others. The defense of these matters can be time consuming, costly to defend in litigation, divert management’s attention and resources, damage our reputation and brand and cause us to incur significant expenses or make substantial payments. Vendors from whom we purchase hardware or software may not indemnify us in the event that such hardware or software is accused of infringing a third-party’s patent or trademark or of misappropriating a third-party’s trade secret.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since patent applications are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our products. Competitors may also contest our patents, if issued, by showing the patent examiner that the invention was not original, was not novel or was obvious. In litigation, a competitor could claim that our patents, if issued, are not valid for a number of reasons. If a court agrees, we would lose our rights to those challenged patents. Because we have not conducted a formal freedom to operate analysis for patents related to our products, we may not be aware of issued patents that a third party might assert are infringed by one of our current products or future product candidates, which could materially impair our ability to commercialize our products or product candidates. Even if we diligently search third-party patents for potential infringement by our products or product candidates, we may not successfully find patents that our products or product candidates may infringe. If we are unable to secure and maintain freedom to operate, others could preclude us from commercializing our products or product candidates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may in the future be subject to claims by our former employees or consultants asserting an ownership right in our patents, patent applications or other intellectual property, as a result of the work they performed on our behalf. Although we generally require all of our employees and consultants and any other partners or collaborators who have access to our proprietary know-how, information or technology to assign or grant similar rights to their inventions to us, we cannot be certain that we have executed such agreements with all parties who may have contributed to our intellectual property, nor can we be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any lawsuits relating to intellectual property rights could subject us to significant liability for damages and invalidate our proprietary rights. Any potential intellectual property litigation also could force us to do one or more of the following:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">stop making, selling or using products or technologies that allegedly infringe the asserted intellectual property;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lose the opportunity to license our intellectual property to others or to collect royalty payments based upon successful protection and assertion of our intellectual property rights against others; incur significant legal expenses;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pay substantial damages or royalties to the party whose intellectual property rights we may be found to be infringing;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pay the attorney’s fees and costs of litigation to the party whose intellectual property rights we may be found to be infringing;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">redesign those products or technologies that contain the allegedly infringing intellectual property, which could be costly, disruptive and infeasible; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attempt to obtain a license to the relevant intellectual property from third parties, which may not be available on reasonable terms or at all, or from third parties who may attempt to license rights that they do not have.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we are found to willfully infringe third-party patents or trademarks or to have misappropriated trade secrets, we could be required to pay treble damages in addition to other penalties. Although patent, trademark, trade secret, and other intellectual property disputes in the medical device area have often been settled through licensing or similar arrangements, costs associated with such arrangements may be substantial and could include ongoing royalties. We may be unable to obtain necessary licenses on satisfactory terms, if at all. If we do not obtain necessary licenses, we may not be able to redesign our products to avoid infringement.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any litigation or claim against us, even those without merit and even those where we prevail, may cause us to incur substantial costs, and could place a significant strain on our financial resources, divert the attention of management from our core business and harm our reputation. If we are found to infringe the intellectual property rights of third parties, we could be required to pay substantial damages (which may be increased up to three times of awarded damages) or substantial royalties and could be prevented from selling our products unless we obtain a license or are able to redesign our products to avoid infringement. Any such license may not be available on reasonable terms, if at all, and there can be no assurance that we would be able to redesign our products in a way that would not infringe the intellectual property rights of others. We could encounter delays in product introductions while we attempt to develop alternative methods or products. If we fail to obtain any required licenses or make any necessary changes to our products or technologies, we may have to withdraw existing products from the market or may be unable to commercialize one or more of our products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we generally indemnify our customers with respect to infringement by our products of the proprietary rights of third parties. Third parties may assert infringement claims against our customers. These claims may require us to initiate or defend protracted and costly litigation on behalf of our customers, regardless of the merits of these claims. If any of these claims succeed or settle, we may be forced to pay damages or settlement payments on behalf of our customers or may be required to obtain licenses for the products they use. If we cannot obtain all necessary licenses on commercially reasonable terms, our customers may be forced to stop using our products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, interference or derivation proceedings provoked by third parties or brought by the U.S. Patent and Trademark Office (“USPTO”) may be necessary to determine priority with respect to our patents, patent applications, trademarks or trademark applications. We may also become involved in other proceedings, such as reexamination, inter parties review, derivation or opposition proceedings before the USPTO or other jurisdictional body relating to our intellectual property rights or the intellectual property rights of others. Adverse determinations in a judicial or administrative proceeding or failure to obtain necessary licenses could prevent us from manufacturing our products or using product names, which would have a significant adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we may file lawsuits or initiate other proceedings to protect or enforce our patents or other intellectual property rights, which could be expensive, time consuming and unsuccessful. Competitors may infringe our issued </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patents or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property. In addition, in a patent or other intellectual property infringement proceeding, a court may decide that a patent or other intellectual property of ours is invalid or unenforceable, in whole or in part, construe the patent’s claims or other intellectual property narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents or other intellectual property do not cover the technology in question. Furthermore, even if our patents or other intellectual property are found to be valid and infringed, a court may refuse to grant injunctive relief against the infringer and instead grant us monetary damages or ongoing royalties. Such monetary compensation may be insufficient to adequately offset the damage to our business caused by the infringer’s competition in the market. An adverse result in any litigation proceeding could put one or more of our patents or other intellectual property at risk of being invalidated or interpreted narrowly, which could adversely affect our competitive business position, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success will depend on our, and any of our current and future licensors’, ability to obtain, maintain and protect our intellectual property rights.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to remain competitive, we must develop, maintain and protect the proprietary aspects of our brands, technologies and data. We rely on a combination of contractual provisions, confidentiality procedures and patent, copyright, trademark, trade secret and other intellectual property laws to protect the proprietary aspects of our brands, technologies and data. These legal measures afford only limited protection, and competitors or others may gain access to or use our intellectual property and proprietary information. Our success will depend, in part, on preserving our trade secrets, maintaining the security of our data and know-how and obtaining and maintaining other intellectual property rights by us and our current and future licensors. We, and our current and future licensors, may not be able to obtain or maintain intellectual property or other proprietary rights necessary to our business or in a form that provides us with a competitive advantage.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our trade secrets, data and know-how could be subject to unauthorized use, misappropriation, or disclosure to unauthorized parties, despite our efforts to enter into confidentiality agreements with our employees, consultants, clients and other vendors who have access to such information, and could otherwise become known or be independently discovered by third parties. Our intellectual property, including trademarks, could be challenged, invalidated, infringed, and circumvented by third parties, and our trademarks could also be diluted, declared generic or found to be infringing on other marks. If any of the foregoing occurs, we could be forced to re-brand our products, resulting in loss of brand recognition and requiring us to devote resources to advertising and marketing new brands, and suffer other competitive harm. Third parties may also adopt trademarks similar to ours, which could harm our brand identity and lead to market confusion. Failure to obtain and maintain intellectual property rights necessary to our business and failure to protect, monitor and control the use of our intellectual property rights could negatively impact our ability to compete and cause us to incur significant expenses. The intellectual property laws and other statutory and contractual arrangements in the United States and other jurisdictions we depend upon may not provide sufficient protection in the future to prevent the infringement, use, violation or misappropriation of our trademarks, data, technology and other intellectual property and services, and may not provide an adequate remedy if our intellectual property rights are infringed, misappropriated or otherwise violated.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely, in part, on our ability to obtain, maintain, expand, enforce, and defend the scope of our intellectual property portfolio or other proprietary rights, including the amount and timing of any payments we may be required to make in connection with the licensing, filing, defense and enforcement of any patents or other intellectual property rights. The process of applying for and obtaining a patent is expensive, time consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost, in a timely manner, or in all jurisdictions where protection may be commercially advantageous, or we may not be able to protect our proprietary rights at all. Despite our efforts to protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary. In addition, the issuance of a patent does not ensure that it is valid or enforceable, so even if we obtain patents, they may not be valid or enforceable against third parties. Our patent applications may not result in issued patents and our patents may not be sufficiently broad to protect our technology. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of our patents, or any of our pending patent applications, if issued, will include claims having a scope sufficient to protect our products;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of our pending patent applications will issue as patents;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we will be able to successfully commercialize our products on a substantial scale, if approved, before our relevant patents we may have expire;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we were the first to make the inventions covered by each of our patents and pending patent applications;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we were the first to file patent applications for these inventions;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others will not develop similar or alternative technologies that do not infringe our patents; any of our patents will be found to ultimately be valid and enforceable;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any patents issued to us will provide a basis for an exclusive market for our commercially viable products, will provide us with any competitive advantages or will not be challenged by third parties;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we will develop additional proprietary technologies or products that are separately patentable; or</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our commercial activities or products will not infringe upon the patents of others.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, even if we are able to obtain patent protection, such patent protection may be of insufficient scope to achieve our business objectives. Issued patents may be challenged, narrowed, invalidated or circumvented. Decisions by courts and governmental patent agencies may introduce uncertainty in the enforceability or scope of patents owned by or licensed to us. Furthermore, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our own products and practicing our own technology. Alternatively, third parties may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend or assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or agency with jurisdiction may find our patents invalid, unenforceable or not infringed; competitors may then be able to market products and use manufacturing and analytical processes that are substantially similar to ours. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our other proprietary information, our business and competitive position may be harmed.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets, and other proprietary information that is not patentable or that we elect not to patent. However, trade secrets can be difficult to protect, and some courts are less willing or unwilling to protect trade secrets. To maintain the confidentiality of our trade secrets and proprietary information, we rely heavily on confidentiality provisions that we have in contracts with our employees, consultants, collaborators and others upon the commencement of their relationship with us. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. We may not be able to prevent the unauthorized disclosure or use of our technical knowledge or other trade secrets by such third parties, despite the existence generally of these confidentiality restrictions. These contracts may not provide meaningful protection for our trade secrets, know-how, or other proprietary information in the event of any unauthorized use, misappropriation, or disclosure of such trade secrets, know-how, or other proprietary information. There can be no assurance that such third parties will not breach their agreements with us, that we will have adequate remedies for any breach, or that our trade secrets will not otherwise become known or independently developed by competitors. Despite the protections we do place on our intellectual property or other proprietary rights, monitoring unauthorized </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">use and disclosure of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property or other proprietary rights will be adequate. In addition, the laws of many foreign countries will not protect our intellectual property or other proprietary rights to the same extent as the laws of the United States. Consequently, we may be unable to prevent our proprietary technology from being exploited abroad, which could affect our ability to expand to international markets or require costly efforts to protect our technology.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also license rights to use certain proprietary information and technology from third parties. The use of such proprietary information and technology is therefore subject to the obligations of the applicable license agreement between us and the owner. For example, the software we developed for the Chartis System includes the use of open source software that is subject to the terms and conditions of the applicable open source software licenses that grant us permission to use such software. The owner of any such proprietary information or technology also might not enforce or otherwise protect its rights in the proprietary information or technology with the same vigilance that we would, which would allow competitors to use such proprietary information and technology without having to adhere to a license agreement with the owner.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent our intellectual property or other proprietary information protection is incomplete, we are exposed to a greater risk of direct competition. A third party could, without authorization, copy or otherwise obtain and use our products or technology, or develop similar technology. Our competitors could purchase our products and attempt to replicate some or all of the competitive advantages we derive from our development efforts or design around our protected technology. Our failure to secure, protect and enforce our intellectual property rights could substantially harm the value of our products, brand and business. The theft or unauthorized use or publication of our trade secrets and other confidential business information could reduce the differentiation of our products and harm our business, the value of our investment in development or business acquisitions could be reduced and third parties might make claims against us related to losses of their confidential or proprietary information. Any of the foregoing could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, it is possible that others will independently develop the same or similar technology or product or otherwise obtain access to our unpatented technology, and in such cases, we could not assert any trade secret rights against such parties. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our trade secret rights and related confidentiality and nondisclosure provisions. If we fail to obtain or maintain trade secret protection, or if our competitors obtain our trade secrets or independently develop technology or products similar to ours or competing technologies or products, our competitive market position could be materially and adversely affected. In addition, some courts are less willing or unwilling to protect trade secrets and agreement terms that address non-competition are difficult to enforce in many jurisdictions and might not be enforceable in certain cases.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also seek to preserve the integrity and confidentiality of our data and other confidential information by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached and detecting the disclosure or misappropriation of confidential information and enforcing a claim that a party illegally disclosed or misappropriated confidential information is difficult, expensive and time-consuming, and the outcome is unpredictable. Further, we may not be able to obtain adequate remedies for any breach.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non‑compliance with these requirements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees on issued patents often must be paid to the USPTO and foreign patent agencies over the lifetime of the patent. While an unintentional lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non‑compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non‑payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our products, we may not be able to stop a competitor from marketing products that are the same as or similar to our products, which would have a material adverse effect on our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company may attempt to commercialize competing products utilizing our proprietary design, trademarks or tradenames in foreign countries where we do not have any patents or patent applications and where legal recourse may be limited. This may have a significant commercial impact on our foreign business operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents or trademarks on our current and future products in all countries throughout the world would be prohibitively expensive. The requirements for patentability and trademarking may differ in certain countries, particularly developing countries. The laws of some foreign countries do not protect intellectual property rights to the same extent as laws in the United States. Consequently, we may not be able to prevent third parties from utilizing our inventions and trademarks in all countries outside the United States. Competitors may use our technologies or trademarks in jurisdictions where we have not obtained patent or trademark protection to develop or market their own products and further, may export otherwise infringing products to territories where we have patent and trademark protection, but enforcement on infringing activities is inadequate. These products or trademarks may compete with our products or trademarks, and our patents, trademarks or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trademarks and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents and trademarks or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent and trademarks rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents and trademarks at risk of being invalidated or interpreted narrowly and our patent or trademark applications at risk, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, certain countries in Europe and certain developing countries, including India and China, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we may have limited remedies if our patents are infringed or if we are compelled to grant a license to our patents to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license. Finally, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we or our employees have misappropriated the intellectual property of a third party, including trade secrets or know-how, or are in breach of non-competition or non-solicitation agreements with our competitors and third parties may claim an ownership interest in intellectual property we regard as our own.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees and consultants were previously employed at or engaged by other medical device, biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants and contractors, may have executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may be subject to claims that we or these individuals have, inadvertently or otherwise, misappropriated the intellectual property or disclosed the alleged trade secrets or other proprietary information, of these former employers or competitors.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we may be subject to claims from third parties challenging our ownership interest in intellectual property we regard as our own, based on claims that our employees or consultants have breached an obligation to assign inventions to another employer, to a former employer, or to another person or entity. Litigation may be necessary to defend against any other claims, and it may be necessary or we may desire to enter into a license to settle any such claim; however, there can be no assurance that we would be able to obtain a license on commercially reasonable terms, if at all. If our defense to those claims fails, in addition to paying monetary damages, a court could prohibit us from using technologies or features that are essential to our products, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. An inability to incorporate technologies or features that are important or essential to our products could have a material adverse effect on our business, financial condition and results of operations, and may prevent us from selling our products. In addition, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against these claims, litigation could result in substantial costs and could be a distraction to management. Any litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent sales personnel. A loss of key personnel or their work product could hamper or prevent our ability to commercialize our products, which could have an adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our existing and future products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. In 2011, the Leahy-Smith America Invents Act (“Leahy-Smith Act”) was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and also may affect patent litigation. These also include provisions that switched the United States from a first-to-invent system to a first-to-file system, allow third-party submission of prior art to the USPTO during patent prosecution and set forth additional procedures to attack the validity of a patent by the USPTO administered post grant proceedings. Under a first-to-file system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. The USPTO recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective in 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and applications. Furthermore, the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the United States are interpreted. Similarly, foreign courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by U.S. and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The failure of third parties to meet their contractual, regulatory and other obligations could adversely affect our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on suppliers, vendors, outsourcing partners, consultants, alliance partners and other third parties to research, develop, manufacture and commercialize our products and manage certain parts of our business. Using these third parties poses a number of risks, such as: (i) they may not perform to our standards or legal requirements; (ii) they may not produce reliable results; (iii) they may not perform in a timely manner; (iv) they may not maintain confidentiality of our proprietary information; (v) disputes may arise with respect to ownership of rights to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technology developed with our partners; and (vi) disagreements could cause delays in, or termination of, the research, development or commercialization of our products or result in litigation or arbitration. Moreover, some third parties are located in markets subject to political and social risk, corruption, infrastructure problems and natural disasters, in addition to country-specific privacy and data security risk given current legal and regulatory environments. Failure of third parties to meet their contractual, regulatory and other obligations may materially affect our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and tradenames are not adequately protected, then we may not be able to build name recognition in our markets and our business may be adversely affected.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on trademarks, service marks, tradenames and brand names to distinguish our products from the products of our competitors and have registered or applied to register these trademarks. We have not yet registered certain of our trademarks, including “CHARITE” in Germany, and as a result we sell certain products using names that may not be protected or may be subject to third party challenges for infringement of such third party’s trademarks. We cannot assure you that our trademark applications will be approved. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in proceedings before the USPTO and comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources towards advertising and marketing new brands. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. Certain of our current or future trademarks may become so well known by the public that their use becomes generic and they lose trademark protection. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business, financial condition and results of operations may be adversely affected.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may not be able to protect our competitive position for an adequate period of time with respect to our current or future technologies.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, the standard patent term is typically 20 years after filing. Various extensions may be available. Even so, the life of a patent and the protection it affords are limited. As a result, our patent portfolio provides us with limited rights that may not last for a sufficient period of time to exclude others from commercializing products similar or identical to ours. For example, given the large amount of time required for the research, development, testing and regulatory review of implantable medical devices, patents protecting our products might expire before or shortly after they are commercialized.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Extensions of patent term may be available, but there is no guarantee that we would succeed in obtaining any particular extension-and no guarantee any such extension would confer patent term for a sufficient period of time to exclude others from commercializing products similar or identical to ours. In the United States, 35 U.S. Code § 156 Extension of patent term, permits a patent term extension of up to five years beyond the normal expiration of the patent, which is limited to the approved indication (or any additional indications approved during the period of extension). A patent term extension cannot extend the remaining term of a patent beyond 14 years from the date of product approval; only one patent may be extended; and extension is available for only those claims covering the approved device, a method for using it, or a method for manufacturing it. We have applied for such an extension however, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to any patents we obtain, or may grant more limited extensions than we request. An extension may not be granted or may be limited where there is, for example, a failure to exercise due diligence during the testing phase or regulatory review process, failure to apply within applicable deadlines, failure to apply before expiration of relevant patents, or some other failure to satisfy applicable requirements. If this occurs, our competitors may be able to launch their products earlier by taking advantage of our investment in development and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trials along with our clinical and pre-clinical data. This could have a material adverse effect on our business and ability to achieve profitability.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price may be volatile and the value of our common stock may decline.*</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock may be highly volatile and may fluctuate or decline substantially as a result of a variety of factors, some of which are beyond our control or are related in complex ways, including:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated fluctuations in our financial condition and results of operations;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variance in our financial performance from expectations of securities analysts or investors;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the degree to which securities or industry analysts publish research or reports about our business;</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the pricing we offer our customers;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our projected operating and financial results;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in laws or regulations applicable to our solution; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant business developments, acquisitions, or new offerings; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publicity associated with issues related to our solution; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our involvement in litigation;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future sales of our common stock or other securities, by us or our stockholders, as well as the anticipation of lock-up releases;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in senior management or key personnel;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the trading volume of our common stock;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the anticipated future size and growth rate of our market; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, regulatory, and market conditions, including inflation, rising interest rates, economic recessions or economic slowdowns;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning our intellectual property or other proprietary rights.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the trading prices for common stock of other medical device companies have been highly volatile as a result of the COVID-19 pandemic. The COVID-19 pandemic has had a material adverse impact on our business, financial condition and results of operations, and may continue to impact us in the future. The extent to which the pandemic may continue to impact our business, financial condition and results of operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Broad market and industry fluctuations, as well as general economic, political, regulatory, and market conditions, may negatively impact the market price of our common stock. In addition, given the relatively small expected public float of shares of our common stock on the Nasdaq Global Select Market, the trading market for our shares may be </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject to increased volatility. In the past, companies that have experienced volatility in the market price of their securities have been subject to securities class action litigation. We may be the target of this type of litigation in the future, which could result in substantial costs and divert our management’s attention.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales and issuances of our capital stock or rights to purchase capital stock could result in additional dilution of the percentage ownership of our stockholders and could cause the price of our common stock to decline.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future sales and issuances of our capital stock or rights to purchase our capital stock could result in substantial dilution to our existing stockholders. We may sell common stock, convertible securities, and other equity securities in one or more transactions at prices and in a manner as we may determine from time to time. If we sell any such securities in subsequent transactions, investors may be materially diluted. New investors in such subsequent transactions could gain rights, preferences, and privileges senior to those of holders of our common stock.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales of our common stock by existing stockholders could cause the market price of our common stock to decline.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock by existing stockholders in the public market, or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that such sales may have on the prevailing market price of our common stock.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, we had outstanding 37,266,030 shares of common stock. All of our outstanding shares are eligible for sale in the public market, other than shares and options held by directors, executive officers, and other affiliates that are subject to volume limitations under Rule 144 of the Securities Act, and various vesting agreements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, as of June 30, 2022, holders of a substantial number of shares had rights, subject to certain conditions, to require us to file registration statements for the public resale of the common stock or to include such shares in registration statements that we may file on our behalf or for other stockholders.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of ownership of our common stock among our executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive officers, directors and current beneficial owners of 5% or more of our common stock beneficially own approximately 56.4% of our outstanding common stock as of June 30, 2022. These stockholders, acting together, will be able to significantly influence all matters requiring stockholder approval, including the election and removal of directors and any merger or other significant corporate transactions. The interests of this group of stockholders may not coincide with the interests of other stockholders.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of these persons or entities may have interests different than yours. For example, because many of these stockholders purchased their shares at prices substantially below the price at which shares are currently being sold and have held their shares for a longer period, they may be more interested in selling our company to an acquirer than other investors, or they may want us to pursue strategies that deviate from the interests of other stockholders. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends for the foreseeable future and, as a result, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividends on our capital stock, and we do not intend to pay any cash dividends in the foreseeable future. Any determination to pay dividends in the future will be at the discretion of our board of directors and may be restricted by the terms of any then-current credit facility. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any future gains on their investments.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently a “smaller reporting company” and our compliance with the scaled reporting and disclosure requirements applicable to smaller reporting companies could make our common stock less attractive to investors.*</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a “smaller reporting company” as defined by Rule 12b-2 of the Exchange Act. As a result, we may take advantage of certain scaled disclosures available to smaller reporting companies, and we may take advantage of these scaled disclosures for so long as (i) our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred, and will continue to incur, increased costs as a public company, and our management has devoted, and will continue to devote, substantial time to compliance with our public company responsibilities and corporate governance practices.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we incur significant legal, accounting, and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Global Select Market, and other applicable securities rules and regulations impose various requirements on public companies. Furthermore, the senior members of our management team do not have significant experience with operating a public company. As a result, our management and other personnel have devoted, and continue to devote, a substantial amount of time to compliance with these requirements. Moreover, compliance with these rules and regulations increase our legal and financial costs and make some activities more time-consuming and costly.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have identified a material weakness in our internal controls over financial reporting, and if we are unable to remediate such material weakness and maintain an effective system of internal controls in the future, we may fail to timely and accurately report our financial results, experience a loss of investor confidence in the accuracy and completeness of our consolidated financial statements, incur material misstatements in our consolidated financial statements, and the market price of our common stock may be adversely affected.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to maintain internal control over financial reporting and to report any material weaknesses in those internal controls. For example, we are required to perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act (“Section 404”). Our independent registered public accounting firm also needs to attest to the effectiveness of our internal control over financial reporting. We designed, implemented, and tested internal control over financial reporting required to comply with this obligation. The process of compiling the system and processing documentation necessary to perform the evaluation required under Section 404 is costly and challenging, and, in the future, we may not be able to complete our evaluation, testing, and any required remediation in a timely fashion. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified a material weakness in our internal control over financial reporting for the year ended December 31, 2021, which remains unremediated as of June 30, 2022. We determined a material weakness existed relating to ineffective information technology general controls in the areas of user access and segregation of duties related to certain information technology systems that support our financial reporting process specifically related to expenditures. Although these control weaknesses did not result in any material misstatement of our consolidated financial statements for the periods presented, they could lead to a material misstatement of account balances or disclosures. Accordingly, our management has concluded that these control weaknesses constitute a material weakness. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, under the oversight of our Audit Committee of our Board of Directors and in consultation with outside advisors continue to evaluate and implement measures designed to ensure that control deficiencies contributing to the material weakness are remediated, such that these controls are designed, implemented, and operating effectively. These remediation actions are ongoing and include, but are not limited to: (i) evaluating and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">implementing enhanced process controls around user access management; and (ii) expanding the management and governance over user access and system controls. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the above actions will be effective in remediating the material weakness and we will continue to devote time and attention to these remedial efforts. However, as we continue to evaluate and take actions to improve our internal control over financial reporting, we may take additional actions to address control deficiencies or modify certain of the remediation measures described above. Our remediation efforts will not be considered complete until the applicable controls operate for a sufficient period of time and our management has concluded, through testing, that these controls are operating effectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to remediate the material weakness timely and sufficiently or if we identify future material weaknesses in our internal control over financial reporting or are unable to comply with the requirements of Section 404 in a timely manner or assert that our internal control over financial reporting is effective, or if our independent registered public accounting firm is unable to express an opinion or expresses a qualified or adverse opinion about the effectiveness of our internal control over financial reporting, we may experience a loss of investor confidence in the accuracy and completeness of our consolidated financial statements, incur material misstatements in our consolidated financial statements, incur difficulty accessing capital on favorable terms, or at all, be subject to fines, penalties or judgments, incur reputational harm, and the market price of our common stock may be adversely affected. In addition, we could become subject to investigations by the stock exchange on which our securities are listed, the SEC, and other regulatory authorities, which could require additional financial and management resources and materially and adversely affect our business, results of operations and financial condition.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of our company more difficult, limit attempts by our stockholders to replace or remove our current management and limit the market price of our common stock.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws currently in effect may have the effect of delaying or preventing a change of control or changes in our management. Our amended and restated certificate of incorporation and amended and restated bylaws include provisions that:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize our board of directors to issue, without further action by the stockholders, shares of undesignated preferred stock with terms, rights, and preferences determined by our board of directors that may be senior to our common stock; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">specify that special meetings of our stockholders can be called only by our board of directors, the chairperson of our board of directors, or our chief executive officer;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish an advance notice procedure for stockholder proposals to be brought before an annual meeting, including proposed nominations of persons for election to our board of directors;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish that our board of directors is divided into a number of classes, with each class serving staggered terms;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibit cumulative voting in the election of directors;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that our directors may be removed for cause only upon the vote of the holders of a majority of our outstanding shares of common stock;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum; and</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the approval of our board of directors or the holders of at least a majority of our outstanding shares of common stock to amend our bylaws and certain provisions of our certificate of incorporation.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which generally, subject to certain exceptions, prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder. Any delay or prevention of a change of control transaction or changes in our management could cause the market price of our common stock to decline.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and, to the extent enforceable, the federal district courts of the United States are the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.*</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) is the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law for:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any derivative action or proceeding brought on our behalf; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a breach of fiduciary duty; </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim against us arising under the Delaware General Corporation Law;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our amended and restated certificate of incorporation or our amended and restated bylaws; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim against us that is governed by the internal-affairs doctrine.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions do not apply to suits brought to enforce a duty or liability created by the Exchange Act or any claim for which the federal district courts of the United States have exclusive jurisdiction. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such actions under the Securities Act and an investor cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Accordingly, both state and federal courts have jurisdiction to entertain such claims and there is uncertainty as to whether a court would enforce such a forum selection provision as written in connection with claims arising under the Securities Act. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation further provides that the federal district courts of the United States are the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our amended and restated certificate of incorporation described above. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Delaware courts have determined that such choice of forum provisions are facially valid and several state trial courts have enforced such provisions and required that suits asserting Securities Act claims be filed in federal court, there is no guarantee that courts of appeal will affirm the enforceability of such provisions and a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These exclusive-forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If any court were to find either exclusive-forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business.</span></div><div id="i784ba2f3210d43dcbb23721a3c553397_130"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Securities and Use of Proceeds</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no sales of unregistered securities during the six months ended June 30, 2022.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Proceeds</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2020, our registration statement on Form S-1 (File No. 333-248635) relating to our initial public offering (“IPO”) of common stock became effective. There has been no material change in our planned use of the net proceeds from our IPO as described in our final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act with the SEC on October 1, 2020.</span></div><div id="i784ba2f3210d43dcbb23721a3c553397_133"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i784ba2f3210d43dcbb23721a3c553397_136"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i784ba2f3210d43dcbb23721a3c553397_139"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other information</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i784ba2f3210d43dcbb23721a3c553397_142"></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Schedule Form</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File Number</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed Herewith</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.1</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1127537/000162828020014280/exhibit31-8xkxformofam.htm">Amended and Restated Certificate of Incorporation of Pulmonx Corporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">001-39562</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.1</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">October 5, 2020</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1127537/000162828020013874/exhibit34-sx1a1xformof.htm">Amended and Restated Bylaws of Pulmonx Corporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">S-1/A</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">333-248635</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.4</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">September 24, 2020</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.1</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1127537/000162828020013874/exhibit41-sx1a1stockce.htm">Form of common stock certificate of Pulmonx Corporation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">S-1/A</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">333-248635</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.1</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">September 24, 2020</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.2</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1127537/000162828020013340/exhibit42s-1xamendedan.htm">Amended and Restated Investors’ Rights Agreement by and among Pulmonx Corporation and certain of its stockholders, dated April 16, 2019</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">S-1/A</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">333-248635</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.2</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">September 24, 2020</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31.1</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit31_1x080822.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31.2</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit31_2x080822.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32.1*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit32_1x080822.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32.2*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit32_2x080822.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">___________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">+ Indicates management contract or compensatory plan.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*     The certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, irrespective of any general incorporation language continued in such filing.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><div id="i784ba2f3210d43dcbb23721a3c553397_145"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in Redwood City, State of California, on the 8th day of August, 2022.</span></div><div style="margin-bottom:12pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.878%"><tr><td style="width:1.0%"></td><td style="width:8.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PULMONX CORPORATION</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/Glendon E. French</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glendon E. French</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.878%"><tr><td style="width:1.0%"></td><td style="width:8.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.392%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/Derrick Sung</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derrick Sung, Ph.D.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</span></div></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit31_1x080822.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic5c24a130f324a7fa0d8fb33d0a13602_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Glendon E. French, certify that:</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.    I have reviewed this Quarterly Report on Form 10-Q of Pulmonx Corporation;</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.    The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:49.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="margin-top:12pt;padding-left:49.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></div><div style="margin-top:12pt;padding-left:49.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)    Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="margin-top:12pt;padding-left:49.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)    Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.    The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font><br></font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.883%"><tr><td style="width:1.0%"></td><td style="width:44.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.288%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: August 8, 2022</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By:</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Glendon E. French</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Glendon E. French</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">President, Chief Executive Officer and Director</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit31_2x080822.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i733021ec43f743aaab2102117e57d96b_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Derrick Sung, certify that:</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.    I have reviewed this Quarterly Report on Form 10-Q of Pulmonx Corporation;</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.    The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:49.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="padding-left:49.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b)    </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font></div><div style="margin-top:12pt;padding-left:49.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)    Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="margin-top:12pt;padding-left:49.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)    Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.    The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font><br></font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.714%"><tr><td style="width:1.0%"></td><td style="width:43.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: August 8, 2022</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By:</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Derrick Sung</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Derrick Sung, Ph.D.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit32_1x080822.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1be42b5ee49542ca87b066ec909d064c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Pulmonx Corporation (the “Company”) for the quarterly period ended June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Glendon E. French, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)    The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:44.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: August 8, 2022</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By:</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Glendon E. French</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Glendon E. French</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">President, Chief Executive Officer and Director</font></td></tr></table></div><div><font><br></font></div><div style="margin-top:12pt;text-indent:27.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Pulmonx Corporation under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit32_2x080822.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i5a97b6ec1d0549dd857dbd1b66cfad34_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Pulmonx Corporation (the “Company”) for the quarterly period ended June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Derrick Sung, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)    The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:44.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: August 8, 2022</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By:</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Derrick Sung</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Derrick Sung, Ph.D.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="margin-top:12pt;text-indent:27.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Pulmonx Corporation under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>lung-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e27afbe0-c876-445c-ac79-0e3a22d99ad7,g:11f7fccd-ac30-49f3-b9c8-08334e4a7c01-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lung="http://www.pulmonx.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.pulmonx.com/20220630">
<xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
<xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
<xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
<xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
<xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
<xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
<xs:annotation>
<xs:appinfo>
<link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lung-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lung-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lung-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lung-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:roleType id="CoverPage" roleURI="http://www.pulmonx.com/role/CoverPage">
<link:definition>0001001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets">
<link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
<link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
<link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
<link:definition>1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows">
<link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="FormationandBusinessoftheCompany" roleURI="http://www.pulmonx.com/role/FormationandBusinessoftheCompany">
<link:definition>2101101 - Disclosure - Formation and Business of the Company</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="FormationandBusinessoftheCompanyDetails" roleURI="http://www.pulmonx.com/role/FormationandBusinessoftheCompanyDetails">
<link:definition>2402401 - Disclosure - Formation and Business of the Company (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.pulmonx.com/role/SummaryofSignificantAccountingPolicies">
<link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesPolicies">
<link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesDetails">
<link:definition>2405402 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="RecentAccountingPronouncements" roleURI="http://www.pulmonx.com/role/RecentAccountingPronouncements">
<link:definition>2106103 - Disclosure - Recent Accounting Pronouncements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="FairValueMeasurements" roleURI="http://www.pulmonx.com/role/FairValueMeasurements">
<link:definition>2107104 - Disclosure - Fair Value Measurements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="FairValueMeasurementsTables" roleURI="http://www.pulmonx.com/role/FairValueMeasurementsTables">
<link:definition>2308301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" roleURI="http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails">
<link:definition>2409403 - Disclosure - Fair Value Measurements - Fair Value of Assets and Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails" roleURI="http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails">
<link:definition>2410404 - Disclosure - Fair Value Measurements - Unrealized Gains and Losses and Fair Value (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.pulmonx.com/role/FairValueMeasurementsNarrativeDetails">
<link:definition>2411405 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="BalanceSheetComponents" roleURI="http://www.pulmonx.com/role/BalanceSheetComponents">
<link:definition>2112105 - Disclosure - Balance Sheet Components</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="BalanceSheetComponentsTables" roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsTables">
<link:definition>2313302 - Disclosure - Balance Sheet Components (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="BalanceSheetComponentsCashandCashEquivalentsDetails" roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsCashandCashEquivalentsDetails">
<link:definition>2414406 - Disclosure - Balance Sheet Components - Cash and Cash Equivalents (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="BalanceSheetComponentsInventoryDetails" roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsInventoryDetails">
<link:definition>2415407 - Disclosure - Balance Sheet Components - Inventory (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails">
<link:definition>2416408 - Disclosure - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="BalanceSheetComponentsPropertyandEquipmentNetDetails" roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails">
<link:definition>2417409 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="BalanceSheetComponentsCapitalizedImplementationCostsofaHostingArrangementDetails" roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsCapitalizedImplementationCostsofaHostingArrangementDetails">
<link:definition>2418410 - Disclosure - Balance Sheet Components - Capitalized Implementation Costs of a Hosting Arrangement (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="BalanceSheetComponentsNarrativeDetails" roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsNarrativeDetails">
<link:definition>2419411 - Disclosure - Balance Sheet Components - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="BalanceSheetComponentsIntangibleAssetsDetails" roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsIntangibleAssetsDetails">
<link:definition>2420412 - Disclosure - Balance Sheet Components - Intangible Assets (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="BalanceSheetComponentsFutureAmortizationExpenseDetails" roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsFutureAmortizationExpenseDetails">
<link:definition>2421413 - Disclosure - Balance Sheet Components - Future Amortization Expense (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="BalanceSheetComponentsAccruedLiabilitiesDetails" roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails">
<link:definition>2422414 - Disclosure - Balance Sheet Components - Accrued Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="LongTermDebtandConvertibleNotes" roleURI="http://www.pulmonx.com/role/LongTermDebtandConvertibleNotes">
<link:definition>2123106 - Disclosure - Long Term Debt and Convertible Notes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="LongTermDebtandConvertibleNotesTables" roleURI="http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesTables">
<link:definition>2324303 - Disclosure - Long Term Debt and Convertible Notes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails" roleURI="http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails">
<link:definition>2425415 - Disclosure - Long Term Debt and Convertible Notes - CIBC Loan Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="LongTermDebtandConvertibleNotesCIBCLoanComponentsOfDebtDetails" roleURI="http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanComponentsOfDebtDetails">
<link:definition>2426416 - Disclosure - Long Term Debt and Convertible Notes - CIBC Loan Components Of Debt (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="LongTermDebtandConvertibleNotesCreditAgreementandPaycheckProtectionProgramNarrativeDetails" roleURI="http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCreditAgreementandPaycheckProtectionProgramNarrativeDetails">
<link:definition>2427417 - Disclosure - Long Term Debt and Convertible Notes - Credit Agreement and Paycheck Protection Program Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="LongTermDebtandConvertibleNotesContractualMaturitiesofFinancingObligationsDetails" roleURI="http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesContractualMaturitiesofFinancingObligationsDetails">
<link:definition>2428418 - Disclosure - Long Term Debt and Convertible Notes - Contractual Maturities of Financing Obligations (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="RevenueRecognition" roleURI="http://www.pulmonx.com/role/RevenueRecognition">
<link:definition>2129107 - Disclosure - Revenue Recognition</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="RevenueRecognitionDetails" roleURI="http://www.pulmonx.com/role/RevenueRecognitionDetails">
<link:definition>2430419 - Disclosure - Revenue Recognition (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CommitmentsandContingencies" roleURI="http://www.pulmonx.com/role/CommitmentsandContingencies">
<link:definition>2131108 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.pulmonx.com/role/CommitmentsandContingenciesTables">
<link:definition>2332304 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CommitmentsandContingenciesLeasesNarrativeDetails" roleURI="http://www.pulmonx.com/role/CommitmentsandContingenciesLeasesNarrativeDetails">
<link:definition>2433420 - Disclosure - Commitments and Contingencies - Leases, Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CommitmentsandContingenciesLeaseCostDetails" roleURI="http://www.pulmonx.com/role/CommitmentsandContingenciesLeaseCostDetails">
<link:definition>2434421 - Disclosure - Commitments and Contingencies - Lease Cost (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails" roleURI="http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails">
<link:definition>2435422 - Disclosure - Commitments and Contingencies - Maturity Analysis of Lease Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails_1" roleURI="http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails_1">
<link:definition>2435422 - Disclosure - Commitments and Contingencies - Maturity Analysis of Lease Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.pulmonx.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
<link:definition>2436423 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CommitmentsandContingenciesOtherSupplementalInformationDetails" roleURI="http://www.pulmonx.com/role/CommitmentsandContingenciesOtherSupplementalInformationDetails">
<link:definition>2437424 - Disclosure - Commitments and Contingencies - Other Supplemental Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CommitmentsandContingenciesServiceAgreementDetails" roleURI="http://www.pulmonx.com/role/CommitmentsandContingenciesServiceAgreementDetails">
<link:definition>2438425 - Disclosure - Commitments and Contingencies - Service Agreement (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="IncomeTaxes" roleURI="http://www.pulmonx.com/role/IncomeTaxes">
<link:definition>2139109 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="IncomeTaxesDetails" roleURI="http://www.pulmonx.com/role/IncomeTaxesDetails">
<link:definition>2440426 - Disclosure - Income Taxes (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockholdersEquity" roleURI="http://www.pulmonx.com/role/StockholdersEquity">
<link:definition>2141110 - Disclosure - Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockholdersEquityTables" roleURI="http://www.pulmonx.com/role/StockholdersEquityTables">
<link:definition>2342305 - Disclosure - Stockholders' Equity (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails">
<link:definition>2443427 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockholdersEquitySharesReservedforFutureIssuanceDetails" roleURI="http://www.pulmonx.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails">
<link:definition>2444428 - Disclosure - Stockholders' Equity - Shares Reserved for Future Issuance (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockholdersEquityStockOptionActivityDetails" roleURI="http://www.pulmonx.com/role/StockholdersEquityStockOptionActivityDetails">
<link:definition>2445429 - Disclosure - Stockholders' Equity - Stock Option Activity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockholdersEquityOptionsVestedandExpectedtoVestDetails" roleURI="http://www.pulmonx.com/role/StockholdersEquityOptionsVestedandExpectedtoVestDetails">
<link:definition>2446430 - Disclosure - Stockholders' Equity - Options Vested and Expected to Vest (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockholdersEquityRestrictedStockUnitActivityDetails" roleURI="http://www.pulmonx.com/role/StockholdersEquityRestrictedStockUnitActivityDetails">
<link:definition>2447431 - Disclosure - Stockholders' Equity - Restricted Stock Unit Activity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockholdersEquityTotalStockBasedCompensationDetails" roleURI="http://www.pulmonx.com/role/StockholdersEquityTotalStockBasedCompensationDetails">
<link:definition>2448432 - Disclosure - Stockholders' Equity - Total Stock-Based Compensation (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="NetLossperShareAttributabletoCommonStockholders" roleURI="http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholders">
<link:definition>2149111 - Disclosure - Net Loss per Share Attributable to Common Stockholders</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="NetLossperShareAttributabletoCommonStockholdersTables" roleURI="http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersTables">
<link:definition>2350306 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="NetLossperShareAttributabletoCommonStockholdersComputationofBasicandDilutedNetLossperShareDetails" roleURI="http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersComputationofBasicandDilutedNetLossperShareDetails">
<link:definition>2451433 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="NetLossperShareAttributabletoCommonStockholdersExcludedPotentiallyDilutiveSecuritiesOutstandingDetails" roleURI="http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersExcludedPotentiallyDilutiveSecuritiesOutstandingDetails">
<link:definition>2452434 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Excluded Potentially Dilutive Securities Outstanding (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="SegmentInformation" roleURI="http://www.pulmonx.com/role/SegmentInformation">
<link:definition>2153112 - Disclosure - Segment Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="SegmentInformationTables" roleURI="http://www.pulmonx.com/role/SegmentInformationTables">
<link:definition>2354307 - Disclosure - Segment Information (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="SegmentInformationNarrativeDetails" roleURI="http://www.pulmonx.com/role/SegmentInformationNarrativeDetails">
<link:definition>2455435 - Disclosure - Segment Information - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="SegmentInformationRevenuebyGeographicAreaDetails" roleURI="http://www.pulmonx.com/role/SegmentInformationRevenuebyGeographicAreaDetails">
<link:definition>2456436 - Disclosure - Segment Information - Revenue by Geographic Area (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="SegmentInformationLongLivedAssetsbyGeographicalAreaDetails" roleURI="http://www.pulmonx.com/role/SegmentInformationLongLivedAssetsbyGeographicalAreaDetails">
<link:definition>2457437 - Disclosure - Segment Information - Long-Lived Assets by Geographical Area (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
</xs:appinfo>
</xs:annotation>
<xs:element id="lung_OperatingLeaseMonthlyExpense" abstract="false" name="OperatingLeaseMonthlyExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="lung_CashCashEquivalentsAndAvailableForSaleDebtSecurities" abstract="false" name="CashCashEquivalentsAndAvailableForSaleDebtSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="lung_FairValueRecognizedOnBalanceSheetAbstract" abstract="true" name="FairValueRecognizedOnBalanceSheetAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
<xs:element id="lung_NumberOfVehicleLeases" abstract="false" name="NumberOfVehicleLeases" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
<xs:element id="lung_ServiceAgreementPurchaseMember" abstract="true" name="ServiceAgreementPurchaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
<xs:element id="lung_ShareBasedPaymentArrangementSharesSubjectToRepurchase" abstract="false" name="ShareBasedPaymentArrangementSharesSubjectToRepurchase" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
<xs:element id="lung_LesseeOperatingSubleaseRenewalTerm" abstract="false" name="LesseeOperatingSubleaseRenewalTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
<xs:element id="lung_StockOptionsAndRestrictedStockUnitsMember" abstract="true" name="StockOptionsAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
<xs:element id="lung_CIBCAgreementTrancheCMember" abstract="true" name="CIBCAgreementTrancheCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
<xs:element id="lung_DebtInstrumentCovenantUnrestrictedCashRequirementPeriod" abstract="false" name="DebtInstrumentCovenantUnrestrictedCashRequirementPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePriceAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePriceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
<xs:element id="lung_CostOfGoodsAndServicesSoldMember" abstract="true" name="CostOfGoodsAndServicesSoldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
<xs:element id="lung_LesseeOperatingSubleaseExpenseAnnualIncreaseRate" abstract="false" name="LesseeOperatingSubleaseExpenseAnnualIncreaseRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
<xs:element id="lung_TenantImprovementAllowanceReceivableUponLeaseRenewal" abstract="false" name="TenantImprovementAllowanceReceivableUponLeaseRenewal" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="lung_InventoryNetMember" abstract="true" name="InventoryNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
<xs:element id="lung_NumberOfInstallmentsForRepayment" abstract="false" name="NumberOfInstallmentsForRepayment" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
<xs:element id="lung_IncomeTaxDisclosureTable" abstract="true" name="IncomeTaxDisclosureTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
<xs:element id="lung_NumberOfVotesForEachShareOfCommonStockHeld" abstract="false" name="NumberOfVotesForEachShareOfCommonStockHeld" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
<xs:element id="lung_ShareBasedCompensationUnvestedEarlyExercisedOptionsMember" abstract="true" name="ShareBasedCompensationUnvestedEarlyExercisedOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
<xs:element id="lung_DebtInstrumentCovenantCashAndCashEquivalentsMinimumThresholdTriggerForRevenueRequirement" abstract="false" name="DebtInstrumentCovenantCashAndCashEquivalentsMinimumThresholdTriggerForRevenueRequirement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="lung_ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice" abstract="false" name="ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="lung_IncreaseLapseInRepurchaseOfCommonStockRights" abstract="false" name="IncreaseLapseInRepurchaseOfCommonStockRights" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="lung_DebtInstrumentFaceAmountIncludingAccordionFeature" abstract="false" name="DebtInstrumentFaceAmountIncludingAccordionFeature" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="lung_CashAndCashEquivalentsAndMarketableSecurities" abstract="false" name="CashAndCashEquivalentsAndMarketableSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="lung_ShareBasedCompensationEmployeeStockAvailableForGrantMember" abstract="true" name="ShareBasedCompensationEmployeeStockAvailableForGrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
<xs:element id="lung_DebtInstrumentPeriodicPaymentInterestOnlyTerm" abstract="false" name="DebtInstrumentPeriodicPaymentInterestOnlyTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
<xs:element id="lung_ShareBasedCompensationEmployeeStockOutstandingMember" abstract="true" name="ShareBasedCompensationEmployeeStockOutstandingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
<xs:element id="lung_CorporateBondsDebtSecuritiesAtCarryingValue" abstract="false" name="CorporateBondsDebtSecuritiesAtCarryingValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="lung_AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="lung_LesseeOperatingSubleaseOptionToTerminateNoticePeriod" abstract="false" name="LesseeOperatingSubleaseOptionToTerminateNoticePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="lung_CommonStockRestrictedStockUnitsIssuedAndOutstandingMember" abstract="true" name="CommonStockRestrictedStockUnitsIssuedAndOutstandingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
<xs:element id="lung_DebtInstrumentCovenantMinimumRevenueRequirementPeriod" abstract="false" name="DebtInstrumentCovenantMinimumRevenueRequirementPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="lung_IncreaseInLoanInterestRate" abstract="false" name="IncreaseInLoanInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
<xs:element id="lung_ReceivableFromExerciseOfCommonStockOptions" abstract="false" name="ReceivableFromExerciseOfCommonStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="lung_OtherInternationalGeographicalAreasMember" abstract="true" name="OtherInternationalGeographicalAreasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
<xs:element id="lung_LesseeOperatingLeaseOptionToTerminateNoticePeriod" abstract="false" name="LesseeOperatingLeaseOptionToTerminateNoticePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="lung_AccruedInventoryPurchasesCurrent" abstract="false" name="AccruedInventoryPurchasesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="lung_CIBCAgreementMember" abstract="true" name="CIBCAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
<xs:element id="lung_PulmonxInternationalSarlMember" abstract="true" name="PulmonxInternationalSarlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
<xs:element id="lung_HostingArrangementServiceContractImplementationCostCapitalizedAmortizationPeriod" abstract="false" name="HostingArrangementServiceContractImplementationCostCapitalizedAmortizationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="lung_LesseeOperatingSubleaseTenantImprovementAllowanceReceivableUponLeaseRenewal" abstract="false" name="LesseeOperatingSubleaseTenantImprovementAllowanceReceivableUponLeaseRenewal" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="lung_CIBCAgreementTrancheAMember" abstract="true" name="CIBCAgreementTrancheAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
<xs:element id="lung_DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm" abstract="false" name="DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="lung_DebtInstrumentAccordionFeatureIncreaseFaceAmount" abstract="false" name="DebtInstrumentAccordionFeatureIncreaseFaceAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="lung_LesseeOperatingSubleaseOptionToTerminateTerm" abstract="false" name="LesseeOperatingSubleaseOptionToTerminateTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="lung_DebtInstrumentNumberOfPeriodicPayments" abstract="false" name="DebtInstrumentNumberOfPeriodicPayments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
<xs:element id="lung_LesseeOperatingSubleaseTerm" abstract="false" name="LesseeOperatingSubleaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="lung_GainLossOnAmendmentOfDebtInstrument" abstract="false" name="GainLossOnAmendmentOfDebtInstrument" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="lung_IncomeTaxDisclosureLineItems" abstract="true" name="IncomeTaxDisclosureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
<xs:element id="lung_CIBCAgreementTrancheBMember" abstract="true" name="CIBCAgreementTrancheBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
<xs:element id="lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
<xs:element id="lung_DebtInstrumentCovenantMinimumRevenueRequirementsPercentage" abstract="false" name="DebtInstrumentCovenantMinimumRevenueRequirementsPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
<xs:element id="lung_OperatingLeaseExpenseAnnualIncreaseRate" abstract="false" name="OperatingLeaseExpenseAnnualIncreaseRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
<xs:element id="lung_StockRepurchasedDuringPeriodExerciseOfEarlyStockOptionsShares" abstract="false" name="StockRepurchasedDuringPeriodExerciseOfEarlyStockOptionsShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
<xs:element id="lung_LesseeOperatingSubleaseMonthlyExpense" abstract="false" name="LesseeOperatingSubleaseMonthlyExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="lung_COVID19CreditAgreementMember" abstract="true" name="COVID19CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>lung-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e27afbe0-c876-445c-ac79-0e3a22d99ad7,g:11f7fccd-ac30-49f3-b9c8-08334e4a7c01-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="lung-20220630.xsd#CondensedConsolidatedBalanceSheets"/>
<link:calculationLink xlink:role="http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a3970630-ff61-45e7-a619-57fe3d24a3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_11eddb07-35bb-420a-b06b-dd68468f5f13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a3970630-ff61-45e7-a619-57fe3d24a3c3" xlink:to="loc_us-gaap_StockholdersEquity_11eddb07-35bb-420a-b06b-dd68468f5f13" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ad58af27-55cf-47a5-a908-214f7f07f056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a3970630-ff61-45e7-a619-57fe3d24a3c3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ad58af27-55cf-47a5-a908-214f7f07f056" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c892f65c-73ee-4603-85d3-41b0f8be1465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a3970630-ff61-45e7-a619-57fe3d24a3c3" xlink:to="loc_us-gaap_Liabilities_c892f65c-73ee-4603-85d3-41b0f8be1465" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fad93d13-d8e2-4542-8f0f-8e08e0e433ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_69f38042-e40f-4bb6-a10d-67d522e7b612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fad93d13-d8e2-4542-8f0f-8e08e0e433ff" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_69f38042-e40f-4bb6-a10d-67d522e7b612" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_42a9104d-e306-49e4-a4db-b7cc69d17c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fad93d13-d8e2-4542-8f0f-8e08e0e433ff" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_42a9104d-e306-49e4-a4db-b7cc69d17c0f" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_07c94ad5-c92e-4a45-9e01-ba35c4eff06a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fad93d13-d8e2-4542-8f0f-8e08e0e433ff" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_07c94ad5-c92e-4a45-9e01-ba35c4eff06a" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5cefae79-044e-4a88-8edb-b5c156c96ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fad93d13-d8e2-4542-8f0f-8e08e0e433ff" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5cefae79-044e-4a88-8edb-b5c156c96ecb" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_f55bc73a-87c4-4b6a-a37a-de073c1e803f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fad93d13-d8e2-4542-8f0f-8e08e0e433ff" xlink:to="loc_us-gaap_RestrictedCash_f55bc73a-87c4-4b6a-a37a-de073c1e803f" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9633d44e-a286-4d95-8791-f45c0e57616a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
<link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fad93d13-d8e2-4542-8f0f-8e08e0e433ff" xlink:to="loc_us-gaap_InventoryNet_9633d44e-a286-4d95-8791-f45c0e57616a" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0e8502e7-3bfc-4cc7-804e-7422811df551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_29b7ae3d-fe86-4a56-91e1-f7880335376d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0e8502e7-3bfc-4cc7-804e-7422811df551" xlink:to="loc_us-gaap_CommonStockValue_29b7ae3d-fe86-4a56-91e1-f7880335376d" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_535dc719-28bb-438f-a3d1-f436a6bf1d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0e8502e7-3bfc-4cc7-804e-7422811df551" xlink:to="loc_us-gaap_PreferredStockValue_535dc719-28bb-438f-a3d1-f436a6bf1d9d" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a242e40f-1af7-4361-8cb7-3ecbf8d4ba83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0e8502e7-3bfc-4cc7-804e-7422811df551" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a242e40f-1af7-4361-8cb7-3ecbf8d4ba83" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bb604a20-0573-4bec-9e40-33f05f85c46c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0e8502e7-3bfc-4cc7-804e-7422811df551" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bb604a20-0573-4bec-9e40-33f05f85c46c" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6e9b1c44-5cd2-413d-aa36-f773ac75819d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0e8502e7-3bfc-4cc7-804e-7422811df551" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6e9b1c44-5cd2-413d-aa36-f773ac75819d" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_aa55c1ec-1fea-48f7-a8c5-0d2f394f4de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e43418c5-6e81-4f87-9265-f1f27bd7c71c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_aa55c1ec-1fea-48f7-a8c5-0d2f394f4de0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e43418c5-6e81-4f87-9265-f1f27bd7c71c" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_83da9fd9-8c2a-4dd7-9cb3-d9f8a5307862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_aa55c1ec-1fea-48f7-a8c5-0d2f394f4de0" xlink:to="loc_us-gaap_Goodwill_83da9fd9-8c2a-4dd7-9cb3-d9f8a5307862" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b12629a9-8be7-42e3-9e7c-8f4e7c17ce93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_aa55c1ec-1fea-48f7-a8c5-0d2f394f4de0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b12629a9-8be7-42e3-9e7c-8f4e7c17ce93" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0b4285ef-d913-4328-be39-445fa8be3f62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_aa55c1ec-1fea-48f7-a8c5-0d2f394f4de0" xlink:to="loc_us-gaap_AssetsCurrent_0b4285ef-d913-4328-be39-445fa8be3f62" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8b17302a-98fd-4d53-a294-d3575348b7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_aa55c1ec-1fea-48f7-a8c5-0d2f394f4de0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8b17302a-98fd-4d53-a294-d3575348b7ab" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f254563c-67c5-4d44-97fa-1774037c5e38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
<link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_aa55c1ec-1fea-48f7-a8c5-0d2f394f4de0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f254563c-67c5-4d44-97fa-1774037c5e38" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_e06fb3ac-d608-4433-8c41-9e476edcb1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
<link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_aa55c1ec-1fea-48f7-a8c5-0d2f394f4de0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_e06fb3ac-d608-4433-8c41-9e476edcb1f1" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_79959337-6668-4524-80f6-07c913cb5a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a33a9890-4def-4d89-8a68-ae11d634b30d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_79959337-6668-4524-80f6-07c913cb5a1f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a33a9890-4def-4d89-8a68-ae11d634b30d" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f9be847d-6421-4e00-9079-0a3940b5fdf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_79959337-6668-4524-80f6-07c913cb5a1f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f9be847d-6421-4e00-9079-0a3940b5fdf4" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9d87489e-e603-44e6-8ed1-54f34ba14c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_79959337-6668-4524-80f6-07c913cb5a1f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9d87489e-e603-44e6-8ed1-54f34ba14c4f" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_048b0bf8-81bf-4232-b410-0eb5133a7648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_79959337-6668-4524-80f6-07c913cb5a1f" xlink:to="loc_us-gaap_ShortTermBorrowings_048b0bf8-81bf-4232-b410-0eb5133a7648" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_41fcf94c-6173-4a85-9f2d-9cefdff0af69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_79959337-6668-4524-80f6-07c913cb5a1f" xlink:to="loc_us-gaap_AccountsPayableCurrent_41fcf94c-6173-4a85-9f2d-9cefdff0af69" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_d7e34fd7-d414-4390-bed7-19557aff37da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
<link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_79959337-6668-4524-80f6-07c913cb5a1f" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_d7e34fd7-d414-4390-bed7-19557aff37da" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f6b683f1-19dd-4fe6-9b6e-8dedd5455307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_5455fef8-3ec2-4b7f-a06b-ea5c8e554c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f6b683f1-19dd-4fe6-9b6e-8dedd5455307" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_5455fef8-3ec2-4b7f-a06b-ea5c8e554c57" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_6eaa5b8d-5c6b-4d77-bfc7-82a7f2e29bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f6b683f1-19dd-4fe6-9b6e-8dedd5455307" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_6eaa5b8d-5c6b-4d77-bfc7-82a7f2e29bcc" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1ac31b52-f242-484a-a633-b3972a174784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f6b683f1-19dd-4fe6-9b6e-8dedd5455307" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1ac31b52-f242-484a-a633-b3972a174784" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_827dff21-00ae-498e-8e59-66852251fa2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f6b683f1-19dd-4fe6-9b6e-8dedd5455307" xlink:to="loc_us-gaap_LiabilitiesCurrent_827dff21-00ae-498e-8e59-66852251fa2c" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3f4fdc9c-cd1a-4f0d-9895-89018a18d31c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f6b683f1-19dd-4fe6-9b6e-8dedd5455307" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3f4fdc9c-cd1a-4f0d-9895-89018a18d31c" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="lung-20220630.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
<link:calculationLink xlink:role="http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_af6bdfa1-41e3-40c8-bb92-96ed0cace5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_876ee1c5-f743-424a-904d-836b135caa64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_af6bdfa1-41e3-40c8-bb92-96ed0cace5c3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_876ee1c5-f743-424a-904d-836b135caa64" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_6ef6e670-f0df-4da2-ab53-07a6a0e89b84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_af6bdfa1-41e3-40c8-bb92-96ed0cace5c3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_6ef6e670-f0df-4da2-ab53-07a6a0e89b84" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7268b105-60d7-48f3-916c-334855dc1822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_401af876-4d3a-4dd9-9b51-c325367d6ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7268b105-60d7-48f3-916c-334855dc1822" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_401af876-4d3a-4dd9-9b51-c325367d6ee5" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ec40cc0f-a25d-43cd-9bc7-73f830ce7296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7268b105-60d7-48f3-916c-334855dc1822" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ec40cc0f-a25d-43cd-9bc7-73f830ce7296" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_45b72195-0458-41f5-870c-271073e70536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4c26f8dc-a23c-4d24-9540-7f2ba322cc09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_45b72195-0458-41f5-870c-271073e70536" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4c26f8dc-a23c-4d24-9540-7f2ba322cc09" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_62e743df-83c8-4f7d-a729-2d30d47d536f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_45b72195-0458-41f5-870c-271073e70536" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_62e743df-83c8-4f7d-a729-2d30d47d536f" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_f25b42db-0eae-4290-90e6-e9d4e3f30cee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a7de6c44-24ab-40fa-8777-d7bed73e9449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_f25b42db-0eae-4290-90e6-e9d4e3f30cee" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a7de6c44-24ab-40fa-8777-d7bed73e9449" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_4f0a9a28-3491-41e1-a5ee-92e4d30d8fee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_f25b42db-0eae-4290-90e6-e9d4e3f30cee" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_4f0a9a28-3491-41e1-a5ee-92e4d30d8fee" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf179f34-3f3f-4dc9-b647-f75dad01ea11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d501ac70-674b-433e-848e-57349a20a225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf179f34-3f3f-4dc9-b647-f75dad01ea11" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_d501ac70-674b-433e-848e-57349a20a225" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9740bb79-13bb-4269-bf9a-ffe7078facc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf179f34-3f3f-4dc9-b647-f75dad01ea11" xlink:to="loc_us-gaap_NetIncomeLoss_9740bb79-13bb-4269-bf9a-ffe7078facc2" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_28ef4cf4-6d93-4cb0-a51f-9e0b985442f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3e5e70b7-65db-42db-bdf4-07e8c6d69cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_28ef4cf4-6d93-4cb0-a51f-9e0b985442f8" xlink:to="loc_us-gaap_OperatingExpenses_3e5e70b7-65db-42db-bdf4-07e8c6d69cc6" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_8c69ef29-22dd-4249-addd-23964f61e609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_28ef4cf4-6d93-4cb0-a51f-9e0b985442f8" xlink:to="loc_us-gaap_GrossProfit_8c69ef29-22dd-4249-addd-23964f61e609" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e050aad7-4530-497e-9101-b8180428e709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0738ddda-920f-48c6-afe6-0f400abd11ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e050aad7-4530-497e-9101-b8180428e709" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0738ddda-920f-48c6-afe6-0f400abd11ba" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_171de8d1-fe37-4fa6-839d-01ea67442150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e050aad7-4530-497e-9101-b8180428e709" xlink:to="loc_us-gaap_InterestExpense_171de8d1-fe37-4fa6-839d-01ea67442150" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0ad94b3d-40f8-414b-812b-f28b54aee699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e050aad7-4530-497e-9101-b8180428e709" xlink:to="loc_us-gaap_OperatingIncomeLoss_0ad94b3d-40f8-414b-812b-f28b54aee699" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_55ec8ce4-4015-4112-8ccb-2d630f690f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e050aad7-4530-497e-9101-b8180428e709" xlink:to="loc_us-gaap_InvestmentIncomeInterest_55ec8ce4-4015-4112-8ccb-2d630f690f9f" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="lung-20220630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
<link:calculationLink xlink:role="http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ef62bb8-71a2-463b-9613-407f78579aab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6b36913e-0bda-4d8f-9974-9d516ba703aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ef62bb8-71a2-463b-9613-407f78579aab" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6b36913e-0bda-4d8f-9974-9d516ba703aa" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_fdbc076e-ebff-48ad-a9d9-31a5bd56f2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ef62bb8-71a2-463b-9613-407f78579aab" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_fdbc076e-ebff-48ad-a9d9-31a5bd56f2f3" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_1e6341ca-597c-4682-b698-27a452aabf70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ef62bb8-71a2-463b-9613-407f78579aab" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_1e6341ca-597c-4682-b698-27a452aabf70" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_90c6f9ea-68b4-41f7-ab8a-79ccb2da6d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bfea96c0-4a82-4f96-8388-6e9a1e1ae857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_90c6f9ea-68b4-41f7-ab8a-79ccb2da6d6e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bfea96c0-4a82-4f96-8388-6e9a1e1ae857" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c7146854-fffc-4c58-b99e-4fd680877c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_90c6f9ea-68b4-41f7-ab8a-79ccb2da6d6e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c7146854-fffc-4c58-b99e-4fd680877c6b" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4a75bf75-592e-4f82-9a49-cc5d3a98a027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_90c6f9ea-68b4-41f7-ab8a-79ccb2da6d6e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4a75bf75-592e-4f82-9a49-cc5d3a98a027" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_80a7da7b-18d9-414f-9a7c-3e98fb6d8070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_90c6f9ea-68b4-41f7-ab8a-79ccb2da6d6e" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_80a7da7b-18d9-414f-9a7c-3e98fb6d8070" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5fbc6f18-d48a-434d-a121-9ba24ece8932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_eec3aec3-89b3-4434-b113-e84cca44406b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5fbc6f18-d48a-434d-a121-9ba24ece8932" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_eec3aec3-89b3-4434-b113-e84cca44406b" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_edf43668-2a38-4045-8054-20e898cd78a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5fbc6f18-d48a-434d-a121-9ba24ece8932" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_edf43668-2a38-4045-8054-20e898cd78a5" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_dc87c0fd-8d03-4985-8ec1-5d5eaaebee93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
<link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5fbc6f18-d48a-434d-a121-9ba24ece8932" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_dc87c0fd-8d03-4985-8ec1-5d5eaaebee93" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e92bed69-eded-4299-b3b1-350c41ece54c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
<link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5fbc6f18-d48a-434d-a121-9ba24ece8932" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_e92bed69-eded-4299-b3b1-350c41ece54c" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock_471b7a92-7d51-4fbe-9c01-93eae9c9005d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock"/>
<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5fbc6f18-d48a-434d-a121-9ba24ece8932" xlink:to="loc_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock_471b7a92-7d51-4fbe-9c01-93eae9c9005d" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56f6d85b-bb35-4a2a-b23e-0f6ebe9670f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_164e28fa-de6e-4949-93c3-09344c4e1fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56f6d85b-bb35-4a2a-b23e-0f6ebe9670f9" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_164e28fa-de6e-4949-93c3-09344c4e1fcf" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_088686d8-1336-4fa5-aed3-bc4ada798a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56f6d85b-bb35-4a2a-b23e-0f6ebe9670f9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_088686d8-1336-4fa5-aed3-bc4ada798a0f" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_92b1b694-de00-49e2-809e-c03e68d12692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56f6d85b-bb35-4a2a-b23e-0f6ebe9670f9" xlink:to="loc_us-gaap_ShareBasedCompensation_92b1b694-de00-49e2-809e-c03e68d12692" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0ef1df5b-833a-454a-8ad9-a2b920f8bcd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56f6d85b-bb35-4a2a-b23e-0f6ebe9670f9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0ef1df5b-833a-454a-8ad9-a2b920f8bcd1" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_51018ff9-93fb-4e53-8146-cba56fae819b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
<link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56f6d85b-bb35-4a2a-b23e-0f6ebe9670f9" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_51018ff9-93fb-4e53-8146-cba56fae819b" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0159aa3a-85a4-4b86-9ec8-23431049715e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
<link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56f6d85b-bb35-4a2a-b23e-0f6ebe9670f9" xlink:to="loc_us-gaap_NetIncomeLoss_0159aa3a-85a4-4b86-9ec8-23431049715e" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0981910d-d204-49ad-9a19-c42dac752213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
<link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56f6d85b-bb35-4a2a-b23e-0f6ebe9670f9" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0981910d-d204-49ad-9a19-c42dac752213" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7cb7b9cf-9174-40ae-92fc-07bc00c11508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56f6d85b-bb35-4a2a-b23e-0f6ebe9670f9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7cb7b9cf-9174-40ae-92fc-07bc00c11508" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_93903539-4121-4893-9336-2e10b3b06422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
<link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56f6d85b-bb35-4a2a-b23e-0f6ebe9670f9" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_93903539-4121-4893-9336-2e10b3b06422" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_b7388a0d-6936-4509-919e-73936b70d013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDepreciationAndAmortization"/>
<link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56f6d85b-bb35-4a2a-b23e-0f6ebe9670f9" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_b7388a0d-6936-4509-919e-73936b70d013" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0ad9e0c1-d0ac-4585-be9d-dc0a0da7b074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
<link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56f6d85b-bb35-4a2a-b23e-0f6ebe9670f9" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0ad9e0c1-d0ac-4585-be9d-dc0a0da7b074" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_46f319c9-ef06-478f-afa9-1aadeb6ca71a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
<link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56f6d85b-bb35-4a2a-b23e-0f6ebe9670f9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_46f319c9-ef06-478f-afa9-1aadeb6ca71a" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_dadca54b-20b7-49b6-87d5-9ec641bb947d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56f6d85b-bb35-4a2a-b23e-0f6ebe9670f9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_dadca54b-20b7-49b6-87d5-9ec641bb947d" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_cd971a30-7e80-4022-a259-dbbee8f1d87c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
<link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56f6d85b-bb35-4a2a-b23e-0f6ebe9670f9" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_cd971a30-7e80-4022-a259-dbbee8f1d87c" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_73c47376-c084-4aea-9977-8dcda61a09d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
<link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56f6d85b-bb35-4a2a-b23e-0f6ebe9670f9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_73c47376-c084-4aea-9977-8dcda61a09d7" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_c2be4e72-3960-4c24-b6f7-6bd9f422ffc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
<link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56f6d85b-bb35-4a2a-b23e-0f6ebe9670f9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_c2be4e72-3960-4c24-b6f7-6bd9f422ffc5" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_583867a0-f1cb-42c6-a72c-86c07517b2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
<link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56f6d85b-bb35-4a2a-b23e-0f6ebe9670f9" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_583867a0-f1cb-42c6-a72c-86c07517b2bf" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_d0084fa2-0198-4e93-b616-31a7851ece28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
<link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56f6d85b-bb35-4a2a-b23e-0f6ebe9670f9" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_d0084fa2-0198-4e93-b616-31a7851ece28" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_fc4d3f60-edf9-414e-8281-c36011e03ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
<link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56f6d85b-bb35-4a2a-b23e-0f6ebe9670f9" xlink:to="loc_us-gaap_InventoryWriteDown_fc4d3f60-edf9-414e-8281-c36011e03ee3" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0879fee7-6fdc-4685-9b3a-da8125022145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_edd6bbdd-f6b9-450b-9baf-ac85fd387f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0879fee7-6fdc-4685-9b3a-da8125022145" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_edd6bbdd-f6b9-450b-9baf-ac85fd387f5a" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_994d9392-2c71-4e46-9816-9bc139b9acbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0879fee7-6fdc-4685-9b3a-da8125022145" xlink:to="loc_us-gaap_RestrictedCash_994d9392-2c71-4e46-9816-9bc139b9acbc" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"/>
<link:calculationLink xlink:role="http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_81e3fba5-8980-469b-9cbb-1844d801cc5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1d66a968-f706-4639-a99e-9d926925da3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_81e3fba5-8980-469b-9cbb-1844d801cc5f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1d66a968-f706-4639-a99e-9d926925da3c" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ca67b98f-648e-4170-b45b-dbd5cc7d950b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_81e3fba5-8980-469b-9cbb-1844d801cc5f" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ca67b98f-648e-4170-b45b-dbd5cc7d950b" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails"/>
<link:calculationLink xlink:role="http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_lung_CashCashEquivalentsAndAvailableForSaleDebtSecurities_327a83f0-393a-440b-b0da-e283b1abe721" xlink:href="lung-20220630.xsd#lung_CashCashEquivalentsAndAvailableForSaleDebtSecurities"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_2fa261af-325e-4e1b-af4d-69e55368f3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lung_CashCashEquivalentsAndAvailableForSaleDebtSecurities_327a83f0-393a-440b-b0da-e283b1abe721" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_2fa261af-325e-4e1b-af4d-69e55368f3ac" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_667ea5af-7edc-4c18-83f5-9a64ab5fb1be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lung_CashCashEquivalentsAndAvailableForSaleDebtSecurities_327a83f0-393a-440b-b0da-e283b1abe721" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_667ea5af-7edc-4c18-83f5-9a64ab5fb1be" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8822d9e6-0ca9-4c41-b8f3-641450b4ef58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_20a9794f-e35c-4c21-9203-8213559ed724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8822d9e6-0ca9-4c41-b8f3-641450b4ef58" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_20a9794f-e35c-4c21-9203-8213559ed724" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7f704871-c38e-4413-9d20-2de7dcd275e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8822d9e6-0ca9-4c41-b8f3-641450b4ef58" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7f704871-c38e-4413-9d20-2de7dcd275e7" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_482952a5-f497-4201-a6ee-92c18f49d3be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8822d9e6-0ca9-4c41-b8f3-641450b4ef58" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_482952a5-f497-4201-a6ee-92c18f49d3be" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#BalanceSheetComponentsCashandCashEquivalentsDetails"/>
<link:calculationLink xlink:role="http://www.pulmonx.com/role/BalanceSheetComponentsCashandCashEquivalentsDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e884ff71-e041-482e-bd32-6dbd571161a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_CorporateBondsDebtSecuritiesAtCarryingValue_7bc592cc-6dab-47dd-b47d-46e431a66424" xlink:href="lung-20220630.xsd#lung_CorporateBondsDebtSecuritiesAtCarryingValue"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e884ff71-e041-482e-bd32-6dbd571161a8" xlink:to="loc_lung_CorporateBondsDebtSecuritiesAtCarryingValue_7bc592cc-6dab-47dd-b47d-46e431a66424" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_af55c618-1148-462b-814e-21298c901852" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e884ff71-e041-482e-bd32-6dbd571161a8" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_af55c618-1148-462b-814e-21298c901852" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperAtCarryingValue_8ab55507-aded-4b81-9cb7-2dda19a7c087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperAtCarryingValue"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e884ff71-e041-482e-bd32-6dbd571161a8" xlink:to="loc_us-gaap_CommercialPaperAtCarryingValue_8ab55507-aded-4b81-9cb7-2dda19a7c087" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_73a9095a-e773-460b-b4f3-a6149c696cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e884ff71-e041-482e-bd32-6dbd571161a8" xlink:to="loc_us-gaap_Cash_73a9095a-e773-460b-b4f3-a6149c696cb5" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsInventoryDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#BalanceSheetComponentsInventoryDetails"/>
<link:calculationLink xlink:role="http://www.pulmonx.com/role/BalanceSheetComponentsInventoryDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_74a2c144-5998-4403-90b3-fae5820e0cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_39d8772a-802f-46c5-9cd6-0b2db015ec50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_74a2c144-5998-4403-90b3-fae5820e0cbf" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_39d8772a-802f-46c5-9cd6-0b2db015ec50" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_917b0324-bb48-4cf7-8679-7ab753156194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_74a2c144-5998-4403-90b3-fae5820e0cbf" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_917b0324-bb48-4cf7-8679-7ab753156194" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_3398f92e-37f9-45c2-8beb-293a8c3376e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_74a2c144-5998-4403-90b3-fae5820e0cbf" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_3398f92e-37f9-45c2-8beb-293a8c3376e9" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"/>
<link:calculationLink xlink:role="http://www.pulmonx.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f8c2b38d-9920-4073-a0ea-572e9b20036d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_a84cdcc1-407a-41e1-9630-feaf3e73130b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f8c2b38d-9920-4073-a0ea-572e9b20036d" xlink:to="loc_us-gaap_OtherAssetsCurrent_a84cdcc1-407a-41e1-9630-feaf3e73130b" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_05427e9c-7096-4487-9350-24386bbff4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f8c2b38d-9920-4073-a0ea-572e9b20036d" xlink:to="loc_us-gaap_PrepaidInsurance_05427e9c-7096-4487-9350-24386bbff4b5" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_e001c625-0e21-4dd6-ab82-d5eb1f8f57c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f8c2b38d-9920-4073-a0ea-572e9b20036d" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_e001c625-0e21-4dd6-ab82-d5eb1f8f57c3" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_b7246f0d-7595-4e7c-bb1a-580d520dbc62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f8c2b38d-9920-4073-a0ea-572e9b20036d" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_b7246f0d-7595-4e7c-bb1a-580d520dbc62" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#BalanceSheetComponentsPropertyandEquipmentNetDetails"/>
<link:calculationLink xlink:role="http://www.pulmonx.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5a427465-25d7-4997-94f2-8c5374977c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_142eb736-f4af-42e7-8037-8e3b57238f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5a427465-25d7-4997-94f2-8c5374977c3a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_142eb736-f4af-42e7-8037-8e3b57238f24" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_71534191-1cbb-483a-960f-c9ccef264665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5a427465-25d7-4997-94f2-8c5374977c3a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_71534191-1cbb-483a-960f-c9ccef264665" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsIntangibleAssetsDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#BalanceSheetComponentsIntangibleAssetsDetails"/>
<link:calculationLink xlink:role="http://www.pulmonx.com/role/BalanceSheetComponentsIntangibleAssetsDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2a1d4f30-a5b9-427c-8422-9c2d9b5f137b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ce450a0a-d839-4b91-bfe0-99c97b3f3565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2a1d4f30-a5b9-427c-8422-9c2d9b5f137b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ce450a0a-d839-4b91-bfe0-99c97b3f3565" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_42c0f5e7-9543-4d58-b547-f0567795dee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2a1d4f30-a5b9-427c-8422-9c2d9b5f137b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_42c0f5e7-9543-4d58-b547-f0567795dee9" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#BalanceSheetComponentsFutureAmortizationExpenseDetails"/>
<link:calculationLink xlink:role="http://www.pulmonx.com/role/BalanceSheetComponentsFutureAmortizationExpenseDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_152f4208-9af6-4779-8661-e940bef963a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2a4a28a8-d04f-4b83-918c-e9dce0b7a816" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_152f4208-9af6-4779-8661-e940bef963a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2a4a28a8-d04f-4b83-918c-e9dce0b7a816" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d5db5525-1e1f-443b-bbe6-a4ea05b99cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_152f4208-9af6-4779-8661-e940bef963a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d5db5525-1e1f-443b-bbe6-a4ea05b99cbf" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b585eae4-7b77-4e41-8ff9-fde234b0e207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_152f4208-9af6-4779-8661-e940bef963a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b585eae4-7b77-4e41-8ff9-fde234b0e207" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#BalanceSheetComponentsAccruedLiabilitiesDetails"/>
<link:calculationLink xlink:role="http://www.pulmonx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_03f51e6f-91a1-47ba-84ff-a1aafcccf5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_5f9d315d-2f90-4fe3-8a53-2491abe1b6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrent"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_03f51e6f-91a1-47ba-84ff-a1aafcccf5cd" xlink:to="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_5f9d315d-2f90-4fe3-8a53-2491abe1b6eb" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedVacationCurrent_ec82efd0-747d-4ba3-8214-1e439283abe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedVacationCurrent"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_03f51e6f-91a1-47ba-84ff-a1aafcccf5cd" xlink:to="loc_us-gaap_AccruedVacationCurrent_ec82efd0-747d-4ba3-8214-1e439283abe9" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_45c266df-0edf-47b8-8df5-4ab6a894ca4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_03f51e6f-91a1-47ba-84ff-a1aafcccf5cd" xlink:to="loc_us-gaap_TaxesPayableCurrent_45c266df-0edf-47b8-8df5-4ab6a894ca4a" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_AccruedInventoryPurchasesCurrent_ff9586a2-7f77-4f66-b240-049850d34390" xlink:href="lung-20220630.xsd#lung_AccruedInventoryPurchasesCurrent"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_03f51e6f-91a1-47ba-84ff-a1aafcccf5cd" xlink:to="loc_lung_AccruedInventoryPurchasesCurrent_ff9586a2-7f77-4f66-b240-049850d34390" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_3d6053b7-967a-4248-a257-fb8609f2e961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_03f51e6f-91a1-47ba-84ff-a1aafcccf5cd" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_3d6053b7-967a-4248-a257-fb8609f2e961" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_5f2746cc-41de-4c33-a950-abd89ea274e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
<link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_03f51e6f-91a1-47ba-84ff-a1aafcccf5cd" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_5f2746cc-41de-4c33-a950-abd89ea274e7" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6f6a8e38-ed75-4e54-b328-b48e7ef0f9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
<link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_03f51e6f-91a1-47ba-84ff-a1aafcccf5cd" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6f6a8e38-ed75-4e54-b328-b48e7ef0f9b2" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_6da6966e-6afb-4341-ba36-8cdb0fa6ecfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent"/>
<link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_03f51e6f-91a1-47ba-84ff-a1aafcccf5cd" xlink:to="loc_us-gaap_AccruedBonusesCurrent_6da6966e-6afb-4341-ba36-8cdb0fa6ecfd" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanComponentsOfDebtDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#LongTermDebtandConvertibleNotesCIBCLoanComponentsOfDebtDetails"/>
<link:calculationLink xlink:role="http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanComponentsOfDebtDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f43827a3-0ae5-4170-b56d-7e98f79c558a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_025f3962-0ce6-42a1-b6f4-d2f5116cf66e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_f43827a3-0ae5-4170-b56d-7e98f79c558a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_025f3962-0ce6-42a1-b6f4-d2f5116cf66e" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1568be35-47b3-419e-b728-400a2853ae29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
<link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_f43827a3-0ae5-4170-b56d-7e98f79c558a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1568be35-47b3-419e-b728-400a2853ae29" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesContractualMaturitiesofFinancingObligationsDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#LongTermDebtandConvertibleNotesContractualMaturitiesofFinancingObligationsDetails"/>
<link:calculationLink xlink:role="http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesContractualMaturitiesofFinancingObligationsDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_51aa4bdb-8990-403c-8acf-15a3892e8ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_e5106559-2e63-48bb-a513-51d48b56d404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_51aa4bdb-8990-403c-8acf-15a3892e8ba9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_e5106559-2e63-48bb-a513-51d48b56d404" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_a1a1cc41-4daa-4000-b628-d2ef9a910979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_51aa4bdb-8990-403c-8acf-15a3892e8ba9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_a1a1cc41-4daa-4000-b628-d2ef9a910979" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_44b927e9-6e6e-4288-b590-8e74f6aa891d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_51aa4bdb-8990-403c-8acf-15a3892e8ba9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_44b927e9-6e6e-4288-b590-8e74f6aa891d" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_97ccc9db-869e-4730-b808-5855335cba20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_51aa4bdb-8990-403c-8acf-15a3892e8ba9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_97ccc9db-869e-4730-b808-5855335cba20" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_33f07e48-dc9c-461a-93d7-e4aa330a0698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
<link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_51aa4bdb-8990-403c-8acf-15a3892e8ba9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_33f07e48-dc9c-461a-93d7-e4aa330a0698" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_b2c5e7c3-3935-4a84-9d34-f7423d9deb74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
<link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_51aa4bdb-8990-403c-8acf-15a3892e8ba9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_b2c5e7c3-3935-4a84-9d34-f7423d9deb74" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/CommitmentsandContingenciesLeaseCostDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#CommitmentsandContingenciesLeaseCostDetails"/>
<link:calculationLink xlink:role="http://www.pulmonx.com/role/CommitmentsandContingenciesLeaseCostDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_0b896ec3-c08a-4730-a74d-593aa3ae99f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_2ccb06b7-1655-4399-9039-7c3df0024059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_0b896ec3-c08a-4730-a74d-593aa3ae99f8" xlink:to="loc_us-gaap_OperatingLeaseCost_2ccb06b7-1655-4399-9039-7c3df0024059" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_2e356660-18fa-46d6-999e-83946d4d5742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_0b896ec3-c08a-4730-a74d-593aa3ae99f8" xlink:to="loc_us-gaap_ShortTermLeaseCost_2e356660-18fa-46d6-999e-83946d4d5742" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_c8567979-3a42-4e1f-ab34-0e88fcd2feb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_0b896ec3-c08a-4730-a74d-593aa3ae99f8" xlink:to="loc_us-gaap_VariableLeaseCost_c8567979-3a42-4e1f-ab34-0e88fcd2feb9" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails"/>
<link:calculationLink xlink:role="http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0b645291-8c9b-4ff6-8823-db0019a4c59c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d1baf882-f08b-4f96-9347-856e4eb483f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_0b645291-8c9b-4ff6-8823-db0019a4c59c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d1baf882-f08b-4f96-9347-856e4eb483f0" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e39f6935-3770-4e1c-86f9-7f10a8ae3815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_0b645291-8c9b-4ff6-8823-db0019a4c59c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e39f6935-3770-4e1c-86f9-7f10a8ae3815" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_33d553f7-277a-41b1-810d-772a75aca8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7a865f29-aa18-4199-975c-f1b431ea291c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_33d553f7-277a-41b1-810d-772a75aca8b1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7a865f29-aa18-4199-975c-f1b431ea291c" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2d6581bf-243a-43ef-a23e-3d98ea81ecd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_33d553f7-277a-41b1-810d-772a75aca8b1" xlink:to="loc_us-gaap_OperatingLeaseLiability_2d6581bf-243a-43ef-a23e-3d98ea81ecd1" xlink:type="arc"/>
</link:calculationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="lung-20220630.xsd#CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails_1"/>
<link:calculationLink xlink:role="http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails_1" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8b429b84-29b8-453c-90dc-2b5f92317f80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2767caf2-0180-4234-8470-fd04b43731a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
<link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8b429b84-29b8-453c-90dc-2b5f92317f80" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2767caf2-0180-4234-8470-fd04b43731a2" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_38649170-96a6-4884-be4c-0d198fb337d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
<link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8b429b84-29b8-453c-90dc-2b5f92317f80" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_38649170-96a6-4884-be4c-0d198fb337d3" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_eaa40f5b-8172-4819-aa5c-07249d5a18bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
<link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8b429b84-29b8-453c-90dc-2b5f92317f80" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_eaa40f5b-8172-4819-aa5c-07249d5a18bb" xlink:type="arc"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0f432850-cc80-4caa-8a84-fb8591cab4de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
<link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8b429b84-29b8-453c-90dc-2b5f92317f80" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0f432850-cc80-4caa-8a84-fb8591cab4de" xlink:type="arc"/>
</link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>lung-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e27afbe0-c876-445c-ac79-0e3a22d99ad7,g:11f7fccd-ac30-49f3-b9c8-08334e4a7c01-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
<link:roleRef roleURI="http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="lung-20220630.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
<link:definitionLink xlink:role="http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="ie91d9f48c29d447d8d67d7118a11262b_CondensedConsolidatedStatementsofStockholdersEquity">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_01de0c9e-0d88-4c2f-97f4-81c4e61ee326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_01de0c9e-0d88-4c2f-97f4-81c4e61ee326" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9bbbc6f4-82cd-4116-8b6b-74929c7b6347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9bbbc6f4-82cd-4116-8b6b-74929c7b6347" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ee2a7d4e-fc64-436c-8e37-923bd5d0fa83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:to="loc_us-gaap_StockholdersEquity_ee2a7d4e-fc64-436c-8e37-923bd5d0fa83" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_a4b704d4-e461-40cf-8e1d-c2f3f5d94470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_a4b704d4-e461-40cf-8e1d-c2f3f5d94470" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9a2ea43f-6248-4962-adad-bdfd32f87452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9a2ea43f-6248-4962-adad-bdfd32f87452" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_484374a0-a21b-4e5f-9822-d41a273a812d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_484374a0-a21b-4e5f-9822-d41a273a812d" xlink:type="arc" order="5"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_StockRepurchasedDuringPeriodExerciseOfEarlyStockOptionsShares_89777fd0-794b-4810-b2f3-0edbca10db9a" xlink:href="lung-20220630.xsd#lung_StockRepurchasedDuringPeriodExerciseOfEarlyStockOptionsShares"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:to="loc_lung_StockRepurchasedDuringPeriodExerciseOfEarlyStockOptionsShares_89777fd0-794b-4810-b2f3-0edbca10db9a" xlink:type="arc" order="6"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_044aeee7-6726-4357-bd86-a4c2d2fcfb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_044aeee7-6726-4357-bd86-a4c2d2fcfb6d" xlink:type="arc" order="7"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_9dd7a0c8-ccdc-4224-9908-36b14388316c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_9dd7a0c8-ccdc-4224-9908-36b14388316c" xlink:type="arc" order="8"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase_57485673-b32b-49c5-a270-a13857d2fec7" xlink:href="lung-20220630.xsd#lung_AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:to="loc_lung_AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase_57485673-b32b-49c5-a270-a13857d2fec7" xlink:type="arc" order="9"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1f723d08-5d62-48af-9e48-ce2654d36ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1f723d08-5d62-48af-9e48-ce2654d36ad2" xlink:type="arc" order="10"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0d3c0d93-8940-41f0-b0a4-d131ba26812a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0d3c0d93-8940-41f0-b0a4-d131ba26812a" xlink:type="arc" order="11"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_a9d2a8c6-25a6-42c9-85e9-8ef1818e97e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_a9d2a8c6-25a6-42c9-85e9-8ef1818e97e4" xlink:type="arc" order="12"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_83f6b744-d2b4-4458-9572-f2a4ee43ee7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:to="loc_us-gaap_NetIncomeLoss_83f6b744-d2b4-4458-9572-f2a4ee43ee7b" xlink:type="arc" order="13"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d7c334fc-484b-477f-935f-0f0c94667d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5f35735d-e311-4785-829e-f25bcdbc83fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_34470372-e929-4cd4-814d-71bd49749d82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_01de0c9e-0d88-4c2f-97f4-81c4e61ee326" xlink:to="loc_us-gaap_StatementTable_34470372-e929-4cd4-814d-71bd49749d82" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4a71ad4b-6cae-4b59-b477-db13132db2ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_34470372-e929-4cd4-814d-71bd49749d82" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4a71ad4b-6cae-4b59-b477-db13132db2ab" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4a71ad4b-6cae-4b59-b477-db13132db2ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4a71ad4b-6cae-4b59-b477-db13132db2ab" xlink:to="loc_us-gaap_EquityComponentDomain_4a71ad4b-6cae-4b59-b477-db13132db2ab_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6173031d-c279-4ee1-93bc-32096ccf3f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4a71ad4b-6cae-4b59-b477-db13132db2ab" xlink:to="loc_us-gaap_EquityComponentDomain_6173031d-c279-4ee1-93bc-32096ccf3f5f" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5a8861c6-619c-4b05-8465-da4ff6e92be9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6173031d-c279-4ee1-93bc-32096ccf3f5f" xlink:to="loc_us-gaap_CommonStockMember_5a8861c6-619c-4b05-8465-da4ff6e92be9" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_cb24a54a-6ff8-47d0-b320-7c951c341231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6173031d-c279-4ee1-93bc-32096ccf3f5f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_cb24a54a-6ff8-47d0-b320-7c951c341231" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_920c4bf4-8d49-49c6-8175-ad4d9f31cd5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6173031d-c279-4ee1-93bc-32096ccf3f5f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_920c4bf4-8d49-49c6-8175-ad4d9f31cd5e" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_903a1285-717a-4b63-b48f-536bdce7e5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6173031d-c279-4ee1-93bc-32096ccf3f5f" xlink:to="loc_us-gaap_RetainedEarningsMember_903a1285-717a-4b63-b48f-536bdce7e5c6" xlink:type="arc" order="3"/>
</link:definitionLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
<link:definitionLink xlink:role="http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="i02f8438f812e457ebfb1a99008435558_SummaryofSignificantAccountingPoliciesDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_dd6e8c25-d4e4-4ef2-93c6-8738cc889a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount_4122b21a-ba4a-42aa-9c0f-9eed42c51a61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_dd6e8c25-d4e4-4ef2-93c6-8738cc889a9f" xlink:to="loc_us-gaap_CashUninsuredAmount_4122b21a-ba4a-42aa-9c0f-9eed42c51a61" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0ac8477b-e286-4e96-9c42-8b17ae901182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_dd6e8c25-d4e4-4ef2-93c6-8738cc889a9f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0ac8477b-e286-4e96-9c42-8b17ae901182" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized_58a91a73-f9e6-4be1-be26-e0964c1529e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_dd6e8c25-d4e4-4ef2-93c6-8738cc889a9f" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized_58a91a73-f9e6-4be1-be26-e0964c1529e5" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3802535b-95be-4537-a218-9a428916d7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_dd6e8c25-d4e4-4ef2-93c6-8738cc889a9f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3802535b-95be-4537-a218-9a428916d7eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_77d45179-da45-4631-b3e0-9b16e0db0627" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3802535b-95be-4537-a218-9a428916d7eb" xlink:to="loc_srt_RangeAxis_77d45179-da45-4631-b3e0-9b16e0db0627" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_77d45179-da45-4631-b3e0-9b16e0db0627_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_77d45179-da45-4631-b3e0-9b16e0db0627" xlink:to="loc_srt_RangeMember_77d45179-da45-4631-b3e0-9b16e0db0627_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fb4acb42-2cfb-4e99-bad7-e7697fc17b73" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_77d45179-da45-4631-b3e0-9b16e0db0627" xlink:to="loc_srt_RangeMember_fb4acb42-2cfb-4e99-bad7-e7697fc17b73" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_85cc9434-b3b3-49c1-98c1-276291ef46b8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fb4acb42-2cfb-4e99-bad7-e7697fc17b73" xlink:to="loc_srt_MaximumMember_85cc9434-b3b3-49c1-98c1-276291ef46b8" xlink:type="arc" order="0"/>
</link:definitionLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"/>
<link:definitionLink xlink:role="http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="extended" id="i799b3f84e13a4da29735cca59ce29860_FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6fd5b1eb-b267-4961-ad71-210dd1eb1c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1c3dd6b9-acf9-4cdd-9978-b0cda78be9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6fd5b1eb-b267-4961-ad71-210dd1eb1c66" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1c3dd6b9-acf9-4cdd-9978-b0cda78be9a8" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6fb25088-bb7d-4244-9d8e-d2dcd809779d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1c3dd6b9-acf9-4cdd-9978-b0cda78be9a8" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6fb25088-bb7d-4244-9d8e-d2dcd809779d" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a8d0df2c-1f33-4391-8447-d5962dd2fcaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1c3dd6b9-acf9-4cdd-9978-b0cda78be9a8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a8d0df2c-1f33-4391-8447-d5962dd2fcaf" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_038ffd88-5223-4dbd-bc4a-0b8b497801c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6fd5b1eb-b267-4961-ad71-210dd1eb1c66" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_038ffd88-5223-4dbd-bc4a-0b8b497801c9" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_05dd5895-7c1a-4244-9402-9b710474af2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6fd5b1eb-b267-4961-ad71-210dd1eb1c66" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_05dd5895-7c1a-4244-9402-9b710474af2d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_08e1c02f-585d-4aa2-ad00-9dfb421eea2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_05dd5895-7c1a-4244-9402-9b710474af2d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_08e1c02f-585d-4aa2-ad00-9dfb421eea2e" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_08e1c02f-585d-4aa2-ad00-9dfb421eea2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_08e1c02f-585d-4aa2-ad00-9dfb421eea2e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_08e1c02f-585d-4aa2-ad00-9dfb421eea2e_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f3c4f050-e083-4e95-a2e9-9db33afbdc04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_08e1c02f-585d-4aa2-ad00-9dfb421eea2e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f3c4f050-e083-4e95-a2e9-9db33afbdc04" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_afdba5c8-816d-4988-b4d6-8e3122ac6175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_f3c4f050-e083-4e95-a2e9-9db33afbdc04" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_afdba5c8-816d-4988-b4d6-8e3122ac6175" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4e49612-6dc1-4b55-9c32-74751ff6dbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_05dd5895-7c1a-4244-9402-9b710474af2d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4e49612-6dc1-4b55-9c32-74751ff6dbcf" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a4e49612-6dc1-4b55-9c32-74751ff6dbcf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4e49612-6dc1-4b55-9c32-74751ff6dbcf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a4e49612-6dc1-4b55-9c32-74751ff6dbcf_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8befef0d-c3cb-495e-85ac-b65e9315b271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4e49612-6dc1-4b55-9c32-74751ff6dbcf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8befef0d-c3cb-495e-85ac-b65e9315b271" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f4a00937-55a8-4fb0-8530-80fbacfaa939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8befef0d-c3cb-495e-85ac-b65e9315b271" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f4a00937-55a8-4fb0-8530-80fbacfaa939" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_cac6f980-57e4-46f6-af75-66ef011863c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8befef0d-c3cb-495e-85ac-b65e9315b271" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_cac6f980-57e4-46f6-af75-66ef011863c6" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_cb1c4072-d364-4459-ba58-c125c879d352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8befef0d-c3cb-495e-85ac-b65e9315b271" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_cb1c4072-d364-4459-ba58-c125c879d352" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_472fecb8-14b9-4c3a-8494-5c7ac4541ece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_05dd5895-7c1a-4244-9402-9b710474af2d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_472fecb8-14b9-4c3a-8494-5c7ac4541ece" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_472fecb8-14b9-4c3a-8494-5c7ac4541ece_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_472fecb8-14b9-4c3a-8494-5c7ac4541ece" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_472fecb8-14b9-4c3a-8494-5c7ac4541ece_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0d5aaf64-4cde-4fee-a69a-e37a91faee74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_472fecb8-14b9-4c3a-8494-5c7ac4541ece" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0d5aaf64-4cde-4fee-a69a-e37a91faee74" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_be7c89bb-76f4-4a0a-be41-ff5b06f15aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0d5aaf64-4cde-4fee-a69a-e37a91faee74" xlink:to="loc_us-gaap_MoneyMarketFundsMember_be7c89bb-76f4-4a0a-be41-ff5b06f15aad" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_951d9b5e-e39d-4974-9091-69bfe53fba07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0d5aaf64-4cde-4fee-a69a-e37a91faee74" xlink:to="loc_us-gaap_CommercialPaperMember_951d9b5e-e39d-4974-9091-69bfe53fba07" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d52d21e5-021d-4db2-9e4b-d6768e63e300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_05dd5895-7c1a-4244-9402-9b710474af2d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d52d21e5-021d-4db2-9e4b-d6768e63e300" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d52d21e5-021d-4db2-9e4b-d6768e63e300_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d52d21e5-021d-4db2-9e4b-d6768e63e300" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d52d21e5-021d-4db2-9e4b-d6768e63e300_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_273644ba-9563-4092-b339-3ea9f9c2f84a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d52d21e5-021d-4db2-9e4b-d6768e63e300" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_273644ba-9563-4092-b339-3ea9f9c2f84a" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_94ed903d-d037-4af1-85d3-c8f1669447d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_273644ba-9563-4092-b339-3ea9f9c2f84a" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_94ed903d-d037-4af1-85d3-c8f1669447d1" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_7373839b-1571-4447-b3a8-fcbad028e075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_273644ba-9563-4092-b339-3ea9f9c2f84a" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_7373839b-1571-4447-b3a8-fcbad028e075" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_d2585968-2976-47a8-94ba-225e364733b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_273644ba-9563-4092-b339-3ea9f9c2f84a" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_d2585968-2976-47a8-94ba-225e364733b5" xlink:type="arc" order="2"/>
</link:definitionLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails"/>
<link:definitionLink xlink:role="http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails" xlink:type="extended" id="ica83dfd4558e4b8ca5bd92eab6489041_FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a2f2fd3e-0011-40e8-924b-fa7dfc9555bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_f08ba170-f86a-46ad-a3c6-8481a643ddcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a2f2fd3e-0011-40e8-924b-fa7dfc9555bd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_f08ba170-f86a-46ad-a3c6-8481a643ddcd" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_11dd8ddb-d5a0-4909-a3be-f78543ea4fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_f08ba170-f86a-46ad-a3c6-8481a643ddcd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_11dd8ddb-d5a0-4909-a3be-f78543ea4fcc" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2c095f8e-28dc-4119-a47b-001a01046fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_f08ba170-f86a-46ad-a3c6-8481a643ddcd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2c095f8e-28dc-4119-a47b-001a01046fa5" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b121827c-5bab-4abd-b951-1cd316801ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_f08ba170-f86a-46ad-a3c6-8481a643ddcd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b121827c-5bab-4abd-b951-1cd316801ff2" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a40c2693-d984-4f51-b1b3-eaf195c6b4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_f08ba170-f86a-46ad-a3c6-8481a643ddcd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a40c2693-d984-4f51-b1b3-eaf195c6b4cd" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_FairValueRecognizedOnBalanceSheetAbstract_b9b33359-08de-4b1e-aa30-12f9b0eef9d8" xlink:href="lung-20220630.xsd#lung_FairValueRecognizedOnBalanceSheetAbstract"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a2f2fd3e-0011-40e8-924b-fa7dfc9555bd" xlink:to="loc_lung_FairValueRecognizedOnBalanceSheetAbstract_b9b33359-08de-4b1e-aa30-12f9b0eef9d8" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_85acd6c8-69e4-4f89-a1d1-8fabf8e08e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lung_FairValueRecognizedOnBalanceSheetAbstract_b9b33359-08de-4b1e-aa30-12f9b0eef9d8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_85acd6c8-69e4-4f89-a1d1-8fabf8e08e2f" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8e759055-f441-4c58-ac17-f5c5da87ba51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lung_FairValueRecognizedOnBalanceSheetAbstract_b9b33359-08de-4b1e-aa30-12f9b0eef9d8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8e759055-f441-4c58-ac17-f5c5da87ba51" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_CashCashEquivalentsAndAvailableForSaleDebtSecurities_95b1a0f0-ff84-4954-94ae-58afc3e16b82" xlink:href="lung-20220630.xsd#lung_CashCashEquivalentsAndAvailableForSaleDebtSecurities"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lung_FairValueRecognizedOnBalanceSheetAbstract_b9b33359-08de-4b1e-aa30-12f9b0eef9d8" xlink:to="loc_lung_CashCashEquivalentsAndAvailableForSaleDebtSecurities_95b1a0f0-ff84-4954-94ae-58afc3e16b82" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ecbd24d7-d602-4db7-83f2-f66265f39845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a2f2fd3e-0011-40e8-924b-fa7dfc9555bd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ecbd24d7-d602-4db7-83f2-f66265f39845" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3079033b-4acc-409d-b9da-f7f0191e8524" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ecbd24d7-d602-4db7-83f2-f66265f39845" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3079033b-4acc-409d-b9da-f7f0191e8524" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3079033b-4acc-409d-b9da-f7f0191e8524_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3079033b-4acc-409d-b9da-f7f0191e8524" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3079033b-4acc-409d-b9da-f7f0191e8524_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_afb4b690-d5f1-4c79-9201-65ab80ddbeab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3079033b-4acc-409d-b9da-f7f0191e8524" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_afb4b690-d5f1-4c79-9201-65ab80ddbeab" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2c738da0-9c4a-4d90-b855-2b91aecbf178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_afb4b690-d5f1-4c79-9201-65ab80ddbeab" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2c738da0-9c4a-4d90-b855-2b91aecbf178" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_67cde496-328b-44d1-9b1a-d7cda647f492" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_afb4b690-d5f1-4c79-9201-65ab80ddbeab" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_67cde496-328b-44d1-9b1a-d7cda647f492" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_1be7316e-3656-4f48-8569-c426ac91f491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_afb4b690-d5f1-4c79-9201-65ab80ddbeab" xlink:to="loc_us-gaap_CommercialPaperMember_1be7316e-3656-4f48-8569-c426ac91f491" xlink:type="arc" order="2"/>
</link:definitionLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#FairValueMeasurementsNarrativeDetails"/>
<link:definitionLink xlink:role="http://www.pulmonx.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="if8406f5da7a04e51960138d0109c758b_FairValueMeasurementsNarrativeDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_f9dc1f3a-0b22-4466-8cbe-2e4b32ec3e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_65465d69-5cb7-41cd-9999-418f5b4c7ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_f9dc1f3a-0b22-4466-8cbe-2e4b32ec3e0b" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_65465d69-5cb7-41cd-9999-418f5b4c7ba9" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_9031da2a-a6f8-4a0d-ac46-c4b69549429b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_f9dc1f3a-0b22-4466-8cbe-2e4b32ec3e0b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_9031da2a-a6f8-4a0d-ac46-c4b69549429b" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_1206baf8-c1cf-4e35-a46e-0e8e985a97bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_f9dc1f3a-0b22-4466-8cbe-2e4b32ec3e0b" xlink:to="loc_us-gaap_DerivativeTable_1206baf8-c1cf-4e35-a46e-0e8e985a97bd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f4e8088e-f551-40d1-b339-9313c77768c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1206baf8-c1cf-4e35-a46e-0e8e985a97bd" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f4e8088e-f551-40d1-b339-9313c77768c0" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f4e8088e-f551-40d1-b339-9313c77768c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f4e8088e-f551-40d1-b339-9313c77768c0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f4e8088e-f551-40d1-b339-9313c77768c0_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8e460542-f811-4311-9a7f-5e9ba4491523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f4e8088e-f551-40d1-b339-9313c77768c0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8e460542-f811-4311-9a7f-5e9ba4491523" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_54f7fb22-5371-44e8-bf4c-3087bef5da07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8e460542-f811-4311-9a7f-5e9ba4491523" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_54f7fb22-5371-44e8-bf4c-3087bef5da07" xlink:type="arc" order="0"/>
</link:definitionLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#BalanceSheetComponentsPropertyandEquipmentNetDetails"/>
<link:definitionLink xlink:role="http://www.pulmonx.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" xlink:type="extended" id="i3bc80098dd9648a89b7ce5bc50ba6c37_BalanceSheetComponentsPropertyandEquipmentNetDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41456e57-108c-4c04-9a97-9d7340887047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_57687d67-96d0-4719-bed8-eda7966e10ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41456e57-108c-4c04-9a97-9d7340887047" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_57687d67-96d0-4719-bed8-eda7966e10ee" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_50fd2303-ed5d-4a0e-bfc9-1301d51bde7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41456e57-108c-4c04-9a97-9d7340887047" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_50fd2303-ed5d-4a0e-bfc9-1301d51bde7f" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bd191eeb-d0ed-429d-b5f1-fbfcf616e31c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41456e57-108c-4c04-9a97-9d7340887047" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bd191eeb-d0ed-429d-b5f1-fbfcf616e31c" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a622e0ae-aa7a-429d-be8e-cc331e409de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41456e57-108c-4c04-9a97-9d7340887047" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a622e0ae-aa7a-429d-be8e-cc331e409de0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ed3cc427-57d2-4c01-9bca-69aec2aa9876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a622e0ae-aa7a-429d-be8e-cc331e409de0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ed3cc427-57d2-4c01-9bca-69aec2aa9876" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ed3cc427-57d2-4c01-9bca-69aec2aa9876_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ed3cc427-57d2-4c01-9bca-69aec2aa9876" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ed3cc427-57d2-4c01-9bca-69aec2aa9876_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf0dd3d1-b6ee-43ce-b4d8-881cf1fc10e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ed3cc427-57d2-4c01-9bca-69aec2aa9876" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf0dd3d1-b6ee-43ce-b4d8-881cf1fc10e0" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_361b3e92-0e0a-41dc-9a86-5184398211da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf0dd3d1-b6ee-43ce-b4d8-881cf1fc10e0" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_361b3e92-0e0a-41dc-9a86-5184398211da" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_8367c5c3-73a2-4cb2-ab15-f5e1703cc462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf0dd3d1-b6ee-43ce-b4d8-881cf1fc10e0" xlink:to="loc_us-gaap_ComputerEquipmentMember_8367c5c3-73a2-4cb2-ab15-f5e1703cc462" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3884241a-932d-4528-b578-6ef68fec18bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf0dd3d1-b6ee-43ce-b4d8-881cf1fc10e0" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3884241a-932d-4528-b578-6ef68fec18bf" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_ed0d28f2-1f9f-4711-8660-6ff3418bd9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf0dd3d1-b6ee-43ce-b4d8-881cf1fc10e0" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_ed0d28f2-1f9f-4711-8660-6ff3418bd9c0" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_2f6dd97e-0d78-4a3f-8c10-2ef13d55809f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf0dd3d1-b6ee-43ce-b4d8-881cf1fc10e0" xlink:to="loc_us-gaap_ConstructionInProgressMember_2f6dd97e-0d78-4a3f-8c10-2ef13d55809f" xlink:type="arc" order="4"/>
</link:definitionLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsCapitalizedImplementationCostsofaHostingArrangementDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#BalanceSheetComponentsCapitalizedImplementationCostsofaHostingArrangementDetails"/>
<link:definitionLink xlink:role="http://www.pulmonx.com/role/BalanceSheetComponentsCapitalizedImplementationCostsofaHostingArrangementDetails" xlink:type="extended" id="i10e27314e72b44fba9dec72dfa01775b_BalanceSheetComponentsCapitalizedImplementationCostsofaHostingArrangementDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cb84d707-f430-4bc9-ae7e-4fbd3be18310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization_d6acfb02-2c8c-4a1e-bf75-c90889d5fd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cb84d707-f430-4bc9-ae7e-4fbd3be18310" xlink:to="loc_us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization_d6acfb02-2c8c-4a1e-bf75-c90889d5fd5b" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_HostingArrangementServiceContractImplementationCostCapitalizedAmortizationPeriod_0cd052ae-7744-4757-8f31-eaae0f45a05e" xlink:href="lung-20220630.xsd#lung_HostingArrangementServiceContractImplementationCostCapitalizedAmortizationPeriod"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cb84d707-f430-4bc9-ae7e-4fbd3be18310" xlink:to="loc_lung_HostingArrangementServiceContractImplementationCostCapitalizedAmortizationPeriod_0cd052ae-7744-4757-8f31-eaae0f45a05e" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization_49600a09-62f6-4875-a809-8faf0d60d533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cb84d707-f430-4bc9-ae7e-4fbd3be18310" xlink:to="loc_us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization_49600a09-62f6-4875-a809-8faf0d60d533" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7d188f38-a654-48d4-9311-d007baab1b33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cb84d707-f430-4bc9-ae7e-4fbd3be18310" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7d188f38-a654-48d4-9311-d007baab1b33" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a7e62507-f299-4c84-8ae7-06e869d3aae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7d188f38-a654-48d4-9311-d007baab1b33" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a7e62507-f299-4c84-8ae7-06e869d3aae9" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7e62507-f299-4c84-8ae7-06e869d3aae9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a7e62507-f299-4c84-8ae7-06e869d3aae9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7e62507-f299-4c84-8ae7-06e869d3aae9_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4c7db577-dbcb-4bb2-ba5f-60f4f067b1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a7e62507-f299-4c84-8ae7-06e869d3aae9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4c7db577-dbcb-4bb2-ba5f-60f4f067b1d3" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_062487bb-c021-4146-a3b8-2366b689a885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4c7db577-dbcb-4bb2-ba5f-60f4f067b1d3" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_062487bb-c021-4146-a3b8-2366b689a885" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5e47b290-85f2-4231-975b-8aac5f667c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7d188f38-a654-48d4-9311-d007baab1b33" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5e47b290-85f2-4231-975b-8aac5f667c79" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5e47b290-85f2-4231-975b-8aac5f667c79_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5e47b290-85f2-4231-975b-8aac5f667c79" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5e47b290-85f2-4231-975b-8aac5f667c79_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c389274b-e0d5-4920-9f6d-7d0dbbbc2e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5e47b290-85f2-4231-975b-8aac5f667c79" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c389274b-e0d5-4920-9f6d-7d0dbbbc2e3b" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_cdeb5ea9-7cba-461e-bcf4-1296a8faa45f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c389274b-e0d5-4920-9f6d-7d0dbbbc2e3b" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_cdeb5ea9-7cba-461e-bcf4-1296a8faa45f" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_26c8a900-5a1b-4265-b30e-4acffe0d51ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c389274b-e0d5-4920-9f6d-7d0dbbbc2e3b" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_26c8a900-5a1b-4265-b30e-4acffe0d51ac" xlink:type="arc" order="1"/>
</link:definitionLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsIntangibleAssetsDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#BalanceSheetComponentsIntangibleAssetsDetails"/>
<link:definitionLink xlink:role="http://www.pulmonx.com/role/BalanceSheetComponentsIntangibleAssetsDetails" xlink:type="extended" id="i6759021b756b484da00871f0b80a7146_BalanceSheetComponentsIntangibleAssetsDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_90e6c57b-afdf-46c2-bb6a-8d6276696543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_77254758-f02d-4f03-a0fb-25d98ed6c3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_90e6c57b-afdf-46c2-bb6a-8d6276696543" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_77254758-f02d-4f03-a0fb-25d98ed6c3f3" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6fa52268-af0b-4648-8a52-1721f3924012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_90e6c57b-afdf-46c2-bb6a-8d6276696543" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6fa52268-af0b-4648-8a52-1721f3924012" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9f8f57e6-4dd7-442d-86e1-968e81ed93cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_90e6c57b-afdf-46c2-bb6a-8d6276696543" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9f8f57e6-4dd7-442d-86e1-968e81ed93cc" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_12dca7f4-57fd-4bdd-97da-79e19b551d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_90e6c57b-afdf-46c2-bb6a-8d6276696543" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_12dca7f4-57fd-4bdd-97da-79e19b551d4d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ab684e75-65cb-4a05-89fd-7c80b94e40f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_12dca7f4-57fd-4bdd-97da-79e19b551d4d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ab684e75-65cb-4a05-89fd-7c80b94e40f3" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ab684e75-65cb-4a05-89fd-7c80b94e40f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ab684e75-65cb-4a05-89fd-7c80b94e40f3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ab684e75-65cb-4a05-89fd-7c80b94e40f3_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c366de41-af5d-49b4-bfb0-07a59c3e3caf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ab684e75-65cb-4a05-89fd-7c80b94e40f3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c366de41-af5d-49b4-bfb0-07a59c3e3caf" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_47d77a21-16dc-4e25-b6b3-7e88ed0326fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c366de41-af5d-49b4-bfb0-07a59c3e3caf" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_47d77a21-16dc-4e25-b6b3-7e88ed0326fb" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_836b859a-65a6-470d-8096-3bb4fe48a886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c366de41-af5d-49b4-bfb0-07a59c3e3caf" xlink:to="loc_us-gaap_TrademarksMember_836b859a-65a6-470d-8096-3bb4fe48a886" xlink:type="arc" order="1"/>
</link:definitionLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"/>
<link:definitionLink xlink:role="http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails" xlink:type="extended" id="i54283d01e3f14e05ab3df3a591605caa_LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_DebtInstrumentFaceAmountIncludingAccordionFeature_d3af68f6-e3b1-4719-9683-bef84ec1badb" xlink:href="lung-20220630.xsd#lung_DebtInstrumentFaceAmountIncludingAccordionFeature"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_lung_DebtInstrumentFaceAmountIncludingAccordionFeature_d3af68f6-e3b1-4719-9683-bef84ec1badb" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c9de548c-2afc-4d37-b394-a719ff866a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c9de548c-2afc-4d37-b394-a719ff866a29" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_DebtInstrumentAccordionFeatureIncreaseFaceAmount_2e203a6b-8e1a-41c9-ba8c-c9f8b4eb40c7" xlink:href="lung-20220630.xsd#lung_DebtInstrumentAccordionFeatureIncreaseFaceAmount"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_lung_DebtInstrumentAccordionFeatureIncreaseFaceAmount_2e203a6b-8e1a-41c9-ba8c-c9f8b4eb40c7" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_259a4af5-e160-4344-8d82-f90a05677930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_us-gaap_DebtInstrumentTerm_259a4af5-e160-4344-8d82-f90a05677930" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_DebtInstrumentPeriodicPaymentInterestOnlyTerm_26e4eb58-9e5f-4551-ad93-d2c5651dda0e" xlink:href="lung-20220630.xsd#lung_DebtInstrumentPeriodicPaymentInterestOnlyTerm"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_lung_DebtInstrumentPeriodicPaymentInterestOnlyTerm_26e4eb58-9e5f-4551-ad93-d2c5651dda0e" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm_2444a29d-b84d-4155-be05-e496100fd1f7" xlink:href="lung-20220630.xsd#lung_DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_lung_DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm_2444a29d-b84d-4155-be05-e496100fd1f7" xlink:type="arc" order="5"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1d27b7cc-33c7-4da8-9729-f2cb61af87a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1d27b7cc-33c7-4da8-9729-f2cb61af87a9" xlink:type="arc" order="6"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_0a1e3853-c19d-463b-9e50-cbe3a9f3d14f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_0a1e3853-c19d-463b-9e50-cbe3a9f3d14f" xlink:type="arc" order="7"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_GainLossOnAmendmentOfDebtInstrument_c4ccc9e6-79e1-45f1-82c5-906e1cd2e512" xlink:href="lung-20220630.xsd#lung_GainLossOnAmendmentOfDebtInstrument"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_lung_GainLossOnAmendmentOfDebtInstrument_c4ccc9e6-79e1-45f1-82c5-906e1cd2e512" xlink:type="arc" order="8"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_DebtInstrumentNumberOfPeriodicPayments_31244248-11fe-40e9-b969-79c7b665e4db" xlink:href="lung-20220630.xsd#lung_DebtInstrumentNumberOfPeriodicPayments"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_lung_DebtInstrumentNumberOfPeriodicPayments_31244248-11fe-40e9-b969-79c7b665e4db" xlink:type="arc" order="9"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_ddc28568-7e0c-4e16-b617-5a0c60cffead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_ddc28568-7e0c-4e16-b617-5a0c60cffead" xlink:type="arc" order="10"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_IncreaseInLoanInterestRate_94567679-de3e-4caa-9ed3-ea9aba64597e" xlink:href="lung-20220630.xsd#lung_IncreaseInLoanInterestRate"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_lung_IncreaseInLoanInterestRate_94567679-de3e-4caa-9ed3-ea9aba64597e" xlink:type="arc" order="11"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_87d6479b-e678-4095-b7b3-50368ab0a84d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_87d6479b-e678-4095-b7b3-50368ab0a84d" xlink:type="arc" order="12"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_DebtInstrumentCovenantCashAndCashEquivalentsMinimumThresholdTriggerForRevenueRequirement_35654690-11e1-4069-be7c-63aead529c0b" xlink:href="lung-20220630.xsd#lung_DebtInstrumentCovenantCashAndCashEquivalentsMinimumThresholdTriggerForRevenueRequirement"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_lung_DebtInstrumentCovenantCashAndCashEquivalentsMinimumThresholdTriggerForRevenueRequirement_35654690-11e1-4069-be7c-63aead529c0b" xlink:type="arc" order="13"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_DebtInstrumentCovenantMinimumRevenueRequirementPeriod_1046d5e7-77ea-489a-8240-f8ff2dcb7b6b" xlink:href="lung-20220630.xsd#lung_DebtInstrumentCovenantMinimumRevenueRequirementPeriod"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_lung_DebtInstrumentCovenantMinimumRevenueRequirementPeriod_1046d5e7-77ea-489a-8240-f8ff2dcb7b6b" xlink:type="arc" order="14"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_DebtInstrumentCovenantMinimumRevenueRequirementsPercentage_863697c5-65fb-48aa-a7c8-780b7f3b8c23" xlink:href="lung-20220630.xsd#lung_DebtInstrumentCovenantMinimumRevenueRequirementsPercentage"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_lung_DebtInstrumentCovenantMinimumRevenueRequirementsPercentage_863697c5-65fb-48aa-a7c8-780b7f3b8c23" xlink:type="arc" order="15"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_DebtInstrumentCovenantUnrestrictedCashRequirementPeriod_9290ce6a-077d-4433-b611-083e69d8c8a7" xlink:href="lung-20220630.xsd#lung_DebtInstrumentCovenantUnrestrictedCashRequirementPeriod"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_lung_DebtInstrumentCovenantUnrestrictedCashRequirementPeriod_9290ce6a-077d-4433-b611-083e69d8c8a7" xlink:type="arc" order="16"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_e8e36bc5-1ed2-47ce-80ed-4b2af6bf02e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_e8e36bc5-1ed2-47ce-80ed-4b2af6bf02e2" xlink:type="arc" order="17"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_6a33c405-e389-4b57-b42e-cd7dc6e0b8c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_6a33c405-e389-4b57-b42e-cd7dc6e0b8c0" xlink:type="arc" order="18"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5d31c777-c307-437a-b1f0-9a824fba9148" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_us-gaap_DebtInstrumentTable_5d31c777-c307-437a-b1f0-9a824fba9148" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ada642b7-9e53-4d96-8064-29d17e422cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5d31c777-c307-437a-b1f0-9a824fba9148" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ada642b7-9e53-4d96-8064-29d17e422cd6" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ada642b7-9e53-4d96-8064-29d17e422cd6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ada642b7-9e53-4d96-8064-29d17e422cd6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ada642b7-9e53-4d96-8064-29d17e422cd6_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fa8810e4-1ba0-479a-8f39-c694d654e395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ada642b7-9e53-4d96-8064-29d17e422cd6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fa8810e4-1ba0-479a-8f39-c694d654e395" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_92da3d1c-6071-48ac-abcf-f5b7c4d96934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MediumTermNotesMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fa8810e4-1ba0-479a-8f39-c694d654e395" xlink:to="loc_us-gaap_MediumTermNotesMember_92da3d1c-6071-48ac-abcf-f5b7c4d96934" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9f29fc80-8614-4566-b0c9-f8929e046176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5d31c777-c307-437a-b1f0-9a824fba9148" xlink:to="loc_us-gaap_DebtInstrumentAxis_9f29fc80-8614-4566-b0c9-f8929e046176" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9f29fc80-8614-4566-b0c9-f8929e046176_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9f29fc80-8614-4566-b0c9-f8929e046176" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9f29fc80-8614-4566-b0c9-f8929e046176_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9d0990f3-bf16-44cd-9c6a-30a7adf5e733" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9f29fc80-8614-4566-b0c9-f8929e046176" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9d0990f3-bf16-44cd-9c6a-30a7adf5e733" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_CIBCAgreementMember_36ad9ab0-99c8-428f-b5c5-883fa53e70aa" xlink:href="lung-20220630.xsd#lung_CIBCAgreementMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9d0990f3-bf16-44cd-9c6a-30a7adf5e733" xlink:to="loc_lung_CIBCAgreementMember_36ad9ab0-99c8-428f-b5c5-883fa53e70aa" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_CIBCAgreementTrancheAMember_cccc8b61-449e-4859-88b1-ecc763d26d17" xlink:href="lung-20220630.xsd#lung_CIBCAgreementTrancheAMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lung_CIBCAgreementMember_36ad9ab0-99c8-428f-b5c5-883fa53e70aa" xlink:to="loc_lung_CIBCAgreementTrancheAMember_cccc8b61-449e-4859-88b1-ecc763d26d17" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_CIBCAgreementTrancheBMember_8c13e7a5-e330-41c3-8a61-1b9cafd5b7b1" xlink:href="lung-20220630.xsd#lung_CIBCAgreementTrancheBMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lung_CIBCAgreementMember_36ad9ab0-99c8-428f-b5c5-883fa53e70aa" xlink:to="loc_lung_CIBCAgreementTrancheBMember_8c13e7a5-e330-41c3-8a61-1b9cafd5b7b1" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_CIBCAgreementTrancheCMember_49db1b5f-ce60-451c-8abd-f3b455fe62c4" xlink:href="lung-20220630.xsd#lung_CIBCAgreementTrancheCMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lung_CIBCAgreementMember_36ad9ab0-99c8-428f-b5c5-883fa53e70aa" xlink:to="loc_lung_CIBCAgreementTrancheCMember_49db1b5f-ce60-451c-8abd-f3b455fe62c4" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_bb8463e3-a2ae-41eb-bda4-e8f354e826f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5d31c777-c307-437a-b1f0-9a824fba9148" xlink:to="loc_us-gaap_VariableRateAxis_bb8463e3-a2ae-41eb-bda4-e8f354e826f9" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_bb8463e3-a2ae-41eb-bda4-e8f354e826f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_bb8463e3-a2ae-41eb-bda4-e8f354e826f9" xlink:to="loc_us-gaap_VariableRateDomain_bb8463e3-a2ae-41eb-bda4-e8f354e826f9_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_b24000b1-af16-4029-a3ce-824396471936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_bb8463e3-a2ae-41eb-bda4-e8f354e826f9" xlink:to="loc_us-gaap_VariableRateDomain_b24000b1-af16-4029-a3ce-824396471936" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_54de4eb4-5d4c-441c-acd9-230d22c028a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_b24000b1-af16-4029-a3ce-824396471936" xlink:to="loc_us-gaap_PrimeRateMember_54de4eb4-5d4c-441c-acd9-230d22c028a3" xlink:type="arc" order="0"/>
</link:definitionLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanComponentsOfDebtDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#LongTermDebtandConvertibleNotesCIBCLoanComponentsOfDebtDetails"/>
<link:definitionLink xlink:role="http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanComponentsOfDebtDetails" xlink:type="extended" id="id012335faaf240fabd390caeb476e357_LongTermDebtandConvertibleNotesCIBCLoanComponentsOfDebtDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_92aa4c67-cc9e-4e6f-baee-b4842d948ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c338b44a-6bc0-4181-945b-0dc68abdc406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92aa4c67-cc9e-4e6f-baee-b4842d948ec1" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c338b44a-6bc0-4181-945b-0dc68abdc406" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_d3280b9b-35fa-4d2c-92c8-743d762c7ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92aa4c67-cc9e-4e6f-baee-b4842d948ec1" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_d3280b9b-35fa-4d2c-92c8-743d762c7ec5" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6d0e3c42-50f4-4368-a652-05cdb26759e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92aa4c67-cc9e-4e6f-baee-b4842d948ec1" xlink:to="loc_us-gaap_LongTermDebt_6d0e3c42-50f4-4368-a652-05cdb26759e1" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_10848bb9-8ac2-4619-ae94-6033abd9394b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92aa4c67-cc9e-4e6f-baee-b4842d948ec1" xlink:to="loc_us-gaap_DebtInstrumentTable_10848bb9-8ac2-4619-ae94-6033abd9394b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_883ad5fc-c625-419c-ba55-488831049ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_10848bb9-8ac2-4619-ae94-6033abd9394b" xlink:to="loc_us-gaap_DebtInstrumentAxis_883ad5fc-c625-419c-ba55-488831049ac4" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_883ad5fc-c625-419c-ba55-488831049ac4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_883ad5fc-c625-419c-ba55-488831049ac4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_883ad5fc-c625-419c-ba55-488831049ac4_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_81e9a2ad-0ae6-4f57-a49e-4e5b259f1f80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_883ad5fc-c625-419c-ba55-488831049ac4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_81e9a2ad-0ae6-4f57-a49e-4e5b259f1f80" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_CIBCAgreementMember_7b555d3f-b80d-47c2-b751-9297678922b1" xlink:href="lung-20220630.xsd#lung_CIBCAgreementMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_81e9a2ad-0ae6-4f57-a49e-4e5b259f1f80" xlink:to="loc_lung_CIBCAgreementMember_7b555d3f-b80d-47c2-b751-9297678922b1" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cf34b958-93d8-4add-8ea0-8108629494f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_10848bb9-8ac2-4619-ae94-6033abd9394b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cf34b958-93d8-4add-8ea0-8108629494f1" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cf34b958-93d8-4add-8ea0-8108629494f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cf34b958-93d8-4add-8ea0-8108629494f1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cf34b958-93d8-4add-8ea0-8108629494f1_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8ff28341-8c15-4722-a409-b888a4f8d924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cf34b958-93d8-4add-8ea0-8108629494f1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8ff28341-8c15-4722-a409-b888a4f8d924" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_87db3043-5ae0-4326-a497-0fc9eab365e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MediumTermNotesMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8ff28341-8c15-4722-a409-b888a4f8d924" xlink:to="loc_us-gaap_MediumTermNotesMember_87db3043-5ae0-4326-a497-0fc9eab365e7" xlink:type="arc" order="0"/>
</link:definitionLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCreditAgreementandPaycheckProtectionProgramNarrativeDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#LongTermDebtandConvertibleNotesCreditAgreementandPaycheckProtectionProgramNarrativeDetails"/>
<link:definitionLink xlink:role="http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCreditAgreementandPaycheckProtectionProgramNarrativeDetails" xlink:type="extended" id="i1f330975a97e4713807e05860bba7e6b_LongTermDebtandConvertibleNotesCreditAgreementandPaycheckProtectionProgramNarrativeDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_72352f0c-1ae6-462f-a72d-295e024fc0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c27d3ff0-57a6-48ad-8448-5f518fce64f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72352f0c-1ae6-462f-a72d-295e024fc0ff" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c27d3ff0-57a6-48ad-8448-5f518fce64f1" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_4aa6ed0c-8ce3-4e6c-86f4-2b7e5624bc00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72352f0c-1ae6-462f-a72d-295e024fc0ff" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_4aa6ed0c-8ce3-4e6c-86f4-2b7e5624bc00" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_NumberOfInstallmentsForRepayment_c83f3ef4-80bb-47fd-a972-66037e9ed371" xlink:href="lung-20220630.xsd#lung_NumberOfInstallmentsForRepayment"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72352f0c-1ae6-462f-a72d-295e024fc0ff" xlink:to="loc_lung_NumberOfInstallmentsForRepayment_c83f3ef4-80bb-47fd-a972-66037e9ed371" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_283cec3b-a819-4886-91bf-dd95711e7dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72352f0c-1ae6-462f-a72d-295e024fc0ff" xlink:to="loc_us-gaap_RepaymentsOfDebt_283cec3b-a819-4886-91bf-dd95711e7dd1" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_fd8edd57-f2fd-4dc6-840d-8e2016da2ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72352f0c-1ae6-462f-a72d-295e024fc0ff" xlink:to="loc_us-gaap_DebtInstrumentTable_fd8edd57-f2fd-4dc6-840d-8e2016da2ca9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_63ba1b6b-1f99-4430-8cd4-739370dda444" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fd8edd57-f2fd-4dc6-840d-8e2016da2ca9" xlink:to="loc_dei_LegalEntityAxis_63ba1b6b-1f99-4430-8cd4-739370dda444" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_63ba1b6b-1f99-4430-8cd4-739370dda444_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_63ba1b6b-1f99-4430-8cd4-739370dda444" xlink:to="loc_dei_EntityDomain_63ba1b6b-1f99-4430-8cd4-739370dda444_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f36efa29-fca9-4710-8bcb-a6d3d54f9533" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_63ba1b6b-1f99-4430-8cd4-739370dda444" xlink:to="loc_dei_EntityDomain_f36efa29-fca9-4710-8bcb-a6d3d54f9533" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_PulmonxInternationalSarlMember_d076a940-8090-406f-8757-afb76858c925" xlink:href="lung-20220630.xsd#lung_PulmonxInternationalSarlMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_f36efa29-fca9-4710-8bcb-a6d3d54f9533" xlink:to="loc_lung_PulmonxInternationalSarlMember_d076a940-8090-406f-8757-afb76858c925" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5dc3c77a-b901-4804-99bc-0fdef0773269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fd8edd57-f2fd-4dc6-840d-8e2016da2ca9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5dc3c77a-b901-4804-99bc-0fdef0773269" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5dc3c77a-b901-4804-99bc-0fdef0773269_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5dc3c77a-b901-4804-99bc-0fdef0773269" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5dc3c77a-b901-4804-99bc-0fdef0773269_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_034718a2-b6d7-42ec-a99d-7e1fb15b7ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5dc3c77a-b901-4804-99bc-0fdef0773269" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_034718a2-b6d7-42ec-a99d-7e1fb15b7ae9" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_33457485-a650-4455-b2bd-d855440a4ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_034718a2-b6d7-42ec-a99d-7e1fb15b7ae9" xlink:to="loc_us-gaap_LineOfCreditMember_33457485-a650-4455-b2bd-d855440a4ad0" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fd5af59e-0c3f-4e38-ac40-150d4fbe96cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fd8edd57-f2fd-4dc6-840d-8e2016da2ca9" xlink:to="loc_us-gaap_DebtInstrumentAxis_fd5af59e-0c3f-4e38-ac40-150d4fbe96cb" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fd5af59e-0c3f-4e38-ac40-150d4fbe96cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_fd5af59e-0c3f-4e38-ac40-150d4fbe96cb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fd5af59e-0c3f-4e38-ac40-150d4fbe96cb_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d37c5e20-9797-4a4a-ab96-f4a97b2f45c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_fd5af59e-0c3f-4e38-ac40-150d4fbe96cb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d37c5e20-9797-4a4a-ab96-f4a97b2f45c6" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_COVID19CreditAgreementMember_48ef7940-c2d2-4af7-91b6-5ee66a936dcb" xlink:href="lung-20220630.xsd#lung_COVID19CreditAgreementMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d37c5e20-9797-4a4a-ab96-f4a97b2f45c6" xlink:to="loc_lung_COVID19CreditAgreementMember_48ef7940-c2d2-4af7-91b6-5ee66a936dcb" xlink:type="arc" order="0"/>
</link:definitionLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/CommitmentsandContingenciesLeasesNarrativeDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#CommitmentsandContingenciesLeasesNarrativeDetails"/>
<link:definitionLink xlink:role="http://www.pulmonx.com/role/CommitmentsandContingenciesLeasesNarrativeDetails" xlink:type="extended" id="i990b0ba2103c4e17a8e78ba5a42171d9_CommitmentsandContingenciesLeasesNarrativeDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a3be72a6-fec6-4c9d-b6c7-c65607a31bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a3be72a6-fec6-4c9d-b6c7-c65607a31bee" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_OperatingLeaseMonthlyExpense_d69100c5-28e9-47e2-97ee-deb49fdaa01e" xlink:href="lung-20220630.xsd#lung_OperatingLeaseMonthlyExpense"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_lung_OperatingLeaseMonthlyExpense_d69100c5-28e9-47e2-97ee-deb49fdaa01e" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_OperatingLeaseExpenseAnnualIncreaseRate_47b27dce-5afd-45e9-93c5-9495369c0af8" xlink:href="lung-20220630.xsd#lung_OperatingLeaseExpenseAnnualIncreaseRate"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_lung_OperatingLeaseExpenseAnnualIncreaseRate_47b27dce-5afd-45e9-93c5-9495369c0af8" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_TenantImprovementAllowanceReceivableUponLeaseRenewal_a445cc90-ecdb-4ed8-99df-9f63f58f8949" xlink:href="lung-20220630.xsd#lung_TenantImprovementAllowanceReceivableUponLeaseRenewal"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_lung_TenantImprovementAllowanceReceivableUponLeaseRenewal_a445cc90-ecdb-4ed8-99df-9f63f58f8949" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_55da35ff-ee3c-444a-9917-783af3302638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_55da35ff-ee3c-444a-9917-783af3302638" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_LesseeOperatingLeaseOptionToTerminateNoticePeriod_e141b1aa-00da-4456-ba81-7651baa1397f" xlink:href="lung-20220630.xsd#lung_LesseeOperatingLeaseOptionToTerminateNoticePeriod"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_lung_LesseeOperatingLeaseOptionToTerminateNoticePeriod_e141b1aa-00da-4456-ba81-7651baa1397f" xlink:type="arc" order="5"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_LesseeOperatingSubleaseTerm_4f344a12-1192-435e-90d7-c6e1c2bd6869" xlink:href="lung-20220630.xsd#lung_LesseeOperatingSubleaseTerm"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_lung_LesseeOperatingSubleaseTerm_4f344a12-1192-435e-90d7-c6e1c2bd6869" xlink:type="arc" order="6"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_LesseeOperatingSubleaseOptionToTerminateNoticePeriod_0ae4bb82-17ff-4116-ae56-4e36e1f7b1d7" xlink:href="lung-20220630.xsd#lung_LesseeOperatingSubleaseOptionToTerminateNoticePeriod"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_lung_LesseeOperatingSubleaseOptionToTerminateNoticePeriod_0ae4bb82-17ff-4116-ae56-4e36e1f7b1d7" xlink:type="arc" order="7"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_LesseeOperatingSubleaseOptionToTerminateTerm_d2cb4353-8fac-4775-b2dc-05ea07ea0d57" xlink:href="lung-20220630.xsd#lung_LesseeOperatingSubleaseOptionToTerminateTerm"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_lung_LesseeOperatingSubleaseOptionToTerminateTerm_d2cb4353-8fac-4775-b2dc-05ea07ea0d57" xlink:type="arc" order="8"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_LesseeOperatingSubleaseMonthlyExpense_979bda44-0be2-4e53-9b54-94fba8513918" xlink:href="lung-20220630.xsd#lung_LesseeOperatingSubleaseMonthlyExpense"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_lung_LesseeOperatingSubleaseMonthlyExpense_979bda44-0be2-4e53-9b54-94fba8513918" xlink:type="arc" order="9"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_LesseeOperatingSubleaseExpenseAnnualIncreaseRate_340d7c47-2ccd-4bc9-9c0d-68f1f47338ae" xlink:href="lung-20220630.xsd#lung_LesseeOperatingSubleaseExpenseAnnualIncreaseRate"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_lung_LesseeOperatingSubleaseExpenseAnnualIncreaseRate_340d7c47-2ccd-4bc9-9c0d-68f1f47338ae" xlink:type="arc" order="10"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_LesseeOperatingSubleaseTenantImprovementAllowanceReceivableUponLeaseRenewal_9b4f3da8-ca2f-4866-88ca-813195e0ecf4" xlink:href="lung-20220630.xsd#lung_LesseeOperatingSubleaseTenantImprovementAllowanceReceivableUponLeaseRenewal"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_lung_LesseeOperatingSubleaseTenantImprovementAllowanceReceivableUponLeaseRenewal_9b4f3da8-ca2f-4866-88ca-813195e0ecf4" xlink:type="arc" order="11"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_LesseeOperatingSubleaseRenewalTerm_9de73cb0-181b-4bea-8b69-4c9677f37b33" xlink:href="lung-20220630.xsd#lung_LesseeOperatingSubleaseRenewalTerm"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_lung_LesseeOperatingSubleaseRenewalTerm_9de73cb0-181b-4bea-8b69-4c9677f37b33" xlink:type="arc" order="12"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_NumberOfVehicleLeases_af071158-933e-4bd1-ac87-075fefac0892" xlink:href="lung-20220630.xsd#lung_NumberOfVehicleLeases"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_lung_NumberOfVehicleLeases_af071158-933e-4bd1-ac87-075fefac0892" xlink:type="arc" order="13"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_4ceaa65a-6e92-4a68-9b6e-317f61ba2d41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_4ceaa65a-6e92-4a68-9b6e-317f61ba2d41" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a8b4fff5-0f21-474c-b37f-9a1b76c15494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_4ceaa65a-6e92-4a68-9b6e-317f61ba2d41" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a8b4fff5-0f21-474c-b37f-9a1b76c15494" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a8b4fff5-0f21-474c-b37f-9a1b76c15494_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a8b4fff5-0f21-474c-b37f-9a1b76c15494" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a8b4fff5-0f21-474c-b37f-9a1b76c15494_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ad48c48-ea81-4d6a-9cd9-20f22eb4c4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a8b4fff5-0f21-474c-b37f-9a1b76c15494" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ad48c48-ea81-4d6a-9cd9-20f22eb4c4b2" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_b4ec9cf1-a2f2-461d-9648-85beedcbb1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ad48c48-ea81-4d6a-9cd9-20f22eb4c4b2" xlink:to="loc_us-gaap_BuildingMember_b4ec9cf1-a2f2-461d-9648-85beedcbb1d6" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_b2562f58-fd69-40ba-b698-7a8faf0e2b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ad48c48-ea81-4d6a-9cd9-20f22eb4c4b2" xlink:to="loc_us-gaap_VehiclesMember_b2562f58-fd69-40ba-b698-7a8faf0e2b0d" xlink:type="arc" order="1"/>
</link:definitionLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/CommitmentsandContingenciesServiceAgreementDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#CommitmentsandContingenciesServiceAgreementDetails"/>
<link:definitionLink xlink:role="http://www.pulmonx.com/role/CommitmentsandContingenciesServiceAgreementDetails" xlink:type="extended" id="i63f65a649b384e8788c0589c5ba8377b_CommitmentsandContingenciesServiceAgreementDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_44327cae-8f11-43a9-a2ef-16710eb29519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_4cd2247a-286b-454b-88f5-582ebf4233b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_44327cae-8f11-43a9-a2ef-16710eb29519" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_4cd2247a-286b-454b-88f5-582ebf4233b0" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_d2ebacec-ec6b-48e4-bd23-96552eeedb00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_44327cae-8f11-43a9-a2ef-16710eb29519" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_d2ebacec-ec6b-48e4-bd23-96552eeedb00" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_cae0b564-bd8f-46a1-8863-205b137c55de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_44327cae-8f11-43a9-a2ef-16710eb29519" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_cae0b564-bd8f-46a1-8863-205b137c55de" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_79818eaf-6001-43ec-8136-95ddedd7b884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_44327cae-8f11-43a9-a2ef-16710eb29519" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_79818eaf-6001-43ec-8136-95ddedd7b884" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_6a1f8238-30a8-407e-96a2-0d53449c3611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_44327cae-8f11-43a9-a2ef-16710eb29519" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_6a1f8238-30a8-407e-96a2-0d53449c3611" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_f6ae3428-1e0c-43eb-9834-7267c904bd12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_6a1f8238-30a8-407e-96a2-0d53449c3611" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_f6ae3428-1e0c-43eb-9834-7267c904bd12" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_f6ae3428-1e0c-43eb-9834-7267c904bd12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_f6ae3428-1e0c-43eb-9834-7267c904bd12" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_f6ae3428-1e0c-43eb-9834-7267c904bd12_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_366fd4b7-c54e-48d8-8e53-2506ab750bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_f6ae3428-1e0c-43eb-9834-7267c904bd12" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_366fd4b7-c54e-48d8-8e53-2506ab750bfc" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_ServiceAgreementPurchaseMember_cf04c8db-1247-4c66-bc12-23edb6a2af48" xlink:href="lung-20220630.xsd#lung_ServiceAgreementPurchaseMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_366fd4b7-c54e-48d8-8e53-2506ab750bfc" xlink:to="loc_lung_ServiceAgreementPurchaseMember_cf04c8db-1247-4c66-bc12-23edb6a2af48" xlink:type="arc" order="0"/>
</link:definitionLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#IncomeTaxesDetails"/>
<link:definitionLink xlink:role="http://www.pulmonx.com/role/IncomeTaxesDetails" xlink:type="extended" id="i8e4ffb1199a94b50bc639f87c11ff3a5_IncomeTaxesDetails">
<link:loc xlink:type="locator" xlink:label="loc_lung_IncomeTaxDisclosureLineItems_1ac8a11a-4ab1-4fd5-a8d2-bba3790eeb09" xlink:href="lung-20220630.xsd#lung_IncomeTaxDisclosureLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2d7c37b6-6d47-4a11-aec1-5eda442748c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lung_IncomeTaxDisclosureLineItems_1ac8a11a-4ab1-4fd5-a8d2-bba3790eeb09" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2d7c37b6-6d47-4a11-aec1-5eda442748c3" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_IncomeTaxDisclosureTable_f2a208c4-5fdf-47e4-9f72-adcda2755c33" xlink:href="lung-20220630.xsd#lung_IncomeTaxDisclosureTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_lung_IncomeTaxDisclosureLineItems_1ac8a11a-4ab1-4fd5-a8d2-bba3790eeb09" xlink:to="loc_lung_IncomeTaxDisclosureTable_f2a208c4-5fdf-47e4-9f72-adcda2755c33" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_84a96e40-de8f-4c3d-a73a-900d0c694e85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lung_IncomeTaxDisclosureTable_f2a208c4-5fdf-47e4-9f72-adcda2755c33" xlink:to="loc_srt_RangeAxis_84a96e40-de8f-4c3d-a73a-900d0c694e85" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_84a96e40-de8f-4c3d-a73a-900d0c694e85_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_84a96e40-de8f-4c3d-a73a-900d0c694e85" xlink:to="loc_srt_RangeMember_84a96e40-de8f-4c3d-a73a-900d0c694e85_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_450cf840-80d4-4010-97a5-39cde05e04e1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_84a96e40-de8f-4c3d-a73a-900d0c694e85" xlink:to="loc_srt_RangeMember_450cf840-80d4-4010-97a5-39cde05e04e1" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ee47bbe3-f941-48be-bc8c-353c2a0a924f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_450cf840-80d4-4010-97a5-39cde05e04e1" xlink:to="loc_srt_MaximumMember_ee47bbe3-f941-48be-bc8c-353c2a0a924f" xlink:type="arc" order="0"/>
</link:definitionLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#StockholdersEquityNarrativeDetails"/>
<link:definitionLink xlink:role="http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i06bbf42d29b14ccca2c0f08ae14d1d49_StockholdersEquityNarrativeDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b09662b7-c926-4f6a-bd7e-b731bf013119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b09662b7-c926-4f6a-bd7e-b731bf013119" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock_e0583264-3486-4455-a030-f9e8876711d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_us-gaap_DividendsCommonStock_e0583264-3486-4455-a030-f9e8876711d7" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_NumberOfVotesForEachShareOfCommonStockHeld_f9a5d536-a6bb-4004-8d7b-4902f0c42fad" xlink:href="lung-20220630.xsd#lung_NumberOfVotesForEachShareOfCommonStockHeld"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_lung_NumberOfVotesForEachShareOfCommonStockHeld_f9a5d536-a6bb-4004-8d7b-4902f0c42fad" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f0f88c0b-a3be-4568-b459-133b521f017d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f0f88c0b-a3be-4568-b459-133b521f017d" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a1dab4c5-50f2-4290-8fd8-edaf7c207de9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a1dab4c5-50f2-4290-8fd8-edaf7c207de9" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_dbb4cf3b-3372-4f0e-b97c-b191ebd51cac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_dbb4cf3b-3372-4f0e-b97c-b191ebd51cac" xlink:type="arc" order="5"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e3940338-d55c-4f8a-b8c0-7305b355322f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e3940338-d55c-4f8a-b8c0-7305b355322f" xlink:type="arc" order="6"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_098d05cf-f917-439e-b8ce-59e5c360bfc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_098d05cf-f917-439e-b8ce-59e5c360bfc6" xlink:type="arc" order="7"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_f58c0a78-44b5-4f85-8296-fc00d3097df3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_f58c0a78-44b5-4f85-8296-fc00d3097df3" xlink:type="arc" order="8"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchase_58c98e46-b79d-474e-b4af-75f793018688" xlink:href="lung-20220630.xsd#lung_ShareBasedPaymentArrangementSharesSubjectToRepurchase"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchase_58c98e46-b79d-474e-b4af-75f793018688" xlink:type="arc" order="9"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice_a7c485e6-b1de-4e5e-aaff-ff25d2587fe7" xlink:href="lung-20220630.xsd#lung_ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice_a7c485e6-b1de-4e5e-aaff-ff25d2587fe7" xlink:type="arc" order="10"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_22a72d14-28af-4380-8a9d-7898f95b7294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_22a72d14-28af-4380-8a9d-7898f95b7294" xlink:type="arc" order="11"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_28199362-9e3c-4730-8cea-afb3651c83e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_28199362-9e3c-4730-8cea-afb3651c83e6" xlink:type="arc" order="12"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5ad105dc-1eb1-4d5f-b2b0-561dcfd8aa1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5ad105dc-1eb1-4d5f-b2b0-561dcfd8aa1b" xlink:type="arc" order="13"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_e77d9089-7236-47f9-b00a-78d5777c4d80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_e77d9089-7236-47f9-b00a-78d5777c4d80" xlink:type="arc" order="14"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c2f1c01f-8081-4779-a7f7-d204fc128a87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c2f1c01f-8081-4779-a7f7-d204fc128a87" xlink:type="arc" order="15"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f40914d-f2b6-402b-adc2-dea182674d57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f40914d-f2b6-402b-adc2-dea182674d57" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_94239d64-5e2f-411d-8be5-94edbac69616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f40914d-f2b6-402b-adc2-dea182674d57" xlink:to="loc_us-gaap_AwardTypeAxis_94239d64-5e2f-411d-8be5-94edbac69616" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94239d64-5e2f-411d-8be5-94edbac69616_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_94239d64-5e2f-411d-8be5-94edbac69616" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94239d64-5e2f-411d-8be5-94edbac69616_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5cef0de-0aba-4a7d-a6ab-735214a746de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_94239d64-5e2f-411d-8be5-94edbac69616" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5cef0de-0aba-4a7d-a6ab-735214a746de" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2a828a9d-081f-4457-8e41-1e38808545da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5cef0de-0aba-4a7d-a6ab-735214a746de" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2a828a9d-081f-4457-8e41-1e38808545da" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4dd3e48e-8e86-473c-b73e-872bbefabe47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5cef0de-0aba-4a7d-a6ab-735214a746de" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4dd3e48e-8e86-473c-b73e-872bbefabe47" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_StockOptionsAndRestrictedStockUnitsMember_12a22139-3d47-4f3b-984a-4d929d9b6d76" xlink:href="lung-20220630.xsd#lung_StockOptionsAndRestrictedStockUnitsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5cef0de-0aba-4a7d-a6ab-735214a746de" xlink:to="loc_lung_StockOptionsAndRestrictedStockUnitsMember_12a22139-3d47-4f3b-984a-4d929d9b6d76" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_e732a245-6d4c-4416-abba-5596f0de097a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5cef0de-0aba-4a7d-a6ab-735214a746de" xlink:to="loc_us-gaap_EmployeeStockMember_e732a245-6d4c-4416-abba-5596f0de097a" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1e6e1fb2-cd0d-4e14-bcca-f33a5fc1d10c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f40914d-f2b6-402b-adc2-dea182674d57" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1e6e1fb2-cd0d-4e14-bcca-f33a5fc1d10c" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1e6e1fb2-cd0d-4e14-bcca-f33a5fc1d10c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1e6e1fb2-cd0d-4e14-bcca-f33a5fc1d10c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1e6e1fb2-cd0d-4e14-bcca-f33a5fc1d10c_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ca9a4255-3134-403e-9d6c-a6f845c9d1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1e6e1fb2-cd0d-4e14-bcca-f33a5fc1d10c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ca9a4255-3134-403e-9d6c-a6f845c9d1cc" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_InventoryNetMember_68b45519-1237-4774-939f-bb2ba22e410c" xlink:href="lung-20220630.xsd#lung_InventoryNetMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ca9a4255-3134-403e-9d6c-a6f845c9d1cc" xlink:to="loc_lung_InventoryNetMember_68b45519-1237-4774-939f-bb2ba22e410c" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d63eea0f-e567-4b99-bd10-fd7c1cf16e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f40914d-f2b6-402b-adc2-dea182674d57" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d63eea0f-e567-4b99-bd10-fd7c1cf16e7b" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d63eea0f-e567-4b99-bd10-fd7c1cf16e7b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d63eea0f-e567-4b99-bd10-fd7c1cf16e7b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d63eea0f-e567-4b99-bd10-fd7c1cf16e7b_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_80b3dc65-ff52-4965-b488-0e4bfe142950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d63eea0f-e567-4b99-bd10-fd7c1cf16e7b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_80b3dc65-ff52-4965-b488-0e4bfe142950" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_CostOfGoodsAndServicesSoldMember_ae6e4e10-3a80-4d01-a766-519499900546" xlink:href="lung-20220630.xsd#lung_CostOfGoodsAndServicesSoldMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_80b3dc65-ff52-4965-b488-0e4bfe142950" xlink:to="loc_lung_CostOfGoodsAndServicesSoldMember_ae6e4e10-3a80-4d01-a766-519499900546" xlink:type="arc" order="0"/>
</link:definitionLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#StockholdersEquitySharesReservedforFutureIssuanceDetails"/>
<link:definitionLink xlink:role="http://www.pulmonx.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails" xlink:type="extended" id="i9ce7d852eefa4e3e8b7cec5c2b78b8cb_StockholdersEquitySharesReservedforFutureIssuanceDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_2cad93f3-c27a-4be6-9abb-aebd413e293a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f3ca66ba-c074-48d8-bac5-68b484e103b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2cad93f3-c27a-4be6-9abb-aebd413e293a" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f3ca66ba-c074-48d8-bac5-68b484e103b0" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e9f93289-7e5d-4bb1-88a6-b6564579e9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_2cad93f3-c27a-4be6-9abb-aebd413e293a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e9f93289-7e5d-4bb1-88a6-b6564579e9b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3641859d-98c3-45bd-b855-a56e48f0f402" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e9f93289-7e5d-4bb1-88a6-b6564579e9b2" xlink:to="loc_us-gaap_AwardTypeAxis_3641859d-98c3-45bd-b855-a56e48f0f402" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3641859d-98c3-45bd-b855-a56e48f0f402_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3641859d-98c3-45bd-b855-a56e48f0f402" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3641859d-98c3-45bd-b855-a56e48f0f402_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_307dfd75-9b05-47e8-a357-2ee25057fd7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3641859d-98c3-45bd-b855-a56e48f0f402" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_307dfd75-9b05-47e8-a357-2ee25057fd7f" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_ShareBasedCompensationEmployeeStockOutstandingMember_fff5e7c9-e2cd-4a2d-adf5-fab4e24d868f" xlink:href="lung-20220630.xsd#lung_ShareBasedCompensationEmployeeStockOutstandingMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_307dfd75-9b05-47e8-a357-2ee25057fd7f" xlink:to="loc_lung_ShareBasedCompensationEmployeeStockOutstandingMember_fff5e7c9-e2cd-4a2d-adf5-fab4e24d868f" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_CommonStockRestrictedStockUnitsIssuedAndOutstandingMember_716e9e2d-754e-4826-90b5-9ba31975cce0" xlink:href="lung-20220630.xsd#lung_CommonStockRestrictedStockUnitsIssuedAndOutstandingMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_307dfd75-9b05-47e8-a357-2ee25057fd7f" xlink:to="loc_lung_CommonStockRestrictedStockUnitsIssuedAndOutstandingMember_716e9e2d-754e-4826-90b5-9ba31975cce0" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_ShareBasedCompensationEmployeeStockAvailableForGrantMember_a8e4e512-a0dc-448e-98e0-a23cc6dd309a" xlink:href="lung-20220630.xsd#lung_ShareBasedCompensationEmployeeStockAvailableForGrantMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_307dfd75-9b05-47e8-a357-2ee25057fd7f" xlink:to="loc_lung_ShareBasedCompensationEmployeeStockAvailableForGrantMember_a8e4e512-a0dc-448e-98e0-a23cc6dd309a" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_dbd51ff8-2d2f-483b-9b87-2bbb3822a1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_307dfd75-9b05-47e8-a357-2ee25057fd7f" xlink:to="loc_us-gaap_EmployeeStockMember_dbd51ff8-2d2f-483b-9b87-2bbb3822a1ff" xlink:type="arc" order="3"/>
</link:definitionLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/StockholdersEquityRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#StockholdersEquityRestrictedStockUnitActivityDetails"/>
<link:definitionLink xlink:role="http://www.pulmonx.com/role/StockholdersEquityRestrictedStockUnitActivityDetails" xlink:type="extended" id="ia56cf9f1a7b546f3bba389a00a379b00_StockholdersEquityRestrictedStockUnitActivityDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_674af04a-93f1-4e12-8da7-75b812275a28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_47fd5b83-b026-4c0d-814f-b411de4e11bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_674af04a-93f1-4e12-8da7-75b812275a28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_47fd5b83-b026-4c0d-814f-b411de4e11bb" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_577c7c15-f8e7-406c-a65a-862438e1b88c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_47fd5b83-b026-4c0d-814f-b411de4e11bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_577c7c15-f8e7-406c-a65a-862438e1b88c" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4c92c50a-fabc-4ae6-8a1e-1e22dd54a7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_47fd5b83-b026-4c0d-814f-b411de4e11bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4c92c50a-fabc-4ae6-8a1e-1e22dd54a7e8" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_564e95db-dac4-4acb-a7aa-2d1cb7ee0811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_47fd5b83-b026-4c0d-814f-b411de4e11bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_564e95db-dac4-4acb-a7aa-2d1cb7ee0811" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cc647d5f-3fcd-45b7-b42c-5d8523e50f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_47fd5b83-b026-4c0d-814f-b411de4e11bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cc647d5f-3fcd-45b7-b42c-5d8523e50f09" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e2764db6-2bdc-4218-9cba-a4d4a29de19b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f295d889-2505-4bcf-aee8-f243ac765ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_674af04a-93f1-4e12-8da7-75b812275a28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f295d889-2505-4bcf-aee8-f243ac765ff6" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ee42cb76-8fe7-427f-baec-a108244f9d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f295d889-2505-4bcf-aee8-f243ac765ff6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ee42cb76-8fe7-427f-baec-a108244f9d84" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cf193f37-e7d6-4818-a35c-b299804dbf02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f295d889-2505-4bcf-aee8-f243ac765ff6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cf193f37-e7d6-4818-a35c-b299804dbf02" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_dfc4ebfe-2570-482d-b4bd-225a5c5a0636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f295d889-2505-4bcf-aee8-f243ac765ff6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_dfc4ebfe-2570-482d-b4bd-225a5c5a0636" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_561d60c8-fac2-4895-97f0-5418f7330a31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f295d889-2505-4bcf-aee8-f243ac765ff6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_561d60c8-fac2-4895-97f0-5418f7330a31" xlink:type="arc" order="4"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b0d62622-39d0-4f36-b1d1-0ca4c57d637c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_704fdbcd-2a95-466a-ab21-1b8eb1c487c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_674af04a-93f1-4e12-8da7-75b812275a28" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_704fdbcd-2a95-466a-ab21-1b8eb1c487c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bcb07fd2-80b3-4d3c-86eb-c14ef17f2517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_704fdbcd-2a95-466a-ab21-1b8eb1c487c9" xlink:to="loc_us-gaap_AwardTypeAxis_bcb07fd2-80b3-4d3c-86eb-c14ef17f2517" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcb07fd2-80b3-4d3c-86eb-c14ef17f2517_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bcb07fd2-80b3-4d3c-86eb-c14ef17f2517" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bcb07fd2-80b3-4d3c-86eb-c14ef17f2517_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e2bbdcf-b13a-4b87-ad27-d4529c6ba609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bcb07fd2-80b3-4d3c-86eb-c14ef17f2517" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e2bbdcf-b13a-4b87-ad27-d4529c6ba609" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_253880a6-1866-4d30-b377-1de03eaa5ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e2bbdcf-b13a-4b87-ad27-d4529c6ba609" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_253880a6-1866-4d30-b377-1de03eaa5ab0" xlink:type="arc" order="0"/>
</link:definitionLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/StockholdersEquityTotalStockBasedCompensationDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#StockholdersEquityTotalStockBasedCompensationDetails"/>
<link:definitionLink xlink:role="http://www.pulmonx.com/role/StockholdersEquityTotalStockBasedCompensationDetails" xlink:type="extended" id="i393f188383fb4864ae32d64694b13ca1_StockholdersEquityTotalStockBasedCompensationDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_174f8179-5126-4631-915a-79ff03addad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e09f36f6-e9db-472f-a381-988b3f33a7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_174f8179-5126-4631-915a-79ff03addad5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e09f36f6-e9db-472f-a381-988b3f33a7c4" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88c0762c-df1b-4bdc-92c9-40571806355f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_174f8179-5126-4631-915a-79ff03addad5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88c0762c-df1b-4bdc-92c9-40571806355f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8a2e31fd-a2f4-40ca-9452-23854c0f6b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88c0762c-df1b-4bdc-92c9-40571806355f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8a2e31fd-a2f4-40ca-9452-23854c0f6b4a" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8a2e31fd-a2f4-40ca-9452-23854c0f6b4a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8a2e31fd-a2f4-40ca-9452-23854c0f6b4a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8a2e31fd-a2f4-40ca-9452-23854c0f6b4a_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d91762c5-aa70-4d47-aec2-a4ae176bbbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8a2e31fd-a2f4-40ca-9452-23854c0f6b4a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d91762c5-aa70-4d47-aec2-a4ae176bbbc6" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_6d090711-a03f-4bf0-93a6-c18ab8b85d09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d91762c5-aa70-4d47-aec2-a4ae176bbbc6" xlink:to="loc_us-gaap_CostOfSalesMember_6d090711-a03f-4bf0-93a6-c18ab8b85d09" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_45e269fd-f3ad-416f-981f-f3342de202eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d91762c5-aa70-4d47-aec2-a4ae176bbbc6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_45e269fd-f3ad-416f-981f-f3342de202eb" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f6e7ee63-f2ee-4ac6-be3d-bc535cf54820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d91762c5-aa70-4d47-aec2-a4ae176bbbc6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f6e7ee63-f2ee-4ac6-be3d-bc535cf54820" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_99d4d9c5-189e-4d88-9c68-06276e16b3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88c0762c-df1b-4bdc-92c9-40571806355f" xlink:to="loc_us-gaap_AwardTypeAxis_99d4d9c5-189e-4d88-9c68-06276e16b3ab" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99d4d9c5-189e-4d88-9c68-06276e16b3ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_99d4d9c5-189e-4d88-9c68-06276e16b3ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99d4d9c5-189e-4d88-9c68-06276e16b3ab_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b5146e8-8163-423d-b542-9771463dca8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_99d4d9c5-189e-4d88-9c68-06276e16b3ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b5146e8-8163-423d-b542-9771463dca8a" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_StockOptionsAndRestrictedStockUnitsMember_fb9348f4-0032-4fa2-bea3-948a0276d190" xlink:href="lung-20220630.xsd#lung_StockOptionsAndRestrictedStockUnitsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b5146e8-8163-423d-b542-9771463dca8a" xlink:to="loc_lung_StockOptionsAndRestrictedStockUnitsMember_fb9348f4-0032-4fa2-bea3-948a0276d190" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_2d6c36c2-ca32-4be9-a967-2fe83d2b3b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b5146e8-8163-423d-b542-9771463dca8a" xlink:to="loc_us-gaap_EmployeeStockMember_2d6c36c2-ca32-4be9-a967-2fe83d2b3b96" xlink:type="arc" order="1"/>
</link:definitionLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersExcludedPotentiallyDilutiveSecuritiesOutstandingDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#NetLossperShareAttributabletoCommonStockholdersExcludedPotentiallyDilutiveSecuritiesOutstandingDetails"/>
<link:definitionLink xlink:role="http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersExcludedPotentiallyDilutiveSecuritiesOutstandingDetails" xlink:type="extended" id="ie1c0a0f5aac346a2ae7270d83de349a5_NetLossperShareAttributabletoCommonStockholdersExcludedPotentiallyDilutiveSecuritiesOutstandingDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_db20e9c8-49d5-4745-b606-6d3224fbe3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c8dd4249-cd98-46b4-97ba-5ebc068757e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_db20e9c8-49d5-4745-b606-6d3224fbe3c1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c8dd4249-cd98-46b4-97ba-5ebc068757e7" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_498137bf-954d-42c9-9af3-6361dcb5d2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_db20e9c8-49d5-4745-b606-6d3224fbe3c1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_498137bf-954d-42c9-9af3-6361dcb5d2ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5c9cac97-933f-4149-90e8-7c8dddd4f2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_498137bf-954d-42c9-9af3-6361dcb5d2ac" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5c9cac97-933f-4149-90e8-7c8dddd4f2ce" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5c9cac97-933f-4149-90e8-7c8dddd4f2ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5c9cac97-933f-4149-90e8-7c8dddd4f2ce" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5c9cac97-933f-4149-90e8-7c8dddd4f2ce_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5b76ede-7b84-4c67-b5d7-db17a7010e63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5c9cac97-933f-4149-90e8-7c8dddd4f2ce" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5b76ede-7b84-4c67-b5d7-db17a7010e63" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3342312c-eed4-4766-82b5-85e68b281fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5b76ede-7b84-4c67-b5d7-db17a7010e63" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3342312c-eed4-4766-82b5-85e68b281fa1" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_e37feea2-d3e9-4b06-bb95-6e2ee6869b29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5b76ede-7b84-4c67-b5d7-db17a7010e63" xlink:to="loc_us-gaap_RestrictedStockMember_e37feea2-d3e9-4b06-bb95-6e2ee6869b29" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_ShareBasedCompensationUnvestedEarlyExercisedOptionsMember_e6e1cc1c-e0f7-4bc4-a1d3-fdbd9a2a5e04" xlink:href="lung-20220630.xsd#lung_ShareBasedCompensationUnvestedEarlyExercisedOptionsMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5b76ede-7b84-4c67-b5d7-db17a7010e63" xlink:to="loc_lung_ShareBasedCompensationUnvestedEarlyExercisedOptionsMember_e6e1cc1c-e0f7-4bc4-a1d3-fdbd9a2a5e04" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_81c4cfd4-9431-4f9f-be9c-5700aa419b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5b76ede-7b84-4c67-b5d7-db17a7010e63" xlink:to="loc_us-gaap_EmployeeStockMember_81c4cfd4-9431-4f9f-be9c-5700aa419b1d" xlink:type="arc" order="3"/>
</link:definitionLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#SegmentInformationNarrativeDetails"/>
<link:definitionLink xlink:role="http://www.pulmonx.com/role/SegmentInformationNarrativeDetails" xlink:type="extended" id="iaf1d007de3ec473099867231f5f611d3_SegmentInformationNarrativeDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_f286f9cf-db61-4826-93db-3dbb6e86e904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_5e27d5a9-9a1c-41a4-828b-ef930237ddb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f286f9cf-db61-4826-93db-3dbb6e86e904" xlink:to="loc_us-gaap_NumberOfReportableSegments_5e27d5a9-9a1c-41a4-828b-ef930237ddb7" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_a8bb8508-5d01-48f1-befc-35fabb8689d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f286f9cf-db61-4826-93db-3dbb6e86e904" xlink:to="loc_us-gaap_NumberOfOperatingSegments_a8bb8508-5d01-48f1-befc-35fabb8689d7" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_2a00ea0f-6174-4a1e-970e-01157ce7d0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f286f9cf-db61-4826-93db-3dbb6e86e904" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_2a00ea0f-6174-4a1e-970e-01157ce7d0a9" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_e443ed8f-e472-4a5d-a4c5-f6e5e4bbdf23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f286f9cf-db61-4826-93db-3dbb6e86e904" xlink:to="loc_us-gaap_ConcentrationRiskTable_e443ed8f-e472-4a5d-a4c5-f6e5e4bbdf23" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_80da1bc4-7fec-4dd2-b1c1-f45ceac14021" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_e443ed8f-e472-4a5d-a4c5-f6e5e4bbdf23" xlink:to="loc_srt_StatementGeographicalAxis_80da1bc4-7fec-4dd2-b1c1-f45ceac14021" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_80da1bc4-7fec-4dd2-b1c1-f45ceac14021_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_80da1bc4-7fec-4dd2-b1c1-f45ceac14021" xlink:to="loc_srt_SegmentGeographicalDomain_80da1bc4-7fec-4dd2-b1c1-f45ceac14021_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0828d095-4f13-485b-aa0c-0546360d85dc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_80da1bc4-7fec-4dd2-b1c1-f45ceac14021" xlink:to="loc_srt_SegmentGeographicalDomain_0828d095-4f13-485b-aa0c-0546360d85dc" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_country_DE_a67d83d9-6290-4351-8c83-b293a370a04a" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0828d095-4f13-485b-aa0c-0546360d85dc" xlink:to="loc_country_DE_a67d83d9-6290-4351-8c83-b293a370a04a" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_country_FR_90d89ae1-4a43-4d7d-ab04-91d8858bc0cc" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0828d095-4f13-485b-aa0c-0546360d85dc" xlink:to="loc_country_FR_90d89ae1-4a43-4d7d-ab04-91d8858bc0cc" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_440b08ec-581b-4bdd-a1a8-09410d7feb0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_e443ed8f-e472-4a5d-a4c5-f6e5e4bbdf23" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_440b08ec-581b-4bdd-a1a8-09410d7feb0b" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_440b08ec-581b-4bdd-a1a8-09410d7feb0b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_440b08ec-581b-4bdd-a1a8-09410d7feb0b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_440b08ec-581b-4bdd-a1a8-09410d7feb0b_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3269d315-8f4a-4931-9856-85d0007c877f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_440b08ec-581b-4bdd-a1a8-09410d7feb0b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3269d315-8f4a-4931-9856-85d0007c877f" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_dda17315-5b56-4770-acbe-10bf6f3381f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3269d315-8f4a-4931-9856-85d0007c877f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_dda17315-5b56-4770-acbe-10bf6f3381f8" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_9e9f3bcf-92e6-418a-b48d-ea4ce2583585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_e443ed8f-e472-4a5d-a4c5-f6e5e4bbdf23" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_9e9f3bcf-92e6-418a-b48d-ea4ce2583585" xlink:type="arc" order="3"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_9e9f3bcf-92e6-418a-b48d-ea4ce2583585_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_9e9f3bcf-92e6-418a-b48d-ea4ce2583585" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_9e9f3bcf-92e6-418a-b48d-ea4ce2583585_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_132192e1-e2e5-4873-bbf4-42ce7a38f8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_9e9f3bcf-92e6-418a-b48d-ea4ce2583585" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_132192e1-e2e5-4873-bbf4-42ce7a38f8fb" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_e7b632d7-868d-415b-96ac-46d43ee4de9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_132192e1-e2e5-4873-bbf4-42ce7a38f8fb" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_e7b632d7-868d-415b-96ac-46d43ee4de9e" xlink:type="arc" order="0"/>
</link:definitionLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/SegmentInformationRevenuebyGeographicAreaDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#SegmentInformationRevenuebyGeographicAreaDetails"/>
<link:definitionLink xlink:role="http://www.pulmonx.com/role/SegmentInformationRevenuebyGeographicAreaDetails" xlink:type="extended" id="idb36ddf8bf684b518b9e97807ed5619c_SegmentInformationRevenuebyGeographicAreaDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_ed68729f-7f58-4f63-b9e7-d0e5aa0710f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6670065f-0977-4028-9325-f37196175120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_ed68729f-7f58-4f63-b9e7-d0e5aa0710f3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6670065f-0977-4028-9325-f37196175120" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_2b69e2a6-db92-4077-8c5c-8236939726dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_ed68729f-7f58-4f63-b9e7-d0e5aa0710f3" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_2b69e2a6-db92-4077-8c5c-8236939726dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e43925be-3d44-4458-8917-dc38e7b407c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_2b69e2a6-db92-4077-8c5c-8236939726dd" xlink:to="loc_srt_StatementGeographicalAxis_e43925be-3d44-4458-8917-dc38e7b407c7" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e43925be-3d44-4458-8917-dc38e7b407c7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_e43925be-3d44-4458-8917-dc38e7b407c7" xlink:to="loc_srt_SegmentGeographicalDomain_e43925be-3d44-4458-8917-dc38e7b407c7_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_484f2e57-a45b-4090-88e5-724e16e6764e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_e43925be-3d44-4458-8917-dc38e7b407c7" xlink:to="loc_srt_SegmentGeographicalDomain_484f2e57-a45b-4090-88e5-724e16e6764e" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_country_US_9911633f-6f41-4d74-b1fc-6c1249fe6869" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_484f2e57-a45b-4090-88e5-724e16e6764e" xlink:to="loc_country_US_9911633f-6f41-4d74-b1fc-6c1249fe6869" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_b1723e32-91c0-4ee6-aef3-805062c66460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EMEAMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_484f2e57-a45b-4090-88e5-724e16e6764e" xlink:to="loc_us-gaap_EMEAMember_b1723e32-91c0-4ee6-aef3-805062c66460" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_f6062850-c219-47be-8472-e24b8ff68b7e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_484f2e57-a45b-4090-88e5-724e16e6764e" xlink:to="loc_srt_AsiaPacificMember_f6062850-c219-47be-8472-e24b8ff68b7e" xlink:type="arc" order="2"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_OtherInternationalGeographicalAreasMember_54fd5d97-6632-4bef-b238-268861303bf8" xlink:href="lung-20220630.xsd#lung_OtherInternationalGeographicalAreasMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_484f2e57-a45b-4090-88e5-724e16e6764e" xlink:to="loc_lung_OtherInternationalGeographicalAreasMember_54fd5d97-6632-4bef-b238-268861303bf8" xlink:type="arc" order="3"/>
</link:definitionLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/SegmentInformationLongLivedAssetsbyGeographicalAreaDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#SegmentInformationLongLivedAssetsbyGeographicalAreaDetails"/>
<link:definitionLink xlink:role="http://www.pulmonx.com/role/SegmentInformationLongLivedAssetsbyGeographicalAreaDetails" xlink:type="extended" id="i6ab01f692bc14e2b959faf7825447aee_SegmentInformationLongLivedAssetsbyGeographicalAreaDetails">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_b153969b-234d-4ca1-bfa6-a439f50ca92f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_6479a045-607b-4142-8356-0a3e926ce6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncurrentAssets"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_b153969b-234d-4ca1-bfa6-a439f50ca92f" xlink:to="loc_us-gaap_NoncurrentAssets_6479a045-607b-4142-8356-0a3e926ce6aa" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_2cb43c6e-31da-4316-b8f6-969544322579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_b153969b-234d-4ca1-bfa6-a439f50ca92f" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_2cb43c6e-31da-4316-b8f6-969544322579" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3058eade-8a1c-456b-a2cd-88ce6977994e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_2cb43c6e-31da-4316-b8f6-969544322579" xlink:to="loc_srt_StatementGeographicalAxis_3058eade-8a1c-456b-a2cd-88ce6977994e" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3058eade-8a1c-456b-a2cd-88ce6977994e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_3058eade-8a1c-456b-a2cd-88ce6977994e" xlink:to="loc_srt_SegmentGeographicalDomain_3058eade-8a1c-456b-a2cd-88ce6977994e_default" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1cc3f5a5-4251-4981-8028-c030918a1230" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_3058eade-8a1c-456b-a2cd-88ce6977994e" xlink:to="loc_srt_SegmentGeographicalDomain_1cc3f5a5-4251-4981-8028-c030918a1230" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_country_US_3d467020-92fd-45e1-b594-84f2b458765f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1cc3f5a5-4251-4981-8028-c030918a1230" xlink:to="loc_country_US_3d467020-92fd-45e1-b594-84f2b458765f" xlink:type="arc" order="0"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_00f24413-8eec-429a-bd76-db64c23264f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EMEAMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1cc3f5a5-4251-4981-8028-c030918a1230" xlink:to="loc_us-gaap_EMEAMember_00f24413-8eec-429a-bd76-db64c23264f8" xlink:type="arc" order="1"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_1d316e89-e7a4-4cff-a63c-64235fc104aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
<link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1cc3f5a5-4251-4981-8028-c030918a1230" xlink:to="loc_srt_AsiaPacificMember_1d316e89-e7a4-4cff-a63c-64235fc104aa" xlink:type="arc" order="2"/>
</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>lung-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e27afbe0-c876-445c-ac79-0e3a22d99ad7,g:11f7fccd-ac30-49f3-b9c8-08334e4a7c01-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:label id="lab_us-gaap_GeographicConcentrationRiskMember_1dee3990-7e8e-4a78-bb29-1ce47b2bf6c9_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk</link:label>
<link:label id="lab_us-gaap_GeographicConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2fc9b191-26d9-479a-9586-5612d5e206e2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c27fc6e5-a273-4ad2-aadb-136113acd696_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum lease payments</link:label>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_f9d4d0ec-184f-4515-9440-b7252da040e8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
<link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_61843e33-239f-41e8-8e0a-dbf52e4c4b34_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation and Transaction Gains and Losses</link:label>
<link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_db54c5ab-f214-4483-9937-5cb005fdeb4a_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
<link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_b7d6f5e8-2d66-443c-9d31-2327bc48ce74_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan</link:label>
<link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_61f33cb0-e125-466f-8b59-398897bcb76c_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
<link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_64c667d6-26e7-4d25-9b15-37d984c43e7c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of short-term marketable securities</link:label>
<link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Short-Term Investments</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityAddressPostalZipCode_b1a6424b-f0a4-4919-82cd-fe6320c5efa5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
<link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
<link:label id="lab_lung_DebtInstrumentNumberOfPeriodicPayments_306ebdc6-edda-4798-8a38-5bc6d5949126_terseLabel_en-US" xlink:label="lab_lung_DebtInstrumentNumberOfPeriodicPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of periodic payments</link:label>
<link:label id="lab_lung_DebtInstrumentNumberOfPeriodicPayments_label_en-US" xlink:label="lab_lung_DebtInstrumentNumberOfPeriodicPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Periodic Payments</link:label>
<link:label id="lab_lung_DebtInstrumentNumberOfPeriodicPayments_documentation_en-US" xlink:label="lab_lung_DebtInstrumentNumberOfPeriodicPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Periodic Payments</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_DebtInstrumentNumberOfPeriodicPayments" xlink:href="lung-20220630.xsd#lung_DebtInstrumentNumberOfPeriodicPayments"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_DebtInstrumentNumberOfPeriodicPayments" xlink:to="lab_lung_DebtInstrumentNumberOfPeriodicPayments" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_4a64b627-10fd-4253-8a32-db68912603b9_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in unrealized gain (loss) on marketable securities</link:label>
<link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1c52cdf8-d8a4-4906-b78b-c4d2e5d32897_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in unrealized (losses) gains on marketable securities</link:label>
<link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PreferredStockSharesOutstanding_02c98a4b-35fc-4e7c-be48-4ce57c8304c5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
<link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_3f72521b-2359-419f-a238-1a919d27ce2c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
<link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentAxis_8112764d-2134-45b5-86fd-f9b4f4e74f27_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
<link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_17b3f03d-4904-4585-8733-4d492840d360_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, gross</link:label>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_6683fe12-5b9a-4376-b0fa-4e1ec3e3918e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
<link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
<link:label id="lab_lung_ShareBasedCompensationEmployeeStockOutstandingMember_4dc29f31-dfa9-47c2-b4a2-b2b0eeb29d63_terseLabel_en-US" xlink:label="lab_lung_ShareBasedCompensationEmployeeStockOutstandingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options issued and outstanding</link:label>
<link:label id="lab_lung_ShareBasedCompensationEmployeeStockOutstandingMember_label_en-US" xlink:label="lab_lung_ShareBasedCompensationEmployeeStockOutstandingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation, Employee Stock Outstanding [Member]</link:label>
<link:label id="lab_lung_ShareBasedCompensationEmployeeStockOutstandingMember_documentation_en-US" xlink:label="lab_lung_ShareBasedCompensationEmployeeStockOutstandingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation, Employee Stock Outstanding</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_ShareBasedCompensationEmployeeStockOutstandingMember" xlink:href="lung-20220630.xsd#lung_ShareBasedCompensationEmployeeStockOutstandingMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_ShareBasedCompensationEmployeeStockOutstandingMember" xlink:to="lab_lung_ShareBasedCompensationEmployeeStockOutstandingMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_811f1e51-09d7-4d74-953b-745cdf20a5e4_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Systems</link:label>
<link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_0a986514-07a2-4831-aa3f-de0ff82592af_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
<link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_107e97e5-164e-4e6a-ac8c-96b51aad1f5d_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
<link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherDepreciationAndAmortization_7f966c92-9c1a-49c7-8af2-7751172a1281_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
<link:label id="lab_us-gaap_OtherDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_OtherDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Depreciation and Amortization</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDepreciationAndAmortization"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDepreciationAndAmortization" xlink:to="lab_us-gaap_OtherDepreciationAndAmortization" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_33beedb6-154a-414c-88ff-2aea5c8205d2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
<link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
<link:label id="lab_srt_RangeMember_587856eb-01ad-43fb-bd7f-603ab6da34fb_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
<link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_Depreciation_20139671-887b-40b0-911d-017b2c6d5ea4_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
<link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_97fe7668-ecb6-4a6a-8d14-59a5d79b0b7e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options (in shares)</link:label>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_39a978f4-82e2-4d2e-a84c-2681d9b5351f_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_bc3a39ed-7d49-4a37-b39e-0aae667ee4cf_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
<link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_31cfde17-e587-45ea-a414-0f94fcbdcfcd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon vesting of restricted stock units (in share)</link:label>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ae7bc754-732e-4477-95a1-40bdd7e46962_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate (percent)</link:label>
<link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
<link:label id="lab_lung_CashCashEquivalentsAndAvailableForSaleDebtSecurities_86fb0180-1a63-4c72-9a2f-3679c0f2d77a_totalLabel_en-US" xlink:label="lab_lung_CashCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
<link:label id="lab_lung_CashCashEquivalentsAndAvailableForSaleDebtSecurities_label_en-US" xlink:label="lab_lung_CashCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-For-Sale Debt Securities</link:label>
<link:label id="lab_lung_CashCashEquivalentsAndAvailableForSaleDebtSecurities_documentation_en-US" xlink:label="lab_lung_CashCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-For-Sale Debt Securities</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_CashCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:href="lung-20220630.xsd#lung_CashCashEquivalentsAndAvailableForSaleDebtSecurities"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_CashCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:to="lab_lung_CashCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_ca9f1854-68aa-40c5-a1ad-22ed50b0b220_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
<link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NoncurrentAssets_16641693-1479-41d7-aecd-81f2a51ec6ef_terseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived assets</link:label>
<link:label id="lab_us-gaap_NoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncurrentAssets"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets" xlink:to="lab_us-gaap_NoncurrentAssets" xlink:type="arc" order="1"/>
<link:label id="lab_lung_LesseeOperatingSubleaseOptionToTerminateNoticePeriod_a3daf29b-3adb-4170-9d79-e385607788af_terseLabel_en-US" xlink:label="lab_lung_LesseeOperatingSubleaseOptionToTerminateNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease, option to terminate, notice period</link:label>
<link:label id="lab_lung_LesseeOperatingSubleaseOptionToTerminateNoticePeriod_label_en-US" xlink:label="lab_lung_LesseeOperatingSubleaseOptionToTerminateNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Sublease, Option To Terminate, Notice Period</link:label>
<link:label id="lab_lung_LesseeOperatingSubleaseOptionToTerminateNoticePeriod_documentation_en-US" xlink:label="lab_lung_LesseeOperatingSubleaseOptionToTerminateNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Sublease, Option To Terminate, Notice Period</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_LesseeOperatingSubleaseOptionToTerminateNoticePeriod" xlink:href="lung-20220630.xsd#lung_LesseeOperatingSubleaseOptionToTerminateNoticePeriod"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_LesseeOperatingSubleaseOptionToTerminateNoticePeriod" xlink:to="lab_lung_LesseeOperatingSubleaseOptionToTerminateNoticePeriod" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RepaymentsOfDebt_232e6f13-0c8c-4ef6-8a61-4f77821e5e96_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt</link:label>
<link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NetIncomeLoss_bd1a1fdf-c121-4a61-8ebc-a3393ad55342_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
<link:label id="lab_us-gaap_NetIncomeLoss_72d5125f-47ee-4bd7-ab0d-efe5eb537a1e_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
<link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_98bd7f31-16fe-4ba9-b16a-0c1558775445_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
<link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ad8a6650-dfeb-4fb4-845e-765c6c768ed1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
<link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9d9920b3-ab02-4a99-b5e1-bcd93f742a50_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive securities excluded from computation of diluted weighted average shares outstanding (in shares)</link:label>
<link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_7b6ab9e5-c054-439a-9353-85f838abe16d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contractual Maturities of Financing Obligations</link:label>
<link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c2756aff-6550-454f-a756-ceca77ac2e11_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
<link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PrepaidInsurance_cb311b3b-195f-4c13-9891-55757faeca30_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid insurance</link:label>
<link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EquityComponentDomain_8c912ff2-8e98-4988-956f-4df6866f755c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
<link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
<link:label id="lab_lung_LesseeOperatingSubleaseExpenseAnnualIncreaseRate_692fec77-d17d-41cf-b80a-9ee74476fbc3_terseLabel_en-US" xlink:label="lab_lung_LesseeOperatingSubleaseExpenseAnnualIncreaseRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease, expense, annual increase rate</link:label>
<link:label id="lab_lung_LesseeOperatingSubleaseExpenseAnnualIncreaseRate_label_en-US" xlink:label="lab_lung_LesseeOperatingSubleaseExpenseAnnualIncreaseRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Sublease, Expense, Annual Increase Rate</link:label>
<link:label id="lab_lung_LesseeOperatingSubleaseExpenseAnnualIncreaseRate_documentation_en-US" xlink:label="lab_lung_LesseeOperatingSubleaseExpenseAnnualIncreaseRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Sublease, Expense, Annual Increase Rate</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_LesseeOperatingSubleaseExpenseAnnualIncreaseRate" xlink:href="lung-20220630.xsd#lung_LesseeOperatingSubleaseExpenseAnnualIncreaseRate"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_LesseeOperatingSubleaseExpenseAnnualIncreaseRate" xlink:to="lab_lung_LesseeOperatingSubleaseExpenseAnnualIncreaseRate" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AssetsFairValueDisclosure_e984b9b1-235c-4ea0-8bde-6d181f7ec5cc_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial assets</link:label>
<link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization_4140c6df-2b2f-4d00-bccc-b99388ca136b_terseLabel_en-US" xlink:label="lab_us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
<link:label id="lab_us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization_label_en-US" xlink:label="lab_us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hosting Arrangement, Service Contract, Implementation Cost, Expense, Amortization</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization" xlink:to="lab_us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization" xlink:type="arc" order="1"/>
<link:label id="lab_lung_AccruedInventoryPurchasesCurrent_1a2380d2-e623-41c2-a605-564cf880e636_terseLabel_en-US" xlink:label="lab_lung_AccruedInventoryPurchasesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued inventory purchases</link:label>
<link:label id="lab_lung_AccruedInventoryPurchasesCurrent_label_en-US" xlink:label="lab_lung_AccruedInventoryPurchasesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Inventory Purchases Current</link:label>
<link:label id="lab_lung_AccruedInventoryPurchasesCurrent_documentation_en-US" xlink:label="lab_lung_AccruedInventoryPurchasesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Inventory Purchases Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_AccruedInventoryPurchasesCurrent" xlink:href="lung-20220630.xsd#lung_AccruedInventoryPurchasesCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_AccruedInventoryPurchasesCurrent" xlink:to="lab_lung_AccruedInventoryPurchasesCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice_6e328d17-7d4e-484a-95f5-9d46afab4fab_terseLabel_en-US" xlink:label="lab_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate exercise price of shares subject to repurchase</link:label>
<link:label id="lab_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice_label_en-US" xlink:label="lab_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Shares Subject To Repurchase, Aggregate Exercise Price</link:label>
<link:label id="lab_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice_documentation_en-US" xlink:label="lab_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Shares Subject To Repurchase, Aggregate Exercise Price</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice" xlink:href="lung-20220630.xsd#lung_ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice" xlink:to="lab_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_26699f2b-0143-4a39-a5c4-0c58306ea137_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
<link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_b66cec74-f87e-4526-80ae-80f82d17127c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities Measured at Fair Value</link:label>
<link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_55bea8e6-a6d1-47e4-9557-ab35fd97305f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities</link:label>
<link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_158d2c02-a698-4335-b950-98116ef93eb3_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
<link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_9a3e2599-b579-4c9f-99a7-87e78fc7e47c_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
<link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e4495778-9b6a-46c2-a637-3298aef53828_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled (in dollars per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
<link:label id="lab_lung_DebtInstrumentCovenantCashAndCashEquivalentsMinimumThresholdTriggerForRevenueRequirement_f93f667e-03df-467b-8929-194e8b745c8f_terseLabel_en-US" xlink:label="lab_lung_DebtInstrumentCovenantCashAndCashEquivalentsMinimumThresholdTriggerForRevenueRequirement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents trigger for revenue requirement</link:label>
<link:label id="lab_lung_DebtInstrumentCovenantCashAndCashEquivalentsMinimumThresholdTriggerForRevenueRequirement_label_en-US" xlink:label="lab_lung_DebtInstrumentCovenantCashAndCashEquivalentsMinimumThresholdTriggerForRevenueRequirement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Cash And Cash Equivalents Minimum Threshold Trigger For Revenue Requirement</link:label>
<link:label id="lab_lung_DebtInstrumentCovenantCashAndCashEquivalentsMinimumThresholdTriggerForRevenueRequirement_documentation_en-US" xlink:label="lab_lung_DebtInstrumentCovenantCashAndCashEquivalentsMinimumThresholdTriggerForRevenueRequirement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Cash And Cash Equivalents Minimum Threshold Trigger For Revenue Requirement</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_DebtInstrumentCovenantCashAndCashEquivalentsMinimumThresholdTriggerForRevenueRequirement" xlink:href="lung-20220630.xsd#lung_DebtInstrumentCovenantCashAndCashEquivalentsMinimumThresholdTriggerForRevenueRequirement"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_DebtInstrumentCovenantCashAndCashEquivalentsMinimumThresholdTriggerForRevenueRequirement" xlink:to="lab_lung_DebtInstrumentCovenantCashAndCashEquivalentsMinimumThresholdTriggerForRevenueRequirement" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NumberOfOperatingSegments_8d113497-d1b6-45ad-b047-3c01b269e2ac_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
<link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_aecb39e5-c3ae-4044-b529-951f31aed626_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-option unrecognized compensation costs</link:label>
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_300549c5-898a-4a66-ae3b-a345ba026144_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (remaining six months)</link:label>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
<link:label id="lab_lung_StockRepurchasedDuringPeriodExerciseOfEarlyStockOptionsShares_0e6493b5-0b1c-42ee-9620-8f46e97ea731_negatedTerseLabel_en-US" xlink:label="lab_lung_StockRepurchasedDuringPeriodExerciseOfEarlyStockOptionsShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of early exercised common stock options (in shares)</link:label>
<link:label id="lab_lung_StockRepurchasedDuringPeriodExerciseOfEarlyStockOptionsShares_label_en-US" xlink:label="lab_lung_StockRepurchasedDuringPeriodExerciseOfEarlyStockOptionsShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Exercise Of Early Stock Options, Shares</link:label>
<link:label id="lab_lung_StockRepurchasedDuringPeriodExerciseOfEarlyStockOptionsShares_documentation_en-US" xlink:label="lab_lung_StockRepurchasedDuringPeriodExerciseOfEarlyStockOptionsShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Exercise Of Early Stock Options, Shares</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_StockRepurchasedDuringPeriodExerciseOfEarlyStockOptionsShares" xlink:href="lung-20220630.xsd#lung_StockRepurchasedDuringPeriodExerciseOfEarlyStockOptionsShares"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_StockRepurchasedDuringPeriodExerciseOfEarlyStockOptionsShares" xlink:to="lab_lung_StockRepurchasedDuringPeriodExerciseOfEarlyStockOptionsShares" xlink:type="arc" order="1"/>
<link:label id="lab_lung_OtherInternationalGeographicalAreasMember_57de48e5-501f-4aad-b63b-53c30b7e1569_terseLabel_en-US" xlink:label="lab_lung_OtherInternationalGeographicalAreasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other International</link:label>
<link:label id="lab_lung_OtherInternationalGeographicalAreasMember_label_en-US" xlink:label="lab_lung_OtherInternationalGeographicalAreasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other International Geographical Areas [Member]</link:label>
<link:label id="lab_lung_OtherInternationalGeographicalAreasMember_documentation_en-US" xlink:label="lab_lung_OtherInternationalGeographicalAreasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other International Geographical Areas</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_OtherInternationalGeographicalAreasMember" xlink:href="lung-20220630.xsd#lung_OtherInternationalGeographicalAreasMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_OtherInternationalGeographicalAreasMember" xlink:to="lab_lung_OtherInternationalGeographicalAreasMember" xlink:type="arc" order="1"/>
<link:label id="lab_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchase_a1a3e7c5-1417-4a5c-9a34-25255e425ddf_terseLabel_en-US" xlink:label="lab_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares subject to repurchase (in shares)</link:label>
<link:label id="lab_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchase_label_en-US" xlink:label="lab_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Shares Subject To Repurchase</link:label>
<link:label id="lab_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchase_documentation_en-US" xlink:label="lab_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Shares Subject To Repurchase</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchase" xlink:href="lung-20220630.xsd#lung_ShareBasedPaymentArrangementSharesSubjectToRepurchase"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchase" xlink:to="lab_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchase" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityAddressStateOrProvince_f289c5bc-6a9f-4394-a0a5-74ec20108b93_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
<link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueInputsLevel1Member_6d18ea5e-62a8-4f60-b13b-2e8088c04850_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
<link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EmployeeStockMember_7184c9de-5baf-44a9-a265-49851dcc7464_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
<link:label id="lab_us-gaap_EmployeeStockMember_297b8fad-9e9c-4981-ba6f-39676e1c659a_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock available for ESPP</link:label>
<link:label id="lab_us-gaap_EmployeeStockMember_3a2016c7-7b2e-4ee3-b5c6-39924069be8d_netLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares committed under ESPP</link:label>
<link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AwardTypeAxis_d83020c6-2837-4346-afc7-97acbf5097f4_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
<link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_3b902b82-26b7-4240-a6e5-f97e3fe89b14_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
<link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_e96c79c1-1fcb-4ed2-a93c-9f649c4fc9d3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_aae01dd6-9db2-4d1e-bb4e-cded532bb3ea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in operating activities</link:label>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_d3d279e0-aac2-4f27-abcf-e96126d37ea2_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current lease liabilities</link:label>
<link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_c1cf4f4d-3904-4538-ae61-caf43358ba10_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current lease liabilities</link:label>
<link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_8da30254-bb08-4cd3-91f9-914d4eb233a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activity with Respect to Restricted Stock Units</link:label>
<link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_640be443-301e-4cee-a153-d3ca5807a1fc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cost, Unrealized Gains and Losses and Fair Value of Marketable Securities</link:label>
<link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_35da6b15-ed22-4c06-866f-51494a08fc04_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
<link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_662e2ebd-ecf2-44e6-808a-a17a99d1382a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
<link:label id="lab_dei_LegalEntityAxis_7a187976-9d99-4e0d-94e1-eaf211b6c349_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LongTermDebtNoncurrent_938f2b30-08ba-4e4d-ac82-9843e7849c98_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
<link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
<link:label id="lab_lung_LesseeOperatingSubleaseTerm_d7676079-f291-4591-aeef-01734a588b7b_terseLabel_en-US" xlink:label="lab_lung_LesseeOperatingSubleaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease term</link:label>
<link:label id="lab_lung_LesseeOperatingSubleaseTerm_label_en-US" xlink:label="lab_lung_LesseeOperatingSubleaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Sublease, Term</link:label>
<link:label id="lab_lung_LesseeOperatingSubleaseTerm_documentation_en-US" xlink:label="lab_lung_LesseeOperatingSubleaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Sublease, Term</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_LesseeOperatingSubleaseTerm" xlink:href="lung-20220630.xsd#lung_LesseeOperatingSubleaseTerm"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_LesseeOperatingSubleaseTerm" xlink:to="lab_lung_LesseeOperatingSubleaseTerm" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_Liabilities_94e90f7c-9f76-4945-bd25-02ed4762a06a_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
<link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b145ed7a-1a29-419e-b47f-0fc3963f94fc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term (years)</link:label>
<link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
<link:label id="lab_srt_StatementGeographicalAxis_afcb61ef-0c86-4cc9-b291-7eeb5f607702_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
<link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e90927b-0325-46b3-af10-6a0e0bb0fd35_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9a41109d-d4ef-40a0-8380-86157558b96f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_dff859b9-f847-4d27-a3ed-861043038de5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common stock outstanding (in shares)</link:label>
<link:label id="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Issued, Basic</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="arc" order="1"/>
<link:label id="lab_lung_IncreaseInLoanInterestRate_4a1fc16f-326b-4879-a1ae-49cd9b8cb42e_terseLabel_en-US" xlink:label="lab_lung_IncreaseInLoanInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in loan interest rate</link:label>
<link:label id="lab_lung_IncreaseInLoanInterestRate_label_en-US" xlink:label="lab_lung_IncreaseInLoanInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Loan Interest Rate</link:label>
<link:label id="lab_lung_IncreaseInLoanInterestRate_documentation_en-US" xlink:label="lab_lung_IncreaseInLoanInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Loan Interest Rate</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_IncreaseInLoanInterestRate" xlink:href="lung-20220630.xsd#lung_IncreaseInLoanInterestRate"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_IncreaseInLoanInterestRate" xlink:to="lab_lung_IncreaseInLoanInterestRate" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityCommonStockSharesOutstanding_81ad922c-3251-4275-83bf-b390c47f8588_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
<link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_436fbdde-2726-409b-8be9-8bcfe3ffe7da_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
<link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
<link:label id="lab_lung_CashAndCashEquivalentsAndMarketableSecurities_0e3efda6-2603-421e-9f63-2a3d028480fa_terseLabel_en-US" xlink:label="lab_lung_CashAndCashEquivalentsAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and marketable securities</link:label>
<link:label id="lab_lung_CashAndCashEquivalentsAndMarketableSecurities_label_en-US" xlink:label="lab_lung_CashAndCashEquivalentsAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents And Marketable Securities</link:label>
<link:label id="lab_lung_CashAndCashEquivalentsAndMarketableSecurities_documentation_en-US" xlink:label="lab_lung_CashAndCashEquivalentsAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents And Marketable Securities</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_CashAndCashEquivalentsAndMarketableSecurities" xlink:href="lung-20220630.xsd#lung_CashAndCashEquivalentsAndMarketableSecurities"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_CashAndCashEquivalentsAndMarketableSecurities" xlink:to="lab_lung_CashAndCashEquivalentsAndMarketableSecurities" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_c7ee0607-5290-42d7-929c-c318109c13a2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_52498818-0ade-4fa9-80e2-8b785d8d19a6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities</link:label>
<link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PreferredStockSharesIssued_d87b8208-0a5f-42b0-93af-ee852498d240_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
<link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
<link:label id="lab_dei_DocumentType_346f00e5-e18b-4794-9f6d-b50a39555be8_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
<link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_11465b33-bd77-4f12-8005-0346fd9dd111_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_938dbfdf-826e-42d9-9a98-a12c8ab96bfe_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
<link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3ab63e0c-f883-41aa-86cf-496b8b44dfbb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares Underlying Outstanding Restricted Stock</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
<link:label id="lab_dei_CountryRegion_1654c8b2-45a0-4653-af2e-0ccd9148970e_terseLabel_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Country Region</link:label>
<link:label id="lab_dei_CountryRegion_label_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Country Region</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CountryRegion" xlink:to="lab_dei_CountryRegion" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8f84ae13-6ccc-4a48-9494-c3764a3904ad_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
<link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3e60e628-fee5-483b-b8a9-cb0cb16b5219_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, beginning of period (in dollars per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4acdde62-025f-49f0-bfb4-c07016a72c4b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, end of period (in dollars per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtDisclosureTextBlock_2a724170-3071-4922-9a65-ac741856f5fd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt and Convertible Notes</link:label>
<link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_lung_COVID19CreditAgreementMember_69532426-3431-40b7-b013-7e6b4b2fd41e_terseLabel_en-US" xlink:label="lab_lung_COVID19CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Credit Agreement</link:label>
<link:label id="lab_lung_COVID19CreditAgreementMember_label_en-US" xlink:label="lab_lung_COVID19CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Credit Agreement [Member]</link:label>
<link:label id="lab_lung_COVID19CreditAgreementMember_documentation_en-US" xlink:label="lab_lung_COVID19CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Credit Agreement</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_COVID19CreditAgreementMember" xlink:href="lung-20220630.xsd#lung_COVID19CreditAgreementMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_COVID19CreditAgreementMember" xlink:to="lab_lung_COVID19CreditAgreementMember" xlink:type="arc" order="1"/>
<link:label id="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice_acf71838-0a80-4260-8dc0-eadcf47e6f5e_terseLabel_en-US" xlink:label="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested (in dollars per share)</link:label>
<link:label id="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Weighted Average Exercise Price</link:label>
<link:label id="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Weighted Average Exercise Price</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice" xlink:href="lung-20220630.xsd#lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice" xlink:to="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityShellCompany_8d9d979d-11f2-47f6-b3c9-9f4812186d61_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
<link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_2b1fa0a3-7465-4857-9dce-ea9769f5118d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ConcentrationRiskTable_6524fdc1-2c02-4db4-bc5a-478c2c2a15aa_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
<link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8b7047bb-8d12-4c1d-9097-f3545b4df7fd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_MediumTermNotesMember_f91fd5ae-fd28-4908-8182-942a5b0c77e6_terseLabel_en-US" xlink:label="lab_us-gaap_MediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medium-term Notes</link:label>
<link:label id="lab_us-gaap_MediumTermNotesMember_label_en-US" xlink:label="lab_us-gaap_MediumTermNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medium-term Notes [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MediumTermNotesMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MediumTermNotesMember" xlink:to="lab_us-gaap_MediumTermNotesMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_cd337e78-351b-426b-a444-c59046f1fc5b_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technology</link:label>
<link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FinancialInstrumentAxis_9c02fecf-fc5b-48de-935d-71afca878321_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
<link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1119e47c-6168-4386-8d85-49d888738c3f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
<link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_VehiclesMember_11e71b4b-b24c-4062-8858-5da05c69621d_terseLabel_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles</link:label>
<link:label id="lab_us-gaap_VehiclesMember_label_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VehiclesMember" xlink:to="lab_us-gaap_VehiclesMember" xlink:type="arc" order="1"/>
<link:label id="lab_lung_OperatingLeaseExpenseAnnualIncreaseRate_4314be8b-2c0d-446b-96a3-25f944d5f5de_terseLabel_en-US" xlink:label="lab_lung_OperatingLeaseExpenseAnnualIncreaseRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase rate</link:label>
<link:label id="lab_lung_OperatingLeaseExpenseAnnualIncreaseRate_label_en-US" xlink:label="lab_lung_OperatingLeaseExpenseAnnualIncreaseRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense, Annual Increase Rate</link:label>
<link:label id="lab_lung_OperatingLeaseExpenseAnnualIncreaseRate_documentation_en-US" xlink:label="lab_lung_OperatingLeaseExpenseAnnualIncreaseRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense, Annual Increase Rate</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_OperatingLeaseExpenseAnnualIncreaseRate" xlink:href="lung-20220630.xsd#lung_OperatingLeaseExpenseAnnualIncreaseRate"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_OperatingLeaseExpenseAnnualIncreaseRate" xlink:to="lab_lung_OperatingLeaseExpenseAnnualIncreaseRate" xlink:type="arc" order="1"/>
<link:label id="lab_dei_DocumentPeriodEndDate_c45fbe0a-6cac-41b4-b857-8bbc718388ce_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
<link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
<link:label id="lab_lung_GainLossOnAmendmentOfDebtInstrument_3fa474cb-0f0c-4876-ae39-3e44e8dab0b1_terseLabel_en-US" xlink:label="lab_lung_GainLossOnAmendmentOfDebtInstrument" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Loss on Amendment of Debt Instrument</link:label>
<link:label id="lab_lung_GainLossOnAmendmentOfDebtInstrument_label_en-US" xlink:label="lab_lung_GainLossOnAmendmentOfDebtInstrument" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Amendment of Debt Instrument</link:label>
<link:label id="lab_lung_GainLossOnAmendmentOfDebtInstrument_documentation_en-US" xlink:label="lab_lung_GainLossOnAmendmentOfDebtInstrument" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Amendment of Debt Instrument</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_GainLossOnAmendmentOfDebtInstrument" xlink:href="lung-20220630.xsd#lung_GainLossOnAmendmentOfDebtInstrument"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_GainLossOnAmendmentOfDebtInstrument" xlink:to="lab_lung_GainLossOnAmendmentOfDebtInstrument" xlink:type="arc" order="1"/>
<link:label id="lab_lung_CorporateBondsDebtSecuritiesAtCarryingValue_ec7c6ec5-c178-4150-97cc-4ac9f0eabe15_terseLabel_en-US" xlink:label="lab_lung_CorporateBondsDebtSecuritiesAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
<link:label id="lab_lung_CorporateBondsDebtSecuritiesAtCarryingValue_label_en-US" xlink:label="lab_lung_CorporateBondsDebtSecuritiesAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Debt Securities, at Carrying Value</link:label>
<link:label id="lab_lung_CorporateBondsDebtSecuritiesAtCarryingValue_documentation_en-US" xlink:label="lab_lung_CorporateBondsDebtSecuritiesAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Debt Securities, at Carrying Value</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_CorporateBondsDebtSecuritiesAtCarryingValue" xlink:href="lung-20220630.xsd#lung_CorporateBondsDebtSecuritiesAtCarryingValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_CorporateBondsDebtSecuritiesAtCarryingValue" xlink:to="lab_lung_CorporateBondsDebtSecuritiesAtCarryingValue" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_Assets_9bce63bd-54ef-47a1-afd6-40f4ee5b50c2_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
<link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncomeStatementLocationAxis_379f018b-9778-4b12-9d1f-a032dbd6ddb0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
<link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
<link:label id="lab_lung_AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase_7795393a-a16a-4c97-b5a8-20986fcede30_terseLabel_en-US" xlink:label="lab_lung_AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in shares subject to repurchase</link:label>
<link:label id="lab_lung_AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase_label_en-US" xlink:label="lab_lung_AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Change In Shares Subject To Repurchase</link:label>
<link:label id="lab_lung_AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase_documentation_en-US" xlink:label="lab_lung_AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Change In Shares Subject To Repurchase</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase" xlink:href="lung-20220630.xsd#lung_AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase" xlink:to="lab_lung_AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b851a232-1ee0-47df-a961-af72094d63ba_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
<link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_064d0abf-96fd-4fcd-88dc-7ef087808f2d_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
<link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_d3bd59ab-ceb2-4f41-80c1-eb7b3a525658_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued liabilities</link:label>
<link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6025dbed-9312-4778-859f-a39b3cebde6a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in dollars per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_ea43e529-0202-452d-9619-aaae07037a46_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_VariableLeaseCost_d6762313-f37c-47f4-85a1-e318adee1e51_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
<link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LineOfCreditMember_c3d9030f-440f-4537-972a-fa351f98f4c7_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
<link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f66f8778-1972-4b94-85d0-423c1a1d8d9b_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before tax</link:label>
<link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockholdersEquityAbstract_7502c1f2-7cc2-4c93-8545-b4d094d96b6f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders’ equity</link:label>
<link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d5447cb6-3f36-4723-8d5d-efd932edc5f3_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
<link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_483a3f51-fe74-4f29-a6f1-7ddc76cee196_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
<link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7e951cc5-2da3-4115-bf6d-2250e453e7a7_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and debt issuance costs</link:label>
<link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EarningsPerShareTextBlock_f37558e7-db8e-4f05-88f2-2be0adee0214_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share Attributable to Common Stockholders</link:label>
<link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_20d09b2a-5412-47d9-a9a3-07ffc1ba7da2_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components</link:label>
<link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_d3ae2a2f-1061-46dd-9871-667cde514f90_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_fc259134-f892-413b-a60a-9c84ee79804d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of shares vested</link:label>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f87b1dd-c842-40a2-b611-29757a25ca6a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e5579b87-9569-4ac7-86e8-3bf47f811276_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period for recognition of compensation costs</link:label>
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_fcfc4b55-3b80-46c3-8149-8b7bac01e364_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Intangible Assets</link:label>
<link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ComputerEquipmentMember_cb27a35f-25f9-4084-a877-38413eb6b955_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
<link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
<link:label id="lab_lung_LesseeOperatingSubleaseTenantImprovementAllowanceReceivableUponLeaseRenewal_36c2e96b-3c83-4278-abc5-3455050c0a9d_terseLabel_en-US" xlink:label="lab_lung_LesseeOperatingSubleaseTenantImprovementAllowanceReceivableUponLeaseRenewal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease, tenant improvement allowance, receivable upon lease renewal</link:label>
<link:label id="lab_lung_LesseeOperatingSubleaseTenantImprovementAllowanceReceivableUponLeaseRenewal_label_en-US" xlink:label="lab_lung_LesseeOperatingSubleaseTenantImprovementAllowanceReceivableUponLeaseRenewal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Sublease, Tenant Improvement Allowance, Receivable Upon Lease Renewal</link:label>
<link:label id="lab_lung_LesseeOperatingSubleaseTenantImprovementAllowanceReceivableUponLeaseRenewal_documentation_en-US" xlink:label="lab_lung_LesseeOperatingSubleaseTenantImprovementAllowanceReceivableUponLeaseRenewal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Sublease, Tenant Improvement Allowance, Receivable Upon Lease Renewal</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_LesseeOperatingSubleaseTenantImprovementAllowanceReceivableUponLeaseRenewal" xlink:href="lung-20220630.xsd#lung_LesseeOperatingSubleaseTenantImprovementAllowanceReceivableUponLeaseRenewal"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_LesseeOperatingSubleaseTenantImprovementAllowanceReceivableUponLeaseRenewal" xlink:to="lab_lung_LesseeOperatingSubleaseTenantImprovementAllowanceReceivableUponLeaseRenewal" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_GrossProfit_b7686089-e381-4cab-be0a-55d91d686828_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
<link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityRegistrantName_379250fb-f1c3-4ee7-af3f-9ddbf8b39178_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
<link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
<link:label id="lab_lung_CIBCAgreementMember_1549938d-ee5c-4a4d-afa8-29e65f437bfc_terseLabel_en-US" xlink:label="lab_lung_CIBCAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CIBC Agreement</link:label>
<link:label id="lab_lung_CIBCAgreementMember_label_en-US" xlink:label="lab_lung_CIBCAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CIBC Agreement [Member]</link:label>
<link:label id="lab_lung_CIBCAgreementMember_documentation_en-US" xlink:label="lab_lung_CIBCAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CIBC Agreement</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_CIBCAgreementMember" xlink:href="lung-20220630.xsd#lung_CIBCAgreementMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_CIBCAgreementMember" xlink:to="lab_lung_CIBCAgreementMember" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityAddressCityOrTown_4c290088-48b6-43a6-9100-466b75493891_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
<link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EMEAMember_30ed3653-512a-4403-aa7b-dedcde610999_terseLabel_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe, Middle-East and Africa (“EMEA”)</link:label>
<link:label id="lab_us-gaap_EMEAMember_8cfef15b-205d-4b4b-9497-77677401f0c1_verboseLabel_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMEA</link:label>
<link:label id="lab_us-gaap_EMEAMember_label_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMEA [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EMEAMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EMEAMember" xlink:to="lab_us-gaap_EMEAMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_0cdefed9-a718-4f66-945f-8ef0042d31ad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingExpensesAbstract_1162881d-a151-4699-863d-102bca52e592_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
<link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_1e8e2a80-fd98-490d-b9e0-e062c2119140_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
<link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_country_DE_fa271801-8015-465b-9b77-983b29bb09c2_terseLabel_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GERMANY</link:label>
<link:label id="lab_country_DE_label_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GERMANY</link:label>
<link:loc xlink:type="locator" xlink:label="loc_country_DE" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE" xlink:to="lab_country_DE" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityEmergingGrowthCompany_fecb59a0-b599-400b-aac4-b6c92f06b285_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
<link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_0993447a-2abd-4134-aa6b-afef89618a7c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
<link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_1dcabc2e-8ecd-48bf-aec6-dfc2f9f44eb5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
<link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InventoryWriteDown_fc0c864a-fb06-40a9-9570-71264561820f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-downs</link:label>
<link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization_4316545d-3582-4471-9827-b28f88c478c8_terseLabel_en-US" xlink:label="lab_us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized costs</link:label>
<link:label id="lab_us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hosting Arrangement, Service Contract, Implementation Cost, Capitalized, after Accumulated Amortization</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization" xlink:to="lab_us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_697d76c1-64f4-490d-849a-4fc24d3d0eec_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: weighted-average common shares subject to repurchase (in shares)</link:label>
<link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_af7c1149-49a2-4a12-bded-f6f3d9bc392d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
<link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_dei_TradingSymbol_3b56a911-5891-4256-bbd5-3b7f42bef676_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
<link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityFileNumber_238dea14-2151-467f-b1f8-a0a90a0154bd_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
<link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_a2df18ee-5c68-48a1-a9c9-38c428717da0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
<link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock_a688ea38-f46a-47c5-8a48-4632032c158d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under the employee stock purchase plan</link:label>
<link:label id="lab_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Repayment of Loans to Purchase Common Stock</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock" xlink:to="lab_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_995da2a1-0826-4188-9b68-b03888f1bc7c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
<link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4a0b2f40-fa9b-4ea8-8209-0e97abb91fd6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_d7cbcce5-7b92-473b-ba23-8e9ef351d5ca_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
<link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_62e2d2ae-98af-44de-ba81-f5f5941c6914_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from line of credit</link:label>
<link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_395a77c5-ac7d-4df0-9866-92a99e02eaf1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
<link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_01cb79f6-bef2-4a21-af73-ab9caa78d648_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_UseOfEstimates_0cb5d965-1a1c-41da-b537-d41a1bb80b8f_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
<link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_89da6fbd-72a9-49aa-97a5-aa92ea72aa05_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
<link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_8ee982e7-3908-4efe-854b-3ff4576fd1a8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income</link:label>
<link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_a980ff61-f989-4965-8bf0-82121711102f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ConcentrationRiskPercentage1_738a027a-8f3c-4c78-a178-54b0580186c8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
<link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PrimeRateMember_434f8fe4-6a1a-42b0-82e1-2c44254f40d6_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate</link:label>
<link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentFeeAmount_143c4f3f-20bd-4367-9a03-cce8640724b4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee amount</link:label>
<link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_e67f7cf9-6307-4cf1-b26e-ca6193c78a99_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
<link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_a651c94d-84b4-4208-b6be-d0835578af68_terseLabel_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VAT and other receivable</link:label>
<link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value Added Tax Receivable, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:to="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_6b0b4081-67d7-42bc-9907-622bee01df7b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
<link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_e4bea156-cd34-42bc-b190-1d0babfd420b_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense related to intangibles, less than</link:label>
<link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InterestPaidNet_67ac5218-4b07-4ea8-b546-f4008eb483cf_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
<link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EarningsPerShareBasic_af8ec477-08ce-454a-9314-16687e1c15ad_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable common stockholders, basic (in dollars per share)</link:label>
<link:label id="lab_us-gaap_EarningsPerShareBasic_aaec17db-6748-4271-96b4-ebc8ae8f01ae_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders, basic (in dollars per share)</link:label>
<link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_16f71571-e4a3-4503-8b44-3fe6b754bcb6_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-Term Commitment [Line Items]</link:label>
<link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-Term Commitment [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_21bc3c05-3b1e-4881-b4d6-8be5fb54cc31_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_c6e6b581-0066-411c-bca3-53056d82e553_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
<link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_lung_DebtInstrumentAccordionFeatureIncreaseFaceAmount_2398397a-f760-4d72-8451-3ba484b3d37d_terseLabel_en-US" xlink:label="lab_lung_DebtInstrumentAccordionFeatureIncreaseFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accordion feature on face amount of debt</link:label>
<link:label id="lab_lung_DebtInstrumentAccordionFeatureIncreaseFaceAmount_label_en-US" xlink:label="lab_lung_DebtInstrumentAccordionFeatureIncreaseFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Accordion Feature, Increase Face Amount</link:label>
<link:label id="lab_lung_DebtInstrumentAccordionFeatureIncreaseFaceAmount_documentation_en-US" xlink:label="lab_lung_DebtInstrumentAccordionFeatureIncreaseFaceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Accordion Feature, Increase Face Amount</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_DebtInstrumentAccordionFeatureIncreaseFaceAmount" xlink:href="lung-20220630.xsd#lung_DebtInstrumentAccordionFeatureIncreaseFaceAmount"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_DebtInstrumentAccordionFeatureIncreaseFaceAmount" xlink:to="lab_lung_DebtInstrumentAccordionFeatureIncreaseFaceAmount" xlink:type="arc" order="1"/>
<link:label id="lab_lung_DebtInstrumentCovenantMinimumRevenueRequirementsPercentage_8166c3b6-497f-4414-9a9a-17fe9ee73e7c_terseLabel_en-US" xlink:label="lab_lung_DebtInstrumentCovenantMinimumRevenueRequirementsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum percentage of revenue requirement</link:label>
<link:label id="lab_lung_DebtInstrumentCovenantMinimumRevenueRequirementsPercentage_label_en-US" xlink:label="lab_lung_DebtInstrumentCovenantMinimumRevenueRequirementsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Minimum Revenue Requirements, Percentage</link:label>
<link:label id="lab_lung_DebtInstrumentCovenantMinimumRevenueRequirementsPercentage_documentation_en-US" xlink:label="lab_lung_DebtInstrumentCovenantMinimumRevenueRequirementsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Minimum Revenue Requirements, Percentage</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_DebtInstrumentCovenantMinimumRevenueRequirementsPercentage" xlink:href="lung-20220630.xsd#lung_DebtInstrumentCovenantMinimumRevenueRequirementsPercentage"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_DebtInstrumentCovenantMinimumRevenueRequirementsPercentage" xlink:to="lab_lung_DebtInstrumentCovenantMinimumRevenueRequirementsPercentage" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_b65062ce-2af8-4db4-bdc9-6e8ab4af33e8_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-Term Commitment [Axis]</link:label>
<link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-Term Commitment [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_db4142d2-36cf-425e-ad46-4206cab6919f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
<link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
<link:label id="lab_lung_InventoryNetMember_a9cba18f-a910-4518-a459-32114e0161f3_terseLabel_en-US" xlink:label="lab_lung_InventoryNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
<link:label id="lab_lung_InventoryNetMember_label_en-US" xlink:label="lab_lung_InventoryNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net [Member]</link:label>
<link:label id="lab_lung_InventoryNetMember_documentation_en-US" xlink:label="lab_lung_InventoryNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_InventoryNetMember" xlink:href="lung-20220630.xsd#lung_InventoryNetMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_InventoryNetMember" xlink:to="lab_lung_InventoryNetMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockholdersEquity_677bf94d-5fa4-4d51-88fd-583fd6a427d0_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders’ equity</link:label>
<link:label id="lab_us-gaap_StockholdersEquity_9707d696-72ad-4689-b171-880b8d68bd80_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
<link:label id="lab_us-gaap_StockholdersEquity_84d86bf4-22b9-4a26-ab07-11433117024c_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
<link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4e9993c8-55b5-4e83-b1e1-f61475bdc451_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in dollars per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DividendsCommonStock_b2f11724-a83e-4ece-a8e3-19c1c41697ae_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared</link:label>
<link:label id="lab_us-gaap_DividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStock" xlink:to="lab_us-gaap_DividendsCommonStock" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityInteractiveDataCurrent_325c07e9-400e-48fd-8789-5248275f58a2_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
<link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_726faff6-9c15-4713-942d-b34c0603e9b8_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
<link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_321d9121-6ebe-4f79-a352-65447820f8b5_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
<link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bf7c0a3b-1a8e-452e-b831-b3ccb49f7bea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
<link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
<link:label id="lab_lung_ReceivableFromExerciseOfCommonStockOptions_de9d4cdc-65cb-46f8-acae-94659e00d119_terseLabel_en-US" xlink:label="lab_lung_ReceivableFromExerciseOfCommonStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount receivable from exercise of common stock options</link:label>
<link:label id="lab_lung_ReceivableFromExerciseOfCommonStockOptions_label_en-US" xlink:label="lab_lung_ReceivableFromExerciseOfCommonStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable From Exercise Of Common Stock Options</link:label>
<link:label id="lab_lung_ReceivableFromExerciseOfCommonStockOptions_documentation_en-US" xlink:label="lab_lung_ReceivableFromExerciseOfCommonStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable From Exercise Of Common Stock Options</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_ReceivableFromExerciseOfCommonStockOptions" xlink:href="lung-20220630.xsd#lung_ReceivableFromExerciseOfCommonStockOptions"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_ReceivableFromExerciseOfCommonStockOptions" xlink:to="lab_lung_ReceivableFromExerciseOfCommonStockOptions" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cf9ed07a-8e39-4cbf-8bd4-7d189d45eaca_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in operating assets and liabilities:</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_ebe9bf51-ba23-4aa4-8397-a6e44a7bdab8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
<link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_362fe02a-8011-4b56-b174-e1f39e8636d0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivable on marketable securities, less than</link:label>
<link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_MoneyMarketFundsMember_a69e0389-e434-4dc1-b319-6638ae66c981_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
<link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RetainedEarningsMember_825e7b36-09c6-4045-8e0b-b6e85efb85eb_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
<link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LeaseCost_b2036b09-01c9-4d76-9af3-efd216cb2b2c_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
<link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommonStockMember_4cc2d343-0eb5-4177-a63b-a5dce13c34a3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
<link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_faa24e64-de5b-4727-9ede-1e5f3afd5d92_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Stock-Based Compensation</link:label>
<link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_MoneyMarketFundsAtCarryingValue_6c620092-6e64-4b12-a6ea-7c9c3743e7f3_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
<link:label id="lab_us-gaap_MoneyMarketFundsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds, at Carrying Value</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b8ea41a9-d81b-4f6c-888a-fe3ceff3996b_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income (loss)</link:label>
<link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NumberOfReportableSegments_5ba9bff4-ae10-485a-bb33-ea16c00e99f2_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
<link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
<link:label id="lab_lung_TenantImprovementAllowanceReceivableUponLeaseRenewal_4779bdf8-44b6-4cc4-af8c-917841599538_terseLabel_en-US" xlink:label="lab_lung_TenantImprovementAllowanceReceivableUponLeaseRenewal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvement allowance, receivable upon lease renewal</link:label>
<link:label id="lab_lung_TenantImprovementAllowanceReceivableUponLeaseRenewal_label_en-US" xlink:label="lab_lung_TenantImprovementAllowanceReceivableUponLeaseRenewal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement Allowance, Receivable Upon Lease Renewal</link:label>
<link:label id="lab_lung_TenantImprovementAllowanceReceivableUponLeaseRenewal_documentation_en-US" xlink:label="lab_lung_TenantImprovementAllowanceReceivableUponLeaseRenewal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement Allowance, Receivable Upon Lease Renewal</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_TenantImprovementAllowanceReceivableUponLeaseRenewal" xlink:href="lung-20220630.xsd#lung_TenantImprovementAllowanceReceivableUponLeaseRenewal"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_TenantImprovementAllowanceReceivableUponLeaseRenewal" xlink:to="lab_lung_TenantImprovementAllowanceReceivableUponLeaseRenewal" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LeaseCostTableTextBlock_3a4d5397-c0d5-496e-820d-1060ac45f849_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease Cost and Additional Information</link:label>
<link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_19ea303e-5faf-4ffc-8b5b-4d4547b42862_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for repurchase of early exercised common stock options</link:label>
<link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
<link:label id="lab_lung_CIBCAgreementTrancheAMember_a4b4285f-b106-4f45-9375-0cd9aa899078_terseLabel_en-US" xlink:label="lab_lung_CIBCAgreementTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CIBC Agreement, Tranche A</link:label>
<link:label id="lab_lung_CIBCAgreementTrancheAMember_label_en-US" xlink:label="lab_lung_CIBCAgreementTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CIBC Agreement, Tranche A [Member]</link:label>
<link:label id="lab_lung_CIBCAgreementTrancheAMember_documentation_en-US" xlink:label="lab_lung_CIBCAgreementTrancheAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CIBC Agreement, Tranche A</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_CIBCAgreementTrancheAMember" xlink:href="lung-20220630.xsd#lung_CIBCAgreementTrancheAMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_CIBCAgreementTrancheAMember" xlink:to="lab_lung_CIBCAgreementTrancheAMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StatementTable_0cf5f4e1-2bd0-45d6-b47b-1f226a2e0962_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
<link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
<link:label id="lab_lung_FairValueRecognizedOnBalanceSheetAbstract_888fab03-696f-4d94-9314-c70003057524_terseLabel_en-US" xlink:label="lab_lung_FairValueRecognizedOnBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts recognized on the consolidated balance sheet</link:label>
<link:label id="lab_lung_FairValueRecognizedOnBalanceSheetAbstract_label_en-US" xlink:label="lab_lung_FairValueRecognizedOnBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Recognized On Balance Sheet [Abstract]</link:label>
<link:label id="lab_lung_FairValueRecognizedOnBalanceSheetAbstract_documentation_en-US" xlink:label="lab_lung_FairValueRecognizedOnBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Recognized On Balance Sheet</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_FairValueRecognizedOnBalanceSheetAbstract" xlink:href="lung-20220630.xsd#lung_FairValueRecognizedOnBalanceSheetAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_FairValueRecognizedOnBalanceSheetAbstract" xlink:to="lab_lung_FairValueRecognizedOnBalanceSheetAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_8143909a-d90a-439a-aed2-ada45c6cc1f8_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-Term Commitment [Domain]</link:label>
<link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-Term Commitment [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f22f23fe-df58-41f0-aa2f-48a76a097449_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_aa9b3ecb-c410-4ee9-957b-10238144b899_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate</link:label>
<link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_b87a6567-ae8a-4eb8-a60c-e545098ebe6c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease renewal term</link:label>
<link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_900d5e91-c5f3-4c89-9ad2-977a68749e1a_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
<link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
<link:label id="lab_dei_DocumentQuarterlyReport_66852287-4ff8-4ee4-8ae1-1a6af61689ad_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
<link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
<link:label id="lab_lung_DebtInstrumentPeriodicPaymentInterestOnlyTerm_ab1137e4-70f7-48b8-9ec2-ecf66f73ef37_terseLabel_en-US" xlink:label="lab_lung_DebtInstrumentPeriodicPaymentInterestOnlyTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest payments term</link:label>
<link:label id="lab_lung_DebtInstrumentPeriodicPaymentInterestOnlyTerm_label_en-US" xlink:label="lab_lung_DebtInstrumentPeriodicPaymentInterestOnlyTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Interest Only, Term</link:label>
<link:label id="lab_lung_DebtInstrumentPeriodicPaymentInterestOnlyTerm_documentation_en-US" xlink:label="lab_lung_DebtInstrumentPeriodicPaymentInterestOnlyTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Interest Only, Term</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_DebtInstrumentPeriodicPaymentInterestOnlyTerm" xlink:href="lung-20220630.xsd#lung_DebtInstrumentPeriodicPaymentInterestOnlyTerm"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_DebtInstrumentPeriodicPaymentInterestOnlyTerm" xlink:to="lab_lung_DebtInstrumentPeriodicPaymentInterestOnlyTerm" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FurnitureAndFixturesMember_a934de12-934c-4d97-abd1-d3915ea37042_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
<link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AssetsCurrentAbstract_192fa730-96d5-44d0-8d8b-c5886f72288a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
<link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_7924dcf0-dd4a-4d10-adcb-1747c63f19da_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease liabilities</link:label>
<link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
<link:label id="lab_srt_RangeAxis_c69566c1-133d-4100-a19f-c827b428490f_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
<link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_aa640b1c-e177-43f5-8422-afd97d7bd612_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-Term Commitment [Table]</link:label>
<link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-Term Commitment [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LeaseholdImprovementsMember_e901b540-ca35-48dc-bd0d-6739d832167d_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
<link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_6bbe4611-d6f0-4f1c-9c62-171a1f3fb87f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Geographic Area</link:label>
<link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_65dc768e-4145-450a-9e1b-86a54e047e98_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
<link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ae0fced1-01d6-479a-887b-8d57584110fc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
<link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
<link:label id="lab_country_FR_c1233e7a-a24b-4e4d-a576-dafc6fa66476_terseLabel_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FRANCE</link:label>
<link:label id="lab_country_FR_label_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FRANCE</link:label>
<link:loc xlink:type="locator" xlink:label="loc_country_FR" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_FR" xlink:to="lab_country_FR" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AccountsReceivableNetCurrent_22789daf-1458-44f9-a062-2fcac7c41d25_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
<link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b8d57673-3c0f-41ce-a77d-14863ab209b3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
<link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StatementEquityComponentsAxis_3a371303-ec10-40ef-a63b-488b968d8bfd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
<link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_TrademarksMember_bdf18485-7aa5-43e3-8335-79ef0b7e2c2a_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
<link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_4c6a63b9-0ef2-4cf7-889d-401386a0224c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring Basis</link:label>
<link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
<link:label id="lab_lung_IncreaseLapseInRepurchaseOfCommonStockRights_af1086b9-c8d4-4b82-8708-9ca9d97b3f27_terseLabel_en-US" xlink:label="lab_lung_IncreaseLapseInRepurchaseOfCommonStockRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapse in repurchase rights of common stock</link:label>
<link:label id="lab_lung_IncreaseLapseInRepurchaseOfCommonStockRights_label_en-US" xlink:label="lab_lung_IncreaseLapseInRepurchaseOfCommonStockRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Lapse) In Repurchase Of Common Stock Rights</link:label>
<link:label id="lab_lung_IncreaseLapseInRepurchaseOfCommonStockRights_documentation_en-US" xlink:label="lab_lung_IncreaseLapseInRepurchaseOfCommonStockRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Lapse) In Repurchase Of Common Stock Rights</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_IncreaseLapseInRepurchaseOfCommonStockRights" xlink:href="lung-20220630.xsd#lung_IncreaseLapseInRepurchaseOfCommonStockRights"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_IncreaseLapseInRepurchaseOfCommonStockRights" xlink:to="lab_lung_IncreaseLapseInRepurchaseOfCommonStockRights" xlink:type="arc" order="1"/>
<link:label id="lab_dei_DocumentFiscalYearFocus_32c909b6-6a2b-405b-b8d8-b4d587446dae_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
<link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
<link:label id="lab_lung_CIBCAgreementTrancheBMember_b9434c40-bde1-4f69-9101-c56e1748db17_terseLabel_en-US" xlink:label="lab_lung_CIBCAgreementTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CIBC Agreement, Tranche B</link:label>
<link:label id="lab_lung_CIBCAgreementTrancheBMember_label_en-US" xlink:label="lab_lung_CIBCAgreementTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CIBC Agreement, Tranche B [Member]</link:label>
<link:label id="lab_lung_CIBCAgreementTrancheBMember_documentation_en-US" xlink:label="lab_lung_CIBCAgreementTrancheBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CIBC Agreement, Tranche B</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_CIBCAgreementTrancheBMember" xlink:href="lung-20220630.xsd#lung_CIBCAgreementTrancheBMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_CIBCAgreementTrancheBMember" xlink:to="lab_lung_CIBCAgreementTrancheBMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_eaae7844-38fc-48ef-8b27-586d1c655de2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StatementLineItems_271a2ae8-a5f4-4fa0-a594-6aea83755036_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
<link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_addd09a3-c01c-4e78-b0cc-9522679953d9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, beginning of period (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a9c58d47-1199-4654-bd21-4225f5763979_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, end of period (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_VariableRateDomain_abfaaeab-afd5-4374-8e7d-5f654a511416_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
<link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_e33cd351-db42-41ba-a0c8-d39765b03e59_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Value</link:label>
<link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_8f1fe0b2-6660-4690-928e-b60adcd803bd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
<link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_b6a263ad-ce4c-47c5-a132-1202c342f26a_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
<link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_03b9e0bc-6ec5-415a-829c-e7c8603b036a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued personnel related expenses</link:label>
<link:label id="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Employee-related Liabilities, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_62200f74-7851-4e96-9b04-9dba96cec28c_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
<link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d47ff7e9-e568-4c98-887f-1353d5cd7fc4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
<link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_d868cd7c-e257-45f5-a0bc-a6b7dd99cf9f_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets</link:label>
<link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_b6c597b0-8733-46e6-afef-7ce60bb0c582_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use asset</link:label>
<link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_1f69bc2e-7a3e-4a57-8c19-2d65443a4724_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares repurchased, less than (in shares)</link:label>
<link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_44547f4d-62c6-4125-82d1-d0381ef1522c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
<link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_d49571d2-779e-4888-81db-176b1a14dc47_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest (in dollars per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
<link:label id="lab_dei_DocumentTransitionReport_a4ae96e8-0232-4bfe-867d-155430afb994_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
<link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
<link:label id="lab_dei_LocalPhoneNumber_ee1a3505-95a1-4596-830c-3477ce943b0a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
<link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9c075a57-d1b7-4734-a2c5-0bb33020676d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Summary of Stock Option Activity</link:label>
<link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingIncomeLoss_b510c336-cd41-44be-97a3-152138692e5e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
<link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInInventories_17e645ad-a51e-4237-beb6-4e710f0f79cd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f54863be-6cac-45ed-8256-78280d178aec_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</link:label>
<link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e3a63b6d-1961-46ea-8504-b01bc0c9c2d0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0fd13fc1-e8b2-44ac-a946-4353deca6e25_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator</link:label>
<link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommonStockSharesOutstanding_f664ea08-cda3-4edb-9ba0-f60e42e19cb7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
<link:label id="lab_us-gaap_CommonStockSharesOutstanding_f85ed178-71c3-415e-a290-3a07b76d970b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
<link:label id="lab_us-gaap_CommonStockSharesOutstanding_ef5bcd6b-b82a-4508-b4f8-66753c00d647_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
<link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_8b370584-ab08-4e75-94c6-8f550b80966a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for early exercise of stock options</link:label>
<link:label id="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-Based Arrangements, Liability, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:to="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_Goodwill_ef334241-c8af-43d5-ac64-f6fcc696671d_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
<link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
<link:label id="lab_lung_CIBCAgreementTrancheCMember_2065ee3b-6eca-416a-a53c-3c54801f926e_terseLabel_en-US" xlink:label="lab_lung_CIBCAgreementTrancheCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CIBC Agreement, Tranche C</link:label>
<link:label id="lab_lung_CIBCAgreementTrancheCMember_label_en-US" xlink:label="lab_lung_CIBCAgreementTrancheCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CIBC Agreement, Tranche C [Member]</link:label>
<link:label id="lab_lung_CIBCAgreementTrancheCMember_documentation_en-US" xlink:label="lab_lung_CIBCAgreementTrancheCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CIBC Agreement, Tranche C</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_CIBCAgreementTrancheCMember" xlink:href="lung-20220630.xsd#lung_CIBCAgreementTrancheCMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_CIBCAgreementTrancheCMember" xlink:to="lab_lung_CIBCAgreementTrancheCMember" xlink:type="arc" order="1"/>
<link:label id="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm_bf4ad035-c781-4e11-91d3-31e64eaee50c_terseLabel_en-US" xlink:label="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested</link:label>
<link:label id="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Weighted Average Remaining Contractual Term</link:label>
<link:label id="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Weighted Average Remaining Contractual Term</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" xlink:href="lung-20220630.xsd#lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" xlink:to="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_454154df-e2a5-4456-9cfc-5d53e2569561_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_6dbefe68-3225-4a68-9bc9-e1a4241d3e83_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of early exercised common stock options (in shares)</link:label>
<link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9f7d22f8-7d40-4ca4-9783-8068ac879afd_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
<link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4448f94e-5d60-4c86-a3d8-e8a00f2b748b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
<link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
<link:label id="lab_srt_SegmentGeographicalDomain_e050e355-6449-4497-90c0-cc6af62223d5_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
<link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_0cfc594c-1cb6-4f73-b3e4-e1b8222672e1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
<link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_c32ed8ea-730b-4d0d-9100-42b19ae385ab_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
<link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_45e51f40-6958-4293-a410-e99bf2245554_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_e2a2bcff-3492-499a-aaff-539d512b1fa5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
<link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_BalanceSheetLocationDomain_cb33fc6f-caf5-4dab-978d-1186a42ef150_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
<link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
<link:label id="lab_dei_DocumentFiscalPeriodFocus_500d314c-5620-4899-9858-820746444497_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
<link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_5e0d8790-e89d-4a40-9b2c-08a4821c60f6_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
<link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DerivativeLineItems_9a8a1a59-3d62-4fe8-bd5a-2c237742b867_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
<link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4c70a19a-20da-4562-a736-c44dd8d190f4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)</link:label>
<link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f5e0d239-53c6-45b3-a070-4d39c50f21b4_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares used to compute, diluted net loss per share (in shares)</link:label>
<link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7b82b7d4-a701-4a9f-b93f-41691afc96e4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
<link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_561abe93-acc2-4e59-ac1e-c86ff4961ba8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
<link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsAbstract_1576a82b-c697-40e3-8dab-836942aea5b4_terseLabel_en-US" xlink:label="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Options</link:label>
<link:label id="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsAbstract_label_en-US" xlink:label="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Outstanding Options [Abstract]</link:label>
<link:label id="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsAbstract_documentation_en-US" xlink:label="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Outstanding Options</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsAbstract" xlink:href="lung-20220630.xsd#lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsAbstract" xlink:to="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommonStockValue_e4adf4e5-f9ae-4e63-94ea-f52e6b54979d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, 200,000,000 shares authorized as of June 30, 2022 and December 31, 2021; 37,266,030 shares issued and outstanding as of June 30, 2022 and 36,931,762 shares issued and outstanding as of December 31, 2021</link:label>
<link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
<link:label id="lab_lung_LesseeOperatingSubleaseRenewalTerm_4c0c5af5-baa5-46f0-9e25-8148d02ca98f_terseLabel_en-US" xlink:label="lab_lung_LesseeOperatingSubleaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease renewal term</link:label>
<link:label id="lab_lung_LesseeOperatingSubleaseRenewalTerm_label_en-US" xlink:label="lab_lung_LesseeOperatingSubleaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Sublease, Renewal Term</link:label>
<link:label id="lab_lung_LesseeOperatingSubleaseRenewalTerm_documentation_en-US" xlink:label="lab_lung_LesseeOperatingSubleaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Sublease, Renewal Term</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_LesseeOperatingSubleaseRenewalTerm" xlink:href="lung-20220630.xsd#lung_LesseeOperatingSubleaseRenewalTerm"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_LesseeOperatingSubleaseRenewalTerm" xlink:to="lab_lung_LesseeOperatingSubleaseRenewalTerm" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentNameDomain_bf43d6b4-a042-4ed7-964d-ffefb1c56090_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
<link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cd309a63-70d1-43a9-a335-d1583710271f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
<link:label id="lab_srt_AsiaPacificMember_add7faca-58c4-4bb3-9238-3769545ccff8_terseLabel_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific</link:label>
<link:label id="lab_srt_AsiaPacificMember_label_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AsiaPacificMember" xlink:to="lab_srt_AsiaPacificMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6282428e-bed3-4543-b865-6ae82a2341ae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Securities Outstanding</link:label>
<link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d12d6651-a77b-4d54-b24e-70cefef93a15_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
<link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_lung_ShareBasedCompensationUnvestedEarlyExercisedOptionsMember_a7572123-184a-47a5-9027-5b6f15b4970f_terseLabel_en-US" xlink:label="lab_lung_ShareBasedCompensationUnvestedEarlyExercisedOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested early exercised common stock options</link:label>
<link:label id="lab_lung_ShareBasedCompensationUnvestedEarlyExercisedOptionsMember_label_en-US" xlink:label="lab_lung_ShareBasedCompensationUnvestedEarlyExercisedOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation, Unvested Early Exercised Options [Member]</link:label>
<link:label id="lab_lung_ShareBasedCompensationUnvestedEarlyExercisedOptionsMember_documentation_en-US" xlink:label="lab_lung_ShareBasedCompensationUnvestedEarlyExercisedOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation, Unvested Early Exercised Options</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_ShareBasedCompensationUnvestedEarlyExercisedOptionsMember" xlink:href="lung-20220630.xsd#lung_ShareBasedCompensationUnvestedEarlyExercisedOptionsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_ShareBasedCompensationUnvestedEarlyExercisedOptionsMember" xlink:to="lab_lung_ShareBasedCompensationUnvestedEarlyExercisedOptionsMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_645e97fd-b0d2-4fb2-a116-eb21b019f172_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, aggregate intrinsic value</link:label>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
<link:label id="lab_lung_IncomeTaxDisclosureTable_ff4fd39c-97a3-451c-8406-597a7699d356_terseLabel_en-US" xlink:label="lab_lung_IncomeTaxDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Table]</link:label>
<link:label id="lab_lung_IncomeTaxDisclosureTable_label_en-US" xlink:label="lab_lung_IncomeTaxDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Table]</link:label>
<link:label id="lab_lung_IncomeTaxDisclosureTable_documentation_en-US" xlink:label="lab_lung_IncomeTaxDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_IncomeTaxDisclosureTable" xlink:href="lung-20220630.xsd#lung_IncomeTaxDisclosureTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_IncomeTaxDisclosureTable" xlink:to="lab_lung_IncomeTaxDisclosureTable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShortTermLeaseCost_cc37827c-c6bc-4e76-acc8-09ea641fdb1c_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease cost</link:label>
<link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PreferredStockSharesAuthorized_408aa9e4-797d-4dc0-86db-f14afd8e1d76_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
<link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d2ae203c-260e-4919-99b4-7879cace8956_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, at beginning of the period</link:label>
<link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7fac0cb6-c1a5-41fa-a959-42f5b5bfce2e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, at end of the period</link:label>
<link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ba5ff237-10aa-4ccd-86b8-81eab6411e5d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash in consolidated balance sheets</link:label>
<link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AccruedBonusesCurrent_4f681db3-911f-4ada-988c-983a9ac3747d_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued employee bonuses and commissions</link:label>
<link:label id="lab_us-gaap_AccruedBonusesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Bonuses, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedBonusesCurrent" xlink:to="lab_us-gaap_AccruedBonusesCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_40be182d-272d-4703-943e-e9a95258b509_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
<link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_lung_HostingArrangementServiceContractImplementationCostCapitalizedAmortizationPeriod_5c6cd1fb-7866-4fda-b915-f2903db5480d_terseLabel_en-US" xlink:label="lab_lung_HostingArrangementServiceContractImplementationCostCapitalizedAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization period</link:label>
<link:label id="lab_lung_HostingArrangementServiceContractImplementationCostCapitalizedAmortizationPeriod_label_en-US" xlink:label="lab_lung_HostingArrangementServiceContractImplementationCostCapitalizedAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hosting Arrangement, Service Contract, Implementation Cost, Capitalized, Amortization Period</link:label>
<link:label id="lab_lung_HostingArrangementServiceContractImplementationCostCapitalizedAmortizationPeriod_documentation_en-US" xlink:label="lab_lung_HostingArrangementServiceContractImplementationCostCapitalizedAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hosting Arrangement, Service Contract, Implementation Cost, Capitalized, Amortization Period</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_HostingArrangementServiceContractImplementationCostCapitalizedAmortizationPeriod" xlink:href="lung-20220630.xsd#lung_HostingArrangementServiceContractImplementationCostCapitalizedAmortizationPeriod"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_HostingArrangementServiceContractImplementationCostCapitalizedAmortizationPeriod" xlink:to="lab_lung_HostingArrangementServiceContractImplementationCostCapitalizedAmortizationPeriod" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_b2d8cd45-fc66-48d1-a073-6e441a6584f1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, accumulated impairment loss</link:label>
<link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_041547f1-414c-4f66-a648-9b11db93b343_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
<link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8f50ab05-378e-460c-aee5-d0f538304a24_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders, basic</link:label>
<link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1a9eb635-4e5e-443c-b0db-7be65920a7f8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
<link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_052be206-d581-4ce4-a29b-2c7875b9fcd8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of common stock options</link:label>
<link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommonStockSharesIssued_ac690c4f-09d2-4968-8f55-3e1299bc6630_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
<link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ConcentrationRiskLineItems_fa3bfa99-9494-4974-8275-53bc15d13e3f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
<link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_bc69a8d4-5d89-4c91-818f-006ca2c2d8c4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest</link:label>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_9b213154-f1c0-49c6-888c-a4af1760cbda_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
<link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_a7659e64-46ed-4672-8a95-5b29477ebcec_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation, to be paid, year one</link:label>
<link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year One</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8f01264e-0df2-4c9d-9065-b6f2d9bbe46e_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment in accounts payable</link:label>
<link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncomeStatementLocationDomain_3352a1e6-a4a5-4e86-97f1-ee5f28277281_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
<link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7edf7f9e-5063-453c-a623-7a79b5d05397_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
<link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_dei_AmendmentFlag_e5588d9e-6064-48ad-8fb1-1f90afc1d0cd_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
<link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_d20eb3ca-1b38-4439-8d7f-94fc608b1c5e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingLeaseCost_57c2c9fc-3267-444c-995d-de6ae377bc37_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
<link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_a49353ed-8dd3-4326-895d-1c6e4180536b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares pursuant to Employee Stock Purchase Plan</link:label>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_b579f047-3d26-4e0f-86d8-08a46672f6e8_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
<link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
<link:label id="lab_lung_LesseeOperatingSubleaseOptionToTerminateTerm_5cc50019-b096-4662-a197-cbd5b1e0b118_terseLabel_en-US" xlink:label="lab_lung_LesseeOperatingSubleaseOptionToTerminateTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease, period for option to terminate</link:label>
<link:label id="lab_lung_LesseeOperatingSubleaseOptionToTerminateTerm_label_en-US" xlink:label="lab_lung_LesseeOperatingSubleaseOptionToTerminateTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Sublease, Option To Terminate, Term</link:label>
<link:label id="lab_lung_LesseeOperatingSubleaseOptionToTerminateTerm_documentation_en-US" xlink:label="lab_lung_LesseeOperatingSubleaseOptionToTerminateTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Sublease, Option To Terminate, Term</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_LesseeOperatingSubleaseOptionToTerminateTerm" xlink:href="lung-20220630.xsd#lung_LesseeOperatingSubleaseOptionToTerminateTerm"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_LesseeOperatingSubleaseOptionToTerminateTerm" xlink:to="lab_lung_LesseeOperatingSubleaseOptionToTerminateTerm" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_1d4a9830-041c-458e-bcfd-7b8c15e2dfdd_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill acquired</link:label>
<link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ConstructionInProgressMember_eca39525-fd5b-4657-8206-d68423aca41e_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
<link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4392d601-9e60-4894-b164-6c9b97becaa3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
<link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityCurrentReportingStatus_a3a61a6a-465f-49af-897c-a689314039f7_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
<link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherAssetsNoncurrent_96024f9e-bd9a-4728-8b34-996eec36fa33_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
<link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_5ab1666e-6bed-4b8b-9248-2d1aa329d1d0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
<link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fiscal Year Maturity [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_lung_IncomeTaxDisclosureLineItems_c4a86837-b8e7-4468-8868-257b102291fa_terseLabel_en-US" xlink:label="lab_lung_IncomeTaxDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Line Items]</link:label>
<link:label id="lab_lung_IncomeTaxDisclosureLineItems_label_en-US" xlink:label="lab_lung_IncomeTaxDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Line Items]</link:label>
<link:label id="lab_lung_IncomeTaxDisclosureLineItems_documentation_en-US" xlink:label="lab_lung_IncomeTaxDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_IncomeTaxDisclosureLineItems" xlink:href="lung-20220630.xsd#lung_IncomeTaxDisclosureLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_IncomeTaxDisclosureLineItems" xlink:to="lab_lung_IncomeTaxDisclosureLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_b976edb2-f8d9-458c-9599-f15fdc80088f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
<link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_5a523e37-98b8-45f9-a389-eab91cea7b53_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation, to be paid, year two</link:label>
<link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year Two</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:to="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_af22b94b-39d2-4f97-9b9f-350039b62243_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares pursuant to Employee Stock Purchase Plan (in shares)</link:label>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DerivativeTable_9fd6aa0c-4620-4c3a-a455-c26c91086ef0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
<link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract_9cb78dd3-5a5c-408b-9ab4-1158ba7a0dc5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator</link:label>
<link:label id="lab_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, Two Class Method [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicTwoClassMethodAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_866e6a67-ebf2-4673-a36a-11960969a9a8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of period (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c9374f37-f964-413c-8e49-7fc437e0790f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of period (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_f3df3336-7953-47d6-b75a-6e75dab9b93d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
<link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_66823993-6336-40a5-a388-b126c4622029_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
<link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfStockByClassTable_a8957ae2-041a-45ee-95e5-ea1f35107044_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
<link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityIncorporationStateCountryCode_ec171569-35c4-48fe-a8e1-49d08c8b3872_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
<link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
<link:label id="lab_lung_DebtInstrumentCovenantUnrestrictedCashRequirementPeriod_72fc21d6-4f6a-44a4-9426-28c32500f490_terseLabel_en-US" xlink:label="lab_lung_DebtInstrumentCovenantUnrestrictedCashRequirementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrestricted cash requirement period</link:label>
<link:label id="lab_lung_DebtInstrumentCovenantUnrestrictedCashRequirementPeriod_label_en-US" xlink:label="lab_lung_DebtInstrumentCovenantUnrestrictedCashRequirementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Unrestricted Cash Requirement, Period</link:label>
<link:label id="lab_lung_DebtInstrumentCovenantUnrestrictedCashRequirementPeriod_documentation_en-US" xlink:label="lab_lung_DebtInstrumentCovenantUnrestrictedCashRequirementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Unrestricted Cash Requirement, Period</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_DebtInstrumentCovenantUnrestrictedCashRequirementPeriod" xlink:href="lung-20220630.xsd#lung_DebtInstrumentCovenantUnrestrictedCashRequirementPeriod"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_DebtInstrumentCovenantUnrestrictedCashRequirementPeriod" xlink:to="lab_lung_DebtInstrumentCovenantUnrestrictedCashRequirementPeriod" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b04ecc35-140f-4bd3-b400-48cd8a4d3127_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
<link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fe4132d7-f4c6-4cb0-bcd7-4518cc4ff99a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
<link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f1d8e957-94b9-463d-9a0b-9c7bd5ecd591_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4d6359b0-4700-45b4-8c7e-36faf4e8ef0f_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingLeasePayments_0fdc71d1-614a-4cae-909b-1780ee4a8617_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities included in cash flows used in operating activities</link:label>
<link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_8afbafb3-eb65-4a7f-bd76-99194dee70e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Amortization Expense</link:label>
<link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EmployeeStockOptionMember_53525c88-20b1-41c7-b84d-562ad88ec597_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
<link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_c5451fe9-0ac3-4663-b4e8-e28a022c29f3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
<link:label id="lab_lung_CostOfGoodsAndServicesSoldMember_e7df0ca9-7b79-4cd1-a9a7-4bdee59e556b_terseLabel_en-US" xlink:label="lab_lung_CostOfGoodsAndServicesSoldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Goods And Services Sold</link:label>
<link:label id="lab_lung_CostOfGoodsAndServicesSoldMember_label_en-US" xlink:label="lab_lung_CostOfGoodsAndServicesSoldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Goods And Services Sold [Member]</link:label>
<link:label id="lab_lung_CostOfGoodsAndServicesSoldMember_documentation_en-US" xlink:label="lab_lung_CostOfGoodsAndServicesSoldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Goods And Services Sold</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_CostOfGoodsAndServicesSoldMember" xlink:href="lung-20220630.xsd#lung_CostOfGoodsAndServicesSoldMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_CostOfGoodsAndServicesSoldMember" xlink:to="lab_lung_CostOfGoodsAndServicesSoldMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4e1a5cbe-8860-4411-af36-7bee32a38be1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options</link:label>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_91e44872-38c1-4676-a394-0102aa4f50a3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LongTermDebt_2be7e24c-98ea-4e7c-ad59-5195c59bafc0_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan and credit agreement</link:label>
<link:label id="lab_us-gaap_LongTermDebt_dd3f830b-8f3e-4a55-aa2b-eeadd86d74a2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan and credit agreement</link:label>
<link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_4512ce53-3b33-403f-abaf-be95cc748de7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
<link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_BalanceSheetLocationAxis_95607f66-4c43-4f1c-8ad7-fe9778a72012_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
<link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommonStockSharesAuthorized_a21232fc-64ad-4830-a432-0cc12e3ab63b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
<link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_ddfd4970-fdc2-4bdd-980d-060328323409_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
<link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingExpenses_e906d513-1e95-4112-b289-3c6964f1859b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
<link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
<link:label id="lab_srt_MaximumMember_2ff0ccec-e4b3-4f41-928f-395bcc5a278f_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
<link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d4bff2be-10a8-4cce-ba0d-722817b2ee6d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
<link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
<link:label id="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedTermAbstract_b9a70726-094f-4e9a-94e5-febfb4e5ceb7_terseLabel_en-US" xlink:label="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Contractual Life (in Years)</link:label>
<link:label id="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedTermAbstract_label_en-US" xlink:label="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Term [Abstract]</link:label>
<link:label id="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedTermAbstract_documentation_en-US" xlink:label="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Term</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedTermAbstract" xlink:href="lung-20220630.xsd#lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedTermAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedTermAbstract" xlink:to="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedTermAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8c914ebc-beff-4d6c-ab1b-e3cbac975fa0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
<link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0f30af8f-47a4-4765-a9c6-79ec3359e77a_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash and cash equivalents</link:label>
<link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_beb99acd-28fe-43f1-806a-c9ec89d602ab_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AssetsCurrent_f39174bb-8394-44fd-9046-c994c2a4804a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
<link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_TaxesPayableCurrent_e3f41a34-bb59-4a7e-abea-3f33951a2233_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales taxes, franchise tax and VAT</link:label>
<link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncomeTaxesPaidNet_6741a6d7-488e-4f2a-b6dc-943b78c78f65_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
<link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_76bcc51f-3bea-49d6-bf27-a3d0ae9be4d5_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
<link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntitySmallBusiness_c688357e-7ed1-44c6-a4ad-afdc78112dbb_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
<link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_124ad219-b814-4d1f-afbc-afb505c91c58_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
<link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_ec93ee50-c084-4552-9c2f-31faa174e0c5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
<link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_3b3eac11-bab0-4e8c-aa30-f38a61bbbefe_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
<link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_07f9ceb7-5b7f-4244-aa4d-3c2f7d136281_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
<link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_57703bf5-98f7-4920-9a8b-35eee8cfb999_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Value</link:label>
<link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_171244de-bf0c-420e-8e7b-56da96dd1cd8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Options Vested and Expected to Vest</link:label>
<link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RestrictedCash_02fe362e-1308-48f6-a7b5-9fb206ab205a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
<link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_cb7fc658-e967-4f84-83ba-16696734073a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
<link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossRealized_4c003ea2-5ad7-42f7-984b-277ad3a59243_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency transaction gains and (losses)</link:label>
<link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossRealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Realized</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7cbe9e99-fbf5-4773-b4b4-50cc0cd0217c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation costs</link:label>
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a5c9d72d-414a-4243-ba25-b5e73099f91b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ed46e53d-91bd-4024-b275-f178dc001703_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, aggregate intrinsic value</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_0b4f66ca-0730-47ca-ad71-d45a5d4fd5ac_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_b7a4cced-d599-4852-a104-66a04df23bd2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShortTermBorrowings_57de0c52-21e7-4611-84e2-6d95d297f7ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt</link:label>
<link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
<link:label id="lab_dei_Security12bTitle_09386b94-b8d7-4e81-a453-0bf82b3f767d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
<link:label id="lab_lung_ShareBasedCompensationEmployeeStockAvailableForGrantMember_a97a2326-5493-4e38-95b8-505e7da9e1f6_terseLabel_en-US" xlink:label="lab_lung_ShareBasedCompensationEmployeeStockAvailableForGrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock available for future grants</link:label>
<link:label id="lab_lung_ShareBasedCompensationEmployeeStockAvailableForGrantMember_label_en-US" xlink:label="lab_lung_ShareBasedCompensationEmployeeStockAvailableForGrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation, Employee Stock Available For Grant [Member]</link:label>
<link:label id="lab_lung_ShareBasedCompensationEmployeeStockAvailableForGrantMember_documentation_en-US" xlink:label="lab_lung_ShareBasedCompensationEmployeeStockAvailableForGrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation, Employee Stock Available For Grant</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_ShareBasedCompensationEmployeeStockAvailableForGrantMember" xlink:href="lung-20220630.xsd#lung_ShareBasedCompensationEmployeeStockAvailableForGrantMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_ShareBasedCompensationEmployeeStockAvailableForGrantMember" xlink:to="lab_lung_ShareBasedCompensationEmployeeStockAvailableForGrantMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentLineItems_4e37e464-7fd6-458f-98a4-facac3f4b114_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
<link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_43190458-e052-4947-853d-4168d24d9781_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: interest</link:label>
<link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ClassOfStockLineItems_3c0d9653-0650-417b-a607-46ff26324f80_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
<link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_df57291b-7dfb-4a5c-8f07-a39f734b905c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance cost</link:label>
<link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_e3e7bdeb-485d-43e3-8ce6-0cc3cc0d1465_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of fees to lender and third parties (less than)</link:label>
<link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OperatingLeaseLiability_ddd0feef-def7-4323-8834-7d07db2d058c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of future minimum lease payments</link:label>
<link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c2b5e71a-5e96-4a9d-8bbd-d93bedcd58b0_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Government agency bonds</link:label>
<link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_2c044ef8-ed5d-43f6-bcf4-03e0e0d05336_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
<link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_362c6dfe-920c-4407-bb86-ce1964dec2b5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums and discounts on short-term marketable securities</link:label>
<link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_04b28e65-f5df-4da1-9ef7-31d936e29181_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
<link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_bdc33b3f-0ef1-4817-b4a6-b5b0d5e04abd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
<link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CashUninsuredAmount_305a06f6-eeb0-4aca-9c9d-fd6dd28164d2_terseLabel_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash on deposit with foreign banks</link:label>
<link:label id="lab_us-gaap_CashUninsuredAmount_label_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Uninsured Amount</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashUninsuredAmount" xlink:to="lab_us-gaap_CashUninsuredAmount" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a93a8041-51ee-4e3c-bd8c-918512058393_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders’ Equity</link:label>
<link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1ff84733-a8dd-4032-be57-6dae45cb12eb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustment</link:label>
<link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_55f9e13f-9065-4539-8b08-81376efbe38d_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss,) foreign currency translation adjustments</link:label>
<link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2555ab89-f4e2-4311-8c8b-cf3ce1d5bfef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in dollars per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bcc1d071-8342-425c-b576-65d0e888d589_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
<link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_12a2ff72-1bb5-4dc8-a616-9cfe3277f8e7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
<link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_3d436b62-0de9-4c3d-a6cd-4223933d069f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (remaining six months)</link:label>
<link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InventoryNet_7cec1a42-156a-45f6-bf78-f1dcd9c083b8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
<link:label id="lab_us-gaap_InventoryNet_2121ccbf-7735-4f0b-a8a0-f16c93ed1dd9_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
<link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AccountsPayableCurrent_f412c1df-7fd8-4fa6-a09a-115de27de1a1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
<link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_eda6d564-259a-4c55-a8c0-0fd3aa94fb70_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: debt issuance costs</link:label>
<link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_c8976df9-cf7a-4f34-b4e5-b2be9719ad31_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: unamortized debt discount</link:label>
<link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_e5af6b9e-7a09-4254-a28f-adf02f8bc6bb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expenses to vest, intrinsic value</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
<link:label id="lab_lung_StockOptionsAndRestrictedStockUnitsMember_532c1e17-0aa9-4991-b27a-bafc4172e9f2_terseLabel_en-US" xlink:label="lab_lung_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options And Restricted Stock Units</link:label>
<link:label id="lab_lung_StockOptionsAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_lung_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options And Restricted Stock Units [Member]</link:label>
<link:label id="lab_lung_StockOptionsAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_lung_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options And Restricted Stock Units</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_StockOptionsAndRestrictedStockUnitsMember" xlink:href="lung-20220630.xsd#lung_StockOptionsAndRestrictedStockUnitsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_StockOptionsAndRestrictedStockUnitsMember" xlink:to="lab_lung_StockOptionsAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_84460d00-954c-4bc6-adcb-d1dc70f2eee8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
<link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NatureOfOperations_4a8a8fbf-b88a-4d6d-b32c-fe4ba4f9e795_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Formation and Business of the Company</link:label>
<link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityFilerCategory_1015c342-3f84-4a2b-9131-8775eb4b1704_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
<link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c921e465-652a-4ee3-8e01-207ad0863dae_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)</link:label>
<link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7503a0dc-64b7-442c-9808-b9870e288ea2_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares used to compute, basic net loss per share (in shares)</link:label>
<link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
<link:label id="lab_country_US_580e43dc-d4ca-4312-a9d2-7bcb88c03553_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
<link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
<link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
<link:label id="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePriceAbstract_a36b8eb1-b3fa-40c8-8e2e-35c46b080d6b_terseLabel_en-US" xlink:label="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
<link:label id="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePriceAbstract_label_en-US" xlink:label="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested And Expected To Vest, Weighted Average Exercise Price [Abstract]</link:label>
<link:label id="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePriceAbstract_documentation_en-US" xlink:label="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested And Expected To Vest, Weighted Average Exercise Price</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePriceAbstract" xlink:href="lung-20220630.xsd#lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePriceAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePriceAbstract" xlink:to="lab_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePriceAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_lung_NumberOfInstallmentsForRepayment_98f0de5d-ceaf-4d40-9664-7c6c8a775e07_terseLabel_en-US" xlink:label="lab_lung_NumberOfInstallmentsForRepayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of installments for repayment</link:label>
<link:label id="lab_lung_NumberOfInstallmentsForRepayment_label_en-US" xlink:label="lab_lung_NumberOfInstallmentsForRepayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Installments For Repayment</link:label>
<link:label id="lab_lung_NumberOfInstallmentsForRepayment_documentation_en-US" xlink:label="lab_lung_NumberOfInstallmentsForRepayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Installments For Repayment</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_NumberOfInstallmentsForRepayment" xlink:href="lung-20220630.xsd#lung_NumberOfInstallmentsForRepayment"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_NumberOfInstallmentsForRepayment" xlink:to="lab_lung_NumberOfInstallmentsForRepayment" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_51285f98-c4dd-4d8e-a002-db6fb0eb4e65_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
<link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_356fc148-1869-40e9-a4ac-39d794df4a47_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental non-cash items:</link:label>
<link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommitmentsAndContingencies_0e16c80e-fcca-4e8a-88b3-9db3cdd9fd77_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 8)</link:label>
<link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
<link:label id="lab_dei_SecurityExchangeName_5d4d6af7-0558-421e-8629-b55a6ad2f3e0_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
<link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_76a345ca-eb04-481f-acd7-7f53fd71d8f1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of period (in dollars per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fafb83de-be1b-4e1d-a9a1-91329b0fdbb9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of period (in dollars per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_64fc0891-18a9-4995-a72f-118bba499c1a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
<link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PreferredStockValue_e784d3c8-1c74-498c-b2b3-ac25b1dce729_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding as of June 30, 2022 and December 31, 2021</link:label>
<link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RestrictedStockMember_76dcfd59-6b4c-4a17-b47d-8cf3820c4898_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock units</link:label>
<link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_16358226-2bfb-481e-982f-000b9dcae092_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</link:label>
<link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_c25675f3-ff5f-417f-9352-2b8db5562fe6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a92c0762-e00f-4f4a-8fa7-1306f9e42ce9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
<link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CorporateBondSecuritiesMember_786f1662-6ef6-4b10-8354-113cbc53fe47_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
<link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_a8310758-bc03-4047-a53e-b5936c7753fe_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_89ccfd13-ecbe-40d3-9577-71f384cae557_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
<link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
<link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentTable_ff7c9fa4-bedb-4fbd-ab47-5f9f1b264ca1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
<link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueInputsLevel3Member_3176c12b-a465-41fa-a524-6bfcd0507d07_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
<link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_GoodwillImpairmentLoss_6b71678c-e107-4641-982d-f414f87e69c8_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, impairment loss</link:label>
<link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5234c947-2c4a-4110-9cb4-6ff98ff2386e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities</link:label>
<link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
<link:label id="lab_lung_NumberOfVotesForEachShareOfCommonStockHeld_fb057e90-d2d2-4e83-a2f7-edb1f71ebbf7_terseLabel_en-US" xlink:label="lab_lung_NumberOfVotesForEachShareOfCommonStockHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes for each share of common stock held</link:label>
<link:label id="lab_lung_NumberOfVotesForEachShareOfCommonStockHeld_label_en-US" xlink:label="lab_lung_NumberOfVotesForEachShareOfCommonStockHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Votes For Each Share Of Common Stock Held</link:label>
<link:label id="lab_lung_NumberOfVotesForEachShareOfCommonStockHeld_documentation_en-US" xlink:label="lab_lung_NumberOfVotesForEachShareOfCommonStockHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Votes For Each Share Of Common Stock Held</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_NumberOfVotesForEachShareOfCommonStockHeld" xlink:href="lung-20220630.xsd#lung_NumberOfVotesForEachShareOfCommonStockHeld"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_NumberOfVotesForEachShareOfCommonStockHeld" xlink:to="lab_lung_NumberOfVotesForEachShareOfCommonStockHeld" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_c99ba92a-4a54-4631-a2d0-feb113962347_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
<link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_66f9cb70-6674-47f0-a043-f51f99ebbe0b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_45639013-ad49-43e4-ac18-dce2d7e4a683_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
<link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_lung_CommonStockRestrictedStockUnitsIssuedAndOutstandingMember_f7168457-868c-4313-91c0-0f061851ccb6_terseLabel_en-US" xlink:label="lab_lung_CommonStockRestrictedStockUnitsIssuedAndOutstandingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock restricted stock units issued and outstanding</link:label>
<link:label id="lab_lung_CommonStockRestrictedStockUnitsIssuedAndOutstandingMember_label_en-US" xlink:label="lab_lung_CommonStockRestrictedStockUnitsIssuedAndOutstandingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Restricted Stock Units Issued And Outstanding [Member]</link:label>
<link:label id="lab_lung_CommonStockRestrictedStockUnitsIssuedAndOutstandingMember_documentation_en-US" xlink:label="lab_lung_CommonStockRestrictedStockUnitsIssuedAndOutstandingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Restricted Stock Units Issued And Outstanding</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_CommonStockRestrictedStockUnitsIssuedAndOutstandingMember" xlink:href="lung-20220630.xsd#lung_CommonStockRestrictedStockUnitsIssuedAndOutstandingMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_CommonStockRestrictedStockUnitsIssuedAndOutstandingMember" xlink:to="lab_lung_CommonStockRestrictedStockUnitsIssuedAndOutstandingMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_7f0fb2f5-52fb-40a6-a086-36e64af4e79d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill disposed of</link:label>
<link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_50c96b3c-a387-4eb7-986e-791cf9e66d26_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders’ equity</link:label>
<link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DebtInstrumentTerm_4653c8e1-6836-42e2-9f10-c7263991a89e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt term</link:label>
<link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LongtermDebtTypeAxis_425f42cd-f2be-4a1e-ad46-e983550e1ab1_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
<link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AccruedVacationCurrent_3e126d6f-0e21-42ed-be97-8501afcdf437_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedVacationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued vacation</link:label>
<link:label id="lab_us-gaap_AccruedVacationCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedVacationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Vacation, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedVacationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedVacationCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedVacationCurrent" xlink:to="lab_us-gaap_AccruedVacationCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_lung_OperatingLeaseMonthlyExpense_fe113ecd-f80b-4410-95e2-dc2bcf7e9169_terseLabel_en-US" xlink:label="lab_lung_OperatingLeaseMonthlyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly base rent</link:label>
<link:label id="lab_lung_OperatingLeaseMonthlyExpense_label_en-US" xlink:label="lab_lung_OperatingLeaseMonthlyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Expense</link:label>
<link:label id="lab_lung_OperatingLeaseMonthlyExpense_documentation_en-US" xlink:label="lab_lung_OperatingLeaseMonthlyExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Expense</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_OperatingLeaseMonthlyExpense" xlink:href="lung-20220630.xsd#lung_OperatingLeaseMonthlyExpense"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_OperatingLeaseMonthlyExpense" xlink:to="lab_lung_OperatingLeaseMonthlyExpense" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_dddf68c3-3e7a-47c1-abcf-680584f2ad47_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of Credit Agreement</link:label>
<link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Lines of Credit</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_Cash_0ce5435b-e18a-4976-973c-c71469af524e_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
<link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_lung_DebtInstrumentCovenantMinimumRevenueRequirementPeriod_cc0acb61-9305-4550-823b-ac4d9bb877f8_terseLabel_en-US" xlink:label="lab_lung_DebtInstrumentCovenantMinimumRevenueRequirementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum percentage of revenue requirement, trailing period of revenue</link:label>
<link:label id="lab_lung_DebtInstrumentCovenantMinimumRevenueRequirementPeriod_label_en-US" xlink:label="lab_lung_DebtInstrumentCovenantMinimumRevenueRequirementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Minimum Revenue Requirement, Period</link:label>
<link:label id="lab_lung_DebtInstrumentCovenantMinimumRevenueRequirementPeriod_documentation_en-US" xlink:label="lab_lung_DebtInstrumentCovenantMinimumRevenueRequirementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Minimum Revenue Requirement, Period</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_DebtInstrumentCovenantMinimumRevenueRequirementPeriod" xlink:href="lung-20220630.xsd#lung_DebtInstrumentCovenantMinimumRevenueRequirementPeriod"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_DebtInstrumentCovenantMinimumRevenueRequirementPeriod" xlink:to="lab_lung_DebtInstrumentCovenantMinimumRevenueRequirementPeriod" xlink:type="arc" order="1"/>
<link:label id="lab_lung_ServiceAgreementPurchaseMember_4053a673-e8e9-4c36-8e0a-88e5a67f9770_terseLabel_en-US" xlink:label="lab_lung_ServiceAgreementPurchaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Agreement</link:label>
<link:label id="lab_lung_ServiceAgreementPurchaseMember_label_en-US" xlink:label="lab_lung_ServiceAgreementPurchaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Agreement, Purchase [Member]</link:label>
<link:label id="lab_lung_ServiceAgreementPurchaseMember_documentation_en-US" xlink:label="lab_lung_ServiceAgreementPurchaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Agreement, Purchase</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_ServiceAgreementPurchaseMember" xlink:href="lung-20220630.xsd#lung_ServiceAgreementPurchaseMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_ServiceAgreementPurchaseMember" xlink:to="lab_lung_ServiceAgreementPurchaseMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueInputsLevel2Member_5960f174-734e-4e0b-96eb-050eae1a724b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
<link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
<link:label id="lab_dei_CurrentFiscalYearEndDate_91c0be5d-2f6d-4006-bb49-b939f53b8ce4_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
<link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5bfe7115-9b4b-4bbc-be3d-715c07ad9077_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Amount of lease payments representing interest</link:label>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6e8cb9fd-6120-4f95-ac23-bbc1b6843b3a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders, diluted</link:label>
<link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_4b7aa98f-d4e2-4344-8669-b6af176f9fe6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
<link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EarningsPerShareDiluted_69cbbbd0-312c-49c9-829c-042d0174676c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders, diluted (in dollars per share)</link:label>
<link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8f770d47-cef0-42ee-a31d-2249c3cf1b0c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_e66578df-21ab-4218-84a1-de721abb57dd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Shares Reserved for Future Issuance</link:label>
<link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d30d8bec-520b-49f3-a125-4750c03daa5f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
<link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_7c50515b-4bc4-449d-94db-f3d244c59328_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
<link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_740b4910-07d8-4608-9547-6257b7f43418_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
<link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LiabilitiesCurrent_ed664d49-bd2f-48e1-bc27-88a47b92460d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
<link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_a53cfec2-e5a5-48c7-b691-0e9744cd882d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested (in shares)</link:label>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4226563c-a558-4da1-90a9-a45360377e48_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherAssetsCurrent_505a40ed-5337-4a9b-8c49-ec64082ed399_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
<link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_lung_LesseeOperatingSubleaseMonthlyExpense_118f0aef-3f17-4e91-bd4d-eec134ceb423_terseLabel_en-US" xlink:label="lab_lung_LesseeOperatingSubleaseMonthlyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease monthly rent</link:label>
<link:label id="lab_lung_LesseeOperatingSubleaseMonthlyExpense_label_en-US" xlink:label="lab_lung_LesseeOperatingSubleaseMonthlyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Sublease, Monthly Expense</link:label>
<link:label id="lab_lung_LesseeOperatingSubleaseMonthlyExpense_documentation_en-US" xlink:label="lab_lung_LesseeOperatingSubleaseMonthlyExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Sublease, Monthly Expense</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_LesseeOperatingSubleaseMonthlyExpense" xlink:href="lung-20220630.xsd#lung_LesseeOperatingSubleaseMonthlyExpense"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_LesseeOperatingSubleaseMonthlyExpense" xlink:to="lab_lung_LesseeOperatingSubleaseMonthlyExpense" xlink:type="arc" order="1"/>
<link:label id="lab_lung_LesseeOperatingLeaseOptionToTerminateNoticePeriod_f1a5b25c-b80d-4e76-8416-fd17182d1de9_terseLabel_en-US" xlink:label="lab_lung_LesseeOperatingLeaseOptionToTerminateNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option to terminate, notice period</link:label>
<link:label id="lab_lung_LesseeOperatingLeaseOptionToTerminateNoticePeriod_label_en-US" xlink:label="lab_lung_LesseeOperatingLeaseOptionToTerminateNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option To Terminate, Notice Period</link:label>
<link:label id="lab_lung_LesseeOperatingLeaseOptionToTerminateNoticePeriod_documentation_en-US" xlink:label="lab_lung_LesseeOperatingLeaseOptionToTerminateNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option To Terminate, Notice Period</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_LesseeOperatingLeaseOptionToTerminateNoticePeriod" xlink:href="lung-20220630.xsd#lung_LesseeOperatingLeaseOptionToTerminateNoticePeriod"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_LesseeOperatingLeaseOptionToTerminateNoticePeriod" xlink:to="lab_lung_LesseeOperatingLeaseOptionToTerminateNoticePeriod" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommercialPaperAtCarryingValue_cd14ed3a-59fc-449d-b91a-7842bf6b3492_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
<link:label id="lab_us-gaap_CommercialPaperAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CommercialPaperAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper, at Carrying Value</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperAtCarryingValue"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperAtCarryingValue" xlink:to="lab_us-gaap_CommercialPaperAtCarryingValue" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_d4214b5e-4747-4161-928e-ed800da7195a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark</link:label>
<link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d30e65b5-7fa1-4d2b-bfef-338b1cd4d077_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturity Analysis of Lease Liabilities</link:label>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityAddressAddressLine1_a6f7e43a-dd6f-4194-b489-e377d69555bb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
<link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_aecbb4df-dd01-4278-98cf-57bb5cb02f6b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation capitalized into inventory</link:label>
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Amount Capitalized</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
<link:label id="lab_lung_NumberOfVehicleLeases_589e7052-0106-412c-ba24-dacd5076c7e9_terseLabel_en-US" xlink:label="lab_lung_NumberOfVehicleLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of vehicle leases</link:label>
<link:label id="lab_lung_NumberOfVehicleLeases_label_en-US" xlink:label="lab_lung_NumberOfVehicleLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Vehicle Leases</link:label>
<link:label id="lab_lung_NumberOfVehicleLeases_documentation_en-US" xlink:label="lab_lung_NumberOfVehicleLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Vehicle Leases</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_NumberOfVehicleLeases" xlink:href="lung-20220630.xsd#lung_NumberOfVehicleLeases"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_NumberOfVehicleLeases" xlink:to="lab_lung_NumberOfVehicleLeases" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ContractWithCustomerLiability_f9e37070-1f04-4157-8eea-9bdcfa9bc5fd_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
<link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_efe748b2-f384-4d1a-8236-9a1f84657e4d_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
<link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InterestExpense_afcffd43-88e0-4336-b306-d2aa785bd170_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
<link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_23579a96-4fd8-41d5-84ce-a4eeeaa7414d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
<link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_f2b03297-ddf5-4ac9-9b6a-db5b0e605c13_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash to consolidated balance sheets:</link:label>
<link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1b22540f-fc8d-4a5a-ba10-27f57169fea0_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
<link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_0fc79180-451c-4210-82d4-e8478aee7486_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments</link:label>
<link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_MachineryAndEquipmentMember_3773f3cd-d3f8-490f-bb7a-ad3316e72e9f_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
<link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_BuildingMember_36c21cf5-f830-4ea9-b562-f7436b54f0ec_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Facilities</link:label>
<link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9be2b5e8-cb94-45d5-b797-9d1ad99b80fe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityTaxIdentificationNumber_73567927-e8ef-496d-bbde-219f6a3ab9cc_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
<link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_21e82b6c-53e4-41b2-bdf6-79b698e7573c_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-lived Assets by Geographic Area</link:label>
<link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets by Geographic Areas [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PurchaseObligationDueInThirdYear_b847d102-76ea-48ef-8539-d6fa00c7f3f8_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation, to be paid, year three</link:label>
<link:label id="lab_us-gaap_PurchaseObligationDueInThirdYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year Three</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInThirdYear" xlink:to="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:type="arc" order="1"/>
<link:label id="lab_lung_DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm_c88ee641-9dd1-429e-9f54-9d8ca3044104_terseLabel_en-US" xlink:label="lab_lung_DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal and interest payments term</link:label>
<link:label id="lab_lung_DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm_label_en-US" xlink:label="lab_lung_DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal And Interest, Term</link:label>
<link:label id="lab_lung_DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm_documentation_en-US" xlink:label="lab_lung_DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal And Interest, Term</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm" xlink:href="lung-20220630.xsd#lung_DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm" xlink:to="lab_lung_DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_f13e54ea-7b88-481f-948f-8086b6121c7d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-Term Assets</link:label>
<link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_4a8082f5-a477-478e-bf6b-16610bfaa357_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (remaining six months)</link:label>
<link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d1403516-f6c8-49e7-92ee-76c323a3a9a1_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
<link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
<link:label id="lab_lung_PulmonxInternationalSarlMember_bb8200df-6395-46b2-a619-47c69434ddba_terseLabel_en-US" xlink:label="lab_lung_PulmonxInternationalSarlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonx International Sarl</link:label>
<link:label id="lab_lung_PulmonxInternationalSarlMember_label_en-US" xlink:label="lab_lung_PulmonxInternationalSarlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonx International Sarl [Member]</link:label>
<link:label id="lab_lung_PulmonxInternationalSarlMember_documentation_en-US" xlink:label="lab_lung_PulmonxInternationalSarlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonx International Sarl</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_PulmonxInternationalSarlMember" xlink:href="lung-20220630.xsd#lung_PulmonxInternationalSarlMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_PulmonxInternationalSarlMember" xlink:to="lab_lung_PulmonxInternationalSarlMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CommercialPaperMember_563bcb0b-adaf-4e49-b48d-089f42d292d9_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
<link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityCentralIndexKey_3485145d-9d67-4831-8092-d18bbbbb9650_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
<link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_05a3d147-8c93-4548-8c03-bf6d8d5b8f44_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
<link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_f98ab914-4afc-4f89-99d5-9eba20eaab9c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
<link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_InvestmentIncomeInterest_e82435df-54bd-4d33-9703-23192dbe80f6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
<link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
<link:label id="lab_lung_DebtInstrumentFaceAmountIncludingAccordionFeature_a07a1b71-5fe4-4fbf-8d5d-69cf1d760ada_terseLabel_en-US" xlink:label="lab_lung_DebtInstrumentFaceAmountIncludingAccordionFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount including accordion feature</link:label>
<link:label id="lab_lung_DebtInstrumentFaceAmountIncludingAccordionFeature_label_en-US" xlink:label="lab_lung_DebtInstrumentFaceAmountIncludingAccordionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount Including Accordion Feature</link:label>
<link:label id="lab_lung_DebtInstrumentFaceAmountIncludingAccordionFeature_documentation_en-US" xlink:label="lab_lung_DebtInstrumentFaceAmountIncludingAccordionFeature" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount Including Accordion Feature</link:label>
<link:loc xlink:type="locator" xlink:label="loc_lung_DebtInstrumentFaceAmountIncludingAccordionFeature" xlink:href="lung-20220630.xsd#lung_DebtInstrumentFaceAmountIncludingAccordionFeature"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lung_DebtInstrumentFaceAmountIncludingAccordionFeature" xlink:to="lab_lung_DebtInstrumentFaceAmountIncludingAccordionFeature" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_7243f576-a0d5-4fb2-ac3e-8e29dae97aee_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
<link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_67559b88-71b4-4589-8386-c4bdabdbda65_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ab47bbf4-98c1-4237-900e-8619a28a8aed_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
<link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_77772054-b42c-4a51-b857-3f37b7b58236_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
<link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_44ac9e74-71f6-4b90-ba3b-36304cf51e56_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
<link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_15948418-eee0-4a0c-b0cf-77ec6a6c0d46_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
<link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_dei_EntityDomain_a687722f-6192-4d1c-9ec5-b95c4b9bfe5d_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
<link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
<link:label id="lab_dei_CityAreaCode_1e78fc52-8b5a-4fe5-aed1-c8084f9e1091_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
<link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
<link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_d6ec240e-8ece-4a58-abc5-22608f42fe6c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
<link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_AssetsAbstract_98cde087-8f45-4efd-81fd-195b86ebe4e4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
<link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LongtermDebtTypeDomain_bb326636-4c21-4beb-ba65-571ad15545a5_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
<link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_1d61465b-b64f-4f19-ab18-5a829f8460bf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
<link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7a463fa-c865-44a6-bc70-9873ca3a1f0a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_a0766c7d-e48d-4f35-b483-bc9f7478d590_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents:</link:label>
<link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value [Abstract]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_12617dd3-04d3-4516-b5ea-211b27da4ab9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
<link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_9d4f235d-44a2-4797-80e7-878ef9fde6a5_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities measured at fair value on a recurring and non-recurring</link:label>
<link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_780a722c-2511-48aa-883d-1a6d4653281d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share Attributable to Common Stockholders</link:label>
<link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_f81ba85a-e561-40af-b148-eb369a455404_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
<link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ShareBasedCompensation_631c0d73-8008-427f-85ff-a9c32742b611_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_VariableRateAxis_bb84593b-7b24-4307-bba3-14ddd0fda532_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
<link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_84063584-116c-4b38-acb6-d86949d6e259_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
<link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3ff5e163-a227-4fa1-9a97-6a74d6658828_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
<link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6dc61a0a-09d0-4d77-92a2-3651c157e556_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
<link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_ce441b9f-bc49-4ce2-9755-6471bb0e354b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
<link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e7d44dcc-9638-4df6-a273-1c324d1af5ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Basic and Diluted Net Loss per Share</link:label>
<link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_f472224f-009c-45f6-8aa5-bcab6d9f27a2_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right of use assets obtained in exchange for new lease liabilities</link:label>
<link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a54767dc-5da4-4b33-b045-4bc5f34f0e7c_verboseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease liabilities</link:label>
<link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
<link:label id="lab_us-gaap_CostOfSalesMember_e61a02dd-6141-4d83-bcc7-230359012a9a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
<link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>lung-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e27afbe0-c876-445c-ac79-0e3a22d99ad7,g:11f7fccd-ac30-49f3-b9c8-08334e4a7c01-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.pulmonx.com/role/CoverPage" xlink:type="simple" xlink:href="lung-20220630.xsd#CoverPage"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/CoverPage" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e5bedcd0-0d26-4ef3-a1aa-030eddbd1299" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_DocumentType_e5bedcd0-0d26-4ef3-a1aa-030eddbd1299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_8f3f8665-f5f2-4c99-9715-22bd0c56190d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_DocumentQuarterlyReport_8f3f8665-f5f2-4c99-9715-22bd0c56190d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a11a8f40-7849-4393-8ae9-707bcdf56bfc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_DocumentPeriodEndDate_a11a8f40-7849-4393-8ae9-707bcdf56bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_f5dcb485-770e-4e3b-ac9e-d038c6172410" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_DocumentTransitionReport_f5dcb485-770e-4e3b-ac9e-d038c6172410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c1a50798-c3e5-4404-b01c-ff9c51751f14" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_EntityFileNumber_c1a50798-c3e5-4404-b01c-ff9c51751f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_006b5e16-357a-4db3-8835-a13887ef4a5f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_EntityRegistrantName_006b5e16-357a-4db3-8835-a13887ef4a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2bcfa267-5fa1-47de-a6dc-ed8feb886f21" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2bcfa267-5fa1-47de-a6dc-ed8feb886f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_255660b8-d1b4-4a85-85e4-e0f1133c21b0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_EntityTaxIdentificationNumber_255660b8-d1b4-4a85-85e4-e0f1133c21b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b542220a-b6b9-4f31-8000-0fe96b13e2a1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_EntityAddressAddressLine1_b542220a-b6b9-4f31-8000-0fe96b13e2a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_8fe4fa45-6bf5-4cd7-a507-6ccb4f698bdc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
<link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_EntityAddressCityOrTown_8fe4fa45-6bf5-4cd7-a507-6ccb4f698bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_efdd5d11-88b6-4973-b5a0-b30f434e55d2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
<link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_EntityAddressStateOrProvince_efdd5d11-88b6-4973-b5a0-b30f434e55d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_864adf5c-3793-47a5-b6a1-8debf0cc3d98" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
<link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_EntityAddressPostalZipCode_864adf5c-3793-47a5-b6a1-8debf0cc3d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion_002f2f5a-ee51-423e-8b14-2b6a63089f9c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion"/>
<link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_CountryRegion_002f2f5a-ee51-423e-8b14-2b6a63089f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_88265e20-b2f0-48f9-8f65-afdcf9853f43" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
<link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_CityAreaCode_88265e20-b2f0-48f9-8f65-afdcf9853f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b23431cc-e294-4a87-942a-d0dac5c39bd0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
<link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_LocalPhoneNumber_b23431cc-e294-4a87-942a-d0dac5c39bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_882d7f8d-2e61-4c97-a362-497baa2731cb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
<link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_Security12bTitle_882d7f8d-2e61-4c97-a362-497baa2731cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_df6d5bca-a6b5-41ce-ba0c-c2b8aed3262a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
<link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_TradingSymbol_df6d5bca-a6b5-41ce-ba0c-c2b8aed3262a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ccd59697-0647-4e7c-a6d6-166fce4d2ea4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
<link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_SecurityExchangeName_ccd59697-0647-4e7c-a6d6-166fce4d2ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_38815d2a-9859-4468-8508-bb4ed160cdc7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
<link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_EntityCurrentReportingStatus_38815d2a-9859-4468-8508-bb4ed160cdc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_748824fa-f60d-450d-88dc-8d020826e58d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
<link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_EntityInteractiveDataCurrent_748824fa-f60d-450d-88dc-8d020826e58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_353a5075-307a-45eb-aaca-b74ba67fd878" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
<link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_EntityFilerCategory_353a5075-307a-45eb-aaca-b74ba67fd878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c18a78e0-af18-4700-8d41-7ac5983df0db" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
<link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_EntitySmallBusiness_c18a78e0-af18-4700-8d41-7ac5983df0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_82cac7fe-cff1-461c-872d-f521928dae21" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
<link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_EntityEmergingGrowthCompany_82cac7fe-cff1-461c-872d-f521928dae21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_add4c04b-9e7a-4e2c-a438-07abf26f353c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
<link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_EntityShellCompany_add4c04b-9e7a-4e2c-a438-07abf26f353c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_81779ad2-639e-4394-87da-04e60a28bfa9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
<link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_81779ad2-639e-4394-87da-04e60a28bfa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_215ade2c-d67a-4233-a1de-010bde0e68df" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
<link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_EntityCentralIndexKey_215ade2c-d67a-4233-a1de-010bde0e68df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b0e6086d-8453-4209-be6f-a75edad033cd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
<link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_CurrentFiscalYearEndDate_b0e6086d-8453-4209-be6f-a75edad033cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_23cebbaf-ae70-47ac-8131-083171140f33" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
<link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_DocumentFiscalYearFocus_23cebbaf-ae70-47ac-8131-083171140f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_69f67b2b-dbd1-4e5c-9b95-d899fd4a0318" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
<link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_69f67b2b-dbd1-4e5c-9b95-d899fd4a0318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a1afc39f-fb9b-46e9-920b-9a69b6363b6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
<link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_43092846-215a-4169-801c-0e705cac4f2f" xlink:to="loc_dei_AmendmentFlag_a1afc39f-fb9b-46e9-920b-9a69b6363b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="lung-20220630.xsd#CondensedConsolidatedBalanceSheets"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_21a28117-3f44-45e6-b8d3-31a679c5e37f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_02fa508d-d468-41a8-ad1a-53230b1ba077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_21a28117-3f44-45e6-b8d3-31a679c5e37f" xlink:to="loc_us-gaap_AssetsAbstract_02fa508d-d468-41a8-ad1a-53230b1ba077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_e3be04f7-82ed-4ee0-90b5-ee19d4a787ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_02fa508d-d468-41a8-ad1a-53230b1ba077" xlink:to="loc_us-gaap_AssetsCurrentAbstract_e3be04f7-82ed-4ee0-90b5-ee19d4a787ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bceb94bb-eb3c-4289-83e0-c5445b9a6e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e3be04f7-82ed-4ee0-90b5-ee19d4a787ad" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bceb94bb-eb3c-4289-83e0-c5445b9a6e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_a040f3ac-7251-48e0-aad8-36acb15eb6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e3be04f7-82ed-4ee0-90b5-ee19d4a787ad" xlink:to="loc_us-gaap_RestrictedCash_a040f3ac-7251-48e0-aad8-36acb15eb6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ff9f657c-b30f-4bba-ab43-4c6d74ba6151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e3be04f7-82ed-4ee0-90b5-ee19d4a787ad" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ff9f657c-b30f-4bba-ab43-4c6d74ba6151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0371462d-b007-4378-8e1f-f3d12fdc3d33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e3be04f7-82ed-4ee0-90b5-ee19d4a787ad" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0371462d-b007-4378-8e1f-f3d12fdc3d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_8c675c4b-394b-45da-be21-c299cd222be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e3be04f7-82ed-4ee0-90b5-ee19d4a787ad" xlink:to="loc_us-gaap_InventoryNet_8c675c4b-394b-45da-be21-c299cd222be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f1ebc736-d56e-416b-9531-4659a9b9f3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e3be04f7-82ed-4ee0-90b5-ee19d4a787ad" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f1ebc736-d56e-416b-9531-4659a9b9f3cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_394fca6c-f7d2-444d-8357-2fac7d75db9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e3be04f7-82ed-4ee0-90b5-ee19d4a787ad" xlink:to="loc_us-gaap_AssetsCurrent_394fca6c-f7d2-444d-8357-2fac7d75db9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4ece30f1-ff73-478c-af1a-9ab7e9a3ef47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_02fa508d-d468-41a8-ad1a-53230b1ba077" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4ece30f1-ff73-478c-af1a-9ab7e9a3ef47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2cfc10c8-5ff6-43ce-ac4a-028efa88e22c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_02fa508d-d468-41a8-ad1a-53230b1ba077" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2cfc10c8-5ff6-43ce-ac4a-028efa88e22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_de23dd14-d7f4-43ca-96c4-489e7ed9d1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_02fa508d-d468-41a8-ad1a-53230b1ba077" xlink:to="loc_us-gaap_Goodwill_de23dd14-d7f4-43ca-96c4-489e7ed9d1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fdff3dfb-2754-40ef-8140-cb6369898a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_02fa508d-d468-41a8-ad1a-53230b1ba077" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fdff3dfb-2754-40ef-8140-cb6369898a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9216a592-823f-4935-8a00-21ea06aa4fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_02fa508d-d468-41a8-ad1a-53230b1ba077" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9216a592-823f-4935-8a00-21ea06aa4fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_12939aeb-a0b5-46dc-8643-e18abb3d394f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_02fa508d-d468-41a8-ad1a-53230b1ba077" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_12939aeb-a0b5-46dc-8643-e18abb3d394f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8147c944-3faf-4c3e-822f-2ef2df50da29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_02fa508d-d468-41a8-ad1a-53230b1ba077" xlink:to="loc_us-gaap_Assets_8147c944-3faf-4c3e-822f-2ef2df50da29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b2ce73e1-af92-402a-bce2-1fb184551ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_21a28117-3f44-45e6-b8d3-31a679c5e37f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b2ce73e1-af92-402a-bce2-1fb184551ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_cad36396-6e92-4978-afd5-7512acdde4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b2ce73e1-af92-402a-bce2-1fb184551ff0" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_cad36396-6e92-4978-afd5-7512acdde4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_84eefa67-100b-4da2-84b6-571c5963fe31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cad36396-6e92-4978-afd5-7512acdde4f2" xlink:to="loc_us-gaap_AccountsPayableCurrent_84eefa67-100b-4da2-84b6-571c5963fe31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_cfd0b12e-e6fe-4369-b118-75036d5cb4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cad36396-6e92-4978-afd5-7512acdde4f2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_cfd0b12e-e6fe-4369-b118-75036d5cb4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_d2613a44-82c9-4f9d-b484-6e0737a3a75b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cad36396-6e92-4978-afd5-7512acdde4f2" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_d2613a44-82c9-4f9d-b484-6e0737a3a75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2b24a4d4-23be-4a88-ae87-878030413d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cad36396-6e92-4978-afd5-7512acdde4f2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2b24a4d4-23be-4a88-ae87-878030413d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_5e930487-2042-46cb-83ab-51ce96603679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cad36396-6e92-4978-afd5-7512acdde4f2" xlink:to="loc_us-gaap_ShortTermBorrowings_5e930487-2042-46cb-83ab-51ce96603679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_961ea994-283f-459a-9a3f-f811faca7491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cad36396-6e92-4978-afd5-7512acdde4f2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_961ea994-283f-459a-9a3f-f811faca7491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6e9edca0-985f-4c25-8f7f-70429a73cbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cad36396-6e92-4978-afd5-7512acdde4f2" xlink:to="loc_us-gaap_LiabilitiesCurrent_6e9edca0-985f-4c25-8f7f-70429a73cbc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b1f517aa-5c1f-4b5a-81e0-bb4448ea07ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b2ce73e1-af92-402a-bce2-1fb184551ff0" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b1f517aa-5c1f-4b5a-81e0-bb4448ea07ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4c705cd5-f685-4057-bc1c-dc505bfb872d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b2ce73e1-af92-402a-bce2-1fb184551ff0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4c705cd5-f685-4057-bc1c-dc505bfb872d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c7a581e3-57a2-4b5d-83bf-c1f8c0f6583c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b2ce73e1-af92-402a-bce2-1fb184551ff0" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c7a581e3-57a2-4b5d-83bf-c1f8c0f6583c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_49b14430-b96a-4192-bd56-44e647275a83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b2ce73e1-af92-402a-bce2-1fb184551ff0" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_49b14430-b96a-4192-bd56-44e647275a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_66929678-59e5-43a8-aa92-246c8b2e5266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b2ce73e1-af92-402a-bce2-1fb184551ff0" xlink:to="loc_us-gaap_Liabilities_66929678-59e5-43a8-aa92-246c8b2e5266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_9d2c1078-0290-4a25-ab43-ca36011afe8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b2ce73e1-af92-402a-bce2-1fb184551ff0" xlink:to="loc_us-gaap_CommitmentsAndContingencies_9d2c1078-0290-4a25-ab43-ca36011afe8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_fa0c93a2-d63d-4a77-b0e3-539a102cb962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b2ce73e1-af92-402a-bce2-1fb184551ff0" xlink:to="loc_us-gaap_StockholdersEquityAbstract_fa0c93a2-d63d-4a77-b0e3-539a102cb962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a9bd290b-0d60-4ed5-a29f-2ffe2ddcbb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fa0c93a2-d63d-4a77-b0e3-539a102cb962" xlink:to="loc_us-gaap_PreferredStockValue_a9bd290b-0d60-4ed5-a29f-2ffe2ddcbb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b05234fb-65a7-4432-afa0-9fd97354792a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fa0c93a2-d63d-4a77-b0e3-539a102cb962" xlink:to="loc_us-gaap_CommonStockValue_b05234fb-65a7-4432-afa0-9fd97354792a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_eeb31730-0a76-4d5d-b84f-88b7547163d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fa0c93a2-d63d-4a77-b0e3-539a102cb962" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_eeb31730-0a76-4d5d-b84f-88b7547163d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_66272c3d-101f-4071-8404-d0dec45ebd84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fa0c93a2-d63d-4a77-b0e3-539a102cb962" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_66272c3d-101f-4071-8404-d0dec45ebd84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e5a8a640-ec3a-4290-bc01-3d7c82f4d5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fa0c93a2-d63d-4a77-b0e3-539a102cb962" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e5a8a640-ec3a-4290-bc01-3d7c82f4d5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_339d957b-bd6f-4cea-b523-015eba05e2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fa0c93a2-d63d-4a77-b0e3-539a102cb962" xlink:to="loc_us-gaap_StockholdersEquity_339d957b-bd6f-4cea-b523-015eba05e2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f25c8300-2f6e-463a-9e25-6cce44bf1656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b2ce73e1-af92-402a-bce2-1fb184551ff0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_f25c8300-2f6e-463a-9e25-6cce44bf1656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="lung-20220630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2a996c4a-a96b-4546-8b95-7477f53f1dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_80682b0f-d9d9-4d0f-bea6-b55bbd2b00cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2a996c4a-a96b-4546-8b95-7477f53f1dd0" xlink:to="loc_us-gaap_StockholdersEquityAbstract_80682b0f-d9d9-4d0f-bea6-b55bbd2b00cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e94e19e3-2b72-437e-932b-581cc95107be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_80682b0f-d9d9-4d0f-bea6-b55bbd2b00cb" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e94e19e3-2b72-437e-932b-581cc95107be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_64eee9a2-3bca-45e5-990d-81cc0fba0aff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_80682b0f-d9d9-4d0f-bea6-b55bbd2b00cb" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_64eee9a2-3bca-45e5-990d-81cc0fba0aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_61d5aab1-d5c5-4767-808f-42b7062b8f65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_80682b0f-d9d9-4d0f-bea6-b55bbd2b00cb" xlink:to="loc_us-gaap_PreferredStockSharesIssued_61d5aab1-d5c5-4767-808f-42b7062b8f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6e105c39-37fe-46c7-99c9-d25d3f172b48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_80682b0f-d9d9-4d0f-bea6-b55bbd2b00cb" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_6e105c39-37fe-46c7-99c9-d25d3f172b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_046ba5cf-4217-46b4-9c3f-cfe4ca939dba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_80682b0f-d9d9-4d0f-bea6-b55bbd2b00cb" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_046ba5cf-4217-46b4-9c3f-cfe4ca939dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1f261178-b335-48a5-8728-5b9a893e7233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_80682b0f-d9d9-4d0f-bea6-b55bbd2b00cb" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1f261178-b335-48a5-8728-5b9a893e7233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_6fdbe41b-b91a-4aa8-b073-e70b249645f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_80682b0f-d9d9-4d0f-bea6-b55bbd2b00cb" xlink:to="loc_us-gaap_CommonStockSharesIssued_6fdbe41b-b91a-4aa8-b073-e70b249645f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a57f4452-4f09-4bc8-83aa-a5b489227749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_80682b0f-d9d9-4d0f-bea6-b55bbd2b00cb" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a57f4452-4f09-4bc8-83aa-a5b489227749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="lung-20220630.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_148fa1e2-fc24-4213-9d3b-a3cc0696d48b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1f3c3103-7206-46cf-9ca8-fdac1f59055b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_148fa1e2-fc24-4213-9d3b-a3cc0696d48b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1f3c3103-7206-46cf-9ca8-fdac1f59055b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e39fe627-d22c-4b09-948b-582e9f477ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_148fa1e2-fc24-4213-9d3b-a3cc0696d48b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e39fe627-d22c-4b09-948b-582e9f477ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_f22e5792-61ca-42bb-8e05-a6ee9e808fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_148fa1e2-fc24-4213-9d3b-a3cc0696d48b" xlink:to="loc_us-gaap_GrossProfit_f22e5792-61ca-42bb-8e05-a6ee9e808fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_845df165-6845-425a-b36a-b63f78eda6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_148fa1e2-fc24-4213-9d3b-a3cc0696d48b" xlink:to="loc_us-gaap_OperatingExpensesAbstract_845df165-6845-425a-b36a-b63f78eda6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e2eb1d95-4805-4353-bd28-fc85c62c65da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_845df165-6845-425a-b36a-b63f78eda6f5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e2eb1d95-4805-4353-bd28-fc85c62c65da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1a972983-3c2e-4c66-872e-40d0fe8e7686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_845df165-6845-425a-b36a-b63f78eda6f5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1a972983-3c2e-4c66-872e-40d0fe8e7686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d53bdb54-011c-4af0-a5db-d57188d57c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_845df165-6845-425a-b36a-b63f78eda6f5" xlink:to="loc_us-gaap_OperatingExpenses_d53bdb54-011c-4af0-a5db-d57188d57c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e4324598-4c8a-4e5a-ab9c-65721153aa25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_148fa1e2-fc24-4213-9d3b-a3cc0696d48b" xlink:to="loc_us-gaap_OperatingIncomeLoss_e4324598-4c8a-4e5a-ab9c-65721153aa25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_ba30781b-ba5e-4878-a081-5a31da40b816" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_148fa1e2-fc24-4213-9d3b-a3cc0696d48b" xlink:to="loc_us-gaap_InvestmentIncomeInterest_ba30781b-ba5e-4878-a081-5a31da40b816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_764b112b-0b2f-4a4a-80ee-6b73aa705997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_148fa1e2-fc24-4213-9d3b-a3cc0696d48b" xlink:to="loc_us-gaap_InterestExpense_764b112b-0b2f-4a4a-80ee-6b73aa705997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6888efdd-7663-4467-a088-9993d5c6d28a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_148fa1e2-fc24-4213-9d3b-a3cc0696d48b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6888efdd-7663-4467-a088-9993d5c6d28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fdf5250f-683a-419e-a390-f3931b8352bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_148fa1e2-fc24-4213-9d3b-a3cc0696d48b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fdf5250f-683a-419e-a390-f3931b8352bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5ddf9344-a853-41f1-a355-e0cb477645cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
<link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_148fa1e2-fc24-4213-9d3b-a3cc0696d48b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5ddf9344-a853-41f1-a355-e0cb477645cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0bfc79ed-d7f1-4e7b-915b-bdeb952d768c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
<link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_148fa1e2-fc24-4213-9d3b-a3cc0696d48b" xlink:to="loc_us-gaap_NetIncomeLoss_0bfc79ed-d7f1-4e7b-915b-bdeb952d768c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2273ba40-c6b7-46ba-8cde-5d11024db542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
<link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_148fa1e2-fc24-4213-9d3b-a3cc0696d48b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2273ba40-c6b7-46ba-8cde-5d11024db542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0fa7364e-c30c-40ee-b52d-a67ee0952f35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2273ba40-c6b7-46ba-8cde-5d11024db542" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0fa7364e-c30c-40ee-b52d-a67ee0952f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_eef69ffd-4d81-432c-bd05-8459fa806541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2273ba40-c6b7-46ba-8cde-5d11024db542" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_eef69ffd-4d81-432c-bd05-8459fa806541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4f4f0fb2-db95-4fb2-bd06-885d8e74ca1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2273ba40-c6b7-46ba-8cde-5d11024db542" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4f4f0fb2-db95-4fb2-bd06-885d8e74ca1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_84155d5e-b1c7-4f4e-b8d5-3cdc3a05d14f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
<link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_148fa1e2-fc24-4213-9d3b-a3cc0696d48b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_84155d5e-b1c7-4f4e-b8d5-3cdc3a05d14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_117ff04f-4044-4925-9437-a654d45d36b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
<link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_148fa1e2-fc24-4213-9d3b-a3cc0696d48b" xlink:to="loc_us-gaap_EarningsPerShareBasic_117ff04f-4044-4925-9437-a654d45d36b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0409092a-087e-49a5-a630-6d6a184c618a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
<link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_148fa1e2-fc24-4213-9d3b-a3cc0696d48b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_0409092a-087e-49a5-a630-6d6a184c618a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_99a47023-cbfe-4e72-8a3c-c3aabb13bc26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
<link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_148fa1e2-fc24-4213-9d3b-a3cc0696d48b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_99a47023-cbfe-4e72-8a3c-c3aabb13bc26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_048b254b-e63b-4c50-8f61-4dbf2b1472d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
<link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_148fa1e2-fc24-4213-9d3b-a3cc0696d48b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_048b254b-e63b-4c50-8f61-4dbf2b1472d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="lung-20220630.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a63d3d45-71fd-430b-a9b9-925b0fb8a8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_34470372-e929-4cd4-814d-71bd49749d82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a63d3d45-71fd-430b-a9b9-925b0fb8a8ad" xlink:to="loc_us-gaap_StatementTable_34470372-e929-4cd4-814d-71bd49749d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4a71ad4b-6cae-4b59-b477-db13132db2ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_34470372-e929-4cd4-814d-71bd49749d82" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4a71ad4b-6cae-4b59-b477-db13132db2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6173031d-c279-4ee1-93bc-32096ccf3f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4a71ad4b-6cae-4b59-b477-db13132db2ab" xlink:to="loc_us-gaap_EquityComponentDomain_6173031d-c279-4ee1-93bc-32096ccf3f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5a8861c6-619c-4b05-8465-da4ff6e92be9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6173031d-c279-4ee1-93bc-32096ccf3f5f" xlink:to="loc_us-gaap_CommonStockMember_5a8861c6-619c-4b05-8465-da4ff6e92be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_cb24a54a-6ff8-47d0-b320-7c951c341231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6173031d-c279-4ee1-93bc-32096ccf3f5f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_cb24a54a-6ff8-47d0-b320-7c951c341231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_920c4bf4-8d49-49c6-8175-ad4d9f31cd5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6173031d-c279-4ee1-93bc-32096ccf3f5f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_920c4bf4-8d49-49c6-8175-ad4d9f31cd5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_903a1285-717a-4b63-b48f-536bdce7e5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6173031d-c279-4ee1-93bc-32096ccf3f5f" xlink:to="loc_us-gaap_RetainedEarningsMember_903a1285-717a-4b63-b48f-536bdce7e5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_01de0c9e-0d88-4c2f-97f4-81c4e61ee326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_34470372-e929-4cd4-814d-71bd49749d82" xlink:to="loc_us-gaap_StatementLineItems_01de0c9e-0d88-4c2f-97f4-81c4e61ee326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_01de0c9e-0d88-4c2f-97f4-81c4e61ee326" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9bbbc6f4-82cd-4116-8b6b-74929c7b6347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9bbbc6f4-82cd-4116-8b6b-74929c7b6347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ee2a7d4e-fc64-436c-8e37-923bd5d0fa83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:to="loc_us-gaap_StockholdersEquity_ee2a7d4e-fc64-436c-8e37-923bd5d0fa83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_a4b704d4-e461-40cf-8e1d-c2f3f5d94470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_a4b704d4-e461-40cf-8e1d-c2f3f5d94470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9a2ea43f-6248-4962-adad-bdfd32f87452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9a2ea43f-6248-4962-adad-bdfd32f87452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_484374a0-a21b-4e5f-9822-d41a273a812d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_484374a0-a21b-4e5f-9822-d41a273a812d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_StockRepurchasedDuringPeriodExerciseOfEarlyStockOptionsShares_89777fd0-794b-4810-b2f3-0edbca10db9a" xlink:href="lung-20220630.xsd#lung_StockRepurchasedDuringPeriodExerciseOfEarlyStockOptionsShares"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:to="loc_lung_StockRepurchasedDuringPeriodExerciseOfEarlyStockOptionsShares_89777fd0-794b-4810-b2f3-0edbca10db9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_044aeee7-6726-4357-bd86-a4c2d2fcfb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_044aeee7-6726-4357-bd86-a4c2d2fcfb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_9dd7a0c8-ccdc-4224-9908-36b14388316c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_9dd7a0c8-ccdc-4224-9908-36b14388316c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase_57485673-b32b-49c5-a270-a13857d2fec7" xlink:href="lung-20220630.xsd#lung_AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:to="loc_lung_AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase_57485673-b32b-49c5-a270-a13857d2fec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1f723d08-5d62-48af-9e48-ce2654d36ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
<link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1f723d08-5d62-48af-9e48-ce2654d36ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0d3c0d93-8940-41f0-b0a4-d131ba26812a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
<link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0d3c0d93-8940-41f0-b0a4-d131ba26812a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_a9d2a8c6-25a6-42c9-85e9-8ef1818e97e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
<link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_a9d2a8c6-25a6-42c9-85e9-8ef1818e97e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_83f6b744-d2b4-4458-9572-f2a4ee43ee7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
<link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:to="loc_us-gaap_NetIncomeLoss_83f6b744-d2b4-4458-9572-f2a4ee43ee7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d7c334fc-484b-477f-935f-0f0c94667d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
<link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d7c334fc-484b-477f-935f-0f0c94667d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5f35735d-e311-4785-829e-f25bcdbc83fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
<link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5031e301-ee6e-4246-8170-892f91154232" xlink:to="loc_us-gaap_StockholdersEquity_5f35735d-e311-4785-829e-f25bcdbc83fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="lung-20220630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_e592c0c6-bebf-482c-9804-e5f8400367f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dc38c373-0845-4817-ae62-67ecb82c6b22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e592c0c6-bebf-482c-9804-e5f8400367f0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dc38c373-0845-4817-ae62-67ecb82c6b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_969e53a7-4f7a-499d-8b7c-2712702968f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dc38c373-0845-4817-ae62-67ecb82c6b22" xlink:to="loc_us-gaap_NetIncomeLoss_969e53a7-4f7a-499d-8b7c-2712702968f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a7bd96e0-6afe-4aca-9c92-fd782a683581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dc38c373-0845-4817-ae62-67ecb82c6b22" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a7bd96e0-6afe-4aca-9c92-fd782a683581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_dd202d88-0c4e-4d40-b289-96a1e7027382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a7bd96e0-6afe-4aca-9c92-fd782a683581" xlink:to="loc_us-gaap_ShareBasedCompensation_dd202d88-0c4e-4d40-b289-96a1e7027382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_28a1ec0f-f0c4-483c-b47d-3feb161fbf7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a7bd96e0-6afe-4aca-9c92-fd782a683581" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_28a1ec0f-f0c4-483c-b47d-3feb161fbf7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_4dc72a7b-d683-4496-bc8b-4175ab2878c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a7bd96e0-6afe-4aca-9c92-fd782a683581" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_4dc72a7b-d683-4496-bc8b-4175ab2878c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_5ca80d69-e4de-4ea5-9af7-888c083a364c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a7bd96e0-6afe-4aca-9c92-fd782a683581" xlink:to="loc_us-gaap_InventoryWriteDown_5ca80d69-e4de-4ea5-9af7-888c083a364c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_40c58244-33e9-411a-8347-1d6d4bad7f56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDepreciationAndAmortization"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a7bd96e0-6afe-4aca-9c92-fd782a683581" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_40c58244-33e9-411a-8347-1d6d4bad7f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_14aae3d6-0104-4e71-92e8-6e427aa2f332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a7bd96e0-6afe-4aca-9c92-fd782a683581" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_14aae3d6-0104-4e71-92e8-6e427aa2f332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_8dd9af51-f729-461d-9d45-e024f0c7327d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a7bd96e0-6afe-4aca-9c92-fd782a683581" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_8dd9af51-f729-461d-9d45-e024f0c7327d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_45526a17-4b1a-4144-bc91-6e2691d7ca16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a7bd96e0-6afe-4aca-9c92-fd782a683581" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_45526a17-4b1a-4144-bc91-6e2691d7ca16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cb5d0e9b-f201-4c2d-8bf2-d402b26670ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a7bd96e0-6afe-4aca-9c92-fd782a683581" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cb5d0e9b-f201-4c2d-8bf2-d402b26670ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_83b332d6-bf3f-472d-b210-931996e66e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cb5d0e9b-f201-4c2d-8bf2-d402b26670ec" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_83b332d6-bf3f-472d-b210-931996e66e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_eab934f9-db48-49be-b4b0-6d21624016a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cb5d0e9b-f201-4c2d-8bf2-d402b26670ec" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_eab934f9-db48-49be-b4b0-6d21624016a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_bc513c51-3047-4b97-af2d-b11fd09fdc11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cb5d0e9b-f201-4c2d-8bf2-d402b26670ec" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_bc513c51-3047-4b97-af2d-b11fd09fdc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1bf51879-270e-42d9-8299-f2fe7448354d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cb5d0e9b-f201-4c2d-8bf2-d402b26670ec" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1bf51879-270e-42d9-8299-f2fe7448354d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f3b42024-6182-40e4-92c8-aaf4b92dc17a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cb5d0e9b-f201-4c2d-8bf2-d402b26670ec" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f3b42024-6182-40e4-92c8-aaf4b92dc17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_16e7196a-0bf6-472b-899a-85c8e2b0d2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cb5d0e9b-f201-4c2d-8bf2-d402b26670ec" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_16e7196a-0bf6-472b-899a-85c8e2b0d2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_a3cf8c69-e285-41cb-bd3c-c461de14ea79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cb5d0e9b-f201-4c2d-8bf2-d402b26670ec" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_a3cf8c69-e285-41cb-bd3c-c461de14ea79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e7964111-faf5-40ad-9f9f-83f41c26eadd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cb5d0e9b-f201-4c2d-8bf2-d402b26670ec" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e7964111-faf5-40ad-9f9f-83f41c26eadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_ff82f7ce-9c35-4578-befa-d294ab5d6118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cb5d0e9b-f201-4c2d-8bf2-d402b26670ec" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_ff82f7ce-9c35-4578-befa-d294ab5d6118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_391075d5-7291-49eb-9ff5-55e5467c0bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
<link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cb5d0e9b-f201-4c2d-8bf2-d402b26670ec" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_391075d5-7291-49eb-9ff5-55e5467c0bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff8741ac-271c-418a-a2bc-6c057a1e9a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dc38c373-0845-4817-ae62-67ecb82c6b22" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff8741ac-271c-418a-a2bc-6c057a1e9a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0b9ea7e9-c63b-4c17-84ec-54a91d300786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e592c0c6-bebf-482c-9804-e5f8400367f0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0b9ea7e9-c63b-4c17-84ec-54a91d300786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7183344e-f65e-4016-8d43-514ad210414a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0b9ea7e9-c63b-4c17-84ec-54a91d300786" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7183344e-f65e-4016-8d43-514ad210414a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_c69371f6-3578-4d55-8914-d3ab645557d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0b9ea7e9-c63b-4c17-84ec-54a91d300786" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_c69371f6-3578-4d55-8914-d3ab645557d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c5fc5268-9ec1-4193-b0ab-06e89cbe78e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0b9ea7e9-c63b-4c17-84ec-54a91d300786" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c5fc5268-9ec1-4193-b0ab-06e89cbe78e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_45b0c9d6-d576-46bd-8309-710be1c87133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0b9ea7e9-c63b-4c17-84ec-54a91d300786" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_45b0c9d6-d576-46bd-8309-710be1c87133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7093edba-6a4d-448c-b115-4cf03d7a5057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e592c0c6-bebf-482c-9804-e5f8400367f0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7093edba-6a4d-448c-b115-4cf03d7a5057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_dd93378c-d036-4f17-8a21-9cfeabe8df2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7093edba-6a4d-448c-b115-4cf03d7a5057" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_dd93378c-d036-4f17-8a21-9cfeabe8df2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_46b73917-a2d3-47e5-96aa-45534ae79ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7093edba-6a4d-448c-b115-4cf03d7a5057" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_46b73917-a2d3-47e5-96aa-45534ae79ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_2b05ea77-5b12-48b6-aa63-fc04ec7a001e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7093edba-6a4d-448c-b115-4cf03d7a5057" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_2b05ea77-5b12-48b6-aa63-fc04ec7a001e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock_02afb191-1dc5-4986-b27f-f6cce9142b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7093edba-6a4d-448c-b115-4cf03d7a5057" xlink:to="loc_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock_02afb191-1dc5-4986-b27f-f6cce9142b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_a5ae7cf1-d5ce-41f4-a47b-5aa105a0a682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7093edba-6a4d-448c-b115-4cf03d7a5057" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_a5ae7cf1-d5ce-41f4-a47b-5aa105a0a682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_72f4499f-5337-42fd-997b-6af328ac64d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7093edba-6a4d-448c-b115-4cf03d7a5057" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_72f4499f-5337-42fd-997b-6af328ac64d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cf2d5dae-e4fe-4633-afd9-131c3fafb29e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e592c0c6-bebf-482c-9804-e5f8400367f0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cf2d5dae-e4fe-4633-afd9-131c3fafb29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8a5eb17e-5d28-44c5-870b-23e5e44c91df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e592c0c6-bebf-482c-9804-e5f8400367f0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8a5eb17e-5d28-44c5-870b-23e5e44c91df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c243d278-301d-4079-b4e1-c296a2eb9d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e592c0c6-bebf-482c-9804-e5f8400367f0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c243d278-301d-4079-b4e1-c296a2eb9d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_10bdb561-4abc-4f78-a395-e6b0e59f1fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e592c0c6-bebf-482c-9804-e5f8400367f0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_10bdb561-4abc-4f78-a395-e6b0e59f1fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_d3753c89-40e5-4ec0-a573-800702be6883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e592c0c6-bebf-482c-9804-e5f8400367f0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_d3753c89-40e5-4ec0-a573-800702be6883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a53b26e8-b262-4b94-a23b-c75511e02f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_d3753c89-40e5-4ec0-a573-800702be6883" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a53b26e8-b262-4b94-a23b-c75511e02f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_c018f581-6702-4510-8ccc-271a04f4b669" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_d3753c89-40e5-4ec0-a573-800702be6883" xlink:to="loc_us-gaap_RestrictedCash_c018f581-6702-4510-8ccc-271a04f4b669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_99b1fa59-e655-4c06-90c8-aae5d80308ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_d3753c89-40e5-4ec0-a573-800702be6883" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_99b1fa59-e655-4c06-90c8-aae5d80308ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c118fcd2-6240-4a90-8bcd-e3a20ef3ab1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e592c0c6-bebf-482c-9804-e5f8400367f0" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c118fcd2-6240-4a90-8bcd-e3a20ef3ab1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_IncreaseLapseInRepurchaseOfCommonStockRights_dbb3948b-cdce-4c55-a077-69d1f69b15ee" xlink:href="lung-20220630.xsd#lung_IncreaseLapseInRepurchaseOfCommonStockRights"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c118fcd2-6240-4a90-8bcd-e3a20ef3ab1d" xlink:to="loc_lung_IncreaseLapseInRepurchaseOfCommonStockRights_dbb3948b-cdce-4c55-a077-69d1f69b15ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_f991b5a9-c1ed-4a7b-9302-913b5646417d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c118fcd2-6240-4a90-8bcd-e3a20ef3ab1d" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_f991b5a9-c1ed-4a7b-9302-913b5646417d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_ReceivableFromExerciseOfCommonStockOptions_4f6044c0-725e-4591-8252-62fa5f978ae6" xlink:href="lung-20220630.xsd#lung_ReceivableFromExerciseOfCommonStockOptions"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c118fcd2-6240-4a90-8bcd-e3a20ef3ab1d" xlink:to="loc_lung_ReceivableFromExerciseOfCommonStockOptions_4f6044c0-725e-4591-8252-62fa5f978ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b3ff309b-1781-425e-9ec8-0b787bc6f81c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c118fcd2-6240-4a90-8bcd-e3a20ef3ab1d" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b3ff309b-1781-425e-9ec8-0b787bc6f81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_fdd4300c-9020-4d35-ad54-745a7c64e5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
<link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e592c0c6-bebf-482c-9804-e5f8400367f0" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_fdd4300c-9020-4d35-ad54-745a7c64e5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_809ea3b9-1ba3-41b4-863b-874fdf50c27e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_fdd4300c-9020-4d35-ad54-745a7c64e5ee" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_809ea3b9-1ba3-41b4-863b-874fdf50c27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_c5f218f0-505e-434f-b44a-a6dd5b259615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_fdd4300c-9020-4d35-ad54-745a7c64e5ee" xlink:to="loc_us-gaap_InterestPaidNet_c5f218f0-505e-434f-b44a-a6dd5b259615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/FormationandBusinessoftheCompany" xlink:type="simple" xlink:href="lung-20220630.xsd#FormationandBusinessoftheCompany"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/FormationandBusinessoftheCompany" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_97b9a236-602a-491f-b43f-3b479bb6f346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_5decc6d1-76d1-4122-a64c-83959ab9b424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_97b9a236-602a-491f-b43f-3b479bb6f346" xlink:to="loc_us-gaap_NatureOfOperations_5decc6d1-76d1-4122-a64c-83959ab9b424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/FormationandBusinessoftheCompanyDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#FormationandBusinessoftheCompanyDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/FormationandBusinessoftheCompanyDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_de54df63-431b-4255-8306-60c8bd0e3660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5a331078-e154-4f31-9834-9bf928493520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_de54df63-431b-4255-8306-60c8bd0e3660" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5a331078-e154-4f31-9834-9bf928493520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cd666987-df70-40cf-bb78-dad139390381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_de54df63-431b-4255-8306-60c8bd0e3660" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cd666987-df70-40cf-bb78-dad139390381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_CashAndCashEquivalentsAndMarketableSecurities_62c658d4-3a60-4937-bfc6-d0edd9418e3e" xlink:href="lung-20220630.xsd#lung_CashAndCashEquivalentsAndMarketableSecurities"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_de54df63-431b-4255-8306-60c8bd0e3660" xlink:to="loc_lung_CashAndCashEquivalentsAndMarketableSecurities_62c658d4-3a60-4937-bfc6-d0edd9418e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="lung-20220630.xsd#SummaryofSignificantAccountingPolicies"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0ebaf885-65f8-4636-bd57-b9a8aa6fdbfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_064c12af-be2a-42d7-8fd7-28849f9fa855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0ebaf885-65f8-4636-bd57-b9a8aa6fdbfb" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_064c12af-be2a-42d7-8fd7-28849f9fa855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lung-20220630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_df13a786-bb90-4f44-a52b-2dda58116e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c3c0782a-7376-4e26-b66c-fdc612e13c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df13a786-bb90-4f44-a52b-2dda58116e9e" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c3c0782a-7376-4e26-b66c-fdc612e13c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_5a045d27-9a96-40c8-b51a-e2ba6d805eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df13a786-bb90-4f44-a52b-2dda58116e9e" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_5a045d27-9a96-40c8-b51a-e2ba6d805eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_7bb852ab-65f4-4bb3-91c6-74107df731cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df13a786-bb90-4f44-a52b-2dda58116e9e" xlink:to="loc_us-gaap_UseOfEstimates_7bb852ab-65f4-4bb3-91c6-74107df731cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_64038839-8dbf-4297-a720-879b6e739f41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df13a786-bb90-4f44-a52b-2dda58116e9e" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_64038839-8dbf-4297-a720-879b6e739f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_a0683887-2ade-408b-af9d-e35d5f383a12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df13a786-bb90-4f44-a52b-2dda58116e9e" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_a0683887-2ade-408b-af9d-e35d5f383a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_fbc79264-c4e6-4eaf-924b-a71b51731bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df13a786-bb90-4f44-a52b-2dda58116e9e" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_fbc79264-c4e6-4eaf-924b-a71b51731bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_14fe2698-190e-4b45-9619-df2fadf9723f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df13a786-bb90-4f44-a52b-2dda58116e9e" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_14fe2698-190e-4b45-9619-df2fadf9723f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_813c5683-6aab-403e-b26b-683f4f7c4388" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df13a786-bb90-4f44-a52b-2dda58116e9e" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_813c5683-6aab-403e-b26b-683f4f7c4388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1e55514a-0b40-4410-9264-42efafd1989f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df13a786-bb90-4f44-a52b-2dda58116e9e" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1e55514a-0b40-4410-9264-42efafd1989f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_44c2e20c-e327-48e9-b8d3-6ff30e163f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3802535b-95be-4537-a218-9a428916d7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_44c2e20c-e327-48e9-b8d3-6ff30e163f1b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3802535b-95be-4537-a218-9a428916d7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_77d45179-da45-4631-b3e0-9b16e0db0627" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3802535b-95be-4537-a218-9a428916d7eb" xlink:to="loc_srt_RangeAxis_77d45179-da45-4631-b3e0-9b16e0db0627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fb4acb42-2cfb-4e99-bad7-e7697fc17b73" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_77d45179-da45-4631-b3e0-9b16e0db0627" xlink:to="loc_srt_RangeMember_fb4acb42-2cfb-4e99-bad7-e7697fc17b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_85cc9434-b3b3-49c1-98c1-276291ef46b8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fb4acb42-2cfb-4e99-bad7-e7697fc17b73" xlink:to="loc_srt_MaximumMember_85cc9434-b3b3-49c1-98c1-276291ef46b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_dd6e8c25-d4e4-4ef2-93c6-8738cc889a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3802535b-95be-4537-a218-9a428916d7eb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_dd6e8c25-d4e4-4ef2-93c6-8738cc889a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount_4122b21a-ba4a-42aa-9c0f-9eed42c51a61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_dd6e8c25-d4e4-4ef2-93c6-8738cc889a9f" xlink:to="loc_us-gaap_CashUninsuredAmount_4122b21a-ba4a-42aa-9c0f-9eed42c51a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0ac8477b-e286-4e96-9c42-8b17ae901182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_dd6e8c25-d4e4-4ef2-93c6-8738cc889a9f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0ac8477b-e286-4e96-9c42-8b17ae901182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized_58a91a73-f9e6-4be1-be26-e0964c1529e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_dd6e8c25-d4e4-4ef2-93c6-8738cc889a9f" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized_58a91a73-f9e6-4be1-be26-e0964c1529e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/RecentAccountingPronouncements" xlink:type="simple" xlink:href="lung-20220630.xsd#RecentAccountingPronouncements"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/RecentAccountingPronouncements" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ae9c853a-bc0c-4442-b43c-7d0b8c17bac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_d649c3d2-5c61-4fe0-ad76-7d59a0a590a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae9c853a-bc0c-4442-b43c-7d0b8c17bac1" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_d649c3d2-5c61-4fe0-ad76-7d59a0a590a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="lung-20220630.xsd#FairValueMeasurements"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/FairValueMeasurements" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ba115dae-15f6-4957-a2a1-13128c7fbc54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_64819461-7165-43f3-b67a-4a47391f29c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ba115dae-15f6-4957-a2a1-13128c7fbc54" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_64819461-7165-43f3-b67a-4a47391f29c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="lung-20220630.xsd#FairValueMeasurementsTables"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/FairValueMeasurementsTables" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_638256f6-91e9-4460-bf4d-d3df3e947a59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_11acdb28-9e87-4b38-9af2-45532db4b445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_638256f6-91e9-4460-bf4d-d3df3e947a59" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_11acdb28-9e87-4b38-9af2-45532db4b445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_a295966f-8e9e-4de5-8a4e-aeb32e6ce422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_638256f6-91e9-4460-bf4d-d3df3e947a59" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_a295966f-8e9e-4de5-8a4e-aeb32e6ce422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_609a301c-c4e9-4fe3-ada5-b020c627900c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_05dd5895-7c1a-4244-9402-9b710474af2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_609a301c-c4e9-4fe3-ada5-b020c627900c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_05dd5895-7c1a-4244-9402-9b710474af2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_08e1c02f-585d-4aa2-ad00-9dfb421eea2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_05dd5895-7c1a-4244-9402-9b710474af2d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_08e1c02f-585d-4aa2-ad00-9dfb421eea2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f3c4f050-e083-4e95-a2e9-9db33afbdc04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_08e1c02f-585d-4aa2-ad00-9dfb421eea2e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f3c4f050-e083-4e95-a2e9-9db33afbdc04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_afdba5c8-816d-4988-b4d6-8e3122ac6175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_f3c4f050-e083-4e95-a2e9-9db33afbdc04" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_afdba5c8-816d-4988-b4d6-8e3122ac6175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4e49612-6dc1-4b55-9c32-74751ff6dbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_05dd5895-7c1a-4244-9402-9b710474af2d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4e49612-6dc1-4b55-9c32-74751ff6dbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8befef0d-c3cb-495e-85ac-b65e9315b271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4e49612-6dc1-4b55-9c32-74751ff6dbcf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8befef0d-c3cb-495e-85ac-b65e9315b271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f4a00937-55a8-4fb0-8530-80fbacfaa939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8befef0d-c3cb-495e-85ac-b65e9315b271" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f4a00937-55a8-4fb0-8530-80fbacfaa939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_cac6f980-57e4-46f6-af75-66ef011863c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8befef0d-c3cb-495e-85ac-b65e9315b271" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_cac6f980-57e4-46f6-af75-66ef011863c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_cb1c4072-d364-4459-ba58-c125c879d352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8befef0d-c3cb-495e-85ac-b65e9315b271" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_cb1c4072-d364-4459-ba58-c125c879d352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_472fecb8-14b9-4c3a-8494-5c7ac4541ece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_05dd5895-7c1a-4244-9402-9b710474af2d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_472fecb8-14b9-4c3a-8494-5c7ac4541ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0d5aaf64-4cde-4fee-a69a-e37a91faee74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_472fecb8-14b9-4c3a-8494-5c7ac4541ece" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0d5aaf64-4cde-4fee-a69a-e37a91faee74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_be7c89bb-76f4-4a0a-be41-ff5b06f15aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0d5aaf64-4cde-4fee-a69a-e37a91faee74" xlink:to="loc_us-gaap_MoneyMarketFundsMember_be7c89bb-76f4-4a0a-be41-ff5b06f15aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_951d9b5e-e39d-4974-9091-69bfe53fba07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0d5aaf64-4cde-4fee-a69a-e37a91faee74" xlink:to="loc_us-gaap_CommercialPaperMember_951d9b5e-e39d-4974-9091-69bfe53fba07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d52d21e5-021d-4db2-9e4b-d6768e63e300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_05dd5895-7c1a-4244-9402-9b710474af2d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d52d21e5-021d-4db2-9e4b-d6768e63e300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_273644ba-9563-4092-b339-3ea9f9c2f84a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d52d21e5-021d-4db2-9e4b-d6768e63e300" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_273644ba-9563-4092-b339-3ea9f9c2f84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_94ed903d-d037-4af1-85d3-c8f1669447d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_273644ba-9563-4092-b339-3ea9f9c2f84a" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_94ed903d-d037-4af1-85d3-c8f1669447d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_7373839b-1571-4447-b3a8-fcbad028e075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_273644ba-9563-4092-b339-3ea9f9c2f84a" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_7373839b-1571-4447-b3a8-fcbad028e075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_d2585968-2976-47a8-94ba-225e364733b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_273644ba-9563-4092-b339-3ea9f9c2f84a" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_d2585968-2976-47a8-94ba-225e364733b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6fd5b1eb-b267-4961-ad71-210dd1eb1c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_05dd5895-7c1a-4244-9402-9b710474af2d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6fd5b1eb-b267-4961-ad71-210dd1eb1c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1c3dd6b9-acf9-4cdd-9978-b0cda78be9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6fd5b1eb-b267-4961-ad71-210dd1eb1c66" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1c3dd6b9-acf9-4cdd-9978-b0cda78be9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6fb25088-bb7d-4244-9d8e-d2dcd809779d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1c3dd6b9-acf9-4cdd-9978-b0cda78be9a8" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6fb25088-bb7d-4244-9d8e-d2dcd809779d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a8d0df2c-1f33-4391-8447-d5962dd2fcaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_1c3dd6b9-acf9-4cdd-9978-b0cda78be9a8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a8d0df2c-1f33-4391-8447-d5962dd2fcaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_038ffd88-5223-4dbd-bc4a-0b8b497801c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6fd5b1eb-b267-4961-ad71-210dd1eb1c66" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_038ffd88-5223-4dbd-bc4a-0b8b497801c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7655fea1-739f-4238-8e29-40aa436f9c70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ecbd24d7-d602-4db7-83f2-f66265f39845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7655fea1-739f-4238-8e29-40aa436f9c70" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ecbd24d7-d602-4db7-83f2-f66265f39845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3079033b-4acc-409d-b9da-f7f0191e8524" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ecbd24d7-d602-4db7-83f2-f66265f39845" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3079033b-4acc-409d-b9da-f7f0191e8524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_afb4b690-d5f1-4c79-9201-65ab80ddbeab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3079033b-4acc-409d-b9da-f7f0191e8524" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_afb4b690-d5f1-4c79-9201-65ab80ddbeab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2c738da0-9c4a-4d90-b855-2b91aecbf178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_afb4b690-d5f1-4c79-9201-65ab80ddbeab" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2c738da0-9c4a-4d90-b855-2b91aecbf178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_67cde496-328b-44d1-9b1a-d7cda647f492" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_afb4b690-d5f1-4c79-9201-65ab80ddbeab" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_67cde496-328b-44d1-9b1a-d7cda647f492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_1be7316e-3656-4f48-8569-c426ac91f491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_afb4b690-d5f1-4c79-9201-65ab80ddbeab" xlink:to="loc_us-gaap_CommercialPaperMember_1be7316e-3656-4f48-8569-c426ac91f491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a2f2fd3e-0011-40e8-924b-fa7dfc9555bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ecbd24d7-d602-4db7-83f2-f66265f39845" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a2f2fd3e-0011-40e8-924b-fa7dfc9555bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_f08ba170-f86a-46ad-a3c6-8481a643ddcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a2f2fd3e-0011-40e8-924b-fa7dfc9555bd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_f08ba170-f86a-46ad-a3c6-8481a643ddcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_11dd8ddb-d5a0-4909-a3be-f78543ea4fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_f08ba170-f86a-46ad-a3c6-8481a643ddcd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_11dd8ddb-d5a0-4909-a3be-f78543ea4fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2c095f8e-28dc-4119-a47b-001a01046fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_f08ba170-f86a-46ad-a3c6-8481a643ddcd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2c095f8e-28dc-4119-a47b-001a01046fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b121827c-5bab-4abd-b951-1cd316801ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_f08ba170-f86a-46ad-a3c6-8481a643ddcd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b121827c-5bab-4abd-b951-1cd316801ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a40c2693-d984-4f51-b1b3-eaf195c6b4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_f08ba170-f86a-46ad-a3c6-8481a643ddcd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a40c2693-d984-4f51-b1b3-eaf195c6b4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_FairValueRecognizedOnBalanceSheetAbstract_b9b33359-08de-4b1e-aa30-12f9b0eef9d8" xlink:href="lung-20220630.xsd#lung_FairValueRecognizedOnBalanceSheetAbstract"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a2f2fd3e-0011-40e8-924b-fa7dfc9555bd" xlink:to="loc_lung_FairValueRecognizedOnBalanceSheetAbstract_b9b33359-08de-4b1e-aa30-12f9b0eef9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_85acd6c8-69e4-4f89-a1d1-8fabf8e08e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lung_FairValueRecognizedOnBalanceSheetAbstract_b9b33359-08de-4b1e-aa30-12f9b0eef9d8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_85acd6c8-69e4-4f89-a1d1-8fabf8e08e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8e759055-f441-4c58-ac17-f5c5da87ba51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lung_FairValueRecognizedOnBalanceSheetAbstract_b9b33359-08de-4b1e-aa30-12f9b0eef9d8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8e759055-f441-4c58-ac17-f5c5da87ba51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_CashCashEquivalentsAndAvailableForSaleDebtSecurities_95b1a0f0-ff84-4954-94ae-58afc3e16b82" xlink:href="lung-20220630.xsd#lung_CashCashEquivalentsAndAvailableForSaleDebtSecurities"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lung_FairValueRecognizedOnBalanceSheetAbstract_b9b33359-08de-4b1e-aa30-12f9b0eef9d8" xlink:to="loc_lung_CashCashEquivalentsAndAvailableForSaleDebtSecurities_95b1a0f0-ff84-4954-94ae-58afc3e16b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#FairValueMeasurementsNarrativeDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1cb06877-1936-4d1e-bb3a-00715be452ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_1206baf8-c1cf-4e35-a46e-0e8e985a97bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1cb06877-1936-4d1e-bb3a-00715be452ed" xlink:to="loc_us-gaap_DerivativeTable_1206baf8-c1cf-4e35-a46e-0e8e985a97bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f4e8088e-f551-40d1-b339-9313c77768c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1206baf8-c1cf-4e35-a46e-0e8e985a97bd" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f4e8088e-f551-40d1-b339-9313c77768c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8e460542-f811-4311-9a7f-5e9ba4491523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f4e8088e-f551-40d1-b339-9313c77768c0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8e460542-f811-4311-9a7f-5e9ba4491523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_54f7fb22-5371-44e8-bf4c-3087bef5da07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8e460542-f811-4311-9a7f-5e9ba4491523" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_54f7fb22-5371-44e8-bf4c-3087bef5da07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_f9dc1f3a-0b22-4466-8cbe-2e4b32ec3e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1206baf8-c1cf-4e35-a46e-0e8e985a97bd" xlink:to="loc_us-gaap_DerivativeLineItems_f9dc1f3a-0b22-4466-8cbe-2e4b32ec3e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_65465d69-5cb7-41cd-9999-418f5b4c7ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_f9dc1f3a-0b22-4466-8cbe-2e4b32ec3e0b" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_65465d69-5cb7-41cd-9999-418f5b4c7ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_9031da2a-a6f8-4a0d-ac46-c4b69549429b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_f9dc1f3a-0b22-4466-8cbe-2e4b32ec3e0b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_9031da2a-a6f8-4a0d-ac46-c4b69549429b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="lung-20220630.xsd#BalanceSheetComponents"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/BalanceSheetComponents" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d9b9e078-6f2a-4bb2-acae-d2dda65d6d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_26c6a4e5-f0d4-4f4d-ba25-0f4b8eae61cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d9b9e078-6f2a-4bb2-acae-d2dda65d6d2a" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_26c6a4e5-f0d4-4f4d-ba25-0f4b8eae61cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="lung-20220630.xsd#BalanceSheetComponentsTables"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/BalanceSheetComponentsTables" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fecdaf6-bf59-4fd8-980d-c21b24c2ee9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_8684d5b4-420e-4f45-9e77-995757b3a7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fecdaf6-bf59-4fd8-980d-c21b24c2ee9b" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_8684d5b4-420e-4f45-9e77-995757b3a7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ed7d753a-dc34-4691-85d0-f943c17eaeb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fecdaf6-bf59-4fd8-980d-c21b24c2ee9b" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ed7d753a-dc34-4691-85d0-f943c17eaeb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_55b43006-4f94-4ee1-bfd4-a128521cc337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fecdaf6-bf59-4fd8-980d-c21b24c2ee9b" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_55b43006-4f94-4ee1-bfd4-a128521cc337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_347b9302-60d1-4062-b086-bdf6014b01f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fecdaf6-bf59-4fd8-980d-c21b24c2ee9b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_347b9302-60d1-4062-b086-bdf6014b01f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_2802ad73-e339-4958-a70d-72bf04452a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fecdaf6-bf59-4fd8-980d-c21b24c2ee9b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_2802ad73-e339-4958-a70d-72bf04452a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_57fef116-e0c9-4bf5-a9e9-fdbeb67cb6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fecdaf6-bf59-4fd8-980d-c21b24c2ee9b" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_57fef116-e0c9-4bf5-a9e9-fdbeb67cb6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_00a96fea-50b8-4e15-ba9a-ad9be660f745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5fecdaf6-bf59-4fd8-980d-c21b24c2ee9b" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_00a96fea-50b8-4e15-ba9a-ad9be660f745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#BalanceSheetComponentsCashandCashEquivalentsDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/BalanceSheetComponentsCashandCashEquivalentsDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d0b1dbf2-b778-4be3-b084-d20bf52ba9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_2d8b504b-619b-4489-a060-cda071f24abd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d0b1dbf2-b778-4be3-b084-d20bf52ba9a5" xlink:to="loc_us-gaap_Cash_2d8b504b-619b-4489-a060-cda071f24abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_7e0c80ce-7af2-4da4-a3e1-7880ef300918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d0b1dbf2-b778-4be3-b084-d20bf52ba9a5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_7e0c80ce-7af2-4da4-a3e1-7880ef300918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_161bf90a-d06c-4694-890f-3029abcb2a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_7e0c80ce-7af2-4da4-a3e1-7880ef300918" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_161bf90a-d06c-4694-890f-3029abcb2a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperAtCarryingValue_4d0d39af-b6a8-4ce8-bcef-fe7f5dcdb7de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperAtCarryingValue"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_7e0c80ce-7af2-4da4-a3e1-7880ef300918" xlink:to="loc_us-gaap_CommercialPaperAtCarryingValue_4d0d39af-b6a8-4ce8-bcef-fe7f5dcdb7de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_CorporateBondsDebtSecuritiesAtCarryingValue_014c7cab-c668-4ce6-aa64-e394b6f13a1f" xlink:href="lung-20220630.xsd#lung_CorporateBondsDebtSecuritiesAtCarryingValue"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_7e0c80ce-7af2-4da4-a3e1-7880ef300918" xlink:to="loc_lung_CorporateBondsDebtSecuritiesAtCarryingValue_014c7cab-c668-4ce6-aa64-e394b6f13a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c4479dea-e33f-4454-9370-a19e754f8f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d0b1dbf2-b778-4be3-b084-d20bf52ba9a5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c4479dea-e33f-4454-9370-a19e754f8f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsInventoryDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#BalanceSheetComponentsInventoryDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/BalanceSheetComponentsInventoryDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9b78dca8-ab48-4295-ba47-1e5f0bcd2588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_dd608566-c455-4271-9512-8c81e358a6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9b78dca8-ab48-4295-ba47-1e5f0bcd2588" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_dd608566-c455-4271-9512-8c81e358a6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_58d03cfb-63cc-4750-9ab2-17eba260e862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9b78dca8-ab48-4295-ba47-1e5f0bcd2588" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_58d03cfb-63cc-4750-9ab2-17eba260e862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_10d08245-1fb3-4870-8f9f-e55724a94768" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9b78dca8-ab48-4295-ba47-1e5f0bcd2588" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_10d08245-1fb3-4870-8f9f-e55724a94768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_145dcc41-5753-412a-98af-a0ca583a4a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9b78dca8-ab48-4295-ba47-1e5f0bcd2588" xlink:to="loc_us-gaap_InventoryNet_145dcc41-5753-412a-98af-a0ca583a4a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_66e452d2-39f5-4525-aff0-78513f63c080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_49c5cc51-0257-4fbb-ad02-032ae4271cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_66e452d2-39f5-4525-aff0-78513f63c080" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_49c5cc51-0257-4fbb-ad02-032ae4271cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_90c75243-1639-4b78-b718-cb59d80e8cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidInsurance"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_66e452d2-39f5-4525-aff0-78513f63c080" xlink:to="loc_us-gaap_PrepaidInsurance_90c75243-1639-4b78-b718-cb59d80e8cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_079971ff-e259-486d-85b7-9f7f5781b4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_66e452d2-39f5-4525-aff0-78513f63c080" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_079971ff-e259-486d-85b7-9f7f5781b4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_58513744-9f33-40e4-8696-e73152d89d23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_66e452d2-39f5-4525-aff0-78513f63c080" xlink:to="loc_us-gaap_OtherAssetsCurrent_58513744-9f33-40e4-8696-e73152d89d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_488459c8-394f-4839-ba08-230efa553498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_66e452d2-39f5-4525-aff0-78513f63c080" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_488459c8-394f-4839-ba08-230efa553498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#BalanceSheetComponentsPropertyandEquipmentNetDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f90c0f49-6afb-4efd-9b31-7fe32bd0c5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a622e0ae-aa7a-429d-be8e-cc331e409de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f90c0f49-6afb-4efd-9b31-7fe32bd0c5a1" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a622e0ae-aa7a-429d-be8e-cc331e409de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ed3cc427-57d2-4c01-9bca-69aec2aa9876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a622e0ae-aa7a-429d-be8e-cc331e409de0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ed3cc427-57d2-4c01-9bca-69aec2aa9876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf0dd3d1-b6ee-43ce-b4d8-881cf1fc10e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ed3cc427-57d2-4c01-9bca-69aec2aa9876" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf0dd3d1-b6ee-43ce-b4d8-881cf1fc10e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_361b3e92-0e0a-41dc-9a86-5184398211da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf0dd3d1-b6ee-43ce-b4d8-881cf1fc10e0" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_361b3e92-0e0a-41dc-9a86-5184398211da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_8367c5c3-73a2-4cb2-ab15-f5e1703cc462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf0dd3d1-b6ee-43ce-b4d8-881cf1fc10e0" xlink:to="loc_us-gaap_ComputerEquipmentMember_8367c5c3-73a2-4cb2-ab15-f5e1703cc462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3884241a-932d-4528-b578-6ef68fec18bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf0dd3d1-b6ee-43ce-b4d8-881cf1fc10e0" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3884241a-932d-4528-b578-6ef68fec18bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_ed0d28f2-1f9f-4711-8660-6ff3418bd9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf0dd3d1-b6ee-43ce-b4d8-881cf1fc10e0" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_ed0d28f2-1f9f-4711-8660-6ff3418bd9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_2f6dd97e-0d78-4a3f-8c10-2ef13d55809f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf0dd3d1-b6ee-43ce-b4d8-881cf1fc10e0" xlink:to="loc_us-gaap_ConstructionInProgressMember_2f6dd97e-0d78-4a3f-8c10-2ef13d55809f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41456e57-108c-4c04-9a97-9d7340887047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a622e0ae-aa7a-429d-be8e-cc331e409de0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41456e57-108c-4c04-9a97-9d7340887047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_57687d67-96d0-4719-bed8-eda7966e10ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41456e57-108c-4c04-9a97-9d7340887047" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_57687d67-96d0-4719-bed8-eda7966e10ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_50fd2303-ed5d-4a0e-bfc9-1301d51bde7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41456e57-108c-4c04-9a97-9d7340887047" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_50fd2303-ed5d-4a0e-bfc9-1301d51bde7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bd191eeb-d0ed-429d-b5f1-fbfcf616e31c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_41456e57-108c-4c04-9a97-9d7340887047" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bd191eeb-d0ed-429d-b5f1-fbfcf616e31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsCapitalizedImplementationCostsofaHostingArrangementDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#BalanceSheetComponentsCapitalizedImplementationCostsofaHostingArrangementDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/BalanceSheetComponentsCapitalizedImplementationCostsofaHostingArrangementDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9f144896-353c-4eb5-a878-2899bc1e0904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7d188f38-a654-48d4-9311-d007baab1b33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9f144896-353c-4eb5-a878-2899bc1e0904" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7d188f38-a654-48d4-9311-d007baab1b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a7e62507-f299-4c84-8ae7-06e869d3aae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7d188f38-a654-48d4-9311-d007baab1b33" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a7e62507-f299-4c84-8ae7-06e869d3aae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4c7db577-dbcb-4bb2-ba5f-60f4f067b1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a7e62507-f299-4c84-8ae7-06e869d3aae9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4c7db577-dbcb-4bb2-ba5f-60f4f067b1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_062487bb-c021-4146-a3b8-2366b689a885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4c7db577-dbcb-4bb2-ba5f-60f4f067b1d3" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_062487bb-c021-4146-a3b8-2366b689a885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5e47b290-85f2-4231-975b-8aac5f667c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7d188f38-a654-48d4-9311-d007baab1b33" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5e47b290-85f2-4231-975b-8aac5f667c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c389274b-e0d5-4920-9f6d-7d0dbbbc2e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5e47b290-85f2-4231-975b-8aac5f667c79" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c389274b-e0d5-4920-9f6d-7d0dbbbc2e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_cdeb5ea9-7cba-461e-bcf4-1296a8faa45f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c389274b-e0d5-4920-9f6d-7d0dbbbc2e3b" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_cdeb5ea9-7cba-461e-bcf4-1296a8faa45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_26c8a900-5a1b-4265-b30e-4acffe0d51ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c389274b-e0d5-4920-9f6d-7d0dbbbc2e3b" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_26c8a900-5a1b-4265-b30e-4acffe0d51ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cb84d707-f430-4bc9-ae7e-4fbd3be18310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7d188f38-a654-48d4-9311-d007baab1b33" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cb84d707-f430-4bc9-ae7e-4fbd3be18310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization_d6acfb02-2c8c-4a1e-bf75-c90889d5fd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cb84d707-f430-4bc9-ae7e-4fbd3be18310" xlink:to="loc_us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization_d6acfb02-2c8c-4a1e-bf75-c90889d5fd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_HostingArrangementServiceContractImplementationCostCapitalizedAmortizationPeriod_0cd052ae-7744-4757-8f31-eaae0f45a05e" xlink:href="lung-20220630.xsd#lung_HostingArrangementServiceContractImplementationCostCapitalizedAmortizationPeriod"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cb84d707-f430-4bc9-ae7e-4fbd3be18310" xlink:to="loc_lung_HostingArrangementServiceContractImplementationCostCapitalizedAmortizationPeriod_0cd052ae-7744-4757-8f31-eaae0f45a05e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization_49600a09-62f6-4875-a809-8faf0d60d533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cb84d707-f430-4bc9-ae7e-4fbd3be18310" xlink:to="loc_us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization_49600a09-62f6-4875-a809-8faf0d60d533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsNarrativeDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#BalanceSheetComponentsNarrativeDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/BalanceSheetComponentsNarrativeDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_632bda9e-1098-4b29-9898-f28287b193f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_cb679a74-e3c7-47a9-b85e-ab2621007771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_632bda9e-1098-4b29-9898-f28287b193f1" xlink:to="loc_us-gaap_Depreciation_cb679a74-e3c7-47a9-b85e-ab2621007771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_547a6197-c499-4108-9195-ab719aa5b491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_632bda9e-1098-4b29-9898-f28287b193f1" xlink:to="loc_us-gaap_Goodwill_547a6197-c499-4108-9195-ab719aa5b491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_688af42d-4198-4e1b-9dcf-920b36856d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_632bda9e-1098-4b29-9898-f28287b193f1" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_688af42d-4198-4e1b-9dcf-920b36856d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_ae8a35e7-9f0b-4f2b-af01-2db0c20331b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_632bda9e-1098-4b29-9898-f28287b193f1" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_ae8a35e7-9f0b-4f2b-af01-2db0c20331b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_a9ef6bbb-d202-4ad1-8ab7-a9eae6c6c276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_632bda9e-1098-4b29-9898-f28287b193f1" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_a9ef6bbb-d202-4ad1-8ab7-a9eae6c6c276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_7919ea6e-9bcc-4140-91f2-1030e8abd7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_632bda9e-1098-4b29-9898-f28287b193f1" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_7919ea6e-9bcc-4140-91f2-1030e8abd7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_b0fde14d-d601-420c-99c5-7802197d7213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_632bda9e-1098-4b29-9898-f28287b193f1" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_b0fde14d-d601-420c-99c5-7802197d7213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsIntangibleAssetsDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#BalanceSheetComponentsIntangibleAssetsDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/BalanceSheetComponentsIntangibleAssetsDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ce0e05e8-3d5e-4c34-a695-a71469380811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_12dca7f4-57fd-4bdd-97da-79e19b551d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ce0e05e8-3d5e-4c34-a695-a71469380811" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_12dca7f4-57fd-4bdd-97da-79e19b551d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ab684e75-65cb-4a05-89fd-7c80b94e40f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_12dca7f4-57fd-4bdd-97da-79e19b551d4d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ab684e75-65cb-4a05-89fd-7c80b94e40f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c366de41-af5d-49b4-bfb0-07a59c3e3caf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ab684e75-65cb-4a05-89fd-7c80b94e40f3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c366de41-af5d-49b4-bfb0-07a59c3e3caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_47d77a21-16dc-4e25-b6b3-7e88ed0326fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c366de41-af5d-49b4-bfb0-07a59c3e3caf" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_47d77a21-16dc-4e25-b6b3-7e88ed0326fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_836b859a-65a6-470d-8096-3bb4fe48a886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c366de41-af5d-49b4-bfb0-07a59c3e3caf" xlink:to="loc_us-gaap_TrademarksMember_836b859a-65a6-470d-8096-3bb4fe48a886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_90e6c57b-afdf-46c2-bb6a-8d6276696543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_12dca7f4-57fd-4bdd-97da-79e19b551d4d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_90e6c57b-afdf-46c2-bb6a-8d6276696543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_77254758-f02d-4f03-a0fb-25d98ed6c3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_90e6c57b-afdf-46c2-bb6a-8d6276696543" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_77254758-f02d-4f03-a0fb-25d98ed6c3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6fa52268-af0b-4648-8a52-1721f3924012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_90e6c57b-afdf-46c2-bb6a-8d6276696543" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6fa52268-af0b-4648-8a52-1721f3924012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9f8f57e6-4dd7-442d-86e1-968e81ed93cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_90e6c57b-afdf-46c2-bb6a-8d6276696543" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9f8f57e6-4dd7-442d-86e1-968e81ed93cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#BalanceSheetComponentsFutureAmortizationExpenseDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/BalanceSheetComponentsFutureAmortizationExpenseDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_48a748eb-f81e-47f8-b996-c15266f5f8db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_863c98ff-c7b1-436c-a3d1-72fc8756474e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_48a748eb-f81e-47f8-b996-c15266f5f8db" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_863c98ff-c7b1-436c-a3d1-72fc8756474e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_aa6b85d9-4171-4e2d-ab8c-9a02b996715c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_863c98ff-c7b1-436c-a3d1-72fc8756474e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_aa6b85d9-4171-4e2d-ab8c-9a02b996715c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0a51e2db-733d-4eac-8864-ead47de1410c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_863c98ff-c7b1-436c-a3d1-72fc8756474e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0a51e2db-733d-4eac-8864-ead47de1410c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_cacb99bc-8503-494b-bf9b-82be38cc3a77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_863c98ff-c7b1-436c-a3d1-72fc8756474e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_cacb99bc-8503-494b-bf9b-82be38cc3a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ce6366c0-620d-4320-8c71-026fd91adbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_863c98ff-c7b1-436c-a3d1-72fc8756474e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ce6366c0-620d-4320-8c71-026fd91adbe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#BalanceSheetComponentsAccruedLiabilitiesDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bc24bbc5-550a-4ffd-a2e8-7c81472a5786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_a7a2c93a-5513-491f-9a47-29dc049959df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bc24bbc5-550a-4ffd-a2e8-7c81472a5786" xlink:to="loc_us-gaap_AccruedBonusesCurrent_a7a2c93a-5513-491f-9a47-29dc049959df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedVacationCurrent_cf890e56-05f9-4473-82d3-39a3872785d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedVacationCurrent"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bc24bbc5-550a-4ffd-a2e8-7c81472a5786" xlink:to="loc_us-gaap_AccruedVacationCurrent_cf890e56-05f9-4473-82d3-39a3872785d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_0cefbb93-1690-4864-8cd4-1b7c862906e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrent"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bc24bbc5-550a-4ffd-a2e8-7c81472a5786" xlink:to="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent_0cefbb93-1690-4864-8cd4-1b7c862906e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_3e522626-9c34-498c-a81f-c5e6c438fa70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bc24bbc5-550a-4ffd-a2e8-7c81472a5786" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_3e522626-9c34-498c-a81f-c5e6c438fa70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_94f910b1-2bbb-4d57-bfc7-f7daaf89331c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bc24bbc5-550a-4ffd-a2e8-7c81472a5786" xlink:to="loc_us-gaap_TaxesPayableCurrent_94f910b1-2bbb-4d57-bfc7-f7daaf89331c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_c7ec1807-a758-4a15-a7b5-b7e6da98210a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bc24bbc5-550a-4ffd-a2e8-7c81472a5786" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_c7ec1807-a758-4a15-a7b5-b7e6da98210a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_AccruedInventoryPurchasesCurrent_0e59078e-fa75-45e0-8b3d-440a0e003b90" xlink:href="lung-20220630.xsd#lung_AccruedInventoryPurchasesCurrent"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bc24bbc5-550a-4ffd-a2e8-7c81472a5786" xlink:to="loc_lung_AccruedInventoryPurchasesCurrent_0e59078e-fa75-45e0-8b3d-440a0e003b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_faa83b81-3769-4569-8a6e-871432388333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bc24bbc5-550a-4ffd-a2e8-7c81472a5786" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_faa83b81-3769-4569-8a6e-871432388333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d3bdba20-5232-4801-98bf-2b1fde7ad120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bc24bbc5-550a-4ffd-a2e8-7c81472a5786" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d3bdba20-5232-4801-98bf-2b1fde7ad120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/LongTermDebtandConvertibleNotes" xlink:type="simple" xlink:href="lung-20220630.xsd#LongTermDebtandConvertibleNotes"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/LongTermDebtandConvertibleNotes" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_93441bac-af7f-4086-9287-73a3e170e817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_bcf4817b-fe4a-4a53-9d6f-6a9fcab3abbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_93441bac-af7f-4086-9287-73a3e170e817" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_bcf4817b-fe4a-4a53-9d6f-6a9fcab3abbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesTables" xlink:type="simple" xlink:href="lung-20220630.xsd#LongTermDebtandConvertibleNotesTables"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesTables" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6fd99b85-7927-4f86-992a-80da0d105775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_86fee1a2-4762-47cd-b891-57682f5ca2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6fd99b85-7927-4f86-992a-80da0d105775" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_86fee1a2-4762-47cd-b891-57682f5ca2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_831bada7-9118-464a-a402-090846438432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6fd99b85-7927-4f86-992a-80da0d105775" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_831bada7-9118-464a-a402-090846438432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_00eb19f0-f95c-4a64-a119-0225e6213ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5d31c777-c307-437a-b1f0-9a824fba9148" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_00eb19f0-f95c-4a64-a119-0225e6213ed6" xlink:to="loc_us-gaap_DebtInstrumentTable_5d31c777-c307-437a-b1f0-9a824fba9148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ada642b7-9e53-4d96-8064-29d17e422cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5d31c777-c307-437a-b1f0-9a824fba9148" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ada642b7-9e53-4d96-8064-29d17e422cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fa8810e4-1ba0-479a-8f39-c694d654e395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ada642b7-9e53-4d96-8064-29d17e422cd6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fa8810e4-1ba0-479a-8f39-c694d654e395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_92da3d1c-6071-48ac-abcf-f5b7c4d96934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MediumTermNotesMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fa8810e4-1ba0-479a-8f39-c694d654e395" xlink:to="loc_us-gaap_MediumTermNotesMember_92da3d1c-6071-48ac-abcf-f5b7c4d96934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9f29fc80-8614-4566-b0c9-f8929e046176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5d31c777-c307-437a-b1f0-9a824fba9148" xlink:to="loc_us-gaap_DebtInstrumentAxis_9f29fc80-8614-4566-b0c9-f8929e046176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9d0990f3-bf16-44cd-9c6a-30a7adf5e733" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9f29fc80-8614-4566-b0c9-f8929e046176" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9d0990f3-bf16-44cd-9c6a-30a7adf5e733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_CIBCAgreementMember_36ad9ab0-99c8-428f-b5c5-883fa53e70aa" xlink:href="lung-20220630.xsd#lung_CIBCAgreementMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9d0990f3-bf16-44cd-9c6a-30a7adf5e733" xlink:to="loc_lung_CIBCAgreementMember_36ad9ab0-99c8-428f-b5c5-883fa53e70aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_CIBCAgreementTrancheAMember_cccc8b61-449e-4859-88b1-ecc763d26d17" xlink:href="lung-20220630.xsd#lung_CIBCAgreementTrancheAMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lung_CIBCAgreementMember_36ad9ab0-99c8-428f-b5c5-883fa53e70aa" xlink:to="loc_lung_CIBCAgreementTrancheAMember_cccc8b61-449e-4859-88b1-ecc763d26d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_CIBCAgreementTrancheBMember_8c13e7a5-e330-41c3-8a61-1b9cafd5b7b1" xlink:href="lung-20220630.xsd#lung_CIBCAgreementTrancheBMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lung_CIBCAgreementMember_36ad9ab0-99c8-428f-b5c5-883fa53e70aa" xlink:to="loc_lung_CIBCAgreementTrancheBMember_8c13e7a5-e330-41c3-8a61-1b9cafd5b7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_CIBCAgreementTrancheCMember_49db1b5f-ce60-451c-8abd-f3b455fe62c4" xlink:href="lung-20220630.xsd#lung_CIBCAgreementTrancheCMember"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lung_CIBCAgreementMember_36ad9ab0-99c8-428f-b5c5-883fa53e70aa" xlink:to="loc_lung_CIBCAgreementTrancheCMember_49db1b5f-ce60-451c-8abd-f3b455fe62c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_bb8463e3-a2ae-41eb-bda4-e8f354e826f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5d31c777-c307-437a-b1f0-9a824fba9148" xlink:to="loc_us-gaap_VariableRateAxis_bb8463e3-a2ae-41eb-bda4-e8f354e826f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_b24000b1-af16-4029-a3ce-824396471936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_bb8463e3-a2ae-41eb-bda4-e8f354e826f9" xlink:to="loc_us-gaap_VariableRateDomain_b24000b1-af16-4029-a3ce-824396471936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_54de4eb4-5d4c-441c-acd9-230d22c028a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_b24000b1-af16-4029-a3ce-824396471936" xlink:to="loc_us-gaap_PrimeRateMember_54de4eb4-5d4c-441c-acd9-230d22c028a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5d31c777-c307-437a-b1f0-9a824fba9148" xlink:to="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_DebtInstrumentFaceAmountIncludingAccordionFeature_d3af68f6-e3b1-4719-9683-bef84ec1badb" xlink:href="lung-20220630.xsd#lung_DebtInstrumentFaceAmountIncludingAccordionFeature"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_lung_DebtInstrumentFaceAmountIncludingAccordionFeature_d3af68f6-e3b1-4719-9683-bef84ec1badb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c9de548c-2afc-4d37-b394-a719ff866a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c9de548c-2afc-4d37-b394-a719ff866a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_DebtInstrumentAccordionFeatureIncreaseFaceAmount_2e203a6b-8e1a-41c9-ba8c-c9f8b4eb40c7" xlink:href="lung-20220630.xsd#lung_DebtInstrumentAccordionFeatureIncreaseFaceAmount"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_lung_DebtInstrumentAccordionFeatureIncreaseFaceAmount_2e203a6b-8e1a-41c9-ba8c-c9f8b4eb40c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_259a4af5-e160-4344-8d82-f90a05677930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_us-gaap_DebtInstrumentTerm_259a4af5-e160-4344-8d82-f90a05677930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_DebtInstrumentPeriodicPaymentInterestOnlyTerm_26e4eb58-9e5f-4551-ad93-d2c5651dda0e" xlink:href="lung-20220630.xsd#lung_DebtInstrumentPeriodicPaymentInterestOnlyTerm"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_lung_DebtInstrumentPeriodicPaymentInterestOnlyTerm_26e4eb58-9e5f-4551-ad93-d2c5651dda0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm_2444a29d-b84d-4155-be05-e496100fd1f7" xlink:href="lung-20220630.xsd#lung_DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_lung_DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm_2444a29d-b84d-4155-be05-e496100fd1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1d27b7cc-33c7-4da8-9729-f2cb61af87a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1d27b7cc-33c7-4da8-9729-f2cb61af87a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_0a1e3853-c19d-463b-9e50-cbe3a9f3d14f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_0a1e3853-c19d-463b-9e50-cbe3a9f3d14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_GainLossOnAmendmentOfDebtInstrument_c4ccc9e6-79e1-45f1-82c5-906e1cd2e512" xlink:href="lung-20220630.xsd#lung_GainLossOnAmendmentOfDebtInstrument"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_lung_GainLossOnAmendmentOfDebtInstrument_c4ccc9e6-79e1-45f1-82c5-906e1cd2e512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_DebtInstrumentNumberOfPeriodicPayments_31244248-11fe-40e9-b969-79c7b665e4db" xlink:href="lung-20220630.xsd#lung_DebtInstrumentNumberOfPeriodicPayments"/>
<link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_lung_DebtInstrumentNumberOfPeriodicPayments_31244248-11fe-40e9-b969-79c7b665e4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_ddc28568-7e0c-4e16-b617-5a0c60cffead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
<link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_ddc28568-7e0c-4e16-b617-5a0c60cffead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_IncreaseInLoanInterestRate_94567679-de3e-4caa-9ed3-ea9aba64597e" xlink:href="lung-20220630.xsd#lung_IncreaseInLoanInterestRate"/>
<link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_lung_IncreaseInLoanInterestRate_94567679-de3e-4caa-9ed3-ea9aba64597e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_87d6479b-e678-4095-b7b3-50368ab0a84d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
<link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_87d6479b-e678-4095-b7b3-50368ab0a84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_DebtInstrumentCovenantCashAndCashEquivalentsMinimumThresholdTriggerForRevenueRequirement_35654690-11e1-4069-be7c-63aead529c0b" xlink:href="lung-20220630.xsd#lung_DebtInstrumentCovenantCashAndCashEquivalentsMinimumThresholdTriggerForRevenueRequirement"/>
<link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_lung_DebtInstrumentCovenantCashAndCashEquivalentsMinimumThresholdTriggerForRevenueRequirement_35654690-11e1-4069-be7c-63aead529c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_DebtInstrumentCovenantMinimumRevenueRequirementPeriod_1046d5e7-77ea-489a-8240-f8ff2dcb7b6b" xlink:href="lung-20220630.xsd#lung_DebtInstrumentCovenantMinimumRevenueRequirementPeriod"/>
<link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_lung_DebtInstrumentCovenantMinimumRevenueRequirementPeriod_1046d5e7-77ea-489a-8240-f8ff2dcb7b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_DebtInstrumentCovenantMinimumRevenueRequirementsPercentage_863697c5-65fb-48aa-a7c8-780b7f3b8c23" xlink:href="lung-20220630.xsd#lung_DebtInstrumentCovenantMinimumRevenueRequirementsPercentage"/>
<link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_lung_DebtInstrumentCovenantMinimumRevenueRequirementsPercentage_863697c5-65fb-48aa-a7c8-780b7f3b8c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_DebtInstrumentCovenantUnrestrictedCashRequirementPeriod_9290ce6a-077d-4433-b611-083e69d8c8a7" xlink:href="lung-20220630.xsd#lung_DebtInstrumentCovenantUnrestrictedCashRequirementPeriod"/>
<link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_lung_DebtInstrumentCovenantUnrestrictedCashRequirementPeriod_9290ce6a-077d-4433-b611-083e69d8c8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_e8e36bc5-1ed2-47ce-80ed-4b2af6bf02e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
<link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_e8e36bc5-1ed2-47ce-80ed-4b2af6bf02e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_6a33c405-e389-4b57-b42e-cd7dc6e0b8c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
<link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_808d95f9-5506-42d6-8e08-fb1bfe7a628b" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_6a33c405-e389-4b57-b42e-cd7dc6e0b8c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanComponentsOfDebtDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#LongTermDebtandConvertibleNotesCIBCLoanComponentsOfDebtDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanComponentsOfDebtDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_90704d46-527d-4c4a-86f4-08e80dee708e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_10848bb9-8ac2-4619-ae94-6033abd9394b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_90704d46-527d-4c4a-86f4-08e80dee708e" xlink:to="loc_us-gaap_DebtInstrumentTable_10848bb9-8ac2-4619-ae94-6033abd9394b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_883ad5fc-c625-419c-ba55-488831049ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_10848bb9-8ac2-4619-ae94-6033abd9394b" xlink:to="loc_us-gaap_DebtInstrumentAxis_883ad5fc-c625-419c-ba55-488831049ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_81e9a2ad-0ae6-4f57-a49e-4e5b259f1f80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_883ad5fc-c625-419c-ba55-488831049ac4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_81e9a2ad-0ae6-4f57-a49e-4e5b259f1f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_CIBCAgreementMember_7b555d3f-b80d-47c2-b751-9297678922b1" xlink:href="lung-20220630.xsd#lung_CIBCAgreementMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_81e9a2ad-0ae6-4f57-a49e-4e5b259f1f80" xlink:to="loc_lung_CIBCAgreementMember_7b555d3f-b80d-47c2-b751-9297678922b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cf34b958-93d8-4add-8ea0-8108629494f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_10848bb9-8ac2-4619-ae94-6033abd9394b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cf34b958-93d8-4add-8ea0-8108629494f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8ff28341-8c15-4722-a409-b888a4f8d924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cf34b958-93d8-4add-8ea0-8108629494f1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8ff28341-8c15-4722-a409-b888a4f8d924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_MediumTermNotesMember_87db3043-5ae0-4326-a497-0fc9eab365e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MediumTermNotesMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8ff28341-8c15-4722-a409-b888a4f8d924" xlink:to="loc_us-gaap_MediumTermNotesMember_87db3043-5ae0-4326-a497-0fc9eab365e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_92aa4c67-cc9e-4e6f-baee-b4842d948ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_10848bb9-8ac2-4619-ae94-6033abd9394b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_92aa4c67-cc9e-4e6f-baee-b4842d948ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c338b44a-6bc0-4181-945b-0dc68abdc406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92aa4c67-cc9e-4e6f-baee-b4842d948ec1" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c338b44a-6bc0-4181-945b-0dc68abdc406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_d3280b9b-35fa-4d2c-92c8-743d762c7ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92aa4c67-cc9e-4e6f-baee-b4842d948ec1" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_d3280b9b-35fa-4d2c-92c8-743d762c7ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6d0e3c42-50f4-4368-a652-05cdb26759e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_92aa4c67-cc9e-4e6f-baee-b4842d948ec1" xlink:to="loc_us-gaap_LongTermDebt_6d0e3c42-50f4-4368-a652-05cdb26759e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCreditAgreementandPaycheckProtectionProgramNarrativeDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#LongTermDebtandConvertibleNotesCreditAgreementandPaycheckProtectionProgramNarrativeDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCreditAgreementandPaycheckProtectionProgramNarrativeDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_953cedd6-93b7-4cb9-91c4-0d881bd00993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_fd8edd57-f2fd-4dc6-840d-8e2016da2ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_953cedd6-93b7-4cb9-91c4-0d881bd00993" xlink:to="loc_us-gaap_DebtInstrumentTable_fd8edd57-f2fd-4dc6-840d-8e2016da2ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_63ba1b6b-1f99-4430-8cd4-739370dda444" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fd8edd57-f2fd-4dc6-840d-8e2016da2ca9" xlink:to="loc_dei_LegalEntityAxis_63ba1b6b-1f99-4430-8cd4-739370dda444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f36efa29-fca9-4710-8bcb-a6d3d54f9533" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_63ba1b6b-1f99-4430-8cd4-739370dda444" xlink:to="loc_dei_EntityDomain_f36efa29-fca9-4710-8bcb-a6d3d54f9533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_PulmonxInternationalSarlMember_d076a940-8090-406f-8757-afb76858c925" xlink:href="lung-20220630.xsd#lung_PulmonxInternationalSarlMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_f36efa29-fca9-4710-8bcb-a6d3d54f9533" xlink:to="loc_lung_PulmonxInternationalSarlMember_d076a940-8090-406f-8757-afb76858c925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5dc3c77a-b901-4804-99bc-0fdef0773269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fd8edd57-f2fd-4dc6-840d-8e2016da2ca9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5dc3c77a-b901-4804-99bc-0fdef0773269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_034718a2-b6d7-42ec-a99d-7e1fb15b7ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5dc3c77a-b901-4804-99bc-0fdef0773269" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_034718a2-b6d7-42ec-a99d-7e1fb15b7ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_33457485-a650-4455-b2bd-d855440a4ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_034718a2-b6d7-42ec-a99d-7e1fb15b7ae9" xlink:to="loc_us-gaap_LineOfCreditMember_33457485-a650-4455-b2bd-d855440a4ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fd5af59e-0c3f-4e38-ac40-150d4fbe96cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fd8edd57-f2fd-4dc6-840d-8e2016da2ca9" xlink:to="loc_us-gaap_DebtInstrumentAxis_fd5af59e-0c3f-4e38-ac40-150d4fbe96cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d37c5e20-9797-4a4a-ab96-f4a97b2f45c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_fd5af59e-0c3f-4e38-ac40-150d4fbe96cb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d37c5e20-9797-4a4a-ab96-f4a97b2f45c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_COVID19CreditAgreementMember_48ef7940-c2d2-4af7-91b6-5ee66a936dcb" xlink:href="lung-20220630.xsd#lung_COVID19CreditAgreementMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d37c5e20-9797-4a4a-ab96-f4a97b2f45c6" xlink:to="loc_lung_COVID19CreditAgreementMember_48ef7940-c2d2-4af7-91b6-5ee66a936dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_72352f0c-1ae6-462f-a72d-295e024fc0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fd8edd57-f2fd-4dc6-840d-8e2016da2ca9" xlink:to="loc_us-gaap_DebtInstrumentLineItems_72352f0c-1ae6-462f-a72d-295e024fc0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c27d3ff0-57a6-48ad-8448-5f518fce64f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72352f0c-1ae6-462f-a72d-295e024fc0ff" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c27d3ff0-57a6-48ad-8448-5f518fce64f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_4aa6ed0c-8ce3-4e6c-86f4-2b7e5624bc00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72352f0c-1ae6-462f-a72d-295e024fc0ff" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_4aa6ed0c-8ce3-4e6c-86f4-2b7e5624bc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_NumberOfInstallmentsForRepayment_c83f3ef4-80bb-47fd-a972-66037e9ed371" xlink:href="lung-20220630.xsd#lung_NumberOfInstallmentsForRepayment"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72352f0c-1ae6-462f-a72d-295e024fc0ff" xlink:to="loc_lung_NumberOfInstallmentsForRepayment_c83f3ef4-80bb-47fd-a972-66037e9ed371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_283cec3b-a819-4886-91bf-dd95711e7dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72352f0c-1ae6-462f-a72d-295e024fc0ff" xlink:to="loc_us-gaap_RepaymentsOfDebt_283cec3b-a819-4886-91bf-dd95711e7dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesContractualMaturitiesofFinancingObligationsDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#LongTermDebtandConvertibleNotesContractualMaturitiesofFinancingObligationsDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesContractualMaturitiesofFinancingObligationsDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_17790eea-7803-422e-8202-bd41aaff2fee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_1cf61da3-33ff-4b11-9707-19d5e709837e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_17790eea-7803-422e-8202-bd41aaff2fee" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_1cf61da3-33ff-4b11-9707-19d5e709837e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_8b2cfd5e-8981-4f1b-9025-5645d6e6b751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_1cf61da3-33ff-4b11-9707-19d5e709837e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_8b2cfd5e-8981-4f1b-9025-5645d6e6b751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e1c07383-15fd-4133-a69a-de23fd8204f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_1cf61da3-33ff-4b11-9707-19d5e709837e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e1c07383-15fd-4133-a69a-de23fd8204f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_984d038a-d3b2-4c74-86e3-445c3e80fcc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_1cf61da3-33ff-4b11-9707-19d5e709837e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_984d038a-d3b2-4c74-86e3-445c3e80fcc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f591d17c-5b0a-4f91-869d-58a6c567d47e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_1cf61da3-33ff-4b11-9707-19d5e709837e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f591d17c-5b0a-4f91-869d-58a6c567d47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_da24f304-de94-44d9-b72b-1d5c16d673f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_1cf61da3-33ff-4b11-9707-19d5e709837e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_da24f304-de94-44d9-b72b-1d5c16d673f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_88887476-e70a-4163-96d1-0ceb84577aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_1cf61da3-33ff-4b11-9707-19d5e709837e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_88887476-e70a-4163-96d1-0ceb84577aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_1331d3d0-b9b3-4382-b50f-5b6d1ebf0a07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_1cf61da3-33ff-4b11-9707-19d5e709837e" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_1331d3d0-b9b3-4382-b50f-5b6d1ebf0a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4db43af6-75a6-4b39-8f4d-c6a4d8503e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_17790eea-7803-422e-8202-bd41aaff2fee" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4db43af6-75a6-4b39-8f4d-c6a4d8503e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_db886807-4e3d-49a0-ba8f-23b124f4ac3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_17790eea-7803-422e-8202-bd41aaff2fee" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_db886807-4e3d-49a0-ba8f-23b124f4ac3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2b0d0c88-a83f-4a1a-9127-8ea98a70194e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_17790eea-7803-422e-8202-bd41aaff2fee" xlink:to="loc_us-gaap_LongTermDebt_2b0d0c88-a83f-4a1a-9127-8ea98a70194e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/RevenueRecognition" xlink:type="simple" xlink:href="lung-20220630.xsd#RevenueRecognition"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/RevenueRecognition" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c013b337-a524-48e1-8185-70ca47697a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_ae53c8f8-dec2-43c9-bf4f-08339c6913a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c013b337-a524-48e1-8185-70ca47697a17" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_ae53c8f8-dec2-43c9-bf4f-08339c6913a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/RevenueRecognitionDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#RevenueRecognitionDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/RevenueRecognitionDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_33e38a31-c993-40cc-a31f-8b0effef19ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_421ff89d-a7a1-4a4e-a91d-4885f59f5310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_33e38a31-c993-40cc-a31f-8b0effef19ec" xlink:to="loc_us-gaap_ContractWithCustomerLiability_421ff89d-a7a1-4a4e-a91d-4885f59f5310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fce389f6-64c8-4466-8302-81aa3e46d14a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_33e38a31-c993-40cc-a31f-8b0effef19ec" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_fce389f6-64c8-4466-8302-81aa3e46d14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="lung-20220630.xsd#CommitmentsandContingencies"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/CommitmentsandContingencies" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_af90114d-4878-4c7a-882a-9afaff8c7715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c645e183-52e5-4b54-b0d9-9ff523f9ac2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_af90114d-4878-4c7a-882a-9afaff8c7715" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c645e183-52e5-4b54-b0d9-9ff523f9ac2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="lung-20220630.xsd#CommitmentsandContingenciesTables"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b366140a-8a10-4679-9c7a-5e56dd7a7dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_34e59df7-ccb9-4bfe-bf9e-8fd6638dc45a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b366140a-8a10-4679-9c7a-5e56dd7a7dc2" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_34e59df7-ccb9-4bfe-bf9e-8fd6638dc45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5c1a616a-ca4f-4213-9d64-1b3aba598b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b366140a-8a10-4679-9c7a-5e56dd7a7dc2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5c1a616a-ca4f-4213-9d64-1b3aba598b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/CommitmentsandContingenciesLeasesNarrativeDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#CommitmentsandContingenciesLeasesNarrativeDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/CommitmentsandContingenciesLeasesNarrativeDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9b2869f5-793b-4141-8613-165d71cd3f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_4ceaa65a-6e92-4a68-9b6e-317f61ba2d41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9b2869f5-793b-4141-8613-165d71cd3f8e" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_4ceaa65a-6e92-4a68-9b6e-317f61ba2d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a8b4fff5-0f21-474c-b37f-9a1b76c15494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_4ceaa65a-6e92-4a68-9b6e-317f61ba2d41" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a8b4fff5-0f21-474c-b37f-9a1b76c15494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ad48c48-ea81-4d6a-9cd9-20f22eb4c4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a8b4fff5-0f21-474c-b37f-9a1b76c15494" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ad48c48-ea81-4d6a-9cd9-20f22eb4c4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_b4ec9cf1-a2f2-461d-9648-85beedcbb1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ad48c48-ea81-4d6a-9cd9-20f22eb4c4b2" xlink:to="loc_us-gaap_BuildingMember_b4ec9cf1-a2f2-461d-9648-85beedcbb1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_b2562f58-fd69-40ba-b698-7a8faf0e2b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ad48c48-ea81-4d6a-9cd9-20f22eb4c4b2" xlink:to="loc_us-gaap_VehiclesMember_b2562f58-fd69-40ba-b698-7a8faf0e2b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_4ceaa65a-6e92-4a68-9b6e-317f61ba2d41" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a3be72a6-fec6-4c9d-b6c7-c65607a31bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a3be72a6-fec6-4c9d-b6c7-c65607a31bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_OperatingLeaseMonthlyExpense_d69100c5-28e9-47e2-97ee-deb49fdaa01e" xlink:href="lung-20220630.xsd#lung_OperatingLeaseMonthlyExpense"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_lung_OperatingLeaseMonthlyExpense_d69100c5-28e9-47e2-97ee-deb49fdaa01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_OperatingLeaseExpenseAnnualIncreaseRate_47b27dce-5afd-45e9-93c5-9495369c0af8" xlink:href="lung-20220630.xsd#lung_OperatingLeaseExpenseAnnualIncreaseRate"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_lung_OperatingLeaseExpenseAnnualIncreaseRate_47b27dce-5afd-45e9-93c5-9495369c0af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_TenantImprovementAllowanceReceivableUponLeaseRenewal_a445cc90-ecdb-4ed8-99df-9f63f58f8949" xlink:href="lung-20220630.xsd#lung_TenantImprovementAllowanceReceivableUponLeaseRenewal"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_lung_TenantImprovementAllowanceReceivableUponLeaseRenewal_a445cc90-ecdb-4ed8-99df-9f63f58f8949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_55da35ff-ee3c-444a-9917-783af3302638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_55da35ff-ee3c-444a-9917-783af3302638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_LesseeOperatingLeaseOptionToTerminateNoticePeriod_e141b1aa-00da-4456-ba81-7651baa1397f" xlink:href="lung-20220630.xsd#lung_LesseeOperatingLeaseOptionToTerminateNoticePeriod"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_lung_LesseeOperatingLeaseOptionToTerminateNoticePeriod_e141b1aa-00da-4456-ba81-7651baa1397f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_LesseeOperatingSubleaseTerm_4f344a12-1192-435e-90d7-c6e1c2bd6869" xlink:href="lung-20220630.xsd#lung_LesseeOperatingSubleaseTerm"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_lung_LesseeOperatingSubleaseTerm_4f344a12-1192-435e-90d7-c6e1c2bd6869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_LesseeOperatingSubleaseOptionToTerminateNoticePeriod_0ae4bb82-17ff-4116-ae56-4e36e1f7b1d7" xlink:href="lung-20220630.xsd#lung_LesseeOperatingSubleaseOptionToTerminateNoticePeriod"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_lung_LesseeOperatingSubleaseOptionToTerminateNoticePeriod_0ae4bb82-17ff-4116-ae56-4e36e1f7b1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_LesseeOperatingSubleaseOptionToTerminateTerm_d2cb4353-8fac-4775-b2dc-05ea07ea0d57" xlink:href="lung-20220630.xsd#lung_LesseeOperatingSubleaseOptionToTerminateTerm"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_lung_LesseeOperatingSubleaseOptionToTerminateTerm_d2cb4353-8fac-4775-b2dc-05ea07ea0d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_LesseeOperatingSubleaseMonthlyExpense_979bda44-0be2-4e53-9b54-94fba8513918" xlink:href="lung-20220630.xsd#lung_LesseeOperatingSubleaseMonthlyExpense"/>
<link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_lung_LesseeOperatingSubleaseMonthlyExpense_979bda44-0be2-4e53-9b54-94fba8513918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_LesseeOperatingSubleaseExpenseAnnualIncreaseRate_340d7c47-2ccd-4bc9-9c0d-68f1f47338ae" xlink:href="lung-20220630.xsd#lung_LesseeOperatingSubleaseExpenseAnnualIncreaseRate"/>
<link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_lung_LesseeOperatingSubleaseExpenseAnnualIncreaseRate_340d7c47-2ccd-4bc9-9c0d-68f1f47338ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_LesseeOperatingSubleaseTenantImprovementAllowanceReceivableUponLeaseRenewal_9b4f3da8-ca2f-4866-88ca-813195e0ecf4" xlink:href="lung-20220630.xsd#lung_LesseeOperatingSubleaseTenantImprovementAllowanceReceivableUponLeaseRenewal"/>
<link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_lung_LesseeOperatingSubleaseTenantImprovementAllowanceReceivableUponLeaseRenewal_9b4f3da8-ca2f-4866-88ca-813195e0ecf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_LesseeOperatingSubleaseRenewalTerm_9de73cb0-181b-4bea-8b69-4c9677f37b33" xlink:href="lung-20220630.xsd#lung_LesseeOperatingSubleaseRenewalTerm"/>
<link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_lung_LesseeOperatingSubleaseRenewalTerm_9de73cb0-181b-4bea-8b69-4c9677f37b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_NumberOfVehicleLeases_af071158-933e-4bd1-ac87-075fefac0892" xlink:href="lung-20220630.xsd#lung_NumberOfVehicleLeases"/>
<link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_26792e48-f361-4184-b012-9bf75c9a102d" xlink:to="loc_lung_NumberOfVehicleLeases_af071158-933e-4bd1-ac87-075fefac0892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/CommitmentsandContingenciesLeaseCostDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#CommitmentsandContingenciesLeaseCostDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/CommitmentsandContingenciesLeaseCostDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48487c88-87b9-4167-9c79-32e969c8ea03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_6431612c-a51c-408a-b857-26097323e928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48487c88-87b9-4167-9c79-32e969c8ea03" xlink:to="loc_us-gaap_OperatingLeaseCost_6431612c-a51c-408a-b857-26097323e928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_c44d4702-7cfd-4d1c-af98-199bd198187a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48487c88-87b9-4167-9c79-32e969c8ea03" xlink:to="loc_us-gaap_ShortTermLeaseCost_c44d4702-7cfd-4d1c-af98-199bd198187a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_ae8148e6-42ce-4473-9f35-777eb89f101d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48487c88-87b9-4167-9c79-32e969c8ea03" xlink:to="loc_us-gaap_VariableLeaseCost_ae8148e6-42ce-4473-9f35-777eb89f101d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_977705c5-c01e-46bc-b740-9e180665b248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48487c88-87b9-4167-9c79-32e969c8ea03" xlink:to="loc_us-gaap_LeaseCost_977705c5-c01e-46bc-b740-9e180665b248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6767286f-0392-4a5c-9468-747b682c42ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_46225264-554d-4981-a456-1a2dd9b91d61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6767286f-0392-4a5c-9468-747b682c42ba" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_46225264-554d-4981-a456-1a2dd9b91d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2a4b0cac-5734-47fe-8d19-86956db849bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_46225264-554d-4981-a456-1a2dd9b91d61" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2a4b0cac-5734-47fe-8d19-86956db849bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2bbe42bf-e519-4195-bf73-9b592dd13821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_46225264-554d-4981-a456-1a2dd9b91d61" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2bbe42bf-e519-4195-bf73-9b592dd13821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_643d831a-222a-4a68-8709-1811b58b361c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_46225264-554d-4981-a456-1a2dd9b91d61" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_643d831a-222a-4a68-8709-1811b58b361c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d645d4da-a9a8-4efc-9558-15993acb5722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_46225264-554d-4981-a456-1a2dd9b91d61" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d645d4da-a9a8-4efc-9558-15993acb5722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3cac3b7c-8018-426f-bcaf-90abd957b6be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_46225264-554d-4981-a456-1a2dd9b91d61" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3cac3b7c-8018-426f-bcaf-90abd957b6be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9d07e105-00d5-4d3d-af14-e92379c068cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_46225264-554d-4981-a456-1a2dd9b91d61" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9d07e105-00d5-4d3d-af14-e92379c068cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_32ab5ab5-9b03-47b4-a019-b1d296c76b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_46225264-554d-4981-a456-1a2dd9b91d61" xlink:to="loc_us-gaap_OperatingLeaseLiability_32ab5ab5-9b03-47b4-a019-b1d296c76b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3d29a7b1-d169-43ba-9d31-4792fa2007b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_46225264-554d-4981-a456-1a2dd9b91d61" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3d29a7b1-d169-43ba-9d31-4792fa2007b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_297bf93c-82a1-4256-9b5b-2ecfad62d143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_46225264-554d-4981-a456-1a2dd9b91d61" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_297bf93c-82a1-4256-9b5b-2ecfad62d143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="lung-20220630.xsd#CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails_1"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
<link:roleRef roleURI="http://www.pulmonx.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c4eb8d1b-24d7-4061-88e9-9ddba26f6799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4c88081a-7284-4ba3-af52-9d61ce355f56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c4eb8d1b-24d7-4061-88e9-9ddba26f6799" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4c88081a-7284-4ba3-af52-9d61ce355f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6fd91037-098d-4a90-8f66-ea72f2b43972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c4eb8d1b-24d7-4061-88e9-9ddba26f6799" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6fd91037-098d-4a90-8f66-ea72f2b43972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1b8fb479-6ad7-4e24-a3c8-e3ec8dfa9bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c4eb8d1b-24d7-4061-88e9-9ddba26f6799" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1b8fb479-6ad7-4e24-a3c8-e3ec8dfa9bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/CommitmentsandContingenciesOtherSupplementalInformationDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#CommitmentsandContingenciesOtherSupplementalInformationDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/CommitmentsandContingenciesOtherSupplementalInformationDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bef50856-1366-45c6-9697-9498b39fef97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_f07bcf5a-b523-4958-96ba-ec7804759323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bef50856-1366-45c6-9697-9498b39fef97" xlink:to="loc_us-gaap_OperatingLeasePayments_f07bcf5a-b523-4958-96ba-ec7804759323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_69ffbe40-ff58-4fc7-ad67-e1383489b565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bef50856-1366-45c6-9697-9498b39fef97" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_69ffbe40-ff58-4fc7-ad67-e1383489b565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/CommitmentsandContingenciesServiceAgreementDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#CommitmentsandContingenciesServiceAgreementDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/CommitmentsandContingenciesServiceAgreementDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_058e71a4-891f-44a8-8d81-57460fc7a6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_6a1f8238-30a8-407e-96a2-0d53449c3611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_058e71a4-891f-44a8-8d81-57460fc7a6d1" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_6a1f8238-30a8-407e-96a2-0d53449c3611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_f6ae3428-1e0c-43eb-9834-7267c904bd12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_6a1f8238-30a8-407e-96a2-0d53449c3611" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_f6ae3428-1e0c-43eb-9834-7267c904bd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_366fd4b7-c54e-48d8-8e53-2506ab750bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_f6ae3428-1e0c-43eb-9834-7267c904bd12" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_366fd4b7-c54e-48d8-8e53-2506ab750bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_ServiceAgreementPurchaseMember_cf04c8db-1247-4c66-bc12-23edb6a2af48" xlink:href="lung-20220630.xsd#lung_ServiceAgreementPurchaseMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_366fd4b7-c54e-48d8-8e53-2506ab750bfc" xlink:to="loc_lung_ServiceAgreementPurchaseMember_cf04c8db-1247-4c66-bc12-23edb6a2af48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_44327cae-8f11-43a9-a2ef-16710eb29519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_6a1f8238-30a8-407e-96a2-0d53449c3611" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_44327cae-8f11-43a9-a2ef-16710eb29519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_4cd2247a-286b-454b-88f5-582ebf4233b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_44327cae-8f11-43a9-a2ef-16710eb29519" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_4cd2247a-286b-454b-88f5-582ebf4233b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_d2ebacec-ec6b-48e4-bd23-96552eeedb00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_44327cae-8f11-43a9-a2ef-16710eb29519" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_d2ebacec-ec6b-48e4-bd23-96552eeedb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_cae0b564-bd8f-46a1-8863-205b137c55de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_44327cae-8f11-43a9-a2ef-16710eb29519" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_cae0b564-bd8f-46a1-8863-205b137c55de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_79818eaf-6001-43ec-8136-95ddedd7b884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_44327cae-8f11-43a9-a2ef-16710eb29519" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_79818eaf-6001-43ec-8136-95ddedd7b884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lung-20220630.xsd#IncomeTaxes"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/IncomeTaxes" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2bab8f34-a35f-4dbf-9ec5-b07b12b40949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_b6675b6e-7067-4c72-9910-e2fb785fdf26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2bab8f34-a35f-4dbf-9ec5-b07b12b40949" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_b6675b6e-7067-4c72-9910-e2fb785fdf26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#IncomeTaxesDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/IncomeTaxesDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0910d243-9f91-4538-ae60-a591e32cec3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_IncomeTaxDisclosureTable_f2a208c4-5fdf-47e4-9f72-adcda2755c33" xlink:href="lung-20220630.xsd#lung_IncomeTaxDisclosureTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0910d243-9f91-4538-ae60-a591e32cec3d" xlink:to="loc_lung_IncomeTaxDisclosureTable_f2a208c4-5fdf-47e4-9f72-adcda2755c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_84a96e40-de8f-4c3d-a73a-900d0c694e85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lung_IncomeTaxDisclosureTable_f2a208c4-5fdf-47e4-9f72-adcda2755c33" xlink:to="loc_srt_RangeAxis_84a96e40-de8f-4c3d-a73a-900d0c694e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_450cf840-80d4-4010-97a5-39cde05e04e1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_84a96e40-de8f-4c3d-a73a-900d0c694e85" xlink:to="loc_srt_RangeMember_450cf840-80d4-4010-97a5-39cde05e04e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ee47bbe3-f941-48be-bc8c-353c2a0a924f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_450cf840-80d4-4010-97a5-39cde05e04e1" xlink:to="loc_srt_MaximumMember_ee47bbe3-f941-48be-bc8c-353c2a0a924f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_IncomeTaxDisclosureLineItems_1ac8a11a-4ab1-4fd5-a8d2-bba3790eeb09" xlink:href="lung-20220630.xsd#lung_IncomeTaxDisclosureLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lung_IncomeTaxDisclosureTable_f2a208c4-5fdf-47e4-9f72-adcda2755c33" xlink:to="loc_lung_IncomeTaxDisclosureLineItems_1ac8a11a-4ab1-4fd5-a8d2-bba3790eeb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2d7c37b6-6d47-4a11-aec1-5eda442748c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lung_IncomeTaxDisclosureLineItems_1ac8a11a-4ab1-4fd5-a8d2-bba3790eeb09" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2d7c37b6-6d47-4a11-aec1-5eda442748c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/StockholdersEquity" xlink:type="simple" xlink:href="lung-20220630.xsd#StockholdersEquity"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/StockholdersEquity" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_489c7237-89ab-40cc-988a-348a1b465c31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4dd3ee24-2128-455e-8ca5-14a2ea672567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_489c7237-89ab-40cc-988a-348a1b465c31" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4dd3ee24-2128-455e-8ca5-14a2ea672567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="lung-20220630.xsd#StockholdersEquityTables"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/StockholdersEquityTables" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2f2339dc-8e03-423c-9990-9476e37973b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_a7cadf65-1ef0-4492-b673-46ff5bd39e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2f2339dc-8e03-423c-9990-9476e37973b8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_a7cadf65-1ef0-4492-b673-46ff5bd39e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7964f998-c6f8-419d-a83a-c42cd2ac50ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2f2339dc-8e03-423c-9990-9476e37973b8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7964f998-c6f8-419d-a83a-c42cd2ac50ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_390b30f8-0258-4f68-bd69-3f0fbff86e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2f2339dc-8e03-423c-9990-9476e37973b8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_390b30f8-0258-4f68-bd69-3f0fbff86e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_4ff0d20a-01b7-455b-8e25-e7e50b9cf15b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2f2339dc-8e03-423c-9990-9476e37973b8" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_4ff0d20a-01b7-455b-8e25-e7e50b9cf15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_11a6072a-4504-45e8-970c-3ca7235b386f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2f2339dc-8e03-423c-9990-9476e37973b8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_11a6072a-4504-45e8-970c-3ca7235b386f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#StockholdersEquityNarrativeDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_81c9a992-214b-4e03-8cb5-2f775317449b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f40914d-f2b6-402b-adc2-dea182674d57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_81c9a992-214b-4e03-8cb5-2f775317449b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f40914d-f2b6-402b-adc2-dea182674d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_94239d64-5e2f-411d-8be5-94edbac69616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f40914d-f2b6-402b-adc2-dea182674d57" xlink:to="loc_us-gaap_AwardTypeAxis_94239d64-5e2f-411d-8be5-94edbac69616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5cef0de-0aba-4a7d-a6ab-735214a746de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_94239d64-5e2f-411d-8be5-94edbac69616" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5cef0de-0aba-4a7d-a6ab-735214a746de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2a828a9d-081f-4457-8e41-1e38808545da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5cef0de-0aba-4a7d-a6ab-735214a746de" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2a828a9d-081f-4457-8e41-1e38808545da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4dd3e48e-8e86-473c-b73e-872bbefabe47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5cef0de-0aba-4a7d-a6ab-735214a746de" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4dd3e48e-8e86-473c-b73e-872bbefabe47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_StockOptionsAndRestrictedStockUnitsMember_12a22139-3d47-4f3b-984a-4d929d9b6d76" xlink:href="lung-20220630.xsd#lung_StockOptionsAndRestrictedStockUnitsMember"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5cef0de-0aba-4a7d-a6ab-735214a746de" xlink:to="loc_lung_StockOptionsAndRestrictedStockUnitsMember_12a22139-3d47-4f3b-984a-4d929d9b6d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_e732a245-6d4c-4416-abba-5596f0de097a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5cef0de-0aba-4a7d-a6ab-735214a746de" xlink:to="loc_us-gaap_EmployeeStockMember_e732a245-6d4c-4416-abba-5596f0de097a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1e6e1fb2-cd0d-4e14-bcca-f33a5fc1d10c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f40914d-f2b6-402b-adc2-dea182674d57" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1e6e1fb2-cd0d-4e14-bcca-f33a5fc1d10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ca9a4255-3134-403e-9d6c-a6f845c9d1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1e6e1fb2-cd0d-4e14-bcca-f33a5fc1d10c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ca9a4255-3134-403e-9d6c-a6f845c9d1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_InventoryNetMember_68b45519-1237-4774-939f-bb2ba22e410c" xlink:href="lung-20220630.xsd#lung_InventoryNetMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ca9a4255-3134-403e-9d6c-a6f845c9d1cc" xlink:to="loc_lung_InventoryNetMember_68b45519-1237-4774-939f-bb2ba22e410c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d63eea0f-e567-4b99-bd10-fd7c1cf16e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f40914d-f2b6-402b-adc2-dea182674d57" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d63eea0f-e567-4b99-bd10-fd7c1cf16e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_80b3dc65-ff52-4965-b488-0e4bfe142950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d63eea0f-e567-4b99-bd10-fd7c1cf16e7b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_80b3dc65-ff52-4965-b488-0e4bfe142950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_CostOfGoodsAndServicesSoldMember_ae6e4e10-3a80-4d01-a766-519499900546" xlink:href="lung-20220630.xsd#lung_CostOfGoodsAndServicesSoldMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_80b3dc65-ff52-4965-b488-0e4bfe142950" xlink:to="loc_lung_CostOfGoodsAndServicesSoldMember_ae6e4e10-3a80-4d01-a766-519499900546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f40914d-f2b6-402b-adc2-dea182674d57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b09662b7-c926-4f6a-bd7e-b731bf013119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b09662b7-c926-4f6a-bd7e-b731bf013119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock_e0583264-3486-4455-a030-f9e8876711d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_us-gaap_DividendsCommonStock_e0583264-3486-4455-a030-f9e8876711d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_NumberOfVotesForEachShareOfCommonStockHeld_f9a5d536-a6bb-4004-8d7b-4902f0c42fad" xlink:href="lung-20220630.xsd#lung_NumberOfVotesForEachShareOfCommonStockHeld"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_lung_NumberOfVotesForEachShareOfCommonStockHeld_f9a5d536-a6bb-4004-8d7b-4902f0c42fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f0f88c0b-a3be-4568-b459-133b521f017d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f0f88c0b-a3be-4568-b459-133b521f017d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a1dab4c5-50f2-4290-8fd8-edaf7c207de9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a1dab4c5-50f2-4290-8fd8-edaf7c207de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_dbb4cf3b-3372-4f0e-b97c-b191ebd51cac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_dbb4cf3b-3372-4f0e-b97c-b191ebd51cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e3940338-d55c-4f8a-b8c0-7305b355322f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e3940338-d55c-4f8a-b8c0-7305b355322f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_098d05cf-f917-439e-b8ce-59e5c360bfc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
<link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_098d05cf-f917-439e-b8ce-59e5c360bfc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_f58c0a78-44b5-4f85-8296-fc00d3097df3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
<link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_f58c0a78-44b5-4f85-8296-fc00d3097df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchase_58c98e46-b79d-474e-b4af-75f793018688" xlink:href="lung-20220630.xsd#lung_ShareBasedPaymentArrangementSharesSubjectToRepurchase"/>
<link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchase_58c98e46-b79d-474e-b4af-75f793018688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice_a7c485e6-b1de-4e5e-aaff-ff25d2587fe7" xlink:href="lung-20220630.xsd#lung_ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice"/>
<link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice_a7c485e6-b1de-4e5e-aaff-ff25d2587fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_22a72d14-28af-4380-8a9d-7898f95b7294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
<link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_22a72d14-28af-4380-8a9d-7898f95b7294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_28199362-9e3c-4730-8cea-afb3651c83e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
<link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_28199362-9e3c-4730-8cea-afb3651c83e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5ad105dc-1eb1-4d5f-b2b0-561dcfd8aa1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
<link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5ad105dc-1eb1-4d5f-b2b0-561dcfd8aa1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_e77d9089-7236-47f9-b00a-78d5777c4d80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
<link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_e77d9089-7236-47f9-b00a-78d5777c4d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c2f1c01f-8081-4779-a7f7-d204fc128a87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
<link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7ccd1f55-f56a-4643-8299-87c201dcf235" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c2f1c01f-8081-4779-a7f7-d204fc128a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#StockholdersEquitySharesReservedforFutureIssuanceDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c5b9fba9-a9f7-440f-b7a9-92f3d8148eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e9f93289-7e5d-4bb1-88a6-b6564579e9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c5b9fba9-a9f7-440f-b7a9-92f3d8148eee" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e9f93289-7e5d-4bb1-88a6-b6564579e9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3641859d-98c3-45bd-b855-a56e48f0f402" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e9f93289-7e5d-4bb1-88a6-b6564579e9b2" xlink:to="loc_us-gaap_AwardTypeAxis_3641859d-98c3-45bd-b855-a56e48f0f402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_307dfd75-9b05-47e8-a357-2ee25057fd7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3641859d-98c3-45bd-b855-a56e48f0f402" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_307dfd75-9b05-47e8-a357-2ee25057fd7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_ShareBasedCompensationEmployeeStockOutstandingMember_fff5e7c9-e2cd-4a2d-adf5-fab4e24d868f" xlink:href="lung-20220630.xsd#lung_ShareBasedCompensationEmployeeStockOutstandingMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_307dfd75-9b05-47e8-a357-2ee25057fd7f" xlink:to="loc_lung_ShareBasedCompensationEmployeeStockOutstandingMember_fff5e7c9-e2cd-4a2d-adf5-fab4e24d868f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_CommonStockRestrictedStockUnitsIssuedAndOutstandingMember_716e9e2d-754e-4826-90b5-9ba31975cce0" xlink:href="lung-20220630.xsd#lung_CommonStockRestrictedStockUnitsIssuedAndOutstandingMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_307dfd75-9b05-47e8-a357-2ee25057fd7f" xlink:to="loc_lung_CommonStockRestrictedStockUnitsIssuedAndOutstandingMember_716e9e2d-754e-4826-90b5-9ba31975cce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_ShareBasedCompensationEmployeeStockAvailableForGrantMember_a8e4e512-a0dc-448e-98e0-a23cc6dd309a" xlink:href="lung-20220630.xsd#lung_ShareBasedCompensationEmployeeStockAvailableForGrantMember"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_307dfd75-9b05-47e8-a357-2ee25057fd7f" xlink:to="loc_lung_ShareBasedCompensationEmployeeStockAvailableForGrantMember_a8e4e512-a0dc-448e-98e0-a23cc6dd309a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_dbd51ff8-2d2f-483b-9b87-2bbb3822a1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_307dfd75-9b05-47e8-a357-2ee25057fd7f" xlink:to="loc_us-gaap_EmployeeStockMember_dbd51ff8-2d2f-483b-9b87-2bbb3822a1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_2cad93f3-c27a-4be6-9abb-aebd413e293a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e9f93289-7e5d-4bb1-88a6-b6564579e9b2" xlink:to="loc_us-gaap_ClassOfStockLineItems_2cad93f3-c27a-4be6-9abb-aebd413e293a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f3ca66ba-c074-48d8-bac5-68b484e103b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2cad93f3-c27a-4be6-9abb-aebd413e293a" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f3ca66ba-c074-48d8-bac5-68b484e103b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/StockholdersEquityStockOptionActivityDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#StockholdersEquityStockOptionActivityDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/StockholdersEquityStockOptionActivityDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e2ea45d9-bdd7-450e-8fc2-e66f2cc9e2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsAbstract_3a07828e-cef2-4d6d-94a1-ecad25e536a5" xlink:href="lung-20220630.xsd#lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsAbstract"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e2ea45d9-bdd7-450e-8fc2-e66f2cc9e2c5" xlink:to="loc_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsAbstract_3a07828e-cef2-4d6d-94a1-ecad25e536a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_64e39c06-450a-4b6e-852f-b20e01bf8d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsAbstract_3a07828e-cef2-4d6d-94a1-ecad25e536a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_64e39c06-450a-4b6e-852f-b20e01bf8d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fc5943d6-dd74-410d-9fc0-098738953d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_64e39c06-450a-4b6e-852f-b20e01bf8d0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fc5943d6-dd74-410d-9fc0-098738953d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c32eaccf-5be5-4dcf-8ab4-b42500a9029c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_64e39c06-450a-4b6e-852f-b20e01bf8d0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c32eaccf-5be5-4dcf-8ab4-b42500a9029c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1897b7dd-d948-4565-ac1a-437d8bbfa8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_64e39c06-450a-4b6e-852f-b20e01bf8d0d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1897b7dd-d948-4565-ac1a-437d8bbfa8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_39ed7cbc-ca8a-4929-aba9-e55c767386bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_64e39c06-450a-4b6e-852f-b20e01bf8d0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_39ed7cbc-ca8a-4929-aba9-e55c767386bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_73236959-cb7d-4e33-8665-5923c71be780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_64e39c06-450a-4b6e-852f-b20e01bf8d0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_73236959-cb7d-4e33-8665-5923c71be780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_457ce12f-d19b-42ba-b430-e0958595b87a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsAbstract_3a07828e-cef2-4d6d-94a1-ecad25e536a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_457ce12f-d19b-42ba-b430-e0958595b87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4bcaae25-ddd7-45f7-99a7-0c3af52c4145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_457ce12f-d19b-42ba-b430-e0958595b87a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4bcaae25-ddd7-45f7-99a7-0c3af52c4145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_66c5bf3c-6805-4e7f-a17b-6171bf29bcaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_457ce12f-d19b-42ba-b430-e0958595b87a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_66c5bf3c-6805-4e7f-a17b-6171bf29bcaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4ec6c9d3-cc4f-4611-a6e9-8470c7340c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_457ce12f-d19b-42ba-b430-e0958595b87a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4ec6c9d3-cc4f-4611-a6e9-8470c7340c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_622ceef7-ee19-499b-9bca-c86e2289a6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_457ce12f-d19b-42ba-b430-e0958595b87a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_622ceef7-ee19-499b-9bca-c86e2289a6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_303c0765-5784-48d9-9977-a07e647925d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_457ce12f-d19b-42ba-b430-e0958595b87a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_303c0765-5784-48d9-9977-a07e647925d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/StockholdersEquityOptionsVestedandExpectedtoVestDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#StockholdersEquityOptionsVestedandExpectedtoVestDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/StockholdersEquityOptionsVestedandExpectedtoVestDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9b9a0d49-5bb3-4196-a29b-6efc35d08ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_09dc571e-4549-46b3-a5e9-53b03abd5cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9b9a0d49-5bb3-4196-a29b-6efc35d08ff7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_09dc571e-4549-46b3-a5e9-53b03abd5cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_f5e1e96b-ccee-49fa-88fe-4ea052b81835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_09dc571e-4549-46b3-a5e9-53b03abd5cf9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_f5e1e96b-ccee-49fa-88fe-4ea052b81835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_300877cd-1f44-4c77-b4f6-d0e216575e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_09dc571e-4549-46b3-a5e9-53b03abd5cf9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_300877cd-1f44-4c77-b4f6-d0e216575e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePriceAbstract_c5d59320-314e-4404-afb2-7470696f66cf" xlink:href="lung-20220630.xsd#lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePriceAbstract"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9b9a0d49-5bb3-4196-a29b-6efc35d08ff7" xlink:to="loc_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePriceAbstract_c5d59320-314e-4404-afb2-7470696f66cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice_9f84eedb-289e-4597-88a0-e3747b9ae37f" xlink:href="lung-20220630.xsd#lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePriceAbstract_c5d59320-314e-4404-afb2-7470696f66cf" xlink:to="loc_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice_9f84eedb-289e-4597-88a0-e3747b9ae37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a90f14ba-5532-4028-8ae4-e02132bafef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePriceAbstract_c5d59320-314e-4404-afb2-7470696f66cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a90f14ba-5532-4028-8ae4-e02132bafef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedTermAbstract_0ac57aca-93b5-4999-aa8b-02a99d7fb0be" xlink:href="lung-20220630.xsd#lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedTermAbstract"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9b9a0d49-5bb3-4196-a29b-6efc35d08ff7" xlink:to="loc_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedTermAbstract_0ac57aca-93b5-4999-aa8b-02a99d7fb0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm_c9bf41af-8de2-4775-ac65-5f132ff1c52f" xlink:href="lung-20220630.xsd#lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedTermAbstract_0ac57aca-93b5-4999-aa8b-02a99d7fb0be" xlink:to="loc_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm_c9bf41af-8de2-4775-ac65-5f132ff1c52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_34e0ffa0-34cc-4f3e-95ed-10e34cdd3bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedTermAbstract_0ac57aca-93b5-4999-aa8b-02a99d7fb0be" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_34e0ffa0-34cc-4f3e-95ed-10e34cdd3bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/StockholdersEquityRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#StockholdersEquityRestrictedStockUnitActivityDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/StockholdersEquityRestrictedStockUnitActivityDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_44697175-bc4f-4762-a39a-bad840d03248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_704fdbcd-2a95-466a-ab21-1b8eb1c487c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_44697175-bc4f-4762-a39a-bad840d03248" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_704fdbcd-2a95-466a-ab21-1b8eb1c487c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bcb07fd2-80b3-4d3c-86eb-c14ef17f2517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_704fdbcd-2a95-466a-ab21-1b8eb1c487c9" xlink:to="loc_us-gaap_AwardTypeAxis_bcb07fd2-80b3-4d3c-86eb-c14ef17f2517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e2bbdcf-b13a-4b87-ad27-d4529c6ba609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bcb07fd2-80b3-4d3c-86eb-c14ef17f2517" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e2bbdcf-b13a-4b87-ad27-d4529c6ba609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_253880a6-1866-4d30-b377-1de03eaa5ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e2bbdcf-b13a-4b87-ad27-d4529c6ba609" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_253880a6-1866-4d30-b377-1de03eaa5ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_674af04a-93f1-4e12-8da7-75b812275a28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_704fdbcd-2a95-466a-ab21-1b8eb1c487c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_674af04a-93f1-4e12-8da7-75b812275a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_47fd5b83-b026-4c0d-814f-b411de4e11bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_674af04a-93f1-4e12-8da7-75b812275a28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_47fd5b83-b026-4c0d-814f-b411de4e11bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_577c7c15-f8e7-406c-a65a-862438e1b88c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_47fd5b83-b026-4c0d-814f-b411de4e11bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_577c7c15-f8e7-406c-a65a-862438e1b88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4c92c50a-fabc-4ae6-8a1e-1e22dd54a7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_47fd5b83-b026-4c0d-814f-b411de4e11bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4c92c50a-fabc-4ae6-8a1e-1e22dd54a7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_564e95db-dac4-4acb-a7aa-2d1cb7ee0811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_47fd5b83-b026-4c0d-814f-b411de4e11bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_564e95db-dac4-4acb-a7aa-2d1cb7ee0811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cc647d5f-3fcd-45b7-b42c-5d8523e50f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_47fd5b83-b026-4c0d-814f-b411de4e11bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cc647d5f-3fcd-45b7-b42c-5d8523e50f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e2764db6-2bdc-4218-9cba-a4d4a29de19b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_47fd5b83-b026-4c0d-814f-b411de4e11bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e2764db6-2bdc-4218-9cba-a4d4a29de19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f295d889-2505-4bcf-aee8-f243ac765ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_674af04a-93f1-4e12-8da7-75b812275a28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f295d889-2505-4bcf-aee8-f243ac765ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ee42cb76-8fe7-427f-baec-a108244f9d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f295d889-2505-4bcf-aee8-f243ac765ff6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ee42cb76-8fe7-427f-baec-a108244f9d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cf193f37-e7d6-4818-a35c-b299804dbf02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f295d889-2505-4bcf-aee8-f243ac765ff6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cf193f37-e7d6-4818-a35c-b299804dbf02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_dfc4ebfe-2570-482d-b4bd-225a5c5a0636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f295d889-2505-4bcf-aee8-f243ac765ff6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_dfc4ebfe-2570-482d-b4bd-225a5c5a0636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_561d60c8-fac2-4895-97f0-5418f7330a31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f295d889-2505-4bcf-aee8-f243ac765ff6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_561d60c8-fac2-4895-97f0-5418f7330a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b0d62622-39d0-4f36-b1d1-0ca4c57d637c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f295d889-2505-4bcf-aee8-f243ac765ff6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b0d62622-39d0-4f36-b1d1-0ca4c57d637c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/StockholdersEquityTotalStockBasedCompensationDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#StockholdersEquityTotalStockBasedCompensationDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/StockholdersEquityTotalStockBasedCompensationDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c63330c3-da86-4654-9bda-f1ae1d477a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88c0762c-df1b-4bdc-92c9-40571806355f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c63330c3-da86-4654-9bda-f1ae1d477a89" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88c0762c-df1b-4bdc-92c9-40571806355f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8a2e31fd-a2f4-40ca-9452-23854c0f6b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88c0762c-df1b-4bdc-92c9-40571806355f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8a2e31fd-a2f4-40ca-9452-23854c0f6b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d91762c5-aa70-4d47-aec2-a4ae176bbbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8a2e31fd-a2f4-40ca-9452-23854c0f6b4a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d91762c5-aa70-4d47-aec2-a4ae176bbbc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_6d090711-a03f-4bf0-93a6-c18ab8b85d09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d91762c5-aa70-4d47-aec2-a4ae176bbbc6" xlink:to="loc_us-gaap_CostOfSalesMember_6d090711-a03f-4bf0-93a6-c18ab8b85d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_45e269fd-f3ad-416f-981f-f3342de202eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d91762c5-aa70-4d47-aec2-a4ae176bbbc6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_45e269fd-f3ad-416f-981f-f3342de202eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f6e7ee63-f2ee-4ac6-be3d-bc535cf54820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d91762c5-aa70-4d47-aec2-a4ae176bbbc6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f6e7ee63-f2ee-4ac6-be3d-bc535cf54820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_99d4d9c5-189e-4d88-9c68-06276e16b3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88c0762c-df1b-4bdc-92c9-40571806355f" xlink:to="loc_us-gaap_AwardTypeAxis_99d4d9c5-189e-4d88-9c68-06276e16b3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b5146e8-8163-423d-b542-9771463dca8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_99d4d9c5-189e-4d88-9c68-06276e16b3ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b5146e8-8163-423d-b542-9771463dca8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_StockOptionsAndRestrictedStockUnitsMember_fb9348f4-0032-4fa2-bea3-948a0276d190" xlink:href="lung-20220630.xsd#lung_StockOptionsAndRestrictedStockUnitsMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b5146e8-8163-423d-b542-9771463dca8a" xlink:to="loc_lung_StockOptionsAndRestrictedStockUnitsMember_fb9348f4-0032-4fa2-bea3-948a0276d190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_2d6c36c2-ca32-4be9-a967-2fe83d2b3b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b5146e8-8163-423d-b542-9771463dca8a" xlink:to="loc_us-gaap_EmployeeStockMember_2d6c36c2-ca32-4be9-a967-2fe83d2b3b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_174f8179-5126-4631-915a-79ff03addad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_88c0762c-df1b-4bdc-92c9-40571806355f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_174f8179-5126-4631-915a-79ff03addad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e09f36f6-e9db-472f-a381-988b3f33a7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_174f8179-5126-4631-915a-79ff03addad5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e09f36f6-e9db-472f-a381-988b3f33a7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholders" xlink:type="simple" xlink:href="lung-20220630.xsd#NetLossperShareAttributabletoCommonStockholders"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholders" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_640bc3d3-d0c5-45e8-b7c5-6fb6429072b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_67d3b1c7-3181-4061-8930-f26a55dc5990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_640bc3d3-d0c5-45e8-b7c5-6fb6429072b0" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_67d3b1c7-3181-4061-8930-f26a55dc5990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersTables" xlink:type="simple" xlink:href="lung-20220630.xsd#NetLossperShareAttributabletoCommonStockholdersTables"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersTables" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a44d7ca0-0b55-42b0-bbed-a3a243653b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_6a923adc-c757-48d7-a266-bf2bedb67434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a44d7ca0-0b55-42b0-bbed-a3a243653b1d" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_6a923adc-c757-48d7-a266-bf2bedb67434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1511bb2c-e8b3-4ab1-ae33-1de14a17d483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a44d7ca0-0b55-42b0-bbed-a3a243653b1d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1511bb2c-e8b3-4ab1-ae33-1de14a17d483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersComputationofBasicandDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#NetLossperShareAttributabletoCommonStockholdersComputationofBasicandDilutedNetLossperShareDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersComputationofBasicandDilutedNetLossperShareDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_30281428-7391-4c52-8450-c1f6ffde7fce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract_bfd556ba-e119-4a6c-9bba-30604c094e12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicTwoClassMethodAbstract"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_30281428-7391-4c52-8450-c1f6ffde7fce" xlink:to="loc_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract_bfd556ba-e119-4a6c-9bba-30604c094e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_428c4e49-301b-40e3-adbc-e5c3b1e1e0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract_bfd556ba-e119-4a6c-9bba-30604c094e12" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_428c4e49-301b-40e3-adbc-e5c3b1e1e0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_33f161fc-66f2-4d96-bc45-7485e97256b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract_bfd556ba-e119-4a6c-9bba-30604c094e12" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_33f161fc-66f2-4d96-bc45-7485e97256b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0b5774cb-d84f-408a-8673-e5f422c3b551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_30281428-7391-4c52-8450-c1f6ffde7fce" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0b5774cb-d84f-408a-8673-e5f422c3b551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_4b7e1b88-1dd1-4b40-9652-2eeca5b47b64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0b5774cb-d84f-408a-8673-e5f422c3b551" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_4b7e1b88-1dd1-4b40-9652-2eeca5b47b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_8b09bb31-7ed8-463c-a672-cd31309801b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0b5774cb-d84f-408a-8673-e5f422c3b551" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_8b09bb31-7ed8-463c-a672-cd31309801b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_839ca433-2b02-48be-bee9-53002f6f0f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0b5774cb-d84f-408a-8673-e5f422c3b551" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_839ca433-2b02-48be-bee9-53002f6f0f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_81f562d3-b036-49fc-a4ee-6e1bc045b930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0b5774cb-d84f-408a-8673-e5f422c3b551" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_81f562d3-b036-49fc-a4ee-6e1bc045b930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_045187e5-0325-4bf4-aeb9-35c551a90560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
<link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0b5774cb-d84f-408a-8673-e5f422c3b551" xlink:to="loc_us-gaap_EarningsPerShareBasic_045187e5-0325-4bf4-aeb9-35c551a90560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9c0cd5f0-1be1-455f-96fe-80ad937fc92f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
<link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0b5774cb-d84f-408a-8673-e5f422c3b551" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9c0cd5f0-1be1-455f-96fe-80ad937fc92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersExcludedPotentiallyDilutiveSecuritiesOutstandingDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#NetLossperShareAttributabletoCommonStockholdersExcludedPotentiallyDilutiveSecuritiesOutstandingDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersExcludedPotentiallyDilutiveSecuritiesOutstandingDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ad3efaf6-d7e8-465c-9a93-f6ee1c519172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_498137bf-954d-42c9-9af3-6361dcb5d2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ad3efaf6-d7e8-465c-9a93-f6ee1c519172" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_498137bf-954d-42c9-9af3-6361dcb5d2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5c9cac97-933f-4149-90e8-7c8dddd4f2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_498137bf-954d-42c9-9af3-6361dcb5d2ac" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5c9cac97-933f-4149-90e8-7c8dddd4f2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5b76ede-7b84-4c67-b5d7-db17a7010e63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5c9cac97-933f-4149-90e8-7c8dddd4f2ce" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5b76ede-7b84-4c67-b5d7-db17a7010e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3342312c-eed4-4766-82b5-85e68b281fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5b76ede-7b84-4c67-b5d7-db17a7010e63" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3342312c-eed4-4766-82b5-85e68b281fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_e37feea2-d3e9-4b06-bb95-6e2ee6869b29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5b76ede-7b84-4c67-b5d7-db17a7010e63" xlink:to="loc_us-gaap_RestrictedStockMember_e37feea2-d3e9-4b06-bb95-6e2ee6869b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_ShareBasedCompensationUnvestedEarlyExercisedOptionsMember_e6e1cc1c-e0f7-4bc4-a1d3-fdbd9a2a5e04" xlink:href="lung-20220630.xsd#lung_ShareBasedCompensationUnvestedEarlyExercisedOptionsMember"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5b76ede-7b84-4c67-b5d7-db17a7010e63" xlink:to="loc_lung_ShareBasedCompensationUnvestedEarlyExercisedOptionsMember_e6e1cc1c-e0f7-4bc4-a1d3-fdbd9a2a5e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_81c4cfd4-9431-4f9f-be9c-5700aa419b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5b76ede-7b84-4c67-b5d7-db17a7010e63" xlink:to="loc_us-gaap_EmployeeStockMember_81c4cfd4-9431-4f9f-be9c-5700aa419b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_db20e9c8-49d5-4745-b606-6d3224fbe3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_498137bf-954d-42c9-9af3-6361dcb5d2ac" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_db20e9c8-49d5-4745-b606-6d3224fbe3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c8dd4249-cd98-46b4-97ba-5ebc068757e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_db20e9c8-49d5-4745-b606-6d3224fbe3c1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c8dd4249-cd98-46b4-97ba-5ebc068757e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/SegmentInformation" xlink:type="simple" xlink:href="lung-20220630.xsd#SegmentInformation"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/SegmentInformation" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_3e5ffaf1-8199-4ebc-8c43-a634ae973d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_cb226611-7341-45a1-9612-3b53cce42c97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3e5ffaf1-8199-4ebc-8c43-a634ae973d73" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_cb226611-7341-45a1-9612-3b53cce42c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="lung-20220630.xsd#SegmentInformationTables"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/SegmentInformationTables" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a5217967-8d3a-4c49-8f25-58a2253f468b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_9cb03ca8-2d4e-465c-994b-de42dd3628a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a5217967-8d3a-4c49-8f25-58a2253f468b" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_9cb03ca8-2d4e-465c-994b-de42dd3628a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_bf5a991e-048f-4e00-982e-6d0f56363eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a5217967-8d3a-4c49-8f25-58a2253f468b" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_bf5a991e-048f-4e00-982e-6d0f56363eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#SegmentInformationNarrativeDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/SegmentInformationNarrativeDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4045ebbd-09bc-43ad-b77d-c7a4beef8761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_e443ed8f-e472-4a5d-a4c5-f6e5e4bbdf23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4045ebbd-09bc-43ad-b77d-c7a4beef8761" xlink:to="loc_us-gaap_ConcentrationRiskTable_e443ed8f-e472-4a5d-a4c5-f6e5e4bbdf23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_80da1bc4-7fec-4dd2-b1c1-f45ceac14021" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_e443ed8f-e472-4a5d-a4c5-f6e5e4bbdf23" xlink:to="loc_srt_StatementGeographicalAxis_80da1bc4-7fec-4dd2-b1c1-f45ceac14021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0828d095-4f13-485b-aa0c-0546360d85dc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_80da1bc4-7fec-4dd2-b1c1-f45ceac14021" xlink:to="loc_srt_SegmentGeographicalDomain_0828d095-4f13-485b-aa0c-0546360d85dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_country_DE_a67d83d9-6290-4351-8c83-b293a370a04a" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0828d095-4f13-485b-aa0c-0546360d85dc" xlink:to="loc_country_DE_a67d83d9-6290-4351-8c83-b293a370a04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_country_FR_90d89ae1-4a43-4d7d-ab04-91d8858bc0cc" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0828d095-4f13-485b-aa0c-0546360d85dc" xlink:to="loc_country_FR_90d89ae1-4a43-4d7d-ab04-91d8858bc0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_440b08ec-581b-4bdd-a1a8-09410d7feb0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_e443ed8f-e472-4a5d-a4c5-f6e5e4bbdf23" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_440b08ec-581b-4bdd-a1a8-09410d7feb0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3269d315-8f4a-4931-9856-85d0007c877f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_440b08ec-581b-4bdd-a1a8-09410d7feb0b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3269d315-8f4a-4931-9856-85d0007c877f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_dda17315-5b56-4770-acbe-10bf6f3381f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3269d315-8f4a-4931-9856-85d0007c877f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_dda17315-5b56-4770-acbe-10bf6f3381f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_9e9f3bcf-92e6-418a-b48d-ea4ce2583585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_e443ed8f-e472-4a5d-a4c5-f6e5e4bbdf23" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_9e9f3bcf-92e6-418a-b48d-ea4ce2583585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_132192e1-e2e5-4873-bbf4-42ce7a38f8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_9e9f3bcf-92e6-418a-b48d-ea4ce2583585" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_132192e1-e2e5-4873-bbf4-42ce7a38f8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_e7b632d7-868d-415b-96ac-46d43ee4de9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_132192e1-e2e5-4873-bbf4-42ce7a38f8fb" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_e7b632d7-868d-415b-96ac-46d43ee4de9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_f286f9cf-db61-4826-93db-3dbb6e86e904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_e443ed8f-e472-4a5d-a4c5-f6e5e4bbdf23" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_f286f9cf-db61-4826-93db-3dbb6e86e904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_5e27d5a9-9a1c-41a4-828b-ef930237ddb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f286f9cf-db61-4826-93db-3dbb6e86e904" xlink:to="loc_us-gaap_NumberOfReportableSegments_5e27d5a9-9a1c-41a4-828b-ef930237ddb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_a8bb8508-5d01-48f1-befc-35fabb8689d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f286f9cf-db61-4826-93db-3dbb6e86e904" xlink:to="loc_us-gaap_NumberOfOperatingSegments_a8bb8508-5d01-48f1-befc-35fabb8689d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_2a00ea0f-6174-4a1e-970e-01157ce7d0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f286f9cf-db61-4826-93db-3dbb6e86e904" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_2a00ea0f-6174-4a1e-970e-01157ce7d0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/SegmentInformationRevenuebyGeographicAreaDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#SegmentInformationRevenuebyGeographicAreaDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/SegmentInformationRevenuebyGeographicAreaDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_eb7906f1-e5b5-4183-ad52-091531274350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_2b69e2a6-db92-4077-8c5c-8236939726dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_eb7906f1-e5b5-4183-ad52-091531274350" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_2b69e2a6-db92-4077-8c5c-8236939726dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e43925be-3d44-4458-8917-dc38e7b407c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_2b69e2a6-db92-4077-8c5c-8236939726dd" xlink:to="loc_srt_StatementGeographicalAxis_e43925be-3d44-4458-8917-dc38e7b407c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_484f2e57-a45b-4090-88e5-724e16e6764e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_e43925be-3d44-4458-8917-dc38e7b407c7" xlink:to="loc_srt_SegmentGeographicalDomain_484f2e57-a45b-4090-88e5-724e16e6764e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_country_US_9911633f-6f41-4d74-b1fc-6c1249fe6869" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_484f2e57-a45b-4090-88e5-724e16e6764e" xlink:to="loc_country_US_9911633f-6f41-4d74-b1fc-6c1249fe6869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_b1723e32-91c0-4ee6-aef3-805062c66460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EMEAMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_484f2e57-a45b-4090-88e5-724e16e6764e" xlink:to="loc_us-gaap_EMEAMember_b1723e32-91c0-4ee6-aef3-805062c66460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_f6062850-c219-47be-8472-e24b8ff68b7e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_484f2e57-a45b-4090-88e5-724e16e6764e" xlink:to="loc_srt_AsiaPacificMember_f6062850-c219-47be-8472-e24b8ff68b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_lung_OtherInternationalGeographicalAreasMember_54fd5d97-6632-4bef-b238-268861303bf8" xlink:href="lung-20220630.xsd#lung_OtherInternationalGeographicalAreasMember"/>
<link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_484f2e57-a45b-4090-88e5-724e16e6764e" xlink:to="loc_lung_OtherInternationalGeographicalAreasMember_54fd5d97-6632-4bef-b238-268861303bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_ed68729f-7f58-4f63-b9e7-d0e5aa0710f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_2b69e2a6-db92-4077-8c5c-8236939726dd" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_ed68729f-7f58-4f63-b9e7-d0e5aa0710f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6670065f-0977-4028-9325-f37196175120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_ed68729f-7f58-4f63-b9e7-d0e5aa0710f3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6670065f-0977-4028-9325-f37196175120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
<link:roleRef roleURI="http://www.pulmonx.com/role/SegmentInformationLongLivedAssetsbyGeographicalAreaDetails" xlink:type="simple" xlink:href="lung-20220630.xsd#SegmentInformationLongLivedAssetsbyGeographicalAreaDetails"/>
<link:presentationLink xlink:role="http://www.pulmonx.com/role/SegmentInformationLongLivedAssetsbyGeographicalAreaDetails" xlink:type="extended">
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_0b4b1149-40bc-452b-b5ce-5d4e47c55423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_2cb43c6e-31da-4316-b8f6-969544322579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0b4b1149-40bc-452b-b5ce-5d4e47c55423" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_2cb43c6e-31da-4316-b8f6-969544322579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3058eade-8a1c-456b-a2cd-88ce6977994e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_2cb43c6e-31da-4316-b8f6-969544322579" xlink:to="loc_srt_StatementGeographicalAxis_3058eade-8a1c-456b-a2cd-88ce6977994e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1cc3f5a5-4251-4981-8028-c030918a1230" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_3058eade-8a1c-456b-a2cd-88ce6977994e" xlink:to="loc_srt_SegmentGeographicalDomain_1cc3f5a5-4251-4981-8028-c030918a1230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_country_US_3d467020-92fd-45e1-b594-84f2b458765f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1cc3f5a5-4251-4981-8028-c030918a1230" xlink:to="loc_country_US_3d467020-92fd-45e1-b594-84f2b458765f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_00f24413-8eec-429a-bd76-db64c23264f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EMEAMember"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1cc3f5a5-4251-4981-8028-c030918a1230" xlink:to="loc_us-gaap_EMEAMember_00f24413-8eec-429a-bd76-db64c23264f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_1d316e89-e7a4-4cff-a63c-64235fc104aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
<link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1cc3f5a5-4251-4981-8028-c030918a1230" xlink:to="loc_srt_AsiaPacificMember_1d316e89-e7a4-4cff-a63c-64235fc104aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_b153969b-234d-4ca1-bfa6-a439f50ca92f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
<link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_2cb43c6e-31da-4316-b8f6-969544322579" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_b153969b-234d-4ca1-bfa6-a439f50ca92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_6479a045-607b-4142-8356-0a3e926ce6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncurrentAssets"/>
<link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_b153969b-234d-4ca1-bfa6-a439f50ca92f" xlink:to="loc_us-gaap_NoncurrentAssets_6479a045-607b-4142-8356-0a3e926ce6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425448331680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jul. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30, 2022<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39562<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PULMONX CORPORATION<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0424412<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">700 Chesapeake Drive<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94063<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CountryRegion', window );">Country Region</a></td>
<td class="text">1<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">364-0400<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LUNG<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">37,268,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001127537<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CountryRegion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Region code of country</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CountryRegion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425448088160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 121,947<span></span>
</td>
<td class="nump">$ 148,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term marketable securities</a></td>
<td class="nump">40,139<span></span>
</td>
<td class="nump">31,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">7,521<span></span>
</td>
<td class="nump">6,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">19,212<span></span>
</td>
<td class="nump">16,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,731<span></span>
</td>
<td class="nump">4,883<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">192,781<span></span>
</td>
<td class="nump">208,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term marketable securities</a></td>
<td class="nump">4,684<span></span>
</td>
<td class="nump">10,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,932<span></span>
</td>
<td class="nump">4,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">2,333<span></span>
</td>
<td class="nump">2,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets</a></td>
<td class="nump">6,987<span></span>
</td>
<td class="nump">8,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">796<span></span>
</td>
<td class="nump">731<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">212,729<span></span>
</td>
<td class="nump">235,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,599<span></span>
</td>
<td class="nump">1,582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">11,734<span></span>
</td>
<td class="nump">13,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt</a></td>
<td class="nump">2,921<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current lease liabilities</a></td>
<td class="nump">3,061<span></span>
</td>
<td class="nump">2,201<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">20,446<span></span>
</td>
<td class="nump">17,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">5,415<span></span>
</td>
<td class="nump">6,844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">14,460<span></span>
</td>
<td class="nump">17,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">40,547<span></span>
</td>
<td class="nump">41,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders’ equity</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding as of June 30, 2022 and December 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 200,000,000 shares authorized as of June 30, 2022 and December 31, 2021; 37,266,030 shares issued and outstanding as of June 30, 2022 and 36,931,762 shares issued and outstanding as of December 31, 2021</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">492,651<span></span>
</td>
<td class="nump">482,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">1,357<span></span>
</td>
<td class="nump">1,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(321,863)<span></span>
</td>
<td class="num">(291,395)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders’ equity</a></td>
<td class="nump">172,182<span></span>
</td>
<td class="nump">193,239<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders’ equity</a></td>
<td class="nump">$ 212,729<span></span>
</td>
<td class="nump">$ 235,173<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425448300464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders’ equity</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">37,266,030<span></span>
</td>
<td class="nump">36,931,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">37,266,030<span></span>
</td>
<td class="nump">36,931,762<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425447885664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 13,950<span></span>
</td>
<td class="nump">$ 12,203<span></span>
</td>
<td class="nump">$ 24,735<span></span>
</td>
<td class="nump">$ 21,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">3,532<span></span>
</td>
<td class="nump">3,174<span></span>
</td>
<td class="nump">6,206<span></span>
</td>
<td class="nump">5,807<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">10,418<span></span>
</td>
<td class="nump">9,029<span></span>
</td>
<td class="nump">18,529<span></span>
</td>
<td class="nump">15,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,594<span></span>
</td>
<td class="nump">3,506<span></span>
</td>
<td class="nump">7,128<span></span>
</td>
<td class="nump">6,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">21,235<span></span>
</td>
<td class="nump">18,205<span></span>
</td>
<td class="nump">41,480<span></span>
</td>
<td class="nump">34,276<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">24,829<span></span>
</td>
<td class="nump">21,711<span></span>
</td>
<td class="nump">48,608<span></span>
</td>
<td class="nump">40,816<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(14,411)<span></span>
</td>
<td class="num">(12,682)<span></span>
</td>
<td class="num">(30,079)<span></span>
</td>
<td class="num">(25,176)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">304<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(223)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
<td class="num">(421)<span></span>
</td>
<td class="num">(423)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(165)<span></span>
</td>
<td class="num">(96)<span></span>
</td>
<td class="num">(165)<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before tax</a></td>
<td class="num">(14,600)<span></span>
</td>
<td class="num">(12,882)<span></span>
</td>
<td class="num">(30,361)<span></span>
</td>
<td class="num">(25,327)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(14,640)<span></span>
</td>
<td class="num">(12,962)<span></span>
</td>
<td class="num">(30,468)<span></span>
</td>
<td class="num">(25,474)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Currency translation adjustment</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Change in unrealized gain (loss) on marketable securities</a></td>
<td class="num">(92)<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(337)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss)</a></td>
<td class="num">(86)<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="num">(355)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (14,726)<span></span>
</td>
<td class="num">$ (12,893)<span></span>
</td>
<td class="num">$ (30,823)<span></span>
</td>
<td class="num">$ (25,680)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable common stockholders, basic (in dollars per share)</a></td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (0.71)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted (in dollars per share)</a></td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (0.71)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)</a></td>
<td class="nump">37,003,443<span></span>
</td>
<td class="nump">36,042,614<span></span>
</td>
<td class="nump">36,904,952<span></span>
</td>
<td class="nump">35,708,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)</a></td>
<td class="nump">37,003,443<span></span>
</td>
<td class="nump">36,042,614<span></span>
</td>
<td class="nump">36,904,952<span></span>
</td>
<td class="nump">35,708,548<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425444909600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">35,693,753<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 226,134<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 467,147<span></span>
</td>
<td class="nump">$ 1,685<span></span>
</td>
<td class="num">$ (242,734)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">122,856<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">273<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">273<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_StockRepurchasedDuringPeriodExerciseOfEarlyStockOptionsShares', window );">Repurchase of early exercised common stock options (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(12,945)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase', window );">Change in shares subject to repurchase</a></td>
<td class="nump">66<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">2,462<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,462<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Currency translation adjustment</a></td>
<td class="num">(272)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(272)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Change in unrealized (losses) gains on marketable securities</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(12,512)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,512)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">35,803,664<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">216,148<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">469,948<span></span>
</td>
<td class="nump">1,410<span></span>
</td>
<td class="num">(255,246)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">35,693,753<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">226,134<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">467,147<span></span>
</td>
<td class="nump">1,685<span></span>
</td>
<td class="num">(242,734)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Currency translation adjustment</a></td>
<td class="num">(206)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Change in unrealized (losses) gains on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(25,474)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">36,580,617<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">208,868<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">475,561<span></span>
</td>
<td class="nump">1,479<span></span>
</td>
<td class="num">(268,208)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">35,803,664<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">216,148<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">469,948<span></span>
</td>
<td class="nump">1,410<span></span>
</td>
<td class="num">(255,246)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">653,609<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">1,133<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,133<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of shares pursuant to Employee Stock Purchase Plan (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">123,344<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of shares pursuant to Employee Stock Purchase Plan</a></td>
<td class="nump">1,992<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,992<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase', window );">Change in shares subject to repurchase</a></td>
<td class="nump">12<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">2,476<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,476<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Currency translation adjustment</a></td>
<td class="nump">66<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Change in unrealized (losses) gains on marketable securities</a></td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(12,962)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,962)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">36,580,617<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">$ 208,868<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">475,561<span></span>
</td>
<td class="nump">1,479<span></span>
</td>
<td class="num">(268,208)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">36,931,762<span></span>
</td>
<td class="nump">36,931,762<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 193,239<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">482,885<span></span>
</td>
<td class="nump">1,712<span></span>
</td>
<td class="num">(291,395)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (in share)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">21,392<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">99,265<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">221<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of shares pursuant to Employee Stock Purchase Plan (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">46,002<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of shares pursuant to Employee Stock Purchase Plan</a></td>
<td class="nump">1,108<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,108<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase', window );">Change in shares subject to repurchase</a></td>
<td class="nump">59<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,615<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,615<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Currency translation adjustment</a></td>
<td class="num">(24)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Change in unrealized (losses) gains on marketable securities</a></td>
<td class="num">(245)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(245)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(15,828)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(15,828)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">37,098,421<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 182,145<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">487,888<span></span>
</td>
<td class="nump">1,443<span></span>
</td>
<td class="num">(307,223)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">36,931,762<span></span>
</td>
<td class="nump">36,931,762<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 193,239<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">482,885<span></span>
</td>
<td class="nump">1,712<span></span>
</td>
<td class="num">(291,395)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">172,886<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Currency translation adjustment</a></td>
<td class="num">$ (18)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Change in unrealized (losses) gains on marketable securities</a></td>
<td class="num">(337)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (30,468)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">37,266,030<span></span>
</td>
<td class="nump">37,266,030<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 172,182<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">492,651<span></span>
</td>
<td class="nump">1,357<span></span>
</td>
<td class="num">(321,863)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">37,098,421<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">182,145<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">487,888<span></span>
</td>
<td class="nump">1,443<span></span>
</td>
<td class="num">(307,223)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (in share)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">93,988<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">73,621<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">151<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase', window );">Change in shares subject to repurchase</a></td>
<td class="nump">58<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">4,554<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,554<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Currency translation adjustment</a></td>
<td class="nump">6<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Change in unrealized (losses) gains on marketable securities</a></td>
<td class="num">(92)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(92)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,640)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(14,640)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">37,266,030<span></span>
</td>
<td class="nump">37,266,030<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 172,182<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 492,651<span></span>
</td>
<td class="nump">$ 1,357<span></span>
</td>
<td class="num">$ (321,863)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Change In Shares Subject To Repurchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_StockRepurchasedDuringPeriodExerciseOfEarlyStockOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Repurchased During Period, Exercise Of Early Stock Options, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_StockRepurchasedDuringPeriodExerciseOfEarlyStockOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425447064144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (30,468)<span></span>
</td>
<td class="num">$ (25,474)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">7,896<span></span>
</td>
<td class="nump">4,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Allowance for doubtful accounts</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-downs</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherDepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">744<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums and discounts on short-term marketable securities</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expense</a></td>
<td class="nump">1,226<span></span>
</td>
<td class="nump">1,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in operating assets and liabilities:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,073)<span></span>
</td>
<td class="num">(2,732)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(3,030)<span></span>
</td>
<td class="num">(3,125)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,065<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">6<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,062<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(1,296)<span></span>
</td>
<td class="nump">2,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="num">(707)<span></span>
</td>
<td class="num">(1,137)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred tax liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(29)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(24,590)<span></span>
</td>
<td class="num">(22,362)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(21,959)<span></span>
</td>
<td class="num">(15,314)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments', window );">Maturities of short-term marketable securities</a></td>
<td class="nump">19,280<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(863)<span></span>
</td>
<td class="num">(903)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(3,542)<span></span>
</td>
<td class="num">(13,717)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayment of Credit Agreement</a></td>
<td class="num">(44)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of common stock options</a></td>
<td class="nump">382<span></span>
</td>
<td class="nump">1,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock', window );">Proceeds from issuance of common stock under the employee stock purchase plan</a></td>
<td class="nump">1,108<span></span>
</td>
<td class="nump">1,992<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of early exercised common stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,446<span></span>
</td>
<td class="nump">3,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">153<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(26,533)<span></span>
</td>
<td class="num">(32,858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, at beginning of the period</a></td>
<td class="nump">148,711<span></span>
</td>
<td class="nump">231,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, at end of the period</a></td>
<td class="nump">122,178<span></span>
</td>
<td class="nump">198,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash to consolidated balance sheets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">121,947<span></span>
</td>
<td class="nump">198,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash in consolidated balance sheets</a></td>
<td class="nump">122,178<span></span>
</td>
<td class="nump">198,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental non-cash items:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_IncreaseLapseInRepurchaseOfCommonStockRights', window );">Lapse in repurchase rights of common stock</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment in accounts payable</a></td>
<td class="nump">486<span></span>
</td>
<td class="nump">608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_ReceivableFromExerciseOfCommonStockOptions', window );">Amount receivable from exercise of common stock options</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right of use assets obtained in exchange for new lease liabilities</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 375<span></span>
</td>
<td class="nump">$ 360<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_IncreaseLapseInRepurchaseOfCommonStockRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Lapse) In Repurchase Of Common Stock Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_IncreaseLapseInRepurchaseOfCommonStockRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_ReceivableFromExerciseOfCommonStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable From Exercise Of Common Stock Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_ReceivableFromExerciseOfCommonStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash inflow from repayment of loans for purchasing common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425448328272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Formation and Business of the Company<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Formation and Business of the Company</a></td>
<td class="text">Formation and Business of the Company<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pulmonx Corporation (the “Company”) was incorporated in the state of California in December 1995 as Pulmonx and reincorporated in the state of Delaware in December 2013. The Company is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (“COPD”). The Company’s solution, which is comprised of the Zephyr Endobronchial Valve (“Zephyr Valve”), the Chartis Pulmonary Assessment System (“Chartis System”) and the StratX Lung Analysis Platform (“StratX Platform”), is designed to treat a broad pool of patients for whom medical management has reached its limits and either do not want or are ineligible for surgical approaches. The Company has subsidiaries in Germany, Switzerland, Australia, the United Kingdom, Italy, France, Hong Kong, and Japan.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Going Concern</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred operating losses and negative cash flows from operations to date and has an accumulated deficit of $321.9 million as of June 30, 2022. During the six months ended June 30, 2022 and June 30, 2021, the Company used $24.6 million and $22.4 million of cash in its operating activities, respectively. As of June 30, 2022, the Company had cash, cash equivalents and marketable securities of $166.8 million. Historically, the Company’s activities have been financed through the sale of equity securities, debt financing arrangements and sales of our products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s condensed consolidated financial statements have been prepared on the basis of the Company continuing as a going concern for the next 12 months. Management believes that the Company’s existing cash, cash equivalents and marketable securities will allow the Company to continue its planned operations for at least the next 12 months from the date of the issuance of these unaudited interim condensed consolidated financial statements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of the COVID-19 Pandemic</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There continues to be widespread significant impact from the COVID-19 pandemic, which has delayed clinical trials and FDA operations and adversely impacted the number of procedures performed using our products. In the markets in which we operate, elective, specialty and other procedures and appointments have been, and continue to be, suspended or canceled to avoid non-essential patient exposure to medical environments and potential infection with COVID-19 and to focus limited resources and personnel capacity toward the treatment of COVID-19 patients. As a result, the COVID-19 pandemic and the measures taken by many countries in response have materially adversely affected, and could in the future materially adversely affect, our business, financial condition and results of operations, as well as the price of our common stock, from a decrease and delay of procedures involving our products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company saw some level of recovery in procedure volumes in our U.S. and larger international markets in the second quarter of 2022, the smaller international markets were hampered by a slower recovery, including continued lockdowns in China. The Company may continue to see regional variations in procedure volumes in the U.S. and international markets from the COVID-19 pandemic and its variants.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s unaudited interim condensed consolidated financial statements reflect judgments and estimates that could change in the future as a result of the COVID-19 pandemic. The COVID-19 pandemic has adversely impacted the Company’s business, financial condition and results of operations by decreasing and delaying procedures performed using its products. While many regions begin to stabilize with improvements in procedure volumes, there continues to be variability and uncertainty as variants of the virus emerge. The Company can make no assurance regarding any future level of demand for the Company’s products, and COVID-19 may adversely impact the results of operations and financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425450800192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of December 31, 2021 was derived from the Company’s audited financial statements, but does not include all disclosures required by GAAP. The accompanying unaudited condensed consolidated financial statements as of June 30, 2022 and for the three and six months ended June 30, 2022 and 2021, have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. Accordingly, these financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2021 and notes thereto, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the SEC on March 1, 2022. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company’s condensed consolidated financial position as of June 30, 2022 and condensed consolidated results of operations for the three and six months ended June 30, 2022 and 2021 and condensed consolidated cash flows for the six months ended June 30, 2022 and 2021 have been made. The results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2022.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions include reserves and write-downs related to inventories, the recoverability of long term assets, valuation of common stock, stock-based compensation, intangible assets, goodwill, debt and related features, deferred tax assets and related valuation allowances and impact of contingencies.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the Company’s financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the term loan approximates their fair value. The fair value of marketable debt securities is estimated using Level 2 inputs based on their quoted market values (Note 4).</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash, cash equivalents and accounts receivable. The Company maintains its cash and cash equivalents balances with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance Corporation (“FDIC”) insured limits. As of June 30, 2022 and December 31, 2021, the Company also had cash on deposit with foreign banks of approximately $3.5 million and $4.6 million, respectively, that was not federally insured.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company earns revenue from the sale of its products to distributors and other customers such as hospitals. Sales of Zephyr Valves and delivery catheters accounted for most of the Company’s revenue for the six months ended June 30, 2022 and 2021. The Company’s accounts receivable are derived from revenue earned from customers and distributors. The Company performs ongoing credit evaluations of its customers’ and distributors’ financial condition and generally requires no collateral from its customers and distributors. At June 30, 2022 and December 31, 2021, no customer or distributor accounted for more than 10% of accounts receivable. During the three and six months ended June 30, 2022 and June 30, 2021, no customer or distributor accounted for more than 10% of revenue.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on single source suppliers for the components, sub-assemblies and materials for its products. These components, sub-assemblies and materials are critical and there are no or relatively few alternative sources of supply. The Company’s suppliers have generally met the Company’s demand for their products and services on a timely basis in the past.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Transaction Gains and Losses</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currencies of the Company’s wholly owned subsidiaries in Switzerland, Germany, Australia, the United Kingdom, France and Hong Kong are the Swiss franc. The functional currency of the Company’s subsidiary in Italy is the Euro. Accordingly, asset and liability accounts of Switzerland, Germany, Australia, the United Kingdom, Italy and Hong Kong operations are translated into U.S. dollars using the current exchange rate in effect at the balance sheet date and equity accounts are translated into U.S. dollars using historical rates. The revenues and expenses are translated using the average exchange rates in effect during the period, and gains and losses from foreign currency translation adjustments are included as a component of accumulated other comprehensive income in the condensed consolidated balance sheet. Foreign currency translation adjustments are recorded in other comprehensive income (loss) in the condensed consolidated statements of operations and comprehensive loss and was less than $0.1 million and less than $0.1 million during the three months ended June 30, 2022 and 2021, respectively, and less than $(0.1) million and $(0.2) million during the six months ended June 30, 2022 and 2021, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency transaction gains and losses are included in other income (expense), net in the condensed consolidated statements of operations and comprehensive loss and was $(0.2) million and $(0.1) million during the three months ended June 30, 2022 and 2021, respectively, and $(0.2) million and $0.1 million during the six months ended June 30, 2022 and 2021, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share Attributable to Common Stockholders</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, stock options, and common stock subject to repurchase related to early exercise of stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities. The Company considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities, because holders of such shares have non-forfeitable </span></div>dividend rights in the event a dividend is paid on common stock. The holders of the shares issued upon early exercise of stock options subject to repurchase do not have a contractual obligation to share in the Company’s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425534526448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">Recent Accounting Pronouncements<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848) (“ASU 2020-04”). The amendments in ASU 2020-04 provide optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in ASU 2020-04 are effective for all entities as of March 12, 2020 through December 31, 2022. An entity may elect to apply the amendments for contract modifications by Topic or Industry Subtopic as of any date from the beginning an interim period that includes or is subsequent to March 12, 2020, or prospectively from the date that the financial statements are available to be issued. Once elected for a Topic or an Industry Subtopic, the amendments must be applied prospectively for all eligible contract modifications for that Topic or Industry Subtopic. The Company may elect to apply ASU 2020-04 as its contracts referenced in London Interbank Offered Rate (“LIBOR”) are impacted by reference rate reform. The Company is currently evaluating the impact of the adoption of this ASU on the Company’s consolidated financial statements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments – Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new guidance will require financial instruments to be measured at amortized cost, and trade accounts receivable to be presented at the net amount expected to be collected. The new model requires an entity to estimate credit losses based on historical information, current information and reasonable and supportable forecasts, including estimates of prepayments. In November 2019, the FASB issued ASU 2019-10, according to which, the new standard is effective for public business entities that meet the definition of an SEC filer, excluding entities eligible to be smaller reporting companies (“SRC”) as defined by the SEC, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. For all other entities, including the Company, the new standard is effective for fiscal years beginning after December 15, 2022, and interim periods within that fiscal year. Early adoption is permitted. The Company is currently evaluating the impact of the new standard on the Company’s consolidated financial statements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other newly issued accounting pronouncements not yet effective have been deemed either immaterial or not applicable.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&trid=2122394<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425538121984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities are as follows:</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1—Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2—Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities;</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3—Unobservable inputs for the asset or liability only used when there is little, if any, market activity for the asset or liability at the measurement date. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Financial assets and liabilities held by the Company measured at fair value on a recurring basis include money market funds and marketable securities.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Measured and Recorded at Fair Value on a Nonrecurring Basis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company determines the fair value of long-lived assets held and used, such as intangible assets, by reference to independent appraisals, quoted market prices (e.g. an offer to purchase) and other factors. An impairment charge is recorded when the carrying value of the asset exceeds its fair value. As noted above, there have been no impairment charges recorded to date. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the term loan approximates the fair value and is classified as a Level 2 liability. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,689 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,171 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,652 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,823 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,363 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,149 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,512 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no liabilities measured at fair value on a recurring and non-recurring basis as of June 30, 2022.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,241 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,977 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,504 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,914 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,914 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,977 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,525 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,502 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,808 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,935 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,743 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no liabilities measured at fair value on a recurring and non-recurring basis as of December 31, 2021.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the cost, unrealized gains and losses and fair value of marketable securities (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,462 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,183 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(360)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,823 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized on the consolidated balance sheet</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Long-term marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,823 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,509 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,481 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,915 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,914 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,526 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,502 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized on the consolidated balance sheet</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,561 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Long-term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,502 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivable on marketable securities of less than $0.1 million and less than $0.1 million as of June 30, 2022 and December 31, 2021, respectively, is included in prepaid expenses and other current assets on the condensed consolidated balance sheet.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425553925056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s cash and cash equivalents consist of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,239 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,947 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,480 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,776 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,738 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,652 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,029 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,212 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,285 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands): </span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,886 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,869 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT and other receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,731 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,883 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capitalized Implementation Costs of a Hosting Arrangement</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has several software systems that are cloud-based hosting arrangements with service contracts. The Company accounts for costs incurred in connection with the implementation of these various software systems under ASU 2018-15, Intangibles—Goodwill and Other—Internal Use Software (Subtopic 350–40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract. The Company expenses all costs (internal and external) that are incurred in the planning and post-implementation operation stages. As of June 30, 2022, the Company has capitalized approximately $0.6 million in implementation costs related to the application development stage. The capitalized costs are amortized on a straight-line basis over the non-cancelable contract terms, which are generally three years. As of June 30, 2022, approximately $0.2 million </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $0.4 million capitalized costs were included in prepaid expenses and other current assets, and other long-term assets, respectively. Amortization expense, which was included in SG&A expenses, was less than $0.1 million and $0.1 million for the three and six months ended June 30, 2022.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,956 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,635 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,561 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,677 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,795 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,057 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,863)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,243)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,932 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,814 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three months ended June 30, 2022 and June 30, 2021 was $0.3 million and $0.1 million, respectively. Depreciation expense for the six months ended June 30, 2022 and June 30, 2021 was $0.7 million and $0.2 million, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill was $2.3 million as of June 30, 2022 and December 31, 2021 arising from the Company’s acquisition of Emphasys Medical, Inc, in March 2009. No goodwill impairment losses have been recognized since the acquisition. There were no acquisitions or dispositions of goodwill in six months ended June 30, 2022 and 2021. The Company assesses goodwill for impairment annually, or more frequently, when events or changes in circumstances indicate there may be impairment. Through June 30, 2022, there have been no events or changes in circumstances that indicated that the carrying value of goodwill may not be recoverable. As a result, no impairment charge was recorded during the six months ended June 30, 2022.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,464)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,849 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,633)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,410)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,849 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,572)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense relating to the intangibles totaled less than $0.1 million during each of the three months ended June 30, 2022 and June 30, 2021, respectively. Amortization expense relating to the intangibles totaled $0.1 million during each six months ended June 30, 2022 and June 30, 2021, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense is as follows as of June 30, 2022 (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining six months)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization expense</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee bonuses and commissions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,179 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,741 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued vacation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued personnel related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales taxes, franchise tax and VAT</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for early exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued inventory purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,734 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,366 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425451947552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long Term Debt and Convertible Notes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long Term Debt and Convertible Notes</a></td>
<td class="text">Long Term Debt and Convertible Notes<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Term Loan</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CIBC Loan</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2020, the Company executed a Loan and Security Agreement (the “CIBC Agreement”) with Canadian Imperial Bank of Commerce (“CIBC”) to raise up to $32.0 million in debt financing (“CIBC Loan”) consisting of $17.0 million advanced at the closing of the agreement (“Tranche A”), with the option to draw up to an additional $8.0 million (“Tranche B”) and an additional financing tranche (“Tranche C”) of up to $7.0 million on or prior to February 20, 2022. Neither Tranche B nor Tranche C was drawn before the expiration date. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CIBC Loan originally had a five-year term maturing on February 20, 2025, which included 24 months of interest only payments followed by 36 months of equal payments of principal and interest. The CIBC Loan bears interest at a floating rate equal to 1.0% above the Wall Street Journal Prime Rate at any time. The CIBC Loan is collateralized by substantially all of the Company’s assets, including cash and cash equivalents, accounts receivable, intellectual property and equipment. The Company may prepay the loan, subject to certain requirements. The CIBC Agreement includes customary restrictive covenants, financial covenants, events of default and other customary terms and conditions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company entered into a First Amendment to CIBC Agreement that changed the maturity date to March 15, 2022, which would be automatically extended to February 20, 2025 if the maturity of all outstanding convertible notes was extended to a date no earlier than May 21, 2025 or all convertible notes converted into convertible preferred stock of the Company. An amendment fee of $0.2 million was paid. The amendment was accounted for as a debt modification and no gain or loss was recognized. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, to address certain post-close covenants for which the Company was not in compliance, the Company entered into a Second Amendment to the CIBC Agreement that extended the compliance of such covenants to June 30, 2021. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company entered into an Amended and Restated CIBC Agreement which extended the maturity date from March 15, 2022 to February 20, 2025, and modified certain financial covenants. Per the amended terms, 36 equal payments of principal plus accrued interest would be due beginning March 31, 2022. In connection with the Amended and Restated agreement, the Company paid fees to CIBC of less than $0.1 million which were recorded as a discount on the CIBC Loan and are being accreted over the life of the term loan using the effective interest method. The amendment was accounted for as a debt modification and no gain or loss was recognized.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company entered into a First Amendment to the Amended and Restated Loan and Security agreement with CIBC that extended the compliance of certain post-close covenants to March 31, 2022. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into a Second Amendment to the Amended and Restated Loan and Security Agreement with CIBC, which extended the interest only period of the loan from 24 months to 36 months. Under the amended terms, principal repayment will begin in February 2023. There was no change to the loan interest rate or maturity date.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the CIBC Loan had an annual effective interest rate of 4.71% per year.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial covenants in the CIBC Agreement require that, when the cash and cash equivalents of the Company is less than $100.0 million, the Company have revenue for the trailing three-month period ending on the last day of each fiscal quarter of not less than 80.0% of the revenue for the trailing three-month period, as set forth in the annual projections delivered to the CIBC. Further, the Company is required to maintain unrestricted cash in an aggregate amount equal to or greater than the Adjusted EBITDA loss as defined in the CIBC Agreement for the four-month period ending on any date of determination. As of June 30, 2022, the Company was in compliance with all covenants contained in CIBC Agreement.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CIBC Loan consists of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.573%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;padding-right:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;padding-right:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt issuance costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;padding-right:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,901 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,869 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid $0.4 million fees to the lender and third parties which is reflected as a discount on the CIBC Loan and is being accreted over the life of the term loan using the effective interest method. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022 and 2021, the Company recorded interest expense related to debt discount and debt issuance costs of CIBC Loan of less than $0.1 million and less than $0.1 million, respectively. During the six months ended June 30, 2022 and 2021, the Company recorded interest expense related to debt discount and debt issuance costs of CIBC Loan of less than $0.1 million and $0.1 million, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense on the CIBC Loan amounted $0.2 million and $0.2 million during the three months ended June 30, 2022 and 2021, respectively. Interest expense on the CIBC Loan amounted $0.4 million and $0.4 million during the six months ended June 30, 2022 and 2021, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, Pulmonx International Sàrl, a wholly-owned subsidiary of the Company, entered into a COVID-19 Credit Agreement with UBS Switzerland AG to receive up to 0.5 million Swiss Francs ($0.5 million U.S. dollar equivalent) under Swiss Federal Government program to mitigate the economic impact of the spread of the coronavirus. In May 2020, Pulmonx International Sàrl received $0.5 million Swiss Francs ($0.5 million U.S. dollar equivalent) under the COVID-19 Credit Agreement. The COVID-19 Credit Agreement bears no interest and is being repaid in twelve equal installments, paid semi-annually, beginning in March of 2022. As of June 30, 2022, Pulmonx International Sàrl paid less than $0.1 million to the lender.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Maturities of Financing Obligations</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the aggregate future payments under the CIBC Loan and Credit Agreement (including interest payments) are as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining six months)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,779 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,843 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,716 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,236)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Term loan and credit agreement</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,381 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425449662960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue RecognitionThe Company’s contract liabilities consist of deferred revenue for remaining performance obligations by the Company to the customer after delivery, which was $0.1 million and $0.2 million as of June 30, 2022 and <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021, respectively. The deferred revenue as of December 31, 2020 was $0.1 million, which was recognized as revenue during the year ended December 31, 2021. The deferred revenue as of December 31, 2021 was $0.2 million, which was recognized as revenue during the six months ended June 30, 2022.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates its revenue by major geographic region, which has been disclosed in Note 12, “Segment Information”.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425451837280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a lease for its headquarters location in Redwood City, California. In October 2019, the Company renewed its lease for the headquarters location in Redwood City, California for an additional five years commencing in August 2020 and expiring in July 2025. The monthly base rent during the renewed term is $0.1 million and is subject to an annual increase of 3.5%. The Company is responsible for its share of real estate taxes, common area maintenance and management fees. The Company is eligible to receive a tenant improvement allowance of $0.2 million on commencement of the renewal term in August 2020.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2013, the Company entered into a five-year lease for office facilities in Switzerland. The Company had an option to extend the lease through January 2022, which was not exercised by the Company. Per the lease terms, in the event the option to extend is not exercised, the lease remains in force and can be terminated with 12-months’ notice.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company executed a sublease for another office facility in Redwood City, California for a three-year term commencing on June 1, 2020. The lease agreement provides for early termination if the Company or Sublandlord elects to terminate the lease by providing the other party at least 180 days prior written notice. The early termination may only occur on or after the expiration of the 18th full calendar month of the sublease term. The monthly base rent during the term is less than $0.1 million and is subject to an annual increase of 3.5%. The Company is responsible for its share of real estate taxes, common area maintenance and management fees.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company amended a sublease agreement entered into in April 2020, to include additional facility space in Redwood City, California for a four-year term. The amendment was accounted as a separate sublease agreement. The sublease agreement contained a rent-free period through February 14, 2021, after which rent is approximately $0.1 million per month and is subject to an annual increase of 3.5%. The Company is responsible for its share of real estate taxes, common area maintenance and management fees. The Company is eligible to receive a tenant improvement allowance of $0.7 million to fund facility enhancements. The sublease agreement can be extended for an additional twelve-month period, at the Company’s option. For accounting purposes, the lease term is 4 years as it is not reasonably certain that the Company will exercise the renewal option. The amendment also changed the lease term entered into in April 2020, which was extended until May 31, 2024, but left the early termination clause unchanged. In September 2021, the Company became reasonably certain that the early termination clause would not be exercised as capital expenditures on the facility build-out created sufficient disincentive to terminate the lease early. The lease term was reevaluated and extended from November 30, 2021 to May 31, 2024.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has leases on eight vehicles with an average term of 2.9 years.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost consists of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:67.118%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.471%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,446 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,752 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,751 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes a maturity analysis of the Company’s lease liabilities showing the aggregate lease payments as of June 30, 2022 (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining six months)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,452 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,919 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,112 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,476 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,061 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,415 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes additional information related to the Company’s operating leases (in thousands, except weighted average data):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.164%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,987 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,075 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.43</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate (percent)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes other supplemental information related to the Company’s operating leases (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.164%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:4.5pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities included in cash flows used in operating activities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,330 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Agreement</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the Company entered into an agreement with a service provider which requires total minimum purchases of $0.6 million, $0.4 million, and $0.4 million over the next three years. Since the inception of the </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreement, the Company recorded $0.2 million of expense for services related to this agreement in cost of goods sold during the three months ended June 30, 2022.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div>From time to time, the Company may be a party to various litigation claims in the normal course of business. Legal fees and other costs associated with such actions are expensed as incurred. The Company assesses, in conjunction with legal counsel, the need to record a liability for litigation and contingencies. Accrual estimates are recorded when and if it is determinable that such a liability for litigation and contingencies are both probable and reasonably estimable.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425451843440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income TaxesThe income tax expense for the three months ended June 30, 2022 and 2021 was less than $0.1 million and $0.1 million, respectively. The income tax expense for the six months ended June 30, 2022 and 2021 was $0.1 million and $0.1 million, respectively. The income tax expense was determined based upon estimates of the Company’s effective income tax rates in various jurisdictions. The difference between the Company’s effective income tax rate and the U.S. federal statutory rate is primarily attributable to state income taxes, foreign income taxes, and a full valuation allowance against net deferred tax assets. The income tax expense for the six months ended June 30, 2022 and 2021 relates primarily to state minimum income tax and income tax on the Company’s earnings in foreign jurisdictions.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425451829920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders’ Equity<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, the Company’s certificate of incorporation authorized the Company to issue up to 200,000,000 and 200,000,000 shares of common stock, respectively. Common stockholders are entitled to dividends as and when declared by the Board of Directors, subject to the rights of holders of all classes of stock outstanding having priority rights as to dividends. There have been no dividends declared to date. The holder of each share of common stock is entitled to one vote.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shares Reserved for Future Issuance </span></div><div style="margin-bottom:12pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reserved shares of common stock for future issuances as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options issued and outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600,237 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145,131 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock restricted stock units issued and outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock available for future grants</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,838,605 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,751,115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock available for ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255,773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932,458 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,786,572 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,271,132 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Plan</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the six months ended June 30, 2022 is set forth below:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding Options</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145,131 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.44 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172,886)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600,237 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.43 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding as of June 30, 2022 was $15.0 million.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:56.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Contractual Life (in Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904,464</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.56 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.30</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600,237</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.26</span></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intrinsic value of options vested as of June 30, 2022 was $7.5 million.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Early Exercise of Stock Options</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the individual option grants, options are fully exercisable on the grant date, subject to the Company’s repurchase right at the original exercise price. Accordingly, options may be exercised prior to vesting. The shares are subject to the Company’s lapsing repurchase right upon termination of employment or over the options’ vesting period of generally four years at the original purchase price. The proceeds initially are recorded in other liabilities from the early exercise of stock options and are reclassified to additional paid-in capital as the Company’s repurchase right lapses. During the six months ended June 30, 2022, the Company did not repurchase shares of common stock. During the six months ended June 30, 2021, the Company repurchased 12,945 shares of common stock for less than $0.1 million. As of June 30, 2022 and December 31, 2021, 155,969 and 223,195 shares, respectively, were subject to repurchase, with an aggregate exercise price of $0.3 million and $0.4 million, respectively, and were recorded in other current liabilities.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity with respect to restricted stock units was as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares Underlying Outstanding Restricted Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">442,428 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42.36 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799,320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115,380)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,411)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091,957 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.78 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of restricted stock units outstanding as of June 30, 2022 was $16.1 million.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Stock-Based Compensation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is reflected in the statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">189 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">336 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">210 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">977 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">606 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,638 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,583 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,764 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,383 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,312 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,896 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,580 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above stock-based compensation expense related to the following equity-based awards (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and restricted stock units</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,209 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,520 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,521 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,559 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,383 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,312 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,896 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,580 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation of $0.3 million and $0.3 million was capitalized into inventory for the three months ended June 30, 2022 and 2021, respectively. Stock-based compensation of $0.6 million and $0.5 million was capitalized into inventory for the six months ended June 30, 2022 and 2021, respectively. Stock-based compensation capitalized in prior periods of $0.2 million and $0.1 million was recognized as cost of sales in the three months ended June 30, 2022 and 2021, respectively. Stock-based compensation capitalized in prior periods of $0.3 million and $0.2 million was recognized as cost of sales in the six months ended June 30, 2022 and 2021, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, there was $52.6 million of unrecognized compensation costs related to non-vested common stock options and restricted stock units, expected to be recognized over a weighted-average period of 3.14 years. The total grant date fair value of shares vested during the three and six months ended June 30, 2022 was $4.7 million and $7.4 million, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the Company had unrecognized employee stock-based compensation relating to ESPP awards of approximately $0.1 million, which is expected to be recognized over a weighted-average period of 0.1 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425451846864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text">Net Loss per Share Attributable to Common Stockholders<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders which excludes shares which are legally outstanding, but subject to repurchase by the Company (in thousands, except share and per share amounts):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,640)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,468)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,474)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common stock outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,171,893 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,324,022 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,090,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,021,469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: weighted-average common shares subject to repurchase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168,450)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281,408)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185,212)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312,921)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares used to compute basic and diluted net loss per share</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,003,443 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,042,614 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,904,952 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,708,548 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.36)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.83)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.71)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company’s net loss, in common stock equivalent shares:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600,244 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,483,364 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,550 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested early exercised common stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,969 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares committed under ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,865 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,881,205 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,223,356 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425451829920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">Segment InformationThe chief operating decision maker for the Company is the Chief Executive Officer. The Company’s Chief Executive Officer reviews financial information presented on a consolidated basis, accompanied by information about revenue by geographic region, for purposes of allocating resources and evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated unit level. Accordingly, the Company has determined that it has a single reportable and operating segment structure. The Company’s Chief Executive Officer evaluates performance based primarily on revenue in the geographic locations in which the Company operates.<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by geographic area is based on the billing address of the customer. The following table sets forth the Company’s revenue by geographic area (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,616 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,567 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,629 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,856 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle-East and Africa (“EMEA”)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,570 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,749 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,786 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,950 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,203 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,735 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,447 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from Germany and France represented 10% and 9%, respectively, of total revenue for the three months ended June 30, 2022. Revenue from Germany and France represented 11% and 9%, respectively, of total revenue for the three months ended June 30, 2021. Revenue from Germany and France represented 12% and 8%, respectively, of total revenue for the six months ended June 30, 2022. Revenue from Germany and France represented 12% and 10%, respectively, of total revenue for the six months ended June 30, 2021. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets by geographic area are based on physical location of those assets. The following table sets forth the Company’s long-lived assets by geographic area (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,871 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,767 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EMEA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,932 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,814 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425448279872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions include reserves and write-downs related to inventories, the recoverability of long term assets, valuation of common stock, stock-based compensation, intangible assets, goodwill, debt and related features, deferred tax assets and related valuation allowances and impact of contingencies.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the Company’s financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the term loan approximates their fair value. The fair value of marketable debt securities is estimated using Level 2 inputs based on their quoted market values (Note 4).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash, cash equivalents and accounts receivable. The Company maintains its cash and cash equivalents balances with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance Corporation (“FDIC”) insured limits.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation and Transaction Gains and Losses</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Transaction Gains and Losses</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currencies of the Company’s wholly owned subsidiaries in Switzerland, Germany, Australia, the United Kingdom, France and Hong Kong are the Swiss franc. The functional currency of the Company’s subsidiary in Italy is the Euro. Accordingly, asset and liability accounts of Switzerland, Germany, Australia, the United Kingdom, Italy and Hong Kong operations are translated into U.S. dollars using the current exchange rate in effect at the balance sheet date and equity accounts are translated into U.S. dollars using historical rates. The revenues and expenses are translated using the average exchange rates in effect during the period, and gains and losses from foreign currency translation adjustments are included as a component of accumulated other comprehensive income in the condensed consolidated balance sheet. Foreign currency translation adjustments are recorded in other comprehensive income (loss) in the condensed consolidated statements of operations and comprehensive loss and was less than $0.1 million and less than $0.1 million during the three months ended June 30, 2022 and 2021, respectively, and less than $(0.1) million and $(0.2) million during the six months ended June 30, 2022 and 2021, respectively.</span></div>Foreign currency transaction gains and losses are included in other income (expense), net in the condensed consolidated statements of operations and comprehensive loss<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share Attributable to Common Stockholders</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, stock options, and common stock subject to repurchase related to early exercise of stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities. The Company considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities, because holders of such shares have non-forfeitable </span></div>dividend rights in the event a dividend is paid on common stock. The holders of the shares issued upon early exercise of stock options subject to repurchase do not have a contractual obligation to share in the Company’s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848) (“ASU 2020-04”). The amendments in ASU 2020-04 provide optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in ASU 2020-04 are effective for all entities as of March 12, 2020 through December 31, 2022. An entity may elect to apply the amendments for contract modifications by Topic or Industry Subtopic as of any date from the beginning an interim period that includes or is subsequent to March 12, 2020, or prospectively from the date that the financial statements are available to be issued. Once elected for a Topic or an Industry Subtopic, the amendments must be applied prospectively for all eligible contract modifications for that Topic or Industry Subtopic. The Company may elect to apply ASU 2020-04 as its contracts referenced in London Interbank Offered Rate (“LIBOR”) are impacted by reference rate reform. The Company is currently evaluating the impact of the adoption of this ASU on the Company’s consolidated financial statements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments – Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new guidance will require financial instruments to be measured at amortized cost, and trade accounts receivable to be presented at the net amount expected to be collected. The new model requires an entity to estimate credit losses based on historical information, current information and reasonable and supportable forecasts, including estimates of prepayments. In November 2019, the FASB issued ASU 2019-10, according to which, the new standard is effective for public business entities that meet the definition of an SEC filer, excluding entities eligible to be smaller reporting companies (“SRC”) as defined by the SEC, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. For all other entities, including the Company, the new standard is effective for fiscal years beginning after December 15, 2022, and interim periods within that fiscal year. Early adoption is permitted. The Company is currently evaluating the impact of the new standard on the Company’s consolidated financial statements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other newly issued accounting pronouncements not yet effective have been deemed either immaterial or not applicable.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Assets and Liabilities Measured at Fair Value</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Measured and Recorded at Fair Value on a Nonrecurring Basis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company determines the fair value of long-lived assets held and used, such as intangible assets, by reference to independent appraisals, quoted market prices (e.g. an offer to purchase) and other factors. An impairment charge is recorded when the carrying value of the asset exceeds its fair value. As noted above, there have been no impairment charges recorded to date. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the term loan approximates the fair value and is classified as a Level 2 liability. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425447810080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,689 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,171 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,652 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,823 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,363 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,149 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,512 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no liabilities measured at fair value on a recurring and non-recurring basis as of June 30, 2022.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,241 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,977 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,504 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,914 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,914 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,977 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,525 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,502 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,808 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,935 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,743 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no liabilities measured at fair value on a recurring and non-recurring basis as of December 31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Cost, Unrealized Gains and Losses and Fair Value of Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the cost, unrealized gains and losses and fair value of marketable securities (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,462 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,183 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(360)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,823 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized on the consolidated balance sheet</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Long-term marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,823 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,509 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,481 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,915 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,914 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,526 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,502 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized on the consolidated balance sheet</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,561 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Long-term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,502 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425448311296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s cash and cash equivalents consist of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,239 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,947 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,480 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,776 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,738 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,652 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,029 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,212 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,285 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands): </span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,886 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,869 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT and other receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,731 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,883 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,956 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,635 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,561 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,677 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,795 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,057 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,863)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,243)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,932 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,814 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,464)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,849 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,633)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,410)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,849 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,572)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Amortization Expense</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense is as follows as of June 30, 2022 (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining six months)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization expense</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee bonuses and commissions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,179 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,741 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued vacation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued personnel related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales taxes, franchise tax and VAT</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for early exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued inventory purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,734 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,366 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425451802288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long Term Debt and Convertible Notes (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt Instruments</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CIBC Loan consists of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.573%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;padding-right:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;padding-right:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt issuance costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;padding-right:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,901 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,869 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Contractual Maturities of Financing Obligations</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the aggregate future payments under the CIBC Loan and Credit Agreement (including interest payments) are as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining six months)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,779 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,843 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,716 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,236)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Term loan and credit agreement</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,381 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425538182672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Operating Lease Cost and Additional Information</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost consists of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:67.118%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.471%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,446 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,752 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,751 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes additional information related to the Company’s operating leases (in thousands, except weighted average data):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.164%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,987 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,075 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.43</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate (percent)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes other supplemental information related to the Company’s operating leases (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.164%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:4.5pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities included in cash flows used in operating activities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,330 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity Analysis of Lease Liabilities</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes a maturity analysis of the Company’s lease liabilities showing the aggregate lease payments as of June 30, 2022 (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining six months)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,452 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,919 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,112 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,476 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,061 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,415 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425449386832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Shares Reserved for Future Issuance</a></td>
<td class="text"><div style="margin-bottom:12pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reserved shares of common stock for future issuances as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options issued and outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600,237 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145,131 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock restricted stock units issued and outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock available for future grants</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,838,605 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,751,115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock available for ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255,773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932,458 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,786,572 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,271,132 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the six months ended June 30, 2022 is set forth below:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding Options</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145,131 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.44 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172,886)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600,237 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.43 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock', window );">Schedule of Options Vested and Expected to Vest</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:56.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Contractual Life (in Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904,464</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.56 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.30</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600,237</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.26</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Activity with Respect to Restricted Stock Units</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity with respect to restricted stock units was as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares Underlying Outstanding Restricted Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">442,428 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42.36 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799,320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115,380)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,411)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091,957 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.78 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Total Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is reflected in the statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">189 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">336 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">210 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">977 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">606 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,638 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,583 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,764 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,383 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,312 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,896 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,580 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above stock-based compensation expense related to the following equity-based awards (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and restricted stock units</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,209 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,520 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,521 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,559 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,383 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,312 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,896 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,580 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425451821648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss per Share</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders which excludes shares which are legally outstanding, but subject to repurchase by the Company (in thousands, except share and per share amounts):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,640)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,468)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,474)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common stock outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,171,893 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,324,022 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,090,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,021,469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: weighted-average common shares subject to repurchase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168,450)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281,408)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185,212)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312,921)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares used to compute basic and diluted net loss per share</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,003,443 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,042,614 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,904,952 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,708,548 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.36)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.83)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.71)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Outstanding</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company’s net loss, in common stock equivalent shares:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600,244 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,483,364 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,550 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested early exercised common stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,969 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares committed under ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,865 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,881,205 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,223,356 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425451950224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenue by Geographic Area</a></td>
<td class="text">The following table sets forth the Company’s revenue by geographic area (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,616 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,567 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,629 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,856 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle-East and Africa (“EMEA”)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,570 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,749 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,786 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,950 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,203 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,735 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,447 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Schedule of Long-lived Assets by Geographic Area</a></td>
<td class="text">The following table sets forth the Company’s long-lived assets by geographic area (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,871 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,767 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EMEA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,932 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,814 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425440629824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Formation and Business of the Company (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 321,863<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 291,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="nump">24,590<span></span>
</td>
<td class="nump">$ 22,362<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_CashAndCashEquivalentsAndMarketableSecurities', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="nump">$ 166,800<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_CashAndCashEquivalentsAndMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents And Marketable Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_CashAndCashEquivalentsAndMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425447897184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash on deposit with foreign banks</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss,) foreign currency translation adjustments</a></td>
<td class="nump">6<span></span>
</td>
<td class="num">$ (24)<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="num">$ (272)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">$ (206)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Foreign currency transaction gains and (losses)</a></td>
<td class="num">(200)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss,) foreign currency translation adjustments</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (100)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossRealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossRealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425445882864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value of Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="nump">$ 44,823<span></span>
</td>
<td class="nump">$ 42,502<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government agency bonds</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="nump">34,142<span></span>
</td>
<td class="nump">20,481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,914<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">4,689<span></span>
</td>
<td class="nump">7,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="nump">44,823<span></span>
</td>
<td class="nump">42,502<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">49,512<span></span>
</td>
<td class="nump">49,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | U.S. Government agency bonds</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="nump">34,142<span></span>
</td>
<td class="nump">20,481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Commercial paper</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="nump">10,681<span></span>
</td>
<td class="nump">19,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Corporate bonds</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,914<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Money market funds</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,192<span></span>
</td>
<td class="nump">831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Commercial paper</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,497<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Level 1</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,192<span></span>
</td>
<td class="nump">831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="nump">25,171<span></span>
</td>
<td class="nump">14,977<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">27,363<span></span>
</td>
<td class="nump">15,808<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Level 1 | U.S. Government agency bonds</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="nump">25,171<span></span>
</td>
<td class="nump">14,977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Level 1 | Commercial paper</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Level 1 | Corporate bonds</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Level 1 | Money market funds</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,192<span></span>
</td>
<td class="nump">831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Level 1 | Commercial paper</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Level 2</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,497<span></span>
</td>
<td class="nump">6,410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="nump">19,652<span></span>
</td>
<td class="nump">27,525<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">22,149<span></span>
</td>
<td class="nump">33,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Level 2 | U.S. Government agency bonds</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="nump">8,971<span></span>
</td>
<td class="nump">5,504<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Level 2 | Commercial paper</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="nump">10,681<span></span>
</td>
<td class="nump">19,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Level 2 | Corporate bonds</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,914<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Level 2 | Money market funds</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Level 2 | Commercial paper</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,497<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Level 3</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Level 3 | U.S. Government agency bonds</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Level 3 | Commercial paper</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Level 3 | Corporate bonds</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Level 3 | Money market funds</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Level 3 | Commercial paper</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425447844432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Unrealized Gains and Losses and Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 45,183<span></span>
</td>
<td class="nump">$ 42,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(360)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">44,823<span></span>
</td>
<td class="nump">42,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_FairValueRecognizedOnBalanceSheetAbstract', window );"><strong>Amounts recognized on the consolidated balance sheet</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term marketable securities</a></td>
<td class="nump">40,139<span></span>
</td>
<td class="nump">31,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term marketable securities</a></td>
<td class="nump">4,684<span></span>
</td>
<td class="nump">10,941<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_CashCashEquivalentsAndAvailableForSaleDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">44,823<span></span>
</td>
<td class="nump">42,502<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government agency bonds</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">34,462<span></span>
</td>
<td class="nump">20,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(320)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">34,142<span></span>
</td>
<td class="nump">20,481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,914<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">10,721<span></span>
</td>
<td class="nump">19,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(40)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 10,681<span></span>
</td>
<td class="nump">$ 19,107<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_CashCashEquivalentsAndAvailableForSaleDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents And Available-For-Sale Debt Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_CashCashEquivalentsAndAvailableForSaleDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_FairValueRecognizedOnBalanceSheetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Recognized On Balance Sheet</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_FairValueRecognizedOnBalanceSheetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425449386832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss', window );">Accrued interest receivable on marketable securities, less than</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liabilities measured at fair value on a recurring and non-recurring</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&oid=124269663&loc=SL120267853-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -URI https://asc.fasb.org/extlink&oid=126970911&loc=SL121698322-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&oid=124269663&loc=SL120267856-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425448054112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 117,258<span></span>
</td>
<td class="nump">$ 141,239<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">2,192<span></span>
</td>
<td class="nump">831<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommercialPaperAtCarryingValue', window );">Commercial paper</a></td>
<td class="nump">2,497<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_CorporateBondsDebtSecuritiesAtCarryingValue', window );">Corporate bonds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,410<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash and cash equivalents</a></td>
<td class="nump">$ 121,947<span></span>
</td>
<td class="nump">$ 148,480<span></span>
</td>
<td class="nump">$ 198,703<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_CorporateBondsDebtSecuritiesAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Corporate Bonds Debt Securities, at Carrying Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_CorporateBondsDebtSecuritiesAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommercialPaperAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unsecured short-term debt instrument issued by corporations which are highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommercialPaperAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425440588272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 3,776<span></span>
</td>
<td class="nump">$ 3,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">784<span></span>
</td>
<td class="nump">518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">14,652<span></span>
</td>
<td class="nump">12,029<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 19,212<span></span>
</td>
<td class="nump">$ 16,285<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425449657168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 2,886<span></span>
</td>
<td class="nump">$ 1,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">820<span></span>
</td>
<td class="nump">2,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableCurrent', window );">VAT and other receivable</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 3,731<span></span>
</td>
<td class="nump">$ 4,883<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425444862304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 7,795<span></span>
</td>
<td class="nump">$ 7,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(2,863)<span></span>
</td>
<td class="num">(2,243)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,932<span></span>
</td>
<td class="nump">4,814<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">1,956<span></span>
</td>
<td class="nump">1,635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">1,623<span></span>
</td>
<td class="nump">1,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">262<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">2,277<span></span>
</td>
<td class="nump">2,277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 1,677<span></span>
</td>
<td class="nump">$ 1,332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425449410560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Capitalized Implementation Costs of a Hosting Arrangement (Details) - Software Systems<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization', window );">Capitalized costs</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_HostingArrangementServiceContractImplementationCostCapitalizedAmortizationPeriod', window );">Amortization period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization', window );">Amortization expense</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization', window );">Capitalized costs</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Other Long-Term Assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization', window );">Capitalized costs</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_HostingArrangementServiceContractImplementationCostCapitalizedAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Hosting Arrangement, Service Contract, Implementation Cost, Capitalized, Amortization Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_HostingArrangementServiceContractImplementationCostCapitalizedAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of capitalized implementation cost from hosting arrangement that is service contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&oid=118198657&loc=SL118198666-228104<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for capitalized implementation cost from hosting arrangement that is service contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&oid=118198657&loc=SL118198666-228104<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425448358784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">2,333,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,333,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,333,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Goodwill, accumulated impairment loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill disposed of</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, impairment loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense related to intangibles, less than</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425444635200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">$ 1,849<span></span>
</td>
<td class="nump">$ 1,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,633)<span></span>
</td>
<td class="num">(1,572)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">1,658<span></span>
</td>
<td class="nump">1,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,464)<span></span>
</td>
<td class="num">(1,410)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">191<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(169)<span></span>
</td>
<td class="num">(162)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425440684848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Future Amortization Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2022 (remaining six months)</a></td>
<td class="nump">$ 62<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">123<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">31<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">$ 216<span></span>
</td>
<td class="nump">$ 277<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425448105984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued employee bonuses and commissions</a></td>
<td class="nump">$ 3,179<span></span>
</td>
<td class="nump">$ 4,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Accrued vacation</a></td>
<td class="nump">2,134<span></span>
</td>
<td class="nump">1,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent', window );">Other accrued personnel related expenses</a></td>
<td class="nump">2,308<span></span>
</td>
<td class="nump">2,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">2,233<span></span>
</td>
<td class="nump">2,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Sales taxes, franchise tax and VAT</a></td>
<td class="nump">602<span></span>
</td>
<td class="nump">730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent', window );">Liability for early exercise of stock options</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_AccruedInventoryPurchasesCurrent', window );">Accrued inventory purchases</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">868<span></span>
</td>
<td class="nump">823<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 11,734<span></span>
</td>
<td class="nump">$ 13,366<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_AccruedInventoryPurchasesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Inventory Purchases Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_AccruedInventoryPurchasesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred for employer-related costs classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425444580016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long Term Debt and Convertible Notes - CIBC Loan Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 20, 2020 </div>
<div>USD ($) </div>
<div>payment</div>
</th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of fees to lender and third parties (less than)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 41,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember', window );">Medium-term Notes | CIBC Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_DebtInstrumentFaceAmountIncludingAccordionFeature', window );">Debt instrument, face amount including accordion feature</a></td>
<td class="nump">$ 32,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_DebtInstrumentPeriodicPaymentInterestOnlyTerm', window );">Interest payments term</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm', window );">Principal and interest payments term</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Fee amount</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_DebtInstrumentNumberOfPeriodicPayments', window );">Number of periodic payments | payment</a></td>
<td class="nump">36<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of fees to lender and third parties (less than)</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_IncreaseInLoanInterestRate', window );">Increase in loan interest rate</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4.71%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4.71%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_DebtInstrumentCovenantCashAndCashEquivalentsMinimumThresholdTriggerForRevenueRequirement', window );">Cash and cash equivalents trigger for revenue requirement</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_DebtInstrumentCovenantMinimumRevenueRequirementPeriod', window );">Minimum percentage of revenue requirement, trailing period of revenue</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_DebtInstrumentCovenantMinimumRevenueRequirementsPercentage', window );">Minimum percentage of revenue requirement</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_DebtInstrumentCovenantUnrestrictedCashRequirementPeriod', window );">Unrestricted cash requirement period</a></td>
<td class="text">4 months<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Interest expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember', window );">Medium-term Notes | CIBC Agreement | Prime Rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember', window );">Medium-term Notes | CIBC Agreement, Tranche A</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 17,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember', window );">Medium-term Notes | CIBC Agreement, Tranche B</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_DebtInstrumentAccordionFeatureIncreaseFaceAmount', window );">Accordion feature on face amount of debt</a></td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_GainLossOnAmendmentOfDebtInstrument', window );">Gain Loss on Amendment of Debt Instrument</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember', window );">Medium-term Notes | CIBC Agreement, Tranche C</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_DebtInstrumentAccordionFeatureIncreaseFaceAmount', window );">Accordion feature on face amount of debt</a></td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_DebtInstrumentAccordionFeatureIncreaseFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Accordion Feature, Increase Face Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_DebtInstrumentAccordionFeatureIncreaseFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_DebtInstrumentCovenantCashAndCashEquivalentsMinimumThresholdTriggerForRevenueRequirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Cash And Cash Equivalents Minimum Threshold Trigger For Revenue Requirement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_DebtInstrumentCovenantCashAndCashEquivalentsMinimumThresholdTriggerForRevenueRequirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_DebtInstrumentCovenantMinimumRevenueRequirementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Minimum Revenue Requirement, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_DebtInstrumentCovenantMinimumRevenueRequirementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_DebtInstrumentCovenantMinimumRevenueRequirementsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Minimum Revenue Requirements, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_DebtInstrumentCovenantMinimumRevenueRequirementsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_DebtInstrumentCovenantUnrestrictedCashRequirementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Unrestricted Cash Requirement, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_DebtInstrumentCovenantUnrestrictedCashRequirementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_DebtInstrumentFaceAmountIncludingAccordionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Face Amount Including Accordion Feature</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_DebtInstrumentFaceAmountIncludingAccordionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_DebtInstrumentNumberOfPeriodicPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Periodic Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_DebtInstrumentNumberOfPeriodicPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_DebtInstrumentPeriodicPaymentInterestOnlyTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment, Interest Only, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_DebtInstrumentPeriodicPaymentInterestOnlyTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment, Principal And Interest, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_GainLossOnAmendmentOfDebtInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Amendment of Debt Instrument</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_GainLossOnAmendmentOfDebtInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_IncreaseInLoanInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase In Loan Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_IncreaseInLoanInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lung_CIBCAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lung_CIBCAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lung_CIBCAgreementTrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lung_CIBCAgreementTrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lung_CIBCAgreementTrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lung_CIBCAgreementTrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lung_CIBCAgreementTrancheCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lung_CIBCAgreementTrancheCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425448336192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long Term Debt and Convertible Notes - CIBC Loan Components Of Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loan</a></td>
<td class="nump">$ 18,716<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: debt issuance costs</a></td>
<td class="num">(99)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Term loan and credit agreement</a></td>
<td class="nump">17,381<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=lung_CIBCAgreementMember', window );">CIBC Agreement | Medium-term Notes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loan</a></td>
<td class="nump">17,000<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: debt issuance costs</a></td>
<td class="num">(99)<span></span>
</td>
<td class="num">(131)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Term loan and credit agreement</a></td>
<td class="nump">$ 16,901<span></span>
</td>
<td class="nump">$ 16,869<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lung_CIBCAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lung_CIBCAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_MediumTermNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425444663744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long Term Debt and Convertible Notes - Credit Agreement and Paycheck Protection Program Narrative (Details) - Pulmonx International Sarl - Line of Credit<br> SFr in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2020 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>CHF (SFr) </div>
<div>installment</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt | $</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=lung_PulmonxInternationalSarlMember', window );">COVID-19 Credit Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">SFr 0.5<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from line of credit</a></td>
<td class="nump">SFr 0.5<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_NumberOfInstallmentsForRepayment', window );">Number of installments for repayment | installment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_NumberOfInstallmentsForRepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Installments For Repayment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_NumberOfInstallmentsForRepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lung_PulmonxInternationalSarlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lung_PulmonxInternationalSarlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lung_COVID19CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lung_COVID19CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425447990928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long Term Debt and Convertible Notes - Contractual Maturities of Financing Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-term Debt, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2022 (remaining six months)</a></td>
<td class="nump">$ 410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">7,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">8,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">1,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">18,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: unamortized debt discount</a></td>
<td class="num">(99)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Less: interest</a></td>
<td class="num">(1,236)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Term loan and credit agreement</a></td>
<td class="nump">$ 17,381<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425448315856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425445901888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Leases, Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>lease</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text"> <span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_OperatingLeaseMonthlyExpense', window );">Monthly base rent</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_OperatingLeaseExpenseAnnualIncreaseRate', window );">Annual increase rate</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_TenantImprovementAllowanceReceivableUponLeaseRenewal', window );">Tenant improvement allowance, receivable upon lease renewal</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_LesseeOperatingLeaseOptionToTerminateNoticePeriod', window );">Option to terminate, notice period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_LesseeOperatingSubleaseTerm', window );">Sublease term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_LesseeOperatingSubleaseOptionToTerminateNoticePeriod', window );">Sublease, option to terminate, notice period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_LesseeOperatingSubleaseOptionToTerminateTerm', window );">Sublease, period for option to terminate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_LesseeOperatingSubleaseMonthlyExpense', window );">Sublease monthly rent</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_LesseeOperatingSubleaseExpenseAnnualIncreaseRate', window );">Sublease, expense, annual increase rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_LesseeOperatingSubleaseTenantImprovementAllowanceReceivableUponLeaseRenewal', window );">Sublease, tenant improvement allowance, receivable upon lease renewal</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_LesseeOperatingSubleaseRenewalTerm', window );">Sublease renewal term</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_NumberOfVehicleLeases', window );">Number of vehicle leases | lease</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Office Facilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_LesseeOperatingLeaseOptionToTerminateNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Option To Terminate, Notice Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_LesseeOperatingLeaseOptionToTerminateNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_LesseeOperatingSubleaseExpenseAnnualIncreaseRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Sublease, Expense, Annual Increase Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_LesseeOperatingSubleaseExpenseAnnualIncreaseRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_LesseeOperatingSubleaseMonthlyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Sublease, Monthly Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_LesseeOperatingSubleaseMonthlyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_LesseeOperatingSubleaseOptionToTerminateNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Sublease, Option To Terminate, Notice Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_LesseeOperatingSubleaseOptionToTerminateNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_LesseeOperatingSubleaseOptionToTerminateTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Sublease, Option To Terminate, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_LesseeOperatingSubleaseOptionToTerminateTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_LesseeOperatingSubleaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Sublease, Renewal Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_LesseeOperatingSubleaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_LesseeOperatingSubleaseTenantImprovementAllowanceReceivableUponLeaseRenewal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Sublease, Tenant Improvement Allowance, Receivable Upon Lease Renewal</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_LesseeOperatingSubleaseTenantImprovementAllowanceReceivableUponLeaseRenewal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_LesseeOperatingSubleaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Sublease, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_LesseeOperatingSubleaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_NumberOfVehicleLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Vehicle Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_NumberOfVehicleLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_OperatingLeaseExpenseAnnualIncreaseRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Expense, Annual Increase Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_OperatingLeaseExpenseAnnualIncreaseRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_OperatingLeaseMonthlyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Monthly Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_OperatingLeaseMonthlyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_TenantImprovementAllowanceReceivableUponLeaseRenewal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tenant Improvement Allowance, Receivable Upon Lease Renewal</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_TenantImprovementAllowanceReceivableUponLeaseRenewal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425449423936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,446<span></span>
</td>
<td class="nump">$ 1,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 1,752<span></span>
</td>
<td class="nump">$ 1,751<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425445868096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Maturity Analysis of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022 (remaining six months)</a></td>
<td class="nump">$ 1,721<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">3,452<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">2,919<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">1,020<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">9,112<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Amount of lease payments representing interest</a></td>
<td class="nump">636<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">8,476<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current lease liabilities</a></td>
<td class="nump">3,061<span></span>
</td>
<td class="nump">$ 2,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">$ 5,415<span></span>
</td>
<td class="nump">$ 6,844<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425440718192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">$ 6,987<span></span>
</td>
<td class="nump">$ 8,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (years)</a></td>
<td class="text">2 years 5 months 4 days<span></span>
</td>
<td class="text">3 years 2 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate (percent)</a></td>
<td class="nump">5.90%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425451960944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Other Supplemental Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities included in cash flows used in operating activities</a></td>
<td class="nump">$ 966<span></span>
</td>
<td class="nump">$ 1,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease liabilities</a></td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425445943776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Service Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Purchase Commitment, Excluding Long-Term Commitment [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,532<span></span>
</td>
<td class="nump">$ 3,174<span></span>
</td>
<td class="nump">$ 6,206<span></span>
</td>
<td class="nump">$ 5,807<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=lung_ServiceAgreementPurchaseMember', window );">Service Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Purchase Commitment, Excluding Long-Term Commitment [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">Purchase obligation, to be paid, year one</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">Purchase obligation, to be paid, year two</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInThirdYear', window );">Purchase obligation, to be paid, year three</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=lung_ServiceAgreementPurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=lung_ServiceAgreementPurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425444606720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">$ 107<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425447067312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>vote </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>vote </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares) | shares</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends declared</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_NumberOfVotesForEachShareOfCommonStockHeld', window );">Number of votes for each share of common stock held | vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested and expenses to vest, intrinsic value</a></td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of early exercised common stock options (in shares) | shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,945<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Common stock, shares repurchased, less than (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice', window );">Aggregate exercise price of shares subject to repurchase</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=lung_CostOfGoodsAndServicesSoldMember', window );">Cost Of Goods And Services Sold</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock-based compensation capitalized into inventory</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=lung_InventoryNetMember', window );">Inventory, Net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock-based compensation capitalized into inventory</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchase', window );">Shares subject to repurchase (in shares) | shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">155,969<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">223,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value</a></td>
<td class="nump">16,100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 16,100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lung_StockOptionsAndRestrictedStockUnitsMember', window );">Stock Options And Restricted Stock Units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs</a></td>
<td class="nump">52,600,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 52,600,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognition of compensation costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">3 years 1 month 20 days<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="nump">4,700,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognition of compensation costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">1 month 6 days<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Non-option unrecognized compensation costs</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_NumberOfVotesForEachShareOfCommonStockHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Votes For Each Share Of Common Stock Held</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_NumberOfVotesForEachShareOfCommonStockHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Payment Arrangement, Shares Subject To Repurchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_ShareBasedPaymentArrangementSharesSubjectToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Payment Arrangement, Shares Subject To Repurchase, Aggregate Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=lung_CostOfGoodsAndServicesSoldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=lung_CostOfGoodsAndServicesSoldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=lung_InventoryNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=lung_InventoryNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lung_StockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lung_StockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425440575744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Shares Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="nump">8,786,572<span></span>
</td>
<td class="nump">7,271,132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lung_ShareBasedCompensationEmployeeStockOutstandingMember', window );">Common stock options issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="nump">2,600,237<span></span>
</td>
<td class="nump">2,145,131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lung_CommonStockRestrictedStockUnitsIssuedAndOutstandingMember', window );">Common stock restricted stock units issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="nump">1,091,957<span></span>
</td>
<td class="nump">442,428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lung_ShareBasedCompensationEmployeeStockAvailableForGrantMember', window );">Common stock available for future grants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="nump">3,838,605<span></span>
</td>
<td class="nump">3,751,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Common stock available for ESPP</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="nump">1,255,773<span></span>
</td>
<td class="nump">932,458<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lung_ShareBasedCompensationEmployeeStockOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lung_ShareBasedCompensationEmployeeStockOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lung_CommonStockRestrictedStockUnitsIssuedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lung_CommonStockRestrictedStockUnitsIssuedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lung_ShareBasedCompensationEmployeeStockAvailableForGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lung_ShareBasedCompensationEmployeeStockAvailableForGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425445835472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock Option Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance, beginning of period (in shares) | shares</a></td>
<td class="nump">2,145,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares) | shares</a></td>
<td class="nump">655,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares) | shares</a></td>
<td class="num">(172,886)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options canceled (in shares) | shares</a></td>
<td class="num">(27,208)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance, end of period (in shares) | shares</a></td>
<td class="nump">2,600,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance, beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 13.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share) | $ / shares</a></td>
<td class="nump">26.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">2.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options canceled (in dollars per share) | $ / shares</a></td>
<td class="nump">19.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance, end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 17.43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425448289632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Options Vested and Expected to Vest (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>Number of Shares</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options vested (in shares) | shares</a></td>
<td class="nump">904,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest (in shares) | shares</a></td>
<td class="nump">2,600,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice', window );">Options vested (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 17.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedTermAbstract', window );"><strong>Weighted Average Contractual Life (in Years)</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm', window );">Options vested</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest</a></td>
<td class="text">8 years 3 months 3 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested And Expected To Vest, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lung_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425447954832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares Underlying Outstanding Restricted Stock</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, beginning of period (in shares) | shares</a></td>
<td class="nump">442,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">799,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(115,380)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="num">(34,411)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, end of period (in shares) | shares</a></td>
<td class="nump">1,091,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 42.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">25.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">37.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled (in dollars per share) | $ / shares</a></td>
<td class="nump">33.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 30.78<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425444545216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Total Stock-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 4,383<span></span>
</td>
<td class="nump">$ 2,312<span></span>
</td>
<td class="nump">$ 7,896<span></span>
</td>
<td class="nump">$ 4,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lung_StockOptionsAndRestrictedStockUnitsMember', window );">Stock Options And Restricted Stock Units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">4,209<span></span>
</td>
<td class="nump">1,520<span></span>
</td>
<td class="nump">7,521<span></span>
</td>
<td class="nump">2,559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">792<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="nump">2,021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="nump">336<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">556<span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="nump">977<span></span>
</td>
<td class="nump">606<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,638<span></span>
</td>
<td class="nump">$ 1,904<span></span>
</td>
<td class="nump">$ 6,583<span></span>
</td>
<td class="nump">$ 3,764<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lung_StockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lung_StockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425448366928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders, basic</a></td>
<td class="num">$ (14,640)<span></span>
</td>
<td class="num">$ (12,962)<span></span>
</td>
<td class="num">$ (30,468)<span></span>
</td>
<td class="num">$ (25,474)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common stockholders, diluted</a></td>
<td class="num">$ (14,640)<span></span>
</td>
<td class="num">$ (12,962)<span></span>
</td>
<td class="num">$ (30,468)<span></span>
</td>
<td class="num">$ (25,474)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted-average common stock outstanding (in shares)</a></td>
<td class="nump">37,171,893<span></span>
</td>
<td class="nump">36,324,022<span></span>
</td>
<td class="nump">37,090,164<span></span>
</td>
<td class="nump">36,021,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation', window );">Less: weighted-average common shares subject to repurchase (in shares)</a></td>
<td class="num">(168,450)<span></span>
</td>
<td class="num">(281,408)<span></span>
</td>
<td class="num">(185,212)<span></span>
</td>
<td class="num">(312,921)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares used to compute, basic net loss per share (in shares)</a></td>
<td class="nump">37,003,443<span></span>
</td>
<td class="nump">36,042,614<span></span>
</td>
<td class="nump">36,904,952<span></span>
</td>
<td class="nump">35,708,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares used to compute, diluted net loss per share (in shares)</a></td>
<td class="nump">37,003,443<span></span>
</td>
<td class="nump">36,042,614<span></span>
</td>
<td class="nump">36,904,952<span></span>
</td>
<td class="nump">35,708,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic (in dollars per share)</a></td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (0.71)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted (in dollars per share)</a></td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (0.71)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicTwoClassMethodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicTwoClassMethodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425444810416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders - Excluded Potentially Dilutive Securities Outstanding (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted weighted average shares outstanding (in shares)</a></td>
<td class="nump">3,881,205<span></span>
</td>
<td class="nump">3,223,356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted weighted average shares outstanding (in shares)</a></td>
<td class="nump">2,600,244<span></span>
</td>
<td class="nump">2,483,364<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted weighted average shares outstanding (in shares)</a></td>
<td class="nump">1,091,957<span></span>
</td>
<td class="nump">438,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lung_ShareBasedCompensationUnvestedEarlyExercisedOptionsMember', window );">Unvested early exercised common stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted weighted average shares outstanding (in shares)</a></td>
<td class="nump">155,969<span></span>
</td>
<td class="nump">294,577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Shares committed under ESPP</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted weighted average shares outstanding (in shares)</a></td>
<td class="nump">33,035<span></span>
</td>
<td class="nump">6,865<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lung_ShareBasedCompensationUnvestedEarlyExercisedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lung_ShareBasedCompensationUnvestedEarlyExercisedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425444825104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Narrative (Details) - segment<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">GERMANY | Revenue from Contract with Customer Benchmark | Geographic Concentration Risk</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_FR', window );">FRANCE | Revenue from Contract with Customer Benchmark | Geographic Concentration Risk</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425449165648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Revenue by Geographic Area (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 13,950<span></span>
</td>
<td class="nump">$ 12,203<span></span>
</td>
<td class="nump">$ 24,735<span></span>
</td>
<td class="nump">$ 21,447<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">8,616<span></span>
</td>
<td class="nump">6,567<span></span>
</td>
<td class="nump">14,629<span></span>
</td>
<td class="nump">10,856<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember', window );">Europe, Middle-East and Africa (“EMEA”)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">4,570<span></span>
</td>
<td class="nump">4,749<span></span>
</td>
<td class="nump">8,623<span></span>
</td>
<td class="nump">8,793<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember', window );">Asia Pacific</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">724<span></span>
</td>
<td class="nump">875<span></span>
</td>
<td class="nump">1,443<span></span>
</td>
<td class="nump">1,786<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=lung_OtherInternationalGeographicalAreasMember', window );">Other International</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EMEAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaPacificMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=lung_OtherInternationalGeographicalAreasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=lung_OtherInternationalGeographicalAreasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140425444366080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Information - Long-Lived Assets by Geographical Area (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 4,932<span></span>
</td>
<td class="nump">$ 4,814<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">4,871<span></span>
</td>
<td class="nump">4,767<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember', window );">EMEA</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember', window );">Asia Pacific</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EMEAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaPacificMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>lung-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
xml:lang="en-US"
xmlns="http://www.xbrl.org/2003/instance"
xmlns:country="http://xbrl.sec.gov/country/2022"
xmlns:dei="http://xbrl.sec.gov/dei/2022"
xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
xmlns:link="http://www.xbrl.org/2003/linkbase"
xmlns:lung="http://www.pulmonx.com/20220630"
xmlns:srt="http://fasb.org/srt/2022"
xmlns:us-gaap="http://fasb.org/us-gaap/2022"
xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
xmlns:xlink="http://www.w3.org/1999/xlink"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<link:schemaRef xlink:href="lung-20220630.xsd" xlink:type="simple"/>
<context id="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="i13c4ccdef36a4923ac2f86f39c238d7f_I20220729">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
</entity>
<period>
<instant>2022-07-29</instant>
</period>
</context>
<context id="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i23debaac8bf94b7195e8771f793b80bb_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i7c4697ae1aaa496dbaaf2d4679704499_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="ia24f369469a741168a30ae622482853d_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="i10ab7cd963514359bca3cc91d92e2ecc_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="id78b13f427954c0c9d0eaf7f535da90f_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="i19fb5ca4a6fb4af091d289bfc12b61a0_D20220101-20220331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-03-31</endDate>
</period>
</context>
<context id="i725a772a7daa4c27b7de453c618f8b63_D20220101-20220331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-03-31</endDate>
</period>
</context>
<context id="i652d00700fc04edeacaed27e5bb45f8e_D20220101-20220331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-03-31</endDate>
</period>
</context>
<context id="ie32244cce0bb4ac7b0db5c54bbe3378f_D20220101-20220331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-03-31</endDate>
</period>
</context>
<context id="i4f6b9352f27c4329bd7774ca5b92761f_D20220101-20220331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-03-31</endDate>
</period>
</context>
<context id="i194ccf658b8d40dcad4baa33b8140830_I20220331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-03-31</instant>
</period>
</context>
<context id="i90fc2f64290846f9bd78af8a90169410_I20220331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-03-31</instant>
</period>
</context>
<context id="i4e2da5d082cb42229835e719c252d985_I20220331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-03-31</instant>
</period>
</context>
<context id="ifdb2a33757594e479f11368bdb9206b3_I20220331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-03-31</instant>
</period>
</context>
<context id="ib259775b9b9c44278d3b14fa3bc4487c_I20220331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
</entity>
<period>
<instant>2022-03-31</instant>
</period>
</context>
<context id="iec7ebe8c89a545d9a436b69816b227eb_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="i9eb715cb0da94d3da06eec36cb1cb264_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="i72eebbb0bfb6442c835ff9de3799eae7_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="i6858cf3ac89b40e1aa7df89ed53b2a24_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="i91bd715107e14e01ba109bc345441fd3_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i99751b578e1948aab49db6044f4428c2_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i64d27f95511a463b9e9c935f31dfb113_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i259f3776dc6e4cc2a3830d0cb8f9c7c9_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i937e6c62ae494af082d55df28a206b08_I20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-12-31</instant>
</period>
</context>
<context id="ia4bd41d858f34c15860558f9397212b7_I20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-12-31</instant>
</period>
</context>
<context id="i65dfe455b40043c5879a699696671342_I20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-12-31</instant>
</period>
</context>
<context id="i55ca82439e3f4c70b50cc76b61427123_I20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-12-31</instant>
</period>
</context>
<context id="if30e4595cd6d463086f867a5956e9dc6_I20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
</entity>
<period>
<instant>2020-12-31</instant>
</period>
</context>
<context id="i8540e99599c44addac72e276711f6cec_D20210101-20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-03-31</endDate>
</period>
</context>
<context id="ia82be87509cd48adba02800ee6d7620c_D20210101-20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-03-31</endDate>
</period>
</context>
<context id="i1d577c6b24e74d95b9308b0abbea21c0_D20210101-20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-03-31</endDate>
</period>
</context>
<context id="i6381f3fa151c4fa79031cfd4c59f3dd1_D20210101-20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-03-31</endDate>
</period>
</context>
<context id="id8cfddbc76454c0a86d25df73ca052b8_D20210101-20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-03-31</endDate>
</period>
</context>
<context id="i386654d89dcd4305bc2796578a912387_I20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-03-31</instant>
</period>
</context>
<context id="i9301a7535db44e52b62db20ea7d35b36_I20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-03-31</instant>
</period>
</context>
<context id="i26b8aa74725440cfacefcfa508e23b8f_I20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-03-31</instant>
</period>
</context>
<context id="if58fbcaf779342d48308a3b41be27d24_I20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-03-31</instant>
</period>
</context>
<context id="ia9dc423e8a1c41408784d828d38bb8af_I20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
</entity>
<period>
<instant>2021-03-31</instant>
</period>
</context>
<context id="i0c2c4ec32c314b51a25e847eceb0629a_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i71e36e6ab000490aa878482c47257f1f_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i313147cc93cf4996b2b891fed6afd2c8_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i87c0f954d15f47f997c03b4bbe0a518c_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i93f25af4132544699f7cc1911016ca93_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="i2ab786f6b9094a30a403c16621efc3b8_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="i0536fa32537e48f3b61cc43f596ef9ef_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="icf8348b6ab644a16943adf5d6b3b01d1_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="i10d78353ceec4f248af8e917fdcbaa2c_I20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
</entity>
<period>
<instant>2021-06-30</instant>
</period>
</context>
<context id="i2ae7a2862d6f4d7a954dd9a21f9f83d8_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="i1f765278d59148a1ab87392a73044ec0_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i1bcdc8fb272d48f49898d46b5eed3af6_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="ia14d74e4d29945248008eebccb61e736_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i43daee278edf4dd48795e6f8a76b68e6_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i7a1831dadd354b61891c517232e12cb6_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i92dd2cd839a240b486dff359bb786a00_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i7a66461de3154691bdf882e2e5dcd6c5_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i3e4dba1228e34cd98a8abd85532d7cb9_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="iac94117f850b41d5b799ede5098093da_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i3a3f4a74924a4f12a1736df2d0a45713_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="iee1e914ebc684f0b943cae94c69a0f1a_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i6c2edf2f82884f7b832d7b6ce96cef26_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="id934753eb5f84d74951453f74f1c8782_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i513514d73a6d48d88da16ce034ab1bb4_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i33985b0fd2d14a9dbba59257abcfcfbb_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i9d7ee987153a4b9e864751c124470915_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i93d1d7e68d6546828a3bdc6fdcf003c5_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i48eb072a814e40a1b0c537a5e8d1ed0b_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i675913f6b3cc4a0d80c3aedb6ff16277_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i1db3a72d8ab94a5290123d21241fdea7_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="icbcdc9fe2df04354bea1a37f7049921b_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i38d15624d6984f4c8c651151aab177be_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i5cff6d84193e4dc3b07c75074e60392b_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="i327e3148cf134e40be0e4c43a80759bb_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="i7c4a433674ca4a14a572851571072b9b_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="iaa4a290d955f4814b581d6476ee9dc7d_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="icfc26381124441d290073fcf4b193645_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="ib192c97ab709429e8d8bace98b7c84f5_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="i042fafa9d9b249748a84902a33a8986a_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="i7e96426a76854bbeaa9ad9992e1a9dc0_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="i4a0edcb9b6dd478a89e87ca1f2ce26eb_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="i85fa5ce9fad74f399f8c8d25570c9689_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="i45edc210ab0745a5aa6286bb72d334b4_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="ifb589de7e36549c6a8aab0ff0cad6898_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="i4e16bb634cd6409fb8caa8fde1661af6_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="if24e988586d6451fab56769a5c714496_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="i55d83c7769d745868fef46644ba31985_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="i4cd5fa1e86444765a02ded926ba518e5_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="i1438553a44e74136882a9e6307daa44c_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="i3b3656c560c64ebe973f848fc48ad5ad_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="id36ebdf32a5a4301a2002cf016417bf4_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="if2007efd115d4f399413c5ee0cf7dbee_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="id29e377b291b419eba3b2d065798ef5c_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="id75b22a41add4eceb26a8efffed5d602_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="ife09428d3f97465496a4b2c6bd0ba97f_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="ibeec9606af284a379aa614910d3a61ab_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="i0a302b35b1a8429293ae6b864424ecc3_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i50bcd4c228d24da381ad2f53d3c36667_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i838adf7de26c4611806f98bea73a4138_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="iec39bddb1fc94428b8d0d9084e2aba6b_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="if09b01b3b49e4c1cb9a520fc3d129aa1_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="i5e482a0f02a04e4e9a095186ae75202f_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="ia8327b71a4e547faac046ef1de96ead9_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="iec403174da4d4b6f9ff96570a7e5a8f5_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i5b44ef956ce14264a4103fec3f984838_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="idf3e46dc35da4ebb90badd8b66929912_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="i1840bfb02e1b469bbd139ead973986ca_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i809590d3637c40e798f0aed4272f42ca_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="i339317d369b543779f5eb59e6be6a75b_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i178bc0d657d34b21aa1fd8fd4e374909_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="ibc8aa7e2c53d4718b1022132994a93ab_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i40fb5bdc0f7e47eba46c35d13149ff1a_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="i63e0fd137e3246b38ec39ff427bd5719_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="if0aa7a0e30fc4971a837f40cff89c0d8_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="ia81181d7be0d45bcb4069dea54e60219_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="icb23404694384f0c8275849d24245f2e_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="iad04ff000fc942258f4e9cf9f39d4fb5_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i95b7e760966d41e297348550b546a87e_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="ie3cb7048a6fa4bb2bc49e5f307bee1ae_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="i5c65329af5944c1e8409cad224f99d17_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="i69fa9455e50e46f4af26f9c44e3cb740_I20200220">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-02-20</instant>
</period>
</context>
<context id="i662aa5e4c8f94ee688483281db66fe8e_D20200220-20200220">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementTrancheAMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-02-20</startDate>
<endDate>2020-02-20</endDate>
</period>
</context>
<context id="i517ce1c551384aa19ddce0f3e57a8444_I20200220">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementTrancheBMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-02-20</instant>
</period>
</context>
<context id="i365110653de64470b9da2fd7e9534eff_I20200220">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementTrancheCMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-02-20</instant>
</period>
</context>
<context id="i543c3e76e6bb46e1b76eef8fae5afbeb_D20200220-20200220">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-02-20</startDate>
<endDate>2020-02-20</endDate>
</period>
</context>
<context id="i125e5025f90d4542857c5e912e248efa_D20200220-20200220">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-02-20</startDate>
<endDate>2020-02-20</endDate>
</period>
</context>
<context id="i31de136071f4464fa0afd580b08736c2_I20200430">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-04-30</instant>
</period>
</context>
<context id="i0f999a2b8cd8404da746d5c0e0b4fa69_D20200401-20200430">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementTrancheBMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-04-30</endDate>
</period>
</context>
<context id="i6f1e6dd7364444de8ff46bdf5cd1eb03_D20210301-20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-03-01</startDate>
<endDate>2021-03-31</endDate>
</period>
</context>
<context id="i484ba17f04d144eb9aee8b4620710100_D20210301-20210331">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementTrancheBMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-03-01</startDate>
<endDate>2021-03-31</endDate>
</period>
</context>
<context id="i77dd9039bef24911aa020653e86f93f4_D20211001-20211031">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-10-01</startDate>
<endDate>2021-10-31</endDate>
</period>
</context>
<context id="i77c3dfcc442f4078a50db735a19d5748_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="if05f081a56284af8acd87cd18fcceda5_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="i2a6b51ede0b348778de030ce71e1beb5_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="ib7679901e2d74b97a73e37442ab74242_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i8396a841b0dd4c458e576ad2b5d930b5_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="i35a8e4b3abcb47d78dd4215a8467d650_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:CIBCAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:MediumTermNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i397678ceafef497b86b6e43ad8ea3a3b_I20200430">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:COVID19CreditAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">lung:PulmonxInternationalSarlMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-04-30</instant>
</period>
</context>
<context id="ic26de67cef4149c0ad6d575b9330bbf0_D20200501-20200531">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lung:COVID19CreditAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">lung:PulmonxInternationalSarlMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-05-01</startDate>
<endDate>2020-05-31</endDate>
</period>
</context>
<context id="i70d3599672cd4f2badc8f100594638fe_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">lung:PulmonxInternationalSarlMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="iaa8e0cdfe47448be927a5cd420c16bf9_D20200101-20201231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
</entity>
<period>
<startDate>2020-01-01</startDate>
<endDate>2020-12-31</endDate>
</period>
</context>
<context id="i366bdd6cbcb6417f82564f08de535cb9_I20200831">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
</entity>
<period>
<instant>2020-08-31</instant>
</period>
</context>
<context id="i3a0e06bbd8104d1395b00aeca775a8d3_D20200801-20200831">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
</entity>
<period>
<startDate>2020-08-01</startDate>
<endDate>2020-08-31</endDate>
</period>
</context>
<context id="i857cff753eff4ea1888bf30b01ede179_I20131231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2013-12-31</instant>
</period>
</context>
<context id="ifd03a7896aaf49d6b9c4280b7685c129_D20130101-20131231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
</entity>
<period>
<startDate>2013-01-01</startDate>
<endDate>2013-12-31</endDate>
</period>
</context>
<context id="icd1f11aa0462419c94ba74321f470d3a_D20200401-20200430">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
</entity>
<period>
<startDate>2020-04-01</startDate>
<endDate>2020-04-30</endDate>
</period>
</context>
<context id="idc991623af8d40e28c3edf61bacb8247_D20200901-20200930">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
</entity>
<period>
<startDate>2020-09-01</startDate>
<endDate>2020-09-30</endDate>
</period>
</context>
<context id="i0aef2c60dfff4d2db3ecc2c60e4ab869_I20200930">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
</entity>
<period>
<instant>2020-09-30</instant>
</period>
</context>
<context id="ied7db64668494d679f77a1d8d708db3b_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="ibc840713d1034829bc01ad7b74a40d23_I20220430">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">lung:ServiceAgreementPurchaseMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-04-30</instant>
</period>
</context>
<context id="i25ca1d294bfa44ee92ff709c2ea930e0_D20220501-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">lung:ServiceAgreementPurchaseMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-05-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="i784f45acac5747a384b861bd3aabc902_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lung:ShareBasedCompensationEmployeeStockOutstandingMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="ide3a7a3105f148a0abc9848ed7ec1d00_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lung:ShareBasedCompensationEmployeeStockOutstandingMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="i22f7f50179034850b9053aba0a68231a_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lung:CommonStockRestrictedStockUnitsIssuedAndOutstandingMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="iaba5025a1e5243a2b17b2e5661ec7f35_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lung:CommonStockRestrictedStockUnitsIssuedAndOutstandingMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="i714b2da3efed4e42a97fe4d4b6b47a99_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lung:ShareBasedCompensationEmployeeStockAvailableForGrantMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i2e39fbc0a48a47e2a202f2c8f30f4b79_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lung:ShareBasedCompensationEmployeeStockAvailableForGrantMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="i1275d322af1b4c98ba3c7706239395c7_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="ifaa47ca5f34841d0a65dd43f53a08359_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="ieaf5f38983f147c5b391b683b2a5d265_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="ic7b4e5d4bcbd4d4186b94f94cf2b2e0d_D20210101-20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-12-31</endDate>
</period>
</context>
<context id="id02f38cc7de8443687c4dbf744ee7d4a_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="ib214e6ee760c4adcbb895883d757b122_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="i91b890405bde48749a209fc48ed3fd13_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i883a9ab8eaca4207ba3cadcb80ef8eda_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="i0b981dc82dd04a02bb8a9147b2a333de_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i114ea887bbd14b4a95901ff225d7572e_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="i51ff2e29588048e09a217bf20a23f15e_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i405811c8a7064e599bb9622e46610a53_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="i58118a88d93b4eb694a8bc9332e744f5_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="if9b029b9144a4e10b3a37d170bf1098c_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="i0ed501dd475d4cf48aa805abbe19f088_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i08e66e05527d4ffd827c77748a29ae59_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="i0dfbc2d6814744a0ad594767a7b3921c_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="ia73aa5beaf714619a089f8546ba50e49_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="id37e4fe079bc43a8b78bc7d2ed7d7f5a_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i27f5ea6853044003b5d3fe259686cfed_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lung:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="ia4b62e5c7e4d41e599a13d60481720d5_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lung:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="id6ad1ceb870840e0aff0a566353c7eca_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lung:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="if1fb7c022d3f4c5a8ce371332cda0d8e_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lung:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i34dd8820c0384b9f99643fd8282fcfed_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="i18e4908c4d83487a804ab3bb691cfdfd_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="ia5532b33c0264e07931c620be5ee4fdb_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="i913beb06228a48059034fdbd19194be1_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="ie13307b791954390abb618142b11755f_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">lung:InventoryNetMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="iac319f186e3c4549bf1291d73e9ef0c2_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">lung:InventoryNetMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i50d7120120ae48429357a6f238139dcd_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">lung:InventoryNetMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="i53b7b623056a4e2eb2ea7a0f65fc71e9_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">lung:InventoryNetMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="iee27527c02e7424fb0b8f40670bc3dae_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">lung:CostOfGoodsAndServicesSoldMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="ifa0cb1b19d894f169cd980e74653f9fb_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">lung:CostOfGoodsAndServicesSoldMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i77bf9d3e0a0b48409b6cb9f129526c9c_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">lung:CostOfGoodsAndServicesSoldMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="ife4a8ff7e8fb4ffe9f2b64e74d5e97cf_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">lung:CostOfGoodsAndServicesSoldMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i00e81a622be642048db364ba63b6897c_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lung:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i8b60336143e4446eab2f9aef31e69da0_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="if8534ceb95304df4a061131854586927_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i493a546e223e4e349b281de37224fec9_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="i88dc40bd83d7401a9672d7d2df0cbd44_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="icaa76627fc8f47fca67ba3fd4f6b2423_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lung:ShareBasedCompensationUnvestedEarlyExercisedOptionsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="i3c2550a59e904c9fa8983370b3a88d6d_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lung:ShareBasedCompensationUnvestedEarlyExercisedOptionsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i04828ea9cac9458c9dc603bf1c75ae3e_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="ifd4dd78630cd4ade8407c6236aa12b7d_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="ie1359c30612540db9f7d34a1c01b3ad0_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="i76aa19c427d84d68b1168f403a4d9cf0_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i289c4b693d0f4b78a133aca081e4ec62_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="i9dbda9b7680c4fbbb2d796862b9cc528_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i60c47462ac8c42278751a5e88cebb16c_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="id9f15921237f4455b73e6cc819e646c3_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i80d96e293cf64c4a8bc6f7a1a5311f2e_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="ic858ed7791a6420b80be0581b72d5fe2_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i95b08bdad4d14d5ebf4d2815ee5d2afa_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="i6331c9bd120d452f9dbc7f5077c0b308_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i58327cae2f9545909843bc0298fc7738_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="ide14511124ea4c19b7d0d17cf44f7565_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="ibf783eb979ba4c2990809ef7ba464ec1_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lung:OtherInternationalGeographicalAreasMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="i88d9fce60fb74d2b9219ae5f5695bac4_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lung:OtherInternationalGeographicalAreasMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="ia2da15985d8f46c7813cfdff913a5506_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lung:OtherInternationalGeographicalAreasMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="i6b0e39f7311c4c8dafe667c0cc5deee3_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lung:OtherInternationalGeographicalAreasMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i92b67fa545b64980b9a2e36077a0e919_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="i39dcbe49829e478bae65bf4ad7ebe73b_D20220401-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-04-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="ie37b898ed5f549b6a2584d0735ebc6a8_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="iff16a3996ed74e9185638c285d8180e7_D20210401-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-04-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="id116f3f4ef654103a4a17291f98e96cd_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="i14ce772deb444cdc87b44503d5d9c1d5_D20220101-20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2022-01-01</startDate>
<endDate>2022-06-30</endDate>
</period>
</context>
<context id="ia90e44e3c9a34436a33d109bdf77b945_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i800d29a3bc944cd193e54a8b9a0f6afb_D20210101-20210630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2021-01-01</startDate>
<endDate>2021-06-30</endDate>
</period>
</context>
<context id="i9fe4d5c850434aa89e016828fdf266ed_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i5796864d445f4298b6b97e81ee3b2e14_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="i5926e07811564c14a1a7947cce7b6f48_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i5d545a4cc5594760b939659357af4982_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<context id="ic2011b63fd9c4fd7bbc64ec2a1f0ca7a_I20220630">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2022-06-30</instant>
</period>
</context>
<context id="i74632ce2458d45f882a429075d1c2a21_I20211231">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0001127537</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2021-12-31</instant>
</period>
</context>
<unit id="shares">
<measure>shares</measure>
</unit>
<unit id="usd">
<measure>iso4217:USD</measure>
</unit>
<unit id="usdPerShare">
<divide>
<unitNumerator>
<measure>iso4217:USD</measure>
</unitNumerator>
<unitDenominator>
<measure>shares</measure>
</unitDenominator>
</divide>
</unit>
<unit id="number">
<measure>pure</measure>
</unit>
<unit id="payment">
<measure>lung:payment</measure>
</unit>
<unit id="chf">
<measure>iso4217:CHF</measure>
</unit>
<unit id="installment">
<measure>lung:installment</measure>
</unit>
<unit id="lease">
<measure>lung:lease</measure>
</unit>
<unit id="vote">
<measure>lung:vote</measure>
</unit>
<unit id="segment">
<measure>lung:segment</measure>
</unit>
<dei:EntityCentralIndexKey
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180L2ZyYWc6ODBmNzhmZDMyYmJjNGJmMTg0ZDIzNGExOTFkZmMwMzgvdGFibGU6MmRkMGQ4OGUzMzUyNGUwYTg4ZWQ2ZWIxZTFlMWQ3NWYvdGFibGVyYW5nZToyZGQwZDg4ZTMzNTI0ZTBhODhlZDZlYjFlMWUxZDc1Zl8xLTEtMS0xLTM5Mzgz_c8afca6e-62ed-435a-91b6-0d7d8613d2ff">0001127537</dei:EntityCentralIndexKey>
<dei:CurrentFiscalYearEndDate
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180L2ZyYWc6ODBmNzhmZDMyYmJjNGJmMTg0ZDIzNGExOTFkZmMwMzgvdGFibGU6MmRkMGQ4OGUzMzUyNGUwYTg4ZWQ2ZWIxZTFlMWQ3NWYvdGFibGVyYW5nZToyZGQwZDg4ZTMzNTI0ZTBhODhlZDZlYjFlMWUxZDc1Zl8yLTEtMS0xLTM5Mzgz_de70f126-4b6d-4455-a1cf-2c57d251ad12">--12-31</dei:CurrentFiscalYearEndDate>
<dei:DocumentFiscalYearFocus
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180L2ZyYWc6ODBmNzhmZDMyYmJjNGJmMTg0ZDIzNGExOTFkZmMwMzgvdGFibGU6MmRkMGQ4OGUzMzUyNGUwYTg4ZWQ2ZWIxZTFlMWQ3NWYvdGFibGVyYW5nZToyZGQwZDg4ZTMzNTI0ZTBhODhlZDZlYjFlMWUxZDc1Zl8zLTEtMS0xLTM5Mzgz_1d53f4d9-949e-4e61-b02c-94f8bbe93931">2022</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180L2ZyYWc6ODBmNzhmZDMyYmJjNGJmMTg0ZDIzNGExOTFkZmMwMzgvdGFibGU6MmRkMGQ4OGUzMzUyNGUwYTg4ZWQ2ZWIxZTFlMWQ3NWYvdGFibGVyYW5nZToyZGQwZDg4ZTMzNTI0ZTBhODhlZDZlYjFlMWUxZDc1Zl80LTEtMS0xLTM5Mzgz_1ba74fdc-1a0e-49b5-a057-e711a752851c">Q2</dei:DocumentFiscalPeriodFocus>
<dei:AmendmentFlag
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180L2ZyYWc6ODBmNzhmZDMyYmJjNGJmMTg0ZDIzNGExOTFkZmMwMzgvdGFibGU6MmRkMGQ4OGUzMzUyNGUwYTg4ZWQ2ZWIxZTFlMWQ3NWYvdGFibGVyYW5nZToyZGQwZDg4ZTMzNTI0ZTBhODhlZDZlYjFlMWUxZDc1Zl81LTEtMS0xLTM5Mzgz_969c9ce8-1e85-406f-8597-2a13caf97e6f">false</dei:AmendmentFlag>
<dei:DocumentType
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8yMDU4_cd540b55-ea98-49ba-a963-8e6928e95cb2">10-Q</dei:DocumentType>
<dei:DocumentQuarterlyReport
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGFibGU6OGJlNTFmNDU0NmFkNDQwZDhkYzg2MjI3NGRhODcxYmUvdGFibGVyYW5nZTo4YmU1MWY0NTQ2YWQ0NDBkOGRjODYyMjc0ZGE4NzFiZV8wLTAtMS0xLTM5Mzgz_ab325400-f284-4882-8fc6-92badd248afc">true</dei:DocumentQuarterlyReport>
<dei:DocumentPeriodEndDate
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8xMjY_a17a1b9a-9772-4cb6-bd31-3d45d286186b">2022-06-30</dei:DocumentPeriodEndDate>
<dei:DocumentTransitionReport
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGFibGU6NTBiOGZkNTUxNTIyNDE1MWFjMmZlMDRmZGJkNTQyNDAvdGFibGVyYW5nZTo1MGI4ZmQ1NTE1MjI0MTUxYWMyZmUwNGZkYmQ1NDI0MF8wLTAtMS0xLTM5Mzgz_327f98fc-67c7-4d02-8075-096b91c84255">false</dei:DocumentTransitionReport>
<dei:EntityFileNumber
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8yMDQ2_ddc36137-1fe2-4991-b4cd-d939bb72d929">001-39562</dei:EntityFileNumber>
<dei:EntityRegistrantName
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8yMDU5_124d5aab-0752-4d4b-b446-14062f0f586b">PULMONX CORPORATION</dei:EntityRegistrantName>
<dei:EntityIncorporationStateCountryCode
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGFibGU6YzEwYTBmYWI4YmE1NDZjNzhhNzgxNjhkMzg4Y2U1YjQvdGFibGVyYW5nZTpjMTBhMGZhYjhiYTU0NmM3OGE3ODE2OGQzODhjZTViNF8xLTAtMS0xLTM5Mzgz_2c2929d0-5214-4bd8-82fd-d2f1c3e2ce1a">DE</dei:EntityIncorporationStateCountryCode>
<dei:EntityTaxIdentificationNumber
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGFibGU6YzEwYTBmYWI4YmE1NDZjNzhhNzgxNjhkMzg4Y2U1YjQvdGFibGVyYW5nZTpjMTBhMGZhYjhiYTU0NmM3OGE3ODE2OGQzODhjZTViNF8xLTItMS0xLTM5Mzgz_54a97625-fc32-4bd5-8d5e-7e84026be970">77-0424412</dei:EntityTaxIdentificationNumber>
<dei:EntityAddressAddressLine1
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8yMDUz_f44001a5-55bb-48aa-a0d6-149196e7d1e3">700 Chesapeake Drive</dei:EntityAddressAddressLine1>
<dei:EntityAddressCityOrTown
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8yMDQ4_b743fb74-99dd-412d-aa6b-04dfb2ae7457">Redwood City</dei:EntityAddressCityOrTown>
<dei:EntityAddressStateOrProvince
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8yMDYw_b38c17c3-476f-438f-bc5d-22a481e3b228">CA</dei:EntityAddressStateOrProvince>
<dei:EntityAddressPostalZipCode
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8yMDYx_8aa4b98a-c7b5-4000-899d-49e2d71720c1">94063</dei:EntityAddressPostalZipCode>
<dei:CountryRegion
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8yMDUy_cbc7a1f8-c4c6-46e8-9515-f4a696337a0d">1</dei:CountryRegion>
<dei:CityAreaCode
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8yMDUw_3a41243c-0f9c-4ce7-aec2-5ac8bf5b464c">650</dei:CityAreaCode>
<dei:LocalPhoneNumber
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8yMDYy_23b54d73-9bc3-4ee4-bc18-345e5997be42">364-0400</dei:LocalPhoneNumber>
<dei:Security12bTitle
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGFibGU6Y2Q4ZWU2YTZkYjA0NDNmOWE3Y2I1ZmQ3MmM3MzI2OWQvdGFibGVyYW5nZTpjZDhlZTZhNmRiMDQ0M2Y5YTdjYjVmZDcyYzczMjY5ZF8xLTAtMS0xLTM5Mzgz_930c8953-b762-425a-8d4f-0cb30b612e54">Common Stock, $0.001 par value per share</dei:Security12bTitle>
<dei:TradingSymbol
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGFibGU6Y2Q4ZWU2YTZkYjA0NDNmOWE3Y2I1ZmQ3MmM3MzI2OWQvdGFibGVyYW5nZTpjZDhlZTZhNmRiMDQ0M2Y5YTdjYjVmZDcyYzczMjY5ZF8xLTEtMS0xLTM5Mzgz_258e0458-e795-4648-afd0-3719584a230e">LUNG</dei:TradingSymbol>
<dei:SecurityExchangeName
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGFibGU6Y2Q4ZWU2YTZkYjA0NDNmOWE3Y2I1ZmQ3MmM3MzI2OWQvdGFibGVyYW5nZTpjZDhlZTZhNmRiMDQ0M2Y5YTdjYjVmZDcyYzczMjY5ZF8xLTItMS0xLTM5Mzgz_49552f6b-6092-4918-86ec-fda7afe353f2">NASDAQ</dei:SecurityExchangeName>
<dei:EntityCurrentReportingStatus
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8yMDYz_3dd0b64d-cc1d-460a-b3a1-91d54c4d181f">Yes</dei:EntityCurrentReportingStatus>
<dei:EntityInteractiveDataCurrent
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8yMDU2_d7f3b9ac-56e4-443a-9f3f-6d15714f2d65">Yes</dei:EntityInteractiveDataCurrent>
<dei:EntityFilerCategory
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGFibGU6YTYzZTRhMmU3YmNiNGNiNWIwYWU2ZmM2ZjlkNTdmYWQvdGFibGVyYW5nZTphNjNlNGEyZTdiY2I0Y2I1YjBhZTZmYzZmOWQ1N2ZhZF8wLTAtMS0xLTQxNTgx_296daf4e-3bcb-4d91-aeb1-210cc44d202f">Large Accelerated Filer</dei:EntityFilerCategory>
<dei:EntitySmallBusiness
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGFibGU6YTYzZTRhMmU3YmNiNGNiNWIwYWU2ZmM2ZjlkNTdmYWQvdGFibGVyYW5nZTphNjNlNGEyZTdiY2I0Y2I1YjBhZTZmYzZmOWQ1N2ZhZF8xLTQtMS0xLTM5Mzgz_4375e7af-c015-432e-bcb7-96ad523152d9">true</dei:EntitySmallBusiness>
<dei:EntityEmergingGrowthCompany
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGFibGU6YTYzZTRhMmU3YmNiNGNiNWIwYWU2ZmM2ZjlkNTdmYWQvdGFibGVyYW5nZTphNjNlNGEyZTdiY2I0Y2I1YjBhZTZmYzZmOWQ1N2ZhZF8yLTQtMS0xLTM5Mzgz_8276e383-f787-4fda-b2e8-00e534c94594">false</dei:EntityEmergingGrowthCompany>
<dei:EntityShellCompany
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8xMjA5NDYyNzkwNzY1MQ_2094f1bc-5ac3-4033-a237-46a58c52a0e7">false</dei:EntityShellCompany>
<dei:EntityCommonStockSharesOutstanding
contextRef="i13c4ccdef36a4923ac2f86f39c238d7f_I20220729"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xL2ZyYWc6ODYxNzMzMWJmNjMyNDViYWIyNDhhMjJlOWI4ZTdjMDUvdGV4dHJlZ2lvbjo4NjE3MzMxYmY2MzI0NWJhYjI0OGEyMmU5YjhlN2MwNV8xOTYy_fb332fad-fbff-4815-b406-43c0542797a2"
unitRef="shares">37268450</dei:EntityCommonStockSharesOutstanding>
<us-gaap:CashAndCashEquivalentsAtCarryingValue
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfNC0xLTEtMS0zOTM4Mw_ca655d49-0329-4b4b-9392-b85559887da6"
unitRef="usd">121947000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfNC0zLTEtMS0zOTM4Mw_e38b1063-be23-4300-a1ed-7f0a8efc75d2"
unitRef="usd">148480000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:RestrictedCash
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfNS0xLTEtMS0zOTM4Mw_4ec3f7a6-0097-456c-a700-7770e2ef0e27"
unitRef="usd">231000</us-gaap:RestrictedCash>
<us-gaap:RestrictedCash
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfNS0zLTEtMS0zOTM4Mw_32ba07f5-603d-44fd-be23-97e3a139534d"
unitRef="usd">231000</us-gaap:RestrictedCash>
<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfNi0xLTEtMS0zOTM4Mw_340a4776-b78c-4b08-83b5-b75ede7deaaa"
unitRef="usd">40139000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfNi0zLTEtMS0zOTM4Mw_ff888272-5b83-472b-8790-e8f620744de7"
unitRef="usd">31561000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
<us-gaap:AccountsReceivableNetCurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfNy0xLTEtMS0zOTM4Mw_526eaa12-8710-4d81-8216-470c6f1c8e04"
unitRef="usd">7521000</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:AccountsReceivableNetCurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfNy0zLTEtMS0zOTM4Mw_bdcf657a-35cd-4db3-b7c1-427e7b447c3a"
unitRef="usd">6562000</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:InventoryNet
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfOC0xLTEtMS0zOTM4Mw_5229570f-38fb-48ed-bd7d-d54a8158cf5b"
unitRef="usd">19212000</us-gaap:InventoryNet>
<us-gaap:InventoryNet
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfOC0zLTEtMS0zOTM4Mw_9575d66a-64be-4f1b-bda2-e8e7e33bf441"
unitRef="usd">16285000</us-gaap:InventoryNet>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfOS0xLTEtMS0zOTM4Mw_ffb500ab-2ac5-4a67-aaa9-eca5b5d940d6"
unitRef="usd">3731000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfOS0zLTEtMS0zOTM4Mw_9b4f7a33-9c50-448f-8125-7a79a72a2204"
unitRef="usd">4883000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:AssetsCurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTAtMS0xLTEtMzkzODM_5e9d7606-dc22-4eba-adbc-b2b8feeed902"
unitRef="usd">192781000</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTAtMy0xLTEtMzkzODM_45fddbd4-34ce-46cc-89a4-e615235b090d"
unitRef="usd">208002000</us-gaap:AssetsCurrent>
<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTEtMS0xLTEtMzkzODM_208cab8d-2a8a-42c1-be00-28c566117e0f"
unitRef="usd">4684000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTEtMy0xLTEtMzkzODM_dcb69c1c-da47-4b3d-886b-9be137cc6ddb"
unitRef="usd">10941000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
<us-gaap:PropertyPlantAndEquipmentNet
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTItMS0xLTEtMzkzODM_c5d606b6-2842-4973-acdd-53c079813c5b"
unitRef="usd">4932000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTItMy0xLTEtMzkzODM_b17b376e-0387-4cb0-9ecf-1f39fdd727d6"
unitRef="usd">4814000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:Goodwill
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTMtMS0xLTEtMzkzODM_26bfdd6e-69e3-41aa-912a-c2e6a6654dd0"
unitRef="usd">2333000</us-gaap:Goodwill>
<us-gaap:Goodwill
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTMtMy0xLTEtMzkzODM_180f65ca-d586-46fc-a8e0-3337920e52e9"
unitRef="usd">2333000</us-gaap:Goodwill>
<us-gaap:FiniteLivedIntangibleAssetsNet
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTQtMS0xLTEtMzkzODM_11e71908-b5d3-4fb5-8757-9f770a72d1ee"
unitRef="usd">216000</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsNet
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTQtMy0xLTEtMzkzODM_6cebf19c-a6df-4320-8283-b1f869b01045"
unitRef="usd">277000</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:OperatingLeaseRightOfUseAsset
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTUtMS0xLTEtMzkzODM_8f133f09-1b09-4896-ba95-9aab599d8093"
unitRef="usd">6987000</us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OperatingLeaseRightOfUseAsset
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTUtMy0xLTEtMzkzODM_8e662c2c-6e49-407d-bc7f-a6161f109be4"
unitRef="usd">8075000</us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OtherAssetsNoncurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTYtMS0xLTEtMzkzODM_f47c0472-fbd5-4b31-a4a0-5d4f69b380cc"
unitRef="usd">796000</us-gaap:OtherAssetsNoncurrent>
<us-gaap:OtherAssetsNoncurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTYtMy0xLTEtMzkzODM_8bec0d26-e7df-4b14-a3b5-1d7ddd8085f2"
unitRef="usd">731000</us-gaap:OtherAssetsNoncurrent>
<us-gaap:Assets
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTctMS0xLTEtMzkzODM_204e7168-e56b-489e-b809-bceea10bd672"
unitRef="usd">212729000</us-gaap:Assets>
<us-gaap:Assets
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMTctMy0xLTEtMzkzODM_3afe376d-d455-42e5-b621-1068f474e947"
unitRef="usd">235173000</us-gaap:Assets>
<us-gaap:AccountsPayableCurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjEtMS0xLTEtMzkzODM_d3bd33dc-c8dc-46ce-a36e-a01024dd2d86"
unitRef="usd">2599000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjEtMy0xLTEtMzkzODM_620bf6ff-039c-4483-9c4e-fc5babf53d5f"
unitRef="usd">1582000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjItMS0xLTEtMzkzODM_2ea98760-6ab5-4658-a8b6-8f570bc3eebd"
unitRef="usd">11734000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjItMy0xLTEtMzkzODM_47b03635-efdc-4156-a47a-cc87cdde73e5"
unitRef="usd">13366000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedIncomeTaxesCurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjMtMS0xLTEtMzkzODM_099caeb6-6577-4c63-ab6d-524b8337a1dd"
unitRef="usd">0</us-gaap:AccruedIncomeTaxesCurrent>
<us-gaap:AccruedIncomeTaxesCurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjMtMy0xLTEtMzkzODM_007f1614-2ce5-4222-8d2b-00caa0599d82"
unitRef="usd">147000</us-gaap:AccruedIncomeTaxesCurrent>
<us-gaap:ContractWithCustomerLiabilityCurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjQtMS0xLTEtMzkzODM_bdd725c6-79b4-4e28-8446-ed06ed28470b"
unitRef="usd">131000</us-gaap:ContractWithCustomerLiabilityCurrent>
<us-gaap:ContractWithCustomerLiabilityCurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjQtMy0xLTEtMzkzODM_478f705e-d97c-4f67-bd70-ce72d5ccdf88"
unitRef="usd">163000</us-gaap:ContractWithCustomerLiabilityCurrent>
<us-gaap:ShortTermBorrowings
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjUtMS0xLTEtMzkzODM_9d4ca4f5-1457-479b-8466-da1882c7e176"
unitRef="usd">2921000</us-gaap:ShortTermBorrowings>
<us-gaap:ShortTermBorrowings
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjUtMy0xLTEtMzkzODM_baad15dd-cecf-4d15-a614-717df19fcb47"
unitRef="usd">91000</us-gaap:ShortTermBorrowings>
<us-gaap:OperatingLeaseLiabilityCurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjYtMS0xLTEtMzkzODM_01982077-c42f-46c7-87f4-c07fc23b42fe"
unitRef="usd">3061000</us-gaap:OperatingLeaseLiabilityCurrent>
<us-gaap:OperatingLeaseLiabilityCurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjYtMy0xLTEtMzkzODM_a6164455-2903-482d-90ff-13bc3686cea3"
unitRef="usd">2201000</us-gaap:OperatingLeaseLiabilityCurrent>
<us-gaap:LiabilitiesCurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjctMS0xLTEtMzkzODM_3f5818d5-a3f1-438b-93db-1167cf3753f9"
unitRef="usd">20446000</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjctMy0xLTEtMzkzODM_7b7b959d-4d4e-4ed5-a1c9-be8543b680c2"
unitRef="usd">17550000</us-gaap:LiabilitiesCurrent>
<us-gaap:DeferredIncomeTaxLiabilitiesNet
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjgtMS0xLTEtMzkzODM_36d6e0ca-0c61-4ad0-81a7-eacc7ed6c002"
unitRef="usd">47000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
<us-gaap:DeferredIncomeTaxLiabilitiesNet
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjgtMy0xLTEtMzkzODM_0457a91d-d4a2-46cc-b747-24ba9adbb935"
unitRef="usd">37000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
<us-gaap:OperatingLeaseLiabilityNoncurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjktMS0xLTEtMzkzODM_87076136-2155-4983-b203-dd650d9f8af4"
unitRef="usd">5415000</us-gaap:OperatingLeaseLiabilityNoncurrent>
<us-gaap:OperatingLeaseLiabilityNoncurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMjktMy0xLTEtMzkzODM_defbd06c-8dab-4e7d-86a4-353bc87e7815"
unitRef="usd">6844000</us-gaap:OperatingLeaseLiabilityNoncurrent>
<us-gaap:LongTermDebtNoncurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzAtMS0xLTEtMzkzODM_5842a6a4-01cb-40d3-bf80-bee3dcbea69b"
unitRef="usd">14460000</us-gaap:LongTermDebtNoncurrent>
<us-gaap:LongTermDebtNoncurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzAtMy0xLTEtMzkzODM_dcd0c6f7-dca3-4daf-8a13-79dc1f1a2074"
unitRef="usd">17324000</us-gaap:LongTermDebtNoncurrent>
<us-gaap:OtherLiabilitiesNoncurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzEtMS0xLTEtMzkzODM_e60b1ee3-d68a-4b06-974b-066408827a1d"
unitRef="usd">179000</us-gaap:OtherLiabilitiesNoncurrent>
<us-gaap:OtherLiabilitiesNoncurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzEtMy0xLTEtMzkzODM_50512954-ab15-43f5-a6d9-8318794461b2"
unitRef="usd">179000</us-gaap:OtherLiabilitiesNoncurrent>
<us-gaap:Liabilities
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzItMS0xLTEtMzkzODM_a25062bb-cd37-4a3d-aafd-c9af5fd239aa"
unitRef="usd">40547000</us-gaap:Liabilities>
<us-gaap:Liabilities
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzItMy0xLTEtMzkzODM_e875eac6-0cc6-4f97-b163-c9e5ae63277c"
unitRef="usd">41934000</us-gaap:Liabilities>
<us-gaap:CommitmentsAndContingencies
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzMtMS0xLTEtMzkzODM_1fcab47d-e44e-4b08-a2db-05883c108ca1"
unitRef="usd"
xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzMtMy0xLTEtMzkzODM_60658fb0-1124-4879-8c63-f8152f4ae17f"
unitRef="usd"
xsi:nil="true"/>
<us-gaap:PreferredStockParOrStatedValuePerShare
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzUtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjMzNiYjEwNjE1YmQ0NGZhOTg1YmYwZGRkZDUzNTg1NF8yMQ_66436922-1a1a-4f2c-b762-1bbe2055fce1"
unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzUtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjMzNiYjEwNjE1YmQ0NGZhOTg1YmYwZGRkZDUzNTg1NF8yMQ_cd99bbdd-ee1c-42a4-a9eb-c7888a29d8d1"
unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzUtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjMzNiYjEwNjE1YmQ0NGZhOTg1YmYwZGRkZDUzNTg1NF8zNQ_2ddf76dc-d865-474a-a235-6dcd7843d28f"
unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzUtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjMzNiYjEwNjE1YmQ0NGZhOTg1YmYwZGRkZDUzNTg1NF8zNQ_baf6bc24-de69-4420-b3e8-41e82adb653a"
unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesOutstanding
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzUtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjMzNiYjEwNjE1YmQ0NGZhOTg1YmYwZGRkZDUzNTg1NF81Nw_04433138-9565-446e-aedd-b04e4aa832c0"
unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesIssued
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzUtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjMzNiYjEwNjE1YmQ0NGZhOTg1YmYwZGRkZDUzNTg1NF81Nw_3395dfd0-07da-44b5-b1ba-c109629c97a1"
unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzUtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjMzNiYjEwNjE1YmQ0NGZhOTg1YmYwZGRkZDUzNTg1NF81Nw_8a0f62c2-3d6f-42ce-b2e5-07e70787fb17"
unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesIssued
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzUtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjMzNiYjEwNjE1YmQ0NGZhOTg1YmYwZGRkZDUzNTg1NF81Nw_cc2c6b07-bb0a-48db-8bfa-d1b02bbe7e05"
unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockValue
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzUtMS0xLTEtMzkzODM_9f71c4f0-b15b-4f78-8321-46f5a08e404a"
unitRef="usd">0</us-gaap:PreferredStockValue>
<us-gaap:PreferredStockValue
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzUtMy0xLTEtMzkzODM_8872d57e-c68c-4b12-8958-b656aad883f9"
unitRef="usd">0</us-gaap:PreferredStockValue>
<us-gaap:CommonStockParOrStatedValuePerShare
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzYtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjYjQ0OTE0ZmZkMDA0Y2Y2YmNjMzM5Y2E0MGFkYjkyMF8xNjQ5MjY3NDQxOTA4_67ce159b-ddfe-40e3-b96b-9922ec3958db"
unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzYtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjYjQ0OTE0ZmZkMDA0Y2Y2YmNjMzM5Y2E0MGFkYjkyMF8xNjQ5MjY3NDQxOTA4_6b42299c-6210-4be0-a70d-b9d68c32c501"
unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzYtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjYjQ0OTE0ZmZkMDA0Y2Y2YmNjMzM5Y2E0MGFkYjkyMF8xNjQ5MjY3NDQxOTIy_12cde9a3-a5bb-4deb-b3a4-fcb4927bd624"
unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzYtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjYjQ0OTE0ZmZkMDA0Y2Y2YmNjMzM5Y2E0MGFkYjkyMF8xNjQ5MjY3NDQxOTIy_9a5d2434-1c2a-4b80-892f-bfb84af74bfd"
unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzYtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjYjQ0OTE0ZmZkMDA0Y2Y2YmNjMzM5Y2E0MGFkYjkyMF8xNjQ5MjY3NDQxOTM1_5e9a73a3-2524-49dc-ac0f-c52bd3fe0383"
unitRef="shares">37266030</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzYtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjYjQ0OTE0ZmZkMDA0Y2Y2YmNjMzM5Y2E0MGFkYjkyMF8xNjQ5MjY3NDQxOTM1_bf029d27-77e1-4ee2-9b49-4c9995767ea1"
unitRef="shares">37266030</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesIssued
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzYtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjYjQ0OTE0ZmZkMDA0Y2Y2YmNjMzM5Y2E0MGFkYjkyMF8xNjQ5MjY3NDQxOTQ4_4d952d45-c0ca-49ec-95cc-c592328c6d5e"
unitRef="shares">36931762</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzYtMC0xLTEtMzkzODMvdGV4dHJlZ2lvbjpjYjQ0OTE0ZmZkMDA0Y2Y2YmNjMzM5Y2E0MGFkYjkyMF8xNjQ5MjY3NDQxOTQ4_b6b738bf-31ee-4749-92da-db07e24babd5"
unitRef="shares">36931762</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockValue
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzYtMS0xLTEtMzkzODM_1dd709e2-6b46-49e5-8744-0ba7d526e822"
unitRef="usd">37000</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzYtMy0xLTEtMzkzODM_52b16cc3-77e2-45f1-92fe-c02d66687718"
unitRef="usd">37000</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapitalCommonStock
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzctMS0xLTEtMzkzODM_8f8a8e9a-d843-49de-9a1f-9e452c2e83e7"
unitRef="usd">492651000</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AdditionalPaidInCapitalCommonStock
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzctMy0xLTEtMzkzODM_b749ff6e-8015-486e-bf32-c17c73916669"
unitRef="usd">482885000</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzgtMS0xLTEtMzkzODM_8ff78d4c-520b-4726-94ec-75821a911cac"
unitRef="usd">1357000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzgtMy0xLTEtMzkzODM_ffa6c870-7b42-48ed-8ba2-e1fcfa749952"
unitRef="usd">1712000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:RetainedEarningsAccumulatedDeficit
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzktMS0xLTEtMzkzODM_be74fe0e-61b1-492a-bad0-8d71b9401333"
unitRef="usd">-321863000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfMzktMy0xLTEtMzkzODM_df173d92-5bc7-4044-9bd4-54e8db366b28"
unitRef="usd">-291395000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfNDAtMS0xLTEtMzkzODM_cebb5806-d465-4e38-9ae7-6b5ee13c9107"
unitRef="usd">172182000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfNDAtMy0xLTEtMzkzODM_4bf38458-3c0a-4405-9b76-e383fb9209a4"
unitRef="usd">193239000</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfNDEtMS0xLTEtMzkzODM_60de5e64-63c9-4d9c-b797-907a89083397"
unitRef="usd">212729000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18xOS9mcmFnOjIwNzUxOTQ5YWMyYzQ4NjliNTNmYjJjMTI3YTUxODgyL3RhYmxlOmMwMjJjNDI0YjQyMDQwM2FiMDczY2M3NjViN2QxNmVlL3RhYmxlcmFuZ2U6YzAyMmM0MjRiNDIwNDAzYWIwNzNjYzc2NWI3ZDE2ZWVfNDEtMy0xLTEtMzkzODM_c212e30f-b07a-419c-b5b6-08bae3b82ab7"
unitRef="usd">235173000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMi0xLTEtMS0zOTM4Mw_fd43648a-d568-4a76-9921-137fa36dfecc"
unitRef="usd">13950000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMi0zLTEtMS0zOTM4Mw_893e56c2-b513-4549-9fe1-44c08028ac65"
unitRef="usd">12203000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMi01LTEtMS0zOTM4Mw_b5dcab7c-e859-4a7b-b143-54b8c8baf401"
unitRef="usd">24735000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMi03LTEtMS0zOTM4Mw_6683842a-57c9-4e54-81a1-726e8c9ce5c3"
unitRef="usd">21447000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:CostOfGoodsAndServicesSold
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMy0xLTEtMS0zOTM4Mw_82f02f00-eb4b-40b2-8151-cee30a125d2a"
unitRef="usd">3532000</us-gaap:CostOfGoodsAndServicesSold>
<us-gaap:CostOfGoodsAndServicesSold
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMy0zLTEtMS0zOTM4Mw_78d18683-1b61-4e9a-a693-52de7e57f6fc"
unitRef="usd">3174000</us-gaap:CostOfGoodsAndServicesSold>
<us-gaap:CostOfGoodsAndServicesSold
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMy01LTEtMS0zOTM4Mw_28c3a010-04cf-4ccc-932c-215b688b9c90"
unitRef="usd">6206000</us-gaap:CostOfGoodsAndServicesSold>
<us-gaap:CostOfGoodsAndServicesSold
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMy03LTEtMS0zOTM4Mw_33b4bdd3-f593-479b-9f39-b725e3d09234"
unitRef="usd">5807000</us-gaap:CostOfGoodsAndServicesSold>
<us-gaap:GrossProfit
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfNC0xLTEtMS0zOTM4Mw_0a543788-637b-4e58-b109-5e64eff7b860"
unitRef="usd">10418000</us-gaap:GrossProfit>
<us-gaap:GrossProfit
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfNC0zLTEtMS0zOTM4Mw_f8d1cfca-3bb9-40b8-acfe-d64002ce69b3"
unitRef="usd">9029000</us-gaap:GrossProfit>
<us-gaap:GrossProfit
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfNC01LTEtMS0zOTM4Mw_dbe20fc9-cbf2-4541-951c-37ac066a2dfd"
unitRef="usd">18529000</us-gaap:GrossProfit>
<us-gaap:GrossProfit
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfNC03LTEtMS0zOTM4Mw_929e37f1-6cab-4e6a-b92a-7f1510533e0c"
unitRef="usd">15640000</us-gaap:GrossProfit>
<us-gaap:ResearchAndDevelopmentExpense
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfNi0xLTEtMS0zOTM4Mw_ba22bead-4c73-4a46-99eb-6bfef410fdf3"
unitRef="usd">3594000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfNi0zLTEtMS0zOTM4Mw_2f8a178f-7b90-421e-af89-bc2a2f4d9987"
unitRef="usd">3506000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfNi01LTEtMS0zOTM4Mw_759bfd0d-ad1f-4902-8535-fc057873c73c"
unitRef="usd">7128000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfNi03LTEtMS0zOTM4Mw_fa3653d3-ae2d-4d1f-8fa1-fddad18ec8b2"
unitRef="usd">6540000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:SellingGeneralAndAdministrativeExpense
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfNy0xLTEtMS0zOTM4Mw_d8192ce8-694b-4932-857f-39a043dce2d0"
unitRef="usd">21235000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:SellingGeneralAndAdministrativeExpense
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfNy0zLTEtMS0zOTM4Mw_bae72cf3-11bb-4b4d-b3be-b0426b34e0c8"
unitRef="usd">18205000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:SellingGeneralAndAdministrativeExpense
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfNy01LTEtMS0zOTM4Mw_2971851b-6c3e-44eb-9615-7fe0eb7d9a89"
unitRef="usd">41480000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:SellingGeneralAndAdministrativeExpense
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfNy03LTEtMS0zOTM4Mw_3dec3c36-b7e7-4e49-9e49-4af5eca7cd17"
unitRef="usd">34276000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:OperatingExpenses
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfOC0xLTEtMS0zOTM4Mw_9bff6479-72fa-4fd5-b3ca-9bbcd2491f78"
unitRef="usd">24829000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfOC0zLTEtMS0zOTM4Mw_5b0a503b-4756-41d0-ab64-addf35bd1e62"
unitRef="usd">21711000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfOC01LTEtMS0zOTM4Mw_8631fd85-1bc5-4f5a-8374-042f8b152c56"
unitRef="usd">48608000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfOC03LTEtMS0zOTM4Mw_b2a7fb38-d459-4de5-a4aa-7ff592a06d6d"
unitRef="usd">40816000</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfOS0xLTEtMS0zOTM4Mw_d2b2c109-cdd6-4216-9ff3-289e07d387c4"
unitRef="usd">-14411000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfOS0zLTEtMS0zOTM4Mw_006b2c63-13a2-4e5a-b37a-6b4674a3ea78"
unitRef="usd">-12682000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfOS01LTEtMS0zOTM4Mw_d29616e1-1b59-4802-9812-57036d706180"
unitRef="usd">-30079000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfOS03LTEtMS0zOTM4Mw_e91c796e-a8da-4f6c-a43e-732901a4e3c6"
unitRef="usd">-25176000</us-gaap:OperatingIncomeLoss>
<us-gaap:InvestmentIncomeInterest
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTAtMS0xLTEtMzkzODM_94dca236-4e4b-47be-8743-6764203843b2"
unitRef="usd">199000</us-gaap:InvestmentIncomeInterest>
<us-gaap:InvestmentIncomeInterest
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTAtMy0xLTEtMzkzODM_3040c917-537b-46af-ab26-f5a79395fe0d"
unitRef="usd">102000</us-gaap:InvestmentIncomeInterest>
<us-gaap:InvestmentIncomeInterest
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTAtNS0xLTEtMzkzODM_dfaca4d9-ddc5-46c6-85f0-39756bc571cd"
unitRef="usd">304000</us-gaap:InvestmentIncomeInterest>
<us-gaap:InvestmentIncomeInterest
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTAtNy0xLTEtMzkzODM_dbf0b965-c7b5-4416-abfb-ce0cb79f70d5"
unitRef="usd">207000</us-gaap:InvestmentIncomeInterest>
<us-gaap:InterestExpense
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTEtMS0xLTEtMzkzODM_3cb2c77b-1755-4539-97a0-ee8728dcc0fa"
unitRef="usd">223000</us-gaap:InterestExpense>
<us-gaap:InterestExpense
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTEtMy0xLTEtMzkzODM_31545c95-1927-40b3-b2cf-014c5f6d5339"
unitRef="usd">206000</us-gaap:InterestExpense>
<us-gaap:InterestExpense
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTEtNS0xLTEtMzkzODM_048b9000-2ca0-4e51-81bf-5c863bef43a4"
unitRef="usd">421000</us-gaap:InterestExpense>
<us-gaap:InterestExpense
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTEtNy0xLTEtMzkzODM_336f7538-5b66-470e-b143-ec607e18215f"
unitRef="usd">423000</us-gaap:InterestExpense>
<us-gaap:OtherNonoperatingIncomeExpense
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTItMS0xLTEtMzkzODM_f9c2f791-240d-4f39-a9eb-7fc0fab1f78b"
unitRef="usd">-165000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTItMy0xLTEtMzkzODM_4392614e-f900-4103-8688-689813147459"
unitRef="usd">-96000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTItNS0xLTEtMzkzODM_47686a91-511f-415f-aba4-a36443fa43d7"
unitRef="usd">-165000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTItNy0xLTEtMzkzODM_3c1b80c4-9d37-42ff-804b-4ade4dabd9e6"
unitRef="usd">65000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTMtMS0xLTEtMzkzODM_80374340-027b-42ff-a89c-9171fd0e083c"
unitRef="usd">-14600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTMtMy0xLTEtMzkzODM_fc9751e5-e236-4e53-b858-2292bfa16513"
unitRef="usd">-12882000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTMtNS0xLTEtMzkzODM_acc67732-4bd4-4dfa-8699-1372ed5b7cf3"
unitRef="usd">-30361000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTMtNy0xLTEtMzkzODM_2d9b6d25-aabd-4c3e-b2ea-cb53c9222e94"
unitRef="usd">-25327000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeTaxExpenseBenefit
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTQtMS0xLTEtMzkzODM_08a781d9-a851-4704-9db5-d04418868277"
unitRef="usd">40000</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTQtMy0xLTEtMzkzODM_e982e621-4f0d-41a4-b7e3-0c1e0d23887d"
unitRef="usd">80000</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTQtNS0xLTEtMzkzODM_a7556ed4-736a-4067-819c-d05205022653"
unitRef="usd">107000</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTQtNy0xLTEtMzkzODM_fd396c75-789d-4361-ac0d-dabe967c9e8a"
unitRef="usd">147000</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:NetIncomeLoss
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTUtMS0xLTEtMzkzODM_5bbad26d-609d-45a8-84f2-5e43cef0565d"
unitRef="usd">-14640000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTUtMy0xLTEtMzkzODM_5c696de7-bdd7-46a0-851b-9978d3594579"
unitRef="usd">-12962000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTUtNS0xLTEtMzkzODM_3fcb00ad-bc1a-4266-a822-dcc54769d901"
unitRef="usd">-30468000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTUtNy0xLTEtMzkzODM_48db93d0-d1a5-4c08-90df-d4bfc483cf6a"
unitRef="usd">-25474000</us-gaap:NetIncomeLoss>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTctMS0xLTEtMzkzODM_95622538-7a7b-4612-af0a-459b9bc25aa1"
unitRef="usd">6000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTctMy0xLTEtMzkzODM_73346061-46fb-4fe9-a464-bb759b3ebbeb"
unitRef="usd">66000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTctNS0xLTEtMzkzODM_238e090a-ede1-4bc8-b9c1-07eb305714ed"
unitRef="usd">-18000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTctNy0xLTEtMzkzODM_866ae9c2-2c55-404a-9e32-cf47d3bf5601"
unitRef="usd">-206000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTgtMS0xLTEtMzkzODM_14a03607-8189-414e-a465-00bf59ef3aad"
unitRef="usd">-92000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTgtMy0xLTEtMzkzODM_f2e56044-48b6-4d01-bdc1-0ebbec09ec79"
unitRef="usd">3000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTgtNS0xLTEtMzkzODM_aba9ecb8-e6ab-4bd5-8c44-89a602121886"
unitRef="usd">-337000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTgtNy0xLTEtMzkzODM_58338394-3887-48e8-baec-7ff2fff193ab"
unitRef="usd">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTktMS0xLTEtMzkzODM_c8a5f587-09b9-41e3-8673-9164ba6ecc70"
unitRef="usd">-86000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTktMy0xLTEtMzkzODM_f7838a30-1886-40d6-9fb4-b06a1b4c72c2"
unitRef="usd">69000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTktNS0xLTEtMzkzODM_61ddd2fa-5a0d-4bc9-aa13-7be5e3048880"
unitRef="usd">-355000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMTktNy0xLTEtMzkzODM_49c238cf-0c5e-49dc-893b-16919fe6ba60"
unitRef="usd">-206000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
<us-gaap:ComprehensiveIncomeNetOfTax
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjAtMS0xLTEtMzkzODM_0c8666d2-2583-445d-9923-06d856a06f81"
unitRef="usd">-14726000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjAtMy0xLTEtMzkzODM_54bacd86-d6d5-45ee-88bc-489cd5bb0c98"
unitRef="usd">-12893000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjAtNS0xLTEtMzkzODM_e01754f6-baaa-4c58-a423-640a4754ea2c"
unitRef="usd">-30823000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjAtNy0xLTEtMzkzODM_a8ac0f73-319f-4920-bec8-71d4cb9d7ac1"
unitRef="usd">-25680000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:EarningsPerShareDiluted
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjEtMS0xLTEtMzkzODM_8ea0300b-f355-45d3-b9ea-b0078e465415"
unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareBasic
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjEtMS0xLTEtMzkzODM_bc08b91b-e263-48b0-8876-8b658f0ad83a"
unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjEtMy0xLTEtMzkzODM_94c2871d-e2ef-4e3f-8281-468e68668650"
unitRef="usdPerShare">-0.36</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareDiluted
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjEtMy0xLTEtMzkzODM_e07f1e5f-2021-4cd5-b3a1-16cceb9b08ba"
unitRef="usdPerShare">-0.36</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjEtNS0xLTEtMzkzODM_5da0a3e7-88b5-4d19-9080-5bd711e520fb"
unitRef="usdPerShare">-0.83</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareBasic
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjEtNS0xLTEtMzkzODM_97ffffdb-a71d-4137-90d7-b0db784f2bfa"
unitRef="usdPerShare">-0.83</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjEtNy0xLTEtMzkzODM_42cc7c7a-f7d2-4a40-82d4-5da510704000"
unitRef="usdPerShare">-0.71</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareDiluted
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjEtNy0xLTEtMzkzODM_6f308815-15ae-4258-913a-7a1cfd5edfbe"
unitRef="usdPerShare">-0.71</us-gaap:EarningsPerShareDiluted>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjItMS0xLTEtMzkzODM_133e299e-0de6-4c04-bf59-e426bdc6e465"
unitRef="shares">37003443</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjItMS0xLTEtMzkzODM_84653b4f-29b0-403b-a3f3-cafe38accf2c"
unitRef="shares">37003443</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjItMy0xLTEtMzkzODM_26ba52f7-fd5e-4e71-9dd3-1152a9e89adc"
unitRef="shares">36042614</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjItMy0xLTEtMzkzODM_33655c27-7e76-4dc4-b8f9-5e5da3b98f64"
unitRef="shares">36042614</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjItNS0xLTEtMzkzODM_74d11cca-c0b4-45d0-a53e-edc6492b05c3"
unitRef="shares">36904952</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjItNS0xLTEtMzkzODM_a9702e8b-1cf6-43a0-abe0-935737d9fc93"
unitRef="shares">36904952</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjItNy0xLTEtMzkzODM_481eb5e1-23fb-479a-87c3-df33268108b3"
unitRef="shares">35708548</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yMi9mcmFnOjM0OTY4NTkyZmVkNDQ5ZjA5OGNlM2UwMWNmNGU0NjBkL3RhYmxlOmRlNTAzYTA3MzhlMzRmYmU4YzcwYjk0ZDFjZWIzZDVjL3RhYmxlcmFuZ2U6ZGU1MDNhMDczOGUzNGZiZThjNzBiOTRkMWNlYjNkNWNfMjItNy0xLTEtMzkzODM_b7339be8-211c-4657-af2f-2f21a017f74c"
unitRef="shares">35708548</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding
contextRef="i7c4697ae1aaa496dbaaf2d4679704499_I20211231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMi0yLTEtMS0zOTM4Mw_530e1eeb-5257-4315-ac23-a5d4a563a57a"
unitRef="shares">36931762</us-gaap:CommonStockSharesOutstanding>
<us-gaap:StockholdersEquity
contextRef="i7c4697ae1aaa496dbaaf2d4679704499_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMi00LTEtMS0zOTM4Mw_0bf886cb-560d-40fc-b21f-ad31d8b37aab"
unitRef="usd">37000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="ia24f369469a741168a30ae622482853d_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMi02LTEtMS0zOTM4Mw_9607faf4-26a4-4917-a8ed-d3e09c22abce"
unitRef="usd">482885000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i10ab7cd963514359bca3cc91d92e2ecc_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMi04LTEtMS0zOTM4Mw_c7d204c3-0fbe-4979-a3a0-1155268449ff"
unitRef="usd">1712000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="id78b13f427954c0c9d0eaf7f535da90f_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMi0xMC0xLTEtMzkzODM_8c0193af-af7d-4105-9d2d-6a995bf1d494"
unitRef="usd">-291395000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMi0xMi0xLTEtMzkzODM_316778cd-e96b-4a14-bfe7-a240421d2676"
unitRef="usd">193239000</us-gaap:StockholdersEquity>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
contextRef="i19fb5ca4a6fb4af091d289bfc12b61a0_D20220101-20220331"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMy0yLTEtMS0zOTM4Mw_3405b843-c2cd-4c96-8ab8-ae0352de9e6e"
unitRef="shares">21392</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
contextRef="i19fb5ca4a6fb4af091d289bfc12b61a0_D20220101-20220331"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfNC0yLTEtMS00MzYxMg_3041d336-e40e-4d09-abd2-e77eed6123f6"
unitRef="shares">99265</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
contextRef="i725a772a7daa4c27b7de453c618f8b63_D20220101-20220331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfNC02LTEtMS00MzYxMg_836997e3-c6a7-4ca5-9068-78c131107612"
unitRef="usd">221000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
contextRef="i652d00700fc04edeacaed27e5bb45f8e_D20220101-20220331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfNC0xMi0xLTEtNDQ5NTE_ed4e2d96-9d78-449d-95f4-fb7e84a86176"
unitRef="usd">221000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
contextRef="i19fb5ca4a6fb4af091d289bfc12b61a0_D20220101-20220331"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfNC0yLTEtMS0zOTM4Mw_4a671d8c-0cfb-4b0d-8d61-52bc1bbdfceb"
unitRef="shares">46002</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
contextRef="i725a772a7daa4c27b7de453c618f8b63_D20220101-20220331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfNC02LTEtMS0zOTM4Mw_43ce8daa-2063-4dfd-ad3c-0e75791a5212"
unitRef="usd">1108000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
contextRef="i652d00700fc04edeacaed27e5bb45f8e_D20220101-20220331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfNC0xMi0xLTEtNDE2MDM_40867b61-3944-4c7a-9e12-84f9a7460020"
unitRef="usd">1108000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
<lung:AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase
contextRef="i725a772a7daa4c27b7de453c618f8b63_D20220101-20220331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfNS02LTEtMS0zOTM4Mw_6da8c6e1-9c51-4b20-8dd8-4994ad66828e"
unitRef="usd">59000</lung:AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase>
<lung:AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase
contextRef="i652d00700fc04edeacaed27e5bb45f8e_D20220101-20220331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfNS0xMi0xLTEtMzkzODM_9a00de90-c07f-4fec-8df2-a6814a86e240"
unitRef="usd">59000</lung:AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
contextRef="i725a772a7daa4c27b7de453c618f8b63_D20220101-20220331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfNi02LTEtMS0zOTM4Mw_84b17089-15a9-4d87-b4e3-0fd53af8900b"
unitRef="usd">3615000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
contextRef="i652d00700fc04edeacaed27e5bb45f8e_D20220101-20220331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfNi0xMi0xLTEtMzkzODM_0c35041c-17b9-49d4-8710-52ab12001c08"
unitRef="usd">3615000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
contextRef="ie32244cce0bb4ac7b0db5c54bbe3378f_D20220101-20220331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfNy04LTEtMS0zOTM4Mw_4fb3f5ed-75cc-4b95-ab01-9bfa5adc6e12"
unitRef="usd">-24000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
contextRef="i652d00700fc04edeacaed27e5bb45f8e_D20220101-20220331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfNy0xMi0xLTEtMzkzODM_0481db54-0cba-4a0b-8d5d-7a9c684ed517"
unitRef="usd">-24000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
contextRef="ie32244cce0bb4ac7b0db5c54bbe3378f_D20220101-20220331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfOC04LTEtMS0zOTM4Mw_81bc8451-203d-4fcd-a567-3be690100692"
unitRef="usd">-245000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
contextRef="i652d00700fc04edeacaed27e5bb45f8e_D20220101-20220331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfOC0xMi0xLTEtMzkzODM_f71fb51d-38d0-49df-a8b8-1d91297e152e"
unitRef="usd">-245000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:NetIncomeLoss
contextRef="i4f6b9352f27c4329bd7774ca5b92761f_D20220101-20220331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfOS0xMC0xLTEtMzkzODM_5c933424-bd5e-48f3-a4c2-629c7edfbe61"
unitRef="usd">-15828000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss
contextRef="i652d00700fc04edeacaed27e5bb45f8e_D20220101-20220331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfOS0xMi0xLTEtMzkzODM_9de9ed71-3abc-45a7-899c-cbbc107d4fda"
unitRef="usd">-15828000</us-gaap:NetIncomeLoss>
<us-gaap:CommonStockSharesOutstanding
contextRef="i194ccf658b8d40dcad4baa33b8140830_I20220331"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTAtMi0xLTEtMzkzODM_26900f13-b0ba-450d-b870-a44c15801fa7"
unitRef="shares">37098421</us-gaap:CommonStockSharesOutstanding>
<us-gaap:StockholdersEquity
contextRef="i194ccf658b8d40dcad4baa33b8140830_I20220331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTAtNC0xLTEtMzkzODM_9ae01611-36c9-4b7b-a10d-61d058a645d6"
unitRef="usd">37000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i90fc2f64290846f9bd78af8a90169410_I20220331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTAtNi0xLTEtMzkzODM_479762fe-f714-4df9-a358-732d9557acdb"
unitRef="usd">487888000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i4e2da5d082cb42229835e719c252d985_I20220331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTAtOC0xLTEtMzkzODM_0aa20e67-21a9-401d-b9e4-d06863abd0d0"
unitRef="usd">1443000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="ifdb2a33757594e479f11368bdb9206b3_I20220331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTAtMTAtMS0xLTM5Mzgz_f1b1bc2a-cf8d-4a85-aafe-4880cd5364c3"
unitRef="usd">-307223000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="ib259775b9b9c44278d3b14fa3bc4487c_I20220331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTAtMTItMS0xLTM5Mzgz_d7d79545-925f-4928-87ef-99ee54933c36"
unitRef="usd">182145000</us-gaap:StockholdersEquity>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
contextRef="iec7ebe8c89a545d9a436b69816b227eb_D20220401-20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTEtMi0xLTEtMzkzODM_0e153202-dde8-483c-9f8f-8c7b3939b36b"
unitRef="shares">93988</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
contextRef="iec7ebe8c89a545d9a436b69816b227eb_D20220401-20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTItMi0xLTEtNDAwODc_cfbc14d0-365f-4b19-8a6b-6736fb0983da"
unitRef="shares">73621</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
contextRef="i9eb715cb0da94d3da06eec36cb1cb264_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTItNi0xLTEtNDAwODc_2cb7fef2-4e39-4747-b855-bb36d2d26706"
unitRef="usd">151000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTItMTItMS0xLTQxNTkz_e98ce3bd-ef5a-4dcf-850a-56ead05fd843"
unitRef="usd">151000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<lung:AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase
contextRef="i9eb715cb0da94d3da06eec36cb1cb264_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTItNi0xLTEtMzkzODM_44af6c18-76c7-43ed-b398-590820afef01"
unitRef="usd">58000</lung:AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase>
<lung:AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTItMTItMS0xLTM5Mzgz_e96b231d-7be9-4e70-a90c-75394325f924"
unitRef="usd">58000</lung:AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
contextRef="i9eb715cb0da94d3da06eec36cb1cb264_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTQtNi0xLTEtMzkzODM_39482dfe-dcca-4b3a-a1e8-698b1c349970"
unitRef="usd">4554000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTQtMTItMS0xLTM5Mzgz_21377b3b-ce9f-4720-b5b9-7368cd0bf5d7"
unitRef="usd">4554000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
contextRef="i72eebbb0bfb6442c835ff9de3799eae7_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTUtOC0xLTEtMzkzODM_d764b8e5-ab08-477b-a26f-643b0a656301"
unitRef="usd">6000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTUtMTItMS0xLTM5Mzgz_70101f8f-2ab6-4b8c-bea5-de70d973729e"
unitRef="usd">6000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
contextRef="i72eebbb0bfb6442c835ff9de3799eae7_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTYtOC0xLTEtMzkzODM_691627ee-6208-4b62-abcb-aed359ef25ed"
unitRef="usd">-92000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTYtMTItMS0xLTM5Mzgz_d8ef50de-edf8-4746-a15a-619c325f691d"
unitRef="usd">-92000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:NetIncomeLoss
contextRef="i6858cf3ac89b40e1aa7df89ed53b2a24_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTctMTAtMS0xLTM5Mzgz_c7c6221c-11d3-4441-9a4c-40e0b0564f90"
unitRef="usd">-14640000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTctMTItMS0xLTM5Mzgz_dd46e8fe-a782-445e-87fa-2c77e4854178"
unitRef="usd">-14640000</us-gaap:NetIncomeLoss>
<us-gaap:CommonStockSharesOutstanding
contextRef="i91bd715107e14e01ba109bc345441fd3_I20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTgtMi0xLTEtMzkzODM_bdbf3ca2-cde4-4355-8d73-39646c743a68"
unitRef="shares">37266030</us-gaap:CommonStockSharesOutstanding>
<us-gaap:StockholdersEquity
contextRef="i91bd715107e14e01ba109bc345441fd3_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTgtNC0xLTEtMzkzODM_de069342-4382-4f23-a9de-d4f544e6ee4e"
unitRef="usd">37000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i99751b578e1948aab49db6044f4428c2_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTgtNi0xLTEtMzkzODM_509bbde3-fdc1-4665-a0d8-83fccc1c5cee"
unitRef="usd">492651000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i64d27f95511a463b9e9c935f31dfb113_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTgtOC0xLTEtMzkzODM_252ee733-48f3-417d-be37-c305697774e7"
unitRef="usd">1357000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i259f3776dc6e4cc2a3830d0cb8f9c7c9_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTgtMTAtMS0xLTM5Mzgz_d2b81dc4-172c-4bab-8274-4395cc56f334"
unitRef="usd">-321863000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOmNmNjc2Nzc2YjIwMjRiODA5OTQyNTM0MTcwMDMwYWNiL3RhYmxlcmFuZ2U6Y2Y2NzY3NzZiMjAyNGI4MDk5NDI1MzQxNzAwMzBhY2JfMTgtMTItMS0xLTM5Mzgz_d8f9b001-49b4-4024-bdf8-12669d4ea90a"
unitRef="usd">172182000</us-gaap:StockholdersEquity>
<us-gaap:CommonStockSharesOutstanding
contextRef="i937e6c62ae494af082d55df28a206b08_I20201231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMi01LTEtMS0zOTM4Mw_9f4c4ec4-d9e9-4579-9631-6a33812f13cd"
unitRef="shares">35693753</us-gaap:CommonStockSharesOutstanding>
<us-gaap:StockholdersEquity
contextRef="i937e6c62ae494af082d55df28a206b08_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMi03LTEtMS0zOTM4Mw_0f7a9b36-cee6-4529-b95a-dc4a663022bd"
unitRef="usd">36000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="ia4bd41d858f34c15860558f9397212b7_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMi05LTEtMS0zOTM4Mw_4e029c16-b94c-4c22-afe6-3d0dbd107f29"
unitRef="usd">467147000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i65dfe455b40043c5879a699696671342_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMi0xMS0xLTEtMzkzODM_abb3bf9e-1a4f-4ceb-9763-f7ba3836d5e1"
unitRef="usd">1685000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i55ca82439e3f4c70b50cc76b61427123_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMi0xMy0xLTEtMzkzODM_09f7a880-c41e-45b7-9bc5-41af563a028b"
unitRef="usd">-242734000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="if30e4595cd6d463086f867a5956e9dc6_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMi0xNS0xLTEtMzkzODM_f3baec5b-e633-495d-bb7c-c4ecc9f95414"
unitRef="usd">226134000</us-gaap:StockholdersEquity>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
contextRef="i8540e99599c44addac72e276711f6cec_D20210101-20210331"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMy01LTEtMS0zOTM4Mw_80c2e111-d06a-4c32-9ec2-ed950ca33e39"
unitRef="shares">122856</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
contextRef="ia82be87509cd48adba02800ee6d7620c_D20210101-20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMy05LTEtMS0zOTM4Mw_c76362a8-8124-4470-87c0-8c3e224fc888"
unitRef="usd">273000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
contextRef="i1d577c6b24e74d95b9308b0abbea21c0_D20210101-20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMy0xMi0xLTEtNDE2MDc_aeceebb0-bc60-45cd-904f-72175b070d0c"
unitRef="usd">273000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<lung:StockRepurchasedDuringPeriodExerciseOfEarlyStockOptionsShares
contextRef="i8540e99599c44addac72e276711f6cec_D20210101-20210331"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfNC01LTEtMS0zOTM4Mw_d93a28e1-f0ac-493b-bb33-d4782e7752a3"
unitRef="shares">12945</lung:StockRepurchasedDuringPeriodExerciseOfEarlyStockOptionsShares>
<lung:AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase
contextRef="ia82be87509cd48adba02800ee6d7620c_D20210101-20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfNS05LTEtMS0zOTM4Mw_e336e459-a967-4341-93a3-7002c2a03955"
unitRef="usd">66000</lung:AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase>
<lung:AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase
contextRef="i1d577c6b24e74d95b9308b0abbea21c0_D20210101-20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfNS0xNS0xLTEtMzkzODM_772a7b42-a91c-4306-94da-d49379e75ab6"
unitRef="usd">66000</lung:AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
contextRef="ia82be87509cd48adba02800ee6d7620c_D20210101-20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfNi05LTEtMS0zOTM4Mw_7f7047ec-db30-4197-854f-e7448063f9f0"
unitRef="usd">2462000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
contextRef="i1d577c6b24e74d95b9308b0abbea21c0_D20210101-20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfNi0xNS0xLTEtMzkzODM_cc5e0d05-8886-4a09-b5df-300dd250e065"
unitRef="usd">2462000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
contextRef="i6381f3fa151c4fa79031cfd4c59f3dd1_D20210101-20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfNy0xMS0xLTEtMzkzODM_c1678a03-d8ed-4723-8a00-2800242bae81"
unitRef="usd">-272000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
contextRef="i1d577c6b24e74d95b9308b0abbea21c0_D20210101-20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfNy0xNS0xLTEtMzkzODM_77947bfb-b4c1-4c9b-b3ae-2484ec337d6f"
unitRef="usd">-272000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
contextRef="i6381f3fa151c4fa79031cfd4c59f3dd1_D20210101-20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfOC0xMS0xLTEtMzkzODM_7576da49-788c-4414-9c03-1e0df6fe54dd"
unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
contextRef="i1d577c6b24e74d95b9308b0abbea21c0_D20210101-20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfOC0xNS0xLTEtMzkzODM_110e3286-3442-4aa0-ad17-3246a165970e"
unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:NetIncomeLoss
contextRef="id8cfddbc76454c0a86d25df73ca052b8_D20210101-20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfOS0xMy0xLTEtMzkzODM_d0ee8a3d-2c82-4134-a85a-74aca11b5e42"
unitRef="usd">-12512000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss
contextRef="i1d577c6b24e74d95b9308b0abbea21c0_D20210101-20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfOS0xNS0xLTEtMzkzODM_573a8590-c90f-42d8-b659-3677881ee4bf"
unitRef="usd">-12512000</us-gaap:NetIncomeLoss>
<us-gaap:CommonStockSharesOutstanding
contextRef="i386654d89dcd4305bc2796578a912387_I20210331"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTAtNS0xLTEtMzkzODM_d2e5593c-d677-4fe0-92e8-39a1cbac8f41"
unitRef="shares">35803664</us-gaap:CommonStockSharesOutstanding>
<us-gaap:StockholdersEquity
contextRef="i386654d89dcd4305bc2796578a912387_I20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTAtNy0xLTEtMzkzODM_eb3c5489-fc55-48bb-bb6e-2e514e6f3e70"
unitRef="usd">36000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i9301a7535db44e52b62db20ea7d35b36_I20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTAtOS0xLTEtMzkzODM_c557b550-3d97-4d88-a173-74b8b1d7d821"
unitRef="usd">469948000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i26b8aa74725440cfacefcfa508e23b8f_I20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTAtMTEtMS0xLTM5Mzgz_785d1361-bf3d-4b11-8ef7-41ee47e142bb"
unitRef="usd">1410000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="if58fbcaf779342d48308a3b41be27d24_I20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTAtMTMtMS0xLTM5Mzgz_47770663-d0b8-4c06-9925-d17a1c714a2c"
unitRef="usd">-255246000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="ia9dc423e8a1c41408784d828d38bb8af_I20210331"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTAtMTUtMS0xLTM5Mzgz_36ceb990-5e0d-4ea4-a4db-5866ea664692"
unitRef="usd">216148000</us-gaap:StockholdersEquity>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
contextRef="i0c2c4ec32c314b51a25e847eceb0629a_D20210401-20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTEtNS0xLTEtMzkzODM_ae75b7af-b1f5-43b1-97a1-f3cc2f765a84"
unitRef="shares">653609</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
contextRef="i71e36e6ab000490aa878482c47257f1f_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTEtOS0xLTEtMzkzODM_65579f58-6a43-4918-ba41-ac0ab9cb951d"
unitRef="usd">1133000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTEtMTUtMS0xLTM5Mzgz_27c2e8dc-ef6c-46a4-9d9a-53f800ace7e8"
unitRef="usd">1133000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
contextRef="i0c2c4ec32c314b51a25e847eceb0629a_D20210401-20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTItMi0xLTEtNDAwNTQ_d0ae7783-1fb7-4dc0-a8fb-d52852dcf05b"
unitRef="shares">123344</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
contextRef="i71e36e6ab000490aa878482c47257f1f_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTItNi0xLTEtNDAwNTQ_c9f1601b-6c1a-4307-a22f-73c9169ba141"
unitRef="usd">1992000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTItMTItMS0xLTQwMDU0_1a41554b-20b5-4a72-83a0-f39525791a28"
unitRef="usd">1992000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
<lung:AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase
contextRef="i71e36e6ab000490aa878482c47257f1f_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTItOS0xLTEtMzkzODM_b0e23493-d8a1-40f7-a5ea-a16aa4b1a451"
unitRef="usd">12000</lung:AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase>
<lung:AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTItMTUtMS0xLTM5Mzgz_31be5e6f-ff47-479d-801e-f41ebb90e7fb"
unitRef="usd">12000</lung:AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
contextRef="i71e36e6ab000490aa878482c47257f1f_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTMtOS0xLTEtMzkzODM_2748e451-e23b-446a-9798-cdbfd209f32b"
unitRef="usd">2476000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTMtMTUtMS0xLTM5Mzgz_c691c594-b56b-4a9a-a2ff-2cb9833e2643"
unitRef="usd">2476000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
contextRef="i313147cc93cf4996b2b891fed6afd2c8_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTQtMTEtMS0xLTM5Mzgz_d3e71106-1a22-439f-b2fd-ad5dd70112dd"
unitRef="usd">66000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTQtMTUtMS0xLTM5Mzgz_96f450f1-62e9-42b8-bb70-6a458b04948a"
unitRef="usd">66000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
contextRef="i313147cc93cf4996b2b891fed6afd2c8_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTUtMTEtMS0xLTM5Mzgz_f5165a85-abeb-4eb3-bbfd-648b8c3ac8d1"
unitRef="usd">3000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTUtMTUtMS0xLTM5Mzgz_5f600e4f-c38b-4499-a221-fecdc6596b20"
unitRef="usd">3000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:NetIncomeLoss
contextRef="i87c0f954d15f47f997c03b4bbe0a518c_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTYtMTMtMS0xLTM5Mzgz_2396c03a-f64d-4881-8836-76a2ab7799b4"
unitRef="usd">-12962000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTYtMTUtMS0xLTM5Mzgz_ffe86ae9-23a0-4653-9521-3ec78b39a23b"
unitRef="usd">-12962000</us-gaap:NetIncomeLoss>
<us-gaap:CommonStockSharesOutstanding
contextRef="i93f25af4132544699f7cc1911016ca93_I20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTctNS0xLTEtMzkzODM_dffbd63c-a544-4819-988b-7c931714bc1d"
unitRef="shares">36580617</us-gaap:CommonStockSharesOutstanding>
<us-gaap:StockholdersEquity
contextRef="i93f25af4132544699f7cc1911016ca93_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTctNy0xLTEtMzkzODM_5ba5ea67-bba0-44c4-a78e-3a8ab5469cfd"
unitRef="usd">36000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i2ab786f6b9094a30a403c16621efc3b8_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTctOS0xLTEtMzkzODM_c05cdaa5-1648-4dd1-8ab8-a9995cb9a396"
unitRef="usd">475561000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i0536fa32537e48f3b61cc43f596ef9ef_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTctMTEtMS0xLTM5Mzgz_e3a93963-f948-43c8-9e6f-5ccdcd724bad"
unitRef="usd">1479000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="icf8348b6ab644a16943adf5d6b3b01d1_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTctMTMtMS0xLTM5Mzgz_753b23cf-87cc-4676-91fb-a6fb1cfca58c"
unitRef="usd">-268208000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="i10d78353ceec4f248af8e917fdcbaa2c_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yNS9mcmFnOjAzMTA4YmQ5ODViMjQwYmM5MGNlZmY3ODU1NGVlNjQ5L3RhYmxlOjhlMmZlZGI3ZjlhODRkODhhMWY5MjJkNDkyYTdjZTYyL3RhYmxlcmFuZ2U6OGUyZmVkYjdmOWE4NGQ4OGExZjkyMmQ0OTJhN2NlNjJfMTctMTUtMS0xLTM5Mzgz_b0ef5aa9-167f-4929-9aca-12b02bda06be"
unitRef="usd">208868000</us-gaap:StockholdersEquity>
<us-gaap:NetIncomeLoss
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMy0xLTEtMS0zOTM4Mw_a27f2394-8797-4f72-990e-7e87b2399c21"
unitRef="usd">-30468000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMy0zLTEtMS0zOTM4Mw_4a8de7bc-ec11-4046-85ce-25598a4033fd"
unitRef="usd">-25474000</us-gaap:NetIncomeLoss>
<us-gaap:ShareBasedCompensation
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNS0xLTEtMS0zOTM4Mw_f43fcb3b-f682-4ffa-b754-9f52a75238b4"
unitRef="usd">7896000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNS0zLTEtMS0zOTM4Mw_261a7e93-4544-4d1f-9397-b1f2db93e08e"
unitRef="usd">4580000</us-gaap:ShareBasedCompensation>
<us-gaap:GainLossOnDispositionOfAssets1
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNi0xLTEtMS0zOTM4Mw_37a97c0f-a87a-4793-a10b-193ff9b6d05d"
unitRef="usd">-1000</us-gaap:GainLossOnDispositionOfAssets1>
<us-gaap:GainLossOnDispositionOfAssets1
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNi0zLTEtMS0zOTM4Mw_a49e390c-a1d8-4e71-927d-bbec35547231"
unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
<us-gaap:ProvisionForDoubtfulAccounts
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNy0xLTEtMS0zOTM4Mw_18fdd592-d5af-4cfe-b415-accc62034e1a"
unitRef="usd">1000</us-gaap:ProvisionForDoubtfulAccounts>
<us-gaap:ProvisionForDoubtfulAccounts
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNy0zLTEtMS0zOTM4Mw_576c63d7-1032-4064-aaf4-fd33dbf7d288"
unitRef="usd">-1000</us-gaap:ProvisionForDoubtfulAccounts>
<us-gaap:InventoryWriteDown
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfOC0xLTEtMS0zOTM4Mw_856e5e03-8dc9-448f-af48-c44f439c69d2"
unitRef="usd">111000</us-gaap:InventoryWriteDown>
<us-gaap:InventoryWriteDown
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfOC0zLTEtMS0zOTM4Mw_89f9ad62-a484-4427-b560-84d9e2e3a657"
unitRef="usd">665000</us-gaap:InventoryWriteDown>
<us-gaap:OtherDepreciationAndAmortization
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfOS0xLTEtMS0zOTM4Mw_f8459d60-95af-425d-b4e9-2697549248a1"
unitRef="usd">744000</us-gaap:OtherDepreciationAndAmortization>
<us-gaap:OtherDepreciationAndAmortization
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfOS0zLTEtMS0zOTM4Mw_26ae12dd-f649-43c9-9aea-69e42e79dd86"
unitRef="usd">287000</us-gaap:OtherDepreciationAndAmortization>
<us-gaap:AmortizationOfFinancingCostsAndDiscounts
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTAtMS0xLTEtMzkzODM_3ecc346e-74d3-40b1-bd92-b32c7c79ada5"
unitRef="usd">32000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
<us-gaap:AmortizationOfFinancingCostsAndDiscounts
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTAtMy0xLTEtMzkzODM_73611f06-b703-469d-a1f1-a635d28bb0a0"
unitRef="usd">64000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTItMS0xLTEtMzkzODM_73fb6fb3-b3ab-4b8b-89e4-aa3dfdfeee1c"
unitRef="usd">-19000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTItMy0xLTEtMzkzODM_c687780f-9ef3-4744-9142-04378d4b513f"
unitRef="usd">-16000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
<us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTMtMS0xLTEtMzkzODM_e959804b-a463-4cbc-ae82-65485d93fbeb"
unitRef="usd">1226000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
<us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTMtMy0xLTEtMzkzODM_9290a18d-2ea8-462a-aed4-4907e093685f"
unitRef="usd">1149000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
<us-gaap:IncreaseDecreaseInAccountsReceivable
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTUtMS0xLTEtMzkzODM_aa516bfa-c471-48ac-874b-6ef0f346a618"
unitRef="usd">1073000</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInAccountsReceivable
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTUtMy0xLTEtMzkzODM_f32dde1c-e764-46d1-b6e5-4d69a67adad0"
unitRef="usd">2732000</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInInventories
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTYtMS0xLTEtMzkzODM_1c0fbda1-9245-4f03-9606-7bcd8ba567ed"
unitRef="usd">3030000</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInInventories
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTYtMy0xLTEtMzkzODM_67c69833-1a8b-4b55-bca3-380347372250"
unitRef="usd">3125000</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTctMS0xLTEtMzkzODM_8ff00384-577b-46da-9e4b-ec67e3fe8d3a"
unitRef="usd">-1065000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTctMy0xLTEtMzkzODM_1c7b4b6e-43fc-428d-9730-165297075409"
unitRef="usd">-216000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTgtMS0xLTEtMzkzODM_dec49826-9855-4fab-94fa-0608965eeae5"
unitRef="usd">-6000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
<us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTgtMy0xLTEtMzkzODM_258038e5-eddc-40b0-b9b0-4b8ce8713aa7"
unitRef="usd">29000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
<us-gaap:IncreaseDecreaseInAccountsPayable
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTktMS0xLTEtMzkzODM_c076fd79-0e2b-4d5a-be52-89816383027d"
unitRef="usd">1062000</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsPayable
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMTktMy0xLTEtMzkzODM_dcfbedcd-0e6f-4706-9b80-f867e1857a37"
unitRef="usd">293000</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccruedLiabilities
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjAtMS0xLTEtMzkzODM_98b9a4e2-d79d-417f-b658-c8d1362949b8"
unitRef="usd">-1296000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilities
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjAtMy0xLTEtMzkzODM_fad36c37-0d36-43f1-a848-6c1f1b00e450"
unitRef="usd">2926000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjEtMS0xLTEtMzkzODM_c0f31fe8-f2d1-4bc0-a35c-e8d35ba9cd9a"
unitRef="usd">-150000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
<us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjEtMy0xLTEtMzkzODM_41ee32d8-a74a-4d16-a315-67ed2c7c4f0e"
unitRef="usd">-87000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
<us-gaap:IncreaseDecreaseInOperatingLeaseLiability
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjItMS0xLTEtMzkzODM_7f609752-1cc3-4be9-9abc-79bc3b7e26b9"
unitRef="usd">-707000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
<us-gaap:IncreaseDecreaseInOperatingLeaseLiability
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjItMy0xLTEtMzkzODM_82db8984-f765-426f-b257-56382bad8132"
unitRef="usd">-1137000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
<us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjMtMS0xLTEtMzkzODM_71742d92-8d90-40e3-b781-43827c1ee1cb"
unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
<us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjMtMy0xLTEtMzkzODM_f88a1073-1849-4779-9d07-9c6425453328"
unitRef="usd">-11000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
<us-gaap:IncreaseDecreaseInContractWithCustomerLiability
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjQtMS0xLTEtMzkzODM_a5b8bb77-b6ab-4fe5-90cd-0905b4487b2c"
unitRef="usd">-29000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
<us-gaap:IncreaseDecreaseInContractWithCustomerLiability
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjQtMy0xLTEtMzkzODM_767cb779-7f94-415b-afc6-da6467fb653f"
unitRef="usd">16000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
<us-gaap:NetCashProvidedByUsedInOperatingActivities
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjUtMS0xLTEtMzkzODM_0ba0b923-257c-4b39-8135-f3fe15c71b4c"
unitRef="usd">-24590000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjUtMy0xLTEtMzkzODM_d19ea31f-3311-44ff-a6d9-2122be1a6cef"
unitRef="usd">-22362000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjctMS0xLTEtMzkzODM_770ca16e-96f4-4efd-8a5f-392149c7b8b1"
unitRef="usd">21959000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjctMy0xLTEtMzkzODM_da541463-cf2e-4f22-9aca-d8775946b815"
unitRef="usd">15314000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjgtMS0xLTEtMzkzODM_18929e73-42f4-4f90-b9c7-4bbd796a392f"
unitRef="usd">19280000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjgtMy0xLTEtMzkzODM_c301a711-b959-4a50-acb6-0716c210901c"
unitRef="usd">2500000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjktMS0xLTEtMzkzODM_546670a1-0833-4ce0-ae86-495b8d51130d"
unitRef="usd">863000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMjktMy0xLTEtMzkzODM_45b1ca2e-b388-4924-961e-a5e48a8f1af1"
unitRef="usd">903000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:NetCashProvidedByUsedInInvestingActivities
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMzAtMS0xLTEtMzkzODM_f2a1cfd4-3e98-4690-a8fa-dfde1403ec6e"
unitRef="usd">-3542000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMzAtMy0xLTEtMzkzODM_320ca49a-f994-446c-b8fe-9da9e0cf8358"
unitRef="usd">-13717000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:RepaymentsOfLongTermLinesOfCredit
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMzMtMS0xLTEtMzkzODM_7e448ca0-940a-4b3d-912a-96b8b447e439"
unitRef="usd">44000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
<us-gaap:RepaymentsOfLongTermLinesOfCredit
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMzMtMy0xLTEtMzkzODM_6e1b8888-7fdb-4e02-a16a-3886c5b123bd"
unitRef="usd">0</us-gaap:RepaymentsOfLongTermLinesOfCredit>
<us-gaap:PaymentsOfDebtIssuanceCosts
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMzgtMS0xLTEtMzkzODM_f7a0c97d-8630-41d3-9e49-db7de8f5e7d0"
unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
<us-gaap:PaymentsOfDebtIssuanceCosts
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfMzgtMy0xLTEtMzkzODM_bfcac854-d65a-4072-a2fa-42f00ffdaf88"
unitRef="usd">41000</us-gaap:PaymentsOfDebtIssuanceCosts>
<us-gaap:ProceedsFromStockOptionsExercised
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDEtMS0xLTEtMzkzODM_6c3c3d5c-9afe-45e1-9130-d8d3d796f298"
unitRef="usd">382000</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:ProceedsFromStockOptionsExercised
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDEtMy0xLTEtMzkzODM_fa72c4e0-1fe1-499f-a577-bab233664920"
unitRef="usd">1381000</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:ProceedsFromRepaymentOfLoansToPurchaseCommonStock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDItMS0xLTEtMzkzODM_55d44172-aaf3-4932-9a7a-c080c7d83a97"
unitRef="usd">1108000</us-gaap:ProceedsFromRepaymentOfLoansToPurchaseCommonStock>
<us-gaap:ProceedsFromRepaymentOfLoansToPurchaseCommonStock
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDItMy0xLTEtMzkzODM_6aafd813-9a60-4917-8cb8-54e30fddc0f4"
unitRef="usd">1992000</us-gaap:ProceedsFromRepaymentOfLoansToPurchaseCommonStock>
<us-gaap:PaymentsForRepurchaseOfCommonStock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDMtMS0xLTEtMzkzODM_161899f5-eb9e-4add-b64e-619ebb65fb7a"
unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
<us-gaap:PaymentsForRepurchaseOfCommonStock
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDMtMy0xLTEtMzkzODM_a567fe28-f56c-4d9d-b33e-62c36be0e193"
unitRef="usd">26000</us-gaap:PaymentsForRepurchaseOfCommonStock>
<us-gaap:NetCashProvidedByUsedInFinancingActivities
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDQtMS0xLTEtMzkzODM_b0fd9fe9-4ea4-4e6d-8fee-7854e0bc637e"
unitRef="usd">1446000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDQtMy0xLTEtMzkzODM_6cf87b7c-9390-4cca-9103-84e8b1b350f6"
unitRef="usd">3306000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDUtMS0xLTEtMzkzODM_4847d25b-4bfe-446d-a10e-aab0f7799056"
unitRef="usd">153000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDUtMy0xLTEtMzkzODM_ba69924f-0b14-43ad-a627-566ee94891ab"
unitRef="usd">-85000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDYtMS0xLTEtMzkzODM_3c3ac9d7-3cd4-44f6-bd4d-08be193964c1"
unitRef="usd">-26533000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDYtMy0xLTEtMzkzODM_cbb21c4a-9970-4e4d-80f3-cb550ee3ba1d"
unitRef="usd">-32858000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDctMS0xLTEtMzkzODM_2c272739-9031-4af0-8bde-08b61d54cba4"
unitRef="usd">148711000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
contextRef="if30e4595cd6d463086f867a5956e9dc6_I20201231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDctMy0xLTEtMzkzODM_e0ffa24d-4ca0-49f4-871d-f1acd20f7989"
unitRef="usd">231792000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDgtMS0xLTEtMzkzODM_14f7c450-b046-4e27-ace4-3314947bea64"
unitRef="usd">122178000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
contextRef="i10d78353ceec4f248af8e917fdcbaa2c_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNDgtMy0xLTEtMzkzODM_68085a3e-4c5f-4216-87cc-613ae20e61b3"
unitRef="usd">198934000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashAndCashEquivalentsAtCarryingValue
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNTAtMS0xLTEtMzkzODM_ca655d49-0329-4b4b-9392-b85559887da6"
unitRef="usd">121947000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue
contextRef="i10d78353ceec4f248af8e917fdcbaa2c_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNTAtMy0xLTEtMzkzODM_390e41dd-9e3e-4818-bae3-3d5bf2a4d40d"
unitRef="usd">198703000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:RestrictedCash
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNTEtMS0xLTEtMzkzODM_4ec3f7a6-0097-456c-a700-7770e2ef0e27"
unitRef="usd">231000</us-gaap:RestrictedCash>
<us-gaap:RestrictedCash
contextRef="i10d78353ceec4f248af8e917fdcbaa2c_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNTEtMy0xLTEtMzkzODM_7e38f443-7596-46c6-bc3d-ffe28b9d711c"
unitRef="usd">231000</us-gaap:RestrictedCash>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNTItMS0xLTEtMzkzODM_2e1753a0-12d4-48e9-9c22-2f2ff4970685"
unitRef="usd">122178000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
contextRef="i10d78353ceec4f248af8e917fdcbaa2c_I20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNTItMy0xLTEtMzkzODM_4b3462cf-8c9c-41e4-bc52-1367fb404a1a"
unitRef="usd">198934000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<lung:IncreaseLapseInRepurchaseOfCommonStockRights
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNTUtMS0xLTEtMzkzODM_dd4db4c4-3092-45de-9cf1-dc025c696486"
unitRef="usd">117000</lung:IncreaseLapseInRepurchaseOfCommonStockRights>
<lung:IncreaseLapseInRepurchaseOfCommonStockRights
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNTUtMy0xLTEtMzkzODM_d3b724a3-2b85-47cf-8166-f6a12c4c27d6"
unitRef="usd">78000</lung:IncreaseLapseInRepurchaseOfCommonStockRights>
<us-gaap:CapitalExpendituresIncurredButNotYetPaid
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNTYtMS0xLTEtMzkzODM_f62b672b-1a08-4d58-9d63-fe02790371b2"
unitRef="usd">486000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
<us-gaap:CapitalExpendituresIncurredButNotYetPaid
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNTYtMy0xLTEtMzkzODM_c9ad85f5-75f2-4258-bdb6-f13e2bc11b73"
unitRef="usd">608000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
<lung:ReceivableFromExerciseOfCommonStockOptions
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNTktMS0xLTEtMzkzODM_171081cb-a56a-4bb0-ade5-b8d63e590d5a"
unitRef="usd">1000</lung:ReceivableFromExerciseOfCommonStockOptions>
<lung:ReceivableFromExerciseOfCommonStockOptions
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNTktMy0xLTEtMzkzODM_89d9d673-a72a-4666-9c09-d3766d81d3e2"
unitRef="usd">25000</lung:ReceivableFromExerciseOfCommonStockOptions>
<us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNjAtMS0xLTEtMzkzODM_43091dec-ef36-4123-a327-41881adb43df"
unitRef="usd">138000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
<us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNjAtMy0xLTEtMzkzODM_14033202-8546-4e76-b817-edadce525b81"
unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
<us-gaap:IncomeTaxesPaidNet
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNjItMS0xLTEtMzkzODM_0e8807d7-fd7e-4af9-9f92-c9dc337b4310"
unitRef="usd">228000</us-gaap:IncomeTaxesPaidNet>
<us-gaap:IncomeTaxesPaidNet
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNjItMy0xLTEtMzkzODM_3827d520-5d64-449b-84ad-f7138dcc6016"
unitRef="usd">226000</us-gaap:IncomeTaxesPaidNet>
<us-gaap:InterestPaidNet
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNjMtMS0xLTEtMzkzODM_4de1820f-60d1-4416-8423-7230ff031554"
unitRef="usd">375000</us-gaap:InterestPaidNet>
<us-gaap:InterestPaidNet
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18yOC9mcmFnOjZhNmYzYzgyNjRkODQzY2JhMDU3YzdhMzI2ODVlNzVlL3RhYmxlOjM1MDA3ODQyNTI2NjQ5YjFhMWM3MDE5ZTEwZTJmMzBhL3RhYmxlcmFuZ2U6MzUwMDc4NDI1MjY2NDliMWExYzcwMTllMTBlMmYzMGFfNjMtMy0xLTEtMzkzODM_bf713b88-532d-4a78-8938-d0bfa0ccaab3"
unitRef="usd">360000</us-gaap:InterestPaidNet>
<us-gaap:NatureOfOperations
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNC9mcmFnOmQ5MjE1NjdmMjViOTQzZmFhMWQyOWQ1NGUzNzVlMDFlL3RleHRyZWdpb246ZDkyMTU2N2YyNWI5NDNmYWExZDI5ZDU0ZTM3NWUwMWVfNTIyNw_cb9105bd-1eda-46c9-8621-c0ac16bebb58">Formation and Business of the Company<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pulmonx Corporation (the “Company”) was incorporated in the state of California in December 1995 as Pulmonx and reincorporated in the state of Delaware in December 2013. The Company is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (“COPD”). The Company’s solution, which is comprised of the Zephyr Endobronchial Valve (“Zephyr Valve”), the Chartis Pulmonary Assessment System (“Chartis System”) and the StratX Lung Analysis Platform (“StratX Platform”), is designed to treat a broad pool of patients for whom medical management has reached its limits and either do not want or are ineligible for surgical approaches. The Company has subsidiaries in Germany, Switzerland, Australia, the United Kingdom, Italy, France, Hong Kong, and Japan.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Going Concern</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred operating losses and negative cash flows from operations to date and has an accumulated deficit of $321.9 million as of June 30, 2022. During the six months ended June 30, 2022 and June 30, 2021, the Company used $24.6 million and $22.4 million of cash in its operating activities, respectively. As of June 30, 2022, the Company had cash, cash equivalents and marketable securities of $166.8 million. Historically, the Company’s activities have been financed through the sale of equity securities, debt financing arrangements and sales of our products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s condensed consolidated financial statements have been prepared on the basis of the Company continuing as a going concern for the next 12 months. Management believes that the Company’s existing cash, cash equivalents and marketable securities will allow the Company to continue its planned operations for at least the next 12 months from the date of the issuance of these unaudited interim condensed consolidated financial statements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of the COVID-19 Pandemic</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There continues to be widespread significant impact from the COVID-19 pandemic, which has delayed clinical trials and FDA operations and adversely impacted the number of procedures performed using our products. In the markets in which we operate, elective, specialty and other procedures and appointments have been, and continue to be, suspended or canceled to avoid non-essential patient exposure to medical environments and potential infection with COVID-19 and to focus limited resources and personnel capacity toward the treatment of COVID-19 patients. As a result, the COVID-19 pandemic and the measures taken by many countries in response have materially adversely affected, and could in the future materially adversely affect, our business, financial condition and results of operations, as well as the price of our common stock, from a decrease and delay of procedures involving our products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company saw some level of recovery in procedure volumes in our U.S. and larger international markets in the second quarter of 2022, the smaller international markets were hampered by a slower recovery, including continued lockdowns in China. The Company may continue to see regional variations in procedure volumes in the U.S. and international markets from the COVID-19 pandemic and its variants.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s unaudited interim condensed consolidated financial statements reflect judgments and estimates that could change in the future as a result of the COVID-19 pandemic. The COVID-19 pandemic has adversely impacted the Company’s business, financial condition and results of operations by decreasing and delaying procedures performed using its products. While many regions begin to stabilize with improvements in procedure volumes, there continues to be variability and uncertainty as variants of the virus emerge. The Company can make no assurance regarding any future level of demand for the Company’s products, and COVID-19 may adversely impact the results of operations and financial condition.</span></div></us-gaap:NatureOfOperations>
<us-gaap:RetainedEarningsAccumulatedDeficit
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNC9mcmFnOmQ5MjE1NjdmMjViOTQzZmFhMWQyOWQ1NGUzNzVlMDFlL3RleHRyZWdpb246ZDkyMTU2N2YyNWI5NDNmYWExZDI5ZDU0ZTM3NWUwMWVfMjQzNA_b153b4ba-94ec-412c-b43e-4002b229b854"
unitRef="usd">-321900000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:NetCashProvidedByUsedInOperatingActivities
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNC9mcmFnOmQ5MjE1NjdmMjViOTQzZmFhMWQyOWQ1NGUzNzVlMDFlL3RleHRyZWdpb246ZDkyMTU2N2YyNWI5NDNmYWExZDI5ZDU0ZTM3NWUwMWVfMjUwMg_decd3397-de82-4ba9-a760-f086910ab971"
unitRef="usd">-24600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNC9mcmFnOmQ5MjE1NjdmMjViOTQzZmFhMWQyOWQ1NGUzNzVlMDFlL3RleHRyZWdpb246ZDkyMTU2N2YyNWI5NDNmYWExZDI5ZDU0ZTM3NWUwMWVfMjUwOQ_fc1d4ad6-f340-4f51-961f-0273b523a148"
unitRef="usd">-22400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<lung:CashAndCashEquivalentsAndMarketableSecurities
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNC9mcmFnOmQ5MjE1NjdmMjViOTQzZmFhMWQyOWQ1NGUzNzVlMDFlL3RleHRyZWdpb246ZDkyMTU2N2YyNWI5NDNmYWExZDI5ZDU0ZTM3NWUwMWVfMjY0MQ_85107599-56ee-4d5d-8f61-555a4b90635e"
unitRef="usd">166800000</lung:CashAndCashEquivalentsAndMarketableSecurities>
<us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfMTA3MjI_859cc17b-1de6-4bcb-a772-1c3a234227be">Summary of Significant Accounting Policies<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of December 31, 2021 was derived from the Company’s audited financial statements, but does not include all disclosures required by GAAP. The accompanying unaudited condensed consolidated financial statements as of June 30, 2022 and for the three and six months ended June 30, 2022 and 2021, have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. Accordingly, these financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2021 and notes thereto, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the SEC on March 1, 2022. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company’s condensed consolidated financial position as of June 30, 2022 and condensed consolidated results of operations for the three and six months ended June 30, 2022 and 2021 and condensed consolidated cash flows for the six months ended June 30, 2022 and 2021 have been made. The results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2022.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions include reserves and write-downs related to inventories, the recoverability of long term assets, valuation of common stock, stock-based compensation, intangible assets, goodwill, debt and related features, deferred tax assets and related valuation allowances and impact of contingencies.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the Company’s financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the term loan approximates their fair value. The fair value of marketable debt securities is estimated using Level 2 inputs based on their quoted market values (Note 4).</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash, cash equivalents and accounts receivable. The Company maintains its cash and cash equivalents balances with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance Corporation (“FDIC”) insured limits. As of June 30, 2022 and December 31, 2021, the Company also had cash on deposit with foreign banks of approximately $3.5 million and $4.6 million, respectively, that was not federally insured.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company earns revenue from the sale of its products to distributors and other customers such as hospitals. Sales of Zephyr Valves and delivery catheters accounted for most of the Company’s revenue for the six months ended June 30, 2022 and 2021. The Company’s accounts receivable are derived from revenue earned from customers and distributors. The Company performs ongoing credit evaluations of its customers’ and distributors’ financial condition and generally requires no collateral from its customers and distributors. At June 30, 2022 and December 31, 2021, no customer or distributor accounted for more than 10% of accounts receivable. During the three and six months ended June 30, 2022 and June 30, 2021, no customer or distributor accounted for more than 10% of revenue.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on single source suppliers for the components, sub-assemblies and materials for its products. These components, sub-assemblies and materials are critical and there are no or relatively few alternative sources of supply. The Company’s suppliers have generally met the Company’s demand for their products and services on a timely basis in the past.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Transaction Gains and Losses</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currencies of the Company’s wholly owned subsidiaries in Switzerland, Germany, Australia, the United Kingdom, France and Hong Kong are the Swiss franc. The functional currency of the Company’s subsidiary in Italy is the Euro. Accordingly, asset and liability accounts of Switzerland, Germany, Australia, the United Kingdom, Italy and Hong Kong operations are translated into U.S. dollars using the current exchange rate in effect at the balance sheet date and equity accounts are translated into U.S. dollars using historical rates. The revenues and expenses are translated using the average exchange rates in effect during the period, and gains and losses from foreign currency translation adjustments are included as a component of accumulated other comprehensive income in the condensed consolidated balance sheet. Foreign currency translation adjustments are recorded in other comprehensive income (loss) in the condensed consolidated statements of operations and comprehensive loss and was less than $0.1 million and less than $0.1 million during the three months ended June 30, 2022 and 2021, respectively, and less than $(0.1) million and $(0.2) million during the six months ended June 30, 2022 and 2021, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency transaction gains and losses are included in other income (expense), net in the condensed consolidated statements of operations and comprehensive loss and was $(0.2) million and $(0.1) million during the three months ended June 30, 2022 and 2021, respectively, and $(0.2) million and $0.1 million during the six months ended June 30, 2022 and 2021, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share Attributable to Common Stockholders</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, stock options, and common stock subject to repurchase related to early exercise of stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities. The Company considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities, because holders of such shares have non-forfeitable </span></div>dividend rights in the event a dividend is paid on common stock. The holders of the shares issued upon early exercise of stock options subject to repurchase do not have a contractual obligation to share in the Company’s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
<us-gaap:BasisOfAccountingPolicyPolicyTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfMTA3MjM_497c89e6-1168-43d7-8ccd-4e65757212a9"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).</span></div></us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
<us-gaap:ConsolidationPolicyTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfMTA3MTg_39a53d20-6732-4125-abc5-d271fed2f979"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span></div></us-gaap:ConsolidationPolicyTextBlock>
<us-gaap:UseOfEstimates
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfMTA3MTk_36bbe82a-f563-476a-af8a-eadcc1f8071b"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions include reserves and write-downs related to inventories, the recoverability of long term assets, valuation of common stock, stock-based compensation, intangible assets, goodwill, debt and related features, deferred tax assets and related valuation allowances and impact of contingencies.</span></div></us-gaap:UseOfEstimates>
<us-gaap:FairValueOfFinancialInstrumentsPolicy
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfMTA3MjQ_dd52a59d-773a-4bc9-9190-e4fbaf6dfada"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the Company’s financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the term loan approximates their fair value. The fair value of marketable debt securities is estimated using Level 2 inputs based on their quoted market values (Note 4).</span></div></us-gaap:FairValueOfFinancialInstrumentsPolicy>
<us-gaap:ConcentrationRiskCreditRisk
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfMTA3MjA_ed534a31-b21a-4cca-9d1a-431720118e39">Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash, cash equivalents and accounts receivable. The Company maintains its cash and cash equivalents balances with established financial institutions and, at times, such balances with any one financial institution may be in excess of the Federal Deposit Insurance Corporation (“FDIC”) insured limits.</us-gaap:ConcentrationRiskCreditRisk>
<us-gaap:CashUninsuredAmount
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfNTI4Ng_249b2db6-5175-4e4b-9dd5-95d2424998b9"
unitRef="usd">3500000</us-gaap:CashUninsuredAmount>
<us-gaap:CashUninsuredAmount
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfNTI5Mw_cddaa5ba-9d62-4250-82eb-f526b2bea5d9"
unitRef="usd">4600000</us-gaap:CashUninsuredAmount>
<us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfMTA3MjY_89a70483-33c3-45f6-a05d-b9ddde5b4436"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Transaction Gains and Losses</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currencies of the Company’s wholly owned subsidiaries in Switzerland, Germany, Australia, the United Kingdom, France and Hong Kong are the Swiss franc. The functional currency of the Company’s subsidiary in Italy is the Euro. Accordingly, asset and liability accounts of Switzerland, Germany, Australia, the United Kingdom, Italy and Hong Kong operations are translated into U.S. dollars using the current exchange rate in effect at the balance sheet date and equity accounts are translated into U.S. dollars using historical rates. The revenues and expenses are translated using the average exchange rates in effect during the period, and gains and losses from foreign currency translation adjustments are included as a component of accumulated other comprehensive income in the condensed consolidated balance sheet. Foreign currency translation adjustments are recorded in other comprehensive income (loss) in the condensed consolidated statements of operations and comprehensive loss and was less than $0.1 million and less than $0.1 million during the three months ended June 30, 2022 and 2021, respectively, and less than $(0.1) million and $(0.2) million during the six months ended June 30, 2022 and 2021, respectively.</span></div>Foreign currency transaction gains and losses are included in other income (expense), net in the condensed consolidated statements of operations and comprehensive loss</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
contextRef="i2ae7a2862d6f4d7a954dd9a21f9f83d8_D20220401-20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfMTA5OTUxMTY0MTE1MQ_e4621f1f-fb23-4cab-ad28-26adf6b16362"
unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
contextRef="i1f765278d59148a1ab87392a73044ec0_D20210401-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfMTA5OTUxMTY0MTIzOA_764f7855-a34e-4b00-ba98-cd1490321358"
unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
contextRef="i1bcdc8fb272d48f49898d46b5eed3af6_D20220101-20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfMTA5OTUxMTY0MTE3MA_ba552559-d07e-4ebb-a2f5-c365cadc48ef"
unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfODU1NA_33fb6b75-6ee7-40cb-9204-f82a17861fb3"
unitRef="usd">-200000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
<us-gaap:ForeignCurrencyTransactionGainLossRealized
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfODc4Ng_0cd60af5-b16c-4ebd-9d4f-3a005b195a4b"
unitRef="usd">-200000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
<us-gaap:ForeignCurrencyTransactionGainLossRealized
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfODc5Mw_b173257b-79ed-4f64-b0ca-9eb3ab3bc781"
unitRef="usd">-100000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
<us-gaap:ForeignCurrencyTransactionGainLossRealized
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfODg1NQ_89c33a1e-5ce8-479f-88eb-7e07140915cd"
unitRef="usd">-200000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
<us-gaap:ForeignCurrencyTransactionGainLossRealized
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfODg2Mg_ba6c76de-633d-46f4-bd44-8fd1c4706d34"
unitRef="usd">100000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
<us-gaap:EarningsPerSharePolicyTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N18zNy9mcmFnOjk4MDQ0YThkZDNjODRhYzliNDg5NDdlZGVjMjRiYmUwL3RleHRyZWdpb246OTgwNDRhOGRkM2M4NGFjOWI0ODk0N2VkZWMyNGJiZTBfMTA3MjE_6cbc46f0-e7d6-4d43-8b14-733815f4335a"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share Attributable to Common Stockholders</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, stock options, and common stock subject to repurchase related to early exercise of stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities. The Company considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities, because holders of such shares have non-forfeitable </span></div>dividend rights in the event a dividend is paid on common stock. The holders of the shares issued upon early exercise of stock options subject to repurchase do not have a contractual obligation to share in the Company’s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180My9mcmFnOmIzMTc5ODM3NDAzNjQ1ZjViMjdmOGU5Njk4YTU0YTFlL3RleHRyZWdpb246YjMxNzk4Mzc0MDM2NDVmNWIyN2Y4ZTk2OThhNTRhMWVfNDQyNQ_09d1ef12-ede4-4b9f-84a5-70b525040bce">Recent Accounting Pronouncements<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848) (“ASU 2020-04”). The amendments in ASU 2020-04 provide optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in ASU 2020-04 are effective for all entities as of March 12, 2020 through December 31, 2022. An entity may elect to apply the amendments for contract modifications by Topic or Industry Subtopic as of any date from the beginning an interim period that includes or is subsequent to March 12, 2020, or prospectively from the date that the financial statements are available to be issued. Once elected for a Topic or an Industry Subtopic, the amendments must be applied prospectively for all eligible contract modifications for that Topic or Industry Subtopic. The Company may elect to apply ASU 2020-04 as its contracts referenced in London Interbank Offered Rate (“LIBOR”) are impacted by reference rate reform. The Company is currently evaluating the impact of the adoption of this ASU on the Company’s consolidated financial statements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments – Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new guidance will require financial instruments to be measured at amortized cost, and trade accounts receivable to be presented at the net amount expected to be collected. The new model requires an entity to estimate credit losses based on historical information, current information and reasonable and supportable forecasts, including estimates of prepayments. In November 2019, the FASB issued ASU 2019-10, according to which, the new standard is effective for public business entities that meet the definition of an SEC filer, excluding entities eligible to be smaller reporting companies (“SRC”) as defined by the SEC, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. For all other entities, including the Company, the new standard is effective for fiscal years beginning after December 15, 2022, and interim periods within that fiscal year. Early adoption is permitted. The Company is currently evaluating the impact of the new standard on the Company’s consolidated financial statements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other newly issued accounting pronouncements not yet effective have been deemed either immaterial or not applicable.</span></div></us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180My9mcmFnOmIzMTc5ODM3NDAzNjQ1ZjViMjdmOGU5Njk4YTU0YTFlL3RleHRyZWdpb246YjMxNzk4Mzc0MDM2NDVmNWIyN2Y4ZTk2OThhNTRhMWVfNDQyNg_4fad172d-3d19-4072-ba07-80509bb96905"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848) (“ASU 2020-04”). The amendments in ASU 2020-04 provide optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in ASU 2020-04 are effective for all entities as of March 12, 2020 through December 31, 2022. An entity may elect to apply the amendments for contract modifications by Topic or Industry Subtopic as of any date from the beginning an interim period that includes or is subsequent to March 12, 2020, or prospectively from the date that the financial statements are available to be issued. Once elected for a Topic or an Industry Subtopic, the amendments must be applied prospectively for all eligible contract modifications for that Topic or Industry Subtopic. The Company may elect to apply ASU 2020-04 as its contracts referenced in London Interbank Offered Rate (“LIBOR”) are impacted by reference rate reform. The Company is currently evaluating the impact of the adoption of this ASU on the Company’s consolidated financial statements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments – Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new guidance will require financial instruments to be measured at amortized cost, and trade accounts receivable to be presented at the net amount expected to be collected. The new model requires an entity to estimate credit losses based on historical information, current information and reasonable and supportable forecasts, including estimates of prepayments. In November 2019, the FASB issued ASU 2019-10, according to which, the new standard is effective for public business entities that meet the definition of an SEC filer, excluding entities eligible to be smaller reporting companies (“SRC”) as defined by the SEC, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. For all other entities, including the Company, the new standard is effective for fiscal years beginning after December 15, 2022, and interim periods within that fiscal year. Early adoption is permitted. The Company is currently evaluating the impact of the new standard on the Company’s consolidated financial statements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other newly issued accounting pronouncements not yet effective have been deemed either immaterial or not applicable.</span></div></us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:FairValueDisclosuresTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RleHRyZWdpb246YWU0YjcxMGRlYjJhNDU2Y2JlYTNhNjIxZTM5Mjc1YTZfNTA3Mg_8344fa73-9ba2-4adb-8b24-81b201e92e7b">Fair Value Measurements<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities are as follows:</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1—Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2—Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities;</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3—Unobservable inputs for the asset or liability only used when there is little, if any, market activity for the asset or liability at the measurement date. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Financial assets and liabilities held by the Company measured at fair value on a recurring basis include money market funds and marketable securities.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Measured and Recorded at Fair Value on a Nonrecurring Basis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company determines the fair value of long-lived assets held and used, such as intangible assets, by reference to independent appraisals, quoted market prices (e.g. an offer to purchase) and other factors. An impairment charge is recorded when the carrying value of the asset exceeds its fair value. As noted above, there have been no impairment charges recorded to date. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the term loan approximates the fair value and is classified as a Level 2 liability. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,689 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,171 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,652 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,823 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,363 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,149 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,512 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no liabilities measured at fair value on a recurring and non-recurring basis as of June 30, 2022.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,241 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,977 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,504 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,914 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,914 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,977 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,525 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,502 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,808 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,935 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,743 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no liabilities measured at fair value on a recurring and non-recurring basis as of December 31, 2021.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the cost, unrealized gains and losses and fair value of marketable securities (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,462 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,183 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(360)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,823 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized on the consolidated balance sheet</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Long-term marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,823 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,509 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,481 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,915 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,914 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,526 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,502 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized on the consolidated balance sheet</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,561 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Long-term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,502 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivable on marketable securities of less than $0.1 million and less than $0.1 million as of June 30, 2022 and December 31, 2021, respectively, is included in prepaid expenses and other current assets on the condensed consolidated balance sheet.</span></div></us-gaap:FairValueDisclosuresTextBlock>
<us-gaap:FairValueMeasurementPolicyPolicyTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RleHRyZWdpb246YWU0YjcxMGRlYjJhNDU2Y2JlYTNhNjIxZTM5Mjc1YTZfNTA3Mw_6d0224ee-433c-4fd3-b661-c8a5477f7463"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Measured and Recorded at Fair Value on a Nonrecurring Basis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The Company determines the fair value of long-lived assets held and used, such as intangible assets, by reference to independent appraisals, quoted market prices (e.g. an offer to purchase) and other factors. An impairment charge is recorded when the carrying value of the asset exceeds its fair value. As noted above, there have been no impairment charges recorded to date. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the term loan approximates the fair value and is classified as a Level 2 liability. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</span></div></us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RleHRyZWdpb246YWU0YjcxMGRlYjJhNDU2Y2JlYTNhNjIxZTM5Mjc1YTZfNTA3NA_83218604-f8ca-4155-bd53-7c09ab39e138"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarizes the types of assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,689 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,171 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,652 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,823 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,363 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,149 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,512 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no liabilities measured at fair value on a recurring and non-recurring basis as of June 30, 2022.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,241 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,977 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,504 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,914 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,914 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,977 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,525 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,502 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,808 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,935 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,743 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no liabilities measured at fair value on a recurring and non-recurring basis as of December 31, 2021.</span></div></us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure
contextRef="ia14d74e4d29945248008eebccb61e736_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfMy0xLTEtMS0zOTM4Mw_9a8bc5dc-a631-47d5-af81-70e4622275d1"
unitRef="usd">2192000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure
contextRef="i43daee278edf4dd48795e6f8a76b68e6_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfMy0zLTEtMS0zOTM4Mw_fd430442-a2d7-4f6a-ad82-16ddb940111a"
unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure
contextRef="i7a1831dadd354b61891c517232e12cb6_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfMy01LTEtMS0zOTM4Mw_b4cd75b0-2ba2-4a1a-ba14-f8c9a598ba75"
unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure
contextRef="i92dd2cd839a240b486dff359bb786a00_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfMy03LTEtMS0zOTM4Mw_b0b75572-3cca-4639-9670-cbc00b00c804"
unitRef="usd">2192000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure
contextRef="i7a66461de3154691bdf882e2e5dcd6c5_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfNC0xLTEtMS0zOTM4Mw_63509cfa-7242-48da-8623-20a56b078a8b"
unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure
contextRef="i3e4dba1228e34cd98a8abd85532d7cb9_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfNC0zLTEtMS0zOTM4Mw_1808b27f-07dc-4e70-85ac-6a2914477ab4"
unitRef="usd">2497000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure
contextRef="iac94117f850b41d5b799ede5098093da_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfNC01LTEtMS0zOTM4Mw_ffc21905-84b4-4458-984e-d212696efb62"
unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure
contextRef="i3a3f4a74924a4f12a1736df2d0a45713_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfNC03LTEtMS0zOTM4Mw_4d29bde0-8f78-4615-a703-d2a5cd9d64c6"
unitRef="usd">2497000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure
contextRef="iee1e914ebc684f0b943cae94c69a0f1a_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfNS0xLTEtMS0zOTM4Mw_72901445-c582-42c5-8b38-e31f29065da9"
unitRef="usd">2192000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure
contextRef="i6c2edf2f82884f7b832d7b6ce96cef26_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfNS0zLTEtMS0zOTM4Mw_0a587708-bc97-4a15-9d18-07c9ab0820fb"
unitRef="usd">2497000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure
contextRef="id934753eb5f84d74951453f74f1c8782_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfNS01LTEtMS0zOTM4Mw_9fd2347c-cbb7-45ea-a83a-2e8241a88f81"
unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure
contextRef="i513514d73a6d48d88da16ce034ab1bb4_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfNS03LTEtMS0zOTM4Mw_b02d8af2-12d4-4356-964c-16af04f0c8ae"
unitRef="usd">4689000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="i33985b0fd2d14a9dbba59257abcfcfbb_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfNy0xLTEtMS0zOTM4Mw_383eb077-1dee-4af2-9085-5f0290bcb1dc"
unitRef="usd">25171000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="i9d7ee987153a4b9e864751c124470915_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfNy0zLTEtMS0zOTM4Mw_590ee445-2f7e-4f37-b0a8-98a7e7cd7090"
unitRef="usd">8971000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="i93d1d7e68d6546828a3bdc6fdcf003c5_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfNy01LTEtMS0zOTM4Mw_59529b00-b871-41a1-b432-b59facf26877"
unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="i48eb072a814e40a1b0c537a5e8d1ed0b_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfNy03LTEtMS0zOTM4Mw_73a0f442-2f22-4d8a-806c-298d4e90a7a7"
unitRef="usd">34142000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="i675913f6b3cc4a0d80c3aedb6ff16277_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfOS0xLTEtMS0zOTM4Mw_6842e40a-8bdb-41cb-a18d-46f9fe627e5d"
unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="i1db3a72d8ab94a5290123d21241fdea7_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfOS0zLTEtMS0zOTM4Mw_785a4dac-d04d-4345-bbb0-99270b0f72de"
unitRef="usd">10681000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="icbcdc9fe2df04354bea1a37f7049921b_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfOS01LTEtMS0zOTM4Mw_d8988366-31b0-449c-bdca-bb7f6819de4f"
unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="i38d15624d6984f4c8c651151aab177be_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfOS03LTEtMS0zOTM4Mw_3197d5b5-b178-472a-8da3-09f34dede8ad"
unitRef="usd">10681000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="iee1e914ebc684f0b943cae94c69a0f1a_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfMTAtMS0xLTEtMzkzODM_ae2a47cf-7fb9-4b78-bc9f-99f90a86f773"
unitRef="usd">25171000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="i6c2edf2f82884f7b832d7b6ce96cef26_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfMTAtMy0xLTEtMzkzODM_9cd970a3-3ae0-448a-bfc4-c453cfd8bf0f"
unitRef="usd">19652000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="id934753eb5f84d74951453f74f1c8782_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfMTAtNS0xLTEtMzkzODM_beac7994-2149-45e7-abb3-27a824c397ec"
unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="i513514d73a6d48d88da16ce034ab1bb4_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfMTAtNy0xLTEtMzkzODM_aca4f79f-0fae-44eb-abc1-51736e5ed53f"
unitRef="usd">44823000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AssetsFairValueDisclosure
contextRef="iee1e914ebc684f0b943cae94c69a0f1a_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfMTEtMS0xLTEtMzkzODM_e9ceea79-1add-4e4e-8608-714d3aa51540"
unitRef="usd">27363000</us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure
contextRef="i6c2edf2f82884f7b832d7b6ce96cef26_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfMTEtMy0xLTEtMzkzODM_077caca6-a898-4ff1-882f-4c2d3e5db741"
unitRef="usd">22149000</us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure
contextRef="id934753eb5f84d74951453f74f1c8782_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfMTEtNS0xLTEtMzkzODM_7de9e71d-2981-4ae0-9946-389821495516"
unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure
contextRef="i513514d73a6d48d88da16ce034ab1bb4_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmY2ZDUzYmIwODNjYjRmMmNiNWI0YmE0NzEwMTExMDMzL3RhYmxlcmFuZ2U6ZjZkNTNiYjA4M2NiNGYyY2I1YjRiYTQ3MTAxMTEwMzNfMTEtNy0xLTEtMzkzODM_f6bc6f44-0321-4c1c-a849-e6e5b5bc5c74"
unitRef="usd">49512000</us-gaap:AssetsFairValueDisclosure>
<us-gaap:FinancialLiabilitiesFairValueDisclosure
contextRef="i513514d73a6d48d88da16ce034ab1bb4_I20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RleHRyZWdpb246YWU0YjcxMGRlYjJhNDU2Y2JlYTNhNjIxZTM5Mjc1YTZfMzI5ODUzNDg5MDY4Ng_ff951349-028a-4b88-8d3d-8b1c79260938"
unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure
contextRef="i5cff6d84193e4dc3b07c75074e60392b_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMy0xLTEtMS0zOTM4Mw_7ace098c-d19c-4b9b-913e-9d92da41d129"
unitRef="usd">831000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure
contextRef="i327e3148cf134e40be0e4c43a80759bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMy0zLTEtMS0zOTM4Mw_d1c1193c-0b6d-4c6a-b3f2-d1fc85e8478a"
unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure
contextRef="i7c4a433674ca4a14a572851571072b9b_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMy01LTEtMS0zOTM4Mw_fea34d76-73d7-4dfe-bcb5-9ae447387fd5"
unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure
contextRef="iaa4a290d955f4814b581d6476ee9dc7d_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMy03LTEtMS0zOTM4Mw_c8e09e73-4ed5-4f7a-920e-7d922bf9e370"
unitRef="usd">831000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure
contextRef="icfc26381124441d290073fcf4b193645_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfNC0xLTEtMS0zOTM4Mw_97fe4c38-0fdb-4c17-8989-f54e43f3f893"
unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure
contextRef="ib192c97ab709429e8d8bace98b7c84f5_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfNC0zLTEtMS0zOTM4Mw_b318580e-4ad3-48df-a657-3f1e04dd2a54"
unitRef="usd">2000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure
contextRef="i042fafa9d9b249748a84902a33a8986a_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfNC01LTEtMS0zOTM4Mw_86ff5cb7-5087-4ce3-876b-7c6fb0298e81"
unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure
contextRef="i7e96426a76854bbeaa9ad9992e1a9dc0_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfNC03LTEtMS0zOTM4Mw_adffef9b-df2b-41a7-9dc5-0c674200398e"
unitRef="usd">2000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure
contextRef="i4a0edcb9b6dd478a89e87ca1f2ce26eb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfNS0xLTEtMS0zOTM4Mw_e977b7f6-6592-414c-b37f-72db769d4dfb"
unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure
contextRef="i85fa5ce9fad74f399f8c8d25570c9689_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfNS0zLTEtMS0zOTM4Mw_be0afb3a-2bad-4b63-a77f-5469672428e4"
unitRef="usd">4410000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure
contextRef="i45edc210ab0745a5aa6286bb72d334b4_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfNS01LTEtMS0zOTM4Mw_16cdc3a3-af9c-4973-b252-8c9f79c8958d"
unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure
contextRef="ifb589de7e36549c6a8aab0ff0cad6898_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfNS03LTEtMS0zOTM4Mw_ca7794bb-aff7-40a3-a5bb-f040a0bbfddc"
unitRef="usd">4410000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure
contextRef="i4e16bb634cd6409fb8caa8fde1661af6_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfNi0xLTEtMS00MDIxNQ_34d466e9-42e6-482d-b59a-09d1780552d3"
unitRef="usd">831000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure
contextRef="if24e988586d6451fab56769a5c714496_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfNi0zLTEtMS00MDIxNQ_5ba2eebc-6131-4352-b1ff-54ef9d0fab8b"
unitRef="usd">6410000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure
contextRef="i55d83c7769d745868fef46644ba31985_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfNi01LTEtMS00MDIxNQ_06c39159-f464-499b-9116-a8792faee288"
unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:CashAndCashEquivalentsFairValueDisclosure
contextRef="i4cd5fa1e86444765a02ded926ba518e5_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfNi03LTEtMS00MDIxNQ_e858ef82-927a-4cbc-8578-1957c516dfaf"
unitRef="usd">7241000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="i1438553a44e74136882a9e6307daa44c_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfOC0xLTEtMS00MDIxNQ_b44e1910-e8d5-452c-a381-cdbcf5a43edb"
unitRef="usd">14977000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="i3b3656c560c64ebe973f848fc48ad5ad_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfOC0zLTEtMS00MDIxNQ_15d54d42-ee3b-4a44-9e1f-494fc7eeb802"
unitRef="usd">5504000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="id36ebdf32a5a4301a2002cf016417bf4_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfOC01LTEtMS00MDIxNQ_ea58cd79-cd2b-4bbd-9d8b-76fd099604d2"
unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="if2007efd115d4f399413c5ee0cf7dbee_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfOC03LTEtMS00MDIxNQ_d9d58f14-f716-4be8-a1e6-27730682b3ec"
unitRef="usd">20481000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="id29e377b291b419eba3b2d065798ef5c_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfOS0xLTEtMS00MDIxNQ_cb079bf9-0413-4607-bdfd-52c757317021"
unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="id75b22a41add4eceb26a8efffed5d602_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfOS0zLTEtMS00MDIxNQ_bb88d59c-44c4-44a2-8ac9-e691aecca1bd"
unitRef="usd">19107000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="ife09428d3f97465496a4b2c6bd0ba97f_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfOS01LTEtMS00MDIxNQ_79a5ff2e-2e2f-4f63-900f-0d1c9b001c1d"
unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="ibeec9606af284a379aa614910d3a61ab_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfOS03LTEtMS00MDIxNQ_f4b9d50c-622a-44c0-952c-8dc445c50a5f"
unitRef="usd">19107000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="i4a0edcb9b6dd478a89e87ca1f2ce26eb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMTAtMS0xLTEtNDAyMTU_90159a06-3dab-43d8-92a2-aa8a468e4395"
unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="i85fa5ce9fad74f399f8c8d25570c9689_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMTAtMy0xLTEtNDAyMTU_67f83dfb-6294-4e95-9cde-60c1de6775ff"
unitRef="usd">2914000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="i45edc210ab0745a5aa6286bb72d334b4_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMTAtNS0xLTEtNDAyMTU_6ed23069-c7a4-400a-8a60-5911b93af7c1"
unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="ifb589de7e36549c6a8aab0ff0cad6898_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMTAtNy0xLTEtNDAyMTU_d1274910-b2cc-4c50-9b8d-ffc8da4e0311"
unitRef="usd">2914000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="i4e16bb634cd6409fb8caa8fde1661af6_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMTEtMS0xLTEtNDAyMTU_96937b30-1f70-4359-9b58-193c7ff4da40"
unitRef="usd">14977000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="if24e988586d6451fab56769a5c714496_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMTEtMy0xLTEtNDAyMTU_ea4094bc-700c-43d7-8420-22adc56ef152"
unitRef="usd">27525000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="i55d83c7769d745868fef46644ba31985_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMTEtNS0xLTEtNDAyMTU_18e4f507-b02b-4b40-bcb5-9b485d652323"
unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="i4cd5fa1e86444765a02ded926ba518e5_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMTEtNy0xLTEtNDAyMTU_009e2d02-803d-4664-97ed-46bb76373be6"
unitRef="usd">42502000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AssetsFairValueDisclosure
contextRef="i4e16bb634cd6409fb8caa8fde1661af6_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMTItMS0xLTEtNDAyMTU_8afc240e-256f-4f8f-a5c9-e58cd17f28ce"
unitRef="usd">15808000</us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure
contextRef="if24e988586d6451fab56769a5c714496_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMTItMy0xLTEtNDAyMTU_74fa063b-874c-490a-99ca-91703d3d66ab"
unitRef="usd">33935000</us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure
contextRef="i55d83c7769d745868fef46644ba31985_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMTItNS0xLTEtNDAyMTU_e849189b-ac92-4ff4-ba27-c0aaad91e814"
unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure
contextRef="i4cd5fa1e86444765a02ded926ba518e5_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjk2MDM3MDM5MWQxNTQzNTNiZmE0ZTIwZjYzNGJhY2Y4L3RhYmxlcmFuZ2U6OTYwMzcwMzkxZDE1NDM1M2JmYTRlMjBmNjM0YmFjZjhfMTItNy0xLTEtNDAyMTU_3316011a-4cd2-4b48-8bfa-aca2ceab48e4"
unitRef="usd">49743000</us-gaap:AssetsFairValueDisclosure>
<us-gaap:FinancialLiabilitiesFairValueDisclosure
contextRef="i4cd5fa1e86444765a02ded926ba518e5_I20211231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RleHRyZWdpb246YWU0YjcxMGRlYjJhNDU2Y2JlYTNhNjIxZTM5Mjc1YTZfMzI5ODUzNDg5MDY5NA_ccdbed28-94a6-4d51-9435-3e58eaa9d92c"
unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
<us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RleHRyZWdpb246YWU0YjcxMGRlYjJhNDU2Y2JlYTNhNjIxZTM5Mjc1YTZfNTA3NQ_252e416a-70db-416d-953d-99111bc83a88"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the cost, unrealized gains and losses and fair value of marketable securities (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,462 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,681 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,183 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(360)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,823 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized on the consolidated balance sheet</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Long-term marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,823 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Government agency bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,509 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,481 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,915 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,914 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,526 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,502 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts recognized on the consolidated balance sheet</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,561 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Long-term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,502 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
contextRef="i0a302b35b1a8429293ae6b864424ecc3_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfMy0xLTEtMS0zOTM4Mw_99c0cc45-0e52-4b7a-a1f1-57e66eec4a34"
unitRef="usd">34462000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
contextRef="i0a302b35b1a8429293ae6b864424ecc3_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfMy0zLTEtMS0zOTM4Mw_705607d8-0edb-43c5-86ee-be82990d78b4"
unitRef="usd">320000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
contextRef="i0a302b35b1a8429293ae6b864424ecc3_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfMy01LTEtMS0zOTM4Mw_96ed11ff-8248-4fd3-b9d4-98755d431bc1"
unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="i0a302b35b1a8429293ae6b864424ecc3_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfMy03LTEtMS0zOTM4Mw_8e0f7259-74e5-4927-b254-c7de1830e4bf"
unitRef="usd">34142000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
contextRef="i50bcd4c228d24da381ad2f53d3c36667_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfNS0xLTEtMS0zOTM4Mw_0482761c-308c-4c4e-baf2-b07de93dd790"
unitRef="usd">10721000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
contextRef="i50bcd4c228d24da381ad2f53d3c36667_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfNS0zLTEtMS0zOTM4Mw_836a7ca4-1a15-44c5-8204-29eb317c24c8"
unitRef="usd">40000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
contextRef="i50bcd4c228d24da381ad2f53d3c36667_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfNS01LTEtMS0zOTM4Mw_e1fe3007-6cd8-4c25-8d59-7bbc1ef72945"
unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="i50bcd4c228d24da381ad2f53d3c36667_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfNS03LTEtMS0zOTM4Mw_4413f436-b15c-43e4-b529-ed9063965cac"
unitRef="usd">10681000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfNi0xLTEtMS0zOTM4Mw_71e39e8d-8e40-475a-85c9-204063215541"
unitRef="usd">45183000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfNi0zLTEtMS0zOTM4Mw_de119801-65a8-4af3-a1d8-6c3829989baf"
unitRef="usd">360000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfNi01LTEtMS0zOTM4Mw_1767a5d7-c7d3-4a5b-9db9-f1a76d3ca5d8"
unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfNi03LTEtMS0zOTM4Mw_d36e30c4-456f-4410-a315-d6c49676207d"
unitRef="usd">44823000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfOS03LTEtMS0zOTM4Mw_f618a57a-5a64-4745-a725-7bf5da5b0601"
unitRef="usd">40139000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfMTAtNy0xLTEtMzkzODM_ef5cc73d-c3e9-4674-a9a5-de5f14bfbebb"
unitRef="usd">4684000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
<lung:CashCashEquivalentsAndAvailableForSaleDebtSecurities
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOmIxODkxMTcwNDczNzQ5NDQ5OTQyNmQyZWU5ODA3OGYwL3RhYmxlcmFuZ2U6YjE4OTExNzA0NzM3NDk0NDk5NDI2ZDJlZTk4MDc4ZjBfMTEtNy0xLTEtMzkzODM_3ea7f001-e13e-4076-b8a2-61c92007d638"
unitRef="usd">44823000</lung:CashCashEquivalentsAndAvailableForSaleDebtSecurities>
<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
contextRef="i838adf7de26c4611806f98bea73a4138_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfMi0xLTEtMS00MDMxMQ_7c35b8bf-920a-4866-8871-63ee3cb1523c"
unitRef="usd">20509000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
contextRef="i838adf7de26c4611806f98bea73a4138_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfMi0zLTEtMS00MDMxMQ_f392ac1e-aab2-4389-ad35-dda96de4c0ac"
unitRef="usd">28000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
contextRef="i838adf7de26c4611806f98bea73a4138_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfMi01LTEtMS00MDMxMQ_1dec1304-8be3-4a32-850a-40bd6afa673c"
unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="i838adf7de26c4611806f98bea73a4138_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfMi03LTEtMS00MDMxMQ_9919dd43-fbeb-4745-a869-3188d60814da"
unitRef="usd">20481000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
contextRef="iec39bddb1fc94428b8d0d9084e2aba6b_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfMy0xLTEtMS00MDMxMQ_1ca7bce7-f2a5-4381-850f-b8ca7ee4897f"
unitRef="usd">2915000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
contextRef="iec39bddb1fc94428b8d0d9084e2aba6b_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfMy0zLTEtMS00MDMxMQ_2e8bb929-bc0d-4b40-9209-d3e0302b3d9f"
unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
contextRef="iec39bddb1fc94428b8d0d9084e2aba6b_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfMy01LTEtMS00MDMxMQ_fa0b2cd0-c2c4-4fc4-81c2-5c2f0c7a5128"
unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="iec39bddb1fc94428b8d0d9084e2aba6b_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfMy03LTEtMS00MDMxMQ_525d4e20-b2d5-475e-a2eb-d2bcc8e57bed"
unitRef="usd">2914000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
contextRef="if09b01b3b49e4c1cb9a520fc3d129aa1_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfNC0xLTEtMS00MDMxMQ_391a4e72-4764-4b24-8d83-a7dff7d13867"
unitRef="usd">19102000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
contextRef="if09b01b3b49e4c1cb9a520fc3d129aa1_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfNC0zLTEtMS00MDMxMQ_1bb86935-b8f9-46cd-98e6-47c5d2fc92dd"
unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
contextRef="if09b01b3b49e4c1cb9a520fc3d129aa1_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfNC01LTEtMS00MDMxMQ_e4c3475d-c8a3-45cf-aeb4-4cadba2f6f07"
unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="if09b01b3b49e4c1cb9a520fc3d129aa1_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfNC03LTEtMS00MDMxMQ_5c0f7675-f77b-42f2-8515-8e5fecffcf48"
unitRef="usd">19107000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfNS0xLTEtMS00MDMxMQ_92f3cdbd-2562-4a8a-84ac-c1f10a9a704b"
unitRef="usd">42526000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfNS0zLTEtMS00MDMxMQ_725039ba-1064-4cb6-8cd3-ac1c1e83e179"
unitRef="usd">29000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfNS01LTEtMS00MDMxMQ_e0907f6b-f31e-4bb4-9710-83d5b126a14e"
unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfNS03LTEtMS00MDMxMQ_49e04848-562f-454d-8fa4-421366760bf4"
unitRef="usd">42502000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfNy03LTEtMS00MDMxMQ_af036517-d609-4156-8937-35f8e88bdfb5"
unitRef="usd">31561000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfOC03LTEtMS00MDMxMQ_9c0c7dbd-3a06-4d24-8fdb-ff8d9f3cdf23"
unitRef="usd">10941000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
<lung:CashCashEquivalentsAndAvailableForSaleDebtSecurities
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RhYmxlOjRjZTQzYzFjZGFiZTRkNGRiZTk3MjIxYzE2NTY2M2VkL3RhYmxlcmFuZ2U6NGNlNDNjMWNkYWJlNGQ0ZGJlOTcyMjFjMTY1NjYzZWRfOS03LTEtMS00MDMxMQ_630848b3-e180-4cc5-8399-1fb16a02eb05"
unitRef="usd">42502000</lung:CashCashEquivalentsAndAvailableForSaleDebtSecurities>
<us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RleHRyZWdpb246YWU0YjcxMGRlYjJhNDU2Y2JlYTNhNjIxZTM5Mjc1YTZfMzI2Ng_ab5cfaa6-fe31-4517-8223-f8da410dc222"
unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
<us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180Ni9mcmFnOmFlNGI3MTBkZWIyYTQ1NmNiZWEzYTYyMWUzOTI3NWE2L3RleHRyZWdpb246YWU0YjcxMGRlYjJhNDU2Y2JlYTNhNjIxZTM5Mjc1YTZfMTA5OTUxMTYzNTIzMw_445e65aa-0782-4e0d-aeb6-8e3619ad176e"
unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
<us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTczMw_fb19bd5d-41b2-447b-bd0b-4218709948fc">Balance Sheet Components<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s cash and cash equivalents consist of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,239 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,947 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,480 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,776 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,738 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,652 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,029 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,212 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,285 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands): </span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,886 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,869 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT and other receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,731 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,883 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capitalized Implementation Costs of a Hosting Arrangement</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has several software systems that are cloud-based hosting arrangements with service contracts. The Company accounts for costs incurred in connection with the implementation of these various software systems under ASU 2018-15, Intangibles—Goodwill and Other—Internal Use Software (Subtopic 350–40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract. The Company expenses all costs (internal and external) that are incurred in the planning and post-implementation operation stages. As of June 30, 2022, the Company has capitalized approximately $0.6 million in implementation costs related to the application development stage. The capitalized costs are amortized on a straight-line basis over the non-cancelable contract terms, which are generally three years. As of June 30, 2022, approximately $0.2 million </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $0.4 million capitalized costs were included in prepaid expenses and other current assets, and other long-term assets, respectively. Amortization expense, which was included in SG&amp;A expenses, was less than $0.1 million and $0.1 million for the three and six months ended June 30, 2022.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,956 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,635 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,561 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,677 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,795 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,057 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,863)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,243)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,932 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,814 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three months ended June 30, 2022 and June 30, 2021 was $0.3 million and $0.1 million, respectively. Depreciation expense for the six months ended June 30, 2022 and June 30, 2021 was $0.7 million and $0.2 million, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill was $2.3 million as of June 30, 2022 and December 31, 2021 arising from the Company’s acquisition of Emphasys Medical, Inc, in March 2009. No goodwill impairment losses have been recognized since the acquisition. There were no acquisitions or dispositions of goodwill in six months ended June 30, 2022 and 2021. The Company assesses goodwill for impairment annually, or more frequently, when events or changes in circumstances indicate there may be impairment. Through June 30, 2022, there have been no events or changes in circumstances that indicated that the carrying value of goodwill may not be recoverable. As a result, no impairment charge was recorded during the six months ended June 30, 2022.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,464)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,849 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,633)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,410)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,849 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,572)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense relating to the intangibles totaled less than $0.1 million during each of the three months ended June 30, 2022 and June 30, 2021, respectively. Amortization expense relating to the intangibles totaled $0.1 million during each six months ended June 30, 2022 and June 30, 2021, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense is as follows as of June 30, 2022 (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining six months)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization expense</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee bonuses and commissions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,179 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,741 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued vacation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued personnel related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales taxes, franchise tax and VAT</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for early exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued inventory purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,734 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,366 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
<us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTczNA_5c067f3f-13b7-49a6-a40f-6a314ece0960"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s cash and cash equivalents consist of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,239 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,947 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,480 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
<us-gaap:Cash
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjEzMmY1M2NmZDVkNDQ1ODE5MDBiOGM3MmJmMjRjOTc2L3RhYmxlcmFuZ2U6MTMyZjUzY2ZkNWQ0NDU4MTkwMGI4YzcyYmYyNGM5NzZfMi0xLTEtMS0zOTM4Mw_37ddb384-8a2a-428a-9f16-317099387546"
unitRef="usd">117258000</us-gaap:Cash>
<us-gaap:Cash
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjEzMmY1M2NmZDVkNDQ1ODE5MDBiOGM3MmJmMjRjOTc2L3RhYmxlcmFuZ2U6MTMyZjUzY2ZkNWQ0NDU4MTkwMGI4YzcyYmYyNGM5NzZfMi0zLTEtMS0zOTM4Mw_1b3b96de-eb53-493a-a46e-a2c57d6ae6dc"
unitRef="usd">141239000</us-gaap:Cash>
<us-gaap:MoneyMarketFundsAtCarryingValue
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjEzMmY1M2NmZDVkNDQ1ODE5MDBiOGM3MmJmMjRjOTc2L3RhYmxlcmFuZ2U6MTMyZjUzY2ZkNWQ0NDU4MTkwMGI4YzcyYmYyNGM5NzZfNC0xLTEtMS0zOTM4Mw_5116d8ff-09dd-4bc0-9653-c347b1c94790"
unitRef="usd">2192000</us-gaap:MoneyMarketFundsAtCarryingValue>
<us-gaap:MoneyMarketFundsAtCarryingValue
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjEzMmY1M2NmZDVkNDQ1ODE5MDBiOGM3MmJmMjRjOTc2L3RhYmxlcmFuZ2U6MTMyZjUzY2ZkNWQ0NDU4MTkwMGI4YzcyYmYyNGM5NzZfNC0zLTEtMS0zOTM4Mw_cd8adb9e-3d62-4a55-893e-43b6aba5baf1"
unitRef="usd">831000</us-gaap:MoneyMarketFundsAtCarryingValue>
<us-gaap:CommercialPaperAtCarryingValue
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjEzMmY1M2NmZDVkNDQ1ODE5MDBiOGM3MmJmMjRjOTc2L3RhYmxlcmFuZ2U6MTMyZjUzY2ZkNWQ0NDU4MTkwMGI4YzcyYmYyNGM5NzZfNS0xLTEtMS0zOTM4Mw_0d085edc-76b1-4a1c-a387-4acaa62440ed"
unitRef="usd">2497000</us-gaap:CommercialPaperAtCarryingValue>
<us-gaap:CommercialPaperAtCarryingValue
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjEzMmY1M2NmZDVkNDQ1ODE5MDBiOGM3MmJmMjRjOTc2L3RhYmxlcmFuZ2U6MTMyZjUzY2ZkNWQ0NDU4MTkwMGI4YzcyYmYyNGM5NzZfNS0zLTEtMS0zOTM4Mw_736c90a6-3848-41c1-b00f-2fa1ece08c7c"
unitRef="usd">2000000</us-gaap:CommercialPaperAtCarryingValue>
<lung:CorporateBondsDebtSecuritiesAtCarryingValue
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjEzMmY1M2NmZDVkNDQ1ODE5MDBiOGM3MmJmMjRjOTc2L3RhYmxlcmFuZ2U6MTMyZjUzY2ZkNWQ0NDU4MTkwMGI4YzcyYmYyNGM5NzZfNi0xLTEtMS00MDM0Mg_0d792856-935d-4cf4-9e7f-7cadf7bdcc15"
unitRef="usd">0</lung:CorporateBondsDebtSecuritiesAtCarryingValue>
<lung:CorporateBondsDebtSecuritiesAtCarryingValue
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjEzMmY1M2NmZDVkNDQ1ODE5MDBiOGM3MmJmMjRjOTc2L3RhYmxlcmFuZ2U6MTMyZjUzY2ZkNWQ0NDU4MTkwMGI4YzcyYmYyNGM5NzZfNi0zLTEtMS00MDM0Mg_e6062e07-8807-4446-affd-375bcd114b78"
unitRef="usd">4410000</lung:CorporateBondsDebtSecuritiesAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjEzMmY1M2NmZDVkNDQ1ODE5MDBiOGM3MmJmMjRjOTc2L3RhYmxlcmFuZ2U6MTMyZjUzY2ZkNWQ0NDU4MTkwMGI4YzcyYmYyNGM5NzZfNi0xLTEtMS0zOTM4Mw_16fe8f72-30e1-479b-9b4d-59805a9beb41"
unitRef="usd">121947000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjEzMmY1M2NmZDVkNDQ1ODE5MDBiOGM3MmJmMjRjOTc2L3RhYmxlcmFuZ2U6MTMyZjUzY2ZkNWQ0NDU4MTkwMGI4YzcyYmYyNGM5NzZfNi0zLTEtMS0zOTM4Mw_59981612-77a2-4924-9418-bc5f30033b91"
unitRef="usd">148480000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:ScheduleOfInventoryCurrentTableTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTczNQ_96fd4eae-8bb4-4f8c-9232-6a05d263bfd1"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,776 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,738 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,652 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,029 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,212 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,285 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
<us-gaap:InventoryRawMaterialsNetOfReserves
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjc1MDFhOGEwNDNmYTRjNzVhMjJjZDMzYTQ4NjA3NjBkL3RhYmxlcmFuZ2U6NzUwMWE4YTA0M2ZhNGM3NWEyMmNkMzNhNDg2MDc2MGRfMi0xLTEtMS0zOTM4Mw_1d6bdefd-194a-4a76-ab08-cc7557c29ffc"
unitRef="usd">3776000</us-gaap:InventoryRawMaterialsNetOfReserves>
<us-gaap:InventoryRawMaterialsNetOfReserves
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjc1MDFhOGEwNDNmYTRjNzVhMjJjZDMzYTQ4NjA3NjBkL3RhYmxlcmFuZ2U6NzUwMWE4YTA0M2ZhNGM3NWEyMmNkMzNhNDg2MDc2MGRfMi0zLTEtMS0zOTM4Mw_02f3cc44-3196-47ec-9c33-d6fb8c0dd5dc"
unitRef="usd">3738000</us-gaap:InventoryRawMaterialsNetOfReserves>
<us-gaap:InventoryWorkInProcessNetOfReserves
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjc1MDFhOGEwNDNmYTRjNzVhMjJjZDMzYTQ4NjA3NjBkL3RhYmxlcmFuZ2U6NzUwMWE4YTA0M2ZhNGM3NWEyMmNkMzNhNDg2MDc2MGRfMy0xLTEtMS0zOTM4Mw_9b101eac-f15c-4a6e-9b97-57d2b8acc21b"
unitRef="usd">784000</us-gaap:InventoryWorkInProcessNetOfReserves>
<us-gaap:InventoryWorkInProcessNetOfReserves
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjc1MDFhOGEwNDNmYTRjNzVhMjJjZDMzYTQ4NjA3NjBkL3RhYmxlcmFuZ2U6NzUwMWE4YTA0M2ZhNGM3NWEyMmNkMzNhNDg2MDc2MGRfMy0zLTEtMS0zOTM4Mw_bb0f3b28-a1ca-42c4-aba3-6a61cd65d376"
unitRef="usd">518000</us-gaap:InventoryWorkInProcessNetOfReserves>
<us-gaap:InventoryFinishedGoodsNetOfReserves
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjc1MDFhOGEwNDNmYTRjNzVhMjJjZDMzYTQ4NjA3NjBkL3RhYmxlcmFuZ2U6NzUwMWE4YTA0M2ZhNGM3NWEyMmNkMzNhNDg2MDc2MGRfNC0xLTEtMS0zOTM4Mw_08f5e7a4-a164-44c2-bc54-7abc8806ea29"
unitRef="usd">14652000</us-gaap:InventoryFinishedGoodsNetOfReserves>
<us-gaap:InventoryFinishedGoodsNetOfReserves
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjc1MDFhOGEwNDNmYTRjNzVhMjJjZDMzYTQ4NjA3NjBkL3RhYmxlcmFuZ2U6NzUwMWE4YTA0M2ZhNGM3NWEyMmNkMzNhNDg2MDc2MGRfNC0zLTEtMS0zOTM4Mw_3936d3ca-c7c0-4e37-b692-91e7ce541a67"
unitRef="usd">12029000</us-gaap:InventoryFinishedGoodsNetOfReserves>
<us-gaap:InventoryNet
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjc1MDFhOGEwNDNmYTRjNzVhMjJjZDMzYTQ4NjA3NjBkL3RhYmxlcmFuZ2U6NzUwMWE4YTA0M2ZhNGM3NWEyMmNkMzNhNDg2MDc2MGRfNS0xLTEtMS0zOTM4Mw_668ab112-2063-4c15-ab64-855cbbf7975c"
unitRef="usd">19212000</us-gaap:InventoryNet>
<us-gaap:InventoryNet
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjc1MDFhOGEwNDNmYTRjNzVhMjJjZDMzYTQ4NjA3NjBkL3RhYmxlcmFuZ2U6NzUwMWE4YTA0M2ZhNGM3NWEyMmNkMzNhNDg2MDc2MGRfNS0zLTEtMS0zOTM4Mw_a8449b7d-764c-4dbb-a9f6-833fb658d83c"
unitRef="usd">16285000</us-gaap:InventoryNet>
<us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTczNg_bccd94ab-7194-4520-8211-11b8f3e24bfa"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands): </span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,886 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,869 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT and other receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,731 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,883 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
<us-gaap:OtherPrepaidExpenseCurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmRjMmY0MTU3Y2Y5NTQyNjI4NjM2NzMzMjk5ODE5ZDc5L3RhYmxlcmFuZ2U6ZGMyZjQxNTdjZjk1NDI2Mjg2MzY3MzMyOTk4MTlkNzlfMi0xLTEtMS0zOTM4Mw_7c83402b-56bf-4e70-98e3-2666b4a50b88"
unitRef="usd">2886000</us-gaap:OtherPrepaidExpenseCurrent>
<us-gaap:OtherPrepaidExpenseCurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmRjMmY0MTU3Y2Y5NTQyNjI4NjM2NzMzMjk5ODE5ZDc5L3RhYmxlcmFuZ2U6ZGMyZjQxNTdjZjk1NDI2Mjg2MzY3MzMyOTk4MTlkNzlfMi0zLTEtMS0zOTM4Mw_2140779d-890f-400f-a2c6-c38e619de975"
unitRef="usd">1869000</us-gaap:OtherPrepaidExpenseCurrent>
<us-gaap:PrepaidInsurance
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmRjMmY0MTU3Y2Y5NTQyNjI4NjM2NzMzMjk5ODE5ZDc5L3RhYmxlcmFuZ2U6ZGMyZjQxNTdjZjk1NDI2Mjg2MzY3MzMyOTk4MTlkNzlfMy0xLTEtMS0zOTM4Mw_d5a953bf-8ca0-477c-bda5-a55387eb9834"
unitRef="usd">820000</us-gaap:PrepaidInsurance>
<us-gaap:PrepaidInsurance
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmRjMmY0MTU3Y2Y5NTQyNjI4NjM2NzMzMjk5ODE5ZDc5L3RhYmxlcmFuZ2U6ZGMyZjQxNTdjZjk1NDI2Mjg2MzY3MzMyOTk4MTlkNzlfMy0zLTEtMS0zOTM4Mw_f5b551e0-e85f-4879-8c0d-45f0d12db641"
unitRef="usd">2305000</us-gaap:PrepaidInsurance>
<us-gaap:ValueAddedTaxReceivableCurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmRjMmY0MTU3Y2Y5NTQyNjI4NjM2NzMzMjk5ODE5ZDc5L3RhYmxlcmFuZ2U6ZGMyZjQxNTdjZjk1NDI2Mjg2MzY3MzMyOTk4MTlkNzlfNC0xLTEtMS0zOTM4Mw_62b87909-f9d6-4f0f-8ae0-c9b673f28a9f"
unitRef="usd">25000</us-gaap:ValueAddedTaxReceivableCurrent>
<us-gaap:ValueAddedTaxReceivableCurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmRjMmY0MTU3Y2Y5NTQyNjI4NjM2NzMzMjk5ODE5ZDc5L3RhYmxlcmFuZ2U6ZGMyZjQxNTdjZjk1NDI2Mjg2MzY3MzMyOTk4MTlkNzlfNC0zLTEtMS0zOTM4Mw_bd50b920-d73f-40e0-967e-f628fb004d3e"
unitRef="usd">362000</us-gaap:ValueAddedTaxReceivableCurrent>
<us-gaap:OtherAssetsCurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmRjMmY0MTU3Y2Y5NTQyNjI4NjM2NzMzMjk5ODE5ZDc5L3RhYmxlcmFuZ2U6ZGMyZjQxNTdjZjk1NDI2Mjg2MzY3MzMyOTk4MTlkNzlfNS0xLTEtMS0zOTM4Mw_c275e643-a58a-49e8-83a0-d63b64b6c774"
unitRef="usd">0</us-gaap:OtherAssetsCurrent>
<us-gaap:OtherAssetsCurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmRjMmY0MTU3Y2Y5NTQyNjI4NjM2NzMzMjk5ODE5ZDc5L3RhYmxlcmFuZ2U6ZGMyZjQxNTdjZjk1NDI2Mjg2MzY3MzMyOTk4MTlkNzlfNS0zLTEtMS0zOTM4Mw_ac826a64-9e91-4744-af2d-3e1e5bf8209f"
unitRef="usd">347000</us-gaap:OtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmRjMmY0MTU3Y2Y5NTQyNjI4NjM2NzMzMjk5ODE5ZDc5L3RhYmxlcmFuZ2U6ZGMyZjQxNTdjZjk1NDI2Mjg2MzY3MzMyOTk4MTlkNzlfNi0xLTEtMS0zOTM4Mw_211f304d-8bdc-4c24-8ed3-72f02022133e"
unitRef="usd">3731000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmRjMmY0MTU3Y2Y5NTQyNjI4NjM2NzMzMjk5ODE5ZDc5L3RhYmxlcmFuZ2U6ZGMyZjQxNTdjZjk1NDI2Mjg2MzY3MzMyOTk4MTlkNzlfNi0zLTEtMS0zOTM4Mw_193fb91d-f464-438f-ac1e-c49609a132d0"
unitRef="usd">4883000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization
contextRef="i5e482a0f02a04e4e9a095186ae75202f_I20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTY0OTI2NzQ0NDY2NQ_89d72d4c-275f-4d22-8419-1c48251928fc"
unitRef="usd">600000</us-gaap:HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization>
<lung:HostingArrangementServiceContractImplementationCostCapitalizedAmortizationPeriod
contextRef="ia8327b71a4e547faac046ef1de96ead9_D20220401-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTY0OTI2NzQ0NDY3OA_1f97ca34-df99-451b-98a8-eacce0965a03">P3Y</lung:HostingArrangementServiceContractImplementationCostCapitalizedAmortizationPeriod>
<us-gaap:HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization
contextRef="iec403174da4d4b6f9ff96570a7e5a8f5_I20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTY0OTI2NzQ0NDY5Nw_5222215e-673a-435e-a47c-c8316101b48c"
unitRef="usd">200000</us-gaap:HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization>
<us-gaap:HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization
contextRef="i5b44ef956ce14264a4103fec3f984838_I20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTY0OTI2NzQ0NDcxMQ_dbd4ec40-6497-46d2-9502-ba0433f0cd35"
unitRef="usd">400000</us-gaap:HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization>
<us-gaap:HostingArrangementServiceContractImplementationCostExpenseAmortization
contextRef="ia8327b71a4e547faac046ef1de96ead9_D20220401-20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTY0OTI2NzQ0NDcyNQ_f161c36a-25be-4f51-8cb6-abe8c16a8143"
unitRef="usd">100000</us-gaap:HostingArrangementServiceContractImplementationCostExpenseAmortization>
<us-gaap:HostingArrangementServiceContractImplementationCostExpenseAmortization
contextRef="idf3e46dc35da4ebb90badd8b66929912_D20220101-20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTY0OTI2NzQ0NDgwOQ_c23b14f9-4f7b-4d21-98c5-c863d8a0e682"
unitRef="usd">100000</us-gaap:HostingArrangementServiceContractImplementationCostExpenseAmortization>
<us-gaap:PropertyPlantAndEquipmentTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTczNw_23c236ee-951b-4fcb-9139-f56793e3e908"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,956 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,635 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,561 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,677 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,795 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,057 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,863)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,243)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,932 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,814 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:PropertyPlantAndEquipmentTextBlock>
<us-gaap:PropertyPlantAndEquipmentGross
contextRef="i1840bfb02e1b469bbd139ead973986ca_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfMi0xLTEtMS0zOTM4Mw_c1353280-d1e6-41b4-bba3-a7d111a94f5b"
unitRef="usd">1956000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross
contextRef="i809590d3637c40e798f0aed4272f42ca_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfMi0zLTEtMS0zOTM4Mw_d891d619-7f3a-4258-9d57-85f2fee9d221"
unitRef="usd">1635000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross
contextRef="i339317d369b543779f5eb59e6be6a75b_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfMy0xLTEtMS0zOTM4Mw_d644d584-2538-4a2b-93e0-866cad32e158"
unitRef="usd">1623000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross
contextRef="i178bc0d657d34b21aa1fd8fd4e374909_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfMy0zLTEtMS0zOTM4Mw_c538ee06-37f2-4a48-8560-0463f4affbc0"
unitRef="usd">1561000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross
contextRef="ibc8aa7e2c53d4718b1022132994a93ab_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfNC0xLTEtMS0zOTM4Mw_56cc3b72-18b6-4ad8-a0a9-1c10abeb8844"
unitRef="usd">262000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross
contextRef="i40fb5bdc0f7e47eba46c35d13149ff1a_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfNC0zLTEtMS0zOTM4Mw_f19c8d0a-611d-4043-bed6-f44420f3b261"
unitRef="usd">252000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross
contextRef="i63e0fd137e3246b38ec39ff427bd5719_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfNS0xLTEtMS0zOTM4Mw_9d00e41c-5618-4955-936a-ff2e9de480b6"
unitRef="usd">2277000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross
contextRef="if0aa7a0e30fc4971a837f40cff89c0d8_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfNS0zLTEtMS0zOTM4Mw_5f758dbb-5ba2-4ab3-9eac-f7f878200bf0"
unitRef="usd">2277000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross
contextRef="ia81181d7be0d45bcb4069dea54e60219_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfNi0xLTEtMS0zOTM4Mw_e5167e7f-e22d-4b3b-92cf-7fb483b78f43"
unitRef="usd">1677000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross
contextRef="icb23404694384f0c8275849d24245f2e_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfNi0zLTEtMS0zOTM4Mw_57070b65-0d71-4d16-915c-cf02dd230c6c"
unitRef="usd">1332000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfNy0xLTEtMS0zOTM4Mw_f9f7c4e1-db07-4a13-bc98-d1ccc6936187"
unitRef="usd">7795000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfNy0zLTEtMS0zOTM4Mw_0cf3bbfe-b6b2-431f-98f3-1fe3a646d1d2"
unitRef="usd">7057000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfOC0xLTEtMS0zOTM4Mw_22b878d9-bf42-49fa-af8c-e25e1dbf7c7d"
unitRef="usd">2863000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfOC0zLTEtMS0zOTM4Mw_e5b40d84-275d-407b-86d8-add48cf50ed8"
unitRef="usd">2243000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:PropertyPlantAndEquipmentNet
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfOS0xLTEtMS0zOTM4Mw_ed970c1b-9a53-405a-bbf0-61123f19d008"
unitRef="usd">4932000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjQyMjM4ZWFiYjMyZjRmMGE4ODViZDA1MmY2ODRhNDZjL3RhYmxlcmFuZ2U6NDIyMzhlYWJiMzJmNGYwYTg4NWJkMDUyZjY4NGE0NmNfOS0zLTEtMS0zOTM4Mw_4ac34ff9-e4bc-4820-98b1-86ac452af8e2"
unitRef="usd">4814000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:Depreciation
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfNDk1_31ba6960-436f-41f3-91c9-bc195f733dda"
unitRef="usd">300000</us-gaap:Depreciation>
<us-gaap:Depreciation
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfNTAy_4dd4ab64-c276-49df-a263-0e23842b36cd"
unitRef="usd">100000</us-gaap:Depreciation>
<us-gaap:Depreciation
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfNTgw_8e7fabf6-b817-4be2-ae33-ba692bcb2156"
unitRef="usd">700000</us-gaap:Depreciation>
<us-gaap:Depreciation
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfNTg3_d1e421c7-a92f-4149-bcb7-3d9be123d325"
unitRef="usd">200000</us-gaap:Depreciation>
<us-gaap:Goodwill
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfNjI3_832a6d58-4f7a-42ef-9a0c-7c57ed17020a"
unitRef="usd">2300000</us-gaap:Goodwill>
<us-gaap:Goodwill
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfNjI3_e466f5a0-1536-441c-bb47-b12e38e3240d"
unitRef="usd">2300000</us-gaap:Goodwill>
<us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfNzI2_4e9378a7-cd62-4d88-b6e4-16c733a5568d"
unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
<us-gaap:GoodwillAcquiredDuringPeriod
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfODEx_49d6fd56-3ccb-4932-a0c5-34f48bc1c15d"
unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
<us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfODEx_8d52c6a5-bc79-41be-9845-427ff30881e7"
unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
<us-gaap:GoodwillAcquiredDuringPeriod
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfODEx_e448ad3d-6420-4baf-9231-4cac175f75a6"
unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
<us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfODEx_ee6fc928-b6e2-423b-825c-d4d71dd7951b"
unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
<us-gaap:GoodwillImpairmentLoss
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTE4OA_8bfcada9-10f7-407d-a4af-c7b1441ac3b0"
unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
<us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTczOA_a0ff3a1d-f7d5-42d2-a3e1-32dd8b7cd66d"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,464)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,849 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,633)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,410)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,849 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,572)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
<us-gaap:FiniteLivedIntangibleAssetsGross
contextRef="iad04ff000fc942258f4e9cf9f39d4fb5_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjg4ZWViYjVmNjZjNTQxMzBhNDY0YTk5YmEzYTliOTRkL3RhYmxlcmFuZ2U6ODhlZWJiNWY2NmM1NDEzMGE0NjRhOTliYTNhOWI5NGRfMi0xLTEtMS0zOTM4Mw_f0370542-a3af-4c39-bac0-8bdcff6e2745"
unitRef="usd">1658000</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
contextRef="iad04ff000fc942258f4e9cf9f39d4fb5_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjg4ZWViYjVmNjZjNTQxMzBhNDY0YTk5YmEzYTliOTRkL3RhYmxlcmFuZ2U6ODhlZWJiNWY2NmM1NDEzMGE0NjRhOTliYTNhOWI5NGRfMi0zLTEtMS0zOTM4Mw_cc8f2949-66bc-4dd0-913f-fe0222f2706a"
unitRef="usd">1464000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsNet
contextRef="iad04ff000fc942258f4e9cf9f39d4fb5_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjg4ZWViYjVmNjZjNTQxMzBhNDY0YTk5YmEzYTliOTRkL3RhYmxlcmFuZ2U6ODhlZWJiNWY2NmM1NDEzMGE0NjRhOTliYTNhOWI5NGRfMi01LTEtMS0zOTM4Mw_710d7eae-fa14-4184-b66f-3409c7add2f8"
unitRef="usd">194000</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsGross
contextRef="i95b7e760966d41e297348550b546a87e_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjg4ZWViYjVmNjZjNTQxMzBhNDY0YTk5YmEzYTliOTRkL3RhYmxlcmFuZ2U6ODhlZWJiNWY2NmM1NDEzMGE0NjRhOTliYTNhOWI5NGRfMy0xLTEtMS0zOTM4Mw_5b45dc8a-25fd-4c3d-81fc-97343e66ffd9"
unitRef="usd">191000</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
contextRef="i95b7e760966d41e297348550b546a87e_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjg4ZWViYjVmNjZjNTQxMzBhNDY0YTk5YmEzYTliOTRkL3RhYmxlcmFuZ2U6ODhlZWJiNWY2NmM1NDEzMGE0NjRhOTliYTNhOWI5NGRfMy0zLTEtMS0zOTM4Mw_026a471a-2424-499c-ab5f-3287861c55bf"
unitRef="usd">169000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsNet
contextRef="i95b7e760966d41e297348550b546a87e_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjg4ZWViYjVmNjZjNTQxMzBhNDY0YTk5YmEzYTliOTRkL3RhYmxlcmFuZ2U6ODhlZWJiNWY2NmM1NDEzMGE0NjRhOTliYTNhOWI5NGRfMy01LTEtMS0zOTM4Mw_defaace5-45d6-4b0d-b1f5-da93789844f0"
unitRef="usd">22000</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsGross
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjg4ZWViYjVmNjZjNTQxMzBhNDY0YTk5YmEzYTliOTRkL3RhYmxlcmFuZ2U6ODhlZWJiNWY2NmM1NDEzMGE0NjRhOTliYTNhOWI5NGRfNC0xLTEtMS0zOTM4Mw_cdb3a6c9-ab78-4fe6-a52a-b4207e0ed835"
unitRef="usd">1849000</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjg4ZWViYjVmNjZjNTQxMzBhNDY0YTk5YmEzYTliOTRkL3RhYmxlcmFuZ2U6ODhlZWJiNWY2NmM1NDEzMGE0NjRhOTliYTNhOWI5NGRfNC0zLTEtMS0zOTM4Mw_ff07d1cf-6fec-4164-b950-434136569f15"
unitRef="usd">1633000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsNet
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOjg4ZWViYjVmNjZjNTQxMzBhNDY0YTk5YmEzYTliOTRkL3RhYmxlcmFuZ2U6ODhlZWJiNWY2NmM1NDEzMGE0NjRhOTliYTNhOWI5NGRfNC01LTEtMS0zOTM4Mw_26cd660f-d0bf-4dd5-8d8f-bcb2b2847bd8"
unitRef="usd">216000</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsGross
contextRef="ie3cb7048a6fa4bb2bc49e5f307bee1ae_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmY1ODU1YmNiNjRmMjQ3M2RiN2YzNGRmNmZkNzJhOGI5L3RhYmxlcmFuZ2U6ZjU4NTViY2I2NGYyNDczZGI3ZjM0ZGY2ZmQ3MmE4YjlfMi0xLTEtMS0zOTM4Mw_9243e469-b279-489e-9ad2-2bb8e21af867"
unitRef="usd">1658000</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
contextRef="ie3cb7048a6fa4bb2bc49e5f307bee1ae_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmY1ODU1YmNiNjRmMjQ3M2RiN2YzNGRmNmZkNzJhOGI5L3RhYmxlcmFuZ2U6ZjU4NTViY2I2NGYyNDczZGI3ZjM0ZGY2ZmQ3MmE4YjlfMi0zLTEtMS0zOTM4Mw_6472a21d-bf68-4ad9-8738-8b6b1b63a8d1"
unitRef="usd">1410000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsNet
contextRef="ie3cb7048a6fa4bb2bc49e5f307bee1ae_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmY1ODU1YmNiNjRmMjQ3M2RiN2YzNGRmNmZkNzJhOGI5L3RhYmxlcmFuZ2U6ZjU4NTViY2I2NGYyNDczZGI3ZjM0ZGY2ZmQ3MmE4YjlfMi01LTEtMS0zOTM4Mw_4a205029-6cd0-4428-ab0c-ac2299f0e984"
unitRef="usd">248000</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsGross
contextRef="i5c65329af5944c1e8409cad224f99d17_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmY1ODU1YmNiNjRmMjQ3M2RiN2YzNGRmNmZkNzJhOGI5L3RhYmxlcmFuZ2U6ZjU4NTViY2I2NGYyNDczZGI3ZjM0ZGY2ZmQ3MmE4YjlfMy0xLTEtMS0zOTM4Mw_5554ccda-b78d-48f4-a45e-b6e59b8256cd"
unitRef="usd">191000</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
contextRef="i5c65329af5944c1e8409cad224f99d17_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmY1ODU1YmNiNjRmMjQ3M2RiN2YzNGRmNmZkNzJhOGI5L3RhYmxlcmFuZ2U6ZjU4NTViY2I2NGYyNDczZGI3ZjM0ZGY2ZmQ3MmE4YjlfMy0zLTEtMS0zOTM4Mw_c7633750-812b-4e8f-bf6d-2a717076cefb"
unitRef="usd">162000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsNet
contextRef="i5c65329af5944c1e8409cad224f99d17_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmY1ODU1YmNiNjRmMjQ3M2RiN2YzNGRmNmZkNzJhOGI5L3RhYmxlcmFuZ2U6ZjU4NTViY2I2NGYyNDczZGI3ZjM0ZGY2ZmQ3MmE4YjlfMy01LTEtMS0zOTM4Mw_ce3239f7-b7b6-4221-aa4f-521397272165"
unitRef="usd">29000</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsGross
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmY1ODU1YmNiNjRmMjQ3M2RiN2YzNGRmNmZkNzJhOGI5L3RhYmxlcmFuZ2U6ZjU4NTViY2I2NGYyNDczZGI3ZjM0ZGY2ZmQ3MmE4YjlfNC0xLTEtMS0zOTM4Mw_af8c88a9-90f6-420e-8a25-2ad58f6b0d4a"
unitRef="usd">1849000</us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmY1ODU1YmNiNjRmMjQ3M2RiN2YzNGRmNmZkNzJhOGI5L3RhYmxlcmFuZ2U6ZjU4NTViY2I2NGYyNDczZGI3ZjM0ZGY2ZmQ3MmE4YjlfNC0zLTEtMS0zOTM4Mw_d242c4bb-9490-414e-9877-37497896d488"
unitRef="usd">1572000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsNet
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmY1ODU1YmNiNjRmMjQ3M2RiN2YzNGRmNmZkNzJhOGI5L3RhYmxlcmFuZ2U6ZjU4NTViY2I2NGYyNDczZGI3ZjM0ZGY2ZmQ3MmE4YjlfNC01LTEtMS0zOTM4Mw_7d2574d2-502c-44d0-8cb8-479e3cc9920c"
unitRef="usd">277000</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:AmortizationOfIntangibleAssets
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTQwMg_577ce3d7-d867-48c0-8f01-a0a3f15d4db9"
unitRef="usd">100000</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTQwMg_fe87b0ef-7cd1-43d0-bbda-ddfdd71c807d"
unitRef="usd">100000</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTUyNQ_a09a661a-f233-43d5-bceb-ec33210a5003"
unitRef="usd">100000</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTUyNQ_f844cfcb-5818-4886-9ecc-12a17f8bc2b8"
unitRef="usd">100000</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTczOQ_b9cf0929-0409-42f9-837d-4d1ff6ab702f"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense is as follows as of June 30, 2022 (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining six months)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amortization expense</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmU4NDJkYTkzYmYzZjQ3OTc5NDNhMGYzYmM2NDllZDFiL3RhYmxlcmFuZ2U6ZTg0MmRhOTNiZjNmNDc5Nzk0M2EwZjNiYzY0OWVkMWJfMi0xLTEtMS0zOTM4Mw_b5b08737-7c8f-4b5e-9e2d-c95d6e27cd27"
unitRef="usd">62000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmU4NDJkYTkzYmYzZjQ3OTc5NDNhMGYzYmM2NDllZDFiL3RhYmxlcmFuZ2U6ZTg0MmRhOTNiZjNmNDc5Nzk0M2EwZjNiYzY0OWVkMWJfMy0xLTEtMS0zOTM4Mw_61a84535-6acd-4562-a7a2-79851fd60d0d"
unitRef="usd">123000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmU4NDJkYTkzYmYzZjQ3OTc5NDNhMGYzYmM2NDllZDFiL3RhYmxlcmFuZ2U6ZTg0MmRhOTNiZjNmNDc5Nzk0M2EwZjNiYzY0OWVkMWJfNC0xLTEtMS0zOTM4Mw_b922bd6f-1d48-4d67-ac5f-fef330a0be8e"
unitRef="usd">31000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
<us-gaap:FiniteLivedIntangibleAssetsNet
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmU4NDJkYTkzYmYzZjQ3OTc5NDNhMGYzYmM2NDllZDFiL3RhYmxlcmFuZ2U6ZTg0MmRhOTNiZjNmNDc5Nzk0M2EwZjNiYzY0OWVkMWJfNS0xLTEtMS0zOTM4Mw_33dccf3f-d44a-4465-84c9-ed0424817cb1"
unitRef="usd">216000</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RleHRyZWdpb246ZTViZjcxMDY0Y2MxNGM1ZDliZWY0MjJhNzdiMjE1YWJfMTczMg_4f6fb075-a567-4c55-82c0-9621f1a41755"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee bonuses and commissions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,179 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,741 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued vacation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,850 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued personnel related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales taxes, franchise tax and VAT</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability for early exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued inventory purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,734 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,366 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
<us-gaap:AccruedBonusesCurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfMi0xLTEtMS0zOTM4Mw_53d01b9f-d114-4f24-9ace-4bc8377cffc9"
unitRef="usd">3179000</us-gaap:AccruedBonusesCurrent>
<us-gaap:AccruedBonusesCurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfMi0zLTEtMS0zOTM4Mw_99016fd1-bb26-4bec-a35c-eaf1e8688a71"
unitRef="usd">4741000</us-gaap:AccruedBonusesCurrent>
<us-gaap:AccruedVacationCurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfMy0xLTEtMS0zOTM4Mw_05d9e310-7749-4a58-98b7-30d5dcc0e778"
unitRef="usd">2134000</us-gaap:AccruedVacationCurrent>
<us-gaap:AccruedVacationCurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfMy0zLTEtMS0zOTM4Mw_7e3c28c4-60ce-4a5f-9c3d-cd1fb928e08e"
unitRef="usd">1850000</us-gaap:AccruedVacationCurrent>
<us-gaap:OtherEmployeeRelatedLiabilitiesCurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfNC0xLTEtMS0zOTM4Mw_60576fef-0238-40de-9518-766bfed5a657"
unitRef="usd">2308000</us-gaap:OtherEmployeeRelatedLiabilitiesCurrent>
<us-gaap:OtherEmployeeRelatedLiabilitiesCurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfNC0zLTEtMS0zOTM4Mw_8f69108e-3c97-4b85-88dd-74331f8e9836"
unitRef="usd">2145000</us-gaap:OtherEmployeeRelatedLiabilitiesCurrent>
<us-gaap:AccruedProfessionalFeesCurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfNS0xLTEtMS0zOTM4Mw_3c1f05ef-e0f5-42e2-83f7-96aca8ebe707"
unitRef="usd">2233000</us-gaap:AccruedProfessionalFeesCurrent>
<us-gaap:AccruedProfessionalFeesCurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfNS0zLTEtMS0zOTM4Mw_815ac690-0ed6-4851-9139-a0763afe8ee8"
unitRef="usd">2420000</us-gaap:AccruedProfessionalFeesCurrent>
<us-gaap:TaxesPayableCurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfNi0xLTEtMS0zOTM4Mw_94d0f6ca-a53e-4aea-b27e-ce3306560752"
unitRef="usd">602000</us-gaap:TaxesPayableCurrent>
<us-gaap:TaxesPayableCurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfNi0zLTEtMS0zOTM4Mw_76c77bfd-2f03-415f-b884-d67a81b7dee3"
unitRef="usd">730000</us-gaap:TaxesPayableCurrent>
<us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfNy0xLTEtMS0zOTM4Mw_00fc5d71-7d28-44dc-977f-045daef356e1"
unitRef="usd">282000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
<us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfNy0zLTEtMS0zOTM4Mw_ae42984c-67dd-434f-9522-46a24d6dc203"
unitRef="usd">399000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
<lung:AccruedInventoryPurchasesCurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfOC0xLTEtMS0zOTM4Mw_bbdaa6cc-6e00-4a7b-86e2-0a3711dc819c"
unitRef="usd">128000</lung:AccruedInventoryPurchasesCurrent>
<lung:AccruedInventoryPurchasesCurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfOC0zLTEtMS0zOTM4Mw_f5d3b9fe-5cd5-43c2-a69d-d2913b63fed4"
unitRef="usd">258000</lung:AccruedInventoryPurchasesCurrent>
<us-gaap:OtherAccruedLiabilitiesCurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfOS0xLTEtMS0zOTM4Mw_01dbf71f-1cd3-4aef-9718-bf473a0d99cc"
unitRef="usd">868000</us-gaap:OtherAccruedLiabilitiesCurrent>
<us-gaap:OtherAccruedLiabilitiesCurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfOS0zLTEtMS0zOTM4Mw_5a1a6399-4244-4a7a-99a0-01301034c882"
unitRef="usd">823000</us-gaap:OtherAccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfMTAtMS0xLTEtMzkzODM_b4490161-907c-4cc6-9a5b-57019cd7427d"
unitRef="usd">11734000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N180OS9mcmFnOmU1YmY3MTA2NGNjMTRjNWQ5YmVmNDIyYTc3YjIxNWFiL3RhYmxlOmZkMzBiYjQ0NDM5NzQxN2FhOTA1MzE2ZTNkNDAzZDcxL3RhYmxlcmFuZ2U6ZmQzMGJiNDQ0Mzk3NDE3YWE5MDUzMTZlM2Q0MDNkNzFfMTAtMy0xLTEtMzkzODM_7a0c1819-30f5-4928-a5dc-2fbfc3257a9b"
unitRef="usd">13366000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:DebtDisclosureTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMTIxOTI_9c921bfb-6aed-488e-a7e4-272ac1d00b11">Long Term Debt and Convertible Notes<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Term Loan</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CIBC Loan</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2020, the Company executed a Loan and Security Agreement (the “CIBC Agreement”) with Canadian Imperial Bank of Commerce (“CIBC”) to raise up to $32.0 million in debt financing (“CIBC Loan”) consisting of $17.0 million advanced at the closing of the agreement (“Tranche A”), with the option to draw up to an additional $8.0 million (“Tranche B”) and an additional financing tranche (“Tranche C”) of up to $7.0 million on or prior to February 20, 2022. Neither Tranche B nor Tranche C was drawn before the expiration date. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CIBC Loan originally had a five-year term maturing on February 20, 2025, which included 24 months of interest only payments followed by 36 months of equal payments of principal and interest. The CIBC Loan bears interest at a floating rate equal to 1.0% above the Wall Street Journal Prime Rate at any time. The CIBC Loan is collateralized by substantially all of the Company’s assets, including cash and cash equivalents, accounts receivable, intellectual property and equipment. The Company may prepay the loan, subject to certain requirements. The CIBC Agreement includes customary restrictive covenants, financial covenants, events of default and other customary terms and conditions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company entered into a First Amendment to CIBC Agreement that changed the maturity date to March 15, 2022, which would be automatically extended to February 20, 2025 if the maturity of all outstanding convertible notes was extended to a date no earlier than May 21, 2025 or all convertible notes converted into convertible preferred stock of the Company. An amendment fee of $0.2 million was paid. The amendment was accounted for as a debt modification and no gain or loss was recognized. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, to address certain post-close covenants for which the Company was not in compliance, the Company entered into a Second Amendment to the CIBC Agreement that extended the compliance of such covenants to June 30, 2021. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company entered into an Amended and Restated CIBC Agreement which extended the maturity date from March 15, 2022 to February 20, 2025, and modified certain financial covenants. Per the amended terms, 36 equal payments of principal plus accrued interest would be due beginning March 31, 2022. In connection with the Amended and Restated agreement, the Company paid fees to CIBC of less than $0.1 million which were recorded as a discount on the CIBC Loan and are being accreted over the life of the term loan using the effective interest method. The amendment was accounted for as a debt modification and no gain or loss was recognized.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company entered into a First Amendment to the Amended and Restated Loan and Security agreement with CIBC that extended the compliance of certain post-close covenants to March 31, 2022. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into a Second Amendment to the Amended and Restated Loan and Security Agreement with CIBC, which extended the interest only period of the loan from 24 months to 36 months. Under the amended terms, principal repayment will begin in February 2023. There was no change to the loan interest rate or maturity date.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the CIBC Loan had an annual effective interest rate of 4.71% per year.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial covenants in the CIBC Agreement require that, when the cash and cash equivalents of the Company is less than $100.0 million, the Company have revenue for the trailing three-month period ending on the last day of each fiscal quarter of not less than 80.0% of the revenue for the trailing three-month period, as set forth in the annual projections delivered to the CIBC. Further, the Company is required to maintain unrestricted cash in an aggregate amount equal to or greater than the Adjusted EBITDA loss as defined in the CIBC Agreement for the four-month period ending on any date of determination. As of June 30, 2022, the Company was in compliance with all covenants contained in CIBC Agreement.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CIBC Loan consists of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.573%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;padding-right:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;padding-right:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt issuance costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;padding-right:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,901 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,869 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid $0.4 million fees to the lender and third parties which is reflected as a discount on the CIBC Loan and is being accreted over the life of the term loan using the effective interest method. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022 and 2021, the Company recorded interest expense related to debt discount and debt issuance costs of CIBC Loan of less than $0.1 million and less than $0.1 million, respectively. During the six months ended June 30, 2022 and 2021, the Company recorded interest expense related to debt discount and debt issuance costs of CIBC Loan of less than $0.1 million and $0.1 million, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense on the CIBC Loan amounted $0.2 million and $0.2 million during the three months ended June 30, 2022 and 2021, respectively. Interest expense on the CIBC Loan amounted $0.4 million and $0.4 million during the six months ended June 30, 2022 and 2021, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, Pulmonx International Sàrl, a wholly-owned subsidiary of the Company, entered into a COVID-19 Credit Agreement with UBS Switzerland AG to receive up to 0.5 million Swiss Francs ($0.5 million U.S. dollar equivalent) under Swiss Federal Government program to mitigate the economic impact of the spread of the coronavirus. In May 2020, Pulmonx International Sàrl received $0.5 million Swiss Francs ($0.5 million U.S. dollar equivalent) under the COVID-19 Credit Agreement. The COVID-19 Credit Agreement bears no interest and is being repaid in twelve equal installments, paid semi-annually, beginning in March of 2022. As of June 30, 2022, Pulmonx International Sàrl paid less than $0.1 million to the lender.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Maturities of Financing Obligations</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the aggregate future payments under the CIBC Loan and Credit Agreement (including interest payments) are as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining six months)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,779 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,843 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,716 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,236)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Term loan and credit agreement</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,381 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:DebtDisclosureTextBlock>
<lung:DebtInstrumentFaceAmountIncludingAccordionFeature
contextRef="i69fa9455e50e46f4af26f9c44e3cb740_I20200220"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMzAzMw_e662d16c-9048-408a-a6ae-92dd9a45d656"
unitRef="usd">32000000</lung:DebtInstrumentFaceAmountIncludingAccordionFeature>
<us-gaap:ProceedsFromIssuanceOfLongTermDebt
contextRef="i662aa5e4c8f94ee688483281db66fe8e_D20200220-20200220"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMzA4Mg_696efd8f-5376-4094-9e62-d159d413b6af"
unitRef="usd">17000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
<lung:DebtInstrumentAccordionFeatureIncreaseFaceAmount
contextRef="i517ce1c551384aa19ddce0f3e57a8444_I20200220"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMzE4OA_374710c8-6507-48fa-8993-327e99efd759"
unitRef="usd">8000000</lung:DebtInstrumentAccordionFeatureIncreaseFaceAmount>
<lung:DebtInstrumentAccordionFeatureIncreaseFaceAmount
contextRef="i365110653de64470b9da2fd7e9534eff_I20200220"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMzMyNA_f46e3a1b-1354-4859-9787-b508cdd8f360"
unitRef="usd">7000000</lung:DebtInstrumentAccordionFeatureIncreaseFaceAmount>
<us-gaap:DebtInstrumentTerm
contextRef="i543c3e76e6bb46e1b76eef8fae5afbeb_D20200220-20200220"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMTIxOTM_152c4018-abe3-43a2-9476-3ae3ee8b45fd">P5Y</us-gaap:DebtInstrumentTerm>
<lung:DebtInstrumentPeriodicPaymentInterestOnlyTerm
contextRef="i543c3e76e6bb46e1b76eef8fae5afbeb_D20200220-20200220"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMzgxMw_58cd35da-5938-49e3-9ebb-7dd9bbdd72a6">P24M</lung:DebtInstrumentPeriodicPaymentInterestOnlyTerm>
<lung:DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm
contextRef="i543c3e76e6bb46e1b76eef8fae5afbeb_D20200220-20200220"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMzg2MQ_c634a1b6-e202-4759-8a29-cf9d77c44c07">P36M</lung:DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm>
<us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
contextRef="i125e5025f90d4542857c5e912e248efa_D20200220-20200220"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfNDExNw_cd8f0a0c-12d9-4501-9fb1-9c88c428d870"
unitRef="number">0.010</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
<us-gaap:DebtInstrumentFeeAmount
contextRef="i31de136071f4464fa0afd580b08736c2_I20200430"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfNTA4NA_56113432-4638-4167-b4c4-dc0a138154f9"
unitRef="usd">200000</us-gaap:DebtInstrumentFeeAmount>
<lung:GainLossOnAmendmentOfDebtInstrument
contextRef="i0f999a2b8cd8404da746d5c0e0b4fa69_D20200401-20200430"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfNTQ2NA_36d79038-61d1-40b2-981f-58f9a25a4e0d"
unitRef="usd">0</lung:GainLossOnAmendmentOfDebtInstrument>
<lung:DebtInstrumentNumberOfPeriodicPayments
contextRef="i69fa9455e50e46f4af26f9c44e3cb740_I20200220"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfNTk0OA_35f2bea7-1294-47bf-9b5f-bae4e9e44615"
unitRef="payment">36</lung:DebtInstrumentNumberOfPeriodicPayments>
<us-gaap:PaymentsOfDebtIssuanceCosts
contextRef="i6f1e6dd7364444de8ff46bdf5cd1eb03_D20210301-20210331"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfNjI4Mg_878868de-8106-4cc1-90d1-c4ff28e38e5c"
unitRef="usd">100000</us-gaap:PaymentsOfDebtIssuanceCosts>
<lung:GainLossOnAmendmentOfDebtInstrument
contextRef="i484ba17f04d144eb9aee8b4620710100_D20210301-20210331"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfNjQ4Ng_92b7ae8c-50da-4ee4-a68e-fe0527b5b9d8"
unitRef="usd">0</lung:GainLossOnAmendmentOfDebtInstrument>
<lung:DebtInstrumentPeriodicPaymentInterestOnlyTerm
contextRef="i77dd9039bef24911aa020653e86f93f4_D20211001-20211031"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMzI5ODUzNDkwNDAzOQ_f8aee47c-6d95-4164-8a7a-47ebeffe6919">P24M</lung:DebtInstrumentPeriodicPaymentInterestOnlyTerm>
<lung:DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm
contextRef="i77dd9039bef24911aa020653e86f93f4_D20211001-20211031"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMzI5ODUzNDkwNDA1Mg_c529ff6f-149a-44d7-97ed-5439343ddddf">P36M</lung:DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm>
<lung:IncreaseInLoanInterestRate
contextRef="i77dd9039bef24911aa020653e86f93f4_D20211001-20211031"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMzI5ODUzNDkwNDA2NQ_bf5a353f-c052-4bde-9dd9-b78a12ef649d"
unitRef="number">0</lung:IncreaseInLoanInterestRate>
<us-gaap:DebtInstrumentInterestRateEffectivePercentage
contextRef="i77c3dfcc442f4078a50db735a19d5748_I20220630"
decimals="4"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfNjc2NQ_88d84ed0-9fce-4262-ae81-cb889837caf9"
unitRef="number">0.0471</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
<lung:DebtInstrumentCovenantCashAndCashEquivalentsMinimumThresholdTriggerForRevenueRequirement
contextRef="i69fa9455e50e46f4af26f9c44e3cb740_I20200220"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfNjkwMQ_ac7ecb79-873b-42a5-a2b7-1e90d15c96f2"
unitRef="usd">100000000</lung:DebtInstrumentCovenantCashAndCashEquivalentsMinimumThresholdTriggerForRevenueRequirement>
<lung:DebtInstrumentCovenantMinimumRevenueRequirementPeriod
contextRef="i543c3e76e6bb46e1b76eef8fae5afbeb_D20200220-20200220"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMTIxODg_015ea02c-7733-42fc-89ac-a7dd1e6a9a1b">P3M</lung:DebtInstrumentCovenantMinimumRevenueRequirementPeriod>
<lung:DebtInstrumentCovenantMinimumRevenueRequirementsPercentage
contextRef="i69fa9455e50e46f4af26f9c44e3cb740_I20200220"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfNzAyNg_0eb009bb-6d18-42bd-a541-abb21661388a"
unitRef="number">0.800</lung:DebtInstrumentCovenantMinimumRevenueRequirementsPercentage>
<lung:DebtInstrumentCovenantMinimumRevenueRequirementPeriod
contextRef="i543c3e76e6bb46e1b76eef8fae5afbeb_D20200220-20200220"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMTIxODQ_030e7f19-c0af-4797-9afe-4d5e2b818278">P3M</lung:DebtInstrumentCovenantMinimumRevenueRequirementPeriod>
<lung:DebtInstrumentCovenantUnrestrictedCashRequirementPeriod
contextRef="i543c3e76e6bb46e1b76eef8fae5afbeb_D20200220-20200220"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMTIxODk_9a693f10-c958-4212-a153-bf0cdbc52af5">P4M</lung:DebtInstrumentCovenantUnrestrictedCashRequirementPeriod>
<us-gaap:ScheduleOfDebtInstrumentsTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMTIxOTA_e7787031-7962-4b40-b300-ccfbd7fc087c"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CIBC Loan consists of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.573%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;padding-right:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;padding-right:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt issuance costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;padding-right:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,901 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,869 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:ScheduleOfDebtInstrumentsTextBlock>
<us-gaap:DebtInstrumentCarryingAmount
contextRef="i77c3dfcc442f4078a50db735a19d5748_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmJjZmQ0NWZhNTBlZTRlOTdiZmMzZDg4NWFiYWZmMzAzL3RhYmxlcmFuZ2U6YmNmZDQ1ZmE1MGVlNGU5N2JmYzNkODg1YWJhZmYzMDNfMi0yLTEtMS0zOTM4Mw_2f00dca1-0d47-4f20-8f19-8913bf2403bd"
unitRef="usd">17000000</us-gaap:DebtInstrumentCarryingAmount>
<us-gaap:DebtInstrumentCarryingAmount
contextRef="if05f081a56284af8acd87cd18fcceda5_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmJjZmQ0NWZhNTBlZTRlOTdiZmMzZDg4NWFiYWZmMzAzL3RhYmxlcmFuZ2U6YmNmZDQ1ZmE1MGVlNGU5N2JmYzNkODg1YWJhZmYzMDNfMi00LTEtMS0zOTM4Mw_3076fd9e-e2f6-48fe-8646-7678066139c9"
unitRef="usd">17000000</us-gaap:DebtInstrumentCarryingAmount>
<us-gaap:DebtInstrumentUnamortizedDiscount
contextRef="i77c3dfcc442f4078a50db735a19d5748_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmJjZmQ0NWZhNTBlZTRlOTdiZmMzZDg4NWFiYWZmMzAzL3RhYmxlcmFuZ2U6YmNmZDQ1ZmE1MGVlNGU5N2JmYzNkODg1YWJhZmYzMDNfMy0yLTEtMS0zOTM4Mw_83f4215f-0968-45ab-a3e3-c2a3330c4f2d"
unitRef="usd">99000</us-gaap:DebtInstrumentUnamortizedDiscount>
<us-gaap:DebtInstrumentUnamortizedDiscount
contextRef="if05f081a56284af8acd87cd18fcceda5_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmJjZmQ0NWZhNTBlZTRlOTdiZmMzZDg4NWFiYWZmMzAzL3RhYmxlcmFuZ2U6YmNmZDQ1ZmE1MGVlNGU5N2JmYzNkODg1YWJhZmYzMDNfMy00LTEtMS0zOTM4Mw_a58cb214-00e8-454f-b460-78bb66c5cab4"
unitRef="usd">131000</us-gaap:DebtInstrumentUnamortizedDiscount>
<us-gaap:LongTermDebt
contextRef="i77c3dfcc442f4078a50db735a19d5748_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmJjZmQ0NWZhNTBlZTRlOTdiZmMzZDg4NWFiYWZmMzAzL3RhYmxlcmFuZ2U6YmNmZDQ1ZmE1MGVlNGU5N2JmYzNkODg1YWJhZmYzMDNfNC0yLTEtMS0zOTM4Mw_0f7a1eea-8ced-46a1-b44a-f27a3a19e4ff"
unitRef="usd">16901000</us-gaap:LongTermDebt>
<us-gaap:LongTermDebt
contextRef="if05f081a56284af8acd87cd18fcceda5_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmJjZmQ0NWZhNTBlZTRlOTdiZmMzZDg4NWFiYWZmMzAzL3RhYmxlcmFuZ2U6YmNmZDQ1ZmE1MGVlNGU5N2JmYzNkODg1YWJhZmYzMDNfNC00LTEtMS0zOTM4Mw_d72b46fe-b8bb-4e4a-9c42-76b665cf7635"
unitRef="usd">16869000</us-gaap:LongTermDebt>
<us-gaap:PaymentsOfDebtIssuanceCosts
contextRef="i543c3e76e6bb46e1b76eef8fae5afbeb_D20200220-20200220"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfNzUzMw_47cf2a50-8358-40f3-aa83-4f7a3c52e867"
unitRef="usd">400000</us-gaap:PaymentsOfDebtIssuanceCosts>
<us-gaap:AmortizationOfFinancingCostsAndDiscounts
contextRef="i2a6b51ede0b348778de030ce71e1beb5_D20220401-20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMTA5OTUxMTY0ODY5OA_54f9d73e-afac-4701-83c0-9e685dae7637"
unitRef="usd">100000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
<us-gaap:AmortizationOfFinancingCostsAndDiscounts
contextRef="ib7679901e2d74b97a73e37442ab74242_D20210401-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfNzg2OQ_3203efdb-f960-4a16-a417-3b62f11fa01b"
unitRef="usd">100000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
<us-gaap:AmortizationOfFinancingCostsAndDiscounts
contextRef="i8396a841b0dd4c458e576ad2b5d930b5_D20220101-20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMTA5OTUxMTY0ODk0OQ_5237b537-8a95-455b-a2f0-60f71d6908a7"
unitRef="usd">100000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
<us-gaap:AmortizationOfFinancingCostsAndDiscounts
contextRef="i35a8e4b3abcb47d78dd4215a8467d650_D20210101-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMTA5OTUxMTY0ODk1Nw_22fd1ed9-76e0-4bd9-ab0c-d97f67a13815"
unitRef="usd">100000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
<us-gaap:InterestExpenseDebtExcludingAmortization
contextRef="i2a6b51ede0b348778de030ce71e1beb5_D20220401-20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfODEwNw_669e2451-3cb2-4328-9975-14c4119756a5"
unitRef="usd">200000</us-gaap:InterestExpenseDebtExcludingAmortization>
<us-gaap:InterestExpenseDebtExcludingAmortization
contextRef="ib7679901e2d74b97a73e37442ab74242_D20210401-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfODExNA_cdcb4031-34cb-46ef-b20b-3d497b28a035"
unitRef="usd">200000</us-gaap:InterestExpenseDebtExcludingAmortization>
<us-gaap:InterestExpenseDebtExcludingAmortization
contextRef="i8396a841b0dd4c458e576ad2b5d930b5_D20220101-20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfODIxNQ_90261c67-c2a0-4170-a131-8cdb9d612d48"
unitRef="usd">400000</us-gaap:InterestExpenseDebtExcludingAmortization>
<us-gaap:InterestExpenseDebtExcludingAmortization
contextRef="i35a8e4b3abcb47d78dd4215a8467d650_D20210101-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfODIyMg_d4e80c7c-4c7d-458e-8412-77d961f1677b"
unitRef="usd">400000</us-gaap:InterestExpenseDebtExcludingAmortization>
<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
contextRef="i397678ceafef497b86b6e43ad8ea3a3b_I20200430"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfODQ2Mg_96390558-61f6-40b0-a773-6c503862d216"
unitRef="chf">500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
contextRef="i397678ceafef497b86b6e43ad8ea3a3b_I20200430"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfODQ3OQ_1adc85cb-7b72-45a7-8d80-cbe5763e790f"
unitRef="usd">500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
<us-gaap:ProceedsFromLinesOfCredit
contextRef="ic26de67cef4149c0ad6d575b9330bbf0_D20200501-20200531"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfODY2MA_1c4e50fe-635a-44ce-9319-a0ba2e4125b1"
unitRef="chf">500000</us-gaap:ProceedsFromLinesOfCredit>
<us-gaap:ProceedsFromLinesOfCredit
contextRef="ic26de67cef4149c0ad6d575b9330bbf0_D20200501-20200531"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfODY3Nw_9ad471d7-5bdb-4663-b10b-3d1e719eba77"
unitRef="usd">500000</us-gaap:ProceedsFromLinesOfCredit>
<lung:NumberOfInstallmentsForRepayment
contextRef="i397678ceafef497b86b6e43ad8ea3a3b_I20200430"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMzI5ODUzNDkwNDA3NA_9e619da1-52eb-4522-b611-c833decf8ead"
unitRef="installment">12</lung:NumberOfInstallmentsForRepayment>
<us-gaap:RepaymentsOfDebt
contextRef="i70d3599672cd4f2badc8f100594638fe_D20220101-20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMTA5OTUxMTY0NTQzMA_d3a7083f-8fb9-4fa0-a0d8-f04408717e93"
unitRef="usd">100000</us-gaap:RepaymentsOfDebt>
<us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RleHRyZWdpb246OWRhNzRmMjc0ZTJjNGYyYmJjNzBkNDk4MmZmNWFjMjJfMTIxOTE_2ec8bfcc-7fdc-4bd4-93f4-00c6fbda7b22"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the aggregate future payments under the CIBC Loan and Credit Agreement (including interest payments) are as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining six months)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,779 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,843 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,716 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,236)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Term loan and credit agreement</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,381 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmVlZDM1ZWU2MjVjMzRlMjg5OWViZTJmNzdkMjhmM2QwL3RhYmxlcmFuZ2U6ZWVkMzVlZTYyNWMzNGUyODk5ZWJlMmY3N2QyOGYzZDBfMC0xLTEtMS0zOTM4Mw_b3da4ce5-fcb5-404c-8fb2-8d8caf01e2e8"
unitRef="usd">410000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmVlZDM1ZWU2MjVjMzRlMjg5OWViZTJmNzdkMjhmM2QwL3RhYmxlcmFuZ2U6ZWVkMzVlZTYyNWMzNGUyODk5ZWJlMmY3N2QyOGYzZDBfMS0xLTEtMS0zOTM4Mw_0ea676d5-bf52-4e37-81e4-0e64d975c318"
unitRef="usd">7779000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmVlZDM1ZWU2MjVjMzRlMjg5OWViZTJmNzdkMjhmM2QwL3RhYmxlcmFuZ2U6ZWVkMzVlZTYyNWMzNGUyODk5ZWJlMmY3N2QyOGYzZDBfMi0xLTEtMS0zOTM4Mw_747d295f-a2ed-400d-934b-593453b6b26e"
unitRef="usd">8843000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmVlZDM1ZWU2MjVjMzRlMjg5OWViZTJmNzdkMjhmM2QwL3RhYmxlcmFuZ2U6ZWVkMzVlZTYyNWMzNGUyODk5ZWJlMmY3N2QyOGYzZDBfMy0xLTEtMS0zOTM4Mw_aabb5437-c30e-4b1e-9caf-684ce7c4bc70"
unitRef="usd">1510000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmVlZDM1ZWU2MjVjMzRlMjg5OWViZTJmNzdkMjhmM2QwL3RhYmxlcmFuZ2U6ZWVkMzVlZTYyNWMzNGUyODk5ZWJlMmY3N2QyOGYzZDBfNC0xLTEtMS0zOTM4Mw_f8a4339a-fae7-4741-8cca-147c0fa062b9"
unitRef="usd">87000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmVlZDM1ZWU2MjVjMzRlMjg5OWViZTJmNzdkMjhmM2QwL3RhYmxlcmFuZ2U6ZWVkMzVlZTYyNWMzNGUyODk5ZWJlMmY3N2QyOGYzZDBfNS0xLTEtMS00MDYxMw_aed36d98-4659-460c-8684-964b55c625c1"
unitRef="usd">87000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
<us-gaap:DebtInstrumentCarryingAmount
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmVlZDM1ZWU2MjVjMzRlMjg5OWViZTJmNzdkMjhmM2QwL3RhYmxlcmFuZ2U6ZWVkMzVlZTYyNWMzNGUyODk5ZWJlMmY3N2QyOGYzZDBfNS0xLTEtMS0zOTM4Mw_97e998d7-d11c-4614-b0f0-0516b7b3b352"
unitRef="usd">18716000</us-gaap:DebtInstrumentCarryingAmount>
<us-gaap:DebtInstrumentUnamortizedDiscount
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmVlZDM1ZWU2MjVjMzRlMjg5OWViZTJmNzdkMjhmM2QwL3RhYmxlcmFuZ2U6ZWVkMzVlZTYyNWMzNGUyODk5ZWJlMmY3N2QyOGYzZDBfNi0xLTEtMS0zOTM4Mw_bed1adfa-e909-42bc-bcc9-933f5762f532"
unitRef="usd">99000</us-gaap:DebtInstrumentUnamortizedDiscount>
<us-gaap:InterestPayableCurrentAndNoncurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmVlZDM1ZWU2MjVjMzRlMjg5OWViZTJmNzdkMjhmM2QwL3RhYmxlcmFuZ2U6ZWVkMzVlZTYyNWMzNGUyODk5ZWJlMmY3N2QyOGYzZDBfNy0xLTEtMS0zOTM4Mw_6980e638-f050-41ce-bbbc-acfc6a84524a"
unitRef="usd">1236000</us-gaap:InterestPayableCurrentAndNoncurrent>
<us-gaap:LongTermDebt
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181Mi9mcmFnOjlkYTc0ZjI3NGUyYzRmMmJiYzcwZDQ5ODJmZjVhYzIyL3RhYmxlOmVlZDM1ZWU2MjVjMzRlMjg5OWViZTJmNzdkMjhmM2QwL3RhYmxlcmFuZ2U6ZWVkMzVlZTYyNWMzNGUyODk5ZWJlMmY3N2QyOGYzZDBfOC0xLTEtMS0zOTM4Mw_764625c4-df38-445d-8825-eb37ac3a536f"
unitRef="usd">17381000</us-gaap:LongTermDebt>
<us-gaap:RevenueFromContractWithCustomerTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181NS9mcmFnOmE1OWM0YmRiMmU3MDQ4YjE5Zjk4NDA3MjExNjZhYmZkL3RleHRyZWdpb246YTU5YzRiZGIyZTcwNDhiMTlmOTg0MDcyMTE2NmFiZmRfNTc4_e50111ac-b037-451a-920d-2ca74af08e52">Revenue RecognitionThe Company’s contract liabilities consist of deferred revenue for remaining performance obligations by the Company to the customer after delivery, which was $0.1 million and $0.2 million as of June 30, 2022 and <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021, respectively. The deferred revenue as of December 31, 2020 was $0.1 million, which was recognized as revenue during the year ended December 31, 2021. The deferred revenue as of December 31, 2021 was $0.2 million, which was recognized as revenue during the six months ended June 30, 2022.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates its revenue by major geographic region, which has been disclosed in Note 12, “Segment Information”.</span></div></us-gaap:RevenueFromContractWithCustomerTextBlock>
<us-gaap:ContractWithCustomerLiability
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181NS9mcmFnOmE1OWM0YmRiMmU3MDQ4YjE5Zjk4NDA3MjExNjZhYmZkL3RleHRyZWdpb246YTU5YzRiZGIyZTcwNDhiMTlmOTg0MDcyMTE2NmFiZmRfMTA5OTUxMTYyODM1Nw_e3d76ded-419c-44eb-b077-d0fa4adaa5a0"
unitRef="usd">100000</us-gaap:ContractWithCustomerLiability>
<us-gaap:ContractWithCustomerLiability
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181NS9mcmFnOmE1OWM0YmRiMmU3MDQ4YjE5Zjk4NDA3MjExNjZhYmZkL3RleHRyZWdpb246YTU5YzRiZGIyZTcwNDhiMTlmOTg0MDcyMTE2NmFiZmRfMTA5OTUxMTYyODM2Nw_5deb6401-8641-44aa-843f-2559ea79a659"
unitRef="usd">200000</us-gaap:ContractWithCustomerLiability>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized
contextRef="iaa8e0cdfe47448be927a5cd420c16bf9_D20200101-20201231"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181NS9mcmFnOmE1OWM0YmRiMmU3MDQ4YjE5Zjk4NDA3MjExNjZhYmZkL3RleHRyZWdpb246YTU5YzRiZGIyZTcwNDhiMTlmOTg0MDcyMTE2NmFiZmRfMTA5OTUxMTYyODQyNw_4554c0b5-ae1b-4a56-9702-9022f08b94fa"
unitRef="usd">100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181NS9mcmFnOmE1OWM0YmRiMmU3MDQ4YjE5Zjk4NDA3MjExNjZhYmZkL3RleHRyZWdpb246YTU5YzRiZGIyZTcwNDhiMTlmOTg0MDcyMTE2NmFiZmRfNjU5NzA2OTc2NzM0NQ_f2f1eda6-3195-4729-8ee3-eee55a622db4"
unitRef="usd">200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfNDQxOQ_4a65bd1d-f0c2-4c89-a45e-c94e1470d3bd">Commitments and Contingencies<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a lease for its headquarters location in Redwood City, California. In October 2019, the Company renewed its lease for the headquarters location in Redwood City, California for an additional five years commencing in August 2020 and expiring in July 2025. The monthly base rent during the renewed term is $0.1 million and is subject to an annual increase of 3.5%. The Company is responsible for its share of real estate taxes, common area maintenance and management fees. The Company is eligible to receive a tenant improvement allowance of $0.2 million on commencement of the renewal term in August 2020.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2013, the Company entered into a five-year lease for office facilities in Switzerland. The Company had an option to extend the lease through January 2022, which was not exercised by the Company. Per the lease terms, in the event the option to extend is not exercised, the lease remains in force and can be terminated with 12-months’ notice.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company executed a sublease for another office facility in Redwood City, California for a three-year term commencing on June 1, 2020. The lease agreement provides for early termination if the Company or Sublandlord elects to terminate the lease by providing the other party at least 180 days prior written notice. The early termination may only occur on or after the expiration of the 18th full calendar month of the sublease term. The monthly base rent during the term is less than $0.1 million and is subject to an annual increase of 3.5%. The Company is responsible for its share of real estate taxes, common area maintenance and management fees.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company amended a sublease agreement entered into in April 2020, to include additional facility space in Redwood City, California for a four-year term. The amendment was accounted as a separate sublease agreement. The sublease agreement contained a rent-free period through February 14, 2021, after which rent is approximately $0.1 million per month and is subject to an annual increase of 3.5%. The Company is responsible for its share of real estate taxes, common area maintenance and management fees. The Company is eligible to receive a tenant improvement allowance of $0.7 million to fund facility enhancements. The sublease agreement can be extended for an additional twelve-month period, at the Company’s option. For accounting purposes, the lease term is 4 years as it is not reasonably certain that the Company will exercise the renewal option. The amendment also changed the lease term entered into in April 2020, which was extended until May 31, 2024, but left the early termination clause unchanged. In September 2021, the Company became reasonably certain that the early termination clause would not be exercised as capital expenditures on the facility build-out created sufficient disincentive to terminate the lease early. The lease term was reevaluated and extended from November 30, 2021 to May 31, 2024.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has leases on eight vehicles with an average term of 2.9 years.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost consists of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:67.118%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.471%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,446 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,752 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,751 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes a maturity analysis of the Company’s lease liabilities showing the aggregate lease payments as of June 30, 2022 (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining six months)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,452 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,919 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,112 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,476 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,061 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,415 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes additional information related to the Company’s operating leases (in thousands, except weighted average data):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.164%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,987 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,075 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.43</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate (percent)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes other supplemental information related to the Company’s operating leases (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.164%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:4.5pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities included in cash flows used in operating activities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,330 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Agreement</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the Company entered into an agreement with a service provider which requires total minimum purchases of $0.6 million, $0.4 million, and $0.4 million over the next three years. Since the inception of the </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreement, the Company recorded $0.2 million of expense for services related to this agreement in cost of goods sold during the three months ended June 30, 2022.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div>From time to time, the Company may be a party to various litigation claims in the normal course of business. Legal fees and other costs associated with such actions are expensed as incurred. The Company assesses, in conjunction with legal counsel, the need to record a liability for litigation and contingencies. Accrual estimates are recorded when and if it is determinable that such a liability for litigation and contingencies are both probable and reasonably estimable.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:LesseeOperatingLeaseRenewalTerm
contextRef="i366bdd6cbcb6417f82564f08de535cb9_I20200831"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMjU4_96c08da0-c102-4e24-9b73-716e2c780a26">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
<lung:OperatingLeaseMonthlyExpense
contextRef="i3a0e06bbd8104d1395b00aeca775a8d3_D20200801-20200831"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMzYz_9e0a7418-18f4-460b-b0fe-0c97246cc89a"
unitRef="usd">100000</lung:OperatingLeaseMonthlyExpense>
<lung:OperatingLeaseExpenseAnnualIncreaseRate
contextRef="i3a0e06bbd8104d1395b00aeca775a8d3_D20200801-20200831"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfNDA2_95451cfe-a212-4608-ba30-768b19b0b5e8"
unitRef="number">0.035</lung:OperatingLeaseExpenseAnnualIncreaseRate>
<lung:TenantImprovementAllowanceReceivableUponLeaseRenewal
contextRef="i366bdd6cbcb6417f82564f08de535cb9_I20200831"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfNTg3_48937c0c-6a2c-4ac6-839d-b96015d1d85f"
unitRef="usd">200000</lung:TenantImprovementAllowanceReceivableUponLeaseRenewal>
<us-gaap:LesseeOperatingLeaseTermOfContract
contextRef="i857cff753eff4ea1888bf30b01ede179_I20131231"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfNDQyMA_42ee71fd-7762-4d00-8837-34f67a3cef37">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
<lung:LesseeOperatingLeaseOptionToTerminateNoticePeriod
contextRef="ifd03a7896aaf49d6b9c4280b7685c129_D20130101-20131231"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfOTY5_b977858e-fc6b-4dee-8fd0-abb83377a79c">P12M</lung:LesseeOperatingLeaseOptionToTerminateNoticePeriod>
<lung:LesseeOperatingSubleaseTerm
contextRef="icd1f11aa0462419c94ba74321f470d3a_D20200401-20200430"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfNDQyMQ_72819b9f-7b5e-4f61-96f0-231552c592e6">P3Y</lung:LesseeOperatingSubleaseTerm>
<lung:LesseeOperatingSubleaseOptionToTerminateNoticePeriod
contextRef="icd1f11aa0462419c94ba74321f470d3a_D20200401-20200430"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMTI4Nw_bdd2b4dd-2e29-47fc-85e2-e5994ce48645">P180D</lung:LesseeOperatingSubleaseOptionToTerminateNoticePeriod>
<lung:LesseeOperatingSubleaseOptionToTerminateTerm
contextRef="icd1f11aa0462419c94ba74321f470d3a_D20200401-20200430"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMTM4OA_2d805eb6-72b3-4b19-8072-af1c4114b709">P18M</lung:LesseeOperatingSubleaseOptionToTerminateTerm>
<lung:LesseeOperatingSubleaseMonthlyExpense
contextRef="icd1f11aa0462419c94ba74321f470d3a_D20200401-20200430"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMTY0Mg_8621964c-34c1-4129-b744-684f44857488"
unitRef="usd">100000</lung:LesseeOperatingSubleaseMonthlyExpense>
<lung:LesseeOperatingSubleaseExpenseAnnualIncreaseRate
contextRef="icd1f11aa0462419c94ba74321f470d3a_D20200401-20200430"
decimals="3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMTY4NQ_53a9d758-741b-4455-96eb-37a8e853e1fe"
unitRef="number">0.035</lung:LesseeOperatingSubleaseExpenseAnnualIncreaseRate>
<lung:LesseeOperatingSubleaseTerm
contextRef="idc991623af8d40e28c3edf61bacb8247_D20200901-20200930"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfNDQyMg_4c361851-7123-4d62-bc5d-2d33a1e02c42">P4Y</lung:LesseeOperatingSubleaseTerm>
<lung:LesseeOperatingSubleaseMonthlyExpense
contextRef="idc991623af8d40e28c3edf61bacb8247_D20200901-20200930"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMjE0MA_6800015b-12d8-4611-ace0-ba3e87b973bd"
unitRef="usd">100000</lung:LesseeOperatingSubleaseMonthlyExpense>
<lung:LesseeOperatingSubleaseExpenseAnnualIncreaseRate
contextRef="idc991623af8d40e28c3edf61bacb8247_D20200901-20200930"
decimals="3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMjE5Mw_d0e3d2bc-1bd1-4c14-8b22-d79a7275bfef"
unitRef="number">0.035</lung:LesseeOperatingSubleaseExpenseAnnualIncreaseRate>
<lung:LesseeOperatingSubleaseTenantImprovementAllowanceReceivableUponLeaseRenewal
contextRef="i0aef2c60dfff4d2db3ecc2c60e4ab869_I20200930"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMjM3NA_20888a38-1ca9-4220-8364-ced02fa1de09"
unitRef="usd">700000</lung:LesseeOperatingSubleaseTenantImprovementAllowanceReceivableUponLeaseRenewal>
<lung:LesseeOperatingSubleaseRenewalTerm
contextRef="idc991623af8d40e28c3edf61bacb8247_D20200901-20200930"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMTY0OTI2NzQ0NzI0NA_a187da34-c5cb-478d-991c-e2e260566230">P12M</lung:LesseeOperatingSubleaseRenewalTerm>
<lung:LesseeOperatingSubleaseTerm
contextRef="idc991623af8d40e28c3edf61bacb8247_D20200901-20200930"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMjU1MA_215582e2-1200-4968-8976-71b8e55a198a">P4Y</lung:LesseeOperatingSubleaseTerm>
<lung:NumberOfVehicleLeases
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMjg0Mw_4b846a5a-88fd-4cc5-b17c-6297e4c1bf68"
unitRef="lease">8</lung:NumberOfVehicleLeases>
<us-gaap:LesseeOperatingLeaseTermOfContract
contextRef="ied7db64668494d679f77a1d8d708db3b_I20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMTA5OTUxMTYzMzMzMA_6c2f0bd9-a06a-45e4-9bf4-2de591501513">P2Y10M24D</us-gaap:LesseeOperatingLeaseTermOfContract>
<us-gaap:LeaseCostTableTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfNDQyMw_f8e526d0-9abd-496d-a3de-05bbc7102b99"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost consists of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:67.118%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.471%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,446 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,752 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,751 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes additional information related to the Company’s operating leases (in thousands, except weighted average data):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.164%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,987 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,075 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.43</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate (percent)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes other supplemental information related to the Company’s operating leases (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.164%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;padding-right:4.5pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities included in cash flows used in operating activities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,330 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:LeaseCostTableTextBlock>
<us-gaap:OperatingLeaseCost
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjNkNTZhOTlkZjllNzQ0ZGQ5Mzk0NDNhMmIwMWVlMWI5L3RhYmxlcmFuZ2U6M2Q1NmE5OWRmOWU3NDRkZDkzOTQ0M2EyYjAxZWUxYjlfMi0xLTEtMS0zOTM4Mw_771d12e8-cfa1-4c35-8908-8bd475abfc15"
unitRef="usd">1446000</us-gaap:OperatingLeaseCost>
<us-gaap:OperatingLeaseCost
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjNkNTZhOTlkZjllNzQ0ZGQ5Mzk0NDNhMmIwMWVlMWI5L3RhYmxlcmFuZ2U6M2Q1NmE5OWRmOWU3NDRkZDkzOTQ0M2EyYjAxZWUxYjlfMi0zLTEtMS0zOTM4Mw_c65924ab-8637-4f49-8bcd-13832c4b47e8"
unitRef="usd">1452000</us-gaap:OperatingLeaseCost>
<us-gaap:ShortTermLeaseCost
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjNkNTZhOTlkZjllNzQ0ZGQ5Mzk0NDNhMmIwMWVlMWI5L3RhYmxlcmFuZ2U6M2Q1NmE5OWRmOWU3NDRkZDkzOTQ0M2EyYjAxZWUxYjlfMy0xLTEtMS0zOTM4Mw_7f27a344-cf42-49ed-a268-94691d8a8de3"
unitRef="usd">16000</us-gaap:ShortTermLeaseCost>
<us-gaap:ShortTermLeaseCost
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjNkNTZhOTlkZjllNzQ0ZGQ5Mzk0NDNhMmIwMWVlMWI5L3RhYmxlcmFuZ2U6M2Q1NmE5OWRmOWU3NDRkZDkzOTQ0M2EyYjAxZWUxYjlfMy0zLTEtMS0zOTM4Mw_b4f239de-d107-446e-97de-96224c359ce8"
unitRef="usd">6000</us-gaap:ShortTermLeaseCost>
<us-gaap:VariableLeaseCost
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjNkNTZhOTlkZjllNzQ0ZGQ5Mzk0NDNhMmIwMWVlMWI5L3RhYmxlcmFuZ2U6M2Q1NmE5OWRmOWU3NDRkZDkzOTQ0M2EyYjAxZWUxYjlfNC0xLTEtMS0zOTM4Mw_905ab33d-9e15-4f40-aa8d-300df80ed42f"
unitRef="usd">290000</us-gaap:VariableLeaseCost>
<us-gaap:VariableLeaseCost
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjNkNTZhOTlkZjllNzQ0ZGQ5Mzk0NDNhMmIwMWVlMWI5L3RhYmxlcmFuZ2U6M2Q1NmE5OWRmOWU3NDRkZDkzOTQ0M2EyYjAxZWUxYjlfNC0zLTEtMS0zOTM4Mw_3caef42f-468b-4a2d-85c0-acee5c172ad2"
unitRef="usd">293000</us-gaap:VariableLeaseCost>
<us-gaap:LeaseCost
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjNkNTZhOTlkZjllNzQ0ZGQ5Mzk0NDNhMmIwMWVlMWI5L3RhYmxlcmFuZ2U6M2Q1NmE5OWRmOWU3NDRkZDkzOTQ0M2EyYjAxZWUxYjlfNS0xLTEtMS0zOTM4Mw_ce8997f6-c896-4861-8c18-3d67318e9aa8"
unitRef="usd">1752000</us-gaap:LeaseCost>
<us-gaap:LeaseCost
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjNkNTZhOTlkZjllNzQ0ZGQ5Mzk0NDNhMmIwMWVlMWI5L3RhYmxlcmFuZ2U6M2Q1NmE5OWRmOWU3NDRkZDkzOTQ0M2EyYjAxZWUxYjlfNS0zLTEtMS0zOTM4Mw_a84b07f5-31d9-475b-8ff5-c29e335faa78"
unitRef="usd">1751000</us-gaap:LeaseCost>
<us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfNDQyNA_9cd27035-ef3a-47a2-9793-ae517b63ac5f"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes a maturity analysis of the Company’s lease liabilities showing the aggregate lease payments as of June 30, 2022 (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining six months)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,452 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,919 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,112 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,476 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,061 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,415 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjgzMmFlYzFhMTRlNTRhYThiYjkwYjZiNTZjZDYwYzYyL3RhYmxlcmFuZ2U6ODMyYWVjMWExNGU1NGFhOGJiOTBiNmI1NmNkNjBjNjJfMS0xLTEtMS0zOTM4Mw_12d87d5c-4f72-4c6a-aa1c-3854a90ac6bc"
unitRef="usd">1721000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjgzMmFlYzFhMTRlNTRhYThiYjkwYjZiNTZjZDYwYzYyL3RhYmxlcmFuZ2U6ODMyYWVjMWExNGU1NGFhOGJiOTBiNmI1NmNkNjBjNjJfMi0xLTEtMS0zOTM4Mw_2fcc7c11-b19f-494e-afbc-23f38a961982"
unitRef="usd">3452000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjgzMmFlYzFhMTRlNTRhYThiYjkwYjZiNTZjZDYwYzYyL3RhYmxlcmFuZ2U6ODMyYWVjMWExNGU1NGFhOGJiOTBiNmI1NmNkNjBjNjJfMy0xLTEtMS0zOTM4Mw_19848c59-1c53-48e1-9463-7312df05a26b"
unitRef="usd">2919000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjgzMmFlYzFhMTRlNTRhYThiYjkwYjZiNTZjZDYwYzYyL3RhYmxlcmFuZ2U6ODMyYWVjMWExNGU1NGFhOGJiOTBiNmI1NmNkNjBjNjJfNC0xLTEtMS0zOTM4Mw_ff172713-22ff-4fc0-af71-e5de87ca1407"
unitRef="usd">1020000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjgzMmFlYzFhMTRlNTRhYThiYjkwYjZiNTZjZDYwYzYyL3RhYmxlcmFuZ2U6ODMyYWVjMWExNGU1NGFhOGJiOTBiNmI1NmNkNjBjNjJfNS0xLTEtMS0zOTM4Mw_9f21d26b-8131-46f2-bec9-d3aa309892fe"
unitRef="usd">9112000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
<us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjgzMmFlYzFhMTRlNTRhYThiYjkwYjZiNTZjZDYwYzYyL3RhYmxlcmFuZ2U6ODMyYWVjMWExNGU1NGFhOGJiOTBiNmI1NmNkNjBjNjJfNi0xLTEtMS0zOTM4Mw_6e7673ce-ecf1-4b70-858e-34ccc3a17cf5"
unitRef="usd">636000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
<us-gaap:OperatingLeaseLiability
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjgzMmFlYzFhMTRlNTRhYThiYjkwYjZiNTZjZDYwYzYyL3RhYmxlcmFuZ2U6ODMyYWVjMWExNGU1NGFhOGJiOTBiNmI1NmNkNjBjNjJfNy0xLTEtMS0zOTM4Mw_320a8152-bf92-4334-beb7-e71d10eeceeb"
unitRef="usd">8476000</us-gaap:OperatingLeaseLiability>
<us-gaap:OperatingLeaseLiabilityCurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjgzMmFlYzFhMTRlNTRhYThiYjkwYjZiNTZjZDYwYzYyL3RhYmxlcmFuZ2U6ODMyYWVjMWExNGU1NGFhOGJiOTBiNmI1NmNkNjBjNjJfOC0xLTEtMS0zOTM4Mw_01982077-c42f-46c7-87f4-c07fc23b42fe"
unitRef="usd">3061000</us-gaap:OperatingLeaseLiabilityCurrent>
<us-gaap:OperatingLeaseLiabilityNoncurrent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjgzMmFlYzFhMTRlNTRhYThiYjkwYjZiNTZjZDYwYzYyL3RhYmxlcmFuZ2U6ODMyYWVjMWExNGU1NGFhOGJiOTBiNmI1NmNkNjBjNjJfOS0xLTEtMS0zOTM4Mw_3f4b6409-5c94-4436-aa8b-288cd50d7353"
unitRef="usd">5415000</us-gaap:OperatingLeaseLiabilityNoncurrent>
<us-gaap:OperatingLeaseRightOfUseAsset
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjc3MmQ3ZTAwYjJiZDRhYWFhOThiMjEzMWI1YWU2ZWMyL3RhYmxlcmFuZ2U6NzcyZDdlMDBiMmJkNGFhYWE5OGIyMTMxYjVhZTZlYzJfMS0xLTEtMS0zOTM4Mw_f43a5da1-3922-4a03-8e6d-6fa9b1feb99d"
unitRef="usd">6987000</us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OperatingLeaseRightOfUseAsset
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjc3MmQ3ZTAwYjJiZDRhYWFhOThiMjEzMWI1YWU2ZWMyL3RhYmxlcmFuZ2U6NzcyZDdlMDBiMmJkNGFhYWE5OGIyMTMxYjVhZTZlYzJfMS0zLTEtMS0zOTM4Mw_030e0b13-4b34-4a7a-b16b-2e786ecdb739"
unitRef="usd">8075000</us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjc3MmQ3ZTAwYjJiZDRhYWFhOThiMjEzMWI1YWU2ZWMyL3RhYmxlcmFuZ2U6NzcyZDdlMDBiMmJkNGFhYWE5OGIyMTMxYjVhZTZlYzJfMi0xLTEtMS0zOTM4Mw_ccc091d4-f40d-4281-ae9b-48815ff2ce1b">P2Y5M4D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
<us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjc3MmQ3ZTAwYjJiZDRhYWFhOThiMjEzMWI1YWU2ZWMyL3RhYmxlcmFuZ2U6NzcyZDdlMDBiMmJkNGFhYWE5OGIyMTMxYjVhZTZlYzJfMi0zLTEtMS0zOTM4Mw_4bf3a545-5162-48f6-8e57-e43a72b6bad7">P3Y2M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
<us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjc3MmQ3ZTAwYjJiZDRhYWFhOThiMjEzMWI1YWU2ZWMyL3RhYmxlcmFuZ2U6NzcyZDdlMDBiMmJkNGFhYWE5OGIyMTMxYjVhZTZlYzJfMy0xLTEtMS0zOTM4Mw_2f58988a-4549-4703-a082-d522668d1d00"
unitRef="number">0.059</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
<us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjc3MmQ3ZTAwYjJiZDRhYWFhOThiMjEzMWI1YWU2ZWMyL3RhYmxlcmFuZ2U6NzcyZDdlMDBiMmJkNGFhYWE5OGIyMTMxYjVhZTZlYzJfMy0zLTEtMS0zOTM4Mw_5ff70610-0c91-4796-9804-ed2ea6e47b2b"
unitRef="number">0.060</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
<us-gaap:OperatingLeasePayments
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjBjNWZkZGE4ZjgzYzQ3NzA5NmNiMTE0NGVjY2FiNzBlL3RhYmxlcmFuZ2U6MGM1ZmRkYThmODNjNDc3MDk2Y2IxMTQ0ZWNjYWI3MGVfMi0xLTEtMS0zOTM4Mw_e7d87371-07fb-4486-9b95-77f81aae1829"
unitRef="usd">966000</us-gaap:OperatingLeasePayments>
<us-gaap:OperatingLeasePayments
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjBjNWZkZGE4ZjgzYzQ3NzA5NmNiMTE0NGVjY2FiNzBlL3RhYmxlcmFuZ2U6MGM1ZmRkYThmODNjNDc3MDk2Y2IxMTQ0ZWNjYWI3MGVfMi0zLTEtMS0zOTM4Mw_8bdbee30-f448-4679-9369-2d3e55613c4b"
unitRef="usd">1330000</us-gaap:OperatingLeasePayments>
<us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjBjNWZkZGE4ZjgzYzQ3NzA5NmNiMTE0NGVjY2FiNzBlL3RhYmxlcmFuZ2U6MGM1ZmRkYThmODNjNDc3MDk2Y2IxMTQ0ZWNjYWI3MGVfMy0xLTEtMS0zOTM4Mw_2aa5ee39-0daa-4e49-8758-b9fdeb41b7e2"
unitRef="usd">138000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
<us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RhYmxlOjBjNWZkZGE4ZjgzYzQ3NzA5NmNiMTE0NGVjY2FiNzBlL3RhYmxlcmFuZ2U6MGM1ZmRkYThmODNjNDc3MDk2Y2IxMTQ0ZWNjYWI3MGVfMy0zLTEtMS0zOTM4Mw_23d60f14-562a-4370-9276-801ef8e2890f"
unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
<us-gaap:PurchaseObligationDueInNextTwelveMonths
contextRef="ibc840713d1034829bc01ad7b74a40d23_I20220430"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMTY0OTI2NzQ0ODYwMA_c599d25c-e118-4ec6-8df5-f9eb07859df3"
unitRef="usd">600000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
<us-gaap:PurchaseObligationDueInSecondYear
contextRef="ibc840713d1034829bc01ad7b74a40d23_I20220430"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMTY0OTI2NzQ0ODYxNA_020dff5a-a191-4c67-aed0-e7021ac91569"
unitRef="usd">400000</us-gaap:PurchaseObligationDueInSecondYear>
<us-gaap:PurchaseObligationDueInThirdYear
contextRef="ibc840713d1034829bc01ad7b74a40d23_I20220430"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMTY0OTI2NzQ0ODYyOA_b21bc3a9-3e22-43aa-b2bd-be36cacca32d"
unitRef="usd">400000</us-gaap:PurchaseObligationDueInThirdYear>
<us-gaap:CostOfGoodsAndServicesSold
contextRef="i25ca1d294bfa44ee92ff709c2ea930e0_D20220501-20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N181OC9mcmFnOjYxZGQ2MjI4YzQ3MDRkZWNhMzc5MmUyNWNiODkxYzRiL3RleHRyZWdpb246NjFkZDYyMjhjNDcwNGRlY2EzNzkyZTI1Y2I4OTFjNGJfMTY0OTI2NzQ0ODY0Mg_1c3eb175-0bc0-4576-826f-69444e874205"
unitRef="usd">200000</us-gaap:CostOfGoodsAndServicesSold>
<us-gaap:IncomeTaxDisclosureTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N182MS9mcmFnOmQwMWY1ZGM3YmU4MjQ4NTM4ZjYzODU5ZGQ4YjAyN2Q2L3RleHRyZWdpb246ZDAxZjVkYzdiZTgyNDg1MzhmNjM4NTlkZDhiMDI3ZDZfMTAyMA_5babaeff-2f4d-4f18-b941-6553733ee43e">Income TaxesThe income tax expense for the three months ended June 30, 2022 and 2021 was less than $0.1 million and $0.1 million, respectively. The income tax expense for the six months ended June 30, 2022 and 2021 was $0.1 million and $0.1 million, respectively. The income tax expense was determined based upon estimates of the Company’s effective income tax rates in various jurisdictions. The difference between the Company’s effective income tax rate and the U.S. federal statutory rate is primarily attributable to state income taxes, foreign income taxes, and a full valuation allowance against net deferred tax assets. The income tax expense for the six months ended June 30, 2022 and 2021 relates primarily to state minimum income tax and income tax on the Company’s earnings in foreign jurisdictions.</us-gaap:IncomeTaxDisclosureTextBlock>
<us-gaap:IncomeTaxExpenseBenefit
contextRef="i2ae7a2862d6f4d7a954dd9a21f9f83d8_D20220401-20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N182MS9mcmFnOmQwMWY1ZGM3YmU4MjQ4NTM4ZjYzODU5ZGQ4YjAyN2Q2L3RleHRyZWdpb246ZDAxZjVkYzdiZTgyNDg1MzhmNjM4NTlkZDhiMDI3ZDZfMTA5OTUxMTYzMDI2Mg_4d91c627-f570-4399-a3e7-112cc1e7e585"
unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N182MS9mcmFnOmQwMWY1ZGM3YmU4MjQ4NTM4ZjYzODU5ZGQ4YjAyN2Q2L3RleHRyZWdpb246ZDAxZjVkYzdiZTgyNDg1MzhmNjM4NTlkZDhiMDI3ZDZfMTA5OTUxMTYzMDQ3Nw_4b89a76c-28d8-4483-afed-f737a5a6538f"
unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N182MS9mcmFnOmQwMWY1ZGM3YmU4MjQ4NTM4ZjYzODU5ZGQ4YjAyN2Q2L3RleHRyZWdpb246ZDAxZjVkYzdiZTgyNDg1MzhmNjM4NTlkZDhiMDI3ZDZfMTA5OTUxMTYzMDYxMg_4622579d-1a84-4748-9883-050e4147094e"
unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N182MS9mcmFnOmQwMWY1ZGM3YmU4MjQ4NTM4ZjYzODU5ZGQ4YjAyN2Q2L3RleHRyZWdpb246ZDAxZjVkYzdiZTgyNDg1MzhmNjM4NTlkZDhiMDI3ZDZfMTA5OTUxMTYzMDYyMA_b8219d44-1414-4292-a220-e09cc77dd78e"
unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMzE5Nw_55637243-d81d-40c5-b25b-1297063f724b">Stockholders’ Equity<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, the Company’s certificate of incorporation authorized the Company to issue up to 200,000,000 and 200,000,000 shares of common stock, respectively. Common stockholders are entitled to dividends as and when declared by the Board of Directors, subject to the rights of holders of all classes of stock outstanding having priority rights as to dividends. There have been no dividends declared to date. The holder of each share of common stock is entitled to one vote.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shares Reserved for Future Issuance </span></div><div style="margin-bottom:12pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reserved shares of common stock for future issuances as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options issued and outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600,237 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145,131 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock restricted stock units issued and outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock available for future grants</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,838,605 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,751,115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock available for ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255,773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932,458 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,786,572 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,271,132 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Plan</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the six months ended June 30, 2022 is set forth below:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding Options</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145,131 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.44 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172,886)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600,237 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.43 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding as of June 30, 2022 was $15.0 million.</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:56.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Contractual Life (in Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904,464</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.56 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.30</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600,237</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.26</span></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intrinsic value of options vested as of June 30, 2022 was $7.5 million.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Early Exercise of Stock Options</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the individual option grants, options are fully exercisable on the grant date, subject to the Company’s repurchase right at the original exercise price. Accordingly, options may be exercised prior to vesting. The shares are subject to the Company’s lapsing repurchase right upon termination of employment or over the options’ vesting period of generally four years at the original purchase price. The proceeds initially are recorded in other liabilities from the early exercise of stock options and are reclassified to additional paid-in capital as the Company’s repurchase right lapses. During the six months ended June 30, 2022, the Company did not repurchase shares of common stock. During the six months ended June 30, 2021, the Company repurchased 12,945 shares of common stock for less than $0.1 million. As of June 30, 2022 and December 31, 2021, 155,969 and 223,195 shares, respectively, were subject to repurchase, with an aggregate exercise price of $0.3 million and $0.4 million, respectively, and were recorded in other current liabilities.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity with respect to restricted stock units was as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares Underlying Outstanding Restricted Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">442,428 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42.36 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799,320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115,380)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,411)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091,957 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.78 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of restricted stock units outstanding as of June 30, 2022 was $16.1 million.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Stock-Based Compensation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is reflected in the statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">189 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">336 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">210 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">977 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">606 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,638 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,583 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,764 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,383 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,312 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,896 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,580 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above stock-based compensation expense related to the following equity-based awards (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and restricted stock units</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,209 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,520 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,521 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,559 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,383 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,312 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,896 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,580 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation of $0.3 million and $0.3 million was capitalized into inventory for the three months ended June 30, 2022 and 2021, respectively. Stock-based compensation of $0.6 million and $0.5 million was capitalized into inventory for the six months ended June 30, 2022 and 2021, respectively. Stock-based compensation capitalized in prior periods of $0.2 million and $0.1 million was recognized as cost of sales in the three months ended June 30, 2022 and 2021, respectively. Stock-based compensation capitalized in prior periods of $0.3 million and $0.2 million was recognized as cost of sales in the six months ended June 30, 2022 and 2021, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, there was $52.6 million of unrecognized compensation costs related to non-vested common stock options and restricted stock units, expected to be recognized over a weighted-average period of 3.14 years. The total grant date fair value of shares vested during the three and six months ended June 30, 2022 was $4.7 million and $7.4 million, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the Company had unrecognized employee stock-based compensation relating to ESPP awards of approximately $0.1 million, which is expected to be recognized over a weighted-average period of 0.1 years.</span></div></us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:CommonStockSharesAuthorized
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTQx_48fae339-24f4-4ba1-b3bf-06a8905bbca2"
unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTQx_88b658c2-b0be-4f45-a307-4a07dfeab8c8"
unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTA5OTUxMTYzMDk4NA_48fae339-24f4-4ba1-b3bf-06a8905bbca2"
unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTA5OTUxMTYzMDk4NA_88b658c2-b0be-4f45-a307-4a07dfeab8c8"
unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:DividendsCommonStock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMzg3_d960956e-bfe1-4847-be20-bcc879564eff"
unitRef="usd">0</us-gaap:DividendsCommonStock>
<lung:NumberOfVotesForEachShareOfCommonStockHeld
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfNDc0_5925ebe1-da13-452f-94ff-85b45ee6d4dc"
unitRef="vote">1</lung:NumberOfVotesForEachShareOfCommonStockHeld>
<us-gaap:ScheduleOfStockByClassTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMzE5Mw_0d6a8fbe-0900-4d00-b228-fd73a54c60a6"><div style="margin-bottom:12pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reserved shares of common stock for future issuances as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options issued and outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600,237 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145,131 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock restricted stock units issued and outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock available for future grants</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,838,605 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,751,115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock available for ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,255,773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932,458 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,786,572 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,271,132 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></us-gaap:ScheduleOfStockByClassTextBlock>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
contextRef="i784f45acac5747a384b861bd3aabc902_I20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjA3MmQzM2ZlMjMwYTRjZjg4NTczM2NmOGU0NDJkOWFmL3RhYmxlcmFuZ2U6MDcyZDMzZmUyMzBhNGNmODg1NzMzY2Y4ZTQ0MmQ5YWZfMi0xLTEtMS0zOTM4Mw_e3a80942-a4ff-42a6-8b49-4a85ad8caad6"
unitRef="shares">2600237</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
contextRef="ide3a7a3105f148a0abc9848ed7ec1d00_I20211231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjA3MmQzM2ZlMjMwYTRjZjg4NTczM2NmOGU0NDJkOWFmL3RhYmxlcmFuZ2U6MDcyZDMzZmUyMzBhNGNmODg1NzMzY2Y4ZTQ0MmQ5YWZfMi0zLTEtMS0zOTM4Mw_b16358eb-8043-437a-9173-17e7faf7a8bb"
unitRef="shares">2145131</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
contextRef="i22f7f50179034850b9053aba0a68231a_I20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjA3MmQzM2ZlMjMwYTRjZjg4NTczM2NmOGU0NDJkOWFmL3RhYmxlcmFuZ2U6MDcyZDMzZmUyMzBhNGNmODg1NzMzY2Y4ZTQ0MmQ5YWZfMy0xLTEtMS00MDkzOQ_5e1c82ff-fff9-4580-9301-b5b96e1bf096"
unitRef="shares">1091957</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
contextRef="iaba5025a1e5243a2b17b2e5661ec7f35_I20211231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjA3MmQzM2ZlMjMwYTRjZjg4NTczM2NmOGU0NDJkOWFmL3RhYmxlcmFuZ2U6MDcyZDMzZmUyMzBhNGNmODg1NzMzY2Y4ZTQ0MmQ5YWZfMy0zLTEtMS00MDkzOQ_33009022-0cbd-4f53-870a-f15c94b8cf54"
unitRef="shares">442428</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
contextRef="i714b2da3efed4e42a97fe4d4b6b47a99_I20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjA3MmQzM2ZlMjMwYTRjZjg4NTczM2NmOGU0NDJkOWFmL3RhYmxlcmFuZ2U6MDcyZDMzZmUyMzBhNGNmODg1NzMzY2Y4ZTQ0MmQ5YWZfMy0xLTEtMS0zOTM4Mw_48ad0d0d-3d94-4a25-b424-c07db1c8d4f0"
unitRef="shares">3838605</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
contextRef="i2e39fbc0a48a47e2a202f2c8f30f4b79_I20211231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjA3MmQzM2ZlMjMwYTRjZjg4NTczM2NmOGU0NDJkOWFmL3RhYmxlcmFuZ2U6MDcyZDMzZmUyMzBhNGNmODg1NzMzY2Y4ZTQ0MmQ5YWZfMy0zLTEtMS0zOTM4Mw_9557189e-06cf-4318-8d4d-61fa92d940d9"
unitRef="shares">3751115</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
contextRef="i1275d322af1b4c98ba3c7706239395c7_I20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjA3MmQzM2ZlMjMwYTRjZjg4NTczM2NmOGU0NDJkOWFmL3RhYmxlcmFuZ2U6MDcyZDMzZmUyMzBhNGNmODg1NzMzY2Y4ZTQ0MmQ5YWZfNC0xLTEtMS0zOTM4Mw_979f2c10-c86d-4f8a-8c74-ee6cefd24615"
unitRef="shares">1255773</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
contextRef="ifaa47ca5f34841d0a65dd43f53a08359_I20211231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjA3MmQzM2ZlMjMwYTRjZjg4NTczM2NmOGU0NDJkOWFmL3RhYmxlcmFuZ2U6MDcyZDMzZmUyMzBhNGNmODg1NzMzY2Y4ZTQ0MmQ5YWZfNC0zLTEtMS0zOTM4Mw_51f4d8f2-328c-4b40-a3df-9aceab6149b7"
unitRef="shares">932458</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjA3MmQzM2ZlMjMwYTRjZjg4NTczM2NmOGU0NDJkOWFmL3RhYmxlcmFuZ2U6MDcyZDMzZmUyMzBhNGNmODg1NzMzY2Y4ZTQ0MmQ5YWZfNS0xLTEtMS0zOTM4Mw_279051bf-1e72-47a9-8e84-af7d95c6912e"
unitRef="shares">8786572</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjA3MmQzM2ZlMjMwYTRjZjg4NTczM2NmOGU0NDJkOWFmL3RhYmxlcmFuZ2U6MDcyZDMzZmUyMzBhNGNmODg1NzMzY2Y4ZTQ0MmQ5YWZfNS0zLTEtMS0zOTM4Mw_74c8c908-a04c-463c-a566-b2c15ba20ac8"
unitRef="shares">7271132</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMzE5OA_64c2f4f6-d90c-4f1a-99af-5561cfd1a62e"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the six months ended June 30, 2022 is set forth below:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding Options</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145,131 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.44 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172,886)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600,237 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.43 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjUxNTJjMWQyZjIwMjRhNGViMGE3OWU5ZWEzNzc2MDUwL3RhYmxlcmFuZ2U6NTE1MmMxZDJmMjAyNGE0ZWIwYTc5ZTllYTM3NzYwNTBfMi0xLTEtMS0zOTM4Mw_fdb0b08e-eb0f-4930-8d78-ba25dbf1a875"
unitRef="shares">2145131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjUxNTJjMWQyZjIwMjRhNGViMGE3OWU5ZWEzNzc2MDUwL3RhYmxlcmFuZ2U6NTE1MmMxZDJmMjAyNGE0ZWIwYTc5ZTllYTM3NzYwNTBfMi0zLTEtMS0zOTM4Mw_d6c8a3c9-12bc-4803-9203-39bccd589209"
unitRef="usdPerShare">13.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjUxNTJjMWQyZjIwMjRhNGViMGE3OWU5ZWEzNzc2MDUwL3RhYmxlcmFuZ2U6NTE1MmMxZDJmMjAyNGE0ZWIwYTc5ZTllYTM3NzYwNTBfMy0xLTEtMS0zOTM4Mw_73cb5fff-8854-4e51-9bed-141080ea8edd"
unitRef="shares">655200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjUxNTJjMWQyZjIwMjRhNGViMGE3OWU5ZWEzNzc2MDUwL3RhYmxlcmFuZ2U6NTE1MmMxZDJmMjAyNGE0ZWIwYTc5ZTllYTM3NzYwNTBfMy0zLTEtMS0zOTM4Mw_1316485c-e2aa-4af5-9ca5-0b87b12cd482"
unitRef="usdPerShare">26.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjUxNTJjMWQyZjIwMjRhNGViMGE3OWU5ZWEzNzc2MDUwL3RhYmxlcmFuZ2U6NTE1MmMxZDJmMjAyNGE0ZWIwYTc5ZTllYTM3NzYwNTBfNC0xLTEtMS0zOTM4Mw_e11a0ff0-1819-40df-9358-e729729cb479"
unitRef="shares">172886</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjUxNTJjMWQyZjIwMjRhNGViMGE3OWU5ZWEzNzc2MDUwL3RhYmxlcmFuZ2U6NTE1MmMxZDJmMjAyNGE0ZWIwYTc5ZTllYTM3NzYwNTBfNC0zLTEtMS0zOTM4Mw_802e35cd-8e5b-4385-9d6c-496d6995fd47"
unitRef="usdPerShare">2.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjUxNTJjMWQyZjIwMjRhNGViMGE3OWU5ZWEzNzc2MDUwL3RhYmxlcmFuZ2U6NTE1MmMxZDJmMjAyNGE0ZWIwYTc5ZTllYTM3NzYwNTBfNS0xLTEtMS0zOTM4Mw_dd437897-b5ce-4f1d-94d0-21e673014dfc"
unitRef="shares">27208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjUxNTJjMWQyZjIwMjRhNGViMGE3OWU5ZWEzNzc2MDUwL3RhYmxlcmFuZ2U6NTE1MmMxZDJmMjAyNGE0ZWIwYTc5ZTllYTM3NzYwNTBfNS0zLTEtMS0zOTM4Mw_2a5800c3-74ef-4462-9d89-268a1ae34782"
unitRef="usdPerShare">19.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjUxNTJjMWQyZjIwMjRhNGViMGE3OWU5ZWEzNzc2MDUwL3RhYmxlcmFuZ2U6NTE1MmMxZDJmMjAyNGE0ZWIwYTc5ZTllYTM3NzYwNTBfNi0xLTEtMS0zOTM4Mw_ec8a3642-4c67-4aec-8892-707335f68cdc"
unitRef="shares">2600237</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjUxNTJjMWQyZjIwMjRhNGViMGE3OWU5ZWEzNzc2MDUwL3RhYmxlcmFuZ2U6NTE1MmMxZDJmMjAyNGE0ZWIwYTc5ZTllYTM3NzYwNTBfNi0zLTEtMS0zOTM4Mw_632ca1c1-4731-4066-ad77-dbe34531c729"
unitRef="usdPerShare">17.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfODIz_319355d8-866f-4b75-bdfe-8d258587a63b"
unitRef="usd">15000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMzE5OQ_2e445103-093b-4a78-9cd9-261d9a84a0d6"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:56.295%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Contractual Life (in Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904,464</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.56 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.30</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600,237</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.26</span></td></tr></table></us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjQ5YjQ1ODBmYWEzMjQ5MjhhZDc5YTdmM2IyNDJjNDRlL3RhYmxlcmFuZ2U6NDliNDU4MGZhYTMyNDkyOGFkNzlhN2YzYjI0MmM0NGVfMi0xLTEtMS0zOTM4Mw_7c494cb9-6dfa-4a0b-85e8-a38957e739ed"
unitRef="shares">904464</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<lung:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjQ5YjQ1ODBmYWEzMjQ5MjhhZDc5YTdmM2IyNDJjNDRlL3RhYmxlcmFuZ2U6NDliNDU4MGZhYTMyNDkyOGFkNzlhN2YzYjI0MmM0NGVfMi0zLTEtMS0zOTM4Mw_31a43d14-7249-45b0-acc5-9a03c49566e2"
unitRef="usdPerShare">11.56</lung:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice>
<lung:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjQ5YjQ1ODBmYWEzMjQ5MjhhZDc5YTdmM2IyNDJjNDRlL3RhYmxlcmFuZ2U6NDliNDU4MGZhYTMyNDkyOGFkNzlhN2YzYjI0MmM0NGVfMi01LTEtMS0zOTM4Mw_98a87011-ad70-4536-833f-a9dc860c249f">P7Y3M18D</lung:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjQ5YjQ1ODBmYWEzMjQ5MjhhZDc5YTdmM2IyNDJjNDRlL3RhYmxlcmFuZ2U6NDliNDU4MGZhYTMyNDkyOGFkNzlhN2YzYjI0MmM0NGVfMy0xLTEtMS0zOTM4Mw_011aee97-7aee-4856-8652-0f2cfc538e00"
unitRef="shares">2600237</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjQ5YjQ1ODBmYWEzMjQ5MjhhZDc5YTdmM2IyNDJjNDRlL3RhYmxlcmFuZ2U6NDliNDU4MGZhYTMyNDkyOGFkNzlhN2YzYjI0MmM0NGVfMy0zLTEtMS0zOTM4Mw_47e35f64-e794-4101-90e5-91a4384bc03b"
unitRef="usdPerShare">17.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjQ5YjQ1ODBmYWEzMjQ5MjhhZDc5YTdmM2IyNDJjNDRlL3RhYmxlcmFuZ2U6NDliNDU4MGZhYTMyNDkyOGFkNzlhN2YzYjI0MmM0NGVfMy01LTEtMS0zOTM4Mw_3439c797-fd56-4e5b-bda1-e2d444e4b243">P8Y3M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfODk2_47c029bd-7be0-4c57-9841-8bfc8a42fa54"
unitRef="usd">7500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
contextRef="ieaf5f38983f147c5b391b683b2a5d265_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTMwOQ_7ff5e6dd-1440-401b-b337-df092192105e">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:StockRepurchasedDuringPeriodShares
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTA5OTUxMTYzMTIwNw_d976e6dd-7133-4117-98dd-0ddb556ed185"
unitRef="shares">0</us-gaap:StockRepurchasedDuringPeriodShares>
<us-gaap:StockRepurchasedDuringPeriodShares
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTU5MA_562d5b9e-78aa-47e0-b04d-fcbbd7ace56a"
unitRef="shares">12945</us-gaap:StockRepurchasedDuringPeriodShares>
<us-gaap:StockRepurchasedDuringPeriodValue
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTYzMA_5717351d-cd28-43b1-b2dd-bcaedafe8140"
unitRef="usd">100000</us-gaap:StockRepurchasedDuringPeriodValue>
<lung:ShareBasedPaymentArrangementSharesSubjectToRepurchase
contextRef="ieaf5f38983f147c5b391b683b2a5d265_D20220101-20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTczNw_866e5d19-ac31-4281-ad32-e1eac8733070"
unitRef="shares">155969</lung:ShareBasedPaymentArrangementSharesSubjectToRepurchase>
<lung:ShareBasedPaymentArrangementSharesSubjectToRepurchase
contextRef="ic7b4e5d4bcbd4d4186b94f94cf2b2e0d_D20210101-20211231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTc0NA_b3a83805-5054-4f33-b944-a2f2604e9bb1"
unitRef="shares">223195</lung:ShareBasedPaymentArrangementSharesSubjectToRepurchase>
<lung:ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTgzMw_a7b05711-028c-4aac-a737-1b4f8bd3e9a8"
unitRef="usd">300000</lung:ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice>
<lung:ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTg0MA_b8a95538-01cc-4f76-b408-73971093918d"
unitRef="usd">400000</lung:ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice>
<us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMzE5NA_34233d3e-49f6-4e6e-a983-6bc568465565"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity with respect to restricted stock units was as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares Underlying Outstanding Restricted Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">442,428 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42.36 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799,320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115,380)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,411)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091,957 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.78 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
contextRef="id02f38cc7de8443687c4dbf744ee7d4a_I20211231"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOmUzMzdiNWU2ZmY5MTQzNGQ5NTExM2JiMjUyOWFhZjFmL3RhYmxlcmFuZ2U6ZTMzN2I1ZTZmZjkxNDM0ZDk1MTEzYmIyNTI5YWFmMWZfMS0xLTEtMS0zOTM4Mw_7e6597e8-edde-4a63-8af1-a739aba143a1"
unitRef="shares">442428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
contextRef="id02f38cc7de8443687c4dbf744ee7d4a_I20211231"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOmUzMzdiNWU2ZmY5MTQzNGQ5NTExM2JiMjUyOWFhZjFmL3RhYmxlcmFuZ2U6ZTMzN2I1ZTZmZjkxNDM0ZDk1MTEzYmIyNTI5YWFmMWZfMS0zLTEtMS0zOTM4Mw_d45a64f3-85b5-4b75-b1d5-6d78adbeecb2"
unitRef="usdPerShare">42.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
contextRef="ib214e6ee760c4adcbb895883d757b122_D20220101-20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOmUzMzdiNWU2ZmY5MTQzNGQ5NTExM2JiMjUyOWFhZjFmL3RhYmxlcmFuZ2U6ZTMzN2I1ZTZmZjkxNDM0ZDk1MTEzYmIyNTI5YWFmMWZfMi0xLTEtMS0zOTM4Mw_850e5ee3-551d-44ef-98d9-3c91337ed969"
unitRef="shares">799320</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
contextRef="ib214e6ee760c4adcbb895883d757b122_D20220101-20220630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOmUzMzdiNWU2ZmY5MTQzNGQ5NTExM2JiMjUyOWFhZjFmL3RhYmxlcmFuZ2U6ZTMzN2I1ZTZmZjkxNDM0ZDk1MTEzYmIyNTI5YWFmMWZfMi0zLTEtMS0zOTM4Mw_b0f0a741-6e27-43e9-b4cc-d8b70e704b2b"
unitRef="usdPerShare">25.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
contextRef="ib214e6ee760c4adcbb895883d757b122_D20220101-20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOmUzMzdiNWU2ZmY5MTQzNGQ5NTExM2JiMjUyOWFhZjFmL3RhYmxlcmFuZ2U6ZTMzN2I1ZTZmZjkxNDM0ZDk1MTEzYmIyNTI5YWFmMWZfMy0xLTEtMS00MTAxMA_9c2770a5-6093-445e-a52f-8d650ff59974"
unitRef="shares">115380</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
contextRef="ib214e6ee760c4adcbb895883d757b122_D20220101-20220630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOmUzMzdiNWU2ZmY5MTQzNGQ5NTExM2JiMjUyOWFhZjFmL3RhYmxlcmFuZ2U6ZTMzN2I1ZTZmZjkxNDM0ZDk1MTEzYmIyNTI5YWFmMWZfMy0zLTEtMS00MTAxMA_bd5ceb3c-b537-4115-81ed-cb1d2a013811"
unitRef="usdPerShare">37.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
contextRef="ib214e6ee760c4adcbb895883d757b122_D20220101-20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOmUzMzdiNWU2ZmY5MTQzNGQ5NTExM2JiMjUyOWFhZjFmL3RhYmxlcmFuZ2U6ZTMzN2I1ZTZmZjkxNDM0ZDk1MTEzYmIyNTI5YWFmMWZfNC0xLTEtMS00MTAxMA_f61ba8f9-7c48-4f81-a447-c5002413c6c8"
unitRef="shares">34411</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
contextRef="ib214e6ee760c4adcbb895883d757b122_D20220101-20220630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOmUzMzdiNWU2ZmY5MTQzNGQ5NTExM2JiMjUyOWFhZjFmL3RhYmxlcmFuZ2U6ZTMzN2I1ZTZmZjkxNDM0ZDk1MTEzYmIyNTI5YWFmMWZfNC0zLTEtMS00MTAxMA_94aaebdc-c0b1-4152-a125-16631b0b0b86"
unitRef="usdPerShare">33.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
contextRef="i91b890405bde48749a209fc48ed3fd13_I20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOmUzMzdiNWU2ZmY5MTQzNGQ5NTExM2JiMjUyOWFhZjFmL3RhYmxlcmFuZ2U6ZTMzN2I1ZTZmZjkxNDM0ZDk1MTEzYmIyNTI5YWFmMWZfMy0xLTEtMS0zOTM4Mw_37645a6d-2252-47ab-8ce4-241aac6b84cc"
unitRef="shares">1091957</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
contextRef="i91b890405bde48749a209fc48ed3fd13_I20220630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOmUzMzdiNWU2ZmY5MTQzNGQ5NTExM2JiMjUyOWFhZjFmL3RhYmxlcmFuZ2U6ZTMzN2I1ZTZmZjkxNDM0ZDk1MTEzYmIyNTI5YWFmMWZfMy0zLTEtMS0zOTM4Mw_af052ae8-9869-4a2f-bcbe-3fab08c93216"
unitRef="usdPerShare">30.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
contextRef="i91b890405bde48749a209fc48ed3fd13_I20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTA5OTUxMTYzMTM3NQ_07606402-df5a-4321-a4f2-e69260822a50"
unitRef="usd">16100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMzIwMQ_acdea86d-5f71-4962-8c0f-08137a9089ce"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is reflected in the statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">189 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">336 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">210 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">977 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">606 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,638 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,583 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,764 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,383 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,312 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,896 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,580 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above stock-based compensation expense related to the following equity-based awards (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and restricted stock units</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,209 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,520 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,521 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,559 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,021 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,383 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,312 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,896 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,580 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i883a9ab8eaca4207ba3cadcb80ef8eda_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfMi0xLTEtMS0zOTM4Mw_5b91c544-5d1a-4073-a899-5ad71eb1bae6"
unitRef="usd">189000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i0b981dc82dd04a02bb8a9147b2a333de_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfMi0zLTEtMS0zOTM4Mw_62cb1d4c-c639-4f51-83dd-2c5fe898fda4"
unitRef="usd">120000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i114ea887bbd14b4a95901ff225d7572e_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfMi01LTEtMS0zOTM4Mw_14fc5a69-613c-4ba5-a787-ddeb4e5d0694"
unitRef="usd">336000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i51ff2e29588048e09a217bf20a23f15e_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfMi03LTEtMS0zOTM4Mw_14067072-7a37-4721-9839-22cde34142d7"
unitRef="usd">210000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i405811c8a7064e599bb9622e46610a53_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfMy0xLTEtMS0zOTM4Mw_32628216-0b01-40e5-ab5f-8f7cc421e794"
unitRef="usd">556000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i58118a88d93b4eb694a8bc9332e744f5_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfMy0zLTEtMS0zOTM4Mw_b2eb8270-81e2-4849-b6c4-46eb9ca60668"
unitRef="usd">288000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="if9b029b9144a4e10b3a37d170bf1098c_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfMy01LTEtMS0zOTM4Mw_c73b646c-fd2b-4768-aee3-4d6abdb75854"
unitRef="usd">977000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i0ed501dd475d4cf48aa805abbe19f088_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfMy03LTEtMS0zOTM4Mw_c9ad433d-0af3-41b7-b61a-c7bf6e3ffda8"
unitRef="usd">606000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i08e66e05527d4ffd827c77748a29ae59_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfNC0xLTEtMS0zOTM4Mw_f6ebb384-3b96-4aa9-ad3b-aca160ba5205"
unitRef="usd">3638000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i0dfbc2d6814744a0ad594767a7b3921c_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfNC0zLTEtMS0zOTM4Mw_fe8d2fd2-9daf-4dec-a220-40a257ba1ba7"
unitRef="usd">1904000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="ia73aa5beaf714619a089f8546ba50e49_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfNC01LTEtMS0zOTM4Mw_89a4627d-0147-4fc8-8328-ad5a55b0e5a7"
unitRef="usd">6583000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="id37e4fe079bc43a8b78bc7d2ed7d7f5a_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfNC03LTEtMS0zOTM4Mw_e4efe167-3005-45ef-a393-5071ecac6069"
unitRef="usd">3764000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfNS0xLTEtMS0zOTM4Mw_00d69dc0-f601-46bc-9eae-004fc78013a5"
unitRef="usd">4383000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfNS0zLTEtMS0zOTM4Mw_2a27c9eb-d9aa-4553-b37a-514c0348f092"
unitRef="usd">2312000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfNS01LTEtMS0zOTM4Mw_95387d77-c59a-473b-889b-f345ea17ad05"
unitRef="usd">7896000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjBlMzYzOGI2MDQ0YjQzMDE4M2RjOTkzYThmMzM3MWI1L3RhYmxlcmFuZ2U6MGUzNjM4YjYwNDRiNDMwMTgzZGM5OTNhOGYzMzcxYjVfNS03LTEtMS0zOTM4Mw_023992aa-537f-492c-a77a-7c46becec460"
unitRef="usd">4580000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i27f5ea6853044003b5d3fe259686cfed_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjhhZDQxNmNlMzlhZTQyYTY5YmE4ZWM0NDZhMzYzMDE4L3RhYmxlcmFuZ2U6OGFkNDE2Y2UzOWFlNDJhNjliYThlYzQ0NmEzNjMwMThfMi0xLTEtMS0zOTM4Mw_71f9bcb5-c4ad-4e05-bc3d-566b7096f200"
unitRef="usd">4209000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="ia4b62e5c7e4d41e599a13d60481720d5_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjhhZDQxNmNlMzlhZTQyYTY5YmE4ZWM0NDZhMzYzMDE4L3RhYmxlcmFuZ2U6OGFkNDE2Y2UzOWFlNDJhNjliYThlYzQ0NmEzNjMwMThfMi0zLTEtMS0zOTM4Mw_01e559d0-8a0b-4044-ac80-b38b56a781ee"
unitRef="usd">1520000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="id6ad1ceb870840e0aff0a566353c7eca_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjhhZDQxNmNlMzlhZTQyYTY5YmE4ZWM0NDZhMzYzMDE4L3RhYmxlcmFuZ2U6OGFkNDE2Y2UzOWFlNDJhNjliYThlYzQ0NmEzNjMwMThfMi01LTEtMS0zOTM4Mw_bfaf224d-cc18-4ff2-809e-c17b3eaeaf60"
unitRef="usd">7521000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="if1fb7c022d3f4c5a8ce371332cda0d8e_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjhhZDQxNmNlMzlhZTQyYTY5YmE4ZWM0NDZhMzYzMDE4L3RhYmxlcmFuZ2U6OGFkNDE2Y2UzOWFlNDJhNjliYThlYzQ0NmEzNjMwMThfMi03LTEtMS0zOTM4Mw_65526315-4fce-42c2-8061-317da4d04ded"
unitRef="usd">2559000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i34dd8820c0384b9f99643fd8282fcfed_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjhhZDQxNmNlMzlhZTQyYTY5YmE4ZWM0NDZhMzYzMDE4L3RhYmxlcmFuZ2U6OGFkNDE2Y2UzOWFlNDJhNjliYThlYzQ0NmEzNjMwMThfMy0xLTEtMS0zOTM4Mw_252a9f88-27cf-4bbd-9145-87ea6c88134d"
unitRef="usd">174000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i18e4908c4d83487a804ab3bb691cfdfd_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjhhZDQxNmNlMzlhZTQyYTY5YmE4ZWM0NDZhMzYzMDE4L3RhYmxlcmFuZ2U6OGFkNDE2Y2UzOWFlNDJhNjliYThlYzQ0NmEzNjMwMThfMy0zLTEtMS0zOTM4Mw_f0f2113a-2e55-4cd3-8607-abf8ff84d090"
unitRef="usd">792000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="ia5532b33c0264e07931c620be5ee4fdb_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjhhZDQxNmNlMzlhZTQyYTY5YmE4ZWM0NDZhMzYzMDE4L3RhYmxlcmFuZ2U6OGFkNDE2Y2UzOWFlNDJhNjliYThlYzQ0NmEzNjMwMThfMy01LTEtMS0zOTM4Mw_0047812c-2454-48c4-991b-3b9bee9b60a6"
unitRef="usd">375000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i913beb06228a48059034fdbd19194be1_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjhhZDQxNmNlMzlhZTQyYTY5YmE4ZWM0NDZhMzYzMDE4L3RhYmxlcmFuZ2U6OGFkNDE2Y2UzOWFlNDJhNjliYThlYzQ0NmEzNjMwMThfMy03LTEtMS0zOTM4Mw_7c44fee1-dd83-4fe3-ad6c-99cbac5192a9"
unitRef="usd">2021000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjhhZDQxNmNlMzlhZTQyYTY5YmE4ZWM0NDZhMzYzMDE4L3RhYmxlcmFuZ2U6OGFkNDE2Y2UzOWFlNDJhNjliYThlYzQ0NmEzNjMwMThfNC0xLTEtMS0zOTM4Mw_b270ab7c-3a7d-4296-8ca3-b7cf6d26597c"
unitRef="usd">4383000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjhhZDQxNmNlMzlhZTQyYTY5YmE4ZWM0NDZhMzYzMDE4L3RhYmxlcmFuZ2U6OGFkNDE2Y2UzOWFlNDJhNjliYThlYzQ0NmEzNjMwMThfNC0zLTEtMS0zOTM4Mw_4c19f92a-fe70-49b6-87c6-bfdb92930939"
unitRef="usd">2312000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjhhZDQxNmNlMzlhZTQyYTY5YmE4ZWM0NDZhMzYzMDE4L3RhYmxlcmFuZ2U6OGFkNDE2Y2UzOWFlNDJhNjliYThlYzQ0NmEzNjMwMThfNC01LTEtMS0zOTM4Mw_7e17517e-087c-477b-bd85-722e9558863e"
unitRef="usd">7896000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RhYmxlOjhhZDQxNmNlMzlhZTQyYTY5YmE4ZWM0NDZhMzYzMDE4L3RhYmxlcmFuZ2U6OGFkNDE2Y2UzOWFlNDJhNjliYThlYzQ0NmEzNjMwMThfNC03LTEtMS0zOTM4Mw_28c6d2dc-b38e-42d5-8198-61fb6d1eda63"
unitRef="usd">4580000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
contextRef="ie13307b791954390abb618142b11755f_D20220401-20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMjI5MA_5f9b17c9-9c91-4143-9c40-27796e1f7bac"
unitRef="usd">300000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
contextRef="iac319f186e3c4549bf1291d73e9ef0c2_D20210401-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTA5OTUxMTYzMTM5Nw_b34d0326-db9d-488a-bbc3-f585a0afa5a5"
unitRef="usd">300000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
contextRef="i50d7120120ae48429357a6f238139dcd_D20220101-20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMjQxMQ_a1634e7a-6fa8-4587-bf90-a31f40bcecb0"
unitRef="usd">600000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
contextRef="i53b7b623056a4e2eb2ea7a0f65fc71e9_D20210101-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTA5OTUxMTYzMTQwMw_1ed93d45-8040-49c1-9dc9-8b73d4e06ff7"
unitRef="usd">500000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
contextRef="iee27527c02e7424fb0b8f40670bc3dae_D20220401-20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMjU1OQ_67030b9b-35d7-44b0-a4b1-219ea4b04807"
unitRef="usd">200000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
contextRef="ifa0cb1b19d894f169cd980e74653f9fb_D20210401-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTA5OTUxMTYzMTQxMA_072495ce-9b23-4e6c-8449-44c5e12d2ee5"
unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
contextRef="i77bf9d3e0a0b48409b6cb9f129526c9c_D20220101-20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMjcwOQ_8dd82025-0fc1-489e-a609-dd7a7c1094a8"
unitRef="usd">300000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
contextRef="ife4a8ff7e8fb4ffe9f2b64e74d5e97cf_D20210101-20210630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTA5OTUxMTYzMTQxNg_a946a2e0-6920-414d-ba39-4b26a57aa860"
unitRef="usd">200000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
contextRef="i00e81a622be642048db364ba63b6897c_I20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMjgxOQ_da44a799-5d99-4200-bb28-f61f25befccf"
unitRef="usd">52600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
contextRef="id6ad1ceb870840e0aff0a566353c7eca_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMjk4OA_d90bcca5-b1f4-44ea-a506-bf6ffbc10ff3">P3Y1M20D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
contextRef="i27f5ea6853044003b5d3fe259686cfed_D20220401-20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTA5OTUxMTYzMTUxMg_4ff7904b-9203-4566-9bc6-ecae7c652855"
unitRef="usd">4700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
contextRef="id6ad1ceb870840e0aff0a566353c7eca_D20220101-20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMTA5OTUxMTYzMTkwOA_9b8792bf-802a-4906-9208-6d14b6b78313"
unitRef="usd">7400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
contextRef="i1275d322af1b4c98ba3c7706239395c7_I20220630"
decimals="-5"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMzExMg_972a8a45-6489-43cc-8fc4-365fcc8f9592"
unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
contextRef="ia5532b33c0264e07931c620be5ee4fdb_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183MC9mcmFnOjM1OWQ5MzQxMjk2YjQzNTVhNjAwYzcyNDRhMjgzMzdjL3RleHRyZWdpb246MzU5ZDkzNDEyOTZiNDM1NWE2MDBjNzI0NGEyODMzN2NfMzE5Ng_d36ebdbe-4d79-4cc6-8988-884047a48bf4">P0Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
<us-gaap:EarningsPerShareTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RleHRyZWdpb246NTkyZTlmMzQzYTZhNDY4ZmIwYWJiYTM3NmUwMWYzYWZfOTUx_41e92070-9b81-44ab-b50c-15d6d649b97b">Net Loss per Share Attributable to Common Stockholders<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders which excludes shares which are legally outstanding, but subject to repurchase by the Company (in thousands, except share and per share amounts):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,640)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,468)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,474)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common stock outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,171,893 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,324,022 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,090,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,021,469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: weighted-average common shares subject to repurchase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168,450)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281,408)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185,212)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312,921)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares used to compute basic and diluted net loss per share</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,003,443 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,042,614 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,904,952 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,708,548 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.36)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.83)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.71)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company’s net loss, in common stock equivalent shares:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600,244 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,483,364 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,550 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested early exercised common stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,969 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares committed under ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,865 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,881,205 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,223,356 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:EarningsPerShareTextBlock>
<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RleHRyZWdpb246NTkyZTlmMzQzYTZhNDY4ZmIwYWJiYTM3NmUwMWYzYWZfOTUy_35dcb62f-4d54-455e-acde-167093c56d18"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders which excludes shares which are legally outstanding, but subject to repurchase by the Company (in thousands, except share and per share amounts):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,640)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,468)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,474)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common stock outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,171,893 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,324,022 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,090,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,021,469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: weighted-average common shares subject to repurchase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168,450)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281,408)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185,212)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312,921)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares used to compute basic and diluted net loss per share</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,003,443 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,042,614 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,904,952 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,708,548 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.36)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.83)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.71)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfMy0yLTEtMS0zOTM4Mw_1300edc3-037d-4864-a6e5-988a038b4269"
unitRef="usd">-14640000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfMy0yLTEtMS0zOTM4Mw_735b1399-fd87-4d36-94ba-0faed66ab21b"
unitRef="usd">-14640000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfMy00LTEtMS0zOTM4Mw_27304d71-abd5-47aa-a46e-14a0f574c33c"
unitRef="usd">-12962000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfMy00LTEtMS0zOTM4Mw_85391273-3c97-412c-b697-706b5f8676df"
unitRef="usd">-12962000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfMy02LTEtMS0zOTM4Mw_ba04d341-a5b6-4598-a4e0-ba026132c96f"
unitRef="usd">-30468000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfMy02LTEtMS0zOTM4Mw_f6f50916-fc5a-4879-895b-a6bcc04bb3ae"
unitRef="usd">-30468000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfMy04LTEtMS0zOTM4Mw_66b31552-11be-4ca4-9104-f299201ea615"
unitRef="usd">-25474000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfMy04LTEtMS0zOTM4Mw_a05f6493-c1f4-4581-bc87-3a3e9082d514"
unitRef="usd">-25474000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
<us-gaap:WeightedAverageNumberOfSharesIssuedBasic
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNS0yLTEtMS0zOTM4Mw_390923d9-07a6-4cd5-a6f8-b57dbeacbb0c"
unitRef="shares">37171893</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
<us-gaap:WeightedAverageNumberOfSharesIssuedBasic
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNS00LTEtMS0zOTM4Mw_9e941d00-48d2-4d10-abf8-f52d4dd78f0f"
unitRef="shares">36324022</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
<us-gaap:WeightedAverageNumberOfSharesIssuedBasic
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNS02LTEtMS0zOTM4Mw_424c2e9b-a66f-480f-99ea-e34bbe6c4839"
unitRef="shares">37090164</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
<us-gaap:WeightedAverageNumberOfSharesIssuedBasic
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNS04LTEtMS0zOTM4Mw_afe12c90-7bd9-4d8d-8b5a-e6cca06ad4ac"
unitRef="shares">36021469</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
<us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNi0yLTEtMS0zOTM4Mw_af26a41e-7c7a-4c2e-b84a-dd918e72d128"
unitRef="shares">168450</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
<us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNi00LTEtMS0zOTM4Mw_ea791c2b-05c6-4fdc-8bce-01cbb533aad7"
unitRef="shares">281408</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
<us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNi02LTEtMS0zOTM4Mw_93ff9803-545b-4ee6-b3b1-654cc37a1670"
unitRef="shares">185212</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
<us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNi04LTEtMS0zOTM4Mw_32176c72-063e-44a0-8099-cfa7e257af7d"
unitRef="shares">312921</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNy0yLTEtMS0zOTM4Mw_084a4c83-30d7-4f40-9f30-64d24ea2a7e2"
unitRef="shares">37003443</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNy0yLTEtMS0zOTM4Mw_1539839a-d97b-4bb3-b225-9abeb9815d96"
unitRef="shares">37003443</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNy00LTEtMS0zOTM4Mw_aab4bb85-53d1-41ae-bdb5-ab97ea5c3e3d"
unitRef="shares">36042614</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNy00LTEtMS0zOTM4Mw_e55808de-aa77-45da-b4fb-176aae32a9b0"
unitRef="shares">36042614</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNy02LTEtMS0zOTM4Mw_970c1f52-8586-4b2c-b50b-6da9feccc708"
unitRef="shares">36904952</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNy02LTEtMS0zOTM4Mw_da351c5d-31ac-410e-b68d-904aa0875882"
unitRef="shares">36904952</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNy04LTEtMS0zOTM4Mw_87c81359-050c-48c6-9ab1-cc3255051708"
unitRef="shares">35708548</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfNy04LTEtMS0zOTM4Mw_e61c1187-918d-434b-8f21-8f05c8d88359"
unitRef="shares">35708548</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:EarningsPerShareBasic
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfOC0yLTEtMS0zOTM4Mw_1ae17aa8-9a40-461b-96ab-1be3a44b7774"
unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareDiluted
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfOC0yLTEtMS0zOTM4Mw_c6fd9aa2-d6e9-407a-9aff-43f36157347f"
unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareBasic
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfOC00LTEtMS0zOTM4Mw_509b8717-9bca-4efe-884c-7af185b03a5b"
unitRef="usdPerShare">-0.36</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareDiluted
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfOC00LTEtMS0zOTM4Mw_ccf2418a-fe13-476f-b552-ce5a377383a3"
unitRef="usdPerShare">-0.36</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfOC02LTEtMS0zOTM4Mw_6b232008-ea15-4bf7-9e53-33bf6a25f62a"
unitRef="usdPerShare">-0.83</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareBasic
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfOC02LTEtMS0zOTM4Mw_70f7ef33-13cc-47c0-b2d1-5085c6cbbefd"
unitRef="usdPerShare">-0.83</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareDiluted
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfOC04LTEtMS0zOTM4Mw_f2bb9f78-0f04-477e-aa57-48bddf1f3647"
unitRef="usdPerShare">-0.71</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareBasic
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOjhmYzhjMmY0ZDFjNDRlMmM5ODFiZDRmODRlNDBjYzk3L3RhYmxlcmFuZ2U6OGZjOGMyZjRkMWM0NGUyYzk4MWJkNGY4NGU0MGNjOTdfOC04LTEtMS0zOTM4Mw_f6ca3583-896c-4e87-b7c5-c2dfca4dbf2f"
unitRef="usdPerShare">-0.71</us-gaap:EarningsPerShareBasic>
<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RleHRyZWdpb246NTkyZTlmMzQzYTZhNDY4ZmIwYWJiYTM3NmUwMWYzYWZfOTUw_31e64118-4b72-475a-be5a-9113e44320c9"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company’s net loss, in common stock equivalent shares:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600,244 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,483,364 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091,957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,550 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested early exercised common stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,969 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares committed under ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,865 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,881,205 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,223,356 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
contextRef="i8b60336143e4446eab2f9aef31e69da0_D20220101-20220630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOmQxNDEzYzViNzZhMjRjMWE5Y2VmZTY4MzZiMWFjYjdhL3RhYmxlcmFuZ2U6ZDE0MTNjNWI3NmEyNGMxYTljZWZlNjgzNmIxYWNiN2FfMy0xLTEtMS0zOTM4Mw_1df612d9-8914-413e-9137-d4e43de9a84c"
unitRef="shares">2600244</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
contextRef="if8534ceb95304df4a061131854586927_D20210101-20210630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOmQxNDEzYzViNzZhMjRjMWE5Y2VmZTY4MzZiMWFjYjdhL3RhYmxlcmFuZ2U6ZDE0MTNjNWI3NmEyNGMxYTljZWZlNjgzNmIxYWNiN2FfMy0zLTEtMS0zOTM4Mw_b29819ed-e485-405c-8110-9c8afdc68840"
unitRef="shares">2483364</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
contextRef="i493a546e223e4e349b281de37224fec9_D20220101-20220630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOmQxNDEzYzViNzZhMjRjMWE5Y2VmZTY4MzZiMWFjYjdhL3RhYmxlcmFuZ2U6ZDE0MTNjNWI3NmEyNGMxYTljZWZlNjgzNmIxYWNiN2FfMy0xLTEtMS00MTE3NQ_96d20056-6f69-4ea1-85bf-446680b1b87c"
unitRef="shares">1091957</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
contextRef="i88dc40bd83d7401a9672d7d2df0cbd44_D20210101-20210630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOmQxNDEzYzViNzZhMjRjMWE5Y2VmZTY4MzZiMWFjYjdhL3RhYmxlcmFuZ2U6ZDE0MTNjNWI3NmEyNGMxYTljZWZlNjgzNmIxYWNiN2FfMy0zLTEtMS00MTE3NQ_d50fb62e-b57d-4482-87ca-ea695050078c"
unitRef="shares">438550</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
contextRef="icaa76627fc8f47fca67ba3fd4f6b2423_D20220101-20220630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOmQxNDEzYzViNzZhMjRjMWE5Y2VmZTY4MzZiMWFjYjdhL3RhYmxlcmFuZ2U6ZDE0MTNjNWI3NmEyNGMxYTljZWZlNjgzNmIxYWNiN2FfNC0xLTEtMS0zOTM4Mw_58a17c5a-884f-44c6-8a8c-49a5b4d454cd"
unitRef="shares">155969</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
contextRef="i3c2550a59e904c9fa8983370b3a88d6d_D20210101-20210630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOmQxNDEzYzViNzZhMjRjMWE5Y2VmZTY4MzZiMWFjYjdhL3RhYmxlcmFuZ2U6ZDE0MTNjNWI3NmEyNGMxYTljZWZlNjgzNmIxYWNiN2FfNC0zLTEtMS0zOTM4Mw_464dc07a-4942-4f17-8f67-3899d683fbef"
unitRef="shares">294577</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
contextRef="i04828ea9cac9458c9dc603bf1c75ae3e_D20220101-20220630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOmQxNDEzYzViNzZhMjRjMWE5Y2VmZTY4MzZiMWFjYjdhL3RhYmxlcmFuZ2U6ZDE0MTNjNWI3NmEyNGMxYTljZWZlNjgzNmIxYWNiN2FfNi0xLTEtMS0zOTM4Mw_b9375b22-24b1-4a8f-b35d-9a992e5cdf15"
unitRef="shares">33035</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
contextRef="ifd4dd78630cd4ade8407c6236aa12b7d_D20210101-20210630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOmQxNDEzYzViNzZhMjRjMWE5Y2VmZTY4MzZiMWFjYjdhL3RhYmxlcmFuZ2U6ZDE0MTNjNWI3NmEyNGMxYTljZWZlNjgzNmIxYWNiN2FfNi0zLTEtMS0zOTM4Mw_0c14313c-f197-45f2-868e-ad467c41dd69"
unitRef="shares">6865</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOmQxNDEzYzViNzZhMjRjMWE5Y2VmZTY4MzZiMWFjYjdhL3RhYmxlcmFuZ2U6ZDE0MTNjNWI3NmEyNGMxYTljZWZlNjgzNmIxYWNiN2FfNy0xLTEtMS0zOTM4Mw_11559874-f808-4178-ad6b-65db76143031"
unitRef="shares">3881205</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="0"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183My9mcmFnOjU5MmU5ZjM0M2E2YTQ2OGZiMGFiYmEzNzZlMDFmM2FmL3RhYmxlOmQxNDEzYzViNzZhMjRjMWE5Y2VmZTY4MzZiMWFjYjdhL3RhYmxlcmFuZ2U6ZDE0MTNjNWI3NmEyNGMxYTljZWZlNjgzNmIxYWNiN2FfNy0zLTEtMS0zOTM4Mw_32d14486-e48a-4ffe-a035-6c9d0f4cbb51"
unitRef="shares">3223356</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:SegmentReportingDisclosureTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RleHRyZWdpb246YTk4NTUyMzk2MDNmNDBiYTk5NGM2N2VkNTZjMGExZjdfMTY1Nw_5199bc16-fb62-4795-9f3d-cc12000986fb">Segment InformationThe chief operating decision maker for the Company is the Chief Executive Officer. The Company’s Chief Executive Officer reviews financial information presented on a consolidated basis, accompanied by information about revenue by geographic region, for purposes of allocating resources and evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results or plans for levels or components below the consolidated unit level. Accordingly, the Company has determined that it has a single reportable and operating segment structure. The Company’s Chief Executive Officer evaluates performance based primarily on revenue in the geographic locations in which the Company operates.<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by geographic area is based on the billing address of the customer. The following table sets forth the Company’s revenue by geographic area (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,616 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,567 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,629 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,856 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle-East and Africa (“EMEA”)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,570 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,749 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,786 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,950 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,203 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,735 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,447 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from Germany and France represented 10% and 9%, respectively, of total revenue for the three months ended June 30, 2022. Revenue from Germany and France represented 11% and 9%, respectively, of total revenue for the three months ended June 30, 2021. Revenue from Germany and France represented 12% and 8%, respectively, of total revenue for the six months ended June 30, 2022. Revenue from Germany and France represented 12% and 10%, respectively, of total revenue for the six months ended June 30, 2021. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets by geographic area are based on physical location of those assets. The following table sets forth the Company’s long-lived assets by geographic area (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,871 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,767 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EMEA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,932 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,814 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></us-gaap:SegmentReportingDisclosureTextBlock>
<us-gaap:NumberOfOperatingSegments
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RleHRyZWdpb246YTk4NTUyMzk2MDNmNDBiYTk5NGM2N2VkNTZjMGExZjdfMzY5_169ec9c3-07ee-4bac-8f51-b0d2866e10b3"
unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
<us-gaap:NumberOfReportableSegments
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="INF"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RleHRyZWdpb246YTk4NTUyMzk2MDNmNDBiYTk5NGM2N2VkNTZjMGExZjdfMzY5_d9f5c99e-403f-4ea5-9d4b-9d43c4bb357c"
unitRef="segment">1</us-gaap:NumberOfReportableSegments>
<us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RleHRyZWdpb246YTk4NTUyMzk2MDNmNDBiYTk5NGM2N2VkNTZjMGExZjdfMTY1OA_67c596a0-fe7f-41cf-a1d2-86aadc166f58">The following table sets forth the Company’s revenue by geographic area (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,616 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,567 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,629 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,856 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle-East and Africa (“EMEA”)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,570 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,749 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,793 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,786 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,950 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,203 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,735 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,447 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="ie1359c30612540db9f7d34a1c01b3ad0_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfMi0xLTEtMS0zOTM4Mw_4290c043-6d56-430f-bcf2-ff2f36cee421"
unitRef="usd">8616000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="i76aa19c427d84d68b1168f403a4d9cf0_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfMi0zLTEtMS0zOTM4Mw_7721f2da-5c73-4e5e-88b4-cdba29d12d7f"
unitRef="usd">6567000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="i289c4b693d0f4b78a133aca081e4ec62_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfMi01LTEtMS0zOTM4Mw_75b565a1-e287-4ca7-92b2-a92773d693a7"
unitRef="usd">14629000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="i9dbda9b7680c4fbbb2d796862b9cc528_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfMi03LTEtMS0zOTM4Mw_6c0c88a5-98ea-4af1-ad9a-697fc3e47c76"
unitRef="usd">10856000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="i60c47462ac8c42278751a5e88cebb16c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfMy0xLTEtMS0zOTM4Mw_6c2e7ca9-eef6-437f-aab6-a4d9999d3215"
unitRef="usd">4570000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="id9f15921237f4455b73e6cc819e646c3_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfMy0zLTEtMS0zOTM4Mw_a09cfb68-9dac-4588-bf76-397e0dd6572b"
unitRef="usd">4749000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="i80d96e293cf64c4a8bc6f7a1a5311f2e_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfMy01LTEtMS0zOTM4Mw_170e059f-6638-4194-ae92-4bec212194c0"
unitRef="usd">8623000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="ic858ed7791a6420b80be0581b72d5fe2_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfMy03LTEtMS0zOTM4Mw_94a9ad32-d29d-4d36-bf23-b6cdc2b82299"
unitRef="usd">8793000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="i95b08bdad4d14d5ebf4d2815ee5d2afa_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfNC0xLTEtMS0zOTM4Mw_5df11b1f-1830-499c-b0c6-6a630105ad62"
unitRef="usd">724000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="i6331c9bd120d452f9dbc7f5077c0b308_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfNC0zLTEtMS0zOTM4Mw_a5f0414b-e268-4c17-84e0-a18ce3a212b0"
unitRef="usd">875000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="i58327cae2f9545909843bc0298fc7738_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfNC01LTEtMS0zOTM4Mw_1ee2f727-69f6-4d02-87c9-616a8486d84e"
unitRef="usd">1443000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="ide14511124ea4c19b7d0d17cf44f7565_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfNC03LTEtMS0zOTM4Mw_c792cb48-585b-4c62-abea-70091e63ee03"
unitRef="usd">1786000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="ibf783eb979ba4c2990809ef7ba464ec1_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfNS0xLTEtMS0zOTM4Mw_d92f7da9-aca5-4caa-83f4-66bd73f02dd0"
unitRef="usd">40000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="i88d9fce60fb74d2b9219ae5f5695bac4_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfNS0zLTEtMS0zOTM4Mw_64ea0241-5cd5-4f44-b60c-27b3dabbda74"
unitRef="usd">12000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="ia2da15985d8f46c7813cfdff913a5506_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfNS01LTEtMS0zOTM4Mw_195f2fae-52d2-45f0-a560-093aa35b84af"
unitRef="usd">40000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="i6b0e39f7311c4c8dafe667c0cc5deee3_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfNS03LTEtMS0zOTM4Mw_c95e3e22-b0cd-49fc-9a31-081c0d673423"
unitRef="usd">12000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfNi0xLTEtMS0zOTM4Mw_9f46a855-c004-4a49-a1c2-0c2bd950bdda"
unitRef="usd">13950000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="i56b31fcaf2684a93a8412db01a13acee_D20210401-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfNi0zLTEtMS0zOTM4Mw_fc55f348-dce5-46c9-b923-b740bf20c28e"
unitRef="usd">12203000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfNi01LTEtMS0zOTM4Mw_fba71138-4cfe-4f6a-b391-c059515b460b"
unitRef="usd">24735000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="i1f4b1cdc4e9c408b8327a8e5cbaf1fd0_D20210101-20210630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjg5ZGVkZDVhMWFkNTRjNmRhMWEwYzg1Yjk3NjFmZmQ0L3RhYmxlcmFuZ2U6ODlkZWRkNWExYWQ1NGM2ZGExYTBjODViOTc2MWZmZDRfNi03LTEtMS0zOTM4Mw_8778202d-fec5-4438-bd75-c4dfb1b1cfab"
unitRef="usd">21447000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:ConcentrationRiskPercentage1
contextRef="i92b67fa545b64980b9a2e36077a0e919_D20220401-20220630"
decimals="3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RleHRyZWdpb246YTk4NTUyMzk2MDNmNDBiYTk5NGM2N2VkNTZjMGExZjdfMTAxMw_8c40d8a0-400e-4e5f-8a53-c7d22428d760"
unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1
contextRef="i39dcbe49829e478bae65bf4ad7ebe73b_D20220401-20220630"
decimals="3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RleHRyZWdpb246YTk4NTUyMzk2MDNmNDBiYTk5NGM2N2VkNTZjMGExZjdfMTAyMA_9cc876b5-c04f-4389-a8f5-c415a1f2f8c1"
unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1
contextRef="ie37b898ed5f549b6a2584d0735ebc6a8_D20210401-20210630"
decimals="3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RleHRyZWdpb246YTk4NTUyMzk2MDNmNDBiYTk5NGM2N2VkNTZjMGExZjdfMTE0MA_8aff97b7-6375-4283-a177-c415c1badda5"
unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1
contextRef="iff16a3996ed74e9185638c285d8180e7_D20210401-20210630"
decimals="3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RleHRyZWdpb246YTk4NTUyMzk2MDNmNDBiYTk5NGM2N2VkNTZjMGExZjdfMTE0Nw_7a1e595c-9ca3-4a5e-a1df-a5fc5995791f"
unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1
contextRef="id116f3f4ef654103a4a17291f98e96cd_D20220101-20220630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RleHRyZWdpb246YTk4NTUyMzk2MDNmNDBiYTk5NGM2N2VkNTZjMGExZjdfMTI2Nw_f1fc0ab7-cc67-4640-83b2-e6247ae5fdce"
unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1
contextRef="i14ce772deb444cdc87b44503d5d9c1d5_D20220101-20220630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RleHRyZWdpb246YTk4NTUyMzk2MDNmNDBiYTk5NGM2N2VkNTZjMGExZjdfMTI3NA_2a3ea56d-e16f-4222-9cb1-1682a3b555eb"
unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1
contextRef="ia90e44e3c9a34436a33d109bdf77b945_D20210101-20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RleHRyZWdpb246YTk4NTUyMzk2MDNmNDBiYTk5NGM2N2VkNTZjMGExZjdfMTM5Mg_dc04ee38-a8f9-40fb-8ba8-c5dda5e02fdc"
unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1
contextRef="i800d29a3bc944cd193e54a8b9a0f6afb_D20210101-20210630"
decimals="2"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RleHRyZWdpb246YTk4NTUyMzk2MDNmNDBiYTk5NGM2N2VkNTZjMGExZjdfMTM5OQ_a8f6bc13-4cf0-42d6-b66d-958aafcf22dc"
unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock
contextRef="ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RleHRyZWdpb246YTk4NTUyMzk2MDNmNDBiYTk5NGM2N2VkNTZjMGExZjdfMTY1OQ_40ae2448-11e6-4551-a562-5aa88a0d201c">The following table sets forth the Company’s long-lived assets by geographic area (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,871 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,767 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EMEA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,932 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,814 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
<us-gaap:NoncurrentAssets
contextRef="i9fe4d5c850434aa89e016828fdf266ed_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjBlYzQyM2RmNjE0NDQ5YThiYWJjNTMzZGQ0ZjAyMzNmL3RhYmxlcmFuZ2U6MGVjNDIzZGY2MTQ0NDlhOGJhYmM1MzNkZDRmMDIzM2ZfMi0xLTEtMS0zOTM4Mw_f64a22d1-3411-46d7-8a96-d94d5b3820f5"
unitRef="usd">4871000</us-gaap:NoncurrentAssets>
<us-gaap:NoncurrentAssets
contextRef="i5796864d445f4298b6b97e81ee3b2e14_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjBlYzQyM2RmNjE0NDQ5YThiYWJjNTMzZGQ0ZjAyMzNmL3RhYmxlcmFuZ2U6MGVjNDIzZGY2MTQ0NDlhOGJhYmM1MzNkZDRmMDIzM2ZfMi0zLTEtMS0zOTM4Mw_ef336995-c147-467f-9379-35f76a8f1c43"
unitRef="usd">4767000</us-gaap:NoncurrentAssets>
<us-gaap:NoncurrentAssets
contextRef="i5926e07811564c14a1a7947cce7b6f48_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjBlYzQyM2RmNjE0NDQ5YThiYWJjNTMzZGQ0ZjAyMzNmL3RhYmxlcmFuZ2U6MGVjNDIzZGY2MTQ0NDlhOGJhYmM1MzNkZDRmMDIzM2ZfMy0xLTEtMS0zOTM4Mw_8faf6c9a-fb6c-4d90-b8d2-26f0cbe31c26"
unitRef="usd">58000</us-gaap:NoncurrentAssets>
<us-gaap:NoncurrentAssets
contextRef="i5d545a4cc5594760b939659357af4982_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjBlYzQyM2RmNjE0NDQ5YThiYWJjNTMzZGQ0ZjAyMzNmL3RhYmxlcmFuZ2U6MGVjNDIzZGY2MTQ0NDlhOGJhYmM1MzNkZDRmMDIzM2ZfMy0zLTEtMS0zOTM4Mw_f80d9b22-e73f-41dc-9fdb-8d2cc76fff55"
unitRef="usd">42000</us-gaap:NoncurrentAssets>
<us-gaap:NoncurrentAssets
contextRef="ic2011b63fd9c4fd7bbc64ec2a1f0ca7a_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjBlYzQyM2RmNjE0NDQ5YThiYWJjNTMzZGQ0ZjAyMzNmL3RhYmxlcmFuZ2U6MGVjNDIzZGY2MTQ0NDlhOGJhYmM1MzNkZDRmMDIzM2ZfNC0xLTEtMS0zOTM4Mw_8e7debdf-6c6d-4bf6-b94c-fbff0da32ce1"
unitRef="usd">3000</us-gaap:NoncurrentAssets>
<us-gaap:NoncurrentAssets
contextRef="i74632ce2458d45f882a429075d1c2a21_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjBlYzQyM2RmNjE0NDQ5YThiYWJjNTMzZGQ0ZjAyMzNmL3RhYmxlcmFuZ2U6MGVjNDIzZGY2MTQ0NDlhOGJhYmM1MzNkZDRmMDIzM2ZfNC0zLTEtMS0zOTM4Mw_37fd4f0b-be42-4237-96f5-4ba76c175be4"
unitRef="usd">5000</us-gaap:NoncurrentAssets>
<us-gaap:NoncurrentAssets
contextRef="i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjBlYzQyM2RmNjE0NDQ5YThiYWJjNTMzZGQ0ZjAyMzNmL3RhYmxlcmFuZ2U6MGVjNDIzZGY2MTQ0NDlhOGJhYmM1MzNkZDRmMDIzM2ZfNS0xLTEtMS0zOTM4Mw_cc40c7b1-a960-408c-98c0-beb034e0ab8c"
unitRef="usd">4932000</us-gaap:NoncurrentAssets>
<us-gaap:NoncurrentAssets
contextRef="i23debaac8bf94b7195e8771f793b80bb_I20211231"
decimals="-3"
id="id3VybDovL2RvY3MudjEvZG9jOjc4NGJhMmYzMjEwZDQzZGNiYjIzNzIxYTNjNTUzMzk3L3NlYzo3ODRiYTJmMzIxMGQ0M2RjYmIyMzcyMWEzYzU1MzM5N183Ni9mcmFnOmE5ODU1MjM5NjAzZjQwYmE5OTRjNjdlZDU2YzBhMWY3L3RhYmxlOjBlYzQyM2RmNjE0NDQ5YThiYWJjNTMzZGQ0ZjAyMzNmL3RhYmxlcmFuZ2U6MGVjNDIzZGY2MTQ0NDlhOGJhYmM1MzNkZDRmMDIzM2ZfNS0zLTEtMS0zOTM4Mw_6c71a908-e9c4-4761-ba97-6906f6a817c1"
unitRef="usd">4814000</us-gaap:NoncurrentAssets>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>75
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0 ( (&#"%4'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M " "!@PA5=?[( .X K @ $0 &1O8U!R;W!S+V-O<F4N>&ULS9+!
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ML?%94';PZU_(+U!+ P04 " "!@PA5F5R<(Q & "<)P $P 'AL+W1H
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M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 (
M (&#"%7@WM0*Z04 *4? 8 >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
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M'ZO.A%(BRB^7G/E<Z@_@_5P(M;W1/U">S __!5!+ P04 " "!@PA5ST*C
M2\H& !!'@ & 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;*U9;5/;.!#^
M*YJTTVEG K$DOQ;(3 MS/3KWPI3V[K.P%:+!ME))#G"__B0GV(DE*W#'!XB=
M[*Z?74G[/))/[[FXDTM*%7BHREJ>399*K3[.9C)?THK(8[ZBM?YEP45%E+X5
MMS.Y$I04K5-5SE 0Q+.*L'HR/VV_NQ+S4]ZHDM7T2@#95!41CY]IR>_/)G#R
M],4W=KM4YHO9_'1%;NDU53]65T+?S;HH!:MH+1FO@:"+L\DG^/$<I\:AM?B+
MT7NY<PU,*C><WYF;R^)L$AA$M*2Y,B&(_EC3<UJ6)I+&\7,;=-(]TSCN7C]%
M_Z5-7B=S0R0]Y^7?K%#+LTDZ 05=D*94W_C]KW2;4&3BY;R4[7]PO[4-)B!O
MI.+5UEDCJ%B]^20/VT+L.,!PQ %M'=!S'?#6 ;>);I"U:5T01>:G@M\#8:QU
M-'/1UJ;UUMFPV@SCM1+Z5Z;]U/R<UX4>%%H ?25YR0JB],UG4I(ZI^#:!);@
M"/RXO@#OWWX ;P&KP?<E;R2I"WDZ4QJ#B33+M\_[O'D>&GG>UZ8^!CB8 A0@
MY' _][M?T%R[P]8=[KO/=.9=^JA+'[7Q\%CZC1"T5H!(J?-TI;/Q#]W^9I%]
ME"N2T[.)7D62BC6=S-^]@7%PXDKNE8+MI8J[5+$O^OR<R"70@P9R<T%_-FQ-
M2IV[,^M-J+@-93K!>@X1S,+D=+;>S<=A%J9A&G1F>TC##FGH1?J-2B58;N:A
MP>K"MPD0[3P883@ Y[?90Q9UR"(OLNLE%^I(45'I-2CNJ"(W)062YHU@BE%G
M*2,+1AA G W VE881O$(W+B#&WOA?LISWN@1UOTVIWJX-=@IJ*ERP8PM $F$
MAB6UC>(H1FZ020<R\8*\K-=Z%G+QZ$*56 ^$&8)H ,MA%:,T<N-*.URI%]>5
MH"O""D ?5J9!RG;M<+6D0O?E0UTCM8<SL2:H;12F*7:CSCK4F1?U=ZY(^0R
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MWGB\_/52"?A:T?9S[DD-^EFMDP0K\FB:KC-AFYA0E%G#8EO!*!UCAIZ_H)_
M-$#1:.5W:% <!*:GA$4'#C.,X]B-$O7\A?S\=5GGO*) D0?J+26RZ2@80'28
MP'"DBZ&>KY"?KR[H@NK976CII^55XP9GTP^T1(K+*!Y9>FAGV^6GJ!TA7= ;
M)P4@!P=EEB)U6&4CG0OU/(4.;)6>&@,EF@,.S$1DLQ .8@NG@ZM0,(:T)ROD
M)ZM]N7<(J6-'%(3AD T<9C")HI%-'>I)"_E)JYN2>M5T4)VJ'SGV3$-F==C@
ML5734Q;R4U8O2Y\W]#8S12&,AD@=NZ8T'%%YJ&<OY-\W]5A'5Y!C7Z2'VVI
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M$@W>&.C?%US+A>V->8O8O36>_PM02P,$% @ @8,(52;5 9GO @ )PH
M !@ !X;"]W;W)K<VAE971S+W-H965T,RYX;6RMEEUOFS 4AO^*1:>JE;IB
M((&D39#65-,V:5+4:-NU"R?!JK&I;9)VOWXV4!9:F@]MN4AL<][7S[$/L2<;
M(1]4!J#14\ZXFCJ9UL65ZZHD@YRH2U$ -T^60N9$FZY<N:J00-)*E#/7QSAT
M<T*Y$T^JL;F,)Z+4C'*82Z3*/"?R^0:8V$P=SWD9N*.K3-L!-YX49 4+T#^*
MN30]MW5):0Y<4<&1A.74^>1=S3QL!57$3PH;M=5&-I5[(1YLYVLZ=; E @:)
MMA;$_*QA!HQ9)\/QV)@Z[9Q6N-U^<?]<)6^2N2<*9H+]HJG.IL[(02DL2<GT
MG=A\@2:AH?5+!%/5-]K4L6'DH*146N2-V!#DE->_Y*E9B"V!-WA'X#<"_U!!
MT B"*M&:K$KKEF@23Z38(&FCC9MM5&M3J4TVE-MM7&AIGE*CT_%,\-1L"J3(
MM)1@-"7:=&X((SP!M+#&"IW-B02N,] T(>P<?40?D(M49D;5Q-6&P[JY23/G
M33VG_\Z<WTI^B0)\@7SL^SWRV6[Y+21&[E5RKRMW3?;M$OCM$OB57_".WT*+
MY"$3+ 6I3D]&OA==(W@LJ7[N2ZWV&O1[V9?N2A4D@:ECWBH%<@U.?'KBA?BZ
M+]'_9-9).VC3#G:YQW/SOH"49K.578 +5!")UH25@,XH1ZE@C$B%"I#U1I_W
MK48]151-8?\QUC&^Q-CLRGH[S7U1'?Y!RS\XCI^4.A.2_C8C-H&Z.GNI:^/A
M%H^'Z\\K\ ,".^S#EGUX'#M5JMS//7R#\QIX5T2'-&Q)P^-(S5&@-.$IY:M]
MN.%>W%T1'=RHQ8UVXLY$GIO#X1\J.CJHHO=%=>!'+?SH"/C#RWGT9A5]W%_/
MAT1VT,<M^O@(],.J>?P&)HC\,,3!:^J>P' <>%'H]T-[^._AAX_ /J*T&]\#
MX/LB^^G=K5/<7J&^$[FB7"$&2R/%EY'QD/6MI.YH450'^[W0YII0-3-SDP-I
M \SSI1#ZI6/O"NW=,/X#4$L#!!0 ( (&#"%4ZHF(^MP8 &D? 8
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MF8,X&B?4I0W@ HPG;I>%<#0BO1FG'7$Z2/QEJ;EI&]HH<JO:0,[4+]RIEV8
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MN[_18E<?7-X*K4517VXY,VFP //_M1#ZX<:^H#U=G_T+4$L#!!0 ( (&#
M"%7F+W44RPP "-\ 8 >&PO=V]R:W-H965T<R]S:&5E=#4N>&ULQ9W1
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M%G$R<<=;<IDK 5J)F$Y=+0F4BY-X[)ZD_%(CEJ;Z/N-,QS=T(<;QPI?35#Q
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MRN_JKJO7^Y>K(E\635] __VNKKO/;_H?93[^+OCM_P%02P,$% @ @8,(
M5>KC_G\1"0 2L !@ !X;"]W;W)K<VAE971S+W-H965T-BYX;6RM6FUS
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M.6_VHDD+E;:V_!F@ITW#)+I2"PM'-$)J2SA@+@>82R_,ZP(20EIE+ &#G+1
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MZLL=2Z&!5P+P^U8(^7JC7C!\];K^"U!+ P04 " "!@PA5ZO0>C'0( #_
M% & 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;*U8;6\;-Q+^*X1:%#U
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MC-M0E#!&I5F914FB.S1^)7IU#:2PKK"+.C82FD4PN='>$#>%^I'0?78[5M<
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M/KUN2P_1U?**:^%B=)5\++!FD.<+^'[I,.;:!S;0O_,\^R]02P,$% @
M@8,(5<G!Q-W0# -"< !@ !X;"]W;W)K<VAE971S+W-H965T."YX;6R]
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MCQ+\6UU.Q?GI1,Q.9[-'Z)VWPI\SO?,#]$:D%/^<+WUP<)9_C0D<Z5V,TZ,
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M3H_N,!%WTM1M' [(8)A39O=3N*_XZAB0E6P%N^D,@(XO=;45C1TUM;F6VW,
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M-U\?"1=_HQ6_!%OQ[Z*6-J CXH\;)<$^;<!S>@?;?*$+VA_*7?X'4$L#!!0
M ( (&#"%7NT=:-!08 - . 8 >&PO=V]R:W-H965T<R]S:&5E=#DN
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M2+,;,:\7/GR,3DF]$2D'(;.F#-@+0E0U!U9J\.0XE*+"7Y-B7WI\2XHZ!2W
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ML@#V,V-\LV #[2/VXA]02P,$% @ @8,(59MR-]]A" FA@ !D !X
M;"]W;W)K<VAE971S+W-H965T,3 N>&ULM5E;;]LV%/XKA%<,*:#:DBS?TB1
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M67$,P0L&F"\8Q "L,F.( [S XR<N=L9JDI3;J@ N883FJPTU'#!AJLAV $G
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MFALTT/T[XN9?4$L#!!0 ( (&#"%77:=$4$@D '$8 9 >&PO=V]R
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M7U!+ P04 " "!@PA5FO^KXUL* "E'0 &0 'AL+W=O<FMS:&5E=',O
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MYYO+D)AH<Z/ X[139ZO;#%%)[_-\H0]*7F6*(H6$(O4WT7A5LNPTBZ$V X-
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M%JB_S%[\&U!+ P04 " "!@PA5G^J".@T# !+!P &0 'AL+W=O<FMS
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MG+AJJ@:*M*WAW,<8-7P[S8V7?W\J %_]#2^ZYQCT[(")Q&UAD%]A]%T=R<]
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M.HSNL+&J]>,R5Y:*TR]K>NU0NPMT/E?DRVKC#/3OY_0W4$L#!!0 ( (&#
M"%4H]Z'IM @ - 7 9 >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;-58
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M<L=_Q2:,G<<#D=3.FZ*9# \*789/^=#@T)MP-GEB0MQ,B-GOL!
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M6_9V)D' A6NL->>EW3;P2ZVI>?F]TL=. [YR1^#MT:+='@WIUVSWBYI/_XE
MZPEGF!(]*9SNVCYQ1PV/W]&7JG^\Z=P]O.=)<$Q3Z<&M01;Z;G/V;")S^V2C
MK6V' :64E!TS5]B\0W8-&GO_.,1^!KT4ZIAIH^>NT<(UW;AWRUHHN^*[9+I!
M AW#A6OWM+NNO@FWM+OAX:[[@[0K.L73/NAJ@,WI?"!LN#\./[RI^,YV:;PW
M!7^EBR]E:0#>9\;X]@<MT%WB7_\;4$L#!!0 ( (&#"%4C_?P4%P, .4'
M 9 >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;*U5WV_;. S^5PCOL*<B
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MYXUS?##"!>-D7WX#4$L#!!0 ( (&#"%4%I5HF[0@ !X9 9 >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;+59:V_C-A;]*X0;=&< C6Q)EF6G28!D
M'MT6[4XPZ4RQ6.P'6J)M[LBB2E))O+^^YY*2+2=VDMG'AU@21=Y[[N6Y#RIG
M=TI_-2LA++M?EY4Y'ZRLK4^'0Y.OQ)J;4-6BPIN%TFMN\:B70U-KP0NW:%T.
MX]%H,EQS60TNSMS8M;XX4XTM926N-3/->LWUYDJ4ZNY\$ VZ@4]RN;(T,+PX
MJ_E2W C[N;[6>!INI11R+2HC5<6T6)P/+J/3JS'-=Q.^2'%G>O>,+)DK]94>
M?BK.!R,")$J16Y+ <;D5;T59DB# ^*.5.=BJI(7]^T[Z!V<[;)ES(]ZJ\G=9
MV-7Y8#I@A5CPIK2?U-U?16M/2O)R51KWR^[\W!@:\\98M6X7XWDM*W_E]ZT?
M>@NFHR,+XG9!['![10[E.V[YQ9E6=TS3;$BC&V>J6PUPLJ)-N;$:;R76V8L;
MJ_*O*U460IN_L/=_--)NSH86DNG],&^E7'DI\1$I$_:KJNS*L/=5(8K]]4,@
MVL**.UA7\9,"?VZJD"6C@,6C.'Y"7K(U,W'RDB/RO&'L'Y=S8S68\,]#-GH1
MX\,B*#I.3<US<3X _8W0MV)P\?UWT63TPQ, QUN XZ>DOW@?7B[E^^^F<93]
MT,IB;]5ZC2AP,]BE86K!X&2Q=3+C5<'>B5RLYT*S)'*C^+4K06MK7FU:B8;E
M0ENYD#FW@N3(*E>Z5IK[.&OL2FGY;U'TUS*KF#2F$:RIZ1Y)(QCY/Z>Y_VQ6
M' XFR;D';0AT@!Q@:N&BN-R$G4&F9S+#.B8J*VU)VA4KY*TL1%7@C7%J[E:B
M0M#F)686;+YQ$*\4UP6I>R<UY"MM B2I^;]P3T)HBJ;@=I Z5;CE9<D@R1@/
MUB%A2'S&0I6LEFS%;^E2:PF'8 ]:*<#2QQ:RWU8"P#%;L+D P*J/?(N6UL#C
M;GH+@]0*GJ^\RQYZ# [?\X;"=M\JDG#C/?S)T[A@2.[L0V,;R/@)F\2K7#@M
MW>:M %EWDP]OCY.Q\#)D*\.9NE E,K\YW='M(<MB1[6]#66J)C(9SYG"[5W?
MLW$P 5GB),-=-$Z#*'FP'@BMEKDEO&Z@J:0]*BX*1K,HF*49&X_C8!Q/]X7Q
M6RY+/B]%W\BEYA4D)L$TF0)-BKLLC8(H2I]:_/[F^AKJXC0-LBQALP3JTBG[
M35E>LFF032=!FL4L"^(,LI*X#=B/SAWLNN05N^PJ:(]T]:[$$=%($]'6R'NV
M]IE94&9^$/+@AT'=QVR[ O.P3:?L8\\M']M-^%OCM@OJ6N+\[HH=Y%W>"HW:
MS=[?"YU+(]@UG(Z(XB7M?\!^YE5#2+<;O=VM$Q8EX7B\U>'<"8D3> ;)@,63
M,)ULWXI6?L%>15D<3*>3URP.X>IN0D[ZB.>O8OAN-'W-HEDXF_20[%F^XP]P
M9.$X<73GRZ462\IJL@)[T'GD[):7C8NLCI%]WO #>?0.@R=1&HY0KLL22\('
M$[[9FX_>O\664A5KP)E?Y$*P5[)B?Q=<F]=;A]PB +!D-AH'X\F8S(S(H5F8
MC![.H6@0]Y1:?9Z@X0,>FH;QI"7J$^[I9![S3!:F.\>\Y[K<[,PEE_3H;MCG
MBI(<,=D*O78BZ4%6+CV2^2WS?3 &6Q24#1=-">$M<UP 8B(M=Y-=+GV4YQ]6
M.BWJ1N=(?VT)8-RZ><CG2UE!?T=,2O(Y,NMECEI(W"@W.S1KOD%X]4CL*D+G
M:DSV.;U-K(3]&5@EKPWQ[Q&\IB8;X2N <XZA K&N2[5!(VT!FZG;UJ,MN*Y-
M:)&P6@";JX9+48%NY,.%:C3;$+\>V;_5W]I/=M1:Y4*@=$GD7.DDD$VHK7 -
MK =9%81H5DH^ER7FP.J%5FLG6CA.B!XG]BL"L;451[47?8AG+2\*23,(%)?%
M&VC)>2V)KE1P7[*YY%:!>ORNT>2*YS/H7GN$FEV@=-N^W,.U\N4:]ANPGN2"
M17$P&Z=/5>-2&#(<)>-D%$:[J/N&[B]"-IY-9KY%BY,@FG4:]]NQ@-V)?=KN
MH.*=1'T!C%U^W0\;@@.(20?1J</ N!MXJ,RU<N(@I_)&:Z)ZCULA-3I=-^ 3
MS&?7#5QV]=(!;%5X\ >[!TI@_8[F429W^:K<N-K9*Q./U#_*Z#^ZE/2.7/.!
M2\V^N+3ZN?+9]'$=[=J4$S:.PV3BUT->-IL%28SJF8;CC'WQN?@5>I(@F8Y>
MLR0+40O>;FME@N(011A/0@CMJ=OCQJX[.L%@F$V?+Y9''/BRVCGID]47'.>V
M-U>.^!0,HC(^O_D7<_<B[[^@@E89ZD7IVT'IBYOT!0 8K*"$:'SE$O[HXG,+
M2=%B1=\=T(^7RO3WW%5:G&\:@ZGF]2D\H878._WN3+I!9!]^LVMZ^^TOJBZE
M7:60.@WZ>ZJ\TQG]8D?A>NSS"8NCD>O;.8++X2T$8D+5+K^GJ/#Q=,IF6<8F
MHPF[$?!BM0RZ7.Z39X'J(.D<3.&$MG623+''Z!08FL]I0HTL6.(=#X*!.@DI
M#I(HQC4+IK.)&T^G(\^$.8J*W^>G=D*+DK<=!FV"]R@Q0;@3:KN4W^$P]O_T
M\\VC:G*$K&1B/'+^#U*W QFND7-%FL[:5CX;(^AB1%:*89+_,K\=Y>V15+@;
MH!AI"YL[9"/Z<+1&Z.*J=ZV_=0Y[HOGWIVY*\OOGZF>031XB2[\5V3.'DF_&
MM:^R[:U\&V-:T/%#T-$>:*HBR\H)(!/:0#0<!;1+&?][=[X ]B,6Q-\*^S_T
M]8$.P34BJ+@N1:=QCP>8V50]+/M6 I7IAWZEJC?M&2$_=. _'I#!WB%E+OKV
MNZZ6HR?P=?4-;^OJKIM-PFCL>UC?I%H7IKNC %M0W=T6L+:M:I$6NW;-$X%0
M/N-;YZAQF.WO87:LJ3GN]-Y7F&+?T[ZS%T_D7N=X!UWY?-6F5_IZ5:-/OY=K
MV(Y^NQ\3:-A6$M6%/A_]%QXGB=[AA[Z/#GO?K-="+]V7>6)Q4UG_^7H[NOWX
M?^F_>>^F^_\<_,HU#B,X%8D%EJ)!20>^H>\>K*K=%_"YLE:MW>U*<+1J- 'O
M%TK9[H$4;/\E<O$G4$L#!!0 ( (&#"%6@1<S(> 0 )X* 9 >&PO
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MT]\CWF)96B"2\:W''.PIK>.AO4/_R<5.L:RXQEM9?A6Y*6:#= YKGE;FD]R
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M'VBM9%L;?3FA9"C$HY$ :FAT#;T43V?>V%:W/_Z!==]6J+B1"NYWR?F>E/P
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M% @ @8,(5?[Y#0+Y! U P !D !X;"]W;W)K<VAE971S+W-H965T
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M_NU [03H?*F4W7TX!]T_,K._ 5!+ P04 " "!@PA5RKMA050. !V+
M&0 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6S56FN/VS86_2O$[*)( (_'
M=MY-,H!GDFG3IFT0)UTL%ON!EFB;C22JI#0>]]?ON9>D1$ULYX5=8#_,6 _R
M\KYY[J6>;8W]X#9*->*F+"KW_&33-/7W9V<NVZA2NK&I584W*V-+V>#6KL]<
M;97,>5)9G,TFDX=GI=35R?DS?O;&GC\S;5/H2KVQPK5E*>WN0A5F^_QD>A(?
MO-7K34,/SLZ?U7*M%JIY7[^QN#OKJ.2Z5)73IA)6K9Z?S*??7TQG-(%'_*[5
MUB77@D19&O.!;E[EST\FQ)$J5-80"8F?:W6IBH(H@8\_ ]&3;DV:F%Y'ZE<L
M/(192J<N3?$/G3>;YR>/3T2N5K(MFK=F^Z,* CT@>IDI'/\7VS!V<B*RUC6F
M#)/!0:DK_RMO@B(^9\(L3&!%G/F%F,L7LI'GSZS9"DNC08TN6%2>#>9T1599
M-!9O->8UYPMO#6%68J'7E5[I3%:-F&>9::M&5VOQQA0ZT\J)._'J[K.S!DL3
M@;,L+'/AEYD=6.:A^,54S<:)EU6N\N'\,[#<\3V+?%_,CA+\J:W&XMYD)&:3
MV>P(O7N='NXQO7L'Z.T3^%_SI6LL_.;?^P3V].[OIT?!]+VK9::>GR!:G++7
MZN3\N[]-'TZ>'N'V?L?M_6/4SR^DTXYL]H9H5XTD#]_'Y%>0$>\V2ER:LI;5
M[KN_/9Y-'SUUHJUDF^M&Y4)7C;*Z%)F!)2N')[AR4%DNZ?5*5[+*M"R$ SF%
M^&V<V,AK)99*50*ZJ*5E,@C(S-@<HQ5\OMGP?3!!;36(U 6,L%:5LK(H=O1>
MU9X%T8#']Q4SM*!UX)W$ZVSR]/UX,18_S.=O^'[Z].Y8S*L=)1!E%:WE9SLE
M*D/S&B-D7</B<EDHL6ZUYPAZ*15% M[S7+J@567;;(S5I*OKVSSLX76_4-*)
M%1YWHB3>!U)5+FWN8(.<PY&-$L6;+RZC8 (#]\]\7^<#G<P7[[M)L#:M>-79
M:2^%"X.?;O[5?''1J?.(^S[HW/?!4;][TVL"[%QV_G/ B;^:&+ORI]T3\XLV
M5]Z\7ALNZBD$ NM:X_%V8\B^9EN!FFN73N=:6F0+N%E1^.C(PIRE+,B7'$]&
M(JF<Y*TH#0A5:&1U&=PZ2[D_INF'G:8?'E7.>_@Y)'GI&EV22^Q3[Y=18)WZ
M,/8ZQLMORPY>;@(8NMGY5$#QB[#[L]5(3-CN*@ $&DQ!6,H/2JB.'=*M= 5
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M!;I/C<__ U!+ P04 " "!@PA5>V5/(-\$ "1#@ &0 'AL+W=O<FMS
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MLXF2&Z3L:K!F&\Y5MQO <6&3,C<*9CGL,[-/E"OTC68%0[>,ZD(QB+C1J/M
M%QG3%Y.^@5/LVGY<6;PN+9(S%@?H5@J3:O2;2%ARN+\/Z&J(9 ?QFK0:_*,0
M/13X'B(^(2WV@MKEP-D+?N[R1Z[C3%JO-?KK:J&- I;\?<KGTF1XVJ2MG$N]
MIC&;=J T-%//K#-[]P8/_ \M@,,:<-AF?3:'2DR*C"&Y1%=:,T@/%0GZRNF"
M9]QP %_E+D'4H(9_EO;HGL6%4ERLT#757)_RKOW\AY2AI<R@?JT1XXA153'_
M!YH&YLUV#2T 2/< LP; O %P:0$^[P&J&N#" D2++<K8,[.E8%(NG/W&GI0S
M156<;E'73<I"PVGZXA(!4UC-%/35V<#5>]</T(,T-*L">6G)RK904>H)%'!9
M@"'T%A$/CPF\W[T9$4P^'+3*N1N9YTS%'"RMZ9JI>@'QPO'PJ'=#=8K8]X*#
M ZZZ2AN'2T-O,!JCQ]Z\AS[+9Z:$+40$PBCB+5I("XQ$'AYB-/+&\-SM"T(/
MARV L ^&\7'WUCEL4XFT#7^9I>H //8&$=DC"[T1V<5MR045[I@JTQ"1H1<,
M ML O\+Q0;3"L1=A@H!"BJ&-?0CY'XAAZ22D>'],%>HX=Y#W'OK(8I8O( 0!
M=D/X_U!A%. S1+ S+33P??^H=R/56BIJ6)7.?>9#[!_U7E#&GC8X6#CT2(C;
M"8-#H,H015[DAWLPOA>.6J!#]K$_/.Z> T^\,0Z/>J?)58$!MD0DVKM+ !PY
M3RX<>2-_!(T@\,9!=$RN81B\,KE>L*G7(NE1+>G1+TOZC=3&0X\"_JDRT-,$
M?89_J4KB)82A;#95?=F,\+R.\"EE;X5Q^KMU0NZ/U3YVD(L]Y%4-.=M#;D9\
M6=75,2G:)?PJE\JX VR0FC&J(O,B:HTPM5;&6ZN;X<"*?#<@_D6#5><$%91S
M"%K2#1NK6]44" IZ.@K<&0/8=<#=4E3!P\*6-W!/KH1S1(HJQD++C"=0<@D0
M,H/" .ON1WV>0EC>&Z;R,U$-?0\'8PB26+4N _#GJK5&^%)-7S,K($Z1;S\A
M73(Z#%@M6X<Z9!4G0EU\<:1!+]-G=6S_48MVPG;6?1 F,G!(QA9)5(WYY)62
M!O&-!OBG20/*C<,6RI403VE4OW%-@-BLW&5( V9PIKPQU*/U?>NJO&;LEY>7
M-3A]91.;L25L]7M#T!E57H#*CI%K=^E82 -7&-=,X<[(E%T \TLIS:YC#ZAO
MH;-_ 5!+ P04 " "!@PA5"(:.F44& #S$0 &0 'AL+W=O<FMS:&5E
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MDQKBW:C@8=YU&MB^AJX^$P$5VG3$<T.PZ%NR/:5B^U!S/"TB$D8\D,J=%3!
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M2P,$% @ @8,(56&0]^QF P IP< !D !X;"]W;W)K<VAE971S+W-H
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MC@:[WQ[H)47# O1_KVG>M@<VT+W-JW\!4$L#!!0 ( (&#"%4R+><49@0
M H+ 9 >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;*U6;6_B.!#^*Z/L
M:M5*E+Q!@!:0*'NKVU.KJ[:]W0^G^V"2@5B;Q#G;*>5^_8UM&J"E[.IT'\ O
MF7GFQ<^,/5X+^5WEB!J>RJ)2$R_7NK[T?97F6#+5%356]&4I9,DT+>7*5[5$
MEEFELO"C($C\DO'*FX[MWIV<CD6C"U[AG035E"63FVLLQ'KBA=[SQA>^RK79
M\*?CFJWP'O4?]9VDE=^B9+S$2G%1@<3EQ)N%E]=](V\%OG)<J[TYF$@60GPW
MB\_9Q N,0UA@J@T"H^$1YU@4!HC<^'N+Z;4FC>+^_!G]DXV=8EDPA7-1?..9
MSB?>T(,,EZPI]!>Q_A6W\5@'4U$H^P]K)YL$'J2-TJ+<*I,'):_<R)ZV>=A3
M&+ZE$&T5(NNW,V2]_,@TFXZE6(,TTH1F)C94JTW.\<H<RKV6])63GI[.15ER
M35G6"EB5P5Q4FE<KK%*."LX>V*) =3[V-=DR&GZZQ;UVN-$;N G<$E*NX)<J
MP^Q0WR<?6T>C9T>OHY. OS55%^*@ U$012?PXC;PV.+%_RGPCUREA5"-1/AS
MME!:$GO^.I8%9Z1WW(BIJ$M5LQ0G'I6,0OF(WO3#NS )KDZ$T&M#Z)U"G]Y3
MA69-@2"6\'N-DID X :)I!2.TC:N699QPW]6P.?*%3&MCH5RTMCQ4'96"VLU
M-593026K**WDELX1EJ*@TC="9[RB'=$H<DR=7\(]?SJ@"= A8WO(YB^$HR;>
M0]CI]1(W]B.XSX74%QIEN2\5)I# 5R:Y(?'^AV@4T"^&!Z$I+2]P!X3GQA >
M#MS7%L>U+_X/L83M<LMWN:5>53!-T6AAXR>FU:S:?'@WC,+!%:7E,")UF)8.
MX%.*M8:U;2@$PQY)?H6047U3TMH<?<04RP5*B,,.V&YJ,MY0+$PI-,$DG=%P
M0..P$PSZ\.TEH$33M7>IM?D[VR"3ZARB;B^&N!L.7NME5!RBJ310& AG%$Y*
M970._>X(DF[PHZP)2HJY%NJZ0%-__V?V?I)4<Z9RJ!G/R$\)K#31*/(B+1JC
M81$12C) '<#X:#+KDE00FWA!QXZ'"JF!7%+,RAR!W=JY:N\>I_,>1HDC;AP'
M[M@NQ/*B/3:*<*'I6!P$<2%GU)6LGZ\=()AX2/\V.]$5G&@J_;:I]'^ZJ=PR
MW4BN-S CBF^HJ,VFZR\W.R^.]9*3-H[WDA_5&MUZ6V_8GC?'*/(Z3RK?HI(T
M6ZTDK@QSG5S--MM;P (>LN4EN=SFKG 4D:VT9#MW38/(13)4.;8OT;0'46<4
MCLRT3P)!%&S;#EWFO&S*EUZ,.F$849*5NH29)>:.>ZV01)LW>V,13:APD;I7
M$B=PY_;AD16-/<-EH\TM]H8UTQMZ@V1K;]Y(:91?)S#N!$D(-Z):[7?90RKV
M.[VP?Y2"_M[[I$2YLJ\P!;:)N*=*N]L^]&;N?;,3=Z_$6R97O#)GO"35H#L@
MIDGW\G(++6K[VED(36\G.\WIL8K2"-#WI1#Z>6$,M,_?Z;]02P,$% @
M@8,(52*,!$+#!0 *P\ !D !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
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MU5[-VA<CE_8Z-),&+U?V,<?;K% T ;_/I33;%S+0W8\G_P)02P,$% @
M@8,(59"?^32K! %0L !D !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
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M/V))Y)TY,6"S)' B^8F2U(E!S*)I= ;OL98T,9R3[VXZ8?XS?R"W&SPPOI]
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M2AIZ1CFQH'<K*GN!SM>2"-HOK(/A)3S_!U!+ P04 " "!@PA5#6DO<U@#
M #B!P &0 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6RM56UOVS80_BL'
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M%'HU_"C#PLBV?\4WTM"?T(LE?<*HK *=;Z4TSPM[P?BM+_X#4$L#!!0 (
M (&#"%6')03##@, "0) 9 >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM
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M\#,&E-V ZRLIS<W !N@^C-+?4$L#!!0 ( (&#"%4#OMCL$ 0 ! 6 9
M >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;,5877.C-A3]*QJZTTEF-N'#
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M4V-D@ BM89:(3W0?H'(^ \47TH3GOV!?C!W*P6'&!4U+L(P@Q:3XAR_E.AP
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M^6/1$'2;GV8]42%HFE_&"$:(J0'R_II2\=I0 M4A\.QO4$L#!!0 ( (&#
M"%5VQCD2M0@ +Q1 9 >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;+6<
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MVOK/TB4C? /:?6$.;G '!S?N,^CS*'MDTA-]@G$X>#(8=2E@DF(I A#&,D!
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M$3@T()IJ78'!Y[9>WS$$P$1!,9$PP$2G!4*G)/H%@HJ<_*1,-7STVJ$<L
MY)#:LO=JO>:]AN_CXB[)2BL5MW4;^ZRY&2\.KPH\?*GR7?NVO>N\JO)M^W$C
MXAM1- 'UWV_SO/KYI7F!W_&%C:O_ 5!+ P04 " "!@PA5W1O1 ,($ "K
M& &0 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6S%65MOVS84_BN$5@PM
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M931QIJ9Q(9A\&TL_,?N 8P:^XR0GX O!/&=$SI'@8 "^97)9)/%_9 4^RN7
M <Y6X#/EG!PN:YYO[XG <<+?*;?%/7C[YAUX ^(,_+FA.9?&?&(+258-:4='
M8N\/Q% 'L3_R; A<YP8@!R&-^]SL?D\BZ0X+=]ATMV6*RCRA,D^HP',[\98"
M+$B4LUC$A-^ NYV,&"\3,I![:<!Q0F[J*1$4W*64B2)_<\H%^/MNR063R_8?
M73(.HWOZT=5>ON5;')&I)3<K)VQ'K-FOO\# ^4V7FI[ &HERRT2Y)O19,VI=
MJ ?_H/!7568W\WP8NA-[5X]!8X5\%)16#7)>2<XSDJNMZ<-*UO$[0/BUD0=N
MX)S0TQBAL9Z<7Y+S+R57;#@=-[\U["FQMH6OIQ64M (CK6I1ZP@%K>$\+T2G
MDZFQ0KZ#],1&);&1<4O*E9:K4L5(1-=9D3>I"V)#0$0S3I-XA85\ML0)SB("
MBAJI"V'4Y];K":R1D+!,2&B<J<5&;KV!("R5"L&>9$V6Y0GPLFCI@@_;,^-
M=WPR?VTK%_H!U,_?N*0[-M+]3+/UE6S';;9!Z)V0;1M!9^QUD(5.)92.D>Z7
M2TD><<[M"9U9]Z: -4&'YC(R7 S!1[HC+%-2#F0SED4_P9)VR; 1[MKUWQ=:
M,_A*I>'KRC3L5:?[0FLFJU)J^%*I/@(T-K[G!>AT*;?-D.,['7H(*[6&/<@U
MU.DU.I5%G14*.PA6B@U?+MGPO&8;39K4*M6&+Y%MV%9DUX->:V+;9LCQPJY:
M6BDW-.K@;$[9EC(ISX:RU*LL]X76C+<29AB^;EDR-@97)ZLGM&:RJK8 FON"
M"\J2$>#J<-L- QK#CJX95?T",O<+%Q4O,\;5WWWMEF+0L5=1U4^@,_W$!37.
M#'%U&/#2<HAJG^]&+3U3#LW.5_-'N@7E=810R34RR_6<IBEA48P3L,5;PK2!
M&"&N#J0GM&; E?PC[W7/7(S=Q]7)Z@FMF:RJ%4'F5N1\U43M+@,Z(P1/-%]G
M-H9=WR6H:DB0N2&YK!ZV&XZ!=]HN:8RZZD/5D2!S1W)1E1N=[>0T)EU"4C4/
MR/Q9?Z9TA:V#,N@$86M6-69R5D<GY.S:2;(ZQI<?O6MU]IN01^GG#$<R,G8X
M&3_<"+HM#I>75 B:%I<;@E>$*0/Y_I%2\7RCSJO+_T_,_@=02P,$% @
M@8,(517)?L:A @ T@< !D !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL
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M P04 " "!@PA5VN& 12@# <"P &0 'AL+W=O<FMS:&5E=',O<VAE
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MGJHACOX"4$L#!!0 ( (&#"%6J<:1/MP( \' 9 >&PO=V]R:W-H
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MJ9I8SR'I6FE1-&!44#!>_].7QH<=@-\[ @:0/"O@+ !A+;06IDM:T(U3892
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M+$_6X[?>:%':"387&N>A7:[PBP72!.#SA1!ZNS%#L?T&)G\!4$L#!!0 (
M (&#"%62RB<9Z ( /4' 9 >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM
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M\,CW#N#:,7[@#;KA!@W<X"C<X_3>=I.PNTQ"#&Q#EUDGXZ"]_N L1T2A'XW
M8=@0AD<)J_T?U_N?VOW?11>VEC[TKQT1](?=<,,&;G@4[EYHW'#%0?OM.?IW
M[F&KY8)AT#M ;P?U1Z/@@-W=.Y3-A?B5RC4V'<E@A3+O8HBER^J2J09:%/:<
M7@J-I[Y]3?%>!FD"\/M*"+T;F*._N>FC/U!+ P04 " "!@PA54LIN2_ #
M ;% &0 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6RU6-&.FS@4_16+
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M0.T/M?N!P7]02P,$% @ @8,(5>A%%M!9 P ]0P !D !X;"]W;W)K
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MPYG^+@%A#/3S">=J/3$;Y%\ZP3]02P,$% @ @8,(5:O38-7- P $1(
M !D !X;"]W;W)K<VAE971S+W-H965T,S<N>&ULK5A=C^(V%/TK5EI5N])T
M\@5AA@+20,BV*VT[6K3M0]4'DQBPUK&SMC-,^^OW.@E9&#(A=,,#),X]Y]KG
M7!S;D[V0G]6.$(V>4\;5U-IIG8UM6\4[DF)U*S+"X<E&R!1KN)5;6V62X*0
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M["AF: 6-)"U*[N^'M=(2YII_FJJK[,"@N0-F AZK#,=D:F4FEWPBUNRG']S
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ME^7IQ#?Z\K#D Y9;RA6XL8%4SNT(2E66YP_EC199L5]>"PV[[^)R1W!"I F
MYQLA].'&)*A/@69? 5!+ P04 " "!@PA5'-%!"E8# N#@ &0 'AL
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M"\5P;2YT(*V!V5\*H1\F]LI071'CWU!+ P04 " "!@PA51<V+[;D" "7
M!P &0 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6RM55U/VS 4_2M7&9I
M*N2C;9A8&PG:56,:"-'!-$U[<-/;QL*Q,]MIRW[];"=$!4*9T%X2.[GG^)P3
MYWJP%O).98@:-CGC:NAE6A<GOJ_2#'.BCD2!W+Q9")D3;:9RZ:M"(ID[4,[\
M* AB/R>4>\G /;N2R4"4FE&.5Q)4F>=$WI\A$^NA%WH/#Z[I,M/V@9\,"K+$
M*>J;XDJ:F=^PS&F.7%'!0>)BZ)V&)Z/8UKN"6XIKM34&ZV0FQ)V=G,^'7F %
M(<-46P9B;BL<(6.6R,CX77-ZS9(6N#U^8)\X[\;+C"@<"?:=SG4V]#YX,,<%
M*9F^%NO/6/OI6[Y4,.6NL*YK P_24FF1UV"C(*>\NI--G<,6(.R] (AJ0/2O
M@&X-Z#JCE3)G:TPT2092K$'::L-F!RX;AS9N*+=?<:JE>4L-3B=GA!&>(DS=
MEAF)O! <N59P")-2EQ+A-!=2TS_$I?YI8[:/0M@?HR:4J0-3=S,=P_[> >P!
MY? M$Z4B?*X&OC;R[")^6DLYJZ1$+TCY4O(CZ 8=B((H:H&/=L/'F!IXZ.#A
M8[AO0FF2B9ID(L?7?8%O0CG5>/C5[+(YG'--^)+.F,E#*=2J Y>H.ZWA=&!"
M54H8_$ BX8*8%*F^AY^G,Z6EV;:_VJ*IM/3:M=A?^405),6A9_Y5A7*%7O+^
M71@'']N"^D]DCV+K-K%U=[$G]N/!OD3;02A?@J(;R 77F3IH\UV1Q8[,=IQ5
M$IMOO]IVLW.]-[KI-6YZK[GIMLFN4/TMV:$M?*1[)_,;=?<;W?W7=/?:=/>?
MZ>Z&3V3O)'ZC[+B1'>^4?6E[$)'RWNZ<6\)*;#,1/]LS41@_<=%2<WS<U%3B
M_*VV:8^L"R*7E"M@N#"HX.C81"&K8Z"::%&X3CH3VO1E-\S,R8G2%ICW"R'T
MP\0VY^8L3OX"4$L#!!0 ( (&#"%5/&;@+D0, *,* 9 >&PO=V]R
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M-0,C*W>I6$B#5Q3W6. M$I0UP/<K*<UA8.\I[;UT^B]02P,$% @ @8,(
M533K!34!"0 OF !D !X;"]W;W)K<VAE971S+W-H965T-#$N>&ULO9UM
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M?,Y> ]'L4-7!,(OSZB]YK=M>C08DW.1%EC3!J@=)E-:/_%OS0>P$.,<"[";
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M(V$N$N8A810)\Y&P EC(%A'QM=;&5\;C\F5C*.MC-^3A<I$>%(5"5$:QIMY
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MP?:_+)C^%U!+ P04 " "!@PA5YWY(E0<# #3"@ &0 'AL+W=O<FMS
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MF7&%5QKSNL);)P@=@/T+CF>];.A[376/#?\"4$L#!!0 ( (&#"%485G*&
M^0, '\2 9 >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;*V876_B.!2&
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M/??%9.F9#K# HP&C!\14:TE3#]HNK983G&0JL9:"R;>)U(G1%YIMT!_ 4A3
M2B"<Q6A"LSTPD:P(H&<J@*-/:,(@3@1ZVC F59%PP4^RCR/7M&"R69%ILC'
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MCH&I!O+]FLK#=5E0'51W3J/_ %!+ P04 " "!@PA5A$$>JP@# ")"
M&0 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6R-EOMOVC 0Q_\5*ZNF5FJ;
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MN YE9?4T*ROY)PH>QJ]V8$+U5FC.";L6[DW"G<9VIGL6HHQ>0!5DDL8&D)%
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M " "!@PA5[$""998" #)!P &0 'AL+W=O<FMS:&5E=',O<VAE970T
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M&+S!0%7]<-03(TO72K?2X)URPQS?6E#6 /<S*<UQ8AVTKW?T!U!+ P04
M" "!@PA5H5.42Y % "]*0 &0 'AL+W=O<FMS:&5E=',O<VAE970T-BYX
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M/__DCIU?VX3$A/F8L 3%B+!&E(/*ZF'-OHLE]B\A#CL:$PTR*1-52NCJZKV
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M1(LTW]OV)+0627ZX!KH F=U@?E\*H5]/,@?5CLW9?U!+ P04 " "!@PA5
M-0S?+;@" "G!P &0 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6RM56%O
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M\K'WQB,9+&G%S97<?(3&S]#RI9)K]TLV=>X(D]-*&UDT8%10,%'_T_NF#SL
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MDH*R"?A\*:79;FR!=C8GOP%02P,$% @ @8,(5=#$T7]F P H@L !D
M !X;"]W;W)K<VAE971S+W-H965T-#@N>&ULK9;;;N,V$(9?A5 710)XH[-L
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M!!0 ( (&#"%7=CV=WM ( .X& 9 >&PO=V]R:W-H965T<R]S:&5E
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MTE"[<\.<+B14-H#^KZ0TNXGM>=T5E_P&4$L#!!0 ( (&#"%72:9H.U@(
M \' 9 >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;*U576_3,!3]*U=A
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M " "!@PA5T/"3C-8# #\%@ &0 'AL+W=O<FMS:&5E=',O<VAE970U
M,2YX;6R]F-MNVS@0AE^%T!9%"Z31P;:<N+:!Q#JTBQ8(FG9[L=@+6AI+1"72
M2])Q^O9+2HIBU[+61HC>)!(U_S<DYS=ESW3+^ ^1 TCT6!94S*Q<RO7$MD62
M0XG%)5L#54]6C)=8JEN>V6+- :>5J"QLSW%\N\2$6O-I-7;'YU.VD06A<,>1
MV)0EYC]OH6#;F>5:3P-?2)9+/6#/IVN<P3W(;^L[KN[LEI*2$J@@C"(.JYEU
MXTYBU]&"*N(O ENQ<XWT4I:,_= W'].9Y>@900&)U BL_CW HI"D]0\_FV@
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MC-H2C'I+</!6ZJI +^+<"IB$!29AH4E89!(6&X+M.<1O'>+_]E/?-VDHD[#
M)"PT"8M,PF)#L#U#C5M#C7N/G-90;%F0#.O?41=(,K0$M,8DO4 _ 7/$*'0Y
MIQ=]KG-,P@*3L- D+#()B\>'KSW':5]H>X:X:@UQ9< 0<LNZ#-&+/M<0)F&!
M25AH$A:9A,4U;+1CB.$Q0URWAK@V88A<?67ILD0O_%Q+F(0%)F&A25AD$A9?
M'YP11RWA.L_M%<? CX4&LIO;V\G=M$!Z,YU;5*.TT"@M,DJ+3=%J!]@[O;82
M>%:U405*V(;*NBG1CK:MVINJ0?G+^,*=!&['>.A.HKH1^XRO^\*?,<\(%:B
ME4KE7([5\<7K5FM](]FZZO0MF92LK"YSP"EP':">KQB33S<Z0=OPGO\'4$L#
M!!0 ( (&#"%7%B1E#V ( "L, 9 >&PO=V]R:W-H965T<R]S:&5E
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M&("^/^-<;28F0/W_(/P-4$L#!!0 ( (&#"%6>6*K@K < &H^ 9
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M^R$+L-M>/OD?4$L#!!0 ( (&#"%4"+689> , %,0 9 >&PO=V]R
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M>V7[/T+Z/U!+ P04 " "!@PA5VI%(!CD# #U"@ &0 'AL+W=O<FMS
M:&5E=',O<VAE970U-2YX;6RUEFUOVS80@/\*H0U;"[262+W8SFP!<9MA+= M
M:+#U,RV=+2(4J9*TG0+[\2,I179GV7 \[(OX(M[=PR/O>+.=5(^Z C#HJ>9"
MSX/*F.8F#'5104WU2#8@[)^55#4U=JC6H6X4T-(+U3PD492%-64BR&=^[E[E
M,[DQG FX5TAOZIJJ;PO@<C</</ \\9FM*^,FPGS6T#4\@/FSN5=V%/9:2E:#
MT$P*I& U#V[QS0(G3L"O^(O!3A_TD=O*4LI'-_A0SH/($0&'PC@5U#9;> ><
M.TV6XVNG-.AM.L'#_K/V7_WF[6:65,,[R;^PTE3S8!*@$E9TP\UGN?L-N@VE
M3E\AN?9?M&O79FF BHTVLNZ$+4'-1-O2I\X1!P(Q.2% .@'BN5M#GO(]-32?
M*;E#RJVVVES';]5+6S@FW*D\&&7_,BMG\@<CB\=*\A*4_AG=?=TP\PV]17X:
M_=%XS]TZS[GY5^_!4,;UZUEHK&VG(2PZ.XO6#CEA)T.?I#"51G>BA/)[^= R
M]^#D&7Q!SBK\N!$C%$=O$(D(03^B$.F**M!=<\9"W+LF]A;B$Q9^W]1+4$BN
MT,. RI:QU9 ,:W 1=:,;6L \L"&C06TAR'_Z 6?1+V?XDIXO.:<]7U!.10%O
MT!+63 @FUHZU <5DB5XQT7GB-?I[T"?M!EH3J3?A(GB;$YRD.,:S<#O EO9L
MZ5FV]N9HM%94&+@<)SW"R=+49IAAFJRGR2ZB@2=0!=,OX,F.>-[B,9E,LF&@
M<0\TO@BH< ?(7\ S/N8A8Q)-AG$F/<[DLIL$HKSB#DV.[U 6120>#U-->ZKI
MV?C[XC.J=<[M%I1](=!==WSH7K$"ADBF_T,XXFB?2J/_%I"EY)PJ[:9:=SJ_
M[E/78%9M34X.G(OC49(,NQ8?I'W\X@"]!J][79+O#G^4GH@/3/9\Y(J0O8:0
M#!".<'H"</\XX+.Y?3B$K^&+C_GP=#0]Y<']ZX O?!Z.@_H:S.3X'HY'2?PO
MRO"@$JE!K7V]99TD-\*T14D_V]=TMVTELU_>%H2?J+)1I!&'E16-1F.;8%1;
M8[4#(QM?URREL562[U:V+@7E%MC_*RG-\\ 9Z"O=_!]02P,$% @ @8,(
M587!=E@% P =@D !D !X;"]W;W)K<VAE971S+W-H965T-38N>&ULM59M
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M_=0*?P)02P,$% @ @8,(51++I<5> P &PL !D !X;"]W;W)K<VAE
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M+.66N9E>05H!\WXIA'[96 ?-/)S\ %!+ P04 " "!@PA5G20JT[D$ #'
M'0 &0 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6S%F6UOHS@0Q[^*Q:WN
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M=D,X)T5UF6*48"H-Q/,U(?SQ1@9HSV[G_P%02P,$% @ @8,(5>R8L818
M! Q( !D !X;"]W;W)K<VAE971S+W-H965T-3DN>&ULM9AM<^(V$,>_
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MSM]V&&HI*PK"]QS )MF1/OYX]SA/CQ0Y8=]<J L\OO80-G@2,:ZWBLS[W]A
MM@N_?T'-.XL:J'I+#92]I0;*WE"S]PZUZKRP,K<)0G6\KF1SUNA*NQN+>W-.
M[Y4_N*-'%RB/]0V'.42_NF^N1SX3OLHK@0JZ5%6IMJG$X,V-0_,BV=H<J1=,
MJ@.Z><PH48.@!>K[DC&Y>]$5=/<^T^]02P,$% @ @8,(57F K9\'!
M>1, !D !X;"]W;W)K<VAE971S+W-H965T-C N>&ULU5A=;]LV%/TKA 8,
M+;!%W[*=V@82)\,ZM*M1H]M#T0=:NK:(2*1&4G;Z[T=2BBPYBM >G!?;)+B
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M"G-5LF52LMP44\#*C+J#>KYC2OFZHE_0W+8M_P=02P,$% @ @8,(59Z&
MPTV5 P 9Q( !D !X;"]W;W)K<VAE971S+W-H965T-C$N>&ULO9AMCZ,V
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M.5>'$QV@V5L*_P%02P,$% @ @8,(5>,(>LY6! MA@ !D !X;"]W
M;W)K<VAE971S+W-H965T-C(N>&ULQ5G;;N,V$/T50KM8;(!-).IJ)[8!QU+;
M% D:Q$W[4/2!D6A;6(ET2=K._GVIBV5+9M0D)9 76Z+FG.'PC,;D>+2C[#M?
M82S <YX1/C960JPO39/'*YPC?D'7F,@G"\IR).0M6YI\S3!*2E">F;9E^6:.
M4F),1N78/9N,Z$9D*<'W#/!-GB/VXQIG=#<VH+$?>$B7*U$,F)/1&BWQ'(O'
M]3V3=V;#DJ0Y)CRE!#"\&!M3>!E!OP"4%G^D>,>/KD$1RA.EWXN;FV1L6,6,
M<(9C45 @^;7%,YQE!9.<QS\UJ='X+(#'UWOVG\K@93!/B.,9S?Y,$[$:&P,#
M)'B!-IEXH+M?<!V05_#%-./E)]C5MI8!X@T7-*_!<@9Y2JIO]%POQ!% \J@!
M=@VPNP#W!8!3 YS7>G!K@/M:#UX-*$,WJ]C+A0N10),1HSO "FO)5ER4JU^B
MY7JEI$B4N6#R:2IQ8C+'2RF[ #>D2KI"O'/P@+>8;#!X^@%^QG3)T'J5QF J
M,Q%\#;% :<;/I-GC/ 1?/Y^!SR EX/<5W7!$$CXRA9Q806_&]22NJTG8+TS"
M 7>4B!4'$4EPHL"'_7B_!V_*!6E6Q=ZORK7=2_CKAEP Q_H&;,NV%?.9O1X.
M5>'\/^_1N[VW%L-I4L0I^9P7^.IDX&#!: ZB9X$901F8E<F)&0=2='!+R?+\
M5K[S"9ARC@4'?]U*'G C<,[_5J5$Y=15.RWJXR5?HQB/#5D .69;;$R^?(*^
M=:720R=9J),LTD364LYME'/[V/?*J5:_ OHEL/@QV4Z@,_2LD;D]7E:%E6U;
M3MLJ/+6RW<#QVE:1P@JZ;M!8M2+TF@B]W@@?22IDRLT%$EA9>'KA;\TRG62A
M3K)($UE+ [_1P/^(^N#K5$XG6:B3+-)$UE(N:)0+WEL?*J!W]+8.?.AWRL.I
MD>_Y0:<ZG!I!U[>'G>J@L+(&GJ^N#H,FOD%O?-&&R1WU-W"7)DF&SR/$19F,
MTP5+8[F5^?)I(,O957073<M+>'6F6HM>)V_-1)UDH4ZR2!-92ZEAH]3P(VK(
M4*=R.LE"G621)K*6<M ZG""L]U:1&GG\6KM>T-UEJ*P"MU,A0H75P+<[>Y%(
M914,'74=@4>G)-@;XY2G"-RC.%VDL3+07OA;,TTK6ZB5+=+%UA;"/@AA?T2A
MJ+WJTD\G6ZB5+=+%UM;O<):$O0>>WF+AG+RZ@>UV:\6IT2#PNJ7BU$@>-4Y*
MA<(J&+RPY8"',Q?L/W3])E:8@1M29F;13T&9,MI>EC=GG$ZV4"M;I(NMK<?A
MA B]#ZD86D^66ME"K6R1+K:V?H?3)>P] O56#/^DI^">;"Y.;:#=K1?_S1/U
M\U2QF4=]6)E:R[(!SD%,-T14_;9FM&FR3\O6<F?\&E[.H&(\+)KR9=_W0%]U
M].\06Z:$@PPOI"OK(I"BL:I)7MT(NBZ[P$]4R+PO+U<8)9@5!O+Y@E*QORD<
M-']53/X%4$L#!!0 ( (&#"%7_#1J;%@, #L- 9 >&PO=V]R:W-H
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MNT C(4 *-'] WX"M.$XC$N(8C51FT.$$)":Q.%*0V]D$'1X<H0-$*/H9L;7
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M% @ @8,(55'5DJ92 P S!4 T !X;"]S='EL97,N>&ULW5C1;MHP
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M8SL"F-U!&&((W(TX@CD #Q@2AM5[<.=]Y*W?4U[[^^WH#U!+ P04 " "!
M@PA5EXJ[', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0
M(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I
M6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE
M/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6
MFD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#
M!!0 ( (&#"%7]%J2RP@0 #(J / >&PO=V]R:V)O;VLN>&ULQ9K?
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M4$L#!!0 ( (&#"%4G9=6E# ( (0E : >&PO7W)E;',O=V]R:V)O
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M " "!@PA5[M7M&.8! #U) $P %M#;VYT96YT7U1Y<&5S72YX;6S-
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MJE%D+5!D+5!D+5!D+?Y3UF=KEW\</SSSUM3=(9\-_W::O0%02P$"% ,4
M" "!@PA5!T%-8H$ "Q $ @ $ 9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0 ( (&#"%5U_L@ [@ "L" 1
M " :\ !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0 ( (&#"%697)PC
M$ 8 )PG 3 " <P! !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#% @ @8,(5>#>U KI!0 I1\ !@ ("!#0@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0 ( (&#"%7/0J-+
MR@8 $$> 8 " @2P. !X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"% ,4 " "!@PA5)M4!F>\" G"@ &
M@($L%0 >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#% @ @8,(
M53JB8CZW!@ :1\ !@ ("!41@ 'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+ 0(4 Q0 ( (&#"%7F+W44RPP "-\ 8
M " @3X? !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M" "!@PA5ZN/^?Q$) !*P & @($_+ >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L! A0#% @ @8,(5>KT'HQT" _Q0 !@
M ("!AC4 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4
M Q0 ( (&#"%7)P<3=T P #0G 8 " @3 ^ !X;"]W
M;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4 " "!@PA5[M'6C04& #0
M#@ & @($V2P >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L! A0#% @ @8,(59MR-]]A" FA@ !D ("!<5$
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4 " "!@PA5UVG1
M%!() !Q& &0 @($)6@ >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;%!+ 0(4 Q0 ( (&#"%6:_ZOC6PH *4= 9
M " @5)C !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#% @
M@8,(59_J@CH- P 2P< !D ("!Y&T 'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q02P$"% ,4 " "!@PA5*/>AZ;0( #0%P &0
M @($H<0 >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4
M Q0 ( (&#"%4C_?P4%P, .4' 9 " @1-Z !X;"]W
M;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#% @ @8,(506E6B;M"
M'AD !D ("!87T 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6Q02P$"% ,4 " "!@PA5H$7,R'@$ ">"@ &0 @(&%
MA@ >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0 ( (&#"%7^
M^0T"^00 -0, 9 " @32+ !X;"]W;W)K<VAE971S+W-H
M965T,3@N>&UL4$L! A0#% @ @8,(5<J[84%4#@ =BP !D
M ("!9) 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M" "!@PA5>V5/(-\$ "1#@ &0 @('OG@ >&PO=V]R:W-H
M965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0 ( (&#"%4(AHZ9108 /,1 9
M " @06D !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L!
M A0#% @ @8,(56&0]^QF P IP< !D ("!@:H 'AL
M+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4 " "!@PA5,BWG%&8$
M *"P &0 @($>K@ >&PO=V]R:W-H965T<R]S:&5E=#(S
M+GAM;%!+ 0(4 Q0 ( (&#"%4BC 1"PP4 "L/ 9 "
M@;NR !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#% @ @8,(
M59"?^32K! %0L !D ("!M;@ 'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6Q02P$"% ,4 " "!@PA5#6DO<U@# #B!P &0
M @(&7O0 >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0
M ( (&#"%6')03##@, "0) 9 " @2;! !X;"]W;W)K
M<VAE971S+W-H965T,C<N>&UL4$L! A0#% @ @8,(50.^V.P0! $!8
M !D ("!:\0 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q0
M2P$"% ,4 " "!@PA5=L8Y$K4( "\40 &0 @(&RR
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0 ( (&#"%7=&]$
MP@0 *L8 9 " @9[1 !X;"]W;W)K<VAE971S+W-H965T
M,S N>&UL4$L! A0#% @ @8,(517)?L:A @ T@< !D
M ("!E]8 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4 " "!
M@PA5VN& 12@# <"P &0 @(%OV0 >&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;%!+ 0(4 Q0 ( (&#"%6J<:1/MP( \' 9
M " @<[< !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#
M% @ @8,(59+*)QGH @ ]0< !D ("!O-\ 'AL+W=O
M<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4 " "!@PA54LIN2_ # ;
M% &0 @(';X@ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM
M;%!+ 0(4 Q0 ( (&#"%7H11;060, /4, 9 " @0+G
M !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#% @ @8,(5:O3
M8-7- P $1( !D ("!DNH 'AL+W=O<FMS:&5E=',O<VAE
M970S-RYX;6Q02P$"% ,4 " "!@PA5'-%!"E8# N#@ &0
M @(&6[@ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0 (
M (&#"%5%S8OMN0( )<' 9 " @2/R !X;"]W;W)K<VAE
M971S+W-H965T,SDN>&UL4$L! A0#% @ @8,(54\9N N1 P HPH !D
M ("!$_4 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"
M% ,4 " "!@PA5-.L%-0$) "^8 &0 @(';^ >&PO
M=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0 ( (&#"%7G?DB5!P,
M -,* 9 " @1," 0!X;"]W;W)K<VAE971S+W-H965T-#(N
M>&UL4$L! A0#% @ @8,(51A6<H;Y P ?Q( !D ("!
M404! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4 " "!@PA5
MA$$>JP@# ")" &0 @(&!"0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0T+GAM;%!+ 0(4 Q0 ( (&#"%7L0()EE@( ,D' 9
M " @< , 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%
M @ @8,(5:%3E$N0!0 O2D !D ("!C0\! 'AL+W=O<FMS
M:&5E=',O<VAE970T-BYX;6Q02P$"% ,4 " "!@PA5-0S?+;@" "G!P
M&0 @(%4%0$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+
M 0(4 Q0 ( (&#"%70Q-%_9@, *(+ 9 " @4,8 0!X
M;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#% @ @8,(5=V/9W>T
M @ [@8 !D ("!X!L! 'AL+W=O<FMS:&5E=',O<VAE970T
M.2YX;6Q02P$"% ,4 " "!@PA5TFF:#M8" /!P &0
M@('+'@$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0 ( (&#
M"%70\).,U@, /P6 9 " @=@A 0!X;"]W;W)K<VAE971S
M+W-H965T-3$N>&UL4$L! A0#% @ @8,(5<6)&4/8 @ *PP !D
M ("!Y24! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4
M " "!@PA5GEBJX*P' !J/@ &0 @('T* $ >&PO=V]R
M:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0 ( (&#"%4"+689> , %,0
M 9 " @=<P 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL
M4$L! A0#% @ @8,(5=J12 8Y P ]0H !D ("!AC0!
M 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4 " "!@PA5A<%V
M6 4# !V"0 &0 @('V-P$ >&PO=V]R:W-H965T<R]S:&5E
M=#4V+GAM;%!+ 0(4 Q0 ( (&#"%42RZ7%7@, !L+ 9
M " @3([ 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#% @
M@8,(59TD*M.Y! QQT !D ("!QSX! 'AL+W=O<FMS:&5E
M=',O<VAE970U."YX;6Q02P$"% ,4 " "!@PA5[)BQA%@$ #$@ &0
M @(&W0P$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4
M Q0 ( (&#"%5Y@*V?!P0 'D3 9 " @49( 0!X;"]W
M;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#% @ @8,(59Z&PTV5 P
M9Q( !D ("!A$P! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX
M;6Q02P$"% ,4 " "!@PA5XPAZSE8$ "V& &0 @(%0
M4 $ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0 ( (&#"%7_
M#1J;%@, #L- 9 " @=U4 0!X;"]W;W)K<VAE971S+W-H
M965T-C,N>&UL4$L! A0#% @ @8,(55'5DJ92 P S!4 T
M ( !*E@! 'AL+W-T>6QE<RYX;6Q02P$"% ,4 " "!@PA5EXJ[',
M 3 @ "P @ &G6P$ 7W)E;',O+G)E;'-02P$"% ,4
M" "!@PA5_1:DLL($ R*@ #P @ &07 $ >&PO=V]R:V)O
M;VLN>&UL4$L! A0#% @ @8,(52=EU:4, @ A"4 !H
M ( !?V$! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#% @
M@8,(5>[5[1CF 0 ]20 !, ( !PV,! %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4& $< 1P!H$P VF4!
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */
/* DefRef Styles */
..report table.authRefData{
background-color: #def;
border: 2px solid #2F4497;
font-size: 1em;
position: absolute;
}
..report table.authRefData a {
display: block;
font-weight: bold;
}
..report table.authRefData p {
margin-top: 0px;
}
..report table.authRefData .hide {
background-color: #2F4497;
padding: 1px 3px 0px 0px;
text-align: right;
}
..report table.authRefData .hide a:hover {
background-color: #2F4497;
}
..report table.authRefData .body {
height: 150px;
overflow: auto;
width: 400px;
}
..report table.authRefData table{
font-size: 1em;
}
/* Report Styles */
..pl a, .pl a:visited {
color: black;
text-decoration: none;
}
/* table */
..report {
background-color: white;
border: 2px solid #acf;
clear: both;
color: black;
font: normal 8pt Helvetica, Arial, san-serif;
margin-bottom: 2em;
}
..report hr {
border: 1px solid #acf;
}
/* Top labels */
..report th {
background-color: #acf;
color: black;
font-weight: bold;
text-align: center;
}
..report th.void {
background-color: transparent;
color: #000000;
font: bold 10pt Helvetica, Arial, san-serif;
text-align: left;
}
..report .pl {
text-align: left;
vertical-align: top;
white-space: normal;
width: 200px;
white-space: normal; /* word-wrap: break-word; */
}
..report td.pl a.a {
cursor: pointer;
display: block;
width: 200px;
overflow: hidden;
}
..report td.pl div.a {
width: 200px;
}
..report td.pl a:hover {
background-color: #ffc;
}
/* Header rows... */
..report tr.rh {
background-color: #acf;
color: black;
font-weight: bold;
}
/* Calendars... */
..report .rc {
background-color: #f0f0f0;
}
/* Even rows... */
..report .re, .report .reu {
background-color: #def;
}
..report .reu td {
border-bottom: 1px solid black;
}
/* Odd rows... */
..report .ro, .report .rou {
background-color: white;
}
..report .rou td {
border-bottom: 1px solid black;
}
..report .rou table td, .report .reu table td {
border-bottom: 0px solid black;
}
/* styles for footnote marker */
..report .fn {
white-space: nowrap;
}
/* styles for numeric types */
..report .num, .report .nump {
text-align: right;
white-space: nowrap;
}
..report .nump {
padding-left: 2em;
}
..report .nump {
padding: 0px 0.4em 0px 2em;
}
/* styles for text types */
..report .text {
text-align: left;
white-space: normal;
}
..report .text .big {
margin-bottom: 1em;
width: 17em;
}
..report .text .more {
display: none;
}
..report .text .note {
font-style: italic;
font-weight: bold;
}
..report .text .small {
width: 10em;
}
..report sup {
font-style: italic;
}
..report .outerFootnotes {
font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
<Version>3.22.2</Version>
<ProcessingTime/>
<ReportFormat>html</ReportFormat>
<ContextCount>235</ContextCount>
<ElementCount>340</ElementCount>
<EntityCount>1</EntityCount>
<FootnotesReported>false</FootnotesReported>
<SegmentCount>61</SegmentCount>
<ScenarioCount>0</ScenarioCount>
<TuplesReported>false</TuplesReported>
<UnitCount>10</UnitCount>
<MyReports>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R1.htm</HtmlFileName>
<LongName>0001001 - Document - Cover Page</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/CoverPage</Role>
<ShortName>Cover Page</ShortName>
<MenuCategory>Cover</MenuCategory>
<Position>1</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R2.htm</HtmlFileName>
<LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets</Role>
<ShortName>Condensed Consolidated Balance Sheets</ShortName>
<MenuCategory>Statements</MenuCategory>
<Position>2</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R3.htm</HtmlFileName>
<LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
<ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
<MenuCategory>Statements</MenuCategory>
<Position>3</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R4.htm</HtmlFileName>
<LongName>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
<ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
<MenuCategory>Statements</MenuCategory>
<Position>4</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R5.htm</HtmlFileName>
<LongName>1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
<ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
<MenuCategory>Statements</MenuCategory>
<Position>5</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R6.htm</HtmlFileName>
<LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
<ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
<MenuCategory>Statements</MenuCategory>
<Position>6</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R7.htm</HtmlFileName>
<LongName>2101101 - Disclosure - Formation and Business of the Company</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/FormationandBusinessoftheCompany</Role>
<ShortName>Formation and Business of the Company</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>7</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R8.htm</HtmlFileName>
<LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/SummaryofSignificantAccountingPolicies</Role>
<ShortName>Summary of Significant Accounting Policies</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>8</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R9.htm</HtmlFileName>
<LongName>2106103 - Disclosure - Recent Accounting Pronouncements</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/RecentAccountingPronouncements</Role>
<ShortName>Recent Accounting Pronouncements</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>9</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R10.htm</HtmlFileName>
<LongName>2107104 - Disclosure - Fair Value Measurements</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/FairValueMeasurements</Role>
<ShortName>Fair Value Measurements</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>10</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R11.htm</HtmlFileName>
<LongName>2112105 - Disclosure - Balance Sheet Components</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/BalanceSheetComponents</Role>
<ShortName>Balance Sheet Components</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>11</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R12.htm</HtmlFileName>
<LongName>2123106 - Disclosure - Long Term Debt and Convertible Notes</LongName>
<ReportType>Notes</ReportType>
<Role>http://www.pulmonx.com/role/LongTermDebtandConvertibleNotes</Role>
<ShortName>Long Term Debt and Convertible Notes</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>12</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R13.htm</HtmlFileName>
<LongName>2129107 - Disclosure - Revenue Recognition</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/RevenueRecognition</Role>
<ShortName>Revenue Recognition</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>13</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R14.htm</HtmlFileName>
<LongName>2131108 - Disclosure - Commitments and Contingencies</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/CommitmentsandContingencies</Role>
<ShortName>Commitments and Contingencies</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>14</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R15.htm</HtmlFileName>
<LongName>2139109 - Disclosure - Income Taxes</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/IncomeTaxes</Role>
<ShortName>Income Taxes</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>15</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R16.htm</HtmlFileName>
<LongName>2141110 - Disclosure - Stockholders' Equity</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/StockholdersEquity</Role>
<ShortName>Stockholders' Equity</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>16</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R17.htm</HtmlFileName>
<LongName>2149111 - Disclosure - Net Loss per Share Attributable to Common Stockholders</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholders</Role>
<ShortName>Net Loss per Share Attributable to Common Stockholders</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>17</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R18.htm</HtmlFileName>
<LongName>2153112 - Disclosure - Segment Information</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/SegmentInformation</Role>
<ShortName>Segment Information</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>18</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R19.htm</HtmlFileName>
<LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
<ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
<MenuCategory>Policies</MenuCategory>
<ParentRole>http://www.pulmonx.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
<Position>19</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R20.htm</HtmlFileName>
<LongName>2308301 - Disclosure - Fair Value Measurements (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/FairValueMeasurementsTables</Role>
<ShortName>Fair Value Measurements (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://www.pulmonx.com/role/FairValueMeasurements</ParentRole>
<Position>20</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R21.htm</HtmlFileName>
<LongName>2313302 - Disclosure - Balance Sheet Components (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/BalanceSheetComponentsTables</Role>
<ShortName>Balance Sheet Components (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://www.pulmonx.com/role/BalanceSheetComponents</ParentRole>
<Position>21</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R22.htm</HtmlFileName>
<LongName>2324303 - Disclosure - Long Term Debt and Convertible Notes (Tables)</LongName>
<ReportType>Notes</ReportType>
<Role>http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesTables</Role>
<ShortName>Long Term Debt and Convertible Notes (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://www.pulmonx.com/role/LongTermDebtandConvertibleNotes</ParentRole>
<Position>22</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R23.htm</HtmlFileName>
<LongName>2332304 - Disclosure - Commitments and Contingencies (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/CommitmentsandContingenciesTables</Role>
<ShortName>Commitments and Contingencies (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://www.pulmonx.com/role/CommitmentsandContingencies</ParentRole>
<Position>23</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R24.htm</HtmlFileName>
<LongName>2342305 - Disclosure - Stockholders' Equity (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/StockholdersEquityTables</Role>
<ShortName>Stockholders' Equity (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://www.pulmonx.com/role/StockholdersEquity</ParentRole>
<Position>24</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R25.htm</HtmlFileName>
<LongName>2350306 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersTables</Role>
<ShortName>Net Loss per Share Attributable to Common Stockholders (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholders</ParentRole>
<Position>25</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R26.htm</HtmlFileName>
<LongName>2354307 - Disclosure - Segment Information (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/SegmentInformationTables</Role>
<ShortName>Segment Information (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://www.pulmonx.com/role/SegmentInformation</ParentRole>
<Position>26</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R27.htm</HtmlFileName>
<LongName>2402401 - Disclosure - Formation and Business of the Company (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/FormationandBusinessoftheCompanyDetails</Role>
<ShortName>Formation and Business of the Company (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<ParentRole>http://www.pulmonx.com/role/FormationandBusinessoftheCompany</ParentRole>
<Position>27</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R28.htm</HtmlFileName>
<LongName>2405402 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
<ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<ParentRole>http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
<Position>28</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R29.htm</HtmlFileName>
<LongName>2409403 - Disclosure - Fair Value Measurements - Fair Value of Assets and Liabilities (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails</Role>
<ShortName>Fair Value Measurements - Fair Value of Assets and Liabilities (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>29</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R30.htm</HtmlFileName>
<LongName>2410404 - Disclosure - Fair Value Measurements - Unrealized Gains and Losses and Fair Value (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails</Role>
<ShortName>Fair Value Measurements - Unrealized Gains and Losses and Fair Value (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>30</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R31.htm</HtmlFileName>
<LongName>2411405 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/FairValueMeasurementsNarrativeDetails</Role>
<ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>31</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R32.htm</HtmlFileName>
<LongName>2414406 - Disclosure - Balance Sheet Components - Cash and Cash Equivalents (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/BalanceSheetComponentsCashandCashEquivalentsDetails</Role>
<ShortName>Balance Sheet Components - Cash and Cash Equivalents (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>32</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R33.htm</HtmlFileName>
<LongName>2415407 - Disclosure - Balance Sheet Components - Inventory (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/BalanceSheetComponentsInventoryDetails</Role>
<ShortName>Balance Sheet Components - Inventory (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>33</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R34.htm</HtmlFileName>
<LongName>2416408 - Disclosure - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails</Role>
<ShortName>Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>34</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R35.htm</HtmlFileName>
<LongName>2417409 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails</Role>
<ShortName>Balance Sheet Components - Property and Equipment, Net (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>35</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R36.htm</HtmlFileName>
<LongName>2418410 - Disclosure - Balance Sheet Components - Capitalized Implementation Costs of a Hosting Arrangement (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/BalanceSheetComponentsCapitalizedImplementationCostsofaHostingArrangementDetails</Role>
<ShortName>Balance Sheet Components - Capitalized Implementation Costs of a Hosting Arrangement (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>36</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R37.htm</HtmlFileName>
<LongName>2419411 - Disclosure - Balance Sheet Components - Narrative (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/BalanceSheetComponentsNarrativeDetails</Role>
<ShortName>Balance Sheet Components - Narrative (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>37</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R38.htm</HtmlFileName>
<LongName>2420412 - Disclosure - Balance Sheet Components - Intangible Assets (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/BalanceSheetComponentsIntangibleAssetsDetails</Role>
<ShortName>Balance Sheet Components - Intangible Assets (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>38</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R39.htm</HtmlFileName>
<LongName>2421413 - Disclosure - Balance Sheet Components - Future Amortization Expense (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/BalanceSheetComponentsFutureAmortizationExpenseDetails</Role>
<ShortName>Balance Sheet Components - Future Amortization Expense (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>39</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R40.htm</HtmlFileName>
<LongName>2422414 - Disclosure - Balance Sheet Components - Accrued Liabilities (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails</Role>
<ShortName>Balance Sheet Components - Accrued Liabilities (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>40</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R41.htm</HtmlFileName>
<LongName>2425415 - Disclosure - Long Term Debt and Convertible Notes - CIBC Loan Narrative (Details)</LongName>
<ReportType>Notes</ReportType>
<Role>http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails</Role>
<ShortName>Long Term Debt and Convertible Notes - CIBC Loan Narrative (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>41</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R42.htm</HtmlFileName>
<LongName>2426416 - Disclosure - Long Term Debt and Convertible Notes - CIBC Loan Components Of Debt (Details)</LongName>
<ReportType>Notes</ReportType>
<Role>http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanComponentsOfDebtDetails</Role>
<ShortName>Long Term Debt and Convertible Notes - CIBC Loan Components Of Debt (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>42</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R43.htm</HtmlFileName>
<LongName>2427417 - Disclosure - Long Term Debt and Convertible Notes - Credit Agreement and Paycheck Protection Program Narrative (Details)</LongName>
<ReportType>Notes</ReportType>
<Role>http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCreditAgreementandPaycheckProtectionProgramNarrativeDetails</Role>
<ShortName>Long Term Debt and Convertible Notes - Credit Agreement and Paycheck Protection Program Narrative (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>43</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R44.htm</HtmlFileName>
<LongName>2428418 - Disclosure - Long Term Debt and Convertible Notes - Contractual Maturities of Financing Obligations (Details)</LongName>
<ReportType>Notes</ReportType>
<Role>http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesContractualMaturitiesofFinancingObligationsDetails</Role>
<ShortName>Long Term Debt and Convertible Notes - Contractual Maturities of Financing Obligations (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>44</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R45.htm</HtmlFileName>
<LongName>2430419 - Disclosure - Revenue Recognition (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/RevenueRecognitionDetails</Role>
<ShortName>Revenue Recognition (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<ParentRole>http://www.pulmonx.com/role/RevenueRecognition</ParentRole>
<Position>45</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R46.htm</HtmlFileName>
<LongName>2433420 - Disclosure - Commitments and Contingencies - Leases, Narrative (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/CommitmentsandContingenciesLeasesNarrativeDetails</Role>
<ShortName>Commitments and Contingencies - Leases, Narrative (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>46</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R47.htm</HtmlFileName>
<LongName>2434421 - Disclosure - Commitments and Contingencies - Lease Cost (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/CommitmentsandContingenciesLeaseCostDetails</Role>
<ShortName>Commitments and Contingencies - Lease Cost (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>47</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R48.htm</HtmlFileName>
<LongName>2435422 - Disclosure - Commitments and Contingencies - Maturity Analysis of Lease Liabilities (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails</Role>
<ShortName>Commitments and Contingencies - Maturity Analysis of Lease Liabilities (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>48</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R49.htm</HtmlFileName>
<LongName>2436423 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
<ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>49</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R50.htm</HtmlFileName>
<LongName>2437424 - Disclosure - Commitments and Contingencies - Other Supplemental Information (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/CommitmentsandContingenciesOtherSupplementalInformationDetails</Role>
<ShortName>Commitments and Contingencies - Other Supplemental Information (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>50</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R51.htm</HtmlFileName>
<LongName>2438425 - Disclosure - Commitments and Contingencies - Service Agreement (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/CommitmentsandContingenciesServiceAgreementDetails</Role>
<ShortName>Commitments and Contingencies - Service Agreement (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>51</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R52.htm</HtmlFileName>
<LongName>2440426 - Disclosure - Income Taxes (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/IncomeTaxesDetails</Role>
<ShortName>Income Taxes (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<ParentRole>http://www.pulmonx.com/role/IncomeTaxes</ParentRole>
<Position>52</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R53.htm</HtmlFileName>
<LongName>2443427 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails</Role>
<ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>53</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R54.htm</HtmlFileName>
<LongName>2444428 - Disclosure - Stockholders' Equity - Shares Reserved for Future Issuance (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails</Role>
<ShortName>Stockholders' Equity - Shares Reserved for Future Issuance (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>54</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R55.htm</HtmlFileName>
<LongName>2445429 - Disclosure - Stockholders' Equity - Stock Option Activity (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/StockholdersEquityStockOptionActivityDetails</Role>
<ShortName>Stockholders' Equity - Stock Option Activity (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>55</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R56.htm</HtmlFileName>
<LongName>2446430 - Disclosure - Stockholders' Equity - Options Vested and Expected to Vest (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/StockholdersEquityOptionsVestedandExpectedtoVestDetails</Role>
<ShortName>Stockholders' Equity - Options Vested and Expected to Vest (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>56</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R57.htm</HtmlFileName>
<LongName>2447431 - Disclosure - Stockholders' Equity - Restricted Stock Unit Activity (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/StockholdersEquityRestrictedStockUnitActivityDetails</Role>
<ShortName>Stockholders' Equity - Restricted Stock Unit Activity (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>57</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R58.htm</HtmlFileName>
<LongName>2448432 - Disclosure - Stockholders' Equity - Total Stock-Based Compensation (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/StockholdersEquityTotalStockBasedCompensationDetails</Role>
<ShortName>Stockholders' Equity - Total Stock-Based Compensation (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>58</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R59.htm</HtmlFileName>
<LongName>2451433 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersComputationofBasicandDilutedNetLossperShareDetails</Role>
<ShortName>Net Loss per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>59</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R60.htm</HtmlFileName>
<LongName>2452434 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Excluded Potentially Dilutive Securities Outstanding (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersExcludedPotentiallyDilutiveSecuritiesOutstandingDetails</Role>
<ShortName>Net Loss per Share Attributable to Common Stockholders - Excluded Potentially Dilutive Securities Outstanding (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>60</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R61.htm</HtmlFileName>
<LongName>2455435 - Disclosure - Segment Information - Narrative (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/SegmentInformationNarrativeDetails</Role>
<ShortName>Segment Information - Narrative (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>61</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R62.htm</HtmlFileName>
<LongName>2456436 - Disclosure - Segment Information - Revenue by Geographic Area (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/SegmentInformationRevenuebyGeographicAreaDetails</Role>
<ShortName>Segment Information - Revenue by Geographic Area (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>62</Position>
</Report>
<Report instance="lung-20220630.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R63.htm</HtmlFileName>
<LongName>2457437 - Disclosure - Segment Information - Long-Lived Assets by Geographical Area (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.pulmonx.com/role/SegmentInformationLongLivedAssetsbyGeographicalAreaDetails</Role>
<ShortName>Segment Information - Long-Lived Assets by Geographical Area (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>63</Position>
</Report>
<Report>
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<LongName>All Reports</LongName>
<ReportType>Book</ReportType>
<ShortName>All Reports</ShortName>
</Report>
</MyReports>
<InputFiles>
<File doctype="10-Q" original="lung-20220630.htm">lung-20220630.htm</File>
<File>exhibit31_1x080822.htm</File>
<File>exhibit31_2x080822.htm</File>
<File>exhibit32_1x080822.htm</File>
<File>exhibit32_2x080822.htm</File>
<File>lung-20220630.xsd</File>
<File>lung-20220630_cal.xml</File>
<File>lung-20220630_def.xml</File>
<File>lung-20220630_lab.xml</File>
<File>lung-20220630_pre.xml</File>
</InputFiles>
<SupplementalFiles/>
<BaseTaxonomies>
<BaseTaxonomy items="841">http://fasb.org/us-gaap/2022</BaseTaxonomy>
<BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
</BaseTaxonomies>
<HasPresentationLinkbase>true</HasPresentationLinkbase>
<HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>80
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
"instance": {
"lung-20220630.htm": {
"axisCustom": 0,
"axisStandard": 20,
"contextCount": 235,
"dts": {
"calculationLink": {
"local": [
"lung-20220630_cal.xml"
]
},
"definitionLink": {
"local": [
"lung-20220630_def.xml"
]
},
"inline": {
"local": [
"lung-20220630.htm"
]
},
"labelLink": {
"local": [
"lung-20220630_lab.xml"
]
},
"presentationLink": {
"local": [
"lung-20220630_pre.xml"
]
},
"schema": {
"local": [
"lung-20220630.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
"https://xbrl.sec.gov/country/2022/country-2022.xsd",
"https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
]
}
},
"elementCount": 516,
"entityCount": 1,
"hidden": {
"http://xbrl.sec.gov/dei/2022": 5,
"total": 5
},
"keyCustom": 38,
"keyStandard": 302,
"memberCustom": 15,
"memberStandard": 43,
"nsprefix": "lung",
"nsuri": "http://www.pulmonx.com/20220630",
"report": {
"R1": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "document",
"isDefault": "true",
"longName": "0001001 - Document - Cover Page",
"role": "http://www.pulmonx.com/role/CoverPage",
"shortName": "Cover Page",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R10": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueDisclosuresTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2107104 - Disclosure - Fair Value Measurements",
"role": "http://www.pulmonx.com/role/FairValueMeasurements",
"shortName": "Fair Value Measurements",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueDisclosuresTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R11": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2112105 - Disclosure - Balance Sheet Components",
"role": "http://www.pulmonx.com/role/BalanceSheetComponents",
"shortName": "Balance Sheet Components",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R12": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2123106 - Disclosure - Long Term Debt and Convertible Notes",
"role": "http://www.pulmonx.com/role/LongTermDebtandConvertibleNotes",
"shortName": "Long Term Debt and Convertible Notes",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R13": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2129107 - Disclosure - Revenue Recognition",
"role": "http://www.pulmonx.com/role/RevenueRecognition",
"shortName": "Revenue Recognition",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R14": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2131108 - Disclosure - Commitments and Contingencies",
"role": "http://www.pulmonx.com/role/CommitmentsandContingencies",
"shortName": "Commitments and Contingencies",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R15": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:IncomeTaxDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2139109 - Disclosure - Income Taxes",
"role": "http://www.pulmonx.com/role/IncomeTaxes",
"shortName": "Income Taxes",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:IncomeTaxDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R16": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2141110 - Disclosure - Stockholders' Equity",
"role": "http://www.pulmonx.com/role/StockholdersEquity",
"shortName": "Stockholders' Equity",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R17": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:EarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2149111 - Disclosure - Net Loss per Share Attributable to Common Stockholders",
"role": "http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholders",
"shortName": "Net Loss per Share Attributable to Common Stockholders",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:EarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R18": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SegmentReportingDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2153112 - Disclosure - Segment Information",
"role": "http://www.pulmonx.com/role/SegmentInformation",
"shortName": "Segment Information",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SegmentReportingDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R19": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
"role": "http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesPolicies",
"shortName": "Summary of Significant Accounting Policies (Policies)",
"subGroupType": "policies",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R2": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
"role": "http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets",
"shortName": "Condensed Consolidated Balance Sheets",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-3",
"lang": "en-US",
"name": "us-gaap:AccountsReceivableNetCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R20": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2308301 - Disclosure - Fair Value Measurements (Tables)",
"role": "http://www.pulmonx.com/role/FairValueMeasurementsTables",
"shortName": "Fair Value Measurements (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R21": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2313302 - Disclosure - Balance Sheet Components (Tables)",
"role": "http://www.pulmonx.com/role/BalanceSheetComponentsTables",
"shortName": "Balance Sheet Components (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R22": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2324303 - Disclosure - Long Term Debt and Convertible Notes (Tables)",
"role": "http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesTables",
"shortName": "Long Term Debt and Convertible Notes (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R23": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LeaseCostTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2332304 - Disclosure - Commitments and Contingencies (Tables)",
"role": "http://www.pulmonx.com/role/CommitmentsandContingenciesTables",
"shortName": "Commitments and Contingencies (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LeaseCostTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R24": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfStockByClassTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2342305 - Disclosure - Stockholders' Equity (Tables)",
"role": "http://www.pulmonx.com/role/StockholdersEquityTables",
"shortName": "Stockholders' Equity (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfStockByClassTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R25": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2350306 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)",
"role": "http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersTables",
"shortName": "Net Loss per Share Attributable to Common Stockholders (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R26": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2354307 - Disclosure - Segment Information (Tables)",
"role": "http://www.pulmonx.com/role/SegmentInformationTables",
"shortName": "Segment Information (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R27": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:RetainedEarningsAccumulatedDeficit",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2402401 - Disclosure - Formation and Business of the Company (Details)",
"role": "http://www.pulmonx.com/role/FormationandBusinessoftheCompanyDetails",
"shortName": "Formation and Business of the Company (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-5",
"lang": "en-US",
"name": "lung:CashAndCashEquivalentsAndMarketableSecurities",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R28": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:CashUninsuredAmount",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2405402 - Disclosure - Summary of Significant Accounting Policies (Details)",
"role": "http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesDetails",
"shortName": "Summary of Significant Accounting Policies (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i23debaac8bf94b7195e8771f793b80bb_I20211231",
"decimals": "-5",
"lang": "en-US",
"name": "us-gaap:CashUninsuredAmount",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R29": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2409403 - Disclosure - Fair Value Measurements - Fair Value of Assets and Liabilities (Details)",
"role": "http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
"shortName": "Fair Value Measurements - Fair Value of Assets and Liabilities (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i513514d73a6d48d88da16ce034ab1bb4_I20220630",
"decimals": "-3",
"lang": "en-US",
"name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R3": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:PreferredStockParOrStatedValuePerShare",
"reportCount": 1,
"unique": true,
"unitRef": "usdPerShare",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
"role": "http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
"shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
"subGroupType": "parenthetical",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:PreferredStockParOrStatedValuePerShare",
"reportCount": 1,
"unique": true,
"unitRef": "usdPerShare",
"xsiNil": "false"
}
},
"R30": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2410404 - Disclosure - Fair Value Measurements - Unrealized Gains and Losses and Fair Value (Details)",
"role": "http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails",
"shortName": "Fair Value Measurements - Unrealized Gains and Losses and Fair Value (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R31": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2411405 - Disclosure - Fair Value Measurements - Narrative (Details)",
"role": "http://www.pulmonx.com/role/FairValueMeasurementsNarrativeDetails",
"shortName": "Fair Value Measurements - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R32": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:Cash",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2414406 - Disclosure - Balance Sheet Components - Cash and Cash Equivalents (Details)",
"role": "http://www.pulmonx.com/role/BalanceSheetComponentsCashandCashEquivalentsDetails",
"shortName": "Balance Sheet Components - Cash and Cash Equivalents (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:Cash",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R33": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:InventoryRawMaterialsNetOfReserves",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2415407 - Disclosure - Balance Sheet Components - Inventory (Details)",
"role": "http://www.pulmonx.com/role/BalanceSheetComponentsInventoryDetails",
"shortName": "Balance Sheet Components - Inventory (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:InventoryRawMaterialsNetOfReserves",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R34": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherPrepaidExpenseCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2416408 - Disclosure - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)",
"role": "http://www.pulmonx.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails",
"shortName": "Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherPrepaidExpenseCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R35": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:PropertyPlantAndEquipmentTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:PropertyPlantAndEquipmentGross",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2417409 - Disclosure - Balance Sheet Components - Property and Equipment, Net (Details)",
"role": "http://www.pulmonx.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails",
"shortName": "Balance Sheet Components - Property and Equipment, Net (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:PropertyPlantAndEquipmentTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:PropertyPlantAndEquipmentGross",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R36": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i5e482a0f02a04e4e9a095186ae75202f_I20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2418410 - Disclosure - Balance Sheet Components - Capitalized Implementation Costs of a Hosting Arrangement (Details)",
"role": "http://www.pulmonx.com/role/BalanceSheetComponentsCapitalizedImplementationCostsofaHostingArrangementDetails",
"shortName": "Balance Sheet Components - Capitalized Implementation Costs of a Hosting Arrangement (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia8327b71a4e547faac046ef1de96ead9_D20220401-20220630",
"decimals": null,
"lang": "en-US",
"name": "lung:HostingArrangementServiceContractImplementationCostCapitalizedAmortizationPeriod",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R37": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:Depreciation",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2419411 - Disclosure - Balance Sheet Components - Narrative (Details)",
"role": "http://www.pulmonx.com/role/BalanceSheetComponentsNarrativeDetails",
"shortName": "Balance Sheet Components - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:Depreciation",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R38": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:FiniteLivedIntangibleAssetsGross",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2420412 - Disclosure - Balance Sheet Components - Intangible Assets (Details)",
"role": "http://www.pulmonx.com/role/BalanceSheetComponentsIntangibleAssetsDetails",
"shortName": "Balance Sheet Components - Intangible Assets (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:FiniteLivedIntangibleAssetsGross",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R39": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2421413 - Disclosure - Balance Sheet Components - Future Amortization Expense (Details)",
"role": "http://www.pulmonx.com/role/BalanceSheetComponentsFutureAmortizationExpenseDetails",
"shortName": "Balance Sheet Components - Future Amortization Expense (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R4": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
"role": "http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
"shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630",
"decimals": "-3",
"lang": "en-US",
"name": "us-gaap:GrossProfit",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R40": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:AccruedBonusesCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2422414 - Disclosure - Balance Sheet Components - Accrued Liabilities (Details)",
"role": "http://www.pulmonx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails",
"shortName": "Balance Sheet Components - Accrued Liabilities (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:AccruedBonusesCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R41": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:PaymentsOfDebtIssuanceCosts",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2425415 - Disclosure - Long Term Debt and Convertible Notes - CIBC Loan Narrative (Details)",
"role": "http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails",
"shortName": "Long Term Debt and Convertible Notes - CIBC Loan Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i69fa9455e50e46f4af26f9c44e3cb740_I20200220",
"decimals": "INF",
"lang": "en-US",
"name": "lung:DebtInstrumentFaceAmountIncludingAccordionFeature",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R42": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtInstrumentCarryingAmount",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2426416 - Disclosure - Long Term Debt and Convertible Notes - CIBC Loan Components Of Debt (Details)",
"role": "http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanComponentsOfDebtDetails",
"shortName": "Long Term Debt and Convertible Notes - CIBC Loan Components Of Debt (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfDebtInstrumentsTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i77c3dfcc442f4078a50db735a19d5748_I20220630",
"decimals": "-3",
"lang": "en-US",
"name": "us-gaap:DebtInstrumentCarryingAmount",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R43": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i70d3599672cd4f2badc8f100594638fe_D20220101-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:RepaymentsOfDebt",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2427417 - Disclosure - Long Term Debt and Convertible Notes - Credit Agreement and Paycheck Protection Program Narrative (Details)",
"role": "http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCreditAgreementandPaycheckProtectionProgramNarrativeDetails",
"shortName": "Long Term Debt and Convertible Notes - Credit Agreement and Paycheck Protection Program Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i70d3599672cd4f2badc8f100594638fe_D20220101-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:RepaymentsOfDebt",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R44": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2428418 - Disclosure - Long Term Debt and Convertible Notes - Contractual Maturities of Financing Obligations (Details)",
"role": "http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesContractualMaturitiesofFinancingObligationsDetails",
"shortName": "Long Term Debt and Convertible Notes - Contractual Maturities of Financing Obligations (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R45": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:ContractWithCustomerLiability",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2430419 - Disclosure - Revenue Recognition (Details)",
"role": "http://www.pulmonx.com/role/RevenueRecognitionDetails",
"shortName": "Revenue Recognition (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:ContractWithCustomerLiability",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R46": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i366bdd6cbcb6417f82564f08de535cb9_I20200831",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2433420 - Disclosure - Commitments and Contingencies - Leases, Narrative (Details)",
"role": "http://www.pulmonx.com/role/CommitmentsandContingenciesLeasesNarrativeDetails",
"shortName": "Commitments and Contingencies - Leases, Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i366bdd6cbcb6417f82564f08de535cb9_I20200831",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R47": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:LeaseCostTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:OperatingLeaseCost",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2434421 - Disclosure - Commitments and Contingencies - Lease Cost (Details)",
"role": "http://www.pulmonx.com/role/CommitmentsandContingenciesLeaseCostDetails",
"shortName": "Commitments and Contingencies - Lease Cost (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:LeaseCostTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:OperatingLeaseCost",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R48": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2435422 - Disclosure - Commitments and Contingencies - Maturity Analysis of Lease Liabilities (Details)",
"role": "http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails",
"shortName": "Commitments and Contingencies - Maturity Analysis of Lease Liabilities (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R49": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:OperatingLeaseRightOfUseAsset",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2436423 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
"role": "http://www.pulmonx.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
"shortName": "Commitments and Contingencies - Additional Information (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": null,
"lang": "en-US",
"name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R5": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i937e6c62ae494af082d55df28a206b08_I20201231",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:CommonStockSharesOutstanding",
"reportCount": 1,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
"role": "http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
"shortName": "Condensed Consolidated Statements of Stockholders' Equity",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i8540e99599c44addac72e276711f6cec_D20210101-20210331",
"decimals": "INF",
"lang": "en-US",
"name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R50": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:OperatingLeasePayments",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2437424 - Disclosure - Commitments and Contingencies - Other Supplemental Information (Details)",
"role": "http://www.pulmonx.com/role/CommitmentsandContingenciesOtherSupplementalInformationDetails",
"shortName": "Commitments and Contingencies - Other Supplemental Information (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:OperatingLeasePayments",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R51": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:CostOfGoodsAndServicesSold",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2438425 - Disclosure - Commitments and Contingencies - Service Agreement (Details)",
"role": "http://www.pulmonx.com/role/CommitmentsandContingenciesServiceAgreementDetails",
"shortName": "Commitments and Contingencies - Service Agreement (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ibc840713d1034829bc01ad7b74a40d23_I20220430",
"decimals": "-5",
"lang": "en-US",
"name": "us-gaap:PurchaseObligationDueInNextTwelveMonths",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R52": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:IncomeTaxExpenseBenefit",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2440426 - Disclosure - Income Taxes (Details)",
"role": "http://www.pulmonx.com/role/IncomeTaxesDetails",
"shortName": "Income Taxes (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i2ae7a2862d6f4d7a954dd9a21f9f83d8_D20220401-20220630",
"decimals": "-5",
"lang": "en-US",
"name": "us-gaap:IncomeTaxExpenseBenefit",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R53": {
"firstAnchor": {
"ancestors": [
"us-gaap:CommonStockSharesAuthorized",
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:CommonStockSharesAuthorized",
"reportCount": 1,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2443427 - Disclosure - Stockholders' Equity - Narrative (Details)",
"role": "http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails",
"shortName": "Stockholders' Equity - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": "INF",
"lang": "en-US",
"name": "us-gaap:DividendsCommonStock",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R54": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfStockByClassTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2444428 - Disclosure - Stockholders' Equity - Shares Reserved for Future Issuance (Details)",
"role": "http://www.pulmonx.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails",
"shortName": "Stockholders' Equity - Shares Reserved for Future Issuance (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfStockByClassTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R55": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i23debaac8bf94b7195e8771f793b80bb_I20211231",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2445429 - Disclosure - Stockholders' Equity - Stock Option Activity (Details)",
"role": "http://www.pulmonx.com/role/StockholdersEquityStockOptionActivityDetails",
"shortName": "Stockholders' Equity - Stock Option Activity (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i23debaac8bf94b7195e8771f793b80bb_I20211231",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R56": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2446430 - Disclosure - Stockholders' Equity - Options Vested and Expected to Vest (Details)",
"role": "http://www.pulmonx.com/role/StockholdersEquityOptionsVestedandExpectedtoVestDetails",
"shortName": "Stockholders' Equity - Options Vested and Expected to Vest (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R57": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "id02f38cc7de8443687c4dbf744ee7d4a_I20211231",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2447431 - Disclosure - Stockholders' Equity - Restricted Stock Unit Activity (Details)",
"role": "http://www.pulmonx.com/role/StockholdersEquityRestrictedStockUnitActivityDetails",
"shortName": "Stockholders' Equity - Restricted Stock Unit Activity (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "id02f38cc7de8443687c4dbf744ee7d4a_I20211231",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R58": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:AllocatedShareBasedCompensationExpense",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2448432 - Disclosure - Stockholders' Equity - Total Stock-Based Compensation (Details)",
"role": "http://www.pulmonx.com/role/StockholdersEquityTotalStockBasedCompensationDetails",
"shortName": "Stockholders' Equity - Total Stock-Based Compensation (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:AllocatedShareBasedCompensationExpense",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R59": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2451433 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share (Details)",
"role": "http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersComputationofBasicandDilutedNetLossperShareDetails",
"shortName": "Net Loss per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R6": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:NetIncomeLoss",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows",
"role": "http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows",
"shortName": "Condensed Consolidated Statements of Cash Flows",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": "-3",
"lang": "en-US",
"name": "us-gaap:ShareBasedCompensation",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R60": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2452434 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Excluded Potentially Dilutive Securities Outstanding (Details)",
"role": "http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersExcludedPotentiallyDilutiveSecuritiesOutstandingDetails",
"shortName": "Net Loss per Share Attributable to Common Stockholders - Excluded Potentially Dilutive Securities Outstanding (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R61": {
"firstAnchor": {
"ancestors": [
"us-gaap:NumberOfOperatingSegments",
"ix:continuation",
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:NumberOfReportableSegments",
"reportCount": 1,
"unique": true,
"unitRef": "segment",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2455435 - Disclosure - Segment Information - Narrative (Details)",
"role": "http://www.pulmonx.com/role/SegmentInformationNarrativeDetails",
"shortName": "Segment Information - Narrative (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"us-gaap:NumberOfOperatingSegments",
"ix:continuation",
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:NumberOfReportableSegments",
"reportCount": 1,
"unique": true,
"unitRef": "segment",
"xsiNil": "false"
}
},
"R62": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "iadf954d867ac4fff99ab28ed47b8ee2c_D20220401-20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2456436 - Disclosure - Segment Information - Revenue by Geographic Area (Details)",
"role": "http://www.pulmonx.com/role/SegmentInformationRevenuebyGeographicAreaDetails",
"shortName": "Segment Information - Revenue by Geographic Area (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ie1359c30612540db9f7d34a1c01b3ad0_D20220401-20220630",
"decimals": "-3",
"lang": "en-US",
"name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R63": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:NoncurrentAssets",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2457437 - Disclosure - Segment Information - Long-Lived Assets by Geographical Area (Details)",
"role": "http://www.pulmonx.com/role/SegmentInformationLongLivedAssetsbyGeographicalAreaDetails",
"shortName": "Segment Information - Long-Lived Assets by Geographical Area (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "i4ab9cc14349f482ba5aaab8e55c0de1f_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:NoncurrentAssets",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R7": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:NatureOfOperations",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2101101 - Disclosure - Formation and Business of the Company",
"role": "http://www.pulmonx.com/role/FormationandBusinessoftheCompany",
"shortName": "Formation and Business of the Company",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:NatureOfOperations",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R8": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
"role": "http://www.pulmonx.com/role/SummaryofSignificantAccountingPolicies",
"shortName": "Summary of Significant Accounting Policies",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R9": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2106103 - Disclosure - Recent Accounting Pronouncements",
"role": "http://www.pulmonx.com/role/RecentAccountingPronouncements",
"shortName": "Recent Accounting Pronouncements",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "lung-20220630.htm",
"contextRef": "ia1138fdda86e45a7b3d6b9bb30f935c2_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
}
},
"segmentCount": 61,
"tag": {
"country_DE": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "GERMANY",
"terseLabel": "GERMANY"
}
}
},
"localname": "DE",
"nsuri": "http://xbrl.sec.gov/country/2022",
"presentation": [
"http://www.pulmonx.com/role/SegmentInformationNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"country_FR": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "FRANCE",
"terseLabel": "FRANCE"
}
}
},
"localname": "FR",
"nsuri": "http://xbrl.sec.gov/country/2022",
"presentation": [
"http://www.pulmonx.com/role/SegmentInformationNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"country_US": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "UNITED STATES",
"terseLabel": "United States"
}
}
},
"localname": "US",
"nsuri": "http://xbrl.sec.gov/country/2022",
"presentation": [
"http://www.pulmonx.com/role/SegmentInformationLongLivedAssetsbyGeographicalAreaDetails",
"http://www.pulmonx.com/role/SegmentInformationRevenuebyGeographicAreaDetails"
],
"xbrltype": "domainItemType"
},
"dei_AmendmentFlag": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
"label": "Amendment Flag",
"terseLabel": "Amendment Flag"
}
}
},
"localname": "AmendmentFlag",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_CityAreaCode": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Area code of city",
"label": "City Area Code",
"terseLabel": "City Area Code"
}
}
},
"localname": "CityAreaCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_CountryRegion": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Region code of country",
"label": "Country Region",
"terseLabel": "Country Region"
}
}
},
"localname": "CountryRegion",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_CoverAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Cover page.",
"label": "Cover [Abstract]"
}
}
},
"localname": "CoverAbstract",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"xbrltype": "stringItemType"
},
"dei_CurrentFiscalYearEndDate": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "End date of current fiscal year in the format --MM-DD.",
"label": "Current Fiscal Year End Date",
"terseLabel": "Current Fiscal Year End Date"
}
}
},
"localname": "CurrentFiscalYearEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "gMonthDayItemType"
},
"dei_DocumentFiscalPeriodFocus": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
"label": "Document Fiscal Period Focus",
"terseLabel": "Document Fiscal Period Focus"
}
}
},
"localname": "DocumentFiscalPeriodFocus",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "fiscalPeriodItemType"
},
"dei_DocumentFiscalYearFocus": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
"label": "Document Fiscal Year Focus",
"terseLabel": "Document Fiscal Year Focus"
}
}
},
"localname": "DocumentFiscalYearFocus",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "gYearItemType"
},
"dei_DocumentPeriodEndDate": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.",
"label": "Document Period End Date",
"terseLabel": "Document Period End Date"
}
}
},
"localname": "DocumentPeriodEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "dateItemType"
},
"dei_DocumentQuarterlyReport": {
"auth_ref": [
"r650"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as an quarterly report.",
"label": "Document Quarterly Report",
"terseLabel": "Document Quarterly Report"
}
}
},
"localname": "DocumentQuarterlyReport",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentTransitionReport": {
"auth_ref": [
"r651"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as a transition report.",
"label": "Document Transition Report",
"terseLabel": "Document Transition Report"
}
}
},
"localname": "DocumentTransitionReport",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentType": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
"label": "Document Type",
"terseLabel": "Document Type"
}
}
},
"localname": "DocumentType",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "submissionTypeItemType"
},
"dei_EntityAddressAddressLine1": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Address Line 1 such as Attn, Building Name, Street Name",
"label": "Entity Address, Address Line One",
"terseLabel": "Entity Address, Address Line One"
}
}
},
"localname": "EntityAddressAddressLine1",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressCityOrTown": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the City or Town",
"label": "Entity Address, City or Town",
"terseLabel": "Entity Address, City or Town"
}
}
},
"localname": "EntityAddressCityOrTown",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressPostalZipCode": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Code for the postal or zip code",
"label": "Entity Address, Postal Zip Code",
"terseLabel": "Entity Address, Postal Zip Code"
}
}
},
"localname": "EntityAddressPostalZipCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressStateOrProvince": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the state or province.",
"label": "Entity Address, State or Province",
"terseLabel": "Entity Address, State or Province"
}
}
},
"localname": "EntityAddressStateOrProvince",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "stateOrProvinceItemType"
},
"dei_EntityCentralIndexKey": {
"auth_ref": [
"r648"
],
"lang": {
"en-us": {
"role": {
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
"label": "Entity Central Index Key",
"terseLabel": "Entity Central Index Key"
}
}
},
"localname": "EntityCentralIndexKey",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "centralIndexKeyItemType"
},
"dei_EntityCommonStockSharesOutstanding": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
"label": "Entity Common Stock, Shares Outstanding",
"terseLabel": "Entity Common Stock, Shares Outstanding"
}
}
},
"localname": "EntityCommonStockSharesOutstanding",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "sharesItemType"
},
"dei_EntityCurrentReportingStatus": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Current Reporting Status",
"terseLabel": "Entity Current Reporting Status"
}
}
},
"localname": "EntityCurrentReportingStatus",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityDomain": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
"label": "Entity [Domain]",
"terseLabel": "Entity [Domain]"
}
}
},
"localname": "EntityDomain",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCreditAgreementandPaycheckProtectionProgramNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"dei_EntityEmergingGrowthCompany": {
"auth_ref": [
"r648"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate if registrant meets the emerging growth company criteria.",
"label": "Entity Emerging Growth Company",
"terseLabel": "Entity Emerging Growth Company"
}
}
},
"localname": "EntityEmergingGrowthCompany",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_EntityFileNumber": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
"label": "Entity File Number",
"terseLabel": "Entity File Number"
}
}
},
"localname": "EntityFileNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "fileNumberItemType"
},
"dei_EntityFilerCategory": {
"auth_ref": [
"r648"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Filer Category",
"terseLabel": "Entity Filer Category"
}
}
},
"localname": "EntityFilerCategory",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "filerCategoryItemType"
},
"dei_EntityIncorporationStateCountryCode": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Two-character EDGAR code representing the state or country of incorporation.",
"label": "Entity Incorporation, State or Country Code",
"terseLabel": "Entity Incorporation, State or Country Code"
}
}
},
"localname": "EntityIncorporationStateCountryCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "edgarStateCountryItemType"
},
"dei_EntityInteractiveDataCurrent": {
"auth_ref": [
"r659"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
"label": "Entity Interactive Data Current",
"terseLabel": "Entity Interactive Data Current"
}
}
},
"localname": "EntityInteractiveDataCurrent",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityRegistrantName": {
"auth_ref": [
"r648"
],
"lang": {
"en-us": {
"role": {
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
"label": "Entity Registrant Name",
"terseLabel": "Entity Registrant Name"
}
}
},
"localname": "EntityRegistrantName",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityShellCompany": {
"auth_ref": [
"r648"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
"label": "Entity Shell Company",
"terseLabel": "Entity Shell Company"
}
}
},
"localname": "EntityShellCompany",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_EntitySmallBusiness": {
"auth_ref": [
"r648"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
"label": "Entity Small Business",
"terseLabel": "Entity Small Business"
}
}
},
"localname": "EntitySmallBusiness",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_EntityTaxIdentificationNumber": {
"auth_ref": [
"r648"
],
"lang": {
"en-us": {
"role": {
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
"label": "Entity Tax Identification Number",
"terseLabel": "Entity Tax Identification Number"
}
}
},
"localname": "EntityTaxIdentificationNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "employerIdItemType"
},
"dei_LegalEntityAxis": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The set of legal entities associated with a report.",
"label": "Legal Entity [Axis]",
"terseLabel": "Legal Entity [Axis]"
}
}
},
"localname": "LegalEntityAxis",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCreditAgreementandPaycheckProtectionProgramNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"dei_LocalPhoneNumber": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Local phone number for entity.",
"label": "Local Phone Number",
"terseLabel": "Local Phone Number"
}
}
},
"localname": "LocalPhoneNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_Security12bTitle": {
"auth_ref": [
"r647"
],
"lang": {
"en-us": {
"role": {
"documentation": "Title of a 12(b) registered security.",
"label": "Title of 12(b) Security",
"terseLabel": "Title of 12(b) Security"
}
}
},
"localname": "Security12bTitle",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "securityTitleItemType"
},
"dei_SecurityExchangeName": {
"auth_ref": [
"r649"
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the Exchange on which a security is registered.",
"label": "Security Exchange Name",
"terseLabel": "Security Exchange Name"
}
}
},
"localname": "SecurityExchangeName",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "edgarExchangeCodeItemType"
},
"dei_TradingSymbol": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Trading symbol of an instrument as listed on an exchange.",
"label": "Trading Symbol",
"terseLabel": "Trading Symbol"
}
}
},
"localname": "TradingSymbol",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.pulmonx.com/role/CoverPage"
],
"xbrltype": "tradingSymbolItemType"
},
"lung_AccruedInventoryPurchasesCurrent": {
"auth_ref": [],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
"order": 4.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Accrued Inventory Purchases Current",
"label": "Accrued Inventory Purchases Current",
"terseLabel": "Accrued inventory purchases"
}
}
},
"localname": "AccruedInventoryPurchasesCurrent",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"lung_AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Adjustments To Additional Paid In Capital, Change In Shares Subject To Repurchase",
"label": "Adjustments To Additional Paid In Capital, Change In Shares Subject To Repurchase",
"terseLabel": "Change in shares subject to repurchase"
}
}
},
"localname": "AdjustmentsToAdditionalPaidInCapitalChangeInSharesSubjectToRepurchase",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
],
"xbrltype": "monetaryItemType"
},
"lung_CIBCAgreementMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "CIBC Agreement",
"label": "CIBC Agreement [Member]",
"terseLabel": "CIBC Agreement"
}
}
},
"localname": "CIBCAgreementMember",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanComponentsOfDebtDetails",
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"lung_CIBCAgreementTrancheAMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "CIBC Agreement, Tranche A",
"label": "CIBC Agreement, Tranche A [Member]",
"terseLabel": "CIBC Agreement, Tranche A"
}
}
},
"localname": "CIBCAgreementTrancheAMember",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"lung_CIBCAgreementTrancheBMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "CIBC Agreement, Tranche B",
"label": "CIBC Agreement, Tranche B [Member]",
"terseLabel": "CIBC Agreement, Tranche B"
}
}
},
"localname": "CIBCAgreementTrancheBMember",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"lung_CIBCAgreementTrancheCMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "CIBC Agreement, Tranche C",
"label": "CIBC Agreement, Tranche C [Member]",
"terseLabel": "CIBC Agreement, Tranche C"
}
}
},
"localname": "CIBCAgreementTrancheCMember",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"lung_COVID19CreditAgreementMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "COVID-19 Credit Agreement",
"label": "COVID-19 Credit Agreement [Member]",
"terseLabel": "COVID-19 Credit Agreement"
}
}
},
"localname": "COVID19CreditAgreementMember",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCreditAgreementandPaycheckProtectionProgramNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"lung_CashAndCashEquivalentsAndMarketableSecurities": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Cash And Cash Equivalents And Marketable Securities",
"label": "Cash And Cash Equivalents And Marketable Securities",
"terseLabel": "Cash, cash equivalents and marketable securities"
}
}
},
"localname": "CashAndCashEquivalentsAndMarketableSecurities",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/FormationandBusinessoftheCompanyDetails"
],
"xbrltype": "monetaryItemType"
},
"lung_CashCashEquivalentsAndAvailableForSaleDebtSecurities": {
"auth_ref": [],
"calculation": {
"http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Cash, Cash Equivalents And Available-For-Sale Debt Securities",
"label": "Cash, Cash Equivalents And Available-For-Sale Debt Securities",
"totalLabel": "Marketable securities"
}
}
},
"localname": "CashCashEquivalentsAndAvailableForSaleDebtSecurities",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails"
],
"xbrltype": "monetaryItemType"
},
"lung_CommonStockRestrictedStockUnitsIssuedAndOutstandingMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Common Stock Restricted Stock Units Issued And Outstanding",
"label": "Common Stock Restricted Stock Units Issued And Outstanding [Member]",
"terseLabel": "Common stock restricted stock units issued and outstanding"
}
}
},
"localname": "CommonStockRestrictedStockUnitsIssuedAndOutstandingMember",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails"
],
"xbrltype": "domainItemType"
},
"lung_CorporateBondsDebtSecuritiesAtCarryingValue": {
"auth_ref": [],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsCashandCashEquivalentsDetails": {
"order": 1.0,
"parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Corporate Bonds Debt Securities, at Carrying Value",
"label": "Corporate Bonds Debt Securities, at Carrying Value",
"terseLabel": "Corporate bonds"
}
}
},
"localname": "CorporateBondsDebtSecuritiesAtCarryingValue",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsCashandCashEquivalentsDetails"
],
"xbrltype": "monetaryItemType"
},
"lung_CostOfGoodsAndServicesSoldMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Cost Of Goods And Services Sold",
"label": "Cost Of Goods And Services Sold [Member]",
"terseLabel": "Cost Of Goods And Services Sold"
}
}
},
"localname": "CostOfGoodsAndServicesSoldMember",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"lung_DebtInstrumentAccordionFeatureIncreaseFaceAmount": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Debt Instrument, Accordion Feature, Increase Face Amount",
"label": "Debt Instrument, Accordion Feature, Increase Face Amount",
"terseLabel": "Accordion feature on face amount of debt"
}
}
},
"localname": "DebtInstrumentAccordionFeatureIncreaseFaceAmount",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"lung_DebtInstrumentCovenantCashAndCashEquivalentsMinimumThresholdTriggerForRevenueRequirement": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Debt Instrument, Covenant, Cash And Cash Equivalents Minimum Threshold Trigger For Revenue Requirement",
"label": "Debt Instrument, Covenant, Cash And Cash Equivalents Minimum Threshold Trigger For Revenue Requirement",
"terseLabel": "Cash and cash equivalents trigger for revenue requirement"
}
}
},
"localname": "DebtInstrumentCovenantCashAndCashEquivalentsMinimumThresholdTriggerForRevenueRequirement",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"lung_DebtInstrumentCovenantMinimumRevenueRequirementPeriod": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Debt Instrument, Covenant, Minimum Revenue Requirement, Period",
"label": "Debt Instrument, Covenant, Minimum Revenue Requirement, Period",
"terseLabel": "Minimum percentage of revenue requirement, trailing period of revenue"
}
}
},
"localname": "DebtInstrumentCovenantMinimumRevenueRequirementPeriod",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"
],
"xbrltype": "durationItemType"
},
"lung_DebtInstrumentCovenantMinimumRevenueRequirementsPercentage": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Debt Instrument, Covenant, Minimum Revenue Requirements, Percentage",
"label": "Debt Instrument, Covenant, Minimum Revenue Requirements, Percentage",
"terseLabel": "Minimum percentage of revenue requirement"
}
}
},
"localname": "DebtInstrumentCovenantMinimumRevenueRequirementsPercentage",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"
],
"xbrltype": "percentItemType"
},
"lung_DebtInstrumentCovenantUnrestrictedCashRequirementPeriod": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Debt Instrument, Covenant, Unrestricted Cash Requirement, Period",
"label": "Debt Instrument, Covenant, Unrestricted Cash Requirement, Period",
"terseLabel": "Unrestricted cash requirement period"
}
}
},
"localname": "DebtInstrumentCovenantUnrestrictedCashRequirementPeriod",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"
],
"xbrltype": "durationItemType"
},
"lung_DebtInstrumentFaceAmountIncludingAccordionFeature": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Debt Instrument, Face Amount Including Accordion Feature",
"label": "Debt Instrument, Face Amount Including Accordion Feature",
"terseLabel": "Debt instrument, face amount including accordion feature"
}
}
},
"localname": "DebtInstrumentFaceAmountIncludingAccordionFeature",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"lung_DebtInstrumentNumberOfPeriodicPayments": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Debt Instrument, Number Of Periodic Payments",
"label": "Debt Instrument, Number Of Periodic Payments",
"terseLabel": "Number of periodic payments"
}
}
},
"localname": "DebtInstrumentNumberOfPeriodicPayments",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"
],
"xbrltype": "integerItemType"
},
"lung_DebtInstrumentPeriodicPaymentInterestOnlyTerm": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Debt Instrument, Periodic Payment, Interest Only, Term",
"label": "Debt Instrument, Periodic Payment, Interest Only, Term",
"terseLabel": "Interest payments term"
}
}
},
"localname": "DebtInstrumentPeriodicPaymentInterestOnlyTerm",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"
],
"xbrltype": "durationItemType"
},
"lung_DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Debt Instrument, Periodic Payment, Principal And Interest, Term",
"label": "Debt Instrument, Periodic Payment, Principal And Interest, Term",
"terseLabel": "Principal and interest payments term"
}
}
},
"localname": "DebtInstrumentPeriodicPaymentPrincipalAndInterestTerm",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"
],
"xbrltype": "durationItemType"
},
"lung_FairValueRecognizedOnBalanceSheetAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Fair Value Recognized On Balance Sheet",
"label": "Fair Value Recognized On Balance Sheet [Abstract]",
"terseLabel": "Amounts recognized on the consolidated balance sheet"
}
}
},
"localname": "FairValueRecognizedOnBalanceSheetAbstract",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails"
],
"xbrltype": "stringItemType"
},
"lung_GainLossOnAmendmentOfDebtInstrument": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Gain (Loss) on Amendment of Debt Instrument",
"label": "Gain (Loss) on Amendment of Debt Instrument",
"terseLabel": "Gain Loss on Amendment of Debt Instrument"
}
}
},
"localname": "GainLossOnAmendmentOfDebtInstrument",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"lung_HostingArrangementServiceContractImplementationCostCapitalizedAmortizationPeriod": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Hosting Arrangement, Service Contract, Implementation Cost, Capitalized, Amortization Period",
"label": "Hosting Arrangement, Service Contract, Implementation Cost, Capitalized, Amortization Period",
"terseLabel": "Amortization period"
}
}
},
"localname": "HostingArrangementServiceContractImplementationCostCapitalizedAmortizationPeriod",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsCapitalizedImplementationCostsofaHostingArrangementDetails"
],
"xbrltype": "durationItemType"
},
"lung_IncomeTaxDisclosureLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Income Tax Disclosure",
"label": "Income Tax Disclosure [Line Items]",
"terseLabel": "Income Tax Disclosure [Line Items]"
}
}
},
"localname": "IncomeTaxDisclosureLineItems",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/IncomeTaxesDetails"
],
"xbrltype": "stringItemType"
},
"lung_IncomeTaxDisclosureTable": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Income Tax Disclosure",
"label": "Income Tax Disclosure [Table]",
"terseLabel": "Income Tax Disclosure [Table]"
}
}
},
"localname": "IncomeTaxDisclosureTable",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/IncomeTaxesDetails"
],
"xbrltype": "stringItemType"
},
"lung_IncreaseInLoanInterestRate": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Increase In Loan Interest Rate",
"label": "Increase In Loan Interest Rate",
"terseLabel": "Increase in loan interest rate"
}
}
},
"localname": "IncreaseInLoanInterestRate",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"
],
"xbrltype": "pureItemType"
},
"lung_IncreaseLapseInRepurchaseOfCommonStockRights": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Increase (Lapse) In Repurchase Of Common Stock Rights",
"label": "Increase (Lapse) In Repurchase Of Common Stock Rights",
"terseLabel": "Lapse in repurchase rights of common stock"
}
}
},
"localname": "IncreaseLapseInRepurchaseOfCommonStockRights",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"lung_InventoryNetMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Inventory, Net",
"label": "Inventory, Net [Member]",
"terseLabel": "Inventory, Net"
}
}
},
"localname": "InventoryNetMember",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"lung_LesseeOperatingLeaseOptionToTerminateNoticePeriod": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Lessee, Operating Lease, Option To Terminate, Notice Period",
"label": "Lessee, Operating Lease, Option To Terminate, Notice Period",
"terseLabel": "Option to terminate, notice period"
}
}
},
"localname": "LesseeOperatingLeaseOptionToTerminateNoticePeriod",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesLeasesNarrativeDetails"
],
"xbrltype": "durationItemType"
},
"lung_LesseeOperatingSubleaseExpenseAnnualIncreaseRate": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Lessee, Operating Sublease, Expense, Annual Increase Rate",
"label": "Lessee, Operating Sublease, Expense, Annual Increase Rate",
"terseLabel": "Sublease, expense, annual increase rate"
}
}
},
"localname": "LesseeOperatingSubleaseExpenseAnnualIncreaseRate",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesLeasesNarrativeDetails"
],
"xbrltype": "percentItemType"
},
"lung_LesseeOperatingSubleaseMonthlyExpense": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Lessee, Operating Sublease, Monthly Expense",
"label": "Lessee, Operating Sublease, Monthly Expense",
"terseLabel": "Sublease monthly rent"
}
}
},
"localname": "LesseeOperatingSubleaseMonthlyExpense",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesLeasesNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"lung_LesseeOperatingSubleaseOptionToTerminateNoticePeriod": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Lessee, Operating Sublease, Option To Terminate, Notice Period",
"label": "Lessee, Operating Sublease, Option To Terminate, Notice Period",
"terseLabel": "Sublease, option to terminate, notice period"
}
}
},
"localname": "LesseeOperatingSubleaseOptionToTerminateNoticePeriod",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesLeasesNarrativeDetails"
],
"xbrltype": "durationItemType"
},
"lung_LesseeOperatingSubleaseOptionToTerminateTerm": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Lessee, Operating Sublease, Option To Terminate, Term",
"label": "Lessee, Operating Sublease, Option To Terminate, Term",
"terseLabel": "Sublease, period for option to terminate"
}
}
},
"localname": "LesseeOperatingSubleaseOptionToTerminateTerm",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesLeasesNarrativeDetails"
],
"xbrltype": "durationItemType"
},
"lung_LesseeOperatingSubleaseRenewalTerm": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Lessee, Operating Sublease, Renewal Term",
"label": "Lessee, Operating Sublease, Renewal Term",
"terseLabel": "Sublease renewal term"
}
}
},
"localname": "LesseeOperatingSubleaseRenewalTerm",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesLeasesNarrativeDetails"
],
"xbrltype": "durationItemType"
},
"lung_LesseeOperatingSubleaseTenantImprovementAllowanceReceivableUponLeaseRenewal": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Lessee, Operating Sublease, Tenant Improvement Allowance, Receivable Upon Lease Renewal",
"label": "Lessee, Operating Sublease, Tenant Improvement Allowance, Receivable Upon Lease Renewal",
"terseLabel": "Sublease, tenant improvement allowance, receivable upon lease renewal"
}
}
},
"localname": "LesseeOperatingSubleaseTenantImprovementAllowanceReceivableUponLeaseRenewal",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesLeasesNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"lung_LesseeOperatingSubleaseTerm": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Lessee, Operating Sublease, Term",
"label": "Lessee, Operating Sublease, Term",
"terseLabel": "Sublease term"
}
}
},
"localname": "LesseeOperatingSubleaseTerm",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesLeasesNarrativeDetails"
],
"xbrltype": "durationItemType"
},
"lung_NumberOfInstallmentsForRepayment": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Number Of Installments For Repayment",
"label": "Number Of Installments For Repayment",
"terseLabel": "Number of installments for repayment"
}
}
},
"localname": "NumberOfInstallmentsForRepayment",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCreditAgreementandPaycheckProtectionProgramNarrativeDetails"
],
"xbrltype": "integerItemType"
},
"lung_NumberOfVehicleLeases": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Number Of Vehicle Leases",
"label": "Number Of Vehicle Leases",
"terseLabel": "Number of vehicle leases"
}
}
},
"localname": "NumberOfVehicleLeases",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesLeasesNarrativeDetails"
],
"xbrltype": "integerItemType"
},
"lung_NumberOfVotesForEachShareOfCommonStockHeld": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Number Of Votes For Each Share Of Common Stock Held",
"label": "Number Of Votes For Each Share Of Common Stock Held",
"terseLabel": "Number of votes for each share of common stock held"
}
}
},
"localname": "NumberOfVotesForEachShareOfCommonStockHeld",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails"
],
"xbrltype": "integerItemType"
},
"lung_OperatingLeaseExpenseAnnualIncreaseRate": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Operating Lease, Expense, Annual Increase Rate",
"label": "Operating Lease, Expense, Annual Increase Rate",
"terseLabel": "Annual increase rate"
}
}
},
"localname": "OperatingLeaseExpenseAnnualIncreaseRate",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesLeasesNarrativeDetails"
],
"xbrltype": "percentItemType"
},
"lung_OperatingLeaseMonthlyExpense": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Operating Lease, Monthly Expense",
"label": "Operating Lease, Monthly Expense",
"terseLabel": "Monthly base rent"
}
}
},
"localname": "OperatingLeaseMonthlyExpense",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesLeasesNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"lung_OtherInternationalGeographicalAreasMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Other International Geographical Areas",
"label": "Other International Geographical Areas [Member]",
"terseLabel": "Other International"
}
}
},
"localname": "OtherInternationalGeographicalAreasMember",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/SegmentInformationRevenuebyGeographicAreaDetails"
],
"xbrltype": "domainItemType"
},
"lung_PulmonxInternationalSarlMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Pulmonx International Sarl",
"label": "Pulmonx International Sarl [Member]",
"terseLabel": "Pulmonx International Sarl"
}
}
},
"localname": "PulmonxInternationalSarlMember",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCreditAgreementandPaycheckProtectionProgramNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"lung_ReceivableFromExerciseOfCommonStockOptions": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Receivable From Exercise Of Common Stock Options",
"label": "Receivable From Exercise Of Common Stock Options",
"terseLabel": "Amount receivable from exercise of common stock options"
}
}
},
"localname": "ReceivableFromExerciseOfCommonStockOptions",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"lung_ServiceAgreementPurchaseMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Service Agreement, Purchase",
"label": "Service Agreement, Purchase [Member]",
"terseLabel": "Service Agreement"
}
}
},
"localname": "ServiceAgreementPurchaseMember",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesServiceAgreementDetails"
],
"xbrltype": "domainItemType"
},
"lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePriceAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested And Expected To Vest, Weighted Average Exercise Price",
"label": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested And Expected To Vest, Weighted Average Exercise Price [Abstract]",
"terseLabel": "Weighted Average Exercise Price"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePriceAbstract",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityOptionsVestedandExpectedtoVestDetails"
],
"xbrltype": "stringItemType"
},
"lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Weighted Average Exercise Price",
"label": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Weighted Average Exercise Price",
"terseLabel": "Options vested (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityOptionsVestedandExpectedtoVestDetails"
],
"xbrltype": "perShareItemType"
},
"lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Weighted Average Remaining Contractual Term",
"label": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Weighted Average Remaining Contractual Term",
"terseLabel": "Options vested"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityOptionsVestedandExpectedtoVestDetails"
],
"xbrltype": "durationItemType"
},
"lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedTermAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Term",
"label": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Term [Abstract]",
"terseLabel": "Weighted Average Contractual Life (in Years)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedTermAbstract",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityOptionsVestedandExpectedtoVestDetails"
],
"xbrltype": "stringItemType"
},
"lung_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Outstanding Options",
"label": "Share-based Compensation Arrangement By Share-based Payment Award, Outstanding Options [Abstract]",
"terseLabel": "Outstanding Options"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingOptionsAbstract",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityStockOptionActivityDetails"
],
"xbrltype": "stringItemType"
},
"lung_ShareBasedCompensationEmployeeStockAvailableForGrantMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Share Based Compensation, Employee Stock Available For Grant",
"label": "Share Based Compensation, Employee Stock Available For Grant [Member]",
"terseLabel": "Common stock available for future grants"
}
}
},
"localname": "ShareBasedCompensationEmployeeStockAvailableForGrantMember",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails"
],
"xbrltype": "domainItemType"
},
"lung_ShareBasedCompensationEmployeeStockOutstandingMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Share Based Compensation, Employee Stock Outstanding",
"label": "Share Based Compensation, Employee Stock Outstanding [Member]",
"terseLabel": "Common stock options issued and outstanding"
}
}
},
"localname": "ShareBasedCompensationEmployeeStockOutstandingMember",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails"
],
"xbrltype": "domainItemType"
},
"lung_ShareBasedCompensationUnvestedEarlyExercisedOptionsMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Share Based Compensation, Unvested Early Exercised Options",
"label": "Share Based Compensation, Unvested Early Exercised Options [Member]",
"terseLabel": "Unvested early exercised common stock options"
}
}
},
"localname": "ShareBasedCompensationUnvestedEarlyExercisedOptionsMember",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersExcludedPotentiallyDilutiveSecuritiesOutstandingDetails"
],
"xbrltype": "domainItemType"
},
"lung_ShareBasedPaymentArrangementSharesSubjectToRepurchase": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Share-based Payment Arrangement, Shares Subject To Repurchase",
"label": "Share-based Payment Arrangement, Shares Subject To Repurchase",
"terseLabel": "Shares subject to repurchase (in shares)"
}
}
},
"localname": "ShareBasedPaymentArrangementSharesSubjectToRepurchase",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails"
],
"xbrltype": "sharesItemType"
},
"lung_ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Share-based Payment Arrangement, Shares Subject To Repurchase, Aggregate Exercise Price",
"label": "Share-based Payment Arrangement, Shares Subject To Repurchase, Aggregate Exercise Price",
"terseLabel": "Aggregate exercise price of shares subject to repurchase"
}
}
},
"localname": "ShareBasedPaymentArrangementSharesSubjectToRepurchaseAggregateExercisePrice",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"lung_StockOptionsAndRestrictedStockUnitsMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Stock Options And Restricted Stock Units",
"label": "Stock Options And Restricted Stock Units [Member]",
"terseLabel": "Stock Options And Restricted Stock Units"
}
}
},
"localname": "StockOptionsAndRestrictedStockUnitsMember",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails",
"http://www.pulmonx.com/role/StockholdersEquityTotalStockBasedCompensationDetails"
],
"xbrltype": "domainItemType"
},
"lung_StockRepurchasedDuringPeriodExerciseOfEarlyStockOptionsShares": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Stock Repurchased During Period, Exercise Of Early Stock Options, Shares",
"label": "Stock Repurchased During Period, Exercise Of Early Stock Options, Shares",
"negatedTerseLabel": "Repurchase of early exercised common stock options (in shares)"
}
}
},
"localname": "StockRepurchasedDuringPeriodExerciseOfEarlyStockOptionsShares",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
],
"xbrltype": "sharesItemType"
},
"lung_TenantImprovementAllowanceReceivableUponLeaseRenewal": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Tenant Improvement Allowance, Receivable Upon Lease Renewal",
"label": "Tenant Improvement Allowance, Receivable Upon Lease Renewal",
"terseLabel": "Tenant improvement allowance, receivable upon lease renewal"
}
}
},
"localname": "TenantImprovementAllowanceReceivableUponLeaseRenewal",
"nsuri": "http://www.pulmonx.com/20220630",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesLeasesNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"srt_AsiaPacificMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Asia Pacific [Member]",
"terseLabel": "Asia Pacific"
}
}
},
"localname": "AsiaPacificMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.pulmonx.com/role/SegmentInformationLongLivedAssetsbyGeographicalAreaDetails",
"http://www.pulmonx.com/role/SegmentInformationRevenuebyGeographicAreaDetails"
],
"xbrltype": "domainItemType"
},
"srt_MaximumMember": {
"auth_ref": [
"r276",
"r277",
"r278",
"r279",
"r298",
"r337",
"r387",
"r388",
"r544",
"r545",
"r546",
"r547",
"r548",
"r549",
"r568",
"r618",
"r620",
"r644",
"r645"
],
"lang": {
"en-us": {
"role": {
"label": "Maximum [Member]",
"terseLabel": "Maximum"
}
}
},
"localname": "MaximumMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.pulmonx.com/role/IncomeTaxesDetails",
"http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesDetails"
],
"xbrltype": "domainItemType"
},
"srt_RangeAxis": {
"auth_ref": [
"r271",
"r276",
"r277",
"r278",
"r279",
"r298",
"r337",
"r378",
"r387",
"r388",
"r417",
"r418",
"r419",
"r544",
"r545",
"r546",
"r547",
"r548",
"r549",
"r568",
"r618",
"r620",
"r644",
"r645"
],
"lang": {
"en-us": {
"role": {
"label": "Statistical Measurement [Axis]",
"terseLabel": "Statistical Measurement [Axis]"
}
}
},
"localname": "RangeAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.pulmonx.com/role/IncomeTaxesDetails",
"http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesDetails"
],
"xbrltype": "stringItemType"
},
"srt_RangeMember": {
"auth_ref": [
"r271",
"r276",
"r277",
"r278",
"r279",
"r298",
"r337",
"r378",
"r387",
"r388",
"r417",
"r418",
"r419",
"r544",
"r545",
"r546",
"r547",
"r548",
"r549",
"r568",
"r618",
"r620",
"r644",
"r645"
],
"lang": {
"en-us": {
"role": {
"label": "Statistical Measurement [Domain]",
"terseLabel": "Statistical Measurement [Domain]"
}
}
},
"localname": "RangeMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.pulmonx.com/role/IncomeTaxesDetails",
"http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesDetails"
],
"xbrltype": "domainItemType"
},
"srt_SegmentGeographicalDomain": {
"auth_ref": [
"r201",
"r202",
"r371",
"r375",
"r619",
"r635",
"r636",
"r637",
"r638",
"r639",
"r640",
"r641",
"r642",
"r643"
],
"lang": {
"en-us": {
"role": {
"label": "Geographical [Domain]",
"terseLabel": "Geographical [Domain]"
}
}
},
"localname": "SegmentGeographicalDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.pulmonx.com/role/SegmentInformationLongLivedAssetsbyGeographicalAreaDetails",
"http://www.pulmonx.com/role/SegmentInformationNarrativeDetails",
"http://www.pulmonx.com/role/SegmentInformationRevenuebyGeographicAreaDetails"
],
"xbrltype": "domainItemType"
},
"srt_StatementGeographicalAxis": {
"auth_ref": [
"r201",
"r202",
"r371",
"r375",
"r619",
"r632",
"r635",
"r636",
"r637",
"r638",
"r639",
"r640",
"r641",
"r642",
"r643"
],
"lang": {
"en-us": {
"role": {
"label": "Geographical [Axis]",
"terseLabel": "Geographical [Axis]"
}
}
},
"localname": "StatementGeographicalAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.pulmonx.com/role/SegmentInformationLongLivedAssetsbyGeographicalAreaDetails",
"http://www.pulmonx.com/role/SegmentInformationNarrativeDetails",
"http://www.pulmonx.com/role/SegmentInformationRevenuebyGeographicAreaDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AccountingPoliciesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Accounting Policies [Abstract]"
}
}
},
"localname": "AccountingPoliciesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_AccountsPayableCurrent": {
"auth_ref": [
"r43",
"r537"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 5.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accounts Payable, Current",
"terseLabel": "Accounts payable"
}
}
},
"localname": "AccountsPayableCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccountsReceivableNetCurrent": {
"auth_ref": [
"r208",
"r209"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
"label": "Accounts Receivable, after Allowance for Credit Loss, Current",
"terseLabel": "Accounts receivable, net"
}
}
},
"localname": "AccountsReceivableNetCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
"auth_ref": [
"r101"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 14.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
"label": "Accretion (Amortization) of Discounts and Premiums, Investments",
"negatedTerseLabel": "Amortization of premiums and discounts on short-term marketable securities"
}
}
},
"localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccruedBonusesCurrent": {
"auth_ref": [
"r47"
],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
"order": 8.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accrued Bonuses, Current",
"terseLabel": "Accrued employee bonuses and commissions"
}
}
},
"localname": "AccruedBonusesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccruedIncomeTaxesCurrent": {
"auth_ref": [
"r19",
"r582",
"r602"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 6.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
"label": "Accrued Income Taxes, Current",
"terseLabel": "Income taxes payable"
}
}
},
"localname": "AccruedIncomeTaxesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccruedLiabilitiesCurrent": {
"auth_ref": [
"r47"
],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accrued Liabilities, Current",
"terseLabel": "Accrued liabilities",
"totalLabel": "Total accrued liabilities"
}
}
},
"localname": "AccruedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails",
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccruedProfessionalFeesCurrent": {
"auth_ref": [
"r47"
],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
"order": 5.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accrued Professional Fees, Current",
"terseLabel": "Accrued professional fees"
}
}
},
"localname": "AccruedProfessionalFeesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccruedVacationCurrent": {
"auth_ref": [
"r47",
"r377"
],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
"order": 2.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accrued Vacation, Current",
"terseLabel": "Accrued vacation"
}
}
},
"localname": "AccruedVacationCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
"auth_ref": [
"r12",
"r268"
],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails": {
"order": 1.0,
"parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
"label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
"negatedTerseLabel": "Less: accumulated depreciation"
}
}
},
"localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
"terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
"auth_ref": [
"r29",
"r58",
"r59",
"r60",
"r607",
"r625",
"r628"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 4.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
"label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
"terseLabel": "Accumulated other comprehensive income"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
"auth_ref": [
"r67",
"r68",
"r502",
"r503",
"r504",
"r505",
"r506",
"r507"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
"label": "Accumulated Other Comprehensive Income (Loss) [Table]",
"terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeLossTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
"auth_ref": [
"r57",
"r60",
"r67",
"r68",
"r69",
"r119",
"r120",
"r121",
"r459",
"r533",
"r621",
"r622"
],
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
"label": "AOCI Attributable to Parent [Member]",
"terseLabel": "Accumulated Other Comprehensive Income"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
],
"xbrltype": "domainItemType"
},
"us-gaap_AdditionalPaidInCapitalCommonStock": {
"auth_ref": [
"r27"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 5.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
"label": "Additional Paid in Capital, Common Stock",
"terseLabel": "Additional paid-in capital"
}
}
},
"localname": "AdditionalPaidInCapitalCommonStock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdditionalPaidInCapitalMember": {
"auth_ref": [
"r119",
"r120",
"r121",
"r427",
"r428",
"r429",
"r477"
],
"lang": {
"en-us": {
"role": {
"documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
"label": "Additional Paid-in Capital [Member]",
"terseLabel": "Additional Paid-In Capital"
}
}
},
"localname": "AdditionalPaidInCapitalMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
],
"xbrltype": "domainItemType"
},
"us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
"auth_ref": [
"r390",
"r430",
"r431"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
"label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
"terseLabel": "Stock-based compensation expense"
}
}
},
"localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
"terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities"
}
}
},
"localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_AllocatedShareBasedCompensationExpense": {
"auth_ref": [
"r422"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
"label": "Share-Based Payment Arrangement, Expense",
"terseLabel": "Stock-based compensation expense"
}
}
},
"localname": "AllocatedShareBasedCompensationExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityTotalStockBasedCompensationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
"auth_ref": [
"r100",
"r318",
"r328",
"r329",
"r512"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
"label": "Amortization of Debt Issuance Costs and Discounts",
"terseLabel": "Amortization of debt discount and debt issuance costs"
}
}
},
"localname": "AmortizationOfFinancingCostsAndDiscounts",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows",
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AmortizationOfIntangibleAssets": {
"auth_ref": [
"r100",
"r257",
"r262"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
"label": "Amortization of Intangible Assets",
"terseLabel": "Amortization expense related to intangibles, less than"
}
}
},
"localname": "AmortizationOfIntangibleAssets",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
"auth_ref": [
"r153"
],
"lang": {
"en-us": {
"role": {
"documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
"label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
"terseLabel": "Potentially dilutive securities excluded from computation of diluted weighted average shares outstanding (in shares)"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersExcludedPotentiallyDilutiveSecuritiesOutstandingDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
"auth_ref": [
"r153"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of antidilutive security.",
"label": "Antidilutive Securities [Axis]",
"terseLabel": "Antidilutive Securities [Axis]"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersExcludedPotentiallyDilutiveSecuritiesOutstandingDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
"terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersExcludedPotentiallyDilutiveSecuritiesOutstandingDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AntidilutiveSecuritiesNameDomain": {
"auth_ref": [
"r153"
],
"lang": {
"en-us": {
"role": {
"documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
"label": "Antidilutive Securities, Name [Domain]",
"terseLabel": "Antidilutive Securities, Name [Domain]"
}
}
},
"localname": "AntidilutiveSecuritiesNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersExcludedPotentiallyDilutiveSecuritiesOutstandingDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_Assets": {
"auth_ref": [
"r16",
"r113",
"r186",
"r190",
"r196",
"r227",
"r284",
"r285",
"r286",
"r287",
"r288",
"r289",
"r290",
"r291",
"r292",
"r293",
"r294",
"r455",
"r460",
"r495",
"r535",
"r537",
"r580",
"r601"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets",
"totalLabel": "Total assets"
}
}
},
"localname": "Assets",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Assets [Abstract]",
"terseLabel": "Assets"
}
}
},
"localname": "AssetsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_AssetsCurrent": {
"auth_ref": [
"r6",
"r42",
"r113",
"r227",
"r284",
"r285",
"r286",
"r287",
"r288",
"r289",
"r290",
"r291",
"r292",
"r293",
"r294",
"r455",
"r460",
"r495",
"r535",
"r537"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 4.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets, Current",
"totalLabel": "Total current assets"
}
}
},
"localname": "AssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsCurrentAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Assets, Current [Abstract]",
"terseLabel": "Current assets"
}
}
},
"localname": "AssetsCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_AssetsFairValueDisclosure": {
"auth_ref": [
"r483"
],
"calculation": {
"http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets, Fair Value Disclosure",
"totalLabel": "Total financial assets"
}
}
},
"localname": "AssetsFairValueDisclosure",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
"auth_ref": [
"r218"
],
"calculation": {
"http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails": {
"order": 2.0,
"parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
"terseLabel": "Unrealized Gains"
}
}
},
"localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
"auth_ref": [
"r219"
],
"calculation": {
"http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails": {
"order": 1.0,
"parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
"negatedTerseLabel": "Unrealized Losses"
}
}
},
"localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
"auth_ref": [
"r216",
"r237"
],
"calculation": {
"http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Debt Securities, Available-for-Sale, Amortized Cost",
"totalLabel": "Amortized Cost"
}
}
},
"localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
"auth_ref": [
"r213",
"r217",
"r237",
"r586"
],
"calculation": {
"http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": {
"order": 1.0,
"parentTag": "us-gaap_AssetsFairValueDisclosure",
"weight": 1.0
},
"http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails": {
"order": 3.0,
"parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Debt Securities, Available-for-Sale",
"terseLabel": "Short-term marketable securities",
"verboseLabel": "Fair Value"
}
}
},
"localname": "AvailableForSaleSecuritiesDebtSecurities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
"http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
"auth_ref": [
"r215",
"r237"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 4.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
},
"http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails": {
"order": 2.0,
"parentTag": "lung_CashCashEquivalentsAndAvailableForSaleDebtSecurities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
"label": "Debt Securities, Available-for-Sale, Current",
"terseLabel": "Short-term marketable securities"
}
}
},
"localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets",
"http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
"auth_ref": [
"r10",
"r215",
"r237"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 7.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
},
"http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails": {
"order": 1.0,
"parentTag": "lung_CashCashEquivalentsAndAvailableForSaleDebtSecurities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
"label": "Debt Securities, Available-for-Sale, Noncurrent",
"terseLabel": "Long-term marketable securities"
}
}
},
"localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets",
"http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]",
"terseLabel": "Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]"
}
}
},
"localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AwardTypeAxis": {
"auth_ref": [
"r392",
"r393",
"r394",
"r396",
"r397",
"r398",
"r399",
"r400",
"r401",
"r402",
"r403",
"r404",
"r405",
"r406",
"r407",
"r408",
"r409",
"r411",
"r412",
"r414",
"r415",
"r416",
"r417",
"r418",
"r419",
"r420"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of award under share-based payment arrangement.",
"label": "Award Type [Axis]",
"terseLabel": "Award Type [Axis]"
}
}
},
"localname": "AwardTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails",
"http://www.pulmonx.com/role/StockholdersEquityRestrictedStockUnitActivityDetails",
"http://www.pulmonx.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails",
"http://www.pulmonx.com/role/StockholdersEquityTotalStockBasedCompensationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_BalanceSheetLocationAxis": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Information by location on balance sheet (statement of financial position).",
"label": "Balance Sheet Location [Axis]",
"terseLabel": "Balance Sheet Location [Axis]"
}
}
},
"localname": "BalanceSheetLocationAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsCapitalizedImplementationCostsofaHostingArrangementDetails",
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_BalanceSheetLocationDomain": {
"auth_ref": [
"r467",
"r468"
],
"lang": {
"en-us": {
"role": {
"documentation": "Location in the balance sheet (statement of financial position).",
"label": "Balance Sheet Location [Domain]",
"terseLabel": "Balance Sheet Location [Domain]"
}
}
},
"localname": "BalanceSheetLocationDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsCapitalizedImplementationCostsofaHostingArrangementDetails",
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
"label": "Basis of Accounting, Policy [Policy Text Block]",
"terseLabel": "Basis of Presentation"
}
}
},
"localname": "BasisOfAccountingPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
"auth_ref": [
"r118"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
"label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
"terseLabel": "Summary of Significant Accounting Policies"
}
}
},
"localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SummaryofSignificantAccountingPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_BuildingMember": {
"auth_ref": [
"r267"
],
"lang": {
"en-us": {
"role": {
"documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
"label": "Building [Member]",
"terseLabel": "Office Facilities"
}
}
},
"localname": "BuildingMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesLeasesNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
"auth_ref": [
"r104",
"r105",
"r106"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
"label": "Capital Expenditures Incurred but Not yet Paid",
"terseLabel": "Purchases of property and equipment in accounts payable"
}
}
},
"localname": "CapitalExpendituresIncurredButNotYetPaid",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_Cash": {
"auth_ref": [
"r9",
"r537",
"r630",
"r631"
],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsCashandCashEquivalentsDetails": {
"order": 4.0,
"parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
"label": "Cash",
"terseLabel": "Cash"
}
}
},
"localname": "Cash",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsCashandCashEquivalentsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashAndCashEquivalentsAtCarryingValue": {
"auth_ref": [
"r3",
"r9",
"r102"
],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsCashandCashEquivalentsDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
},
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 1.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
"label": "Cash and Cash Equivalents, at Carrying Value",
"terseLabel": "Cash and cash equivalents",
"totalLabel": "Total cash and cash equivalents"
}
}
},
"localname": "CashAndCashEquivalentsAtCarryingValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsCashandCashEquivalentsDetails",
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets",
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Cash and Cash Equivalents, at Carrying Value [Abstract]",
"terseLabel": "Cash equivalents:"
}
}
},
"localname": "CashAndCashEquivalentsAtCarryingValueAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsCashandCashEquivalentsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_CashAndCashEquivalentsAxis": {
"auth_ref": [
"r9"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of cash and cash equivalent balance.",
"label": "Cash and Cash Equivalents [Axis]",
"terseLabel": "Cash and Cash Equivalents [Axis]"
}
}
},
"localname": "CashAndCashEquivalentsAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
"auth_ref": [],
"calculation": {
"http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails": {
"order": 2.0,
"parentTag": "us-gaap_AssetsFairValueDisclosure",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash and Cash Equivalents, Fair Value Disclosure",
"terseLabel": "Cash equivalents"
}
}
},
"localname": "CashAndCashEquivalentsFairValueDisclosure",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
"auth_ref": [
"r96",
"r102",
"r107"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
"periodEndLabel": "Cash, cash equivalents and restricted cash, at end of the period",
"periodStartLabel": "Cash, cash equivalents and restricted cash, at beginning of the period",
"totalLabel": "Cash, cash equivalents and restricted cash in consolidated balance sheets"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
"terseLabel": "Reconciliation of cash, cash equivalents and restricted cash to consolidated balance sheets:"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
"auth_ref": [
"r96",
"r501"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
"totalLabel": "Net decrease in cash and cash equivalents"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashUninsuredAmount": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.",
"label": "Cash, Uninsured Amount",
"terseLabel": "Cash on deposit with foreign banks"
}
}
},
"localname": "CashUninsuredAmount",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ClassOfStockLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Class of Stock [Line Items]",
"terseLabel": "Class of Stock [Line Items]"
}
}
},
"localname": "ClassOfStockLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_CommercialPaperAtCarryingValue": {
"auth_ref": [],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsCashandCashEquivalentsDetails": {
"order": 3.0,
"parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Unsecured short-term debt instrument issued by corporations which are highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
"label": "Commercial Paper, at Carrying Value",
"terseLabel": "Commercial paper"
}
}
},
"localname": "CommercialPaperAtCarryingValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsCashandCashEquivalentsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CommercialPaperMember": {
"auth_ref": [
"r281"
],
"lang": {
"en-us": {
"role": {
"documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
"label": "Commercial Paper [Member]",
"terseLabel": "Commercial paper"
}
}
},
"localname": "CommercialPaperMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
"http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
"auth_ref": [
"r379",
"r487"
],
"lang": {
"en-us": {
"role": {
"documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
"label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
"terseLabel": "Commercial paper"
}
}
},
"localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CommitmentsAndContingencies": {
"auth_ref": [
"r53",
"r588",
"r611"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
"label": "Commitments and Contingencies",
"terseLabel": "Commitments and contingencies (Note 8)"
}
}
},
"localname": "CommitmentsAndContingencies",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Commitments and Contingencies Disclosure [Abstract]"
}
}
},
"localname": "CommitmentsAndContingenciesDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
"auth_ref": [
"r273",
"r274",
"r275",
"r280",
"r634"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for commitments and contingencies.",
"label": "Commitments and Contingencies Disclosure [Text Block]",
"terseLabel": "Commitments and Contingencies"
}
}
},
"localname": "CommitmentsAndContingenciesDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingencies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
"auth_ref": [
"r54"
],
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate number of common shares reserved for future issuance.",
"label": "Common Stock, Capital Shares Reserved for Future Issuance",
"terseLabel": "Shares reserved for future issuance (in shares)"
}
}
},
"localname": "CommonStockCapitalSharesReservedForFutureIssuance",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockMember": {
"auth_ref": [
"r119",
"r120",
"r477"
],
"lang": {
"en-us": {
"role": {
"documentation": "Stock that is subordinate to all other stock of the issuer.",
"label": "Common Stock [Member]",
"terseLabel": "Common Stock"
}
}
},
"localname": "CommonStockMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
],
"xbrltype": "domainItemType"
},
"us-gaap_CommonStockParOrStatedValuePerShare": {
"auth_ref": [
"r25"
],
"lang": {
"en-us": {
"role": {
"documentation": "Face amount or stated value per share of common stock.",
"label": "Common Stock, Par or Stated Value Per Share",
"terseLabel": "Common stock, par value (in dollars per share)"
}
}
},
"localname": "CommonStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "perShareItemType"
},
"us-gaap_CommonStockSharesAuthorized": {
"auth_ref": [
"r25"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
"label": "Common Stock, Shares Authorized",
"terseLabel": "Common stock, authorized (in shares)"
}
}
},
"localname": "CommonStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesIssued": {
"auth_ref": [
"r25"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
"label": "Common Stock, Shares, Issued",
"terseLabel": "Common stock, issued (in shares)"
}
}
},
"localname": "CommonStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesOutstanding": {
"auth_ref": [
"r25",
"r351"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
"label": "Common Stock, Shares, Outstanding",
"periodEndLabel": "Ending balance (in shares)",
"periodStartLabel": "Beginning balance (in shares)",
"terseLabel": "Common stock, outstanding (in shares)"
}
}
},
"localname": "CommonStockSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockValue": {
"auth_ref": [
"r25",
"r537"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
"label": "Common Stock, Value, Issued",
"terseLabel": "Common stock, $0.001 par value, 200,000,000 shares authorized as of June\u00a030, 2022 and December\u00a031, 2021; 37,266,030 shares issued and outstanding as of June\u00a030, 2022 and 36,931,762 shares issued and outstanding as of December\u00a031, 2021"
}
}
},
"localname": "CommonStockValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ComprehensiveIncomeNetOfTax": {
"auth_ref": [
"r63",
"r65",
"r66",
"r74",
"r591",
"r614"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
"label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
"totalLabel": "Comprehensive loss"
}
}
},
"localname": "ComprehensiveIncomeNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ComputerEquipmentMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
"label": "Computer Equipment [Member]",
"terseLabel": "Computer equipment and software"
}
}
},
"localname": "ComputerEquipmentMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ConcentrationRiskBenchmarkDomain": {
"auth_ref": [
"r170",
"r171",
"r206",
"r492",
"r493",
"r633"
],
"lang": {
"en-us": {
"role": {
"documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
"label": "Concentration Risk Benchmark [Domain]",
"terseLabel": "Concentration Risk Benchmark [Domain]"
}
}
},
"localname": "ConcentrationRiskBenchmarkDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SegmentInformationNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ConcentrationRiskByBenchmarkAxis": {
"auth_ref": [
"r170",
"r171",
"r206",
"r492",
"r493",
"r629",
"r633"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by benchmark of concentration risk.",
"label": "Concentration Risk Benchmark [Axis]",
"terseLabel": "Concentration Risk Benchmark [Axis]"
}
}
},
"localname": "ConcentrationRiskByBenchmarkAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SegmentInformationNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ConcentrationRiskByTypeAxis": {
"auth_ref": [
"r170",
"r171",
"r206",
"r492",
"r493",
"r629",
"r633"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
"label": "Concentration Risk Type [Axis]",
"terseLabel": "Concentration Risk Type [Axis]"
}
}
},
"localname": "ConcentrationRiskByTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SegmentInformationNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ConcentrationRiskCreditRisk": {
"auth_ref": [
"r165",
"r599"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for credit risk.",
"label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
"terseLabel": "Concentration of Credit Risk"
}
}
},
"localname": "ConcentrationRiskCreditRisk",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ConcentrationRiskLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Concentration Risk [Line Items]",
"terseLabel": "Concentration Risk [Line Items]"
}
}
},
"localname": "ConcentrationRiskLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SegmentInformationNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ConcentrationRiskPercentage1": {
"auth_ref": [
"r170",
"r171",
"r206",
"r492",
"r493"
],
"lang": {
"en-us": {
"role": {
"documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
"label": "Concentration Risk, Percentage",
"terseLabel": "Concentration risk, percentage"
}
}
},
"localname": "ConcentrationRiskPercentage1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SegmentInformationNarrativeDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_ConcentrationRiskTable": {
"auth_ref": [
"r168",
"r170",
"r171",
"r172",
"r492",
"r494",
"r633"
],
"lang": {
"en-us": {
"role": {
"documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
"label": "Concentration Risk [Table]",
"terseLabel": "Concentration Risk [Table]"
}
}
},
"localname": "ConcentrationRiskTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SegmentInformationNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ConcentrationRiskTypeDomain": {
"auth_ref": [
"r170",
"r171",
"r206",
"r492",
"r493",
"r633"
],
"lang": {
"en-us": {
"role": {
"documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
"label": "Concentration Risk Type [Domain]",
"terseLabel": "Concentration Risk Type [Domain]"
}
}
},
"localname": "ConcentrationRiskTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SegmentInformationNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ConsolidationPolicyTextBlock": {
"auth_ref": [
"r108",
"r457"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
"label": "Consolidation, Policy [Policy Text Block]",
"terseLabel": "Principles of Consolidation"
}
}
},
"localname": "ConsolidationPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ConstructionInProgressMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
"label": "Construction in Progress [Member]",
"terseLabel": "Construction in progress"
}
}
},
"localname": "ConstructionInProgressMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ContractWithCustomerLiability": {
"auth_ref": [
"r360",
"r361",
"r372"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
"label": "Contract with Customer, Liability",
"terseLabel": "Deferred revenue"
}
}
},
"localname": "ContractWithCustomerLiability",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/RevenueRecognitionDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractWithCustomerLiabilityCurrent": {
"auth_ref": [
"r360",
"r361",
"r372"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
"label": "Contract with Customer, Liability, Current",
"terseLabel": "Deferred revenue"
}
}
},
"localname": "ContractWithCustomerLiabilityCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
"auth_ref": [
"r373"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
"label": "Contract with Customer, Liability, Revenue Recognized",
"terseLabel": "Revenue recognized"
}
}
},
"localname": "ContractWithCustomerLiabilityRevenueRecognized",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/RevenueRecognitionDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CorporateBondSecuritiesMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
"label": "Corporate Bond Securities [Member]",
"terseLabel": "Corporate bonds"
}
}
},
"localname": "CorporateBondSecuritiesMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
"http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CostOfGoodsAndServicesSold": {
"auth_ref": [
"r78",
"r571"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
"order": 2.0,
"parentTag": "us-gaap_GrossProfit",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
"label": "Cost of Goods and Services Sold",
"terseLabel": "Cost of goods sold"
}
}
},
"localname": "CostOfGoodsAndServicesSold",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesServiceAgreementDetails",
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CostOfSalesMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption encompassing cost of sales.",
"label": "Cost of Sales [Member]",
"terseLabel": "Cost of goods sold"
}
}
},
"localname": "CostOfSalesMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityTotalStockBasedCompensationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_DebtDisclosureAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Debt Disclosure [Abstract]"
}
}
},
"localname": "DebtDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_DebtDisclosureTextBlock": {
"auth_ref": [
"r109",
"r301",
"r302",
"r303",
"r304",
"r305",
"r306",
"r307",
"r312",
"r319",
"r320",
"r322",
"r330"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
"label": "Debt Disclosure [Text Block]",
"terseLabel": "Long Term Debt and Convertible Notes"
}
}
},
"localname": "DebtDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotes"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DebtInstrumentAxis": {
"auth_ref": [
"r18",
"r19",
"r20",
"r112",
"r117",
"r295",
"r296",
"r297",
"r298",
"r299",
"r300",
"r302",
"r308",
"r309",
"r310",
"r311",
"r313",
"r314",
"r315",
"r316",
"r317",
"r318",
"r326",
"r327",
"r328",
"r329",
"r513",
"r581",
"r583",
"r600"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
"label": "Debt Instrument [Axis]",
"terseLabel": "Debt Instrument [Axis]"
}
}
},
"localname": "DebtInstrumentAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanComponentsOfDebtDetails",
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails",
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCreditAgreementandPaycheckProtectionProgramNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
"label": "Debt Instrument, Basis Spread on Variable Rate",
"terseLabel": "Basis spread on variable rate"
}
}
},
"localname": "DebtInstrumentBasisSpreadOnVariableRate1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_DebtInstrumentCarryingAmount": {
"auth_ref": [
"r20",
"r323",
"r583",
"r600"
],
"calculation": {
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanComponentsOfDebtDetails": {
"order": 1.0,
"parentTag": "us-gaap_LongTermDebt",
"weight": 1.0
},
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesContractualMaturitiesofFinancingObligationsDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
"label": "Long-Term Debt, Gross",
"terseLabel": "Term loan",
"totalLabel": "Total"
}
}
},
"localname": "DebtInstrumentCarryingAmount",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanComponentsOfDebtDetails",
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesContractualMaturitiesofFinancingObligationsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtInstrumentFeeAmount": {
"auth_ref": [
"r50"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
"label": "Debt Instrument, Fee Amount",
"terseLabel": "Fee amount"
}
}
},
"localname": "DebtInstrumentFeeAmount",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
"auth_ref": [
"r49",
"r325",
"r511",
"r513"
],
"lang": {
"en-us": {
"role": {
"documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
"label": "Debt Instrument, Interest Rate, Effective Percentage",
"terseLabel": "Effective interest rate"
}
}
},
"localname": "DebtInstrumentInterestRateEffectivePercentage",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_DebtInstrumentLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Debt Instrument [Line Items]",
"terseLabel": "Debt Instrument [Line Items]"
}
}
},
"localname": "DebtInstrumentLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanComponentsOfDebtDetails",
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails",
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCreditAgreementandPaycheckProtectionProgramNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtInstrumentNameDomain": {
"auth_ref": [
"r51",
"r112",
"r117",
"r295",
"r296",
"r297",
"r298",
"r299",
"r300",
"r302",
"r308",
"r309",
"r310",
"r311",
"r313",
"r314",
"r315",
"r316",
"r317",
"r318",
"r326",
"r327",
"r328",
"r329",
"r513"
],
"lang": {
"en-us": {
"role": {
"documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
"label": "Debt Instrument, Name [Domain]",
"terseLabel": "Debt Instrument, Name [Domain]"
}
}
},
"localname": "DebtInstrumentNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanComponentsOfDebtDetails",
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails",
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCreditAgreementandPaycheckProtectionProgramNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_DebtInstrumentTable": {
"auth_ref": [
"r51",
"r112",
"r117",
"r295",
"r296",
"r297",
"r298",
"r299",
"r300",
"r302",
"r308",
"r309",
"r310",
"r311",
"r313",
"r314",
"r315",
"r316",
"r317",
"r318",
"r321",
"r326",
"r327",
"r328",
"r329",
"r352",
"r355",
"r356",
"r357",
"r510",
"r511",
"r513",
"r514",
"r598"
],
"lang": {
"en-us": {
"role": {
"documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
"label": "Schedule of Long-Term Debt Instruments [Table]",
"terseLabel": "Schedule of Long-term Debt Instruments [Table]"
}
}
},
"localname": "DebtInstrumentTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanComponentsOfDebtDetails",
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails",
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCreditAgreementandPaycheckProtectionProgramNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtInstrumentTerm": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
"label": "Debt Instrument, Term",
"terseLabel": "Debt term"
}
}
},
"localname": "DebtInstrumentTerm",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_DebtInstrumentUnamortizedDiscount": {
"auth_ref": [
"r308",
"r510",
"r514"
],
"calculation": {
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanComponentsOfDebtDetails": {
"order": 2.0,
"parentTag": "us-gaap_LongTermDebt",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after accumulated amortization, of debt discount.",
"label": "Debt Instrument, Unamortized Discount",
"negatedLabel": "Less: unamortized debt discount",
"negatedTerseLabel": "Less: debt issuance costs"
}
}
},
"localname": "DebtInstrumentUnamortizedDiscount",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanComponentsOfDebtDetails",
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesContractualMaturitiesofFinancingObligationsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss": {
"auth_ref": [
"r220",
"r237",
"r238",
"r239"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss",
"terseLabel": "Accrued interest receivable on marketable securities, less than"
}
}
},
"localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
"auth_ref": [
"r223"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Debt Securities, Available-for-Sale [Table Text Block]",
"terseLabel": "Schedule of Cost, Unrealized Gains and Losses and Fair Value of Marketable Securities"
}
}
},
"localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent": {
"auth_ref": [
"r47"
],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
"order": 6.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).",
"label": "Deferred Compensation Share-Based Arrangements, Liability, Current",
"terseLabel": "Liability for early exercise of stock options"
}
}
},
"localname": "DeferredCompensationShareBasedArrangementsLiabilityCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
"label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
"terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
}
}
},
"localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DeferredIncomeTaxLiabilitiesNet": {
"auth_ref": [
"r433",
"r434"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
"label": "Deferred Income Tax Liabilities, Net",
"terseLabel": "Deferred tax liability"
}
}
},
"localname": "DeferredIncomeTaxLiabilitiesNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_Depreciation": {
"auth_ref": [
"r100",
"r266"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
"label": "Depreciation",
"terseLabel": "Depreciation expense"
}
}
},
"localname": "Depreciation",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DerivativeLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Derivative [Line Items]",
"terseLabel": "Derivative [Line Items]"
}
}
},
"localname": "DerivativeLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DerivativeTable": {
"auth_ref": [
"r462",
"r463",
"r464",
"r465",
"r466",
"r469",
"r470",
"r471",
"r472",
"r473",
"r474"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
"label": "Derivative [Table]",
"terseLabel": "Derivative [Table]"
}
}
},
"localname": "DerivativeTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DevelopedTechnologyRightsMember": {
"auth_ref": [
"r452"
],
"lang": {
"en-us": {
"role": {
"documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
"label": "Developed Technology Rights [Member]",
"terseLabel": "Developed technology"
}
}
},
"localname": "DevelopedTechnologyRightsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsIntangibleAssetsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_DividendsCommonStock": {
"auth_ref": [
"r358",
"r597"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
"label": "Dividends, Common Stock",
"terseLabel": "Dividends declared"
}
}
},
"localname": "DividendsCommonStock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EMEAMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Regions of Europe, Middle East and Africa.",
"label": "EMEA [Member]",
"terseLabel": "Europe, Middle-East and Africa (\u201cEMEA\u201d)",
"verboseLabel": "EMEA"
}
}
},
"localname": "EMEAMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SegmentInformationLongLivedAssetsbyGeographicalAreaDetails",
"http://www.pulmonx.com/role/SegmentInformationRevenuebyGeographicAreaDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_EarningsPerShareAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Earnings Per Share [Abstract]"
}
}
},
"localname": "EarningsPerShareAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_EarningsPerShareBasic": {
"auth_ref": [
"r75",
"r128",
"r129",
"r130",
"r131",
"r132",
"r139",
"r143",
"r150",
"r151",
"r152",
"r156",
"r157",
"r478",
"r479",
"r592",
"r615"
],
"lang": {
"en-us": {
"role": {
"documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
"label": "Earnings Per Share, Basic",
"terseLabel": "Net loss per share attributable common stockholders, basic (in dollars per share)",
"verboseLabel": "Net loss per share attributable to common stockholders, basic (in dollars per share)"
}
}
},
"localname": "EarningsPerShareBasic",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
"http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersComputationofBasicandDilutedNetLossperShareDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_EarningsPerShareBasicTwoClassMethodAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Earnings Per Share, Basic, Two Class Method [Abstract]",
"terseLabel": "Numerator"
}
}
},
"localname": "EarningsPerShareBasicTwoClassMethodAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersComputationofBasicandDilutedNetLossperShareDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_EarningsPerShareDiluted": {
"auth_ref": [
"r75",
"r128",
"r129",
"r130",
"r131",
"r132",
"r143",
"r150",
"r151",
"r152",
"r156",
"r157",
"r478",
"r479",
"r592",
"r615"
],
"lang": {
"en-us": {
"role": {
"documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
"label": "Earnings Per Share, Diluted",
"terseLabel": "Net loss per share attributable to common stockholders, diluted (in dollars per share)"
}
}
},
"localname": "EarningsPerShareDiluted",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
"http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersComputationofBasicandDilutedNetLossperShareDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_EarningsPerSharePolicyTextBlock": {
"auth_ref": [
"r153",
"r154"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
"label": "Earnings Per Share, Policy [Policy Text Block]",
"terseLabel": "Net Loss per Share Attributable to Common Stockholders"
}
}
},
"localname": "EarningsPerSharePolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_EarningsPerShareTextBlock": {
"auth_ref": [
"r153",
"r154",
"r155",
"r158"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for earnings per share.",
"label": "Earnings Per Share [Text Block]",
"terseLabel": "Net Loss per Share Attributable to Common Stockholders"
}
}
},
"localname": "EarningsPerShareTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholders"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
"auth_ref": [
"r501"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 4.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
"terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
}
}
},
"localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
"auth_ref": [
"r423"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
"label": "Share-Based Payment Arrangement, Amount Capitalized",
"terseLabel": "Stock-based compensation capitalized into inventory"
}
}
},
"localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
"auth_ref": [
"r424"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
"label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
"terseLabel": "Unrecognized compensation costs"
}
}
},
"localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
"auth_ref": [
"r424"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
"terseLabel": "Weighted-average period for recognition of compensation costs"
}
}
},
"localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
"auth_ref": [
"r424"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
"label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
"terseLabel": "Non-option unrecognized compensation costs"
}
}
},
"localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EmployeeStockMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
"label": "Employee Stock [Member]",
"netLabel": "Shares committed under ESPP",
"terseLabel": "ESPP",
"verboseLabel": "Common stock available for ESPP"
}
}
},
"localname": "EmployeeStockMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersExcludedPotentiallyDilutiveSecuritiesOutstandingDetails",
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails",
"http://www.pulmonx.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails",
"http://www.pulmonx.com/role/StockholdersEquityTotalStockBasedCompensationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_EmployeeStockOptionMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
"label": "Share-Based Payment Arrangement, Option [Member]",
"terseLabel": "Options to purchase common stock"
}
}
},
"localname": "EmployeeStockOptionMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersExcludedPotentiallyDilutiveSecuritiesOutstandingDetails",
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_EquityAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Equity [Abstract]"
}
}
},
"localname": "EquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_EquityComponentDomain": {
"auth_ref": [
"r0",
"r67",
"r68",
"r69",
"r119",
"r120",
"r121",
"r125",
"r133",
"r135",
"r159",
"r228",
"r351",
"r358",
"r427",
"r428",
"r429",
"r439",
"r440",
"r477",
"r502",
"r503",
"r504",
"r505",
"r506",
"r507",
"r533",
"r621",
"r622",
"r623"
],
"lang": {
"en-us": {
"role": {
"documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
"label": "Equity Component [Domain]",
"terseLabel": "Equity Component [Domain]"
}
}
},
"localname": "EquityComponentDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
"terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
}
}
},
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
"http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
"auth_ref": [
"r483",
"r484",
"r488"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
"label": "Fair Value, Recurring and Nonrecurring [Table]",
"terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
}
}
},
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
"http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueByFairValueHierarchyLevelAxis": {
"auth_ref": [
"r310",
"r326",
"r327",
"r379",
"r380",
"r381",
"r382",
"r383",
"r384",
"r385",
"r386",
"r484",
"r541",
"r542",
"r543"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
"label": "Fair Value Hierarchy and NAV [Axis]",
"terseLabel": "Fair Value Hierarchy and NAV [Axis]"
}
}
},
"localname": "FairValueByFairValueHierarchyLevelAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueByMeasurementFrequencyAxis": {
"auth_ref": [
"r483",
"r484",
"r485",
"r486",
"r489"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by measurement frequency.",
"label": "Measurement Frequency [Axis]",
"terseLabel": "Measurement Frequency [Axis]"
}
}
},
"localname": "FairValueByMeasurementFrequencyAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
"http://www.pulmonx.com/role/FairValueMeasurementsNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueDisclosuresAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Fair Value Disclosures [Abstract]"
}
}
},
"localname": "FairValueDisclosuresAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_FairValueDisclosuresTextBlock": {
"auth_ref": [
"r487"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
"label": "Fair Value Disclosures [Text Block]",
"terseLabel": "Fair Value Measurements"
}
}
},
"localname": "FairValueDisclosuresTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurements"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FairValueInputsLevel1Member": {
"auth_ref": [
"r310",
"r379",
"r380",
"r385",
"r386",
"r484",
"r541"
],
"lang": {
"en-us": {
"role": {
"documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
"label": "Fair Value, Inputs, Level 1 [Member]",
"terseLabel": "Level 1"
}
}
},
"localname": "FairValueInputsLevel1Member",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueInputsLevel2Member": {
"auth_ref": [
"r310",
"r326",
"r327",
"r379",
"r380",
"r385",
"r386",
"r484",
"r542"
],
"lang": {
"en-us": {
"role": {
"documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
"label": "Fair Value, Inputs, Level 2 [Member]",
"terseLabel": "Level 2"
}
}
},
"localname": "FairValueInputsLevel2Member",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueInputsLevel3Member": {
"auth_ref": [
"r310",
"r326",
"r327",
"r379",
"r380",
"r381",
"r382",
"r383",
"r384",
"r385",
"r386",
"r484",
"r543"
],
"lang": {
"en-us": {
"role": {
"documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
"label": "Fair Value, Inputs, Level 3 [Member]",
"terseLabel": "Level 3"
}
}
},
"localname": "FairValueInputsLevel3Member",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementFrequencyDomain": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Measurement frequency.",
"label": "Measurement Frequency [Domain]",
"terseLabel": "Measurement Frequency [Domain]"
}
}
},
"localname": "FairValueMeasurementFrequencyDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
"http://www.pulmonx.com/role/FairValueMeasurementsNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
"label": "Fair Value Measurement, Policy [Policy Text Block]",
"terseLabel": "Assets and Liabilities Measured at Fair Value"
}
}
},
"localname": "FairValueMeasurementPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
"auth_ref": [
"r310",
"r326",
"r327",
"r379",
"r380",
"r381",
"r382",
"r383",
"r384",
"r385",
"r386",
"r541",
"r542",
"r543"
],
"lang": {
"en-us": {
"role": {
"documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
"label": "Fair Value Hierarchy and NAV [Domain]",
"terseLabel": "Fair Value Hierarchy and NAV [Domain]"
}
}
},
"localname": "FairValueMeasurementsFairValueHierarchyDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementsRecurringMember": {
"auth_ref": [
"r487",
"r489"
],
"lang": {
"en-us": {
"role": {
"documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
"label": "Fair Value, Recurring [Member]",
"terseLabel": "Recurring Basis"
}
}
},
"localname": "FairValueMeasurementsRecurringMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
"http://www.pulmonx.com/role/FairValueMeasurementsNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueOfFinancialInstrumentsPolicy": {
"auth_ref": [
"r490",
"r491"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
"label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
"terseLabel": "Fair Value of Financial Instruments"
}
}
},
"localname": "FairValueOfFinancialInstrumentsPolicy",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FinancialInstrumentAxis": {
"auth_ref": [
"r221",
"r222",
"r224",
"r225",
"r226",
"r231",
"r233",
"r234",
"r235",
"r236",
"r240",
"r241",
"r242",
"r243",
"r321",
"r349",
"r474",
"r538",
"r539",
"r540",
"r541",
"r542",
"r543",
"r544",
"r545",
"r546",
"r547",
"r548",
"r549",
"r550",
"r551",
"r552",
"r553",
"r554",
"r555",
"r556",
"r557",
"r558",
"r559",
"r560",
"r561",
"r562",
"r563",
"r564",
"r565",
"r566",
"r567",
"r652",
"r653",
"r654",
"r655",
"r656",
"r657",
"r658"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of financial instrument.",
"label": "Financial Instrument [Axis]",
"terseLabel": "Financial Instrument [Axis]"
}
}
},
"localname": "FinancialInstrumentAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
"http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
"terseLabel": "Assets:"
}
}
},
"localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FinancialLiabilitiesFairValueDisclosure": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
"label": "Financial Liabilities Fair Value Disclosure",
"terseLabel": "Liabilities measured at fair value on a recurring and non-recurring"
}
}
},
"localname": "FinancialLiabilitiesFairValueDisclosure",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
"auth_ref": [
"r14",
"r261"
],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsIntangibleAssetsDetails": {
"order": 2.0,
"parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
"label": "Finite-Lived Intangible Assets, Accumulated Amortization",
"negatedLabel": "Accumulated Amortization"
}
}
},
"localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsIntangibleAssetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
"auth_ref": [
"r263"
],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsFutureAmortizationExpenseDetails": {
"order": 2.0,
"parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
"terseLabel": "2023"
}
}
},
"localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsFutureAmortizationExpenseDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
"auth_ref": [],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsFutureAmortizationExpenseDetails": {
"order": 1.0,
"parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
"label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
"terseLabel": "2022 (remaining six months)"
}
}
},
"localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsFutureAmortizationExpenseDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
"auth_ref": [
"r263"
],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsFutureAmortizationExpenseDetails": {
"order": 3.0,
"parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
"terseLabel": "2024"
}
}
},
"localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsFutureAmortizationExpenseDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
"auth_ref": [
"r258",
"r259",
"r261",
"r264",
"r572",
"r576"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by major type or class of finite-lived intangible assets.",
"label": "Finite-Lived Intangible Assets by Major Class [Axis]",
"terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
}
}
},
"localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsIntangibleAssetsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]",
"terseLabel": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]"
}
}
},
"localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsFutureAmortizationExpenseDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsGross": {
"auth_ref": [
"r261",
"r576"
],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsIntangibleAssetsDetails": {
"order": 1.0,
"parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
"label": "Finite-Lived Intangible Assets, Gross",
"terseLabel": "Gross Carrying Value"
}
}
},
"localname": "FiniteLivedIntangibleAssetsGross",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsIntangibleAssetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Finite-Lived Intangible Assets [Line Items]",
"terseLabel": "Finite-Lived Intangible Assets [Line Items]"
}
}
},
"localname": "FiniteLivedIntangibleAssetsLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsIntangibleAssetsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
"auth_ref": [
"r258",
"r260"
],
"lang": {
"en-us": {
"role": {
"documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
"label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
"terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
}
}
},
"localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsIntangibleAssetsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsNet": {
"auth_ref": [
"r261",
"r572"
],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsFutureAmortizationExpenseDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.pulmonx.com/role/BalanceSheetComponentsIntangibleAssetsDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 6.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
"label": "Finite-Lived Intangible Assets, Net",
"totalLabel": "Net Carrying Value",
"verboseLabel": "Intangible assets, net"
}
}
},
"localname": "FiniteLivedIntangibleAssetsNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsFutureAmortizationExpenseDetails",
"http://www.pulmonx.com/role/BalanceSheetComponentsIntangibleAssetsDetails",
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ForeignCurrencyTransactionGainLossRealized": {
"auth_ref": [
"r499",
"r500"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.",
"label": "Foreign Currency Transaction Gain (Loss), Realized",
"terseLabel": "Foreign currency transaction gains and (losses)"
}
}
},
"localname": "ForeignCurrencyTransactionGainLossRealized",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
"auth_ref": [
"r508"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
"label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
"terseLabel": "Foreign Currency Translation and Transaction Gains and Losses"
}
}
},
"localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FurnitureAndFixturesMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
"label": "Furniture and Fixtures [Member]",
"terseLabel": "Furniture and fixtures"
}
}
},
"localname": "FurnitureAndFixturesMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_GainLossOnDispositionOfAssets1": {
"auth_ref": [
"r100"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 17.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
"label": "Gain (Loss) on Disposition of Assets",
"negatedTerseLabel": "Loss on disposal of fixed assets"
}
}
},
"localname": "GainLossOnDispositionOfAssets1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GeographicConcentrationRiskMember": {
"auth_ref": [
"r169",
"r633"
],
"lang": {
"en-us": {
"role": {
"documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
"label": "Geographic Concentration Risk [Member]",
"terseLabel": "Geographic Concentration Risk"
}
}
},
"localname": "GeographicConcentrationRiskMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SegmentInformationNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_Goodwill": {
"auth_ref": [
"r13",
"r248",
"r250",
"r254",
"r256",
"r537",
"r579"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
"label": "Goodwill",
"terseLabel": "Goodwill"
}
}
},
"localname": "Goodwill",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsNarrativeDetails",
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GoodwillAcquiredDuringPeriod": {
"auth_ref": [
"r251",
"r256"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
"label": "Goodwill, Acquired During Period",
"terseLabel": "Goodwill acquired"
}
}
},
"localname": "GoodwillAcquiredDuringPeriod",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
"auth_ref": [
"r250",
"r254",
"r256"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
"label": "Goodwill, Impaired, Accumulated Impairment Loss",
"terseLabel": "Goodwill, accumulated impairment loss"
}
}
},
"localname": "GoodwillImpairedAccumulatedImpairmentLoss",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GoodwillImpairmentLoss": {
"auth_ref": [
"r100",
"r249",
"r253",
"r255",
"r256"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
"label": "Goodwill, Impairment Loss",
"terseLabel": "Goodwill, impairment loss"
}
}
},
"localname": "GoodwillImpairmentLoss",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
"auth_ref": [
"r252",
"r256"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
"label": "Goodwill, Written off Related to Sale of Business Unit",
"terseLabel": "Goodwill disposed of"
}
}
},
"localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GrossProfit": {
"auth_ref": [
"r77",
"r113",
"r186",
"r189",
"r192",
"r195",
"r198",
"r227",
"r284",
"r285",
"r286",
"r288",
"r289",
"r290",
"r291",
"r292",
"r293",
"r294",
"r495"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
"order": 2.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
"label": "Gross Profit",
"totalLabel": "Gross profit"
}
}
},
"localname": "GrossProfit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization": {
"auth_ref": [
"r265",
"r267"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after accumulated amortization, of capitalized implementation cost from hosting arrangement that is service contract.",
"label": "Hosting Arrangement, Service Contract, Implementation Cost, Capitalized, after Accumulated Amortization",
"terseLabel": "Capitalized costs"
}
}
},
"localname": "HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortization",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsCapitalizedImplementationCostsofaHostingArrangementDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_HostingArrangementServiceContractImplementationCostExpenseAmortization": {
"auth_ref": [
"r265",
"r266"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of amortization expense for capitalized implementation cost from hosting arrangement that is service contract.",
"label": "Hosting Arrangement, Service Contract, Implementation Cost, Expense, Amortization",
"terseLabel": "Amortization expense"
}
}
},
"localname": "HostingArrangementServiceContractImplementationCostExpenseAmortization",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsCapitalizedImplementationCostsofaHostingArrangementDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
"auth_ref": [
"r72",
"r186",
"r189",
"r192",
"r195",
"r198",
"r577",
"r589",
"r594",
"r616"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
"order": 1.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
"label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
"totalLabel": "Net loss before tax"
}
}
},
"localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncomeStatementAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Income Statement [Abstract]"
}
}
},
"localname": "IncomeStatementAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_IncomeStatementLocationAxis": {
"auth_ref": [
"r270",
"r272"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by location in the income statement.",
"label": "Income Statement Location [Axis]",
"terseLabel": "Income Statement Location [Axis]"
}
}
},
"localname": "IncomeStatementLocationAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails",
"http://www.pulmonx.com/role/StockholdersEquityTotalStockBasedCompensationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncomeStatementLocationDomain": {
"auth_ref": [
"r272"
],
"lang": {
"en-us": {
"role": {
"documentation": "Location in the income statement.",
"label": "Income Statement Location [Domain]",
"terseLabel": "Income Statement Location [Domain]"
}
}
},
"localname": "IncomeStatementLocationDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails",
"http://www.pulmonx.com/role/StockholdersEquityTotalStockBasedCompensationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_IncomeTaxDisclosureAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Income Tax Disclosure [Abstract]"
}
}
},
"localname": "IncomeTaxDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_IncomeTaxDisclosureTextBlock": {
"auth_ref": [
"r114",
"r436",
"r437",
"r438",
"r444",
"r446",
"r448",
"r449",
"r450"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
"label": "Income Tax Disclosure [Text Block]",
"terseLabel": "Income Taxes"
}
}
},
"localname": "IncomeTaxDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/IncomeTaxes"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_IncomeTaxExpenseBenefit": {
"auth_ref": [
"r115",
"r134",
"r135",
"r185",
"r435",
"r445",
"r447",
"r617"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
"order": 2.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
"label": "Income Tax Expense (Benefit)",
"terseLabel": "Income tax expense"
}
}
},
"localname": "IncomeTaxExpenseBenefit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
"http://www.pulmonx.com/role/IncomeTaxesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncomeTaxesPaidNet": {
"auth_ref": [
"r103"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
"label": "Income Taxes Paid, Net",
"terseLabel": "Cash paid for income taxes"
}
}
},
"localname": "IncomeTaxesPaidNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInAccountsPayable": {
"auth_ref": [
"r99"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 4.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
"label": "Increase (Decrease) in Accounts Payable",
"terseLabel": "Accounts payable"
}
}
},
"localname": "IncreaseDecreaseInAccountsPayable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInAccountsReceivable": {
"auth_ref": [
"r99"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 12.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
"label": "Increase (Decrease) in Accounts Receivable",
"negatedTerseLabel": "Accounts receivable"
}
}
},
"localname": "IncreaseDecreaseInAccountsReceivable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
"auth_ref": [
"r99"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
"label": "Increase (Decrease) in Income Taxes Payable",
"terseLabel": "Income taxes payable"
}
}
},
"localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInAccruedLiabilities": {
"auth_ref": [
"r99"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 13.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
"label": "Increase (Decrease) in Accrued Liabilities",
"terseLabel": "Accrued liabilities"
}
}
},
"localname": "IncreaseDecreaseInAccruedLiabilities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
"auth_ref": [
"r99",
"r569"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 7.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
"label": "Increase (Decrease) in Contract with Customer, Liability",
"terseLabel": "Deferred revenue"
}
}
},
"localname": "IncreaseDecreaseInContractWithCustomerLiability",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
"auth_ref": [
"r99"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 9.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
"label": "Increase (Decrease) in Deferred Income Taxes",
"negatedTerseLabel": "Deferred tax liability"
}
}
},
"localname": "IncreaseDecreaseInDeferredIncomeTaxes",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInInventories": {
"auth_ref": [
"r99"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 5.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
"label": "Increase (Decrease) in Inventories",
"negatedTerseLabel": "Inventory"
}
}
},
"localname": "IncreaseDecreaseInInventories",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Increase (Decrease) in Operating Capital [Abstract]",
"terseLabel": "Net changes in operating assets and liabilities:"
}
}
},
"localname": "IncreaseDecreaseInOperatingCapitalAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
"auth_ref": [
"r99",
"r525"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 11.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in obligation for operating lease.",
"label": "Increase (Decrease) in Operating Lease Liability",
"terseLabel": "Lease liabilities"
}
}
},
"localname": "IncreaseDecreaseInOperatingLeaseLiability",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
"auth_ref": [
"r99"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 16.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
"label": "Increase (Decrease) in Other Noncurrent Assets",
"negatedTerseLabel": "Other assets"
}
}
},
"localname": "IncreaseDecreaseInOtherNoncurrentAssets",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
"auth_ref": [
"r99"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 8.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
"label": "Increase (Decrease) in Prepaid Expense and Other Assets",
"negatedTerseLabel": "Prepaid expenses and other current assets"
}
}
},
"localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
"label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
"terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
}
}
},
"localname": "IncreaseDecreaseInStockholdersEquityRollForward",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
],
"xbrltype": "stringItemType"
},
"us-gaap_InterestExpense": {
"auth_ref": [
"r70",
"r184",
"r509",
"r512",
"r593"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
"order": 2.0,
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
"label": "Interest Expense",
"negatedTerseLabel": "Interest expense"
}
}
},
"localname": "InterestExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestExpenseDebtExcludingAmortization": {
"auth_ref": [
"r83",
"r317",
"r328",
"r329"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
"label": "Interest Expense, Debt, Excluding Amortization",
"terseLabel": "Interest expense"
}
}
},
"localname": "InterestExpenseDebtExcludingAmortization",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestPaidNet": {
"auth_ref": [
"r95",
"r97",
"r103"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
"label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
"terseLabel": "Cash paid for interest"
}
}
},
"localname": "InterestPaidNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestPayableCurrentAndNoncurrent": {
"auth_ref": [
"r587",
"r612"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
"label": "Interest Payable",
"negatedLabel": "Less: interest"
}
}
},
"localname": "InterestPayableCurrentAndNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesContractualMaturitiesofFinancingObligationsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryFinishedGoodsNetOfReserves": {
"auth_ref": [
"r33",
"r245"
],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsInventoryDetails": {
"order": 2.0,
"parentTag": "us-gaap_InventoryNet",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
"label": "Inventory, Finished Goods, Net of Reserves",
"terseLabel": "Finished goods"
}
}
},
"localname": "InventoryFinishedGoodsNetOfReserves",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsInventoryDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryNet": {
"auth_ref": [
"r4",
"r39",
"r537"
],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsInventoryDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 6.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
"label": "Inventory, Net",
"terseLabel": "Inventory",
"totalLabel": "Total inventory"
}
}
},
"localname": "InventoryNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsInventoryDetails",
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryRawMaterialsNetOfReserves": {
"auth_ref": [
"r35",
"r245"
],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsInventoryDetails": {
"order": 1.0,
"parentTag": "us-gaap_InventoryNet",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
"label": "Inventory, Raw Materials, Net of Reserves",
"terseLabel": "Raw materials"
}
}
},
"localname": "InventoryRawMaterialsNetOfReserves",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsInventoryDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryWorkInProcessNetOfReserves": {
"auth_ref": [
"r34",
"r245"
],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsInventoryDetails": {
"order": 3.0,
"parentTag": "us-gaap_InventoryNet",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
"label": "Inventory, Work in Process, Net of Reserves",
"terseLabel": "Work in process"
}
}
},
"localname": "InventoryWorkInProcessNetOfReserves",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsInventoryDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryWriteDown": {
"auth_ref": [
"r244"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 19.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
"label": "Inventory Write-down",
"terseLabel": "Inventory write-downs"
}
}
},
"localname": "InventoryWriteDown",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InvestmentIncomeInterest": {
"auth_ref": [
"r81",
"r183"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
"order": 4.0,
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
"label": "Investment Income, Interest",
"terseLabel": "Interest income"
}
}
},
"localname": "InvestmentIncomeInterest",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LeaseCost": {
"auth_ref": [
"r529",
"r531"
],
"calculation": {
"http://www.pulmonx.com/role/CommitmentsandContingenciesLeaseCostDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lease cost recognized by lessee for lease contract.",
"label": "Lease, Cost",
"totalLabel": "Total lease cost"
}
}
},
"localname": "LeaseCost",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesLeaseCostDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LeaseCostTableTextBlock": {
"auth_ref": [
"r529"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
"label": "Lease, Cost [Table Text Block]",
"terseLabel": "Schedule of Operating Lease Cost and Additional Information"
}
}
},
"localname": "LeaseCostTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_LeaseholdImprovementsMember": {
"auth_ref": [
"r267"
],
"lang": {
"en-us": {
"role": {
"documentation": "Additions or improvements to assets held under a lease arrangement.",
"label": "Leasehold Improvements [Member]",
"terseLabel": "Leasehold improvements"
}
}
},
"localname": "LeaseholdImprovementsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_LesseeLeaseDescriptionLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Lessee, Lease, Description [Line Items]",
"terseLabel": "Lessee, Lease, Description [Line Items]"
}
}
},
"localname": "LesseeLeaseDescriptionLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesLeasesNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LesseeLeaseDescriptionTable": {
"auth_ref": [
"r521"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about lessee's leases.",
"label": "Lessee, Lease, Description [Table]",
"terseLabel": "Lessee, Lease, Description [Table]"
}
}
},
"localname": "LesseeLeaseDescriptionTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesLeasesNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
"auth_ref": [
"r530"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
"label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
"terseLabel": "Schedule of Maturity Analysis of Lease Liabilities"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
"auth_ref": [
"r530"
],
"calculation": {
"http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails_1": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
"label": "Lessee, Operating Lease, Liability, to be Paid",
"totalLabel": "Total minimum lease payments"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
"auth_ref": [
"r530"
],
"calculation": {
"http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails_1": {
"order": 3.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
"terseLabel": "2023"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
"auth_ref": [
"r530"
],
"calculation": {
"http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails_1": {
"order": 2.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
"terseLabel": "2025"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
"auth_ref": [
"r530"
],
"calculation": {
"http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails_1": {
"order": 1.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
"terseLabel": "2024"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
"auth_ref": [
"r530"
],
"calculation": {
"http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails_1": {
"order": 4.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
"label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
"terseLabel": "2022 (remaining six months)"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
"auth_ref": [
"r530"
],
"calculation": {
"http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails": {
"order": 1.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
"label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
"terseLabel": "Less: Amount of lease payments representing interest"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseRenewalTerm": {
"auth_ref": [
"r520"
],
"lang": {
"en-us": {
"role": {
"documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Lessee, Operating Lease, Renewal Term",
"terseLabel": "Lease renewal term"
}
}
},
"localname": "LesseeOperatingLeaseRenewalTerm",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesLeasesNarrativeDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_LesseeOperatingLeaseTermOfContract": {
"auth_ref": [
"r520"
],
"lang": {
"en-us": {
"role": {
"documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Lessee, Operating Lease, Term of Contract",
"terseLabel": "Lease term"
}
}
},
"localname": "LesseeOperatingLeaseTermOfContract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesLeasesNarrativeDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_Liabilities": {
"auth_ref": [
"r46",
"r113",
"r191",
"r227",
"r284",
"r285",
"r286",
"r288",
"r289",
"r290",
"r291",
"r292",
"r293",
"r294",
"r456",
"r460",
"r461",
"r495",
"r535",
"r536"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
"label": "Liabilities",
"totalLabel": "Total liabilities"
}
}
},
"localname": "Liabilities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquity": {
"auth_ref": [
"r32",
"r113",
"r227",
"r495",
"r537",
"r585",
"r609"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
"label": "Liabilities and Equity",
"totalLabel": "Total liabilities and stockholders\u2019 equity"
}
}
},
"localname": "LiabilitiesAndStockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Liabilities and Equity [Abstract]",
"terseLabel": "Liabilities and Stockholders\u2019 Equity"
}
}
},
"localname": "LiabilitiesAndStockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_LiabilitiesCurrent": {
"auth_ref": [
"r7",
"r48",
"r113",
"r227",
"r284",
"r285",
"r286",
"r288",
"r289",
"r290",
"r291",
"r292",
"r293",
"r294",
"r456",
"r460",
"r461",
"r495",
"r535",
"r536",
"r537"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 4.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
"label": "Liabilities, Current",
"totalLabel": "Total current liabilities"
}
}
},
"localname": "LiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesCurrentAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Liabilities, Current [Abstract]",
"terseLabel": "Current liabilities"
}
}
},
"localname": "LiabilitiesCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
"auth_ref": [
"r44"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
"label": "Line of Credit Facility, Maximum Borrowing Capacity",
"terseLabel": "Maximum borrowing capacity"
}
}
},
"localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCreditAgreementandPaycheckProtectionProgramNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LineOfCreditMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
"label": "Line of Credit [Member]",
"terseLabel": "Line of Credit"
}
}
},
"localname": "LineOfCreditMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCreditAgreementandPaycheckProtectionProgramNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
"auth_ref": [
"r204"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.",
"label": "Long-Lived Assets by Geographic Areas [Table Text Block]",
"terseLabel": "Schedule of Long-lived Assets by Geographic Area"
}
}
},
"localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SegmentInformationTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_LongTermDebt": {
"auth_ref": [
"r20",
"r309",
"r324",
"r326",
"r327",
"r583",
"r604"
],
"calculation": {
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanComponentsOfDebtDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
"label": "Long-Term Debt",
"terseLabel": "Term loan and credit agreement",
"totalLabel": "Term loan and credit agreement"
}
}
},
"localname": "LongTermDebt",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanComponentsOfDebtDetails",
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesContractualMaturitiesofFinancingObligationsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtByMaturityAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Long-Term Debt, Fiscal Year Maturity [Abstract]",
"terseLabel": "Long-term Debt, Fiscal Year Maturity [Abstract]"
}
}
},
"localname": "LongTermDebtByMaturityAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesContractualMaturitiesofFinancingObligationsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
"auth_ref": [
"r117",
"r282",
"r314"
],
"calculation": {
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesContractualMaturitiesofFinancingObligationsDetails": {
"order": 4.0,
"parentTag": "us-gaap_DebtInstrumentCarryingAmount",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Long-Term Debt, Maturity, Year One",
"terseLabel": "2023"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesContractualMaturitiesofFinancingObligationsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
"auth_ref": [
"r117",
"r282",
"r314"
],
"calculation": {
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesContractualMaturitiesofFinancingObligationsDetails": {
"order": 6.0,
"parentTag": "us-gaap_DebtInstrumentCarryingAmount",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Long-Term Debt, Maturity, Year Five",
"terseLabel": "2027"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesContractualMaturitiesofFinancingObligationsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
"auth_ref": [
"r117",
"r282",
"r314"
],
"calculation": {
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesContractualMaturitiesofFinancingObligationsDetails": {
"order": 2.0,
"parentTag": "us-gaap_DebtInstrumentCarryingAmount",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Long-Term Debt, Maturity, Year Four",
"terseLabel": "2026"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesContractualMaturitiesofFinancingObligationsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
"auth_ref": [
"r117",
"r282",
"r314"
],
"calculation": {
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesContractualMaturitiesofFinancingObligationsDetails": {
"order": 3.0,
"parentTag": "us-gaap_DebtInstrumentCarryingAmount",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Long-Term Debt, Maturity, Year Three",
"terseLabel": "2025"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesContractualMaturitiesofFinancingObligationsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
"auth_ref": [
"r117",
"r282",
"r314"
],
"calculation": {
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesContractualMaturitiesofFinancingObligationsDetails": {
"order": 5.0,
"parentTag": "us-gaap_DebtInstrumentCarryingAmount",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Long-Term Debt, Maturity, Year Two",
"terseLabel": "2024"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesContractualMaturitiesofFinancingObligationsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
"auth_ref": [
"r117"
],
"calculation": {
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesContractualMaturitiesofFinancingObligationsDetails": {
"order": 1.0,
"parentTag": "us-gaap_DebtInstrumentCarryingAmount",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
"label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
"terseLabel": "2022 (remaining six months)"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesContractualMaturitiesofFinancingObligationsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtNoncurrent": {
"auth_ref": [
"r20"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 5.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
"label": "Long-Term Debt, Excluding Current Maturities",
"terseLabel": "Long-term debt"
}
}
},
"localname": "LongTermDebtNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongtermDebtTypeAxis": {
"auth_ref": [
"r51"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of long-term debt.",
"label": "Long-Term Debt, Type [Axis]",
"terseLabel": "Long-term Debt, Type [Axis]"
}
}
},
"localname": "LongtermDebtTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanComponentsOfDebtDetails",
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails",
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCreditAgreementandPaycheckProtectionProgramNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LongtermDebtTypeDomain": {
"auth_ref": [
"r51",
"r283"
],
"lang": {
"en-us": {
"role": {
"documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
"label": "Long-Term Debt, Type [Domain]",
"terseLabel": "Long-term Debt, Type [Domain]"
}
}
},
"localname": "LongtermDebtTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanComponentsOfDebtDetails",
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails",
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCreditAgreementandPaycheckProtectionProgramNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_MachineryAndEquipmentMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
"label": "Machinery and Equipment [Member]",
"terseLabel": "Machinery and equipment"
}
}
},
"localname": "MachineryAndEquipmentMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_MediumTermNotesMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Debt instruments with maturities ranging from five to ten years.",
"label": "Medium-term Notes [Member]",
"terseLabel": "Medium-term Notes"
}
}
},
"localname": "MediumTermNotesMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanComponentsOfDebtDetails",
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_MoneyMarketFundsAtCarryingValue": {
"auth_ref": [],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsCashandCashEquivalentsDetails": {
"order": 2.0,
"parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
"label": "Money Market Funds, at Carrying Value",
"terseLabel": "Money market funds"
}
}
},
"localname": "MoneyMarketFundsAtCarryingValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsCashandCashEquivalentsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_MoneyMarketFundsMember": {
"auth_ref": [
"r379"
],
"lang": {
"en-us": {
"role": {
"documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
"label": "Money Market Funds [Member]",
"terseLabel": "Money market funds"
}
}
},
"localname": "MoneyMarketFundsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_NatureOfOperations": {
"auth_ref": [
"r162",
"r176"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
"label": "Nature of Operations [Text Block]",
"terseLabel": "Formation and Business of the Company"
}
}
},
"localname": "NatureOfOperations",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FormationandBusinessoftheCompany"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivities": {
"auth_ref": [
"r96"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 1.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
"label": "Net Cash Provided by (Used in) Financing Activities",
"totalLabel": "Net cash provided by financing activities"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
"terseLabel": "Cash flows from financing activities"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivities": {
"auth_ref": [
"r96"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 3.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
"label": "Net Cash Provided by (Used in) Investing Activities",
"totalLabel": "Net cash used in investing activities"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
"terseLabel": "Cash flows from investing activities"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivities": {
"auth_ref": [
"r96",
"r98",
"r101"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 2.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
"label": "Net Cash Provided by (Used in) Operating Activities",
"negatedTerseLabel": "Cash used in operating activities",
"totalLabel": "Net cash used in operating activities"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows",
"http://www.pulmonx.com/role/FormationandBusinessoftheCompanyDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
"terseLabel": "Cash flows from operating activities"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetIncomeLoss": {
"auth_ref": [
"r2",
"r61",
"r64",
"r69",
"r73",
"r101",
"r113",
"r124",
"r128",
"r129",
"r130",
"r131",
"r134",
"r135",
"r148",
"r186",
"r189",
"r192",
"r195",
"r198",
"r227",
"r284",
"r285",
"r286",
"r288",
"r289",
"r290",
"r291",
"r292",
"r293",
"r294",
"r479",
"r495",
"r590",
"r613"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 6.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
},
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
"order": 2.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
"label": "Net Income (Loss) Attributable to Parent",
"terseLabel": "Net loss",
"totalLabel": "Net loss"
}
}
},
"localname": "NetIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows",
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
"auth_ref": [
"r128",
"r129",
"r130",
"r131",
"r139",
"r140",
"r149",
"r152",
"r186",
"r189",
"r192",
"r195",
"r198"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
"label": "Net Income (Loss) Available to Common Stockholders, Basic",
"terseLabel": "Net loss attributable to common stockholders, basic"
}
}
},
"localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersComputationofBasicandDilutedNetLossperShareDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
"auth_ref": [
"r142",
"r144",
"r145",
"r146",
"r147",
"r149",
"r152"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
"label": "Net Income (Loss) Available to Common Stockholders, Diluted",
"terseLabel": "Net loss attributable to common stockholders, diluted"
}
}
},
"localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersComputationofBasicandDilutedNetLossperShareDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
"auth_ref": [
"r1",
"r122",
"r123",
"r126",
"r127",
"r136",
"r137",
"r138",
"r211",
"r212",
"r229",
"r230",
"r441",
"r442",
"r443",
"r476",
"r480",
"r481",
"r482",
"r496",
"r497",
"r498",
"r515",
"r516",
"r532",
"r534",
"r573",
"r574",
"r575",
"r624",
"r625",
"r626",
"r627",
"r628"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
"label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
"terseLabel": "Recent Accounting Pronouncements"
}
}
},
"localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/RecentAccountingPronouncements"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
"label": "New Accounting Pronouncements, Policy [Policy Text Block]",
"terseLabel": "Recently Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted"
}
}
},
"localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Noncash Investing and Financing Items [Abstract]",
"terseLabel": "Supplemental non-cash items:"
}
}
},
"localname": "NoncashInvestingAndFinancingItemsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_NoncurrentAssets": {
"auth_ref": [
"r202"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.",
"label": "Long-Lived Assets",
"terseLabel": "Long-lived assets"
}
}
},
"localname": "NoncurrentAssets",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SegmentInformationLongLivedAssetsbyGeographicalAreaDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NumberOfOperatingSegments": {
"auth_ref": [
"r178"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
"label": "Number of Operating Segments",
"terseLabel": "Number of operating segments"
}
}
},
"localname": "NumberOfOperatingSegments",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SegmentInformationNarrativeDetails"
],
"xbrltype": "integerItemType"
},
"us-gaap_NumberOfReportableSegments": {
"auth_ref": [
"r178"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
"label": "Number of Reportable Segments",
"terseLabel": "Number of reportable segments"
}
}
},
"localname": "NumberOfReportableSegments",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SegmentInformationNarrativeDetails"
],
"xbrltype": "integerItemType"
},
"us-gaap_OperatingExpenses": {
"auth_ref": [],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
"order": 1.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
"label": "Operating Expenses",
"totalLabel": "Total operating expenses"
}
}
},
"localname": "OperatingExpenses",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingExpensesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Operating Expenses [Abstract]",
"terseLabel": "Operating expenses"
}
}
},
"localname": "OperatingExpensesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
],
"xbrltype": "stringItemType"
},
"us-gaap_OperatingIncomeLoss": {
"auth_ref": [
"r186",
"r189",
"r192",
"r195",
"r198"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
"order": 3.0,
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The net result for the period of deducting operating expenses from operating revenues.",
"label": "Operating Income (Loss)",
"totalLabel": "Loss from operations"
}
}
},
"localname": "OperatingIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseCost": {
"auth_ref": [
"r522",
"r531"
],
"calculation": {
"http://www.pulmonx.com/role/CommitmentsandContingenciesLeaseCostDetails": {
"order": 1.0,
"parentTag": "us-gaap_LeaseCost",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
"label": "Operating Lease, Cost",
"terseLabel": "Operating lease cost"
}
}
},
"localname": "OperatingLeaseCost",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesLeaseCostDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
"terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]"
}
}
},
"localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_OperatingLeaseLiability": {
"auth_ref": [
"r518"
],
"calculation": {
"http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails": {
"order": 2.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
"label": "Operating Lease, Liability",
"totalLabel": "Present value of future minimum lease payments"
}
}
},
"localname": "OperatingLeaseLiability",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiabilityCurrent": {
"auth_ref": [
"r518"
],
"calculation": {
"http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails": {
"order": 2.0,
"parentTag": "us-gaap_OperatingLeaseLiability",
"weight": 1.0
},
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
"label": "Operating Lease, Liability, Current",
"terseLabel": "Less: Current lease liabilities",
"verboseLabel": "Current lease liabilities"
}
}
},
"localname": "OperatingLeaseLiabilityCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails",
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiabilityNoncurrent": {
"auth_ref": [
"r518"
],
"calculation": {
"http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails": {
"order": 1.0,
"parentTag": "us-gaap_OperatingLeaseLiability",
"weight": 1.0
},
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
"label": "Operating Lease, Liability, Noncurrent",
"terseLabel": "Long-term lease liabilities"
}
}
},
"localname": "OperatingLeaseLiabilityNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesMaturityAnalysisofLeaseLiabilitiesDetails",
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeasePayments": {
"auth_ref": [
"r519",
"r525"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
"label": "Operating Lease, Payments",
"terseLabel": "Cash paid for amounts included in the measurement of lease liabilities included in cash flows used in operating activities"
}
}
},
"localname": "OperatingLeasePayments",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesOtherSupplementalInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseRightOfUseAsset": {
"auth_ref": [
"r517"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's right to use underlying asset under operating lease.",
"label": "Operating Lease, Right-of-Use Asset",
"terseLabel": "Right of use asset",
"verboseLabel": "Right of use assets"
}
}
},
"localname": "OperatingLeaseRightOfUseAsset",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
"auth_ref": [
"r100"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 15.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
"label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
"terseLabel": "Non-cash lease expense"
}
}
},
"localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
"auth_ref": [
"r528",
"r531"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average discount rate for operating lease calculated at point in time.",
"label": "Operating Lease, Weighted Average Discount Rate, Percent",
"terseLabel": "Weighted average discount rate (percent)"
}
}
},
"localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
"auth_ref": [
"r527",
"r531"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Operating Lease, Weighted Average Remaining Lease Term",
"terseLabel": "Weighted average remaining lease term (years)"
}
}
},
"localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
}
}
},
"localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_OtherAccruedLiabilitiesCurrent": {
"auth_ref": [
"r47"
],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
"order": 7.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
"label": "Other Accrued Liabilities, Current",
"terseLabel": "Other"
}
}
},
"localname": "OtherAccruedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherAssetsCurrent": {
"auth_ref": [
"r41",
"r537"
],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
"order": 1.0,
"parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of current assets classified as other.",
"label": "Other Assets, Current",
"terseLabel": "Other current assets"
}
}
},
"localname": "OtherAssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherAssetsNoncurrent": {
"auth_ref": [
"r15"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 5.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of noncurrent assets classified as other.",
"label": "Other Assets, Noncurrent",
"terseLabel": "Other long-term assets"
}
}
},
"localname": "OtherAssetsNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
"auth_ref": [
"r453",
"r454",
"r458"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
"order": 1.0,
"parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
"label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
"terseLabel": "Change in unrealized (losses) gains on marketable securities",
"verboseLabel": "Change in unrealized gain (loss) on marketable securities"
}
}
},
"localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
"auth_ref": [
"r453",
"r454",
"r458"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
"order": 2.0,
"parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
"label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
"terseLabel": "Currency translation adjustment",
"verboseLabel": "Other comprehensive income (loss,) foreign currency translation adjustments"
}
}
},
"localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
"http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
"auth_ref": [
"r62",
"r65",
"r453",
"r454",
"r458"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
"order": 1.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
"label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
"totalLabel": "Total other comprehensive income (loss)"
}
}
},
"localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
"terseLabel": "Other comprehensive income"
}
}
},
"localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
],
"xbrltype": "stringItemType"
},
"us-gaap_OtherDepreciationAndAmortization": {
"auth_ref": [
"r79",
"r100",
"r266"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 10.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.",
"label": "Other Depreciation and Amortization",
"terseLabel": "Depreciation and amortization expense"
}
}
},
"localname": "OtherDepreciationAndAmortization",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherEmployeeRelatedLiabilitiesCurrent": {
"auth_ref": [
"r47"
],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
"order": 1.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of obligations incurred for employer-related costs classified as other, payable within one year or the normal operating cycle, if longer.",
"label": "Other Employee-related Liabilities, Current",
"terseLabel": "Other accrued personnel related expenses"
}
}
},
"localname": "OtherEmployeeRelatedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherLiabilitiesNoncurrent": {
"auth_ref": [
"r52"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
"label": "Other Liabilities, Noncurrent",
"terseLabel": "Other long-term liabilities"
}
}
},
"localname": "OtherLiabilitiesNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherNoncurrentAssetsMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption encompassing other noncurrent assets.",
"label": "Other Noncurrent Assets [Member]",
"terseLabel": "Other Long-Term Assets"
}
}
},
"localname": "OtherNoncurrentAssetsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsCapitalizedImplementationCostsofaHostingArrangementDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_OtherNonoperatingIncomeExpense": {
"auth_ref": [
"r82"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
"order": 1.0,
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
"label": "Other Nonoperating Income (Expense)",
"terseLabel": "Other income (expense), net"
}
}
},
"localname": "OtherNonoperatingIncomeExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherPrepaidExpenseCurrent": {
"auth_ref": [
"r40",
"r247"
],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
"order": 4.0,
"parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
"label": "Other Prepaid Expense, Current",
"terseLabel": "Prepaid expenses"
}
}
},
"localname": "OtherPrepaidExpenseCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsForRepurchaseOfCommonStock": {
"auth_ref": [
"r92"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 4.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow to reacquire common stock during the period.",
"label": "Payments for Repurchase of Common Stock",
"negatedTerseLabel": "Payments for repurchase of early exercised common stock options"
}
}
},
"localname": "PaymentsForRepurchaseOfCommonStock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsOfDebtIssuanceCosts": {
"auth_ref": [
"r94"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 3.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
"label": "Payments of Debt Issuance Costs",
"negatedTerseLabel": "Debt issuance cost",
"terseLabel": "Payment of fees to lender and third parties (less than)"
}
}
},
"localname": "PaymentsOfDebtIssuanceCosts",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows",
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
"auth_ref": [
"r84",
"r86",
"r214"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Payments to Acquire Debt Securities, Available-for-Sale",
"negatedTerseLabel": "Purchases of investments"
}
}
},
"localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
"auth_ref": [
"r87"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
"label": "Payments to Acquire Property, Plant, and Equipment",
"negatedTerseLabel": "Purchases of property and equipment"
}
}
},
"localname": "PaymentsToAcquirePropertyPlantAndEquipment",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PreferredStockParOrStatedValuePerShare": {
"auth_ref": [
"r24",
"r335"
],
"lang": {
"en-us": {
"role": {
"documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
"label": "Preferred Stock, Par or Stated Value Per Share",
"terseLabel": "Preferred stock, par value (in dollars per share)"
}
}
},
"localname": "PreferredStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "perShareItemType"
},
"us-gaap_PreferredStockSharesAuthorized": {
"auth_ref": [
"r24"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
"label": "Preferred Stock, Shares Authorized",
"terseLabel": "Preferred stock, authorized (in shares)"
}
}
},
"localname": "PreferredStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockSharesIssued": {
"auth_ref": [
"r24",
"r335"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
"label": "Preferred Stock, Shares Issued",
"terseLabel": "Preferred stock, issued (in shares)"
}
}
},
"localname": "PreferredStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockSharesOutstanding": {
"auth_ref": [
"r24"
],
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
"label": "Preferred Stock, Shares Outstanding",
"terseLabel": "Preferred stock, outstanding (in shares)"
}
}
},
"localname": "PreferredStockSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockValue": {
"auth_ref": [
"r24",
"r537"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
"label": "Preferred Stock, Value, Issued",
"terseLabel": "Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding as of June\u00a030, 2022 and December\u00a031, 2021"
}
}
},
"localname": "PreferredStockValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
"auth_ref": [
"r42"
],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
"label": "Prepaid Expense and Other Assets, Current",
"terseLabel": "Prepaid expenses and other current assets",
"totalLabel": "Total prepaid expenses and other current assets"
}
}
},
"localname": "PrepaidExpenseAndOtherAssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails",
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
"label": "Prepaid Expenses and Other Current Assets [Member]",
"terseLabel": "Prepaid Expenses and Other Current Assets"
}
}
},
"localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsCapitalizedImplementationCostsofaHostingArrangementDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_PrepaidInsurance": {
"auth_ref": [
"r5",
"r246",
"r247"
],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
"order": 2.0,
"parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
"label": "Prepaid Insurance",
"terseLabel": "Prepaid insurance"
}
}
},
"localname": "PrepaidInsurance",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PrimeRateMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
"label": "Prime Rate [Member]",
"terseLabel": "Prime Rate"
}
}
},
"localname": "PrimeRateMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
"auth_ref": [
"r90"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
"label": "Proceeds from Issuance of Long-Term Debt",
"terseLabel": "Proceeds from issuance of debt"
}
}
},
"localname": "ProceedsFromIssuanceOfLongTermDebt",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromLinesOfCredit": {
"auth_ref": [
"r90",
"r112"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
"label": "Proceeds from Lines of Credit",
"terseLabel": "Proceeds from line of credit"
}
}
},
"localname": "ProceedsFromLinesOfCredit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCreditAgreementandPaycheckProtectionProgramNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": {
"auth_ref": [
"r85",
"r88"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 3.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
"label": "Proceeds from Maturities, Prepayments and Calls of Short-Term Investments",
"terseLabel": "Maturities of short-term marketable securities"
}
}
},
"localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock": {
"auth_ref": [
"r91"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 5.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Cash inflow from repayment of loans for purchasing common stock.",
"label": "Proceeds from Repayment of Loans to Purchase Common Stock",
"terseLabel": "Proceeds from issuance of common stock under the employee stock purchase plan"
}
}
},
"localname": "ProceedsFromRepaymentOfLoansToPurchaseCommonStock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromStockOptionsExercised": {
"auth_ref": [
"r89",
"r426"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
"label": "Proceeds from Stock Options Exercised",
"terseLabel": "Proceeds from exercise of common stock options"
}
}
},
"localname": "ProceedsFromStockOptionsExercised",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
"auth_ref": [
"r269"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
"label": "Long-Lived Tangible Asset [Axis]",
"terseLabel": "Long-Lived Tangible Asset [Axis]"
}
}
},
"localname": "PropertyPlantAndEquipmentByTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsCapitalizedImplementationCostsofaHostingArrangementDetails",
"http://www.pulmonx.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails",
"http://www.pulmonx.com/role/CommitmentsandContingenciesLeasesNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_PropertyPlantAndEquipmentGross": {
"auth_ref": [
"r11",
"r267"
],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails": {
"order": 2.0,
"parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
"label": "Property, Plant and Equipment, Gross",
"terseLabel": "Total property and equipment, gross"
}
}
},
"localname": "PropertyPlantAndEquipmentGross",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PropertyPlantAndEquipmentLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Property, Plant and Equipment [Line Items]",
"terseLabel": "Property, Plant and Equipment [Line Items]"
}
}
},
"localname": "PropertyPlantAndEquipmentLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsCapitalizedImplementationCostsofaHostingArrangementDetails",
"http://www.pulmonx.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_PropertyPlantAndEquipmentNet": {
"auth_ref": [
"r269",
"r537",
"r596",
"r610"
],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
"label": "Property, Plant and Equipment, Net",
"terseLabel": "Property and equipment, net",
"totalLabel": "Property and equipment, net"
}
}
},
"localname": "PropertyPlantAndEquipmentNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails",
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PropertyPlantAndEquipmentTextBlock": {
"auth_ref": [
"r269"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
"label": "Property, Plant and Equipment [Table Text Block]",
"terseLabel": "Schedule of Property and Equipment, Net"
}
}
},
"localname": "PropertyPlantAndEquipmentTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_PropertyPlantAndEquipmentTypeDomain": {
"auth_ref": [
"r267"
],
"lang": {
"en-us": {
"role": {
"documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
"label": "Long-Lived Tangible Asset [Domain]",
"terseLabel": "Long-Lived Tangible Asset [Domain]"
}
}
},
"localname": "PropertyPlantAndEquipmentTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsCapitalizedImplementationCostsofaHostingArrangementDetails",
"http://www.pulmonx.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails",
"http://www.pulmonx.com/role/CommitmentsandContingenciesLeasesNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ProvisionForDoubtfulAccounts": {
"auth_ref": [
"r76",
"r232"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 18.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
"label": "Accounts Receivable, Credit Loss Expense (Reversal)",
"terseLabel": "Allowance for doubtful accounts"
}
}
},
"localname": "ProvisionForDoubtfulAccounts",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": {
"auth_ref": [
"r21",
"r584",
"r605"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers.",
"label": "Purchase Commitment, Excluding Long-Term Commitment [Axis]",
"terseLabel": "Purchase Commitment, Excluding Long-Term Commitment [Axis]"
}
}
},
"localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesServiceAgreementDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": {
"auth_ref": [
"r21",
"r584",
"r605"
],
"lang": {
"en-us": {
"role": {
"documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.",
"label": "Purchase Commitment, Excluding Long-Term Commitment [Domain]",
"terseLabel": "Purchase Commitment, Excluding Long-Term Commitment [Domain]"
}
}
},
"localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesServiceAgreementDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Purchase Commitment, Excluding Long-Term Commitment [Line Items]",
"terseLabel": "Purchase Commitment, Excluding Long-Term Commitment [Line Items]"
}
}
},
"localname": "PurchaseCommitmentExcludingLongtermCommitmentLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesServiceAgreementDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable": {
"auth_ref": [
"r21",
"r584",
"r605"
],
"lang": {
"en-us": {
"role": {
"documentation": "Summarization of information required or determined to be disclosed about arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers. Such disclosure may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing for failing to reach minimum quantities required to be purchased (such as penalties), cancellation rights, and termination provisions.",
"label": "Purchase Commitment, Excluding Long-Term Commitment [Table]",
"terseLabel": "Purchase Commitment, Excluding Long-Term Commitment [Table]"
}
}
},
"localname": "PurchaseCommitmentExcludingLongtermCommitmentTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesServiceAgreementDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_PurchaseObligationDueInNextTwelveMonths": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Purchase Obligation, to be Paid, Year One",
"terseLabel": "Purchase obligation, to be paid, year one"
}
}
},
"localname": "PurchaseObligationDueInNextTwelveMonths",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesServiceAgreementDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PurchaseObligationDueInSecondYear": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Purchase Obligation, to be Paid, Year Two",
"terseLabel": "Purchase obligation, to be paid, year two"
}
}
},
"localname": "PurchaseObligationDueInSecondYear",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesServiceAgreementDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PurchaseObligationDueInThirdYear": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Purchase Obligation, to be Paid, Year Three",
"terseLabel": "Purchase obligation, to be paid, year three"
}
}
},
"localname": "PurchaseObligationDueInThirdYear",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesServiceAgreementDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RepaymentsOfDebt": {
"auth_ref": [
"r93"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
"label": "Repayments of Debt",
"terseLabel": "Repayments of debt"
}
}
},
"localname": "RepaymentsOfDebt",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCreditAgreementandPaycheckProtectionProgramNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RepaymentsOfLongTermLinesOfCredit": {
"auth_ref": [
"r93"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
"label": "Repayments of Long-Term Lines of Credit",
"negatedTerseLabel": "Repayment of Credit Agreement"
}
}
},
"localname": "RepaymentsOfLongTermLinesOfCredit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ResearchAndDevelopmentExpense": {
"auth_ref": [
"r432",
"r570",
"r646"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
"order": 2.0,
"parentTag": "us-gaap_OperatingExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
"label": "Research and Development Expense",
"terseLabel": "Research and development"
}
}
},
"localname": "ResearchAndDevelopmentExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ResearchAndDevelopmentExpenseMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
"label": "Research and Development Expense [Member]",
"terseLabel": "Research and development"
}
}
},
"localname": "ResearchAndDevelopmentExpenseMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityTotalStockBasedCompensationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_RestrictedCash": {
"auth_ref": [
"r9",
"r107",
"r578",
"r606"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 5.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
},
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 2.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
"label": "Restricted Cash",
"terseLabel": "Restricted cash"
}
}
},
"localname": "RestrictedCash",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets",
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
"auth_ref": [
"r9"
],
"lang": {
"en-us": {
"role": {
"documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash and Cash Equivalents [Domain]",
"terseLabel": "Cash and Cash Equivalents [Domain]"
}
}
},
"localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_RestrictedStockMember": {
"auth_ref": [
"r153"
],
"lang": {
"en-us": {
"role": {
"documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
"label": "Restricted Stock [Member]",
"terseLabel": "Unvested restricted stock units"
}
}
},
"localname": "RestrictedStockMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersExcludedPotentiallyDilutiveSecuritiesOutstandingDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_RestrictedStockUnitsRSUMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
"label": "Restricted Stock Units (RSUs) [Member]",
"terseLabel": "Restricted Stock Units (RSUs)"
}
}
},
"localname": "RestrictedStockUnitsRSUMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails",
"http://www.pulmonx.com/role/StockholdersEquityRestrictedStockUnitActivityDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_RetainedEarningsAccumulatedDeficit": {
"auth_ref": [
"r28",
"r358",
"r537",
"r608",
"r624",
"r628"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Retained Earnings (Accumulated Deficit)",
"negatedTerseLabel": "Accumulated deficit",
"terseLabel": "Accumulated deficit"
}
}
},
"localname": "RetainedEarningsAccumulatedDeficit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets",
"http://www.pulmonx.com/role/FormationandBusinessoftheCompanyDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RetainedEarningsMember": {
"auth_ref": [
"r0",
"r119",
"r120",
"r121",
"r125",
"r133",
"r135",
"r228",
"r427",
"r428",
"r429",
"r439",
"r440",
"r477",
"r621",
"r623"
],
"lang": {
"en-us": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Retained Earnings [Member]",
"terseLabel": "Accumulated Deficit"
}
}
},
"localname": "RetainedEarningsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
],
"xbrltype": "domainItemType"
},
"us-gaap_RevenueFromContractWithCustomerAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Revenue from Contract with Customer [Abstract]"
}
}
},
"localname": "RevenueFromContractWithCustomerAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
"auth_ref": [
"r181",
"r182",
"r188",
"r193",
"r194",
"r200",
"r201",
"r206",
"r370",
"r371",
"r571"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
"order": 1.0,
"parentTag": "us-gaap_GrossProfit",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
"label": "Revenue from Contract with Customer, Excluding Assessed Tax",
"terseLabel": "Revenue"
}
}
},
"localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
"http://www.pulmonx.com/role/SegmentInformationRevenuebyGeographicAreaDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RevenueFromContractWithCustomerMember": {
"auth_ref": [
"r170",
"r206"
],
"lang": {
"en-us": {
"role": {
"documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
"label": "Revenue from Contract with Customer Benchmark [Member]",
"terseLabel": "Revenue from Contract with Customer Benchmark"
}
}
},
"localname": "RevenueFromContractWithCustomerMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SegmentInformationNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_RevenueFromContractWithCustomerTextBlock": {
"auth_ref": [
"r362",
"r363",
"r364",
"r365",
"r366",
"r367",
"r368",
"r369",
"r374",
"r376"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
"label": "Revenue from Contract with Customer [Text Block]",
"terseLabel": "Revenue Recognition"
}
}
},
"localname": "RevenueFromContractWithCustomerTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/RevenueRecognition"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
"auth_ref": [
"r203"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
"label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
"terseLabel": "Schedule of Revenue by Geographic Area"
}
}
},
"localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SegmentInformationTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
"terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
}
}
},
"localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SegmentInformationLongLivedAssetsbyGeographicalAreaDetails",
"http://www.pulmonx.com/role/SegmentInformationRevenuebyGeographicAreaDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
"auth_ref": [
"r526",
"r531"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
"label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
"terseLabel": "Operating lease right of use assets obtained in exchange for new lease liabilities",
"verboseLabel": "Right-of-use assets obtained in exchange for lease liabilities"
}
}
},
"localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesOtherSupplementalInformationDetails",
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the components of accrued liabilities.",
"label": "Schedule of Accrued Liabilities [Table Text Block]",
"terseLabel": "Schedule of Accrued Liabilities"
}
}
},
"localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
"auth_ref": [
"r153"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
"label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
"terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
}
}
},
"localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersExcludedPotentiallyDilutiveSecuritiesOutstandingDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
"auth_ref": [
"r153"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
"label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
"terseLabel": "Schedule of Potentially Dilutive Securities Outstanding"
}
}
},
"localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the components of cash and cash equivalents.",
"label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
"terseLabel": "Schedule of Cash and Cash Equivalents"
}
}
},
"localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
"auth_ref": [
"r51",
"r117",
"r326",
"r328",
"r352",
"r355",
"r356",
"r357",
"r510",
"r511",
"r514",
"r598"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
"label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
"terseLabel": "Schedule of Long-term Debt Instruments"
}
}
},
"localname": "ScheduleOfDebtInstrumentsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
"auth_ref": [
"r152"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
"label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
"terseLabel": "Schedule of Basic and Diluted Net Loss per Share"
}
}
},
"localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
"auth_ref": [
"r421"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
"label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
"terseLabel": "Schedule of Total Stock-Based Compensation"
}
}
},
"localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
"auth_ref": [
"r483",
"r484"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
"label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
"terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis"
}
}
},
"localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
"auth_ref": [
"r258",
"r260",
"r572"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
"label": "Schedule of Finite-Lived Intangible Assets [Table]",
"terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
}
}
},
"localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsIntangibleAssetsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
"auth_ref": [
"r258",
"r260"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
"label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
"terseLabel": "Schedule Intangible Assets"
}
}
},
"localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
"auth_ref": [
"r8",
"r36",
"r37",
"r38"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
"label": "Schedule of Inventory, Current [Table Text Block]",
"terseLabel": "Schedule of Inventory"
}
}
},
"localname": "ScheduleOfInventoryCurrentTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
"auth_ref": [
"r282"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
"label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
"terseLabel": "Schedule of Contractual Maturities of Financing Obligations"
}
}
},
"localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
"auth_ref": [
"r269"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
"label": "Property, Plant and Equipment [Table]",
"terseLabel": "Property, Plant and Equipment [Table]"
}
}
},
"localname": "ScheduleOfPropertyPlantAndEquipmentTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsCapitalizedImplementationCostsofaHostingArrangementDetails",
"http://www.pulmonx.com/role/BalanceSheetComponentsPropertyandEquipmentNetDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
"auth_ref": [
"r71",
"r205"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
"label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
"terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
}
}
},
"localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SegmentInformationLongLivedAssetsbyGeographicalAreaDetails",
"http://www.pulmonx.com/role/SegmentInformationRevenuebyGeographicAreaDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock": {
"auth_ref": [
"r414"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
"label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]",
"terseLabel": "Schedule of Options Vested and Expected to Vest"
}
}
},
"localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
"auth_ref": [
"r389",
"r391",
"r392",
"r393",
"r394",
"r396",
"r397",
"r398",
"r399",
"r400",
"r401",
"r402",
"r403",
"r404",
"r405",
"r406",
"r407",
"r408",
"r409",
"r411",
"r412",
"r414",
"r415",
"r416",
"r417",
"r418",
"r419",
"r420"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about share-based payment arrangement.",
"label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
"terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
}
}
},
"localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails",
"http://www.pulmonx.com/role/StockholdersEquityRestrictedStockUnitActivityDetails",
"http://www.pulmonx.com/role/StockholdersEquityTotalStockBasedCompensationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
"auth_ref": [
"r395",
"r410",
"r413"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
"label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
"terseLabel": "Schedule of Summary of Stock Option Activity"
}
}
},
"localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
"label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
"terseLabel": "Schedule of Activity with Respect to Restricted Stock Units"
}
}
},
"localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfStockByClassTable": {
"auth_ref": [
"r22",
"r24",
"r25",
"r110",
"r160",
"r161",
"r331",
"r333",
"r334",
"r335",
"r336",
"r337",
"r338",
"r340",
"r344",
"r349",
"r351",
"r352",
"r353",
"r354",
"r355",
"r356",
"r357",
"r358"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
"label": "Schedule of Stock by Class [Table]",
"terseLabel": "Schedule of Stock by Class [Table]"
}
}
},
"localname": "ScheduleOfStockByClassTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfStockByClassTextBlock": {
"auth_ref": [
"r23",
"r24",
"r25",
"r332",
"r333",
"r334",
"r352",
"r353",
"r354",
"r355",
"r356",
"r357",
"r358"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
"label": "Schedule of Stock by Class [Table Text Block]",
"terseLabel": "Schedule of Shares Reserved for Future Issuance"
}
}
},
"localname": "ScheduleOfStockByClassTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
"auth_ref": [
"r260"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
"label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
"terseLabel": "Schedule of Future Amortization Expense"
}
}
},
"localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SegmentReportingAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Segment Reporting [Abstract]"
}
}
},
"localname": "SegmentReportingAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_SegmentReportingDisclosureTextBlock": {
"auth_ref": [
"r177",
"r179",
"r180",
"r186",
"r187",
"r192",
"r196",
"r197",
"r198",
"r199",
"r200",
"r205",
"r206",
"r207"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
"label": "Segment Reporting Disclosure [Text Block]",
"terseLabel": "Segment Information"
}
}
},
"localname": "SegmentReportingDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SegmentInformation"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SellingGeneralAndAdministrativeExpense": {
"auth_ref": [
"r80"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
"order": 1.0,
"parentTag": "us-gaap_OperatingExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
"label": "Selling, General and Administrative Expense",
"terseLabel": "Selling, general and administrative"
}
}
},
"localname": "SellingGeneralAndAdministrativeExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
"label": "Selling, General and Administrative Expenses [Member]",
"terseLabel": "Selling, general and administrative"
}
}
},
"localname": "SellingGeneralAndAdministrativeExpensesMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityTotalStockBasedCompensationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ShareBasedCompensation": {
"auth_ref": [
"r99"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows": {
"order": 3.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of noncash expense for share-based payment arrangement.",
"label": "Share-Based Payment Arrangement, Noncash Expense",
"terseLabel": "Stock-based compensation expense"
}
}
},
"localname": "ShareBasedCompensation",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
"auth_ref": [
"r392"
],
"lang": {
"en-us": {
"role": {
"documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
"terseLabel": "Award vesting period"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
"auth_ref": [
"r409"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
"negatedTerseLabel": "Canceled (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityRestrictedStockUnitActivityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
"auth_ref": [
"r409"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
"terseLabel": "Canceled (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityRestrictedStockUnitActivityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
"auth_ref": [
"r407"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
"terseLabel": "Granted (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityRestrictedStockUnitActivityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
"auth_ref": [
"r407"
],
"lang": {
"en-us": {
"role": {
"documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
"terseLabel": "Granted (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityRestrictedStockUnitActivityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
"auth_ref": [
"r404",
"r405"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
"periodEndLabel": "Unvested, end of period (in shares)",
"periodStartLabel": "Unvested, beginning of period (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityRestrictedStockUnitActivityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
"terseLabel": "Number of Shares Underlying Outstanding Restricted Stock"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityRestrictedStockUnitActivityDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
"auth_ref": [
"r404",
"r405"
],
"lang": {
"en-us": {
"role": {
"documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
"periodEndLabel": "Unvested, end of period (in dollars per share)",
"periodStartLabel": "Unvested, beginning of period (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityRestrictedStockUnitActivityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
"terseLabel": "Weighted Average Grant Date Fair Value"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityRestrictedStockUnitActivityDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
"auth_ref": [
"r408"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
"negatedTerseLabel": "Vested (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityRestrictedStockUnitActivityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
"auth_ref": [
"r408"
],
"lang": {
"en-us": {
"role": {
"documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
"terseLabel": "Vested (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityRestrictedStockUnitActivityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
"terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails",
"http://www.pulmonx.com/role/StockholdersEquityRestrictedStockUnitActivityDetails",
"http://www.pulmonx.com/role/StockholdersEquityTotalStockBasedCompensationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
"auth_ref": [
"r402"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
"negatedTerseLabel": "Options canceled (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityStockOptionActivityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
"auth_ref": [
"r400"
],
"lang": {
"en-us": {
"role": {
"documentation": "Gross number of share options (or share units) granted during the period.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
"terseLabel": "Options granted (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityStockOptionActivityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
"auth_ref": [
"r425"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
"terseLabel": "Options outstanding, aggregate intrinsic value"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
"auth_ref": [
"r396",
"r397"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of options outstanding, including both vested and non-vested options.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
"periodEndLabel": "Balance, end of period (in shares)",
"periodStartLabel": "Balance, beginning of period (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityStockOptionActivityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
"terseLabel": "Number of Shares"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityStockOptionActivityDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
"auth_ref": [
"r396",
"r397"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
"periodEndLabel": "Balance, end of period (in dollars per share)",
"periodStartLabel": "Balance, beginning of period (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityStockOptionActivityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
"terseLabel": "Weighted Average Exercise Price"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityStockOptionActivityDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]",
"terseLabel": "Number of Shares"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityOptionsVestedandExpectedtoVestDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
"auth_ref": [
"r414"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
"terseLabel": "Options vested and expenses to vest, intrinsic value"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
"auth_ref": [
"r414"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
"terseLabel": "Options vested and expected to vest (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityOptionsVestedandExpectedtoVestDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
"auth_ref": [
"r414"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
"terseLabel": "Options vested and expected to vest (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityOptionsVestedandExpectedtoVestDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
"auth_ref": [
"r392",
"r393",
"r394",
"r396",
"r397",
"r398",
"r399",
"r400",
"r401",
"r402",
"r403",
"r404",
"r405",
"r406",
"r407",
"r408",
"r409",
"r411",
"r412",
"r414",
"r415",
"r416",
"r417",
"r418",
"r419",
"r420"
],
"lang": {
"en-us": {
"role": {
"documentation": "Award under share-based payment arrangement.",
"label": "Award Type [Domain]",
"terseLabel": "Award Type [Domain]"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails",
"http://www.pulmonx.com/role/StockholdersEquityRestrictedStockUnitActivityDetails",
"http://www.pulmonx.com/role/StockholdersEquitySharesReservedforFutureIssuanceDetails",
"http://www.pulmonx.com/role/StockholdersEquityTotalStockBasedCompensationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
"auth_ref": [
"r401"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
"label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
"terseLabel": "Options exercised (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityStockOptionActivityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
"auth_ref": [
"r402"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
"label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
"terseLabel": "Options canceled (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityStockOptionActivityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
"auth_ref": [
"r400"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
"label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
"terseLabel": "Options granted (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityStockOptionActivityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
"auth_ref": [
"r425"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
"terseLabel": "Options exercisable, aggregate intrinsic value"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
"auth_ref": [
"r414"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
"terseLabel": "Options vested and expected to vest"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityOptionsVestedandExpectedtoVestDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
"auth_ref": [
"r412"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
"terseLabel": "Fair value of shares vested"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Number of options vested.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
"terseLabel": "Options vested (in shares)"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityOptionsVestedandExpectedtoVestDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShortTermBorrowings": {
"auth_ref": [
"r17",
"r537",
"r581",
"r603"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 4.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
"label": "Short-Term Debt",
"terseLabel": "Short-term debt"
}
}
},
"localname": "ShortTermBorrowings",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShortTermLeaseCost": {
"auth_ref": [
"r523",
"r531"
],
"calculation": {
"http://www.pulmonx.com/role/CommitmentsandContingenciesLeaseCostDetails": {
"order": 2.0,
"parentTag": "us-gaap_LeaseCost",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
"label": "Short-Term Lease, Cost",
"terseLabel": "Short-term lease cost"
}
}
},
"localname": "ShortTermLeaseCost",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesLeaseCostDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
"label": "Software and Software Development Costs [Member]",
"terseLabel": "Software Systems"
}
}
},
"localname": "SoftwareAndSoftwareDevelopmentCostsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsCapitalizedImplementationCostsofaHostingArrangementDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_StatementEquityComponentsAxis": {
"auth_ref": [
"r0",
"r55",
"r67",
"r68",
"r69",
"r119",
"r120",
"r121",
"r125",
"r133",
"r135",
"r159",
"r228",
"r351",
"r358",
"r427",
"r428",
"r429",
"r439",
"r440",
"r477",
"r502",
"r503",
"r504",
"r505",
"r506",
"r507",
"r533",
"r621",
"r622",
"r623"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by component of equity.",
"label": "Equity Components [Axis]",
"terseLabel": "Equity Components [Axis]"
}
}
},
"localname": "StatementEquityComponentsAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Statement [Line Items]",
"terseLabel": "Statement [Line Items]"
}
}
},
"localname": "StatementLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfCashFlowsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Statement of Cash Flows [Abstract]"
}
}
},
"localname": "StatementOfCashFlowsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfFinancialPositionAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Statement of Financial Position [Abstract]"
}
}
},
"localname": "StatementOfFinancialPositionAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfStockholdersEquityAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Statement of Stockholders' Equity [Abstract]"
}
}
},
"localname": "StatementOfStockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_StatementTable": {
"auth_ref": [
"r119",
"r120",
"r121",
"r159",
"r571"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
"label": "Statement [Table]",
"terseLabel": "Statement [Table]"
}
}
},
"localname": "StatementTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
],
"xbrltype": "stringItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
"auth_ref": [
"r24",
"r25",
"r351",
"r358"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
"label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
"terseLabel": "Issuance of shares pursuant to Employee Stock Purchase Plan (in shares)"
}
}
},
"localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
"auth_ref": [
"r24",
"r25",
"r351",
"r358"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
"label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
"terseLabel": "Issuance of common stock upon vesting of restricted stock units (in share)"
}
}
},
"localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
"auth_ref": [
"r24",
"r25",
"r351",
"r358",
"r401"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of share options (or share units) exercised during the current period.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
"negatedLabel": "Options exercised (in shares)",
"terseLabel": "Issuance of common stock upon exercise of stock options (in shares)"
}
}
},
"localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
"http://www.pulmonx.com/role/StockholdersEquityStockOptionActivityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
"auth_ref": [
"r24",
"r25",
"r351",
"r358"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
"label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
"terseLabel": "Issuance of shares pursuant to Employee Stock Purchase Plan"
}
}
},
"localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
"auth_ref": [
"r55",
"r351",
"r358"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Value of stock issued as a result of the exercise of stock options.",
"label": "Stock Issued During Period, Value, Stock Options Exercised",
"terseLabel": "Issuance of common stock upon exercise of stock options"
}
}
},
"localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockRepurchasedDuringPeriodShares": {
"auth_ref": [
"r24",
"r25",
"r351",
"r358"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
"label": "Stock Repurchased During Period, Shares",
"terseLabel": "Repurchase of early exercised common stock options (in shares)"
}
}
},
"localname": "StockRepurchasedDuringPeriodShares",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockRepurchasedDuringPeriodValue": {
"auth_ref": [
"r24",
"r25",
"r351",
"r358"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
"label": "Stock Repurchased During Period, Value",
"terseLabel": "Common stock, shares repurchased, less than (in shares)"
}
}
},
"localname": "StockRepurchasedDuringPeriodValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquityNarrativeDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquity": {
"auth_ref": [
"r25",
"r30",
"r31",
"r113",
"r210",
"r227",
"r495",
"r537"
],
"calculation": {
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
"label": "Stockholders' Equity Attributable to Parent",
"periodEndLabel": "Ending balance",
"periodStartLabel": "Beginning balance",
"totalLabel": "Total stockholders\u2019 equity"
}
}
},
"localname": "StockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets",
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquityAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Stockholders' Equity Attributable to Parent [Abstract]",
"terseLabel": "Stockholders\u2019 equity"
}
}
},
"localname": "StockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheets",
"http://www.pulmonx.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "stringItemType"
},
"us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
"auth_ref": [
"r111",
"r336",
"r339",
"r340",
"r341",
"r342",
"r343",
"r344",
"r345",
"r346",
"r347",
"r348",
"r350",
"r358",
"r359",
"r475"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
"label": "Stockholders' Equity Note Disclosure [Text Block]",
"terseLabel": "Stockholders' Equity"
}
}
},
"localname": "StockholdersEquityNoteDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/StockholdersEquity"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
"auth_ref": [
"r56"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
"label": "Supplemental Balance Sheet Disclosures [Text Block]",
"terseLabel": "Balance Sheet Components"
}
}
},
"localname": "SupplementalBalanceSheetDisclosuresTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponents"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SupplementalCashFlowElementsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Supplemental Cash Flow Elements [Abstract]",
"terseLabel": "Supplemental disclosure of cash flow information:"
}
}
},
"localname": "SupplementalCashFlowElementsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_TaxesPayableCurrent": {
"auth_ref": [
"r45"
],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails": {
"order": 3.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Taxes Payable, Current",
"terseLabel": "Sales taxes, franchise tax and VAT"
}
}
},
"localname": "TaxesPayableCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsAccruedLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_TrademarksMember": {
"auth_ref": [
"r451"
],
"lang": {
"en-us": {
"role": {
"documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
"label": "Trademarks [Member]",
"terseLabel": "Trademarks"
}
}
},
"localname": "TrademarksMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsIntangibleAssetsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
"auth_ref": [
"r221",
"r222",
"r224",
"r225",
"r226",
"r321",
"r349",
"r474",
"r538",
"r539",
"r540",
"r541",
"r542",
"r543",
"r544",
"r545",
"r546",
"r547",
"r548",
"r549",
"r550",
"r551",
"r552",
"r553",
"r554",
"r555",
"r556",
"r557",
"r558",
"r559",
"r560",
"r561",
"r562",
"r563",
"r564",
"r565",
"r566",
"r567",
"r652",
"r653",
"r654",
"r655",
"r656",
"r657",
"r658"
],
"lang": {
"en-us": {
"role": {
"documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
"label": "Financial Instruments [Domain]",
"terseLabel": "Financial Instruments [Domain]"
}
}
},
"localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
"http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
"auth_ref": [
"r116",
"r379",
"r595"
],
"lang": {
"en-us": {
"role": {
"documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
"label": "US Government Agencies Debt Securities [Member]",
"terseLabel": "U.S. Government agency bonds"
}
}
},
"localname": "USGovernmentAgenciesDebtSecuritiesMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesDetails",
"http://www.pulmonx.com/role/FairValueMeasurementsUnrealizedGainsandLossesandFairValueDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_UseOfEstimates": {
"auth_ref": [
"r163",
"r164",
"r166",
"r167",
"r173",
"r174",
"r175"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
"label": "Use of Estimates, Policy [Policy Text Block]",
"terseLabel": "Use of Estimates"
}
}
},
"localname": "UseOfEstimates",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ValueAddedTaxReceivableCurrent": {
"auth_ref": [
"r26"
],
"calculation": {
"http://www.pulmonx.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails": {
"order": 3.0,
"parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
"label": "Value Added Tax Receivable, Current",
"terseLabel": "VAT and other receivable"
}
}
},
"localname": "ValueAddedTaxReceivableCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/BalanceSheetComponentsPrepaidExpensesandOtherCurrentAssetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_VariableLeaseCost": {
"auth_ref": [
"r524",
"r531"
],
"calculation": {
"http://www.pulmonx.com/role/CommitmentsandContingenciesLeaseCostDetails": {
"order": 3.0,
"parentTag": "us-gaap_LeaseCost",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
"label": "Variable Lease, Cost",
"terseLabel": "Variable lease cost"
}
}
},
"localname": "VariableLeaseCost",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesLeaseCostDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_VariableRateAxis": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of variable rate.",
"label": "Variable Rate [Axis]",
"terseLabel": "Variable Rate [Axis]"
}
}
},
"localname": "VariableRateAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_VariableRateDomain": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
"label": "Variable Rate [Domain]",
"terseLabel": "Variable Rate [Domain]"
}
}
},
"localname": "VariableRateDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/LongTermDebtandConvertibleNotesCIBCLoanNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_VehiclesMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Equipment used primarily for road transportation.",
"label": "Vehicles [Member]",
"terseLabel": "Vehicles"
}
}
},
"localname": "VehiclesMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CommitmentsandContingenciesLeasesNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
"auth_ref": [
"r142",
"r152"
],
"lang": {
"en-us": {
"role": {
"documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
"label": "Weighted Average Number of Shares Outstanding, Diluted",
"terseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)",
"verboseLabel": "Weighted-average common shares used to compute, diluted net loss per share (in shares)"
}
}
},
"localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
"http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersComputationofBasicandDilutedNetLossperShareDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": {
"auth_ref": [
"r141"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).",
"label": "Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation",
"negatedTerseLabel": "Less: weighted-average common shares subject to repurchase (in shares)"
}
}
},
"localname": "WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersComputationofBasicandDilutedNetLossperShareDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
"auth_ref": [
"r139",
"r141"
],
"lang": {
"en-us": {
"role": {
"documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).",
"label": "Weighted Average Number of Shares Issued, Basic",
"terseLabel": "Weighted-average common stock outstanding (in shares)"
}
}
},
"localname": "WeightedAverageNumberOfSharesIssuedBasic",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersComputationofBasicandDilutedNetLossperShareDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
"auth_ref": [
"r139",
"r152"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
"label": "Weighted Average Number of Shares Outstanding, Basic",
"terseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)",
"verboseLabel": "Weighted-average common shares used to compute, basic net loss per share (in shares)"
}
}
},
"localname": "WeightedAverageNumberOfSharesOutstandingBasic",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
"http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersComputationofBasicandDilutedNetLossperShareDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
"terseLabel": "Denominator"
}
}
},
"localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.pulmonx.com/role/NetLossperShareAttributabletoCommonStockholdersComputationofBasicandDilutedNetLossperShareDetails"
],
"xbrltype": "stringItemType"
}
},
"unitCount": 10
}
},
"std_ref": {
"r0": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "105",
"URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
},
"r1": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "105",
"URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
},
"r10": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(12))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r100": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
},
"r101": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
},
"r102": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
},
"r103": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
},
"r104": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
},
"r105": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
},
"r106": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
},
"r107": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
},
"r108": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
},
"r109": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(c))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r11": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(13))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r110": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(d))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r111": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(e)(1))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r112": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(f))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r113": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r114": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(h)(2))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r115": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(h))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r116": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r117": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.12-04(a))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
},
"r118": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "235",
"URI": "https://asc.fasb.org/topic&trid=2122369"
},
"r119": {
"Name": "Accounting Standards Codification",
"Paragraph": "23",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
},
"r12": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(14))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r120": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
},
"r121": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
},
"r122": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r123": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(1)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r124": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r125": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(3)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r126": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(4)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r127": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r128": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
},
"r129": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
},
"r13": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(15))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r130": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
},
"r131": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
},
"r132": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
},
"r133": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
},
"r134": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
},
"r135": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
},
"r136": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.M.Q2)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
},
"r137": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
},
"r138": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "250",
"URI": "https://asc.fasb.org/topic&trid=2122394"
},
"r139": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
},
"r14": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(16))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r140": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
},
"r141": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2646-109256"
},
"r142": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
},
"r143": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
},
"r144": {
"Name": "Accounting Standards Codification",
"Paragraph": "40",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
},
"r145": {
"Name": "Accounting Standards Codification",
"Paragraph": "40",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)(1)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
},
"r146": {
"Name": "Accounting Standards Codification",
"Paragraph": "40",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
},
"r147": {
"Name": "Accounting Standards Codification",
"Paragraph": "40",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)(3)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
},
"r148": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
},
"r149": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
},
"r15": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(17))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r150": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
},
"r151": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
},
"r152": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
},
"r153": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
},
"r154": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
},
"r155": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
},
"r156": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
},
"r157": {
"Name": "Accounting Standards Codification",
"Paragraph": "52",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
},
"r158": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "260",
"URI": "https://asc.fasb.org/topic&trid=2144383"
},
"r159": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "272",
"URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
},
"r16": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(18))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r160": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "272",
"URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
},
"r161": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "272",
"URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
},
"r162": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
},
"r163": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
},
"r164": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
},
"r165": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
},
"r166": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
},
"r167": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
},
"r168": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
},
"r169": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
},
"r17": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(19)(a))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r170": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
},
"r171": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
},
"r172": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
},
"r173": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
},
"r174": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
},
"r175": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
},
"r176": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "275",
"URI": "https://asc.fasb.org/topic&trid=2134479"
},
"r177": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
},
"r178": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
},
"r179": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
},
"r18": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(19))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r180": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
},
"r181": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r182": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r183": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r184": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r185": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r186": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r187": {
"Name": "Accounting Standards Codification",
"Paragraph": "26",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599"
},
"r188": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r189": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r19": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(20))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r190": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r191": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r192": {
"Name": "Accounting Standards Codification",
"Paragraph": "31",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
},
"r193": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r194": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r195": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r196": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r197": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r198": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r199": {
"Name": "Accounting Standards Codification",
"Paragraph": "34",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599"
},
"r2": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "205",
"URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
},
"r20": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(22))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r200": {
"Name": "Accounting Standards Codification",
"Paragraph": "40",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
},
"r201": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
},
"r202": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
},
"r203": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "a",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
},
"r204": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "b",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
},
"r205": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
},
"r206": {
"Name": "Accounting Standards Codification",
"Paragraph": "42",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
},
"r207": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "280",
"URI": "https://asc.fasb.org/topic&trid=2134510"
},
"r208": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
},
"r209": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
},
"r21": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(25))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r210": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 4.E)",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
},
"r211": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "20",
"Subparagraph": "(d)(1)",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
},
"r212": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "20",
"Subparagraph": "(d)(2)",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
},
"r213": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "320",
"URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
},
"r214": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "320",
"URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
},
"r215": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "320",
"URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
},
"r216": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "320",
"URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
},
"r217": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(aa)",
"Topic": "320",
"URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
},
"r218": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "320",
"URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
},
"r219": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "320",
"URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
},
"r22": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(27)(b))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r220": {
"Name": "Accounting Standards Codification",
"Paragraph": "2A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "320",
"URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL121698322-111563"
},
"r221": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "320",
"URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
},
"r222": {
"Name": "Accounting Standards Codification",
"Paragraph": "5A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "320",
"URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
},
"r223": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "320",
"URI": "https://asc.fasb.org/topic&trid=2196928"
},
"r224": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "321",
"URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
},
"r225": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "321",
"URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
},
"r226": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "321",
"URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
},
"r227": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "323",
"URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
},
"r228": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
},
"r229": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(1)",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
},
"r23": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(27))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r230": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(2)",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
},
"r231": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
},
"r232": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
},
"r233": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
},
"r234": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
},
"r235": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
},
"r236": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
},
"r237": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
},
"r238": {
"Name": "Accounting Standards Codification",
"Paragraph": "3A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL120267853-210455"
},
"r239": {
"Name": "Accounting Standards Codification",
"Paragraph": "3B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL120267856-210455"
},
"r24": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(28))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r240": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
},
"r241": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
},
"r242": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
},
"r243": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "30",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
},
"r244": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "330",
"URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
},
"r245": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.BB)",
"Topic": "330",
"URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
},
"r246": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "05",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "340",
"URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
},
"r247": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "340",
"URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
},
"r248": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
},
"r249": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
},
"r25": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(29))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r250": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r251": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r252": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r253": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(e)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r254": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r255": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
},
"r256": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
},
"r257": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
},
"r258": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
},
"r259": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
},
"r26": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(3)(a)(4))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r260": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r261": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)(1)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r262": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)(2)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r263": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)(3)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r264": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r265": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=118198657&loc=SL118198666-228104"
},
"r266": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r267": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r268": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r269": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r27": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(1))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r270": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
},
"r271": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(c)",
"Topic": "410",
"URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
},
"r272": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "420",
"URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r273": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "440",
"URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
},
"r274": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "440",
"URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
},
"r275": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "440",
"URI": "https://asc.fasb.org/topic&trid=2144648"
},
"r276": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
},
"r277": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
},
"r278": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "20",
"Subparagraph": "(SAB Topic 5.Y.Q2)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
},
"r279": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "20",
"Subparagraph": "(SAB Topic 5.Y.Q4)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
},
"r28": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(3))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r280": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "450",
"URI": "https://asc.fasb.org/topic&trid=2127136"
},
"r281": {
"Name": "Accounting Standards Codification",
"Paragraph": "12A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
},
"r282": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
},
"r283": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
},
"r284": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(i))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r285": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(ii))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r286": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r287": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r288": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iv))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r289": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(5))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r29": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(4))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r290": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(i))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r291": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r292": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r293": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iv))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r294": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(5))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r295": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r296": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r297": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r298": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r299": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(e)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r3": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r30": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r300": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(f)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r301": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r302": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r303": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(i)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r304": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r305": {
"Name": "Accounting Standards Codification",
"Paragraph": "1C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
},
"r306": {
"Name": "Accounting Standards Codification",
"Paragraph": "1C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
},
"r307": {
"Name": "Accounting Standards Codification",
"Paragraph": "1C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
},
"r308": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
},
"r309": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
},
"r31": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(31))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r310": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
},
"r311": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r312": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r313": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r314": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r315": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r316": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r317": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r318": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r319": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
},
"r32": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(32))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r320": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
},
"r321": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
},
"r322": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
},
"r323": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
},
"r324": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
},
"r325": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
},
"r326": {
"Name": "Accounting Standards Codification",
"Paragraph": "69B",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
},
"r327": {
"Name": "Accounting Standards Codification",
"Paragraph": "69C",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
},
"r328": {
"Name": "Accounting Standards Codification",
"Paragraph": "69E",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
},
"r329": {
"Name": "Accounting Standards Codification",
"Paragraph": "69F",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
},
"r33": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(a)(1))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r330": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "470",
"URI": "https://asc.fasb.org/topic&trid=2208564"
},
"r331": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(CFRR 211.02)",
"Topic": "480",
"URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
},
"r332": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Topic": "480",
"URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
},
"r333": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
},
"r334": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
},
"r335": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r336": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r337": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r338": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r339": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(g)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r34": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(a)(3))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r340": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r341": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(i)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r342": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r343": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
},
"r344": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
},
"r345": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
},
"r346": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
},
"r347": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
},
"r348": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
},
"r349": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
},
"r35": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(a)(4))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r350": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
},
"r351": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
},
"r352": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
},
"r353": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
},
"r354": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
},
"r355": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
},
"r356": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
},
"r357": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
},
"r358": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.3-04)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
},
"r359": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "505",
"URI": "https://asc.fasb.org/topic&trid=2208762"
},
"r36": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(a))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r360": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
},
"r361": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
},
"r362": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
},
"r363": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
},
"r364": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
},
"r365": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
},
"r366": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
},
"r367": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
},
"r368": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
},
"r369": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045"
},
"r37": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(b))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r370": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
},
"r371": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
},
"r372": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
},
"r373": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
},
"r374": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045"
},
"r375": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
},
"r376": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "606",
"URI": "https://asc.fasb.org/topic&trid=49130388"
},
"r377": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "10",
"Topic": "710",
"URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361"
},
"r378": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(i)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r379": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(ii)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r38": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(c))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r380": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(01)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r381": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r382": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(A)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r383": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(B)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r384": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(C)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r385": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(03)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r386": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
},
"r387": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(d)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
},
"r388": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "80",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
},
"r389": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "10",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
},
"r39": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r390": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "10",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
},
"r391": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "10",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
},
"r392": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r393": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r394": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(3)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r395": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r396": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r397": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r398": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r399": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r4": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r40": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(7))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r400": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(01)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r401": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(02)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r402": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(03)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r403": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(04)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r404": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r405": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r406": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r407": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(01)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r408": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(02)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r409": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(03)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r41": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(8))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r410": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r411": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r412": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r413": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r414": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r415": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r416": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r417": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r418": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r419": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(iv)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r42": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(9))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r420": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(v)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r421": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r422": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(1)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r423": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(1)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r424": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r425": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r426": {
"Name": "Accounting Standards Codification",
"Paragraph": "2A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
},
"r427": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
},
"r428": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
},
"r429": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
},
"r43": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(a))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r430": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
},
"r431": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
},
"r432": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "730",
"URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
},
"r433": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
},
"r434": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
},
"r435": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
},
"r436": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
},
"r437": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
},
"r438": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
},
"r439": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(2)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
},
"r44": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(b),22(b))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r440": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(3)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
},
"r441": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(1)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
},
"r442": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(2)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
},
"r443": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(3)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
},
"r444": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
},
"r445": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB TOPIC 6.I.7)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
},
"r446": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.C)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
},
"r447": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
},
"r448": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "270",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
},
"r449": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
},
"r45": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19,20)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r450": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "740",
"URI": "https://asc.fasb.org/topic&trid=2144680"
},
"r451": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "805",
"URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
},
"r452": {
"Name": "Accounting Standards Codification",
"Paragraph": "38",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "805",
"URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
},
"r453": {
"Name": "Accounting Standards Codification",
"Paragraph": "19",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
},
"r454": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
},
"r455": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
},
"r456": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
},
"r457": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
},
"r458": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(3)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r459": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c),(3)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r46": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19-26)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r460": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bb)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
},
"r461": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
},
"r462": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
},
"r463": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
},
"r464": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
},
"r465": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
},
"r466": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
},
"r467": {
"Name": "Accounting Standards Codification",
"Paragraph": "4A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
},
"r468": {
"Name": "Accounting Standards Codification",
"Paragraph": "4B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
},
"r469": {
"Name": "Accounting Standards Codification",
"Paragraph": "4B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
},
"r47": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.20)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r470": {
"Name": "Accounting Standards Codification",
"Paragraph": "4C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
},
"r471": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
},
"r472": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
},
"r473": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "25",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
},
"r474": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Subparagraph": "(f)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
},
"r475": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Subparagraph": "(a)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
},
"r476": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)(1)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
},
"r477": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)(3)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
},
"r478": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)(4)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
},
"r479": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
},
"r48": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.21)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r480": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(c)(1)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
},
"r481": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(c)(2)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
},
"r482": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(c)(3)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
},
"r483": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
},
"r484": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
},
"r485": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bbb)(1)",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
},
"r486": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bbb)(2)",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
},
"r487": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
},
"r488": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
},
"r489": {
"Name": "Accounting Standards Codification",
"Paragraph": "6A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
},
"r49": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.22(a)(1))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r490": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "60",
"SubTopic": "10",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
},
"r491": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
},
"r492": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
},
"r493": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
},
"r494": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
},
"r495": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
},
"r496": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(1)",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
},
"r497": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(2)",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
},
"r498": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(3)",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
},
"r499": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
},
"r5": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(g)(1)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r50": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.22(b))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r500": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
},
"r501": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "230",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
},
"r502": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
},
"r503": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r504": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(b)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r505": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(c)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r506": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r507": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
},
"r508": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "830",
"URI": "https://asc.fasb.org/topic&trid=2175825"
},
"r509": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
},
"r51": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.22)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r510": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
},
"r511": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
},
"r512": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
},
"r513": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
},
"r514": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
},
"r515": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(1)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
},
"r516": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(3)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
},
"r517": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
},
"r518": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
},
"r519": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
},
"r52": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.24)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r520": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(3)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
},
"r521": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
},
"r522": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
},
"r523": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
},
"r524": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
},
"r525": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)(1)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
},
"r526": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)(2)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
},
"r527": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)(3)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
},
"r528": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)(4)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
},
"r529": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
},
"r53": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.25)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r530": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
},
"r531": {
"Name": "Accounting Standards Codification",
"Paragraph": "53",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
},
"r532": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(1)",
"Topic": "848",
"URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
},
"r533": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(a)(3)(iii)(03)",
"Topic": "848",
"URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
},
"r534": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "848",
"URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
},
"r535": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "852",
"URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
},
"r536": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "852",
"URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
},
"r537": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "852",
"URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
},
"r538": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)(i)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r539": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)(ii)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r54": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.29)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r540": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r541": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r542": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r543": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r544": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r545": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r546": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r547": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r548": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r549": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r55": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.29-31)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r550": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r551": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
},
"r552": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
},
"r553": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
},
"r554": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
},
"r555": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
},
"r556": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(4)(i)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
},
"r557": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r558": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r559": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r56": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "210",
"URI": "https://asc.fasb.org/topic&trid=2122208"
},
"r560": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(4)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r561": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(5)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r562": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(6)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r563": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(a)(7)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r564": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(b)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r565": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(e)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r566": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(e)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r567": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Subparagraph": "(e)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
},
"r568": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "910",
"URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
},
"r569": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "310",
"Subparagraph": "(b)",
"Topic": "912",
"URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406"
},
"r57": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
},
"r570": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "730",
"Topic": "912",
"URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
},
"r571": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.L)",
"Topic": "924",
"URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
},
"r572": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "926",
"URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
},
"r573": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "20",
"Subparagraph": "(f)(1)",
"Topic": "926",
"URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
},
"r574": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "20",
"Subparagraph": "(f)(2)",
"Topic": "926",
"URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
},
"r575": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "20",
"Subparagraph": "(f)(3)",
"Topic": "926",
"URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
},
"r576": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "340",
"Topic": "928",
"URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
},
"r577": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "20",
"Topic": "940",
"URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
},
"r578": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(1)(a))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r579": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(10)(1))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r58": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
},
"r580": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(11))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r581": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(13))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r582": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(15)(1))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r583": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(16))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r584": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(17))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r585": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(23))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r586": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(6))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r587": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03.15(5))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r588": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03.17)",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r589": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(15))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r59": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
},
"r590": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(22))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r591": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(26))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r592": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(27))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r593": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04.9)",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r594": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "235",
"Subparagraph": "(SX 210.9-05(b)(2))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
},
"r595": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "320",
"Subparagraph": "(b)",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
},
"r596": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "360",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
},
"r597": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "405",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
},
"r598": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "470",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
},
"r599": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "825",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
},
"r6": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r60": {
"Name": "Accounting Standards Codification",
"Paragraph": "14A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
},
"r600": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(16))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r601": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(12))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r602": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r603": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r604": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(16))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r605": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(19))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r606": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(2))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r607": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r608": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r609": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(25))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r61": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
},
"r610": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(8))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r611": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03.(a),19)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r612": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03.15(a))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r613": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(18))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r614": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(22))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r615": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(23))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r616": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(8))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r617": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(9))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r618": {
"Name": "Accounting Standards Codification",
"Paragraph": "7A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Subparagraph": "(d)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
},
"r619": {
"Name": "Accounting Standards Codification",
"Paragraph": "13H",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Subparagraph": "(b)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
},
"r62": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
},
"r620": {
"Name": "Accounting Standards Codification",
"Paragraph": "29F",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
},
"r621": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r622": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(1)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r623": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(2)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r624": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(i)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r625": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(ii)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r626": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(iii)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r627": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(iv)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r628": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(h)(2)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r629": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "825",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
},
"r63": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
},
"r630": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "210",
"Topic": "946",
"URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
},
"r631": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "210",
"Topic": "946",
"URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
},
"r632": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "310",
"Subparagraph": "(SX 210.12-29(Footnote 4))",
"Topic": "948",
"URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
},
"r633": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "310",
"Topic": "954",
"URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
},
"r634": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "440",
"Subparagraph": "(a)",
"Topic": "954",
"URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
},
"r635": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column B))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r636": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column C))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r637": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column D))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r638": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column E))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r639": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column F))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r64": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
},
"r640": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column G))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r641": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column H))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r642": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column I))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r643": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Footnote 2))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r644": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "310",
"Subparagraph": "(c)",
"Topic": "976",
"URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
},
"r645": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "310",
"Subparagraph": "(b)",
"Topic": "978",
"URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
},
"r646": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "985",
"URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
},
"r647": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b"
},
"r648": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b-2"
},
"r649": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "d1-1"
},
"r65": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
},
"r650": {
"Name": "Form 10-Q",
"Number": "240",
"Publisher": "SEC",
"Section": "308",
"Subsection": "a"
},
"r651": {
"Name": "Forms 10-K, 10-Q, 20-F",
"Number": "240",
"Publisher": "SEC",
"Section": "13",
"Subsection": "a-1"
},
"r652": {
"Name": "Regulation S-K (SK)",
"Number": "229",
"Paragraph": "(a)",
"Publisher": "SEC",
"Section": "1402"
},
"r653": {
"Name": "Regulation S-K (SK)",
"Number": "229",
"Paragraph": "(b)",
"Publisher": "SEC",
"Section": "1402",
"Subparagraph": "(1)"
},
"r654": {
"Name": "Regulation S-K (SK)",
"Number": "229",
"Paragraph": "(b)",
"Publisher": "SEC",
"Section": "1402",
"Subparagraph": "(2)"
},
"r655": {
"Name": "Regulation S-K (SK)",
"Number": "229",
"Paragraph": "(b)",
"Publisher": "SEC",
"Section": "1402",
"Subparagraph": "(3)"
},
"r656": {
"Name": "Regulation S-K (SK)",
"Number": "229",
"Paragraph": "(c)",
"Publisher": "SEC",
"Section": "1402",
"Subparagraph": "(2)(i)"
},
"r657": {
"Name": "Regulation S-K (SK)",
"Number": "229",
"Paragraph": "(c)",
"Publisher": "SEC",
"Section": "1402",
"Subparagraph": "(2)(ii)"
},
"r658": {
"Name": "Regulation S-K (SK)",
"Number": "229",
"Paragraph": "(c)",
"Publisher": "SEC",
"Section": "1402",
"Subparagraph": "(2)(iii)"
},
"r659": {
"Name": "Regulation S-T",
"Number": "232",
"Publisher": "SEC",
"Section": "405"
},
"r66": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
},
"r67": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
},
"r68": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
},
"r69": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
},
"r7": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
},
"r70": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(210.5-03(11))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r71": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(1))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r72": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(10))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r73": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(20))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r74": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(24))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r75": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(25))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r76": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(5))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r77": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.1,2)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r78": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.2(a),(d))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r79": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.3)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r8": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
},
"r80": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.4)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r81": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.7(b))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r82": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.9)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r83": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "8",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r84": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585"
},
"r85": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
},
"r86": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
},
"r87": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
},
"r88": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
},
"r89": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
},
"r9": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(1))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r90": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
},
"r91": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
},
"r92": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
},
"r93": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
},
"r94": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
},
"r95": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
},
"r96": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
},
"r97": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
},
"r98": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
},
"r99": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
}
},
"version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>81
<FILENAME>0001127537-22-000037-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001127537-22-000037-xbrl.zip
M4$L#!!0 ( (&#"%4@=C2=BP@ .TF 6 97AH:6)I=#,Q7S%X,#@P
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M\B"S!1ZY6.J:NWG_N8YVQ=4]*^73_TIE6?$_!',_23O]#U!+ P04 " "!
M@PA5M.-Y3Y@( #.)P %@ &5X:&EB:70S,5\R># X,#@R,BYH=&WM6EMS
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M!7JT,Y(B8A_O.M=S/R>O>[7BFIN5'NF?TCY6_"_=W&_N3OX'4$L#!!0 (
M (&#"%7V=@8:QP4 *46 6 97AH:6)I=#,R7S%X,#@P.#(R+FAT;>U8
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M2W3)8H [/54E_XT@NX\&F:78OTG9Y;A=2((" GRK@[;* &&ZK;+#KBDSB
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MNK>K<XD6;5V!WHX$&MW;MRQDAIMZ(;=9/G-K6CW+"UQ]E7SR%U!+ P04
M" "!@PA5O H$'K8% !W%@ %@ &5X:&EB:70S,E\R># X,#@R,BYH=&WM
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M"IG@]IVK[2E?N <MG\65K+D</OT+4$L#!!0 ( (&#"%6'OM,9Q3<# $H4
M'@ 1 ;'5N9RTR,#(R,#8S,"YH=&WLO6E3&\FV+OS]_@J]['O/[8YPX9P'
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M#RS#$6FE#XQ3)["*R@JZ>( ^F4^;/;B"$X^01"@ZQ((/QIG@B0S<6L:C"C,
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M04L:%5/1,64\-Q5()EDP65Z2L9\O:4-%L#Y28KAA:?=H@A!Q$6'!L+1Q$<;
MJB7+2U[X"Y$I0C)$CS'WY80$$ W'0T N2F]#6,KR4GR^90J)#E1*2S2V#.L
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M/N1K[\*1:6V5[W,-M/>#5KO;.=^&SRPZ92D#T]HS16M:TO)M$7V7=\).?%V
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M,8=#=I?H# K7!,%,1<?S?KIYZSSMIP+$8!)_79VZ%OSMA>(T=^%R6SF,#
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M'70'G7FWLK^-/>F+&K"AUB %]K6+_*26<LI>U$S'U_JA%4Z2"-0ZI0Q<O]*
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M K$9=7;7'H=RH_6RO?;EFLMRCYKQ V\]Y=K[E1UJX)).</ (4X"4UGPX24A
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M7DK;7VK3; JHU0X6X)PS2"7HVO%D>GD%R5.2WP>$Y\R.H8V2@#&P%P.4TVL
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M-*,"\?3U R^*)0I,VFFI3?LI:56@/EX$+B<N[DJP5L.HX0TK7,I',D\I]2P
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MNB;K6BJR1A&,3=7YMNA)U?D5Z_P")5%..2-, P8 6/1?NH-N*@%<B<U\:6:
M0O6%(&NA\YMP</NLO&)JOYR1E<O/XE_!=]I4V&J+JIQ*Y*S>ZQR.U<$#UX6I
M]\O41 89B;= O,S4Q 8"FEH%T7JO8I">D Q3MZ_YNI8ZK%%L9%/UNRU:4O6[
M9?U>+.I$H:RAI5N3927(Z<$I5,#066.#<X:+K6V^'OJ]"0&3?YWU!6\G';,1
M"> 5IV/.]R*N/E-;8/5Q>?J((DI2+H'1TEK.E %(C' (00H23-(VX=:VZ"/M
MTLR"6L[146Y1M?ENM7F!>H287"#2@P[6 4850$N+P 5W7JNH-!5EEI#&6Y\G
M[U[QQYIPC!O7A6Y$:KBU?$M>[U)6]BRO=D6?%:#/MR=+7$)H9+; #:$^HP\)
MF4LD3<#%R(-WT4I3CI1@'^6MXZ^UO*.[.MQ:_J3J\.IU>)%!^$"\3 J"MQPP
MV 3:4@[*!$\3M8PH;'(HG'6I)<TFA"D6AYC5,,5=3S(['RBMLY)N!CG+G4*C
M)(YFB@!!:@OHB 2CT &1$HG6K#2L*)#S /N$5CU=R3BSJJ>MZ.D"-1!$4&8$
M@G54 /)4CI4$ YI3K0RBI(YU34\W(;0PK_=LZ0S)IB975U#G61V5]M!HN7>F
M98)(YASXP!6@Y0&L37D[&YM$"HP;:[>VD?1%K:2HRK[R L^J[*TJ^P+UR.(1
MT7H)Q.<?F(P"1R7/RAZ%C9(SI7Q6=MHWK37*K645MS[C.CHZ&DR/8IG<4B8O
M%17,UQZ'OLQB^MON:!I[^O]N,W7IYS(Z1<?5$($OD\'CX>#P_]V:CF=QN2?.
MV>T_&8:GYV^^HL 54&"YL25-WCI4 2*6^FY'-%@6'!"A-?>4:&]I4; %_;^W
M85RKV)[7,5UU>ZYV>R[.ER!2Z.0(Y.5'P.P3@R[-5Y.F@B6TD:ITZ?;<!$?U
MHM%[\>:C]]9F5-O?IZ75=/Y_&'S:_D?^<?I9)ZNC6%Z^X]%D4/;#XW$\M-/!
MI_C+YT&8'IR2VW/OFLOP,?G^%NLRMLRFE[_ER([?#X9P\LXR8_/\1O$9!.+X
M[C<%*Y=)SV3?K,[YGP=GPT&/[?L(;ASM1[ I7^MC>_C9?IUL_?W'N\RW>'Y)
MK[X:E]][2BN[][D(LHLP*B5368QY3\5Q>56^'-N9:^D=C(OE^9^!TN@L2YQ1
M$K D]!WCBE'+O1"<&_5.;6WOEYW>&Z5>,2C%MOSC[W;[(@G_3!R-RGS?\8TA
MS4MQ:(\G\?'I@U_"8')\:+\^'@R;&VK>],N/GR>6YY$V]SI_^F2/&/U(456V
MR0D$GWSQR0YZU.R@!<]A_IQBCRC%2Y\FC^BES_W5QU+VB*"YT<?^]7.2WNR=
M?WFQ])%B\DH?>]=^S[EM=O(14%[_V)Q^QKFQM?=D%5^.3T_ 38I][/?^]Z_H
MX,LX?GU@Q[&5\.6+W=\6:>'9U33&^J4=[XU?3^TTAG_;PUG\_NTG 0U2N>(5
MN.*?TYVG/W#%3^'W?V/X__YY^)8=?G(?CC_L?"MK\OSS[H?G],W1'V3W][<'
M>_OO\^,WG]_^_NKCVV=_?MO-O^_^IK_N_/%.2N32, ;44@N86#EB(O.OSD5&
MA$@^TK]V*R[91S>+C-5]M*;[R =CG O9HX[4 S*+8$UTX)76VC(3=,C[B#PB
M%S1Q6?I#[]B.>Y^*>/N]2[?>I(A]<C>[KMEBDR>SZ<%HG $Y7"U&6[?BG6_%
M;[M_O&,A)"6#AZ"E %1HP3(N(/\I9.;) ]/I+R#MPGVU(JM8]]4:[2MGDW2>
M89:'-(#("#@>-2"-FMG@I. V>Z&DGUE>^>\*.#??:SU[M@%^N2;>K71?[LVF
MDZD=%J[[TQ%+=4_>^9ZDNY_?$43.*==@1,$Z+&.Q8[;"CF!$:S5GGEP7ZU9J
M0U],)K-%G*O;J2O;B7,C0@H$B K9&T GP%%GP5-B)#/>*/M7WL#=;Z<*49W?
M4]J2))EGP(-,V3/P$1R+(F^QJ(C2*CFJ.D7'*D1U>3MYS[QT1(%S)$.4#@XR
MLE@(U!'F7%21B*WMX>CG[.OJ_&S0[(BF]&#T'7!Z=E+BT_^<#>.\,(23?J_L
MN^:%SZ*/1RZ.3YZBS5.+*8I:O+VBXLD?];J)%-4IH6TI].(<CZ2HQY2](2H<
M8%(:,N^D@#()2W1$@K9."=T Y6VK&+(J[PJ5=Z'41.LR\DM%\%)[0$<9:",T
M."FDM4'KIKMM]Y3WKJM<UB#]5^JP1L-.Y/[FEU(3-NUI[IN?\NC\_61O_SEY
M>_3VX\ZS)^0-R_\<[7XH]_F&/2<[O__V\<V'CU]W?M-?=C_\(78^O.&[S_[(
M]_L$WTGE(Q7&00@I I+(P1GIP!C&HN<9$8*[WS1@W5+KMJ4<,F:,!\DHR98E
M$K"*A+RO0C8UG'E!UBHC>&X#UK3->N[*%U_?4>9#-):#%2X[*WEO@.,6H8PR
M,TRY(!G>6S2J;K&'L,6,%8'ES0#4L]*%0)-,J5D"EYQ&FQ2Z%,K B%LE"F\2
M?+JWY.+2OKXHQ%KW=%?W] Y])S)F*IYADXER(L$$#]:3!%XP%WB*A&O>'=B\
M-"M4]UB']YA+A)G %"@5*6",#$PVRH#>&".45+$D'[GJ,RG[A%\#-F\2O^\*
MRZQ0N4[;^ ]\A\$(%E" +Y,9T$0/1GB?H=(PSK270<1[RZ%7J'P0>\Q)IWC>
M#,!IC*7$T8!AP4)P1,4R'<"%,AA ]DWF?DJREJ"R]9SF1C2Q;"NG>4YW3W(B
M-?=Q/95</ 4>@B(FTPSI4!:D%J 5(A!G51!,1LU8B^,UUK2UR\-6SK9REE4Y
M;ZN<BSWBF*/2>UZ\ 08H$LTF+L7,JEB04A8AZ8XI9TM'$N<ZQAXQT?%3^$_R
M99<EMX>]8SL(,!CVO#T>3.UA[2*[:C+P?>U?YJ5_,7PZ7_AS,%3[2+4'3\M3
M@7725D>3*;=&7@)B$8RE"4Q$P3R+FD>UM8V&]:6X]=CR6O34785NBT!4A;YC
MA5[@&RX[T2G)")J4GK0Z/W*),_!4><4-S9S#9(76K*]UEP98M50(M3ZDP_O9
MT>RP%'_T1DT?>S\Z.A['@SB<##[%WJ"915G'XJR<@'R70],I^^EY*<P'@OYK
M-"EC0/?2OOU2P:L]\%H>!*Q34CJ@!\&( U1,@L'H00G-J#64>NNWMFF?BR[Y
M2S68T54N4G7['G5[@9BD9*77BH!RR#(QB0&TLPPR5OMD,VLQHC3+[RNZ'.:O
ML9#[H"4AIH$?W&PTW_KZ3'^[$Q(RR?>9'RTBUJLXM?F*PG,['N9UFYP3Q[.Y
M-"I(M0=2R\-_7528(HD@J:. AEEP-A#005%GD%#.^=8V9[2O)5^"J:76S342
MLHY:?7/Z4;6Z&UJ].,(O4<6#82"<5X $$8P+" *C#HY+Z9C>VF8F.Q9F.29R
M+UJ]"=V/YV-Z)M?O@7R;01X/?Y9'6Y&1\\VIGS<"J2C5%DKEYY:XAX_."4TD
M!"P]D&+IAF2C NE$C)1[0XDJT\18G^JV7*0KJ\D:Q48V6/7;"IQ4U5^QZB\0
M%'2):Q0:N"_-8)"(3%"4A(P!/#G#B+%EQK#A?<9O/4SPKE2_U= )N8#++)Y7
M[Y36+LT@;&I1KTYVKCA*Y:2G.\_K%$:STB'^]-9N!X.=(XO_>X\+]&#LPPIF
M.CX9AFHM5FDMEL=#RRPK$26"S*00,)C2Z]PH,$19;8@NHR>R.TM97[&V1L^V
MITWW'.>JN%IQM;.\N^+JG>+J @OW&3(C)PE<!E) 6G!5. E$.QNS()EU!5>Y
MZ%.U'/Q?5US]ZX%<UYD,M=*I6/L'L6=]J9&RPZ_E*-=P-"VD>IS_/.P-LC*^
M'S<%W.-I.>(U/8B3F%76SL*@Y#++"\:#HZ*VV5^8Q&;X9K.83:HS#89VZ =-
M.#+_H1D"^.C' V%U2MD/\F"73RDK-] T$_G8Y5S276TV6:/-KN'':TNW-$O
M9X='H^&7?#?CXY.5N10!.GP;3\\0[NEYA'M]AFM%8GO'<7Z'\[#$#X51O5(3
M=>F==^4V_S889I ?S?)GA$F_%[_X6,SCP=P@A%Z^P=/?CK+=G4[^K_NW=&:N
M+K_6#HP&S!C[B,QQ]KJS ;EYI*18Q6Q C6P%LP$-6\%LP'JQJ[S85J8N_C0-
M999>>H&O/P>3N_%I]<\09AZ4SN8]]G;RZPXFO>?93H2F;4R/D_X5!@X_U%5Y
M/?ARA36Y[98Y%[/ZZ13T>UXV=:5E*Z'BJXRIOO+,]XU8,MJ&HEUA8=9Q;6ZU
MG=K:4>NX</0Z2/4@:L=>Q4]Q.%LZ'[?:VI#.K<+5@_?7OO\'$YNW(1F!04ME
M/::4C+&.Z1A0.1TC\^^>-3E/)!2NEOP\V7J_C4=')?!1+N$_@^G!T]DDKT<<
M/__B#V=E'9],)C'_&];E9-'7G<%IW'Z'[.V_P=W]CU_?'OW[X^ZS/\3;#T_$
MWN^[ASOLS\\[_]D]VOW]3[+[X=>/W^/VKPYW]Y]\>[/_A.]\.SC<^?;JZ,W1
MG_CFF__\YL-'\O;9;Q_>_N?%M[?/_OUA,6[_]O=\#<]V#TJ,?^_W/[_M_OYV
M\';_X,/NMU\'>_NO/N;O.WSS8??C[G]VT\[@)&;_FGS;V]_!G<_O4D N45L(
M0FI JV1I]TZ!<I4LER%%7PX-\KX1R[T6.UH[TU+97(7#"H<+<"BDXS1YFYC4
M: VW&BD+CE!+N<VKTL A/85#6N&PZW#X;0$.M>%12,_ "<H!1>FIF$HC6O1$
M$Z:MER+#(>LS<NLD9H7#"H?K#8>64JY3"%;+B,(JQX-TQCE.DN'"LQ-V2"L[
M7!,XI MPZ$3PUBD/40M3V*$#1Y�*>]=C9A&=_"L*_XK=OA5#BL<+C><$@3
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MMT_C5XWNKD:OX!Q4U>B[T>C%\)D2QJ5 MA $Z A#+3@ I(G0FG%L^7./K3J
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MU@10%L,HUGNI%&> +B!@2!:T- 8H5RP&X91O9BV3/I>U85 %E#MK$% !95T
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MIJ+!R%K14"'@SBH:*@2L# (6 PH\>4>(#> \M8!,2K":,0C>"U32!$-H4X.
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M?3C/A[.\1%<9LCD'T!?#D^#F'#WW1Z_.L+-2AQMZTV>'O= FZ:D&);T"Y#&
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MD%VE5*54I;0Y4NJBC__DDQT<%EN61N-)IGNOSRQ:)8NK(XM_+GOU2=#2XU>
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M$AR9)*A5@C*=<P2H;6TV*8UVDR=@S:$UMV>;C23?LR0OLDTJB571,,3+,=M
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M1+H.(JV(B=!<F 09(IY@8J ',_9UZ51@IN<>8)L[2J^'+37&!B>BM"NG3@T
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MFUOU)KT?Q!)*/@M6+ZN9:<ZOK0^O#I8X2#3":,P=LEP"7GGGD8V:(BFX%L$
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MQ)P<VWFDC//,J4AA1K=V%;X-&B\V5X?MD%)?*<&/+6*. +Y -38/31G.4
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M OJL2%\3*'0)9E(6HK/6:Y<,=XH8$;52)"G#G,;.?7J=H9)01GYLF[JE>MD
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MI*,A*@50>"SUE6;;X.%CPL/%-M; L MT5"7%*)-!=[Y$DS$:*HR2.Y0J)
M>MNPY<RI&XJ'S\"F]S:"I/IVIVV+$.?T!5=FQZUA+\MY&7>;/W2V4Y(@#$YB
M' Y^N5&Z\&7?.8/9"[U1+DR[.+DW2O=]52/%W;1RG6DRJ-A1&WZJ],557?:W
M/@"_:3V_-B]XDEO_.E6A4@QU;D_?&[ZP_?X%C-I_;&<4FRU^;5O\T7*A'V]E
M3M=A$&;4(.ZXRP'G%#DMA#!:JV!S?"4EVZ ;= Y_GO2:AJ VIRN/9!NT@#4
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M/,V>:$CM;S&@[['?:V#KNK!UL9A2%3,&TX>T*"E5E005ER@4@PT^"BK@KRV
M*$T)_76#H.M)90F\0OQH: ]\IS<8]>,X76 K=7KGP"<KP<BQVK=)_;<I!RON
M/'W?(U H2OJ^,]L.14-H=WWO-+:&]ENC&#R3G7?MBL'KLH:.\A+*?KG#.&PV
MSFMMG,N'H7'4&JN@4 HJYJHR!IED*/(F>,84\'V"MW8I;?A^@SJ/ W76SO<;
MU+D]ZBQFV]-4!4$Q$D'FRJ#&(<UM0$G!CA&\EYC(C#J;%)STS ("%MG;,.8<
M.XV__UFXV>Z N57KIP'0FP#HP;*9-D2B*4Y(XD 0'/)!$X94A2F*&%&A.!;
MNTQMDC^M\>PWD'.OM*V!G%M!S@)G<YF<.:V18#2 IJ@TTH9I%+!+%GMO;:[2
MPB3>(,CY<;Z2ZR3.N-.D(4<GL1RP.85WYWS?K6YO"$^W??BX6[C7<=]V@(WU
MAW4UP4$$6;*CT!X69SRL]/9IEJ<0NX.< W$V]V%J=VW7M^$!@R%\D"VQ@YWY
M)!9-$I>Y^5"7)W')'2CP\=/T(8QLW6_F%]DD?KG/Q"^7S@-[D)6\Y'RAU>F^
MSFFO^PVZT3^KA^01]N*PP.&PUWI=(]V+"=*]F$6Z5Q.D>S=!NM8_WH^!\I]7
M[/JE6/1HLO@8O6/PY5^OR&"S /\_3)I6=7P\6)=63[M&YK E(+MTZ>W^E^O_
MZ[(43.M>G5?:+%K+J^J*&P3?V@Q2LEKHR$[%VY9_UJS^<'0*3_9KL!S,$_=#
MFX]BO4EU#$6)OGU(QO[]<,S83_\2\'QR^#F<'GS^3_O-$;SG-+/OOR[>_/T7
M.?S]_??,U@_V7V7&WHG__?;BX]_AS%$N/^Y_N3@X>D\/Z8>+P[]?B\-]X/[
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M1[J>]*4)*.;/U?O48B=OB#IYK=8P4CCF&$CR'S_8 NMFVR E;06O*T6)SP6
M_NV6%3LLQ_._QVKO@#[T01ZJ@5RU:HNTK6 (90U6!_U+*T>9 6<+;/Y[ND3'
M0PQ[&>Q)\!Z0^GF1@CT2FOH%=OI>SKPS*NZ$W&[8E*HAN!A/W01J8#;R.\=T
M>W'LQR-1;1J3:<S"NSA[Y?[5,U'>L#QW"T+WKP67<!-?N( >BWQA:J)+VSB
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M&8V$ I-J &I# 8HL )3C/BCA,*+5\3EBD0.&G-V*Q@JCG56B :@&H#:B;]<
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M>! H6. #UEL@=: *X&0C\('H H\02)G](@B!@#XK5W.MS5ECP()GD-:B%+V
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MP?X'?GC\*26@E0QD"E-M$7=:(QU80-H1KPR5V#"]M=OM+8E7JS,=^]9IM'G
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MAKM #,%$$6I*D/+J^Y)D,E! ZDL5TH"$2;<^A!,8"1H\;-MZ=X7BS$[FIF;
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MZ5F.%M+&V7PB)A<H6*A@WF)@W@N"O.*$>P0H''?"$265%4'E: &4"@<,L$9
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M)N&]8B#,+!K$I>+(&BM@?D4BW"47G8-=95EJ7D*FYB]D:NZH=[G&79QQI=7
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MYVDOS.*QL.K+!+/ 6L1@T=*.@)813RR3"MXY:V5E',\:/G'S8/+\\^POD&I
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M]O><]\$ 44 FAQQ03'2@)2($*<3BY2[9%]$(L#?M^X$?-L.5+62*% 2!18V
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MOHSR%4,8T=.JB6!%,<XNE]V&%QB(;;7ZMMD\6<YC.&H#JTB=^-\^?)3?^WD
MG"3^J!K#PN?^(+=<RTT&:[[1 =[8[5D@*?F-S')[%5V!2QS9$Z S%VZ3!]5I
M]_</IO9A'_SHG 2UVK>Y9^_ ]LYN' ;_S&S)VT[G)'/U'[;9CY>F,H^KU>[E
ML66B]2-V\D%2U2+>9J])O]E;O@NK>CPM+E3\AE9>[_C6VIYVR=N0"[KAI'*@
M8$"6 S9[Y0C8BM8SAZ<J[$4- 'K[,?*@9.%HI/U*U0[XFW=ZV,^MM+[_:;>
M[Z+T?B^]W^>M:WKI_5YZOR]R[_?Y[>5^Q],CD'R@C(TL?VM5#^VG[+KZQ1_$
MT,_V%F@8:-)?L*V'\Q$-!E1!YB*W807N9F%O8Y8$E%3(WI% D661($9S=VCE
M@Y3A1;1AO2!N@Y;MB]Y\58@5KFZ'J*^[^>J+&NSMNN4^M"TH$2^S,>:H56QM
MHD'H[!JEWB5X=KYGJRKV4'L[<L3\DQTQM^BJ>JL)6*B)O' X6[N8EUHF\QZ3
M68^]ZV1R$>I-K,<?L=D^SN[2Z ]:<-?]D]+GMO1]O#%I /.4LCO*&TZIT"D?
M.2>3F D\.7';W,MK3**%J0^TSW>__0-C@>\<[L(X/OW://WSH)X-I^WO\%NX
MUW:SL;7]^?MXNM#6^D%S]]O'1OW;#JT?;9+Z^KO3S9P>=/CY8 M^ \]UL/5M
M0]0_?)[6Z39AIK#@V<RR"7'/# (9QTB[X%.2D2HNJNJC0K^4SH^ETVU!O$<J
M./($D'>!W%WD=@4$9PB"$QWHO$[4<(.DS#F3(6!D"$LH15A-FJC"TF80Y'(R
M9_+.I44*_A7\FZ<'GR_XJ]+#"YK=!<W(&)HI@H.*-H*X$(XXT1PY*1-B'!NO
M0#!IRIUQS8/SOTLK[QE6J.[8$(]LYWOIHG4E_!CA5%02&RD#)Y$:Q;@6 CO!
MI=4JSL[@+ !T>P":K#@M'!?!:XNH2"';E %IDCS*Z\4B0%$*)@/0/+7S+8VR
M9FTK/8&V7FDK%?V]B_Y.U(RFTG)%0'\Y!0)AC$?6"2 05"LMB1?")=!?:1Y@
M#!757>A]MM#\.VOI.,T/,5GKHT"PV4K$'0[(D210L#D7T6C.JS9VLRJ;5XJW
MWZ'53*TQ'OYS3Z.J%.][@@EZ-< ]JVJHY43NJ7"]/EG7W@?'K/0&.)?*U2FB
M1%90BQRG6,5<Y9I5)W*:3_*O!SEP7D!%U-FXK NH+CRH/D=7D7+H]ZPX.V[E
MIH15(#XAF:)'G$B.G!&Y%",G3 II$AE$/K 9]!,H$%L@=L$@=KX0MC@<[@R8
MXPX'*G/Z#4XH8)=RE(1 .NB4*Q%21S57KFK 0N2KH:5WR;DK^3@O-,7E10VV
MY.-<%\L_*M-7&U7H*SDY)2>GY.2\N,DL.3DE)Z=$:-['DHK,.X6YMC)9[H"7
M>VZB2 PK%R.Q\;;M>\H)P-;1#ME:S[^K-^JY?<_A)P;W:M3ISBD82$?UH]WO
M]=./!UL?-L2XH;5[^)77M\%(HQMPOYV3^KJ'Y]I@NX>;>/?##MT]@FL=O>,[
MA\UI.3F&<A:Y-,C17"Q2FXB,#111!S8Q)39IJ4I.3D&\UXMX=W'//P'D+:Y[
M_NE <-P]+[FBEI* 7)(:<1L,THIII)UTQ$EF=2!53@[!)2>GX-_KPK_Y@K]7
MXSM_.C0;]YUS2[' U"#I T:<4XVLPQY93ZDQ"4>C^=(JY2^&T)6<G!(K7+43
M]%(P:FP2AG-/HLY)9F"L4)Z,"43-SN L '1[ )J2DR,$]SY8Y)0.8%,FCBP7
M,1<U%\9I*JKV@R4GY^4IZUULI2?0UE>=D_-T^CM1HD!)QI3 2!/J$(_YW#W)
M@*A51&$E?4PNY^1,AON7G)RY5=WYTMQ"\^^LI>,TWT=&F4D*=EDG$:>4(&MY
M0H(29A15E$@!-/_!@=LE)Z?DY,RO^Z7$-CZ\I6LYD7LV7)^2DV.3]EI;@PQ.
M&==Q1-I2 >PK")VDPX';DI-3 L8+J#Z1(?L$J%H._1X?9\>MW$ Y]=PY9+C!
MN<]];I.I%&**&Z6-#%SGTE7+0CW$SBT06R!V,2%VOA"V.!SN#)@3M?X"%8H'
MB@2F'G$>,-+>:<25B<Q[8RCV2ZM4J5=#2Z?DY/S[4O.F^>P'=)%"U.*OX]Q\
MK3;H\)A;2K:KGD#G'HK<K*T'BA%J\+KJ:MJJ_>]=W(72,9*\351J;@VSFA,:
M'":6, M+.6P"SJ]H H[$N!I?'/]6&M?DVY$B^3)U_ $]K3[]W-S?$TKYR()"
M04N%N,[5U1-,O,66)2("#\[<L0QK,H+GJUG/4TK&6$=U#%PY'2/UPX9D_(H&
MLV5Q9[BX"79%AV-"R@>". , =BY8%$(*01&OL0I+JWAE\ESU"D0&[&GF]1\V
MFXW6'XQ:AO4..C'>JN7SQ-MD.7<R/HX^-Y1MGJS4[HU'=T$ADK@C/OA<)9AC
M[32CRNHHO+.)I("'*$0*"CVJH'X]J7_:L]A8*8E%B3*6!54@YZ-#T;/<R-4*
MC-G=4.AA;:[+XLYP<9/FW"?OD- $R)_6$IGH/2+4$I6T\]3I!Z/0;?O-WP@^
MS]%YLWU=Y\WW_5Z_$R_*W[L!(I:6G)_VG/$)&VH0$ J#.$T&::8"XH&D)*U3
MF*87T9)SL,HU.VWG:W1KMCOLR5F]A"UWBG@O1JM.S5>,4(^3P,YFD<!^GT/I
MPWZWUT@G<^6.&<A4)QY9P": V7.$O;,S<P&\=*_3S_84U<4F-[;/E<P! N6.
MU)D[[43;>27.N*^\OO[Q^\[V]U/X[>GNX2>VM>U%?;U^L/EA!][;I/7U9G-W
M_?PW9\ZX[7V\>92+X=1AEZS#/>!WI]]AK/",A_!\ISMXZ]L_WS?S[CB9M^F$
MPUHQ!;:@3H@[$8&%41!C(T+NI.8#54NK4T+T[N>+*V'\MT995@+XYPM_ZG#_
M[9^Q^2-N5OM=@9Z[0,]D>#\8]IH+)I"T'JBYD!1992E21@N2@L0!Y_!^.EG*
ML$0>/C+V\'MASVUI7<&>.V-/ICK;/]L%<NX .5-BXIRAU 69$ E<(QZD0M:+
MW#0Q,88M=E''I57VX(2B%\QV+G@$AI= G8'FK(BIUNFSQD=/<XQ<]G#<=G>X
M]I3XZB/B5VW$SG)JR@:PB$$F3X3T7R:0GK'@?6()!<XMXEP*I+DW* ;,*==$
M>4=F4OAUACKR^L)+JBN^:0!2-_SU-?3HL"!AIQ]#[:^&=8UFH]>(W><X=]E*
MPX%<&,?"GZIL[N_Q))/#2B K<E"(%Z!3U&-D)"6)6$Z4$"_B5&4D9\WS]<W"
MU&UT>Z.XA<&Q2G9P+\;YB<(KE-RN4N_KKE8\D\.>.U1 ?5%%3O/Q8HWAY5M4
MB'VM4W"Q7O,CE6I^4?.1-],%%H>[5NQ^%1["T?X9CXZ;[9,8:Z[=ZG?A^CF4
MQK>/CAK=+E#I^R8K+WI.QR*E;,S*FAZ*Y)\#07S;[W0 *A8A[VWW^^;IGS"6
M3[B^#M<[_?2K3M^#U;P&UW]'=[?KW^OK:Z>[Z_[7A(5]].ET\\/'1GT=Q@=C
MKZ^_8SO?WHG-=7B6[=WF)H7WU^'WI^^GG1P+%C!Q!BQL0CCBB7)DK(^(.Z^9
M4CXE;Y96V3)1,\XO?BVY;07F%@?F9I695F#NL6%N/+W7&$QD"@0Y1W/+ZNB1
M9<*C:!.)6FIM%5E:Y<N*S^K4J-3!G"%%_6']]3U-2C#-;!G8/\,)+]@T:VR:
MC*#!(IC("$9*<8.X%1H9[11B.(C@/8Y*Y>YVRX3Q.8JA*77VYIM<% U^/ T>
M9Q<J,D^UYTCB;#I9D9#Q#,0WD.0,U1'G@!2RK,5DQX 2!?>8^K?5.XB=FAW2
MB./8Z;9;K=@<Y)MFW]<@V.1^9;9+I-P=B$6U$N^&KL;/@^F_<#);8&K&,#4E
M;DYBH62*"6'*-.*P?,@(HI&2TJ48A)5"9:+!\*R: <R1.Z=H]*R)1M'H)]?H
M<>*ADS0$R 5BWBC$G19(ZQ"0XHR1I*/13%:F Q=SI-&+Y+DX[K13K,[1;+.6
MXCV9QD(80#-V8?Q]8>;?QX)'L\>C*?&:GB0L@&%$G 3B-%*D65+(2+!&=711
MX8IA4#9/Z4#%E3&G#*-H\I-I\@2S(,)Z:3#",4C$M2#($&:0Q4HRFZ*.L7)*
M<EI<&D^KAU]L513+_HK=Y5KJV)8_:'1C?J,*W/EG;;LX,QZ;8FSGV?_;GN00
MWS,T*H!S>\"9TGJ:!YRDM\@*EGVHT>8FU!'YR!B60F(EZ-*JQ/-4PZ"X)N:4
M.!3]?+!^3IQQ2*^42P'1A!GB1"3DM.8H2&4U<2K$R)96%7LP'2B.ACMIU\CC
M=I+9<"W:3O.D%G_%CL^DH)U@.&W_O=8^[DT+Y2TFRZR9P7I,$? FO&T?Y9.E
MZ@CVRX'MQ#]M-X:U#O"U_7@$>-0]6[@"4/< J"EA%#AY$11!*E"="Y)[9)1*
M"',1;$Q,R)AS1?6#"43Q/,RO&L^*0!0U?BHU'N<9-G)J-/=(JA 0X'%"1E"*
MN+24!QD\S=6"F2F=#)_G0*/1^@%2WNZ<U([['7]@2_#$([**9A^F9CCS&Z.)
M_WLT[P5Q[HXX6U/*";E@K?2 .!%CQ*UR2,M($;9,$1*\)L;G"F8E*.(5:^I#
MB4/1U$?0U'%ND$1@SJ2(A \"N(&GR$H34*"&,"=9BH$#Q1?SI*F+X(.H(H&*
M;^%)0B@GB]H4<+D'N$S&+F 27 +$1\0'E@\@P/!01".7N&(6!P-KN+2JY8/!
MI?@/YE=59QH;651U1JHZS@.$)58RDWN"<)X9NT7&6(PP89A@QKW6%%2UU!Q^
M8D4;5O.<K,OUC&U17W7R?>D;^WCQHR64_1%SZ+;7,IX/*-CI]].M]<T]QWE.
MTB?(8.41]UXB8X5#0F%B?%"<YGZ&A"RKA^?!SDU/V=*'N^#IO.+IC*-X"YX^
M,IZ>7,939;$GFAC$JEA\0S6R(GA$DTN>4:&L<8"G;)G)!Y=/GAL\O441Y?SO
M+.>-5M\.&E%>*/\ZU!5%09F.V]U&_L*;07/:'_&\/NN_+I?$'3XP/O^)=?!L
M_=[5/YFL,SM9(?&9ZNKF:MJ7:N]?^)N?H-)&I;FS-.4&KH&SX)VC3%%BF1>"
M,:/V<K3F\$<'G?.BD/L1N4ZTWY%-\(1O;/.G/>DN_?ORW,#$7%R(V\VAO*X0
M<4J/-F&#=0/4:G<J>7K3S]W-\K=@.'9NQE([Z&14_Y^;5TZ!(5<5/&ZGVMN\
M(;1Z8,#9U5O63&;/(LK32Y'_W6\>M5N_X#$ZQ\,I>8%/46_WJC;8M8T\B,91
M7I60RQ:$_*H"T:J8P?M&R[9\ TSP+SUXHPI/J?WVM67[H0&?_W[+1[\2C%Y,
M&6RC5PR^^N,I):#'\)\-RGY/)^>7-KFKM[%+''W*OG0=D%TI>JO_<9U_KT[#
MY^>MT#Y=<.7*@$=,_GWD'@#KT?76&UW?;'?[G7DI^$\V&T,F>=C\#FP1[QYN
ML/J'KR<[IY^/-H\^-G9.?;ZGV%K_>+1[^,_!SNG&R7C!_ZUOGP_J^?N'\/OM
MCX?U#SLG.T?PW],_@4E^YYM'NT? 0 \W#W/!_XU?6]L;>\8;2EQR2-H8<H_N
MB*R*'%%%K2<!8T?(@/L#)XIA+1-R'1/8V\8EJP5GU%DN%3:,6<,448Z,=PCX
MJ]W:KVW'SE$MSWV5B0385"EY!HT*PB:IV%A7B(NT;+!4-P_C\K#A;2J-D"8F
MQKTU\#.O@R&&"$^D?,96!M45;]]$HYK*O]KVMOO5,PU^.H-\N_'GV_D9_+5#
MW6K5WD?7Z=O.28T.FFW#W]P[(H=^VE853._[>7NUU2-5HOT%WNKDF/NU_4ZL
M-MK:;_DW_^]_- #2']7SGWU4O4G^^+WVL]$[J+VU+1L:<)V-HV,8,FS6?]K6
M]P'7.@*]\+'VVX7+G/T8MO^.S3']_>/\^G_O8,A+DZSA0D2!(Y>)VT1E,I[S
MR+Q3'%>&/,Y0>M&0WZB_OQ3<DO5ZH]4%=<\/]=[ZW+:^WX+W?+.?=SRP\V%K
MA+&\CS;W.[^=>2\7#91/UTXW?^Y%*6D@TB.#<P\[K"VR ,_(T!",Y2)((9=6
M&5VY*I\&=*%9P60+U@P0-PW(7VYU<E$*L\B>R="P.TK^$LC;G41(4FM%Y%XG
MPV.46G/-J";!29F3@:L]N1(A-$V6D!C?H?_NM'V,H?N^TS[:Z';[,/:XE?(N
MDI$ORUH1GRO$AV_N[TDC8PHZ(<&4!/$Q')DH*0I$F,!S,)1-8,FK&\7'AA]Y
MZ@'=>A7J9<HTE(_\3WN.;T.IVJXRCF-M;215RP-<R]\>9!EE> H=^W.(5!DR
M@1'W!B50[B)T@B@?"9BEP >YM<2$X"-.+ IE->?\/K@U#E* 7IUHN_$<SXK<
M39>[=WQK;8\IK@CV&DF!%5#)9)$VAB%&531 NH(29FE5WRAVX]+TYQE&Y>WU
MLLB<(UMO^.WQ7Y_ODB"V=]\?F12$8"E8B))SA9T)EL*C1",8CRD5.7M*.=L\
MJ:_M)2XCL\0AP@3/Y2<,,DHKY 36/@#P,8F75F^&M_Q_G=IQIP%_02K&J1Y=
M 1[9J&I$GDEBK=4^_]?;VD_;K="L57,1%BQ60!=_'3<&[J1:=KVLU.:?Z&[G
MIQDQ IB4!@S+-ILGM0.;J>UU!CE87IY%):-T#M:%.'@9$^A^%#:YZ*9N_I,&
M^;ERY"W^DOC#0_DWH=_Y"3K3C:U%D_G*3M_<(X)ZCHE&UD6&.+,4&0[;.[.1
MQ:@=%RDLK:;&CXA.HNV,F].U7K89CS+<5#OXI&4C8*\^:/@#((V9L\.N_TC+
M/@40_X8;M$/#_VU/\C\K5V;L]K9:S9,KQ>$(AG.P:,)PNO\KA[@!S#$1+!(F
MU^HT(! F.H<4F ?.A:"HS97]^(005'/6S1MA8SC%( F@YL>#>>\.>R+"VKN3
MYUO^OT%$?>/8-M=:820*10PNBP'=_+3G)>.P#4H488X1!W:%M*4&^62"4F#"
M^UQ0C<EKQ"#^MP\DZFSYX9WCT>179&LD)BNURUN$ XCIG@L1V >VEIIM6YF/
ML/G%X95A6[V2:P&K<;$S1K<(S9X(*I+!@0M.M5!>1$-HI%S'9&^P)2_PKNF[
MRY\6C-POQT"WPE;K']MI9*_[9Q@P.6-5B"Z8.-77W_VJ_]SSP)RPQ1X1&@SB
M A-DDH,_7FL/*Q&T EI%IM"J?]6L:_\8L)]OP!MJ7WI@&?9J']O]3B;IH-!'
ML99GN9*4UDFM!V^,RU0C=VAMYDJQ'=L$\E*!4+?ONCW;ZC4J.I*O/30^AQZX
M3.Z)^J-;LU5;[>7A[I7%T-ONP:!=77X!\MCX >O;RE^R0,#[6> [T4=X&V1@
MN9+F9C/Z7J42G?9Q[/1.J@ODWQYGZ1D.>>C\.[* G)T(VE.-",2_M9P'? C7
MR)+OX0*VT8*;P.\[@R.W"P]][AX<[KCP_/TN,,&\*6>U EW-D04P*S\B6#EY
MX.GL%._"F_''2'D#:$B_.?"PMROF>G[%3 !&[?M: _NINS+_U'2C55L#3&I.
M<[Y6\%.!5!OPYWVC U"T!C,:JEF%-\?FN7< XN</<GI^J*XTX$.PRIFHYQ]L
MV@XP("(&!L"($?UL]YL@C2"]_3R9U=%D54FE!_?*EYHT'D2MD2[? I:G$M]^
M+POT0$(O'(*TJG/<;%!<O*P=C*S5KHJW-&!!X1E:,$RX$1G>""R2?.')BPW?
M&<W0Q2^ V YJ&(Q*P%Q2JI7:&AC99Q.98KRK2Y"1$ F888HDSB5/%ML4A,8.
M:\6DIT.KF;,;/(%C?N58S./K<'Q[C8-Y+"0AC+-<%2&S0R+!,N:>H^"Q)4P3
MP9-96L4K5]4Z&9G'61:/;2,,(.M<'/+[0P %^<F%A?(; T?S$="XU!@T%ZFP
MY@XR@Y,QQE('Y%9SS(-57 ;A<<0.!$B:X=;/!T>[$\(S[G+Y -#[5[O;W6J=
M0<)6NBQ/E\4H-7[%@$YCI[W $O2)@@0Q&93!(#R2!((X=F!K:I*0T D62%@>
M,=B:K?:$ -7V\WX'$M&$B:\$!3;8]GXK[^8OP0\"F\U9\^?A?M/.WD;8C;MG
MV_EQN]M#V15^86>NU&"P65S<H?(, !;G<Q@/;S4;V9U^[2;V)>;=^?(NUIMD
M#-5.=KY19-_\V?6KPEY]&,GYZ. BH[[>^;G("UF+P6Z<!WS=G+4&LY6/*6#F
M/@-QJ@*>QF9LL#B7INSR[I\Z[:.Q_7_JQKY<W68 ='"AD51,868KM;^K#7L(
MGOFNF8,M7PV*0T/L"8YHZY7QM97&3._N&?3AA8.^[SB?88A$P;A58 09#C:U
M2\BX7,[01AY-!#)#Q$6;^ASZKC.ECYO][EGJVYG5?$8K0S_"?T#M6ID5#F20
MD9$3>B.#1ZL5![)R=IXV5>C/CN0N*TS>QJL& V>D&(;7S*!6T<D['?8F$F4(
MP.(X_"]$G1*7+B3A XD.LVJ7)I@-=FEX,98!,'G8.YRQX>8\/.Y]"R#;+31O
MJJ0>;N137JVTECI$I F6.24J)T?!=NUY2E1'IJ/PF>9=U;/TC.8-3!P0R6JS
M[E0R51&Z1K<B>=E9W+MDJ5?'<)TLLUE>LUS'+'R >P.X:S92')D4E=\YF\:U
M?G5V7)V0I!0'INV9+AS%WD'[R:@FSV'.1"5@F01@U!E;N= E!8,%$XQO$.+'
MH)H+A[>'GWA]?\]0IVS4'@D<+.(Q<F2ECBA%+*ARPIF@[TXU7P2[J1C93>1F
MFE?C2O2?#$$[#]$8Q)=E%;Z).U[+<\]\).?[TXN8["W?:P]9_?7S?14!O^6$
MKTU.^/(T[CEV_E*QL!%D5FA9T='KCF!4/NW!S+B8*#>$6 LD4 H6-9!#EO@
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MR>G:21W$)CJ,C7-@VA(-8N,"LH(39)VC1$K"M+9+JWH:G/QKM!T5W'B!ZS_
MC4][F.&H$C%@F]B$N#)@Z]H$'"V(2)TFFBI]&]Q8SH[[;NSE&>X=C C/D+P?
M=]J'@].M+JAQ$[AQ9Q#]-")%*[7W_4X.9UL>)SA#CE1]^\@"]\^.RWYK%#T7
MARRIT:ILA7W@5OM5%&(5170>HPJB"1_ER,,!3%4.OW#8[^8KO/MS8WM];>!G
MSOD>$2A<Y2^<1MI&4O[TPOWUPE-G?E7$^R;Q_KYGK#0L$8R\$1G?"!@>1##D
M$O;!>4%M$DNKJ=WOW'97S'(9AI9GB-FO WP_B_9*[0;+]D+(R*5PD8$C>1#A
M-S(8LCC9D11>EL Q,Z@4M+JIH)6ZNJ!5J4TU!V,IM:E*;:I2F^KUUJ::6MKG
M%J5Z'K=(U!=_$$._&<?C.+J+72]J;2\JI15F!"DC\VD%QPCF%1B43RZHY+%6
M?KS^T]PZ8\^/$X;53\Z<J(-$R*IB2D7TVWVX5^C^_N9N7N87@SS2K C%;H4\
M=_M,XOO]\KK!$KJB.7V$P7+^2(.]W<S>T ;BQ@XM#_KJE-+= P1_FA+5^B9&
M4<GU*(K]RGY2KW\*SA(4&+D\#45Z;IJZO-DOL.3D4(Z[2,S,V\Y<V"V'ET#Y
M^V_DBLK[V^B]SF#77A&C2S>RU=![@ZJWGJM]S2B.>8S#/GVCAD7OP[!(;1;N
M%XXRK67Y)9>Q[71.<E'&.R33/G.GA?O:.\-."Q\/=X\^X?JWW8/Z]I_-W>W/
MS:WMT-B%.^^N[_/<E6'G6_[7VNEXIX6=H_H17)?L'KTCFQ_^:<(]19U^A*>L
M?]]:WR<[WSX>[.9G7J^GS08^&>M&1A/&P5N"<. *\40QTOD\1>>FI(ERS%QN
M7*.60>1FVVCAM?2E*7"W.'"7L$A8$RLDU=PF;7W0R@>B 0)CL.*V764*W#T1
MW.$QN&-8R11,1)$FF4M 1J0EETA)I7$.&##>O#2X>^HFS2^9)?\5N]TW@_R\
MQC"3$^:LV^L^@#4O=G_:WYZ=+7Z%#]LP(:<QK ]30@M,W@4F3R98H6:)4R(2
MPD9JQ(5UR++(D*>6,88]\$1@A<9,0.3OMT;'TDAZCA7U<7A.4=0'*^HXG[%"
M>T<)1QC'K*@\(<<E1DH[)Z47WCJ>^^1-)B8\BZ86A]Y+=.A-;XEX-;%=(./W
M85,SWQO&,Q"[N[?0*/O&S?M&_>T$P<-)61*C1=KGKEK2$M@WN$6)*LM@U2)/
MN06'7#;XJOHLSZ$Q+\,C6#I5ET[53\^U"W8^$G:.<^Z@*'#L%)$#DHUX!-@T
MGE.D)%!NX9.23%38J>6D@?R*>U//;1#=Q2)S=VKA=)\\F%)*;J9I?E]SOSFN
M?*+ *9%F.0T&)X:LU0QQ8#',"QJU5+F4')\L03&J(C<J+EAEA<:JP$G.4>\=
M-#H!) ,D/U>W'O07R6E;*1=:OUVE.?C^(Q2:F_]J >N#5BW5L^4$NU&]H$')
MF,D\HFJR)NM;G17U.YN"^.LX!^'7JDR?0>Y<Y;$_6X9\H2D^_"JOXKQ+T'TK
M2%(KG2 Q1.P8UTII>,6PCXH !$0GAM'9_%)T]G5JOS;P>E7AXUOI_:@C6*7W
M:ZTS7UC!@"L"N]?$UO;77YO;.WAK?4=LK>WE"N%!L8ALLAYQ!2NAF<>YBZ 6
MP0)D,S6]M.09'F01NI]XP"Z@#)A%D0;%G5$6!L(46+[6*4XY'=9FY*/:C$4\
M'GF+V*=;G_88Q2RFX% R$B-NB426$X68DS01DBS.!02N$XGEW-/B> #'S9.5
MV@5XZS9^O19PT\Q(JSEQ. 3NN=!1*&D#=2(8AL_ C11P>P9P^XY!D@5ER@FF
MD+:Y7)\0#EF:,)(X*1*DP=K>!MSNU U#6!VY8]9YQU6 '2_DXS^0$ZF"%*-R
MLZ1 VG,(!:G_W*,T!: D!HS,B',--H.LPQX%HY)4@[89=X*W^:>7&^.(.4F^
MCX:%EY^5W8W&^6XPS&S9O?LUZBI^00^*K$^3]:WU=S]!OJ4TD7)!$/..(LZH
M1L8H@0CL483 *VG%])XP]P:]F?.X(@@/%(1?];4]'V +RNF;C'N'N(P).8H=
M8H$;Y:BVF-TD".'^=NEE!OA("#1S"E8$[V&"M_&K_FG/8"J)ERK'.,$.2Q1&
ML*V"8>F#,T$2&KB^P<?T[+2K",(#!>%D<W\O\*BQ5QYQKP+*ZHE 62E2*AA)
M$I%*N1L$(=S7=)P_BE9=\4VC9YL-?XN*&F\[,31ZY]5^YN(9[M*_<538I%*E
M066D7/;C__T/I?R/3G.Y9FL_#]K-Y@EJ_\SUC7+_ST9HY)+7E\N;+H\7[G^[
M]<_&.B*F-CY'@P)*7__\4OL"KTYCIYD%8NU#=@T,^G_&6O_XVE:U_B"-8XO)
M(>T^VA13WCFU=#)R9H..EEGF;MO@\"^8L*TT&/)[ZQO-1N]DT_[*9>K^;'<Z
M50F"M_88/NF=%%B9#BN?*,"*D<Q@(7+/NIQY@!WL+THQ)+W 3$L:*)$95L0-
M[7! 1KK=&GS8\MW:;W?:;HI(S(](L*U/>\0&KP707.44S5'6"NF@,?(N,T(6
ME<'I-B+Q=>7+2BWD8AV="_66?Z]5-:I& @,6;P>0[$,^FVI5L'/<:>]W[%%5
MFK#1:U2%!ZM#*9":]E'#UQH 9+XWPK5NU91Z]"_?[@ R_FAT^MVJ UC5\?4V
M"#J"M.NHTB2<>2I#E,J#Y!)N/+9!!J&$,PP8LTMX>!0K1KTWQ8U=O3IM'V/H
MON^TC[) =T<2721VNL3NT,VU/>)Y%#A%)(&[(LY]1(81@RQVED9@2<*1QP6Q
M(@C/+@BL_G//V, 5"0H)%[*9+AERI#+3253$1 =[V\.AJZ)35]&F8:?R*UF5
MB[:3NYN>'[U<.JS/'4P:57W**Z6OT>H"[VU.Z7AYOZUTO/#SJ,?EQOE]NE5-
M^;,VF^,%44$*SPJBE@8EN4$)JZ_MF2B)"98@02,(HZ 4.4D(\IHQF/T$BQ*6
M5GL_8_-'O*HOYH6USHUNLFATXU$##4H -X'.GS? ;(PZO\)>.&@Q=G7IU)MV
MP^I.]SO*4S@P88Q4U >>J,ML(A& /),;:Z=X9S_2F> - Y0* MYT.E/?_G0*
MVV)@5F'-$M+)&92[R<..*F'.L%5'1L-NTNKP4G_0R[7_X1GZVK%*;@\X^
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MUMHEAAW.[46)*NR=L#+R>C^QRXQN*UU$NBIN=]T+/:MO['$:HR(I(*4DX&[
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M\)M<F0;4_C) ]2FZ7A&A(OPB;;4DFF6LJJ 2 ;V&/R74P#I0026,0M]>)0U
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M[1^LD;]O\]?Y5C./]^/9SN'&Z>[VC].=PW:J3S9H4XH$< U\LGF1!<FD#98
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MOA6F%K*BPZ=6YH([10W_VZ>,^^?UHT_PG9\.ZLUO[4837F\>P-A^G>P<[K:
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M*'&>68-8S%6>#-PG1UU +C+IK?>6T? 2ZAU@2\4.U$'GC7\ -M.K:B^6:M]
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M+;TZ&8*E,^BU?"ZN*U_(Z_A>;O1B#<F6!=\H32H)3)3)>CD".X,%LPZ 3FH
M-5L1GR7 MRN]4ES?_'6^]75/1.(U!<X#%@QT1VB,#,,$.>&,C,0E;&16EL:&
MK!KQ9.+S).6_1W";5^\WN"S+&U:RP%18$@7ES%)'E*-12$FB5XF)BKXLQ?(^
M'UO>C&$,7BE%V+M<DRH8T@I;E(CP!EQ7GP1?6>><KG+ZNI+$3^$G;SN:8W_;
M5KLXTKAV%K+?LX5.TU-#.6\;U13AC@;+8HJ!1W#KC4J1!^YDEL@QIB(M2X%J
MX]$:\*\#AO\A%@Q'W%*!'*<<>:R" SX3>,(KZVQ5,[TJL9B34[:, 9FWO;QI
M9"8YCRT8!%>16EC-B7J=&$[<*5.1EJ58WN,Q%R.$(MI$A*5/B#.B$2SI@"1)
MUE!8\CB8O+R5(*N$+,SR?E]AE9NLY./WO_^N8B>WX12A2@1&J4W$<6^TL\PK
MA25EAAGA545#%A^G&A\F:(A1!G8;@I'7,CM7VB+M%4<Q2A]3H%P2D6,G5(A5
MI=BBN%=5[&3.RSM98!_>BL2XYB1@*T4(G(&S;;%FHJ(AR[&\QVF(((D'G2AB
M5'O$'<?(LI"0L3Y:)PDW3JVL&T97N7B?L9/76)K-W!;D453CYMG:E?!S+72'
MF<<4W0V?T!IUJ3'L.2J[*@Q[80S[/MF.3ADLB$N(1$51CGDA'35'-JD S%,:
M0N/*NEY56JX*=9N@[B./KY^TQ)8EPE+!R4M5 E=P\N)P,DZ)%/?:&ZR1Q1PH
MD60>62$E<N &"6<IMKGD5*U2158)6WHXN:6YW TUE6D"V;>+]U=M9&ZVD2'3
M>AM4;6069BQ5&YFJC4S51N:=M9&Y5\]K3/]+VA@TLXX0(KDP24L5<[2;&BW
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M_SR[>LO?]BR_M'%B>V&$OM< N428]Q _G'::/YU6-_^>K9[^.6D?OCMH/'Y
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MQ+T\T?=[Z[C'0F9:,VNR?K#UEE.LG&4^)Y-H')..P8XB!?R6+!+$QN,&HT!
M#-/C!!]++_$RUL66,QPP:I#W9[L.5]OZ_ 5<_Z\X?Z:^^9'G[]MJ_CK?:1[
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M#0JIEZ-2UB1>RIJ46P?#J[4,-(5!9LM9S47TQ]'G'HCML[7:O(!/X* 2N$_
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M(<$62%>-G"RTK;; :@M<@BUP#D+4%9(M')+1\?8I%O8_QF$#%$XB+HR!B
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M'N<@5[EMI6[F6($=!SSD:2KR#.5J?(<D&N#G)UD*O7+%>O&*H<Y.H-,]35
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M"4_!%@8\AA\SH\8'!.Q$(QJ=M-VB/F8-HI<O0+_9C?TKKBKJ+BM%U@X;F5=
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MS3>TD4S//=\!\5[?&;EV=#@M@WS_AEH	N]J<U>K"'5 VW&]!'T?&&\@=^-
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M8Y&/7< '.KZ_=,S<C#E!$@=9G/LACV+'XWF6YXGCL2"PP]OQ#PQTO L=K[D
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MR" O<^PDS?(H2A/_O/JS 9LNB$UO@C='?V>@F0H!9C[HI0D8('EJ@4T06SQ
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MN9U:J?!=RW>]R$K"/ B95'(G2B ST$7WR/2? AV_6ZMO=0!AR+<V[N@>\.7
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MM"YNCM@$_&A6+H3\M*1%VX>*F50 J,YBANV+X.=B4HL3^)TPJ*P#SO#[DE5
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MHJ4:Y9:>*"Q1'!O$>B5&Y*)2: ^[0V^A]K8^%XL9<.3_72)GD)Y.ZK*GEI\
MSL"E&S]- M?$%727S^,"S')I&>V8]$\G\%#4UA.L F@,ZEU'] MQ/%R*S H
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ML@+R'@*U>):)XQ+)I%ZF [0:Z7A.)FTZF8-_\'((( :_<(4MR*R0'0HY]+:
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M@ _$3TRZ&7B(> [&UM&+I'@!?(*:.O7@)FOD$#KP:BXH606 %2(XX*DEN:5
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M#BSR9E5*CDYLY&O:<=E A1*WL0P"10JPPX3U:U%:6D383URJ_.A*,5Z0FYO
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MP.P ?%X+BHY0;; .*0V3] $$30<MR;4;.3/';$X9&>]TFU!'FG49\:;\B[5
MK4D*>+<!5IMM):8"Z!'/#UN9Z<NAI"[-3E6N2%=DX<=*9I&7H\![.T)1.),%
M6/)!T/[$0C;/T@*JZ3=&N014K7SVJCKG0-5'MUR^7^F1PY.<4QDQW0$V^.!H
M=(CY0N<LZ5^8JM"5F,(AZ"N8O]U)FNM"4OKOJ2F;V>_(MII70NC32_G?K N0
MV*!$/(5P5TFSF$^(_U<BERKD:O\O<U//,-TR[$(-[+:#;P@=/GKFQM?2PS,>
M>GA>K(F:;N;WG(2K5I!_TBHNV^O&G.>EWW?R8"J90*.3?X%5H,:%G=.ZW0QE
M-$-G_$E.#A^W"<(D-GL!CG6>LYV]Z.B)?N<EHB-[DVN*Q0K/E72#>W@/FO.R
M6)C&QTH+R_>"Y";^\ ,97#^3WY-RO^%F?E-UD!C]W8L+N% Q!]9)Z JP;1GY
MYEF%%)6\*,HA;UR'$F,6ZE^(3+TV&V2IJH)24I;J6N>IU[UWM1XPJ:VH!<F@
M:.S>-NL2+1P^;E+%FBPZZ@M#6AJU+X-S\M.VQ6Q3("#;K-:*-F1TOS6A=0+H
M$:.R"*QU)S.J"4* ]";]5&VN39G]8XX::8FA4ZTKR7Q0>1QS\UE.YZH@7F?P
M+P#^C8U'W0-P-Y7,.2^H0 "]\=1K3N57=5N0"/6S>0=/M1*BBE4;OC R/G0[
M*ET QAWM:/4DVC6CSI%UP:3;?O0L3M!P6D)DBP7&;&65,!P[6UN_21R416CH
M%FK.*-9W0S:GZF;7."I:W9YJ/=K7T_UVN>$!:*MMH9:R*&L9EE$\O^\FP (6
MU(]DAHIN;KN0E#*K%?5U"V4;PE%76Y6YH*(9\CFI#IJJAH2:?"ZGQA%HD$#0
M@DH5IFU-%+$ -,D;(:7R?]MWXZYGM:C7CM-*L4()LJPTJ+2H<[[] ->.LN@W
MS71,T->EBQ\/_+_:F?&\UV+H><_&(O&D:N+VXNQGHBKN]JA$!88\/4WDO]]_
M@_I^4>4EYM)CRTG9?:E:ZURZ4F77E62R0Y/H]&=:[</4%)%W69P20=T0&9I5
M3=>E2HPENU"=K66RCTG9R>4<UH$/P0;+=-$=VM=8RZ@K$:2-3E6H,]U<!=U!
MYW?"7.&:)UL/+GMM=EETLWC&%@P)1N^JF&78L43Y'=K&G5]D#T+537U&67!*
M'JK^IYCWM+8*;$/WRB;(8+N;WO8:X:E#62UT-#1:[6%SR*M3![_*?<C7MBAJ
M$ER]4%CG&(V.<69Q(J8R]9% \9D"I3WZ4>"]>!O:;]G6NXS;ACK:-]EHSCI>
MUU3I;52T4!'I5VAVFA5T2D%-C6&GRA4F<R,T8NFM-P5O.AM*E^GTEI$BD^)*
MHFEXCE\<"8PSS>&F9=\0I=+L0A[=!$>)QTV,:TW@$F;+2(P0FRM&SU!/M]#R
MQB!);U>:'"GF1K[L-7[1- 'H%O:L<:2]8,(["B 0RU5FH:\(73Z=E-.].,R9
M$N5#@8)0ZI<(Z4YY;].8<G/?L-7>EJ1#3=ARQL=B0UO%%NI-GQ8J.J<P+#(P
M61]*#EV\S3G=)G4/ZZ?QJK@B=I52P0\R'QI&HCN[TD &$@: K56QVAJ;K!=B
MF:"Q1\'W38YEXX'L;;]):B[G>#]2RVO?]*/\2Y'U7VGBJLJ-WFLNZ-G?-[UX
MJ)YG?2'M2):)77@Q?J > BIM9-/:@R/C>>]5[F7.!OJ%'(#0!09?Z>K6=$F#
M5Y( %S+9M:%\F4]XJHX@ZSFK$J ^4WJKZK:&AF-5'$NPK *_?<G056[7KG(?
M,*US%6RU[BQ_*A;-FGU6O;&]7"I[%]1H)$Z%NK6K=Y73"&QV&M2CS81Q J8#
M(_TK/#4OWR9OVT;.Z9Z']Y6)FE=%BJ[!M#P6UW#V_9</;2O[C.Z20L:*7VRN
MKL"LQ6U=9-&96E9?L3_@A$+?I(@J@/>5P4;W:S+C24!(5Q7=.K ,Y!CP'PPW
M]6Y>BRX24TT:4-X*(9(%7<5(ZCJBX4,-X#>>1#D^^G9!MPI%MN$F*ZDLU39F
M2GW%UPU!H+."0,GAUX_=T=7U4%HV6EEI7+!5*)F]W+E>,Q?5\6I?.X#NL67P
M@ASHQ>%XEQI?!#H:9=8'UV=0O9OJ)0U&HU0C-B\H?0_G4C6=. IL3*F;7*H2
MYEY;H:;QO [[2[G;2>.D/I!J)TT9+AF_U^\">Z7[V#32H6X=LAMF^-!$ Y6<
M5@E]3LH3J]KFS[_^^?Y#.T>(G@'$GM6H-BGKOM/305[ 63.>:J7-M3T?""BH
MSLDQ#2JTV8-68XQW$W/ZK?2EPE^/B[ER5:^T4C\9EZK!A)X5L3)IJC-BJN-8
M@!\?T6")BH8+4^;IT:S-O]C\TTW-NYJ>(3T'GG1LT%%5A$MUF:K'I$N>*-^4
MBF 9#.-0M59@Y9 MK8DWT8[N+:T&4#H-6=J@DQ[\UVJ7&V,@Q@N5-K4!>)3[
MIO-?FT[O$U0?EC)+&=Z'!;(R05$V[NKZ)IM+H(%0J/VC<;%*82IN*'0K,WDK
M-'B!'9$!+A4Q2>!UFS;,6PXFN\ R;8[0J^3 +PRUT?P&3.S$B-$:K-IF4>W9
MS5;?5M# ,S(N?7LEWH0%;!;#&3VT[O$2/>!0=J-O3D:HN90V_Q3.TU/V>O-/
M]!,XJP29X08@*0]@O[N;"@CU-J.3E; ]B_Z=='KV6IWVWJ_P5H46.^XUI+RE
MDL#[U9YE1R'X*[&F([P0Y-YO>C5M+W2F*?#S9CX/7,;KJ3:L\)E?2%EX0V?<
MBRLXVVAJQK&J/OPJ!P2;.>/X!15G[K:&;5UH-->K[8>TPBE[>EF_.K#M+ W4
MEU-?5,V)=,M2HFX4.43XF-6N-+>\^":RE?5DW_^F4D!E52(+Z#[=M+/2V3;T
M ,G%39M4PP30((8[L7"1COV-3&=9S73G2GJ^VTWU0C&<7F_>_MMU&31?+17I
M[)?TXLEDT[Y'QO^6)XC,9K\9X9EY0=W]MQZK3E1@6GPS>QQ#-Y]NVJ!*\8VN
MNV,YN;;7QV U<[*FK'%J$GZ0[.)U%W[ONS4_+SLU/W#)/\OI**]G,[#UM:!Y
M):T>RD_J]*!\0UQV+Z[C/'_+>2B]TF.TW[ZS)_BQIE'5\G0IJB\_M0\#3"T0
M>33L6!:*;W!F4/V+\N#*Y((US[%4&N#B4M$?+;;6%Z]'Q[H=U::Z+_+X8$D1
M=I0ET0O+4E%1W_F/Q21Z2BBY74;&&^!4Y;$J.5'O(";9[13>U)7!<KI.#.>E
MMB2E^_7V4^0O%M'J30=MIAZWZB4NLB52DFE#GDO]3+K-%J3GTTBCB8K$'@!>
M4].V[15\74Q<*%QG.HL+G=2R[E9J?#5(0K/?Z8P*UYJ.,YN,3@W#;AL$E<.F
M:$-W+3:[K8SQ;:K4!2! H7;T;G0TE95NPMOF5NT)E'9DQA]:8;(7VS\3R?ZW
MP'D4TN/?*E1M\F'6E8W4GAR=62I(M.+/:H<E-#F$E<JDHAB5T4P#H:Z<,]4I
M3,@2 *#A/@M?X7BL[J2$D9JVR<],9Z"JES9_LGN"9D[5F)K9GL(#QZS;5+FO
MI:2JJS+MD#2N#1UY+CTN/''V>EPX>N+*F5!%JZ@>[&]B^XXT^EYJ]WNQ]?.4
MFS;&!YHW)9RN#P?I&"R-3U%/*>EG()<KO:,Z0^^4Z7_6J,,+3#7<'/Z13$ ^
MW'M4OD<ZXKJ1[.Z^C'94MFX56FYSJ\LP57-E>LX%&&!UXZ?8>%7KZ6^Z#VQ!
M]=_ ),9"MMG265S-XJQI;,JFL@5&_T5#[.H,%/?L(79UR:LC!$9$ZT\L;K(4
M:W+)507)O+Q%<\3Y%+O)8\*<QFO36-88W<J%)LONS_4;9!]XV=9,=R;\#? 5
MZQ5--9%3CZK%'H:+(C]M]7D@IJ,"C4NR \ZHMC:-K!0RAP"[?E!/[CY!R^8,
MBI!A-?1<OD7?S^P(AX)JAX J5%!60S,V5XZ <=;G>&9M@SHY>D>ZWL^=JD._
MVS!V9O]%S/LN-]PXG\K()^AR(T;>*%!MKP%,SZB-QYL:O/]@JLI>&3C=UER
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MO&L9ZBOZ[EZ@P*Z=)IK<B5=*;=J+4YR+R&W.1Z/N43A"*8P8C 1.E%6TY:X
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ME"G1F3[$:9O&TM'LMJ!JEX%M91(;Y>V&(R/'D(-B5,LX<DTOJVXL055[;&
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M_57.>#&A%>CKDC+TVT?*/*_% D&K99L^<-!=A=.T3U;7)2_HO"<%RLYE97#
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MTDUHNRZ\D[/BDCLWUYE6E\2T2Z*S7;A9AOH6D ->^QC K10B<6R HT+=LU9
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M\M1_L<G$^+ _%@8_P$M *'P&Z@9PGB/C^%*,\!5^$!B>'N)].(3@!6]_:(O
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M#, %.)"L6B)W;1%]$G,D)MPS&3,VA=HYZ+V):/LOXB!1/I:<W#XQQ97!SZ^
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M:PJ96P'*3&AKHB8/DSS+7"8+PE9(^S<6)P)S$J4I4F :S*92K6?UJK%M+#8
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M]O[01B#3TR<7(>%+=[0Z]#6NJ2$357Y'HRC8<U11F5'DH-;U$9?"CRMV[G@
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M"=O@V+P.=+MCU9826]B!D2.P0U1-9Z;FV])[N: Y&NBPF)(&2&RM7D[G^B@
M,=GUD1I:$N,XJ4J<HZ+$""^7D\Q8+@IL5"G[47:.J7FT;DA1E^6,%#]LK*EQ
M[0!(]2?!V;)NFMK-EL#72L#YJJB_JC8;,]7(4,YA6IF.I!F;V1_<1+TI5P4A
M>E/ ^,0Y2O#C@@M)ESBC92F)#>"@0:94=&R7)*6&)A\M,3?)2:FL*(1&FI4J
M3@>GB18R@1H XL046\[E\!+RI3?JT9/]!QPUU V;-,_;WX+.@[ P5>:)YXX"
MO O9R4IUWUM'@8YMU]$!NK\CY;2CM&Z>5TN"=E*+$VQ^V=5KI9"F/C*B AY3
M5L1E5/"%AA61VM9R)/RL.WM(-HN509M%@:TX%VT ;'V2D=:3\;/9$E%)MJPC
M08_3C8ITN9 N3[B5IP?0F7B/,:O?/ZWI0(8@%]A?32D"Z?]G[UV;'#>.;=&_
MPO ]/B&=P'3,Z&5Y*\(1HY%DS]ZR)6MD^][[#4T6F_" #= =(O^]:=RY:.R
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M!>4JQPASX=HN#XYWDC&-O8B-]8\#Y7?/KAN35H7,^E-="?ET\<0X0*"F@X]
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M8V\LN>Q(I] W=2F^)&!CC+:VT;7?!T/D?-E&=Y1#,BI3$-R;N[<QSW&=\_#
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MM0<:9 LVWE6?E:%*\+%5^SY;=J,IO8Q;9%WQ,1W/[K[*G,+1XVK.5ESQRK
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MJSTIA1 1YI?$@WD#EDWA==#1CRM.2Z3^YMI7E$":P#<>Y2X,R[KO)'LN#3.
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M*H162PH1 D-T<W?"]D+8P0&.7^G/R4+4R+M1R:):P-)())<OBN2%P2@E@]5
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MPXRNDW%]VDK/]]'K/0>0]PT@C]+FSP%7=-D<381DZ[,^',]LG:?N_:<.!Y%
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MRK\9GN_(0N<'P7ZM$?;( 9B"=A/BR*PY2:TN$:):S'&Q^(O)'^)(I G(V:[
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MU 0X$GJV;Y_IGD]= O%(V%?84WG#9(Q$>52YXTE_&._6QO. 'D(=_9R,*$T
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MQ3O.,;D\E ?^X@*"0 %870+4)IPF*>&_#4IE-*R!I47]9M6'6/! ?33JW?E
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MAE:IH@<4'DN,,Q2]2P_?_U" 158R=_N:AB).:XRFZVI]F&"6%M4Z9T/<M?O
M34E6_V5 O9>W.OQ/0^H>\^+#/$.7+7QS;"<H+M'=TV2D6GU6SXL[T?Y?BQ]
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MCCIB6&G$,"X^>'[Q^<G#3>#(" 7#3_'([BY+Q>H<M_1"#\]*,'<Q\M*LV%
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MB&GXTPN@3O< _DD*5J9) ZBQ],[2O&AOQ'$L$@FPE;&94?8GFQ[*?QD75ZW
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M%"VS0+\<HB(/[.\XN#I86><XT:3UJ# 0(&+FI/#'@1':Z,0&M"[+B(->L29
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M3DGD43..N-QX+"\]K5PT=.;HR7F#9>8.7:SBC.@V)Z J8K <Y#.UQ67J=3J
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M9NQ"$A.>:A>B5[-W@ &/6FQ4&)S6=E;JPI/[S+E+JKAY7!@R/S\?"_'892,
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M<,^FL#&3UYNH>CR R89*Y^W&"7,K",O:?IRP5;J+GS<*4\DC+5Z]LH_KX]2
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M ,C[P L:Z$<K8S:C]7?9#7%/+]TN7-F#>D>2Y:)Q;&C_=4[SOQ"*2LI*DD9
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MA<J:+E 2'R!"CP,)5-KSO>1@:0JOM=HR02 O&L;#8(M;B! X@9ZPA4W2AR8
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M^4H#[VW*QHY>QG.&<5K(JA^Q?FO9 $'L)'(\E L&^OSP-(2(:TE<*C_YC
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M"&B4FY]<( SU=?0XD8Y8^)4R3R1'*RQ^? *ZZ**AVON0FG-T64S9\0<0BJ9
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M?[_=%1NCN.WN[[N:^F\7J4^>N-XS*)KGTI;:4<9=4DB^/:HN.X-.:AZ8N
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M&^8-<8?!-N.0- P[&(__7FN6>*"&TN[D7HI<,2%CW%58-AG1JOQ C)-62Z<
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M;M;W,DA;4G*9:+, =7+9</]+)]O/[:F!=0[ 0+$DKAD#T7_,8Z9&<_D"$BY
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M[T-P(%AXDHW37:+5 FZ]/1SD9:3QHYH HS-5(1F?6@9? _]9H1ZG+LTW"\.
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MF.\S?XA*4U53H>ASSC=CD&%Z_8;[M&/K8-Q]LHV+B #?\^; RQ8;HA!?NQ
MK 6]9UL6-3+A^W.649C^1&<*$.TK*M_YTQL@ !S.V1/3 <YE-WAH8AN,(UJ^
MA2U%$5A2&C8A P'QX?EHL[@MX1]BJ+?$ ,T;)'T.(4'DSL0P) 3T&CWK0'5!
M]N?1H*_FA]]:>P1I?+LY=BMC/?#N%1^:VX/VU9):HR-R7:X6$BXIC%+M'_EL
MTOUA81+7RA+?U_@:N\2#/96XCI6X?G\J<7WBT/D@!#4G08$7 N()JW 9G.5\
M?]'VM:"K.!1UR;6Y-LS@ZXIIMY@H*=]?0[(-R>Y>=0T,8\?2X[P)U;,798AP
M1,Z)LM;K^)%W^B .P+>1P-KEM8D98>1F:0E1':@&8!MV4:[@L8NSDQFMQ/)M
MJ%F3?M_E-M/N[RIBP4,&ZQF'PG20@.5P8CFD+.B>M\O";6/*PB(+#Y(UW)#.
MA57\ID>@'1W3A9I9PKM-F>S(_,;'OD&6Z&BQO@;&.%W5*8<=3O?"_+J4A <\
M>[5W\R:?>33.6>9,.41XN_$+3#G HW[D=SIFUR8A\O'#YR>;FLV(QYC#4?7,
M:1J/D'I%[%;T5*MZ3<D$1,!'7*:IF$'01^,1FW+5QY'-]-!%-H('U]&=-T:1
MPS1P?,#;&93U4 5E?#\C0!V9P[992P8 G\PYES LM5QW%0Q)1R),,N1%8L&M
M&F)(U>![K;H-]U9W;C67Z%<EO2<6-5/'>1:&)3QRA]9LYAZ*?XGR 0;MYTGU
M6BP]Y\8ZJA(V'[@1X25F5*/"M,7J&2^Z2*CHR)$XH?7*0Q2MMW/V\@,!K)).
MN!<O(W.*8X#D<&PM<-=-$WQH4)8FEH?C$.IY'P4&_(AU2Z&'OFJ$?8T\WF?"
M!K-B1MJ%LY6C;\8ILX_REI$K!FB\6YJB3+)(IF;HBN+UJB^)!&D.H KWK$F*
M@3+ILBR1\V,B^'DYU)I\)IH]0B7N.^D^D\C+8?D8V5W/]MTNA7:OZ[AU?V8B
M2O> T0I)P@%?'[T':6'DFZ4Z$DN/7'O7N5L";!*5/HI1S1D'GQ2='X"=.<_=
M,$]\Z4^#C HUYCPNCOP@\I5ZMLLPCLBE2IXS@DXC1ZH_[$*X?&T%-3J%QSMH
M%8:S%KD97)- RJQNP.G9I!4-/9%T'%&,2JXO-^+LH2'=[QHE5]7>E"%U/,7T
MI/N/_"".["Q UUHEM7#9B:0GLB-1.L3\<RL^I;_)3EDU[REOI,0<ZO,DM,J9
M4Z#LJWP0NYDCPS7*@&6HMX6G9F97)[(V+Q+;M^*<O?S(.AK<FTREG=64:/W$
M-</&-<L=VI1022;44<&8IOJ!E(JH!,4,#*-)^I[+<.,TZ#ND!T$#IU5-3>/E
M.@:1-$N7G2"5R?R(12DTS@)-6D]KN.[I5!;#.94M\<)* JMQ:03),$1L#1LZ
M,#^IM>]G7CXG>?Q))\QJ.?]Q4F.\0S7&:6I>(4HD[^7%R]P9L4!<S!OE.:4R
M%7EKP\G$?+[BND 6<!=>83S3U@QJW,L_*SXKOSNW/9+A-$BET@,AK+AL5$8X
M^EOJJYR6T1TN(_/X!N\31J:!XZQE:>A>&L.H&%7J'U";6AXQ&J<Y_DQS7,Q>
MO?DNJJX)YREM<6FR,C)TH4#3'#,G9'1_TFI)@YMT0HN9FA#+IECC9?Y=)/.,
M"5J8LZWUB+\R-!0,G=;(W1\G#+PCS68'10"=J*9.*2LK?/9^TE2[A_S2X"T1
M&X CDADL5CY_\].0T(QFJX&F6H Z?*=(RL/>E\-01,:7MK[LO)=%KX)@-%.A
M0']0I'2CAQ'4I]W[M,[N=)U-91:U]J50;V9/9LR5$/JXW/2UQ<TA%BN2 MB0
M)6"+F\*;K0$HRXMP[:Z=S& I^N>T-.YT:=">C\&*!N, .VK2RUS=Q3AAKNXP
MXGMI4[SV6<[")P*,JOC 5:BUQQ+=="(Y%MSLJNH&QV<?E<1KP073TJ+,$->O
M+ALPVE,52^Y*9+Q9?]*BIOM&HBH;"Q6GX*M,',#V36R7OMM09!K#S:FBFK(!
M2U(^?]<C&^!48/[5'[Y]_/ +S">S];%F*R<H5$^(Y4\SO=J4YL(GR>:',4""
MC[^HE^5JP<JO4VR5APBK*9<JR>ZFM\>CA+[3=^2&\4E5A8YQ+ZO5Z?R[<Q<<
M12SE@[D5%@+ZL%*=DSR@7W:E4KQ$!):=K&!+KEE](1A@SB =Q$F<9O]S!& F
MY[ZNQ\%1L!?;+CRD-QC>K]4,,O=/H-:O!-YI!3RW#\1_S910)E]P.+G(_(VO
MWGR7@<\BD(>+>8](ET:4SDZ+Y[-F>(J8XD$YJDXC(Z:I1/:FLF3L9);GN FR
M6/\&(R30#@K&)=QJ0W"7M2L<6)ZGE7/G01<5?*;"%C$!E]15.1G[G.;F\^1*
MD)B*N=D*'$&2:K<OZ>&@4#<?\>5)U]/$?:;:7(2A&5S (^@.I0Q.J<A_[J$Y
M61?1F$N:YZ7M6K"N*\&6+DK*VQB(=13O"<5]UV=\M%,4]WP9\\B0VB!8;.>2
M\TDB3 &VD0AUY%T.OZU=^*!\75C*WF"SE$/\Q8ILL+#9'&^;UW."ODN7T2@
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M"&M\!^!U2Z5'%<Z]+E% "$N ]US&2[:1+OA\(*#L0TORBDVW2'R*(IVI<V1
M!7\T<F6[HZS/TV]U\%Z'.X+ >O8=_1]G;(FH/,ZJBF:ALB<EGTJ3(J6'FPE@
M!09DL^O)-/.A:_Z/%'JHI8M]'3-'VV4/V<]#;\TIB<VJ)#SKNXBUM.=#A91,
M2,]0-%UAT_!EI(.1#^>#SV0N&41;?VB8&]J:W_"UW4J-&!O3DOT*JV#13DX
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M-U%346F9C\ 63[/U319LV.>"%_Q\0PV=BIO4O6B:P4C[7=;FZP$7F$<6(QR
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MMYD6R,\RHAK=7A(NIXP7-L]+!@NALQ@Y2!*,E=&Q(E*B7E!2UYED^G_"[C=
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M?9W8TUGY43+N:8:C*''[+;85+"6.$3H8F:I\X]>:MY",HH#?>KMGY!8["*,
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M*:_)-L>FS2$<K2#Q):FVE+C*J>&="YG]R3RL_A-)=,Y+5W6_%.\UU;9[X9!
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M2%S!2&A.N&A6B#)GB\I8JU^S#5>G?*N(8KVE:!2T&[_+PY;!>K.FSNF@7TH
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MIKB0NH&5&G<A0%JT$!2 MHKF24,MK.IUVO7006U8,Q>TG5P46A>!M%IO>UG
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M.LT5JW_<XT+;CWCGEF'O:Q_8<\;)1? \2OT)&4_[(RE5MO(S$L!)%8#0DYS
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M!!]G6NZ#4V*HI6ZG!H]/6&C3J4KQ[(=YOB64ZB>;<4.#754- R\48O6<#>?
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M,B6YT1C)V:"_%K[W]/GTY-FSZ='ID5E684AT3N2A*&]A_I(O1V$"Y_>KF%
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MG-V@(#/$3.H#L]5S$\F==F:-A*$D+Z,*=N&DAUSZ>M90S ::E&XZK11# 4Q
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M56BVI.>X3BONVT$ A0!?8,X,C%AU C.01)!Y(CD3.XMKZ@/-+J\Q'0)>@[C
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M7;+WR2PA$0210"<E26SM*72[9*:!(H83\">&F<-&I@0",)7_)0AL FP5(DM
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MB<)YARW0J8(HP\G2/'! ISC6ZQY\7G@R".%&: (3 'ZLY@LTKAQMM_MF+BI
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MJ YS,&#PPOH3+#BR^M#OJ]9BK-/Z/[]+G+\YFT<GB].3X*#X[C>>SV<GI
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M>NDW=$A]^/AV/*3Z#JD/95(Y>S:F_KZ!2\>S:KST]WKI-W-6G?U.SZG7Q14
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MH4/Q,S1LNP2?,#OPH-F;O4@2#"5J3H<3-4]F1;QQ_V=9K[(__']02P,$%
M @ @8,(5>=JTD6C$0 =;P !$ !L=6YG+3(P,C(P-C,P+GAS9.U=7V_;
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MBL%8LN%I"Z>1=NHE__3HX!VT)'VD(]/'V'I P[RKK24J+UG?:"@ C\6Z
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M^-E'A&XI=R]%<D+8^1C-_5+4+_BMB?O&QBP5B<-X]#_X./"Y .Y]D-8%*S(
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MP0',4Q/ZX:?_ 5!+ P04 " "!@PA5\'#K,@ D "O9P$ %0 &QU;F<M
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MY20$1-%J-I 7NDBVEFH	FN(AI3N-R9&1U%T?$XPWR]Q+S^UW3]X<7Q:KTX
MHN4U9+$$;T(DH%9+;0RY5LDCP9K*K$5ILNFM&+?!-:;PNC-5NHNE7TG&A\5R
M_8Z61\\7R^7B<]LWFPB. D2J 8),K-B45I",%" H6<E*SSO3VQV_ <:8HN_.
M=-AWTKL7>K_!K\W'^U9@+&NNT7! (-NF%@8+L:H",1-KK2JPNMC?M;@!R9@B
M\OY^Q;Y3WY,&S<<YV=Y\AU_.1U@\:5.+AV*D :/9VTG$+V6TUF.MVI?>A7BW
M@AE34#Z,D[FG 8Y\%9=<D%7R4\L!4QEJQ23(PB%2K'&MJV!X:*H+@G'"]]W
M(4QMV"NQPM64%9CD*V [;DIH<R!K3;:]!W8[FI$&4 ^2_HWYQ_WGOANK?SXM
M'?NVRBYBH_7$$:)-H8#-#,44[R'55@.@T%=%*J;<>S?Y'D@C#9[V8D5/*0P=
M55]@K,2L9;(*JC+,V& 0T&D-24>O4'KCPX$"ZX<IC4<(F/93&ETE,61Z,2C/
M#AF']D(@@8F!!T@VLOD/5BDK*ZK>ZF*WQ-LC!$E[46#/N>XG\\7\?0O26J+[
M O]T97\LQPRY2.2A"7;.0SL^$84,*$/1W8N.;D8RTN!H/]GO/^=7Y/_7IU>G
MYQ6_[ME=Z/<U_]RTJUC44_7%O\76NN)"[6BK&KT,<8_60P]XY%!]B78==:>F
M1=L4Y[Y9+#?+8;U>3M/QNH79[Q9O\"1YSRPM%24821QGBQP@I:@@.BHB8R;;
MO:?1GI"[A$(W//[;#E]=+%>7=OB>E?]WO%J?5OS=.Z/!.R*9+51O>$85V^78
M#JD'[9+4-B.Z[A[2L$,:4U!V2+[?&,B-A#E]2Y%N&-3+Q9+E.3_Q//+7=TMD
MK98WV.=E\^J4 P\:HJ/JR'D!;+K:7B$JP&0U"(\.!868^H</AQS@F"+5,2Z5
MQV=5MX7#P,[G<^*5"TD*"TX4WVI+-$3I,FAM@K4ERZ!ZUVA> K#_L?.S;WK)
M1#II-G;,X>>Y2_.\J3>ZD)K]Y<MZB<SIZ1R77W]E*FXR6VV';S'CQ[S_=;ZF
M):W6$R,DUDU?T*(W)=61'6$K(6MEM?.%M5[O7F$##F=,UG!W#EX_%#\.^7?L
MHW *]+0SS'.:4YVN)Y19DV51 97EJ$QG#J%2]N!U#5ID\BKV;F9X"Y0'V@KX
MKIBTW\3W3VB>@EE-C$U>28Z9A;&!35MM#1]$!N6E\)J\8$H.E< \ [%WL0)M
M%MA_\LPN<<:6\UDYFLZGJW5[S"<Z?<S$9.5J*)EG7&=>=\I M$: KRJA5HJE
MT7O[>CMD8U*A^S'D6D5#?\GT["%$_#6MV=[/](EFB\TAMC-(3A%''>P^!<V.
MGJF^ /*2!%6T*,87'O0 +85N!S0J3[HK1_K)H=^!PB5K_3?+1=/35=ED5$D@
MJ.6856SU>N2 8C&D:U/5U)D(%QZ_/\D_T?R8SIR8J\5FOWS)L^/6%;^5A/-_
MI9U=1U_(M0/)''$G#G1JZ_CD/13?2@PT16-ZZ\D=8(Y):>[*E^M+85AI=:PG
M77$8V@Z);IK\TO+3--/J]\6L3$P5&%$%T"9N8F4):(D@*C)MS8;:?;W<CF94
M/F4OEG2:_)Z]TJ_F-;[UP<A5^EBU 1Y32T7D",D9#]7;@D5(0MG[;,X=<(9*
M#FZ;0BJ60[_L!3AO6DLB31!,(+">Y85*H%*](_^NNPN/JV5[\6S;Y-P04ATH
MW1:]$2GY"%)O[DAP//P:$6IEW\N'BCD?,-WVN-[I4#39?<;[A^\7@*A U>1J
MP)6HP>0D6.7+VCKZIABL,:KVKLJ_ 4;_Q(0FRS.9/#A;V@2WEK*%ARD\A>R*
MBSD?.#%QK_8;UGW85_BWEE3M-.6#Q%K\E$BU17>JE8@H$P$+_TWIZ$QUDESW
M#,VML=9(0NQ.PMYUECOGGX=)J).P K%E9NWF&C7/#J]L_<R#;'<D!"9U;]H<
M;$-E1R>5OWIQF4)G"17A=6!I(\<$[>8()@-@J\42U0B!J4B9>A_=N!O1F%S,
ML;#T1A>UCTP[KNB3@9V!D%X6"JW!*FD>9$4'0<<"S:MBS]@H:7OWDKL"8531
M_EBIM(_8!G5D!99HDBXMA]5RR!Q+!:D25!62-4CD8F\M?J\C^[C%\V.ET+[2
MZWHYP$E9S F2;Z.SEG+(9!B-M(Q&*@@Y)U#%:5%=%#7VWKVY#<N82O''2J@N
M<GS4 N]V0<;+V>+S,+7<Y]]^B++M6\;2J4*[75C%#^!8Y-.4O^WYUS]6[=37
M"07:WD9>3S^=G!BP5)U**8"7J, XG2"ZUI5.^.J#]1&[-X#;'MW>'6SQZV:^
MWRV>Y?\^GB[IUKZJ$Y>TBU(3B%1:P5#@F"]Z [%8Z1)ZH;'[_5E;HQM5CF0@
M<EUK@3N,[/K=07$5W]WMNB:UI"R\(Z!46_R !3"6"%JB3<6ZJFKO4P\/A#@J
MU_ZQ6-91BAVO.UEDHK)Q*'[#]2F>S2UT7[_=U8NSV>IUW;0W8<-^=&[N5Q-)
M3AN9$6STF2<H*$@N!E >C54\.]7WCAKWA#RF".%03#R@D/MM2_/$7+E%]?*%
M9@SZ\AL7/OF&EM-%.XR^;.>-?Z:3/_GU20'&+U_R!YR_I[?L-?U2*^7U)(KL
M:B0$%Y)I)5 >, 4$']EA505=<=WK'@XZP@X[EC=Q]25'%O-\F:NI$D:716MT
MPURML>4D0@!'$25)I-"]!\?VZ,:4KQPQQV_8/AU"_#TWU&_"]RW7<0%?]I)U
MF#50Z^9"$!L@Q4B,M+@@@O?9'2@NN0'=F':QOG]Z[BO^H>EYDZ4WZ"U;5,O6
MMEWO6WD-1301<K:EM29%H0ZD/>\-FQ_7>_K^Z;FO^+O1\V2(K^O%8;^>[S7!
MDR#0%_0)9. HQDC#H3.R_Z@IAII<":)[:## ,,:4__V."/_8A!I:<=_D]]B:
M>,)D@,+!.QAM.("72D),J QE"E$/4,6WD]N[7Z)@<_'9ZX^;'8=?OM R3_FI
M$Z*LD?^'$%-K=*L-),D1*@63,QIC1'>WZEY08W+V!V+27<'^_H+J>%SK+-GP
MNIZU WHUG1._?+&DTDY4EG:UJPN@4 <PPE@(@MTTU8Z\AUQ\P-[5U?>"^A[R
MEKT)U%=2W9/BKVO+EOZZ6AWSJ*D=IEA-2@X^BUH@E-9C.P8&1%F"+980*5'_
M*\7N@/- '_F'($TOZ72GR\O%D@E]O&0W9$7,X LW=U)4B8J+0#PQ[1!/A*23
M!&U%-I(';$WW>R;O1?5 ?_.'(D\G60VR.?)-*S:EB//5N\6;4Z 781HOD\>H
MP!?;[L],!#$+G@5-2#%'(6S_F^(?"'),#08?P2?J+\C'R&%:5SG@L0E2TA8,
M*H2DVC9U=:Q0H_.B]JZVVS6'^?!Y>';4CFO]SX9 K^LW,FRL23MF/EV=--F?
M2&=(A8I0R+4&HB:R@-BQ%5$;DPVUKON=9V%;;-]!Y+$OKZZUNQ]";#U/,%S)
M?%QOSW]Z:\-$A. "SP-(K5TKJK6 5#2D;+"@;TFX_O6'6\,;TQ;!@:@UE/ Z
M7KB#2WJ.F[*\HU:9O9F\"7LM,KEV#V>[*,I$4API18(L-+E0I'*Q=TKH9B1C
MRML?B#,=1#*L\KEX4<Q$4)6E\DB#;EW%K$$(6"*@2NU42$BY]#YI?R^H,>6^
M'U/1["RH ?G3MH[F_(\V Y9"AEJ;%:T)#%D-01H'.2'/!5*0L7?F]4Y #XPP
M'B6&'9XXNTIHH!X#0MJ(R)0-%@V8%!Q$R@&4-EH*$[VTO0N<'MQCX%#W/!V(
M$[L+8$#%<>>EA1,1F8I2%"A*,,B(!2+*"-FH@ME;I63O3.H#(8[I)N9'TRW]
MA#@@TS8%IM-R=C70Z8E%C@0O7&$_\3GY%'.%*'T[)X2MVU'-('S*0F0IK>C=
M_V(WI-OP+OSP1JV[3 ?DW[4[J7@VHHY"6]W*!]KUO2%J-LD<)BJ2(NDDG.G>
MV'HK8-NP*_[P[-I78GVO$?B9/BXI3_&TG_O%]-8D>1T"LHIUL249KIG(4
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M&,C?__3_ 5!+ P04 " "!@PA5A]<MF1M( !W)P, %0 &QU;F<M,C R
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M>;I18UMP3X(FO6BBAT3AMSBGN6+^.4S'Y(#/+E$Q&;@@7]ER&VA?,Y(.15=
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M:\R,VUM>0P7T\3KW^L'13_AQBFD8JK3IZQ$NQ#[.JQ<IB^]OG,Q LY*%9)*
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M9^\PFR3+ >=]I,?AS1FRIO!@.S7T<-3=@V]3-D+MEBJ$(:^2EC6)HY9PI>\
MMX(7Z85BO'5>^>XHGQ>56JBJCW3TS8CK*V-?7-$6#:B<+2A%_'<&R?DP#AW'
M[&7S3N#W(WI>I-E5!;W>GM^#\[)X7D[!D@^@;:%],N9,3FH.8#UR'[7F6;4N
M/KD]NH/UJNJ;+CTIY%1NT>^9U(]??@W_-9F^'(79;'E#$XU3:#487</L@6EP
MGF9JDV/1*U3LD/;1;7C'CSVW)<CVVU8G11WVD+L&^EOX<'6GNP7<ODI@[@;U
M:&VD^E']]A1KIK<3H%N2QF14G$Z#6N/'1P6Q1 ;,!NV31)E"\W=_IT"SAWM
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MTD:�_P"F6)8A4MV ;'%F'4AW5Z<]3#ADH[BW_24'9]ZK)(0X/5CBA$PMJV
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MA.0L,*L+DM7$G!=;Z7KMQS\A]787WQJ--@IKWI[N,DU-)0S!Z &JP<=#*&,
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MJ[LH(65L7GQN.VA'V _[Y]0=NZ@'-?51O' ]S'>8)N/\?S%,!YEPA(0),%6
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MQX]=1-\#+Y:%VM^%$5[V>68YA\!DH9VR,/"2?.[$78@N.IV;1^/N@#BU
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MH]/NDMP85]T05%M]N_X1PPS__=_^?U!+ P04 " "!@PA5;-$;^D?O #M
M! H %0 &QU;F<M,C R,C V,S!?;&%B+GAM;-R]:W/=-I8N_'U^!=Z>JC-)
ME= A2) $>BZG%-O)N,JQ5;;2??JXWMJ%J\3.%K>&Y%:L^?4'(+EOVC> FZ28
M^1#;D4A@K0?$@P5@7?[M?W][F(,G5939(O_W/Z$_!W\"*A<+F>5W__ZG7V]_
M@N1/__L__NF?_NW_@_#__/CY WB[$,L'E5?@3:%8I23X/:ONP=^D*G\#NE@\
M@+\MBM^R)P;A?]0OO5D\/A?9W7T%PB ,7_ZV^(L*4Z:Y"J @:0(QC@5D(J4P
M4!$+0TDID^G5W5\0TJD60II?1@'$5$>04T%@0*((*\Q2$:"ZT7F6__87^P=G
MI0)&N;RL__??_W1?58]_^>&'WW___<_?>#'_\Z*X^R$,@NB'U=-_:A__MO?\
M[U']-**4_E#_=OUHF1UZT#2+?O@_OWSX(N[5 X-97E8L%[:#,OM+6?_PPT*P
MJL;\K%S@Z!/V_^#J,6A_!%$((_3G;Z7\TW_\$P -',5BKCXK#>S?OWY^?[1+
M^H-]XH=<W=F1O5%%MI!?*E94'QA7<R-]W5KU_*C^_4]E]O X5ZN?W1=*'VYV
M7A0[K5HIJ942)5;*?S[6V0\7B-^3O-6^K#T(5ZO[L2\93V'ZL3=Q;PT_J.$%
MWNKF8I&;#^I=+L?Z=M==72SZ\!+W]5DL*C8?X;/8=+,E\MS^X(/Y5]N-;>@$
MF=;]M-2]):KZ5JE<JH8M=YH&F?SW/YE_S98EO&/L<?:S6MP5[/$^$V\6ALSS
MJJ@)_'-6_O:+>N"JF"&I5$1I %-%%#2+$H&<AT8CH7#*0ZX306?5^B.?J1S^
M^F4E3]VI9X]_\M"].C*'"U4NEH78K'X/\T-+FEG-[/I'?LC9@RH?6?N"$=L:
M"HTF_[$1&.Q(#*S(__;#1L\^T)Z/C^'\%>$#7QMY__^C."[$CF1S:V$LBI?8
M+(0_-ILI7!JU:F T*WFM6=O8#]:\^T'-JW+U$VA_4L]C]_Y^V/LPKHN55JP0
M9\:H?>('85M_K.#.<%GCM*/ZU:+C-]4,A!'K3V!12%48 _N BGO?_OM<&..Z
M5&]5\_?[_$NU$+_=+^:FC?+=?RVSZOGS8C[_:5'\S@HY"[6@'%$$PT12B%/*
M((U) N,$A3)689"HT(=W//N?&@NMQ ??K13X'F0YV-;A7T"C!?AJ]0"M(L>G
M5B_#Y$98 X(_,'T-@+LWI75$KR>"\^U]5+KK",U+\NO:3#<J_*#*4JE/C\I2
M;'[WP?;X(6,\FYMN;MBS/8HHWR[53(2I%HF*(0O3R-A>,H2,20Y1E" 4,2$3
MFLRJM25Y=AJZ=NQ%?D?LY3XG86TL@X<LSQZ6#V!>S\?'5EP_>G.&WHW7A@!T
M8$)K1+X":Z%!+?456,M]!:H%X K<L$SV1V*^4/7$7L[=CDI;OF"\Y"OO][L1
ME3WJD\NY^J3?L/+^.I?V+\N&3VQN>[AE?*YNS7;S1Z/<;S--)9:!$A 1K"&.
M40PIQ@'D:1B'D@4X4,3'9//K?FH6VTIZL-# "@Y8+IM_;*G@QUZ>X^'&8<.A
M/#"3.0$,OM;R ZL J#7HT3#K!EU/S.;9^:C\U@V8ERS7L95N7&=,.Y7=Y6^6
M1:%R\7Q;L+QDPFZ!2]-S_;_S>D=<WBSFF7E@/<T20W>1BB(81M30'E($$A4P
M*+F.0X4%YA'VH;W.DDR- 5M%P$H3L"5[/5FW5 ,_LRPOZY]^6)C%S9,9NX^>
M&TF.,B8#\^7AX6BUV(Q'JP=H% %?V[\'(="+8>V)2[O+,2JM7@S72X:]O,%N
M9'M3+)XR>SMO!'B[6/)*+^?70BR6AM5GDL=8Q(Q#'2(,,281I#1*82QX$,1:
M*HZ9#Y^>ZFQJE'D]GR]^M]?J0"\*(%MI 6O%]2/%DRB[\5Y?V U,;2N1P&<E
ME#$/C%UP99TY9%;5RPEX]^U1Y?84[[.R?B%L_GU_).:"44\\=;*K4:G(1>F7
M;./T3C=">:MX]3XOJZ+VXWG#BN+9[(NO'VS;,Y[*1,?&+ ME8MUQ(@&IC)"Q
MU\*4"TR$2KT,M%.=38U0;E7Q .8+EOM1QTD\$Z2CR) Q5"B,(4X2#0F/*8PH
M(=0@RM-$^!Q+]H;G6$>1/6+I1L-](33TV>(BOX/U%V<%O@(_%X9[^R-:%Q1Z
M(MJ378U*M"Y*OR1:IW<Z6VY"*5G^9 3]A57+(JLR5=X4:G4>7V_3Y_/RD_YR
MOR@JPW$/[_,G55;U;V<)%DEB^!B&B4HAEH9 *$<QC%))B=DK1RH5GL;=)?),
MC:XW*MA3K=)*#*W(X($5OZFJ/LHJE6B?\38'+QHZ9XMQK $9F,U6FC0NP!M=
MKL"6-NVAH]''#EBM4<. 6SKU:FKV 6Y_UNA%THQML/8!W0&;MI=F_=A8JFSV
M+J^RZOE:2O/-F^UY:>R2_YL]OEE(->.()3C$9@<=,+.#IHA"$@H)M4JB,!"Q
MTBQV(=G3W4R-.QM)02NJF:6UL,!("ZRX;F1Y!MG3'-@?7@-36U>HG G+#8D#
M/&06MS_?+9Y^, TT%&3^L6&>,\V.0BANJJUXPO%IO^D_7^9W+XR\CTOKH_=)
M-W[;F5A= L^B(%%<B@0J*9GUHR.0L(C F(M$QM200YBX<(%'GU,CAD9.NSX_
MMI)Z>H_XX'V:(09"<6"ZL *#C<17H$7TDP8KJ<'-8(C*-CJK/H@>&]F=SB>.
ML#,[=\"JH6K[8LW&01(%-2/[-#4*/7?0;<7575[MMHO^5-VKXLWBX;%0]RHO
MLR?U/A>+!W7]Q+*YW>3IA3VD5E_66[UK^8]E8S-^5-4G?<N^W1AKTGR3UU55
M9'Q9;PUO%S>L,(_,L+'_>!*F$ 5:0AS&D27]$$J>$$OX0<3I[$D5?.&ZSQY8
M8I\IN2WW<#/RS;WY/V5]?9=YH=@\^V\EP1TS___=?%&6WX-%WL>F?.@O 8G8
M6/Z:0$GJK4"00)X2#@66H8IE%!*:^IRW3.@[&,-T./@5U!^ ,I_ 7>VS\,?X
M$-Q.;R8TO /;-+6F8$=5T.@*OK-7AM]?@;72T&@-OQBUP49OL%'<K-:JLN:E
M4=[NI6KUP;;^UJ.V0:"_LZ"1AJJGLZ*AI1WU+&DDZ%^>-8W5;=>; :5542A9
MATY\N3=MEI^6E<T28!,OS()04+,&<1C%6D"L4@&YP@1BH>)4D"C PNE0RK&_
MJ:TD:W%!:>6] HN-K. [L\"4M0;'_1(Z@>YZ9M\;E(.?R:]0_-*@V @+MJ3M
M\[3="9;>3M-/]S;R:;F3ZONGX6ZO=8R;6N1W]F[%;M$V9^V?UT?M9IM69+G(
M'MG\??YWQ8K;WQ>S2-OH \1A&,448D0U9&%$(&(441FF0H5>%XY=A)@:%YEO
M#WO&376!WHU\A@9T8$9ZZ?/0JO!\!:RLP C;8PS5!5#U%4_5181Q8ZLN &DO
MSNJ2MOKP9+O^EI4S@E"8)EC"$$5F#Q_S&))$2Z@IQ]H84EB'7GOX_2ZF1E O
MCD/!5RND9R3[ 2#=".DR>,8]BC^'S(4^5MO*#^)957?PBOY4VPJ>]J+:>;*S
M[]2C*JKG&S.BU74N;2C3HVV[]I.;H91'.HBD/:6STYR8:9Y&$<02TY#@0$9)
MX.D:=:*[J4WY)L;[L96Y=JM1*X&OP-U)3\(N:+ONC/K"</"-42/H%:A%K?%[
MM\&O9T],-UCZ<S,ZU=G87D0.BA]P$G)YJW-BG<6#NF7?WF:EF"_*9:&NN6$M
M)EP/?4^T,*$OO#V<-6*"C9QF_6LE[3??RCD\^LNM<K2GL?.HG%/Y0,Z4LZ]T
MW.=GN8WYK<-W?F*B3FKP"_MFDW_\N"B*Q>]9?O>&F<_$_'R6)"32"H4PYI1!
M'*4)Y($V_U)(B4A%%!'EM;_WZ'QJ:V@K)^ K08%H)?7<[?L,@.,N?R!8A][=
M&['K_ )-+-E*<KO-;Z!>"P_>G(/:?[O? ;.^MOD^78^[O>\ RMZVODL;'5ST
MZ@/0'UFII+VU47E9>Q&]>WB<+YZ5JL](MTY'VQ206(J0Z@A!J9E-?"="R#$S
M?X0\4(J'5":1L\->%PFFQFI&\H=%WER;@,5C$YV>E>52R=K,73B<_?<T-J>Y
M;A3$!R:\6GQ0RP^V%;@"*Q6:FY?M&Y?S63Q[@M_#$W#H81C)+[#+</3D'W@)
M@B>]!3LU/)[OX"5Z[W@27M10QX1="UW];GHU>\S5/]^J)S5?U+O--XNR*MNI
M1!#22,4(!E3:.+P40QI''*8X%E*' 8N55TRT<\]36UU6TH(OSV6E'GPS<CD#
M[F8F#P+CT$O&"D&[&*__9TML4,L]0*YG;[3Z2KWEW.^X6;=\X=A+N.7=0,=<
M6RPK_LKF2V.$_Y3E+!>9O3];G;2WN69F :,DB1&&06K,7TR,2<Q8I*%4@=8D
MC&G(M%=>+9=>IT9/5FA02VVWH6NYMZZ ?#-E.6'OQE:](SHP4SF >35.WBL?
MX/K*<>74Y[CYK'Q@V,M=Y?5R-Z*J,V!I,\TM(ZKB*1/&4CO<WZWIH3S\J[>+
M!Y;E,Q2DBJ8JABC!"F*5,,@$$9 F/$:,2:1CZ<-G?0HW.=H[-#?!UT983T>
M7@?1C1A?:VB&YL]NH^)-CT/ UQ.+]BK:J&0[!*@O.7F0/BX(L7NK'@ME6J]=
MWG-Y_6"]W_^[.3Y*-4T204-(!6(04Y%"PG0(TS1&* T9"@GRCHPZT>'4*'9;
MU'KKQK:$!:I)F-<AAND4YF[LV2>2 S-B$T6T!^6VM#U'_#C@TF?(SJGNQH^Y
M<5#^8-",RWM]N&O^R,JL_&+Z8O)3_E=69#:^YC.K%)I%$5=*\@2B&!NZ05A
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MH0CLF;WUYXVB&'(:!Y 2A!*E::1X-'M2!5^\Y@!L"S &SPT$MML2,02 Z\0
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MEECQ,(J8DV/0&,).C<Q6NMH3A)7$X/>LN@=&I\?6)WNC7GM542OHF5EZR"_
MC2:G,JX#D^S9'#-[PVE/BPZ.\=7FF_A:ZSM,L:LQ!J8OM\TA11W7[7,$T/?<
M1L?HL]L*M5OVY65YF!=\D^" *XPC& 5(F15'*<A0'$$9"1:3(&5(>Z5F].E\
MRBN(3=9S99BC4&Q>YS3[F65Y6Z!P49:J^>=673WSSB^;JE]?.E;]\AH[M[5B
MJ!$9F/L="E(-RN1=8.N)F;VZ'I5INX#RDCD[M7&IK7Z=5YG,YDM#MUL%LIJ,
M=$K^9!2UY+UL+A?JF'F;VJF\445-[[54LRB6+.$HADJ&H>'*(($D232,$::8
M!42+P.OZM%_QILRFV_IM36JPTA#83PULZ6A?6FEI,U<T 63MA/?TT.CY*_"U
MT,<>VZ%M\E<8U@O,\#[1[]WP[D6X5S*U^P3VN''=:R\#E1?SK^$R2Y)0A8I+
MJ(0V*PE6MNXW8<;T3AFE$D4D[')'.8"H$[W,/%@RS"O"?LCA=5PB7FFTIE/M
MZZ)B7R/6\NH^$&.5Z^H@X;0J<G6'V+OHU@5=^<<!?S"<.&\#"JV#<,H026EJ
MO5,HA5@%$E*L$%1,APCQ1$38*2'6@;:GM@&HQ0-M"*N/:_4AW$Y3ZH5H#$R%
M/D!XQ>T>4;E3J.[+MD:+SCVBQ'9 [K%'.B;%7N1WQD9YL <1'XU\[04UC8@.
M>13 @'!F9B:6D D20DIPI%*"J:!>55T/=S.Y26JDA*:C!R"-G)[YJP\#Z6;]
M7 [/T+/6(F,E!%;$[?(%*X>)7UAU[I#7/[?T25CZRAM]N)-Q<T*?5'0OW_/I
MISOD/7N10?K+DM?^+[:3F4R3- E2"G5($<2Q^8,II6& T@BSF!"><N?L9B<Z
MFAH9K&0#EA \\F2=PO(T&_2)T."K^,L\]"M!K\!M?WAY9 _K";>1<H1UQL\O
M#9@#*">3?9UZ?[R47@Y:["3N<GF^H[6T\0><F9T*#71J8QK,#@93'$,NPQ@&
MH9(X34(6),PGQ&&K;2\J'"&&H:[>TMT9<ALU1WNH&Q9#DYX# /XVSKZJ?1DV
M6RV/:\WLJ[1GPAQXI _?\1<%P3^OZM)\6!$ FG&$8R53!A$+*<2(*LAQ:NP9
M+2*:1)IB/R</7P&F9N>L) :L$1ELBOEL[!_PW;-BA>]QLO?8N+'#D(@/3"%[
MGM)K]%OQP5K^YHF>K(%+H1O$G=JA^U=TL'8'Y[3+M4<[?@Q8%M4F8>-.,FQ[
M1LBTX FR^S1!C'DB!(7<;N!2I7BLS88N#4(7FCO9R]2X;"<[N\\IZVDL3]-2
M;P@-S#T^X#@3BY/RI]C#-+#%'.;_-JQQNNU1J,%)O=7\=WMXY(OW#UFNWAN1
MREEH]BLT3#D,(K--P0F/(-,H@ D+5,!YH&44>WEL72S2U.AC.W/W^6O:%QF^
MZW0Q7ZUNH%;.US'K\@%VLY[&';:!.>WBBW6W$1OO%GT/Y->^--\(],>X(]\#
ML+<K\?V6>TVC\;XNF+L35KW._$X91BB@$DIL+#H<L "2B)@_$A2G<4PX39PJ
MC'0786I47><9T'7&^-JO,EN)WG<.AU/#XD:XPX(],,&>R>FP5F(KI\,@*?R[
M@SALFH=3 DPAW8,#0(YI'UQ:ZD:(+W;('Y<VAV,;2U:^+\NE$8*5F9A)K4E,
M.86:X!1B:1-!1$I:&@QP%$1$*B\+UK7CJ9'?2FZX.K+;K0.[K,J*Y?7M?&=/
M4.<Q<>/ (9 >F/GV3N8:H>N<>$T*W$;N*U!+WA_5^6+5$\$Y=SLJK?F"\9+,
MO-_OX#WQ/A>V_)QZGW]8L+RN46>8\C.KU S;D%%DDVR'"8>8I!0RQ!3$5$C*
MB> X5,[.$\?[F1I!K22U#LIS(ZOYNQ$6%$9:#^> $]">)IX> 1N89]98O<^!
M%1.LY 2?>\/*PX^B'\Q&<J/HB)V?$\5Y1$[Z4)QX?3P7BO,Z['A0.#S>M0I4
MDXZ_COIO2/C3QER9$<0D#4-AZ#)&$(=I;/:Y7$,>T4#@U%A_Q,GMU*V[J;%F
MZQ3=%BRH95X7"]P2V[<NU$G$3[-H_S@.3*:70MBA4I0+,A?4BSK9_,A5HUQ4
MW:\=Y?36A16D?C%LM2SJX[MR_</_S(S-5XC[Y[<+>^<ZPU&BN90*AFF80!Q0
M#@E7U/PAM(JT5JEDG6I*N?0^-;+9RM:QEK1.X_'Q^J_@:R.SYQ6&WVBX;1P'
MPWA@(KH,WNZ%JGQ@ZKMTE5/?KU/,R@>6H^6MO!KIL(^TIV[7N;1_O?NO9?;$
MYK8G\Y--+IU-V/<L4)'2DB4P3(+(V$I(V>S:$0Q9)(.08!)H)S;S[WIJ5&:E
MOFJ2;*N-\/5L>]AD(2H]LQ!U&!*'+>E@0 _,9_4=@!&SN0S8$KW^X07)GCK
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M\$!PE/ X1'3V6%>Q^E*QHIK,IO^L:C[D\5+!X7CDU_6.C9O%-*^S%IM-6R-
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M_Q;1-X62675]5ZB:RWY1]@YIEM X"G&8P A'AA@"GD(>H BF*N&8AUIBY)Z
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MI2#V1%J=Q1B5UBX%ZR7Q7=Q>-VK\1<EL^6!=5FKGE/9>5%.D9<P4U#(D$-.
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MAB7$..&0)BR"8:PIQC+6L71WC7?L=&ISNI$09"N7"J.#CS^R*]2G9_U0 [,
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MIK8Y;40%:UG!2MA._JFG0'8CB9Z@&Y@G.J/6)9G .3SZRR%PM*>Q4P><4_E
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M4TYWH >F7Y?BJN69ZJKKJA%K$.R1:P/#"%4C7G<,QRJ6VJ_PTRJ+.LC >!=
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MB2.LB588)@PQB$-N+1"%8"@P#F.L<> 7/_&B_:D11"T>L/+Y.H_MPN8V_R\
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M^!)>N]S@L()KU@ <":W9/]EC5_WZ_:O7-[=+62V?OBWUVNE.WK0),-"03ZX
MTZL834PP!R0K<A!S02C%A,2%_>:YHZ&Q+6J,J='&UDG46!O=.&S"NG"UV.AZ
M0BLPC9P%JD^URB[$'':GGI ;:!/J_E5SVV):H-&YD^QZ?K@-HX47>_M"F\_W
M+7>I5T%;N<.8JUQ!F8"4"5.>5R# ])(-)"I-$4UE3)!;=.+>Z\?&BQOK>HI(
M[F-GMZSJCTA@[K,'HT=QP%,^>RL,N/?R@8L"GG+LN"#@R4_U6-QLR@AMX](^
MS5_5I2^_WDFYW@@_88P597$&$$%Z#R8(U$N=! )>Q-K/."_R%%HO=:R;'=L
MKX-'5^8:H+';2#"L[TRNT'RUF)6B2@ULBH=&*^.+PPQOWQT6*Z0@( ?FC&TY
MN&AK=?1I'C5V1Y7A-@I<UX#KL)@* O) 2RL[L#VMLYR!ZEQUV;]MN#68LX=[
M*S+WIWL>MS7[8[,[+M?F6_;V!Y\]FIK'1DU(D^C]]I_>+.YI.9_B!&8D)A0(
M$E.@?Z: 2I$"*BC,.>(\44Y293UL&-M$T+H0;0TU20>-%]%6>6O[[]&?M2N.
MB\(^'69Y(!>V&T*?T(7H ?=CN_X8^CK'ZV'!L =[_2$Z.NF[XE5C*Y7]AURM
MC79/G0=RN>:QWC"K-%,2")5C !,5 TI3O13'M$ T)@5TNS\=C6=CH_;:_)&7
MRW;]]EB>)8S%WA'-,\,5S6Z^>/I[5Z/T7ZER=L_^'WWQ;%>__HO4S^[9G<.5
MT.YK8']-U*TQK1[?%]W"6Z5D5;M3&\+-EOY63BDE+).< 0Y-R+Z4!)#<G(G'
M:::W6I!AXC23.[4^MMEV8^*.OJFVW%VUU!Y_N[DP&*J!YZM*?W1K^&2C,1H9
MV_5DM %\:[Y?=5%GU#Q*B-JW/;A.J#,LI\1 W5_2-XISM9)R$["X&Q]J-M53
MA@N*<E0 *C'5',8PH"CF0.8PCPF63"+N%LW9V=[86.O#;MA_9/:=KL&:W?#:
M491'T *34FWIY# "=M+&BT??NB#L$<-I!8RW6,[NU@:.Z;1R_3BVT^ZQ_BIF
M)B*1SCY3W<3'A68O<VXCQ=_+]=UKNKJ[F0OS'[.N>Z(SLZ)K EM('(M<D@3P
M7&4 <JP72U2D@!2:@' !B4R<:@#U-V5L'+3U)'HPKKAKH_7L$CMR&@;HP+RU
M@W'EQ232?D2M(]%?VI/(^-#(#.D?=KP)),]V':@>==QZ&C*XX-MU@)U2AKOR
MC6XD*F0Y?=/<"/_?1[K4W#)[KC-'IPCA/$UQ88+BL=E*0H"I3$!"$54H05AS
MI0T[=K0Q-MIKS8PV=C;IS';\UX5F-[%YPBCT]L\9'FL2L@#@!+NL)/_;[>+I
M/_33-;'H'[9\TO7.08C"PJF6 6P^VB,&:W];5Q]8E;PY[6IW>9_FL^=J9T!9
MDF2%'N=%K/2PQWKC121/@>0*(55D4F6%=1R64]-C(X+-N49;[<AA']8#^&YR
M" OGT$=&K>GM1<;.(9(Q?]*]7;L6:8?PJV"(#Q2"Y1EYMY"L7N!UAF6YO7&X
MT*Q>GNZ%9_5[0[_=\KO'Y;Q</RZE7DB^*W^8GS85=T@&A4ST]C>#W$3A%H R
MD0"1D227-"MBZ!1.?[ZIL;']QM)JJZ4:6]WVO!W VNUI_< 5F,WWD6K-#+ 9
MO8R&I\UF1T.#;B8O.WRX6;1XHA]'W%1UGU\_+HVZV"9P.2&IHD46 X*,Q@(4
M,< ",\!SC/7B4.\4L=-AV<E6QL8,C7E-*6PW1C@-HQT97 U.8!ZH[9M$+3XA
MRE9W8N!I])]N8]"!W^GFX9CO_G!/+=:]@_D/3:7WYX_:_+J=:4%2*+B*@1"0
MZI5!$@,J. -) 0N.,I40X33T+[8X-AJH G[-#K#1Y)HU)I>NJX3+6-OQ@U<$
M W/%T;W<QEQSXMT:[%'@U!8;7Q*F%]L;5J34UOTC&5+K!]UX9K5<3[^8H*N;
M'^5JRA')$>()2+), )C$FDL2H@#'::6V DFL;+AD[ZUCXPN31%FNUB6GL^AW
MC:9>FM4Y L98RQR-?=BZ::$W&(&'?D\<K(?\2;^[AK5^8&=(Z[]MA_/^NP89
MLB?-;X?EZ7\<(#&K3A"G%,&8)1Q(4P4,9BH'&*8IH$J00A1,H,3I-,#=A+$-
MZEY)07U2]7OTEMVJ(6P?!.:2$/"'3<D*(2#0PX#Q)F1U"A%<\:8KQ"7O%C.Q
M(VG9'N%)$B<LAS'@-,L!Q((#)F(!4)$1@;,T08757;A%6V.CO8VIN[+%CMN>
M+FCMJ,L38($Y:HO5KID!CD<MX/ I)GFFI>$%);M=/BDJ>>&1OH7+G^3\4;[3
M5K[]H4?AG,Y>/Z[6BWL](%\]_R87MTOZ<%?RFZ4VX4 T%3$F(4H2()"* 51Z
MC44X2D%2)#11F6*XL-H!>;!E;%RS*VC;N&72W[8^1,8)UZKH_;O*CIL&ZH#
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M">D PE%.I,NS/?0TWL_YLLJ.H \K^7Y^IB3D%Z,(NYI2E<08:<+A6$ &4X!
M+F(,"*=$D()E*K67TW!I>6RL4]ELM*=WZLDN*TO-WGZWC*R#[H-35W2S4E"
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M^][8.(F8O"WG)M/%W$?4!E0U6JNZK*O1%&8]^E80GF,!"Y!H7P%$.01,I F
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M@A"NB)H^R25;]*OA>]">R]C>;37@NM@8:"+Z'E>R5S7O;GP9XCDI6 QPD64
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M-ZSPM6:%VM*]<'!_L[@-(I[FYLZF!IUQ;9P^G$>MGNDW.[9;H[T;_,V]_DX
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M&O@BVL+MXQMEFX?Z<<BK6DGHZYV4:U-VRK337&9PEF6*(P4X53F @C(3421
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MS7"+4WN?]M::#H_U#;]CZ_=SO0JMOD<?]9>@22QA"F8",0AH#,T)M2@ 05
MI:1B"<]13)Q2=\XU-#;2-79&6T,GD3&U9][.67#MEEP^( O,MSW1ZA&@UPV%
MMRB],\T,'*K7[>QQO-Z%SP\L*&%NT];/6XM6G]9W<OGMCLY/YC$?1&!4__B&
MKN4[6B[K'0H764RHWL06L4@ S"@!-,MR()(<9T42IT5BM0X<G6=C([_?=D0K
MKI69&@W(H54O7O)+,<BQ^%5:&34Z.W/$*JKPB=8:H"XEC:/0N^HCD8$J,EC5
M&_T12&V$ZO^7%NCP[M?/(>L1JCN]B8$$,]!=%/IF5=+/E)>JY(V>!16B4)13
MD&,. 60L R3-,,@*1'*8<ZZ456#+R;>/;;HT!D:-A?;:S\>@=4]05T,1>)+8
M1<&CS$>GVU=H/!^_<S!MY[/N[&HZG__0M3%I-_-U624-E$_RJ^2/RTK<]>T/
M/GL44KS3IKZN<@LJ(OJDWM*EJ>&X:D45MY%4*,4I3+$$3(H,P!QF@&&4 T0E
M3FF:P83*?M%KODP<&U/LAFA]7JPU:Y=T-GNN$P9,7MO6V=U[Y;Z1<-YZVG+I
M_*+]%WH-O--UN^[M=EGK8&3&>[3CHGFH=7*K*CM02)[OSO >O.?-P!<*\_,-
M\/F 0.\M73N7;%:/54U4DQ.^HQ?^NZ2KQZ44G^9?C*VF]IU>Q9:K@X!<D:0"
MH3P!M"B,VG<. 4NA!$7,I9**9#1QDI?S:MV89Y#:JRI&8,>OJ'4LHNN='7)D
MLBBBC:M1Y6O?B<5'M[O.*0-WYH#3R;:3)A?[5/?B01\.-(MXA-_[!.+#MA>:
M.SS">G[:\-F(MV#S[_.GJG[\6U,D^&U;([@YNVB/$8J\2),T PF&%,""YH#$
M:0%RAE22,TB*V#[RH[<98YL#6I.MZBM?'7%LTT\6\2.#H#_$.7AT? X^B39=
M4CD2;3S9AH!?.A#QV1U7AWE[[I8A@[E[=4_0@&T','N$9=N\_:6#KQT0L BQ
M=GG;%5?>[/*9/#LCT-T892;0]_.UGE%7):_FWV2*8"Y)H01@L3":5BP%-$D0
MD"Q-6)P0E12I\QUV$%/'-NNU3"JW%D\B>GN[K'0#HK*UO@[V[G%)':;#'6Z=
M7[P;QW^-O+DH?KO[+=BX'.0R.&BW^+S=#6/H\->U00$_>?\:ML4>6Z9-^;TW
MY8K/%F:#5NW'IDI!9;2Q "FHN7-)., P1B#7?R\0(2++K<12.UL9&_7OU(K<
M6MJ<>[BLJ,^B:K%_\8%58'X-#I/#OL('7 -M&T["YFE'< F&S@7_V8>'6\]?
MLG]ON7[QPWU7XXOEVL2X?S Q[T:!=LIY5N"TX( CQ@&4!3(**AC$1%($$R58
MPMU6T8=-C(T"*PN!R?R)ZF0@KHUT7>0>X6B[.+T&G>"+2@.,L2[Z4*>BO.Y"
MIL<2\)SSWI9N1PT,O.0ZY^#Q4NGL)WV4 ZY%]FXV";E3&&-*B82@((4 4/ 8
M8"084 FD2F"9B,))&+Z[N;&-^*/ROSNIRKV%/2\@;L<'_G ,S U'17X;L<ZM
ML:$*^YX#)4A!WZ/&7K"0[SG'NPOXGGVJIQ "7=V9_YL0V2<Z,\&Q7^1*;\[X
M6F_S]#_<S,7^+W8^.14IE6F<<9"B6 )($@((89J%<$&X_J)AHK=8#U50[=<U
M7:[MR.<JFUS&U*%EX8:7,7(2<?UG)+>V5G?7RXTGU;]/3"P"D[?EW,2CF#OO
M]9V,:DL=90NNZEH3DQQSA@!/3"9YHBB@)"< IBIG.5-<IK+IVK=S,<J.;>T:
M3;=*(U'Q4AW*:*Y4FA4@B2D%D'.AEP@, YQ(RO1.()&YF*X7:SH;66=N;1I#
M1];J\?/58E:*2H>5-4785J;REV.8T'4]:K<$&:R? J]0ZBXR?T8[!IIT^DW_
MU!\QG7;PR]TG/ J<^$#6EQK*5;8,*YWB [8CG14O+^TM4;Y\E.+58OZXDJM&
M@'(*%<*),-D\2:( I(("@C'7?V244)X5L'!2E#K9RMAV8HV1D;Q_F"V>I8Q8
M;6XU*$W,3;E:V8?:= -L1W]7PQ:8UEK$&@,W(K1>9;G/(^!/8_M$&T,+9I]W
M\X3Z=<>'^VO*E>LJOU"3S>O%W.B/R#DOY6KGE'<3U MC)A.<"I 6^@]8Q$9Q
M+I- $KW.3G/,\IBX*L[9-S\VXMBQON**/?O=Y=H<^L%R%14,W=#+IBY@]R^_
M0D1%]\/-HT2<0^.#"\BY W-*7J['6WI<L__OQ<J\>^>VOREI:!HUBISO]90O
M-W>0YLB[*9EN3JGV2@E46]]ISA$7B6*@P @!J/3ZB)$D!RHE<298#G%LM3X*
M8MW8Z''70J>S@S!]9Q$$\)(]$IA2&]=V8[$F;:'5J'5O$NT[6-VUF?WKQL?)
M7IF61L7C)7O5(6;A)7MWH%B'%^EEMY")4+W0&6KAO='A0C1"X;47VA&LD7Z[
M$E. ^*]R-M.MTG*I&]C6_:E_92SYL%BMIBP5F NH9V!N)F0L$E-@,@-(0IA0
ME&.H$I<-B77+8YML6\,G>W7/RHW-5>U(MSV)?2_8;4>"8!MXVMS"VEJMN7$'
MX*WAT8<N@)WW(,Y@>=I^V+<[Z,[#&8[#38?["_I1UT[F97-"LZG.$<,DAX5*
M $P@UYL'35@400P(2Q+!2,8RF+EPU?FFQD9.;8VJV=9B-RKJ0-6.>_Q@%9AL
M=HS<J>MUN;B,,[E<1L,3FW0T-"A]7';XD"\LGNA'$!_EN@ZD-61S\T3+696(
MO=@1W6_J=9LT;3[%*H\IBW.0%5@"B&(.J)0Y$+'*,YS%D*9.1=(=VQ\;E7QL
MRV!;%3QGQ@4WJG'M'SO^"8AZ8%(R@#<A]+\8XW^--N8;V'>K<FQ@?]4)NS-=
M]03/$X>YMCXHL?6$YI#M^KZF;USP@DLI5D;0R!1P,:$HG]2'Q?S61!\;G>MI
M0HED*,M-T53->C#C)J.6@8))E),TIH6=P*1]DV,CNM;B6FRL;&PVH5A"6^L:
M%GP1<#L:\PMC8.;:1_#]#H+&X#JGX$T7ECV"A&WA\18H?+'!@8.%;0$X#ABV
M?O)ZTJD(;3_!4XIIG*=,IC$"(L=ZD\8E!#0E#*2\P$7.B.*B-^><;''<E-/J
MSI@!TU]YQAY^=P:Z&M1!":BR=B,8L[$W#/MT0A. ?$ZW]V+<T^E^%_5T/WAU
MW<8Z$:(N6C>E')&80P5B8K1"",) ;_;T1D\F*2&,(Y0YU=XYT\[86&:_BF-3
M"+%WQM,Y<.W8Q -D@3EDO^IA;630LH>G</!?_7"OE9<J@GC*U8Y:B"<_WI<2
MM*WF9LT0S9=R]<\/Y5R^7\O[U531C"E*"""00,T*!00X+7*09XPGN4@RF3E5
MP3G?U/B(8<?2R)@:_6F,C2IK'8MR=2!L2PT^< O.#OT@ZT$0E]#PQA%G&QJ8
M)BXY?,P4%Y]X&;FR/RHYM9NY>/OC09I,@F\+\ZL= ?J#XB%?I*DKIG_?WOX_
MUD4(DZE>E!"*!02YP$1OD4@"<(+U"B9&G*;<7,8['4:/Q[6QD6&[3VB$#4T4
MK&Q\-,>NYM?#:J!Y_!;9$?!X#!X1X?O46/MC^]5ZN_/5,K^>[):G.%&D:P-5
MM(.5I^*PX^W_D8BY>73LIQ)_\]^AOL7B EC8>W]1O>[OY?KN]:/>:M_+97NC
M_=SFHA&6)EF20Z 2'NN=!D< FV0_"JE*"A1S)JCC3N-BHV.;9M^T"B)+^23G
MKKJB5C!;;S>\@A=^XU&9&_VE[8U:@R>;H@;/ 7("72#RMQNYW.30^Q)K$$[L
M4.R?[7G+HK]@=YH=/[%9>5NQYYM'^7[^4?Y8?_M+SI[D[]J&N]64%B@G$D$
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M.=2VX:'S0AT!.9$2ZOJ&?C3VZ4&:F,GY[;9N45[PE!/%09:B0M,5Y("07 A
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M[&0K8R."RLAH9B3CS;E_1"M['8.S3L)IMUJZ&J3 ([_&IS9P$FU-]!BEU86
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M;Y<</J[N=O&)GH<E_$Z*QYG\I*J+GU?/U7E,/=523/*"RM1H\E <RD!R64.
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MDJ6B IRO93F+ :,Z[_"/,&<0Z4(L5)#"&CCV,BN=M$,5MDX&2W-!K7^>67J
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MXE9P\\HRMO;H!2EP:]'\"Y:^M0>GNRBNPWMZ+K#.UVLT=R9QH8A)1 (Y*Q2
M*82:VZ F5Y@%2+)4(J3Z9-<LH7UZJJS09<!M]MLR"N737E4V@1,."LY7@ Y
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MH,0?'.[#>2)\@P/7N6^.'7?.%[\L9C,]'9I_G-*<$U&D L $4A-.H><4FN:
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M"8FAR0>,\Q1 @N 35 &3! 6*12DP$E[A&U[>GVQU1Z'UZ&OT.1J];],Z$1E
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MPN,K*JGO(.[+>7G_>-](?C\TW7&-YK=KB7</ ;FC",%[P#%VB^@$$2)^X6*
MKU]PM5M7VU<Q]>]??UL\R>6\BNJ^E7/>J+1L-5N:6QJ>FAS/A()<$J17=T0
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M#,60I5BB'*A<* %30 Q)UA9HG>B2*8DP8G;$L^A]?$M]BKC)]%M;7XU-.F>
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MXE"5IC<781J+2=2@$>W"82+2:T \QD.^1#_ZBK(<U/9A8S=?HEN.(D)?Q(A
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M-/?+<[%SKON[I-65TZ?Y%V/!LIS?UF(ER_:OE0G?*NGW)*6I4D4*$L9R 7'
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MT5R!0T!3K 5*DX59APQIR#Z%_-D;(O4-N#KJ7*HNI*0K<;!>E']>F)*9=0N
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MQ3%8PP=2[-@PUNB)8YBN")DX\;)^;/?1M",_J:8NAN;6*:288L448!A3 42
M@.D5+5 2,@H5D05Q*HYUW,38>.I=J_%>[:]?/:[*N:RK[:WO9+5UIW/'R( 3
MN-JQU'5H!::@VC@#S-:\0*KNYW'PQ"XG&AB4.LX[>,@+'9]T&_1"EM.W\[6>
M,]Z5,[E\K??'MXOE\S2)DYR;+*A,80@@31D@298 7!2Y9) E16Q5W/S,^\<V
MW&L3H\K&J#72;GB?0[![;'O )?# =H/$>C!?</S$2%Y)_K?;Q=-_Z"?K0:Q_
MV([=<^\;9.!><*8=M9<^UF^>/LB<_/AH=CJ?5'5,MMHY^#+!ZGS*29I(B'*
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MV]3V1OM+AOF!Q"Y3=;)N9 Y8O:Z"[;&+B0GAT&:]"KU/)CD4UJ5X3KX,@5[
M AT3Q9%6T5YHAJUPONBT+D-7&QEOK?#5YQFA>[_4,?IZ40Z"5N<7CKJXUPS#
MC&+#*)#(%:105 .>IAE0HC BU0+I(LAKPJ_;J?%PZ8M7[PSEX0ZR#G\)C-;V
M@][O0CT^H*,< (_"0O;;E)NF;&K$X.X@B&(%>_MU.F[P=Q 0)\'@86]W=-RR
MFO#-?55 NDI:]FZ^Y$MI__Q^J[]M=L?A'!=&0D0!I 4#*-4,<,0ER)DB#"F#
M. K*]^C=\^3(Z?'A85'.';Y(EJLE<&HD<R?RGP.]N[S!]^.F02 =>M-8R9SL
MA"Z=YW9B)Z7<@U0'"T8KEL>8=[_C.I*%PG'B7Q;<0,?2I:MOW^95:2#;Q>O5
MTG6F;3=Z,TLUM,?45 ,CG;5/4PXH%3E@2N12*684"2*IEKZF1DL'HI932!X*
MF_ST<;75"0WT2&B#VH^2(@$X, D=8_=,SHA53J^#$:O::4M/XU8]O:[R2?53
MCU?"'5;KG-I/;W_(>[?W_6@_AQE62!7<$)!B3 '*H :TR!@0&/."J\SD.O7U
M6#W7P=0XHI$Q:81,G)3^/JMG06PG@AC0#'U""D,ER&VU3?5.?JMG&QS-<;5-
MG4//U=;G7B:_R8%K46N5(E+P'&&[>] B10!1: "7B@!B<&ZW#U!1 V</91V2
M7[9\O?7;2(PD?<BL.M9AN GVBB]<$JV;1.BO\V694WEEDJK_<:I81?HV##>"
MYDH#H:&PVTNH &<<NC"'C(G4*"%8_6V\77JF[)KLE]%H,,)WH>V>ZU_SB_#;
M!4]PC$>\=>R;M.:9I^]T*IG%';.)Y*+QE?I?*O-,X%#$SC,3VGVW_=%?^7SI
MBNI^6KZ9;QY6F[GK^Y.IBE7 68&,3"F# -(JFPP&G&0&0$B%X/;O$O(..3[;
M>_4BI!=(\.D"-BP7J5)DOG!KCYG_<(FQ2KG#EIHKP/NM$!%P'(?8G:!U]68'
MX8&T#L7;=OR"2=@/EDC<>:6S42G/3_%CIO)\JQO!?+8HZ_6ZSI12IWXD%*E<
M4@ EL8<E1J5+7IO;$U.&!512DXR%W+>>Z6-J=R@[$:OHO9OD?Z3_*TUA\L#7
M50;&FP2F-VE:_K^)'N./V_O5VF7[_$NR7#4_==F%ZVQ\J_T:84G(3:7__;C4
M__'OL$C_DJ<W25F3QCWX1LLR/4W]3[#\)QC&6.=&TH^F>H[/P-RT'YI?JJ&I
MJWJ]+W&.QTHM*$2BHG,]C,H_+2H>DT[;H]V8YB@I4YTOC!1*&H49*(3+C<0A
M 0(1!:@T.<U2B2@+RHUTMI>IL<VORSKYZWJ?-*SDG>31/^M=.ZY^,[\W6@//
M_9.D:E=SUP5/^U8((DW\\WV,.O5;U3R>_.T/QZG!O"^'NBO!=[<ZK8RZ<Y:
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M?A$_MB!8+KFWA372C= ^U%?'<^VJEY4,>K]:V/<W+JG1]FF&4\D*D4O <TH
MTH( 1@L-B-U[&Z:+0F5VU[W:\H4?AUWK,(BV=MT.-]'N7!^[&W:71<)MHS<'
M<O_'O],,DK\DNI0_C-*NPN_'8C%!'9BX/APA^;8=M6!B\H4B$A==[6Y4^O%5
M_IAQO-^+$I"GU]]FJ,"YI!J"@N8%0)G. #,P!9)D1<X8Y)0%N<Z>=C&U_4_I
MM^E<8WM%VCGL_#BA'R(#L\!11-U-<M<&3-]PN@/=AXFF<QV\9##=@8)78ND.
MG^RX8U@MO[K/V#5\9YNX_3'?S%"&#<JD B9S>2DXU,XB5@#-:(YQJB$70>&U
MYSJ9VH1^'E-K/V';0_*;DS0PF/8LHIX+?T^<AE[LGX70^D$4ON*W8!!KE3_7
MQ;@K>XN2)ZMYV[,=@V.J##A_X[*\J7M=AUOD&F:%*@Q(=0;=*JZ T(P BE/(
MC50&Y4&^@.>[F=K$KZ5,OM=B!D:UG(?2;[[W!VC@&=]@TTAXD[R.'H?2BD&L
M6)/SG8P;3]*JZ$G,2/O3'4QUGQ[TFCN[WP?G9_/S:KF]7SR]_>%*"NJ9T1#F
MVJWX-!4 (1?[ANTN7LE,2$,T@X57NN&K/4UM]M?2)<)YC[5^V8&(>IC*8N$T
M, GLQ$Q*.6^2!K-:U%B(!5BS8B$WDL&J,X)A9BD?5%HM3ZT-C&=<\M'CF?W(
MZX6NOH,/54W5S2?C=F)N^_O!7==^,E4EDYE2RA14YB#7A -$) 3<<B8H:(HI
M,ID].9$.[LQ7._;ZSL=W9=[)[<P5=;&7VZ]K7=:J#?4BO(:]WS8K#I1C^0TV
MLCY/6E3*NX<TIKN@)SC1_ 2O]3>R@Z"G^J>>@;XO=LPFRC?WLU1JC'(L@(;4
M<@LC!6 DET 2B K&#<Y0T+VJ:W1J.S G4V B3P>-W]0/57C@V=VJ:WCFS /E
M8B7#=$V.F]_R0(F3E)6'_]9M&GU:?^7+^3^K0]1JN5DMYJJJH+Y4GUV>V7KS
M]\F\FR_Y4L[YXA?[DW*U"JW]%J6O"7VMA_K<),\T*HU]ASJYI6FG5;)7:Q W
MWZA 1YHY<60:=>I%A?%X[L9MO,-]QW-3B<M(:KO9_CQ?SK\]?JO]^K\X*_^Z
M[/.S7L]7:B9ERJ4H(&!YB@'". 4TRP7@$BDF!"7$>&4(ZR["U-;G6MS$GK&D
M&[2OI2/2NHYO6>_%OTGLF,T7[IC[4&IR\%S '4&W<?.X;AE\-,:VLC8JW"3-
M&.T#MPY&I5)D\!$(N+X9?"1&NM<9:$3";GUZ@=EZ'=2MY?'NB7II_NP"J5]+
M'1:G7_3Z^USJW<7(9_M)WKN[J\JQ'Z4XYP7)@::: 23S E"=<D"IQO;GAA&2
M>J]"[7U-;;FII0V],_)!U6.-B(?5P(O!"4R656I9N\2@7$$N@-OC(3@2B;<@
M&8FA_2!II>(K38S'N7ZZ/"-7SU?BI0+/ZJ\6LR(UD"! <J0!TJD K- "I#C5
M7$-.,B3ZI@+/ILFB56;KK'\J\*QW*O ." W,G9=3@6<CI0+/1DL%GDTE%7@6
MG@K\^)4.=6@JMXEW\XWDB_^K^?KM4KWA6SUSH<9"8P4R4RB TK0 0B &!,N9
MP;F@4B,?:FCK9&J<4,N95((F3M+$BIHX6?V(HA72=H:(!=30%_1=, HK_G,%
MA&YU@"XU.EY)H"MJ/:L.=.W9CJ[,KFJQ?NX+T(1"//VZ5+:[U>-RJ]7;'R[Q
MV>TW][<9%D83"#%@ @F A)! Z%P! K%,"5<L)4%.CYVDF!I5."7^G%2RN5N\
M19E<:V>97NN'Z@;7W?7-K3(N4T&@EW2GP?+;A0P^! .34"7_37+B-K13XB8Y
M5".I]*C'*Z(K=A\<8_EJ=Y)A7&?N/C"=>'OW:JP;<7[4VRK9FJN[L$M6?K<Z
M",NOX\?>S!>/MN]9H:D4S"A0P"P%R# ,N,QRNX>24!04Y2+G(:09+,'4"-.E
M/'4551*^W:[GXK$JE;!=/<L<7JMPDZA*B3#&#!\E/[8<%/N!F=+!7N=V_,F)
M_Z=]^00'_F&BD!WX;ZZ 'TR3G0&,1)'A_8]*CYWA.:;&[@UUO%J:+^=;2[[?
M72[*K?WLYK:[6TO/]G@Z7^KW6_UM,T."<,ZH 0KI#* <(4"+PAXD"VX@*0PS
MVBN-54BG4R._2F90"IWLI4XJL9/?G.!)*7E@*)W7"'C>3$7&=>@KJ@B0AM]4
M!6 4Z\K*I\MQ[ZX"0#BYQ IYMQLIO>7KI=T7;C[K=5DS8+<C8U((H5*0PTP"
MQ"0#-&,2I"A3*22H((4,X:$+_4R->G;[+KMAKLNUA.S RF+R:K58\/5!$X%U
MY2\-B1\Q10!Z8"YJ)'1N"U4!D0$V45=@B$0WEWH9E6&NJ'I,*M<>[YAQUC7U
MRAXNE=T^N4"9RC=OO;8C7UKI7CWM'_E<7?S<_L'7JOSE;WKC3J>5'P2<44-(
MJA !4IO4!0YKP'.H0)99(LJE@2(-(I^8PDV-L4H1D^^5C+6C7!C?1!TZ/Y)Z
MJ0$9F-E*F4$I='*H6'*@62*>DL/G:NV24K.;ZK>DUC":8]>0N,?*@1Q3M''S
M)@\ ZDFNY2'ZZ,CT\EZK1Y=HKCPBOWIZO>";S3X%ORX*3*@R((-<6/*&%%#$
M(5":N)\(3%106LLK_4V-CQMQG9FC'))-4[A(E84 WSUN'^VNTN4@Y?;S"J3J
M*]A[LF\\1(<FU$,PRVR\ECU+:9/?[LH-^2 E#SP!BL5\5WH;E\S\5#_A)\_7
M.N:74?_]N-F6ML*[U:U29041OOC,Y_9<_)H_S+=\4<XU<<R0I9/MQAZB:Z>Q
MB@(/ZI"4/B(SE:>*"BT!SERZ"F9RP&&& 2(XE6FN.,<F*%/-P )/CO3<H(-2
M&7<^WF]\=$A*A]&&VX\FIS2( _/L[>?WKV_.;TOW6PSGW%:7Q7(+V>O59NM5
MT2<\A<](P,=*!C2TN..F%1H)_),$16/UVW?76X=O;%P-G[<_++M:*9OZ/2X_
MJ@O>+Z]LJXO:<ILR(Q*G&&+G$"010(@IP) 2P.0J0TABEF=>88!QQ)G<\G&P
MS6OTJ2I=-1KMBEQ5:8'+/!:5,:.Q8)2*!=J#>@YJZ&Y[Z*$:<3,^T"CUV*GW
M 3?Z1KZ3,"^TS^\#W.5C0*]6.V8X<9J[FFKEHC#?V%/(+E\J0:E #*8@)8H"
M5*04,(P(*#),!#$H1S"(?UOZFAJY/A,U<;)VST7;!K$?&T8";F"JZXA9>,:5
MZVC$2L32TM.X^5FNJWR2ML7CE=[U+9I,JUH5!7+E6H7*#$ N";V0&0&4<D0$
MRRQWJ(X5+;HDK!VMAH6L(Q4.:EET+E81EK6V'T(#,\&!< ,DJ[VL>OP"%"^2
MI/:R@BU%)OHEIWUF,CDY+)Z:3,2QR>33@WMPXXPF6GU\="%CGTQUE3_C.)=&
MRPQHS+%E!TF *!@$J6;$GN,4I5F8<6, (:>V :E%+6W4M8M,Z1:S"?2+&61
M ^S5+SA,T[=;UXK>))6J-TFE[-X*%MF(/=!@Q#1FQQ9Q?*/V0""?-6X/U=<
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M4?8^5.%[)695G\3S!-P"I8?=N#= [-AC<TGD]025N?7_M@$&'=[8S22 3<8
MJS#K;"L,K1;8\V^.9V5ME?R9);7]R<YY 4ZN)G=G\9EA]BR<DA1 DR)+=Y@
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M901HJHT]U1;*GFJ5!AEDIN Y%TQZ;5JO]C2U_6N=$L1*FSP7MZ[H%9H\Y1+
M[6M!5-B&OE'OBEB')"I7T.B12.52RR,G4[FBX&E"E6LO=,PZ][P\]:NGO^K5
MUS5_N)_+V[7F)PZ?4--,%!+@7+L@4I$!H4P!"!,%HYI@D@<=<<.ZGQJ%G%PF
M+PYKP-MMS%Z;Q*D3F&DN;&C\]IS# 3XP^93X?FC'=]A[^V[0Q<HI%];YN.GD
M.@%SDDFN6RO=:.^S_2SO7?)RL9A_+=GTS:-^O[R[GZ^5JT(V$Q01!=,,D$)S
M5QW; (IS!E1A>)I*8G(35.?P6H=3H[9&WF2U$[BIP_=0UN%[<G7XMO;K#HQK
MN8J\'X_%Q'-@YMI!^>D$RL.2AJU0!I.5+SZ1Z.EJ=Z,2DJ_RQQ3D_5Z''$3/
M#9;5H6XNZQ/AY_5\*></?'&[5$TPCS-,SR2E6A<( J:4RTW'-& &(_M7*GF>
M(@13Y)VCJ),(DR.F1L[2NC9OHLH>ZBJ29=V<@)P]W8:EG:/& 7M@UCIRB;A)
M&A6:^SC[D]U06#621H^;LGC+X$,0D%9I\*$8*>W24$,2EIVI%YJMV9NZM3Q>
M=J=>FC_+_M2OI1YE<3]:-:MBG-4NN[:^&IAKC.Q&EPA*[6X7&L 0M5O>E!:B
M@!F4)"B.LZ6OJ:TGE>U@[PIVV[54[@5H_;:SD0 ;>$VHL-J+V9S$XQN]/?"(
M65#W0D_C5]9M5_ELB=TKKPQ2-B?01]RSM0E]Z3Y%6X;P+ ]$:IQR+2_CBQX(
M16#)EEB9?.;+^5:7UU9VJ;9?T%PL=#4/;[^MUMOY/\L]89V8X8MV43O*Y7U\
M-]](OB@O/!"WRVQF,."($( (U< 5KP.P*& J#.<Y#BKB$D&FJ2W2[HM-?EJ7
MHCHOJ\W\1U7@.M0#),9X^7'>R*,P,!]6VM3W[WM]J@W 39G3I0P)/E3-!1#7
M6CD#2:57>=D5-;M:+)3C)5CK+='8.=9B07@FS5JTIE\@%T1U+GN_E,[\H-_H
MZG?[]\6C\TA\^T/>.R^/+WRKWQIC)\!,093FV%6O+J0+$= $L$QK0 J99SG/
M.>-PMEUM^<*/RL<5/XCU=TH,1SH?]391M=C.D4LV\;#'Z25&3!41_DWX+1?3
M'>F!5Y98R2>:V["D@2'YJ0'B3S?)#HND 2-Q:"05'!/)5M%Y&*>0UB)<^'^=
M_!>=!R9JHHSN4G0P5WU^7-@-]H_R_G%9KM)\\0M?+^I;+2&H'05E0)$S#% A
M,L +R.SI118,Y4@IX54PUZ.OJ9U%:FF39^(F3MX F\<5>#WL2_% &]S\?0FO
MZ_>&P< %6(7B 3B2^:?#AQ=FV?%#I-6$<Z6)\6PU?KH\,\IXOM*U-L>S(N?U
MYXJ+7$B1"L 5-P!IQ%S52@52R@S*5,8RY56"J+67J1'H7LCDP4D96HOC')">
MF^R^\ R]%]XC4PHX@&&E%8)HM3;.]3%RC8T6-4]K:[0]W#7@XK5VM\Z+]TNE
M?_P?_33+$<408068*@A -(> IBP#"E+A_F,%]LHQ=K&'J<WS.ER@EC(IQ4RL
MG*&!%<= ML_U*/ ,/,^#D>D00'%!^QZ!$\<MCAPP<4&ATT")2P]V6[AO;9MJ
MOGC<SK_K7[1T]:SG>O/1CFZ5@VV68IXKB B@DN4 843MG]+<V7 455A0@[Q<
M]'P[G-HT/Y0WV0M\DSB1.^8(O JZWWH?$\J!*:$GBL'[ %]H(FT)KG8WZN[
M5_GCC8+W>]&-R>\>MX]K?<9HLL]7S2@7#"* N)$ &<H 8PH#I@7/4LU=(&<D
M*_)58:9&4:W62S?'=%7M>*=/4Z3BYM!JF?S,MV[(O7(*QA_@WF;GJ,/VDO;F
M848LINW9&^KAC<[719F*M=D;M SLW^;70L>?=>;K;O\>[^4JV^Z\=>=:9JA
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MM98T.1#5,DDE;.1$CE=!B9G+\7)GXZ=SO*KXV8R.U]_J&I-81\_P@MIC969
M 5D&D((2,"TQ$ Q+N_T01F.O*[7CAJ?&!'6<75@,T@E:[;._#P8#SW-?]3M$
M%UX-$O(-*APS_.>2^*<AA+W">5PSKVTCKFK)ZY72,Z@)-1)G@ K, ;*S"W"M
M() TI<@P#5,&?:?;8<-3FVY.MK(.3^*D\Y]MS\"Z/MNZ0C#TQMQ/^Z#)=D[5
M3I/M64.C3;9SXA].MK/_WC%,MUHS/Z]71F\V9>Z.=WJ_@U.%EAER5B,MM;M'
MI8 +N^)E69%2@S*CBZ#HN/;NIC8QFZW>PX&XB=&A);NO8.RW2XZ'W,#SN0'M
M4-+$B3K +MD/E%BQN.V=C1N)ZZ7X21RNWUL=F:3*3]J$73(JE4XI 98F,$#:
M*$"A_04R+&BAA48Z++S_6?.38XH.U0^. /.D@<XP##WMZY(& W@1G=<YUJQ^
MWOBXL_BL8B>S]OQ3W>N6NE)/SA?_SC91G]6$R+.BR N 9 8!$EH P0L,,(%<
M08P1YD&^HN>[F=JL+:N7.#$3)^=-XB3MF'GC JY^D[H_6@-/[GV9EQ"@.E4*
MO8Q#Q(J@9SH9O?+G947/5?AL>;JCK\66;TOSW2?SRW8E?[]?+>S+F\KM+7!1
M\FIK0I_S3M[26GX@\?]LW&L'<88-02F6>=NKSW%-UR$PG)BE@U[N823ZO-:N
M7FN=]6!G(%(%1 6VBV.!#$ &,GL<AA1@3C-F*"I288(-1&>[FMI260N9Z$K*
M+H6^SD,:8"/J#=0H]J$&J5UBE6%L0ZU@Q+0+G>]H?)M0J\)G[4'M;W0CAX]Z
MZ]*+VR/T][G2ZM73KQOG%OENON1+68:P;N??2]O3;@U5A*,B-QQ(:G?4"/$"
M"$E2P"C))<\Y-*E7SH+N(DR-3,H:!&:Q^F-3%0HSC>@)W\D>1C =AL6/>(8%
M>V!"<H5 2JP;\9W3WT].@V2^_%.R4R+9:S'(SJ<[B)&(K(, HQ)<=X".B:]'
M2]TK!=TNCVLNW%HIUNLGVV$9 ;.;=#PE12&) MJEZT8FQRYQ=VX)D1F""%68
M>27S[=3[)&GPH!S/G\/K\?@C[T=W@^$YM!&Q*7%T6MZ&.PZLI!\PTK$3<!'K
MS_CW/7KYF&!8SE5_"6^D&YV]T4;;?:)ZO=IL-Z_YPWS+%_-_.IM)N9>T8E2N
M1N6=[)OY1BY6+I> \Q8MG45G,"L@42H'*5(NK3&TNSVL.<@@%!E1''$15)J@
MKT!3([W#0(6CH]*FG,'5*>KULTK)8<38>PS]N'+,D1F8/AM5DE(75U9LI\U-
M,THW!Z-3&WOV2M4!(\-X3<<".A+=]A9G5 :.!=XQ*4=KMW,DM-O0\L6!M^<N
MX'K?W8PI9+(<*W?NS@ BC "::OL+H=HPHW019MCR['=JK'L@;?*M2G^CW,[(
MN/P/W\M=T6J9\&3MLG.ORY.XG>S+U1+L?A(<$.TU/GY4.P#J S/J3N)#/_'#
M=!M[J:/&/X? %"_VV:O7L>.>0Z X$_,<]'HW$GO+UZXLMZM06$;05:%'^WT(
MH2DG629!AB$$B'(.*,T5@+Q0J,!Y1F%0"H<K_4V-M-SUU8?59I.XDDZEP,GM
M=KN>B\=MN=G8KEQXZS=+7(>VH#">NC8$?OP4$=B!>:F1U%5]K3 =)_+-$Z%(
ME'2MMU&IR%/U8PKR?:V[']!=[5-09_NW%/?%[MV>JFPWYK-=].7\P14$^F@[
MO?M#+[[KGU?+[?UF9B@4G&(.-"XL,:7< $1!5KD!>,(8Y0&.??UDF9JM&6_
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M!VC[&]UHHM[';>Y6M_(?C_.U_KQ>/>CU]NFS_1*VM\LR<_"#>V26&X,U+'+
MLXP 9#@$C#,""DZ0*@I,:49G2_W5\I>Z\V</?PF\9@:K9L:)',/-DL^VH7ON
M#/XKXX*K2^%+BY-N) \CEX Q\2.;R!"/0SZ-T.YBO!8[:>2^24K)*R/^VZLH
M!S-2.&"1&"J@XU$9*QR08P;KT$(W1ONB-]J^Y'RLWNCO>K$J&ZV/I#_K;T*O
M9X62!>0I!RE3*4"*$, RGH&\P%!"3#0.R[7HT>?4MD*-R.444GNAPZC*!VP_
MCHH,X<#D] R] WF;JX_DMTKDB(>D ( BD9%/CZ.R4 $Q_03\FKT:@9G*@^?
MV#VD1@@*9H"0B $D=088P1@4B$ A4IUC)"(5./ 09VIL%6Z%ZCD<?J0U'L@#
M\UEKI8.;DM5D673G0*LA;%1Q !V^#(*/,%.IC! 7$"QA)!6^]9/.'8>>,4W
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M[1RW/W*%G0OJG=;5N?3@I>E\. 8?[)_^\]^:G]A?G OH?_[;_P-02P,$%
M @ @8,(51HT",(PC0 5)(& !4 !L=6YG+3(P,C(P-C,P7W!R92YX;6SD
MO6F3F[F.+OB]?T5-S=?!*>Y+1W??\%*NZ[BNLL?VN>?V?%%P 6UU*26WI'39
M_>L'5.ZKM?#52[LCSK'3F5DBEH<@ +@O_R/+R>SGS[C<C5=S/_U9_XW]O-/
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MZ7_]DCZ&^0?<9-E3RMH;PBHSRH)"FVJZU WIB1466 X[,;JOE6WPT#'V<6#
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M<WE[H>T1>L89PC(@M%K)O@,<O9Q_)JH7RZ_$PL0E8W52$20=U!1\Y 1!8<D
MO$]9"$$R:XR;Z^N/,Z9E.)SL+=L.</%FB9_"-/_ZY5/-F9!W]WK]$9<W9#0I
M'&.RTD#6!FM>+(+7LI97:!]\]$6FUEF++<@:9\S+<"AJK8D.P'63>-H0)063
MH-@L0"F5*3#0%BC(339;G:,?-,0?9][+@,?3WM+='QJ+=9@=U;'^8S%/YQPJ
M.H;)9^-0BJV=PR[5*L /D2+/D@LJGE:<6<J>PC?VN2/AE50!];IS7+Q"9?K
MKV]F@7;D/-><QJ>:MZW'N$@E<98<Z%(,N7<)(205@ F')3B'0CQ6BK??F?<P
M/3U$;4U@U4SH'0#HM\4B_S6=S289A<R9*\BVJ$HW8=XD^LIYM)A]YK&U@W2Q
M=@\Q5Q-@["7,#D#P8CJ?KO'5]#/FER3Y^8<IV<PSN51(EUPH(BP1A-7$ \,"
MCBL&J5X%>^==:'[C]SA%/01?30#34/![P^@S+N.B$9!>DUT,M3ON%885OJW/
M%[PN?U^=L33Q@IN@O2!'41907FIP@3$0' ,S(9#SUSID?Y2@'J*O)C!J)_8^
M4'05-%[SS+CPTH?:-%6#"U4G0#JC)"!W(4:9:_#0&CWW$=)#"-8&-0>+N8.C
MZXS^"9E%F[Q2($L@C*<ZFT>( @*+R$6S',1C#0;[Q^7C3-4<[*Y])T%V$(*_
MFH8XG6V".'+$-VT1'Q<S$OJJ.N7KKY>BB2*AE<@IFB-+J)@($!,*X"5RI[3F
MI;0^>[:E;=QP>_!*GT%4U('EN<;7[8Q8"ED:Z0T8])MQ,:Y.C-)@-1<AY8RJ
M/#:7\4"P=54--(SV'X;8(:KH %07UW5OPM>:M[I(C#J%6&BK 6<L@B(C#$Y%
M ]KRI+V1!67S*_E[*>D&3 ?I^8$[T@.$W@=TEJ>TZAT935+)=/H+!#2EM@4:
M#Y%S1[)ATF2=H@JZ/7KN)V;<PVXX #40?3\8JO/X3_!]^'+%2!:&RT"'OQ.I
MCM'V&:)RBJ3%K+1!!JL?F_YP (;N$C-N(GE8#!TH^@XP]&PQWTCC']/UQV>G
MJS6QL[R0V<44I8F(0@65%0@9L4Y6)$FAL^"L8Y(I+K-H?8^Z#5WC9J('0E9S
MA70 LG<?%\OU>UR>/%TLEXN_IO,/JXE&3Y02S8(IDI%)$9P,$31/Z(TA@VM;
MYP#N(6/<W/1 $#I4W!T@YF:.] [^O>$8O"?\NYHDU;Y>^=)7A<+>$E*PRK?V
ML!^G:-SD]$ X:JB$+C+5]WA\)!7,*; Z$+ FT(0&5VP!2[O$!RM33*V!M*>7
M/5B.>B#P'"CL#K*5S\^7O73RKK%4[_LB+YK;$$ G7NNZ=0#'D=5ADDHY#,R6
MUE<<WR"IFW!MN.112Z7T>\Y=+W%*M16<-ETQ3I.PM"5A\00Y::9CB778V'&.
MNATOU8X1T@V'L[:*Z0!IKQ;S#]4GK+5TU[A(-FC:(!*T#:+NEUK$&0O0[G&)
M%:/=HP/@]CH [Z6DFV!NP,3WX2KH $B;B^CK5O?:EO"1*R7)VGI3QUF0A&+6
M!I1"HZRP.KC6W4$/4]--:#>@D6JCB@Y =8V)B3%>>$.^IO;U"6)9[\4#T2\H
M:G51H!:F=4/LM>6[B>2.<@&WD[ [\,GK0,7I^F33!3ZO\U;J$8WS5%GQ623.
MB!4F/ ,5*+S8]%FF( WC/!1\="CZ?EG*!\GI)J@;#D>ME-&!_7E$0B6PY"6=
MS-G(3)Q8\O-8/:VE#YR)1 :V=7G @=4G@Q4P'055C531 :C>7*R[8>EL5D7P
M,=..B,"RH7V!%#\$X0N(4E#DG"+9W,9HNH>,L<<5M='PW7;&@\3= 6*NS0L^
M'VW"M)"J1# Z6'+>I* M53-H)7LKM;+^T;>A]CW3KM,P=L';(%@Y2- = .5)
MSIN:OS![$Z;YY?Q9^#0E'^L:6Q/$*+FE"( %2WY_IK R.E7J$[F6^.$DM-;G
MUK>I&C=S-!"8&BNC!WBE='IR.JMS##<Q9IUSO\2/.%]-/^-9ZO758E43KJ_+
M^_"%H@AA12+!<5:SKLQR<(JI^O0BIOIV2G:/O6*V9[W)+B2.FUX:"G@#JJD#
M%+[%=9C.,?\:EO-ZB7V-W>=8IFFZGJ .+AC% ).L4],IUHB)<9#9)B<*;;38
M^O[NVU2-FWD:"&N-E=$!O.X*:B*ESU[;"#&;>D.)%+>07P"LS@D+3)//V+KA
M_RX5XV:@!H+/@<+N(/7TK>!W4H1.3M96O5)'I1C: QZ%!I,2*A4+-WK O.6]
M-&T%I>:3SL=*9AZNEF8P._9T[#<;A7S$]32%V4UN6HW*OKG$<>9F/\+648=H
M!U\' @0(WM0)6\J JV/UK;*V:%EX?O1Q]EZ':#^R(QTS3D16().-IGB%OHH8
M#!EH'6.FG[!'WR,?(>DY\G#M'1"R0\)S%S5TX%'=S,#1YGV]W$@O;W(L;W"Y
M>01K@EXA]^0XB&A%'62(X*6(H!U/R6O.;!PV!_H096,#K0T.'DV+-E%*=U [
M>USMR>GZXV(Y_2_,$Z,0T9.K*NO;\!3::O"^/N5+S+!"WF5H7IOW.$7=9E';
M0>L@)70*J9>KU6GEA&<=0N20==*@K+'@F*.@A38+,R*Z8EKWY#U,3;<YU-90
MVD/XG<+H^K./!CG327J0]=5899*E79$\9*$S.0I61/78PU>ML+3K8YMCY$9;
M VI?-72 JFN7"0\>X4R9&'2J.X-;8BDJ\$D62 55"E[Z' >\+#S(J1HC&WH(
MNEJKHR^$W3G)>1&&<^L@2DDFV 5='[EV4%_7<%ZB%<W'OC]"3K<)TD:(.DC\
M/2+IXB O.:+B$:+GY ^&0 PQ*P$MBT)YHW1IG5U_@)1QB_..A: ]Q-XC>JZ?
MVD';HI2F +4PDD],KK:Q!@B:CFLOA+6J==?PP<^4#U:.=RP<[:N [^FMR<LL
MWVI1SGM_Z*>AEK5>NU.OM^G-LNL[+#E8MGU?MAMEW\]J%"Z)N(0O5ZX$C@)*
M$JKZ3Q)\EA&"3(D9;[)RK=//#Y!R> W#9YR?X@O:O/=-=OCU2YJ=UHU5!_K1
M_W(MT^!%)LF9!$L(JJ%)(<>1K';)(?&B/=/-I[?L0>:XR=(6R+E;XC"LKKHX
M7%?KUZ5.OM[<EN+R\S3AZAV=(1.4OJ 1EB)@D<BRDWGW)"S03J ORMJ K:^O
M'Z9FW'3I$.!J)/D.,/3;DHZ#-\M%F:XG10C4U@LPO*9X18S@D&D(!M%C3=/%
MULFL:\N/FPD= B7[RK:#^IC+CNGS]X2N!MTZI7,MLP!#7Q$C.E @:^@/(XMU
MF(,IK;/G#Q(S;JYS",BTD7L'=N4MZ8((J ^^/J>3>+;8O-)QSM4$!4:>?4U_
ML-JHJ"50($,';7(Z&9&,SJV3FX\2-*[[TTCI=U].;:2!#N#T#F?THP^_X9Q$
M-2.6GN23Z7Q:Q;2FF.:"*QZ\%=Y)D$E@?9/3U-P:?<4H:$:'UKC6;L]VE(WK
M @T#L %TT@'2[LAJDK6,.6H%C'/RZ$)A$'2.D+7ESM&?J?EPNSM$C.L<#8.?
MPR3=DY-TU9TQ026%TMX1T!WY>:CK^\ ^@=%6<*YE"&(P]^B*C'&OZ09UC/:4
M=0=PJ>^\KC8=]F<\O)R3U:+O3&*0S+J:TP^:[**KD]F8XZ"#Y#DH%AUO?6H]
M1,NXMW%# *>)U#LXER[HOCA6K5&1<Q&!15'(5JH CB&"B9: ;YGVOO7]VRT2
MQKUW&P8K^\MX=XCX,XC,\4--WK]O.]/IC\5\<=-D7C!EG'-8<@9KC 2EC*VX
M=^"]EYE\?XH"6L=>CU,T[KW;((=5.PUT87DN3MR+9/IT?DI,75TQ/<6R6.*U
M^>F_?B$ADN:F\[#\^I(DNYEF5=/PBTW,<&F$2RY::%;(?Y2;R59( O8,BO22
M1R>UB*W'_ S(SK@=6L-8Q#YTWX7[=L[B^39^2G%OS>SJG(N72D%PFG8S+YS8
MT!J0I:@L'2&Z^?/V#Y"R71:+?7_X.TSH'9C0/W!]+6YAL5 @B[D^4<LI;K$1
M/->U=1:CUR);XUJ/Z;Q!P'8X^:YN>_<7< >699MQ#V\6RXV"UNOE-)ZNZV-)
M[Q=G'957?6O"RACJ([7DH-8:57)74T;0F7,F5,VLM!X2TXCT[1#Y75T1CZ'4
M#BS=0VR_("=A^F%^-CT^?7V_#/,5L5>YG^?-OV9G^L[_<7H6KF\AI DKP4JC
M$))DJ;[2C'7J0(9@+"*CK5YD\VS;,1D<^5YJ# AON8W&QU/'F^W)YS"=5<;(
M-5^%&;[#=+H\FZJPDS@0B_&E9%#9T3DJ1:(CE&EP2OL2'#-:-7^995B61KZ'
MZWA#C8&9+AZ2.5 I$U54824*R'5&@*I?$<,&G-/9H56)/(B^O*Z1+Q,[W@1#
MZ+R# .,>3B_'R#G%M<Z:#CJ>2(R%#K_HL@:9<I*!D315Z_3%(^1LY_!\5U6
MK83? 8XNQL5==$4^#:MIFG!N2V&JSB"L+Y1[H<$K:<EITBHKG:6)K>=%WDO(
M=MCYKLH!#Q=X!U[J;2:>3V>G:\P3IIAG7@1@SB*Q$6HUK&1@L@G<J61X\XNH
M!TC9#CG?5;U$"Z%W@)U_4)#WD>A^0AY?^(!_G)Y$7+XN=UK9SC:&]T%9)B2D
M6,< H!7@2%@4S840(Y<QB=:%%#L1N!W.OJORBN$4U"_ZSO?2W7Y*1H(26D5
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M6JFE(Z!="\3N?P5.1*;)6[&@(Z^O!40#(1@))3'R66Q@C&-KN'V+J"[CD,%
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M3.O[OBW(^A$R+DVPV$AS/8&Q7DRN/F+^;;'(MUCB+#,GE 9>H@3ER.UPQ1=
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MV=#^BDR 2/6B*%0#7JR&Y)ES/NN2=6N7;3AN.@U0]\3=HDL0C#T3_$ Q7+]
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MGYZN*!9;K?X^GZXG)+!B8HSU42@!*F0.CNQ]?;L]H$DFB>:C@'8B\(>8_-<
MF>VUV1%4;QEZ2UX'!H-UV$VJ)4",_)#::,TDH[T8LVT^+NA^2K8"G_GQP7>
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MRJO2>OWNWG,YCSH$[9!+YF!)=XB6JP-4BG!2<7")D_FT0M0!V9Z.@'-!%0I
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M.?D,*E!HU1A;6Y U_G-P8W2U5D47^+K3^R\BRRPY!\'5RM+ W@N;!W!Y5VP
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M5TDC./))Z_(A;7)TRL?6\S?WIW9<K Z'H%WF@;13YZD E\3Z8,V@B!'IM!=
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M%4'#'8_QE-[5 7A+$=+\%^*Z\FF#Y3A;_4CZU8?R"=/\ZVSZ?\EPX&(ZS[6
MZI9?R'DPS-;E!IHI^B]TX"U+(%.@P%9'Z<QP7E)C9L8=SCX(],=4]\FD$OX(
MBSI0X2<>4/BRQ4\=)KWP-/'#)!H<3SYX"@$%5Q%4!:A+48,HUFK)+86'K:^\
MP1(-S[E.RTV^T^7SD2J*>:XR%!$-*"9B?3D2D#%P)XQ563=/=;8BOJODQ2Z8
M.L 3;JC.#N[U2\KI+Z\J&3S=$C[7Z<XH"@6\/(.+J.G*P!Q#,M[PUG6@=P@8
M%T\C@6#>2B,=P&E_P=VP/<L?S\+LC_ =U[W#62<D9QF!A5B?26V&8$($*S4=
M]6"5:=Y>,P0?XX+[ %@]V"T_LHX[P/FU5WR31%S7\XC@A L^ W.K033:DO^M
M.'"4=9*P5CJW?F'82,S(YG1TG,R'4%H'Z'LLS?#I\Y]7=6GUL58Y)!8<73Y6
MUA7LDO[1UB67A7Z<:NU0/DG0N"\*W:&PG?+&+@>\\X+R>/)KS14700@N/<A5
M/5*1=:*,(LEE+WSVT61[SZ_<-!9EVT^.FZ/O!G0#ZJD#.WC'H%_5TUI)3"A=
M2]\2F7)N($22E];>5.DQ;P>]?W> WV Y\&[@UTI1'6#M=2!QU/PGXOG[=;)S
MY4IS-,A+%) RRZ"0*X@I!2A2!ET2SYRUGD&VB9:1;]HNPN<F>NH4;^N3F((/
M2F@-DLO:>$#N <5RB8YC<4HGGWGSO0B;J1DWQFBC[2T@M(?HQW;/?I_]) G.
M%[_^P/.US34N*ET7W/-:,JJL5>"E+Q"CB'3S4\ASWU9M[-&X_[/[P\$^*INW
MDU\'-N2R/> SJ6%E=>\<D&PD8F %4->&\^@]1#H44+)-/!5NT+9^@7F"G)'=
M]2YNKE;:ZA=XZQ/I6)0Y&5W'S M0GGX5E7/ 4,5"EEIXW7I*UY,$]=!3WD#M
MV\%I#QV,?9%MGKBS-LN!+GNZXAG(X!@%JXQ#L,8 66I52QZ85MNE%Y[[4I=(
MV4>C\Z'$VX'QV;N6\?UU3YY-*?-"/D/1AF)=HR0X08?/V208SZD(V7JUR>%4
MCYQSZ.(./;+N.T!['6^V+F9?<;9\=7'^;;ZH]5>3R+PQH@Y=]L+4(MM UX?%
MFE'FL3 N>?.QP4^0T_EK5&-D/)@:UT9-'2#NM^G/:<997M[B:8),.UGW@DM5
MWRTH2H+ )'DJ'IVSQG*>6S\Z/49'YV]-PV+L8,6,[>C]<5']C0_E'_-S7+Z;
M+]Z&]&TEL _E%DO_&\_RI/B@LY:&POA8^UZ9 I<M_<HS45A2HH2\E<NW_3<[
M?U(:!EM#ZJ4#6W9HW\NM!I??9^>+Z6PY3?\(9Q<X*:PXEQCY+C(B*%T;7)3V
MP*6,6G RZ[9Y1]10S'3^FC6L5>T#(KV<E0=-, \%$3<(XNU?N$C39?7Q[PJ"
M3P+/(:JD0;-"L:M8;;+.#C"'4E5D,[9V5(?C9MPFD!Y.R_@@Z>6X#-I2^>KK
MUP5^#>?W)#7)D<14:S>DM"2HPBB4\#9!Y)YCS)JGT/I]<#1FMSILYB4?MNXA
M=LIG<?5?528DB\MV-CY!Z163TD'6.A'OCL)UNL;!2J:CU%H*T;QAL2']6YT8
M^_]/3%L@]' (:I#V"7^L5R;DWRX6U\Q<YJ0FS+O,="I0/+>@I,?*$8+VJ),T
M=4E;Z_Z?YZG:"K#NI0*VK=(ZA^$Z+M)TBH)UH%34]5SI*B\#)3&6)?,VE]8S
M(Y\E:BL0^G]#$.ZNLK&SC \E=2/'RR/U^2+^'_*'OLQO>)X0@]ZA,A"MSZ"L
MHE.F0@&KB_62<6?<EIL]]_G\=F\G[(7A[TCJ.DE 7GOFZX@9/RZF">N4->4T
M$M\\(RC4""$4NAN*T%EH9PO:X6#Z.%';@?>EO?R-JMH.[ODV@T/>A!_3\W!6
M?_?5]_G%['PB1+ B<P7"T7E6TC%8M>Y9YUWQ.EKA6V\_&XB5[<[%2WVM[ $?
MIW),_IC/?E[F:JK\EU_FQ/+M/Z^B^&-^_E]X?B.DB7#<>VD$>)2IMA*2(!(&
M""5*HWER$EL'<X,QL]U1>6F/KWUAY"4?EDN+\FZ^6/]6_7M\HD/F3.<$'.MH
M_JP+1!$9:%,5EET(O/F4HJ-RN-VQ>JDONQVCJ8.S=NA+WN7CPN^SM3#"=+%^
MQT-KLV?.@Q6RMK@7#Y&Q0!=TUM:2DYM=Z_+_H7C9[OS\_[?> 1'2P4D9S([<
M_*3+_].'\V^X^/(MS-8"G"11>&*\@&..UWXT#\$6"UDP51(G#]BUKKH<C=GM
MSMI+?>H]#8R=S,#.R]S+)_KIBY^8RWSQ[N+\8H&_+Y<7M8^TZ1C/+;\US'#/
M?1@=9N1GTM&76#>M>T*/4HS<'TO_Z$61V7'E$%M/<3O*;I%5SPKZXJ6H-Q;J
M#"J2@^=<,!"--DI;CSZ*UC[-9G*Z&LNYB]ZWW"FRL\@[<!+NSM^31G&G?0;O
MD@2E8X;H:FF^-JA<846QUGCI<]#F86I]<G3F+C+N ""##.V1S.:2K08?F:Z[
M*5W=7&]!( K-M*4_.WJMTHF/SMP)5L<8G;F+COMYZKPM@+N#&6^J#]?]QZ44
MC39Y0)'() 21(>1";G2("@4%@\:5Y]RRO;_>>=?BX(!Y_#5S(.V-#<];W4R/
M3<FK7O.J7O8AEY8;]$B\6:T0E!,&/(M5Q$%R;W5*R+;"Z-XD=-[Z>%2@'D>/
M8Z-UB^/XZB>%=]6O>C=?_(UT<37(*#A4J+F P'(=ON>0KC-D$(1,R>1:LA5:
MF=0--'3>3MF;86VAR0Z\W,<F0>;:,%"* Y'K,')7IXY&1V*+,4HG1* _'"J+
M^:)'=NZ#QU:*VAMK/W$1YZV&8]2X<AUEWN1A10K9RR(A"1LHQ$2R\2%&"!BS
MXA*%EZU'Q#Y*2#?C.IL&X8?+O ,S=<N!6%<8W4VDOKN?2)T4F8(Q,4!B5M'9
MR YB2!KJR$!7IR?)V/I5<V<BQXUE&@!C\U"5 ;1T.H\9-_.]KY8-MGW V/SS
M!WJTV)*A81XJ4&!0.M=1>[EN9F0(KB0!:$P1*5%TD%H/_VKS4/&$*[E-3^A-
M+'0U*_Y*(C(PZP1YE@EKYW4V&;P*')#.KM"HI0GZ@&CA(.*Z>NO8!3I;! #'
MTUH'5V[#.1N?YF=G9/OK'TZ,0ND3,U4;]7XQI!(M:ND50\9C<9EU/(?E%B?C
M +T/= XWDF5?J+RL W,YX&E2DO9*9@-DO<@[XHQT4A(#YIV5SFN9E>OWK%PR
MT7F^_@C('.ZP[ &3O<_)C\L6Y_.P.._BM*QR;LNK8L6_+>;+Y21)NN]3*J#K
M[CR5Z5<N1 51"<U8\$SXW@:M/,)&YP\'IW=B#H5*#W=+C< NGTD>3ARXO4_J
MJD4Q3[CS-MJ<(7OEZC0S#2%QDKVTV<58@LN#=.WO1&7GCPXC8'U81>\.97\)
MY=FJ 39W8?I)S@6G-8]T?:@GTF.V*29(P1'K7G@(M<@-M4[6T#5H8F]AQ2-L
M=/[F<7JF_U"H''I>OG0<75@II/':0R+K :0D"<Z0\=!>R&1Y1#M,W\_1HXO^
M^GWZ/3"'P>3 Z.+MK(\+YI80_A.G7[_5#HZ?N A?[TZ J#HK:YTI;1-R4E+F
M/H(2,9 K*1D@\]IIKZ-KON;R^%R.$YF\])37$!#K(60YCH0F*J804&C(ESG^
M8L'[8($E&8H627'5S6Z8W5A[,:FS01 ^SH'<"6ZGDVS;6,WT: KE20$9DW0L
M,H%QM<@);8' ;03#R5DHPI/\^FEQV)F]%Y.<Z^),C@2[4[@=GQ/-%??;24=A
M,LEG"2FI LIP#L&@!Z<L2U8JEGCS9.!1.7PQB<23.)?#@>\E',U'DDY/FRXA
M$B(Y$HC<@_*^EO&F ,D9%,)Y$E;K3NQC\_AB$ILG<3R'!. I'-!&KKYD,C%;
M4UW6K8I3/;GZUD)@%HVR7NC\DB/+4TB;=G$<1X!;TT3KT/70=\9+A9OM)N>K
M[29-2Z.W^]0P5=)[L#E,P;2//K"L/.@8)2CN#00*@,!@25)GYDII/H6J[627
M T_<ACTZUP)B/B=M>=WQ1E)2AJ04-#FD6D8F0\PZE4'6FPW'4E=5U[O@[T@K
ME/92?2^N3GQ>'/%)<5SM"[VL(ID4C1R]B12/(0G"EP#.E3K"/# MHN-NF&WJ
MC?DX[?1X4Z .,@CR -3T<G+:Z^?A^[ADS%F;,O"BR&U+Y+%%50QDAH(;;36:
MUD.)C\7;:2>[!S]AO:&KS_D7!POEJ:#IUE2[K+T4#"2O<T(44W5FN@"K+#/>
M%&/2(3.)CL+$N,>M@1,WM@!W0L'+."W;)A=\<0HQ1Q#.5XOG;9T@P ER894
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M *?]!??$M&N&(L8Z6"=R6=O8G860A86LM/#)QT:NL3GS7S4ZP.L:NFUUT
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M%<,2_]?_^']02P$"% ,4 " "!@PA5('8TG8L( #M)@ %@
M @ $ 97AH:6)I=#,Q7S%X,#@P.#(R+FAT;5!+ 0(4 Q0 ( (&#
M"%6TXWE/F @ ,XG 6 " ;\( !E>&AI8FET,S%?,G@P
M.# X,C(N:'1M4$L! A0#% @ @8,(5?9V!AK'!0 I18 !8
M ( !BQ$ &5X:&EB:70S,E\Q># X,#@R,BYH=&U02P$"% ,4 " "!
M@PA5O H$'K8% !W%@ %@ @ &&%P 97AH:6)I=#,R7S)X
M,#@P.#(R+FAT;5!+ 0(4 Q0 ( (&#"%6'OM,9Q3<# $H4'@ 1
M " 7 = !L=6YG+3(P,C(P-C,P+FAT;5!+ 0(4 Q0 ( (&#"%7G
M:M)%HQ$ '6\ 1 " 615 P!L=6YG+3(P,C(P-C,P+GAS
M9%!+ 0(4 Q0 ( (&#"%7P<.LR "0 *]G 0 5 " 39G
M P!L=6YG+3(P,C(P-C,P7V-A;"YX;6Q02P$"% ,4 " "!@PA5A]<MF1M(
M !W)P, %0 @ %IBP, ;'5N9RTR,#(R,#8S,%]D968N>&UL
M4$L! A0#% @ @8,(56S1&_I'[P [00* !4 ( !M],#
M &QU;F<M,C R,C V,S!?;&%B+GAM;%!+ 0(4 Q0 ( (&#"%4:- C",(T
M %22!@ 5 " 3'#! !L=6YG+3(P,C(P-C,P7W!R92YX;6Q0
52P4& H "@": @ E% %
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>